<SEC-DOCUMENT>0001842952-22-000029.txt : 20220323
<SEC-HEADER>0001842952-22-000029.hdr.sgml : 20220323
<ACCEPTANCE-DATETIME>20220323161757
ACCESSION NUMBER:		0001842952-22-000029
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220323
DATE AS OF CHANGE:		20220323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Context Therapeutics Inc.
		CENTRAL INDEX KEY:			0001842952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				863738787
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40654
		FILM NUMBER:		22763399

	BUSINESS ADDRESS:	
		STREET 1:		2001 MARKET STREET
		STREET 2:		SUITE 3915 UNIT #15
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		267-225-7416

	MAIL ADDRESS:	
		STREET 1:		2001 MARKET STREET
		STREET 2:		SUITE 3915 UNIT #15
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Context Therapeutics LLC
		DATE OF NAME CHANGE:	20210128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cntx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:26b5d880-9edc-4480-83e2-744a98c761b2,g:c86f1f4d-7057-497b-9a16-bf3850b7383a,d:10e0e1fe4e654d20bde04f42c409d9dd--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:cntx="http://www.contexttherapeutics.com/20211231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cntx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV8wLTEtMS0xLTExNzU4_0950ba9c-9a76-48e9-8595-7a74e4250407">0001842952</ix:nonNumeric><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV8xLTEtMS0xLTExNzU4_d01ff163-1377-4a1c-addf-80ed0995d677">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV8yLTEtMS0xLTI2MjEy_9d8ef5e3-c381-4fa8-b8b8-c473e4ec3727">2021</ix:nonNumeric><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV8zLTEtMS0xLTI2MjEy_d2210b5c-1e0c-4b51-af3c-8dce718a9d09">FY</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i7d018297e2234b888007658079c886f7_I20210630" decimals="-3" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV80LTEtMS0xLTI5MDgw_84ee0607-92e5-44b1-816b-ea90c757b2ce">0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if7f73c1e9e5a43a7aeb2e6b60176ae83_D20210601-20210630" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjcvZnJhZzpkMzUwYjYwMzk4NTI0OTA3ODg5NTczN2RkMTE3ZWVmOC90YWJsZTozNzA1YTU0OTNlZjY0YzgwOTViYzMwZWEyZjE1ODlkYi90YWJsZXJhbmdlOjM3MDVhNTQ5M2VmNjRjODA5NWJjMzBlYTJmMTU4OWRiXzQtMC0xLTEtMTE3NTg_20d900f6-f979-4a8d-ba99-de2ed3ea71d1">0.1667</ix:nonFraction><ix:nonNumeric contextRef="i71a428ef7a1b4d19bf600eeaf6b76bff_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4NjE_01118990-dc7d-4e7f-96e0-43c8e460d916">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ice47411318244bb2a350092f360fd3ee_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwNDQ_d169f036-bec1-4a91-89bb-ca2c7da81f4f">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cntx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id3806566135d43128a2459f8523168f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87bc250d89df4abbb4e488707f760dc5_I20220318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7d018297e2234b888007658079c886f7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic683c6b9022b4f92a00ac3868a3f9346_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a0d98182ab34ee7baec49057ce8676f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68f213b55483406f9f85d99b2a65fa12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51367b5fc58744139f31963837e98df8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i285ef89c1ae14c19928c2e368283074d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd11c091e024a7a92541bbe11337dd7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadbb65d9f6724cb6a5cd710b45cc033f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb93a595192045d2ad7ef4eaa1b20c05_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe019d635614547bf06c09e991419b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8740cca1c745199eda7ed1a4c1f483_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d1bf6b4dac47b7984ca62205cdf5ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e33079a371457f957e34b3350067ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce49c28af0b41f0ad1acb06f7f428c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f2f9c93a454fe2a0edbcc51fd35e05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0d5097ed154ff1ba3d972352d2867d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddeb956fa4494216b6ca445ac804fd36_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7ed393336144da884a7c61ce2da7a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i625d9f20831b4f60bfb06856c3aea35c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2dcdb9bd37f420e9dc8c7b39ea998eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07db14fa05f64cf3bdaba6c0231f7ef8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117b2aa3311747edb244e9aeee8fc1de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3251068f24e94754a128ec78c77f7334_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b71ff94d7e42dc8077cc9688deb3f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1ad6b33cea4855b42055c26af30d02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449ce80766bf4e398973559957e68f41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa7323ee88a439a91a0ce98d394f1b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b6d70f7b20444b83ad2461cd950758_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77193cc910d458e928d0612bcad6229_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243e310d4e9f4b44810d72c76300cb01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5ac1e9d0f1a4ddbaf6c8ceda2b4372b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a2f3ed31f33425492aeff13156184d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd53ac676234dc686b2453d0815dd41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0843156761eb42e38470d03cf3e6bf74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2caaf4d5a53246158004742c606c9ef6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045d90f6713c40aca3bb010b300e93c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b12ba6b5674eebb227199023ca61fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie50b1aaa60bf499993eee4785c15824f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa6d7d44de0047f1bb1cbadc0b046365_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aeee7d03a0640068206aa28850aa627_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69779aa1bd2d45a6ae2b2ae5627e59df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000327aebd1d4982bbd9d962da1fdf97_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:DemandNotesToConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1870092b17d54844b0aa4cbcc3f8ca0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:DemandNotesToConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b39b2be197f4335a69486c43230e142_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:BridgeNotesToSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f53e07ae1ec473f8c5c078ea26659c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:BridgeNotesToSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8e22b696e144e3ac3f230b33279167_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001e36ae235344e082b79a6dc0a8bcdb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d9b23ad16c43aa8572a0ac6ca614b4_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cntx:ContextTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4173532c9b754389b02c47c17758a39e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib574e9442de340bba7e8df59de0aa8ea_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaec33cca2ed463caf5a7211bdf75d02_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9fe5d1cf7064523ac856ef87a48d0ed_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:PlacementAgentsWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i536b13a96232407dbc13d841f1fce5a7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6affe466c51c4622a311e2ed55837af8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5177f9964b244a76b68f2abaac086c21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i839fbb147c914876bf372cc7e6439da1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cntx:segment</xbrli:measure></xbrli:unit><xbrli:context id="icc8935fc9d464f29836a2a16fe277e98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id255264c0c894b67a64f0a3ef3d68e1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f9e0e12992402d90ec7a6af875e1fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aebf98410d2455caa4d29b128109b43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d242a6318ef4c6bbdd7b8627be0cff1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i887b64939c5845d2a4612345d96858c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce232c5ed264fc1a5e2e91833604312_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcee81aa26da40c7aa01c8ed07319386_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d84cd8ac404ffb9652dfeadc1a177f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68566af59223448eb22d5006be5194ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77004ca7aa1445119a9a78b5703984df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c0a790ca1c4e73b5def12d29757201_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c39b33c88a8458686857dd42b2e64f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic199b723275d45d2bc21be1587aae664_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34409531cae4268bc173922ce57ac3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib510cda252c24e72b8fa50da53cf17e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16b5edd019244d8c9ac599aebe563739_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908727eba5bc4358b2ac0822d99cd9ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id55d52b883b8439db64cf84da4088ed2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie62db008cf5d41d287747c3ee2afb05c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58cb9ed855944a858084c633831e74b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0dff24cca894323a3974079199c467e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b4298623094156bda38964f2ca6d72_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb6e5f4b103e4e5482b8dc8b7527a3cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cbdfcd435a84616aec15c81c9bb7b06_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89d4008efcc04a669ef14e103f9a6a6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia686afec9e234c72967a01ae8d98a108_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:BridgeNotesToSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie234c0a724cd46029a0f0307bcf0e78b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:BridgeNotesToSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4296ddef4cfc4b709b45e518ab9c281c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2c5ebbe3b814fed872de2b6750f3337_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i969ca1b809854daabd8f8995c295fec4_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cntx:ChiefFinancialOfficerAndImmediateFamilyMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e45ef9fdc642a0ac8a1d88dfeb09cb_D20200531-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-31</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5bffb2e3fd7430997f0e5cd07ec38b3_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7a5cded79d49a4a18179828d3d9f12_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:BridgeNoteQualifiedFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f07fc75d54b479cb5bf55f32da7bf1c_D20201222-20201222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:BridgeNoteQualifiedFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-22</xbrli:startDate><xbrli:endDate>2020-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b93a5662e8a4c92ba2e140ae85fb825_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i453801845a4245559bdf44e3c243247b_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00def9c120e34dfd81ad8cc464be10c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6cc68e23a644ccb73a6bd8317cac15_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00ba2e7eb0484b1295d941578acf8031_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cdb9eb262764bb9ad359f4cd6409d95_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff833741a565408283759dc258048916_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica3de374ebb14eb283c5fa464ed31769_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2caffc25ed4f42e195b906a4eab85ec8_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bcdc4632b004d2e82615143090acd9c_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a8b2942cc1406a9a317b357d09884d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60dcae9af0d042a6808422ea713c8707_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ebfb8391004e768936ed5a183ccbe7_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3d5bf929d841bd8562efa81175ada4_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5785bd98b84141148e297a25af4b1ae4_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd17b8baad484309af4929360d734817_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5007a2b8df544622bbb6844a27b85941_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70476cf5f23e40b7a8e694276c179049_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToSeriesAStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee66bc4c666546b5827d8f9046ce2e6e_D20210201-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1de5d059a75a4d8e960f6f97b1e4b44e_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if041032296804b76bd219f45c1d66fab_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToSeriesAStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib058079deb3c476694d758a0ce02221e_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1de2115c90540ebb9bb07d72b519bf0_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c63a7c492b249a2823508e305461100_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d1cfe7096e34e6ea497fb994bda8378_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4631fd77028469dbd1afde77f30a01b_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f3867dedb684f8482d09a62b1bef50c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ba1a5fd4aa54bd18b6277a18720bbb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36c3e785908e44e893746fd8fb714979_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedAsPartOfPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f73c1e9e5a43a7aeb2e6b60176ae83_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6e09006c2a4e438d001a5d8e06267e_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e1c00a5a0c46b7827110eaaccd2bde_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ff1ceb32174558b92e60058255b0fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b4d526304e44d59c45f6d02124e335_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cntx:StockGrantedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a428ef7a1b4d19bf600eeaf6b76bff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ad2696d269b4e0593b847bc2847d326_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e63271831534a1c9f0c9dafdc78b906_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88a6a22c984641faab12a3f3aecdfa8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76aea4c250d247f696a873ec46ad8c83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89568e4239cb4b4dbc069d2edc09f071_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0abf375441494967be6030dfc54f96ad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16167060dd4a411bbbf08ccef55b90ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87304bb5deed428b929244468618ab9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice47411318244bb2a350092f360fd3ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6d5e19e9c2468da79c3794e7c72abb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i572c857cebbe4fc1982b32de57c0220a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992c3c31612041b88458293caef78ce6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied12b91ed1cb4150a7ff06c8518ebfab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic066948fc7ad43b0956073d48292abac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090b28e5ec1a4e8eaa2a115e3b70282b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92dfdc8947244a08927a080fc1dfb72b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce6960f11854815999679040b558ff7_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:DrexelUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fbe4d1c3214a428e35dd1f8055123c_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:DrexelUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a58857b70524568849add997a11e677_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:DrexelUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7d7b9cfd5348869e9ddcb95a366ed4_I20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:DrexelUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e81531d0aa47a7b6d49a7c6551bbd4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5037d579dc114c0484a17c0cae6d7468_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp100KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e8fa04e6e04b7499dd9509fedc5611_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp300KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ae36474bc442648e5731b2aae1cdd7_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32152868968f47f78b1854b4910902e8_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a5ea7538cec4d73a63f42512b7cb189_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9f956c8b3ce4d38a8596ee10f01e3d5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69aa76103ac748efb2f5d056d2cf8104_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1bf28a7fb38490592f0eae3e1f12ce1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i760a27b106d14efc85f77118941e7eec_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c01fc0d079243d0863dab34c442d2d6_I20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc572ca47de84c2097d086542a0002b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80101d4b12c34ca8aac0080981f8868e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f59721c4e142388846035376f047f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cntx:StateJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb11fc45a9024916b87e1c43f8c7f43e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cntx:StateJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10821272b4754a39be917949dd892095_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cntx:LocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae70c994731842459a8bf4cb62e7db3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cntx:LocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73cb300b7bdf4e6a842303015e1050c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae15c2289054f01bddc88f4e06f1c45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8661fa5883274943a3502b6df99bcb33_I20220323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2661b361222b4e279fdb7c4c8e9cc8cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1"></div><div style="min-height:9pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.792%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTU3_ee3b8787-194c-4dcf-8e8a-b4cb94e88f43">10-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.792%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"><tr><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6NTRmOTc1ZTY5NGVmNDNkZThiN2U1ODBiZWI3NTJmY2YvdGFibGVyYW5nZTo1NGY5NzVlNjk0ZWY0M2RlOGI3ZTU4MGJlYjc1MmZjZl8wLTAtMS0xLTE3Mjk1_f1be4109-49cc-4100-b263-dde05ccf9738">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:128%">For the fiscal year ended <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTkx_3ae41e00-2e2a-4783-b4fa-32f6febbc474"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTkx_77748eab-86c2-4779-bad3-4b30ce5ece6c">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="margin-bottom:9pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:167%">OR</span></div><div style="margin-bottom:6pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"><tr><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6NzljNzA0YmYyMzJkNGRjMGI5Y2I0MjU4M2RkNTJkY2IvdGFibGVyYW5nZTo3OWM3MDRiZjIzMmQ0ZGMwYjljYjQyNTgzZGQ1MmRjYl8wLTAtMS0xLTI2MTMz_c762e371-2459-4475-ae31-35875db49c4c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 3.27pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:167%">Commission file number <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTU4_7d0bbe7e-c283-412a-b80e-822d06f063f4">001-04321</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8zNzQ4_b8d2b665-2182-4feb-bf09-6f1790f1ebee">CONTEXT THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.878%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZGNlYzA5M2MzYjY4NDg1NjkyODhiYjBiMjU1MGE5ODEvdGFibGVyYW5nZTpkY2VjMDkzYzNiNjg0ODU2OTI4OGJiMGIyNTUwYTk4MV8wLTAtMS0xLTI2MTM5_1fb76b2e-5373-491f-9504-8252b5545cb2">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZGNlYzA5M2MzYjY4NDg1NjkyODhiYjBiMjU1MGE5ODEvdGFibGVyYW5nZTpkY2VjMDkzYzNiNjg0ODU2OTI4OGJiMGIyNTUwYTk4MV8wLTEtMS0xLTI2MTQy_0187197d-df14-42a3-a102-ebbce063673f">86-3738787</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(State of other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTU5_774aa62d-471d-4c09-90ad-6365b3618e6c">2001 Market Street</ix:nonNumeric>, <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTYw_675231ec-256b-4d7d-bc4d-baf0f8c40ba1">Suite 3915</ix:nonNumeric>, <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityAddressAddressLine3" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTYx_638137b5-e5e3-48d4-afa6-39fe7d21991c">Unit #15</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTYy_821bfd12-b38d-4303-bd91-ed7496ac1d2a">Philadelphia</ix:nonNumeric>, <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTYz_6bf1472d-d596-4fd1-8da1-231d4fb36335">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY0_0c8d5007-b9c0-407f-b1af-788417c22a95">19103</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY1_5d1f9621-4984-41eb-9c0d-a65db582316b">267</ix:nonNumeric>) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY2_32d7a5e9-b455-47a6-bbc4-041110c6147b">225-7416</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;padding-left:8.52pt;padding-right:8.52pt;text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.595%"><tr><td style="width:1.0%"></td><td style="width:39.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZWI2ZWFmMjc4ZjIzNGI5MDhlNGIzMmQ1NmFjYWQ2MTIvdGFibGVyYW5nZTplYjZlYWYyNzhmMjM0YjkwOGU0YjMyZDU2YWNhZDYxMl8yLTAtMS0xLTI2MTYw_91bf4309-7711-405b-bd03-b8f6959fffbd">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZWI2ZWFmMjc4ZjIzNGI5MDhlNGIzMmQ1NmFjYWQ2MTIvdGFibGVyYW5nZTplYjZlYWYyNzhmMjM0YjkwOGU0YjMyZDU2YWNhZDYxMl8yLTEtMS0xLTI2MTYw_391b8085-1ab7-4b33-b582-da8af7f00ff3">CNTX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZWI2ZWFmMjc4ZjIzNGI5MDhlNGIzMmQ1NmFjYWQ2MTIvdGFibGVyYW5nZTplYjZlYWYyNzhmMjM0YjkwOGU0YjMyZDU2YWNhZDYxMl8yLTItMS0xLTI2MTYw_03d55012-2b4c-4a40-8919-2a0d45c11c56">The NASDAQ Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">  Yes  </span><span style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:139%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY3_ce001a0b-d3d2-443f-b470-0966b19fa6cc">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes </span><span style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:139%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY4_b96ba7f9-e618-4375-8309-700b29618b15">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 &#160;&#160;&#160;&#160;months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY5_ad72677b-e725-43bb-abcb-30cd2af86d53">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:167%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTcy_f7729cdc-4ecc-4850-b324-dbf49e4c9030">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:167%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:167%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.363%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6YjUyZmJlNDkyOTI3NDgzMjlhODI3NWEyY2E1MzIzZTkvdGFibGVyYW5nZTpiNTJmYmU0OTI5Mjc0ODMyOWE4Mjc1YTJjYTUzMjNlOV8xLTAtMS0xLTI2MTkx_d62a0d71-4a16-4f73-aba0-4f4a23c10c96">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6YjUyZmJlNDkyOTI3NDgzMjlhODI3NWEyY2E1MzIzZTkvdGFibGVyYW5nZTpiNTJmYmU0OTI5Mjc0ODMyOWE4Mjc1YTJjYTUzMjNlOV8xLTQtMS0xLTI2MTkx_f7e7b2be-9c87-4922-a8f4-5a23cbcd9f0a">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6YjUyZmJlNDkyOTI3NDgzMjlhODI3NWEyY2E1MzIzZTkvdGFibGVyYW5nZTpiNTJmYmU0OTI5Mjc0ODMyOWE4Mjc1YTJjYTUzMjNlOV8yLTQtMS0xLTI2MTkx_28571e69-55c7-4411-be5f-72329e8a61e8">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    </span><span style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:139%"></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTcz_a0a8d791-62db-4ca3-9953-0ca27b8b8f90"></ix:nonNumeric>Indicated by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its audit report.      &#160;&#160;</span><span style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" xsi:nil="true" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTc0_88d24d0f-7154-4ea8-8d08-381f38fbf08f"></ix:nonNumeric>&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:128%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes&#160;&#9744;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:128%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTc1_05fdf7ce-ced8-4d0e-89bf-4545783d85c6">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As of June 30, 2021 (the last business day of the registrant's most recently completed second fiscal quarter), the registrant's common stock was not listed on any exchange or over-the-counter market. The registrant's common stock began trading on the Nasdaq Stock Market on October 20, 2021. Therefore, the registrant is unable to calculate the aggregate market value of its voting and non-voting common equity held by non-affiliates as of June 30, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">As of March&#160;18, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i87bc250d89df4abbb4e488707f760dc5_I20220318" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTc3_6e723a11-d671-49e7-b6d3-ac78d67a1840">15,966,053</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTg4_b9c0812a-01eb-43ab-8528-12122213c485" escape="true">Portions of the registrant&#8217;s definitive Proxy Statement for its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXPLANATORY NOTE</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">On April 23, 2021, we completed a reverse triangular merger, resulting in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger,  all of the common units, preferred units and all options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock and all options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. (the &#8220;reorganization&#8221;). </span></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1437">Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1437">ii</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1452">Risk Factor Summary</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1452">iv</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1457">Market, Industry and Other Data</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1457">v</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_995">Part I</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_46">Item 1. Business</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_46">1</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_31">Item 1A. Risk Factors&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_31">36</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1029">Item 1B. Unresolved Staff Comments&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1029">70</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1045">Item 2. Properties&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1045">70</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1057">Item 3. Legal Proceedings</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1057">70</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1052">Item 4. Mine Safety Disclosures&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1052">70</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1066">Part II</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1073">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1073">71</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1080">Item 6. [Reserved]</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1080">71</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_43">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_43">72</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1317">Item 7A. Quantitative and Qualitative Disclosures About Market Risk&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1317">80</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_85">Item 8. Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_85">81</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1154">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1154">105</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1162">Item 9A. Controls and Procedures&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1162">105</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1169">Item 9B. Other Information</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1169">106</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1496">Item 9C.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1496">106</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1183">Part III</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1383">Item 10. Directors, Executive Officers and Corporate Governance&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1383">107</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1346">Item 11. Executive Compensation&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1346">107</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1355">Item 12. Security Ownership of Certain Beneficial Owner</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1355">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1355"> and Management and Related Stockholder Matters&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1355">107</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1363">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1363">107</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1371">Item 14. Principal Accounting Fees and Services&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1371">107</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1249">Part IV</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_205">Item 15. Exhibits, Financial Statement Schedules&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_205">108</a></span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1291">Item 16. Form 10-K Summary&#160;</a></span></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1291">111</a></span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_211">Signatures</a></span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_211">112</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Form 10-K to "Context," "Company," "we," "us," and "our" refer to Context Therapeutics Inc. and its subsidiaries.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trademark Notice</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Context Therapeutics&#174; is a registered trademark of Context in the United States. All other trademarks, trade names and service marks appearing in this Form 10-K are the property of their respective owners. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1437"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements are based on our management&#8217;s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. The forward-looking statements are contained principally in, but not limited to, the sections entitled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business.&#8221; These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of preliminary results for our ongoing investigator-sponsored trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, progress and results of preclinical studies and clinical trials for ONA-XR, CLDN6 bsAb, and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope and likelihood of U.S. and foreign regulatory filings and approvals, including timing of Investigational New Drug applications and final FDA approval of ONA-XR, CLDN6 bsAb and any other future product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and advance ONA-XR, CLDN6 bsAb, and any other future product candidates, and successfully complete, clinical studies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our manufacturing, commercialization, and marketing capabilities, implementations thereof, and strategy;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus, sales strategy, and our ability to grow a sales team;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business and operations, including clinical trials, manufacturing suppliers, collaborators, use of contract research organizations and employees;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel and our ability to attract and retain such personnel;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the approval and use of our product candidates in combination with other drugs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing therapies that are or may become available;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development of our product candidates, including additional indications we may pursue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the United States, Europe and other jurisdictions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ONA-XR, CLDN6 bsAb, and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of ONA-XR, CLDN6 bsAb and other product candidates we may develop, if approved;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of ONA-XR, CLDN6 bsAb and other product candidates we may develop;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current plans to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources and the availability of such future sources of capital;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of laws and regulations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing cash and cash equivalents; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221;.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading &#8220;Risk Factors&#8221; and elsewhere in this Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-K also contains certain data and information which we obtained from various government and private publications. Although we believe that the publications and reports are reliable, we have not independently verified the data. Statistical data in these publications includes projections that are based on a number of assumptions. If any one or more of the assumptions underlying the market data is later found to be incorrect, actual results may differ from the projections based on these assumptions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements made in this Form 10-K relate only to events or information as of the date on which the statements are made in this Form 10-K. Although we are a public company and have ongoing disclosure obligations under United States federal securities laws, we do not intend to update or otherwise revise the forward-looking statements in this Form 10-K, whether as a result of new information, future events or otherwise.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1452"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors summarized below could materially harm our business, operating results and/or financial condition, impair our future prospects and/or cause the price of our common stock to decline. For more information, see &#8220;Item 1A. Risk Factors&#8221; in this Annual Report on Form 10-K for the year ended December&#160;31, 2021. Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Business and Industry</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We have never been profitable and may never achieve or maintain profitability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We may expend our limited resources pursuing particular research programs or product candidates that may be less successful or profitable than other programs or product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Our business may be adversely affected by the ongoing coronavirus pandemic.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to our Product Candidates</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Our business is dependent on the successful development, regulatory approval and commercialization of our therapeutic product candidates, ONA-XR and CLDN6xCD3 bsAb, which are in the early stages of development.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">The success of our business depends primarily upon our ability to identify, develop and commercialize products using our proprietary technologies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Organization, Structure and Operations</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Our reliance on a central team consisting of a limited number of employees and consultants who provide various administrative, research and development, and other services across our organization presents operational challenges that may adversely affect our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Our future success depends on our ability to retain our executive officers, and other key executives and to attract, retain and motivate qualified personnel.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Reliance on Third Parties</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We expect to depend on collaborations with third parties for certain research, development and commercialization activities, and to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical testing, as well as for the manufacturing process of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any such collaborations or services by such third parties are not successful or not performed in a satisfactory manner, it may harm our business and prospects, and we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">If we are unable to obtain sufficient quantities of raw materials and supplies, at acceptable prices and on a timely basis, it could harm our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Government Regulation</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We expect that CLDN6xCD3 bsAb will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Intellectual Property</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our business position.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Our ability to compete effectively in our markets may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantages.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of product candidates, prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to the Market for Our Common Stock</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Our common stock may be volatile or may decline regardless of our operating performance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to advance or complete the development and commercialization of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We may issue additional debt and equity securities, which are senior to our common stock as to distributions and in liquidation, which could materially adversely affect the market price of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">We may fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures. If we fail to remediate any material weaknesses, we may not be able to report our financial results accurately or to prevent fraud, which could materially adversely affect the market price of our common stock.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1457"></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET, INDUSTRY AND OTHER DATA</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains estimates, projections, market research and other information concerning our industry, our business, markets for our product candidates, the size of those markets, and the prevalence of certain medical conditions. Unless otherwise expressly stated, we obtain this information from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources as well as from our own internal estimates and research and from publications, research, surveys and studies conducted by third parties on our behalf. Information that is based on estimates, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are reflected in this information. As a result, you are cautioned not to give undue weight to such information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_995"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profound advancements in oncology drug development have expanded the treatment options available to women with cancer, yet therapeutic resistance and relapse continue to limit the efficacy and duration of such treatments. Collectively, our founders and management team have decades of experience identifying and characterizing the mechanisms that drive cancer initiation and subsequent relapse in women with cancer and who have been associated with the development of products such as Kisqali (ribociclib), Arimidex (anastrozole), and Afinitor (everolimus) to treat such cancers. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers. Our first program and lead product candidate, onapristone extended release (&#8220;ONA-XR&#8221;), builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependent cancers. ONA-XR is a selective and potentially potent antagonist of the progesterone receptor (PR), a receptor that is activated by the hormone progesterone and that has been linked to resistance to multiple classes of cancer therapeutics, including anti-estrogen therapies, that are prescribed to treat female hormone-dependent cancers. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to evaluate ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b/2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021, MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4/6 and/or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate a sub-study of its Phase 2 trial in 2L/3L metastatic breast cancer that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors. Our second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple cancers, including ovarian and endometrial tumors, and absent from healthy adult tissues. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022. Beyond these two product candidates, we continue to evaluate opportunities to expand our pipeline. We believe our team and capabilities uniquely position us to be a leader in developing novel therapies to address female cancers. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Context retains worldwide development and commercialization rights for ONA-XR outside of Greater China and retains full worldwide development and commercialization rights to certain CLDN6 antibody patents in the field of bispecific antibodies. Our product candidates are shown in the table below:</span></div><div style="margin-bottom:9pt"><img src="cntx-20211231_g1.jpg" alt="cntx-20211231_g1.jpg" style="height:351px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline and Development </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PR antagonist program: ONA-XR </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there are no approved therapies that selectively target progesterone receptor positive (PR+) cancers. Preclinical and clinical data suggest that onapristone extended release (ONA-XR) has anticancer activity by inhibiting PR binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. ONA-XR is currently being evaluated in three Phase 2 trials, and one Phase 1b/2 trial in women with primary or metastatic breast, ovarian, and endometrial cancers. These trials are intended to establish safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity at the recommended Phase 2 dose of ONA-XR to guide potential advancement in Phase 3 development in 2023. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help inform which patients may be most suitable for treatment with ONA-XR, we are evaluating multiple biomarker assays, including tools to monitor activated progesterone receptor as well as a PR gene activation signature that measures PR signaling activity, both of which are being utilized in our ongoing clinical trials and may be used for patient selection in future clinical trials. We expect to report preliminary data from two of our ongoing trials in mid-2022 and from the other two trials in the second half of 2022. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLDN6xCD3 bispecific antibody program </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in ovarian and endometrial tumors and absent from healthy adult tissues. The structural complexity of CLDN6 and its similarity to proteins expressed on healthy tissue, particularly Claudin 9 (CLDN9), have limited its exploitation for targeted oncology therapies. Several pharmaceutical companies are developing anti-CLDN6 antibodies and/or bispecific antibodies. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other preclinical programs </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product candidates, we are leveraging our knowledge in female cancers to pursue discovery stage research programs. We continue to evaluate new opportunities to expand our pipeline in female cancers.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Management Team </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a management team to develop novel products to treat female cancers. Members of our management team have experience leading organizations that have advanced multiple oncology therapeutics from early-stage research to clinical trials, and ultimately to regulatory approval and commercialization. Our team&#8217;s select accomplishments include: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Executive Officer co-founded Context in 2015 and was previously a venture capitalist at Osage University Partners, where he led multiple oncology investments for the firm that resulted in successful public offerings or acquisitions. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Financial Officer previously served as Chief Financial Officer of Millendo Therapeutics, a publicly-traded biopharmaceutical company.  Prior to Millendo, our CFO served as Director of Technical Accounting at PAREXEL International and began her career as an auditor at Ernst &amp; Young.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Legal Officer previously severed as Vice President, Deputy General Counsel and Assistant Corporate Secretary of OptiNose, a publicly-traded specialty pharmaceutical company. Prior to OptiNose, he served as Associate General Counsel of Teva Pharmaceuticals, a global pharmaceuticals company. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chief Medical Officer previously held the same position at H3 Biomedicine, where he led the early phase development for an oral selective estrogen receptor covalent antagonist (SERCA). During his career, he has either led or supported global drug development programs for several novel oncology drugs, including Kisqali (ribociclib), Arimidex (anastrozole), and Afinitor (everolimus), resulting in successful global registrations. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our management team has been involved in several multimillion-dollar strategic transactions, including as part of the leadership teams at Celgene, and Novartis. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supported by our advisors who are leading experts in female cancers. Our arrangements with these individuals do not entitle us to any of their existing or future intellectual property derived from their independent research or research with other third parties beyond what has previously been licensed to us. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to develop and commercialize innovative and differentiated oncology products that address significant unmet medical needs in the field of female cancer, with a primary focus on the hormone-dependent subcategory. The key components of our strategy to achieve this goal include: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Leveraging the insights, experience, and networks of our management team and advisors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management team and advisors have extensive experience identifying, developing, and commercializing innovative cancer therapeutics aimed at novel targets, including Kisqali, Arimidex, and Afinitor. We are using this broad oncology experience together with our internal search and development capabilities to build a diverse pipeline of therapies targeting multiple cancer resistance mechanisms. For example, our first program and lead product candidate, ONA-XR, while acquired from Arno Therapeutics, builds on academic work originally conducted by the laboratory of our scientific advisor, Dr.&#160;Carol Lange. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Focusing on product candidates that can be first or second in market based on current competition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that being first or second in market provides a unique advantage that later competitors may not be able to overcome. Based on the current competitors that are developing similar product candidates, we believe that we have the opportunity to be the first anti-progestin approved for PR+&#160;cancer and one of the early market participants with our CLDN6xCD3 bsAb. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Completing clinical development and obtaining regulatory approval for ONA-XR for the treatment of breast, ovarian, and endometrial cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The PR signaling pathway has been implicated in resistance to anti-estrogen therapies in female hormone-dependent cancers, including breast, ovarian, and endometrial cancer. Our clinical development effort for ONA-XR, a selective and potentially potent small molecule antagonist of PR, will initially focus on indications where there is evidence suggesting PR-mediated signaling contributes to resistance and disease progression. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to evaluate ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b/2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021, MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4/6 and/or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate a sub-study of its Phase 2 trial in 2L/3L metastatic breast cancer that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Advancing our second program, CLDN6xCD3 bsAb, as rapidly as reasonably possible through preclinical and clinical development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our second program, CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a membrane protein target expressed in multiple female cancers, including ovarian and endometrial, and absent from healthy adult tissues. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Evaluating opportunities to accelerate development timelines and enhance the commercial potential of our programs in collaboration with third parties, including through the potential out-licensing of our product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established collaborations and intend to continue evaluating opportunities to work with partners that meaningfully enhance our capabilities with respect to the development and commercialization of our product candidates, which may entail the potential out-licensing of the development and commercialization of our product candidates to larger pharmaceutical organizations, including our lead product candidate ONA-XR. For example, we entered into a manufacturing and development agreement with Tyligand Bioscience (Shanghai) Limited for ONA-XR that is intended to enhance our ability to meet drug manufacturing demands and expand our clinical trial footprint into Greater China. It is also possible that similar arrangements for ONA-XR could be sought for other geographic footprints. In addition, we intend to commercialize our product candidates in key markets either alone or with partners in order to maximize the worldwide commercial potential of our programs. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">In-licensing or acquiring additional drug candidates to build a fully integrated company focused on female cancers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that accessing external innovation and expertise is important to our success and plan to leverage our leadership team&#8217;s prior business development experience as we evaluate potential in-licensing and acquisition opportunities to further expand our portfolio. For example, CLDN6xCD3 bsAb was licensed from Integral Molecular, Inc. (&#8220;Integral&#8221;), a company where our management and advisors </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have long-standing relationships. We aim to be the partner of choice for academic groups and companies in the field of female cancers. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our focus on female hormone-dependent cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 70% of women with breast, ovarian, and endometrial cancer have hormone-dependent cancer. The hormones estrogen and progesterone drive cancer progression in those patients, but anti-estrogens are the only antihormonal therapy that is FDA approved and available to clinicians. Therefore, treatment of those patients to date has consisted of anti-estrogens alone or in combination with drugs that enhance the antitumor activity of anti-estrogens, including inhibitors of CDK4/6 or PI3K&#945;. Given the broad use of anti-estrogens, anti-estrogen resistance is now a major clinical challenge. Treatment options for anti-estrogen resistance are limited, provide modest therapeutic benefit, and are associated with side effects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estrogen and progesterone are master regulators of normal female sex organ development and function, acting via estrogen receptors (&#8220;ER&#8221;) and progesterone receptors (&#8220;PR&#8221;). Mechanistically, published data suggest that in hormone-dependent cancers, ER and PR are often hyperactive, constantly pushing breast, ovary, and endometrial tissues to grow, divide, and metastasize. One such strategy to block this hormone-mediated growth is to administer anti-estrogen therapy (fulvestrant, letrozole, anastrozole, or tamoxifen), which may be used in combination with inhibitors of CDK4/6 or PI3K&#945; to enhance anti-estrogen mediated effects. However, the cancer cells respond to this selective pressure of ER inhibition by further activating progesterone signaling as a compensatory mechanism, along with other resistance mechanisms that can further activate PR, including ER ligand binding mutations (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), growth factor signaling, and enrichment of cancer stem cells. Over time, it is believed that all patients become resistant to anti-estrogens due to direct or indirect compensatory signaling mediated by the PR and other factors. These findings suggest that progesterone receptor and proteins that regulate PR could represent promising drug targets to address anti-estrogen resistance. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of antiestrogen resistance mechanisms </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g2.jpg" alt="cntx-20211231_g2.jpg" style="height:274px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building a portfolio of novel agents targeting multiple anti-estrogen resistance mechanisms by leveraging our specialized expertise in hormone-dependent cancers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PR antagonist program: ONA-XR </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Published data suggest that the PR signaling pathway is implicated in resistance to anti-estrogen therapies in female hormone-dependent cancer, including breast, ovarian, and endometrial cancer. Our clinical development effort for ONA-XR, a selective and potentially potent small molecule antagonist of PR, will initially focus on indications where there is evidence suggesting PR-mediated signaling contributes to resistance and disease progression. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">evaluate ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b/2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021, MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4/6 and/or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate a sub-study of its Phase 2 trial in 2L/3L metastatic breast cancer that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Progesterone receptor background </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progesterone receptor (PR) is a member of the nuclear hormone receptor family of ligand-dependent transcription factors that is expressed primarily in female reproductive tissues. In response to the endogenous steroid hormone, progesterone, PR regulates the expression of gene networks to control development, differentiation, and proliferation of target tissues and the pathological processes in endocrine-based cancers. Anti-progestins are a class of nuclear receptor ligands that act to antagonize PR by binding to the progesterone binding site within the PR-ligand binding domain. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, the role of progesterone in carcinogenesis has gained further clarity. Mechanistically, published data suggest that progesterone promotes oncogenic progression and maintenance of stem cells, creating a reservoir of pre-malignant cells to seed metastasis. Initial evidence for this tumorigenic role is derived from longitudinal studies of the use of hormone replacement therapy in menopausal women. As shown in the figure below, these studies determined that supplemental estrogen was associated with a 23% decrease in cancer risk, whereas supplemental progesterone was associated with a 25% increase in cancer risk. The results demonstrated that women who were consistently exposed to progesterone had a higher risk of developing breast cancer than those who did not. This finding was confirmed by published data wherein mice treated with progesterone exhibited enhanced breast tumor growth whereas progesterone receptor inhibition via genetic knockdown conversely inhibited tumor growth. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Association of progesterone and breast cancer risk </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g3.jpg" alt="cntx-20211231_g3.jpg" style="height:316px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source: Reprinted from the Journal of the American Medical Association Oncology, Chlebowski et al, Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women&#8217;s Health Initiative Randomized Clinical Trials, Copyright 2015. Reprinted with permission from American Medical Association. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: CEE: synthetic estrogen; E: estrogen; HRT: hormone replacement therapy; MPA: synthetic progesterone; P: progesterone. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the figure above, PR can be activated by ligand (progesterone) or ligand-independent (growth factor-mediated) mechanisms. Consistent with other steroid hormone receptor family members, PR is heavily post-translationally modified and thus acts as a molecular sensor for abnormally elevated or active signaling pathways. Little overlap exists between PR transcriptomes assayed in normal relative to neoplastic cells. In cancer cells, post-translational modifications (namely, phosphorylation and SUMOylation) via members of the growth factor signaling cascade create unique PR species whose altered behavior as ligand-dependent transcription factors is predicted to impact tumor initiation and progression. Due to the breadth of post-translational modifications of PR, there is limited selective mutational pressure to modify PR itself - thus, PR mutations are rare. However, when present, the PR mutations have a profound impact on PR activity and tumorigenesis. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Illustrative mechanism of action </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g2.jpg" alt="cntx-20211231_g2.jpg" style="height:274px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: ER: estrogen receptor; ESR1Y537S: estrogen receptor mutation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The progesterone receptor as a mechanism of resistance </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, progesterone receptor has emerged as anti-estrogen resistance mechanism. Long term exposure of cancer cells to anti-estrogens results in a complex resistance profile that limits the utility of standard of care anti-estrogen and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Mechanisms of resistance include mutations in the estrogen receptor (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) estrogen binding domain and ER pathway signaling (e.g., MAPK, PI3K&#945;/mTOR proteins and associated signaling pathways). The prevalence of resistance mutations is associated with PR enrichment and activity. Based on our preclinical data and recent published data, we believe therapeutic inhibition of PR with either ONA-XR alone or in combination with anti-estrogens and/or CDK4/6 inhibitors may result in the impaired growth or death of resistant cells. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of other PR antagonists </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-progestins, the therapeutic inhibitors of PR, were first developed as oral contraceptives to block the maturation of the endometrium and subsequent ovulation. The first commercially available anti-progestin, Korlym (mifepristone), is a steroid derivative that acts both as a competitive progesterone receptor (PR) antagonist and as a partial PR agonist, depending on the physiological milieu. Mifepristone is approved for controlling hyperglycemia secondary to hypercortisolism in adult Cushing&#8217;s syndrome associated with Type 2 diabetes. Mifepristone was also clinically evaluated in breast and ovarian carcinomas, and while showing evidence of efficacy in clinical studies, mifepristone was also associated with off-target glucocorticoid receptor (GR) modulation leading to cortisolemia and rare cases of cholestasis. In order to optimize PR antagonism while minimizing off-target activities, additional anti-progestins&#8212;including ulipristal, telapristone, lonaprisan and onapristone&#8212;were developed and evaluated in gynecological cancer. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unique Properties of Onapristone &#8211; Stereochemical Basis </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g4.jpg" alt="cntx-20211231_g4.jpg" style="height:210px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: AR: androgen receptor; C-13: carbon 13; n.a.: not applicable;1L mBCa: first-line metastatic breast cancer. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ONA-XR differentiation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onapristone is a competitive PR antagonist that has no intrinsic activity for activating the receptor. As such, onapristone is also termed a &#8220;full&#8221; PR antagonist (inhibitor). Based on published data, all other anti-progestins that have reached the clinic demonstrate partial PR agonism. This differentiation may have a structural basis. It is well established that high energy, conformationally complex chemicals have improved selectivity and target affinity relative to low energy, flat counterparts. As shown above, all other anti-progestins have a roughly planar ring, low energy, A thru D conformation. In contrast, onapristone shows an inversion of stereochemistry at the C-13 methyl group that results in a high energy, chair conformation. This structural property is unique among clinically evaluated anti-progestins and may be important for onapristone&#8217;s full PR antagonist properties, as shown below. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Onapristone PR binding properties vs. other anti-progestins and progesterone </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g5.jpg" alt="cntx-20211231_g5.jpg" style="height:228px;margin-bottom:5pt;vertical-align:text-bottom;width:326px"/></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source: Reprinted from Steroids, Elger et al, Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity, Copyright 2000. Reprinted with permission from Elsevier. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: RU 486: mifepristone; J 867: asoprisnil; Ona: onapristone. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> models have provided limited benefit in determining PR agonist versus antagonist properties. As the cost of gene expression profiling has decreased considerably over the last decade, it is now feasible to run comparative studies to determine how compounds are affecting the expression, positively or negatively, of target genes. Afhuppe </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2009)&#160;conducted the first such study comparing anti-progestins in a gene array panel. T47D breast cancer cells (ER+, PR+) were grown in 2D, stimulated with estrogen (estradiol), and treated with anti-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progestins. An Affymetrix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene chip analysis of the cells was then conducted to determine transcriptional activity on the level of target genes. Onapristone demonstrated the purest PR antagonist activity as indicated downregulation (green blocks) of almost all PR target genes analyzed, whereas mifepristone had a transcriptional profile closer to R5020, which is pure progesterone. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modulation of PR signaling genes by different anti-progestins </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g6.jpg" alt="cntx-20211231_g6.jpg" style="height:190px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source: Reprinted from The Journal of Steroid Biochemistry and Molecular Biology, Afh&#252;ppe et al, Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system, Copyright 2009. Reprinted with permission from Elsevier. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-progestin clinical trial data </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In subjects with breast cancer, clinical trials with mifepristone, lonapristone and onapristone demonstrated partial responses. Onapristone clinical efficacy in breast cancer was studied in two Phase 1-2 clinical studies treating hormone therapy-na&#239;ve and tamoxifen-resistant metastatic breast cancer, while the safety component of a third Phase 1-2 study has been reported by Cottu </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2018). The earlier onapristone trials in breast cancer dosed orally with a simple solid dosage form (an &#8220;immediate release&#8221; or &#8220;IR&#8221; form; onapristone IR; ONA-IR), ONA-IR 100mg once per day (QD), for periods exceeding 12 months. The third breast cancer study used the extended release form, ONA-XR, dosed at 50mg twice per day (BID). Robertson </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1999)&#160;reported a 67% clinical benefit rate (CBR), defined as tumor shrinkage or tumor growth stabilization lasting for more than 6&#160;months, while Jonat </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2002)&#160;reported a 49% CBR. Both studies, therefore, indicated that onapristone could have a clinically meaningful impact on treatment of hormone-dependent breast cancer. Clinical development of ONA-IR for use in reproductive medicine and benign gynecological conditions was discontinued by the original sponsor (Schering AG), possibly due to concerns around drug-induced liver injury. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extensive use of anti-estrogens, together with efficacy limits with earlier anti-progestins, has led to renewed interest in anti-progestins as therapies for breast and gynecologic cancer, as well as for uterine fibroids and endometriosis. Compared to earlier anti-progestin clinical trials, we believe we have a better tolerated formulation of onapristone (ONA-XR) and we will be able to better identify those patients who are most likely to benefit from anti-progestin therapy through the incorporation of biomarkers in our trials. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current opportunities for ONA-XR </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the G7 (EU5, Japan, US) countries, it is estimated that there are over 362,000 patients living with metastatic breast, ovarian, or endometrial cancer. Up to 70% of these patients are expected to be progesterone receptor positive and would potentially be eligible for treatment with ONA-XR. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prevalence in G7 countries for metastatic breast, ovarian, and endometrial cancers </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g7.jpg" alt="cntx-20211231_g7.jpg" style="height:304px;margin-bottom:5pt;vertical-align:text-bottom;width:569px"/></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source: secondary epidemiologic estimates, 2020 estimates. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: EU5: France, Germany, Italy, Spain, United Kingdom. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Resistance to anti-estrogen therapy in breast cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have chosen PR antagonism in breast cancer as our initial therapeutic focus due to the well-documented biology of PR signaling as a mechanism of resistance to anti-estrogen therapy in patients with hormone-dependent breast cancer. Hormone-dependent breast cancer cells express estrogen (ER) and/or progesterone receptors (PR) that allow the cells to grow in the presence of the hormones estrogen and/or progesterone. Published data suggests that PR signaling is predominantly required for breast cancer cell renewal (i.e., stemness) and metastatic spread, whereas ER is predominantly required for breast cancer cell proliferation. By combining anti-progestin and anti-estrogen therapy, we have shown preclinically that breast cancer cell growth, renewal, and spread can be mitigated. Based on these data, we believe that ONA-XR, in combination with current standard-of-care anti-estrogens, has the potential to significantly improve clinical outcomes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breast cancer overview </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breast cancer is the most frequent cancer among women, impacting 2.1&#160;million women globally each year, and causing the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer worldwide &#8212; that is approximately 15% of all cancer deaths among women according to the World Health Organization. According to the American Cancer Society, the prevalence of women in the United States living with adjuvant, first line metastatic, or second/third line metastatic breast cancer are an estimated 250,000, 75,000, and 35,000 respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breast cancer treatment is primarily determined by the presence or absence of three proteins: estrogen receptor (ER), progesterone receptor (PR), and HER2. The presentation of these proteins determines the subtype of breast cancer, which helps determine the optimal form of treatment for the patient. Patients who are ER+,PR+,HER2- are considered to be hormone receptor positive (i.e., hormone-dependent) and represent about 70% of breast cancers. HER2+ patients and triple negative patients (ER-,PR-,HER2-) represent the remaining 30% of breast cancers. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estrogen-deprivation (anti-estrogen) therapy is the core treatment modality in patients with hormone receptor positive metastatic breast cancer according to NCCN Guidelines&#174;. Anti-estrogen therapy options for postmenopausal women with ER+ advanced breast cancer include: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective ER modulators (SERM): tamoxifen </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ER antagonists: fulvestrant </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective nonsteroidal aromatase inhibitors: anastrozole and letrozole </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Steroidal aromatase inhibitors: exemestane </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are rapidly transforming the care of patients with ER+, HER2- advanced breast cancer. There are currently three CDK4/6 inhibitors that have been approved by the U.S. Food and Drug Administration: Ibrance, Kisqali, and Verzenio. It is generally recommended to use the combination of a CDK4/6 inhibitor along with an aromatase inhibitor (i.e., letrozole) for first line locally advanced or metastatic breast cancer treatment. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Illustrative breast cancer treatment landscape </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g8.jpg" alt="cntx-20211231_g8.jpg" style="height:235px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"/></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: ORR: overall response rate; PFS: progression free survival. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon first line disease progression, second line therapy is most often fulvestrant (anti-estrogen) or fulvestrant plus alpelisib (Piqray), a PI3K&#945; inhibitor, if the patients have PIK3CA-mutated hormone receptor-positive breast cancer. Fulvestrant plus Piqray was FDA approved in 2019 based on a Phase III trial of 572 patients that demonstrated a progression free survival (PFS) of 11.0 months vs. 5.7 months in the Piqray plus fulvestrant arm compared with fulvestrant alone (HR, 0.65, 95% CI 0.50&#8211;0.85). However, a total of 25% of patients discontinued Piqray plus fulvestrant therapy due to toxicities, thus, emphasizing the need for novel agents. Upon progression on second line therapy, mammalian target of rapamycin (mTOR) inhibitors, including everolimus (Afinitor), plus anti-estrogen based regimen or chemotherapy is administered. One key limitation of both the Afinitor and Piqray studies is the lack of data for the role of these agents after prior CDK4/6 inhibitor therapy. Most patients progress on these treatments and ultimately develop resistance. At that time, patients typically live for less than two years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical data </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The female ovarian hormones estrogen and progesterone are master regulators of normal breast development and play a key role in breast cancer. Acting through ER and PR, estrogen and progesterone play complex, essential, and coordinated roles in the development of the lobular alveolar epithelial structures of the normal breast during puberty, the normal menstrual cycle, and pregnancy. It is likely that these actions become subverted in the development of breast cancer, implicating both estrogen and progesterone in the development and progression of this disease. Breast cancer is acknowledged to be a hormone-dependent disease and most breasts express ER and/or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PR. PR is expressed in humans as two major forms, progesterone receptor A (PR-A) and progesterone receptor B (PR-B), in normal cells and in certain malignant tissues. PR-A and PR-B mediate the effects of progesterone by association with a range of co-regulatory proteins and progesterone-regulated gene promoters. Over the past few decades, the estrogen receptor signaling pathway remains the most effective treatment for the management of ER+ breast cancer. Treatments include the selective estrogen receptor modulator (SERM) tamoxifen that binds to ER and prevents its activation, and aromatase inhibitors that block endogenous hormone synthesis. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent published data suggests that progesterone receptor may function as an anti-estrogen resistance mechanism. Long term exposure of cancer cells to anti-estrogens results in a complex resistance profile that limits the utility of standard of care anti-estrogen and CDK4/6 inhibitors. Mechanisms of resistance include mutations in estrogen receptor gene (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and ER pathway signaling (MAPK, PI3K&#945;, mTOR), as 20-35% of ER+,PR+,HER2-metastatic breast tumors are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutated. The prevalence of resistance mutations is correlated with PR enrichment and activity. We have presented data showing that therapeutic inhibition of PR with either onapristone alone or in combination with anti-estrogens and/or CDK4/6 inhibitors results in the impaired growth or death of resistant cells. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown below, estrogen receptor (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) mutational profiles of tumor biopsies were taken before and after prolonged treatment with anti-estrogen (fulvestrant) and CDK4/6 inhibitor (palbociclib) therapy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">Y537S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutations are enriched by the end of therapy and are associated with worse outcomes in patients. To determine the effect of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutations, wild type (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and mutant (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">Y537S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">Y537N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) estrogen receptors were overexpressed in the T47D breast cancer cell line. The orange box denotes that both the PR-A and PR-B isoforms of progesterone receptor demonstrated increased expression upon exposure to the mutant form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increased expression of PR was found to be correlated with enhanced PR activity. To establish that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">Y537S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cells require PR for growth and dual ER-PR inhibition (i.e., complete hormone blockade) results in growth inhibition, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> organoid model was conducted using the rapidly proliferating, CDK4/6 inhibitor resistant WHIM20 cell line. Organoid data demonstrates that dual blockade of ER and PR via treatment with fulvestrant and onapristone results in growth inhibition in a cell model that is intended to mimic human disease. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Role of PR in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESR1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> mutations </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g9.jpg" alt="cntx-20211231_g9.jpg" style="height:191px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source: Reprinted from Cancer Cell, Razavi et al, The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers, Copyright 2018. Reprinted with permission from British Journal of Cancer, Lopez-Knowles et al, Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations, Copyright 2018. Reprinted with permission from Nature Springer. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Addition of Onapristone to Standard of Care Enhances Tumor Regression </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hypothesis is that complete hormone blockade via downregulation of estrogen receptor (ER) and progesterone receptor (PR) signaling pathways, and their compensatory pathways, including CDK4/6, will lead to enhanced therapeutic outcomes in patients. To test this hypothesis, we utilized a patient-derived xenograft (PDX) model to evaluate the efficacy of the antiprogestin onapristone in combination with fulvestrant (antiestrogen) and palbociclib (CDK4/6 inhibitor) in PDX mouse models established from ER and PR positive bone metastasis of breast cancer. Two PDX models were tested, one with low level (data not shown) and one with high level of PR expression (data shown below). In the PDX model with high expression of PR, treatment by onapristone combined with palbociclib and fulvestrant resulted in enhanced tumor regressions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All treatment arms were well tolerated. Blood and tumor samples were taken at the end of the study from both experiments. Different biological analyses will be performed to analyze ER/PR signaling by protein and RNAseq analyses. </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g10.jpg" alt="cntx-20211231_g10.jpg" style="height:166px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"/></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results from the experiment with the PR High Expression PDX are shown above. Treatment by onapristone alone resulted in a tumor growth inhibition (TGI) of 42%, while the combination onapristone (10 mg/kg) + palbociclib (75 mg/kg) resulted in a TGI of 67% and the triple combo onapristone + palbociclib + fulvestrant (5 mg/mouse) in a TGI of 92% with 6/7 xenografts showing tumor regression. The statistical analysis was performed with GraphPad software. Plasma and tumor samples were taken at the end of the study from 5 xenografts/group for further analysis. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Resistance to hormone-dependent gynecologic cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gynecologic cancer overview </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ovarian and endometrial cancer represent the majority of gynecologic cancers. It is estimated that there are more than 22,000 new cases of ovarian cancer and 61,000 new cases of endometrial cancer annually, resulting in 14,000 ovarian and 12,000 endometrial deaths in the United States (US) every year. As of 2019, it is estimated that there are 235,000 patients living with ovarian cancer and over 770,000 patients living with endometrial cancer in the US. By applying PR positivity (PR+) rates to the 2019 prevalence count, it is estimated that there are 300,000 patients with recurrent gynecologic cancer in the US, 130,000 of whom are PR+. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximal surgical debulking and platinum chemotherapy are the cornerstone treatments for primary gynecologic cancer. The aim of surgery is to confirm diagnosis, define extent of disease spread (staging), and resect all visible tumor tissue. The goal of cytoreductive surgery is removal of the entire tumor burden to achieve either complete removal of the tumor upon visual inspection (complete cytoreductive surgery) or a residual tumor of &lt;&#160;1 cm (optimal cytoreductive surgery). Even centers experienced in ovarian tumor cytoreductive surgery achieve optimal resection in only 50% of patients. Patients with incomplete/suboptimal cytoreductive surgery are at a significantly higher risk of recurrence and poor prognosis. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following primary treatment for gynecologic cancer, the relapse rate is approximately 20-25% for early-stage disease and 70% for advanced (spread beyond primary site) disease. The survival curve after recurrence never plateaus, which means that the goal of treatment for recurrent gynecologic cancer is controlling the disease and disease-related symptoms, limiting treatment-related toxicity, and maintaining or improving quality of life. Primary or secondary resistance is the main cause for diminished effectiveness over time of platinum-based chemotherapy, contributing to the dismal outcome of advanced patients whose 5-year survival rate is less than 30%. Patients who are hormone receptor positive will often receive anti-estrogen therapy in the recurrent setting; however, anti-estrogen efficacy is modest in this setting. In general, treatment of recurrent disease is palliative and is initiated with the goals of controlling disease-related symptoms, limiting treatment-related toxicity, maintaining or improving quality of life, delaying time to progression, and prolonging survival. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Illustrative hormone-dependent gynecologic treatment landscape </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g11.jpg" alt="cntx-20211231_g11.jpg" style="height:339px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reasons Why Such a Therapy is Needed </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cytoreductive surgery followed by combination platinum and taxane chemotherapy is the first-line treatment for most gynecologic cancer patients regardless of type. Outside of DNA repair deficient high grade serous ovarian cancer, there are limited treatment options for all other forms of ovarian and endometrial cancer. Given the above-mentioned 5-year survival rate of less than 30%, there is a critical need to identify a targeted treatment in the recurrent setting. Ovarian and endometrial cancer remains a serious, life threatening, unmet medical need, resulting in more than 26,000 estimated deaths in the US every year. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical data </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PR in Endometrial Cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progesterone receptor (PR)-targeted therapies are modestly active in patients with endometrial cancer, which may be attributed to an evolving understanding of the underlying molecular mechanisms of PR-targeted therapies for this disease. In the normal endometrium, estrogen drives proliferation of the endometrial glandular epithelium, whereas progesterone counteracts the effects of estrogen. Progesterone acts by binding to the PR and has a dual role through both genomic and nongenomic pathways. Anti-progestins such as onapristone have recently been shown to be efficacious in mouse models of uterine cancer, suggesting that PR blockade may be an effective approach for treating uterine cancer. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Role of PR in endometrial cancer </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g12.jpg" alt="cntx-20211231_g12.jpg" style="height:187px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source: Reprinted from Molecular Cancer Therapeutics, Huang et al, Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer, Copyright 2017. Reprinted with permission from Elsevier. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: In vivo&#160;effect of onapristone, trametinib, and the combination of both drugs on tumor weight, number of tumor nodules, and body weight. Error bars indicate the SEM; *,&#160;P&#160;&lt; 0.05. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It has been reported that mitogen-activated protein kinases (MAPK) play a dual role in PR subcellular trafficking and aid in the rapid nuclear association of PR via Serine 294 (S294) phosphorylation in response to growth factors and in response to ligand (i.e., progesterone). In Huang </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2017, PR+ endometrial cancer cells were implanted in mice and upon tumor engraftment were treated with onapristone and/or trametinib, a MEK inhibitor. If progesterone receptor does coordinate endometrial cancer response through MAPK via MEK signaling, then the MEK inhibitor, trametinib, should be anticipated to enhance onapristone sensitivity through blocking the nuclear translocation of phosphorylated PR. The study demonstrates that PR+ endometrial xenografts are sensitive to both onapristone and trametinib alone, and exhibit synergy when combined, indicating a rationale to develop onapristone alone or in combination with a MEK inhibitor for PR+ endometrial cancer. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PR in Ovarian cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progesterone and progesterone receptors (PR) are increasingly gaining attention for their emerging role as critical regulators of breast, ovarian, and endometrial cancer. Progesterone is a steroid hormone that is produced primarily by the corpus luteum in the ovaries during the second half of the menstrual cycle or luteal phase. Cyclical hormone exposure beginning at menarche and ending in menopause occurs monthly and regulates the growth and differentiation of specialized tissues within the reproductive tract and breast tissues. Until recently, little was known about the relative distribution of PR within the subtypes of ovarian tumors. In a cohort of 504 ovarian tumors, Diep </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013)&#160;reported that 35% of the tumors were progesterone receptor-positive (PR+) and that PR expression is associated with better outcomes, indicating a potential role for hormone therapy in PR+ ovarian cancer. Importantly, several subtypes were found to be highly enriched for PR. Retrospective studies evaluating the association of total PR expression and progression-free disease survival support the concept that subsets of PR+ ovarian tumors are highly sensitive to hormones and thus more likely to respond to endocrine therapy. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development of extended release formulation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Precedent Formulation &#8211; Onapristone IR (ONA-IR) </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onapristone was originally developed in an immediate release or &#8220;IR&#8221; form (onapristone IR; ONA-IR). ONA-IR was first evaluated as an oral contraceptive and was dosed up to 400 mg/day for periods of 7 days during single ovulatory cycles in healthy female subjects. Later, ONA-IR 100 mg/day was administered for periods exceeding 12 months in breast cancer studies. Discontinuation of ONA-IR development by the original sponsor, Schering AG, is thought to have been due to the observation of liver test abnormalities and the perceived risk of drug-induced liver injury (DILI) during a Phase 2 study of ONA-IR as first line therapy in breast cancer subjects. Liver test elevations were considered a concern for the planned contraception and benign gynecological indications (e.g., uterine fibroids, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">endometriosis). However, renewed interest in anti-progestin therapy for PR-positive malignancies has led to the consideration of new strategies for reducing potential hepatotoxic effects of onapristone. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing new strategies for anti-progestin use, one consideration is that mifepristone, ulipristal, telapristone, and onapristone all contain a 17-carbon steroid ring structure that is typical of steroids. Anti-progestins with steroidal cores often display significant cross-reactivity with closely related steroid receptors, namely, androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). This functional overlap is partly responsible for the side effects linked with the steroidal drugs, which themselves carry a potential DILI risk. Because onapristone binds to GRs less efficiently than to PRs, one strategy to minimize liver test elevations was to seek a new onapristone formulation that yielded steady state pharmacokinetic (PK) parameters where: (a)&#160;C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is lower than the C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> associated with ONA-IR 100mg QD (to target a reduced risk for LFT elevations); and (b)&#160;C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">min</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is at least approximately equal to the C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">min</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> associated ONA-IR 100mg QD (to target at least equivalent, sustained suppression of PR activity). Various formulation strategies were evaluated and a 50mg, BID (twice-daily), extended release tablet (onapristone XR; ONA-XR) was selected to be the second-generation dosage form for the clinical evaluation of onapristone in PR-positive cancers. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacokinetic Comparison of ONA-XR versus ONA-IR </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g13.jpg" alt="cntx-20211231_g13.jpg" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source: Reprinted from Drug Safety, Lewis et al, Onapristone Extended Release: Safety Evaluation from Phase I&#8211;II Studies with an Emphasis on Hepatotoxicity, Copyright 2020. Reprinted with permission from Nature Springer. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novel Formulation &#8211; Onapristone XR </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacokinetic (PK) parameters for ONA-IR 100mg QD and ONA-XR 50mg BID were previously evaluated within a dose escalation component of a Phase 1-2 clinical study in female subjects with endometrial carcinoma, breast cancer or ovarian cancer. This study (Cottu </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2018) reported that ONA-XR showed &#8220;Clinical benefit with excellent tolerance&#8221;, while defining a recommended phase 2 dose level of ONA-XR of 50mg, BID. The PK dataset from this clinical study enabled a direct comparison between C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">min</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for ONA-IR 100mg QD and ONA-XR 50mg BID. Steady-state pharmacokinetics of ONA were estimated using standard noncompartmental methods and the nonparametric superposition tool in Phoenix WinNonlin version 8.3 (Certara Inc., Princeton, NJ). These methods assume linear pharmacokinetics from the first dose to steady state. Dosing with ONA-XR 50mg BID resulted in a steady-state C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> almost 3 times lower than the C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for ONA-IR 100mg QD, while the steady-state C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">min</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for both formulations were similar: 829 ng/mL versus 790 ng/mL for ONA-IR versus ONA-XR, respectively. The findings of the Phase 1-2 PK and safety evaluation support that the recently developed, extended release form of onapristone appears to have achieved the PK goals of the formulation exercise. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed clinical trials </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial IR formulation (ONA-IR), developed by Schering AG at various strengths, was dosed up to 400 mg/day in healthy volunteers and 100 mg/day for periods exceeding six months in oncology studies. Arno Therapeutics (Cranbury, NJ) subsequently developed onapristone extended release (&#8220;ONA-XR&#8221;) formulation and administered it in doses of 10, 20, 30, 40 and 50 mg ONA-XR BID for up to 52 weeks. We acquired ONA-XR from Arno Therapeutics. There are no associated future payments due to Arno. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of clinical trials evaluating on a pristone with IR or XR formulation </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Antiprogestin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stage </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patients</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(n) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Indication</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prior</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treatments</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Median</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Range) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biomarker </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Data</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reference </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone IR </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100mg QD)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breast&#160;Cancer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Locally Advanced or Metastatic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hormone<br/>na&#239;ve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56% ORR <br/>17.5-month DoR 67% CBR <br/>14.0 month PFS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Robertson 1999</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone IR </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100mg QD)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breast Cancer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metastatic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 (1-2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10% ORR </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48% CBR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0 month PFS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jonat 2002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone XR </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50mg BID)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granulosa Cell Tumor of Ovary Metastatic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 (2-17)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PR+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*57% DCR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*21% 6-month PFS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ongoing</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone IR </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10&#8212;50mg BID) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#177;Abiraterone</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase&#160;1b/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Castrate Resistant Prostate Cancer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active progression on Abiraterone</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 (1-4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PR+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ONA-XR&#160;(10-50 mg)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 month PFS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ONA-XR (50 mg) + Abiraterone</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4 month PFS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jayaram&#160;2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone XR </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10&#8212;50mg BID)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breast Cancer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metastatic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 (2-14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PR+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25% DCR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15% 6-month PFS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cottu 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Onapristone XR </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10&#8212;50mg BID)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ovarian Cancer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metastatic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 (2-10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PR+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8% ORR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31% 6-month PFS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cottu 2018</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: BID: twice per day; DoR: duration of response; ORR: overall response rate; PFS: progression free survival. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onapristone IR Clinical Data </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across first and second line metastatic breast cancer, onapristone IR (ONA-IR) demonstrated clinical activity comparable to anti-estrogen standard of care. We believe that by selecting for PR+ status and combining ONA-XR, an improved form of ONA-IR, with anti-estrogen therapy to promote complete hormone blockade, we will potentially generate superior efficacy data compared to the current standard of care treatment options. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Line Locally Advanced or Metastatic Breast Cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2 study investigating onapristone (ONA-IR, 100 mg/day as a single daily dose) as first-line endocrine therapy in patients with breast cancer was conducted as an investigator-initiated study, as shown below. Nineteen patients, either with locally advanced breast cancer (n = 12) or who were elderly with primary breast cancer and considered unfit for standard of care (n = 7) received ONA-IR. In 17 of the 19 patients, tumors expressed ER while 12 of 18 tumors tested expressed PR. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among 18 patients who were evaluable for response, 10 had a partial response and 2 had stable disease (&#8220;SD&#8221;) for six months or more. The median duration of objective response and SD was 70 weeks. Ten patients were ER-positive/PR-positive, of whom 7 achieved partial response (PR; tumor shrinkage of &gt;30%) and 1 had SD. Overall, the clinical benefit rate was considered comparable to the current standard of care of letrozole (anti-estrogen) and palbociclib (CDK4/6 inhibitor). </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of ONA-IR to standard of care in 1L locally advanced or metastatic breast cancer </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treatment &#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subtype &#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patients<br/>(n)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CBR<br/>(%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ORR<br/>(%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grade 3,4 AE<br/>(%) &#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reference &#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONA-IR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PR+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#94;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GT (&lt;5%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robertson (1999)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAL + LET</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+,HER2-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutropenia (55%), Leukopenia&#160;(25%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PALOMA-1 (2014)</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: CBR: clinical benefit rate; LET: letrozole; ONA: onapristone, ORR: overall response rate; PAL: palbociclib. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Line Metastatic Breast Cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-randomized, open label, multicenter Phase 2 study was conducted at 13 sites in Germany and the United Kingdom, as shown below. The study goal was to investigate the efficacy and safety of ONA-IR when given 100 mg/day to post-menopausal women with advanced breast cancer who had progressed on tamoxifen, a selective estrogen receptor modulator therapy. The study was also designed to assess the influence of onapristone on the levels of relevant endocrine parameters (cortisol, androstenedione, estrone and estradiol). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 101 evaluable patients, 1 had a complete response (&#8220;CR&#8221;), 9 had a partial response, and 39 had SD for three months or more. The median duration of response was 11 months. Median time to progression was 4 months. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In second line metastatic breast cancer, ONA-IR exhibited monotherapy activity in patients who had progressed while on tamoxifen. In this trial, patients were not screened for progesterone receptor positive (PR+) status, meaning that only 60% of enrolled patients would have expected to be PR+ based upon historical prevalence in this setting and therefore derive clinical benefit from ONA-IR. Therefore, this trial potentially under-represents the likely true clinical benefit of ONA-IR had patients been stratified for the partial response biomarker. Despite administering a monotherapy without patient selection for PR+, ONA-IR demonstrated comparable clinical activity to standard of care anti-estrogens (FUL), CDK4/6 inhibitors (PAL), and the combination of the two (FUL + PAL). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of ONA-IR to standard of care in 2L metastatic breast cancer </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treatment &#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subtype &#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patients<br/>(n)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CBR<br/>(%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ORR<br/>(%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grade 3,4 AE (%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reference</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Comers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None reported</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonat (1996)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+,HER2-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutropenia&#160;(55%), Leukopenia&#160;(25%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TREnd (2017)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FUL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+,HER2-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fatigue (&lt;5%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PALOMA-3 (2015)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAL + FUL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+,HER2-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutropenia&#160;(65%), Leukopenia&#160;(25%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PALOMA-3 (2015)</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: CBR: clinical benefit rate; FUL: fulvestrant; LET: letrozole; ONA: onapristone, ORR: overall response rate; PAL: palbociclib. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onapristone XR Clinical Data </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Overall, over 140 subjects received at least a single dose of ONA-XR across both healthy volunteer and cancer trials through December&#160;31, 2021. Multiple drug product formulations of onapristone have been developed for evaluation throughout the clinical development program. Clinical development was initiated with a 10 mg immediate release (IR) capsule. An IR tablet formulation (10mg, 25 mg) and extended release (XR) tablet formulation (2.5 mg, 5 mg, 10 mg, and 20 mg) were also developed. The tablets have been administered as a single tablet or in multiples in order to obtain the desired dosage. The XR tablet has been used in ongoing safety and efficacy studies. ONA-XR 50 mg BID (twice-per-day) is the recommended dose for our ongoing investigational trials.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed clinical studies incorporating new formulation </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Study Protocol</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Status)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Study Design</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dosage<br/>and Regimen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Endpoints</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AR18-CT-001</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single dose PK study of oral immediate release (IR) formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 Healthy female volunteers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;mg single dose, fasting&#160;and&#160;2&#160;weeks later with food or vice-versa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PK profile, food effect, safety</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AR18-CT-101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-center, open- label, randomized, two-stage study with a phase 2 expansion component in patients PR+ breast, ovarian, or endometrioid adenocarcinoma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 post- menopausal females, recurrent or metastatic PR+ cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 mg XR BID 20 mg XR BID 30 mg XR BID 40 mg XR BID 50 mg XR BID 100 mg IR QD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety, RP2D, Efficacy, PK, Bioavailability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AR18-CT-102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Open-label, randomized, two-stage phase 1 study and a phase 2 expansion in combination with abiraterone in males with castration-resistant prostate cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 males with adenocarcinoma of prostate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 mg XR BID 20 mg XR BID 30 mg XR BID 40 mg XR BID 50 mg XR BID</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety, RP2D PK</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONAWA </span><div></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-center, open-label, randomized, two-stage window of opportunity trial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 females, primary PR+ cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 mg XR BID</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety, Efficacy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single Patient INDs (Closed)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single patient IND in patients with PR+ ovarian or endometrioid adenocarcinoma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 females, recurrent or metastatic PR+ cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 mg XR BID</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety, Efficacy</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: BID: twice per day; IR: immediate release; PK: pharmacokinetic; PR: progesterone receptor; QD: once per day; XR: extended release. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of December 31, 2021 thirty-two subjects (22%) of the total onapristone safety set (n = 144) experienced any treatment emergent adverse event (TEAE). Adverse events were generally consistent across all defined groups. Thirteen subjects experienced Grade 3 or Grade 4 TEAEs that were deemed related to ONA-XR with no correlation across dosing groups. The most common drug-related TEAEs included fatigue, abdominal pain, and an increase in gamma-glutamyltransferase. These events are generally consistent with disease progression and/or prior anti-progestin experience, including onapristone. In addition, there were no clinically significant post-dose changes in electrocardiograms (ECGs), vital signs, or safety laboratory results. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Primary Breast Cancer</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a multicenter, open label, window of opportunity trial, Bellet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2021) enrolled 10 adult patients with ER+, PR+, HER2- breast cancer and Ki-67 &#8805; 15%. Patients received ONA-XR tablets of 50 mg BID for a short course of endocrine therapy before surgery. Assessment of the treatment effects was possible for the 10 patients who successfully completed the protocol and the 10 paired samples (100%) were analyzed. Main patient characteristics were mean age 68, mean tumor size 20.2&#8197;mm, stage I (40%) and grade 2 (100%).  No patients achieved a CCCR (cell-cycle complete response). Tumor Ki-67 expression decreased, was stable and increased in 6, 1 and 3 patients, respectively. Mean percentage suppression of Ki-67 was 19.58%. Overall, no statistically significant change was observed in Ki-67 between paired samples (p=0.234). Baseline IHC PgR (%) expression correlated with Ki-67 decrease (r = -0.60). Mean percentage suppression of Ki-67 for tumors with IHC PgR expression &#8805;90% (N=4) and &lt;90% (N=6) was -62.0% and +8.7%, respectively. Six (60%) patients reported adverse events at any grade. Most </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common grade 1 or 2 adverse events were post procedural pain, dry mouth and GGT (gamma-glutamyl transferase) increased. Grade 3 reversible GGT and AST (aspartate aminotransferase) increase occurred in one patient.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced, Recurrent Metastatic Breast Cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a multicenter, open label, Phase 1 trial, Cottu </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2018)&#160;enrolled 52 adult patients with PR+ tumors, including 20 patients with breast cancer. Patients were randomized to five cohorts of ONA-XR tablets of 10, 20, 30, 40 or 50 mg BID, or immediate release 100 mg QD until progressive disease or intolerability. All patients were heavily pre-treated; prior treatments included median (range): chemotherapy 4 (1&#8211;11), endocrine therapy 1 (1&#8211;7), biologic/small molecule therapy 1 (1&#8211;2), and radiotherapy 1 (1&#8211;3). Among the 20 heavily pre-treated breast cancer patients, no CR or partial response were observed, 7 patients had SD, including 3 patients with SD lasting for at least 24 weeks (15% clinical benefit rate). The number of prior therapies was 3, 7 and 7, respectively, for these 3 patients and 2 of these 3 patients had liver metastases at baseline. The study authors concluded that the new XR formulation of onapristone was well tolerated and resulted in meaningful clinical benefit in heavily pretreated patients with breast cancer. The only treatment-related serious adverse events were G3 LFT elevations (n = 4; 8%), all associated with disease progression in the liver as reviewed. These occurred across dose cohorts: 10 mg BID (AST increased, bilirubin increased), 20 mg BID (LFTs abnormal), and 40 mg BID (bilirubin increased). No relationship was found between adverse events and study drug exposure. No treatment-related deaths were reported. One patient died within 30 days of last dose (respiratory distress syndrome due to progressive lung metastases). No other significant adverse events attributable to the mechanism of action were recorded. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced, Recurrent Metastatic Gynecologic Cancers </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase I dose escalation study of ONA-XR in breast, endometrial, and ovarian cancer patients found all doses tested to be safe and well tolerated, with 50mg BID administered orally recommended as the Phase 2 dose. The most common treatment-related adverse events reported by investigators (&gt;10%) were nausea, fatigue and constipation. In that Phase I study, 33% of ovarian and 25% of endometrial cancer patients were seen to have sustained disease control. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Focusing on the ovarian cancer (n=13) subpopulation, all PR+ ovarian patients were heavily pre-treated; prior treatments included median (range): chemotherapy 4 (2&#8211;6), and treatment lines in metastatic setting 4 (2-10). All patients were platinum resistant. Clinical data is shown below. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1 ovarian cancer data </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g14.jpg" alt="cntx-20211231_g14.jpg" style="height:261px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced, Recurrent Granulosa Cell Tumor of the Ovary </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granulosa cell tumors (GCT) of the ovary is a rare form of ovarian cancer. These tumors account for 2-5% of all ovarian malignancies and it is estimated that there are approximately 5,000 patients with recurrent disease in the US and EU. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Almost all GCT tumors are progesterone receptor (PR) positive, whereas about 50% are estrogen receptor (ER) positive. These tumors often produce estrogen and progesterone, which can cause symptoms such as abnormal vaginal bleeding or breast tenderness. Further, PR expression is correlated with worse outcomes in GCT patients. GCT tumors have a low mitotic ratio and few actionable mutations, which limits the applicability of chemotherapeutic and precision medicine approaches. Platinum-based chemotherapy is recommended as the first line of treatment for patients in the metastatic setting. Following progression to metastatic disease, patients typically cycle through chemotherapy, antihormonal treatments, and cytoreductive surgeries. There are currently no FDA treatments for GCT tumors of the ovary, and few, if any, open clinical trials. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that GCT tumors are hormone driven, it is plausible that complete hormone blockade via antiprogestin and antiestrogen therapy may provide a therapeutic benefit to patients. In 2019, Memorial Sloan Kettering Cancer Center initiated an Investigator-sponsored Trial to evaluate onapristone extended release (ONA-XR) in women with GCT of the ovary who had progressed on multiple prior therapies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 data evaluating ONA-XR in late line GCT of the ovary </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fourteen patients with progesterone receptor positive (PR+) GCT of the ovary were enrolled in the stage I trial, with thirteen of those patients completing at least one full cycle of treatment. </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g15.jpg" alt="cntx-20211231_g15.jpg" style="height:246px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"/></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four of the 14 patients (29%) had clinical benefit lasting at least 24 weeks, and 5 additional patients (64%) experienced stable disease as best response. Importantly, two patients (14%) remain on treatment after 12 months. To date, no significant treatment-related adverse events have been identified. The most common treatment-related adverse events reported were nausea, fatigue, and constipation. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the Phase 2 monotherapy data presented above, a combination arm seeking to enroll 25 patients was activated to evaluate the combination of ONA-XR with Arimidex (anastrozole), a selective nonsteroidal aromatase inhibitor. Aromatase inhibitors are commonly used to treat recurrent granulosa cell tumors based on low response rates to chemotherapy and historically high rates of ER/PR expression within these tumors. However, objective response rate for anastrozole remains low and was found to be 2.5% in a recent clinical trial (Banerjee, JCO, 2018). We seek to test the combination of ONA-XR and anastrozole to enhance the response rate in patients with PR+ GCT tumors of the ovary. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have FDA Fast Track designation for PR+ ovarian cancer </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we received FDA Fast Track designation for ONA-XR in PR+ ovarian cancer. Fast Track designation is designed to facilitate the development and expedite the review of therapies for serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the product candidate and the specific indication for which it is being studied. If any of our product candidates receive Fast Track designation but do not continue to meet the criteria for Fast Track designation, or if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical development plan for&#160;ONA-XR </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PR signaling pathway has been implicated in female hormone-dependent cancers, including breast, ovarian, and endometrial cancer. Our clinical development effort for ONA-XR, a selective and potentially potent small molecule antagonist of PR, will initially focus on indications where there is evidence suggesting PR-mediated signaling contributes to resistance and disease progression. In 2020, we initiated a Phase 2 investigator-sponsored trial in collaboration with Jefferson Health to evaluate ONA-XR in combination with Arimidex (anastrozole) in PR+ endometrial cancer and preliminary data is expected in mid-2022. Also, in 2020 we initiated a Phase 0 trial of ONA-XR in a window of opportunity study in primary breast cancer, and we reported preliminary data at the San Antonio Breast Cancer Symposium in December 2021. In 2021, a Phase 1b/2 investigator-sponsored trial was initiated in collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate ONA-XR in combination with Ibrance (palbociclib) and Femara (leterozole) in first line (1L) metastatic breast cancer patients with biochemically recurrent disease, defined as circulating tumor DNA (ctDNA) positive. This is potentially a new clinical opportunity for the estimated 20% of 1L patients who are at high risk of early disease progression on Ibrance plus Femara combination therapy and Phase 1b data is expected in mid-2022. In 2021, the first stage of a Phase 2 investigator-sponsored trial initiated by MSK to evaluate ONA-XR in recurrent granulosa cell tumors (GCT) of the ovary was completed. In July 2021, MSK initiated the second stage of this trial evaluating ONA-XR in combination with Arimidex, and preliminary data is expected in the second half of 2022. Also in 2021, a Phase 2 investigator-sponsored trial was initiated in collaboration with Wisconsin Oncology Network (WON) to evaluate ONA-XR in combination with Faslodex (fulvestrant) in second line (2L) or third line (3L) metastatic breast cancer. This trial is intended to evaluate potential ONA-XR plus Faslodex drug synergy after treatment failure of CDK4/6 and/or PIK3&#945; inhibitors, and preliminary data is expected in the second half of 2022. In 2022, WON intends to initiate a sub-study of its Phase 2 trial in 2L/3L metastatic breast cancer that will evaluate the uptake of radiolabeled progesterone (F-FFNP) via PET imaging in breast tumors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLDN6xCD3 bispecific antibody program: CLDN6xCD3 bsAb </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background CLDN6 </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claudin 6 (CLDN6) is an oncofetal tight junction protein involved in the cell-to-cell adhesion of epithelial and endothelial cell sheets. Although silenced in healthy adult human tissues, CLDN6 expression has been found in ovarian, gastric, pediatric, and other cancer tissues and can lead to a poor prognosis. Monoclonal antibody (MAb) discovery against CLDN6 has been encumbered by the high homology of endogenously expressed claudin&#160;9 (CLDN9), which varies from CLDN6 by only 3 amino acids in the extracellular domain.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proposed mechanism of action </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g16.jpg" alt="cntx-20211231_g16.jpg" style="height:214px;margin-bottom:5pt;vertical-align:text-bottom;width:258px"/></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rationale for bispecific antibody </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cytotoxic T cells are considered to be the most potent effector cells of the immune system. As a consequence, broad T cell activation can lead to significant and sometimes lethal side effects. Therefore, to harness the potential of cytotoxic T cells, therapeutic strategies seek to pair T cell activation with drug targets that are restricted to cancer tissue so as to avoid unwanted toxicity. CLDN6 expression is restricted to various cancer types (i.e., a tumor specific antigen or TSA), making it an ideal target to help T cells recognize and eliminate cancer cells. Recently, a class of bispecific antibodies (TSAxCD3) with a native immunoglobulin format has emerged that can efficiently trigger T cell&#8211;mediated killing of tumor cells by linking a T cell to a tumor cell and activating the CD3/t cell receptor complex, as shown above. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLDN6 expression in cancer versus normal tissue </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g17.jpg" alt="cntx-20211231_g17.jpg" style="height:276px;margin-bottom:5pt;vertical-align:text-bottom;width:434px"/></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Source: Cancer RNAseq data from The Cancer Genome Atlas (TCGA); normal tissue RNAseq data from the Genotype-Tissue Expression (GTEx) project. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical data </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLDN6xCD3 bsAb, is an anti-CD3 x anti-Claudin 6 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. As shown below, preclinical studies demonstrate that CLDN6xCD3 bsAb exhibits selectivity for CLDN6 over CLDN9 and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that CLDN6xCD3 bsAb mediates strong T-cell activation and specific lysis of cells expressing CLDN6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies with a prototype bispecific of CLDN6xCD3 bsAb demonstrated dose-dependent tumor regressions in an established ovarian cancer xenograft model with an intact immune system. We expect to select a candidate to support IND-enabling studies for CLDN6xCD3 bsAb in the second half of 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLDN6 x CD3 bispecific retains selectivity of parental mAb </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g18.jpg" alt="cntx-20211231_g18.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:617px"/></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure above illustrates the results of a binding assay showing that Context&#8217;s Claudin 6 monoclonal and bispecific antibodies bind to Claudin 6 preferentially over other Claudin proteins. Human embryonic kidney 293T (HEK-293T) cells were transiently transfected with DNA for the indicated Claudin protein along with GFP (pUC) for 22 hours. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context bispecifics activate T cells against CLDN6+ cells </span></div><div style="margin-bottom:9pt;text-align:center"><img src="cntx-20211231_g19.jpg" alt="cntx-20211231_g19.jpg" style="height:171px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"/></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure above illustrates the results of immune assays showing that Context&#8217;s CLDN6 x CD3 bispecific antibodies activate T cells and drive T-cell dependent cytotoxicity. All bispecific formats contain the same CD3 cassette. Activity was measured after 72 hours of treatment. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of CLDN6 development programs </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have performed head-to-head </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies comparing internally developed CLDN6 monoclonal antibodies and those from BioNTech and Xencor. Antibodies for BioNTech and comparative data for Xencor were derived from publicly available reports published independent of the Company and may differ in material ways from the actual antibody that is in development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results presented in the below table have been derived from publicly available reports of preclinical studies and clinical trials run independently of our trials or meta-analyses of such clinical results. We have not performed any head-to-head trials comparing any of these other therapies with CLDN6xCD3 bsAb. As such, the results of these other clinical trials may not be comparable to clinical results for CLDN6xCD3 bsAb. The design of these other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials vary in material ways from the design of the clinical trials for CLDN6xCD3 bsAb. For further information and to understand these material differences, you should read the relevant reports or meta-analyses. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the BioNTech and Xencor&#8217;s product candidates are not intended to compete with our CLDN6xCD3 bsAb, it is useful to compare the symptomatic results achieved by their devices and approaches a good proxy to understand the adoption of these therapies. </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Context &#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xencor &#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BioNTech &#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLDN6xCD3 bsAb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLDN6xCD3 bsAb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BNT211 BNT142</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Antibody Format</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bispecific <br/>CLDN6xCD3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bispecific <br/>CLDN6xCD3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLDN6 <br/>CAR-T, and <br/>CLDN6xCD3 (bi(sFc))</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1, Phase 1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selectivity CLDN6:9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100x</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10x</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7x</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other preclinical programs </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product candidates, we are leveraging our knowledge in hormone-dependent cancer to pursue discovery stage research programs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the Company entered into a patent license agreement, as amended, (the &#8220;Drexel License Agreement&#8221;) with Drexel University (&#8220;Drexel&#8221;) for license rights to patents for certain intellectual property and know-how related to certain Sigma1 technology.  As part of a strategic review of our pipeline, we have recently notified Drexel that we are terminating the Drexel License Agreement, effective as of April 27, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our collaboration and license agreements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into a manufacturing and development agreement with Tyligand Bioscience (Shanghai) Limited for ONA-XR (the &#8220;Tyligand Process Development Agreement&#8221;) that is intended to enhance our ability to meet manufacturing demands for commercial launch and expand our clinical trial footprint into Greater China. Under the terms of the agreement, Tyligand is responsible for ONA-XR manufacturing process optimization. As a part of the agreement, Tyligand is eligible to receive development milestone payments of $0.8 million and a certain number of warrants exercisable for common stock upon successful completion of the manufacturing development plan, $2.0 million upon the completion of scale-up of the first cumulative 100 kilograms of the GMP-grade compound and $3.0 million upon our completion of scale-up of the first cumulative 300 kilograms of the GMP-grade compound. We will also pay Tyligand a 1% royalty of net sales of finished product commercialized in any country (other than the People&#8217;s Republic of China, including Hong Kong and Macau) utilizing the compound substantially manufactured in accordance with the process and specifications outlined in this agreement. This agreement terminated in August of 2021, subject to certain surviving and ongoing obligations. Please note that the foregoing is a summary of the agreement and is therefore qualified in its entirety by reference to the agreement attached hereto as Exhibit 10.2 and which is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August of 2021, Tyligand achieved &#8220;successful completion&#8221; under the Tyligand Process Development Agreement as a result of Tyligand&#8217;s successful optimization of the ONA-XR manufacturing process. Because of this achievement, Tyligand has entered into a license agreement with us (the &#8220;Tyligand License Agreement&#8221;) whereby we have granted Tyligand an exclusive license to develop and commercialize ONA-XR in the People&#8217;s Republic of China, including Hong Kong and Macau (the &#8220;Tyligand Territory&#8221;), subject to Tyligand paying Context a mid-single digit royalty of net sales of ONA-XR in such countries. The royalty term of such exclusive license shall be the from period beginning on the date of the first commercial sale of ONA-XR in the Tyligand Territory and ending on the latest of (i) the sale of a generic product containing the same active pharmaceutical ingredients as ONA-XR in the Tyligand Territory, and (ii) fifteen (15) years after the date of the first commercial sale of ONA-XR in the Tyligand Territory. We have retained our global exclusive rights for ONA-XR for the remainder of the world. As a result of the completion of this milestone, Tyligand  was granted a warrant to purchase 111,576 shares of our common stock at an exercise price of $7.17 per share (which was automatically exercised and cancelled in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with our initial public offering), we paid Tyligand $800,000, and Tyligand will be eligible to receive manufacturing and development milestone payments totaling up to $5.0 million upon the achievement of certain future milestones. The Tyligand License Agreement provides for termination in the event of (a) insolvency, (b) a material breach of the agreement, and (c) in the event that Tyligand does not meet certain regulatory milestones. Please note that the foregoing is a summary of the agreement and is therefore qualified in its entirety by reference to the agreement attached hereto as Exhibit 10.5 and which is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a license agreement with Integral for the exclusive worldwide rights (the &#8220;Integral License Agreement&#8221;) to certain Claudin 6 antibody patents in the field of bispecific antibodies. Under the terms of the license and development agreement, we are responsible for all costs associated with CLDN6xCD3 bsAb development as well as certain success-based payments, including milestone and royalty payments, to Integral. We paid an upfront license fee of $0.3 million and granted 418,559 shares of Series A Stock with a fair market value of approximately $2.8 million. As a part of the agreement, Integral will be eligible to receive development and regulatory milestone payments totaling up to $55.3 million, sales milestone payments totaling up to $130 million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement. We shall continue to pay royalties on a country-by-country and licensed-by-licensed product basis, until the later of: (i) the expiration of the patent covering such product in such territory, (ii) the expiration of any regulatory exclusivity granted with respect to a product in such territory and (iii) ten years from the first commercial sale of such product in such country. The agreement shall continue in full force and effect, until either (a) royalty payments for all products in all territories have expired or (b)(i) we provide written notice of termination, (ii) during three successive quarters we do not use commercially reasonable efforts to develop a product, (iii) if the agreement is breached or (iv) if a party goes bankrupt. Please note that the foregoing is a summary of the agreement and is therefore qualified in its entirety by reference to the agreement attached hereto as Exhibit 10.1 and which is incorporated herein by reference.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain worldwide development and commercialization rights for ONA-XR outside of Greater China and retain full worldwide development and commercialization rights to certain CLDN6 antibody patents in the field of bispecific antibodies. We periodically evaluate out-license opportunities for our product candidates, including our lead product candidate ONA-XR, and seek to identify drug candidates for novel indications and/or patient subpopulations with an oncology focus that we might in-license. Our commercial plans and strategy for each particular program may change as programs advance, markets change, and we receive more clinical data, and will depend on availability of current and future capital. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and marketing </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing, or commercial product distribution capabilities, and we may explore partnerships with larger pharmaceutical organizations to out-license our product candidates, including our lead product candidate ONA-XR. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates obtain marketing approval. We also rely, and expect to continue to rely, on third parties to package, label, store and distribute our investigational product candidates, as well as for our commercial products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have obtained active pharmaceutical ingredients (API) and drug product for our product candidates from several third party contract manufacturers. We are in the process of developing our supply chain for each of our product candidates and intend to put in place additional framework agreements under which third-party contract </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers will generally provide us with necessary quantities of API and drug product on a&#160;project-by-project&#160;basis based on our development needs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance our product candidates through development, we will consider our lack of redundant supply for the API and drug product for each of our product candidates to protect against any potential supply disruptions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expect to rely on third parties for the manufacture of any companion diagnostics we may develop. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our executive and scientific team, research, clinical capabilities, development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and convenience. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For ONA-XR, our small molecule PR antagonist, we are aware of several companies developing PR antagonists, including Allergan, Evestra, and Gedeon Richter. To our knowledge, there are no PR antagonists approved for the treatment of cancer and the most advanced such PR antagonist is in a Phase 2 clinical trial. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For CLDN6xCD3 bsAb, our CLDN6xCD3 bispecific antibody, we are aware of several companies developing antibodies against this target, including Abbvie, Amgen, Astellas, AstraZeneca, BioNTech, Chugai, I-Mab, NovaRock, and Xencor. These companies are developing CDLN6 products in naked antibody, bispecific, CAR-T, and mRNA vaccine formats. To our knowledge, BioNTech has the only CLDN6 product in clinical trials.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual property </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including seeking, maintaining and defending our patent rights. We own the issued patent and patent applications relating to our first program and lead product candidate ONA-XR, and retain full worldwide development and commercialization rights to certain CLDN6 antibody patents in the field of bispecific antibodies. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in jurisdictions outside of the United States directed to our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and&#160;know-how&#160;relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position in the field of oncology. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our product candidates, technology, inventions and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we may own or license in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 14, 2022, our patent portfolio consisted of pending or issued patents that we own or license related to our ONA-XR product candidate and various other compounds and programs. Specifically, we owned four issued U.S. patents, three pending U.S. patent applications, one granted Canadian patent, two granted Chinese patents, one granted Japanese patent, three granted Australian patents, one granted Hong Kong patent, and 18 pending foreign patent applications, two of which are Australian applications, three of which are Canadian applications, two of which are Chinese applications, three of which are European regional patent applications, two of which are Hong Kong applications, one of which is a Mexican application, two of which are Japanese applications, two of which are Korean applications, and one international PCT application. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More specifically with respect to ONA-XR,&#160;our issued U.S. patents in our owned portfolio described above have claims directed to our ONA-XR as pharmaceutical compositions, formulations, and related methods of use, and methods of making. These U.S. patents are expected to expire between 2034 and 2036, subject to any extensions or disclaimers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our product candidates and processes we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a&#160;product-by-product&#160;basis, from&#160;country-to-country&#160;and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of oncology has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our product candidates, technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even our issued patents may not guarantee us the right to commercialize our product candidates, if approved. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing our product candidates and practicing our proprietary product candidates, and our issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar products. Furthermore, our competitors may independently develop similar products that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Pathway </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that ONA-XR will be classified and regulated by the FDA as a drug. We expect that our CLDN6xCD3 bsAb will be classified and regulated by the FDA as a biologic. A new drug application (&#8220;NDA&#8221;) is required to introduce a drug into interstate commerce. A biologics license application (&#8220;BLA&#8221;) is required to introduce a biologic product into interstate commerce. The specific requirements of NDAs and BLAs include applicant information, product information, manufacturing information, pre-clinical data, clinical data, and labelling. The most important, time-consuming, and expensive aspect of preparing for a BLA or NDA is conducting clinical trials to demonstrate safety and effectiveness. The requirements of such clinical trials heavily influence the eventual allowable product label claims. The FDA has a performance goal as defined in the Prescription Drug User Fee Act of ten months for a standard submission and six months for priority review. It is not uncommon for NDAs and BLAs to require medical advisory board review prior to the FDA granting marketing approval. A facility inspection verifying the manufacturing systems is also usually performed prior to FDA approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past used and intend to continue to utilize the services of third-party experts to supplement internal regulatory planning and implementation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing FDA Regulation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA permits a product to enter commercial distribution, numerous and pervasive regulatory requirements continue to apply to our business operations, products and technologies. These include: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s quality system regulation, or QSR, which requires manufacturers, including third party manufacturers, to follow stringent design, testing, production, control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of the manufacturing process; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling and marketing regulations which require that promotion is truthful, not misleading, fairly balanced and provide adequate directions for use and that all claims are substantiated; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advertising and promotion requirements, including FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses and FDA guidance on off-label dissemination of information and responding to unsolicited requests for information; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on sale, distribution or use; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product establishment, registration and listing requirements and reporting requirements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall requirements, including a mandatory recall if there is a reasonable probability that a product would cause serious adverse health consequences or death; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an order of repair, replacement or refund; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market surveillance activities and regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad post-market and regulatory enforcement powers. Manufacturers of biologic products and drug products like our product candidates are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters, untitled letters, Form&#160;483s, fines, injunctions, consent decrees and civil penalties; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall or seizure of products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions, partial suspension or total shutdown of production; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s refusal of requests for approval of new products or indications for existing products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawing approvals that have already been granted; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Privacy and Security Laws </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information, including health information. Among others, the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, (collectively referred to as HIPAA), establish privacy and security standards that limit the use and disclosure of protected health information, or PHI, and require covered entities and business associates to implement administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form, among other requirements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of HIPAA may result in civil and criminal penalties. Companies subject to HIPAA must also comply with HIPAA&#8217;s breach notification rule which requires notification of affected patients and the U.S. Department of Health and Human Services, or HHS, and in certain cases of media outlets, in the case of a breach of unsecured PHI. The regulations also require business associates of covered entities to notify the covered entity of breaches by the business associate. State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states, and HIPAA standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business associates for compliance. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have laws that protect the privacy and security of sensitive and personal information, including health information, to which we are subject. These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, California enacted the California Consumer Privacy Act, or CCPA, which creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA went into effect on January&#160;1, 2020, and the California Attorney General may bring enforcement actions for violations as of July&#160;1, 2020. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security, laws that place specific requirements on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain types of activities, such as data security and texting, and laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Union member states, the United Kingdom, Switzerland and other jurisdictions have also adopted data protection laws and regulations, which impose significant compliance obligations. In the EEA and the United Kingdom, the collection and use of personal data, including clinical trial data, is governed by the provisions of the General Data Protection Regulation, or GDPR. The GDPR became effective on May&#160;25, 2018, repealing its predecessor directive and increasing responsibility and liability of pharmaceutical and medical device companies in relation to the processing of personal data of EU data subjects. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the individuals, the transfer of personal data out of the EEA or the United Kingdom, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for breaches of the data protection obligations. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Healthcare Reform </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our products. By way of example, the Patient Protection and Affordable Care Act, or PPACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the pharmaceutical, medical device and biologics industries, among others. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the PPACA, and we expect there will be additional challenges and amendments to the PPACA in the future. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the PPACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the PPACA are invalid as well. While the Texas District Court Judge, as well as then-president Trump&#8217;s Administration and CMS, have stated that the ruling will have no immediate effect, and on December&#160;30, 2018 the Texas District Court Judge issued an order staying the judgment pending appeal. In December 2019, a U.S. District Court upheld a ruling that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In November 2020, the Supreme Court of the United States heard oral arguments in the appeal of this case.  While the Supreme Court issued its ruling in July 2021, in part finding that the plaintiff&#8217;s lacked standing, it is unclear how this and other efforts to challenge, repeal, or replace the ACA, or how future changes in the Presidency, Congress or Senate, will impact the ACA or our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge and/or patients&#8217; willingness to pay for our products. While in general it is too early to predict what effect, if any, any future healthcare reform legislation or policies will have on our business, current and future healthcare reform legislation and policies could have a material adverse effect on our business and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing and Reimbursement </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third party payors. Third party payors include government health administrative authorities, managed care providers, private health insurers, and other organizations. These third-party payors are increasingly challenging the price and examining the cost-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products, and efforts are underway to reduce the cost of medical products and services overall. We may need to conduct expensive studies in order to demonstrate the cost-effectiveness of our products. Our product candidates may not be considered cost-effective. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product or procedure using the product does not ensure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate revenue levels. Future legislation could limit payments for our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of less costly products. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our products. The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on medical product and service pricing. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback and False Claims Laws </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the research, manufacturing, distribution, sale and promotion of pharmaceutical products and devices are subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare &amp; Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state Attorneys General, and other federal, state and local government agencies. For example, sales, marketing and scientific/educational grant programs must comply with the FFDCA, Anti-Kickback Statute, as amended, the False Claims Act, as amended, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, in the United States, we are subject to complex laws and regulations pertaining to healthcare &#8220;fraud and abuse,&#8221; including, but not limited to, the federal Anti-Kickback Statute, the federal False Claims Act, and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any person, including a biological product manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase or order of an item for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties, and exclusion from participation in federal healthcare programs. In addition, many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to the referral of patients for healthcare services reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. Due to the breadth of these federal and state anti-kickback laws and the potential for additional legal or regulatory change in this area, it is possible that our sales and marketing practices and/or our relationships with physicians might be challenged under anti-kickback laws, which could harm us. Because we plan to commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs, we plan to develop a comprehensive compliance program that establishes internal controls to facilitate adherence to the rules and program requirements to which we are subject. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including pharmaceutical products, that are false or fraudulent. Although we would not submit claims directly to payers, manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our activities relating to the reporting of wholesaler or estimated retail prices for our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been prosecuted under the federal False Claims Act in connection with their off-label promotion of drugs. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $11,665 and $23,331 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial fine and may suffer a decline in our stock price. In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims Act. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what is required to comply with the laws. In addition, a provision of the Patient Protection and Affordable Care Act, referred to as the Sunshine Act, requires pharmaceutical product manufacturers to track and report to the federal government certain payments or other transfers of value made to physicians, registered nurses and teaching hospitals, among others, in the previous calendar year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Federal Healthcare Fraud and Abuse Laws </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to other federal healthcare fraud and abuse laws, including provisions of HIPAA, which prohibit knowingly and recklessly executing a scheme or artifice to defraud any healthcare benefit program, including private payors, as well as knowingly and willfully falsifying, concealing or covering up a material fact by any trick, scheme or device or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government-sponsored programs. Similar to the federal Anti-Kickback Statute, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Corrupt Practices Act </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act, or FCPA, prohibits U.S. businesses and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records, which in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the corporation, including international subsidiaries, if any, and to devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, we had seven full-time employees, no part-time employees and three consultants. None of these employees are represented by labor unions or covered by collective bargaining agreements. We believe that our employee relations are good.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Culture is a critical element in the management of our organization. Our talented employees are focused on driving our business with the foundation for all our efforts being the development of treatments to transform care for female cancers and improving the lives of women living with cancer. Our goal is that each colleague feels a deep connection to what they do, loves coming to work, and is aligned to our mission.     </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Culture begins with our hiring process and continues throughout an employee&#8217;s time with Context. We support our colleagues with a comprehensive offering of competitive pay and benefits. During the ongoing COVID-19 pandemic began, we strive to ensure the safety of our colleagues and continue to adapt over time to the changing environment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facilities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal office is located in Philadelphia, Pennsylvania, where we lease approximately 3,500 square feet of office space pursuant to a lease that expires in July 2023. We believe our facility is adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space will be readily available on commercially reasonable terms.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we may be involved in disputes or litigation relating to claims arising out of our operations. We are not currently a party to any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in April 2021. Our corporate office is located at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103. Our telephone number is (267) 225-7416. We maintain an Internet website at www.contexttherapeutics.com. The information contained on our website is not incorporated by reference into this Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge under the &#8220;Investors &amp; News&#8221; &#8212; &#8220;Financials&#8221; &#8212; &#8220;SEC Filings&#8221; section of our website all of our filings with the SEC, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and amendments to such documents, each of which is provided on our website as soon as reasonably practicable after we electronically file or furnish, as applicable, the information with the SEC.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with general economic and business risks and all of the other information contained in this Annual Report on Form 10-K, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes, before making a decision to invest in our common stock. Our business, results of operations, financial condition or prospects could also be harmed by risks and uncertainties that are not presently known to us or that we currently believe are not material. If any of the risks actually occur, our business, results of operations, financial condition and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose all or part of your investment. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks described below. See "Note Regarding Forward-Looking Statements."</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never been profitable and may never achieve or maintain profitability. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not commercialized any products and have yet to generate any revenue from product sales. The amount of our future net losses will depend, in part, on our expenses and our ability to generate revenues. Our current and future product candidates will require substantial additional development time and resources before we may realize revenue from product sales, if at all. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our current research and development programs, including conducting laboratory, preclinical and clinical studies for product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate clinical trials for product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, assess, acquire or develop additional research programs or product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that may successfully complete development; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any products that may obtain marketing approval; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop and refine the manufacturing process for our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or add additional manufacturers or suppliers of pharmaceutical or biological materials or product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our anti-hormonal resistance therapies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other technologies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to attract and retain new and existing personnel; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our facilities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first program and lead product candidate, ONA-XR, is currently in Phase 2 clinical trials. No clinical studies have begun on our second program, CLDN6xCD3 bsAb. It will be several years, if ever, before we obtain regulatory approval for a therapeutic product candidate, at which time any revenues for such product candidate will depend upon many factors, including, market conditions, costs and effectiveness of manufacturing, sales, marketing and distribution operations related to such product candidate, and the terms of any collaboration or other strategic </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangement we may have with respect to such product candidate and levels of reimbursement from third-party payors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to develop and commercialize one or more product candidates either alone or with collaborators, including through the potential out-licensing of our product candidates, or if revenues from any product candidate that receives marketing approval or is commercialized are insufficient, we may not achieve profitability or sustain profitability, which would have an adverse effect on the value of our common stock which would be materially adversely affected. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of identifying product candidates and conducting preclinical and clinical trials is time consuming, expensive, uncertain and takes years to complete. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate clinical trials of, and seek marketing approval for, product candidates. In addition, if any therapeutic product candidate that we develop alone or with collaborators obtains marketing approval, we may incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution efforts. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise sufficient capital when needed, we may be forced to delay, reduce or eliminate current or future research programs, product development activities and/or commercialization efforts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis or on favorable terms, we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and/or commercialization efforts or we might have to obtain funds through arrangements, such as out-licensing our product candidates, with collaborative partners or others that may require us to relinquish rights to our technologies or product candidates that we otherwise would not relinquish. We may also be unable to expand our operations or otherwise capitalize on business opportunities as desired. Any of these events could materially adversely affect our financial condition and business prospects. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history. We were founded in 2015 and spent the first three years of our company&#8217;s history developing and refining our therapeutic approach, and only since then have we focused our efforts on advancing the development of product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is a highly speculative endeavor and entails substantial upfront capital expenditures. There is significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain any required regulatory approvals or become commercially viable. Our product candidates and the therapeutic approach we are using are new and unproven. We have commenced Phase 2 human clinical trials for one of our product candidates, but have not demonstrated an ability to initiate clinical trials for our other product candidates or successfully complete any clinical trials, obtain any required marketing approvals, manufacture products, conduct sales, marketing and distribution activities, or arrange for a third party to do any of the foregoing on our behalf. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing products. Our limited operating history, particularly in light of the rapidly evolving nature of the biopharmaceutical industries and the female cancer therapeutics field, may make it difficult to evaluate our technology and business prospects or to predict our future performance. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources pursuing particular research programs or product candidates that may be less successful or profitable than other programs or product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. The successful completion of a clinical trial with regard to any of our product candidates is not assured despite the expenditure of significant resources in pursuit of their development, and our spending on current and future research and development programs and product candidates may not yield any commercially viable products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected by the ongoing coronavirus pandemic. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the novel Coronavirus (&#8220;COVID-19&#8221;) has evolved into a global pandemic. The extent to which the COVID-19 pandemic impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain the virus or treat its impact, among others. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should COVID-19 continue to spread, our business operations could be delayed or interrupted. For instance, our research and development may be affected by the pandemic. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If COVID-19 continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our research activities, including clinical trials. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infections and deaths related to the pandemic have disrupted and may continue to disrupt the United States&#8217; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA review and/or approval. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a shelter-in-place order or other mandated local travel restrictions, our employees and consultants conducting research and development or manufacturing activities may not be able to access their laboratory or manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business. New or renewed restrictions may be implemented in response to evolving conditions, new variants of the virus (including the Omicron variant) and overall uncertainty about the timing of widespread availability of vaccines. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business and the value of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our governing documents designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of state law actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended &amp; restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the United States District Court for the District of Delaware) will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our amended &amp; restated certificate of incorporation or amended &amp; restated bylaws; (4) any action to interpret, apply, enforce or determine the validity of our amended &amp; restated certificate of incorporation or amended &amp; restated bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. In addition, our amended &amp; restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Notwithstanding the foregoing, the exclusive forum provision shall not apply to claims seeking to enforce any liability or duty created by the Exchange Act. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Product Candidates </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent on the successful development, regulatory approval and commercialization of our therapeutic product candidates, ONA-XR and CLDN6xCD3 bsAb, which are in the early stages of development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for sale. The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of ONA-XR and CLDN6xCD3 bsAb, as well as other product candidates derived from our anti-hormone resistant therapy approach, which may never occur. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may also become dependent on other product candidates that we may develop or acquire; however, not all of our product candidates have been tested in humans and given our early stage of development, it may be many years, if at all, before we have demonstrated the safety and efficacy of a female cancer treatment sufficient to warrant approval for commercialization. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously submitted a new drug application (&#8220;NDA&#8221;) or biologics license application (&#8220;BLA&#8221;), to the FDA or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. Further, any future product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market a product candidate, our revenue will be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical and commercial success of our current and any future product candidates will depend on a number of factors, including the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise any additional required capital on acceptable terms, or at all; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete IND-enabling studies and successfully submit an IND; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely completion of our preclinical studies and clinical trials, which may be slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support approval of our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to consistently provide for manufacturing of our product candidates on a timely basis; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices (&#8220;cGMPs&#8221;); </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk-benefit profile of our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our lead product candidates or any future product candidates or approved products, if any; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our anti-hormone resistant therapy approach; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully develop a commercial strategy and thereafter commercialize our current product candidates or any future product candidates in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others, including through the potential out-licensing of our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our product candidates that may be approved; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience of our treatment or dosing regimen; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient demand for our current or future product candidates, if approved; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and enforce intellectual property rights in and to our product candidates; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidate or any future product candidates to continue our business or achieve profitability. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our innovative therapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foundational science and product development approach are based on the selective targeting of female cancers, including by inhibiting progesterone receptor binding to chromatin, and by inhibiting CLDN6, in each case to elicit meaningful anticancer activity. We believe that this approach may offer an improved therapeutic effect by downregulating PR effector functions associated with anti-estrogen resistant and inhibit tumor growth, as well as redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. However, this approach to treating cancer is novel and the scientific research that forms the basis of our efforts to develop therapeutics that effectively target anti-hormone treatment resistance and inhibit membrane protein targets is both preliminary and limited. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, we cannot assure you that even if we are able to develop cancer therapeutic candidates capable of addressing anti-estrogen resistance or redirecting T-cell-mediated lysis toward malignant cells, that such therapy would safely and effectively treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, no regulatory authority has granted approval for a cancer therapy based on a selective targeting of PR+ or Claudin 6 positive cancers. As such, we believe the FDA has limited experience with evaluating our approach, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We may never receive approval to market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications, lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our ongoing clinical trials for ONA-XR and future clinical trials for our other product candidates are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from our clinical studies. Interim or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serious adverse events or undesirable side effects caused by ONA-XR, CLDN6xCD3 bsAb or any other product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Patients treated with ONA-XR to date, at high doses have experienced adverse events that include, but are not limited to, fatigue, liver enzyme elevations and nausea. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If unacceptable side effects arise in the development of our product candidates, we, the FDA or the institutional review boards at the institutions in which our studies are conducted, or the data safety monitoring board, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize products using our proprietary technologies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Besides our ONA-XR product candidate, all of our current product candidates and product development programs are still in the IND validation process. We may be unsuccessful in advancing those product candidates into clinical development or in identifying and developing additional product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to identify and develop product candidates is subject to the numerous risks associated with preclinical and early stage biopharmaceutical development activities, including that: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to assemble sufficient resources to acquire or discover additional product candidates, including through the potential out-licensing of our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to enter into collaborative arrangements to facilitate development of product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our product candidates obsolete or less attractive; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may be covered by third parties&#8217; patents or other exclusive rights; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory pathway for a product candidate may be too complex, expensive or otherwise difficult to navigate successfully; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may be shown to not be effective, have harmful side effects or otherwise pose risks not outweighed by such product candidate&#8217;s benefits or have other characteristics that may make the products impractical to manufacture, unlikely to receive any required marketing approval, unlikely to generate sufficient market demand or otherwise not achieve profitable commercialization. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we do commence additional clinical trials of product candidates and continue to identify new product candidates, such product candidates may never be approved. Failure to successfully identify and develop new product candidates and obtain regulatory approvals for our products would have a material adverse effect on our business and financial condition and could cause us to cease operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies or clinical trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization objectives. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, including assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from our estimates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborators or ourselves fail to achieve announced milestones in the expected timeframes, the commercialization of the product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the price of our common stock may decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability and professional indemnity exposure related to the testing in clinical trials of our product candidates. We will face an even greater liability risk if we commercially sell any products that we or our collaborators may develop for human use. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing defects, errors in product distribution or storage processes, improper administration or application and known or unknown side effects of product usage may result in liability claims against us or third parties with which we have relationships. These actions could include claims resulting from acts by our collaborators, licensees and subcontractors over which we have little or no control. For example, our liability could be sought by patients participating in clinical trials for potential therapeutic product candidates as a result of unexpected side effects, improper product administration or the deterioration of a patient&#8217;s condition, patient injury or even death. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Criminal or civil proceedings might be filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing any product candidates or products that we develop alone or with collaborators. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that product candidates or products we develop alone or with collaborators caused harm, we could incur substantial liabilities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug or biologic, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product liability insurance coverage may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage when we expand our clinical trials and if our collaborators or ourselves successfully commercialize any products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Organization, Structure and Operations </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on a central team consisting of a limited number of employees and consultants who provide various administrative, research and development, and other services across our organization presents operational challenges that may adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, we had seven full-time employees. We also have three consultants who we rely on for research and development, business development and other services. While we believe this structure enables us to reduce certain infrastructure costs, the small size of our centralized team may limit our ability to devote adequate personnel, time and resources to support the operations of our business, including our research and development activities, and the management of financial, accounting and reporting matters. If our centralized team fails to provide adequate administrative, research and development, or other services across our entire organization, our business, financial condition and results of operations could be harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our Chief Executive Officer, Chief Financial Officer, Chief Legal Officer, Chief Medical Officer, and other key executives and to attract, retain and motivate qualified personnel. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development experience, technical skills, leadership and continued service of certain members of our management and scientific teams, including Martin Lehr, our Chief Executive Officer, Jennifer Minai-Azary, our Chief Financial Officer, Alex Levit, our Chief Legal Officer, and Tarek Sahmoud, our Chief Medical Officer. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have formal employment agreements and consulting agreements with substantially all of our executive officers, these agreements do not prevent them from terminating their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and, if we retain commercialization responsibility for any product candidate we develop alone or with collaborators, sales and marketing personnel, will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms or at all given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inability to recruit, integrate, motivate and retain additional skilled and qualified personnel, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to significantly expand our organization, and our future financial performance, ability to develop and commercialize product candidates alone or with collaborators and ability to compete effectively will depend in part on our ability to effectively manage any future growth. We may have difficulty identifying, hiring and integrating new personnel. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the biopharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can identify and develop product candidates, enter into collaborative arrangements and otherwise operate our business will be limited. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources from other projects, such as the development of product candidates. If we are not able to effectively manage the expansion of our operations, it may result in weaknesses in our infrastructure, increase our expenses more than expected, give rise to operational mistakes, loss of business opportunities, loss of employees, consultants and contractors and reduced productivity. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter. If we obtain marketing approval for any product candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and clinical trials or regulatory approvals for any of our product candidates could be suspended. As a public company it may be more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors, our board committees or as our executive officers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance coverage is becoming increasingly expensive, and in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. We do not know if we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. A successful liability claim or series of claims brought against us could require us to pay substantial amounts and cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working with collaborators poses several significant risks, including the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limited availability of resource allocation and other developmental decisions made by our collaborators about the product candidates that we seek to develop with them may result in the delay or termination of research programs, studies or trials, repetition of or initiation of new studies or trials or provision of insufficient funding or resources for the completion of studies or trials or the successful marketing and distribution of any product candidates that may receive approval; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, product candidates that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization activities or that result in costly litigation or arbitration that diverts management attention and resources. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. If our collaborations, including those in which we may out-license our product candidates, do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive the expected deliverables or services from our collaborators, nor receive any future funding or milestone or royalty payments under the collaboration. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not receive the funding or expected deliverables or services from our collaborators, we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop such product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and may need to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These events could delay development programs and negatively impact the perception of our company in business and financial communities. Failure to develop or maintain relationships with any current collaborators could result in the loss of opportunity to work with that collaborator or reputational damage that could impact our relationships with other collaborators in the relatively small industry communities in which we operate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, all of the risks relating to product development, regulatory approval and commercialization described in this Form 10-K apply to the activities of our collaborators. If our existing collaboration agreements or any collaborative or strategic relationships we may establish in the future are not effective and successful, it may damage </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our reputation and business prospects, delay or prevent the development and commercialization of product candidates and inhibit or preclude our ability to realize any revenues. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied on and we expect to continue to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or otherwise perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied on and we expect to continue to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#8220;CROs&#8221;) to conduct preclinical studies and clinical trials for our product candidates. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on such third parties will not relieve us of our regulatory responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have designed and intend to design future trials for our product candidates either alone or with collaborators, third parties may conduct some parts of or all of the trials. As a result, many important aspects of our research and development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future studies and trials will also result in less direct control over the management of data developed through studies and trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes and difficulties in coordinating activities. Such third parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs or other third parties, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our collaborators, our CROs or other third parties fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We also are required to register certain ongoing clinical trials and post the results of such completed clinical trials on a government-sponsored database, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our CROs or other third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, trials for product candidates may be extended, delayed or terminated, and we or our collaborators may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. If we are required to repeat, extend the duration of or increase the size of any trials we conduct, it could significantly delay commercialization and require significantly greater expenditures. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any of these factors, our financial results and the commercial prospects for any product candidate that we or our collaborators may develop would be harmed, our costs could increase and our ability to generate revenues could be delayed. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain sufficient quantities of raw materials and supplies, at acceptable prices and on a timely basis, it could harm our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on third parties for the supply of various pharmaceutical and biological materials and the manufacture of product supplies that are necessary to produce our product candidates. The supply of these materials could be reduced or interrupted at any time. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we or our collaborators may not be able to develop, manufacture and market product candidates in a timely and competitive manner, or at all. If any of our product candidates receives approval, we will likely need to seek alternative sources of supply of raw materials or manufactured product supplies and there can be no assurance that we will be able to establish such relationships to provide such supplies on commercially reasonable terms or at acceptable quality levels, if at all. If we are unable to identify and procure additional sources of supply that fit our required needs, we could face substantial delays or incur additional costs in procuring such materials. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on third parties for the manufacturing process of product candidates, and failure by those parties to adequately perform their obligations could harm our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and expect that we will rely on outside vendors, including vendors outside the United States, for at least a portion of the manufacturing process of product candidates that we or our collaborators may develop. The facilities used by our contract manufacturers to manufacture product candidates must be approved by the FDA or other foreign regulatory agencies pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. To the extent that we or our collaborators engage third parties for manufacturing services, we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing providers for compliance with cGMP requirements for manufacture of the product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet caused any product candidates to be manufactured or processed on a commercial scale and may not be able to do so. We will make changes as we work to optimize the manufacturing process, and we cannot be sure that even minor changes in the process will result in products that are safe and effective. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market any of our or our collaborators&#8217; potential products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements, including the potential out-licensing of our product candidates, for the development and potential commercialization of current and future product candidates or the development of ancillary technologies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulted in a reduced number of potential future collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product, an assessment of the opportunities and risks of our product candidate, the design or results of studies or trials, the likelihood of approval, if necessary, by the USDA, the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and industry and market conditions generally. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, including out-licensing our lead product candidate, ONA-XR, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. Such collaborations may also impact our ability to control the nature, timing and cadence of developing and commercializing the product candidates subject to such collaborations. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics and pharmaceuticals, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of anti-estrogen resistance inhibition therapies for cancer. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often makes decisions consistent with the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory authorization to begin a trial, if applicable; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of financial resources to commence and complete the planned trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining approval at each clinical trial site by an independent institutional review board, or IRB; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruiting suitable patients to participate in a trial; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites deviating from trial protocol or dropping out of a trial; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any patient safety concerns that arise during the course of a trial; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adding new clinical trial sites; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient basis for use in clinical trials. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. The FDA&#8217;s review of our data of our ongoing clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that CLDN6xCD3 bsAb will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the Biologics Price Competition and Innovation Act, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the Biologics Price Competition and Innovation Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that CLDN6xCD3 bsAb, if approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when our ongoing Phase 2 clinical trials for ONA-XR and planned clinical trials for our other initial product candidates are completed and, assuming positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. If the results from our clinical trials are sufficiently compelling, we intend to discuss with the FDA submission of a BLA or NDA, as applicable for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA or NDA, as applicable for the relevant product candidate. For example, the FDA may require that we conduct a comparative trial against an approved therapy, which would significantly delay our development timelines and require substantially more resources. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe an accelerated approval strategy is warranted given the limited alternatives for patients that our initial product candidates target, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or NDA, as applicable, or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a risk evaluation and mitigation strategy program. Other potential consequences include, among other things: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of progesterone receptor and protein inhibitors as potential cancer treatments are recent developments and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community and we may not be able to convince them to use our product candidates for many reasons. Additional factors will influence whether our product candidates are accepted in the market, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which our product candidates are approved; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential and perceived advantages of our product candidates over alternative treatments; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA or other regulatory authorities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the labeling approved by the FDA; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of our product candidates as well as competitive products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by third-party payors and government authorities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the Centers for Medicare&#160;&amp; Medicaid Services, or the CMS, revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers, and reduce the willingness of physicians to use our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of drugs and biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA of importance to the pharmaceutical and biotechnology industries, which includes biologics, are the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturers and importers of certain biologics with annual sales of more than $5 million made to or covered by specified federal healthcare programs are required to pay an annual, nondeductible fee according to their market share of all such sales; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% of the average manufacturer price for most branded drugs, biologics,and biosimilars and to 13.0% for generic drug, and cap of the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted, or injected; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health program, commonly referred to as the &#8220;340B Program;&#8221; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians, also known as the &#8220;Physician Payments Sunshine Act;&#8221; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a licensure framework for follow-on biologic products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation enacted in 2017 informally titled the Tax Cuts and Jobs Act of 2017, repealed the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage that is commonly referred to as the &#8220;individual mandate.&#8221; In December&#160;2019, a U.S. District Court upheld a ruling that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In November 2020, the Supreme Court of the United States heard oral arguments in the appeal of this case.  While the Supreme </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court issued its ruling in July 2021, in part finding that the plaintiff&#8217;s lacked standing, it is unclear how this and other efforts to challenge, repeal, or replace the ACA, or how future changes in the Presidency, Congress or Senate, will impact the ACA or our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted which, among other things, have reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new laws or any other similar laws introduced in the future, as well as regulatory actions that may be taken by CMS, may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. Additionally, individual states in the United States have passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing and costs. Similar developments have occurred outside of the United States, including in the European Union where healthcare budgetary constraints have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain reimbursement or pricing approval in some European Union member states, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care. It is also possible that additional governmental action is taken in response to address the COVID-19 pandemic. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States, particularly as a result of the recent presidential election, or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our business position. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies and other actors in our fields of business can be highly uncertain and typically involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in some patents covering biopharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office (the USPTO) and its foreign counterparts are sometimes uncertain and could change in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or designed around. U.S. patents and patent applications may also be subject to interference or derivation proceedings, and U.S. patents may be subject to reexamination, post-grant review and/or inter parties review proceedings in the USPTO. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International patents may also be subject to opposition or comparable proceedings in the corresponding international patent office, which could result in either loss of the patent or denial of the patent application, or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, derivation, reexamination, post-grant review, inter parties review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, even if not challenged, our patents and patent applications may not adequately protect our technology and any product candidates or products that we develop alone or with collaborators or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications that we hold with respect to our product candidates or potential products is </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">threatened, it could dissuade companies from collaborating with us to develop, and could threaten our or their ability to successfully commercialize, such product candidates or potential products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use our discoveries or to develop and commercialize our technology and product candidates or products without providing any compensation to us, or may limit the scope of patent protection that we are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We rely on our outside counsel and employ an outside firm to pay these fees due to USPTO and non-US patent agencies. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Although an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market which would have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the patent applications we hold or have in-licensed with respect to our current and future research and development programs and product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our technology or any products and product candidates that we or our collaborators may develop, it could dissuade companies from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our or our collaborators&#8217; ability to commercialize future product candidates. Any such outcome could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to compete effectively in our markets may decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantages. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as trademark, trade secret and other intellectual property rights protection and contractual restrictions to protect ONA-XR, CLDN6xCD3 bsAb and other product candidates. Our commercial success depends upon obtaining and maintaining proprietary rights to our intellectual property estate, including rights relating to ONA-XR, CLDN6xCD3 bsAb and other product candidates, as well as successfully defending these rights against third-party challenges and successfully enforcing these rights to prevent third-party infringement. We will only be able to protect ONA-XR, CLDN6xCD3 bsAb and other product candidates from unauthorized use by third parties to the extent that valid and enforceable patents or effectively protected trade secrets cover them. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain and maintain patent protection for ONA-XR, CLDN6xCD3 bsAb and other product candidates is uncertain due to a number of factors, including the following factors: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have been the first to invent the technology covered by our pending patent applications or issued patents; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be the first to file patent applications covering product candidates, including their compositions or methods of use, as patent applications in the United States and most other countries are confidential for a period of time after filing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our compositions and methods may not be patentable; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any or all of our pending patent applications may not result in issued patents; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop identical, similar or alternative technologies, products or compositions, or methods of use thereof; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may design around our patent claims to produce competitive technologies or products that fall outside of the scope of our patents; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not seek or obtain patent protection in countries and jurisdictions that may eventually provide us a significant business opportunity; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide not to maintain or pursue patents and patent applications that, at some point in time, may cover our products, potential products, or product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages or may be successfully challenged by third parties; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may identify prior art or other bases upon which to challenge and ultimately invalidate our patents or otherwise render them unenforceable; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our representatives or their agents may fail to apply for patents in a timely fashion; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">despite our efforts to enter into agreements with employees, consultants, collaborators, and advisors to confirm ownership and chain of title in patents and patent applications, an inventorship or ownership dispute could arise that may permit one or more third parties to practice our technologies or enforce our patent rights, including possible efforts to enforce patent rights against us. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we have or obtain patents covering ONA-XR, CLDN6xCD3 bsAb or any other product candidates or compositions, others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our ability to successfully develop any product candidates or to successfully commercialize any approved products alone or with collaborators. In addition, because patent applications can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that may cover ONA-XR, CLDN6xCD3 bsAb or any other product candidates or compositions. These patent applications may have priority over patent applications filed by us. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without patent protection for current or future product candidates, we may be open to competition from generic or biosimilar versions of such potential products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to those we or our collaborators may develop. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we also try to protect our trade secrets, know-how and other proprietary information through non-disclosure and confidentiality provisions in our agreements with parties who have access to them, such as our employees, consultants and research partners. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets, know-how and/or other proprietary information in the event of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unauthorized uses or disclosure or other breaches of the provisions, and we may not be able to prevent such unauthorized uses or disclosure. Moreover, if a party having an agreement with us has an overlapping or conflicting obligation to a third party, our rights in and to certain intellectual property could be undermined. Monitoring unauthorized and inadvertent disclosure and uses is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are, or will be, adequate. In addition, monitoring unauthorized disclosure and uses of our trade secrets is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable, and any remedy may be inadequate. In addition, courts outside the United States may be less willing to protect trade secrets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we may rely on third parties to manufacture our potential product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our current and potential product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our manufacturers, collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, are used inappropriately to create new inventions or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. Additionally, we may need to outsource and rely on third parties for many aspects of the development, sales and marketing of any products covered under our current and future license agreements. Delay or failure by these third parties could adversely affect the continuation of our license agreements with our licensors. If we fail to comply with any of our obligations under these agreements, or we are subject to a bankruptcy, our licensors may have the right to terminate the license, in which event we would not be able to market any products covered by the license. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, patent prosecution of our licensed technology is controlled solely by the licensor. If such licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property we license from such licensor, we could lose our rights to such intellectual property or the exclusivity of such rights, and our competitors could market competing products using such intellectual property. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to do so, we or our collaborators may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. In other cases, we control the prosecution of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our product candidates, thereby potentially extending the term of marketing exclusivity for such product candidates, our business may be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of product candidates, prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to develop, manufacture, market and sell product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical, biotechnology is common, including patent infringement lawsuits, and such interference, derivation, reexamination, post-grant review, inter parties review and opposition proceedings before the USPTO and corresponding international patent offices. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous United States, EU and other internationally issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates, and as the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any patent infringement claims, or in order to avoid any potential infringement claims, we may choose to seek, or be required to seek, a license from a third party, which may require payment of substantial royalties or fees, or require us to grant a cross-license under our intellectual property rights. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we or our collaborators could be prevented from commercializing one or more product candidates, or forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators might also be forced to redesign or modify our technology or product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if a patent infringement suit is brought against us, our collaborators or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the suit may be delayed or terminated. In addition, defending such claims has in the past and may in the future cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages if we are found to be infringing a third party&#8217;s patent rights. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These damages potentially include increased damages and attorneys&#8217; fees if we are found to have infringed such rights willfully. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future be subject to third-party claims and similar adversarial proceedings or litigation in other jurisdictions regarding our infringement of the patent rights of third parties. Even if such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our or our collaborators&#8217; ability to further develop or commercialize the applicable product candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our technologies, compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to prohibit our use of those technologies, compositions, formulations, methods of treatment, prevention or use or other technologies, effectively blocking our or our collaborators&#8217; ability to develop and commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we or our collaborators obtain a license. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents. In the event of infringement or unauthorized use, we may file one or more infringement lawsuits, which can be expensive and time-consuming. An adverse result in any such litigation proceedings could put one or more of our patents at risk of being invalidated, being found to be unenforceable, and/or being interpreted narrowly and could put our patent applications at risk of not issuing and/or could impact the validity or enforceability positions of our other patents. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law, and the laws of other countries, could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO, and the courts and regulatory agencies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Market for Our Common Stock </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock may be volatile or may decline regardless of our operating performance. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price for our common stock is likely to be volatile, in part because our shares have been traded publicly for a short time. In addition, the market price of our common stock may fluctuate significantly in response to several factors, most of which we cannot control, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quarterly variations in our operating results compared to market expectations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity about us, the industries we participate in or individual scandals; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of new offerings or significant price reductions by us or our competitors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock price performance of our competitors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in stock market prices and volumes; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in senior management or key personnel; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates by securities analysts; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market&#8217;s reaction to our reduced disclosure as a result of being an &#8220;emerging growth company&#8221; under the JOBS Act; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative earnings or other announcements by us or our competitors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defaults on indebtedness, incurrence of additional indebtedness, or issuances of additional capital stock; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global economic, legal and regulatory factors unrelated to our performance; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors listed in this &#8220;Risk Factors&#8221; section. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility in the market price of our common stock may prevent investors from being able to sell their shares at or above their purchase price. As a result, you may suffer a loss on your investment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our common stock or publishes inaccurate or unfavorable research about our business, the market price for our common stock would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our common stock to decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to advance or complete the development and commercialization of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for ONA-XR, CLDN6xCD3 bsAb or any other future product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical development plans we establish for ONA-XR, CLDN6xCD3 bsAb and any other future product candidates; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obligation to make milestone, royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our licensing agreements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">number and characteristics of product candidates that we discover or in-license and develop; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property rights; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effects of competing technological and market developments; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and timing of the implementation of commercial-scale manufacturing activities; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not expect to pay dividends in the foreseeable future, and you must rely on price appreciation of your shares for return on your investment. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on any class of our stock to date and we do not anticipate paying cash dividends in the near term. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate paying any cash dividends on our stock. Accordingly, investors must be prepared to rely on sales of their shares after price appreciation to earn an investment return, which may never occur. Investors seeking cash dividends should not purchase our shares. Any determination to pay dividends in the future will be made at the discretion of our board of directors and will depend on our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board deems relevant. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may issue additional debt and equity securities, which are senior to our common stock as to distributions and in liquidation, which could materially adversely affect the market price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may attempt to increase our capital resources by entering into additional debt or debt-like financing that is secured by all or up to all of our assets, or issuing debt or equity securities, which could include issuances of commercial paper, medium-term notes, senior notes, subordinated notes or shares. In the event of our liquidation, our lenders and holders of our debt securities would receive a distribution of our available assets before distributions to our stockholders. In addition, any additional preferred stock, if issued by our company, may have a preference with respect to distributions and upon liquidation, which could further limit our ability to make distributions to our stockholders. Because our decision to incur debt and issue securities in our future offerings will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings and debt financing. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, market conditions could require us to accept less favorable terms for the issuance of our securities in the future. Thus, you will bear the risk of our future offerings reducing the value of your common stock and diluting your interest in our company. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies and our stockholders could receive less information than they might expect to receive from more mature public companies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to publicly report on an ongoing basis as an &#8220;emerging growth company&#8221; (as defined in the JOBS Act) under the reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not emerging growth companies, including but not limited to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">being permitted to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">being exempt from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until October 19, 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of any June&#160;30 before that time, we would cease to be an emerging growth company as of the following December 31. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, our stockholders could receive less information than they might expect to receive from more mature public companies. We cannot predict if investors will find our common stock less attractive if we elect to rely on these exemptions, or if taking advantage of these exemptions would result in less active trading or more volatility in the price of our common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, as well as the Sarbanes-Oxley Act and the rules and regulations of the stock market on which our common stock is listed. The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting. Commencing with our fiscal year ending December 31, 2022, we will be required, under Section 404 of the Sarbanes-Oxley Act, to include in our Form 10-K filing a report by management on, among other things, the effectiveness of our internal control over financial reporting as of December 31, 2022. As an emerging growth company, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until we are no longer an emerging growth company. At such time, our independent registered public accounting firm may issue a report that is adverse in the event material weaknesses have been identified in our internal control over financial reporting.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To comply with the requirements of being a public company, we have undertaken and will need to undertake additional actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. Testing and maintaining internal control can divert our management&#8217;s attention from other matters that are important to the operation of our business. In addition, when evaluating our internal control over financial reporting, we may identify material weaknesses that we may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section 404. If we identify any material weaknesses in our internal controls over financial reporting or we are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting once we are no longer an emerging growth company, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investors may lose confidence in the accuracy and completeness of our financial reports. As a result, the market price of our common stock could be materially adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and/or debt financings and collaborations, licensing agreements or other strategic arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through debt financing, it would result in increased fixed payment obligations and a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness. In addition, debt financing may involve agreements that include restrictive covenants that impose operating restrictions, such as restrictions on the incurrence of additional debt, the making of certain capital expenditures or the declaration of dividends. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we raise additional capital through arrangements with collaborators or otherwise, we may be required to relinquish some of our technologies, research programs, product development activities, product candidates and/or future revenue streams, license our technologies and/or product candidates on unfavorable terms or otherwise agree to terms unfavorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:109%">A significant portion of our total outstanding shares are restricted from resale but may be sold into the market in the near future. Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall, even if our business is doing well.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that the holders of a large number of shares intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">As of March 18, 2022, there were 15,966,053 outstanding shares of our common stock. Various shareholders who held shares of our common stock before our October 2021 initial public offering are currently restricted from selling their shares for a 180-day period, which ends as of the end of the day April 17, 2022, pursuant to contractual lock-up agreements with the underwriters. Furthermore, the directors and certain officers of the Company are restricted from selling their shares for a 365-day period, which ends at the close of the market on October 19, 2022, pursuant to contractual lock-up agreements with the underwriters. The representatives of the underwriters may, in their sole discretion and at any time or from time to time before the termination of the 180-day period or 365-day period, respectively, release all or any portion of the securities subject to lock-up agreements. Additionally, these shares are also eligible for sale without registration under Rule 144, subject to volume limitations applicable to affiliates. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur increased costs as a result of becoming a public company and in the administration of our organizational structure. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we have incurred significant legal, accounting, insurance, and other expenses, including costs associated with public company reporting requirements. We also have incurred and will incur costs associated with the Sarbanes-Oxley Act and related rules implemented by the SEC and ongoing periodic expenses in connection with the administration of our organizational structure. The expenses incurred by public companies generally for reporting and corporate governance purposes have been increasing. We expect these rules and regulations to increase our legal and financial compliance costs and to make some activities more time-consuming </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and costly, although we are currently unable to estimate these costs with any significant degree of certainty. In estimating these costs however, we took into account expenses related to insurance, legal, accounting, and compliance activities, as well as other expenses not currently incurred. These laws and regulations could also make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to complex tax rules relating to our business, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and non-income taxes in the United States and Ireland, as well as the tax laws and regulations related to such matters. Tax accounting and compliance often involves complex issues, and judgment and interpretation is required in determining our provision for income taxes and other tax liabilities as well as the application of tax laws and regulations. We could become subject to income and non-income taxes in non-US jurisdictions other than Ireland as well. In addition, many jurisdictions have detailed transfer pricing rules, which require that all transactions with related parties be priced using arm&#8217;s length pricing principles within the meaning of such rules. The application of such transfer pricing rules, as well as of withholding taxes, goods and services taxes, sales taxes and other taxes is not always clear and we may be subject to tax audits relating to such rules or taxes. We believe that our tax positions are reasonable, and our tax provisions and reserves are adequate to cover any potential liability. We are also currently not subject to any tax audits. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, various items cannot be accurately forecasted and future events may be treated as discrete to the period in which they occur. In addition, the Internal Revenue Service or other taxing authorities may disagree with our positions. In addition, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us (possibly with retroactive effect). If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, or existing tax laws, statutes, rules, regulations or ordinances are so interpreted, changed or modified, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results and operations and future cash flow. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures or security breaches. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our computer systems, as well as those of third parties with which we have relationships, are vulnerable to damage from computer viruses, unauthorized access, natural and manmade disasters, terrorism, war and telecommunication and electrical failures. If we or a third party with which we have relationships were to experience a system failure, accident or security breach such an event could cause interruptions in our or their operations, or it could result in delays and/or material disruptions of our research and development programs. For example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals, and U.S. federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use and dissemination of data. In the ordinary course of our business, we and third parties with which we have relationships collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, consultants and contractors, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators&#8217; security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">actors, breaches due to employee error, technical vulnerabilities, malfeasance or other disruptions, and any such breach could compromise our or their networks and the information stored there could be accessed, publicly disclosed, lost or stolen. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant costs, including regulatory penalties, fines and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or such third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or third parties with whom we have relationships may be adversely affected by natural or manmade disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural or manmade disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our facilities, that damaged our infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time, and our research and development activities could be setback or delayed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disaster recovery and business continuity plan(s) we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may now and in the future employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees and consultants. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to securities class action litigation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1029"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1045"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103, where we occupy approximately 3,500 square feet of office space pursuant to a sublease entered into in January 2022. Our lease for this space began on February 1, 2022 and is set to expire on July 30, 2023. </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1057"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any material legal proceedings.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1052"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1066"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1073"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been traded on the Nasdaq Stock Market under the symbol &#8220;CNTX&#8221; since October 20, 2021 following our initial public offering.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 18, 2022, we had 15,966,053 shares of common stock outstanding held by 98 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have not paid cash dividends on any class of our stock to date, and we do not anticipate paying any cash dividends in the near term. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not anticipate paying any cash dividends on our stock. Any determination to pay dividends in the future will be made at the discretion of our board of directors and will depend on our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board deems relevant.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by Item 5 of Form 10-K regarding our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, we sold an aggregate of 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock in a private placement to Altium Growth Fund, L.P., Hudson Bay Master Fund Ltd., Kepos Alpha Master Fund L.P., Sabby Volatility Warrant Master Fund L.P., Empery Asset Master, LTD and Empery Tax Efficient, LP for gross proceeds of $31.3 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These shares were issued in a private placement exempt from registration under Rule 506(b) of Regulation D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Parties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1080"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, and the potential impacts of the ongoing COVID-19 pandemic, contains forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below. Please also see the section entitled &#8220;Note Regarding Forward-Looking Statements.&#8221; On April 23, 2021, we completed a reverse triangular merger, resulting in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger, all of the common units, preferred units and all options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock and all options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. Prior to the reorganization we operated as Context Therapeutics LLC. Based on this being a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities, and equity of Context Therapeutics LLC. Further, as a common control transaction, the consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, including breast, ovarian, and endometrial (uterine) cancer. Our first program and lead product candidate, ONA-XR, builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependent cancers. ONA-XR is a potent and selective antagonist of the progesterone receptor, which has been linked to resistance to multiple classes of cancer therapeutics, including anti-estrogen therapies, across female hormone-dependent cancers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in April 2015 under the laws of the State of Delaware. Since inception, we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our company, business planning and raising capital. We operate as one business segment and have incurred recurring losses, the majority of which are attributable to research and development activities, and negative cash flows from operations. We have funded our operations primarily through the sale of convertible debt, convertible preferred stock and common stock. Our net loss was $10.5 million for the year ended December&#160;31, 2021. As of December&#160;31, 2021, we had an accumulated deficit of $29.3 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we closed an initial public offering (&#8220;IPO&#8221;) on the Nasdaq Stock Market, in which we issued and sold 5,750,000 shares at a public offering price of $5.00 per share. We received gross proceeds of approximately $28.8 million as a result of the offering. In December 2021, we sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock in a private placement for gross proceeds of approximately $31.3 million. We expect our existing cash and cash equivalents will be sufficient to fund our operations into 2024. Currently, our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, in connection with the closing of our initial public offering, we have incurred and continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenses on other research and development activities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur net operating losses for at least the next several&#160;years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we: </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our ongoing and planned research and development of our first program and lead product candidate ONA-XR; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue nonclinical studies and initiate clinical trials for our anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) product and for any additional product candidates that we may pursue; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity requirements for clinical trials and potential commercialization; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related additional commercial manufacturing costs; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know how; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract, hire and retain additional executive officers, clinical, scientific, quality control, and manufacturing management and administrative personnel; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operations in the United States and to other geographies; and </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting, investor relations and other expenses associated with operating as a public company. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings and/or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The COVID-19 Pandemic and its Impacts on Our Business </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic instability and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#8217;s ongoing or planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations (&#8220;CROs&#8221;), and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-process Research and Development Expense </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development expense consists of initial up-front payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under Accounting Standards Codification Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquired in-process research and development expense reflects the cash paid and/or the estimated fair value of the equity consideration given. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses have consisted primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred, including: </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred to conduct the necessary discovery-stage laboratory work, preclinical studies and clinical trials required to obtain regulatory approval; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel expenses, including salaries, benefits and share-based compensation expense for our employees and consultants engaged in research and development functions; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of funding research performed by third parties, including pursuant to agreements with clinical research organizations, or CROs, that conduct our clinical trials, as well as investigative sites, consultants and CROs that conduct our preclinical and clinical studies; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract manufacturing organizations, or CMOs, including manufacturing scale-up expenses, milestone-based payments, and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants who assist with research and development activities; </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to regulatory activities, including filing fees paid to regulatory agencies; and </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocated expenses for facility costs, including rent, utilities and maintenance. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track outsourced development costs and other external research and development costs to specific product candidates on a program-by-program basis, fees paid to CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to compensation, early research and other costs which are deployed across multiple projects under development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including share-based compensation, conduct our clinical trials, including later-stage clinical trials, for current and future product candidates and prepare regulatory filings for our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses have consisted primarily of personnel expenses, including salaries, benefits and share-based compensation expense, for employees and consultants in executive, finance and accounting, legal, operations support, information technology and business development functions. General and administrative expense also includes corporate facility costs not otherwise included in research and development expense, including rent, utilities and insurance, as well as legal fees related to intellectual property and corporate matters and fees for accounting and consulting services. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization efforts and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, legal support and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the Securities and Exchange Commission, or SEC, insurance and investor relations costs. If any of our current or future product candidates obtain U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense has consisted primarily of interest related to our convertible promissory notes that converted to Series A stock in 2020 and 2021. All of the outstanding Convertible Promissory Notes were converted as of February 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily due to the recognition of a gain on extinguishment of debt as a result of the forgiveness of our outstanding Paycheck Protection Program loan in July 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2021 and 2020 </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the years ended December&#160;31, 2021 and 2020: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;Change &#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change &#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,087,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,087,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,805,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,641,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,163,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,632,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,702,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,525,819)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,572,168)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,953,651)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,877,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,868,540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,644,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,101,335)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development expense of $3.1 million for the year ended December&#160;31, 2021 reflects the fair value of consideration paid/issued under the collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) for gynecologic cancer therapy. There was no such consideration paid/issued under collaboration arrangements in 2020. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $2.2 million from $1.6 million for the year ended December&#160;31, 2020 to $3.8 million&#160;for the year ended December&#160;31, 2021. The increase was mainly due to an increase of $0.6 million in clinical trial costs related to our Phase 2 trials evaluating ONA-XR, $0.6 million in preclinical costs associated with conducting research for the development of a CLDN6 BsMAb for gynecologic cancer therapy, and an increase in contract manufacturing costs of $0.5 million for ONA-XR. Additionally, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consulting services increased by approximately $0.4 million as we increased the use of third-party contractors to focus on developing our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $2.7 million from $0.9 million for the year ended December&#160;31, 2020 to $3.6 million&#160; for the year ended December&#160;31, 2021. The increase was mainly due to an increase of $1.1 million in compensation and share-based compensation as a result of an increase in our general and administrative headcount and changes to compensation arrangements. Additionally, expenses increased by $1.6 million due to higher insurance costs of $0.3 million, professional fees and consulting services of $1.0 million, and other costs associated with operating as a public company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased by $0.6 million from $0.7 million for the year ended December&#160;31, 2020 to $0.1 million for the year ended December&#160;31, 2021 due to the conversion of all previously outstanding convertible promissory notes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Convertible Promissory Notes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of convertible promissory notes was $9.9 million for the year ended December&#160;31, 2020 and $9,000 for the year ended December&#160;31, 2021. This change was attributable to a decrease in the fair value of our common stock as well as  the conversion of all previously outstanding convertible promissory notes.   </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income of $0.1 million for the year ended December&#160;31, 2021 is primarily due to the recognition of a gain on extinguishment of debt as a result of the forgiveness of our outstanding Paycheck Protection Program loan in July 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not recognized any revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. Since our inception through December&#160;31, 2021, we have funded our operations through the sale of convertible debt, convertible preferred stock and common stock. As of December&#160;31, 2021, we had $49.6 million in cash and cash equivalents and had an accumulated deficit of $29.3 million. In October 2021, we closed an initial public offering (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on the Nasdaq Stock Market and received gross proceeds of approximately $28.8 million as a result of the offering. Additionally, in December 2021, we sold 5,000,000 shares of our common stock together with warrants to purchase 5,000,000 shares of our common stock in a private placement and received gross proceeds of approximately $31.3 million. We expect our existing cash and cash equivalents will be sufficient to fund our operations into 2024. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund operating expenses, which consist of research and development expenditures and various general and administrative expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of manufacturing our product candidates for clinical trials and in preparation for regulatory approval and commercialization; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses needed to attract and retain skilled personnel; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with being a public company; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs required to scale up our clinical, regulatory and manufacturing capabilities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive regulatory approval; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive regulatory approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need additional funds to meet our operational needs and capital requirements for clinical trials, other research and development expenditures, and general and administrative expenses. We currently have no credit facility or committed sources of capital. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.833%"><tr><td style="width:1.0%"></td><td style="width:58.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.585%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,799,487)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,034,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,394,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,149,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net increase in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,344,549&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2021 and 2020</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we used $8.8 million of cash in operating activities. Cash used in operating activities reflected our net loss of $10.5 million, a gain of $0.1 million from the extinguishment of debt and a net change in our operating assets and liabilities of $2.2 million. This was primarily offset by non-cash in-process research and development charges of $3.1 million, the non-cash fair value measurement of warrants for services of $0.4 million and share-based compensation of $0.5 million. The primary uses of cash were to fund our operations related to the development of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, we used $1.0 million of cash in operating activities. Cash used in operating activities reflected the noncash change in fair value of convertible promissory notes of $9.9&#160;million, offset by our net income of $6.6&#160;million, noncash interest expense of $0.7&#160;million, share-based compensation of $0.2&#160;million and a $1.3&#160;million net change in our operating assets and liabilities. The primary use of cash was to fund our operations related to the development of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, cash used in investing activities was attributable to the initial upfront license fee of $0.3 million related to the Company&#8217;s acquired in-process research and development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have cash flows from investing activities during the year ended December&#160;31, 2020. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, financing activities provided $58.4 million, consisting of net proceeds of $5.0 million from the sale of Series A Stock and warrants for common stock, net proceeds of $24.4 million from the sale of common stock in connection with our IPO and net proceeds of $29.0 million from the sale of common stock and warrants in connection with our private placement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, financing activities provided $1.1&#160;million, consisting of $1.0&#160;million of proceeds from the sale of Series A Stock and warrants for common stock, $25,000 from the issuance of convertible bridge notes, $50,000 from the sale of Series Seed Stock and $0.1&#160;million of proceeds from the Paycheck Protection Program loan. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, we did not have, nor do we currently have, any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to prepaid/accrued research and development expenses, share-based compensation and fair value of convertible promissory notes. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note&#160;3 to our audited consolidated financial statements included elsewhere in this Form 10-K, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue an expense for preclinical studies and clinical trial activities performed by our vendors based upon estimates of the proportion of work completed. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our prepaid/accrued expenses as of each balance sheet date in our consolidated financial statements based upon facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the prepaid/accrual accordingly. Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed, or services are performed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure compensation expense for all share-based awards based on the estimated fair value of the share-based awards on the grant date. We use the Black-Scholes option pricing model to value our share-based awards. We recognize compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. We have not issued awards for which vesting is subject to market or performance conditions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model requires the use of subjective assumptions that include the expected stock price volatility and the fair value of the underlying common stock on the date of grant. See Note&#160;8 to our audited consolidated financial statements included elsewhere in this Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our awards granted. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;3 to our audited consolidated financial statements found elsewhere in this Form 10-K for a description of recent accounting pronouncements applicable to our consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qualitative and Quantitative Disclosures About Market Risk </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of December&#160;31, 2021, we had cash and cash equivalents of $49.6 million consisting of bank deposits and a commercial money market account. Due to the short-term duration of our cash equivalents, an immediate 10% change in interest rates would not have a material effect on the fair market value. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our labor and clinical trial costs. We do not believe inflation had a material effect on our business, financial condition or results of operations during the years ended December&#160;31, 2021 and 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other exemptions and reduced reporting requirements under the JOBS Act include, without limitation, the requirements for providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. We will remain an emerging growth company until the earlier to occur of (a)&#160;the last day of the fiscal year (i)&#160;following October 19, 2026, (ii)&#160;in which we have total annual gross revenues of at least $1.07&#160;billion or (iii)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means that we have been required to file annual and quarterly reports under the Exchange Act for a period of at least 12 months and have filed at least one annual report pursuant to the Exchange Act and either (a)&#160;the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30th, or (b)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We will continue to be a smaller reporting company until either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1317"></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not required for smaller reporting companies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1417"></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index To Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1423">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDE3L2ZyYWc6MzA0OWE5MzE5ZjFkNDU0Y2EzZTFhZWU0ZTQxNjQ4NDgvdGFibGU6NTA4NTNlYTc5OTk1NDU2YmEwMDUyNTcyZDQ3MzUyMjYvdGFibGVyYW5nZTo1MDg1M2VhNzk5OTU0NTZiYTAwNTI1NzJkNDczNTIyNl8xLTAtMS0xLTMwMDM5L3RleHRyZWdpb246Yjk5NzdiZjVhOWI4NGRmMTgzOWI2YWM2YTUyZWRjOWRfMjc0ODc3OTA2OTU3OQ_b0fa9113-180d-44bb-ac42-2c327d86da0b">596</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_1423">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_91">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_91">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_97">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_97">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_100">Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_100">E</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_100">quity </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_100">(</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_100">Deficit</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_100">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_103">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_103">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_106">Notes to</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_106"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_106">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i10e0e1fe4e654d20bde04f42c409d9dd_106">88</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1423"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Board of Directors and Stockholders of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Context Therapeutics Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Context Therapeutics Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of operations, changes in convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020 and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIzL2ZyYWc6NDAzODI0Mjg5MGY0NGE0Y2E0ZWJmNDU2MmE3YmRkNjQvdGV4dHJlZ2lvbjo0MDM4MjQyODkwZjQ0YTRjYTRlYmY0NTYyYTdiZGQ2NF8yNzQ4Nzc5MDgxNDg3_3da35103-ef19-48d1-b5b9-2c119b5c1abc">CohnReznick LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since January 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIzL2ZyYWc6NDAzODI0Mjg5MGY0NGE0Y2E0ZWJmNDU2MmE3YmRkNjQvdGV4dHJlZ2lvbjo0MDM4MjQyODkwZjQ0YTRjYTRlYmY0NTYyYTdiZGQ2NF8yNzQ4Nzc5MDgxNDg4_543a60ae-d5f0-4b16-b79e-515a2c0ec913">Holmdel, New Jersey</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 23, 2022</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNC0xLTEtMS0xMTc1OA_12930f03-53c0-4b00-a2c5-33f739d942e0">49,635,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNC0zLTEtMS0xMTc1OA_079ac6de-df8f-44e9-aadf-3a5164383814">290,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNS0xLTEtMS0xMTc1OA_17bc2a40-a0a3-461e-9b27-adbc29de902d">1,620,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNS0zLTEtMS0xMTc1OA_3844a98b-3d76-4e9d-9151-c66773932928">8,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNi0xLTEtMS0xMTc1OA_84875f08-e7bb-419c-a267-3019440c42fa">51,255,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNi0zLTEtMS0xMTc1OA_ce78cc9f-be37-4d32-9472-e4ee64a9f911">299,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNy0xLTEtMS0yMjQ1OQ_76a594c8-65d5-48f0-a585-b77afe6959e0">50,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNy0zLTEtMS0yMjQ2Nw_f1637c5e-acdf-4c17-ae21-4e0b9556e156">50,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNy0xLTEtMS0xMTc1OA_612e505e-fdce-47c9-bfd3-c3fb8ca9ab8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNy0zLTEtMS0xMTc1OA_809ebb46-a13c-4a1f-8418-38bfb713a903">117,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfOC0xLTEtMS0xMTc1OA_b48cbdc9-b828-40b1-9fa4-74c8de7914ed">51,305,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfOC0zLTEtMS0xMTc1OA_cc000052-83dc-4cc6-8e0f-9b0bdd9bde0f">467,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Equity (Deficit)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible promissory notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTEtMS0xLTEtMTE3NTg_cfe517b7-63bb-4da5-bf1f-10735fa2d389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTEtMy0xLTEtMTE3NTg_f4b4848c-bb22-44a0-822b-c7a938c58ac0">5,829,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable&#8212;current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTMtMS0xLTEtMTE3NTg_bfcfd7e0-b6aa-42cd-ae97-44210aaf9d89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTMtMy0xLTEtMTE3NTg_e8394ba9-856a-41f4-a0a0-11e2c957fb25">55,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTQtMS0xLTEtMTE3NTg_0f60cc57-13d3-4f1a-94dd-bdfd67bfcc2c">1,826,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTQtMy0xLTEtMTE3NTg_5a1644d1-2cdc-4d1a-ab59-81b2fc10058b">2,707,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTUtMS0xLTEtMTE3NTg_826cdb05-00d5-471c-9476-e77978761d8f">1,207,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTUtMy0xLTEtMTE3NTg_697d3ebc-f428-40b2-aaff-e3ffd84f7bab">955,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTYtMS0xLTEtMTE3NTg_c39ac748-1f6d-4bb4-8578-6f4cc1f40eb1">3,033,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTYtMy0xLTEtMTE3NTg_63636d8c-9c10-4300-8a9d-694bc3539d1b">9,548,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable&#8212;noncurrent</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:LongTermNotesPayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTctMS0xLTEtMTE3NTg_87a377e5-4952-45b0-bf00-ae3bbb5f117b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTctMy0xLTEtMTE3NTg_b1291fb2-eb99-4da6-9ed1-569f449bd5bb">69,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTgtMS0xLTEtMTE3NTg_151f939a-5921-4ab1-a21d-9bb2d701ab97">3,033,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTgtMy0xLTEtMTE3NTg_557a9b5a-4f28-4ea8-b048-dba4bffe9be9">9,617,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 9)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTktMS0xLTEtMTE3NTg_d16a37d5-9c66-49de-930e-12a997a662d4"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTktMy0xLTEtMTE3NTg_dca0bfb7-482d-46d6-b256-9468886a81ae"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock and redeemable common stock (<ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjEtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo2ZjE1Y2Y1YTEyY2U0ODFkOTAzNDQ0N2M3OTU1NWYzZF85MzQ1ODQ4ODM2MjA5_03b859cc-9817-4c69-8ea6-554dcc6e70ba">no</ix:nonFraction> shares authorized at December 31, 2021):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Series A preferred stock&#8212;$<ix:nonFraction unitRef="usdPerShare" contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231" decimals="3" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2MzMx_187eae98-b604-4e36-8dc3-12725995651a"><ix:nonFraction unitRef="usdPerShare" contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231" decimals="3" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2MzMx_2f8f2675-255c-4b9c-8bd5-0f3201490e9b">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2Mzg3_04784901-2883-4134-90de-a030dd4c9aaf"><ix:nonFraction unitRef="shares" contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2Mzg3_09c07840-4115-4dd9-b516-382bfcf5fbf1">no</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2Mzcy_18c1729d-388a-45e0-b2cc-99e2b7873e45"><ix:nonFraction unitRef="shares" contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2Mzcy_36279a38-a871-4de6-88f8-99a408e2378d">210,715</ix:nonFraction></ix:nonFraction> issued and outstanding at  December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMS0xLTEtMTE3NTg_514313cc-13dc-4e17-97f0-8547855ea109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMy0xLTEtMTE3NTg_0008cd16-a9e1-4daa-b602-9d228fc3f011">1,400,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Series Seed preferred stock&#8212;$<ix:nonFraction unitRef="usdPerShare" contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231" decimals="3" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl85MzQ1ODQ4ODM2MzI3_7075dbf2-9499-4fbe-989e-1fda7838d986"><ix:nonFraction unitRef="usdPerShare" contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231" decimals="3" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl85MzQ1ODQ4ODM2MzI3_aaa76190-956b-454b-852f-aba5723e604e">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl83MTQ2ODI1NTgwODAy_5129dd91-7457-46ff-b522-e589ccbbf97c"><ix:nonFraction unitRef="shares" contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl83MTQ2ODI1NTgwODAy_a6301993-38d1-4a9a-bcd9-06b0cc02e432">no</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl85MzQ1ODQ4ODM2MzQ2_204efed7-d2af-4e74-bb1a-36c132f3871a"><ix:nonFraction unitRef="shares" contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl85MzQ1ODQ4ODM2MzQ2_371feb37-84a8-47f2-9930-8c3f45fdeecf">2,624,324</ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMS0xLTEtMTE3NTg_3c7b4f3e-5bfa-49e9-84ee-8a62cd903928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMy0xLTEtMTE3NTg_a9f594b3-5435-4a40-b95e-3770ab1925f7">6,341,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Redeemable common stock&#8212;$<ix:nonFraction unitRef="usdPerShare" contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231" decimals="3" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl85MzQ1ODQ4ODM2MjYz_6a5efece-cceb-4e9f-ad24-c180536d40b2"><ix:nonFraction unitRef="usdPerShare" contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231" decimals="3" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl85MzQ1ODQ4ODM2MjYz_ea06823c-7ed7-45ff-9244-8b560397a95a">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl83MTQ2ODI1NTgwNjg1_06efb1a1-b862-4ae9-9033-9e2feddfb707"><ix:nonFraction unitRef="shares" contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl83MTQ2ODI1NTgwNjg1_1f93ac99-14d1-414a-8777-2e8d99b8a249">no</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl85MzQ1ODQ4ODM2MjI5_45ddcbb7-4bbf-4e57-8e5a-1dbcadffbb42"><ix:nonFraction unitRef="shares" contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl85MzQ1ODQ4ODM2MjI5_b103d400-cdb8-4b5e-9bbe-1b184c01e77a">16,666</ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2021 and 2020, respectively </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMS0xLTEtMTE3NTg_3511c860-1938-4796-ab00-422ea12037ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMy0xLTEtMTE3NTg_8c67869d-fe38-4a07-9144-ad04f420f619">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible preferred stock and redeemable common stock</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjUtMS0xLTEtMTE3NTg_df27d363-90ba-4ce5-b093-8ed80bcd9df0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjUtMy0xLTEtMTE3NTg_694572c5-3700-4798-9bf9-35b30917f299">7,771,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#8212;$<ix:nonFraction unitRef="usdPerShare" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF85MzQ1ODQ4ODM2Mzk2_0ac163f5-1d62-4740-9670-39da330309a6"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF85MzQ1ODQ4ODM2Mzk2_396a6c8d-55f7-4a16-9a27-ad66f6ef5975">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF85MzQ1ODQ4ODM2NDEx_98dcfd23-ff6d-49b4-bacc-a9cb75924dfc"><ix:nonFraction unitRef="shares" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF85MzQ1ODQ4ODM2NDEx_a9344ca1-c6fe-4920-9333-592913d240ee">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF83MTQ2ODI1NTgwOTA3_0b2f60ba-4dc3-4073-b6ad-2deac96f24be"><ix:nonFraction unitRef="shares" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF83MTQ2ODI1NTgwOTA3_3997e419-d8e6-4568-bdff-213f435bafb4"><ix:nonFraction unitRef="shares" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF83MTQ2ODI1NTgwOTA3_8f6ea2ab-1926-4dc9-89d2-29a1ea187bb0"><ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF83MTQ2ODI1NTgwOTA3_c178a2f1-dfed-4910-ae40-c155dc281a2c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMS0xLTEtMTE3NTg_699f439f-c7e7-421f-b4dc-6ca67cc2b7be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMy0xLTEtMTE3NTg_465deb1f-c14e-4cd9-a665-f6217b4fac44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;$<ix:nonFraction unitRef="usdPerShare" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2MjU3_55b92f21-3d61-4d99-96a2-71d4170fa7ca"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2MjU3_f361ba4e-79ce-41f5-a011-661781bbba26">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2Mjcx_79d6ce06-9bb3-460e-811a-cd748cc6ac49"><ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2Mjcx_b6265676-6c6e-4ab7-913e-6646cb377747">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM183MTQ2ODI1NTgwODA1_0acb6cc9-ff8b-40ca-bcdf-14f44ec264c3"><ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM183MTQ2ODI1NTgwODA1_5a28ab2d-4801-4154-8509-5257479deff3">15,966,053</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2Mjk0_18a431a5-3ce3-4c1e-8953-65a37eb7a831"><ix:nonFraction unitRef="shares" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2Mjk0_5d54b5e5-02bf-401c-82c4-ad0db48fae71">331,789</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMS0xLTEtMjQ5MDA_281b3b5c-7ed1-490c-951f-c712bd993a58">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMy0xLTEtMjQ5MDA_5adffe74-6e65-4bf5-9df1-53888bd9ab1a">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMS0xLTEtMTE3NTg_2627eac7-c0fe-45ef-8ebb-74ee681eaa2d">77,510,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMy0xLTEtMTE3NTg_d0de9355-fa5e-4ef4-8c26-912b8eb8629e">1,876,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjktMS0xLTEtMTE3NTg_a723bebc-2a7d-4f59-a13a-765c161978d8">29,254,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjktMy0xLTEtMTE3NTg_75e43be3-2357-4cc0-9d53-cc722180a2be">18,797,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMzAtMS0xLTEtMTE3NTg_c8535dcb-7301-4850-920e-9ad43953072f">48,272,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMzAtMy0xLTEtMTE3NTg_0b285caf-6e43-4319-a31b-3c6b967ffc5e">16,921,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMzEtMS0xLTEtMTE3NTg_096dd00b-e6e2-43e6-96e6-de1a788ba76f">51,305,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMzEtMy0xLTEtMTE3NTg_4b5b5860-a565-431d-a43c-7f622be7a7d8">467,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMy0xLTEtMS0yMjQyNw_460b1c63-61cc-456f-a9e1-e44df60558c4">3,087,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMy0zLTEtMS0yMjQzNA_3c89a410-7863-4da8-8b06-e6fc883b61fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMy0xLTEtMS0xMTc1OA_9ebcb735-06d5-48b7-bb88-35ce28742dd3">3,805,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMy0zLTEtMS0xMTc1OA_50d25c78-7ba6-4f82-bf1d-f20e1fb94970">1,641,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNC0xLTEtMS0xMTc1OA_1e28d671-e4e7-4534-a1b0-329135e1b3d5">3,632,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNC0zLTEtMS0xMTc1OA_6c69d996-8c74-4803-8b6b-82072f56f02c">930,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNS0xLTEtMS0xMTc1OA_0641488f-c6fe-4c91-aae0-71552818453e">10,525,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNS0zLTEtMS0xMTc1OA_5f2cca4b-8044-4a1a-b3df-418d5c1ab5c4">2,572,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNi0xLTEtMS0xMTc1OA_5a806be5-6f71-47ec-8b51-8e6af7eb2fe1">64,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNi0zLTEtMS0xMTc1OA_64880c12-1b43-43f5-ad05-b48e66027287">661,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible promissory notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNy0xLTEtMS0xMTc1OA_cb93e9ed-925b-4c12-b0c7-09bb310712f4">9,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNy0zLTEtMS0xMTc1OA_3b4dc549-1bbb-4ffa-b704-e72f9c421cf2">9,877,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOS0xLTEtMS0yNTA4Ng_dcc55c0a-617c-427c-85fc-240fa6771a4e">123,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOS0zLTEtMS0yNTA5Mw_8d428c72-500a-4793-8b43-c71e59636938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOC0xLTEtMS0xMTc1OA_b61b4a52-030e-4e01-a13a-c5cf14b9003f">10,456,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOC0zLTEtMS0xMTc1OA_740535c9-b250-406b-938b-46f17093fcfd">6,644,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per common share, basic</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOS0xLTEtMS0xMTc1OA_58a4253e-711d-4fce-a3ab-a966582dd845">3.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOS0zLTEtMS0xMTc1OA_37955766-93c8-450e-b949-df54092b3054">3.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTAtMS0xLTEtMTE3NTg_86dcb69f-7c9d-4b88-853e-ea4df1137302">3.69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTAtMy0xLTEtMTE3NTg_cf124d86-1ec1-4cdc-8673-0a38fe901d53">3.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTEtMS0xLTEtMTE3NTg_76051f47-f817-4c34-98ce-946b7ed3c8cc">2,833,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTEtMy0xLTEtMTE3NTg_4ea3f75c-e8e3-4bbc-a2cf-85a5342c92a5">348,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTItMS0xLTEtMTE3NTg_bb42eb86-dc70-4a39-a174-48c3f952f1b0">2,833,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTItMy0xLTEtMTE3NTg_50e75fd6-1260-4ee5-8478-f04eaac397a9">2,054,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Equity (Deficit) </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.438%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Series A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Preferred Stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Series Seed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Preferred Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Redeemable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Deficit </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity (Deficit)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance at January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51367b5fc58744139f31963837e98df8_I20191231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMS0xLTEtMTE3NTg_27275dca-1553-463d-bea3-c666f739da91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51367b5fc58744139f31963837e98df8_I20191231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMy0xLTEtMTE3NTg_88309c6b-4ef1-45c3-8335-ff985ae08c1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i285ef89c1ae14c19928c2e368283074d_I20191231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtNS0xLTEtMTE3NTg_feee1a42-d8b0-40cf-a6eb-12f413ca7794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285ef89c1ae14c19928c2e368283074d_I20191231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtNy0xLTEtMTE3NTg_bda91b5e-b679-473a-ba90-f59b138e2fd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1bd11c091e024a7a92541bbe11337dd7_I20191231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtOS0xLTEtMTE3NTg_de4675aa-9341-4296-9fb8-c00fb9d79c54">16,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd11c091e024a7a92541bbe11337dd7_I20191231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMTEtMS0xLTExNzU4_fe6f1e2a-2e2d-406f-875e-c1e833778be3">126,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadbb65d9f6724cb6a5cd710b45cc033f_I20191231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMTQtMS0xLTExNzU4_347723d0-10ee-4cab-9ced-fd163f32fb59">324,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadbb65d9f6724cb6a5cd710b45cc033f_I20191231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMTYtMS0xLTExNzU4_cb567107-991e-42dd-b105-3d561fbc409b">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb93a595192045d2ad7ef4eaa1b20c05_I20191231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMTgtMS0xLTExNzU4_18384050-3946-4504-bc85-55a457a34ed7">1,480,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfe019d635614547bf06c09e991419b0_I20191231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMjAtMS0xLTExNzU4_bf1cc7a0-179d-460d-a997-b62504422f50">25,442,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f8740cca1c745199eda7ed1a4c1f483_I20191231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMjItMS0xLTExNzU4_dbd5ae82-3c96-49bf-8938-2468a2de69fe">23,960,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sale of Series A preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzctMS0xLTEtMTE3NTg_788866f1-ceba-47d0-9562-83077ef46ce9">132,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231" decimals="0" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzctMy0xLTEtMTE3NTg_d3f4fa5c-38f0-4fa2-bcc5-460ba06083d9">950,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of bridge notes, including accrued interest, to Series A preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzgtMS0xLTEtMTE3NTg_ca23ea9c-85f3-409c-b9f0-23524f3395dd">78,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzgtMy0xLTEtMTE3NTg_f6a36e0e-daae-4e94-bb7a-b669b1874613">529,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of warrants issued in conjunction with the Series A preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231" decimals="0" name="cntx:TemporaryEquityDecreaseDueToConversionToWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzktMy0xLTEtMTE3NTg_a531e757-c429-40b3-ad2a-abb83603d3fa">78,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47d1bf6b4dac47b7984ca62205cdf5ab_D20200101-20201231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzktMTgtMS0xLTExNzU4_6a6f4b1b-8d18-4475-9b96-8accc557aa7b">78,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e33079a371457f957e34b3350067ba_D20200101-20201231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzktMjItMS0xLTExNzU4_6008c9da-6581-4f6d-aa1c-55700e6f5224">78,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sale of Series Seed preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEwLTUtMS0xLTExNzU4_b1631cbe-0165-4b00-907d-2254e472c156">8,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231" decimals="0" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEwLTctMS0xLTExNzU4_03b1c3bb-0bb6-4bb6-bc16-f58d45b386ba">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of Junior Convertible Notes to Series Seed preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzExLTUtMS0xLTExNzU4_446fd917-a335-44a8-a8a3-d361eecdc782">2,615,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzExLTctMS0xLTExNzU4_ef5b6616-b030-4780-b424-f42f56de110f">6,291,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ce49c28af0b41f0ad1acb06f7f428c1_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTE0LTEtMS0xMTc1OA_64e79fba-37bc-406c-a708-9461280d51eb">7,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce49c28af0b41f0ad1acb06f7f428c1_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTE2LTEtMS0xMTc1OA_f55ef17a-2609-4de6-85db-e0ad4fbb9f57">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f2f9c93a454fe2a0edbcc51fd35e05_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTE4LTEtMS0xMTc1OA_dbb3db5c-056d-47ac-82b9-ae2f07359fcb">219,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTIyLTEtMS0xMTc1OA_673f66c6-fb0f-491a-a29d-284284ad39a0">219,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in fair value of redeemable common stock to redemption value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f0d5097ed154ff1ba3d972352d2867d_D20200101-20201231" decimals="0" sign="-" name="cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTExLTEtMS0xMTc1OA_82d36b69-7aa5-444a-9867-bcbfee340bc6">97,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f2f9c93a454fe2a0edbcc51fd35e05_D20200101-20201231" decimals="0" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTE4LTEtMS0xMTc1OA_77e91858-509c-4486-a19d-1b73d12cbef0">97,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTIyLTEtMS0xMTc1OA_733bddb2-7fe9-4cd8-8a49-7eedd7c36465">97,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeb956fa4494216b6ca445ac804fd36_D20200101-20201231" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE0LTIwLTEtMS0xMTc1OA_73712e6e-84d2-459d-b0f2-92b491758a89">6,644,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE0LTIyLTEtMS0xMTc1OA_210e1ff6-a39b-4ba4-91dc-0cb1a354da64">6,644,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTEtMS0xLTExNzU4_30d938e9-70db-4bd9-ae31-beaee624deea">210,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTMtMS0xLTExNzU4_6c48b0a1-3434-4102-b962-cd351cb588bd">1,400,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTUtMS0xLTExNzU4_c93e61cf-b23f-4771-94bd-829626c7d1a3">2,624,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTctMS0xLTExNzU4_59425f06-adbe-4177-acb7-207802bd16a6">6,341,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTktMS0xLTExNzU4_66825d03-6297-4dff-bc85-d04bdc15c39f">16,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTExLTEtMS0xMTc1OA_0785e87a-d452-4ed9-8f7d-4fbb1787aea7">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b7ed393336144da884a7c61ce2da7a2_I20201231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTE0LTEtMS0xMTc1OA_191f5b8c-79fa-4639-91a9-7023ba147919">331,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7ed393336144da884a7c61ce2da7a2_I20201231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTE2LTEtMS0xMTc1OA_dc85f3b4-305d-4436-b5e6-000b32592860">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625d9f20831b4f60bfb06856c3aea35c_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTE4LTEtMS0xMTc1OA_1777aae9-ac12-49df-b2fe-0d05ffcc5301">1,876,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2dcdb9bd37f420e9dc8c7b39ea998eb_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTIwLTEtMS0xMTc1OA_60bdcea9-ac13-4f7c-b18d-787e2e709b6a">18,797,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTIyLTEtMS0xMTc1OA_b0c66080-3f24-496b-9a02-2a1ca170e3a3">16,921,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sale of Series A preferred shares, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityOfferingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTAtMS0xLTIyNjMwL3RleHRyZWdpb246NjFhYmU5YmE1YTFjNDg1MzkzNTJlZjQ3ZTE2NzRiZDJfOTM0NTg0ODgzNjE3NQ_6f9b77ae-9318-4a6e-9a4b-c33fb6dff122">310,021</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTEtMS0xLTIyNjMw_7586df95-dbf6-4166-b886-123d5a38d0b1">738,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTMtMS0xLTIyNjMw_26358f8f-bc96-4d09-b50e-bb6ffc25dd43">4,982,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of Senior Convertible Notes, including accrued interest, to Series A preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTEtMS0xLTIyNjMw_f6995407-6f94-4d7f-8bf3-88512fb24456">844,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTMtMS0xLTIyNjMw_7eba5a40-88f2-4490-88ac-36219907225f">5,728,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTE4LTEtMS0yMjYzMA_acb51cb4-39fd-495e-8eb5-515dae6c018b">137,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTIyLTEtMS0yMjYzMA_2605e48a-f51e-47a7-9d72-5fa4c1479c7e">137,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE0LTEtMS0xLTIyNjMw_b27921ce-dd8a-47ec-a1c3-702f33908353">418,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE0LTMtMS0xLTIyNjMw_43c4b90b-ce29-4c28-95f7-d63361b3ad6b">2,837,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of warrants issued in conjunction with the Series A preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityDecreaseDueToConversionToWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTMtMS0xLTIyNjMw_2c7058ac-5421-4182-a010-34e18828ed71">265,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i07db14fa05f64cf3bdaba6c0231f7ef8_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTE4LTEtMS0yMjYzMA_24120b6c-2245-40f7-b4cc-cdb08982c524">265,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i117b2aa3311747edb244e9aeee8fc1de_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTIyLTEtMS0yMjYzMA_16e758bc-d78f-4530-875b-ef38274e40a0">265,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of warrants issued as placement agent fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" sign="-" name="cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE2LTMtMS0xLTI5Nzcz_bb79b69f-b146-4767-afff-e8223dcb7e1f">43,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3251068f24e94754a128ec78c77f7334_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE2LTE4LTEtMS0yOTc3Mw_8ac203e8-aaa4-44b3-8575-54c5220075da">43,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1b71ff94d7e42dc8077cc9688deb3f4_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE2LTIyLTEtMS0yOTc3Mw_83a4d851-5dfa-433e-ace1-c2c0b5530c5f">43,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of warrants issued for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf1ad6b33cea4855b42055c26af30d02_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE3LTE4LTEtMS0yMjYzMA_1d374784-7164-41fe-87aa-0ac590979606">371,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i449ce80766bf4e398973559957e68f41_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE3LTIyLTEtMS0yMjYzMA_49a87dbf-f40e-4569-baf0-41ca38009af9">371,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in fair value of redeemable common stock to redemption value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfa7323ee88a439a91a0ce98d394f1b9_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE4LTExLTEtMS0yMjYzMA_acf542e1-425b-4037-8b6d-83a2f10bf843">53,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE4LTE4LTEtMS0yMjYzMA_53ac4ea7-95b0-4359-b84d-f6cc57aabe44">53,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE4LTIyLTEtMS0yMjYzMA_c971a884-60d5-48a6-abb6-be21253e1cf4">53,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of convertible preferred shares and redeemable common shares upon initial public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" sign="-" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTEtMS0xLTIyNjMw_b71a0984-839f-4ee8-a60e-36db2d3b72a4">2,212,543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" sign="-" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTMtMS0xLTIyNjMw_a812bd68-ac21-40af-a60c-8c75f8d64a0c">14,641,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i14b6d70f7b20444b83ad2461cd950758_D20210101-20211231" decimals="0" sign="-" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTUtMS0xLTIyNjMw_893a43e8-00c2-459b-9d37-d51a8d330b36">2,624,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i14b6d70f7b20444b83ad2461cd950758_D20210101-20211231" decimals="0" sign="-" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTctMS0xLTIyNjMw_10bcfa1d-7eba-4a73-ac3d-d07ed13d74b3">6,341,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ibfa7323ee88a439a91a0ce98d394f1b9_D20210101-20211231" decimals="0" sign="-" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTktMS0xLTIyNjMw_2986e945-8d4a-4d1b-8f98-eb531073b576">16,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibfa7323ee88a439a91a0ce98d394f1b9_D20210101-20211231" decimals="0" sign="-" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTExLTEtMS0yMjYzMA_3b3c2ba5-6d27-497a-8488-88a3cd18ec6f">82,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231" decimals="0" name="cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTE0LTEtMS0yMjYzMA_6939c148-d0ca-4c75-91c2-3290edb6f78a">4,853,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231" decimals="0" name="cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTE2LTEtMS0yMjYzMA_af9e08d3-b91f-4f07-a78a-2822f0d1ed5b">4,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231" decimals="0" name="cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTE4LTEtMS0yMjYzMA_f225e124-c409-4bdf-8a4c-daca636bf247">21,059,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTIyLTEtMS0yMjYzMA_47e45a91-ef13-4fc2-9abf-fd67120ef2fa">21,064,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cashless exercise of warrants upon initial public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic77193cc910d458e928d0612bcad6229_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIwLTE0LTEtMS0yMjYzMA_04e83f5e-0086-4cc3-9a58-bbbe011c68ca">9,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic77193cc910d458e928d0612bcad6229_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIwLTE2LTEtMS0yMjYzMA_a6bed914-5e5b-4c6e-a0eb-c22d2262032c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i243e310d4e9f4b44810d72c76300cb01_D20210101-20211231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIwLTE4LTEtMS0yMjYzMA_6f2ba0d4-81e1-4e38-bb18-215d669a048e">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie5ac1e9d0f1a4ddbaf6c8ceda2b4372b_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIwLTIyLTEtMS0yMjYzMA_dd5059de-cf12-4f5c-9257-38cf21005b53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sale of common stock in initial public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i0a2f3ed31f33425492aeff13156184d7_D20210101-20211231" decimals="0" name="cntx:StockIssuedDuringPeriodIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTAtMS0xLTIyNjMwL3RleHRyZWdpb246ODM0MTk4OTM5NDkwNDQxYmE1MjE2MDYwODY5NDZlMGNfOTM0NTg0ODgzNjE5NA_6ac68844-8daf-402f-9743-4e1589ca3139">4,321,374</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9bd53ac676234dc686b2453d0815dd41_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTE0LTEtMS0yMjYzMA_398b4775-c4ad-4cb3-bfe0-1ae9f7fa72af">5,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9bd53ac676234dc686b2453d0815dd41_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTE2LTEtMS0yMjYzMA_f5f73b3d-61ff-4af5-bb28-53e0a3b52981">5,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0843156761eb42e38470d03cf3e6bf74_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTE4LTEtMS0yMjYzMA_7a77ee2c-451a-4153-8de3-049878b8493c">24,422,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0a2f3ed31f33425492aeff13156184d7_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTIyLTEtMS0yMjYzMA_8874b99f-4838-4d53-b2d2-8128217345af">24,428,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sale of common stock in private placement, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i2caaf4d5a53246158004742c606c9ef6_D20210101-20211231" decimals="0" name="cntx:StockIssuedDuringPeriodIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTAtMS0xLTIyNjMwL3RleHRyZWdpb246NzFjNDRhNmZiZTU2NGVlNTlmYjk3NWUxNDI2MmQ0YjhfOTM0NTg0ODgzNjE4OA_7e305489-fece-45ae-a59f-174a8a3ce75e">2,369,496</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i045d90f6713c40aca3bb010b300e93c3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTE0LTEtMS0yMjYzMA_97ad3446-803f-4002-9a63-ee29c720028b">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i045d90f6713c40aca3bb010b300e93c3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTE2LTEtMS0yMjYzMA_1b72ad29-8ff2-4a19-90c0-b58142c53499">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25b12ba6b5674eebb227199023ca61fc_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTE4LTEtMS0yMjYzMA_2cf708fe-0835-4726-ac39-7211278abec5">28,875,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2caaf4d5a53246158004742c606c9ef6_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTIyLTEtMS0yMjYzMA_caeded41-c333-4de4-bda5-7dcd3e114f2e">28,880,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIzLTE0LTEtMS0yMjYzMA_99ec26db-79c4-4ed9-9098-6146e25cf4a7">20,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIzLTE2LTEtMS0yMjYzMA_9fc380bd-22cc-4c0b-baf0-fd5d046a8bb3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIzLTE4LTEtMS0yMjYzMA_8fcfd107-2d19-4a6a-94b0-58719fafeb80">511,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIzLTIyLTEtMS0yMjYzMA_592221f7-1362-4fc6-a400-f2ece3eed5da">511,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie50b1aaa60bf499993eee4785c15824f_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI0LTIwLTEtMS0yMjYzMA_014f404d-2cb4-4f7d-99ae-97c89d892cad">10,456,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI0LTIyLTEtMS0yMjYzMA_e870d914-e33b-48b3-b8ea-7ba8d2f4a320">10,456,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTEtMS0xLTIyNjMw_bbe73ed5-5074-42f7-b713-17356267e5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTMtMS0xLTIyNjMw_d6a542dd-34e2-4cb1-b980-749085c37955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTUtMS0xLTIyNjMw_b1acf9b9-a56e-4566-8621-15fe4f6c2fc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTctMS0xLTIyNjMw_217a3f88-10dd-41d1-acce-bc97035a7768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTktMS0xLTIyNjMw_6c112f04-40b6-41a9-9895-18557fe994f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTExLTEtMS0yMjYzMA_2fccfab7-b177-498a-be46-20db83ba6c39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaa6d7d44de0047f1bb1cbadc0b046365_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTE0LTEtMS0yMjYzMA_1aff104f-15ae-402b-bdea-fa2062342059">15,966,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaa6d7d44de0047f1bb1cbadc0b046365_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTE2LTEtMS0yMjYzMA_a0cd8d5a-0193-4b90-a1c1-005ff8fb6963">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1aeee7d03a0640068206aa28850aa627_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTE4LTEtMS0yMjYzMA_ec7313fb-dde5-4865-b060-bf84f598aada">77,510,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i69779aa1bd2d45a6ae2b2ae5627e59df_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTIwLTEtMS0yMjYzMA_1b2f4bd5-1119-41df-8837-5ed3e20fa182">29,254,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTIyLTEtMS0yMjYzMA_294348f4-7d09-40b3-8b3e-3b77ec07210d">48,272,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Context Therapeutics Inc. </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzMtMS0xLTEtMTE3NTg_38569b1c-00a2-41ab-8bf9-94424c882454">10,456,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzMtMy0xLTEtMTE3NTg_f0d79cbd-18f4-4967-bfda-c9ed5f7d8ff9">6,644,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzUtMS0xLTEtMjI0OTM_b42de82d-1259-4472-a917-e19317746a3d">3,087,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzYtMy0xLTEtMTgwNjk_90252981-618c-49a4-975b-44c951c1930e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of warrants for services provided</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzYtMS0xLTEtMjI0OTY_14cc4dcb-7e5e-4157-b728-3491975be036">371,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzctMy0xLTEtMTgwNjk_36b05c05-8db1-4ae5-9644-a96f7b12d877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzUtMS0xLTEtMTE3NTg_92a0b571-47ce-464c-a326-341efd90a3d0">511,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzUtMy0xLTEtMTE3NTg_56449f69-ff4e-4294-8897-24347e23e660">219,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzYtMS0xLTEtMTE3NTg_47429286-2221-46a5-bff3-e7855facffcc">46,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzYtMy0xLTEtMTE3NTg_f808de09-b475-4d5e-8610-633e87432f43">661,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible promissory notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzgtMS0xLTEtMTE3NTg_f97a979d-b7e1-4030-8ffc-127d84527af6">9,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="cntx:FairValueAdjustmentOnConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzgtMy0xLTEtMTE3NTg_78931868-8efc-49c0-aeee-fd13abc97f3c">9,877,857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEwLTEtMS0xLTIyNTI0_0583186e-6e5a-4040-a4ad-d513070d3470">125,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEwLTMtMS0xLTIyNTI3_ce3cd741-3a14-4429-8443-31e97223085d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEwLTEtMS0xLTExNzU4_17decdc3-c91e-4deb-a93d-0db9d06a300d">1,611,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEwLTMtMS0xLTExNzU4_e4ce556b-5e47-41b9-8ade-3ffee27db568">4,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzExLTEtMS0xLTExNzU4_95831726-7498-4ea5-9de0-e63c6905c52e">866,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzExLTMtMS0xLTExNzU4_60e7bcd9-ccd4-4806-bc46-bc75357b0054">556,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEyLTEtMS0xLTExNzU4_5461d46a-9154-4096-b8b0-c34a59ea5124">252,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEyLTMtMS0xLTExNzU4_20c4707a-8ccf-419c-bb4a-ac7a9d236473">757,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:81pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEzLTEtMS0xLTExNzU4_767f0773-8fd0-4fe5-afa1-bb58df7d9256">8,799,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEzLTMtMS0xLTExNzU4_77aa4c43-22f3-4847-9161-cc436a467f87">1,034,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE2LTEtMS0xLTIyNDkw_94b45272-f259-43ef-85b9-51398cc26708">250,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE0LTMtMS0xLTE4MDU5_06d23e59-08d9-413c-a4d6-3aa94f104a7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:81pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE1LTEtMS0xLTE4MDU5_c13c3de7-d07d-445b-8082-197c82986934">250,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE1LTMtMS0xLTE4MDU5_6dd7bb09-47f8-4ab6-b228-6afaf8364aef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of convertible bridge notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE2LTEtMS0xLTExNzU4_ba446cc2-33ec-4157-83b6-5f4eb17e5973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE2LTMtMS0xLTExNzU4_204d8c1e-7e93-4dda-99ca-3b1d74dba3e1">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of note payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE3LTEtMS0xLTExNzU4_1f52f014-c7e8-4378-b9e8-47dcc2413c76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE3LTMtMS0xLTExNzU4_e3db9b74-a18f-4f80-b81f-e2f726d3ffed">124,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of Series A preferred stock, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b6d70f7b20444b83ad2461cd950758_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE4LTEtMS0xLTExNzU4_22f3b4dc-b013-42a8-87f9-124e55610484">4,982,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE4LTMtMS0xLTExNzU4_159097f5-9653-4614-82b6-9c0b330f18d0">950,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of Series Seed preferred stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE5LTEtMS0xLTExNzU4_9dd449e9-142c-4005-8ab3-57f53501332b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE5LTMtMS0xLTExNzU4_e59e63aa-2c78-4764-9ec9-b20383cf6189">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of common stock in initial public offering, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIzLTEtMS0xLTIyNTAy_724f24b0-62f6-4145-84ac-70a4407e1389">24,428,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIzLTMtMS0xLTIyNTA4_0cf5b6f9-0ebe-4314-b7e0-661663461b2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of common stock in private placement, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI0LTEtMS0xLTIyNTA1_fd65f675-56db-4940-9a9b-7ae0ead7fe2a">28,982,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI0LTMtMS0xLTIyNTE1_df1ca1a0-57de-4527-b561-1e8aa82ed629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:81pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIwLTEtMS0xLTExNzU4_8532b4a1-7e3b-445c-8eba-2179b8c3703c">58,394,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIwLTMtMS0xLTExNzU4_18e2d5ac-8cfc-4c62-af04-c7fb328a2195">1,149,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIxLTEtMS0xLTExNzU4_85c4cd18-aac3-4b9e-930f-46a8d89a0dd2">49,344,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIxLTMtMS0xLTExNzU4_f6acc2fc-5dc0-4c98-afb2-44e3733f1406">114,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIyLTEtMS0xLTExNzU4_3957d2aa-3bef-4661-b604-874a5e30fc85">341,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8740cca1c745199eda7ed1a4c1f483_I20191231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIyLTMtMS0xLTExNzU4_6bbc2251-da00-46a1-bb20-1807b5c98c68">226,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of year</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIzLTEtMS0xLTExNzU4_1ab4e205-fc6d-468a-b068-95fc3350f17c">49,685,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIzLTMtMS0xLTExNzU4_2fd4f0b7-b260-4c2b-9c0c-93ec520e3982">341,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of convertible promissory notes, including accrued interest, to Series A preferred stock and warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000327aebd1d4982bbd9d962da1fdf97_D20210101-20211231" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI1LTEtMS0xLTExNzU4_a0af5c3f-375d-4443-9a04-ccc32c332203">5,866,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1870092b17d54844b0aa4cbcc3f8ca0c_D20200101-20201231" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI1LTMtMS0xLTExNzU4_ce0b2935-db3e-4093-8e79-805bddddf7e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of bridge notes, including accrued interest, to Series A preferred stock</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b39b2be197f4335a69486c43230e142_D20210101-20211231" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI2LTEtMS0xLTExNzU4_5f1451b3-182b-4d03-9064-1fb82f02533e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f53e07ae1ec473f8c5c078ea26659c1_D20200101-20201231" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI2LTMtMS0xLTExNzU4_b7f4b470-6d71-4736-b113-f575b7b0b20c">529,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of convertible promissory notes, including accrued interest, to Series Seed preferred stock</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8e22b696e144e3ac3f230b33279167_D20210101-20211231" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI3LTEtMS0xLTExNzU4_c09d2110-c3ec-4319-8acf-217afad03e05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001e36ae235344e082b79a6dc0a8bcdb_D20200101-20201231" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI3LTMtMS0xLTExNzU4_0279a08e-b4ec-4185-a2f6-901b2fa1c90c">6,291,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of warrants in conjunction with Series A preferred stock and placement agent fees</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="cntx:WarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI4LTEtMS0xLTExNzU4_a5f40bc4-ea9b-4d78-bb61-ae627a628573">309,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="cntx:WarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI4LTMtMS0xLTExNzU4_24a55514-7554-4977-b5e1-596318cac325">78,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A preferred stock issued for acquired in-process research and development</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzM1LTEtMS0xLTI1NjI0_db0b999e-b945-483f-9a06-1440233d1ed0">2,837,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzM1LTMtMS0xLTI1NjI0_2a35987d-ab13-4a11-be3e-4e5876f7ac99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid offering costs in accounts payable</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="cntx:DeferredOfferingCostIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI5LTEtMS0xLTExNzU4_ea520afc-1b22-4186-86df-4819983ee97d">102,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="cntx:DeferredOfferingCostIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI5LTMtMS0xLTExNzU4_4c7f7a53-a299-4fb2-86ee-b557afcee125">117,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of redeemable common stock to redemption value</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzMwLTEtMS0xLTExNzU4_e4ec53c7-8eed-4c59-8c26-8ad4822acc64">53,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzMwLTMtMS0xLTExNzU4_bb2c497c-7980-4d2e-afc7-663511d6a80a">97,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of preferred stock and redeemable common stock upon initial public offering</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzM4LTEtMS0xLTIyNTM1_d7d32327-32a2-40f3-aa10-27855c1054a8">21,064,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzM4LTMtMS0xLTIyNTUy_1836d37b-776b-48f3-a884-bf6ba9c80f51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTEXT THERAPEUTICS INC. </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_109"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDkvZnJhZzozMjg5YTg5NDg1NGM0NmZjYjcwNzE5ODY2Zjg2YzI5NS90ZXh0cmVnaW9uOjMyODlhODk0ODU0YzQ2ZmNiNzA3MTk4NjZmODZjMjk1XzE2NDkyNjc0NDE5NDA5_4e3bae1c-7ac2-429e-9efe-0bc46d92dc36" continuedAt="i9e2d5c504a7845fd967d27f775450e3b" escape="true">Nature of Business </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9e2d5c504a7845fd967d27f775450e3b">Context Therapeutics Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#8217;s operations are located in Philadelphia, Pennsylvania. In April 2021, the Company completed a reverse triangular merger, which resulted in Context Therapeutics Inc. becoming the sole holder of <ix:nonFraction unitRef="number" contextRef="id7d9b23ad16c43aa8572a0ac6ca614b4_I20210430" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDkvZnJhZzozMjg5YTg5NDg1NGM0NmZjYjcwNzE5ODY2Zjg2YzI5NS90ZXh0cmVnaW9uOjMyODlhODk0ODU0YzQ2ZmNiNzA3MTk4NjZmODZjMjk1XzE2NDkyNjc0NDE5NDA0_b71bd307-219a-4801-ab49-c3bb44b96ae8">100</ix:nonFraction>% of the membership interests in Context Therapeutics LLC. In connection with the merger, all common units, preferred units, options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock, options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. As this was a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities and equity of Context Therapeutics LLC. Further, as a common control transaction, the consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.</ix:continuation></span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_112"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="cntx:RisksAndLiquidityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzM4Mzk_0ff5aba5-d4fb-43e6-a57a-28c0d7873b07" continuedAt="i86213625adb140229fcb85fda4630908" escape="true">Risks and Liquidity </ix:nonNumeric></span></div><ix:continuation id="i86213625adb140229fcb85fda4630908" continuedAt="i94fe6748241e42928776904cc2fe7d5d"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzYwNDczMTM5NTY2MzA_7bac54d1-3de7-45b0-bb6d-af8b3c1c6e3e">29.3</ix:nonFraction> million as of December&#160;31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its product candidates currently in development. The Company&#8217;s primary source of liquidity to date has been the issuance of convertible promissory notes, convertible preferred stock and common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first half of 2021, the Company raised $<ix:nonFraction unitRef="usd" contextRef="i4173532c9b754389b02c47c17758a39e_D20210101-20210630" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzYwNDczMTM5NTY2NjI_03470299-36c5-4431-8661-2de05ee0ce5e">5.0</ix:nonFraction> million in net proceeds related to the sale of its Series A convertible preferred stock (&#8220;Series A Stock&#8221;) and warrants for common stock (see Note 7 for further discussion). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2021, the Company closed an initial public offering (&#8220;IPO&#8221;) on the Nasdaq Stock Market, in which it issued and sold <ix:nonFraction unitRef="shares" contextRef="ib574e9442de340bba7e8df59de0aa8ea_D20211001-20211031" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDQ1_bea5e9c6-31de-46cf-a726-438667d90470">5,750,000</ix:nonFraction> shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifaec33cca2ed463caf5a7211bdf75d02_I20211031" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDU2_5ceef92e-0b44-40bc-807a-925505ea73e4">5.00</ix:nonFraction> per share. In addition, at the closing of the IPO, the Company issued warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ic9fe5d1cf7064523ac856ef87a48d0ed_I20211031" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDYz_229b565b-9612-4c8f-b0e8-c03c45b3c583">250,000</ix:nonFraction> shares of common stock to designees of the placement agent. The placement agent&#8217;s warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9fe5d1cf7064523ac856ef87a48d0ed_I20211031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDkw_c21ef994-d0b6-4689-ac95-8fed74d07c55">6.25</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="ic9fe5d1cf7064523ac856ef87a48d0ed_I20211031" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTA1_e47a7a01-a431-4cfe-acdb-e14bead803a6">five years</ix:nonNumeric> from the date of issuance. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDc5_fb9de2a5-058c-4359-bb30-921ef8d4552a">4,853,533</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i536b13a96232407dbc13d841f1fce5a7_I20210930" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDk3_644138b9-ff89-4e25-8415-77be358e0d79">480,415</ix:nonFraction> warrants converted into <ix:nonFraction unitRef="shares" contextRef="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031" decimals="0" name="cntx:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDcy_e90355df-3bbd-4eb1-bd1b-ff1eb630fa43">9,816</ix:nonFraction> shares of common stock. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzkzNDU4NDg4NTg3NTQ_9fce6798-a28e-4a1f-a532-c9fda99a4b25">24.4</ix:nonFraction>&#160;million as a result of its initial public offering. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTIy_02841ab3-5fc2-40ab-a618-8b830ab134ac">5,000,000</ix:nonFraction> shares of its common stock together with warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTMz_9c10140d-bd38-41b1-8884-630f5432de35">5,000,000</ix:nonFraction> shares of its common stock in a private placement and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231" decimals="0" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzEyMDk0NjI3OTI3Mzk5_6b262aa8-e907-4587-b76b-ee1e38c1222a">28.9</ix:nonFraction> million.  Each share of common stock and accompanying warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5177f9964b244a76b68f2abaac086c21_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTUx_8e864815-b73e-4143-8d84-eff0599373dd">6.25</ix:nonFraction>. The warrants have a term of <ix:nonNumeric contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTcz_7d61c121-6941-4bf7-8ac2-7fdc12a1bb3f">5.5</ix:nonNumeric> years and an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTQ0_f3c42900-95cb-405c-96db-4d3e6841af51">6.25</ix:nonFraction> per share. In addition, at the closing of the private placement, the Company issued warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTY1_b315ff77-e5c4-49e3-81f3-1295bbfe423a">250,000</ix:nonFraction> shares of common stock to designees of the placement agent. The placement agent&#8217;s warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTU4_c6641284-6895-497d-99b5-6dcbc9cdd6fe">6.25</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTg5_538bcd98-a0b7-42cc-843d-8d20485058ec">5.5</ix:nonNumeric> years from the date of issuance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its cash and cash equivalents at December&#160;31, 2021 are sufficient to fund its projected operations into fiscal year 2024. However, substantial additional capital will be needed by the Company to fund its operations and to commercially develop its current and future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to secure additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#8217;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#8217;s product candidates, length of time and cost of developing and commercializing these </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i94fe6748241e42928776904cc2fe7d5d" continuedAt="ic384e721d90840fe83a6dc8ee6aec2b0"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#8217;s financial condition and future operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. </span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic384e721d90840fe83a6dc8ee6aec2b0">In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.</ix:continuation> </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_115"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTM3_2f7a1fb5-54d4-4afa-8b26-6fecae5def03" continuedAt="i4390777564684576af6b64a0e1f9d138" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i4390777564684576af6b64a0e1f9d138" continuedAt="ic1c0ac3f99c74367abb4a4095dd5831f"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQx_d2507a54-693b-4f05-b66c-adf02cd5b8cc" continuedAt="i6c07abb614b04fc4bde7f848bd16fca1" escape="true">Basis of Presentation and Principles of Consolidation </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6c07abb614b04fc4bde7f848bd16fca1">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</ix:continuation> <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTM4_f16a10bd-d843-4a15-8023-cc1d6f68af09" escape="true">The consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMTQ4OTI_15f1bbe3-245b-4d0e-8b13-817b22ab1ade" continuedAt="ifc83c1d50b1c48f2880a3e185fe3e642" escape="true">Reclassification of Prior Year Presentation</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc83c1d50b1c48f2880a3e185fe3e642">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQy_1628e52a-76f9-4538-8299-b774c48a7afa" continuedAt="i7a7804364e6d49038cfb2b1d25ba59ab" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a7804364e6d49038cfb2b1d25ba59ab">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of warrants, the fair value of convertible debt, and prepayments, accruals and associated expense related to research and development activities performed for the Company by third parties.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTM5_bf01e21d-fb38-4294-8312-1ea7190c68ec" continuedAt="i341749f3fdb04dceafd8184ed993d2af" escape="true">Concentrations of Credit Risk </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i341749f3fdb04dceafd8184ed993d2af">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ic1c0ac3f99c74367abb4a4095dd5831f" continuedAt="i2a6091fab2344f5e9537e033f535dea5"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTUw_118d4f8a-e19d-47f0-83bd-d5dbea7cee11" continuedAt="i727dcfe3a31444bd88c9b50ab3634756" escape="true">Segment Information </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i727dcfe3a31444bd88c9b50ab3634756">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzYwNDczMTM5NzA5NTI_4090d2b8-bf1d-46c2-a1f0-a901ff0c9a11">one</ix:nonFraction> segment.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQ1_5d08da13-138c-4818-883e-6a4e30a274ae" continuedAt="i753b089d34214daaa13788dfcaabc278" escape="true">Fair Value of Financial Instruments </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i753b089d34214daaa13788dfcaabc278">At December&#160;31, 2021 and 2020, the Company&#8217;s level 1 financial instruments included cash equivalents and accounts payable. The carrying amounts of these assets and liabilities approximate fair value due to their short-term nature. Convertible promissory notes are recorded at approximate fair value on a recurring basis</ix:continuation> (see Note 4 for further discussion). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQ2_fe920f94-9b8f-4130-b9cb-702a230c4623" continuedAt="i2880957e09e94a60b55c4748278c7482" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2880957e09e94a60b55c4748278c7482">The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains approximately $<ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDU0ODA_d38ec7bc-b8a2-4e00-b48c-7b5cf4661100">50,000</ix:nonFraction> as collateral for the Company&#8217;s credit card program. The Company has recorded this deposit and accumulated interest thereon as restricted cash on its consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMjExMDc_4113f1de-ba13-4da4-b886-5ebd3d56d33a" continuedAt="i8728cbfbfab44d9381ba6b39dabde852" escape="true">The following table presents the Company&#8217;s cash, cash equivalents, and restricted cash as of December 31, 2021 and 2020:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:continuation id="i8728cbfbfab44d9381ba6b39dabde852"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"></td><td style="width:51.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzItMi0xLTEtMjk2NzY_0497eab4-52a0-435a-931b-af5dd562cf64">49,635,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzItNC0xLTEtMjk2ODM_a9a5f0ba-1178-447f-b98f-eae2825630e8">290,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzMtMi0xLTEtMjk2NzY_c55c822b-0991-403b-83a6-8932ffbefb23">50,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzMtNC0xLTEtMjk2ODM_ad5e3611-dbc4-49ec-b3fe-1198082bda75">50,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzQtMi0xLTEtMjk4ODk_e1945a6c-a2ee-47aa-98dc-0c9dd895141d">49,685,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzQtNC0xLTEtMjk4ODk_204e15d8-a40f-4734-9eec-dd700b960d10">341,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQz_aa932e5c-684c-48ea-980b-7cda9dc206bd" continuedAt="i9c3e8efb4852498d9b8bfe127bf1aa7a" escape="true">Deferred Offering Costs </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9c3e8efb4852498d9b8bfe127bf1aa7a">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations.</ix:continuation>  As of December&#160;31, 2020, the Company had deferred offering costs of $<ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="-5" name="us-gaap:DeferredCostsCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzQzOTgwNDY1NDA1MTI_2b5b4ec8-0a99-4eee-915d-b9de0af1d280">0.1</ix:nonFraction> million related to the Company&#8217;s IPO and the Company&#8217;s Series A Stock financing.  All deferred offering costs related to the Company&#8217;s Series A Stock financing were recorded against Series A Stock upon completion of the financing in April 2021 and all deferred offering costs related to the Company&#8217;s IPO were recorded against additional paid-in capital upon completion of the IPO financing in October 2021. There were <ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="-5" name="us-gaap:DeferredCostsCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMTY3NDY_f747db5f-7132-439d-8039-0500388ad591">no</ix:nonFraction> deferred offering costs recorded as of December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="cntx:TemporaryEquityPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMjExMDg_32c506dd-428a-478a-ac92-dd1e4e961963" continuedAt="i15c771cf7d344ea0903e8d9bbde5c6bb" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock and Redeemable Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its convertible preferred stock subject to possible conversion in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Conditionally convertible preferred stock (including shares that feature conversion rights that are either within the control of the holder or subject to conversion upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. The Company&#8217;s convertible preferred stock feature redemption rights that are considered by the Company to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020, the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i2a6091fab2344f5e9537e033f535dea5" continuedAt="if714b009278b4604aa356e527de0d2fa"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i15c771cf7d344ea0903e8d9bbde5c6bb">convertible preferred stock subject to contingent redemption are presented as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheets.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMTQ4OTM_7a534eba-91d6-4188-9512-a519c800d2b0" continuedAt="ia28be6757a2f48eda218ce018c715028" escape="true">Acquired In-Process Research and Development Costs</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:continuation id="ia28be6757a2f48eda218ce018c715028" continuedAt="i9bd2e7243cf048ea90f580ec11c47825"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expense consists of the initial up-front payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9bd2e7243cf048ea90f580ec11c47825">.</ix:continuation> The Company&#8217;s acquired IPR&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMTQ5MDA_ca4d7f11-ce2f-4fe2-884c-ba7c4b9a5030">3.1</ix:nonFraction>&#160;million for the year ended December 31, 2021 reflects the fair value of consideration ascribed to the collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) for gynecologic cancer therapy. See Note 9 for further discussion.</span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQ3_d07fe6e7-31da-48de-813b-e87f9c07ebfe" continuedAt="i82fd529219854f98a81e505b52f86c57" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of prepaid/accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the prepaid/accrual accordingly. </span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i82fd529219854f98a81e505b52f86c57">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</ix:continuation> </span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="cntx:PatentCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDU0Nzc_20c2004c-0e43-45f9-b91e-8785505374d9" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTI_f2bf962a-c72c-43e6-8901-9479aa169669" continuedAt="idd3a7408330d48ce94de1c679b14ac45" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients&#8217; service payments are classified. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. Until its IPO that closed in October 2021, the Company had been a private company and lacked Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="if714b009278b4604aa356e527de0d2fa" continuedAt="i8a441c4ee4e84602a273b623b2e58604"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd3a7408330d48ce94de1c679b14ac45">In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted stock awards based on the grant date fair value of the awards.</ix:continuation> </span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTM_ed25594d-7145-488e-ad9b-f04559038abf" continuedAt="id6dbe6a7bec14edcae0fadae35c2f9d4" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to April 2021, the Company was a limited liability company that was treated as a pass-through entity for income tax purposes. In April 2021, upon the completion of its reverse triangular merger, the Company converted to a corporation and is subject to federal, state and local corporate income taxes which have been provided for in the financial statements based upon ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 740&#8221;).  Context BioPharma, Inc. has always been subject to corporate income taxes. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under ASC 740, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting. Deferred tax assets are reduced by a valuation allowance if a determination is made that it is more likely than not that some or all of the deferred tax assets will not be realized based on the weight of all available evidence.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an examination. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50&#160;percent likelihood of being realized upon settlement with the relevant authority. </span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id6dbe6a7bec14edcae0fadae35c2f9d4">The Company will recognize interest and penalties related to uncertain tax positions in income tax expense.</ix:continuation> As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzkzNDU4NDg5MDQ1MTU_25b65691-0af3-423c-9d47-39ab19c1c537"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzkzNDU4NDg5MDQ1MTU_c6cb5699-852a-411d-b823-4aad573902f4">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzkzNDU4NDg5MDQ1ODg_98687dac-eb39-49f4-9953-a17f6e1256bb"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzkzNDU4NDg5MDQ1ODg_ff272b86-0df4-4273-b566-48cbe451e414">no</ix:nonFraction></ix:nonFraction> amounts have been recognized in the Company&#8217;s consolidated statements of operations. </span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTQ_90f4bae8-dd6c-433b-bc1d-9f5e033eede2" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income Per Share </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes net (loss) income per share using the weighted-average number of common shares outstanding during the year. For years with a net loss, basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which includes convertible promissory notes, preferred stock, warrants and share-based awards outstanding, would be anti-dilutive.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was in a net loss position for the year ended December 31, 2021 and therefore basic and diluted net loss per share was the same. <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTY_60f85450-db54-4528-8839-9706cd0039fa" continuedAt="ib51e8e16886149bd8f20ab94928cce9a" escape="true">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020, as they would be anti-dilutive:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="ib51e8e16886149bd8f20ab94928cce9a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:67.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc8935fc9d464f29836a2a16fe277e98_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzItMi0xLTEtMzAzMDY_01deb4e6-b3c1-4d72-ba3b-98074a7d8648">506,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id255264c0c894b67a64f0a3ef3d68e1c_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzItNC0xLTEtMzAzMDY_29dd9127-bb0f-44d3-8b7c-abe7084516a3">24,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5f9e0e12992402d90ec7a6af875e1fc_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzMtMi0xLTEtMzAzMDY_f73989ad-0cb8-4a9b-98f0-1365e5875a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5aebf98410d2455caa4d29b128109b43_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzMtNC0xLTEtMzAzMDY_6542ae7b-a79b-4e90-88c2-1a248e8c5c88">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d242a6318ef4c6bbdd7b8627be0cff1_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzQtMi0xLTEtMzAzMDY_57bb7617-791c-42c4-a3a6-8ea284dc99bb">5,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i887b64939c5845d2a4612345d96858c2_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzQtNC0xLTEtMzAzMDY_5b7698a9-65e5-4895-9b69-7c25d8b52d1f">160,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzUtMi0xLTEtMzAzMDY_fe500906-b9c5-4b40-ac81-09f52338ffce">6,006,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzUtNC0xLTEtMzAzMDY_fa02bb6d-b176-4a5f-a297-f716cf00272a">184,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, the Company was in a net income position and therefore, used the two-class method to compute basic net income per common share. Under this method, undistributed earnings are allocated to common stock, the Series Seed Preferred Stock and the Series A Preferred Stock to the extent that the preferred stockholders may share in earnings. In periods of net loss, losses are not allocated to participating securities as the holders of such securities have no obligation to fund losses. The total earnings allocated to common stock is then divided by the weighted average common shares outstanding to determine the basic earnings per share. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i8a441c4ee4e84602a273b623b2e58604" continuedAt="ide9df619b6fc48fbb17222e8cfdff8be"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants and share-based awards using the treasury stock method. In addition, the Company considers the potential dilutive impact of its preferred stock and convertible debt using the treasury stock and if-converted methods, if either is more dilutive than the two-class method. <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTc_5c33de48-689f-4585-ba28-91d62e2d4d6a" continuedAt="ibb81ce3dd0d54d5f927e089241b3f408" escape="true">The two-class method was more dilutive for the year ended December 31, 2020. </ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="ibb81ce3dd0d54d5f927e089241b3f408"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net (loss) income per common share calculation:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzMtMS0xLTEtMzAyNjE_42cffb12-12e0-4632-9404-4ce793554ec6">10,456,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzMtMy0xLTEtMzAyNjE_7841d148-b318-448c-afe5-5c44d4486af6">6,644,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed earnings to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzQtMS0xLTEtMzAyNjE_794cf4c5-9e5c-48eb-af74-ef00ab81a9a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzQtMy0xLTEtMzAyNjE_1d8a3dc7-c247-402c-ac4b-bd1a0e8f2fa2">5,573,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders - basic</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzUtMS0xLTEtMzAyNjE_ee7836eb-9058-42ff-ae39-6e7bb415d0cc">10,456,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzUtMy0xLTEtMzAyNjE_1fe22436-a09f-4474-aef7-19ae090564f0">1,070,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzYtMS0xLTEtMzAyNjE_b2e8ede6-0c7c-48ac-9e07-fc2211965a5e">2,833,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzYtMy0xLTEtMzAyNjE_67602241-46f7-4f45-8a31-a6372e78f73c">348,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - basic</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzctMS0xLTEtMzAyNjE_ccf26cb3-c077-4f92-a6a6-aab62125ed8e">3.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzctMy0xLTEtMzAyNjE_10b2aa1e-0395-4e96-9bad-d5ae6b8e8ad6">3.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net (loss) income per common share calculation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzktMS0xLTEtMzAyNjE_30fcf021-c648-44cf-9c1b-edad9cc4c929">10,456,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzktMy0xLTEtMzAyNjE_7a22689a-cadd-48d3-b9bc-383f10ab9fbc">6,644,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed earnings to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEwLTEtMS0xLTMwMjYx_e0c71af3-7e86-43ad-b29b-f6686148370c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEwLTMtMS0xLTMwMjYx_94036e09-2dba-4790-b68f-87fe5f3bae76">5,573,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: change in fair value of convertible promissory notes and interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzExLTEtMS0xLTMwMjYx_a9e7c68d-2f54-4e7e-bd29-af0c8ef48487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" sign="-" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzExLTMtMS0xLTMwMjYx_97d7c567-9a7b-4838-8cca-c21183687732">9,216,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders &#8211; diluted</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEyLTEtMS0xLTMwMjYx_b06df87e-0b40-439d-8325-51e3035ae39d">10,456,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEyLTMtMS0xLTMwMjYx_e92f74f1-681d-4590-a09a-a87e1332ae17">8,145,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEzLTEtMS0xLTMwMjYx_a472fee7-6053-4456-b1de-49592afe03d1">2,833,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEzLTMtMS0xLTMwMjYx_97298817-b26b-4086-8cfc-7c02d3187553">348,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE0LTEtMS0xLTMwMjYx_5b5e3e87-d3d8-4485-89c4-163b79b83074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE0LTMtMS0xLTMwMjYx_8f396a93-9a9b-4ebd-bde0-dd8ff0b5e77c">1,706,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE1LTEtMS0xLTMwMjYx_d7e08134-10ca-4323-9ccf-d9dbb579fd0d">2,833,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE1LTMtMS0xLTMwMjYx_4aa60bef-ca8a-474b-ab80-14e7ec10aac7">2,054,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - diluted</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE2LTEtMS0xLTMwMjYx_bead1cf0-f622-481c-90e8-3df6902af998">3.69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE2LTMtMS0xLTMwMjYx_5e849307-c397-411a-b8e4-9285ee618e50">3.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTU_10ee73bc-3eb8-439a-a619-a24aed06ea57" continuedAt="ic6f7b81815d04c5a9bc3653ed99e759e" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt&#8212;Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 470-20) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminated the beneficial conversion (and cash conversion) accounting models in ASC 470-20 that require separate accounting for embedded conversion features and simplified the settlement assessment to determine whether it qualifies for equity classification by removing certain conditions in ASC 815-40-25. In addition, the new guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments and to include the effect of share settlement for instruments that may be settled in cash or shares. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its financial statements and related disclosures. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ide9df619b6fc48fbb17222e8cfdff8be" continuedAt="i864fd734ef1142c59e6e7780bfcfc61d"><ix:continuation id="ic6f7b81815d04c5a9bc3653ed99e759e" continuedAt="ia8968fd9d0ba48dbb1f7c41aa28a7af2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div></ix:continuation></ix:continuation><div style="text-indent:18pt"><ix:continuation id="i864fd734ef1142c59e6e7780bfcfc61d" continuedAt="i4fd1df72625e46ddb009dd9bb3c4d352"><ix:continuation id="ia8968fd9d0ba48dbb1f7c41aa28a7af2" continuedAt="i36218edbafc64b16a8033e612f65c1bc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2016, the FASB issued ASU 2016-02,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,&#160;in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a)&#160;the existence of a lease, (b)&#160;the lease classification or (c)&#160;the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases (Topic 842): Targeted Improvements</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i4fd1df72625e46ddb009dd9bb3c4d352"><ix:continuation id="i36218edbafc64b16a8033e612f65c1bc">, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.</ix:continuation></ix:continuation>  </span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_118"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90ZXh0cmVnaW9uOmQ5YTA1MTY4YjY4ZTQ1NDRhZmQzZjhlNmE4YTRjYzFmXzQwODY_2fef9c9a-2c6d-4f6f-b9f4-73285b95ae8e" continuedAt="i9dc8027dfc354dfab473b9a5b10a4252" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="i9dc8027dfc354dfab473b9a5b10a4252" continuedAt="ie963648ef3f94510a4e8e8b442003494"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2 &#8211; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3 &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90ZXh0cmVnaW9uOmQ5YTA1MTY4YjY4ZTQ1NDRhZmQzZjhlNmE4YTRjYzFmXzQwODc_ec821465-5841-48a6-8347-7ecb08a86338" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Active Markets for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets (Level 1) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant&#160;Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Observable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 2) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unobservable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 3) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents and restricted cash (Money Market Accounts)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce232c5ed264fc1a5e2e91833604312_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTpjNTA5Y2M0YjY1YjM0YWIzOWU4MTQ2NTQwODgwNjhmZS90YWJsZXJhbmdlOmM1MDljYzRiNjViMzRhYjM5ZTgxNDY1NDA4ODA2OGZlXzMtMS0xLTEtMTE3NTg_d2a82c12-3fd1-4bf5-b728-aaa464f60ed1">49,051,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcee81aa26da40c7aa01c8ed07319386_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTpjNTA5Y2M0YjY1YjM0YWIzOWU4MTQ2NTQwODgwNjhmZS90YWJsZXJhbmdlOmM1MDljYzRiNjViMzRhYjM5ZTgxNDY1NDA4ODA2OGZlXzMtMy0xLTEtMTE3NTg_708908f2-868d-4249-919d-e83e92c16efb">49,051,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d84cd8ac404ffb9652dfeadc1a177f_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTpjNTA5Y2M0YjY1YjM0YWIzOWU4MTQ2NTQwODgwNjhmZS90YWJsZXJhbmdlOmM1MDljYzRiNjViMzRhYjM5ZTgxNDY1NDA4ODA2OGZlXzMtNS0xLTEtMTE3NTg_b81de7f8-cc0d-4554-b828-ced336df0b8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68566af59223448eb22d5006be5194ba_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTpjNTA5Y2M0YjY1YjM0YWIzOWU4MTQ2NTQwODgwNjhmZS90YWJsZXJhbmdlOmM1MDljYzRiNjViMzRhYjM5ZTgxNDY1NDA4ODA2OGZlXzMtNy0xLTEtMTE3NTg_7a16833e-8998-4258-a775-2f3fe359f6e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Active Markets for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets (Level 1) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant&#160;Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Observable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 2) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unobservable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 3) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (Money Market Account)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77004ca7aa1445119a9a78b5703984df_I20201231" decimals="0" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzMtMS0xLTEtMTE3NTg_a97a320e-fe6e-4e48-8770-f4a3c85fd569">50,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c0a790ca1c4e73b5def12d29757201_I20201231" decimals="0" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzMtMy0xLTEtMTE3NTg_14340175-8616-443f-a6d4-cf8d730ace1c">50,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c39b33c88a8458686857dd42b2e64f9_I20201231" decimals="0" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzMtNS0xLTEtMTE3NTg_6602d7b4-44ce-4d90-ab44-57a4633bee91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic199b723275d45d2bc21be1587aae664_I20201231" decimals="0" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzMtNy0xLTEtMTE3NTg_2caeb5c3-f946-45b1-a2ad-577bce9dcfc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Promissory Notes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34409531cae4268bc173922ce57ac3f_I20201231" decimals="0" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzUtMS0xLTEtMTE3NTg_dd64e2e0-599c-49ef-bd79-89ed99eeb4e4">5,829,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib510cda252c24e72b8fa50da53cf17e1_I20201231" decimals="0" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzUtMy0xLTEtMTE3NTg_0f418563-37ed-419d-9294-fcf76f6ae960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b5edd019244d8c9ac599aebe563739_I20201231" decimals="0" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzUtNS0xLTEtMTE3NTg_94110193-c2f5-46be-8277-863f99ff0563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908727eba5bc4358b2ac0822d99cd9ba_I20201231" decimals="0" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzUtNy0xLTEtMTE3NTg_15dc1384-6238-4ba7-aef5-479993e8d411">5,829,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 6, the Company issued convertible promissory notes from inception through April 2019 (the &#8220;Junior Convertible Notes&#8221;) to various investors and from October 2019 through March 2020, the Company issued convertible bridge notes to the Co-Founder and Chief Executive Officer (the &#8220;Convertible Bridge </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ie963648ef3f94510a4e8e8b442003494"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes&#8221;). During April 2020, certain of the Junior Convertible Notes were converted into Senior Convertible Notes (the &#8220;Senior Convertible Notes&#8221;) (collectively, the &#8220;Convertible Promissory Notes&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the number of embedded provisions contained in the Convertible Promissory Notes and Convertible Bridge Notes, the fair value option, as prescribed by ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was elected and applied to all Convertible Promissory Note and Convertible Bridge Note issuances since the Company&#8217;s inception in 2015, in connection with the preparation of these financial statements. The fair value of the Convertible Promissory Notes and Convertible Bridge Notes was determined using a scenario-based analysis that estimates the fair value based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the noteholders, including various IPO, settlement, equity financing, corporate transaction and dissolution scenarios. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adjusted the carrying value of its Convertible Promissory Notes and Convertible Bridge Notes to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as change in fair value of convertible promissory notes in the consolidated statement of operations. The change in fair value of convertible promissory notes within the years ended December 31, 2021 and 2020 consolidated statement of operations also includes reversals of gains and losses previously recognized by the Company upon conversion of the notes (Note 6).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Convertible Notes at  December 31, 2020 was calculated using an option pricing model (&#8220;OPM&#8221;) framework and utilized the back-solve method for inferring and allocating the equity value predicated on the concurrent sale of Series A Stock. This method was selected as it was concluded that the sale of the Series A Stock was an arm&#8217;s-length transaction. Application of the OPM back-solve method involves making assumptions for the expected time to liquidity and volatility, and then solving for the value of equity such that value for the most recent financing equals the amount paid.</span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90ZXh0cmVnaW9uOmQ5YTA1MTY4YjY4ZTQ1NDRhZmQzZjhlNmE4YTRjYzFmXzQwODg_8fcf473e-5e5f-4d92-8538-2af0301ca1d3" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of the aggregate fair values of the Company&#8217;s Convertible Promissory Notes (Note 6) for which fair value is determined by Level&#160;3 inputs: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55d52b883b8439db64cf84da4088ed2_I20201231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzEtMS0xLTEtMTE3NTg_e216fc79-d41b-49f4-b900-b609753762d9">5,829,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62db008cf5d41d287747c3ee2afb05c_I20191231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzEtMy0xLTEtMTE3NTg_12beb84b-a3d3-4a11-8786-edd71e808f75">21,842,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Convertible Bridge Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58cb9ed855944a858084c633831e74b3_D20210101-20211231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzMtMS0xLTEtMTE3NTg_d2cb5f0e-460e-418c-9e9e-4b8b8386617f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0dff24cca894323a3974079199c467e_D20200101-20201231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzMtMy0xLTEtMTE3NTg_b40ecc38-1e2c-47c8-bf6a-261e6ee080ae">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98b4298623094156bda38964f2ca6d72_D20210101-20211231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzYtMS0xLTEtMTE3NTg_abdad9f6-58f0-48ad-96ee-2b45678820fb">9,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb6e5f4b103e4e5482b8dc8b7527a3cc_D20200101-20201231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzYtMy0xLTEtMTE3NTg_dba8ad76-8969-476e-8371-caf90688e389">9,877,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b4298623094156bda38964f2ca6d72_D20210101-20211231" decimals="0" name="cntx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzctMS0xLTEtMTE3NTg_544055e2-9193-4123-aa35-d60aada42965">46,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6e5f4b103e4e5482b8dc8b7527a3cc_D20200101-20201231" decimals="0" name="cntx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzctMy0xLTEtMTE3NTg_9451333d-49d4-408b-8d8f-ecd25bdcca77">660,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of Junior Convertible Notes into Series Seed Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbdfcd435a84616aec15c81c9bb7b06_D20210101-20211231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzgtMS0xLTEtMTE3NTg_d1ff7312-4487-49aa-b991-5bf73effebe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89d4008efcc04a669ef14e103f9a6a6a_D20200101-20201231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzgtMy0xLTEtMTE3NTg_5de86270-9a50-4546-9156-c4e1a0b3c3e6">6,291,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of Senior and Convertible Bridge Notes into Series A Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia686afec9e234c72967a01ae8d98a108_D20210101-20211231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzktMS0xLTEtMTE3NTg_9e6e33d8-8584-4ab5-bd3b-66e4a44a24ed">5,866,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie234c0a724cd46029a0f0307bcf0e78b_D20200101-20201231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzktMy0xLTEtMTE3NTg_3d0acfc4-1a9a-4b94-9361-1e5188d6ca6f">529,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4296ddef4cfc4b709b45e518ab9c281c_I20211231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzEwLTEtMS0xLTExNzU4_8a7d0e03-0a5a-41c9-9ef4-4e6f2a6c2745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55d52b883b8439db64cf84da4088ed2_I20201231" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzEwLTMtMS0xLTExNzU4_fd708782-9e08-48ec-a2f2-e0e5541a909c">5,829,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1472"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGV4dHJlZ2lvbjo4ZDNiNWRjMzUzMWI0MGY3ODBlYWI1Mzc5YzFlNzM4M18yNzQ4Nzc5MDY5NzU0_095f6ac2-304c-4724-930a-4fef006b431c" continuedAt="ifb98b9c4638a4ba5af7e286e7ded527a" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="ifb98b9c4638a4ba5af7e286e7ded527a"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGV4dHJlZ2lvbjo4ZDNiNWRjMzUzMWI0MGY3ODBlYWI1Mzc5YzFlNzM4M18yNzQ4Nzc5MDY5NzU1_bc5153ae-5e03-48e9-ac88-d9c4c532c65a" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV8yLTItMS0xLTI1MjA0_86d52454-1d28-42b4-849c-29222f99c5e2">436,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV8yLTQtMS0xLTI1MjA0_7d76dfbd-bfa3-4b75-8f79-9f385956aac4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="cntx:ClinicalTrialLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV8zLTItMS0xLTI1MjA0_800a0d86-5062-4b04-ad3d-194290a52fd2">339,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="cntx:ClinicalTrialLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV8zLTQtMS0xLTI1MjA0_0af66e0a-2cb3-42c3-b801-e80dec0cebcc">126,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="cntx:ManufacturingDevelopmentLiabilitiesCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV80LTItMS0xLTI1MjA0_af6f1092-6cd3-4a0d-8033-1cdf2ed3379a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="cntx:ManufacturingDevelopmentLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV80LTQtMS0xLTI1MjA0_edb0fc2e-1234-4bef-9c7d-2684a494804f">560,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV81LTEtMS0xLTI1OTMz_bba45393-f0c1-466f-b3f1-39c8ef888396">345,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV81LTMtMS0xLTI1OTMz_2fbfaaa3-c27a-48ca-a609-60a59feba5a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV81LTItMS0xLTI1MjA0_d1fe9526-2757-47dd-b365-dc664ea49937">85,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV81LTQtMS0xLTI1MjA0_736d938f-5de9-41a7-b29b-20797eb27658">269,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV82LTItMS0xLTI1MjA0_641d650f-c32d-46fb-9905-34dc6dbd3253">1,207,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV82LTQtMS0xLTI1MjA0_d15f2141-0c00-4215-92b4-09933c6a09b3">955,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_121"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzk0OTE_37d755c2-1a4a-4163-aea9-b30d5d7ce676" continuedAt="ife71aa1b8d624a7789e2993b03023df2" escape="true">Convertible Promissory Notes </ix:nonNumeric></span></div><ix:continuation id="ife71aa1b8d624a7789e2993b03023df2" continuedAt="i6d90d016c6434feb8031f3402ef32c10"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Junior Convertible Notes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December 2018, the Company issued Junior Convertible Notes and demand notes that converted into Junior Convertible Notes which, due to certain embedded features within the Junior Convertible Notes, the Company elected to account for these notes and all their embedded features under the fair value option. All of the outstanding principal and accrued but unpaid interest associated with the Junior Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="ic2c5ebbe3b814fed872de2b6750f3337_D20200501-20200531" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjI5Mzc_5953571c-8291-4b8d-b874-c9c10935be27">2,615,553</ix:nonFraction> shares of Series Seed Stock in May 2020, of which <ix:nonFraction unitRef="shares" contextRef="i969ca1b809854daabd8f8995c295fec4_D20200501-20200531" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjI5NTk_e6005ab6-7b58-4140-a487-96c1c42286b2">840,363</ix:nonFraction> shares were issued to the Company&#8217;s Chief Executive Officer and an immediate family member (&#8220;Related Party&#8221;). At the time of conversion, the estimated fair value of the Junior Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="ib2e45ef9fdc642a0ac8a1d88dfeb09cb_D20200531-20200531" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjI5Nzc_42d474b1-4354-4285-975e-f86adcb849b8">6.3</ix:nonFraction> million and was reclassified to Series Seed convertible preferred equity. In connection with the conversion in 2020, the Company recorded a non-cash credit of $<ix:nonFraction unitRef="usd" contextRef="if5bffb2e3fd7430997f0e5cd07ec38b3_D20200501-20200531" decimals="-5" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMwMDY_c42eb2c7-0bad-4912-8924-58a4b6a6288f">7.7</ix:nonFraction> million related to the final decrease in fair value of the Junior Convertible Notes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Bridge Notes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From October 2019 through March 2020, the Company issued convertible bridge notes to the Related Party in the amount of $<ix:nonFraction unitRef="usd" contextRef="i3a7a5cded79d49a4a18179828d3d9f12_I20200331" decimals="-5" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMxMzc_de9a8559-8ef9-4e44-8858-9bfdeaa2bc7f">0.5</ix:nonFraction> million. On December&#160;22, 2020, the outstanding principal and accrued but unpaid interest associated with the Convertible Bridge Notes converted into <ix:nonFraction unitRef="shares" contextRef="i0f07fc75d54b479cb5bf55f32da7bf1c_D20201222-20201222" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMyMzc_065cb55a-2aad-4c83-93d1-d852eff91aa3">78,178</ix:nonFraction> Series A Stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to certain embedded features within the Convertible Bridge Notes, the Company elected to account for these notes and all their embedded features under the fair value option. At the time of conversion, the estimated fair value of the Convertible Bridge Notes was $<ix:nonFraction unitRef="usd" contextRef="i1b93a5662e8a4c92ba2e140ae85fb825_I20201231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMyNTM_c9ffe1c9-bc97-4a0f-90c8-ca87efb74175">0.5</ix:nonFraction> million and was reclassified to Series A convertible preferred equity.  In connection with the conversion in December 2020, the Company recorded a non-cash credit of $<ix:nonFraction unitRef="usd" contextRef="i453801845a4245559bdf44e3c243247b_D20201201-20201231" decimals="-5" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMyODI_58458cdc-ee90-4ca0-8468-a8055f0e9482">0.1</ix:nonFraction> million related to the final decrease in fair value of the Convertible Bridge Notes. For the year ended December 31, 2020, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i00def9c120e34dfd81ad8cc464be10c9_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMzNDA_7e7793d4-f250-47bd-8ddd-2856bbfcb8a9">30,000</ix:nonFraction> of interest expense in connection with the Convertible Bridge Notes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Convertible Notes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, $<ix:nonFraction unitRef="usd" contextRef="iee6cc68e23a644ccb73a6bd8317cac15_I20200430" decimals="-5" name="cntx:DebtInstrumentConvertedInstrumentPrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM0MDQ_a5945e54-7b52-4f51-8010-1d7bf58d8d64">5.1</ix:nonFraction> million of principal and $<ix:nonFraction unitRef="usd" contextRef="iee6cc68e23a644ccb73a6bd8317cac15_I20200430" decimals="-5" name="cntx:DebtInstrumentConvertedInstrumentInterestAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM0MzM_9954b41f-6128-42e5-961b-f457d75f9d73">0.6</ix:nonFraction> million of accrued interest related to certain Junior Convertible Notes were converted into Senior Convertible Notes. Of the Senior Convertible Notes issued in 2020, $<ix:nonFraction unitRef="usd" contextRef="i00ba2e7eb0484b1295d941578acf8031_I20200430" decimals="-5" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM0NjI_61ad03e3-05ce-4846-b6a8-6dcfa586bfed">2.5</ix:nonFraction> million of principal and $<ix:nonFraction unitRef="usd" contextRef="i00ba2e7eb0484b1295d941578acf8031_I20200430" decimals="-5" name="cntx:AccruedInterestRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM0OTE_ab2e84b2-cee3-4a22-9903-8c1c16f394d2">0.4</ix:nonFraction> million of accrued interest were issued to the Related Party. During the year ended December 31, 2021, the outstanding principal and accrued but unpaid interest associated with the Senior Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="i4cdb9eb262764bb9ad359f4cd6409d95_D20210201-20210228" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzkzNDU4NDg4NTgzMDU_06ecb544-f630-43d4-8eb1-10e3816243da">844,824</ix:nonFraction> shares of Series A Stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, the Company recognized a credit of $<ix:nonFraction unitRef="usd" contextRef="iff833741a565408283759dc258048916_D20200101-20201231" decimals="-5" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM1Nzc_8b15fc68-2fae-4756-b302-debe71659a0a">2.1</ix:nonFraction> million in the consolidated statement of operations related to decreases in the fair value of the Senior Convertible Notes. For the year ended December 31, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ica3de374ebb14eb283c5fa464ed31769_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM2MDY_12eb10fa-29f6-4b54-902a-3dc80ac90fe2">0.3</ix:nonFraction> million of interest expense in connection with the Senior Convertible Notes, including $<ix:nonFraction unitRef="usd" contextRef="ica3de374ebb14eb283c5fa464ed31769_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpenseRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM2MzU_64ffcedd-7dca-4724-92fa-57a325de5ffa">0.1</ix:nonFraction> million payable to the Related Party. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i6d90d016c6434feb8031f3402ef32c10"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into an original loan agreement with Pacific Western Bank as the lender (&#8220;Lender&#8221;) for a loan in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i2caffc25ed4f42e195b906a4eab85ec8_I20200531" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM2NjQ_e10fb9ac-5e22-42d3-968b-1122f8cf5528">0.1</ix:nonFraction> million (the &#8220;Loan&#8221;) pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Coronavirus Aid, Relief, and Economic Security (CARES) Act and implemented by the U.S. Small Business Administration. In June 2020, the Paycheck Protection Program Flexibility Act was enacted, which among other things, extended the deferral period for loan payments to either (1)&#160;the date that Small Business Administration remits the borrower&#8217;s loan forgiveness amount to the lender or (2)&#160;if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower&#8217;s loan forgiveness covered period. The Loan was set to mature in <ix:nonNumeric contextRef="i3bcdc4632b004d2e82615143090acd9c_D20200501-20200531" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM2OTM_9ab6079c-580d-478d-a5a0-991c608245f1">two years</ix:nonNumeric> and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="i2caffc25ed4f42e195b906a4eab85ec8_I20200531" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM3MTE_74983698-7a80-429c-bba8-4095a5b95b70">1.0</ix:nonFraction>% per year, with all payments deferred through September&#160;5, 2021. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The outstanding principal balance of the Loan of $<ix:nonFraction unitRef="usd" contextRef="i06a8b2942cc1406a9a317b357d09884d_I20210630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzEwNDQ1MzYwNDg2NTE2_a194d60d-363e-4fc1-9f06-e68f32e74c81">0.1</ix:nonFraction> million was forgiven in July 2021 and was recognized as a gain on extinguishment of debt within other income in the consolidated statement of operations.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_124"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzcwODA_fc9ec707-6607-4088-8027-5b0bf296b7d1" continuedAt="i79041ff292e544909c90a16368b5a724" escape="true">Convertible Preferred Stock, Redeemable Common Stock and Common Stock </ix:nonNumeric></span></div><ix:continuation id="i79041ff292e544909c90a16368b5a724" continuedAt="icbc603d45e55429a98f466b3844c5679"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company converted $<ix:nonFraction unitRef="usd" contextRef="if5bffb2e3fd7430997f0e5cd07ec38b3_D20200501-20200531" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NTk5NTk_e755c17a-41d1-4325-9e7b-c00ad243d53f">11.7</ix:nonFraction> million of principal and interest related to certain Junior Convertible Notes into <ix:nonFraction unitRef="shares" contextRef="ic2c5ebbe3b814fed872de2b6750f3337_D20200501-20200531" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NTk5OTA_027177b9-5553-4f83-abaf-fb14877eda0f">2,615,553</ix:nonFraction> shares of Series Seed Stock at prices ranging from $<ix:nonFraction unitRef="usdPerShare" contextRef="i60dcae9af0d042a6808422ea713c8707_I20200531" decimals="2" name="cntx:DebtConversionConvertedInstrumentPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwMTI_46936c3c-e442-4f5b-ae67-535b04214efb">4.28</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="if4ebfb8391004e768936ed5a183ccbe7_I20200531" decimals="2" name="cntx:DebtConversionConvertedInstrumentPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwMjY_81ffb0e6-1f7b-41b4-9048-2f93e76d0fcf">4.56</ix:nonFraction> per share. In May 2020, the Related Party purchased <ix:nonFraction unitRef="shares" contextRef="i7c3d5bf929d841bd8562efa81175ada4_D20200501-20200531" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwNDA_0b048f15-b6e1-481b-a978-341925b9639c">8,771</ix:nonFraction> shares of Series Seed Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5785bd98b84141148e297a25af4b1ae4_I20200531" decimals="2" name="cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwNTQ_f1370bc8-4ed7-4a7e-8123-bafe21ea2ea9">5.70</ix:nonFraction> per share for $<ix:nonFraction unitRef="usd" contextRef="i7c3d5bf929d841bd8562efa81175ada4_D20200501-20200531" decimals="0" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwNjg_bc6d1933-2a84-4870-bbce-75c6b8c8669b">50,000</ix:nonFraction>. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwODY_802907e6-fd2e-4130-8a6d-eefc7e8eea62">132,537</ix:nonFraction> shares of Series A Stock to the Related Party for $<ix:nonFraction unitRef="usdPerShare" contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231" decimals="3" name="cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAxMDQ_fbb9341a-da42-4577-b881-33cfd36eaae7">7.168</ix:nonFraction> per share for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAxMjA_f7139f83-7244-4dba-9c90-15f04a1ff48a">1.0</ix:nonFraction> million. The Company also issued <ix:nonFraction unitRef="shares" contextRef="ifd17b8baad484309af4929360d734817_I20201231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAxNDk_7a7d6fae-8680-4af4-9e68-e898674b5d75">33,129</ix:nonFraction> warrants to purchase common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifd17b8baad484309af4929360d734817_I20201231" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAxNjU_7358e475-99bd-4355-8d8e-da382925add4">7.168</ix:nonFraction> per share to the Series A Stock holder as part of the Series A Stock financing. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, $<ix:nonFraction unitRef="usd" contextRef="i453801845a4245559bdf44e3c243247b_D20201201-20201231" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAyMDA_66ea354d-6143-456f-9e33-4fcfafc1cd8d">0.6</ix:nonFraction> million in principal and accrued interest related to the Convertible Bridge Notes were converted into <ix:nonFraction unitRef="shares" contextRef="i5007a2b8df544622bbb6844a27b85941_D20201201-20201231" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAyMjk_52d238ba-46af-40e2-8eac-82173bafd436">78,178</ix:nonFraction> shares of Series A Stock. The Company also issued <ix:nonFraction unitRef="shares" contextRef="i70476cf5f23e40b7a8e694276c179049_I20201231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAyNDU_90b326d3-0b15-43af-8d98-881c7902a6ba">19,544</ix:nonFraction> warrants to purchase common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i70476cf5f23e40b7a8e694276c179049_I20201231" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAyNjE_360f7d0c-30bf-4dd7-be5f-56487cab9c0d">7.168</ix:nonFraction> per share to the Series A stockholders as part of the conversion from Convertible Bridge Notes to Series A Stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February, March and April 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="iee66bc4c666546b5827d8f9046ce2e6e_D20210201-20210430" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc3NzI_a51c1f7d-1e00-47c3-9485-44cc68a79aae">738,445</ix:nonFraction> shares of Series A Stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="i1de5d059a75a4d8e960f6f97b1e4b44e_I20210430" decimals="3" name="cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc3ODE_7a0a661b-779d-4494-8126-84f2bd0a9a0c">7.168</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iee66bc4c666546b5827d8f9046ce2e6e_D20210201-20210430" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4Nzk_70925a23-f3ed-4a5e-a281-c65476d09159">5.0</ix:nonFraction> million. The Company also issued <ix:nonFraction unitRef="shares" contextRef="if041032296804b76bd219f45c1d66fab_I20210430" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc3OTc_bb31e473-980d-4fa6-b247-acdb6649b885">184,597</ix:nonFraction> warrants to purchase common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if041032296804b76bd219f45c1d66fab_I20210430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc3ODk_5533e973-9c01-4840-925d-f4892775cd44">7.168</ix:nonFraction> to the Series A stockholders as part of the Series A Stock financing. Additionally, the Company issued <ix:nonFraction unitRef="shares" contextRef="ib058079deb3c476694d758a0ce02221e_I20210430" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4MDY_527e7791-cc80-4d23-ae8c-1162db4da0ca">24,134</ix:nonFraction> warrants to purchase common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib058079deb3c476694d758a0ce02221e_I20210430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4MTQ_8c09ae83-f0f0-4e95-9ce0-7227a86e2295">7.168</ix:nonFraction> to placement agents as a part of the Series A Stock financing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company converted $<ix:nonFraction unitRef="usd" contextRef="id1de2115c90540ebb9bb07d72b519bf0_D20210201-20210228" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4NDU_697248b6-2e99-47bf-b106-93f8184882d9">6.1</ix:nonFraction>&#160;million of principal and interest related to Senior Convertible Notes into <ix:nonFraction unitRef="shares" contextRef="i4cdb9eb262764bb9ad359f4cd6409d95_D20210201-20210228" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4MjI_c94ac82f-069d-418d-b1ec-b687aa6551d5">844,824</ix:nonFraction> shares of Series A Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1c63a7c492b249a2823508e305461100_I20210228" decimals="3" name="cntx:DebtConversionConvertedInstrumentPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4NTk_eeae1371-5014-4440-a207-3af3837c26a6">7.168</ix:nonFraction> per share. In addition, warrants with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i8d1cfe7096e34e6ea497fb994bda8378_D20210201-20210228" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4MzE_d38ef3ab-d2f9-4d08-99d9-3f851e86b5a2">0.1</ix:nonFraction>&#160;million associated with the Senior Convertible Notes were reclassified into additional paid-in capital.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company completed its IPO in which the Company sold <ix:nonFraction unitRef="shares" contextRef="ib574e9442de340bba7e8df59de0aa8ea_D20211001-20211031" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzkzNDU4NDg4NTQ1NDE_c078a8e4-be8f-4115-9336-c47db456fc1a">5,750,000</ix:nonFraction> shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifaec33cca2ed463caf5a7211bdf75d02_I20211031" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3ODg_5ceef92e-0b44-40bc-807a-925505ea73e4">5.00</ix:nonFraction> per share. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231" decimals="0" name="cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzEyMDk0NjI3OTE4NTU2_6939c148-d0ca-4c75-91c2-3290edb6f78a">4,853,533</ix:nonFraction> shares of common stock and all of the outstanding warrants converted into <ix:nonFraction unitRef="shares" contextRef="ic77193cc910d458e928d0612bcad6229_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzEyMDk0NjI3OTE4NTY0_04e83f5e-0086-4cc3-9a58-bbbe011c68ca">9,816</ix:nonFraction> shares of common stock. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzkzNDU4NDg4NTQ1Mjc_9fce6798-a28e-4a1f-a532-c9fda99a4b25">24.4</ix:nonFraction>&#160;million as a result of the offering. The Company issued <ix:nonFraction unitRef="shares" contextRef="id4631fd77028469dbd1afde77f30a01b_I20211031" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY4MDE_96015c8c-dd6e-4016-8c05-373685eaeff9">250,000</ix:nonFraction> warrants to a placement agent as part of the offering with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f3867dedb684f8482d09a62b1bef50c_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY4MTA_271addad-57d2-4954-8062-9b96b23e9a02">6.25</ix:nonFraction> per shares and a term of <ix:nonNumeric contextRef="id4631fd77028469dbd1afde77f30a01b_I20211031" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY4MTY_4d0c8076-f464-423c-b0d4-44e684d04c85">5.0</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwOTU1NDk_b288ba13-dfa3-426a-ab2e-fa6f2e912b50">5,000,000</ix:nonFraction> shares of common stock together with warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3MjI_9c10140d-bd38-41b1-8884-630f5432de35">5,000,000</ix:nonFraction> shares of common stock and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231" decimals="0" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzEyMDk0NjI3OTIxMjU4_6b262aa8-e907-4587-b76b-ee1e38c1222a">28.9</ix:nonFraction> million in a private placement. Each share of common stock and accompanying warrant were sold together at a combined offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5177f9964b244a76b68f2abaac086c21_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3MzA_8e864815-b73e-4143-8d84-eff0599373dd">6.25</ix:nonFraction>. The warrants </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="icbc603d45e55429a98f466b3844c5679"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have a term of <ix:nonNumeric contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3NDI_7d61c121-6941-4bf7-8ac2-7fdc12a1bb3f">5.5</ix:nonNumeric> years and an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3NTA_f3c42900-95cb-405c-96db-4d3e6841af51">6.25</ix:nonFraction> per share. The Company also issued <ix:nonFraction unitRef="shares" contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3NjA_b315ff77-e5c4-49e3-81f3-1295bbfe423a">250,000</ix:nonFraction> warrants to a placement agent as part of the offering with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3Njg_c6641284-6895-497d-99b5-6dcbc9cdd6fe">6.25</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3ODA_538bcd98-a0b7-42cc-843d-8d20485058ec">5.5</ix:nonNumeric> years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants for Common Stock </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzcwNzk_e673902e-33cf-4833-95f6-376d7d4c9646" continuedAt="i095d8226ee1f4fbf9d11d97a8920c405" escape="true">At December&#160;31, 2021, the Company had the following warrants outstanding to acquire common stock: </ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i095d8226ee1f4fbf9d11d97a8920c405"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:47.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration&#160;dates</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued in connection with IPO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ba1a5fd4aa54bd18b6277a18720bbb6_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzUtMS0xLTEtMjMyNDk_bb5cb1bb-d363-45d0-b947-49c97e12a039">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ba1a5fd4aa54bd18b6277a18720bbb6_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzUtMy0xLTEtMjMyNDk_0252383d-c371-4bde-8a38-7154440c048e">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued as part of December 2021 private placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36c3e785908e44e893746fd8fb714979_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzYtMS0xLTEtMjMyNDk_01e96f18-6bad-4dff-9b21-004dbd6acf4c">5,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i36c3e785908e44e893746fd8fb714979_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzYtMy0xLTEtMjMyNDk_6869578a-58f4-476c-ae7f-eb766969acf5">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzUtMS0xLTEtMTE3NTg_43fd57f1-3943-4549-97d4-590be8590984">5,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During its evaluation of equity classification for the Company's common stock warrants issued in 2021, the Company considered the conditions as prescribed within ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging, Contracts in an Entity&#8217;s own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The conditions within ASC 815-40 are not subject to a probability assessment. The warrants do not fall under the liability criteria within ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Distinguishing Liabilities from Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as they are not puttable and do not represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company effected a one-for-6 reverse stock split of its common stock and convertible preferred stock. No fractional shares were issued in connection with the reverse stock split. Any fractional share resulting from the reverse stock split was rounded down to the nearest whole share, and in lieu of any fractional shares, the Company paid in cash to the holders of such fractional shares an amount equal to the fair value, as determined by the board of directors, of such fractional shares. All common stock, convertible preferred stock, per share and related information presented in the consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split.</span></div></ix:continuation><div id="i10e0e1fe4e654d20bde04f42c409d9dd_130"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI4ODM_7fd7b16c-cb24-4aa4-bfc7-6d883a536872" continuedAt="ib6271d28845446d1a090cfd4f3099249" escape="true">Share-based Compensation </ix:nonNumeric></span></div><ix:continuation id="ib6271d28845446d1a090cfd4f3099249" continuedAt="ie61852d67f8e4c28add83813d399d8b5"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Context Therapeutics Inc. adopted the 2021 Long-Term Incentive Plan (&#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units and stock grants. The 2021 Incentive Plan allows for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="ibf6e09006c2a4e438d001a5d8e06267e_I20210430" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIwMTE_c2a5e7c8-606f-4ce5-91d6-cf2efedc71bc">1,266,092</ix:nonFraction> shares of common stock (the &#8220;Share Limit&#8221;). The Share Limit will automatically increase on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (<ix:nonFraction unitRef="number" contextRef="ib1e1c00a5a0c46b7827110eaaccd2bde_D20210401-20210430" decimals="2" name="cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI3NDg3NzkwNzczNDU_b12b9023-a082-4798-a025-e4082e83d1bc">4</ix:nonFraction>%) of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i10ff1ceb32174558b92e60058255b0fb_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIwMjE_f47b6336-dc04-498d-8ea0-ac9855b14db5">742,706</ix:nonFraction> shares remained available for future grants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Grants</span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI3NDg3NzkwNzkyODg_bafbf3d5-2fb5-43a6-8378-b5c3c35410d8">7,512</ix:nonFraction> shares of common stock to members of the board of managers as compensation for their services. The Company recorded share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i92b4d526304e44d59c45f6d02124e335_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzEwNDQ1MzYwNDczNTky_7d7b879d-1ca9-4497-a97c-9f11c146d4ee">0.1</ix:nonFraction> million in general and administrative expense during the year ended December 31, 2020.  </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options generally vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4NjE_01118990-dc7d-4e7f-96e0-43c8e460d916">one</span> to <ix:nonNumeric contextRef="i4ad2696d269b4e0593b847bc2847d326_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4NzE_ffecce64-ae3e-4981-9b6d-561e932d0286">four years</ix:nonNumeric>, and stock options that lapse or are forfeited are available to be granted again. The contractual life of all stock options is <ix:nonNumeric contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4ODg_99901803-7913-463a-bdd6-53adc9173e0a">10</ix:nonNumeric> years. The expiration dates of the outstanding stock options range from January 2028 to November 2031. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock options at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Stock option compensation expense is allocated to </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ie61852d67f8e4c28add83813d399d8b5" continuedAt="i57a5b988439045f5afe6ec4f215e4886"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees and consultants based on their respective departments. All board of directors&#8217; compensation is charged to general and administrative expense. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock option compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i5e63271831534a1c9f0c9dafdc78b906_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzkzNDU4NDg4NDE4MzE_691fecbd-4b14-4fc6-b195-93e3b0a71dc4">74,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i88a6a22c984641faab12a3f3aecdfa8a_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU5MjA_5cca054c-eb9a-4dda-9a76-9af2d008cf2e">404,000</ix:nonFraction> in research and development and general and administrative expense, respectively, during the year ended December&#160;31, 2021.  The Company recorded stock option compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i76aea4c250d247f696a873ec46ad8c83_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIwMjc_0a257cff-c85e-420a-aea0-20afb48740dc">75,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i89568e4239cb4b4dbc069d2edc09f071_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIwMzE_fdd67453-f833-401d-b9e2-c5df802e6d8b">29,000</ix:nonFraction> in research and development and general and administrative expense, respectively, during the year ended December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI4ODE_fad636fe-3bc4-4d59-b9b1-fb260d68da8f" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option awards granted to employees during 2021 and 2020 were as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzEtMS0xLTEtMTE3NTg_74c39282-6a35-4c68-9368-6fac0f74fbd5">97.06</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzEtMi0xLTEtMjM5NjA_613ba24c-7830-47cf-9afd-fa87316c0b95">97.86</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzItMS0xLTEtMTE3NTg_726be605-b32b-4ba4-af54-6dd2c74fd9ab">1.07</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzItMi0xLTEtMjM5NjA_bee18f99-6fac-4f5a-9834-44a7a2daeecc">0.51</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzMtMS0xLTEtMTE3NTg_17b07c38-f657-483e-b259-67c72a3e67d2">5.78</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzMtMi0xLTEtMjM5NjA_7500e6d4-dedf-4d14-8b33-8ce7cf555bdf">5.44</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzQtMS0xLTEtMTE3NTg_0c2eabba-0424-4071-8861-883b8bb724f9">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzQtMi0xLTEtMjM5NjA_db517272-5834-40dc-a492-fb99363936fe">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI4NzY_0da07e6b-646b-4a20-a418-61c07fd61b4a" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity for the periods presented: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(years) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f8740cca1c745199eda7ed1a4c1f483_I20191231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzEtMS0xLTEtMjM5NTA_7cc70e8d-9ddd-439d-92cb-e821e767f608">10,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f8740cca1c745199eda7ed1a4c1f483_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzEtMy0xLTEtMjM5NTA_94456049-495e-4a56-8587-00458e974b36">20.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abf375441494967be6030dfc54f96ad_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzEtNS0xLTEtMjM5NTA_db838477-48ac-4389-82f3-b22488729c6a">8.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzItMS0xLTEtMjM5NTA_e15a42c6-bc21-4aa0-b01b-814a613d1bfe">14,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzItMy0xLTEtMjM5NTA_bd3f0fec-f7c4-4721-985e-11bdda77c69e">15.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtMS0xLTEtMjM5NTA_0fc830c6-bdcf-4ef1-880f-1a05664f2a02">24,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtMy0xLTEtMjM5NTA_81670d29-b4b1-40c4-9782-7b76f0318e08">17.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtNS0xLTEtMjM5NTA_84402abf-9dbf-4df9-a4d1-d75897bfe0c4">8.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzItMS0xLTEtMTE3NTg_cb7122ce-0014-41ed-b688-470b1b4b6a57">481,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzItMy0xLTEtMTE3NTg_a3dce039-0570-4ad4-ba79-8ef8f56a1baf">5.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtMS0xLTEtMTE3NTg_e66567f4-6a25-4691-a60c-473b2173be4f">506,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtMy0xLTEtMTE3NTg_23a224f4-5b31-47f3-b9fc-f974f7c15ba4">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtNS0xLTEtMTE3NTg_8ff7fd88-8a16-483e-80fd-1002b85fe6df">9.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzQtMS0xLTEtMTE3NTg_ada10bd2-7baa-48f5-80d9-1d724b6f4fab"><ix:nonFraction unitRef="shares" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzQtMS0xLTEtMTE3NTg_cf91cc94-d0c9-4fc0-8b75-d2f1990ce303">130,059</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzQtMy0xLTEtMTE3NTg_c9a6c2bf-d0f8-4e4d-8ccb-6de8717df205">7.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16167060dd4a411bbbf08ccef55b90ca_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzQtNS0xLTEtMTE3NTg_f00a7bba-e804-46aa-aafe-6849a15d8ba3">9.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzctMS0xLTEtMjQ4MjU_790be4c0-07aa-43b5-8263-5023e1378945">506,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzctMy0xLTEtMjQ4MjU_6a69c15e-d808-4322-816e-25d2cb2492ef">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzctNS0xLTEtMjQ4MjU_e93486dd-9465-4051-8585-d9c9c5ffc0ce">9.3</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The weighted average fair value of share-based awards granted during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDQ5NTM_61523ebc-784e-44ed-9343-68b8f5633a4f">3.84</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDQ5NjE_08c084a0-5ddd-43ed-8cd3-9e54534119d7">9.34</ix:nonFraction>, respectively. The aggregate intrinsic value of the options outstanding and exercisable as of December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDUxMTQ_4d0a6c79-b20a-4d22-b6af-04ab4a946452">0</ix:nonFraction>. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of December&#160;31, 2021, the unrecognized compensation cost related to outstanding stock options was $<ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU5OTk_1ed68680-4594-4a27-ab06-118032fd7078">1.5</ix:nonFraction> million and is expected to be recognized as expense over a weighted-average period of approximately <ix:nonNumeric contextRef="i87304bb5deed428b929244468618ab9a_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwMjg_15b7d991-4796-4353-9231-1c7b195ab3e4">1.73</ix:nonNumeric> years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues restricted stock units (&#8220;RSU&#8221;) to employees and consultants that generally vest monthly over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwNDQ_d169f036-bec1-4a91-89bb-ca2c7da81f4f">one</span> to <ix:nonNumeric contextRef="i6a6d5e19e9c2468da79c3794e7c72abb_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI3NDg3NzkwNzczNDg_cf33e4be-4eb8-41bc-ab9a-0f1235cd99ed">three-year</ix:nonNumeric> periods. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the service period. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i57a5b988439045f5afe6ec4f215e4886"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI4Nzg_05b57e9a-6e39-43e5-8da3-45853e96c484" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to RSU share-based payment awards: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date&#160;Fair&#160;value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at January&#160;1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i572c857cebbe4fc1982b32de57c0220a_I20191231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzEtMS0xLTEtMTE3NTg_834824a0-55fc-43cf-954f-2e63f8e7c2c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzItMS0xLTEtMTkyMjc_e7d5dac8-f0e6-4f45-9298-31140c281868">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="usdPerShare" contextRef="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzItMy0xLTEtMTkyMjc_84263482-06a6-45dd-aa0b-c257849637c3">13.55</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzItMS0xLTEtMTE3NTg_ee78a9cd-2290-4c57-85b4-1489f2a19e2b">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="usdPerShare" contextRef="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzItMy0xLTEtMTE3NTg_9ed0a91e-c7dc-466d-a5b1-94a2b2e653a4">13.55</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i992c3c31612041b88458293caef78ce6_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzMtMS0xLTEtMTE3NTg_daa79f21-8a76-4ab8-a89d-f67f527a8cb9">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="usdPerShare" contextRef="i992c3c31612041b88458293caef78ce6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzMtMy0xLTEtMTE3NTg_e36b1777-72b8-490e-999a-760b9b843b28">13.55</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzQtMS0xLTEtMTE3NTg_49439773-d48f-49f8-9e90-4fe5650ca447">50,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzQtMy0xLTEtMTE3NTg_95cc6ee2-f314-4f60-87ce-4be8c54d5aac">1.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzUtMS0xLTEtMTE3NTg_070cb96d-ca32-4487-b2d0-3ab6c6bb9a89">20,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzUtMy0xLTEtMTE3NTg_e50e37a8-77e6-4d9c-a7df-998fa4f438da">1.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzctMS0xLTEtMTkyMjc_4663e139-f2aa-47d3-914d-dc80cbcda2cb">29,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzctMy0xLTEtMTkyMjc_d42c3417-85a8-4dec-8881-fd14d317fbba">1.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied12b91ed1cb4150a7ff06c8518ebfab_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzYtMS0xLTEtMTE3NTg_5341f44b-a7f3-496c-b2a2-9ca68467976e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ic066948fc7ad43b0956073d48292abac_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwODA_913fbb9f-f0be-4581-ae44-9238d1bbefca">33,000</ix:nonFraction> in research and development expense for the year ended December&#160;31, 2021 related to RSUs. The Company recorded share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i090b28e5ec1a4e8eaa2a115e3b70282b_D20200101-20201231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIxODY_e6f6b9d2-690e-41fb-bb45-81e30aea2b48">2,000</ix:nonFraction> in general and administrative expense for the year ended December&#160;31, 2020 related to RSUs. As of December&#160;31, 2021, there was <ix:nonFraction unitRef="usd" contextRef="i92dfdc8947244a08927a080fc1dfb72b_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI3NDg3NzkwNzczNTE_c703a30c-03c5-48db-8220-c92b37354887">no</ix:nonFraction> remaining unrecognized expense related to RSUs.</span></div></ix:continuation><div id="i10e0e1fe4e654d20bde04f42c409d9dd_133"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzQ5Mjg_3c2a0b91-ec8d-4cf4-bc67-311e972aa03e" continuedAt="ie65239725e75466eb344df61d5bbe5c0" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="ie65239725e75466eb344df61d5bbe5c0" continuedAt="i5a3a5540db174458ace78347f41ac306"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent License Agreement with Drexel University </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the Company entered into a patent license agreement, as amended, (the &#8220;Drexel License Agreement&#8221;) with Drexel for license rights to patents for certain intellectual property and know-how related to certain technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Drexel License Agreement, the Company issued Drexel <ix:nonFraction unitRef="shares" contextRef="ifce6960f11854815999679040b558ff7_D20151101-20151130" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc3NzE_a8f1e6de-f4d4-4ab7-a83c-f41d6bf1bba0">16,666</ix:nonFraction> shares of common stock. In partial consideration of the Drexel License Agreement, the Company is required to pay to Drexel certain milestone payments, ranging from $<ix:nonFraction unitRef="usd" contextRef="i78fbe4d1c3214a428e35dd1f8055123c_I20151130" decimals="-3" name="cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc3ODc_affc98bf-2b7c-4a37-a7fc-da14b40a90fe">10,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i1a58857b70524568849add997a11e677_I20151130" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc4MDU_29e2b5fc-3fa7-4425-9fbc-6a4d454fca8a">0.2</ix:nonFraction> million on the achievement of certain milestone events for each licensed product. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to pay Drexel a royalty in the low single digits of net sales for each licensed product on a country-by-country, licensed product-by-licensed product basis on issued or pending valid claims. The Company may credit against amounts payable to Drexel, on a country-by-country, licensed product-by-licensed product basis up to <ix:nonFraction unitRef="number" contextRef="i3a7d7b9cfd5348869e9ddcb95a366ed4_I20151130" decimals="2" name="cntx:CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc4NzQ_1ae5dbff-cdac-4e80-9f82-d584be20878a">50</ix:nonFraction>% of any third-party payments which the Company must make on account of third-party license agreements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration of the Drexel License Agreement, the Company will pay to Drexel a de-escalating sublicense fee on a quarterly basis of a high single-digit percentage that decreases to a mid-single digit percentage as time passes. In addition, the Company will make payments of the fair market value of all other consideration received by the Company from sublicensees during the quarter, other than: (a)&#160;royalties paid to the Company by a sublicensee based upon sales or net sales by the sublicensee; (b)&#160;equity investments in the Company by a sublicensee up to the amount of fair market value of the equity purchased on the date of the investment; (c)&#160;loan proceeds paid to the Company by a sublicensee in an arm&#8217;s length, full recourse debt financing to the extent that such loan is not forgiven; and (d)&#160;sponsored research funding, paid to the Company by a sublicensee in a bona fide transaction for future research to be performed by the Company. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a strategic review of its pipeline, the Company recently notified Drexel that it is terminating the Drexel License Agreement, effective as of April 27, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreement with Tyligand Bioscience </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a license (the &#8220;Tyligand License Agreement&#8221;) and process development agreement (the &#8220;Tyligand Process Development Agreement&#8221;) (collectively, the &#8220;Tyligand </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i5a3a5540db174458ace78347f41ac306" continuedAt="if6ca5ea6a03f4d4dba6f57879fe20293"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements&#8221;) with Tyligand Bioscience (Shanghai) Limited (&#8220;Tyligand&#8221;) for the development, manufacturing, registration and future commercialization of onapristone extended release (&#8220;ONA-XR&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Tyligand Agreements, Tyligand will be solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand will be granted the exclusive right to ONA-XR and will be solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#8220;Territory&#8221;). The Company will retain rest of world rights to commercialize ONA-XR. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tyligand Process Development Agreement, the Company is obligated to pay Tyligand $<ix:nonFraction unitRef="usd" contextRef="i91e81531d0aa47a7b6d49a7c6551bbd4_I20200331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc4OTk_49d8d35c-0e6d-44c3-971c-65f18ed8985e">0.8</ix:nonFraction> million and a certain number of warrants exercisable for common stock upon successful completion of the manufacturing development plan, $<ix:nonFraction unitRef="usd" contextRef="i5037d579dc114c0484a17c0cae6d7468_I20200331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc5Mjg_85f88420-927e-47be-ae71-4a8e7de2883f">2.0</ix:nonFraction> million upon the completion of scale-up of the first cumulative 100 kilograms of the GMP-grade compound and $<ix:nonFraction unitRef="usd" contextRef="i72e8fa04e6e04b7499dd9509fedc5611_I20200331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc5NTc_1351a1f8-7d07-4421-9973-c30cbeaae449">3.0</ix:nonFraction> million upon the Company&#8217;s completion of scale-up of the first cumulative 300 kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#8217;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand <ix:nonFraction unitRef="number" contextRef="if9ae36474bc442648e5731b2aae1cdd7_D20200301-20200331" decimals="2" name="cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc5ODY_a826367c-558b-411e-88a1-4a5257fbe99b">1</ix:nonFraction>% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i)&#160;the sale of a generic product in the territory and (ii) <ix:nonNumeric contextRef="if9ae36474bc442648e5731b2aae1cdd7_D20200301-20200331" name="cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc5OTY_967955cb-1c13-4138-8d96-f17ecd6e2acd">15</ix:nonNumeric> years after the date of the first commercial sale of product in the territory. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, upon successful completion of the process development plan with Tyligand, the Company issued Tyligand warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i32152868968f47f78b1854b4910902e8_I20210831" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyMjk_d4ef3d67-a0e8-4d27-b081-74b557514599">111,576</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i32152868968f47f78b1854b4910902e8_I20210831" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyMzg_fd40f892-c68c-47f6-8c77-ca33511e7840">7.17</ix:nonFraction> per share all of which were cancelled in connection with the IPO. The Company recognized an expense and liability of $<ix:nonFraction unitRef="usd" contextRef="i0a5ea7538cec4d73a63f42512b7cb189_I20210630" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyNDU_2d28494b-823c-4eea-8692-96b5f6241063">0.4</ix:nonFraction>&#160;million to account for the fair value of the warrants upon completion of the manufacturing development plan in June 2021. Upon issuance of the warrants in August 2021, the Company reclassified the $<ix:nonFraction unitRef="usd" contextRef="i32152868968f47f78b1854b4910902e8_I20210831" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyNTk_8fa05ea6-ec35-4e98-b212-cd88ddf045d3">0.4</ix:nonFraction>&#160;million liability into equity. The Company has expensed $<ix:nonFraction unitRef="usd" contextRef="if9f956c8b3ce4d38a8596ee10f01e3d5_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyNzM_0b590c51-e719-4fb4-a2ca-83791540b63f">0.8</ix:nonFraction>&#160;million related to the process development plan as of December 31, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, while the Company&#8217;s license agreement with Tyligand was signed in March 2020, the parties acknowledged that such signature was premature since the &#8216;successful completion&#8217; under the process development agreement had not yet occurred, and as such, the parties properly executed the license agreement upon such successful completion in August 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and Licensing Agreement with Integral Molecular</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) for gynecologic cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The Company paid an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i69aa76103ac748efb2f5d056d2cf8104_I20211231" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyODc_7670795e-6add-463f-890e-b61a02ca5b7d">0.3</ix:nonFraction>&#160;million and granted <ix:nonFraction unitRef="shares" contextRef="ia1bf28a7fb38490592f0eae3e1f12ce1_D20210101-20211231" decimals="0" name="cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzMDE_ed7ed727-2142-4734-80b8-3347d7153988">418,559</ix:nonFraction> shares of Series A Stock with a fair market value of approximately $<ix:nonFraction unitRef="usd" contextRef="ia1bf28a7fb38490592f0eae3e1f12ce1_D20210101-20211231" decimals="-5" name="cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzMTA_934b733e-0c5d-4eb9-954f-a54b70d5717f">2.8</ix:nonFraction>&#160;million, and these costs were expensed to acquired in-process research and development during the year ended December 31, 2021. As a part of the agreement, Integral will be eligible to receive development and regulatory milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i760a27b106d14efc85f77118941e7eec_I20210430" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzMjQ_7135b31e-d7db-4bec-a40a-f157224c7724">55.3</ix:nonFraction>&#160;million, sales milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i760a27b106d14efc85f77118941e7eec_I20210430" decimals="-6" name="cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzMzk_31505b8d-771b-4ea9-8b69-b92a252fa4d2">130</ix:nonFraction>&#160;million, and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="i760a27b106d14efc85f77118941e7eec_I20210430" decimals="2" name="cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzNTM_02cad234-606b-4e31-b815-85719c64f21e">12</ix:nonFraction>% of net sales of certain products developed under this agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company leased its corporate offices in Philadelphia, Pennsylvania under a month-to-month lease arrangement. The Company recorded rent expense of approximately $<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="-3" name="us-gaap:LeaseAndRentalExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTgwMTA_590761bd-eda5-49d8-b63e-d56c7ff93cbd"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="-3" name="us-gaap:LeaseAndRentalExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTgwMTA_d126f772-054f-4f19-82ca-e9a5f875acdb">10,000</ix:nonFraction></ix:nonFraction> for the years ended December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="if6ca5ea6a03f4d4dba6f57879fe20293" continuedAt="icff53d4d8226452a831463e0c944af79"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 30, 2023. The minimum lease payments under the sublease is $<ix:nonFraction unitRef="usd" contextRef="i5c01fc0d079243d0863dab34c442d2d6_I20220201" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzkzNDU4NDg4NDc2MTc_c4287b2d-a942-4c5b-9dfc-27878b57e47e">0.1</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icff53d4d8226452a831463e0c944af79">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company believes no matters existed at either December&#160;31, 2021 or 2020 that will have a material impact to the Company&#8217;s financial position, results of operations or cash flows.</ix:continuation> </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI5MjU_1756db34-8804-45e0-a8f9-3e5f15733add" continuedAt="i93feb8342e8b4eb4a8433d238a0e0381" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i93feb8342e8b4eb4a8433d238a0e0381" continuedAt="ia86e802c20484067bd8af904accb1398"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI3NDg3NzkwNzM1MjI_2b1731ac-b80a-4a82-81cd-0a75cd4989c3"><ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI3NDg3NzkwNzM1MjI_ff03a8bf-2e1b-47e0-a473-044495af5396">no</ix:nonFraction></ix:nonFraction> income tax expense due to operating losses incurred for the years ended December 31, 2021 and 2020. The Company had also not recorded any income tax benefits for the net operating losses incurred in each period due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI5MjE_c362a798-10bf-4346-bd8c-53989b4df32e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzMtMS0xLTEtMTE3NTg_32031c5e-e94c-45e5-8f31-5c6fc0b3ebd0"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzMtMS0xLTEtMTE3NTg_c79b9a54-e31d-4bbf-b79d-618961bc0d66">4,983,415</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzMtMy0xLTEtMTE3NTg_e535398f-f23c-4bc4-8207-4194eabd340b">3,199,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzQtMS0xLTEtMTE3NTg_a62c9f49-79df-4934-8685-50c8d5b733b7"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzQtMS0xLTEtMTE3NTg_f413ffd4-4439-4e0d-a29f-cbfd1ea4a28a">421,880</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzQtMy0xLTEtMTE3NTg_b2b1045b-24a3-4507-92f3-1f718df9b7cd">326,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzUtMS0xLTEtMTE3NTg_1af72eb0-5bd3-4492-8d33-e47a4e81773a"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzUtMS0xLTEtMTE3NTg_474f1518-c498-444f-9373-7ac55dc0609c">249,874</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzUtMy0xLTEtMTE3NTg_7d7ee4b4-55f8-4ad3-af63-af61d51ee68f">43,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzYtMS0xLTEtMjc1NzE_feb2f465-f3f2-416b-984f-5732a1dfd2b9">147,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzYtMy0xLTEtMjc2MzI_7f0f8ab1-c6a4-428c-b47a-6430968b6722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMS0xLTEtMjc1NzE_2ff00526-4ea0-42b4-8546-d7a09db269d9">5,802,828</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMy0xLTEtMjc2Mzk_f7409749-811f-44e8-af9e-e5649f69b240">3,569,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzktMS0xLTEtMjc1NzE_d4cbfe7f-9247-4c02-923c-ff7873f47fa5">527,181</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzktMy0xLTEtMjc2NDU_4c01817a-24ae-4963-9229-1e8b0e13741c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="cntx:NetDeferredTaxAssetLiabilitiesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzYtMS0xLTEtMTE3NTg_d2cc13ea-a74d-4ea8-b42f-f1a6278128b8">5,275,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="cntx:NetDeferredTaxAssetLiabilitiesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzYtMy0xLTEtMTE3NTg_4de040e9-3642-454e-851c-13d6845a52eb">3,569,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMS0xLTEtMTE3NTg_70464d39-956d-4c22-a603-abff59399a37"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMS0xLTEtMTE3NTg_78ecb3ab-2264-401e-804c-e3c461bb1666">5,275,647</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMy0xLTEtMTE3NTg_16623e33-f7f7-40a1-ad73-2c7898815134">3,569,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzgtMS0xLTEtMTE3NTg_238c8c77-91e2-4cf4-aba0-d2bd68d2a031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzgtMy0xLTEtMTE3NTg_d6e8ecfc-a157-44d8-ae21-a0361c913231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2021 and 2020. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzM4NDgyOTA3MDA0MjE_76871ca2-0bbe-4ef8-915d-70dc70161bb9">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU4Mjc_ef576e9e-30cc-4787-8f23-45ad01a88e60">0.2</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ia86e802c20484067bd8af904accb1398" continuedAt="i1762aa05f1e9472ab1cd57ca4f1dcc98"><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI5MjI_33416e80-4bac-41cb-a64e-1ab41bac36fc" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense/(benefit) at statutory rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzItMS0xLTEtMTE3NTg_b4612eb6-9483-4a49-94e7-125735a78e2c">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzItMy0xLTEtMTE3NTg_4982f9c7-0f01-48b5-a98c-1fcbec437bf9">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzMtMS0xLTEtMTE3NTg_0dde9b1d-e808-48d8-8404-264994e1d928">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzMtMy0xLTEtMTE3NTg_e2bfb66e-d051-4c75-8458-384fb223463d">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable partnership income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzQtMS0xLTEtMTE3NTg_f6a99200-3bac-418d-b614-5af6e0a11a6a">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzQtMy0xLTEtMTE3NTg_98604e64-33c4-4bb2-aa0f-fcc3869bcdc9">25.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzUtMS0xLTEtMTE3NTg_a4627652-a192-452f-b4f9-a00dee180f61">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzUtMy0xLTEtMTE3NTg_7bfa2b1a-3ad0-40b2-a6db-bc7f07dae4ef">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzYtMS0xLTEtMTE3NTg_1b772bef-b532-4f98-83f9-a1e9d72f58c1">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzYtMy0xLTEtMTE3NTg_cdebbc86-d9db-4a01-8832-cc5345119aa5">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzctMS0xLTEtMjkyNDg_56545541-868e-4a5c-9b0a-f4827e17d25b">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzctMy0xLTEtMjc2ODU_09902872-cfe9-4a06-94f4-ef81fd3b17d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzctMS0xLTEtMTE3NTg_0404eea6-625a-4ae0-87ff-64186a7d16ed">16.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzctMy0xLTEtMTE3NTg_17b2d53d-d1eb-41c3-96d6-e232b2fb64e5">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzgtMS0xLTEtMTE3NTg_00168abd-21b1-4c99-9ee8-ddaa0f58300e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzgtMy0xLTEtMTE3NTg_66aaa890-29d8-4213-9f0e-bca46497f4ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI5MjM_efdf4b3c-ad5f-470e-aa87-2c0bec5baf3a" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes carryforwards of federal, state and local net operating losses (&#8220;NOL&#8221;) and research tax credits: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;Federal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc572ca47de84c2097d086542a0002b6_I20211231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzItMS0xLTEtMTE3NTg_c0626a9c-b2a0-43cb-b200-353cee84fd8f">14,887,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80101d4b12c34ca8aac0080981f8868e_I20201231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzItMy0xLTEtMTE3NTg_65c74f21-08ab-43aa-98e8-61913fe6f191">8,030,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f59721c4e142388846035376f047f3_I20211231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzMtMS0xLTEtMTE3NTg_0a4654c9-210c-4874-826d-7eee8fef6c5c">14,887,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb11fc45a9024916b87e1c43f8c7f43e_I20201231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzMtMy0xLTEtMTE3NTg_9c2411f0-d87f-4e15-91e6-4df395bc064a">8,030,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;Local</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10821272b4754a39be917949dd892095_I20211231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzQtMS0xLTEtMTE3NTg_0c5e8ba7-4ce4-439e-b581-738fbfa7e726">13,926,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae70c994731842459a8bf4cb62e7db3d_I20201231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzQtMy0xLTEtMTE3NTg_514890df-21b2-4f49-9a82-e60c7a1d87e6">15,399,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits&#8212;Federal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73cb300b7bdf4e6a842303015e1050c5_I20211231" decimals="0" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzUtMS0xLTEtMTE3NTg_34f62f2c-acfa-45cc-9256-c5e9c0a013ff">421,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae15c2289054f01bddc88f4e06f1c45_I20201231" decimals="0" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzUtMy0xLTEtMTE3NTg_995e4bfd-7fa6-438d-8afb-21116e9332ae">326,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL carryforwards begin expiring in 2037 for federal and state income tax purposes; however, all federal NOL carryforwards generated subsequent to January&#160;1, 2018, are able to be carried forward indefinitely. Local NOL carryforwards expire after <ix:nonNumeric contextRef="i10821272b4754a39be917949dd892095_I20211231" name="cntx:OperatingLossCarryforwardsExpirationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU4NDc_def11d26-e9d9-4dc6-8bf6-141ba7401bf6">three years</ix:nonNumeric> with the 2019 NOL set to expire in 2022. As of December&#160;31, 2021 and 2020, the Company had federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i73cb300b7bdf4e6a842303015e1050c5_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU4NzQ_53d5b4ef-d79c-4711-958e-e9bc5a236cca">0.4</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="ieae15c2289054f01bddc88f4e06f1c45_I20201231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU4OTQ_7e5b3acd-59ee-4d85-9e04-4fd2f6fcde5d">0.3</ix:nonFraction> million, respectively, that will begin to expire in 2037, unless previously utilized. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception. State and local NOLs may also be limited. </span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1762aa05f1e9472ab1cd57ca4f1dcc98">As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU5MTQ_52fc6e82-13aa-40f0-bef3-7c6d6950ba8e"><ix:nonFraction unitRef="usd" contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU5MTQ_6cf647c0-5cf1-4370-b432-680f54984993">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="usd" contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU5MjQ_850e49a9-b9de-464b-9ad5-4b7c591377b3"><ix:nonFraction unitRef="usd" contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU5MjQ_8d86728c-abe8-4c2d-a458-6e6ada1c1dcd">no</ix:nonFraction></ix:nonFraction> amounts have been recognized in the Company&#8217;s consolidated statement of operations. Due to NOLs and tax credit carry forwards that remain unutilized, income tax returns for tax years from all years remain subject to examination by the taxing jurisdictions. The NOL carryforwards remain subject to review until utilized.</ix:continuation> </span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_139"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzkvZnJhZzo5ZTk1N2I1YTdjOTI0MjY5YWNmMGYzN2VkYjRhZmI4Yy90ZXh0cmVnaW9uOjllOTU3YjVhN2M5MjQyNjlhY2YwZjM3ZWRiNGFmYjhjXzI5Mg_8f83b41b-007e-4b4c-ac9b-8b26a3bbe862" continuedAt="i35a945dcbf0b483d9b6fbd616774a7c1" escape="true">Related Party Transactions </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i35a945dcbf0b483d9b6fbd616774a7c1">Since inception through December&#160;31, 2021, the Company entered into various convertible note agreements with the Related Party. The terms of the convertible notes and their subsequent conversions are further described in more detail in Note 6 and Note 7.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12) <ix:nonNumeric contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzIzMzk_e68f5d19-fe1c-4164-b952-8f38ab0b55df" continuedAt="ia5925dc32ca145159e5d34f7f7ce4213" escape="true">Subsequent Events </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia5925dc32ca145159e5d34f7f7ce4213">In March 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i8661fa5883274943a3502b6df99bcb33_I20220323" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzI3NDg3NzkwNzY3NDU_cd12958d-c4af-4bce-8950-4b5a87b080b7">360,000</ix:nonFraction> warrants to purchase common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8661fa5883274943a3502b6df99bcb33_I20220323" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzI3NDg3NzkwNzY3NTQ_b04ca3b0-2de4-4545-b9ef-43b37547c58b">10.00</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="i8661fa5883274943a3502b6df99bcb33_I20220323" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzI3NDg3NzkwNzY3NjE_d4156410-1eaa-4958-aea5-516ed7ef8e40">5.76</ix:nonNumeric> years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $<ix:nonFraction unitRef="usd" contextRef="i2661b361222b4e279fdb7c4c8e9cc8cb_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzI3NDg3NzkwNzY3NjM_ffe999de-ff3e-41ec-b8c4-2ff2882a683d">0.3</ix:nonFraction>&#160;million was recorded in general and administrative expense on the consolidated statement of operations for the year ended December 31, 2021.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1162"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2021, our disclosure controls and procedures were effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting due to a transition period established by the rules of the SEC for newly public companies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except as follows:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Weaknesses Remediation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously reported, management recognized that the Company had material weaknesses in its internal control over financial reporting as of December 31, 2020. The material weaknesses that we and our independent registered public accounting firm identified related to the lack of an appropriate review of the internally prepared financial statements which resulted in the Company&#8217;s failure to timely detect and correct certain misstatements within the consolidated financial statements. We also identified a material weakness as it relates to a lack of adequate segregation of accounting functions.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management determined that the deficiencies, evaluated in the aggregate, could have potentially resulted in a material misstatement of the financial statements in a future annual or interim period that would not be prevented or detected. Therefore, the deficiencies constituted material weaknesses in internal control.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We initiated several steps to evaluate and implement measures designed to improve our internal control over financial reporting in order to remediate the control deficiencies noted above. These steps include hiring a Chief Financial Officer and a Controller who are responsible for the preparation and review of the Company&#8217;s financial statements and related disclosures. In addition, we enhanced our reporting process thereby reducing the risk of undetected errors by (i) implementing a quarterly financial statement close process that includes formal reviews of financial statement account balances and journal entries, and (ii) creating a disclosure committee consisting of key executives and accounting personnel who review the Company&#8217;s financial statements and related disclosures on a quarterly basis.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of these efforts, the Company determined that the material weaknesses were remediated as of December 31, 2021.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1169"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1496"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1183"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1383"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for our 2022 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our system of corporate governance, our board of directors has adopted a code of business conduct and ethics. The code applies to all of our employees, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), contractors, consultants and agents and representatives, including our independent directors and consultants, who are not employees of ours, with regard to their Company-related activities. Our code of business conduct and ethics is available on our website at www.contexttherapeutics.com within the &#8220;Investors &amp; News &#8212; Governance&#8221; section. We intend to post on this section of our website any amendment to our code of business conduct and ethics, as well as any waivers of our code of business conduct and ethics, that are required to be disclosed by the rules of the SEC or the Nasdaq Stock Market.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1346"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for our 2022 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1355"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owner and Management and Related Stockholder Matters&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for our 2022 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1363"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for our 2022 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1371"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to our Proxy Statement for our 2022 Annual Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1249"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV.</span></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_205"></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed the following documents as part of this Annual Report:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(1)     Financial Statements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements are included in Item 8. &#8220;Financial Statements and Supplementary Data.&#8221;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(2)     Financial Statement Schedules</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted as information required is inapplicable or the information is presented in the financial statements and the related notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed under Item 15(b), which are incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)  Exhibits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521305465/d251040dex31.htm">Amended &amp; Restated Certificate of Incorporation of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521305465/d251040dex32.htm">Amended &amp; Restated Bylaws of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex41.htm">Form of Stock Certificate of Common Stock (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000184295221000015/cntx-20210930x10qexhibit41.htm">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on December 2, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex101.htm">Research Collaboration and License Agreement, dated April&#160;6, 2021, between Context Therapeutics LLC and Integral Molecular, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex102.htm">Process Development Agreement, dated March&#160;6, 2020, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex103.htm">Amendment No. 1 to Process Development Agreement, dated April 21, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521192240/d46596dex104.htm">Amendment No. 2 to Process Development Agreement, dated June 3, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1/A (File No. 333-256572), as filed with the SEC on June 16, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521270533/d46596dex105.htm">License Agreement, dated August 23, 2021, between Context Therapeutics LLC and Tyligand&#160;Bioscience (Shanghai) Limited (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1/A (File No. 333-256572), as filed with the SEC on September 13, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex105.htm">Context Therapeutics LLC 2015 Option Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex106.htm">Context Therapeutics Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex107.htm">Form of Stock Option Agreement under the Context Therapeutics Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex108.htm">Form of Stock Grant Agreement under the Context Therapeutics Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521192240/d46596dex1010.htm">Form of Indemnification Agreement between Context Therapeutics Inc. and its officers and directors (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1/A (File No. 333-256572), as filed with the SEC on June 16, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex1012.htm">Consulting Agreement, dated May 7, 2021, between OncoStrategy, LLC and Context Therapeutics Inc. (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex1013.htm">Form of Director Services Agreement (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521305465/d251040dex101.htm">Amended and Restated Employment Agreement, dated October 22, 2021, between Context Therapeutics Inc. and Martin Lehr (incorporated by reference to the Company&#8217;s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000184295221000005/jminaiemploymentagreementc.htm">Employment Agreement, dated November 1, 2021, between Context Therapeutics Inc. and Jennifer Minai-Azary (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on November 1, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000184295221000015/cntx-20210930x10qexhibit103.htm">Securities Purchase Agreement, dated December 1, 2021, by and between Context Therapeutics Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on December 2, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000184295221000015/cntx-20210930x10qexhibit104.htm">Registration Rights Agreement, dated December 1, 2021, by and between Context Therapeutics Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on December 2, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="levitemploymentagreement10.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="levitemploymentagreement10.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="levitemploymentagreement10.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="levitemploymentagreement10.htm">dated October 22, 2021, between Context Therapeutics Inc. and Alex Levit</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amendment1tosahmoud-oncost.htm">Amendment No. 1 to Consulting Agreement, dated March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amendment1tosahmoud-oncost.htm">21,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amendment1tosahmoud-oncost.htm"> 2022, between OncoStrategy, LLC and Context Therapeutics Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000119312521175568/d46596dex211.htm">Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021). </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231cohnreznickconse.htm">Consent of CohnReznick LLP.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="contexttherapeuticsex311ce.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="contexttherapeuticsex312ce.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="contexttherapeuticsex321ce.htm">Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial statements from Context Therapeutics Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Deficit; (iv) Consolidated Statements of Cash Flows; and (v) Notes to the Consolidated Financial Statements.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Filed herewith </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Executive Compensation Plan or Agreement </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain information has been excluded from the exhibit because it both (i) is not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. <br/>+       This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_1291"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i10e0e1fe4e654d20bde04f42c409d9dd_211"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTEXT THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Martin Lehr</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNATURE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TITLE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Martin Lehr</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">rincipal Executive Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer Minai-Azary</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">rincipal Financial and Accounting Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2022</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Minai-Azary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard Berman</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Berman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Philip Kantoff</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philip Kantoff</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer Evans Stacey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Evans Stacey</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Linda West</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda West</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>2
<FILENAME>levitemploymentagreement10.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i562b5812110249e8955e0c698802b0ab_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.5pt;padding-right:-0.25pt;text-align:center;text-indent:1.55pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:218%;text-decoration:underline">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.2pt;padding-right:6.5pt;text-align:justify;text-indent:36pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This EMPLOYMENT AGREEMENT</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is made and entered into effective as of this 22</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of October, 2021 (&#8220;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between Context Therapeutics Inc. (the &#8220;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Alex Levit (&#8220;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Company and Executive are each referred to herein as a &#8220;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or together as the &#8220;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  Capitalized words not immediately defined shall have the meaning in the &#8220;Definitions&#8221; Section below.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-right:5.8pt;text-align:justify;text-indent:36.2pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants contained and incorporated herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">intending to be legally bound, hereby expressly covenant and agree as follows&#58;</font></div><div style="padding-right:5.8pt;text-align:justify;text-indent:36.2pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall employ Executive pursuant to this Agreement beginning on the Effective Date and continuing until such employment is terminated pursuant to Section 4 below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  During the Employment Period, Executive shall remain in the employ of the Company and provide services to the Company in accordance with the terms of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall employ Executive during the Employment Period as its Chief Legal Officer &#38; Corporate Secretary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  During the Employment Period, Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall devote his full business time, energy, and talent to serving as Executive Officer of the Company, subject to the direction of the Company&#8217;s Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or the compensation committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Executive shall have the duties and responsibilities that are commensurate with his position as Executive Officer and any other or different duties that may be assigned to Executive</font><font style="color:#365f91;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by the CEO, Board or the Compensation Committee, and Executive shall perform all such duties faithfully and efficiently in compliance with applicable law and the policies of the Company, as such policies may be in effect from time to time.  Executive shall have such authority and powers as are inherent to the undertakings applicable to Executive&#8217;s position and necessary to carry out the duties required of Executive hereunder.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive&#8217;s principal place of business shall be at the Company&#8217;s corporate headquarters&#59; however, it is understood that Executive may be required to travel both domestically and internationally in fulfillment of his duties as set forth herein.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Notwithstanding the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, during the Employment Period, Executive may devote reasonable time to activities other than those required under this Agreement, including activities of a charitable, educational, religious, or similar nature to the extent such activities do not, in the judgment of the CEO or the Board, inhibit, prohibit, interfere with, or conflict with Executive&#8217;s duties under this Agreement or conflict in any material way with the business of the Company or any Affiliate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Executive shall not serve on the board of directors of any business (other than the Company or an Affiliate, or Strados Labs, Inc.) or hold any other position with any business without receiving the prior written consent of the CEO or the Board.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the Employment Period, the Company shall compensate Executive for Executive&#8217;s services as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive shall be paid a base salary at an annual rate of $350,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall be payable in accordance with the normal payroll practices of the Company then in effect. The Executive&#8217;s Annual Base Salary may be increased annually by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Compensation Committee beginning in the first calendar quarter of 2022&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;that the decision&#160;whether&#160;to increase the Executive&#8217;s Annual Base Salary and by what amount, if any, shall be made&#160;in the good faith&#160;discretion of the Compensation Committee.&#160; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Executive shall be eligible to receive performance-based annual incentive bonuses (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Incentive Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from the Company for each fiscal year ending during the Employment Period.  Incentive Bonuses shall be as determined in the discretion of the Compensation Committee, or as may be pursuant to a new annual incentive plan as may be adopted and in effect from time to time, with any applicable performance metrics and goals to be established by the Compensation Committee, after consultation with Executive.  Executive&#8217;s initial target Incentive Bonus shall be 40% of Annual Base Salary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which Target Bonus may be increased annually by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Compensation Committee beginning in the first calendar quarter of 2022&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;that the decision whether to increase the percentage of the Target Bonus and by what amount, if any, shall be made in the good faith discretion of the Compensation Committee.  The actual amount of the Executive&#8217;s Incentive Bonus, if any, shall be determined in the good faith discretion of the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Notwithstanding the Effective Date of this Agreement being during the 2021 calendar year, the Executive&#8217;s Incentive Bonus for 2021, if any, shall be based on the full 2021 calendar year.  Except as otherwise provided herein, as may be provided by the Compensation Committee or as may otherwise be set forth in any applicable incentive compensation plan, the Executive must be employed by the Company on the day such Incentive Bonus is paid in order to earn or receive such Incentive Bonus.  The Incentive Bonus, if any, will be paid to Executive during the period from January 1 through March 15 of the calendar year following the calendar year to which it relates.&#160; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive and Company acknowledge that Executive received stock options (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) intended to represent 0.75% (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target Equity Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Company&#8217;s common stock on a fully diluted basis as of the date the Options were granted.  The Options will vest in substantially equal installments of 1&#47;36 on the last day of each of the 36 months immediately following the respective grant date, subject to Executive&#8217;s continuous service to the Company through each such date.  Upon a Qualifying Financing, the Compensation Committee shall in good faith consider making an additional award of stock options in such amount necessary to maintain Executive&#8217;s Target Equity Percentage.  The Options will be subject to the terms and conditions of the Company&#8217;s equity incentive plan under which such Options have been granted (attached hereto as Exhibit B), and the Option Agreement (as attached hereto as Exhibit C).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Executive shall be eligible to participate, subject to the terms thereof, in all incentive plans of the Company as may be in effect from time to time with respect to senior executives employed by the Company in the United States, on as favorable a basis as other similarly situated and performing executives.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall be eligible to participate, subject to the terms thereof, in all employee benefit plans (including pension, 401(k) and welfare benefit plans) available to the Company&#8217;s executive employees, subject to the terms and conditions of such benefit plans as in effect from time to time.  If the Company does not have in place a medical, vision and dental </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance program, Company shall pay to Executive a monthly amount for Executive to purchase coverage in such amounts and on such terms as Executive and Company may agree. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Executive shall be entitled to accrue paid time off and holidays in accordance with and subject to the Company&#8217;s paid time off programs and policies relating to its employees in the United States as may be in effect from time to time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Executive shall be entitled to a minimum of 20 days of paid time off per calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive shall be reimbursed by the Company for all reasonable out-of-pocket expenses for entertainment, travel, meals, lodging, and similar items that are consistent with the Company&#8217;s expense reimbursement policy and that are actually incurred by Executive in the promotion of the Company&#8217;s business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment relationship with the Company shall be at-will.  Either Party may terminate Executive&#8217;s employment at any time, with or without Cause or Good Reason, for any or no reason (such date of termination, for any reason, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Minimum Benefits upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon termination of Executive&#8217;s employment by the Company for any reason, Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be entitled, in addition to any other benefits to which Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be entitled under the following provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or the express terms of any employee benefit plan or as required by law, to the following (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accrued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Executive&#8217;s earned but unpaid Annual Base Salary for the period ending on the Termination Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive&#8217;s earned but unpaid Incentive Bonus, if any, for any completed fiscal year preceding the Termination Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not be entitled to any Incentive Bonus in the event of a Termination for Cause if the events giving rise to the Termination for Cause occurred in such prior fiscal year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Executive&#8217;s accrued but unpaid paid time off&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Executive&#8217;s unreimbursed business expenses through and including the Termination Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that all required submissions for expense reimbursement are made in accordance with the Company&#8217;s expense reimbursement policy and within 45 days following the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The benefits, incentives, and awards described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;4(h)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any benefits to be provided to Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be provided within 30 days after the Termination Date (except that payments under Section 4(a)(iv) shall be made within 30 days following submission for reimbursement)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any benefits, incentives, or awards payable as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;4(h)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be provided in accordance with the terms of the applicable plan, program, or arrangement.  Except as may expressly be provided to the contrary in this Agreement, nothing in this Agreement shall be construed as requiring Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be treated as employed by the Company or any Affiliate following the Termination Date for purposes of any plan, program, or arrangement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Termination for Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive&#8217;s employment shall terminate automatically upon his death.  The Company shall be entitled to terminate the employment of Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Disability by giving written notice to Executive, in which event the date that the Company gives such notice shall be deemed the Termination Date.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon a Termination due to Executive&#8217;s death or Disability, Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(or Executive&#8217;s estate, if applicable) shall be entitled to the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Accrued Benefits&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">A payment, payable on the 45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day following the Termination Date, equal to the Target Bonus for the fiscal year in which the Termination Date occurs, prorated on a per diem basis for the number of days employed during such fiscal year prior to the Termination Date, divided by 365 (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pro-Rated Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">All unvested Options and any other unvested incentive equity awards then held by Executive that are scheduled to vest within twelve (12) months after the Termination Date shall immediately vest&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">The continuation of benefits as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, provided such benefit shall only be for a maximum period of twelve (12) months.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by Executive for Good Reason or by Company Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be entitled to terminate his employment for Good Reason by giving at least 10 days&#8217;, but not more than 30 days&#8217;, prior written notice of termination to the Company, in which event the date specified in the notice of termination shall be deemed the Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#59; provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (A) prior to giving such notice of Termination for Good Reason, Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">must give the Company written notice of the existence of any condition giving rise to Good Reason within 30 days of its initial existence and the Company shall have 30 days from the date of such notice in which to cure the condition giving rise to Good Reason, if curable, and if, during such 30-day period, the Company cures the condition giving rise to Good Reason, such condition shall not constitute Good Reason and (B)&#160;any Termination for Good Reason must occur within six months of the initial existence of the condition constituting Good Reason. The Company shall be entitled to terminate Executive&#8217;s employment for any reason that does not constitute Cause, or no reason, by giving at least 10 days&#8217; prior written notice to Executive, in which event the date specified in the notice of termination shall be deemed the Termination Date.  Upon a Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Good Reason or a Termination by the Company without Cause, Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be entitled to the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Accrued Benefits&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Payment in an amount equal to 75% of Executive&#8217;s Annual Base Salary in effect on the Termination Date, paid ratably over a period of nine (9) months in accordance with the Company&#8217;s regular payroll cycle&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">All unvested Options and any other unvested incentive equity awards then held by Executive that are scheduled to vest within twelve (12) months after the Termination Date shall immediately vest&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">The continuation of benefits as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Termination Upon a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding Section 4(c) above, and in lieu of any payment owed under Section 4(c), if any, in the event that the Company (or its successor) terminates the Executive without Cause or the Executive resigns from employment with the Company for Good Reason, in each case upon a Change of Control (as such terms are defined below) or within the twelve (12) month period following the Change in Control, then Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be entitled to the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Accrued Benefits&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Payment in an amount equal to the sum of (x) 100% of Executive&#8217;s Annual Base Salary in effect on the Termination Date, and (y) 100% of the Target Bonus for the fiscal year in which the Termination Date occurs, paid ratably over a period of twelve (12) months in accordance with the Company&#8217;s regular payroll cycle&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">All unvested Options and any other unvested incentive equity awards then held by Executive that are scheduled to vest after the Termination Date shall immediately vest and become immediately exercisable on the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">The continuation of benefits as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company shall be entitled to terminate Executive&#8217;s employment for Cause by giving written notice of termination to Executive, in which event the date that the Company gives such notice shall be deemed the Termination Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that with respect to clauses (iii) or (iv) of the definition of Cause set forth below, to the extent curable, Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be entitled to at least 30 days&#8217; prior written notice of the Company&#8217;s intention to terminate Executive&#8217;s employment for Cause, which notice shall specify the grounds for Cause&#59; and Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be provided a reasonable opportunity to cure any conduct or act, if curable, alleged as grounds for Cause, and a reasonable opportunity to present to the Board Executive&#8217;s position regarding any dispute relating to the existence of any grounds for Cause. Further, all rights Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has or may have under this Agreement shall be suspended automatically during (i) the pendency of any investigation by the Board or the Compensation Committee, or (ii) any negotiations between the Board and Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regarding any actual or alleged act or omission by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the type that would warrant a Termination for Cause and any such suspension shall not give rise to a claim of Good Reason by Executive. Upon a Termination for Cause, Executive shall only be entitled to the Accrued Benefits, and all vested and unvested Options and any other incentive equity awards then held by Executive shall immediately be forfeited and expire on the Termination Date.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt;text-decoration:underline">Termination due to Voluntary Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive shall be entitled to terminate his employment without Good Reason by giving at least 30 days&#8217; prior written notice to the Company, in which event the date that is 30 days after the date that Executive gives such notice shall be deemed to be the Termination Date.  Upon a Termination by Executive without Good Reason, Executive shall only be entitled to the Accrued Benefits, and all unvested Options and other unvested incentive equity awards then held by Executive shall immediately expire on the Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Medical, Vision and Dental Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Executive&#8217;s employment is terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> 4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, then, to the extent that Executive or any of Executive&#8217;s dependents may be covered under the terms of any medical, vision or dental plans of the Company (or an Affiliate) for active employees immediately prior to the Termination Date and provided Executive is eligible for and elects to continue coverage (under the health care continuation rules of COBRA, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if, on the Termination Date, the Company is not subject to COBRA, the Company shall provide for continuation coverage as if it were subject to COBRA for the entire period to which COBRA would have applied if the Company had been subject to COBRA (collectively for purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)), the Company shall provide Executive and those dependents with coverage equivalent to the coverage in effect immediately prior to the applicable Termination Date for a period of up to 12-months following the Termination Date, such that Executive shall be required to pay, on a monthly after-tax basis, the same amount as Executive would pay if Executive continued in employment with the Company during such period (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subsidized Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#365f91;font-family:'Cambria',sans-serif;font-size:13pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the Company&#8217;s portion of the cost of the Subsidized Coverage will be treated as taxable income to Executive, and thereafter Executive shall be responsible for the full cost of such continued coverage&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Subsidized Coverage shall be provided as described above unless the Company determines, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based on a written legal opinion of counsel, that the Company&#8217;s provision of Subsidized Coverage results in the violation of non-discrimination provisions of applicable law, as may be applicable to the Company, the imposition of a material additional tax or other material penalty being imposed on the Company (or an Affiliate) or any employee participating in such plans.  If the Company makes such a determination, then the Company shall pay Executive an additional severance benefit equal to the cost to the Company of the Subsidized Coverage (had such Subsidized coverage been provided) to assist Executive with the cost of COBRA or, if not available, to assist Executive with the cost of comparable coverage for Executive and his eligible dependents.  In the event Executive or any of Executive&#8217;s dependents is or becomes eligible for coverage under the terms of any other medical and&#47;or dental plan of a subsequent employer with plan benefits that are comparable to Company (or Affiliate) plan benefits, the Company&#8217;s and its Affiliates&#8217; obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;4(g) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall cease with respect to the eligible Executive and&#47;or dependent.  Executive and Executive&#8217;s dependents must notify the Company of any subsequent employment and provide information regarding medical and&#47;or dental coverage available.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Executive&#8217;s rights following a Termination with respect to any benefits, incentives, or awards provided to Executive pursuant to the terms of any plan, program, or arrangement sponsored or maintained by the Company or its Affiliates, whether tax-qualified or not, which are not specifically addressed herein, shall be subject to the terms of such plan, program, or arrangement and this Agreement shall have no effect upon such terms except as specifically provided herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Except as specifically provided in this Agreement, the Company and its Affiliates shall have no further obligations to Executive under this Agreement following a Termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt;text-decoration:underline">Removal from any Boards, Committees and Positions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Unless otherwise agreed to in writing by the Parties at the time of Termination, upon a Termination, Executive shall be deemed to resign (i)&#160;if a member, from the Board and from the board of directors of any Affiliate and any other board or committee to which Executive has been appointed or nominated by or on behalf of the Company or an Affiliate, (ii)&#160;from each position with the Company and any Affiliate, including as an officer of the Company or an Affiliate and (iii) as a fiduciary of any employee benefit plan of the Company and any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision of this Agreement to the contrary, Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not be entitled to any benefits under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;4(b), 4(c), 4(d) or 4(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (other than the Accrued Benefits), and shall repay to the Company any such benefits received, unless Executive (or Executive&#8217;s estate, if applicable) executes (without subsequent revocation) and delivers to the Company a Release within 21 days (or such longer period to the extent required by applicable law) following the Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that Executive has been and will continue to be provided intimate knowledge of the business practices, trade secrets, and other confidential and proprietary information of the Company (including the Confidential Information), which, if exploited by Executive, would seriously, adversely, and irreparably affect the interests of the Company and the ability of the Company to continue its business.  Executive further acknowledges that, during the course of Executive&#8217;s employment with the Company, Executive has produced and had access, and will continue to produce and have access, to Confidential Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the course of Executive&#8217;s employment and following a Termination&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Executive shall not directly or through others use, disclose, copy, or make lists of Confidential Information for the benefit of anyone other than the Company, except to the extent that such information is, at the time of disclosure, lawfully available from public sources, or such disclosure is authorized in writing by the Company, required or permitted by law, or otherwise as reasonably necessary or appropriate in connection with the performance by Executive of Executive&#8217;s duties to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive shall abide by the Company&#8217;s policies, as in effect from time to time, respecting avoidance of interests conflicting with those of the Company and its Affiliates.  In this regard, Executive shall not directly or indirectly render services to any person or Entity where Executive&#8217;s service would involve the use or disclosure of Confidential Information other than as authorized on behalf of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Notwithstanding the foregoing, nothing in this Agreement prohibits Executive from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation.  In connection with any such activity, Executive must identify any information that is confidential and ask the Regulator for confidential treatment of such information, except as permitted by law.  Despite the foregoing, Executive is not permitted to reveal to any third party, including any governmental, law enforcement, or regulatory authority, information Executive came to learn during the course of Executive&#8217;s employment with the Company that is protected from disclosure by any applicable privilege, including but not limited to the attorney-client privilege, attorney work product doctrine and&#47;or other applicable legal privileges, except as otherwise required by law.  The Company and its Affiliates do not waive any applicable privileges or the right to continue to protect its privileged attorney-client information, attorney work product, and other privileged information.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Documents and Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">All records, files, documents, and other materials or copies thereof relating to the business of the Company or its Affiliates that Executive prepares, receives, or uses shall be and remain the sole property of the Company and, other than in connection with the performance by Executive of Executive&#8217;s duties to the Company, shall not be removed from the premises of the Company or its Affiliates without the Company&#8217;s prior written consent, and shall be immediately returned to the Company upon a Termination, together with all copies (including copies or recordings in electronic form), abstracts, notes, or reproductions of any kind made from or about the records, files, documents, or other materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive acknowledges that Executive&#8217;s access to and permission to use the Company&#8217;s and its Affiliates&#8217; computer systems, networks, and equipment, and all the Company and Affiliate information contained therein, is restricted to legitimate business purposes on behalf of the Company and reasonable personal use in accordance with the Company&#8217;s applicable policies and procedures.  Any other access to or use of such systems, networks, equipment, and information is without authorization and is prohibited.  The restrictions contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> extend to any personal computers or other electronic devices of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive that are used for business purposes relating to the Company or its Affiliates.  Executive shall not transfer any Company or Affiliate information to any personal computer or other electronic device that is not otherwise used for any business purpose relating to the Company or an Affiliate.  Upon a Termination, Executive&#8217;s authorization to access and permission to use the Company&#8217;s and its Affiliates&#8217; computer systems, networks, and equipment, and any Company and Affiliate information contained therein, shall cease, and Executive shall delete any Company and Affiliate information from Executive&#8217;s personal computer or other electronic device. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-Competition and Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of the enhanced compensation and benefits provided in this Agreement, and Executive&#8217;s employment hereunder, Executive shall not, during Executive&#8217;s employment with the Company or during the Restricted Period, directly or through others (all of which are collectively referred to in this Agreement as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restrictive Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Own, manage, operate, or control, participate in the management, operation, or control of, be employed by, serve as a director, officer, or consultant to, or render services to a Competitor conducting business in the Restricted Area.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">However</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the ownership by Executive of shares of the capital stock of any Entity, which shares are listed on a securities exchange and that do not represent more than 5% of the Entity&#8217;s outstanding capital stock, shall not violate any terms of this Agreement. Additionally, Executive&#8217;s participation or inclusion on the board of any other entity, shall not violate any terms of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">(A)&#160;Induce or attempt to induce any employee of the Company or an Affiliate to leave the employ of the Company or any Affiliate&#59; (B)&#160;interfere with the relationship between the Company or an Affiliate, on the one hand, and any employee of the Company or an Affiliate, on the other hand&#59; or (C)&#160;induce or attempt to induce any customer, supplier, licensee, advisor, consultant, or other business relation of the Company to cease doing business with the Company or interfere with the relationship between the Company and its respective customers, suppliers, licensees, advisors, consultants or other business relations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Works Made for Hire&#59; Ownership of Company Work Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Parties understand and agree that all work prepared by Executive for the Company or for its Affiliates shall be a Work Made For Hire as such phrase is defined under the U.S. Copyright laws, 17 U.S.C. &#167; 101 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and if such work does not qualify as a Work Made For Hire, Executive shall, and does, assign to the Company all of Executive&#8217;s right, title, and interest in and to the work, including all patent, copyright, trademark, and other proprietary rights thereto.&#160; Executive waives and releases all moral rights in any of the works as Executive may possess by virtue of the Visual Artist&#8217;s Moral Rights Act of 1990 and various country or state laws of attribution, authorship, and integrity commonly referred to as Moral Rights Law.&#160; Executive shall not assert any claim based upon such moral rights against the Company, the Affiliates, or any of their respective successors in interest or assigns.&#160; Executive shall have no right, title, or interest in any of the work and shall not be entitled to any royalties or other proceeds received by the Company or its Affiliates from the commercialization in any manner of the work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive hereby assigns to the Company any right, title, and interest in and to all Company Work Product that Executive may have, by law or equity, without additional consideration of any kind whatsoever from the Company or its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Executive shall execute and deliver any instruments or documents and do all further acts (including the giving of testimony and executing any applications, oaths, and assignments) requested by the Company (both before and after a Termination) in order to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vest more fully in the Company or its Affiliates all ownership rights in the Company Work Product (including obtaining patent, copyright, trademark, or other intellectual property protection therefore in the United States and foreign countries).&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">The Company or its Affiliates shall at all times own and have exclusive right, title, and interest in and to all Confidential Information and Company Work Product, and the Company or its Affiliates shall retain the exclusive right to use, license, sell, transfer, and otherwise exploit and dispose of the same.&#160; Executive shall, and does, assign to the Company all of Executive&#8217;s right, title, and interest in and to any and all Company Work Product work, including all patent, copyright, trademark, and other proprietary rights thereto.&#160; Executive acknowledges the Company&#8217;s or its Affiliates&#8217; exclusive right, title, and interest in and to the Confidential Information and Company Work Product, and shall not contest, challenge or make any claim adverse to the Company&#8217;s or its Affiliates&#8217; ownership of or the validity of the Confidential Information and Company Work Product, any future application for registration or registration thereof, or any rights of the Company or its Affiliates therein, or which, directly or indirectly, may impair any part of the Company&#8217;s or its Affiliates&#8217; right, title, and interest therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;6(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not apply to an invention by Executive for which no equipment, supplies, facility, or trade secret information of the Company or its Affiliates was used and that was developed entirely on Executive&#8217;s own time, unless the invention (i) relates to the business of the Company or an Affiliate or to the Company&#8217;s or an Affiliate&#8217;s actual or demonstrably anticipated research or development or (ii) results from any work performed by Executive for the Company or an Affiliate.&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Consent and Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">From time to time, the Company&#8217;s business locations may be the subject of a Promotional Work.&#160; Executive acknowledges that Executive is aware that Executive&#8217;s name, image, and likeness may be captured in such Promotional Work, and hereby consents and agrees that the Company may use Executive&#8217;s name, image, and likeness as captured in the Promotional Work in any manner, in connection with the Company&#8217;s products and services or as part of any promotion of the Company, and, at all times, including after the term of this Agreement, the Company, its Affiliates, and, without limitation, their respective customers, successors, licensees, and assigns, may continue to use the Promotional Work that includes Executive&#8217;s name, image, or likeness.&#160; Executive, Executive&#8217;s heirs, predecessors, successors, assigns, and all affiliated entities hereby fully and finally release, remise, and forever discharge the Company, its Affiliates, their respective predecessors, successors, assigns, and all affiliated entities, and each of their respective directors, officers, members, shareholders, partners, employees, customers, agents, and attorneys, to the extent that such apply, of and from any and all manner of actions, causes of action, losses, claims, demands, liabilities, obligations, suits, debts, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, controversies, agreements, promises, variances, trespasses, damages, judgments, and executions, in law or in equity, that arise out of or are related to the Company&#8217;s or its Affiliates&#8217; use of a Promotional Work that includes Executive&#8217;s name, image, or likeness.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt;text-decoration:underline">Company Proprietary and Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Company or its Affiliates shall at all times own and have exclusive right, title, and interest in and to all Company Proprietary and Intellectual Property, and the Company or its Affiliates shall retain the exclusive right to use, license, sell, transfer, and otherwise exploit and dispose of the same.&#160; Executive acknowledges the Company&#8217;s or its Affiliates&#8217; exclusive right, title, and interest in and to Company Proprietary and Intellectual Property, and shall not contest, challenge, or make any claim adverse to the Company&#8217;s or its Affiliates&#8217; ownership of or the validity of Company Proprietary and Intellectual Property, any future application for registration or registration thereof, or any rights of the Company or its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliates therein, or which, directly or indirectly, may impair any part of the Company&#8217;s or its Affiliates&#8217; right, title, and interest therein.&#160; Executive shall not use or otherwise exploit any of Company Proprietary and Intellectual Property in any manner not authorized by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Notwithstanding any other provisions of this Agreement, pursuant to 18 USC Section 1833(b), Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of the Company&#8217;s or its Affiliate&#8217;s trade secret that is made&#58; (A) confidentially to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  If Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose a Company&#8217;s or its Affiliate&#8217;s trade secret to Executive&#8217;s attorney and use the trade secret information in related court proceedings, provided that Executive files any document containing the trade secret information under seal and does not disclose the trade secret, except pursuant to court order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Remedies for Breach of Restrictive Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Executive has reviewed the provisions of this Agreement with legal counsel, or has been given adequate opportunity to seek such counsel, and Executive acknowledges that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are reasonable with respect to their duration, geographical area, and scope.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive acknowledges that (A) the restrictions contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are reasonable and necessary for the protection of the legitimate business interests of the Company, (B) such restrictions create no undue hardships, and (C) such restrictions were a material inducement to the Company to employ Executive and to enter into this Agreement and to provide the compensation, benefits and opportunities hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Executive agrees to communicate the existence and terms of this Agreement to any third party with whom Executive may seek or obtain future employment or other similar arrangement during the Restricted Period.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">In the event of any violation or threatened violation of the restrictions contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company, in addition to and not in limitation of, any other rights, remedies, or damages available to the Company under this Agreement or otherwise at law or in equity, may be entitled to preliminary and permanent injunctive relief to prevent or restrain any such violation by Executive and all persons directly or indirectly acting for or with Executive, as the case may be.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If Executive violates the Restrictive Covenant and the Company brings legal action for injunctive or other relief, the Company shall not, as a result of the time involved in obtaining such relief, be deprived of the benefit of the full period of the Restrictive Covenant&#59; accordingly, the Restrictive Covenant shall be deemed to have the duration specified herein computed from the date the relief is granted but reduced by the time between the period when the Restricted Period began to run and the date of the first violation of the Restrictive Covenant by Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Section 280G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event it shall be determined that any payment, distribution or other action by the Company to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) would be subject to an excise tax imposed by Section 4999 of the Code (such excise tax referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company shall either </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make a payment to Executive of all amounts due without any adjustment, or  reduce whatever payments are deemed to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contingent on a transaction that constitutes either a &#8220;change in the ownership or effective control&#8221; of the Company, a &#8220;change in the ownership of a substantial portion of the assets&#8221; of the Company (as such phrases are used for purposes of Code Section 280G), to the extent necessary that no payments or benefits provided to Executive are subject to the Excise Tax, whichever approach results in a better economic result for Executive on a better economic result for Executive net of all taxes, including the Excise Tax.  The determination of which approach shall be applied shall be made by a public accounting firm retained by the Company for purposes of making this determination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which need not be the same firm otherwise retained by the Company for the provision of general accounting services.  The reduction in payments or benefits provided to Executive under approach (b) shall be applied in a manner that the Accounting Firm determines to be the most appropriate, taking into account possible tax implications of Code Section 409A, and that avoids any unnecessary losses to Executive that may occur in the case of a reduction achieved by reducing the extent to which equity is vested on an accelerated basis.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">No Set-Off&#59; No Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as provided herein, the Company&#8217;s obligation to provide benefits under this Agreement and otherwise to perform its obligations hereunder shall not be affected by any circumstances, including any set-off, counterclaim, recoupment, defense, or other right the Company may have against Executive or others.  In no event shall Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under any of the provisions of this Agreement, and such amounts shall not be reduced whether or not Executive obtains other employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices and all other communications under this Agreement shall be in writing and shall be deemed given when mailed by United States registered or certified mail, return receipt requested, postage prepaid, addressed as follows&#58; if to the Company, to the principal headquarters of the Company, attention&#58; Chairman of the Board&#59; and if to Executive, to Executive&#8217;s most recent address in the Company&#8217;s records&#59; or, in each respective case, to such other address as either Party may furnish to the other in writing, except that notices of changes of address shall be effective only upon receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be governed by and construed under the laws of the State of Delaware, without regard to principles of conflict of laws (whether in Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Choice of Venue and Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party hereby irrevocably submits to the exclusive jurisdiction of the federal and state courts located within Philadelphia County, Pennsylvania and New Castle County, Delaware for the purpose of any suit, action, or other proceeding arising out of or based on this Agreement or any other agreement contemplated hereby or any subject matter hereof, whether in tort, contract, or otherwise. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement constitutes the entire agreement between the Parties concerning the subject matter hereof, and supersedes all prior negotiations, undertakings, agreements, and arrangements with respect thereto, whether written or oral.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Withholding of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company may withhold from any benefits payable under this Agreement all federal, state, city and other taxes as may be required pursuant to any law, governmental regulation, or ruling.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive&#8217;s right to receive benefits under this Agreement shall not be assignable or transferable whether by pledge, creation of a security interest, or otherwise, other than a transfer by will, by the laws of descent or distribution, or as otherwise provided in this Agreement.  The Company may assign this Agreement, including to any Affiliate or in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection with a merger or sale of equity or assets, and upon any such assignment all references to the Company herein shall be deemed to include the assignee.  The Company need not obtain Executive&#8217;s authorization or permission to assign this Agreement&#59; however, if the Company assigns this Agreement, for any reason, the Company agrees to provide advance notice thereof to Executive and ensure the party to whom this Agreement is assigned has the resources to comply with the terms set forth herein.  This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s personal and legal representatives, executors, administrators, successors, heirs, distributees, devisees, and legatees.  This Agreement shall be binding upon and inure to the benefit of the Company, its successors, and assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may not be amended or modified except by written agreement signed by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Executive Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive hereby represents that from and after the Effective Date the performance of Executive&#8217;s duties hereunder will not breach any other agreement to which Executive is a party.  Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#8217;s own judgment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent any provision of this Agreement or action by the Company would subject Executive to liability for interest or additional taxes under Code Section 409A, it shall be deemed null and void, to the extent permitted by law and deemed advisable by the Company.  Payments under this agreement are intended to be exempt from Code Section 409A, and, if not exempt, to be compliant with the requirements of Code Section 409A.  Notwithstanding any provision of this Agreement to the contrary, to the extent any payments are part of a plan or agreement that is subject to Code Section 409A and such payments are payable on termination of employment (or other similar concept), such payments shall only be made if the payment triggering event also constitutes a &#8220;separation from service&#8221; within the meaning of Code Section 409A.  In addition, if (A) the Company has any class of equity securities traded on a stock exchange and (B) Executive is a &#8220;specified employee&#8221; (as that phrase is used for purposes of Code Section 409A) as of the date of Executive&#8217;s &#8220;separation from service,&#8221; any payment that is subject to Code Section 409A and is payable by reason of Executive&#8217;s &#8220;separation from service,&#8221; such payment shall not be made prior to the first day of the seventh (7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) calendar month following the date of Executive&#8217;s &#8220;separation from service&#8221; or the date of Executive&#8217;s death, if earlier.  For purposes of Code Section 409A, all installment payments of deferred compensation made hereunder, or pursuant to another plan or arrangement, shall be deemed to be separate payments.  To the extent any reimbursements or in-kind benefit payments under this Agreement are subject to Code Section 409A, such reimbursements and in-kind benefit payments shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv).  This Agreement may be amended to the extent necessary (including retroactively) by the Company to avoid the application of taxes or interest under Code Section 409A, while maintaining to the maximum extent practicable the original intent of this Agreement.  This Section&#160;17 shall not be construed as a guarantee of any particular tax effect for Executive&#8217;s benefits under this Agreement and the Company does not guarantee that any such benefits will satisfy the provisions of Code Section&#160;409A or any other provision of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In this Agreement, unless otherwise stated, the following uses apply&#58; (i)&#160;references to a statute refer to the statute and any amendments and any successor statutes, and to all regulations promulgated under or implementing the statute, as amended, or its successors, as in effect at the relevant time&#59; (ii)&#160;in computing periods from a specified date to a later specified date, the words &#8220;from&#8221; and &#8220;commencing on&#8221; (and the like) mean &#8220;from and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including,&#8221; and the words &#8220;to,&#8221; &#8220;until,&#8221; and &#8220;ending on&#8221; (and the like) mean &#8220;to, and including&#8221;&#59; (iii)&#160;references to a governmental or quasi-governmental agency, authority, or instrumentality also refer to a regulatory body that succeeds to the functions of the agency, authority, or instrumentality&#59; (iv)&#160;the words &#8220;include,&#8221; &#8220;includes,&#8221; and &#8220;including&#8221; (and the like) mean &#8220;include, without limitation,&#8221; &#8220;includes, without limitation,&#8221; and &#8220;including, without limitation,&#8221; (and the like) respectively&#59; (v)&#160;all references to sections and exhibits are to sections and exhibits in or to this Agreement&#59; (vi)&#160;the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereto,&#8221; &#8220;hereby,&#8221; &#8220;hereunder,&#8221; (and the like) refer to this Agreement as a whole (including exhibits)&#59; (vii)&#160;any reference to a document or set of documents, and the rights and obligations of the Parties under any such documents, means such document or documents as amended from time to time, and all modifications, extensions, renewals, substitutions, or replacements thereof&#59; (viii)&#160;all words used shall be construed to be of such gender or number as the circumstances and context require&#59; and (ix)&#160;the captions and headings of preambles, recitals, sections, and exhibits appearing in or attached to this Agreement have been inserted solely for convenience of reference and shall not be considered a part of this Agreement, nor shall any of them affect the meaning or interpretation of this Agreement or any of its provisions.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If a court of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, then the invalidity or unenforceability of that provision shall not affect the validity or enforceability of any other provision of this Agreement and all other provisions shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The various covenants and provisions of this Agreement are intended to be severable and to constitute independent and distinct binding obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Without limiting the generality of the foregoing, if the scope of any covenant contained in this Agreement is too broad to permit enforcement to its full extent, such covenant shall be enforced to the maximum extent permitted by law, and such scope may be judicially modified accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in this Agreement, the terms defined in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> have the meanings set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each Entity that, directly or indirectly, is controlled by, controls, or is under common control with, the Company, where &#8220;control&#8221; means (i) the ownership of more than 50% of the Voting Securities or other voting or equity interests of any Entity, or (ii) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Entity.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any of the following (in each case as determined by the Compensation Committee or the Board)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Executive&#8217;s conviction of, or plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or equivalent to, a crime of embezzlement or fraud or any felony under the laws of the United States or any state thereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">An act of fraud, willful misconduct or dishonesty by Executive in the course of or related to his employment hereunder or that could reasonably be expected to be materially injurious to the Company or an Affiliate&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">A material breach by Executive of any of the provisions of the Agreement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">An act of moral turpitude by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the course of, or related to, his employment hereunder or that could reasonably be expected to lead to a material harm (financial or reputational) to the Company or an Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change in Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the date on which</font><font style="color:#365f91;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group (&#8220;Person&#8221;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock of the Company&#59; provided, however, that for purposes of this subsection (i), the acquisition of additional stock by any one Person, who is considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.36pt">A change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this clause (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.03pt">A sale or other disposition of all or substantially all of the Company&#8217;s assets in one or more transactions, other than to any entity of which more than 50% of the total voting power is owned, directly or indirectly, by stockholders of the Company in substantially the same proportions as their ownership of the voting power of the stock of the Company immediately prior to the transaction which results in a sale or disposition as to all or substantially all of the Company&#8217;s assets&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.69pt">A merger, consolidation or similar transaction directly or indirectly involving the Company in which immediately after the consummation of such transaction, the stockholders of the Company immediately prior to such transaction do not directly or indirectly own more than 50% of the total voting power of the surviving entity in such transaction (or of any applicable Parent of such surviving entity), in substantially the same proportions as their ownership of the voting power of the stock of the Company immediately prior to the transaction. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For purposes of this definition of Change in Control, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, the occurrence of any event shall not be deemed a Change in Control&#58; (i) with respect to any award or payment that is subject to Code Section 409A unless such event qualifies as a change in control event within the meaning of Code Section 409A, or (ii) if the sole purpose of the underlying transaction(s) is to change the jurisdiction of the Company&#8217;s incorporation or to create a holding company of which the total voting power is owned, directly or indirectly, by stockholders of the Company in substantially the same </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">proportions as their ownership of the voting power of the stock of the Company immediately prior to such transaction(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company Proprietary and Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all products, systems, methods, procedures, techniques, manuals, databases, plans, lists, inventions, discoveries, innovations, improvements, enhancements, concepts, ideas, and software conceived, created, compiled, or otherwise developed by the Company or its Affiliates and&#47;or comprised, in whole or part, of Confidential Information, together with all patent rights, copyrights, trademarks, service marks, trade name rights and other source identifiers, trade secrets, and other intellectual property and property rights therein, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company Work Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all products, systems, methods, procedures, techniques, manuals, databases, plans, lists, inventions, discoveries, innovations, improvements, enhancements, concepts, ideas, and software conceived, created, compiled, or otherwise developed by Executive, alone or with others, in the course of Executive&#8217;s employment with the Company or its Affiliates and&#47;or comprised, in whole or part, of Confidential Information, together with all patent rights, copyrights, trademarks, service marks, trade name rights, trade secrets, and other intellectual property and propriety rights therein, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any entity offering, or having proposed to offer, the specific products offered by the Company during the two years prior to Executive&#8217;s separation. For purposes of clarity, &#8220;Competitor&#8221; does not include an entity simply because it offers oncology products or operates in the oncology field&#59; rather, for an entity to be a Competitor, the entity must offer or have proposed to offer the specific products offered by the Company during the two years prior to Executive&#8217;s separation.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means trade secret, confidential, proprietary or other non-public information concerning the Company or its Affiliates, including research, development, designs, formulae, processes, specifications, technologies, marketing materials, financial and other information concerning customers and prospective customers, customer lists, records, data, computer programs, source codes, object codes, database structures, trade secrets, proprietary business information, pricing and profitability information, policies, strategic planning, commitments, plans, procedures, litigation, pending litigation, and other information not generally available to the public.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that (i)&#160;Executive is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or (ii)&#160;Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under long-term disability plan covering employees of the Company.  In the event of a dispute regarding whether Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has incurred a Disability, each of Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the Company shall choose a physician who together shall choose a third physician to make a final determination regarding whether Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has incurred a Disability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">&#8220;Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any corporation, partnership, limited liability company, joint venture, association, partnership, business trust or other business entity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">&#8220;Financing&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means a transaction involving equity, debt, joint venture, licensing, merger or other similar arrangement resulting in cash proceeds to the Company, including the aggregate amount of capital raised without regard to any conditions placed on the Financing (such as milestone targets).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any one of the following events, unless Executive agrees in writing that such event shall not constitute Good Reason&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">A material and adverse change in the nature, scope, or status of Executive&#8217;s position, authorities, responsibilities or duties from those in effect in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, including, without limitation, Executive ceasing to be an &#8220;executive officer&#8221; (as defined under Rule&#160;3b-7 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) of a company with a class of securities registered under Section&#160;12(b)&#160;of the Exchange Act, or the assignment to Executive of any duties materially inconsistent with the duties and responsibilities of Executive Officer&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">A material reduction in Executive&#8217;s then-current Annual Base Salary and&#47;or Target Bonus, or a material reduction in Executive&#8217;s aggregate benefits or other compensation plans in effect immediately following the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">A permanent relocation of Executive&#8217;s primary place of employment that increases Executive&#8217;s commuting distance from his primary residence by more than twenty-five (25) miles, as compared with Executive&#8217;s commute to Executive&#8217;s primary place of employment as initially agreed to by Executive and the Company&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">A material breach by the Company of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Promotional Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, without limitation, photographs, films, clips, sketches, segments, and other media and promotional works, including any derivative works thereof, used for reasonable purposes in connection with the business of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">&#8220;Qualifying Financing&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means one or more Financings within the 12 months before or following the Effective Date resulting in gross proceeds of not less than $15,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a general release and waiver as substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and otherwise as agreed upon by the Company and Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each state in the United States in which the Company or its Affiliates are actively engaged in or pursing business at the time of Executive&#8217;s termination of employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a period of 6 months immediately following the applicable Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means termination of Executive&#8217;s employment with the Company and all Affiliates for any reason or no reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any securities that ordinarily possess the power to vote in the election of directors without the happening of any precondition or contingency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The provisions of Section&#160;6 shall survive the termination of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Signature page to follow&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company has caused this Agreement to be executed in its name and on its behalf, and Executive acknowledges understanding and acceptance of, and agrees to, the terms of this Agreement, all as of the Effective Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTEXT THERAPEUTICS INC.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Martin Lehr</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Name&#58;  Martin Lehr<br>Title&#58;  Chief Executive Officer</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alex Levit</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Alex Levit</font></div></td></tr></table></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Agreement and Release and Waiver</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Agreement and Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) is made and entered into by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Context Therapeutics Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and &#91;&#9679;&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, Executive and the Company desire to settle fully and amicably all issues that Executive has with the Company, including any issues arising out of Executive&#8217;s employment with the Company and the termination of that employment&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, Executive and the Company are parties to that certain Employment Agreement, made and entered into as of &#91;&#9679;&#93;, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Now, therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, for and in consideration of the mutual promises contained herein, and for other good and sufficient consideration, receipt of which is hereby acknowledged, Executive and the Company (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; and, individually, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), intending to be legally bound, hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">1.&#160;&#160;&#160;&#160;Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Executive&#8217;s employment with the Company terminated effective as of the close of business on &#91;&#9679;&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">2.&#160;&#160;&#160;&#160;Compensation and Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Subject to the terms of this Agreement, the Company shall compensate Executive under this Agreement as follows (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Severance Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Severance Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  &#91;&#9679;&#93;.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Accrued Salary and Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Executive shall be entitled to a lump sum payment in an amount equal to Executive&#8217;s earned but unpaid annual base salary and vacation pay for the period ending on the Termination Date, with such payment to be made on the first payroll date following the Termination Date.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Executive Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Executive acknowledges that, subject to fulfillment of all obligations provided for herein, Executive has been fully compensated by the Company, including under all applicable laws, and that nothing further is owed to Executive with respect to wages, bonuses, severance, other compensation, or benefits.  Executive further acknowledges that the Severance Payments (other than (b) above) are consideration for Executive&#8217;s promises contained in this Agreement, and that the Severance Payments are above and beyond any wages, bonuses, severance, other compensation, or benefits to which Executive is entitled from the Company under the terms of Executive&#8217;s employment or under any other contract or law, absent his execution of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The Severance Payments shall be treated as wages and subject to all taxes and other payroll deductions required by law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">3.&#160;&#160;&#160;&#160;Termination of Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> above or as may be required by law, Executive&#8217;s participation in all employee benefit (pension and welfare) and compensation plans of the Company shall cease as of the Termination Date.  Nothing contained </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">herein shall limit or otherwise impair Executive&#8217;s right to receive pension or similar benefit payments that are vested as of the Termination Date under any applicable tax-qualified pension or other plans, pursuant to the terms of the applicable plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">4.&#160;&#160;&#160;&#160;Release of Claims and Waiver of Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Executive, on Executive&#8217;s own behalf and that of Executive&#8217;s heirs, executors, attorneys, administrators, successors, and assigns, fully releases and discharges the Company&#59; each of its predecessors, successors, parents, subsidiaries, affiliates, and assigns&#59; all of its and their current and former directors, officers, trustees, employees, and agents, both in their individual and official capacities&#59; and the current and former trustees and administrators of each retirement and other benefit plan applicable to the employees and former employees of the Company, both in their official and individual capacities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) from all liability, claims, demands, and actions Executive now has, may have had, or may ever have, whether currently known or unknown, as of or prior to Executive&#8217;s execution of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), including liability claims, demands, and actions&#58; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Arising from or relating to Executive&#8217;s employment or other association with the Company, or the termination of such employment,</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;Relating to wages, bonuses, incentive pay, equity, other compensation, or benefits,</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;Relating to any employment or change in control contract, </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;Relating to any employment law, including</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;The laws of the United States and Commonwealth of Pennsylvania, </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;The Civil Rights Act of 1964, </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)&#160;&#160;&#160;&#160;The Civil Rights Act of 1991,</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv)&#160;&#160;&#160;&#160;The Equal Pay Act,</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(v)&#160;&#160;&#160;&#160;The Employee Retirement Income Security Act of 1974, </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vi)&#160;&#160;&#160;&#160;The Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;),</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vii)&#160;&#160;&#160;&#160;The Americans with Disabilities Act,</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(viii)&#160;&#160;&#160;&#160;Executive Order 11246, and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ix)&#160;&#160;&#160;&#160;Any other federal, state, or local statute, ordinance, or regulation relating to employment,</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(e)&#160;&#160;&#160;&#160;Relating to any right of payment for disability,</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(f)&#160;&#160;&#160;&#160;Relating to any statutory or contractual right of payment, and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(g)&#160;&#160;&#160;&#160;For relief on the basis of any alleged tort or breach of contract under the common law of the Commonwealth of Pennsylvania, or any other state, including defamation, intentional or negligent infliction of emotional distress, wrongful termination, breach of the covenant of good faith and fair dealing, promissory estoppel, and negligence.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Executive acknowledges that Executive is aware that statutes exist that render null and void releases and discharges of any claims, rights, demands, liabilities, actions, and causes of action that are unknown to the releasing or discharging party at the time of execution of the release and discharge.  Executive waives, surrenders, and shall forego any protection to which Executive would otherwise be entitled by virtue of the existence of any such statutes in any jurisdiction, including the Commonwealth of Pennsylvania.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">5.&#160;&#160;&#160;&#160;Exclusions from General Release.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Excluded from the Release are any claims or rights that cannot be waived by law, claims for indemnification by the Company as an officer or former officer of the Company, whether by law, contract or articles or bylaws of the Company, as well as Executive&#8217;s right to file a charge with an administrative agency or participate in any agency investigation.  Executive is, however, waiving the right to recover any money from the Company and other Releasees in connection with a charge or investigation.  Executive is also waiving the right to recover any money from the Company and other Releasees in connection with a charge filed by any other individual or by the Equal Employment Opportunity Commission or any other federal or state agency.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">6.&#160;&#160;&#160;&#160;Covenant Not to Sue.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;A &#8220;covenant not to sue&#8221; is a legal term that means Executive promises not to file a lawsuit in court.  It is different from the release of claims and waiver of rights contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> above.  Besides waiving and releasing the claims covered by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> above, Executive shall never sue the Releasees in any forum for any reason covered by the Release.  Notwithstanding this covenant not to sue, Executive may bring a claim against the Company to enforce this Agreement, to challenge the validity of this Agreement under the ADEA or for any claim that arises after execution of this Agreement.  Executive may also file an administrative complaint or charge with a government agency, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Executive shall not be entitled recover any monies from the Releasees as a result of filing such administrative complaint or charge.  If Executive sues any of the Releasees in violation of this Agreement, Executive shall be liable to them for their reasonable attorneys&#8217; fees and costs (including the costs of experts, evidence, and counsel) and other litigation costs incurred in defending against Executive&#8217;s suit.  In addition, if Executive sues any of the Releasees in violation of this Agreement, the Company can require Executive to return all but a sum of $100 of the Severance Payments, which sum is, by itself, adequate consideration for the promises and covenants in this Agreement.  In that event, the Company shall have no obligation to make any further Severance Payments.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;If Executive has previously filed any lawsuit against any of the Releasees, Executive shall immediately take all necessary steps and execute all necessary documents to withdraw or dismiss such lawsuit to the extent Executive&#8217;s agreement to withdraw, dismiss, or not file a lawsuit would not be a violation of any applicable law or regulation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">7.&#160;&#160;&#160;&#160;Representations by Executive.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Executive warrants that Executive is legally competent to execute this Agreement and that Executive has not relied on any statements or explanations made by the Company or its attorneys.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">acknowledges that Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">has been advised to consult legal counsel regarding the terms of this Agreement, including the Release.  Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">acknowledges that Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">has been offered at least 21 days to consider this Agreement.  After being so advised, and without coercion of any kind, Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">freely, knowingly, and voluntarily enters into this Agreement.  Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">acknowledges that Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">may revoke this Agreement within seven days after Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">has signed this Agreement and acknowledges understanding that this Agreement shall not become effective or enforceable until seven days after Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">has signed this Agreement (the &#8220;Effective Date&#8221;), as evidenced by the date set forth below Executive&#8217;s signature on the signature page hereto.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Any revocation must be in writing and directed to &#91;&#9679;&#93;.  If sent by mail, any revocation must be postmarked within the seven-day period described above and sent by certified mail, return receipt requested.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">8.&#160;&#160;&#160;&#160;Restrictive Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Section 6 of the Employment Agreement (entitled &#8220;Restrictive Covenants&#8221;) shall continue in full force and effect as if fully restated herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">9.&#160;&#160;&#160;&#160;Non-Disparagement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Executive shall not engage in any disparagement or vilification of the Releasees, and shall refrain from making any false, negative, critical, or disparaging statements, implied or expressed, concerning the Releasees, including regarding management style, methods of doing business, the quality of products and services, role in the community, or treatment of employees.  The Company and its directors, officers and senior management employees, while associated with the Company, shall not engage in any disparagement or vilification of the Releasees, and shall refrain from making any false, negative, critical, or disparaging statements, implied or expressed, concerning Executive&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that each Party may make truthful statements as required by applicable law and the Company may make internal statements and statements to its attorneys and advisors for legitimate business reasons.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">10.&#160;&#160;&#160;&#160;Company Property.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Executive shall return to the Company all information, property, and supplies belonging to the Company or any of its affiliates, including any confidential or proprietary information, Company autos, keys (for equipment or facilities), laptop computers and related equipment, cellular phones, smart phones or PDAs (including SIM cards), security cards, corporate credit cards, and the originals and all copies of all files, materials, and documents (whether in tangible or electronic form) containing confidential or proprietary information or relating to the business of the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;Executive shall not, at any time on or after the Termination Date, directly or indirectly use, access, or in any way alter or modify any of the databases, e-mail systems, software, computer systems, or hardware or other electronic, computerized, or technological systems of the Company or any of its affiliates.  Executive acknowledges that any such conduct by Executive would be illegal and would subject Executive to legal action by the Company, including claims for damages and&#47;or appropriate injunctive relief.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">11.&#160;&#160;&#160;&#160;No Admissions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  The Company denies that it or any of its affiliates, or any of their employees or agents, has taken any improper action against Executive, and this Agreement shall not be admissible in any proceeding as evidence of improper action by the Company or any of its affiliates or any of their employees or agents. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">12.&#160;&#160;&#160;&#160;Confidentiality of Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Executive shall keep the existence and the terms of this Agreement confidential, except for Executive&#8217;s immediate family members and Executive&#8217;s legal and tax advisors in connection with services related hereto and except as may be required by law or in connection with the preparation of tax returns.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">13.&#160;&#160;&#160;&#160;Non-Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  The Company&#8217;s waiver of a breach of this Agreement by Executive shall not be construed or operate as a waiver of any subsequent breach by Executive of the same or of any other provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">14.&#160;&#160;&#160;&#160;Governing Law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">This Agreement shall be governed by and construed under the laws of the State of Delaware, without regard to principles of conflict of laws (whether in Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than Delaware.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">15.&#160;&#160;&#160;&#160;Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  This Agreement sets forth the entire agreement of the Parties regarding the subject matter hereof, and shall be final and binding as to all claims that have been or could have been advanced on behalf of Executive pursuant to any claim arising out of or related in any way to Executive&#8217;s employment with the Company and the termination of that employment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> that nothing contained herein shall supersede or eliminate any post-separation obligations that Executive has pursuant to the Employment Agreement or otherwise.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">16.&#160;&#160;&#160;&#160;Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">17.&#160;&#160;&#160;&#160;Successors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  This Agreement shall be binding upon and inure to the benefit of the Company, its successors and assigns.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">18.&#160;&#160;&#160;&#160;Construction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  In this Agreement, unless otherwise stated, the following uses apply&#58; (a)&#160;references to a statute refer to the statute and any amendments and any successor statutes, and to all regulations promulgated under or implementing the statute, as amended, or its successors, as in effect at the relevant time&#59; (b)&#160;in computing periods from a specified date to a later specified date, the words &#8220;from&#8221; and &#8220;commencing on&#8221; (and the like) mean &#8220;from and including, &#8220; and the words &#8220;to,&#8221; &#8220;until,&#8221; and &#8220;ending on&#8221; (and the like) mean &#8220;to, and including&#8221;&#59; (c)&#160;references to a governmental or quasi-governmental agency, authority, or instrumentality also refer to a regulatory body that succeeds to the functions of the agency, authority, or instrumentality&#59; (d)&#160;the words &#8220;include,&#8221; &#8220;includes,&#8221; and &#8220;including&#8221; (and the like) mean &#8220;include, without limitation,&#8221; &#8220;includes, without limitation,&#8221; and &#8220;including, without limitation,&#8221; (and the like) respectively&#59; (e)&#160;all references to sections are to sections to this Agreement&#59; (f)&#160;the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereto,&#8221; &#8220;hereby,&#8221; &#8220;hereunder,&#8221; (and the like) refer to this Agreement as a whole (including exhibits)&#59; (g)&#160;any reference to a document or set of documents, and the rights and obligations of the parties under any such documents, means such document or documents as amended from time to time, and all modifications, extensions, renewals, substitutions, or replacements thereof&#59; (h)&#160;all words used shall be construed to be of such gender or number as the circumstances and context require&#59; (i)&#160;the captions and headings have been inserted solely for convenience of reference and shall not be considered a part of this Agreement, nor shall any of them affect the meaning or interpretation of this Agreement or any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">of its provisions&#59; and (j)&#160;all accounting terms not specifically defined herein shall be construed in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">19.&#160;&#160;&#160;&#160;Future Cooperation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  In connection with any and all claims, disputes, negotiations, governmental, internal or other investigations, lawsuits, or administrative proceedings (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Legal Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) involving the Company or any affiliate, or any of their current or former officers, employees or board members (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Disputing Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; and, individually, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Disputing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), Executive shall make himself reasonably available, upon reasonable notice from the Company and without the necessity of subpoena, to provide information and documents, provide declarations and statements regarding a Disputing Party, meet with attorneys and other representatives of a Disputing Party, prepare for and give depositions and testimony, and otherwise cooperate in the investigation, defense, and prosecution of any and all such Legal Matters, as may, in the good faith and judgment of the Company, be reasonably requested.  The Company shall consult with Executive and make reasonable efforts to schedule such assistance so as not to materially disrupt Executive&#8217;s business and personal affairs.  The Company shall reimburse all reasonable expenses incurred by Executive in connection with such assistance, including travel, meals, rental car, and hotel expenses, if any.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">In witness whereof,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> the Parties have duly executed this Agreement as of the dates set forth below their respective signatures below.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;CONTEXT THERAPEUTICS INC.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Print Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#91;INSERT NAME&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>amendment1tosahmoud-oncost.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2200b29a168c4c56bfaf0cb00ddbe332_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT NO. 1 TO CONSULTING AGREEMENT</font></div><div><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">AMENDMENT NO. 1 TO CONSULTING AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) is entered into as of the 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> day of March 2022, but effective as of the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> day of February, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), and is entered into by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OncoStrategy LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Context Therapeutics Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, a Delaware corporation, having its principal place of business at 2001 Market Street, Suite 3915, Unit#15, Philadelphia, PA 19103 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;).  Provider and Company are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.&#8221;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Provider and Company entered into that certain Consulting Agreement dated as of May 7, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which outlines the rights and obligations of Provider and Company with respect to the conduct of certain services to be performed by Provider&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Parties wish to enter into this Amendment in order to temporarily increase the hours and related compensation for services in accordance with the terms and conditions set forth herein&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All capitalized terms used herein shall have the meaning ascribed to&#160;&#160;&#160;&#160;each of them as defined herein and, if not defined herein, shall have the meaning ascribed to each &#160;&#160;&#160;&#160;of them in the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment to Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of the Amendment Effective Date, for the months of February, March, April and May 2022, Provider shall receive $20,000 per calendar month in arrears, provided that Consultant provides on average approximately 40 hours of Consulting Services per month.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party acknowledges that this Amendment, together with the Agreement, constitutes the entire agreement of the Parties with respect to the subject matter hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Full Force and Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly amended hereby, all of the other terms and conditions of the Agreement shall remain unchanged and in full force and effect in accordance with their original terms.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party hereby represents and warrants that is has full power and authority to enter into this Amendment.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Signature page follows.&#93;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amd1 to Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have each caused a duly authorized representative to execute this Amendment as of the Amendment Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COMPANY&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Context Therapeutics Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Martin Lehr&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Martin Lehr&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PROVIDER&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OncoStrategy, LLC</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Tarek Sahmoud&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tarek Sahmoud</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Principal&#160;&#38; Founder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amd1 to Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit231cohnreznickconse.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1222e66633c24adbb070aa3ed9b2d57d_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Exhibit 23.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in the Registration Statement of Context Therapeutics Inc. on Form S-8 (No. 333-260385) of our report dated March 23, 2022, on our audits of the consolidated financial statements of Context Therapeutics Inc. and Subsidiaries as of December 31, 2021 and 2020 and for the years then ended, included in this Annual Report on Form 10-K of Context Therapeutics Inc. for the year ended December 31, 2021. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; CohnReznick LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Holmdel, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 23, 2022 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>contexttherapeuticsex311ce.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaaee6e4a712747f3bbcc69a7ee54ae10_33"></div><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I, Martin Lehr, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Context Therapeutics Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58; March 23, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Martin Lehr                  </font></div><div style="padding-left:324pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Martin Lehr</font></div><div style="padding-left:324pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Executive Officer</font></div><div style="padding-left:324pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Principal Executive Officer)</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>contexttherapeuticsex312ce.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iebfdaeb0d3a74950b8f74488412b1262_33"></div><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 31.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I, Jennifer Minai-Azary, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Context Therapeutics Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58; March 23, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Jennifer Minai-Azary                  </font></div><div style="padding-left:324pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jennifer Minai-Azary</font></div><div style="padding-left:324pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Financial Officer</font></div><div style="padding-left:324pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Principal Financial Officer)</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>contexttherapeuticsex321ce.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i730255c72bd447488975a86b0056e64b_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXHIBIT&#160;32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATIONS PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Martin Lehr, Chief Executive Officer (Principal Executive Officer) of Context Therapeutics Inc. (the &#8220;Company&#8221;), and Jennifer Minai-Azary, Chief Financial Officer (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;Annual Report&#8221;), and to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 23, 2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 23, 2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8220;This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Context Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cntx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:26b5d880-9edc-4480-83e2-744a98c761b2,g:c86f1f4d-7057-497b-9a16-bf3850b7383a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cntx="http://www.contexttherapeutics.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.contexttherapeutics.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.contexttherapeutics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.contexttherapeutics.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit">
        <link:definition>1004006 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlows" roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://www.contexttherapeutics.com/role/NatureofBusiness">
        <link:definition>2101101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://www.contexttherapeutics.com/role/NatureofBusinessDetails">
        <link:definition>2402401 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandLiquidity" roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidity">
        <link:definition>2103102 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandLiquidityNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails">
        <link:definition>2404402 - Disclosure - Risks and Liquidity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2105103 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2206201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2307301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2408403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2409404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>2410405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails" roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails">
        <link:definition>2411406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurements">
        <link:definition>2112104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables">
        <link:definition>2313302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails">
        <link:definition>2415408 - Disclosure - Fair Value Measurements - Roll-forward of fair values of liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>2116105 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>2317303 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails">
        <link:definition>2418409 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePromissoryNotes" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotes">
        <link:definition>2119106 - Disclosure - Convertible Promissory Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePromissoryNotesDetails" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails">
        <link:definition>2420410 - Disclosure - Convertible Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedeemableCommonStockandCommonStock" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock">
        <link:definition>2121107 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables">
        <link:definition>2322304 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails">
        <link:definition>2423411 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails">
        <link:definition>2424412 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensation">
        <link:definition>2125108 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>2326305 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>2427413 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails">
        <link:definition>2428414 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofShareBasedActivityDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails">
        <link:definition>2429415 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails">
        <link:definition>2430416 - Disclosure - Share-Based Compensation - Schedule of RSU Share-Based Payment Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingencies">
        <link:definition>2131109 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails">
        <link:definition>2432417 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.contexttherapeutics.com/role/IncomeTaxes">
        <link:definition>2133110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesTables">
        <link:definition>2334306 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2435418 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2436419 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences That Give Rise To The Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2437420 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofOperatingLossCarryforwardsDetails" roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails">
        <link:definition>2438421 - Disclosure - Income Taxes - Summary of Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.contexttherapeutics.com/role/RelatedPartyTransactions">
        <link:definition>2139111 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.contexttherapeutics.com/role/SubsequentEvents">
        <link:definition>2140112 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails">
        <link:definition>2441422 - Disclosure - Subsequent Events - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cntx_StateJurisdictionMember" abstract="true" name="StateJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_ContextTherapeuticsLLCMember" abstract="true" name="ContextTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_IssuedToPlacementAgentsMember" abstract="true" name="IssuedToPlacementAgentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_AccruedInterestRelatedParties" abstract="false" name="AccruedInterestRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_ConvertibleBridgeNotesMember" abstract="true" name="ConvertibleBridgeNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_IssuedForServicesMember" abstract="true" name="IssuedForServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_TemporaryEquityPolicyPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" abstract="true" name="ScaleUp100KilogramsOfGMPGradeCompoundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" abstract="false" name="StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_ManufacturingDevelopmentLiabilitiesCurrent" abstract="false" name="ManufacturingDevelopmentLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_PatentCostsPolicyPolicyTextBlock" abstract="false" name="PatentCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cntx_TemporaryEquityDecreaseDueToConversionToWarrants" abstract="false" name="TemporaryEquityDecreaseDueToConversionToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cntx_ClinicalTrialLiabilitiesCurrent" abstract="false" name="ClinicalTrialLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" abstract="false" name="IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_FairValueAdjustmentOnConvertibleDebt" abstract="false" name="FairValueAdjustmentOnConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" abstract="true" name="WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_DebtInstrumentConvertedInstrumentPrincipalAmount" abstract="false" name="DebtInstrumentConvertedInstrumentPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_SeniorConvertibleNotesApril2020Member" abstract="true" name="SeniorConvertibleNotesApril2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_IssuedAsPartOfPrivatePlacementMember" abstract="true" name="IssuedAsPartOfPrivatePlacementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_DemandNotesToConvertiblePromissoryNotesMember" abstract="true" name="DemandNotesToConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_PaymentProtectionProgramLoanMember" abstract="true" name="PaymentProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_PlacementAgentsWarrantsMember" abstract="true" name="PlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_BridgeNotesToSeriesAPreferredStockMember" abstract="true" name="BridgeNotesToSeriesAPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_DrexelUniversityMember" abstract="true" name="DrexelUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_NetDeferredTaxAssetLiabilitiesGross" abstract="false" name="NetDeferredTaxAssetLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_JuniorConvertibleNotesMember" abstract="true" name="JuniorConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cntx_DebtInstrumentConvertedInstrumentInterestAmount" abstract="false" name="DebtInstrumentConvertedInstrumentInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_OperatingLossCarryforwardsExpirationTerm" abstract="false" name="OperatingLossCarryforwardsExpirationTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cntx_RisksAndLiquidityTextBlock" abstract="false" name="RisksAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" abstract="false" name="TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cntx_DebtConversionConvertedInstrumentPricePerShare" abstract="false" name="DebtConversionConvertedInstrumentPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cntx_WarrantsIssued" abstract="false" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_TemporaryEquityOfferingCosts" abstract="false" name="TemporaryEquityOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_IntegralMolecularIncMember" abstract="true" name="IntegralMolecularIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember" abstract="true" name="ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_SeriesSeedPreferredStockMember" abstract="true" name="SeriesSeedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" abstract="true" name="ScaleUp300KilogramsOfGMPGradeCompoundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_IssuedToSeriesAStockholdersMember" abstract="true" name="IssuedToSeriesAStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cntx_RedeemableCommonStockMember" abstract="true" name="RedeemableCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_IssuedInConnectionWithIPOMember" abstract="true" name="IssuedInConnectionWithIPOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_StockIssuedDuringPeriodIssuanceCosts" abstract="false" name="StockIssuedDuringPeriodIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_StockGrantedForServicesMember" abstract="true" name="StockGrantedForServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember" abstract="true" name="ChiefFinancialOfficerAndImmediateFamilyMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_December2021PrivatePlacementAgentWarrantsMember" abstract="true" name="December2021PrivatePlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_LocalJurisdictionMember" abstract="true" name="LocalJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_RisksAndLiquidityAbstract" abstract="true" name="RisksAndLiquidityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cntx_BridgeNoteQualifiedFinancingMember" abstract="true" name="BridgeNoteQualifiedFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_DeferredOfferingCostIncurredButNotYetPaid" abstract="false" name="DeferredOfferingCostIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" abstract="false" name="TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_December2021PrivatePlacementWarrantsMember" abstract="true" name="December2021PrivatePlacementWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TyligandBioscienceShanghaiLimitedMember" abstract="true" name="TyligandBioscienceShanghaiLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_IssuedForProfessionalConsultingServicesMember" abstract="true" name="IssuedForProfessionalConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cntx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:26b5d880-9edc-4480-83e2-744a98c761b2,g:c86f1f4d-7057-497b-9a16-bf3850b7383a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7ec7c4-67d2-4545-99a5-d702e8c89b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_01629347-024f-4f5d-8fb7-ac2b043d3d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7ec7c4-67d2-4545-99a5-d702e8c89b77" xlink:to="loc_us-gaap_Liabilities_01629347-024f-4f5d-8fb7-ac2b043d3d8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_18a2dffe-f0cf-420a-9913-1d8e149cc905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7ec7c4-67d2-4545-99a5-d702e8c89b77" xlink:to="loc_us-gaap_CommitmentsAndContingencies_18a2dffe-f0cf-420a-9913-1d8e149cc905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0d29ec3-e59f-4c11-9408-3c9c594bd73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7ec7c4-67d2-4545-99a5-d702e8c89b77" xlink:to="loc_us-gaap_StockholdersEquity_a0d29ec3-e59f-4c11-9408-3c9c594bd73b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4478316d-9a94-4ef6-a55d-b9c265d1624d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c7ec7c4-67d2-4545-99a5-d702e8c89b77" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4478316d-9a94-4ef6-a55d-b9c265d1624d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_08902a4c-f874-4c5c-8790-057d5f8d0e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bfcf0e1f-4c51-4649-9092-92b38ea1b116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08902a4c-f874-4c5c-8790-057d5f8d0e43" xlink:to="loc_us-gaap_LiabilitiesCurrent_bfcf0e1f-4c51-4649-9092-92b38ea1b116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_1c39a280-e49c-4c6d-a537-c3e465553557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08902a4c-f874-4c5c-8790-057d5f8d0e43" xlink:to="loc_us-gaap_LongTermNotesPayable_1c39a280-e49c-4c6d-a537-c3e465553557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2ad8f487-7774-45b5-a746-936c63d8a00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a890633f-d0e8-4f22-8df1-4fc7d86ac45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2ad8f487-7774-45b5-a746-936c63d8a00f" xlink:to="loc_us-gaap_PreferredStockValue_a890633f-d0e8-4f22-8df1-4fc7d86ac45b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7d4a352f-aaf1-4c94-b1bd-6bd97a64ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2ad8f487-7774-45b5-a746-936c63d8a00f" xlink:to="loc_us-gaap_CommonStockValue_7d4a352f-aaf1-4c94-b1bd-6bd97a64ce5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0c6ded56-d914-4187-a96e-7edf01f19562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2ad8f487-7774-45b5-a746-936c63d8a00f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0c6ded56-d914-4187-a96e-7edf01f19562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c64df2b0-fb65-4040-b779-ed68dd7b0b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2ad8f487-7774-45b5-a746-936c63d8a00f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c64df2b0-fb65-4040-b779-ed68dd7b0b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_600219b2-cc13-488d-a476-547490f48afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_1d1137e6-842f-43e2-a472-eb9710238574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_600219b2-cc13-488d-a476-547490f48afc" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_1d1137e6-842f-43e2-a472-eb9710238574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4d3e0eb3-8490-4a29-8552-9afa01e3d175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_600219b2-cc13-488d-a476-547490f48afc" xlink:to="loc_us-gaap_AccountsPayableCurrent_4d3e0eb3-8490-4a29-8552-9afa01e3d175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_372de53e-6ca3-451e-a896-a458238179f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_600219b2-cc13-488d-a476-547490f48afc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_372de53e-6ca3-451e-a896-a458238179f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_aab2082f-0670-4ed8-a264-bbcfa228623e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_600219b2-cc13-488d-a476-547490f48afc" xlink:to="loc_us-gaap_NotesPayableCurrent_aab2082f-0670-4ed8-a264-bbcfa228623e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_38d9ffa9-c1c7-43e4-b6e5-4abfaae66d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bcee5be3-55b6-48e5-a62f-6c7018d5a3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38d9ffa9-c1c7-43e4-b6e5-4abfaae66d6b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bcee5be3-55b6-48e5-a62f-6c7018d5a3e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0f2e3fff-dba7-4a0a-888d-3de32eeacd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38d9ffa9-c1c7-43e4-b6e5-4abfaae66d6b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0f2e3fff-dba7-4a0a-888d-3de32eeacd01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5dd368f7-73c1-471d-9b79-242a10224463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_23ec9445-f23e-4bed-acc2-e80b4a92d87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5dd368f7-73c1-471d-9b79-242a10224463" xlink:to="loc_us-gaap_DeferredCosts_23ec9445-f23e-4bed-acc2-e80b4a92d87f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b54c35f1-f893-4efa-8c28-68c2063a2181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5dd368f7-73c1-471d-9b79-242a10224463" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b54c35f1-f893-4efa-8c28-68c2063a2181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1bb59f27-dc43-4dd7-b1f5-e28e00386012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5dd368f7-73c1-471d-9b79-242a10224463" xlink:to="loc_us-gaap_AssetsCurrent_1bb59f27-dc43-4dd7-b1f5-e28e00386012" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ef6442c5-8352-47ab-bd7b-eef59dc53f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_593c4bcc-5587-4dec-b6c9-28809b05eecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ef6442c5-8352-47ab-bd7b-eef59dc53f13" xlink:to="loc_us-gaap_InterestExpense_593c4bcc-5587-4dec-b6c9-28809b05eecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a0d91e9c-175e-4c3a-bada-07f318372b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ef6442c5-8352-47ab-bd7b-eef59dc53f13" xlink:to="loc_us-gaap_OperatingIncomeLoss_a0d91e9c-175e-4c3a-bada-07f318372b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_085147da-2144-4c8e-a9a6-1822f787cad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ef6442c5-8352-47ab-bd7b-eef59dc53f13" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_085147da-2144-4c8e-a9a6-1822f787cad3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_5b0eebb9-2eee-4d59-9910-f6b7e19933e0" xlink:href="cntx-20211231.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ef6442c5-8352-47ab-bd7b-eef59dc53f13" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_5b0eebb9-2eee-4d59-9910-f6b7e19933e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6afb8c7a-d045-466e-8737-3aef1683924e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4de76772-ccf9-4ad4-a578-1ad84b8343b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6afb8c7a-d045-466e-8737-3aef1683924e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4de76772-ccf9-4ad4-a578-1ad84b8343b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ef1506e1-0266-4972-a4d6-cbc5ae5bc489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6afb8c7a-d045-466e-8737-3aef1683924e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ef1506e1-0266-4972-a4d6-cbc5ae5bc489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_371c8e72-5e21-44ea-ac66-1b202c74eee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6afb8c7a-d045-466e-8737-3aef1683924e" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_371c8e72-5e21-44ea-ac66-1b202c74eee0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3782c7ba-e173-46c2-8e46-27fa0970cca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3782c7ba-e173-46c2-8e46-27fa0970cca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_098a88ab-4ab7-4450-848a-73eec0f64231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_098a88ab-4ab7-4450-848a-73eec0f64231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9384d1b4-c2ad-4369-b695-3900fb920333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9384d1b4-c2ad-4369-b695-3900fb920333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_c2f406ca-75d8-4453-bea5-b236b2627f64" xlink:href="cntx-20211231.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_c2f406ca-75d8-4453-bea5-b236b2627f64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3d7a6586-b8a3-43ee-8c65-1b5c0c69059a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_ShareBasedCompensation_3d7a6586-b8a3-43ee-8c65-1b5c0c69059a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0c1b8ac-0e75-4247-be6b-648ad7f61aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_NetIncomeLoss_a0c1b8ac-0e75-4247-be6b-648ad7f61aeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_488decc0-f810-49d5-8ac6-2e0c04e10483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_488decc0-f810-49d5-8ac6-2e0c04e10483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_07ae51bd-a63a-41b5-a015-9f541787b767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_PaidInKindInterest_07ae51bd-a63a-41b5-a015-9f541787b767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e4eb60df-2d4a-411d-901e-5e6d3ab269e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e4eb60df-2d4a-411d-901e-5e6d3ab269e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fcee4213-da43-43d1-a46b-49de32190e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5b83d93d-15c2-4a46-903e-6d28ecad3feb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fcee4213-da43-43d1-a46b-49de32190e97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be4000f-0e72-4e53-8bfa-659d8c6e107b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_aa51fa8a-53d4-442e-bb6b-3f45682de7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be4000f-0e72-4e53-8bfa-659d8c6e107b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_aa51fa8a-53d4-442e-bb6b-3f45682de7e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_3f1a56ae-4559-47dc-8b0a-96efbc32364b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be4000f-0e72-4e53-8bfa-659d8c6e107b" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_3f1a56ae-4559-47dc-8b0a-96efbc32364b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_9c824c11-149f-4f12-b3f1-f77fc0bf042d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be4000f-0e72-4e53-8bfa-659d8c6e107b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_9c824c11-149f-4f12-b3f1-f77fc0bf042d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f82f2890-c1ef-4fb9-90c3-f45b917a1dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be4000f-0e72-4e53-8bfa-659d8c6e107b" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f82f2890-c1ef-4fb9-90c3-f45b917a1dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_84d007b2-2cfe-4e10-8d2b-d27b3060f77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9be4000f-0e72-4e53-8bfa-659d8c6e107b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_84d007b2-2cfe-4e10-8d2b-d27b3060f77a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b7c856a-db46-4b0d-b306-b0ef4cc46246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d0633c35-5753-43fb-839f-fc1908b699dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b7c856a-db46-4b0d-b306-b0ef4cc46246" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d0633c35-5753-43fb-839f-fc1908b699dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_defe01f7-effd-4544-88fa-fff4d1b501cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d888ee66-feb9-4bfb-8ec9-b0b310c6f4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_defe01f7-effd-4544-88fa-fff4d1b501cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d888ee66-feb9-4bfb-8ec9-b0b310c6f4f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754e46f0-7648-491f-ac77-ec99f560b9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_defe01f7-effd-4544-88fa-fff4d1b501cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754e46f0-7648-491f-ac77-ec99f560b9d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5475ba8-6fc9-455a-ae2a-2331248bc945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_defe01f7-effd-4544-88fa-fff4d1b501cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5475ba8-6fc9-455a-ae2a-2331248bc945" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21720db8-b25f-474a-8e62-a5f9dd3e9654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_ef16b422-dc98-44be-b35b-b0bb50046113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21720db8-b25f-474a-8e62-a5f9dd3e9654" xlink:to="loc_us-gaap_RestrictedCash_ef16b422-dc98-44be-b35b-b0bb50046113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1f1dfc6-2808-4ad7-8d7f-9f2151de47f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21720db8-b25f-474a-8e62-a5f9dd3e9654" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1f1dfc6-2808-4ad7-8d7f-9f2151de47f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_dbc29719-0d1c-498e-aea3-3babfbb01522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_3f398929-7030-4a2b-84d5-8492fb8c6615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_dbc29719-0d1c-498e-aea3-3babfbb01522" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_3f398929-7030-4a2b-84d5-8492fb8c6615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_6f99f22d-f6f4-4a8c-af2e-a8e686f0dd93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_dbc29719-0d1c-498e-aea3-3babfbb01522" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_6f99f22d-f6f4-4a8c-af2e-a8e686f0dd93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91bbfd40-29c6-4031-9c61-3eb0bdf27112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_dbc29719-0d1c-498e-aea3-3babfbb01522" xlink:to="loc_us-gaap_NetIncomeLoss_91bbfd40-29c6-4031-9c61-3eb0bdf27112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99981f1c-3244-419f-87a6-4c3484dbf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f082496a-3fdc-4fb8-877f-5c3104ee7771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99981f1c-3244-419f-87a6-4c3484dbf16f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f082496a-3fdc-4fb8-877f-5c3104ee7771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e1032622-0385-43d4-964f-1b69d4eeb4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99981f1c-3244-419f-87a6-4c3484dbf16f" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e1032622-0385-43d4-964f-1b69d4eeb4bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c57cbf0b-8d05-4563-924b-9d43e8bc1e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70b87491-6ec0-4f9c-9b92-845308cf996f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c57cbf0b-8d05-4563-924b-9d43e8bc1e85" xlink:to="loc_us-gaap_NetIncomeLoss_70b87491-6ec0-4f9c-9b92-845308cf996f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_164cec16-2be2-4a20-8750-87ddc946f889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c57cbf0b-8d05-4563-924b-9d43e8bc1e85" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_164cec16-2be2-4a20-8750-87ddc946f889" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_99cacde0-665e-4fdf-a00d-3e6e341eeeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ManufacturingDevelopmentLiabilitiesCurrent_60adf0c5-9ca8-43bf-b8fd-4575f807956e" xlink:href="cntx-20211231.xsd#cntx_ManufacturingDevelopmentLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_99cacde0-665e-4fdf-a00d-3e6e341eeeb0" xlink:to="loc_cntx_ManufacturingDevelopmentLiabilitiesCurrent_60adf0c5-9ca8-43bf-b8fd-4575f807956e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5b40c7e4-84f7-4585-84ee-d5a417d8918e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_99cacde0-665e-4fdf-a00d-3e6e341eeeb0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5b40c7e4-84f7-4585-84ee-d5a417d8918e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d7b77c49-37d9-4656-b4c4-512b50ba29eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_99cacde0-665e-4fdf-a00d-3e6e341eeeb0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d7b77c49-37d9-4656-b4c4-512b50ba29eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c7e46b43-6021-4cb2-a7da-d93e0c2e8efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_99cacde0-665e-4fdf-a00d-3e6e341eeeb0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c7e46b43-6021-4cb2-a7da-d93e0c2e8efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ClinicalTrialLiabilitiesCurrent_eb68735b-6312-431c-a605-ec9e22bbd85a" xlink:href="cntx-20211231.xsd#cntx_ClinicalTrialLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_99cacde0-665e-4fdf-a00d-3e6e341eeeb0" xlink:to="loc_cntx_ClinicalTrialLiabilitiesCurrent_eb68735b-6312-431c-a605-ec9e22bbd85a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cntx_NetDeferredTaxAssetLiabilitiesGross_58b65ca6-a806-4734-8b49-618c0a204120" xlink:href="cntx-20211231.xsd#cntx_NetDeferredTaxAssetLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2b2428b0-d2ae-4ed0-8618-900353becb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cntx_NetDeferredTaxAssetLiabilitiesGross_58b65ca6-a806-4734-8b49-618c0a204120" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2b2428b0-d2ae-4ed0-8618-900353becb5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_55b14cd3-e0e6-4217-8999-e060bff3bdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cntx_NetDeferredTaxAssetLiabilitiesGross_58b65ca6-a806-4734-8b49-618c0a204120" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_55b14cd3-e0e6-4217-8999-e060bff3bdbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_743d9120-4289-4a90-91d7-73753325f815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_74ef80d8-85b2-49ea-a0bb-0fc1cf6925e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_743d9120-4289-4a90-91d7-73753325f815" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_74ef80d8-85b2-49ea-a0bb-0fc1cf6925e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6cb58b1e-43bf-4abc-8d8e-c4dcad7ec93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_743d9120-4289-4a90-91d7-73753325f815" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6cb58b1e-43bf-4abc-8d8e-c4dcad7ec93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7ba3b1b5-8808-4b6e-b6c2-f2042f1cc389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_743d9120-4289-4a90-91d7-73753325f815" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7ba3b1b5-8808-4b6e-b6c2-f2042f1cc389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_0b222a10-7128-43a6-bb61-f1efc7c499c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_743d9120-4289-4a90-91d7-73753325f815" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_0b222a10-7128-43a6-bb61-f1efc7c499c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_20674546-198a-4876-b79d-04ba17e388d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c14ed801-9933-4a4c-92c6-311c21d2389d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_20674546-198a-4876-b79d-04ba17e388d7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c14ed801-9933-4a4c-92c6-311c21d2389d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_NetDeferredTaxAssetLiabilitiesGross_795c6e4c-7cd8-4770-83cc-bd421192531a" xlink:href="cntx-20211231.xsd#cntx_NetDeferredTaxAssetLiabilitiesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_20674546-198a-4876-b79d-04ba17e388d7" xlink:to="loc_cntx_NetDeferredTaxAssetLiabilitiesGross_795c6e4c-7cd8-4770-83cc-bd421192531a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db63e7d6-ea4c-4877-b310-8ef3a7e9f113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e46d5c8a-cde2-481f-ae4d-11051593a194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db63e7d6-ea4c-4877-b310-8ef3a7e9f113" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e46d5c8a-cde2-481f-ae4d-11051593a194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_c824a5c3-c0de-454e-a436-00c743856c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db63e7d6-ea4c-4877-b310-8ef3a7e9f113" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_c824a5c3-c0de-454e-a436-00c743856c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3f0c924d-908b-471a-a819-a4b1fb2eccdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db63e7d6-ea4c-4877-b310-8ef3a7e9f113" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3f0c924d-908b-471a-a819-a4b1fb2eccdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_67c63082-566f-4155-b6a3-3b57066b9731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db63e7d6-ea4c-4877-b310-8ef3a7e9f113" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_67c63082-566f-4155-b6a3-3b57066b9731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3c5aa6bd-014e-4de9-899b-dc1e0bf0b4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db63e7d6-ea4c-4877-b310-8ef3a7e9f113" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3c5aa6bd-014e-4de9-899b-dc1e0bf0b4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_8ead2b7a-cd81-4c80-b635-93f0ff3a56eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db63e7d6-ea4c-4877-b310-8ef3a7e9f113" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_8ead2b7a-cd81-4c80-b635-93f0ff3a56eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3c45583d-fad3-4266-814a-360cb5f050a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db63e7d6-ea4c-4877-b310-8ef3a7e9f113" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3c45583d-fad3-4266-814a-360cb5f050a0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cntx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:26b5d880-9edc-4480-83e2-744a98c761b2,g:c86f1f4d-7057-497b-9a16-bf3850b7383a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i3abae771e3e0439da57e6096ef5f02ca_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_211b4072-f21f-464e-8d03-e2327116c576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211b4072-f21f-464e-8d03-e2327116c576" xlink:to="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c2bfd5c-767f-4099-a7b9-032d81cde088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c2bfd5c-767f-4099-a7b9-032d81cde088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_90c114e1-b76f-4904-8824-c7ea8f58bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_90c114e1-b76f-4904-8824-c7ea8f58bbd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_810e683e-c342-4847-9561-d76a9f6fe78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:to="loc_us-gaap_AssetsCurrent_810e683e-c342-4847-9561-d76a9f6fe78b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e282c2b6-744c-4b27-9ac6-1f4228ade559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e282c2b6-744c-4b27-9ac6-1f4228ade559" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_d4179728-203a-4670-b98e-2a60f1a39b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:to="loc_us-gaap_DeferredCosts_d4179728-203a-4670-b98e-2a60f1a39b20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_433c5b36-6d6d-45c8-b75f-0f2d962bc666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:to="loc_us-gaap_Assets_433c5b36-6d6d-45c8-b75f-0f2d962bc666" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211b4072-f21f-464e-8d03-e2327116c576" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_e58bcb63-947f-44d5-93fa-b0bff11fb2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_e58bcb63-947f-44d5-93fa-b0bff11fb2aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f29be3bc-732e-47cc-9b3a-6c8de1947b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_NotesPayableCurrent_f29be3bc-732e-47cc-9b3a-6c8de1947b86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_04ea78ba-6338-432f-963c-5e5812c60ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_AccountsPayableCurrent_04ea78ba-6338-432f-963c-5e5812c60ac9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0afbcae4-fb14-492d-9f79-a70198495a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0afbcae4-fb14-492d-9f79-a70198495a33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9a7a1b03-87fe-4709-a777-d2cf5a40e7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_LiabilitiesCurrent_9a7a1b03-87fe-4709-a777-d2cf5a40e7a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_abb388ba-03db-4200-8fa5-9ed2315fb897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_LongTermNotesPayable_abb388ba-03db-4200-8fa5-9ed2315fb897" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7d952414-6384-411a-94c8-9bcc63f83eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_Liabilities_7d952414-6384-411a-94c8-9bcc63f83eb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fccb4905-5080-4829-a9f6-097ac6fb691b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fccb4905-5080-4829-a9f6-097ac6fb691b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_be8bf743-61c8-4f53-913c-f5de2183ed88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_TemporaryEquityAbstract_be8bf743-61c8-4f53-913c-f5de2183ed88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_03e14b7c-4ed8-4dda-97ea-b0d72d43a5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_be8bf743-61c8-4f53-913c-f5de2183ed88" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_03e14b7c-4ed8-4dda-97ea-b0d72d43a5e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c76236db-b7a5-45f4-86fe-2296378085d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_PreferredStockValue_c76236db-b7a5-45f4-86fe-2296378085d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90612e47-f665-40a5-b488-9f5b08ac0c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90612e47-f665-40a5-b488-9f5b08ac0c26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_13fdd143-d005-44e0-95cf-519e32999822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_CommonStockValue_13fdd143-d005-44e0-95cf-519e32999822" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1ddf5c45-0bdf-4496-8c6e-9f32f976ee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1ddf5c45-0bdf-4496-8c6e-9f32f976ee6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2552a6d4-ca72-4dbb-bdc0-cf02dd9a6ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2552a6d4-ca72-4dbb-bdc0-cf02dd9a6ea2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704bc713-20b9-4d17-b8ee-5a6079811795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_StockholdersEquity_704bc713-20b9-4d17-b8ee-5a6079811795" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_03ea8c57-3b32-455d-a4f4-5dc8342ca974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_03ea8c57-3b32-455d-a4f4-5dc8342ca974" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dd9de7fc-f3c4-4398-bb91-aa4940ae4bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_211b4072-f21f-464e-8d03-e2327116c576" xlink:to="loc_us-gaap_StatementTable_dd9de7fc-f3c4-4398-bb91-aa4940ae4bca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_39454efb-7e48-4a70-b60d-94655adbd533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dd9de7fc-f3c4-4398-bb91-aa4940ae4bca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_39454efb-7e48-4a70-b60d-94655adbd533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_39454efb-7e48-4a70-b60d-94655adbd533_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39454efb-7e48-4a70-b60d-94655adbd533" xlink:to="loc_us-gaap_ClassOfStockDomain_39454efb-7e48-4a70-b60d-94655adbd533_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39454efb-7e48-4a70-b60d-94655adbd533" xlink:to="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f5763a20-0f62-4c3c-8423-fafe6561414e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f5763a20-0f62-4c3c-8423-fafe6561414e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_c7e2b490-8ae3-4a53-b57c-fd84b24be567" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_c7e2b490-8ae3-4a53-b57c-fd84b24be567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_b8be6edb-efe7-489e-9109-caa9d107b345" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:to="loc_cntx_RedeemableCommonStockMember_b8be6edb-efe7-489e-9109-caa9d107b345" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i1cc94fc2027f45e19cfb2ad6a19689bd_ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_770241cf-8ad5-4682-a92b-0a039415a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_770241cf-8ad5-4682-a92b-0a039415a3ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_996da938-51cd-4b6e-963c-b689ba6e147a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_996da938-51cd-4b6e-963c-b689ba6e147a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_7ae9f244-04ef-443d-9c43-b4e23e3d38b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_7ae9f244-04ef-443d-9c43-b4e23e3d38b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_f2ba77b9-7ede-4875-93d8-5724d117a3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_f2ba77b9-7ede-4875-93d8-5724d117a3de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_272c541f-9f7a-4a5e-9a06-714c07d9d3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_272c541f-9f7a-4a5e-9a06-714c07d9d3ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1d056512-4f17-4235-9065-b4b73aef0711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1d056512-4f17-4235-9065-b4b73aef0711" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c38e9429-e850-4d7f-876c-921842522a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c38e9429-e850-4d7f-876c-921842522a26" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8ce680c5-6bf4-42fb-afd5-45fb3fa4ae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8ce680c5-6bf4-42fb-afd5-45fb3fa4ae6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14d8e069-c167-4ccd-86ba-c30dcd531050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14d8e069-c167-4ccd-86ba-c30dcd531050" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6f2ed036-c913-4a24-a6bb-f28af395677c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_CommonStockSharesIssued_6f2ed036-c913-4a24-a6bb-f28af395677c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_08cabd6b-15d8-48d9-9be8-d71a5a6a49f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_08cabd6b-15d8-48d9-9be8-d71a5a6a49f6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_306a602c-47ba-4c90-b106-29ae0e9327a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_StatementTable_306a602c-47ba-4c90-b106-29ae0e9327a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1871318e-8275-4845-a4a6-2a81e5904bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_306a602c-47ba-4c90-b106-29ae0e9327a3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1871318e-8275-4845-a4a6-2a81e5904bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1871318e-8275-4845-a4a6-2a81e5904bd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1871318e-8275-4845-a4a6-2a81e5904bd2" xlink:to="loc_us-gaap_ClassOfStockDomain_1871318e-8275-4845-a4a6-2a81e5904bd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1871318e-8275-4845-a4a6-2a81e5904bd2" xlink:to="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_e6a49801-1d6b-4dc7-97bf-1ee054a886a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_e6a49801-1d6b-4dc7-97bf-1ee054a886a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_0a08ebb0-57d8-4877-84f0-f07d67c48c99" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_0a08ebb0-57d8-4877-84f0-f07d67c48c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_e151825e-4de9-438c-9847-d95c865a92b2" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:to="loc_cntx_RedeemableCommonStockMember_e151825e-4de9-438c-9847-d95c865a92b2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" xlink:type="extended" id="ic6b8597826a147abae3e4220fed7c50f_ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9f1962e8-7148-4dbc-831d-382b54712393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f1962e8-7148-4dbc-831d-382b54712393" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ae3e4854-378b-403d-91ce-fc3751aacac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ae3e4854-378b-403d-91ce-fc3751aacac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_038e7c3b-1a8d-4527-bae6-2a60a3964a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_038e7c3b-1a8d-4527-bae6-2a60a3964a83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c71dd2d3-b8c1-4a8a-a0c1-7c6303f9b5a0" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c71dd2d3-b8c1-4a8a-a0c1-7c6303f9b5a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_89c7fa30-9ca7-4dc6-b65a-5faa360d243e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_89c7fa30-9ca7-4dc6-b65a-5faa360d243e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f80020d0-4cad-4dfd-a1df-642a38e1772e" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f80020d0-4cad-4dfd-a1df-642a38e1772e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_22125d61-6578-4338-a8f0-e00df681a73d" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_22125d61-6578-4338-a8f0-e00df681a73d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_392f9c02-1bb7-4de2-8a77-14857b403c35" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_392f9c02-1bb7-4de2-8a77-14857b403c35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_9a979359-3067-4435-b6ba-717423ddf8e3" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_9a979359-3067-4435-b6ba-717423ddf8e3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_985c4d73-e093-4d01-a6e4-10d979f64dd1" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_985c4d73-e093-4d01-a6e4-10d979f64dd1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_12c44832-0936-4de4-9d7c-bc87fb895d81" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_12c44832-0936-4de4-9d7c-bc87fb895d81" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_ec41780b-c455-44b6-882d-3dbd25271f2f" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_ec41780b-c455-44b6-882d-3dbd25271f2f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_b5640ce3-a350-40a0-b458-6cbc7b145680" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_b5640ce3-a350-40a0-b458-6cbc7b145680" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_4a627ded-d3d7-4e9e-88b0-bd3cd602f947" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_4a627ded-d3d7-4e9e-88b0-bd3cd602f947" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_54eb21b5-80b8-48fa-8baf-a85eb1465f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_752a4138-2aa9-4112-b3ec-0433e9cd0e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f1962e8-7148-4dbc-831d-382b54712393" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_050749ee-efc2-4da7-b27d-fc29be47ae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_SharesOutstanding_050749ee-efc2-4da7-b27d-fc29be47ae8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a034cdd1-d5c6-43f5-abf7-c36a266fa35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockholdersEquity_a034cdd1-d5c6-43f5-abf7-c36a266fa35e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6fe1fc36-6fb3-4321-8ff2-653432d12c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6fe1fc36-6fb3-4321-8ff2-653432d12c0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_c45bbfcb-25ff-4245-bfa6-3e124c790747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_c45bbfcb-25ff-4245-bfa6-3e124c790747" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_0ff35573-9f9d-44bd-8d42-9091532aeab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_0ff35573-9f9d-44bd-8d42-9091532aeab6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a24c246a-3aed-46b2-800a-bdd0e0682ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a24c246a-3aed-46b2-800a-bdd0e0682ba4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1c904d89-be01-41cb-b6d8-05dcbaeee79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1c904d89-be01-41cb-b6d8-05dcbaeee79d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_007bd2fb-f566-42e6-97eb-1f4139d822f0" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_007bd2fb-f566-42e6-97eb-1f4139d822f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_b9b95e1a-6ae2-44a5-9700-fca1bb35c291" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_b9b95e1a-6ae2-44a5-9700-fca1bb35c291" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_00970871-9e1a-4b4d-bdc9-9dbf28be3017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_00970871-9e1a-4b4d-bdc9-9dbf28be3017" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52b5038b-adef-4529-9140-e355108fca60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52b5038b-adef-4529-9140-e355108fca60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a9719bde-afa4-4519-a5b5-63f1db004589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a9719bde-afa4-4519-a5b5-63f1db004589" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a42b4759-3f84-4c5b-bfe7-1a6bb55c6af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_NetIncomeLoss_a42b4759-3f84-4c5b-bfe7-1a6bb55c6af6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_daf5e8dc-5f02-4b42-81d2-572b19c54676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e8d48ef8-b800-4ad7-b430-19f7eb9e72ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9f1962e8-7148-4dbc-831d-382b54712393" xlink:to="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3f7ff496-0b97-4103-a7f1-bbff6e1c576f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3f7ff496-0b97-4103-a7f1-bbff6e1c576f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3f7ff496-0b97-4103-a7f1-bbff6e1c576f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f7ff496-0b97-4103-a7f1-bbff6e1c576f" xlink:to="loc_us-gaap_EquityComponentDomain_3f7ff496-0b97-4103-a7f1-bbff6e1c576f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f7ff496-0b97-4103-a7f1-bbff6e1c576f" xlink:to="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f1d8c35d-ff6c-4e4c-b867-8705d7833834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:to="loc_us-gaap_CommonStockMember_f1d8c35d-ff6c-4e4c-b867-8705d7833834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_977ca77b-d557-4646-8625-fd2d3eb9231c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_977ca77b-d557-4646-8625-fd2d3eb9231c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9389bce6-5440-4393-8fba-e15cb1c4164e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:to="loc_us-gaap_RetainedEarningsMember_9389bce6-5440-4393-8fba-e15cb1c4164e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36f62267-18fe-401c-9a9e-94a05047ac98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36f62267-18fe-401c-9a9e-94a05047ac98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_36f62267-18fe-401c-9a9e-94a05047ac98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36f62267-18fe-401c-9a9e-94a05047ac98" xlink:to="loc_us-gaap_ClassOfStockDomain_36f62267-18fe-401c-9a9e-94a05047ac98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36f62267-18fe-401c-9a9e-94a05047ac98" xlink:to="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b8bb6d9b-2063-461b-857e-ec5b4749a2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b8bb6d9b-2063-461b-857e-ec5b4749a2b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_32c5ae74-6b3b-4aba-b833-74012aa79342" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_32c5ae74-6b3b-4aba-b833-74012aa79342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_0d761723-622c-4477-a61f-bc63c83e6091" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:to="loc_cntx_RedeemableCommonStockMember_0d761723-622c-4477-a61f-bc63c83e6091" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_c06fad26-0e38-44f5-9dd5-79391d3ee733" xlink:href="cntx-20211231.xsd#cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:to="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_c06fad26-0e38-44f5-9dd5-79391d3ee733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_fa5fd474-d488-4876-acbb-6698e75f270f" xlink:href="cntx-20211231.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_fa5fd474-d488-4876-acbb-6698e75f270f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember_4bafb1dc-76de-4f2c-bb01-871ef7530ddc" xlink:href="cntx-20211231.xsd#cntx_IssuedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:to="loc_cntx_IssuedForServicesMember_4bafb1dc-76de-4f2c-bb01-871ef7530ddc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedInConnectionWithIPOMember_bac65053-34d9-4b51-9439-201f3e6f8fc6" xlink:href="cntx-20211231.xsd#cntx_IssuedInConnectionWithIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:to="loc_cntx_IssuedInConnectionWithIPOMember_bac65053-34d9-4b51-9439-201f3e6f8fc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b459c22f-91b2-4dbb-a09b-b1121d05725c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b459c22f-91b2-4dbb-a09b-b1121d05725c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b459c22f-91b2-4dbb-a09b-b1121d05725c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b459c22f-91b2-4dbb-a09b-b1121d05725c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b459c22f-91b2-4dbb-a09b-b1121d05725c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_412bf247-a354-4a87-8f78-00ce97a3fdea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b459c22f-91b2-4dbb-a09b-b1121d05725c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_412bf247-a354-4a87-8f78-00ce97a3fdea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_cb4d6363-222c-461d-b2b0-795adedf4d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_412bf247-a354-4a87-8f78-00ce97a3fdea" xlink:to="loc_us-gaap_IPOMember_cb4d6363-222c-461d-b2b0-795adedf4d6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_644667a3-12e5-42c4-a29a-b351e5b65fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_412bf247-a354-4a87-8f78-00ce97a3fdea" xlink:to="loc_us-gaap_PrivatePlacementMember_644667a3-12e5-42c4-a29a-b351e5b65fc4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" xlink:type="extended" id="if42d99f7abc74ab09e8db0555339db7c_ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_586ddfaf-a800-4201-b8b9-769c582d1c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityOfferingCosts_8bfa8eca-11ee-4903-97b2-d586b6e82197" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_586ddfaf-a800-4201-b8b9-769c582d1c3e" xlink:to="loc_cntx_TemporaryEquityOfferingCosts_8bfa8eca-11ee-4903-97b2-d586b6e82197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodIssuanceCosts_0de86a83-f395-40ac-b030-2abef1e83f5f" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_586ddfaf-a800-4201-b8b9-769c582d1c3e" xlink:to="loc_cntx_StockIssuedDuringPeriodIssuanceCosts_0de86a83-f395-40ac-b030-2abef1e83f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_64e61854-4321-440f-97d5-12b9331c256d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_586ddfaf-a800-4201-b8b9-769c582d1c3e" xlink:to="loc_us-gaap_StatementTable_64e61854-4321-440f-97d5-12b9331c256d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cd17359f-ecbf-4456-9c54-22c62ff08268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_64e61854-4321-440f-97d5-12b9331c256d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cd17359f-ecbf-4456-9c54-22c62ff08268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cd17359f-ecbf-4456-9c54-22c62ff08268_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd17359f-ecbf-4456-9c54-22c62ff08268" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cd17359f-ecbf-4456-9c54-22c62ff08268_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8142bd74-4aec-4b2e-8cbb-adf045d1ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd17359f-ecbf-4456-9c54-22c62ff08268" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8142bd74-4aec-4b2e-8cbb-adf045d1ccd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9ea94d07-d84f-47dc-bce7-5bb125d83556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8142bd74-4aec-4b2e-8cbb-adf045d1ccd2" xlink:to="loc_us-gaap_IPOMember_9ea94d07-d84f-47dc-bce7-5bb125d83556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f7e545af-af81-4cf0-9ee9-b425ee496a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8142bd74-4aec-4b2e-8cbb-adf045d1ccd2" xlink:to="loc_us-gaap_PrivatePlacementMember_f7e545af-af81-4cf0-9ee9-b425ee496a8e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended" id="ifa2bceb3a74c4aed87c2c8dba6f90f43_ConsolidatedStatementofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f48bcccb-1aec-428a-84c4-5f1d7c3bffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:to="loc_us-gaap_NetIncomeLoss_f48bcccb-1aec-428a-84c4-5f1d7c3bffa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_d86f6f72-0b7f-4dc0-9ccb-adfae4d76ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_d86f6f72-0b7f-4dc0-9ccb-adfae4d76ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a54333eb-a76e-4b26-a6ef-1fc0aa8da9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a54333eb-a76e-4b26-a6ef-1fc0aa8da9e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_15bfbc8c-4160-420b-b1e0-7393ab7457d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_ShareBasedCompensation_15bfbc8c-4160-420b-b1e0-7393ab7457d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_dbe04fc4-0ece-46ae-9e42-8f6d8d489463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_PaidInKindInterest_dbe04fc4-0ece-46ae-9e42-8f6d8d489463" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_0c83d0fb-fc08-4006-97e8-24440e8332e7" xlink:href="cntx-20211231.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_0c83d0fb-fc08-4006-97e8-24440e8332e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d81432f-4004-4b10-a2ad-f1a1cf6ee176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d81432f-4004-4b10-a2ad-f1a1cf6ee176" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86e629f6-5f3c-406a-aa99-63a78305cab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86e629f6-5f3c-406a-aa99-63a78305cab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_be22c1d8-98df-4300-93b8-e4f03920d1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_be22c1d8-98df-4300-93b8-e4f03920d1cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6b900e30-9e59-4509-947b-8073bb118491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6b900e30-9e59-4509-947b-8073bb118491" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287b1153-a0c0-4473-9cdd-53c0c0d563fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287b1153-a0c0-4473-9cdd-53c0c0d563fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09b3813a-0920-4f0a-90e5-516438fcb755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09b3813a-0920-4f0a-90e5-516438fcb755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e63e2da7-5c2e-4940-baf9-f8ba4c05b7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09b3813a-0920-4f0a-90e5-516438fcb755" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e63e2da7-5c2e-4940-baf9-f8ba4c05b7b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9407e-ba0c-41a3-aa04-0ff829d557df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09b3813a-0920-4f0a-90e5-516438fcb755" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9407e-ba0c-41a3-aa04-0ff829d557df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_21699f51-2264-4395-a602-ca2941b30cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_21699f51-2264-4395-a602-ca2941b30cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_68caaf05-ca3d-4f20-920e-c677a116a690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_68caaf05-ca3d-4f20-920e-c677a116a690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_3c75dd81-d84e-4a50-ab39-6293765d0c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_3c75dd81-d84e-4a50-ab39-6293765d0c3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_108576d0-9a1d-4cbc-ba6a-318e9720e8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_108576d0-9a1d-4cbc-ba6a-318e9720e8b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d9bd1d4-d2e8-4e79-9562-3cb30b3c0015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d9bd1d4-d2e8-4e79-9562-3cb30b3c0015" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16d01cfd-b497-433b-93f4-2147f675bcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16d01cfd-b497-433b-93f4-2147f675bcf7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de0d46d5-ed51-4c1e-bf43-36bd65b9b0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de0d46d5-ed51-4c1e-bf43-36bd65b9b0c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e9906dd-da3f-43d5-8372-9eb42c83ed78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e9906dd-da3f-43d5-8372-9eb42c83ed78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2434418f-8cb7-4c1f-adac-03da37472e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7bba280a-2cd7-402d-9c7d-6dbaf1c33e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7bba280a-2cd7-402d-9c7d-6dbaf1c33e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued_586931ef-812d-4c08-937b-7cb9ad820d7d" xlink:href="cntx-20211231.xsd#cntx_WarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_cntx_WarrantsIssued_586931ef-812d-4c08-937b-7cb9ad820d7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_73482cd4-e701-4442-a7fa-f1b89eab00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_us-gaap_StockIssued1_73482cd4-e701-4442-a7fa-f1b89eab00dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid_666320e2-d9b5-4ba9-b47e-200390a718af" xlink:href="cntx-20211231.xsd#cntx_DeferredOfferingCostIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid_666320e2-d9b5-4ba9-b47e-200390a718af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_c2f42eee-fa07-4af2-92d6-376b5661bc59" xlink:href="cntx-20211231.xsd#cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_c2f42eee-fa07-4af2-92d6-376b5661bc59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_1b7accaa-b0ea-4616-9e20-4475b6a34d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_1b7accaa-b0ea-4616-9e20-4475b6a34d42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_15b25ea8-e96c-4779-95b3-0b959ecae06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:to="loc_us-gaap_StatementClassOfStockAxis_15b25ea8-e96c-4779-95b3-0b959ecae06e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_15b25ea8-e96c-4779-95b3-0b959ecae06e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15b25ea8-e96c-4779-95b3-0b959ecae06e" xlink:to="loc_us-gaap_ClassOfStockDomain_15b25ea8-e96c-4779-95b3-0b959ecae06e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_83d43e72-8bef-4f85-8521-089c238d6ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15b25ea8-e96c-4779-95b3-0b959ecae06e" xlink:to="loc_us-gaap_ClassOfStockDomain_83d43e72-8bef-4f85-8521-089c238d6ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_10274fe1-3dbb-4ba9-a24b-d99ecb5cd1e8" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_83d43e72-8bef-4f85-8521-089c238d6ca9" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_10274fe1-3dbb-4ba9-a24b-d99ecb5cd1e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_075235a9-ad0d-4274-b8d1-691342f7e02e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_83d43e72-8bef-4f85-8521-089c238d6ca9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_075235a9-ad0d-4274-b8d1-691342f7e02e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b9203535-b465-4321-9690-6c931cf60df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b9203535-b465-4321-9690-6c931cf60df7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_b9203535-b465-4321-9690-6c931cf60df7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b9203535-b465-4321-9690-6c931cf60df7" xlink:to="loc_us-gaap_DebtConversionNameDomain_b9203535-b465-4321-9690-6c931cf60df7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b9203535-b465-4321-9690-6c931cf60df7" xlink:to="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DemandNotesToConvertiblePromissoryNotesMember_b93661ad-54ab-4e6e-ad56-840a9e72ed8d" xlink:href="cntx-20211231.xsd#cntx_DemandNotesToConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:to="loc_cntx_DemandNotesToConvertiblePromissoryNotesMember_b93661ad-54ab-4e6e-ad56-840a9e72ed8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_BridgeNotesToSeriesAPreferredStockMember_6ddc2697-b48a-48b6-8e06-7f6b1bdc9749" xlink:href="cntx-20211231.xsd#cntx_BridgeNotesToSeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:to="loc_cntx_BridgeNotesToSeriesAPreferredStockMember_6ddc2697-b48a-48b6-8e06-7f6b1bdc9749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember_2942fe89-cf7d-4634-b192-1b7d4ba7fea2" xlink:href="cntx-20211231.xsd#cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:to="loc_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember_2942fe89-cf7d-4634-b192-1b7d4ba7fea2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#NatureofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/NatureofBusinessDetails" xlink:type="extended" id="iefede34ddf59476bb9ebde1461f6b8bd_NatureofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_dd511827-153c-4c7c-9f24-62574c6eb5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6bcf3bd6-b5ab-46ef-87eb-ec11e1ec8fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_dd511827-153c-4c7c-9f24-62574c6eb5bb" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6bcf3bd6-b5ab-46ef-87eb-ec11e1ec8fc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_d8d62ab2-88dc-413a-8682-9ed79d0fa142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_dd511827-153c-4c7c-9f24-62574c6eb5bb" xlink:to="loc_us-gaap_MinorityInterestTable_d8d62ab2-88dc-413a-8682-9ed79d0fa142" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_63a42301-b471-4a9f-bee5-8bb8058d5f0f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_d8d62ab2-88dc-413a-8682-9ed79d0fa142" xlink:to="loc_srt_OwnershipAxis_63a42301-b471-4a9f-bee5-8bb8058d5f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_63a42301-b471-4a9f-bee5-8bb8058d5f0f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_63a42301-b471-4a9f-bee5-8bb8058d5f0f" xlink:to="loc_srt_OwnershipDomain_63a42301-b471-4a9f-bee5-8bb8058d5f0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4b9e2adc-30d7-41a1-bdd8-3eb578e5b212" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_63a42301-b471-4a9f-bee5-8bb8058d5f0f" xlink:to="loc_srt_OwnershipDomain_4b9e2adc-30d7-41a1-bdd8-3eb578e5b212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ContextTherapeuticsLLCMember_320e2fb0-c2d6-4cf1-8e95-a817a34e4bfd" xlink:href="cntx-20211231.xsd#cntx_ContextTherapeuticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_4b9e2adc-30d7-41a1-bdd8-3eb578e5b212" xlink:to="loc_cntx_ContextTherapeuticsLLCMember_320e2fb0-c2d6-4cf1-8e95-a817a34e4bfd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#RisksandLiquidityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="extended" id="i6fa142e292604c22abd39890cd5e3324_RisksandLiquidityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_db2be319-a44e-478b-89df-6acd73fbc38c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_db2be319-a44e-478b-89df-6acd73fbc38c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_31cd77a0-4ab4-4b31-967d-9dda9907a12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_31cd77a0-4ab4-4b31-967d-9dda9907a12c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26690dde-f64e-4510-a74b-18d9f06aac28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26690dde-f64e-4510-a74b-18d9f06aac28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_845a7795-0dfe-4964-a74f-51349a6a4d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_845a7795-0dfe-4964-a74f-51349a6a4d7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ac0eac37-b3f7-4652-93a8-93714cc747a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ac0eac37-b3f7-4652-93a8-93714cc747a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c767667d-ae61-4034-874d-6b2ede709c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c767667d-ae61-4034-874d-6b2ede709c3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4a1f238a-a0e1-4aa6-a8bc-d24cbf75a5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4a1f238a-a0e1-4aa6-a8bc-d24cbf75a5ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b1812b8-3000-45ad-9dc8-c309808f8276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b1812b8-3000-45ad-9dc8-c309808f8276" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2e6c9481-920c-4cd2-8cce-34bdc13ba582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2e6c9481-920c-4cd2-8cce-34bdc13ba582" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7366d3d3-130f-4445-b048-20014eaa34b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7366d3d3-130f-4445-b048-20014eaa34b2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_5666629f-d4b2-4339-965d-8908bbca9763" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_5666629f-d4b2-4339-965d-8908bbca9763" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f1eab37d-76e7-4537-ad53-8a89e7d802cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f1eab37d-76e7-4537-ad53-8a89e7d802cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f1eab37d-76e7-4537-ad53-8a89e7d802cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1eab37d-76e7-4537-ad53-8a89e7d802cd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f1eab37d-76e7-4537-ad53-8a89e7d802cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e080ab74-065a-47b5-b281-8a785bf264a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1eab37d-76e7-4537-ad53-8a89e7d802cd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e080ab74-065a-47b5-b281-8a785bf264a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f037d2db-9948-4bc2-959f-7c2b39b14e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e080ab74-065a-47b5-b281-8a785bf264a5" xlink:to="loc_us-gaap_IPOMember_f037d2db-9948-4bc2-959f-7c2b39b14e44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_394cca2e-372b-492b-a0f1-6712f31e1940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e080ab74-065a-47b5-b281-8a785bf264a5" xlink:to="loc_us-gaap_PrivatePlacementMember_394cca2e-372b-492b-a0f1-6712f31e1940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_41be9881-9513-4d79-a9a8-508c1ff84c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_41be9881-9513-4d79-a9a8-508c1ff84c84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_41be9881-9513-4d79-a9a8-508c1ff84c84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_41be9881-9513-4d79-a9a8-508c1ff84c84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_41be9881-9513-4d79-a9a8-508c1ff84c84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_41be9881-9513-4d79-a9a8-508c1ff84c84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PlacementAgentsWarrantsMember_8a1bcecd-8b13-4b19-9056-11bcb798156f" xlink:href="cntx-20211231.xsd#cntx_PlacementAgentsWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:to="loc_cntx_PlacementAgentsWarrantsMember_8a1bcecd-8b13-4b19-9056-11bcb798156f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementWarrantsMember_6199c041-b08b-4e5d-8011-0cb9434e5c3c" xlink:href="cntx-20211231.xsd#cntx_December2021PrivatePlacementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:to="loc_cntx_December2021PrivatePlacementWarrantsMember_6199c041-b08b-4e5d-8011-0cb9434e5c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_d23763bd-d18e-407a-a2ab-36b6393e633d" xlink:href="cntx-20211231.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_d23763bd-d18e-407a-a2ab-36b6393e633d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i282f7d563c144944b228b3024bc211df_SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64b75ebf-f939-40a4-858d-23a95c19e6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3519d87a-a261-48a6-a22f-92739cee92f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64b75ebf-f939-40a4-858d-23a95c19e6a7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3519d87a-a261-48a6-a22f-92739cee92f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c20c6b51-83c2-41cd-8f4f-db84681f8a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64b75ebf-f939-40a4-858d-23a95c19e6a7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c20c6b51-83c2-41cd-8f4f-db84681f8a16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c20c6b51-83c2-41cd-8f4f-db84681f8a16" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5dd03723-2704-427a-a66f-f2ccc501a96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5dd03723-2704-427a-a66f-f2ccc501a96d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8f6bdb0c-0bf4-48b9-b365-6781b5069d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8f6bdb0c-0bf4-48b9-b365-6781b5069d1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0d7a45a7-23f6-4634-a097-e223dccee8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:to="loc_us-gaap_WarrantMember_0d7a45a7-23f6-4634-a097-e223dccee8f1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="extended" id="i70b1f608a0b640dabf06adead171802c_FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ee40aa4-feaf-4ebf-88c5-fa871f70dcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0f04a-c9d2-4aae-9253-7bbc87905193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ee40aa4-feaf-4ebf-88c5-fa871f70dcd8" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0f04a-c9d2-4aae-9253-7bbc87905193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f945d58-dd6f-4ea9-ba58-f42fd2d121af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0f04a-c9d2-4aae-9253-7bbc87905193" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f945d58-dd6f-4ea9-ba58-f42fd2d121af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b9d77e01-1f7c-4df3-8334-300e38bf3e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0f04a-c9d2-4aae-9253-7bbc87905193" xlink:to="loc_us-gaap_RestrictedCash_b9d77e01-1f7c-4df3-8334-300e38bf3e3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_824e0b40-7b2b-480d-b172-2aef5706a014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ee40aa4-feaf-4ebf-88c5-fa871f70dcd8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_824e0b40-7b2b-480d-b172-2aef5706a014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_5b914ffd-56bf-4938-a2a6-b6f06f834368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_824e0b40-7b2b-480d-b172-2aef5706a014" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_5b914ffd-56bf-4938-a2a6-b6f06f834368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ee40aa4-feaf-4ebf-88c5-fa871f70dcd8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e21b8b-cb16-4647-833d-e2b618115086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e21b8b-cb16-4647-833d-e2b618115086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_08e21b8b-cb16-4647-833d-e2b618115086_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e21b8b-cb16-4647-833d-e2b618115086" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_08e21b8b-cb16-4647-833d-e2b618115086_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_809b3cbe-a1f0-4f88-b595-ec5388ed89ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e21b8b-cb16-4647-833d-e2b618115086" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_809b3cbe-a1f0-4f88-b595-ec5388ed89ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a7e5ba0f-293a-4a7f-b7b4-60035afd4ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_809b3cbe-a1f0-4f88-b595-ec5388ed89ab" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a7e5ba0f-293a-4a7f-b7b4-60035afd4ae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a22ec442-dacc-432d-b020-43a3b7bdd24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a22ec442-dacc-432d-b020-43a3b7bdd24e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a22ec442-dacc-432d-b020-43a3b7bdd24e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a22ec442-dacc-432d-b020-43a3b7bdd24e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a22ec442-dacc-432d-b020-43a3b7bdd24e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a10061b-a9f8-4ed6-b468-eecf67131e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a22ec442-dacc-432d-b020-43a3b7bdd24e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a10061b-a9f8-4ed6-b468-eecf67131e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_541e3a6c-7065-47b8-a119-4314b938f424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a10061b-a9f8-4ed6-b468-eecf67131e3f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_541e3a6c-7065-47b8-a119-4314b938f424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbe6b072-49d9-4885-b202-579f3d944c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbe6b072-49d9-4885-b202-579f3d944c5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbe6b072-49d9-4885-b202-579f3d944c5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbe6b072-49d9-4885-b202-579f3d944c5c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbe6b072-49d9-4885-b202-579f3d944c5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbe6b072-49d9-4885-b202-579f3d944c5c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ddab8457-4ae5-416a-8dca-71d5d1dbf7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ddab8457-4ae5-416a-8dca-71d5d1dbf7a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_73a46e73-c356-418f-a977-990ec5a33ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_73a46e73-c356-418f-a977-990ec5a33ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_75ea90dd-be70-473e-985b-f6eb6a44c46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_75ea90dd-be70-473e-985b-f6eb6a44c46e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails" xlink:type="extended" id="i93c0d7e089f24d6c90226e8f871d3de9_FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f7edd2ce-1bf6-442b-88b2-480a5ec603d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f7edd2ce-1bf6-442b-88b2-480a5ec603d9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2fab4fc8-9578-4137-98d4-65a579367ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2fab4fc8-9578-4137-98d4-65a579367ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_96f3a4a4-fae9-4c31-8e91-2d8c14b585d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_96f3a4a4-fae9-4c31-8e91-2d8c14b585d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d31fe260-f641-4bf6-b2f2-db90097690df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d31fe260-f641-4bf6-b2f2-db90097690df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_2404ff25-89be-4fe7-a435-8f66f73f56c2" xlink:href="cntx-20211231.xsd#cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_2404ff25-89be-4fe7-a435-8f66f73f56c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_01a16223-8632-49c0-afed-b8e1a140e96e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_01a16223-8632-49c0-afed-b8e1a140e96e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_904c2fe1-51af-4706-ad90-491a8165164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f7edd2ce-1bf6-442b-88b2-480a5ec603d9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_135c26e6-e75e-43cb-aeaa-6c87227c7a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_135c26e6-e75e-43cb-aeaa-6c87227c7a11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_135c26e6-e75e-43cb-aeaa-6c87227c7a11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_135c26e6-e75e-43cb-aeaa-6c87227c7a11" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_135c26e6-e75e-43cb-aeaa-6c87227c7a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f5f1090e-5d8f-46f2-9988-2ae19070ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_135c26e6-e75e-43cb-aeaa-6c87227c7a11" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f5f1090e-5d8f-46f2-9988-2ae19070ca01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_bfcf2d88-7fb3-4f10-aaec-511e26d0b401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f5f1090e-5d8f-46f2-9988-2ae19070ca01" xlink:to="loc_us-gaap_ConvertibleDebtMember_bfcf2d88-7fb3-4f10-aaec-511e26d0b401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_10aefe2d-2bde-44c0-a104-b8aa505721b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:to="loc_us-gaap_DebtInstrumentAxis_10aefe2d-2bde-44c0-a104-b8aa505721b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_10aefe2d-2bde-44c0-a104-b8aa505721b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_10aefe2d-2bde-44c0-a104-b8aa505721b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_10aefe2d-2bde-44c0-a104-b8aa505721b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_10aefe2d-2bde-44c0-a104-b8aa505721b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertibleBridgeNotesMember_c1181662-2fca-4130-b192-ae6cfa68cda1" xlink:href="cntx-20211231.xsd#cntx_ConvertibleBridgeNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:to="loc_cntx_ConvertibleBridgeNotesMember_c1181662-2fca-4130-b192-ae6cfa68cda1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_JuniorConvertibleNotesMember_03b80dc5-af19-47d6-a43e-ee7fc3c96da8" xlink:href="cntx-20211231.xsd#cntx_JuniorConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:to="loc_cntx_JuniorConvertibleNotesMember_03b80dc5-af19-47d6-a43e-ee7fc3c96da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_BridgeNotesToSeriesAPreferredStockMember_f9c4de15-3921-4a12-a426-e93e2236283c" xlink:href="cntx-20211231.xsd#cntx_BridgeNotesToSeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:to="loc_cntx_BridgeNotesToSeriesAPreferredStockMember_f9c4de15-3921-4a12-a426-e93e2236283c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePromissoryNotesDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails" xlink:type="extended" id="i6fce749135eb4e55a4b0c3814119d2be_ConvertiblePromissoryNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_81a3b061-3b9a-4ab6-b435-4ee71ba4b663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_81a3b061-3b9a-4ab6-b435-4ee71ba4b663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4266d225-2595-48bd-ad07-6a7fc48793c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4266d225-2595-48bd-ad07-6a7fc48793c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_c2b9a181-c1ca-49a0-a43c-17a718233613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_c2b9a181-c1ca-49a0-a43c-17a718233613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2c51311b-a21f-4ee4-aa21-076cf14c2d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2c51311b-a21f-4ee4-aa21-076cf14c2d8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_4e3318a9-cf24-4f31-8b48-023a661b17cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_4e3318a9-cf24-4f31-8b48-023a661b17cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8d62ff1e-3b61-43c5-a13c-61fa159c2b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_InterestExpense_8d62ff1e-3b61-43c5-a13c-61fa159c2b87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount_2a64a525-4875-45e6-a26b-fac4ef4c801f" xlink:href="cntx-20211231.xsd#cntx_DebtInstrumentConvertedInstrumentPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount_2a64a525-4875-45e6-a26b-fac4ef4c801f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtInstrumentConvertedInstrumentInterestAmount_9da12c3d-3fba-4ef9-96a8-ef7be27248ce" xlink:href="cntx-20211231.xsd#cntx_DebtInstrumentConvertedInstrumentInterestAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_cntx_DebtInstrumentConvertedInstrumentInterestAmount_9da12c3d-3fba-4ef9-96a8-ef7be27248ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedInterestRelatedParties_f9de0604-a24c-4ff9-915b-969f2319342a" xlink:href="cntx-20211231.xsd#cntx_AccruedInterestRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_cntx_AccruedInterestRelatedParties_f9de0604-a24c-4ff9-915b-969f2319342a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b56458a9-72c7-4e81-b2f7-114ff768500e" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b56458a9-72c7-4e81-b2f7-114ff768500e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_6bb1b8ab-ab5a-404e-8bd0-f01f8e0136df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_6bb1b8ab-ab5a-404e-8bd0-f01f8e0136df" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32131f69-78e7-46fe-81f0-90f13609470a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32131f69-78e7-46fe-81f0-90f13609470a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8e90bc18-103e-4d4f-9241-010a97e9045f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentTerm_8e90bc18-103e-4d4f-9241-010a97e9045f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_496581d2-acaa-4b31-ad72-324b9fefaf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_496581d2-acaa-4b31-ad72-324b9fefaf0c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_40510872-8372-4d7d-9b79-352857a56a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_40510872-8372-4d7d-9b79-352857a56a3b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3c142a07-cca7-4f8b-b55c-08ad852b9a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3c142a07-cca7-4f8b-b55c-08ad852b9a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3c142a07-cca7-4f8b-b55c-08ad852b9a9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c142a07-cca7-4f8b-b55c-08ad852b9a9a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3c142a07-cca7-4f8b-b55c-08ad852b9a9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80351ddd-c9a8-4396-961b-0ca9f585bb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c142a07-cca7-4f8b-b55c-08ad852b9a9a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80351ddd-c9a8-4396-961b-0ca9f585bb79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3265ced6-bd0d-420e-84be-d9baad779222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80351ddd-c9a8-4396-961b-0ca9f585bb79" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3265ced6-bd0d-420e-84be-d9baad779222" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PaymentProtectionProgramLoanMember_a931543b-78cf-45dd-b782-e609e3a165af" xlink:href="cntx-20211231.xsd#cntx_PaymentProtectionProgramLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80351ddd-c9a8-4396-961b-0ca9f585bb79" xlink:to="loc_cntx_PaymentProtectionProgramLoanMember_a931543b-78cf-45dd-b782-e609e3a165af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_67304466-0b8c-4fb8-a3ce-be4773669423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_DebtInstrumentAxis_67304466-0b8c-4fb8-a3ce-be4773669423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_67304466-0b8c-4fb8-a3ce-be4773669423_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_67304466-0b8c-4fb8-a3ce-be4773669423" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_67304466-0b8c-4fb8-a3ce-be4773669423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_67304466-0b8c-4fb8-a3ce-be4773669423" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_JuniorConvertibleNotesMember_089ac032-e6b8-4a96-ba6f-0bbe6a46c9e0" xlink:href="cntx-20211231.xsd#cntx_JuniorConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:to="loc_cntx_JuniorConvertibleNotesMember_089ac032-e6b8-4a96-ba6f-0bbe6a46c9e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_BridgeNoteQualifiedFinancingMember_8328de02-1283-4440-8ccb-9ad8ed75770d" xlink:href="cntx-20211231.xsd#cntx_BridgeNoteQualifiedFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:to="loc_cntx_BridgeNoteQualifiedFinancingMember_8328de02-1283-4440-8ccb-9ad8ed75770d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertibleBridgeNotesMember_43ecf64c-34d5-43a0-b319-4b0af6cdf02f" xlink:href="cntx-20211231.xsd#cntx_ConvertibleBridgeNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:to="loc_cntx_ConvertibleBridgeNotesMember_43ecf64c-34d5-43a0-b319-4b0af6cdf02f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member_5a6c034f-701f-48d1-88eb-502594e43584" xlink:href="cntx-20211231.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:to="loc_cntx_SeniorConvertibleNotesApril2020Member_5a6c034f-701f-48d1-88eb-502594e43584" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dc0fb9a8-1c7b-4be1-a452-c16c754bee66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dc0fb9a8-1c7b-4be1-a452-c16c754bee66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc0fb9a8-1c7b-4be1-a452-c16c754bee66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dc0fb9a8-1c7b-4be1-a452-c16c754bee66" xlink:to="loc_us-gaap_ClassOfStockDomain_dc0fb9a8-1c7b-4be1-a452-c16c754bee66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d0306d6d-0bdc-46e2-82e2-153fdcd61998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dc0fb9a8-1c7b-4be1-a452-c16c754bee66" xlink:to="loc_us-gaap_ClassOfStockDomain_d0306d6d-0bdc-46e2-82e2-153fdcd61998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_46882a97-f442-4b71-b4ca-ad34b41d7132" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d0306d6d-0bdc-46e2-82e2-153fdcd61998" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_46882a97-f442-4b71-b4ca-ad34b41d7132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f2b99f88-7567-46a2-b5b8-1e983faf71dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d0306d6d-0bdc-46e2-82e2-153fdcd61998" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f2b99f88-7567-46a2-b5b8-1e983faf71dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_62ea909e-ec9b-49cd-bc2f-e2357f639147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_62ea909e-ec9b-49cd-bc2f-e2357f639147" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_62ea909e-ec9b-49cd-bc2f-e2357f639147_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_62ea909e-ec9b-49cd-bc2f-e2357f639147" xlink:to="loc_us-gaap_RelatedPartyDomain_62ea909e-ec9b-49cd-bc2f-e2357f639147_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_81024c57-708d-4719-8a22-d61775210fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_62ea909e-ec9b-49cd-bc2f-e2357f639147" xlink:to="loc_us-gaap_RelatedPartyDomain_81024c57-708d-4719-8a22-d61775210fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember_17432355-a15d-4c4c-b5fa-ba807031fc15" xlink:href="cntx-20211231.xsd#cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_81024c57-708d-4719-8a22-d61775210fef" xlink:to="loc_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember_17432355-a15d-4c4c-b5fa-ba807031fc15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_913667bc-1a31-4ee0-a6a9-5e5d4752a055" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_81024c57-708d-4719-8a22-d61775210fef" xlink:to="loc_srt_AffiliatedEntityMember_913667bc-1a31-4ee0-a6a9-5e5d4752a055" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" xlink:type="extended" id="i043c31fdee264a33aa72898bb781632b_ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6675c18f-6d7d-46fe-9fe5-4950577504ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6675c18f-6d7d-46fe-9fe5-4950577504ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_be09af82-5e17-47c7-a69b-55107144f576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_be09af82-5e17-47c7-a69b-55107144f576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtConversionConvertedInstrumentPricePerShare_ecc0ea0e-f5fe-458d-b454-27f341a5892a" xlink:href="cntx-20211231.xsd#cntx_DebtConversionConvertedInstrumentPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_cntx_DebtConversionConvertedInstrumentPricePerShare_ecc0ea0e-f5fe-458d-b454-27f341a5892a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bde1213a-13df-443c-ba61-e2a3dfdcf682" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bde1213a-13df-443c-ba61-e2a3dfdcf682" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_8db22417-2adf-4d49-a8df-55e7c133afa2" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_8db22417-2adf-4d49-a8df-55e7c133afa2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ddfdaf40-2cda-49c7-896d-8d3ceb3f6c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ddfdaf40-2cda-49c7-896d-8d3ceb3f6c90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8661e584-94e0-41d0-8f1f-0752cb628b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8661e584-94e0-41d0-8f1f-0752cb628b79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2d432346-d3ca-48d2-b08f-481c5e29a3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2d432346-d3ca-48d2-b08f-481c5e29a3c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f8dced8a-fd15-48dd-86e9-14335ab257bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f8dced8a-fd15-48dd-86e9-14335ab257bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00f61df4-8f6a-41dd-a9be-67e93ce0d991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00f61df4-8f6a-41dd-a9be-67e93ce0d991" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c2abf310-70cd-41fb-ba45-b03673f923c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c2abf310-70cd-41fb-ba45-b03673f923c9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1bc4c3fe-a733-4b4b-96fa-123b6e13f169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1bc4c3fe-a733-4b4b-96fa-123b6e13f169" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d3125633-bcdd-4afc-a9fe-3ee7226bc64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d3125633-bcdd-4afc-a9fe-3ee7226bc64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d3125633-bcdd-4afc-a9fe-3ee7226bc64f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3125633-bcdd-4afc-a9fe-3ee7226bc64f" xlink:to="loc_us-gaap_ClassOfStockDomain_d3125633-bcdd-4afc-a9fe-3ee7226bc64f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3125633-bcdd-4afc-a9fe-3ee7226bc64f" xlink:to="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1b5140e1-bf11-40d6-8bfe-17dce8767ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1b5140e1-bf11-40d6-8bfe-17dce8767ce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_342acd42-08f0-4a4d-b5dc-c5ecacfcaac6" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_342acd42-08f0-4a4d-b5dc-c5ecacfcaac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_b35e50c2-d101-40d5-bad3-8c22633c2dd4" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:to="loc_cntx_RedeemableCommonStockMember_b35e50c2-d101-40d5-bad3-8c22633c2dd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_87fcf6f4-c2f0-4948-93e9-e33408117a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_87fcf6f4-c2f0-4948-93e9-e33408117a7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_87fcf6f4-c2f0-4948-93e9-e33408117a7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_87fcf6f4-c2f0-4948-93e9-e33408117a7d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_87fcf6f4-c2f0-4948-93e9-e33408117a7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ffff465d-1a96-4e1e-b8a0-21d70f807fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_87fcf6f4-c2f0-4948-93e9-e33408117a7d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ffff465d-1a96-4e1e-b8a0-21d70f807fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_46cdff3c-62ed-40d2-b4d4-065a9433b988" xlink:href="cntx-20211231.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffff465d-1a96-4e1e-b8a0-21d70f807fb8" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_46cdff3c-62ed-40d2-b4d4-065a9433b988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToSeriesAStockholdersMember_98d21651-8abe-4c76-a7aa-98ecbef5e53e" xlink:href="cntx-20211231.xsd#cntx_IssuedToSeriesAStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffff465d-1a96-4e1e-b8a0-21d70f807fb8" xlink:to="loc_cntx_IssuedToSeriesAStockholdersMember_98d21651-8abe-4c76-a7aa-98ecbef5e53e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_015f6dcc-efd6-4631-a66b-7a2264053b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_DebtInstrumentAxis_015f6dcc-efd6-4631-a66b-7a2264053b9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_015f6dcc-efd6-4631-a66b-7a2264053b9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_015f6dcc-efd6-4631-a66b-7a2264053b9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_015f6dcc-efd6-4631-a66b-7a2264053b9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_015f6dcc-efd6-4631-a66b-7a2264053b9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_JuniorConvertibleNotesMember_03f60cdd-4e09-425b-a457-92ba09f7443b" xlink:href="cntx-20211231.xsd#cntx_JuniorConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:to="loc_cntx_JuniorConvertibleNotesMember_03f60cdd-4e09-425b-a457-92ba09f7443b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertibleBridgeNotesMember_3012d85f-07f2-4c0a-ad56-b856044ac982" xlink:href="cntx-20211231.xsd#cntx_ConvertibleBridgeNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:to="loc_cntx_ConvertibleBridgeNotesMember_3012d85f-07f2-4c0a-ad56-b856044ac982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member_44d508fc-9ff6-4071-a6b0-04e50efe76d2" xlink:href="cntx-20211231.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:to="loc_cntx_SeniorConvertibleNotesApril2020Member_44d508fc-9ff6-4071-a6b0-04e50efe76d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_378776f4-f04c-4f0b-b4a1-8cbe7845861c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_378776f4-f04c-4f0b-b4a1-8cbe7845861c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_378776f4-f04c-4f0b-b4a1-8cbe7845861c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_378776f4-f04c-4f0b-b4a1-8cbe7845861c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_378776f4-f04c-4f0b-b4a1-8cbe7845861c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c671de68-b382-4cfb-8ccc-99b1bdf81f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_378776f4-f04c-4f0b-b4a1-8cbe7845861c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c671de68-b382-4cfb-8ccc-99b1bdf81f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_27a3334e-e765-4c6f-8a44-bdd88728552d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c671de68-b382-4cfb-8ccc-99b1bdf81f9d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_27a3334e-e765-4c6f-8a44-bdd88728552d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2c92363e-a90e-4591-8ed3-fa295bdb129c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_srt_RangeAxis_2c92363e-a90e-4591-8ed3-fa295bdb129c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c92363e-a90e-4591-8ed3-fa295bdb129c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2c92363e-a90e-4591-8ed3-fa295bdb129c" xlink:to="loc_srt_RangeMember_2c92363e-a90e-4591-8ed3-fa295bdb129c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e516e563-b32b-442d-a105-23b255e52c7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2c92363e-a90e-4591-8ed3-fa295bdb129c" xlink:to="loc_srt_RangeMember_e516e563-b32b-442d-a105-23b255e52c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4cfd143b-a0d0-464d-8052-530354e6edd8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e516e563-b32b-442d-a105-23b255e52c7d" xlink:to="loc_srt_MinimumMember_4cfd143b-a0d0-464d-8052-530354e6edd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb9dc762-044c-49df-b910-768ffb965da6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e516e563-b32b-442d-a105-23b255e52c7d" xlink:to="loc_srt_MaximumMember_fb9dc762-044c-49df-b910-768ffb965da6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_951f9510-5296-4045-9896-a7572b4ddfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_951f9510-5296-4045-9896-a7572b4ddfbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_951f9510-5296-4045-9896-a7572b4ddfbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_951f9510-5296-4045-9896-a7572b4ddfbc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_951f9510-5296-4045-9896-a7572b4ddfbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_43b2dfad-b1d4-456d-a54a-c7cf2d4c7eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_951f9510-5296-4045-9896-a7572b4ddfbc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_43b2dfad-b1d4-456d-a54a-c7cf2d4c7eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_077dbf97-776b-45a5-844f-a259e28a75a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_43b2dfad-b1d4-456d-a54a-c7cf2d4c7eb4" xlink:to="loc_us-gaap_SubsequentEventMember_077dbf97-776b-45a5-844f-a259e28a75a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_baf87df1-beee-4e3a-a09a-c2bc5fabeb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_baf87df1-beee-4e3a-a09a-c2bc5fabeb79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_baf87df1-beee-4e3a-a09a-c2bc5fabeb79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_baf87df1-beee-4e3a-a09a-c2bc5fabeb79" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_baf87df1-beee-4e3a-a09a-c2bc5fabeb79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a278c9bd-b827-4c5c-a382-bff4ef1afdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_baf87df1-beee-4e3a-a09a-c2bc5fabeb79" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a278c9bd-b827-4c5c-a382-bff4ef1afdb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7c834392-7e22-4a5a-8285-f1c2a597e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a278c9bd-b827-4c5c-a382-bff4ef1afdb2" xlink:to="loc_us-gaap_IPOMember_7c834392-7e22-4a5a-8285-f1c2a597e5f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_0cc1920c-acae-429f-9a0c-28ae4c4c6ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a278c9bd-b827-4c5c-a382-bff4ef1afdb2" xlink:to="loc_us-gaap_PrivatePlacementMember_0cc1920c-acae-429f-9a0c-28ae4c4c6ebc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" xlink:type="extended" id="ia7c685ffc8dc4248946c3b5824c8ea52_ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_96ee573d-ea01-432c-a1aa-b324fcda90cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7cca349b-a13f-441f-8483-c78082808c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_96ee573d-ea01-432c-a1aa-b324fcda90cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7cca349b-a13f-441f-8483-c78082808c95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dedec95b-4120-4932-8d5a-38a03be65fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_96ee573d-ea01-432c-a1aa-b324fcda90cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dedec95b-4120-4932-8d5a-38a03be65fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1c502181-3a49-4e66-8194-cc5c3314a19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_96ee573d-ea01-432c-a1aa-b324fcda90cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1c502181-3a49-4e66-8194-cc5c3314a19c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3f4ea457-880b-4318-a647-53cd0bd7ed36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1c502181-3a49-4e66-8194-cc5c3314a19c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3f4ea457-880b-4318-a647-53cd0bd7ed36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3f4ea457-880b-4318-a647-53cd0bd7ed36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3f4ea457-880b-4318-a647-53cd0bd7ed36" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3f4ea457-880b-4318-a647-53cd0bd7ed36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0f7d0427-a53a-435f-8c55-b9967f0f8589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3f4ea457-880b-4318-a647-53cd0bd7ed36" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0f7d0427-a53a-435f-8c55-b9967f0f8589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedInConnectionWithIPOMember_6d990de8-5146-471c-a0e2-4ef4977bdb2a" xlink:href="cntx-20211231.xsd#cntx_IssuedInConnectionWithIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0f7d0427-a53a-435f-8c55-b9967f0f8589" xlink:to="loc_cntx_IssuedInConnectionWithIPOMember_6d990de8-5146-471c-a0e2-4ef4977bdb2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedAsPartOfPrivatePlacementMember_bc2098d2-bb5b-41cd-adbb-a3ed645e4c7d" xlink:href="cntx-20211231.xsd#cntx_IssuedAsPartOfPrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0f7d0427-a53a-435f-8c55-b9967f0f8589" xlink:to="loc_cntx_IssuedAsPartOfPrivatePlacementMember_bc2098d2-bb5b-41cd-adbb-a3ed645e4c7d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i550461e8e0b24acf8c4d73e4c3b88784_ShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0b96e05c-7854-4148-94a6-c33c7932a428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0b96e05c-7854-4148-94a6-c33c7932a428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_9d493235-9194-49b5-9ff9-fd4250569c50" xlink:href="cntx-20211231.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_9d493235-9194-49b5-9ff9-fd4250569c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c1fa5151-adbe-4045-b845-48db22d77015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c1fa5151-adbe-4045-b845-48db22d77015" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_ede30ba3-8356-4052-bee4-6fb37284d3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_ede30ba3-8356-4052-bee4-6fb37284d3b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_028e4fc4-38c5-4267-8278-2309fb8e9caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_028e4fc4-38c5-4267-8278-2309fb8e9caa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cdbd0262-59b3-42ee-900c-86755fa99e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cdbd0262-59b3-42ee-900c-86755fa99e1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1d6f7509-e4d3-4536-b2fe-6380117683c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1d6f7509-e4d3-4536-b2fe-6380117683c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ed9ebe40-49d3-44eb-ab83-d445dfd2be93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ed9ebe40-49d3-44eb-ab83-d445dfd2be93" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1708e3d2-ca90-4aa7-9517-dac125ad2001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1708e3d2-ca90-4aa7-9517-dac125ad2001" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23f78341-34fc-43b9-b0e7-77c23009cd50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23f78341-34fc-43b9-b0e7-77c23009cd50" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b58bdb2d-611e-47cd-96a7-c11be973e3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b58bdb2d-611e-47cd-96a7-c11be973e3f9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e818bd0-8f6a-4c3c-a1f8-55c46ec15f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e818bd0-8f6a-4c3c-a1f8-55c46ec15f56" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5b3852c3-d844-4a52-9f2f-69ec1cbd88b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5b3852c3-d844-4a52-9f2f-69ec1cbd88b3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_85d22675-7b21-4801-a68b-f4737fc282e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_us-gaap_StatementClassOfStockAxis_85d22675-7b21-4801-a68b-f4737fc282e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_85d22675-7b21-4801-a68b-f4737fc282e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_85d22675-7b21-4801-a68b-f4737fc282e4" xlink:to="loc_us-gaap_ClassOfStockDomain_85d22675-7b21-4801-a68b-f4737fc282e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_85d22675-7b21-4801-a68b-f4737fc282e4" xlink:to="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_21ee6211-e7df-444d-98f7-c8877b6305a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:to="loc_us-gaap_CommonClassAMember_21ee6211-e7df-444d-98f7-c8877b6305a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ebae243e-1a33-479c-baae-7d8df5efa9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ebae243e-1a33-479c-baae-7d8df5efa9e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e16e870-fba2-49ca-bb6d-0c9fb83b32ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e16e870-fba2-49ca-bb6d-0c9fb83b32ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28ec6ebf-bad9-461b-baa2-336c431d7386" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_srt_RangeAxis_28ec6ebf-bad9-461b-baa2-336c431d7386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28ec6ebf-bad9-461b-baa2-336c431d7386_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_28ec6ebf-bad9-461b-baa2-336c431d7386" xlink:to="loc_srt_RangeMember_28ec6ebf-bad9-461b-baa2-336c431d7386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b059905-20d3-483f-8c23-2fcdfb79b89a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_28ec6ebf-bad9-461b-baa2-336c431d7386" xlink:to="loc_srt_RangeMember_8b059905-20d3-483f-8c23-2fcdfb79b89a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9f90f543-88ff-4685-979e-2b49207c8eb1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8b059905-20d3-483f-8c23-2fcdfb79b89a" xlink:to="loc_srt_MinimumMember_9f90f543-88ff-4685-979e-2b49207c8eb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_41c2c27d-9013-4ea0-b9d0-b4fdeb2dab15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8b059905-20d3-483f-8c23-2fcdfb79b89a" xlink:to="loc_srt_MaximumMember_41c2c27d-9013-4ea0-b9d0-b4fdeb2dab15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_22ca5e1d-0ca3-4271-8332-4748dfcd86a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_22ca5e1d-0ca3-4271-8332-4748dfcd86a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_22ca5e1d-0ca3-4271-8332-4748dfcd86a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22ca5e1d-0ca3-4271-8332-4748dfcd86a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_22ca5e1d-0ca3-4271-8332-4748dfcd86a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_566c3f67-8ab8-485d-8c2d-fad40b5b612e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22ca5e1d-0ca3-4271-8332-4748dfcd86a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_566c3f67-8ab8-485d-8c2d-fad40b5b612e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_415cddb9-d03e-4832-8a2a-a151bd0eeb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566c3f67-8ab8-485d-8c2d-fad40b5b612e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_415cddb9-d03e-4832-8a2a-a151bd0eeb55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cfa15ef9-d14c-4e22-afc9-5d5f8b1a99a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566c3f67-8ab8-485d-8c2d-fad40b5b612e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cfa15ef9-d14c-4e22-afc9-5d5f8b1a99a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d27f1d3f-2365-4f99-8058-42053474f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_us-gaap_AwardTypeAxis_d27f1d3f-2365-4f99-8058-42053474f8f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d27f1d3f-2365-4f99-8058-42053474f8f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d27f1d3f-2365-4f99-8058-42053474f8f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d27f1d3f-2365-4f99-8058-42053474f8f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_203afe22-7bf7-4d72-aa9e-e32de15a8358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d27f1d3f-2365-4f99-8058-42053474f8f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_203afe22-7bf7-4d72-aa9e-e32de15a8358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a5825ef1-6400-4093-9b16-61a32de7642e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_203afe22-7bf7-4d72-aa9e-e32de15a8358" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a5825ef1-6400-4093-9b16-61a32de7642e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockGrantedForServicesMember_db2f0fa1-aeb0-4333-ac1e-b9e0a046544a" xlink:href="cntx-20211231.xsd#cntx_StockGrantedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_203afe22-7bf7-4d72-aa9e-e32de15a8358" xlink:to="loc_cntx_StockGrantedForServicesMember_db2f0fa1-aeb0-4333-ac1e-b9e0a046544a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="extended" id="i877db3fe8b2f481cb2361c21237351e2_ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bb109103-9296-422a-9887-c724c3248bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bb109103-9296-422a-9887-c724c3248bbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_838f4e77-afd2-4fc1-9911-b2e4f753c034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_838f4e77-afd2-4fc1-9911-b2e4f753c034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d37c608a-b4f1-41a2-bdfe-12bfe78ec873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d37c608a-b4f1-41a2-bdfe-12bfe78ec873" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3c600d99-e387-4d11-a66f-cb56e867206e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3c600d99-e387-4d11-a66f-cb56e867206e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d5876b7-293e-4612-b82e-f5220b722497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d5876b7-293e-4612-b82e-f5220b722497" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8eab999f-661a-4118-918d-59042072eefb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d5876b7-293e-4612-b82e-f5220b722497" xlink:to="loc_us-gaap_AwardTypeAxis_8eab999f-661a-4118-918d-59042072eefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8eab999f-661a-4118-918d-59042072eefb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8eab999f-661a-4118-918d-59042072eefb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8eab999f-661a-4118-918d-59042072eefb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17bba547-ebcf-4a99-b483-aa332e08b7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8eab999f-661a-4118-918d-59042072eefb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17bba547-ebcf-4a99-b483-aa332e08b7a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_09bafae2-6b5f-4d63-84f7-2efe3cd3d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17bba547-ebcf-4a99-b483-aa332e08b7a6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_09bafae2-6b5f-4d63-84f7-2efe3cd3d07f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails" xlink:type="extended" id="i0012cf9703df4c7a8d891e4ad5937d52_ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_173d39a8-38be-4fbc-bbcc-1da70aa0818a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_173d39a8-38be-4fbc-bbcc-1da70aa0818a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6185d229-4fed-4a3c-a046-2396a5e7dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6185d229-4fed-4a3c-a046-2396a5e7dc67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1e821c52-2ae0-4ec9-b4c3-6729806f218b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1e821c52-2ae0-4ec9-b4c3-6729806f218b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4fed7bcd-e1c0-424b-9cd1-a5ca3801c934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4fed7bcd-e1c0-424b-9cd1-a5ca3801c934" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f77525b-fe43-4bd4-9291-a9dc99e35598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f77525b-fe43-4bd4-9291-a9dc99e35598" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bee604d0-11b2-4b56-b007-7b431a1c5892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_173d39a8-38be-4fbc-bbcc-1da70aa0818a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11b4fce0-a6a4-4fac-9415-9806e1867f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11b4fce0-a6a4-4fac-9415-9806e1867f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_721cf39d-8b44-4c9d-809e-fe57897e3a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_721cf39d-8b44-4c9d-809e-fe57897e3a96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d0f6da6b-b232-4dee-b8d0-5628dfa33763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d0f6da6b-b232-4dee-b8d0-5628dfa33763" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8486772-463f-4f33-8f4a-a3c796f4d685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8486772-463f-4f33-8f4a-a3c796f4d685" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8492a40a-91e0-41b2-b15c-08db8a1ae087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33485dab-6a7b-49ff-b3df-980103ef9981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_173d39a8-38be-4fbc-bbcc-1da70aa0818a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33485dab-6a7b-49ff-b3df-980103ef9981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a9519e8-5133-4266-bfed-32465ca676cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33485dab-6a7b-49ff-b3df-980103ef9981" xlink:to="loc_us-gaap_AwardTypeAxis_2a9519e8-5133-4266-bfed-32465ca676cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a9519e8-5133-4266-bfed-32465ca676cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2a9519e8-5133-4266-bfed-32465ca676cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a9519e8-5133-4266-bfed-32465ca676cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddd143e2-48e8-419d-a983-cab42cdb1331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2a9519e8-5133-4266-bfed-32465ca676cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddd143e2-48e8-419d-a983-cab42cdb1331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1cefa321-5312-4707-898d-b04f5e9ef302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddd143e2-48e8-419d-a983-cab42cdb1331" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1cefa321-5312-4707-898d-b04f5e9ef302" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails" xlink:type="extended" id="ifdfac5f5ba7f4b82ac68917e16e1300f_CommitmentandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_8ef83d8a-6e99-4661-9163-341a69179ad6" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_8ef83d8a-6e99-4661-9163-341a69179ad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_5e61b672-0dc3-4a9a-918e-18bc65f3994c" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_5e61b672-0dc3-4a9a-918e-18bc65f3994c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent_d289227b-01ba-4fc5-abb8-214a398db3ca" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent_d289227b-01ba-4fc5-abb8-214a398db3ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_f654e8b3-00c4-43ad-93dc-039b17c44c0b" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_f654e8b3-00c4-43ad-93dc-039b17c44c0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_700eeedf-7e84-4413-8c4e-3fb06021c0f9" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_700eeedf-7e84-4413-8c4e-3fb06021c0f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_3f08abec-8f1e-47c8-8557-bf14bb091937" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_3f08abec-8f1e-47c8-8557-bf14bb091937" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3aeed004-895f-47ff-af7f-9b7df7c38f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3aeed004-895f-47ff-af7f-9b7df7c38f16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eeada07e-61b8-4dbe-9d84-ecab0f0ad6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eeada07e-61b8-4dbe-9d84-ecab0f0ad6b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_69c94179-9de0-48b1-b0ba-2d52b0d11d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_69c94179-9de0-48b1-b0ba-2d52b0d11d6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a15e700f-f0b8-468a-8276-4e68446e70e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a15e700f-f0b8-468a-8276-4e68446e70e1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_3ac52c7d-7776-4fe1-ace0-0a825e58026b" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_3ac52c7d-7776-4fe1-ace0-0a825e58026b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_c10e0ea9-e63a-4253-af45-f1fa2ec45af5" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_c10e0ea9-e63a-4253-af45-f1fa2ec45af5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_00b4394a-929c-4948-87ba-8d192dbe749d" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_00b4394a-929c-4948-87ba-8d192dbe749d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_3e16ea90-9622-44bf-a8f5-cefdcbfaac0f" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_3e16ea90-9622-44bf-a8f5-cefdcbfaac0f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_1dba5d04-4ab8-49e5-a936-7a7d0517063c" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_1dba5d04-4ab8-49e5-a936-7a7d0517063c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_546a44e4-835f-423c-977f-6ae6f691eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_LeaseAndRentalExpense_546a44e4-835f-423c-977f-6ae6f691eb3c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_26b371e2-abe8-4350-a0c3-5e229e24d432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_26b371e2-abe8-4350-a0c3-5e229e24d432" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef" xlink:to="loc_us-gaap_ProjectMember_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_eb4fd162-c5ef-429f-b39d-989480674a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef" xlink:to="loc_us-gaap_ProjectMember_eb4fd162-c5ef-429f-b39d-989480674a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_c5266068-eb45-4f6b-b14a-c8ab13ff2f74" xlink:href="cntx-20211231.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_eb4fd162-c5ef-429f-b39d-989480674a74" xlink:to="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_c5266068-eb45-4f6b-b14a-c8ab13ff2f74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_73d5b5c1-82f2-4efd-9a4a-4208fb563bb6" xlink:href="cntx-20211231.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_eb4fd162-c5ef-429f-b39d-989480674a74" xlink:to="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_73d5b5c1-82f2-4efd-9a4a-4208fb563bb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_da262236-fb29-41a3-a8bd-fc91f7bbcdf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_srt_CounterpartyNameAxis_da262236-fb29-41a3-a8bd-fc91f7bbcdf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da262236-fb29-41a3-a8bd-fc91f7bbcdf9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_da262236-fb29-41a3-a8bd-fc91f7bbcdf9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da262236-fb29-41a3-a8bd-fc91f7bbcdf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_da262236-fb29-41a3-a8bd-fc91f7bbcdf9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DrexelUniversityMember_0192188e-f475-4616-a99c-7869ac891f6f" xlink:href="cntx-20211231.xsd#cntx_DrexelUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:to="loc_cntx_DrexelUniversityMember_0192188e-f475-4616-a99c-7869ac891f6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember_d261ba9f-bf7e-4a28-b34d-62303561611b" xlink:href="cntx-20211231.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:to="loc_cntx_TyligandBioscienceShanghaiLimitedMember_d261ba9f-bf7e-4a28-b34d-62303561611b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember_9cfc41f7-7674-44a3-b6b1-4959ec3d9401" xlink:href="cntx-20211231.xsd#cntx_IntegralMolecularIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:to="loc_cntx_IntegralMolecularIncMember_9cfc41f7-7674-44a3-b6b1-4959ec3d9401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e8e691dd-0a56-408f-a4da-d4d84ca211ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e8e691dd-0a56-408f-a4da-d4d84ca211ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8e691dd-0a56-408f-a4da-d4d84ca211ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e8e691dd-0a56-408f-a4da-d4d84ca211ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8e691dd-0a56-408f-a4da-d4d84ca211ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca6ad80d-7363-4aa1-b0b0-d8451f6d0254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e8e691dd-0a56-408f-a4da-d4d84ca211ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca6ad80d-7363-4aa1-b0b0-d8451f6d0254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8b2d1a21-0270-4eae-9aab-19de866d115c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca6ad80d-7363-4aa1-b0b0-d8451f6d0254" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8b2d1a21-0270-4eae-9aab-19de866d115c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c0f871aa-f294-493d-a724-0383f4d7d03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c0f871aa-f294-493d-a724-0383f4d7d03d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c0f871aa-f294-493d-a724-0383f4d7d03d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c0f871aa-f294-493d-a724-0383f4d7d03d" xlink:to="loc_us-gaap_ClassOfStockDomain_c0f871aa-f294-493d-a724-0383f4d7d03d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_129f2ac5-a329-4e00-879a-9231cd78da87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c0f871aa-f294-493d-a724-0383f4d7d03d" xlink:to="loc_us-gaap_ClassOfStockDomain_129f2ac5-a329-4e00-879a-9231cd78da87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_86163382-7b49-4f99-a77e-e8e31eb246b9" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_129f2ac5-a329-4e00-879a-9231cd78da87" xlink:to="loc_cntx_RedeemableCommonStockMember_86163382-7b49-4f99-a77e-e8e31eb246b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a9c51e82-1eb7-4806-ad22-ad9c9c6d19ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_129f2ac5-a329-4e00-879a-9231cd78da87" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a9c51e82-1eb7-4806-ad22-ad9c9c6d19ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8340e90f-07b8-46b5-9b88-e088fc76da3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_srt_RangeAxis_8340e90f-07b8-46b5-9b88-e088fc76da3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8340e90f-07b8-46b5-9b88-e088fc76da3d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8340e90f-07b8-46b5-9b88-e088fc76da3d" xlink:to="loc_srt_RangeMember_8340e90f-07b8-46b5-9b88-e088fc76da3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b70d081a-027b-4d0b-8cdc-d17f79a6126b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8340e90f-07b8-46b5-9b88-e088fc76da3d" xlink:to="loc_srt_RangeMember_b70d081a-027b-4d0b-8cdc-d17f79a6126b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f24c5593-b681-4be7-bdba-e155691ec0da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b70d081a-027b-4d0b-8cdc-d17f79a6126b" xlink:to="loc_srt_MinimumMember_f24c5593-b681-4be7-bdba-e155691ec0da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1a0cc0c-362a-4f9f-9312-b16f122c5ef7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b70d081a-027b-4d0b-8cdc-d17f79a6126b" xlink:to="loc_srt_MaximumMember_f1a0cc0c-362a-4f9f-9312-b16f122c5ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7ce1846e-4c54-4325-b5e0-64f8317dcc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7ce1846e-4c54-4325-b5e0-64f8317dcc2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7ce1846e-4c54-4325-b5e0-64f8317dcc2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7ce1846e-4c54-4325-b5e0-64f8317dcc2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7ce1846e-4c54-4325-b5e0-64f8317dcc2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2515bfa5-5320-4f7f-ab6d-6a99feeb5b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7ce1846e-4c54-4325-b5e0-64f8317dcc2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2515bfa5-5320-4f7f-ab6d-6a99feeb5b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cb229f73-ab80-4e8e-bee1-30a5128646ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2515bfa5-5320-4f7f-ab6d-6a99feeb5b43" xlink:to="loc_us-gaap_SubsequentEventMember_cb229f73-ab80-4e8e-bee1-30a5128646ae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="ibf94caac2a3441a48de438c5670098c2_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_698ae490-cfe6-42ab-a927-2d3e6f3bf40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_698ae490-cfe6-42ab-a927-2d3e6f3bf40b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c836d532-fdd2-4e16-97cb-1a28c19e4954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c836d532-fdd2-4e16-97cb-1a28c19e4954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_OperatingLossCarryforwardsExpirationTerm_f0a81d05-1f16-429f-a868-080467101d3c" xlink:href="cntx-20211231.xsd#cntx_OperatingLossCarryforwardsExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_cntx_OperatingLossCarryforwardsExpirationTerm_f0a81d05-1f16-429f-a868-080467101d3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_757320f1-dffa-4844-a93d-22af10fb5323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_757320f1-dffa-4844-a93d-22af10fb5323" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a1aa6afb-7a85-4b78-b141-d71290471245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a1aa6afb-7a85-4b78-b141-d71290471245" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_039f9ad7-2994-4aee-bad8-0feeaa88b70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_039f9ad7-2994-4aee-bad8-0feeaa88b70f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e51746c4-1840-4fe2-874d-a7ffd86ba350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e51746c4-1840-4fe2-874d-a7ffd86ba350" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ab245840-3346-4b41-916d-d087155d463e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e51746c4-1840-4fe2-874d-a7ffd86ba350" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ab245840-3346-4b41-916d-d087155d463e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ab245840-3346-4b41-916d-d087155d463e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ab245840-3346-4b41-916d-d087155d463e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ab245840-3346-4b41-916d-d087155d463e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f731ec96-bee8-4d4b-b6e8-56d061cc61ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ab245840-3346-4b41-916d-d087155d463e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f731ec96-bee8-4d4b-b6e8-56d061cc61ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_LocalJurisdictionMember_9e02248d-4a86-4a52-8b42-2fbc38261381" xlink:href="cntx-20211231.xsd#cntx_LocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f731ec96-bee8-4d4b-b6e8-56d061cc61ae" xlink:to="loc_cntx_LocalJurisdictionMember_9e02248d-4a86-4a52-8b42-2fbc38261381" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails" xlink:type="extended" id="ic63f79c9cb0c4a06bc325f6ca66254b5_IncomeTaxesSummaryofOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_457ed091-23e7-45d8-acde-1c2505b6237d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d265cee5-037c-483d-a80f-8d8f8dc055b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_457ed091-23e7-45d8-acde-1c2505b6237d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d265cee5-037c-483d-a80f-8d8f8dc055b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_20f9d0c0-e669-4c1f-982b-44c9f61dea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_457ed091-23e7-45d8-acde-1c2505b6237d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_20f9d0c0-e669-4c1f-982b-44c9f61dea7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_457ed091-23e7-45d8-acde-1c2505b6237d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1fbc138a-6728-4510-9fdb-11c55382a5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1fbc138a-6728-4510-9fdb-11c55382a5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1fbc138a-6728-4510-9fdb-11c55382a5ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1fbc138a-6728-4510-9fdb-11c55382a5ea" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1fbc138a-6728-4510-9fdb-11c55382a5ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1fbc138a-6728-4510-9fdb-11c55382a5ea" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8c573d77-9bac-4205-a8b2-edd329b374a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:to="loc_us-gaap_DomesticCountryMember_8c573d77-9bac-4205-a8b2-edd329b374a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StateJurisdictionMember_b818e9a6-6b8d-45ad-aebd-1b800477b156" xlink:href="cntx-20211231.xsd#cntx_StateJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:to="loc_cntx_StateJurisdictionMember_b818e9a6-6b8d-45ad-aebd-1b800477b156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_LocalJurisdictionMember_0eead66a-fc09-4eaf-bdf1-f2bc32404a2b" xlink:href="cntx-20211231.xsd#cntx_LocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:to="loc_cntx_LocalJurisdictionMember_0eead66a-fc09-4eaf-bdf1-f2bc32404a2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_e136ccb8-ab01-4c64-a777-e4e5051a0e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_e136ccb8-ab01-4c64-a777-e4e5051a0e82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_e136ccb8-ab01-4c64-a777-e4e5051a0e82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e136ccb8-ab01-4c64-a777-e4e5051a0e82" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_e136ccb8-ab01-4c64-a777-e4e5051a0e82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_9d407bba-c39a-450b-a73e-3a33727b0ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e136ccb8-ab01-4c64-a777-e4e5051a0e82" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_9d407bba-c39a-450b-a73e-3a33727b0ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_8cba566f-ca25-488d-a5a9-6e0c424b322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_9d407bba-c39a-450b-a73e-3a33727b0ed6" xlink:to="loc_us-gaap_ResearchMember_8cba566f-ca25-488d-a5a9-6e0c424b322e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SubsequentEventsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended" id="i3f06536966004935bd1955171e1c587f_SubsequentEventsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b9dd6fc3-431b-4123-baae-b9fde052e685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b9dd6fc3-431b-4123-baae-b9fde052e685" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15aa04d5-9ac2-4d3f-b8e3-3443d59be39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15aa04d5-9ac2-4d3f-b8e3-3443d59be39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_54b095ae-da82-466d-80be-6c8edcf95e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_54b095ae-da82-466d-80be-6c8edcf95e70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5da54acc-8723-4fd1-ac86-f9f2c5dc53d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5da54acc-8723-4fd1-ac86-f9f2c5dc53d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5428c6b8-11c0-4052-abbb-bff60c8244bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5428c6b8-11c0-4052-abbb-bff60c8244bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_5d81aa38-c7e2-4fad-9411-35653929072a" xlink:href="cntx-20211231.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5428c6b8-11c0-4052-abbb-bff60c8244bd" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_5d81aa38-c7e2-4fad-9411-35653929072a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d0ee4d5c-c861-4bc6-9444-72c74c7c9818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d0ee4d5c-c861-4bc6-9444-72c74c7c9818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d0ee4d5c-c861-4bc6-9444-72c74c7c9818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d0ee4d5c-c861-4bc6-9444-72c74c7c9818" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d0ee4d5c-c861-4bc6-9444-72c74c7c9818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f342f948-6422-419b-bde7-9aee8bcfbe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d0ee4d5c-c861-4bc6-9444-72c74c7c9818" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f342f948-6422-419b-bde7-9aee8bcfbe49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a101e7f1-df5a-4a63-9d2f-b13a42fe6e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f342f948-6422-419b-bde7-9aee8bcfbe49" xlink:to="loc_us-gaap_SubsequentEventMember_a101e7f1-df5a-4a63-9d2f-b13a42fe6e60" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cntx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:26b5d880-9edc-4480-83e2-744a98c761b2,g:c86f1f4d-7057-497b-9a16-bf3850b7383a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cntx_DrexelUniversityMember_4e7591ef-13db-4a4c-84af-ec8cd44511c3_terseLabel_en-US" xlink:label="lab_cntx_DrexelUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drexel University</link:label>
    <link:label id="lab_cntx_DrexelUniversityMember_label_en-US" xlink:label="lab_cntx_DrexelUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drexel University [Member]</link:label>
    <link:label id="lab_cntx_DrexelUniversityMember_documentation_en-US" xlink:label="lab_cntx_DrexelUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drexel University</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DrexelUniversityMember" xlink:href="cntx-20211231.xsd#cntx_DrexelUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_DrexelUniversityMember" xlink:to="lab_cntx_DrexelUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5bef1f5f-fe13-46a7-b91f-7b8a266aa8c7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax expense/(benefit) at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_dc1eac1f-8a35-4909-a9c2-97fb200da67d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_363dee27-569c-439c-9a57-3de693e06b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c63cb946-bd23-4b41-8feb-7af5581b4ab1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea8bac67-37d8-4b1e-ae68-e0bc2682dbac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_12822778-8d1d-4f25-92f7-c13459045769_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_34e93935-3c40-4da8-b085-84de3e1d525c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7175e67f-184b-4cd8-a875-6ac197aa0bc0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_33aca388-58f7-4f2a-9b32-5710b268708a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9e2a0a5d-1533-42d5-a62a-a04f2bbfa349_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_833c5077-8680-4889-a124-c92cbc267179_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c5125fa7-05c0-4a1f-a63d-d06420bc0f89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a3d5defd-2f0b-4adf-89a0-6edf1f20db54_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_DebtInstrumentConvertedInstrumentInterestAmount_82668983-557f-4fc8-a0bc-c04f65f952f4_terseLabel_en-US" xlink:label="lab_cntx_DebtInstrumentConvertedInstrumentInterestAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted interest</link:label>
    <link:label id="lab_cntx_DebtInstrumentConvertedInstrumentInterestAmount_label_en-US" xlink:label="lab_cntx_DebtInstrumentConvertedInstrumentInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Converted Instrument, Interest Amount</link:label>
    <link:label id="lab_cntx_DebtInstrumentConvertedInstrumentInterestAmount_documentation_en-US" xlink:label="lab_cntx_DebtInstrumentConvertedInstrumentInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Converted Instrument, Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtInstrumentConvertedInstrumentInterestAmount" xlink:href="cntx-20211231.xsd#cntx_DebtInstrumentConvertedInstrumentInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_DebtInstrumentConvertedInstrumentInterestAmount" xlink:to="lab_cntx_DebtInstrumentConvertedInstrumentInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5cbf2a00-f151-4e06-95e3-c154f2110f9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_f160eaf5-17ce-4514-beb0-23aa8c4a1185_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-taxable partnership income</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_080e24eb-65ee-49f7-9ed8-866f21e371cd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_NetDeferredTaxAssetLiabilitiesGross_23f28c5b-49f5-4f93-bca8-f2a5ca5429aa_totalLabel_en-US" xlink:label="lab_cntx_NetDeferredTaxAssetLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_cntx_NetDeferredTaxAssetLiabilitiesGross_label_en-US" xlink:label="lab_cntx_NetDeferredTaxAssetLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Asset (Liabilities) Gross</link:label>
    <link:label id="lab_cntx_NetDeferredTaxAssetLiabilitiesGross_documentation_en-US" xlink:label="lab_cntx_NetDeferredTaxAssetLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Asset (Liabilities) Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_NetDeferredTaxAssetLiabilitiesGross" xlink:href="cntx-20211231.xsd#cntx_NetDeferredTaxAssetLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_NetDeferredTaxAssetLiabilitiesGross" xlink:to="lab_cntx_NetDeferredTaxAssetLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c7e817dc-d2af-42b4-a988-b2d5c99f64e0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_dcd7af92-9708-4d42-98ea-175030c6a2ff_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_29a44cba-d812-4ad0-b9dd-a1cfc03c2b5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d43a1cdd-9f25-43e0-b346-7cc51b58efb9_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible securities (in shares)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_508f32f2-b90e-406a-957d-f3f94c7dc445_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_3d9157dc-2a6c-4d52-81f3-17204aad82b3_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_42e78e34-81dc-44f4-833b-064f4b5fd919_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_dc7632ca-45e6-4946-a84a-ea0bf99403f4_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76d27f2f-7eff-4d3a-b3e7-03031a98f073_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember_1d7d797e-5f27-4f6a-8ea0-b68c4412e62b_terseLabel_en-US" xlink:label="lab_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer And Immediate Family Member</link:label>
    <link:label id="lab_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember_label_en-US" xlink:label="lab_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer And Immediate Family Member [Member]</link:label>
    <link:label id="lab_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember_documentation_en-US" xlink:label="lab_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer And Immediate Family Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember" xlink:href="cntx-20211231.xsd#cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember" xlink:to="lab_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_JuniorConvertibleNotesMember_7a52a848-4c4f-42eb-b83a-434ac85b7917_terseLabel_en-US" xlink:label="lab_cntx_JuniorConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junior Convertible Notes</link:label>
    <link:label id="lab_cntx_JuniorConvertibleNotesMember_label_en-US" xlink:label="lab_cntx_JuniorConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junior Convertible Notes [Member]</link:label>
    <link:label id="lab_cntx_JuniorConvertibleNotesMember_documentation_en-US" xlink:label="lab_cntx_JuniorConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junior Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_JuniorConvertibleNotesMember" xlink:href="cntx-20211231.xsd#cntx_JuniorConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_JuniorConvertibleNotesMember" xlink:to="lab_cntx_JuniorConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_599fa9ab-433d-45d9-b86f-4abc340c0727_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cb179de5-05c1-47f7-b944-79bbe4ed3527_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c3f929b9-cbeb-4a90-8122-422a36d500ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2dccb5a8-2447-45ef-9d9d-5532c03b727a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCosts_08c2a0f3-5a4f-4c21-8851-17a06cdca6cc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredCosts_label_en-US" xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_5fd17600-5072-4370-959b-9a0207ecfa39_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable common stock to redemption value</link:label>
    <link:label id="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_label_en-US" xlink:label="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</link:label>
    <link:label id="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:to="lab_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a430b0f2-a87f-49fa-9e0c-e4638cb0e50a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_PaymentProtectionProgramLoanMember_0bdd619f-a312-4a6e-9859-6434f16366aa_terseLabel_en-US" xlink:label="lab_cntx_PaymentProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program Loan</link:label>
    <link:label id="lab_cntx_PaymentProtectionProgramLoanMember_label_en-US" xlink:label="lab_cntx_PaymentProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program Loan [Member]</link:label>
    <link:label id="lab_cntx_PaymentProtectionProgramLoanMember_documentation_en-US" xlink:label="lab_cntx_PaymentProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PaymentProtectionProgramLoanMember" xlink:href="cntx-20211231.xsd#cntx_PaymentProtectionProgramLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_PaymentProtectionProgramLoanMember" xlink:to="lab_cntx_PaymentProtectionProgramLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_a52c82bb-623b-40e5-99a4-3a7ab3a3e26e_terseLabel_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand</link:label>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_label_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand Bioscience (Shanghai) Limited [Member]</link:label>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_documentation_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand Bioscience (Shanghai) Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:href="cntx-20211231.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:to="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fcdb4407-36c9-4883-8db9-987bbc21ee91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_39af4c68-4a8b-442a-ae5e-ad6e732a7b8b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2bc97cca-ac31-49ef-8ded-dd565daa68b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2b197a14-47f1-4a2e-91f5-ea8c6b05127a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_6e1667ed-f13f-4263-9c29-263cbdfa681c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d188d304-c97e-4ed7-a694-b29941457204_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_f4272d2f-fba8-4c07-8b1c-a17c935f1b0f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7d079073-c9ef-4e15-af7b-0514443789ff_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2685a86e-55ca-43e2-ab2f-f3070b7ef2a0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_abae796e-7c81-4862-98e4-9fa73b331a0e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_33a9c1d0-71d7-4d72-b5fe-570e780f6359_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_RedeemableCommonStockMember_147a0297-f370-4dd0-b816-1ad5e3423b75_terseLabel_en-US" xlink:label="lab_cntx_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock</link:label>
    <link:label id="lab_cntx_RedeemableCommonStockMember_label_en-US" xlink:label="lab_cntx_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock [Member]</link:label>
    <link:label id="lab_cntx_RedeemableCommonStockMember_documentation_en-US" xlink:label="lab_cntx_RedeemableCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_RedeemableCommonStockMember" xlink:to="lab_cntx_RedeemableCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_cb1ef890-41ec-4bb5-b4fe-4de734552f93_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ddd6c081-e3ec-4298-aee9-3685f59d9d22_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_54cb6d91-a27a-40d1-8c3b-677c1e7fc8ca_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f260483b-9c0e-4e27-9456-e74e64e142b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_34d0c772-953d-453d-b85a-1bb59c3ecf9a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as a result of converted debt (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7381fdf-1589-4bdb-a594-b01250ff38d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_fee4e81f-a34a-4d23-9e80-3bae4126ada3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable&#8212;noncurrent</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_SeniorConvertibleNotesApril2020Member_19e96740-52be-4b99-a105-b1dba5c44d5a_terseLabel_en-US" xlink:label="lab_cntx_SeniorConvertibleNotesApril2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes, April 2020</link:label>
    <link:label id="lab_cntx_SeniorConvertibleNotesApril2020Member_label_en-US" xlink:label="lab_cntx_SeniorConvertibleNotesApril2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes, April 2020 [Member]</link:label>
    <link:label id="lab_cntx_SeniorConvertibleNotesApril2020Member_documentation_en-US" xlink:label="lab_cntx_SeniorConvertibleNotesApril2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes, April 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member" xlink:href="cntx-20211231.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_SeniorConvertibleNotesApril2020Member" xlink:to="lab_cntx_SeniorConvertibleNotesApril2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_293f3315-4572-4f8f-a0c8-17deb1b8ec60_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_239b61bd-f331-47b1-84da-52fe35ceba45_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_045c9b5b-e41b-463b-bb76-59186e0662cf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ce40c00-d334-463f-9d56-18e6b1ca09cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_4834bb89-df6f-4ba3-a061-63da987e5dcc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a0c346b3-11fa-4f6f-b427-d070c1021ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3ab3b1bf-7379-49dd-9b5d-f0c597472250_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_OperatingLossCarryforwardsExpirationTerm_513ca8d9-de1f-4dbf-90f3-d6698ad8f856_terseLabel_en-US" xlink:label="lab_cntx_OperatingLossCarryforwardsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local NOL expiration term</link:label>
    <link:label id="lab_cntx_OperatingLossCarryforwardsExpirationTerm_label_en-US" xlink:label="lab_cntx_OperatingLossCarryforwardsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration Term</link:label>
    <link:label id="lab_cntx_OperatingLossCarryforwardsExpirationTerm_documentation_en-US" xlink:label="lab_cntx_OperatingLossCarryforwardsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_OperatingLossCarryforwardsExpirationTerm" xlink:href="cntx-20211231.xsd#cntx_OperatingLossCarryforwardsExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_OperatingLossCarryforwardsExpirationTerm" xlink:to="lab_cntx_OperatingLossCarryforwardsExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_d9d10a94-d938-4fc1-9248-4d49afdedb43_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly sales payment due upon completion, percentage</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c3f93b5b-6a3c-4967-a3d2-fd8d662703cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_06bda86e-febe-4c2a-bdac-7d5293333709_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_32c643ed-68c1-4514-a7f7-dc41950ba672_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock&#8212;$0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10be2d5c-6921-4647-92c4-9c234181e9ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period ( in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ffb7a31d-cc88-4560-ae97-c72593c34405_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b317bf2e-d8b0-41d9-b62c-cd5f66c96712_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_317b72ea-8d8b-4ce0-a862-ab312c1cf233_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_BridgeNoteQualifiedFinancingMember_50915c7c-74f5-46d7-b8dc-556697afdeda_terseLabel_en-US" xlink:label="lab_cntx_BridgeNoteQualifiedFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Note Qualified Financing</link:label>
    <link:label id="lab_cntx_BridgeNoteQualifiedFinancingMember_label_en-US" xlink:label="lab_cntx_BridgeNoteQualifiedFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Note Qualified Financing [Member]</link:label>
    <link:label id="lab_cntx_BridgeNoteQualifiedFinancingMember_documentation_en-US" xlink:label="lab_cntx_BridgeNoteQualifiedFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Note Qualified Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_BridgeNoteQualifiedFinancingMember" xlink:href="cntx-20211231.xsd#cntx_BridgeNoteQualifiedFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_BridgeNoteQualifiedFinancingMember" xlink:to="lab_cntx_BridgeNoteQualifiedFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_14601723-53e2-4b10-bac2-481592cb0123_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_74b55991-71fa-4d21-bb30-4c50096af499_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount_95e68104-4ba5-4031-ab27-8e3e09d26da9_terseLabel_en-US" xlink:label="lab_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted principal</link:label>
    <link:label id="lab_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount_label_en-US" xlink:label="lab_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Converted Instrument, Principal Amount</link:label>
    <link:label id="lab_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount_documentation_en-US" xlink:label="lab_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Converted Instrument, Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount" xlink:href="cntx-20211231.xsd#cntx_DebtInstrumentConvertedInstrumentPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount" xlink:to="lab_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_39db9176-6b45-4795-bc22-e7b83d255c44_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of convertible bridge notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_7406cd9e-2bc8-49bc-86f8-55fc77920b90_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e0804201-90ed-4788-89d0-367fef74176e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8baa5b20-984a-45aa-b77c-b42b4f04244c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible securities</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3a083834-faa1-4151-b149-1c90e7588062_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_a93d9fde-9d57-42d5-9457-d77411cfac19_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2647e53a-83c5-4f63-82f6-019b171ea248_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ConvertibleBridgeNotesMember_b9f569b5-b91a-49bb-9a84-f735ad1b64e2_terseLabel_en-US" xlink:label="lab_cntx_ConvertibleBridgeNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bridge Notes</link:label>
    <link:label id="lab_cntx_ConvertibleBridgeNotesMember_label_en-US" xlink:label="lab_cntx_ConvertibleBridgeNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bridge Notes [Member]</link:label>
    <link:label id="lab_cntx_ConvertibleBridgeNotesMember_documentation_en-US" xlink:label="lab_cntx_ConvertibleBridgeNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bridge Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertibleBridgeNotesMember" xlink:href="cntx-20211231.xsd#cntx_ConvertibleBridgeNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ConvertibleBridgeNotesMember" xlink:to="lab_cntx_ConvertibleBridgeNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid_f2c6b801-8e00-4d0f-a4a3-73fb163768b0_terseLabel_en-US" xlink:label="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid offering costs in accounts payable</link:label>
    <link:label id="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid_label_en-US" xlink:label="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Cost Incurred but Not yet Paid</link:label>
    <link:label id="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Cost Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:href="cntx-20211231.xsd#cntx_DeferredOfferingCostIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:to="lab_cntx_DeferredOfferingCostIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_01892837-df56-42c3-b6ca-3732699cfb35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of tax effects of temporary differences that give rise to the deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_c0aa0734-282c-498b-9365-863f09f2a17c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a20d53b8-44a9-4a66-b7bf-c90cac6ac3df_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseRelatedParty_1e4d1164-30f2-4b97-9eb9-42c19835a43f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense payable to related party</link:label>
    <link:label id="lab_us-gaap_InterestExpenseRelatedParty_label_en-US" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty" xlink:to="lab_us-gaap_InterestExpenseRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9731233d-9c43-44a9-ad93-1501815a209f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_61f996c2-c625-4fd3-974e-f5f5297a2b48_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_63792a6f-f59b-45fa-aad0-08af7adef92d_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: change in fair value of convertible promissory notes and interest expense</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyTable_151a12e0-4763-4f1f-a227-58bbf775b10a_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyTable_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4a672963-5bc5-4162-b155-32d98e322d26_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2b2ef5c-23fe-439d-a57d-46498cd11e20_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cf80fd02-c0fb-4d46-a0e8-c661332bcfb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f46f8ac6-c7e6-42c8-81d0-df82cdb57263_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_1b912609-698d-49c3-b4a8-873d916b3347_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_508d715a-7ba1-486d-85ab-e6f472620221_terseLabel_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred shares and redeemable common shares upon initial public offering (in shares)</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_label_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_documentation_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:to="lab_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_f5931186-5c8f-466d-8d47-d5c445b3e28e_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, stock issued for services (in shares)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Issued For Services</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Issued For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_b0d1e34c-9687-4391-8978-025bd593040f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net (loss) income per common share calculation:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0ff57fb6-e47c-4a99-9f58-a813bb2337e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_PlacementAgentsWarrantsMember_2c7205f2-ce8b-46d8-bfd1-2c321d1737fb_terseLabel_en-US" xlink:label="lab_cntx_PlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agent Warrants</link:label>
    <link:label id="lab_cntx_PlacementAgentsWarrantsMember_label_en-US" xlink:label="lab_cntx_PlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agents Warrants [Member]</link:label>
    <link:label id="lab_cntx_PlacementAgentsWarrantsMember_documentation_en-US" xlink:label="lab_cntx_PlacementAgentsWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agents Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PlacementAgentsWarrantsMember" xlink:href="cntx-20211231.xsd#cntx_PlacementAgentsWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_PlacementAgentsWarrantsMember" xlink:to="lab_cntx_PlacementAgentsWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2e2b0b67-c39c-4908-9e46-dd8afe4ab3d5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IntegralMolecularIncMember_9641ac9c-08f0-4e7f-b655-c2351d48b7bc_terseLabel_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral</link:label>
    <link:label id="lab_cntx_IntegralMolecularIncMember_label_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral Molecular, Inc. [Member]</link:label>
    <link:label id="lab_cntx_IntegralMolecularIncMember_documentation_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral Molecular, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember" xlink:href="cntx-20211231.xsd#cntx_IntegralMolecularIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IntegralMolecularIncMember" xlink:to="lab_cntx_IntegralMolecularIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6ac7a113-4e47-4415-b36c-d2d7e1215b36_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding principal balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_62001495-2808-425d-ad0f-efa828230f4d_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_9068a191-9bc6-44eb-bffa-86ea6b5c7f75_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_db1ad7d1-2ae9-4570-9377-05296870f0c2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5b023518-94f9-4193-8886-ef5ecb337b57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fed1fdcf-34d5-4f2e-ac13-d23a6753064d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4fedadc6-a81d-4796-81c7-0f48dbc6017d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8567f317-6639-4dcd-b641-458d424bb0ac_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_295c04c5-3a57-49d4-b39c-c16d4b43a965_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a85e95c7-d393-49a9-9d4f-7826aaf1b29d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_977d00ea-28d9-4fb7-be7a-c661613f39ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_720e94de-98b9-4e6c-8038-156761b5fbda_terseLabel_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to placement agents</link:label>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_label_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Placement Agents [Member]</link:label>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_documentation_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Placement Agents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember" xlink:href="cntx-20211231.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedToPlacementAgentsMember" xlink:to="lab_cntx_IssuedToPlacementAgentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_58b5383f-89a4-4900-8b38-276fa38261d7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_7a47ba00-58ec-4907-9dec-2f8ae114abd2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_384f92d5-b099-4c60-ba19-a7100681626e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8c53cb62-53c5-4fbb-ba65-8ea4a1e0a10b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Convertible Preferred Stock, Redeemable Common Stock and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ed14eabb-510d-4c85-947d-24606249d249_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock in initial public offering, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8fc0f555-7a72-4def-8872-fcf39bc5fcb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_124bb8d9-dfe3-4a1d-8e5a-724210d30a88_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_62c7780d-cc02-451a-980a-822d21fd8f03_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fe49feeb-90c8-41ba-8caf-dcb0b9c564ec_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_91ba3c22-0b0f-49c9-b6bf-3f8d8d9c64a8_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2205581d-02ce-4065-9be1-5a8eb67f1dad_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_43cbbe16-4a52-4aae-8d79-814c9956c999_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_5cf3632b-f1a8-4377-ab13-0a76163212fb_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_9a25cb03-da8d-4790-b23f-60046f6fda65_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_1aec0cee-7e88-43b6-9534-36a63594707f_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Prior Year Presentation</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d29d7997-f98a-4e49-9d5b-3cfec76d5c9f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c9be0a89-2ef8-4468-a1ce-957a8b2dff06_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_ec4f9545-2705-495e-8231-ca1024f10f22_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_8c991c32-7628-4882-88ff-a02f7a0f5646_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_d08a9fa3-2f26-4d81-b71f-714528ad0dff_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0372956f-7e69-42e2-ae1c-6806e26e3637_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_96c59f38-f159-43cf-8437-1921c5b7679f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_d25e401a-53a6-49bf-818f-dab280fefe27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember_abc32278-ae5c-463d-82d9-89d5f16a899d_terseLabel_en-US" xlink:label="lab_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Notes To Series Seed Preferred Stock</link:label>
    <link:label id="lab_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember_label_en-US" xlink:label="lab_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Notes To Series Seed Preferred Stock [Member]</link:label>
    <link:label id="lab_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember_documentation_en-US" xlink:label="lab_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Notes To Series Seed Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember" xlink:href="cntx-20211231.xsd#cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember" xlink:to="lab_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_adf9a540-fe0d-4b90-8b91-f1e634bfd92c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_ecfc734d-7424-48fe-95eb-9c918c763c38_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8e94e99c-3ed5-486e-bee1-32c7e5888fd1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Initial Public Offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d02fa553-0ece-4bbb-a798-bb8374f79fa9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b0722e13-a52f-4629-a373-6a367adf17d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_ea0b161f-f039-4bc0-92ae-a4541041f869_terseLabel_en-US" xlink:label="lab_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_label_en-US" xlink:label="lab_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Accrued Interest</link:label>
    <link:label id="lab_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_documentation_en-US" xlink:label="lab_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:href="cntx-20211231.xsd#cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:to="lab_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_3b064830-d5d6-4e21-a9a9-f883c0743579_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_caeffb63-6e52-4b40-a196-db94ee2f89c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8dd6ff9e-1f39-4adf-84db-4b5cebff82fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e894eb92-9b5e-4934-a53e-990e8d2df256_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b1f47b02-2bdc-450b-a403-a2e6775ee774_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b077907e-5ec5-4c57-9898-94747ff72fd8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_42fbef37-5afd-4e25-8d26-f843d3145f77_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7f3c1ea3-9094-4c22-a906-43f2933a8d0d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a940d0d5-308f-457e-a665-4c4761e6b22f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c41e2674-d1d2-4616-9f13-ce6000d1eb36_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock in initial public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_ce282660-77cb-4898-ae0f-1c09f51ae50a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_e0666a6b-8c9a-4bd0-83ce-13ddd6516b69_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum obligation amount</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5e058973-f83b-4a11-a581-04ce9e6a8118_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7476e71e-2d3c-40a1-a647-08c42b5f2b05_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;$0.001 par value; 100,000,000 shares authorized; 15,966,053 and 331,789 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_fd7e13b9-d5d2-46e6-812e-50bbf5b5783a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_2fd4a3e4-60c4-4a2e-8b73-ef630cf0698c_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, price per share (in dollars per share)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Price Per Share</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0b63966d-fe3a-407e-9cf4-c229f948d885_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2b4f9731-b9c9-46b8-b2b1-21ddf62d2383_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0c4a1ed0-344b-4e94-929f-ff53955a7865_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_d40e0f3b-42b3-4cc7-8e87-c79b13413467_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt beneficial conversion feature</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82af013b-050a-4a75-89ca-ece88d523f45_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f4c69153-fa59-4233-b60c-1b947bff35dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_b4adc5d5-6849-4a38-94e4-a966c4bb9359_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3e7d49eb-b142-4205-8ac4-b72502e095c7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_534698c4-385d-4aef-92de-97ef892318cd_terseLabel_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PatentCostsPolicyPolicyTextBlock" xlink:href="cntx-20211231.xsd#cntx_PatentCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_PatentCostsPolicyPolicyTextBlock" xlink:to="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_7a2d2fde-da9b-40e9-816f-fdd038fb7a5a_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_09638610-dd06-476e-ba30-6c927884de69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityPolicyPolicyTextBlock_88285d43-f50b-4ad2-8250-8b03a8d7c4db_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock and Redeemable Common Stock</link:label>
    <link:label id="lab_cntx_TemporaryEquityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cntx_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cntx_TemporaryEquityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityPolicyPolicyTextBlock" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityPolicyPolicyTextBlock" xlink:to="lab_cntx_TemporaryEquityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_30a2fcc3-7517-48ee-b93d-2d646570035c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_46f39d08-9724-4225-90aa-43b0921b6fdf_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_4d28c6e8-ecf0-4973-a832-18fbe2e7522f_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum development and regulatory milestone payments</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_AuditorInformationAbstract_label_en-US" xlink:label="lab_cntx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_cntx_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_cntx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AuditorInformationAbstract" xlink:href="cntx-20211231.xsd#cntx_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_AuditorInformationAbstract" xlink:to="lab_cntx_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_e92c08be-bff9-44aa-b1b4-02dd60f40208_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_dbe5e844-2193-472a-ae0a-3b8fc29ef477_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d1264c0d-2cae-4116-8ee0-29bca183ebd8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_21dd762e-b823-4a99-91b8-3e94a8cd236c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_34914548-3f11-4720-bccc-6d7bf5ee9057_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_beb73284-edd6-49a2-9a4d-13567973e4f8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants prior to conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_AccruedInterestRelatedParties_e9df5acd-559d-4df9-8304-07e8c2f0a2e2_terseLabel_en-US" xlink:label="lab_cntx_AccruedInterestRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_cntx_AccruedInterestRelatedParties_label_en-US" xlink:label="lab_cntx_AccruedInterestRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest, Related Parties</link:label>
    <link:label id="lab_cntx_AccruedInterestRelatedParties_documentation_en-US" xlink:label="lab_cntx_AccruedInterestRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedInterestRelatedParties" xlink:href="cntx-20211231.xsd#cntx_AccruedInterestRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_AccruedInterestRelatedParties" xlink:to="lab_cntx_AccruedInterestRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_843846b4-3ca4-43a2-9892-2a39bddb7a7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f63abd08-fcb5-4d96-b0a0-2e584b0fbb8b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_27cf8664-bf09-473d-8376-844ca88eb8d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable common stock to redemption value</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_c54f62ff-e6d5-4482-b991-408256dd1647_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a47cea28-bd82-44e1-89a5-a9399344db42_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyLineItems_bde4691e-2281-420e-a1ba-7e3a97d4cdb0_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_de1a5414-91e3-4492-999f-f6097790394f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0660d9fa-6c53-41b9-bdc9-8bc047f91188_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8970e8f4-1dd2-4eda-92f1-61415d4fe194_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f14b059f-88aa-4fca-99be-2e1aafda8b0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1b4bdff9-0b1d-40b2-b32a-991529d6b5eb_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a576826c-660f-4a97-83f3-279cf50bd87e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_08f5c0cd-62e8-4127-9da4-50101ce3da74_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock in private placement, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c711f2c4-d1f6-4231-94d1-ef5d68a47cb7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_56144ef1-f9ef-40ba-8c28-15239deb1553_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_ee3c9929-49ca-43e7-9eeb-6b2319d71cc9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants for services provided</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_a3eebacf-8b17-4e66-96d7-d91b111c9a76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_0f7f4e2c-5c9b-4351-8447-647a9f70cb55_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b4d37a3a-01e1-403c-b949-f5fea3601291_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e4d33eb1-321f-49ca-9522-8ce63b3d2243_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_38d99d8b-2d39-4176-9d2b-91c8044e78cf_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity new shares issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_6f5a0345-d0e8-4c28-9126-dba6ca927337_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1b7abf7-1ee6-4938-9a18-83d7d8361f7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_93ac252d-b179-4615-a956-15d25261ddf8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3a217901-7af8-472c-aeeb-a40e43eca6f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1127d6f5-84a7-46dc-8ce6-7e93c9388e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8bdbc1ec-4549-4316-9f49-a698a36a52c4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4df36bed-3807-4156-a69a-2bdd77faad31_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c31da372-14ea-4969-8ab2-76d97a438e69_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_896a882d-47bb-42a1-ae44-26c1259671ce_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_DebtConversionConvertedInstrumentPricePerShare_2a01ff3c-dc64-485f-b559-8e61db24c650_terseLabel_en-US" xlink:label="lab_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, price per share (in dollars per share)</link:label>
    <link:label id="lab_cntx_DebtConversionConvertedInstrumentPricePerShare_label_en-US" xlink:label="lab_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Price Per Share</link:label>
    <link:label id="lab_cntx_DebtConversionConvertedInstrumentPricePerShare_documentation_en-US" xlink:label="lab_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:href="cntx-20211231.xsd#cntx_DebtConversionConvertedInstrumentPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:to="lab_cntx_DebtConversionConvertedInstrumentPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1baf42e3-70d0-407a-9016-a4d9540cd7dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Share-Based Payment Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f8ca5bb7-227d-4db7-958f-a8d9965f178c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2e25f2a4-8205-4d98-8476-0e54eedaab8b_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible securities</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_7795cfa4-ab2a-4b86-809e-e54ca1952823_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants in conjunction with Series A preferred stock and placement agent fees</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_8bcbaaa0-a092-4cec-b2fb-d22ec63e62a2_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6a9d52fb-d84d-4b10-841a-432266b121c8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1a271484-9caf-4694-bd94-b3cafdc07d98_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity new shares issued (in shares)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41811c83-7fdf-48ad-a4f6-51361a29a215_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_2208f9b2-e615-4f9e-a3e9-d04325a74cfc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b92f4918-62a9-4d14-9984-ae404693ca70_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_StateJurisdictionMember_5a64e45d-aeb4-480d-9477-e8a17656251b_terseLabel_en-US" xlink:label="lab_cntx_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards&#8212;State</link:label>
    <link:label id="lab_cntx_StateJurisdictionMember_label_en-US" xlink:label="lab_cntx_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Jurisdiction [Member]</link:label>
    <link:label id="lab_cntx_StateJurisdictionMember_documentation_en-US" xlink:label="lab_cntx_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StateJurisdictionMember" xlink:href="cntx-20211231.xsd#cntx_StateJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_StateJurisdictionMember" xlink:to="lab_cntx_StateJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_8b3b5090-78d5-4da5-96fd-0a29910a9a4b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_de3032fc-a02b-442f-a796-fc2d3b6b3041_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum sales milestone payments</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_db00cad2-9b8e-4b35-a3ce-5d125adbdcc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c5c01ab4-fcfd-4777-a6d8-c1dee27cd98a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d1e84665-80fb-4d4d-abe6-3d96a2d4516c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77c63a4b-557b-4c12-89fe-81082eaeeea9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_LocalJurisdictionMember_97673944-405f-4161-948d-6c107366f591_terseLabel_en-US" xlink:label="lab_cntx_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards&#8212;Local</link:label>
    <link:label id="lab_cntx_LocalJurisdictionMember_82918666-903a-4de2-b9c5-44d864e5f83b_verboseLabel_en-US" xlink:label="lab_cntx_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local</link:label>
    <link:label id="lab_cntx_LocalJurisdictionMember_label_en-US" xlink:label="lab_cntx_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Jurisdiction [Member]</link:label>
    <link:label id="lab_cntx_LocalJurisdictionMember_documentation_en-US" xlink:label="lab_cntx_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_LocalJurisdictionMember" xlink:href="cntx-20211231.xsd#cntx_LocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_LocalJurisdictionMember" xlink:to="lab_cntx_LocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6bd670ef-f634-4f7b-b92e-7016ebd119b6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0eeedc0d-782e-41a9-8c9f-55d1afdaa53c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_44c27879-fd47-4801-b552-5bc1dcd66505_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_b10ddd8d-dcf2-40d1-afdb-ef8cb3026a31_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_82cf8c4c-1c7a-4118-b345-b83624b9d831_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6a726d58-f9bd-4e16-95f7-31e547bcca6b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6c8f3aab-f6d0-4d14-b449-781ce0e3776c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_877979a1-89e1-407d-8a35-50f20a0675d6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e3683e26-4279-4de1-9b10-25ebef557dad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of debt into equity</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_f6c1af27-6bcd-4da4-9b6a-170ebffb8704_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly sales payment due upon completion, period of payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Payment Period</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedToSeriesAStockholdersMember_9cc459a1-221f-4626-a514-581c6d3e1209_terseLabel_en-US" xlink:label="lab_cntx_IssuedToSeriesAStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Series A Stockholders</link:label>
    <link:label id="lab_cntx_IssuedToSeriesAStockholdersMember_label_en-US" xlink:label="lab_cntx_IssuedToSeriesAStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Series A Stockholders [Member]</link:label>
    <link:label id="lab_cntx_IssuedToSeriesAStockholdersMember_documentation_en-US" xlink:label="lab_cntx_IssuedToSeriesAStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Series A Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToSeriesAStockholdersMember" xlink:href="cntx-20211231.xsd#cntx_IssuedToSeriesAStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedToSeriesAStockholdersMember" xlink:to="lab_cntx_IssuedToSeriesAStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_331b0115-5a2c-401d-bc87-6c3a7d4d7b84_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_3fbf7fd3-2ed1-482e-b791-2236c95288d2_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible promissory notes</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_4f194643-bfc5-4726-af3b-f94c18ad88fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_eec9f7ee-31e5-4668-8e58-1811a499f144_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ManufacturingDevelopmentLiabilitiesCurrent_0cb9e542-770b-4205-8071-5d19f409c2a2_terseLabel_en-US" xlink:label="lab_cntx_ManufacturingDevelopmentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing development expenses</link:label>
    <link:label id="lab_cntx_ManufacturingDevelopmentLiabilitiesCurrent_label_en-US" xlink:label="lab_cntx_ManufacturingDevelopmentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Development Liabilities, Current</link:label>
    <link:label id="lab_cntx_ManufacturingDevelopmentLiabilitiesCurrent_documentation_en-US" xlink:label="lab_cntx_ManufacturingDevelopmentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Development Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ManufacturingDevelopmentLiabilitiesCurrent" xlink:href="cntx-20211231.xsd#cntx_ManufacturingDevelopmentLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ManufacturingDevelopmentLiabilitiesCurrent" xlink:to="lab_cntx_ManufacturingDevelopmentLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_a0717bb6-aaba-4c93-a4ea-3030ce86c1a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6307c1fd-b931-4da6-a9be-b6e9c6dc1c36_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_52133906-9712-4d71-a4b3-609834b494b5_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable&#8212;current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_RisksAndLiquidityAbstract_a56bb4c8-4b04-4d33-a2c1-1009e4a5bb61_terseLabel_en-US" xlink:label="lab_cntx_RisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity [Abstract]</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityAbstract_label_en-US" xlink:label="lab_cntx_RisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity [Abstract]</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityAbstract_documentation_en-US" xlink:label="lab_cntx_RisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract" xlink:href="cntx-20211231.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_RisksAndLiquidityAbstract" xlink:to="lab_cntx_RisksAndLiquidityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_5880b102-3e11-4728-8170-1f5df8a6b488_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_97b2d118-1b57-4752-a246-660db231fc94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_7a1c300b-57aa-44fd-9697-6ce6728feaf8_terseLabel_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred shares and redeemable common shares upon initial public offering</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_label_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_documentation_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:to="lab_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c2b7f2f7-8574-416a-af84-51bb7c4fbd80_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_71a17214-9a42-4aff-b50c-675cf79b4993_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_9182d8ed-cd8e-43f5-8ade-9fca4160738f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ClinicalTrialLiabilitiesCurrent_51cb7fdb-f545-48e9-a686-1280a49b7302_terseLabel_en-US" xlink:label="lab_cntx_ClinicalTrialLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial expenses</link:label>
    <link:label id="lab_cntx_ClinicalTrialLiabilitiesCurrent_label_en-US" xlink:label="lab_cntx_ClinicalTrialLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Liabilities, Current</link:label>
    <link:label id="lab_cntx_ClinicalTrialLiabilitiesCurrent_documentation_en-US" xlink:label="lab_cntx_ClinicalTrialLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ClinicalTrialLiabilitiesCurrent" xlink:href="cntx-20211231.xsd#cntx_ClinicalTrialLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ClinicalTrialLiabilitiesCurrent" xlink:to="lab_cntx_ClinicalTrialLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5ac15d8b-fa25-48b8-8265-f7a9bbdf9de0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_fa80b6ce-4543-49a8-b562-d47cb2926818_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_14291f63-3cab-4eaf-916e-807fca736cda_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent_1644fa6c-3ea0-4a47-9b2e-f52201bb7c72_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of payments as to credits accounts payable</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payments as Credits to Accounts Payable, Percent</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payments as Credits to Accounts Payable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e8d64445-f463-4267-9f71-a3f877bf5476_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_590b3f36-1078-438d-beb8-a41440e61132_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock and redeemable common stock upon initial public offering</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_03261b7e-e505-43ab-8d55-796780f974e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_44fe44dc-b51d-47d6-9c6f-3cb16dfad8b0_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_StockIssuedDuringPeriodIssuanceCosts_6a5cb4c7-ce63-4d47-a21e-eea05548d0f4_terseLabel_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodIssuanceCosts_label_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Issuance Costs</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodIssuanceCosts_documentation_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodIssuanceCosts" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_StockIssuedDuringPeriodIssuanceCosts" xlink:to="lab_cntx_StockIssuedDuringPeriodIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7377bc18-95d4-4d55-9c32-42b4c7ca7bae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_69e3e584-ac2c-4e3b-b157-1ada841bec07_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_9b35bd66-c6cb-4a04-b55b-256a619c3fb3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_be7c40cd-a284-4f82-95d9-c602f0528cd0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a63326ce-6d19-4de6-866f-7cd8f3893bb7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4962909d-b215-41e7-99d0-eb5c56efb8de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roll-forward of fair values of liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_ea10d3de-35a2-41ea-afae-f13d8fd8ff71_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value disclosure</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2743affb-5d38-487c-bd82-368ac3f1e402_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_SeriesSeedPreferredStockMember_89f449ff-a356-45da-8b9c-cda0d3f8ca22_terseLabel_en-US" xlink:label="lab_cntx_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Preferred Stock</link:label>
    <link:label id="lab_cntx_SeriesSeedPreferredStockMember_label_en-US" xlink:label="lab_cntx_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Preferred Stock [Member]</link:label>
    <link:label id="lab_cntx_SeriesSeedPreferredStockMember_documentation_en-US" xlink:label="lab_cntx_SeriesSeedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Seed Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_SeriesSeedPreferredStockMember" xlink:to="lab_cntx_SeriesSeedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_98fcc3c8-75ca-4ffc-977e-ba14c8b395ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_51469560-b0cb-4b87-b8b4-a588108a45a8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3a6312ea-a46c-4bc3-87de-c121fb1b48d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedAsPartOfPrivatePlacementMember_f7fe31cb-d406-4253-9891-7b3b955a022b_terseLabel_en-US" xlink:label="lab_cntx_IssuedAsPartOfPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued as part of December 2021 private placement</link:label>
    <link:label id="lab_cntx_IssuedAsPartOfPrivatePlacementMember_label_en-US" xlink:label="lab_cntx_IssuedAsPartOfPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued as part of Private Placement [Member]</link:label>
    <link:label id="lab_cntx_IssuedAsPartOfPrivatePlacementMember_documentation_en-US" xlink:label="lab_cntx_IssuedAsPartOfPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued as part of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedAsPartOfPrivatePlacementMember" xlink:href="cntx-20211231.xsd#cntx_IssuedAsPartOfPrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedAsPartOfPrivatePlacementMember" xlink:to="lab_cntx_IssuedAsPartOfPrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f7f6cb0c-b2b6-446f-bc22-c4b093fde836_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_06a1b883-7f78-490d-ac72-04e7ef04a8df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_88a6e2f7-2c26-4942-900f-36e2098186d5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7067da34-2b2c-4411-806b-a72437d2f6db_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_be703a76-fc2a-4b8d-a851-6d2ed24793af_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_11421981-59f3-458c-95fb-d0ebfc54f40b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ed914b7-40ce-40aa-aa62-1d17427da480_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_0d1ed362-5c01-4e3f-9048-6d147083b480_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued as placement agent fees</link:label>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_label_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees</link:label>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:to="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_517aaceb-7d0e-4b7b-9069-e7d74b085ad5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_cb1a403e-b0ff-415f-acdc-d4b2f3352e94_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued in conjunction with the Series A preferred stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3de6fffe-1218-468c-8bc7-dbf55c47cff3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c80c9d66-5275-4922-83b4-1651fd1bfc2e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_48c29c76-384b-46e0-9798-664d7d1048ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: undistributed earnings to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityOfferingCosts_dcc5e139-c1e1-4606-ac46-a2bdcafa13c9_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_cntx_TemporaryEquityOfferingCosts_label_en-US" xlink:label="lab_cntx_TemporaryEquityOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Offering Costs</link:label>
    <link:label id="lab_cntx_TemporaryEquityOfferingCosts_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityOfferingCosts" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityOfferingCosts" xlink:to="lab_cntx_TemporaryEquityOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9b726ae5-ab22-4d44-a8b6-b0d959b30c2f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_70cafac1-6919-41dd-8993-1183b8300230_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_81dd5fff-daaf-421d-b530-90476279d528_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_00d841e1-92ed-4f7f-b3b3-92f3814e49b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_WarrantsIssued_add8249b-e736-41f7-af6f-9b9771300cba_terseLabel_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants in conjunction with Series A preferred stock and placement agent fees</link:label>
    <link:label id="lab_cntx_WarrantsIssued_label_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:label id="lab_cntx_WarrantsIssued_documentation_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued" xlink:href="cntx-20211231.xsd#cntx_WarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_WarrantsIssued" xlink:to="lab_cntx_WarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5cf68b87-449f-4279-a516-eef2b7804c6e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_4b3038e3-e030-47cc-b52d-2579c6ac37a9_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_ee3d1c0c-c09b-4cea-a8a6-f218bf35fd3e_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ef3a689c-2f69-4190-aa59-957b80da5795_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized expense related to RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74581468-8b9e-4430-b8bd-12265871d572_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of grants during period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c704f7d0-805a-430b-9019-499564682d24_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2217b211-c5b0-4466-8c32-cdfab793437c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_721dce85-d80b-4139-9815-ca57fa5c18b6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_97554707-96ad-4b23-b293-702b03a55556_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_02e90cae-dd76-4755-aa55-c8e70ed98a45_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_bd377ba3-4578-447c-9227-6bb4137ed64c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_6f7c2dea-5425-49d5-b4b1-c122ec533835_terseLabel_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Warrants</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_label_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:href="cntx-20211231.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:to="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ContextTherapeuticsLLCMember_53f2c877-10e8-4414-8a67-6e4c8b202c93_terseLabel_en-US" xlink:label="lab_cntx_ContextTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Context Therapeutics LLC</link:label>
    <link:label id="lab_cntx_ContextTherapeuticsLLCMember_label_en-US" xlink:label="lab_cntx_ContextTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Context Therapeutics LLC [Member]</link:label>
    <link:label id="lab_cntx_ContextTherapeuticsLLCMember_documentation_en-US" xlink:label="lab_cntx_ContextTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Context Therapeutics LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ContextTherapeuticsLLCMember" xlink:href="cntx-20211231.xsd#cntx_ContextTherapeuticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ContextTherapeuticsLLCMember" xlink:to="lab_cntx_ContextTherapeuticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17d90220-1b24-4a21-acfe-3283b6b5c6cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_e4caf8cf-d5b1-4d97-a3d8-efaaac772a15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of convertible debt</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_ffac9ce4-cfbd-4d18-b0c4-0157f2744f84_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards&#8212;Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4932aca2-fb01-4e68-96d6-58cf3a9131aa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0a83bf6d-2f84-4af4-9bb0-581cb1bea876_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_863b00ec-a02d-4d0a-a910-33ff38d699d4_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_09e959a7-3b4c-4b6d-8440-3160daf12320_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease minimum payments due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b94ff05d-6a9d-4d40-89ff-5de52dd99365_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0db2557a-42b4-4abe-88d5-20630b3b345a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b9aa0191-dab1-41d9-8ad1-2ea2f7a357c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_54b9d113-c804-4504-92b1-6f43e52da70f_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_4775386a-91e0-47e1-9ff4-72b631aa2757_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock and redeemable common stock (no shares authorized at December 31, 2021):</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6e435b7e-0fa1-4f8d-a8fa-7737f9fc8344_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e60f562d-da58-4aa9-a1b4-dd2265f7cce0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b58e366b-5dfb-4597-802f-6bf9d3fb4e35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a8c33ace-202d-407e-82f7-2d4209a16077_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_aa2b52ea-9cd4-4864-aa2d-9ca68601436e_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f18ec84e-68b8-4aaa-b091-feb59bec69b4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bdd9e351-e42c-451e-9a16-163e9fbe6887_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5a9c6b7c-1649-49e4-8c7d-e6ebacc7beb3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8a292cce-efea-47f5-9bfe-eec15e323873_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to common shareholders &#8211; diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_01e8ecaf-22fc-4563-879d-2831d6f02f40_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to common shareholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d8dcf237-886a-4022-9d75-90691004cf41_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_87aba95b-8df6-4d3e-a5db-4642bd82aa33_terseLabel_en-US" xlink:label="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable common stock to redemption value</link:label>
    <link:label id="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_label_en-US" xlink:label="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</link:label>
    <link:label id="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_documentation_en-US" xlink:label="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:href="cntx-20211231.xsd#cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:to="lab_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_13d4981d-5719-42c9-b565-dc40e90c20b9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_bed0bc00-46a4-4c1e-877f-1c0f72a5baba_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_e34a020b-a29a-4cff-bc23-279bf357d263_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da8d87f2-bffc-4646-bcee-302785d59751_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6687ae42-402a-4766-8f69-1f220f2ef3c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_72c96148-9ace-4d5b-9911-991c5004cd27_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_e959ec11-0ba9-45cd-af70-4991fad22fec_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_665c9d76-661f-4f2c-a512-c4a929921f97_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred shares and redeemable common shares upon initial public offering</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_773db644-691e-4c1d-a5e4-685214e55403_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_c4c049b6-d6fb-47bc-a392-c33ab9722305_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3463b4b9-27f5-4d1a-88f9-bbf4b3f63aea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_d40c5436-2b48-4a9b-b225-ad8466b3e41d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_65768f46-3f95-4384-9614-b6bed4580767_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_083808e1-fe13-443e-9fab-1420eb4c29c7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net (loss) income per common share calculation:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_052989f6-e48f-4b6b-8168-4226851e4ffa_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_206ea2cb-2fe4-4027-8849-d503f914e13b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f88978cd-674f-4c9f-99f5-069ed14a15cf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c0e3baa2-87d9-42b3-bec8-f4c851f7c307_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1e591558-a05a-44bf-9eff-0ffdbbd83f95_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_917317d2-4c3c-4df8-b7fe-dd6bb34c1405_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_e188c2e3-1847-4c89-ac9c-40845ea25475_negatedTerseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued in conjunction with the Series A preferred stock</link:label>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_label_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due To Conversion To Warrants</link:label>
    <link:label id="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due To Conversion To Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:to="lab_cntx_TemporaryEquityDecreaseDueToConversionToWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7bb9e3dc-dfab-4ac4-aad3-430773affc1e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3210c178-113f-4f4f-a8c8-39ae87010a88_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0862c2b1-137c-417c-a14e-93ca796fdeca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_FairValueAdjustmentOnConvertibleDebt_23dc0602-8c2c-40a7-8aae-1651a3642364_terseLabel_en-US" xlink:label="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
    <link:label id="lab_cntx_FairValueAdjustmentOnConvertibleDebt_65d8abbd-14b1-4848-83d4-fd0a2058cfe2_negatedTerseLabel_en-US" xlink:label="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
    <link:label id="lab_cntx_FairValueAdjustmentOnConvertibleDebt_label_en-US" xlink:label="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment On Convertible Debt</link:label>
    <link:label id="lab_cntx_FairValueAdjustmentOnConvertibleDebt_documentation_en-US" xlink:label="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment On Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:href="cntx-20211231.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:to="lab_cntx_FairValueAdjustmentOnConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_3f61dc31-47c5-4312-9449-0c9b365b8d74_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b2ce5ce-4299-4918-8e03-436998dd70ca_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_BridgeNotesToSeriesAPreferredStockMember_0d724807-4708-4575-84dc-75da3a49f8e0_terseLabel_en-US" xlink:label="lab_cntx_BridgeNotesToSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Notes to Series A Preferred Stock</link:label>
    <link:label id="lab_cntx_BridgeNotesToSeriesAPreferredStockMember_label_en-US" xlink:label="lab_cntx_BridgeNotesToSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Notes to Series A Preferred Stock [Member]</link:label>
    <link:label id="lab_cntx_BridgeNotesToSeriesAPreferredStockMember_documentation_en-US" xlink:label="lab_cntx_BridgeNotesToSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Notes to Series A Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_BridgeNotesToSeriesAPreferredStockMember" xlink:href="cntx-20211231.xsd#cntx_BridgeNotesToSeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_BridgeNotesToSeriesAPreferredStockMember" xlink:to="lab_cntx_BridgeNotesToSeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82c3d01d-62bc-447c-8cb6-41b9d664264a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d0330203-611b-4578-ae6c-b2c1720bd61e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expensed interest related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_30c34d5e-b119-43e5-b529-825af63ccb29_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible securities (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6e41c273-4d44-4dee-8366-81590dcd45cc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_188ef892-4e9a-4f10-a904-54af6049f2e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_43a53cc8-5e10-46a9-98ee-2c4020f09a86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_10b16e3f-c3e6-4a51-afa6-4522c36388bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_b53161bc-8552-4199-86ca-cd9b581d98d8_terseLabel_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-up, 100 kilograms of GMP-grade compound</link:label>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_label_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 100 kilograms of GMP-Grade Compound [Member]</link:label>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_documentation_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 100 kilograms of GMP-Grade Compound</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:href="cntx-20211231.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:to="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c669c4e4-49ad-4795-8384-3b041181afce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1088b2cc-3f0f-4f6c-8fa9-c41663547ba4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_7f1d3e07-fc02-4bdc-9f0a-1dc9fe7388f0_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6aec99fc-58a6-454b-8886-955d6b264d80_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_bef29956-dd26-4b8a-9e20-2549a95e25f0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_329db36b-6c33-4231-b86a-c3c4304b42c2_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred shares and redeemable common shares upon initial public offering (in shares)</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_be714c24-54de-4682-8c92-c3116b14abb6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e0e8e619-7931-47c9-ad69-72bce346ba9e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3f6c01e1-5739-4d70-abe9-34568ae0bfad_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_1a69ecdf-54fe-4218-932f-50ed3f45d2c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible promissory notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5db8f61d-baea-45c1-b82d-0bc12804b736_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ace3cfe0-50e1-4540-8772-be3e5797d81d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0b685cdc-e91d-46a7-b24f-9ff2f1de124a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_378cebc4-098f-46d4-ba4d-a2a63ce4b892_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_af17894c-8626-4772-a0e4-f2598a324f81_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_a87486e7-dbd5-499a-9c9e-dbf181c496d6_terseLabel_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion of warrants (in shares)</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:label id="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_3000e3e5-bf65-4e1a-b1c0-8dbcc48cb4bd_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_848e173c-fe70-4e2b-8f02-879f230026b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: undistributed earnings to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_46f7a67f-ec7b-483a-8311-72831225272f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_091759fe-a36a-436e-8c29-f44381c95173_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedInConnectionWithIPOMember_15e95a46-ec6b-4ecf-8871-ac99c5058e6a_terseLabel_en-US" xlink:label="lab_cntx_IssuedInConnectionWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in connection with IPO</link:label>
    <link:label id="lab_cntx_IssuedInConnectionWithIPOMember_label_en-US" xlink:label="lab_cntx_IssuedInConnectionWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in Connection with IPO [Member]</link:label>
    <link:label id="lab_cntx_IssuedInConnectionWithIPOMember_documentation_en-US" xlink:label="lab_cntx_IssuedInConnectionWithIPOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in Connection with IPO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedInConnectionWithIPOMember" xlink:href="cntx-20211231.xsd#cntx_IssuedInConnectionWithIPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedInConnectionWithIPOMember" xlink:to="lab_cntx_IssuedInConnectionWithIPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_946b885d-cad0-42ae-9195-97bc40e4a15e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af366a2d-4c7c-4bf1-b8e2-92e8ad38e268_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_67c55893-d2b7-4377-a4a0-c833a666b6fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_aea71f6d-a88d-485a-b603-c735099a53b6_terseLabel_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, stock issued for services</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Issued For Services</link:label>
    <link:label id="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_documentation_en-US" xlink:label="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Issued For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee642e9f-46cb-4bbe-9389-1578c714da01_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa1b9542-4b56-4c9f-9007-781cbf8281cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_78c3b820-1861-441b-97b0-1be95fb9145a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_eb30de8c-d6f0-49d6-9aa0-2012160f3bfd_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, term from date of issuance</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_d923fa06-a87a-43ea-b3e0-a4e88e71ef4c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a1a58430-3b92-4300-a286-4845e7239acc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_efa8a1b0-a382-476c-a30b-b3e6a5b1293f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at December 31, 2021</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_8da3b4ef-5cd9-4398-8360-2f7f0cd69cdc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credits&#8212;Federal</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_63aa931f-4d56-4f45-989b-ad846d894662_terseLabel_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Liquidity</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_label_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity [Text Block]</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_documentation_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityTextBlock" xlink:href="cntx-20211231.xsd#cntx_RisksAndLiquidityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_RisksAndLiquidityTextBlock" xlink:to="lab_cntx_RisksAndLiquidityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f0141db6-e6d8-4013-a311-f97e3cf6297c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea490837-ec3f-4782-a21f-e2d6ead8c288_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_326a742c-665c-4fde-a545-e0a3433d1ba2_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_85ba2f05-42d8-4917-a304-f1013aba8165_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1af9e7f1-a47a-4688-8628-71eabf5a7a78_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_7da36adc-694f-4cf8-9a1d-5f8f8c178980_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_3da708f0-d6bf-48fd-ad61-5bccd8ba06b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_1d18c5c3-accf-42a2-92b8-3640745c22f9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_966c912b-3776-4a26-8279-654d9aa01642_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79fae229-770c-48f5-8e06-c96831dc3cb5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a220416-9708-4890-b8d8-f7a948f5f908_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ced0e8c-2b3a-4d73-891c-bd57c9a4de28_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and restricted cash (Money Market Accounts)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_07f083c7-5f0b-422c-a10a-0b14ce1df4da_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_df53c237-8f0d-4532-ace5-f5b1acc6f12f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_15ae7b50-fcc3-4d1b-b3eb-5a5f7d17538b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_36b9f944-a027-480a-be98-3068d6b355ec_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3b18f01a-286d-4b41-8cb6-d677378539f5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_59d1f5c7-2826-4661-98bc-d8664923b3d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_DemandNotesToConvertiblePromissoryNotesMember_7bdd01bc-482d-4a9b-928d-6a7b1688192e_terseLabel_en-US" xlink:label="lab_cntx_DemandNotesToConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Notes to Convertible Promissory Notes</link:label>
    <link:label id="lab_cntx_DemandNotesToConvertiblePromissoryNotesMember_label_en-US" xlink:label="lab_cntx_DemandNotesToConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Notes to Convertible Promissory Notes [Member]</link:label>
    <link:label id="lab_cntx_DemandNotesToConvertiblePromissoryNotesMember_documentation_en-US" xlink:label="lab_cntx_DemandNotesToConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Notes to Convertible Promissory Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DemandNotesToConvertiblePromissoryNotesMember" xlink:href="cntx-20211231.xsd#cntx_DemandNotesToConvertiblePromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_DemandNotesToConvertiblePromissoryNotesMember" xlink:to="lab_cntx_DemandNotesToConvertiblePromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f665470b-ff00-4ad9-a5f1-9aeceda966ae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4d44f513-5d84-45d5-9302-d82f169eb91e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74a2d85b-12ad-416e-912d-748e78949b1f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_8bb89842-fbfa-4f34-be97-324ed95651ff_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant fair value</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_52eb0225-323a-4356-83c0-4d42f34ed9a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a16d9416-820a-4f8b-80ec-a798bdb2d1a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5f94696f-c294-48f0-bbe0-0eb3cf4a41ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedForServicesMember_b79f2033-6871-4a7e-af8c-87c6534e8622_terseLabel_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for services</link:label>
    <link:label id="lab_cntx_IssuedForServicesMember_label_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Services [Member]</link:label>
    <link:label id="lab_cntx_IssuedForServicesMember_documentation_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember" xlink:href="cntx-20211231.xsd#cntx_IssuedForServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedForServicesMember" xlink:to="lab_cntx_IssuedForServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3eb21952-df84-4e13-bf3e-5f3bda4e7889_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_41adace4-7c6e-41c0-8b2e-a32895d2df41_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b54bcc89-78fe-4661-ad57-aca9719251d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_998d62bb-3669-462d-bcf8-5e820d50a67c_terseLabel_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rate at which authorized shares of common stock increase</link:label>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_label_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</link:label>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_documentation_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:href="cntx-20211231.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:to="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f0875a1d-0157-4f22-a4e0-1282781d3e8c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Redeemable Common Stock and Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_092f5388-73cf-4882-92fd-198c032366bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_StockGrantedForServicesMember_a0ac6161-43a6-4232-a357-b226e8337ca4_terseLabel_en-US" xlink:label="lab_cntx_StockGrantedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Granted For Services</link:label>
    <link:label id="lab_cntx_StockGrantedForServicesMember_label_en-US" xlink:label="lab_cntx_StockGrantedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Granted For Services [Member]</link:label>
    <link:label id="lab_cntx_StockGrantedForServicesMember_documentation_en-US" xlink:label="lab_cntx_StockGrantedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Granted For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockGrantedForServicesMember" xlink:href="cntx-20211231.xsd#cntx_StockGrantedForServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_StockGrantedForServicesMember" xlink:to="lab_cntx_StockGrantedForServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_472fca18-561c-47c4-b289-98ffc2e7a8e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_908c2089-698c-4f71-a6b3-bd229610f51d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_8f792d5b-0c36-4205-b84a-8e9ea47b2fd8_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9a357aa1-b636-4cdf-85bf-cbb463e2aa38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2532f811-b01f-4f38-8632-695d79385d73_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_3063246e-ecfd-4a30-a681-6b903d0c90a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_046233e4-1930-44ac-ae9e-7f8d8b5099b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine3_41a5c175-e52b-45a6-9760-500f58d661b4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine3_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3" xlink:to="lab_dei_EntityAddressAddressLine3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a1f45617-ab40-41da-9c82-a47ee0ecff75_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f95d00c-0fb0-434c-807d-217ff5b9826b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_d05c728b-4430-4256-bf73-ff5222f77371_terseLabel_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-up, 300 kilograms of GMP-grade compound</link:label>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_label_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 300 kilograms of GMP-Grade Compound [Member]</link:label>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_documentation_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 300 kilograms of GMP-Grade Compound</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:href="cntx-20211231.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:to="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_556d6ee6-6d96-4ebc-9641-35445aeea2a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_d97e4198-ac3a-4646-96e0-0138d80f914b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a87947dc-a495-4e0c-be88-a7977e514830_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_98bd3760-a76d-4ffd-9d83-244470ebe338_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_46a5b1cf-6a76-416b-b636-36b42c21dd56_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d14ef866-23df-4fab-b1c5-f86fe43f160d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_95c5d40d-8ff6-4fde-bd0e-b1a5fd18f541_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_203eb869-c904-4fbc-9e56-509f02142b56_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_6057a290-abd8-4b1b-aa3b-8931a6cd67e8_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_58fbcb21-7494-42c2-9bba-85fc67273d0e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_c3303b33-9c23-4ef2-bed8-562a10ccbd01_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payment, percent (up to)</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c04e57a5-578c-4863-8cc3-4b9f262874b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_December2021PrivatePlacementWarrantsMember_feecceab-06f1-4bd8-abd3-c298ca4dfc45_terseLabel_en-US" xlink:label="lab_cntx_December2021PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Warrants</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementWarrantsMember_label_en-US" xlink:label="lab_cntx_December2021PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Warrants [Member]</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementWarrantsMember_documentation_en-US" xlink:label="lab_cntx_December2021PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementWarrantsMember" xlink:href="cntx-20211231.xsd#cntx_December2021PrivatePlacementWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_December2021PrivatePlacementWarrantsMember" xlink:to="lab_cntx_December2021PrivatePlacementWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b84a0089-ebe9-4246-9e2f-dc60d6133165_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ddf9fd3f-c6dd-491f-bd2f-5da0503b0891_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_195c05b8-5cb1-457f-895e-97e293486a0e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_0df862c4-ee05-4af2-a83d-fedb18b807e4_terseLabel_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Professional Consulting Services</link:label>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_label_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Professional Consulting Services [Member]</link:label>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_documentation_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Professional Consulting Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember" xlink:href="cntx-20211231.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedForProfessionalConsultingServicesMember" xlink:to="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_66b51fd0-964a-4af9-8f68-b70f30fa02e2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_c67af3eb-da37-406a-aa28-978e34211046_terseLabel_en-US" xlink:label="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued in conjunction with series A preferred stock</link:label>
    <link:label id="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_label_en-US" xlink:label="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued in Conjunction With Series A Preferred Stock [Member]</link:label>
    <link:label id="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_documentation_en-US" xlink:label="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued in Conjunction With Series A Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:href="cntx-20211231.xsd#cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:to="lab_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_dd86b02f-1fc4-4325-97e3-338acc5d2b00_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_d36bce5b-8335-4ca1-b197-0fb2a66cc9a6_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e6fd11c-0272-46d8-b496-e9eb265d5436_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_823f1333-6bfc-4ef0-a67d-951a826cac4b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes issued to related parties</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_75801e9d-2d7b-4202-9fa7-8b4d0bc88914_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_a1398b18-20ba-4e26-abad-0ce4589fcea0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ae60984c-6801-4299-b41c-e3fc6d785b15_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_d8b80f3b-4282-4863-88ef-69a5df87b003_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0741abee-666c-4d71-9a4b-8140825b7dc6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at December 31, 2021</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cntx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:26b5d880-9edc-4480-83e2-744a98c761b2,g:c86f1f4d-7057-497b-9a16-bf3850b7383a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/Cover" xlink:type="simple" xlink:href="cntx-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_90913dcb-c290-4dbf-b979-cb8daa337bd1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_DocumentType_90913dcb-c290-4dbf-b979-cb8daa337bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_d7a1306f-4f47-49db-b58c-6ede0523fae7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_DocumentAnnualReport_d7a1306f-4f47-49db-b58c-6ede0523fae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dfd46a8c-96a2-4416-b4fd-13809757fe48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_DocumentPeriodEndDate_dfd46a8c-96a2-4416-b4fd-13809757fe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f6cfcb21-36a4-4b96-b1d1-f248c35d5830" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_CurrentFiscalYearEndDate_f6cfcb21-36a4-4b96-b1d1-f248c35d5830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3292ca6f-15bb-4931-8a4a-e4ee73ca8291" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_DocumentTransitionReport_3292ca6f-15bb-4931-8a4a-e4ee73ca8291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_534982b6-3c17-410d-9326-367de8e90007" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityFileNumber_534982b6-3c17-410d-9326-367de8e90007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_617c25e5-7131-4ed6-bfb4-af583cb4f79c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityRegistrantName_617c25e5-7131-4ed6-bfb4-af583cb4f79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_64645fa2-59af-4957-a788-2268dfaf7776" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityIncorporationStateCountryCode_64645fa2-59af-4957-a788-2268dfaf7776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_033f0f9c-5aa3-42ca-99e4-c0da7bc09890" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityTaxIdentificationNumber_033f0f9c-5aa3-42ca-99e4-c0da7bc09890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_df11da79-45c3-4679-9a86-4e07983b5184" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityAddressAddressLine1_df11da79-45c3-4679-9a86-4e07983b5184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_796743fe-bf8f-4f72-8c1a-38aac03a73ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityAddressAddressLine2_796743fe-bf8f-4f72-8c1a-38aac03a73ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3_6c8cb8f1-30ca-43c0-87ff-c1e6542f130b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityAddressAddressLine3_6c8cb8f1-30ca-43c0-87ff-c1e6542f130b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eb634707-2c6c-4a81-90e9-0439749c3c61" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityAddressCityOrTown_eb634707-2c6c-4a81-90e9-0439749c3c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4594e997-01fe-4d69-b54b-345e1ce41cba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityAddressStateOrProvince_4594e997-01fe-4d69-b54b-345e1ce41cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_56e66982-f62f-4dc2-894f-b9815b2ac1b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityAddressPostalZipCode_56e66982-f62f-4dc2-894f-b9815b2ac1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_19d57d42-9df7-4529-b8f0-69b81ef97fc9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_CityAreaCode_19d57d42-9df7-4529-b8f0-69b81ef97fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a94770ff-7fe2-40d3-a931-1d65713574c9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_LocalPhoneNumber_a94770ff-7fe2-40d3-a931-1d65713574c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_74e67c41-ae9a-4c3a-bd4b-86be9b26796b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_Security12bTitle_74e67c41-ae9a-4c3a-bd4b-86be9b26796b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_50e57bce-5f86-4510-98ff-a918fc848e9f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_TradingSymbol_50e57bce-5f86-4510-98ff-a918fc848e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9d3d27a2-7e34-46aa-bc8e-6c55405344b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_SecurityExchangeName_9d3d27a2-7e34-46aa-bc8e-6c55405344b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_37b38ec7-f024-44c5-8b42-6b77afa4db42" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_37b38ec7-f024-44c5-8b42-6b77afa4db42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_34778acc-e0bc-48ca-b3b0-6b5d89a1b4b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityVoluntaryFilers_34778acc-e0bc-48ca-b3b0-6b5d89a1b4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1cbd4863-14b5-4c7e-86a6-fcfa3d680ca4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityCurrentReportingStatus_1cbd4863-14b5-4c7e-86a6-fcfa3d680ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8434c610-1b74-48a7-be4f-5a7980a23f26" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityInteractiveDataCurrent_8434c610-1b74-48a7-be4f-5a7980a23f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_228ae2af-a304-4651-afc9-24bdd6feee2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityFilerCategory_228ae2af-a304-4651-afc9-24bdd6feee2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_767e30a5-25f0-412d-a696-d9d62576ac36" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntitySmallBusiness_767e30a5-25f0-412d-a696-d9d62576ac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_221dd108-9c7d-4710-b988-9ebfc8852e3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityEmergingGrowthCompany_221dd108-9c7d-4710-b988-9ebfc8852e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_ec7858e4-b6cb-4a28-8dca-41adb067994d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityExTransitionPeriod_ec7858e4-b6cb-4a28-8dca-41adb067994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_fcc7b825-abaf-4129-a183-f31a4c0190eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_IcfrAuditorAttestationFlag_fcc7b825-abaf-4129-a183-f31a4c0190eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_da50794e-aa82-4f7c-9525-19d1d03b5959" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityShellCompany_da50794e-aa82-4f7c-9525-19d1d03b5959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7001aaa3-34d2-4719-8bf6-6f74731e200f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7001aaa3-34d2-4719-8bf6-6f74731e200f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e2ce2d83-bb1d-4140-b07d-df38fa9fda30" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e2ce2d83-bb1d-4140-b07d-df38fa9fda30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_907c37b6-d6f3-4702-81c4-f86949b48815" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityCentralIndexKey_907c37b6-d6f3-4702-81c4-f86949b48815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_eae5a88a-a588-4adc-8e26-f69c038efd65" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_AmendmentFlag_eae5a88a-a588-4adc-8e26-f69c038efd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7400fc7b-9e82-4b6f-a756-f7be09995a69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_DocumentFiscalYearFocus_7400fc7b-9e82-4b6f-a756-f7be09995a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b04dd4cb-1e5c-4b15-b5c8-a83e783ee812" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b04dd4cb-1e5c-4b15-b5c8-a83e783ee812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7c64345b-2125-48d8-83a7-4d44cbf017b1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_75ec7150-4720-4292-8044-2ef673d3de84" xlink:to="loc_dei_EntityPublicFloat_7c64345b-2125-48d8-83a7-4d44cbf017b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AuditInformation" xlink:type="simple" xlink:href="cntx-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AuditorInformationAbstract_279f8f2d-e050-45e5-86b2-2dfb37faf885" xlink:href="cntx-20211231.xsd#cntx_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_c8a18bcc-46cf-4b38-a31b-53b05b0ada81" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_AuditorInformationAbstract_279f8f2d-e050-45e5-86b2-2dfb37faf885" xlink:to="loc_dei_AuditorName_c8a18bcc-46cf-4b38-a31b-53b05b0ada81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_fd398564-9963-40eb-8e1d-5942e6a8cd53" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_AuditorInformationAbstract_279f8f2d-e050-45e5-86b2-2dfb37faf885" xlink:to="loc_dei_AuditorLocation_fd398564-9963-40eb-8e1d-5942e6a8cd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d0664903-656c-4449-9741-8e92bdac9d77" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_AuditorInformationAbstract_279f8f2d-e050-45e5-86b2-2dfb37faf885" xlink:to="loc_dei_AuditorFirmId_d0664903-656c-4449-9741-8e92bdac9d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3144c74c-983c-4134-81eb-6bbf9de9ee36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dd9de7fc-f3c4-4398-bb91-aa4940ae4bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3144c74c-983c-4134-81eb-6bbf9de9ee36" xlink:to="loc_us-gaap_StatementTable_dd9de7fc-f3c4-4398-bb91-aa4940ae4bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_39454efb-7e48-4a70-b60d-94655adbd533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dd9de7fc-f3c4-4398-bb91-aa4940ae4bca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_39454efb-7e48-4a70-b60d-94655adbd533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39454efb-7e48-4a70-b60d-94655adbd533" xlink:to="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f5763a20-0f62-4c3c-8423-fafe6561414e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f5763a20-0f62-4c3c-8423-fafe6561414e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_c7e2b490-8ae3-4a53-b57c-fd84b24be567" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_c7e2b490-8ae3-4a53-b57c-fd84b24be567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_b8be6edb-efe7-489e-9109-caa9d107b345" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5758bc40-3764-48dd-ad14-499e4db37b0d" xlink:to="loc_cntx_RedeemableCommonStockMember_b8be6edb-efe7-489e-9109-caa9d107b345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_211b4072-f21f-464e-8d03-e2327116c576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dd9de7fc-f3c4-4398-bb91-aa4940ae4bca" xlink:to="loc_us-gaap_StatementLineItems_211b4072-f21f-464e-8d03-e2327116c576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211b4072-f21f-464e-8d03-e2327116c576" xlink:to="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c2bfd5c-767f-4099-a7b9-032d81cde088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c2bfd5c-767f-4099-a7b9-032d81cde088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_90c114e1-b76f-4904-8824-c7ea8f58bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_90c114e1-b76f-4904-8824-c7ea8f58bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_810e683e-c342-4847-9561-d76a9f6fe78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0b841d35-3b12-48ea-ac92-fc5cb2158803" xlink:to="loc_us-gaap_AssetsCurrent_810e683e-c342-4847-9561-d76a9f6fe78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e282c2b6-744c-4b27-9ac6-1f4228ade559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e282c2b6-744c-4b27-9ac6-1f4228ade559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_d4179728-203a-4670-b98e-2a60f1a39b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:to="loc_us-gaap_DeferredCosts_d4179728-203a-4670-b98e-2a60f1a39b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_433c5b36-6d6d-45c8-b75f-0f2d962bc666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f9599cc5-6acf-425f-b2dc-c7d33e22fe64" xlink:to="loc_us-gaap_Assets_433c5b36-6d6d-45c8-b75f-0f2d962bc666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211b4072-f21f-464e-8d03-e2327116c576" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_e58bcb63-947f-44d5-93fa-b0bff11fb2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_e58bcb63-947f-44d5-93fa-b0bff11fb2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f29be3bc-732e-47cc-9b3a-6c8de1947b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_NotesPayableCurrent_f29be3bc-732e-47cc-9b3a-6c8de1947b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_04ea78ba-6338-432f-963c-5e5812c60ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_AccountsPayableCurrent_04ea78ba-6338-432f-963c-5e5812c60ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0afbcae4-fb14-492d-9f79-a70198495a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0afbcae4-fb14-492d-9f79-a70198495a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9a7a1b03-87fe-4709-a777-d2cf5a40e7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8ff4fd74-da17-4ac9-a0b6-f061ef3ddd83" xlink:to="loc_us-gaap_LiabilitiesCurrent_9a7a1b03-87fe-4709-a777-d2cf5a40e7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_abb388ba-03db-4200-8fa5-9ed2315fb897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_LongTermNotesPayable_abb388ba-03db-4200-8fa5-9ed2315fb897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7d952414-6384-411a-94c8-9bcc63f83eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_Liabilities_7d952414-6384-411a-94c8-9bcc63f83eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fccb4905-5080-4829-a9f6-097ac6fb691b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fccb4905-5080-4829-a9f6-097ac6fb691b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_be8bf743-61c8-4f53-913c-f5de2183ed88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_TemporaryEquityAbstract_be8bf743-61c8-4f53-913c-f5de2183ed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_03e14b7c-4ed8-4dda-97ea-b0d72d43a5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_be8bf743-61c8-4f53-913c-f5de2183ed88" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_03e14b7c-4ed8-4dda-97ea-b0d72d43a5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c76236db-b7a5-45f4-86fe-2296378085d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_PreferredStockValue_c76236db-b7a5-45f4-86fe-2296378085d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90612e47-f665-40a5-b488-9f5b08ac0c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90612e47-f665-40a5-b488-9f5b08ac0c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_13fdd143-d005-44e0-95cf-519e32999822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_CommonStockValue_13fdd143-d005-44e0-95cf-519e32999822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1ddf5c45-0bdf-4496-8c6e-9f32f976ee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1ddf5c45-0bdf-4496-8c6e-9f32f976ee6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2552a6d4-ca72-4dbb-bdc0-cf02dd9a6ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2552a6d4-ca72-4dbb-bdc0-cf02dd9a6ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704bc713-20b9-4d17-b8ee-5a6079811795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17e29528-5856-45fb-944a-61097d100fb9" xlink:to="loc_us-gaap_StockholdersEquity_704bc713-20b9-4d17-b8ee-5a6079811795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_03ea8c57-3b32-455d-a4f4-5dc8342ca974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38520b00-0015-4e1b-acf5-5df465109d82" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_03ea8c57-3b32-455d-a4f4-5dc8342ca974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_236c14d5-4e56-4bbf-80b3-ad5b14430643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_306a602c-47ba-4c90-b106-29ae0e9327a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_236c14d5-4e56-4bbf-80b3-ad5b14430643" xlink:to="loc_us-gaap_StatementTable_306a602c-47ba-4c90-b106-29ae0e9327a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1871318e-8275-4845-a4a6-2a81e5904bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_306a602c-47ba-4c90-b106-29ae0e9327a3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1871318e-8275-4845-a4a6-2a81e5904bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1871318e-8275-4845-a4a6-2a81e5904bd2" xlink:to="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_e6a49801-1d6b-4dc7-97bf-1ee054a886a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_e6a49801-1d6b-4dc7-97bf-1ee054a886a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_0a08ebb0-57d8-4877-84f0-f07d67c48c99" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_0a08ebb0-57d8-4877-84f0-f07d67c48c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_e151825e-4de9-438c-9847-d95c865a92b2" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_708a3688-f17d-4d0b-9493-614e3ae94356" xlink:to="loc_cntx_RedeemableCommonStockMember_e151825e-4de9-438c-9847-d95c865a92b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_306a602c-47ba-4c90-b106-29ae0e9327a3" xlink:to="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_770241cf-8ad5-4682-a92b-0a039415a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_770241cf-8ad5-4682-a92b-0a039415a3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_996da938-51cd-4b6e-963c-b689ba6e147a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_996da938-51cd-4b6e-963c-b689ba6e147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_7ae9f244-04ef-443d-9c43-b4e23e3d38b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_7ae9f244-04ef-443d-9c43-b4e23e3d38b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_f2ba77b9-7ede-4875-93d8-5724d117a3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_f2ba77b9-7ede-4875-93d8-5724d117a3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_272c541f-9f7a-4a5e-9a06-714c07d9d3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_272c541f-9f7a-4a5e-9a06-714c07d9d3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1d056512-4f17-4235-9065-b4b73aef0711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1d056512-4f17-4235-9065-b4b73aef0711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c38e9429-e850-4d7f-876c-921842522a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c38e9429-e850-4d7f-876c-921842522a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8ce680c5-6bf4-42fb-afd5-45fb3fa4ae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8ce680c5-6bf4-42fb-afd5-45fb3fa4ae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14d8e069-c167-4ccd-86ba-c30dcd531050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14d8e069-c167-4ccd-86ba-c30dcd531050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6f2ed036-c913-4a24-a6bb-f28af395677c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_CommonStockSharesIssued_6f2ed036-c913-4a24-a6bb-f28af395677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_08cabd6b-15d8-48d9-9be8-d71a5a6a49f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e878864-f268-497f-8133-72c89171aa96" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_08cabd6b-15d8-48d9-9be8-d71a5a6a49f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a5ac41ad-6be6-4e02-bab1-44845f687972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a5ac41ad-6be6-4e02-bab1-44845f687972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9045e7cf-33c9-4bb5-8774-6ae8bfd657c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5ac41ad-6be6-4e02-bab1-44845f687972" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9045e7cf-33c9-4bb5-8774-6ae8bfd657c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d213d00b-68d6-4c63-9eab-34445d0b1739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5ac41ad-6be6-4e02-bab1-44845f687972" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d213d00b-68d6-4c63-9eab-34445d0b1739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a5e81ad3-285f-4b8c-9e86-21ed7cf416bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5ac41ad-6be6-4e02-bab1-44845f687972" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a5e81ad3-285f-4b8c-9e86-21ed7cf416bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_68b2e5f9-9143-4ef1-be04-2aa0ee1a20c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_OperatingIncomeLoss_68b2e5f9-9143-4ef1-be04-2aa0ee1a20c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e9151798-7bca-4538-ba22-07d3ed2c5b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_InterestExpense_e9151798-7bca-4538-ba22-07d3ed2c5b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_6c164aa6-9cd8-490c-af6d-db60950220d9" xlink:href="cntx-20211231.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_6c164aa6-9cd8-490c-af6d-db60950220d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1e7823be-4ddd-43d0-b37a-4b077c2aeca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1e7823be-4ddd-43d0-b37a-4b077c2aeca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf5960a8-9fe7-4c0e-8e73-7b38172723c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_NetIncomeLoss_cf5960a8-9fe7-4c0e-8e73-7b38172723c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7d69c349-d259-4e59-bf4e-049f7110efc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_EarningsPerShareBasic_7d69c349-d259-4e59-bf4e-049f7110efc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4fc04e0c-d997-49aa-8780-52bcc5c26fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4fc04e0c-d997-49aa-8780-52bcc5c26fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a199221d-f822-4620-8c12-501beb2c63b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a199221d-f822-4620-8c12-501beb2c63b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6b5edbc4-5eeb-461e-afd5-2a549fa65fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54c21d5c-70de-4242-924b-83f0e051d86a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6b5edbc4-5eeb-461e-afd5-2a549fa65fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1df34c4d-695a-4d13-bbc4-0a7dc4ae52b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1df34c4d-695a-4d13-bbc4-0a7dc4ae52b6" xlink:to="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3f7ff496-0b97-4103-a7f1-bbff6e1c576f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3f7ff496-0b97-4103-a7f1-bbff6e1c576f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f7ff496-0b97-4103-a7f1-bbff6e1c576f" xlink:to="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f1d8c35d-ff6c-4e4c-b867-8705d7833834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:to="loc_us-gaap_CommonStockMember_f1d8c35d-ff6c-4e4c-b867-8705d7833834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_977ca77b-d557-4646-8625-fd2d3eb9231c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_977ca77b-d557-4646-8625-fd2d3eb9231c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9389bce6-5440-4393-8fba-e15cb1c4164e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08cf173d-9200-4bd6-bef4-7d300a761fdc" xlink:to="loc_us-gaap_RetainedEarningsMember_9389bce6-5440-4393-8fba-e15cb1c4164e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36f62267-18fe-401c-9a9e-94a05047ac98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36f62267-18fe-401c-9a9e-94a05047ac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36f62267-18fe-401c-9a9e-94a05047ac98" xlink:to="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b8bb6d9b-2063-461b-857e-ec5b4749a2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b8bb6d9b-2063-461b-857e-ec5b4749a2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_32c5ae74-6b3b-4aba-b833-74012aa79342" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_32c5ae74-6b3b-4aba-b833-74012aa79342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_0d761723-622c-4477-a61f-bc63c83e6091" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c6094092-ddb6-42fc-bc66-970bbea52d2b" xlink:to="loc_cntx_RedeemableCommonStockMember_0d761723-622c-4477-a61f-bc63c83e6091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d9367962-2d2a-4ef1-8d64-d8d8e957f4e6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_c06fad26-0e38-44f5-9dd5-79391d3ee733" xlink:href="cntx-20211231.xsd#cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:to="loc_cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember_c06fad26-0e38-44f5-9dd5-79391d3ee733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_fa5fd474-d488-4876-acbb-6698e75f270f" xlink:href="cntx-20211231.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_fa5fd474-d488-4876-acbb-6698e75f270f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember_4bafb1dc-76de-4f2c-bb01-871ef7530ddc" xlink:href="cntx-20211231.xsd#cntx_IssuedForServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:to="loc_cntx_IssuedForServicesMember_4bafb1dc-76de-4f2c-bb01-871ef7530ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedInConnectionWithIPOMember_bac65053-34d9-4b51-9439-201f3e6f8fc6" xlink:href="cntx-20211231.xsd#cntx_IssuedInConnectionWithIPOMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b3de5e3-64b5-46de-9fb2-9a76e4a3a6bd" xlink:to="loc_cntx_IssuedInConnectionWithIPOMember_bac65053-34d9-4b51-9439-201f3e6f8fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b459c22f-91b2-4dbb-a09b-b1121d05725c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b459c22f-91b2-4dbb-a09b-b1121d05725c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_412bf247-a354-4a87-8f78-00ce97a3fdea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b459c22f-91b2-4dbb-a09b-b1121d05725c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_412bf247-a354-4a87-8f78-00ce97a3fdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_cb4d6363-222c-461d-b2b0-795adedf4d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_412bf247-a354-4a87-8f78-00ce97a3fdea" xlink:to="loc_us-gaap_IPOMember_cb4d6363-222c-461d-b2b0-795adedf4d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_644667a3-12e5-42c4-a29a-b351e5b65fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_412bf247-a354-4a87-8f78-00ce97a3fdea" xlink:to="loc_us-gaap_PrivatePlacementMember_644667a3-12e5-42c4-a29a-b351e5b65fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9f1962e8-7148-4dbc-831d-382b54712393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1f95953-daae-4bef-bfde-9780a5a43a63" xlink:to="loc_us-gaap_StatementLineItems_9f1962e8-7148-4dbc-831d-382b54712393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f1962e8-7148-4dbc-831d-382b54712393" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ae3e4854-378b-403d-91ce-fc3751aacac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ae3e4854-378b-403d-91ce-fc3751aacac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_038e7c3b-1a8d-4527-bae6-2a60a3964a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_038e7c3b-1a8d-4527-bae6-2a60a3964a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c71dd2d3-b8c1-4a8a-a0c1-7c6303f9b5a0" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c71dd2d3-b8c1-4a8a-a0c1-7c6303f9b5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_89c7fa30-9ca7-4dc6-b65a-5faa360d243e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_89c7fa30-9ca7-4dc6-b65a-5faa360d243e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f80020d0-4cad-4dfd-a1df-642a38e1772e" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f80020d0-4cad-4dfd-a1df-642a38e1772e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_22125d61-6578-4338-a8f0-e00df681a73d" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_22125d61-6578-4338-a8f0-e00df681a73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_392f9c02-1bb7-4de2-8a77-14857b403c35" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_392f9c02-1bb7-4de2-8a77-14857b403c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_9a979359-3067-4435-b6ba-717423ddf8e3" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_9a979359-3067-4435-b6ba-717423ddf8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_985c4d73-e093-4d01-a6e4-10d979f64dd1" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrants_985c4d73-e093-4d01-a6e4-10d979f64dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_12c44832-0936-4de4-9d7c-bc87fb895d81" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees_12c44832-0936-4de4-9d7c-bc87fb895d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_ec41780b-c455-44b6-882d-3dbd25271f2f" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_ec41780b-c455-44b6-882d-3dbd25271f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_b5640ce3-a350-40a0-b458-6cbc7b145680" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_b5640ce3-a350-40a0-b458-6cbc7b145680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_4a627ded-d3d7-4e9e-88b0-bd3cd602f947" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_4a627ded-d3d7-4e9e-88b0-bd3cd602f947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_54eb21b5-80b8-48fa-8baf-a85eb1465f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_54eb21b5-80b8-48fa-8baf-a85eb1465f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_752a4138-2aa9-4112-b3ec-0433e9cd0e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8844c981-0728-4cc1-b287-67220a92f7e7" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_752a4138-2aa9-4112-b3ec-0433e9cd0e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f1962e8-7148-4dbc-831d-382b54712393" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_050749ee-efc2-4da7-b27d-fc29be47ae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_SharesOutstanding_050749ee-efc2-4da7-b27d-fc29be47ae8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a034cdd1-d5c6-43f5-abf7-c36a266fa35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockholdersEquity_a034cdd1-d5c6-43f5-abf7-c36a266fa35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6fe1fc36-6fb3-4321-8ff2-653432d12c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6fe1fc36-6fb3-4321-8ff2-653432d12c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_c45bbfcb-25ff-4245-bfa6-3e124c790747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_c45bbfcb-25ff-4245-bfa6-3e124c790747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_0ff35573-9f9d-44bd-8d42-9091532aeab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_0ff35573-9f9d-44bd-8d42-9091532aeab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a24c246a-3aed-46b2-800a-bdd0e0682ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a24c246a-3aed-46b2-800a-bdd0e0682ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1c904d89-be01-41cb-b6d8-05dcbaeee79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1c904d89-be01-41cb-b6d8-05dcbaeee79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_007bd2fb-f566-42e6-97eb-1f4139d822f0" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares_007bd2fb-f566-42e6-97eb-1f4139d822f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_b9b95e1a-6ae2-44a5-9700-fca1bb35c291" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares_b9b95e1a-6ae2-44a5-9700-fca1bb35c291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_00970871-9e1a-4b4d-bdc9-9dbf28be3017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_00970871-9e1a-4b4d-bdc9-9dbf28be3017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52b5038b-adef-4529-9140-e355108fca60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52b5038b-adef-4529-9140-e355108fca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a9719bde-afa4-4519-a5b5-63f1db004589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a9719bde-afa4-4519-a5b5-63f1db004589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a42b4759-3f84-4c5b-bfe7-1a6bb55c6af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_NetIncomeLoss_a42b4759-3f84-4c5b-bfe7-1a6bb55c6af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_daf5e8dc-5f02-4b42-81d2-572b19c54676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_SharesOutstanding_daf5e8dc-5f02-4b42-81d2-572b19c54676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e8d48ef8-b800-4ad7-b430-19f7eb9e72ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80831df6-a51b-4c52-bb4c-c8dddfb6cb73" xlink:to="loc_us-gaap_StockholdersEquity_e8d48ef8-b800-4ad7-b430-19f7eb9e72ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ed0ec3a1-740a-4168-b423-2e800124fcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_64e61854-4321-440f-97d5-12b9331c256d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ed0ec3a1-740a-4168-b423-2e800124fcd8" xlink:to="loc_us-gaap_StatementTable_64e61854-4321-440f-97d5-12b9331c256d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cd17359f-ecbf-4456-9c54-22c62ff08268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64e61854-4321-440f-97d5-12b9331c256d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cd17359f-ecbf-4456-9c54-22c62ff08268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8142bd74-4aec-4b2e-8cbb-adf045d1ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd17359f-ecbf-4456-9c54-22c62ff08268" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8142bd74-4aec-4b2e-8cbb-adf045d1ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9ea94d07-d84f-47dc-bce7-5bb125d83556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8142bd74-4aec-4b2e-8cbb-adf045d1ccd2" xlink:to="loc_us-gaap_IPOMember_9ea94d07-d84f-47dc-bce7-5bb125d83556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f7e545af-af81-4cf0-9ee9-b425ee496a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8142bd74-4aec-4b2e-8cbb-adf045d1ccd2" xlink:to="loc_us-gaap_PrivatePlacementMember_f7e545af-af81-4cf0-9ee9-b425ee496a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_586ddfaf-a800-4201-b8b9-769c582d1c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64e61854-4321-440f-97d5-12b9331c256d" xlink:to="loc_us-gaap_StatementLineItems_586ddfaf-a800-4201-b8b9-769c582d1c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityOfferingCosts_8bfa8eca-11ee-4903-97b2-d586b6e82197" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityOfferingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_586ddfaf-a800-4201-b8b9-769c582d1c3e" xlink:to="loc_cntx_TemporaryEquityOfferingCosts_8bfa8eca-11ee-4903-97b2-d586b6e82197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodIssuanceCosts_0de86a83-f395-40ac-b030-2abef1e83f5f" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_586ddfaf-a800-4201-b8b9-769c582d1c3e" xlink:to="loc_cntx_StockIssuedDuringPeriodIssuanceCosts_0de86a83-f395-40ac-b030-2abef1e83f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_53a9b045-694e-4c5b-b560-3dc7c09fb42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53a9b045-694e-4c5b-b560-3dc7c09fb42b" xlink:to="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_15b25ea8-e96c-4779-95b3-0b959ecae06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:to="loc_us-gaap_StatementClassOfStockAxis_15b25ea8-e96c-4779-95b3-0b959ecae06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_83d43e72-8bef-4f85-8521-089c238d6ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15b25ea8-e96c-4779-95b3-0b959ecae06e" xlink:to="loc_us-gaap_ClassOfStockDomain_83d43e72-8bef-4f85-8521-089c238d6ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_10274fe1-3dbb-4ba9-a24b-d99ecb5cd1e8" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_83d43e72-8bef-4f85-8521-089c238d6ca9" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_10274fe1-3dbb-4ba9-a24b-d99ecb5cd1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_075235a9-ad0d-4274-b8d1-691342f7e02e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_83d43e72-8bef-4f85-8521-089c238d6ca9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_075235a9-ad0d-4274-b8d1-691342f7e02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b9203535-b465-4321-9690-6c931cf60df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b9203535-b465-4321-9690-6c931cf60df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b9203535-b465-4321-9690-6c931cf60df7" xlink:to="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DemandNotesToConvertiblePromissoryNotesMember_b93661ad-54ab-4e6e-ad56-840a9e72ed8d" xlink:href="cntx-20211231.xsd#cntx_DemandNotesToConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:to="loc_cntx_DemandNotesToConvertiblePromissoryNotesMember_b93661ad-54ab-4e6e-ad56-840a9e72ed8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_BridgeNotesToSeriesAPreferredStockMember_6ddc2697-b48a-48b6-8e06-7f6b1bdc9749" xlink:href="cntx-20211231.xsd#cntx_BridgeNotesToSeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:to="loc_cntx_BridgeNotesToSeriesAPreferredStockMember_6ddc2697-b48a-48b6-8e06-7f6b1bdc9749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember_2942fe89-cf7d-4634-b192-1b7d4ba7fea2" xlink:href="cntx-20211231.xsd#cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_151629e7-714b-4080-98b2-d519351b8c67" xlink:to="loc_cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember_2942fe89-cf7d-4634-b192-1b7d4ba7fea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71f9d52c-b04b-4384-9752-b697c8d96106" xlink:to="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f48bcccb-1aec-428a-84c4-5f1d7c3bffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:to="loc_us-gaap_NetIncomeLoss_f48bcccb-1aec-428a-84c4-5f1d7c3bffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_d86f6f72-0b7f-4dc0-9ccb-adfae4d76ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_d86f6f72-0b7f-4dc0-9ccb-adfae4d76ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a54333eb-a76e-4b26-a6ef-1fc0aa8da9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a54333eb-a76e-4b26-a6ef-1fc0aa8da9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_15bfbc8c-4160-420b-b1e0-7393ab7457d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_ShareBasedCompensation_15bfbc8c-4160-420b-b1e0-7393ab7457d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_dbe04fc4-0ece-46ae-9e42-8f6d8d489463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_PaidInKindInterest_dbe04fc4-0ece-46ae-9e42-8f6d8d489463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueAdjustmentOnConvertibleDebt_0c83d0fb-fc08-4006-97e8-24440e8332e7" xlink:href="cntx-20211231.xsd#cntx_FairValueAdjustmentOnConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_cntx_FairValueAdjustmentOnConvertibleDebt_0c83d0fb-fc08-4006-97e8-24440e8332e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d81432f-4004-4b10-a2ad-f1a1cf6ee176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d81432f-4004-4b10-a2ad-f1a1cf6ee176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92271cf4-e569-4225-b730-c7473543554b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86e629f6-5f3c-406a-aa99-63a78305cab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86e629f6-5f3c-406a-aa99-63a78305cab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_be22c1d8-98df-4300-93b8-e4f03920d1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_be22c1d8-98df-4300-93b8-e4f03920d1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6b900e30-9e59-4509-947b-8073bb118491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a466cb3a-d522-492c-9b42-dde4a8789a1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6b900e30-9e59-4509-947b-8073bb118491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287b1153-a0c0-4473-9cdd-53c0c0d563fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ecb26a5-845f-4ef3-be49-42a44632bc1b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_287b1153-a0c0-4473-9cdd-53c0c0d563fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09b3813a-0920-4f0a-90e5-516438fcb755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09b3813a-0920-4f0a-90e5-516438fcb755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e63e2da7-5c2e-4940-baf9-f8ba4c05b7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09b3813a-0920-4f0a-90e5-516438fcb755" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_e63e2da7-5c2e-4940-baf9-f8ba4c05b7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9407e-ba0c-41a3-aa04-0ff829d557df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09b3813a-0920-4f0a-90e5-516438fcb755" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07a9407e-ba0c-41a3-aa04-0ff829d557df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_21699f51-2264-4395-a602-ca2941b30cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_21699f51-2264-4395-a602-ca2941b30cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_68caaf05-ca3d-4f20-920e-c677a116a690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_68caaf05-ca3d-4f20-920e-c677a116a690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_3c75dd81-d84e-4a50-ab39-6293765d0c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_3c75dd81-d84e-4a50-ab39-6293765d0c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_108576d0-9a1d-4cbc-ba6a-318e9720e8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_108576d0-9a1d-4cbc-ba6a-318e9720e8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d9bd1d4-d2e8-4e79-9562-3cb30b3c0015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d9bd1d4-d2e8-4e79-9562-3cb30b3c0015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16d01cfd-b497-433b-93f4-2147f675bcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2bf19c8-0799-43fe-8909-cad4a00ffbff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16d01cfd-b497-433b-93f4-2147f675bcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de0d46d5-ed51-4c1e-bf43-36bd65b9b0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de0d46d5-ed51-4c1e-bf43-36bd65b9b0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e9906dd-da3f-43d5-8372-9eb42c83ed78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e9906dd-da3f-43d5-8372-9eb42c83ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2434418f-8cb7-4c1f-adac-03da37472e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2434418f-8cb7-4c1f-adac-03da37472e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c66b3e7c-b6d3-482b-9bc5-3053ba6794b0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7bba280a-2cd7-402d-9c7d-6dbaf1c33e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7bba280a-2cd7-402d-9c7d-6dbaf1c33e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued_586931ef-812d-4c08-937b-7cb9ad820d7d" xlink:href="cntx-20211231.xsd#cntx_WarrantsIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_cntx_WarrantsIssued_586931ef-812d-4c08-937b-7cb9ad820d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_73482cd4-e701-4442-a7fa-f1b89eab00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_us-gaap_StockIssued1_73482cd4-e701-4442-a7fa-f1b89eab00dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid_666320e2-d9b5-4ba9-b47e-200390a718af" xlink:href="cntx-20211231.xsd#cntx_DeferredOfferingCostIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_cntx_DeferredOfferingCostIncurredButNotYetPaid_666320e2-d9b5-4ba9-b47e-200390a718af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_c2f42eee-fa07-4af2-92d6-376b5661bc59" xlink:href="cntx-20211231.xsd#cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue_c2f42eee-fa07-4af2-92d6-376b5661bc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_1b7accaa-b0ea-4616-9e20-4475b6a34d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24282ecf-4f48-4232-8a79-1c107c2d3cf1" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_1b7accaa-b0ea-4616-9e20-4475b6a34d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/NatureofBusiness" xlink:type="simple" xlink:href="cntx-20211231.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c45b5af8-d936-4579-a97e-7a1658d9f324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_73bcb995-3e06-4aa9-9547-ad2e8f6ca011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c45b5af8-d936-4579-a97e-7a1658d9f324" xlink:to="loc_us-gaap_NatureOfOperations_73bcb995-3e06-4aa9-9547-ad2e8f6ca011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_731ac068-7c3d-480a-a94c-19d4298113cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_d8d62ab2-88dc-413a-8682-9ed79d0fa142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_731ac068-7c3d-480a-a94c-19d4298113cd" xlink:to="loc_us-gaap_MinorityInterestTable_d8d62ab2-88dc-413a-8682-9ed79d0fa142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_63a42301-b471-4a9f-bee5-8bb8058d5f0f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d8d62ab2-88dc-413a-8682-9ed79d0fa142" xlink:to="loc_srt_OwnershipAxis_63a42301-b471-4a9f-bee5-8bb8058d5f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4b9e2adc-30d7-41a1-bdd8-3eb578e5b212" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_63a42301-b471-4a9f-bee5-8bb8058d5f0f" xlink:to="loc_srt_OwnershipDomain_4b9e2adc-30d7-41a1-bdd8-3eb578e5b212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ContextTherapeuticsLLCMember_320e2fb0-c2d6-4cf1-8e95-a817a34e4bfd" xlink:href="cntx-20211231.xsd#cntx_ContextTherapeuticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_4b9e2adc-30d7-41a1-bdd8-3eb578e5b212" xlink:to="loc_cntx_ContextTherapeuticsLLCMember_320e2fb0-c2d6-4cf1-8e95-a817a34e4bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_dd511827-153c-4c7c-9f24-62574c6eb5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d8d62ab2-88dc-413a-8682-9ed79d0fa142" xlink:to="loc_us-gaap_MinorityInterestLineItems_dd511827-153c-4c7c-9f24-62574c6eb5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6bcf3bd6-b5ab-46ef-87eb-ec11e1ec8fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_dd511827-153c-4c7c-9f24-62574c6eb5bb" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6bcf3bd6-b5ab-46ef-87eb-ec11e1ec8fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidity" xlink:type="simple" xlink:href="cntx-20211231.xsd#RisksandLiquidity"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/RisksandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract_84440b46-58cb-4f6c-ba65-abd9ae5a709a" xlink:href="cntx-20211231.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityTextBlock_f3103ec5-3e4c-47e3-8eff-4ff95ef42c24" xlink:href="cntx-20211231.xsd#cntx_RisksAndLiquidityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_RisksAndLiquidityAbstract_84440b46-58cb-4f6c-ba65-abd9ae5a709a" xlink:to="loc_cntx_RisksAndLiquidityTextBlock_f3103ec5-3e4c-47e3-8eff-4ff95ef42c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#RisksandLiquidityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract_1b683121-cfca-4d2f-b572-1148e0d46a7c" xlink:href="cntx-20211231.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_RisksAndLiquidityAbstract_1b683121-cfca-4d2f-b572-1148e0d46a7c" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f1eab37d-76e7-4537-ad53-8a89e7d802cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f1eab37d-76e7-4537-ad53-8a89e7d802cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e080ab74-065a-47b5-b281-8a785bf264a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1eab37d-76e7-4537-ad53-8a89e7d802cd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e080ab74-065a-47b5-b281-8a785bf264a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_f037d2db-9948-4bc2-959f-7c2b39b14e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e080ab74-065a-47b5-b281-8a785bf264a5" xlink:to="loc_us-gaap_IPOMember_f037d2db-9948-4bc2-959f-7c2b39b14e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_394cca2e-372b-492b-a0f1-6712f31e1940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e080ab74-065a-47b5-b281-8a785bf264a5" xlink:to="loc_us-gaap_PrivatePlacementMember_394cca2e-372b-492b-a0f1-6712f31e1940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_41be9881-9513-4d79-a9a8-508c1ff84c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_41be9881-9513-4d79-a9a8-508c1ff84c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_41be9881-9513-4d79-a9a8-508c1ff84c84" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PlacementAgentsWarrantsMember_8a1bcecd-8b13-4b19-9056-11bcb798156f" xlink:href="cntx-20211231.xsd#cntx_PlacementAgentsWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:to="loc_cntx_PlacementAgentsWarrantsMember_8a1bcecd-8b13-4b19-9056-11bcb798156f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementWarrantsMember_6199c041-b08b-4e5d-8011-0cb9434e5c3c" xlink:href="cntx-20211231.xsd#cntx_December2021PrivatePlacementWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:to="loc_cntx_December2021PrivatePlacementWarrantsMember_6199c041-b08b-4e5d-8011-0cb9434e5c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_d23763bd-d18e-407a-a2ab-36b6393e633d" xlink:href="cntx-20211231.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bf503c0a-7db7-4234-af00-45a67d41d654" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_d23763bd-d18e-407a-a2ab-36b6393e633d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_864b6916-a393-4f8a-b1a8-66fc53df6c9b" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_db2be319-a44e-478b-89df-6acd73fbc38c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_db2be319-a44e-478b-89df-6acd73fbc38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_31cd77a0-4ab4-4b31-967d-9dda9907a12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_31cd77a0-4ab4-4b31-967d-9dda9907a12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26690dde-f64e-4510-a74b-18d9f06aac28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26690dde-f64e-4510-a74b-18d9f06aac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_845a7795-0dfe-4964-a74f-51349a6a4d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_845a7795-0dfe-4964-a74f-51349a6a4d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ac0eac37-b3f7-4652-93a8-93714cc747a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ac0eac37-b3f7-4652-93a8-93714cc747a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c767667d-ae61-4034-874d-6b2ede709c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c767667d-ae61-4034-874d-6b2ede709c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4a1f238a-a0e1-4aa6-a8bc-d24cbf75a5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4a1f238a-a0e1-4aa6-a8bc-d24cbf75a5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b1812b8-3000-45ad-9dc8-c309808f8276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b1812b8-3000-45ad-9dc8-c309808f8276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2e6c9481-920c-4cd2-8cce-34bdc13ba582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2e6c9481-920c-4cd2-8cce-34bdc13ba582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7366d3d3-130f-4445-b048-20014eaa34b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7366d3d3-130f-4445-b048-20014eaa34b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_5666629f-d4b2-4339-965d-8908bbca9763" xlink:href="cntx-20211231.xsd#cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_455cab85-aaf5-47b5-8541-6ca73ea18998" xlink:to="loc_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants_5666629f-d4b2-4339-965d-8908bbca9763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6db89efe-8f2f-4ef1-9588-e19d96dfd07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c566b929-f62b-4d57-b0d9-0299012c0dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6db89efe-8f2f-4ef1-9588-e19d96dfd07d" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c566b929-f62b-4d57-b0d9-0299012c0dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7621ca3c-f83a-4d5b-a465-78fa3dc7dcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7621ca3c-f83a-4d5b-a465-78fa3dc7dcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f1aee197-9654-48c5-98e2-20aa60f43b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f1aee197-9654-48c5-98e2-20aa60f43b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2b64ed23-523e-46d6-bb28-d02dca6d517c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2b64ed23-523e-46d6-bb28-d02dca6d517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d5fe1274-6fe3-46a1-aa33-881fdd24b0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_UseOfEstimates_d5fe1274-6fe3-46a1-aa33-881fdd24b0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_32edc06a-fd37-439f-a1cd-96a5d6b636f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_32edc06a-fd37-439f-a1cd-96a5d6b636f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6c107517-cf33-4ef6-a300-e22728335f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6c107517-cf33-4ef6-a300-e22728335f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8808a84f-5c83-44e3-a9e8-6564ed5d048e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8808a84f-5c83-44e3-a9e8-6564ed5d048e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_84e32147-c020-4fb4-bdcf-b2a7486c6f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_84e32147-c020-4fb4-bdcf-b2a7486c6f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_ce3d66f6-daee-431e-8e8b-d36ea9aa23ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_ce3d66f6-daee-431e-8e8b-d36ea9aa23ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityPolicyPolicyTextBlock_843025a2-50d7-498b-b73c-80bd68362842" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_cntx_TemporaryEquityPolicyPolicyTextBlock_843025a2-50d7-498b-b73c-80bd68362842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_0080f8c6-36b7-43f2-bcdd-2dc995875d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_0080f8c6-36b7-43f2-bcdd-2dc995875d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_599f7da9-e0ad-4bf2-bdfe-8d6625e8c217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_599f7da9-e0ad-4bf2-bdfe-8d6625e8c217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PatentCostsPolicyPolicyTextBlock_b474a226-a7f9-4516-95ac-eafc7b94af77" xlink:href="cntx-20211231.xsd#cntx_PatentCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_cntx_PatentCostsPolicyPolicyTextBlock_b474a226-a7f9-4516-95ac-eafc7b94af77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8c6b7d16-8186-4268-b8fe-4e79f894f5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8c6b7d16-8186-4268-b8fe-4e79f894f5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4a65645b-f64d-4d42-aca9-e5bbf11a9e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4a65645b-f64d-4d42-aca9-e5bbf11a9e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b71ecfed-6f37-45b6-b3b1-053327a61bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b71ecfed-6f37-45b6-b3b1-053327a61bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2344e218-3d5b-4850-ae6e-887100ace745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50663f9a-9eca-4e15-b553-c02c5c91be1c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2344e218-3d5b-4850-ae6e-887100ace745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_74b807d4-79db-4b00-9a96-8f425c6f83f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8bc2ed0a-fcf3-4163-9d68-a9307fd00c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74b807d4-79db-4b00-9a96-8f425c6f83f8" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8bc2ed0a-fcf3-4163-9d68-a9307fd00c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f13998bf-e918-4a1c-98cc-ebec57b7caa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74b807d4-79db-4b00-9a96-8f425c6f83f8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f13998bf-e918-4a1c-98cc-ebec57b7caa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9faa553a-a820-4a6c-bc63-0e89982c246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74b807d4-79db-4b00-9a96-8f425c6f83f8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9faa553a-a820-4a6c-bc63-0e89982c246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9f8b600a-adbe-451a-b36c-38f09bf735fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7f4db1f8-8da5-4881-b3d5-3b8fa8435a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f8b600a-adbe-451a-b36c-38f09bf735fb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7f4db1f8-8da5-4881-b3d5-3b8fa8435a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_f3658590-6d84-4d8a-a3f2-feb4bffbe29e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f8b600a-adbe-451a-b36c-38f09bf735fb" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_f3658590-6d84-4d8a-a3f2-feb4bffbe29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_da2f1e32-7013-4978-86e6-1811a1b487ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f8b600a-adbe-451a-b36c-38f09bf735fb" xlink:to="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_da2f1e32-7013-4978-86e6-1811a1b487ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_abece0d0-0bba-4bf5-9639-41dc7a51a069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f8b600a-adbe-451a-b36c-38f09bf735fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_abece0d0-0bba-4bf5-9639-41dc7a51a069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b25f008f-5e56-4490-b729-5e7f1d07ab3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f8b600a-adbe-451a-b36c-38f09bf735fb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b25f008f-5e56-4490-b729-5e7f1d07ab3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_fe77f931-8ed2-4510-8e31-c737c83e44d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9f8b600a-adbe-451a-b36c-38f09bf735fb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_fe77f931-8ed2-4510-8e31-c737c83e44d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39a64a7a-2aba-4fe2-b7bd-d8602ec367eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1f8f80ca-793b-4030-83fd-b6b39be93673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39a64a7a-2aba-4fe2-b7bd-d8602ec367eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1f8f80ca-793b-4030-83fd-b6b39be93673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e0326abc-e2d6-4ba0-a847-b440543a71c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1f8f80ca-793b-4030-83fd-b6b39be93673" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e0326abc-e2d6-4ba0-a847-b440543a71c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_e6813709-0aec-4630-9636-5c073c88886a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1f8f80ca-793b-4030-83fd-b6b39be93673" xlink:to="loc_us-gaap_RestrictedCash_e6813709-0aec-4630-9636-5c073c88886a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33f0b7b5-496b-411b-af41-720dc83778eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1f8f80ca-793b-4030-83fd-b6b39be93673" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33f0b7b5-496b-411b-af41-720dc83778eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_11e99783-5be2-4009-9d3e-70a980b18a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c20c6b51-83c2-41cd-8f4f-db84681f8a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11e99783-5be2-4009-9d3e-70a980b18a88" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c20c6b51-83c2-41cd-8f4f-db84681f8a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c20c6b51-83c2-41cd-8f4f-db84681f8a16" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b30c21e-01dd-4d9d-844c-8d00dcb18a1d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5dd03723-2704-427a-a66f-f2ccc501a96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5dd03723-2704-427a-a66f-f2ccc501a96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8f6bdb0c-0bf4-48b9-b365-6781b5069d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8f6bdb0c-0bf4-48b9-b365-6781b5069d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0d7a45a7-23f6-4634-a097-e223dccee8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf73a6a7-a4eb-45b1-a68e-5db6fec3c2ad" xlink:to="loc_us-gaap_WarrantMember_0d7a45a7-23f6-4634-a097-e223dccee8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64b75ebf-f939-40a4-858d-23a95c19e6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c20c6b51-83c2-41cd-8f4f-db84681f8a16" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64b75ebf-f939-40a4-858d-23a95c19e6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3519d87a-a261-48a6-a22f-92739cee92f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_64b75ebf-f939-40a4-858d-23a95c19e6a7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3519d87a-a261-48a6-a22f-92739cee92f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_83522223-5199-4850-bf8f-1d2a5d124ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_7e6266d3-43e1-4399-9e91-c4ac2deeeb05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83522223-5199-4850-bf8f-1d2a5d124ab0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_7e6266d3-43e1-4399-9e91-c4ac2deeeb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ffd2aabf-758a-4edd-9f27-7c6cc835020f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7e6266d3-43e1-4399-9e91-c4ac2deeeb05" xlink:to="loc_us-gaap_NetIncomeLoss_ffd2aabf-758a-4edd-9f27-7c6cc835020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_0eb9fe9a-0313-429f-bd42-417ecf8b785a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7e6266d3-43e1-4399-9e91-c4ac2deeeb05" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_0eb9fe9a-0313-429f-bd42-417ecf8b785a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1a7158e9-101c-4933-9f63-a127ca001607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7e6266d3-43e1-4399-9e91-c4ac2deeeb05" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1a7158e9-101c-4933-9f63-a127ca001607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_195d385f-9143-4e0e-903a-05429f5072f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7e6266d3-43e1-4399-9e91-c4ac2deeeb05" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_195d385f-9143-4e0e-903a-05429f5072f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a0425a34-6756-4a66-9670-a545d0c99b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7e6266d3-43e1-4399-9e91-c4ac2deeeb05" xlink:to="loc_us-gaap_EarningsPerShareBasic_a0425a34-6756-4a66-9670-a545d0c99b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83522223-5199-4850-bf8f-1d2a5d124ab0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e767e63-739e-4b81-9404-ed144cca2a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:to="loc_us-gaap_NetIncomeLoss_6e767e63-739e-4b81-9404-ed144cca2a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_08c47ae6-8f0a-411c-96a0-75c715feccea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_08c47ae6-8f0a-411c-96a0-75c715feccea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_b48b6aee-cce6-44a4-b76d-ab7018eb46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_b48b6aee-cce6-44a4-b76d-ab7018eb46d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7e70bf33-aade-454b-8980-3a6ae0fec545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7e70bf33-aade-454b-8980-3a6ae0fec545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f446e61-e449-4d74-a3d5-815f97104d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f446e61-e449-4d74-a3d5-815f97104d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b37f538-00a2-4037-92ae-64b8f88e5adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b37f538-00a2-4037-92ae-64b8f88e5adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44f240ce-1314-4c0e-9512-08d1c443cd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44f240ce-1314-4c0e-9512-08d1c443cd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fbc03cf4-b554-46d2-9fe5-68975e924793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_61b337ca-613c-4cef-9e6a-5f384603e263" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fbc03cf4-b554-46d2-9fe5-68975e924793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cntx-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_110aaffb-96e8-45f3-b063-c40a540e8acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f1816514-7189-423e-9721-4dcee15a1b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_110aaffb-96e8-45f3-b063-c40a540e8acc" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f1816514-7189-423e-9721-4dcee15a1b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cntx-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e17f7679-44d6-4a31-86bd-ba87e08b0680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ac8e64e8-4a75-40fc-b11d-6264353320dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e17f7679-44d6-4a31-86bd-ba87e08b0680" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ac8e64e8-4a75-40fc-b11d-6264353320dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_27c8bac0-0ce7-4feb-a2d4-e33d0ede9a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e17f7679-44d6-4a31-86bd-ba87e08b0680" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_27c8bac0-0ce7-4feb-a2d4-e33d0ede9a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a991c461-1890-43c0-8ce7-c2475b634d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a991c461-1890-43c0-8ce7-c2475b634d01" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e21b8b-cb16-4647-833d-e2b618115086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e21b8b-cb16-4647-833d-e2b618115086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_809b3cbe-a1f0-4f88-b595-ec5388ed89ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e21b8b-cb16-4647-833d-e2b618115086" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_809b3cbe-a1f0-4f88-b595-ec5388ed89ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a7e5ba0f-293a-4a7f-b7b4-60035afd4ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_809b3cbe-a1f0-4f88-b595-ec5388ed89ab" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a7e5ba0f-293a-4a7f-b7b4-60035afd4ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a22ec442-dacc-432d-b020-43a3b7bdd24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a22ec442-dacc-432d-b020-43a3b7bdd24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a10061b-a9f8-4ed6-b468-eecf67131e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a22ec442-dacc-432d-b020-43a3b7bdd24e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a10061b-a9f8-4ed6-b468-eecf67131e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_541e3a6c-7065-47b8-a119-4314b938f424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a10061b-a9f8-4ed6-b468-eecf67131e3f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_541e3a6c-7065-47b8-a119-4314b938f424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbe6b072-49d9-4885-b202-579f3d944c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbe6b072-49d9-4885-b202-579f3d944c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cbe6b072-49d9-4885-b202-579f3d944c5c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ddab8457-4ae5-416a-8dca-71d5d1dbf7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ddab8457-4ae5-416a-8dca-71d5d1dbf7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_73a46e73-c356-418f-a977-990ec5a33ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_73a46e73-c356-418f-a977-990ec5a33ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_75ea90dd-be70-473e-985b-f6eb6a44c46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b507aa03-37de-474c-ba22-af008f2b6559" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_75ea90dd-be70-473e-985b-f6eb6a44c46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ee40aa4-feaf-4ebf-88c5-fa871f70dcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6174eab-e68f-4111-8e62-11bc668cd7ce" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ee40aa4-feaf-4ebf-88c5-fa871f70dcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0f04a-c9d2-4aae-9253-7bbc87905193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ee40aa4-feaf-4ebf-88c5-fa871f70dcd8" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0f04a-c9d2-4aae-9253-7bbc87905193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f945d58-dd6f-4ea9-ba58-f42fd2d121af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0f04a-c9d2-4aae-9253-7bbc87905193" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f945d58-dd6f-4ea9-ba58-f42fd2d121af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b9d77e01-1f7c-4df3-8334-300e38bf3e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ef0f04a-c9d2-4aae-9253-7bbc87905193" xlink:to="loc_us-gaap_RestrictedCash_b9d77e01-1f7c-4df3-8334-300e38bf3e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_824e0b40-7b2b-480d-b172-2aef5706a014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ee40aa4-feaf-4ebf-88c5-fa871f70dcd8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_824e0b40-7b2b-480d-b172-2aef5706a014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_5b914ffd-56bf-4938-a2a6-b6f06f834368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_824e0b40-7b2b-480d-b172-2aef5706a014" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_5b914ffd-56bf-4938-a2a6-b6f06f834368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ee36b1f-ea2e-42c7-ab10-985f2ae93b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ee36b1f-ea2e-42c7-ab10-985f2ae93b97" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_135c26e6-e75e-43cb-aeaa-6c87227c7a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_135c26e6-e75e-43cb-aeaa-6c87227c7a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f5f1090e-5d8f-46f2-9988-2ae19070ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_135c26e6-e75e-43cb-aeaa-6c87227c7a11" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f5f1090e-5d8f-46f2-9988-2ae19070ca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_bfcf2d88-7fb3-4f10-aaec-511e26d0b401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f5f1090e-5d8f-46f2-9988-2ae19070ca01" xlink:to="loc_us-gaap_ConvertibleDebtMember_bfcf2d88-7fb3-4f10-aaec-511e26d0b401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_10aefe2d-2bde-44c0-a104-b8aa505721b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:to="loc_us-gaap_DebtInstrumentAxis_10aefe2d-2bde-44c0-a104-b8aa505721b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_10aefe2d-2bde-44c0-a104-b8aa505721b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertibleBridgeNotesMember_c1181662-2fca-4130-b192-ae6cfa68cda1" xlink:href="cntx-20211231.xsd#cntx_ConvertibleBridgeNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:to="loc_cntx_ConvertibleBridgeNotesMember_c1181662-2fca-4130-b192-ae6cfa68cda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_JuniorConvertibleNotesMember_03b80dc5-af19-47d6-a43e-ee7fc3c96da8" xlink:href="cntx-20211231.xsd#cntx_JuniorConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:to="loc_cntx_JuniorConvertibleNotesMember_03b80dc5-af19-47d6-a43e-ee7fc3c96da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_BridgeNotesToSeriesAPreferredStockMember_f9c4de15-3921-4a12-a426-e93e2236283c" xlink:href="cntx-20211231.xsd#cntx_BridgeNotesToSeriesAPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_21ef4af9-c673-4070-905e-65f0f2d81c5a" xlink:to="loc_cntx_BridgeNotesToSeriesAPreferredStockMember_f9c4de15-3921-4a12-a426-e93e2236283c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f7edd2ce-1bf6-442b-88b2-480a5ec603d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_62071bc4-d8c6-45b2-9d7f-a686b1b8a381" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f7edd2ce-1bf6-442b-88b2-480a5ec603d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f7edd2ce-1bf6-442b-88b2-480a5ec603d9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2fab4fc8-9578-4137-98d4-65a579367ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2fab4fc8-9578-4137-98d4-65a579367ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_96f3a4a4-fae9-4c31-8e91-2d8c14b585d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_96f3a4a4-fae9-4c31-8e91-2d8c14b585d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d31fe260-f641-4bf6-b2f2-db90097690df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d31fe260-f641-4bf6-b2f2-db90097690df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_2404ff25-89be-4fe7-a435-8f66f73f56c2" xlink:href="cntx-20211231.xsd#cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_2404ff25-89be-4fe7-a435-8f66f73f56c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_01a16223-8632-49c0-afed-b8e1a140e96e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_01a16223-8632-49c0-afed-b8e1a140e96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_904c2fe1-51af-4706-ad90-491a8165164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6d33a3d-a6c4-45cf-830b-ef2aa224e4fa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_904c2fe1-51af-4706-ad90-491a8165164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="cntx-20211231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_dae815a4-30c5-4609-a921-5f68fa6eabdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_454e2f8a-cc21-493e-b69c-1ea453e290b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_dae815a4-30c5-4609-a921-5f68fa6eabdb" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_454e2f8a-cc21-493e-b69c-1ea453e290b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="cntx-20211231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_fb4f869d-2326-4143-809a-782a850157b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6b462a1b-2d51-4ab7-a9dc-257b1164f2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_fb4f869d-2326-4143-809a-782a850157b0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6b462a1b-2d51-4ab7-a9dc-257b1164f2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae7bcf77-111f-43b4-a4e1-d184236c8be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f8f57da-391c-468a-99e4-eba9bf3fe286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae7bcf77-111f-43b4-a4e1-d184236c8be2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f8f57da-391c-468a-99e4-eba9bf3fe286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ClinicalTrialLiabilitiesCurrent_3f7e022e-b0e9-41af-8236-b3dda9cbcb60" xlink:href="cntx-20211231.xsd#cntx_ClinicalTrialLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae7bcf77-111f-43b4-a4e1-d184236c8be2" xlink:to="loc_cntx_ClinicalTrialLiabilitiesCurrent_3f7e022e-b0e9-41af-8236-b3dda9cbcb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ManufacturingDevelopmentLiabilitiesCurrent_06e27fdb-a7b8-4fb7-92a6-ce1ba5322756" xlink:href="cntx-20211231.xsd#cntx_ManufacturingDevelopmentLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae7bcf77-111f-43b4-a4e1-d184236c8be2" xlink:to="loc_cntx_ManufacturingDevelopmentLiabilitiesCurrent_06e27fdb-a7b8-4fb7-92a6-ce1ba5322756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9f259480-4dcd-4232-bf76-72db27762dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae7bcf77-111f-43b4-a4e1-d184236c8be2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9f259480-4dcd-4232-bf76-72db27762dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a9a21176-818f-4a6b-a9b4-9d2e7306f034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae7bcf77-111f-43b4-a4e1-d184236c8be2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a9a21176-818f-4a6b-a9b4-9d2e7306f034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_72505422-e7dc-43ba-a257-89e0f2b0b42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ae7bcf77-111f-43b4-a4e1-d184236c8be2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_72505422-e7dc-43ba-a257-89e0f2b0b42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotes" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePromissoryNotes"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b2675e6b-b814-40f4-a26f-cb3b6044c191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cfc52d12-5d3e-4b89-a48a-dc056dbdf2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b2675e6b-b814-40f4-a26f-cb3b6044c191" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cfc52d12-5d3e-4b89-a48a-dc056dbdf2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePromissoryNotesDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_968bf2e0-820a-48b7-919d-476ac90d4c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_968bf2e0-820a-48b7-919d-476ac90d4c7f" xlink:to="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3c142a07-cca7-4f8b-b55c-08ad852b9a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3c142a07-cca7-4f8b-b55c-08ad852b9a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80351ddd-c9a8-4396-961b-0ca9f585bb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3c142a07-cca7-4f8b-b55c-08ad852b9a9a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80351ddd-c9a8-4396-961b-0ca9f585bb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3265ced6-bd0d-420e-84be-d9baad779222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80351ddd-c9a8-4396-961b-0ca9f585bb79" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3265ced6-bd0d-420e-84be-d9baad779222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PaymentProtectionProgramLoanMember_a931543b-78cf-45dd-b782-e609e3a165af" xlink:href="cntx-20211231.xsd#cntx_PaymentProtectionProgramLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80351ddd-c9a8-4396-961b-0ca9f585bb79" xlink:to="loc_cntx_PaymentProtectionProgramLoanMember_a931543b-78cf-45dd-b782-e609e3a165af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_67304466-0b8c-4fb8-a3ce-be4773669423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_DebtInstrumentAxis_67304466-0b8c-4fb8-a3ce-be4773669423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_67304466-0b8c-4fb8-a3ce-be4773669423" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_JuniorConvertibleNotesMember_089ac032-e6b8-4a96-ba6f-0bbe6a46c9e0" xlink:href="cntx-20211231.xsd#cntx_JuniorConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:to="loc_cntx_JuniorConvertibleNotesMember_089ac032-e6b8-4a96-ba6f-0bbe6a46c9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_BridgeNoteQualifiedFinancingMember_8328de02-1283-4440-8ccb-9ad8ed75770d" xlink:href="cntx-20211231.xsd#cntx_BridgeNoteQualifiedFinancingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:to="loc_cntx_BridgeNoteQualifiedFinancingMember_8328de02-1283-4440-8ccb-9ad8ed75770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertibleBridgeNotesMember_43ecf64c-34d5-43a0-b319-4b0af6cdf02f" xlink:href="cntx-20211231.xsd#cntx_ConvertibleBridgeNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:to="loc_cntx_ConvertibleBridgeNotesMember_43ecf64c-34d5-43a0-b319-4b0af6cdf02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member_5a6c034f-701f-48d1-88eb-502594e43584" xlink:href="cntx-20211231.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_acfc66c5-a030-42b4-b5a2-870109fd7507" xlink:to="loc_cntx_SeniorConvertibleNotesApril2020Member_5a6c034f-701f-48d1-88eb-502594e43584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dc0fb9a8-1c7b-4be1-a452-c16c754bee66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dc0fb9a8-1c7b-4be1-a452-c16c754bee66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d0306d6d-0bdc-46e2-82e2-153fdcd61998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dc0fb9a8-1c7b-4be1-a452-c16c754bee66" xlink:to="loc_us-gaap_ClassOfStockDomain_d0306d6d-0bdc-46e2-82e2-153fdcd61998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_46882a97-f442-4b71-b4ca-ad34b41d7132" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d0306d6d-0bdc-46e2-82e2-153fdcd61998" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_46882a97-f442-4b71-b4ca-ad34b41d7132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f2b99f88-7567-46a2-b5b8-1e983faf71dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d0306d6d-0bdc-46e2-82e2-153fdcd61998" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f2b99f88-7567-46a2-b5b8-1e983faf71dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_62ea909e-ec9b-49cd-bc2f-e2357f639147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_62ea909e-ec9b-49cd-bc2f-e2357f639147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_81024c57-708d-4719-8a22-d61775210fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_62ea909e-ec9b-49cd-bc2f-e2357f639147" xlink:to="loc_us-gaap_RelatedPartyDomain_81024c57-708d-4719-8a22-d61775210fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember_17432355-a15d-4c4c-b5fa-ba807031fc15" xlink:href="cntx-20211231.xsd#cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_81024c57-708d-4719-8a22-d61775210fef" xlink:to="loc_cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember_17432355-a15d-4c4c-b5fa-ba807031fc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_913667bc-1a31-4ee0-a6a9-5e5d4752a055" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_81024c57-708d-4719-8a22-d61775210fef" xlink:to="loc_srt_AffiliatedEntityMember_913667bc-1a31-4ee0-a6a9-5e5d4752a055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c306e1ea-65e9-4fcc-87f2-bd116ebc7b90" xlink:to="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_81a3b061-3b9a-4ab6-b435-4ee71ba4b663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_81a3b061-3b9a-4ab6-b435-4ee71ba4b663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4266d225-2595-48bd-ad07-6a7fc48793c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4266d225-2595-48bd-ad07-6a7fc48793c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_c2b9a181-c1ca-49a0-a43c-17a718233613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_c2b9a181-c1ca-49a0-a43c-17a718233613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2c51311b-a21f-4ee4-aa21-076cf14c2d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2c51311b-a21f-4ee4-aa21-076cf14c2d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_4e3318a9-cf24-4f31-8b48-023a661b17cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_4e3318a9-cf24-4f31-8b48-023a661b17cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8d62ff1e-3b61-43c5-a13c-61fa159c2b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_InterestExpense_8d62ff1e-3b61-43c5-a13c-61fa159c2b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount_2a64a525-4875-45e6-a26b-fac4ef4c801f" xlink:href="cntx-20211231.xsd#cntx_DebtInstrumentConvertedInstrumentPrincipalAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount_2a64a525-4875-45e6-a26b-fac4ef4c801f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtInstrumentConvertedInstrumentInterestAmount_9da12c3d-3fba-4ef9-96a8-ef7be27248ce" xlink:href="cntx-20211231.xsd#cntx_DebtInstrumentConvertedInstrumentInterestAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_cntx_DebtInstrumentConvertedInstrumentInterestAmount_9da12c3d-3fba-4ef9-96a8-ef7be27248ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedInterestRelatedParties_f9de0604-a24c-4ff9-915b-969f2319342a" xlink:href="cntx-20211231.xsd#cntx_AccruedInterestRelatedParties"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_cntx_AccruedInterestRelatedParties_f9de0604-a24c-4ff9-915b-969f2319342a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b56458a9-72c7-4e81-b2f7-114ff768500e" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b56458a9-72c7-4e81-b2f7-114ff768500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_6bb1b8ab-ab5a-404e-8bd0-f01f8e0136df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_6bb1b8ab-ab5a-404e-8bd0-f01f8e0136df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32131f69-78e7-46fe-81f0-90f13609470a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32131f69-78e7-46fe-81f0-90f13609470a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8e90bc18-103e-4d4f-9241-010a97e9045f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentTerm_8e90bc18-103e-4d4f-9241-010a97e9045f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_496581d2-acaa-4b31-ad72-324b9fefaf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_496581d2-acaa-4b31-ad72-324b9fefaf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_40510872-8372-4d7d-9b79-352857a56a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01f7e659-e19f-4b04-b33e-a8432b9be67d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_40510872-8372-4d7d-9b79-352857a56a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStock"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_18d7554f-5fc5-4ac2-a60f-a68fbfe10249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2ca545fe-6f25-4e21-90e2-5d45069902fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_18d7554f-5fc5-4ac2-a60f-a68fbfe10249" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2ca545fe-6f25-4e21-90e2-5d45069902fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_88c03839-ce7d-4b3e-916e-f55752627795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_46021ced-b530-4130-aef4-795d4f632de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_88c03839-ce7d-4b3e-916e-f55752627795" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_46021ced-b530-4130-aef4-795d4f632de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_49d8b301-6fc2-4115-9f2e-78517f9f35ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_49d8b301-6fc2-4115-9f2e-78517f9f35ea" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d3125633-bcdd-4afc-a9fe-3ee7226bc64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d3125633-bcdd-4afc-a9fe-3ee7226bc64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3125633-bcdd-4afc-a9fe-3ee7226bc64f" xlink:to="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1b5140e1-bf11-40d6-8bfe-17dce8767ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1b5140e1-bf11-40d6-8bfe-17dce8767ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeriesSeedPreferredStockMember_342acd42-08f0-4a4d-b5dc-c5ecacfcaac6" xlink:href="cntx-20211231.xsd#cntx_SeriesSeedPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:to="loc_cntx_SeriesSeedPreferredStockMember_342acd42-08f0-4a4d-b5dc-c5ecacfcaac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_b35e50c2-d101-40d5-bad3-8c22633c2dd4" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9941414e-d654-4803-a4d5-8ced30d8f38b" xlink:to="loc_cntx_RedeemableCommonStockMember_b35e50c2-d101-40d5-bad3-8c22633c2dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_87fcf6f4-c2f0-4948-93e9-e33408117a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_87fcf6f4-c2f0-4948-93e9-e33408117a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ffff465d-1a96-4e1e-b8a0-21d70f807fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_87fcf6f4-c2f0-4948-93e9-e33408117a7d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ffff465d-1a96-4e1e-b8a0-21d70f807fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_46cdff3c-62ed-40d2-b4d4-065a9433b988" xlink:href="cntx-20211231.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffff465d-1a96-4e1e-b8a0-21d70f807fb8" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_46cdff3c-62ed-40d2-b4d4-065a9433b988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToSeriesAStockholdersMember_98d21651-8abe-4c76-a7aa-98ecbef5e53e" xlink:href="cntx-20211231.xsd#cntx_IssuedToSeriesAStockholdersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ffff465d-1a96-4e1e-b8a0-21d70f807fb8" xlink:to="loc_cntx_IssuedToSeriesAStockholdersMember_98d21651-8abe-4c76-a7aa-98ecbef5e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_015f6dcc-efd6-4631-a66b-7a2264053b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_DebtInstrumentAxis_015f6dcc-efd6-4631-a66b-7a2264053b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_015f6dcc-efd6-4631-a66b-7a2264053b9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_JuniorConvertibleNotesMember_03f60cdd-4e09-425b-a457-92ba09f7443b" xlink:href="cntx-20211231.xsd#cntx_JuniorConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:to="loc_cntx_JuniorConvertibleNotesMember_03f60cdd-4e09-425b-a457-92ba09f7443b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ConvertibleBridgeNotesMember_3012d85f-07f2-4c0a-ad56-b856044ac982" xlink:href="cntx-20211231.xsd#cntx_ConvertibleBridgeNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:to="loc_cntx_ConvertibleBridgeNotesMember_3012d85f-07f2-4c0a-ad56-b856044ac982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_SeniorConvertibleNotesApril2020Member_44d508fc-9ff6-4071-a6b0-04e50efe76d2" xlink:href="cntx-20211231.xsd#cntx_SeniorConvertibleNotesApril2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cb344bca-bd85-4ef3-9e31-a75d2a2fd0e5" xlink:to="loc_cntx_SeniorConvertibleNotesApril2020Member_44d508fc-9ff6-4071-a6b0-04e50efe76d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_378776f4-f04c-4f0b-b4a1-8cbe7845861c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_378776f4-f04c-4f0b-b4a1-8cbe7845861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c671de68-b382-4cfb-8ccc-99b1bdf81f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_378776f4-f04c-4f0b-b4a1-8cbe7845861c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c671de68-b382-4cfb-8ccc-99b1bdf81f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_27a3334e-e765-4c6f-8a44-bdd88728552d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c671de68-b382-4cfb-8ccc-99b1bdf81f9d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_27a3334e-e765-4c6f-8a44-bdd88728552d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2c92363e-a90e-4591-8ed3-fa295bdb129c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_srt_RangeAxis_2c92363e-a90e-4591-8ed3-fa295bdb129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e516e563-b32b-442d-a105-23b255e52c7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2c92363e-a90e-4591-8ed3-fa295bdb129c" xlink:to="loc_srt_RangeMember_e516e563-b32b-442d-a105-23b255e52c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4cfd143b-a0d0-464d-8052-530354e6edd8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e516e563-b32b-442d-a105-23b255e52c7d" xlink:to="loc_srt_MinimumMember_4cfd143b-a0d0-464d-8052-530354e6edd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb9dc762-044c-49df-b910-768ffb965da6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e516e563-b32b-442d-a105-23b255e52c7d" xlink:to="loc_srt_MaximumMember_fb9dc762-044c-49df-b910-768ffb965da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_951f9510-5296-4045-9896-a7572b4ddfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_951f9510-5296-4045-9896-a7572b4ddfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_43b2dfad-b1d4-456d-a54a-c7cf2d4c7eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_951f9510-5296-4045-9896-a7572b4ddfbc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_43b2dfad-b1d4-456d-a54a-c7cf2d4c7eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_077dbf97-776b-45a5-844f-a259e28a75a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_43b2dfad-b1d4-456d-a54a-c7cf2d4c7eb4" xlink:to="loc_us-gaap_SubsequentEventMember_077dbf97-776b-45a5-844f-a259e28a75a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_baf87df1-beee-4e3a-a09a-c2bc5fabeb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_baf87df1-beee-4e3a-a09a-c2bc5fabeb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a278c9bd-b827-4c5c-a382-bff4ef1afdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_baf87df1-beee-4e3a-a09a-c2bc5fabeb79" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a278c9bd-b827-4c5c-a382-bff4ef1afdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7c834392-7e22-4a5a-8285-f1c2a597e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a278c9bd-b827-4c5c-a382-bff4ef1afdb2" xlink:to="loc_us-gaap_IPOMember_7c834392-7e22-4a5a-8285-f1c2a597e5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_0cc1920c-acae-429f-9a0c-28ae4c4c6ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a278c9bd-b827-4c5c-a382-bff4ef1afdb2" xlink:to="loc_us-gaap_PrivatePlacementMember_0cc1920c-acae-429f-9a0c-28ae4c4c6ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38f56cf4-1992-4da6-ba64-2d29b4b310f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6675c18f-6d7d-46fe-9fe5-4950577504ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6675c18f-6d7d-46fe-9fe5-4950577504ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_be09af82-5e17-47c7-a69b-55107144f576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_be09af82-5e17-47c7-a69b-55107144f576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DebtConversionConvertedInstrumentPricePerShare_ecc0ea0e-f5fe-458d-b454-27f341a5892a" xlink:href="cntx-20211231.xsd#cntx_DebtConversionConvertedInstrumentPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_cntx_DebtConversionConvertedInstrumentPricePerShare_ecc0ea0e-f5fe-458d-b454-27f341a5892a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bde1213a-13df-443c-ba61-e2a3dfdcf682" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bde1213a-13df-443c-ba61-e2a3dfdcf682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_8db22417-2adf-4d49-a8df-55e7c133afa2" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare_8db22417-2adf-4d49-a8df-55e7c133afa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ddfdaf40-2cda-49c7-896d-8d3ceb3f6c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_ddfdaf40-2cda-49c7-896d-8d3ceb3f6c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8661e584-94e0-41d0-8f1f-0752cb628b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8661e584-94e0-41d0-8f1f-0752cb628b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2d432346-d3ca-48d2-b08f-481c5e29a3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2d432346-d3ca-48d2-b08f-481c5e29a3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f8dced8a-fd15-48dd-86e9-14335ab257bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f8dced8a-fd15-48dd-86e9-14335ab257bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00f61df4-8f6a-41dd-a9be-67e93ce0d991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_00f61df4-8f6a-41dd-a9be-67e93ce0d991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c2abf310-70cd-41fb-ba45-b03673f923c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c2abf310-70cd-41fb-ba45-b03673f923c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1bc4c3fe-a733-4b4b-96fa-123b6e13f169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_08f33c06-bbe4-4e1f-95d9-e638a98f3146" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1bc4c3fe-a733-4b4b-96fa-123b6e13f169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_546a5980-04ae-49de-88ec-370c55048587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1c502181-3a49-4e66-8194-cc5c3314a19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_546a5980-04ae-49de-88ec-370c55048587" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1c502181-3a49-4e66-8194-cc5c3314a19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3f4ea457-880b-4318-a647-53cd0bd7ed36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1c502181-3a49-4e66-8194-cc5c3314a19c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3f4ea457-880b-4318-a647-53cd0bd7ed36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0f7d0427-a53a-435f-8c55-b9967f0f8589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3f4ea457-880b-4318-a647-53cd0bd7ed36" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0f7d0427-a53a-435f-8c55-b9967f0f8589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedInConnectionWithIPOMember_6d990de8-5146-471c-a0e2-4ef4977bdb2a" xlink:href="cntx-20211231.xsd#cntx_IssuedInConnectionWithIPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0f7d0427-a53a-435f-8c55-b9967f0f8589" xlink:to="loc_cntx_IssuedInConnectionWithIPOMember_6d990de8-5146-471c-a0e2-4ef4977bdb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedAsPartOfPrivatePlacementMember_bc2098d2-bb5b-41cd-adbb-a3ed645e4c7d" xlink:href="cntx-20211231.xsd#cntx_IssuedAsPartOfPrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0f7d0427-a53a-435f-8c55-b9967f0f8589" xlink:to="loc_cntx_IssuedAsPartOfPrivatePlacementMember_bc2098d2-bb5b-41cd-adbb-a3ed645e4c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_96ee573d-ea01-432c-a1aa-b324fcda90cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1c502181-3a49-4e66-8194-cc5c3314a19c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_96ee573d-ea01-432c-a1aa-b324fcda90cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7cca349b-a13f-441f-8483-c78082808c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_96ee573d-ea01-432c-a1aa-b324fcda90cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7cca349b-a13f-441f-8483-c78082808c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dedec95b-4120-4932-8d5a-38a03be65fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_96ee573d-ea01-432c-a1aa-b324fcda90cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dedec95b-4120-4932-8d5a-38a03be65fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14cb6009-3508-47f4-8a1b-3b6603aa6688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f9a5b70d-e5d2-4c32-8c7d-a209a37632d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14cb6009-3508-47f4-8a1b-3b6603aa6688" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f9a5b70d-e5d2-4c32-8c7d-a209a37632d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4b27268-4b3d-4410-90b1-755ed2477ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5f68e35c-e812-49e5-b9bb-a8d4b753f373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4b27268-4b3d-4410-90b1-755ed2477ea1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5f68e35c-e812-49e5-b9bb-a8d4b753f373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_054dbcac-01c0-44c6-889b-3ccf281f4a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4b27268-4b3d-4410-90b1-755ed2477ea1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_054dbcac-01c0-44c6-889b-3ccf281f4a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ec66ef21-5f22-48bc-bc4f-0802bd9b53d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4b27268-4b3d-4410-90b1-755ed2477ea1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ec66ef21-5f22-48bc-bc4f-0802bd9b53d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c030c3b7-00d1-4937-92a4-452452a129ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c030c3b7-00d1-4937-92a4-452452a129ce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_85d22675-7b21-4801-a68b-f4737fc282e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_us-gaap_StatementClassOfStockAxis_85d22675-7b21-4801-a68b-f4737fc282e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_85d22675-7b21-4801-a68b-f4737fc282e4" xlink:to="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_21ee6211-e7df-444d-98f7-c8877b6305a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:to="loc_us-gaap_CommonClassAMember_21ee6211-e7df-444d-98f7-c8877b6305a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ebae243e-1a33-479c-baae-7d8df5efa9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ebae243e-1a33-479c-baae-7d8df5efa9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e16e870-fba2-49ca-bb6d-0c9fb83b32ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_461ed93c-bc54-42a4-9550-999e449fd6fd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e16e870-fba2-49ca-bb6d-0c9fb83b32ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28ec6ebf-bad9-461b-baa2-336c431d7386" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_srt_RangeAxis_28ec6ebf-bad9-461b-baa2-336c431d7386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b059905-20d3-483f-8c23-2fcdfb79b89a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_28ec6ebf-bad9-461b-baa2-336c431d7386" xlink:to="loc_srt_RangeMember_8b059905-20d3-483f-8c23-2fcdfb79b89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9f90f543-88ff-4685-979e-2b49207c8eb1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8b059905-20d3-483f-8c23-2fcdfb79b89a" xlink:to="loc_srt_MinimumMember_9f90f543-88ff-4685-979e-2b49207c8eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_41c2c27d-9013-4ea0-b9d0-b4fdeb2dab15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8b059905-20d3-483f-8c23-2fcdfb79b89a" xlink:to="loc_srt_MaximumMember_41c2c27d-9013-4ea0-b9d0-b4fdeb2dab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_22ca5e1d-0ca3-4271-8332-4748dfcd86a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_22ca5e1d-0ca3-4271-8332-4748dfcd86a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_566c3f67-8ab8-485d-8c2d-fad40b5b612e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22ca5e1d-0ca3-4271-8332-4748dfcd86a7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_566c3f67-8ab8-485d-8c2d-fad40b5b612e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_415cddb9-d03e-4832-8a2a-a151bd0eeb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566c3f67-8ab8-485d-8c2d-fad40b5b612e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_415cddb9-d03e-4832-8a2a-a151bd0eeb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cfa15ef9-d14c-4e22-afc9-5d5f8b1a99a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_566c3f67-8ab8-485d-8c2d-fad40b5b612e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cfa15ef9-d14c-4e22-afc9-5d5f8b1a99a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d27f1d3f-2365-4f99-8058-42053474f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_us-gaap_AwardTypeAxis_d27f1d3f-2365-4f99-8058-42053474f8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_203afe22-7bf7-4d72-aa9e-e32de15a8358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d27f1d3f-2365-4f99-8058-42053474f8f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_203afe22-7bf7-4d72-aa9e-e32de15a8358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a5825ef1-6400-4093-9b16-61a32de7642e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_203afe22-7bf7-4d72-aa9e-e32de15a8358" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a5825ef1-6400-4093-9b16-61a32de7642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StockGrantedForServicesMember_db2f0fa1-aeb0-4333-ac1e-b9e0a046544a" xlink:href="cntx-20211231.xsd#cntx_StockGrantedForServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_203afe22-7bf7-4d72-aa9e-e32de15a8358" xlink:to="loc_cntx_StockGrantedForServicesMember_db2f0fa1-aeb0-4333-ac1e-b9e0a046544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb677d25-a210-4240-bc42-dbd7783f0028" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0b96e05c-7854-4148-94a6-c33c7932a428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0b96e05c-7854-4148-94a6-c33c7932a428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_9d493235-9194-49b5-9ff9-fd4250569c50" xlink:href="cntx-20211231.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_9d493235-9194-49b5-9ff9-fd4250569c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c1fa5151-adbe-4045-b845-48db22d77015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c1fa5151-adbe-4045-b845-48db22d77015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_ede30ba3-8356-4052-bee4-6fb37284d3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_ede30ba3-8356-4052-bee4-6fb37284d3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_028e4fc4-38c5-4267-8278-2309fb8e9caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_028e4fc4-38c5-4267-8278-2309fb8e9caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cdbd0262-59b3-42ee-900c-86755fa99e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cdbd0262-59b3-42ee-900c-86755fa99e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1d6f7509-e4d3-4536-b2fe-6380117683c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1d6f7509-e4d3-4536-b2fe-6380117683c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ed9ebe40-49d3-44eb-ab83-d445dfd2be93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ed9ebe40-49d3-44eb-ab83-d445dfd2be93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1708e3d2-ca90-4aa7-9517-dac125ad2001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1708e3d2-ca90-4aa7-9517-dac125ad2001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23f78341-34fc-43b9-b0e7-77c23009cd50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23f78341-34fc-43b9-b0e7-77c23009cd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b58bdb2d-611e-47cd-96a7-c11be973e3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b58bdb2d-611e-47cd-96a7-c11be973e3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e818bd0-8f6a-4c3c-a1f8-55c46ec15f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e818bd0-8f6a-4c3c-a1f8-55c46ec15f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5b3852c3-d844-4a52-9f2f-69ec1cbd88b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefa37ad-3807-4be0-8868-e448528ba237" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5b3852c3-d844-4a52-9f2f-69ec1cbd88b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f907033f-dc68-4d18-805b-28bf07350ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d5876b7-293e-4612-b82e-f5220b722497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f907033f-dc68-4d18-805b-28bf07350ea0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d5876b7-293e-4612-b82e-f5220b722497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8eab999f-661a-4118-918d-59042072eefb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d5876b7-293e-4612-b82e-f5220b722497" xlink:to="loc_us-gaap_AwardTypeAxis_8eab999f-661a-4118-918d-59042072eefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17bba547-ebcf-4a99-b483-aa332e08b7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8eab999f-661a-4118-918d-59042072eefb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17bba547-ebcf-4a99-b483-aa332e08b7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_09bafae2-6b5f-4d63-84f7-2efe3cd3d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17bba547-ebcf-4a99-b483-aa332e08b7a6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_09bafae2-6b5f-4d63-84f7-2efe3cd3d07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d5876b7-293e-4612-b82e-f5220b722497" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bb109103-9296-422a-9887-c724c3248bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bb109103-9296-422a-9887-c724c3248bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_838f4e77-afd2-4fc1-9911-b2e4f753c034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_838f4e77-afd2-4fc1-9911-b2e4f753c034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d37c608a-b4f1-41a2-bdfe-12bfe78ec873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d37c608a-b4f1-41a2-bdfe-12bfe78ec873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3c600d99-e387-4d11-a66f-cb56e867206e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a40c651-1e8c-4165-a92e-e96516b1df39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3c600d99-e387-4d11-a66f-cb56e867206e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensationScheduleofShareBasedActivityDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_875c537a-cf3c-4391-a953-90b6884fdad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_43b01312-53f6-4e51-a098-2b7009700ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_875c537a-cf3c-4391-a953-90b6884fdad0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_43b01312-53f6-4e51-a098-2b7009700ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_47c57881-f5ec-43ce-a7d4-6723fd086818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_43b01312-53f6-4e51-a098-2b7009700ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_47c57881-f5ec-43ce-a7d4-6723fd086818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_521b192a-f5ae-4f74-9a46-7258f7192854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_43b01312-53f6-4e51-a098-2b7009700ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_521b192a-f5ae-4f74-9a46-7258f7192854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ac22360-e31b-4784-b4a8-bdff8acfdaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_43b01312-53f6-4e51-a098-2b7009700ae5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ac22360-e31b-4784-b4a8-bdff8acfdaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_610ab7b5-ae1c-47ef-bcfc-01257c98687c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_875c537a-cf3c-4391-a953-90b6884fdad0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_610ab7b5-ae1c-47ef-bcfc-01257c98687c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3b2e1b91-41af-40f1-b292-bdf665062446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_875c537a-cf3c-4391-a953-90b6884fdad0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3b2e1b91-41af-40f1-b292-bdf665062446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_81c14b45-3888-4f11-a54c-8867af94e40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_875c537a-cf3c-4391-a953-90b6884fdad0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_81c14b45-3888-4f11-a54c-8867af94e40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3a05c89-aec5-42af-870c-089e656a9522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_81c14b45-3888-4f11-a54c-8867af94e40e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3a05c89-aec5-42af-870c-089e656a9522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_69a7805e-2413-4ae4-bcf2-e103bdd6617c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_81c14b45-3888-4f11-a54c-8867af94e40e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_69a7805e-2413-4ae4-bcf2-e103bdd6617c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_670aea92-661d-4aa0-9a7a-e0940d470094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_81c14b45-3888-4f11-a54c-8867af94e40e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_670aea92-661d-4aa0-9a7a-e0940d470094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0c8d88e0-eb6b-47fe-93a2-58ea280c20a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_875c537a-cf3c-4391-a953-90b6884fdad0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0c8d88e0-eb6b-47fe-93a2-58ea280c20a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_65fd3cc5-edb3-4b55-98c7-4e8286ed10e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_875c537a-cf3c-4391-a953-90b6884fdad0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_65fd3cc5-edb3-4b55-98c7-4e8286ed10e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9cafa317-1973-43e5-a89a-0b32629784ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_875c537a-cf3c-4391-a953-90b6884fdad0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9cafa317-1973-43e5-a89a-0b32629784ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2909bc5d-d53e-41d8-9508-e3efb98b1b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9cafa317-1973-43e5-a89a-0b32629784ac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2909bc5d-d53e-41d8-9508-e3efb98b1b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_415c6f6b-1555-4204-8f3e-41756ed1a181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9cafa317-1973-43e5-a89a-0b32629784ac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_415c6f6b-1555-4204-8f3e-41756ed1a181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_263eef7c-3bd0-43b0-84a6-42ce569c7082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9cafa317-1973-43e5-a89a-0b32629784ac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_263eef7c-3bd0-43b0-84a6-42ce569c7082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f109c565-c5f4-4d5d-b4b1-e0d19c43fbde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9cafa317-1973-43e5-a89a-0b32629784ac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f109c565-c5f4-4d5d-b4b1-e0d19c43fbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3351cfd-950d-49f2-823a-e6dfd8a3bb61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33485dab-6a7b-49ff-b3df-980103ef9981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3351cfd-950d-49f2-823a-e6dfd8a3bb61" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33485dab-6a7b-49ff-b3df-980103ef9981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a9519e8-5133-4266-bfed-32465ca676cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33485dab-6a7b-49ff-b3df-980103ef9981" xlink:to="loc_us-gaap_AwardTypeAxis_2a9519e8-5133-4266-bfed-32465ca676cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddd143e2-48e8-419d-a983-cab42cdb1331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2a9519e8-5133-4266-bfed-32465ca676cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddd143e2-48e8-419d-a983-cab42cdb1331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1cefa321-5312-4707-898d-b04f5e9ef302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ddd143e2-48e8-419d-a983-cab42cdb1331" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1cefa321-5312-4707-898d-b04f5e9ef302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_173d39a8-38be-4fbc-bbcc-1da70aa0818a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33485dab-6a7b-49ff-b3df-980103ef9981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_173d39a8-38be-4fbc-bbcc-1da70aa0818a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_173d39a8-38be-4fbc-bbcc-1da70aa0818a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6185d229-4fed-4a3c-a046-2396a5e7dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6185d229-4fed-4a3c-a046-2396a5e7dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1e821c52-2ae0-4ec9-b4c3-6729806f218b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1e821c52-2ae0-4ec9-b4c3-6729806f218b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4fed7bcd-e1c0-424b-9cd1-a5ca3801c934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4fed7bcd-e1c0-424b-9cd1-a5ca3801c934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f77525b-fe43-4bd4-9291-a9dc99e35598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f77525b-fe43-4bd4-9291-a9dc99e35598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bee604d0-11b2-4b56-b007-7b431a1c5892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_08a246d7-321d-4ee8-b09a-b94aa7dc7823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bee604d0-11b2-4b56-b007-7b431a1c5892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_173d39a8-38be-4fbc-bbcc-1da70aa0818a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11b4fce0-a6a4-4fac-9415-9806e1867f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11b4fce0-a6a4-4fac-9415-9806e1867f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_721cf39d-8b44-4c9d-809e-fe57897e3a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_721cf39d-8b44-4c9d-809e-fe57897e3a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d0f6da6b-b232-4dee-b8d0-5628dfa33763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d0f6da6b-b232-4dee-b8d0-5628dfa33763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8486772-463f-4f33-8f4a-a3c796f4d685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8486772-463f-4f33-8f4a-a3c796f4d685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8492a40a-91e0-41b2-b15c-08db8a1ae087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6726c005-0183-4184-9216-807b5ecf61b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8492a40a-91e0-41b2-b15c-08db8a1ae087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="cntx-20211231.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_030277e1-0d97-4763-8e53-ccce159ec645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d6e05d74-e1e2-4217-9727-7a3cde0d15a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_030277e1-0d97-4763-8e53-ccce159ec645" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d6e05d74-e1e2-4217-9727-7a3cde0d15a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ac544e-8d7d-4437-ae40-4a907ac9e466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ac544e-8d7d-4437-ae40-4a907ac9e466" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_eb4fd162-c5ef-429f-b39d-989480674a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7c4b16b6-2532-4dcd-b55c-f417a6b1b2ef" xlink:to="loc_us-gaap_ProjectMember_eb4fd162-c5ef-429f-b39d-989480674a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_c5266068-eb45-4f6b-b14a-c8ab13ff2f74" xlink:href="cntx-20211231.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_eb4fd162-c5ef-429f-b39d-989480674a74" xlink:to="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_c5266068-eb45-4f6b-b14a-c8ab13ff2f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_73d5b5c1-82f2-4efd-9a4a-4208fb563bb6" xlink:href="cntx-20211231.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_eb4fd162-c5ef-429f-b39d-989480674a74" xlink:to="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_73d5b5c1-82f2-4efd-9a4a-4208fb563bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_da262236-fb29-41a3-a8bd-fc91f7bbcdf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_srt_CounterpartyNameAxis_da262236-fb29-41a3-a8bd-fc91f7bbcdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_da262236-fb29-41a3-a8bd-fc91f7bbcdf9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_DrexelUniversityMember_0192188e-f475-4616-a99c-7869ac891f6f" xlink:href="cntx-20211231.xsd#cntx_DrexelUniversityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:to="loc_cntx_DrexelUniversityMember_0192188e-f475-4616-a99c-7869ac891f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember_d261ba9f-bf7e-4a28-b34d-62303561611b" xlink:href="cntx-20211231.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:to="loc_cntx_TyligandBioscienceShanghaiLimitedMember_d261ba9f-bf7e-4a28-b34d-62303561611b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember_9cfc41f7-7674-44a3-b6b1-4959ec3d9401" xlink:href="cntx-20211231.xsd#cntx_IntegralMolecularIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6485142-58bf-4a1b-b3fd-3e3fc48295da" xlink:to="loc_cntx_IntegralMolecularIncMember_9cfc41f7-7674-44a3-b6b1-4959ec3d9401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e8e691dd-0a56-408f-a4da-d4d84ca211ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e8e691dd-0a56-408f-a4da-d4d84ca211ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca6ad80d-7363-4aa1-b0b0-d8451f6d0254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e8e691dd-0a56-408f-a4da-d4d84ca211ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca6ad80d-7363-4aa1-b0b0-d8451f6d0254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8b2d1a21-0270-4eae-9aab-19de866d115c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ca6ad80d-7363-4aa1-b0b0-d8451f6d0254" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8b2d1a21-0270-4eae-9aab-19de866d115c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c0f871aa-f294-493d-a724-0383f4d7d03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c0f871aa-f294-493d-a724-0383f4d7d03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_129f2ac5-a329-4e00-879a-9231cd78da87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c0f871aa-f294-493d-a724-0383f4d7d03d" xlink:to="loc_us-gaap_ClassOfStockDomain_129f2ac5-a329-4e00-879a-9231cd78da87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RedeemableCommonStockMember_86163382-7b49-4f99-a77e-e8e31eb246b9" xlink:href="cntx-20211231.xsd#cntx_RedeemableCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_129f2ac5-a329-4e00-879a-9231cd78da87" xlink:to="loc_cntx_RedeemableCommonStockMember_86163382-7b49-4f99-a77e-e8e31eb246b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a9c51e82-1eb7-4806-ad22-ad9c9c6d19ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_129f2ac5-a329-4e00-879a-9231cd78da87" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a9c51e82-1eb7-4806-ad22-ad9c9c6d19ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8340e90f-07b8-46b5-9b88-e088fc76da3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_srt_RangeAxis_8340e90f-07b8-46b5-9b88-e088fc76da3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b70d081a-027b-4d0b-8cdc-d17f79a6126b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8340e90f-07b8-46b5-9b88-e088fc76da3d" xlink:to="loc_srt_RangeMember_b70d081a-027b-4d0b-8cdc-d17f79a6126b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f24c5593-b681-4be7-bdba-e155691ec0da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b70d081a-027b-4d0b-8cdc-d17f79a6126b" xlink:to="loc_srt_MinimumMember_f24c5593-b681-4be7-bdba-e155691ec0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1a0cc0c-362a-4f9f-9312-b16f122c5ef7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b70d081a-027b-4d0b-8cdc-d17f79a6126b" xlink:to="loc_srt_MaximumMember_f1a0cc0c-362a-4f9f-9312-b16f122c5ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7ce1846e-4c54-4325-b5e0-64f8317dcc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7ce1846e-4c54-4325-b5e0-64f8317dcc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2515bfa5-5320-4f7f-ab6d-6a99feeb5b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7ce1846e-4c54-4325-b5e0-64f8317dcc2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2515bfa5-5320-4f7f-ab6d-6a99feeb5b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cb229f73-ab80-4e8e-bee1-30a5128646ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2515bfa5-5320-4f7f-ab6d-6a99feeb5b43" xlink:to="loc_us-gaap_SubsequentEventMember_cb229f73-ab80-4e8e-bee1-30a5128646ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c70c5e24-ab33-43cf-a859-e87d6a190c11" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_8ef83d8a-6e99-4661-9163-341a69179ad6" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_8ef83d8a-6e99-4661-9163-341a69179ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_5e61b672-0dc3-4a9a-918e-18bc65f3994c" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_5e61b672-0dc3-4a9a-918e-18bc65f3994c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent_d289227b-01ba-4fc5-abb8-214a398db3ca" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent_d289227b-01ba-4fc5-abb8-214a398db3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_f654e8b3-00c4-43ad-93dc-039b17c44c0b" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_f654e8b3-00c4-43ad-93dc-039b17c44c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_700eeedf-7e84-4413-8c4e-3fb06021c0f9" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_700eeedf-7e84-4413-8c4e-3fb06021c0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_3f08abec-8f1e-47c8-8557-bf14bb091937" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_3f08abec-8f1e-47c8-8557-bf14bb091937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3aeed004-895f-47ff-af7f-9b7df7c38f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3aeed004-895f-47ff-af7f-9b7df7c38f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eeada07e-61b8-4dbe-9d84-ecab0f0ad6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eeada07e-61b8-4dbe-9d84-ecab0f0ad6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_69c94179-9de0-48b1-b0ba-2d52b0d11d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_69c94179-9de0-48b1-b0ba-2d52b0d11d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a15e700f-f0b8-468a-8276-4e68446e70e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a15e700f-f0b8-468a-8276-4e68446e70e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_3ac52c7d-7776-4fe1-ace0-0a825e58026b" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices_3ac52c7d-7776-4fe1-ace0-0a825e58026b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_c10e0ea9-e63a-4253-af45-f1fa2ec45af5" xlink:href="cntx-20211231.xsd#cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices_c10e0ea9-e63a-4253-af45-f1fa2ec45af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_00b4394a-929c-4948-87ba-8d192dbe749d" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_00b4394a-929c-4948-87ba-8d192dbe749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_3e16ea90-9622-44bf-a8f5-cefdcbfaac0f" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_3e16ea90-9622-44bf-a8f5-cefdcbfaac0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_1dba5d04-4ab8-49e5-a936-7a7d0517063c" xlink:href="cntx-20211231.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_1dba5d04-4ab8-49e5-a936-7a7d0517063c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_546a44e4-835f-423c-977f-6ae6f691eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_LeaseAndRentalExpense_546a44e4-835f-423c-977f-6ae6f691eb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_26b371e2-abe8-4350-a0c3-5e229e24d432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ad303a1-4546-4054-8b7c-b6c561319cf1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_26b371e2-abe8-4350-a0c3-5e229e24d432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b158594f-1ccb-48b4-93ac-b637c18a032d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4d2ce524-2b4e-43c3-9196-2fda001a61a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b158594f-1ccb-48b4-93ac-b637c18a032d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4d2ce524-2b4e-43c3-9196-2fda001a61a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5cdc982e-8093-4fe5-ac74-e43f12bf0b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d2fdd863-0b8d-432f-8957-7b2a4d46f0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5cdc982e-8093-4fe5-ac74-e43f12bf0b4f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d2fdd863-0b8d-432f-8957-7b2a4d46f0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fd29c339-9afc-43a1-bf1f-6c459692d000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5cdc982e-8093-4fe5-ac74-e43f12bf0b4f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fd29c339-9afc-43a1-bf1f-6c459692d000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_52da8bb4-980c-4870-bc13-961e9d5b6408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5cdc982e-8093-4fe5-ac74-e43f12bf0b4f" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_52da8bb4-980c-4870-bc13-961e9d5b6408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3261bc93-6f1b-49e2-aa2c-d18fd9296244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e51746c4-1840-4fe2-874d-a7ffd86ba350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3261bc93-6f1b-49e2-aa2c-d18fd9296244" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e51746c4-1840-4fe2-874d-a7ffd86ba350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ab245840-3346-4b41-916d-d087155d463e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e51746c4-1840-4fe2-874d-a7ffd86ba350" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ab245840-3346-4b41-916d-d087155d463e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f731ec96-bee8-4d4b-b6e8-56d061cc61ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ab245840-3346-4b41-916d-d087155d463e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f731ec96-bee8-4d4b-b6e8-56d061cc61ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_LocalJurisdictionMember_9e02248d-4a86-4a52-8b42-2fbc38261381" xlink:href="cntx-20211231.xsd#cntx_LocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f731ec96-bee8-4d4b-b6e8-56d061cc61ae" xlink:to="loc_cntx_LocalJurisdictionMember_9e02248d-4a86-4a52-8b42-2fbc38261381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e51746c4-1840-4fe2-874d-a7ffd86ba350" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_698ae490-cfe6-42ab-a927-2d3e6f3bf40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_698ae490-cfe6-42ab-a927-2d3e6f3bf40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c836d532-fdd2-4e16-97cb-1a28c19e4954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c836d532-fdd2-4e16-97cb-1a28c19e4954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_OperatingLossCarryforwardsExpirationTerm_f0a81d05-1f16-429f-a868-080467101d3c" xlink:href="cntx-20211231.xsd#cntx_OperatingLossCarryforwardsExpirationTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_cntx_OperatingLossCarryforwardsExpirationTerm_f0a81d05-1f16-429f-a868-080467101d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_757320f1-dffa-4844-a93d-22af10fb5323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_757320f1-dffa-4844-a93d-22af10fb5323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a1aa6afb-7a85-4b78-b141-d71290471245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a1aa6afb-7a85-4b78-b141-d71290471245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_039f9ad7-2994-4aee-bad8-0feeaa88b70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_109f9d89-bf04-46a3-b246-b19130df5f02" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_039f9ad7-2994-4aee-bad8-0feeaa88b70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d4f4d9-4665-47ca-bf0d-0b2aeaabec2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_f7906fc1-9a09-45ec-93da-171359feca54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d4f4d9-4665-47ca-bf0d-0b2aeaabec2a" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_f7906fc1-9a09-45ec-93da-171359feca54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8c425eae-3742-4186-894b-b8f46625d179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_f7906fc1-9a09-45ec-93da-171359feca54" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8c425eae-3742-4186-894b-b8f46625d179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7569fa15-cf0b-4d00-8323-212ba5ba4d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_f7906fc1-9a09-45ec-93da-171359feca54" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7569fa15-cf0b-4d00-8323-212ba5ba4d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2d75350c-32a2-4226-80fe-39d10c662351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_f7906fc1-9a09-45ec-93da-171359feca54" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2d75350c-32a2-4226-80fe-39d10c662351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_fc247a74-8d26-42d6-b602-513fab67f716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_f7906fc1-9a09-45ec-93da-171359feca54" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_fc247a74-8d26-42d6-b602-513fab67f716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bd4b1ef0-9a7c-43f5-b42d-baaacfe2a85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_f7906fc1-9a09-45ec-93da-171359feca54" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_bd4b1ef0-9a7c-43f5-b42d-baaacfe2a85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1638f434-9f31-41f7-b9c9-f8b5a9729bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d4f4d9-4665-47ca-bf0d-0b2aeaabec2a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1638f434-9f31-41f7-b9c9-f8b5a9729bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_ef673f54-0bf2-4bc2-9a2f-4b913064d1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1638f434-9f31-41f7-b9c9-f8b5a9729bdb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_ef673f54-0bf2-4bc2-9a2f-4b913064d1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_NetDeferredTaxAssetLiabilitiesGross_80c3e356-5d03-49a1-9dbb-da549228c26c" xlink:href="cntx-20211231.xsd#cntx_NetDeferredTaxAssetLiabilitiesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d4f4d9-4665-47ca-bf0d-0b2aeaabec2a" xlink:to="loc_cntx_NetDeferredTaxAssetLiabilitiesGross_80c3e356-5d03-49a1-9dbb-da549228c26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b7068bd4-1c0b-4757-aa16-f11e52b53303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d4f4d9-4665-47ca-bf0d-0b2aeaabec2a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b7068bd4-1c0b-4757-aa16-f11e52b53303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_04c2ee39-b994-4392-96fd-99419abec363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d4f4d9-4665-47ca-bf0d-0b2aeaabec2a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_04c2ee39-b994-4392-96fd-99419abec363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ebdfa97-17fb-4fb5-92f1-becee87bd147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4ebdfa97-17fb-4fb5-92f1-becee87bd147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_546029a3-d6dc-4d3c-b71b-5aca821f2c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_546029a3-d6dc-4d3c-b71b-5aca821f2c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_410d4b32-2952-4314-8127-d1ba627a31da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_410d4b32-2952-4314-8127-d1ba627a31da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_a446f3ac-b864-4126-83f8-d0d47a1a4ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_a446f3ac-b864-4126-83f8-d0d47a1a4ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_bee0efe6-3a42-4e2e-b0ee-7359514aeed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_bee0efe6-3a42-4e2e-b0ee-7359514aeed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a68c642e-69da-4682-be6b-401a5183aab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a68c642e-69da-4682-be6b-401a5183aab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_016ee408-485e-4bde-bd1e-04a23c3aa3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_016ee408-485e-4bde-bd1e-04a23c3aa3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3899c55e-e3e6-4476-9e51-082984858f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_72d29f9c-7965-4464-8bff-1a6888b7539d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3899c55e-e3e6-4476-9e51-082984858f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e78a9195-72ad-420c-9a13-b11ccf264196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e78a9195-72ad-420c-9a13-b11ccf264196" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1fbc138a-6728-4510-9fdb-11c55382a5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1fbc138a-6728-4510-9fdb-11c55382a5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1fbc138a-6728-4510-9fdb-11c55382a5ea" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8c573d77-9bac-4205-a8b2-edd329b374a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:to="loc_us-gaap_DomesticCountryMember_8c573d77-9bac-4205-a8b2-edd329b374a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_StateJurisdictionMember_b818e9a6-6b8d-45ad-aebd-1b800477b156" xlink:href="cntx-20211231.xsd#cntx_StateJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:to="loc_cntx_StateJurisdictionMember_b818e9a6-6b8d-45ad-aebd-1b800477b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_LocalJurisdictionMember_0eead66a-fc09-4eaf-bdf1-f2bc32404a2b" xlink:href="cntx-20211231.xsd#cntx_LocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_75e24da2-444f-4747-8073-0570216243d8" xlink:to="loc_cntx_LocalJurisdictionMember_0eead66a-fc09-4eaf-bdf1-f2bc32404a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_e136ccb8-ab01-4c64-a777-e4e5051a0e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_e136ccb8-ab01-4c64-a777-e4e5051a0e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_9d407bba-c39a-450b-a73e-3a33727b0ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e136ccb8-ab01-4c64-a777-e4e5051a0e82" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_9d407bba-c39a-450b-a73e-3a33727b0ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_8cba566f-ca25-488d-a5a9-6e0c424b322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_9d407bba-c39a-450b-a73e-3a33727b0ed6" xlink:to="loc_us-gaap_ResearchMember_8cba566f-ca25-488d-a5a9-6e0c424b322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_457ed091-23e7-45d8-acde-1c2505b6237d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3375ce0c-5d60-4a2c-9923-7071acc6343d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_457ed091-23e7-45d8-acde-1c2505b6237d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d265cee5-037c-483d-a80f-8d8f8dc055b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_457ed091-23e7-45d8-acde-1c2505b6237d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d265cee5-037c-483d-a80f-8d8f8dc055b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_20f9d0c0-e669-4c1f-982b-44c9f61dea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_457ed091-23e7-45d8-acde-1c2505b6237d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_20f9d0c0-e669-4c1f-982b-44c9f61dea7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="cntx-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6555a3e0-1996-4659-93c5-1c0be674b419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2db4ae11-bace-4b7e-9ec4-0985452432a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6555a3e0-1996-4659-93c5-1c0be674b419" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2db4ae11-bace-4b7e-9ec4-0985452432a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cntx-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_22f262d5-55dc-463c-a602-c270bcd72638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_39065836-8d00-4088-a021-c1e64e588fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_22f262d5-55dc-463c-a602-c270bcd72638" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_39065836-8d00-4088-a021-c1e64e588fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="cntx-20211231.xsd#SubsequentEventsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d1727aae-18f0-4986-909a-18da53c847e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d1727aae-18f0-4986-909a-18da53c847e2" xlink:to="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5428c6b8-11c0-4052-abbb-bff60c8244bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8cfd0111-36c1-4ec3-90cc-20c48fa9dccf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5428c6b8-11c0-4052-abbb-bff60c8244bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_5d81aa38-c7e2-4fad-9411-35653929072a" xlink:href="cntx-20211231.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5428c6b8-11c0-4052-abbb-bff60c8244bd" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_5d81aa38-c7e2-4fad-9411-35653929072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d0ee4d5c-c861-4bc6-9444-72c74c7c9818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d0ee4d5c-c861-4bc6-9444-72c74c7c9818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f342f948-6422-419b-bde7-9aee8bcfbe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d0ee4d5c-c861-4bc6-9444-72c74c7c9818" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f342f948-6422-419b-bde7-9aee8bcfbe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a101e7f1-df5a-4a63-9d2f-b13a42fe6e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f342f948-6422-419b-bde7-9aee8bcfbe49" xlink:to="loc_us-gaap_SubsequentEventMember_a101e7f1-df5a-4a63-9d2f-b13a42fe6e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_90c51329-0f7f-4bac-b092-bf034d9e990f" xlink:to="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b9dd6fc3-431b-4123-baae-b9fde052e685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b9dd6fc3-431b-4123-baae-b9fde052e685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15aa04d5-9ac2-4d3f-b8e3-3443d59be39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15aa04d5-9ac2-4d3f-b8e3-3443d59be39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_54b095ae-da82-466d-80be-6c8edcf95e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_54b095ae-da82-466d-80be-6c8edcf95e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5da54acc-8723-4fd1-ac86-f9f2c5dc53d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_882f52ee-4117-44b0-bc46-cb9dde8f589b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5da54acc-8723-4fd1-ac86-f9f2c5dc53d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cntx-20211231_g1.jpg
<TEXT>
begin 644 cntx-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" C*#Z # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#COBC\4=*^$OA^WUC6+>\N;:>Z6T5+%$=PY1V!(9E&,(>
M_I7E_P#PVQX'_P"@5X@_\!X/_CU'[;'_ "2O2O\ L-1?^B)Z^** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_Q
MZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/
M_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_
MX#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^
M*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_
M (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_]
M KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P"
M\'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_A
MMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P!
MKQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?
M_'J^*** /M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^***
M/M?_ (;8\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8
M\#_] KQ!_P" \'_QZC_AMCP/_P! KQ!_X#P?_'J^*** /M?_ (;8\#_] KQ!
M_P" \'_QZNP^%W[0_ASXM>(+C1]'LM4MKF"U:[9[Z*-$*!T4@%9&.<N.WK7Y
M\5] _L3_ /)5-5_[ LO_ */@H ^UZ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /G[]MC_ ))7I7_8:B_]$3U\45]K_ML?\DKT
MK_L-1?\ HB>OBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^@?V)_^2J:K_V!9?\ T?!7S]7T#^Q/_P E4U7_
M + LO_H^"@#[7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^?OVV/^25Z5_V&HO\ T1/7Q17VO^VQ_P DKTK_ +#47_HB>OBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^@?V)_\ DJFJ_P#8%E_]'P5\_5] _L3_ /)5-5_[ LO_ */@H ^U
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G[
M]MC_ ))7I7_8:B_]$3U\45]K_ML?\DKTK_L-1?\ HB>OBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?0/[$_\ R535?^P++_Z/@KY^KZ!_8G_Y*IJO_8%E_P#1\% 'VO1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\_?ML?\DKTK_L
M-1?^B)Z^**^U_P!MC_DE>E?]AJ+_ -$3U\44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!H:3XCU;01*-,U2]T
MX2X\P6EP\6_&<9VD9QD_G4>JZUJ.N3K-J5_<ZA,J[%DNIFE8+DG +$\9)X]Z
MIT4 %%%% &KIGBS7-$MC;Z=K.H6%N6+^5:W3QID]3A2!G@5;_P"%A^*O^AFU
MC_P/E_\ BJY^B@#4U/Q7K>M0B'4-8U"_B!R([FZ>11^#$UET44 :6E>)]8T*
M)XM-U:^T^-VW,EK<O$&/J0I&34.J:UJ&N7"SZE?7.H3JNQ9+J9I6"Y)P"Q)Q
MDGCWJG10 4^WN);2>.>"1X9HF#I)&Q5D8'(((Z$'O3** -RY\=^);RWE@N/$
M.JSP2J4DBDO965U(P006P01VK#HHH **** "BBB@ HHHH **** "OH']B?\
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M_A;2YHVV&U(@0QG_ &A_#_P+% 'YUT5^@_C'X!^ OB5I9GATZTLYYTWPZII
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ML+Q9IGPJ7X:ZR]I:>#AJ0TB8Q-#':><)?).TK@9W;L8QSF@#X8HHHH ****
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M?Q%?:;X9T?3[V+[/Y=S:V$44B9N8@<,J@C()'T)KX>H **^EOV,O"6A^*?\
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M]/TJS"F[OKB.UA#G"[W8*N3V&2* *5%?2'C_ /9FT[X7?!G6-;U"\;5/$2&
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M!M6742)3[A1CK]*\^^,/[(ECH'AR_P!<\*7MRQLHFN)M/O&#[HU&6\MP 00
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MX]>WGX5F#$ D*,D@=!T_K24 ?>_[)O\ R1#1_P#KM<_^CFKXX^,?_)6?&/\
MV%[K_P!&M7V/^R;_ ,D0T?\ Z[7/_HYJ^./C'_R5GQC_ -A>Z_\ 1K4 ?27B
M7]E#P5I/@'5=9@EU4W=MIDMV@>Y4IO6(N,C9TR*^<O@SX/L/'OQ+T70=3,RV
M-XTHD,#!7^6)W&"0>ZCM7WEXX_Y)!X@_[ 5Q_P"D[5\4?LQ_\ES\+_[\_P#Z
M3R4 >S^-OV-=-DN]&MO"]S=VZ33/]NN[Z595AB"\%5 4EB> ,_EUKJ](_9)^
M&XLY+4O>:G=1826?[;AT;K]U, ?0BM7]JKQ;?^$OA-</IMQ):W%]=1V1FB.'
M5&#,V#VR$(_$U\B_ C7KO0?B[X6EM9WB-S?PVDH4\/'*X1E/J/F_, ]J .M_
M:$_9['PC%IJFEW<U]H5U)Y/^D >;!)@D*Q  ((!P<#H1[D_9I^$&A?%J^UZ'
M7'NT2QCA>+[)*$.6+@YRIS]T5]%_M:(K?!+5B0"5GMR">Q\U1_4UY7^PU_R%
M?%W_ %QMO_0I* /-OVC_ (8:/\*?&&GZ9HK7+VT]@MRYNI [;S(Z\$ <844W
MX'_ +4OC!=37+SG3-!MGV37FS<TC]?+C'<X(R3P,CKTKL/VVO^2E:-_V"$_]
M'2U],?!/0K?PM\)/#%M$HC4V$=U*<=7D7S')_%C^5 '$V_[(OPXL;98+B._N
M)7PJS3WI5R?8*%7/X5YG\8OV0T\/:+=:UX0NKF\CMD\R;3+G#R%!]YHW &<#
MG:1D\X). ?G_ ,:>,=2\<^)[W6]2N))KFXE+J&8D1+DE47T51P!7K6B_M?\
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MQFMHT 5YM/MP3ZDNXS_*OK?Q%=Q_#?X9:A/81KY>BZ4YMHV'RGRHCL!]L@4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY%M,JGB2-N"I'<=#]0#VH U_V@?@(_P?O+.[L;N2_P!"OG:.*291YL+CG8Y
M .1R" ,X;@8Y\@K[I_;"A23X-RLR@M'?P,I/8_,,_D3^=?"U !1110 4444
M%%%% !1110 4444 %?IQXL_Y$#6?^P9-_P"BC7YCU^ICI;R:.R78C-HT&)A+
MC9LV_-NSQC&<T ?EG7V'^Q&=9_X1CQ +KSO[$\^+[#YF=GF8?SMGM_J\XXS[
MYKT.#P[\&;=]R6O@PG&/G-JX_(DU-XB^/'P[\ Z25CUJPN1 NV+3]'9)FX_@
M 3Y5_$@4 > _MO"'_A.?#Y7'VC^S3O\ ]WS6V_KNKZ;^%R&3X1^$5499M#M
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M&'CE2V,L1Z@@?7K6IK_['W@?Q!IKR^'K^ZTRX(/E2QSBY@SZ,#R?P8=:Z/\
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M"SZJTI:X-XT'FE^^\,<Y^M 'RQ^R*^LK\7K0:<)CIS02C4=F?+$?EMLW]O\
M6;,>_P"->^?MBB'_ (4ZWFD;_P"T(/*_WL-_[+NKL%\?_#'X?6$BVFL>'-)M
MS\[6^FO$"WOY<7)_*ODS]HKX[+\6M2M;'2XY(/#]@Q>/S1A[B0C'F$?P@#(
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MM7Z*>*M/U*U\#7]AX62*WU)+,V]@I;8D1V[5(/;:.1]!0!Y=<?LF?#2\1[&
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M7]S9741ANK:5H98VZHZDA@?H0: (**** "BBB@ HHHH **** "BBB@ HHHH
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MOGZOH']B?_DJFJ_]@67_ -'P4 ?:]%%% !1110 4444 %%%% !1110 4444
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M2(>*O^N,?_HY*^ _#VHIH^OZ9?RJSQVMU%.RIU(5PQ ]^*^C_BO^U9X>\?\
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M,9('5A0!]3_MKDCX5:6 2,ZS$#[_ +B>OE/X2_\ )5/!G_8:LO\ T>E>J?M
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M%/'N_P!DEQGZD"@"A^R)<^+?$E]K_B'7[[4;^QEBCM[::^F=U=MQ+>7N.,#
MSCCGZUQ7[;H/_"?:"<<?V9U_[:O6VO[:JCQ;;%-">U\*PQ.C01E6N9&Q\C=E
M4#&-H/<\G@5Y]^T/\9/#_P 83HUSIFG7]C?6/F1NUT$VR1M@@?*QY!!_[Z-
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M&ZMI7@N(762.6-MK(P.00>Q!%?5?P_\ VU+:/3H;7Q?I=R]W&H4W^G!6$O\
MM-&2NT^N"1["@#Q_X)?!*_\ B=XO2TU"UOK+0X%9KR\1/+*?*=J*64C<6QQ@
M\9/:MO\ :"^ ^C_!RQTR>RURYO9[^9D2TN(5!"*,L^\$="4&-O\ %UXKV37/
MVU_"EK:2?V5I&J7]WMRBW"I#%GW;<Q_):^6?B1\1]8^*'B676-8D7>1Y<-O%
MD1P1CHJ@_F3W)- 'WO\ #?0[7P7\)M*@T2U68IIRW2HG6YF:/>23W+,?Y#M7
MQCJ_QB^)WQ'UW^RX]6U%;JXE,2:;I@-O@YP4PF"0.^XGW-=_\%_VLT\&>'K7
M0?%%C<W]I9H(K:]L]K2J@^ZC*Q ( X!!Z #!ZUUWB3]L;PIIT,]QX:\/7%UK
M$RX,]W$D"9[%V4EFQZ<?44 >V^*;.6R^%.KVLS>9/#HLT3L#G<P@()_.OA#X
M"RB'XQ^$6..;]%Y]\C^M>[:%^V;H\WA:"R\2:-?WNHO"T5X]JL:Q2YR#@;@1
MD5\OZ5K3^&_$MKJNE,RO8W:W-J9@,_(^Y=P'T&1]: /N#]K/2[G5?@]=+:6T
MUU)%=P2E(4+$*"020.W-?&G@K3KO2_B/X:@O;6:TG&I6C>5/&4;!D0@X/.""
M"*^J]&_;5\(75C&VIZ9JMC>8'F1PQI+'GOM;>"1]0*^?OB5\5M*\8_&:R\86
M-E=06%O-:R/%.%$K^4P). 2 2 !C- 'UK^TY_P D,\4?[D'_ *41UX=^Q'XG
M@L?$OB'0I7"RZA!'<0;CC)B+!E'J2),_134WQ=_:I\/_ !#^'>L>'K+2=3MK
MF]6,)+.(]B[94<YPQ/137SAHNLWOAW5K34]-N'M+ZUD$L,T?56'\_H>#0!]2
M?MA_"K6-;U/3O%>DV4VH0Q6HM+R*W3>\6UV9'VCD@[R"0.-HSUKRG]G[X2:Y
MXP^(.CWKZ?<6VCZ==1W=S=S1%4(C;<$!.-Q8J!@=,D]J]9\$?MLVGV.*#Q9H
MMPMTH"M>:9M99#ZF-B-OO@GV Z5M:_\ MK^%;2R8Z1I.IZA>$':EPJ01@^[!
MF/Y"@#HOVL_%MMX>^$E[I[2*+W5Y$MH(\\E0ZN[8] JXSZL*\U_87_X^_&?^
MY:?SFKP+XC?$C6OBAXA?5M9F#/C9#;QC$4"9R%0?U/)[UW7[.OQKTOX.3:\^
MIV-Y>C4%@$?V39\NPOG.XC^^/RH WOVV"?\ A:>E#)P-&B./^V\]'[$__)5-
M5_[ LO\ Z/@KBOV@/BGI_P 7/&5GK&FVES9P06"6C1W6W<6621LC:2,8<?D:
M/V?_ (IZ?\(_&5YK&I6ES>03V#VBQVNW<&:2-LG<0,80_F* /5?VY?\ D*^$
M?^N-S_Z%'7R]7K_[1'QGTOXQ7NAS:98W=DMA'*CB[VY8N5(QM)_NFO(* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR(]F%.2.&)KYSH **** "BBB@ HHHH **** "BBB@ K]./%G_(@:S_V#)O\
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MSH5:4;MSL >=N0H![\^E<G^VOXBAU#QQHVD1.'?3;-GFQ_"\K [3[[44_P#
MA7<>,/VUM#@TR1/#6E7MWJ+J0DE^JQ0QGL2 Q+8]./K7R3K>M7OB+5KO4]2N
M'N[ZZD,LTS]68_R^@X% 'Z-^!-6M?B#\+=)ND<-#J.FK%+MYVL4V2+^#!A^%
M? /B?X8>)O"GB271;S1[QKL2&.(Q0,ZW SPT9 .X'V^G6NM^"?[06J_"%Y;-
MH/[5T&=][V3/L:-^[QM@X..H/!QVZU]"1_MI>!FM5D>QUM)<9,(MXR0?0'S,
M4 <CI'[&FER^";&_UG6[[1]8^S>?>J1')#"<%B,8!^48S\QY!KEOV./$MIHW
MQ+U/2&F)BU.U9+>1QL+O&VY01DX)4N<9/2JWQF_:JO\ XA:5/H>AV3Z-H\_R
MSRROFXG7NAQPBGN 23CK@D5X787]QI=];WEI,]M=6\BRQ31G#(P.00?4&@#[
M _;!^%NJ^*K/2O$>CVLE_)IZ/!=6\";I!&3N5P!R0#NR!_>!Z U\_P#P?^$6
MN^/?&NG0+IUS!IT$ZR7EW-"5CCC5LL,G&6., =<^P)KV3P%^VNL-E%;>+](F
MGG08-_IFW,GNT3%0#ZD-CT KJ-8_;5\(6MFS:=I>JW]U_#%*B0I^+;F(_ &@
M#L_VEO%EOX5^$&N"60"XU&/[!;QD\NTG#8^B;S^%>-?L-?\ (5\7?]<;;_T*
M2O$?BE\5];^+.NC4-6D6.&(%+:SASY4"GKCU)P,L>3@=@ .L_9W^,^E_!V]U
MR;4[&[O5OXXD06FW*E"Q.=Q']X4 =/\ MM?\E*T;_L$)_P"CI:ZO]A?_ (]/
M&?\ OVG\IJ\=_:"^*VG?%WQ98:KIMI<V<-O9+:LEUMW%A([9&TGC#"MK]G7X
MY:3\'(=>34["]O3J#0&/[)L^78),YW,/[X_*@"[^V9_R5V'_ +!</_H<E>E_
ML/?\BIXF_P"OV/\ ]%UX)\>?B98?%?QO'K6G6MQ9VZV<=OY=UMWY5F)/RDC'
MS"NM_9Y^/FC_  ?T;5K/4M.OKV2\N%F1K0)A0%Q@[F% %+]KG_DM6H?]>MO_
M .@"OL'P]_R2#3/^P%%_Z3BOA3XW?$*R^)_C^ZUZPMI[2VEABC$5SMW@JN#T
M)%>YZ7^U[X;L? UIHCZ-JK7$.G)9F11%L+"()G[^<9% 'A?P)_Y+%X1_["$?
M\Z^LOVOB1\&;K!QF\MP??YC7QK\.?$T'@SQUHFN744D]O8723O'#C>P'89(&
M:]I^./[3&A?%'P%+H6GZ7J-I</<1RB2Y$>S"G)'#$T >$>$O^1KT7_K]A_\
M1BU]^_M$_P#)%?%?_7J/_0UK\^M$ODTS6;"\D5GCM[B.9E7J0K D#\J^EOBC
M^UAX=\=> -:T&TTC4[>YOH1&DLPCV*=P/.&)[4 3_L0>)K=#XD\/R2;;J3R[
MV%#T91\C_B,I^?M3?VM?@YK^M>)X/%.B:?/JMO+;K!=0VD9DEB=,X;:.2I4C
MD XV\]17@_PRM/&$.NC6O!MC>WE_I;*[FSB,I4-D891U5@&!%?3<?[7DGAZS
MBC\7^!]7T?4F& JH424CJ0)-I')''S8SUH P/V3/@QKNA>)+CQ5KVGSZ5%';
MM!:072&.61FQN8J>0 H(Y SNXZ5J_MP_\BIX9_Z_9/\ T74OPP_:%UCXP?&3
M3["WL_[*T"WMYYFMD?>\A"8#2-@< D8 & 3W.*J_MQW*KX?\*VY(WO=3N!WP
MJ*#_ .A"@#Y#HHHH _1+]G;_ )(KX4_Z]3_Z&U?./[+OB7^QOCQJFG.^(M56
MY@"GIO1C(I_)''_ JW_A=^UAX=\"^ -%T&[TC4[BYL83&\L(CV,=Q/&6![UX
M#X;\8'PY\1+'Q+"CE;;41>&,8W,F_++^*DC\: /TNV10-+-A(RPS))P,@#N?
M85\;?L_>(SXN_:<U36225O1>3)GLA/RC\%P/PKJ?&7[9.A:WX2UC3M-TC5+>
M_N[26WAFF\L+&SJ5W'#$\9S7AGP.^(ME\+?'D6NZA;7%W;I;R0F.VV[\L!@\
MD"@#W;]N7_D%>$?^NUS_ .@QUU?[&G_)(IO^PG-_Z!'7A7[1'QUTGXQ6>APZ
M9I][9-822NYN]F&WA0,;6/\ =-;7P&_:1T/X4>")-%U'3-0O+AKR2X\RU";,
M,J@#YF!S\IH \^_:)_Y+5XK_ .OH?^@+7W%X>_Y)!IG_ & HO_2<5\ _%'Q;
M;>.O'^M:]:0RV]M?3"1(IL;U&T#G!([5]#:7^U[X;L? UIHCZ-JK7$.G)9F1
M1%L+"()G[^<9% 'GO[(7B2#0?BZEO<2>6NIV<EG'GH9,JZ@_7RR![GWKZ"_:
M>U7QQX;\.:=K/@^]N+:"UDD74$MH5D.P@%9""IPJE6!(_O#-?"UE>3Z=>07=
MK,]O<P.LL4L;;61P<A@>Q!&:^J_A_P#MJ6J:=#:^,-+N#=QKM-_IP5A+@=6C
M)&TGO@D9[ 4 <E\*?&?QE^+FJW-II7BJ2VBMXC)+>7-O&(5/&$)$9^8YZ>QK
M%_:!M?B7H%EINF>.O$%KJUI/,T]M';,A^9!M+X\M6 PY'/K[5[)K'[:?A&PL
MI/[(T;4[VZP2D<J1P1$D\Y8,Q'KPIKY8^(OQ$U?XG>)9M9UB4-*PV101\1P1
M@DA$'H,GW)))H ]A^'/[,WCI-.L_$VB>*K'2VN;87%M)87$OF2*PR%;Y5'/&
M021ZU4TG]K/XB>$+Y].UZUM=3FMW\N:*^MC!.I';*;0#]5-9GP5_::U3X76*
MZ/J%H=:T(-F*/S-LMMDY.PD$$9.=I[]",FO:V_; ^'-RPNI=)U8W* [?,LH3
M(/H?,X_.@#V/POJH\<^";&_U'2VLDU.T#3Z?=#=M5ARK9 R"/4#(/2OSW^'S
M6]K\7_#36S;[6/7;8Q,>,H+A<'\L5Z[\7/VN[GQ=H]SHWABPFTFSND,<U[<L
M/M#(>JJJDA,C@G)X)QCK7SQ8WLVG7MO=V[F.X@D66-Q_"RG(/YB@#] OVF=,
MN=6^"7B."TMY;FX @D6*%2S$+/&6.!Z*&/X5\6?#749OAY\3O#.I:K;3V,4-
MU')(+B,QGR6)5G (Y&"WY5],>'/VUO"]SIL/]M:7J5EJ 4>:+6-)82W<J2X.
M/8CCU-?/_P"T'\3M*^*_C>#6-(M;JUMXK-+4_:PH=RKNV["DXX<#KVH ^Q?C
MWX"N/B9\,-0TS3BLE^I2[M5R,2.G.T'H-RD@'IDCM7P=9?#SQ/J&MKH\&@Z@
MVI%_+^SM;LK*<X^;(PH]S@"O6_A#^UAJG@/3+?1M=LVUO2;=1'!*CA+B!!T7
M)X< < '!'KC KV!_VT? HMC(MEK;28R(C;1@Y],^9B@#TKP5H]O\)_A9I]GJ
M5RB0Z/8E[J<?=! +R$>V2V/6OB3X5:LVO_M Z)J;KL>]UHW)7T+N6Q^M:WQJ
M_:0U?XKP_P!EVUO_ &/H 8,;57W23D=#(V!P#R%'&>N< C@?ASXF@\&>.M$U
MRZBDGM["Z2=XX<;V [#) S0!]E?M?$CX,W6#C-Y;@^_S&OB?PE_R->B_]?L/
M_HQ:]W^./[3&A?%'P%+H6GZ7J-I</<1RB2Y$>S"G)'#$UX!HE\FF:S87DBL\
M=O<1S,J]2%8$@?E0!^@O[1/_ "17Q7_UZC_T-:\P_8C\203^%->T$R?Z7;7@
MO A[QNBKD?0Q\_[P]:Y_XH_M8>'?'7@#6M!M-(U.WN;Z$1I+,(]BG<#SAB>U
M?/W@+Q[J_P -_$EOK>C3"*YB^5XW&8YHSC<CCNIP/?@$8(!H ^BOVEO'7Q*^
M'/C>2XTO5[JT\-7D<;6K1P1M'&X4!XRQ0_-E2V">C<=*K?#@?'/XF>&)-;L/
M%R6,'F%(5U")8S.  2R$1'CG&>F0?2NIT+]M/PI?Z<!K>CZC971&)(H$2>)O
M7!+*?P(_.LGQQ^VO8?V;+;^$M(NC>NI5;O4@B)$>S*BEM_T)'X]* /$?B)I?
MB[Q'\4[?P_XJUBTO?$(,5@MR\BB%-QW(I9%&.9/3C=S7IO\ PI;XI? WPM>Z
M[HGB96:W(DFTW3-\R.N<%RCJ%; Y/RYQFOG.^U2[U/4I]0NKF2>^GE,TEP[9
M=G)R6)]<U]+?#3]LV32=,@T_QAIUQJ)A38-2LBIFDQTWHQ4$^K!A],T ,^&W
M[7GBS5->TW2-3T2UUHW4Z0[[)&BG^8@%L E3CKC Z=17M'[3ME8W?P4\0O?(
MA^SK%+ [+DI+YBJI7T)W%?HQKCF_;!^'=CON+72-5:Y?KY5G"C$X_B;S/\:\
M%^-G[0FJ_%XQ6*6PTK0H)/,2T5RSRMT#2-P#CG  P,GKUH \FHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /MS]BW_DDU]_V%YO_ $5#7S]^U9_R7/7_ /<MO_2>.NH^ 7[1NB?"7P5<
M:-J.F:A>3R7KW0DM0FT*R(H'S,#GY#7F7QF\=VGQ)^(FI^(;&WFM;:Z6(+%<
M8WC9$J'."1U4T <31110!^E%AI4?P[^%K6WANR2Y?3=,>2T@1<_:)5C+#..2
M7;D]SFOBA_BA\3OBUX@@T>+6]1EN+N3RQ9V)-O&H)P=RQX^4=RV>G->F_"+]
MKZ#PYX>M-&\66-W=_9$6&'4+/:[L@X D5BO('\0))QTSR=OQ3^V-X;TVUN7\
M)>'II=5N!\US>1)#&&_O-M)9_IQ]: /:?C)"P^#_ (MC4[BNDS\^PC.?Y5\/
M_"7X*ZQ\7Y;X:1J&GV;6)0S"\D=7PV<%0JG/W3Z=/<5[=%^V'X?UCP7_ &1X
MAT;4[F[NK$VE]+;+$$D9DVNR@L, Y)QCC-?.WP\^(>K_  Q\31:SHLP$B@I+
M#*/W<\9/*. >AP/<$ B@#V;Q?XP^*_[..HV6GW.NG7=+FB#0S7D)FA8C@QAV
M^<%<#C<.".*]E_9\^.FJ?&#^THM1T-+%K)%8WMJS&"1B<;,-G![_ 'CQZ=^5
MTC]L_P (ZKIJ1:_H6H6UPP_>111QW,!^A9E//H5_&HM>_;2\,Z;ISP^'- OK
MBY Q&+I8[> 'U^5F)^F!]>] ' _MJV%A:_$72I[=52^N=/#W(5<;L.RHQ]3@
M$?117N_[*3 _ W00#DB2Y!]OW\E?#WC/QCJGCWQ'>:WK$_GWMRV3M&$C4?=1
M1V4#@#\\G)KV3]G_ /:6M?A?H,N@:Y87-YIPF::WGL]K21;OO*58@$9YSG(R
M>O8 \]^,?AK5K/XD^,[J;3+N.U&K7,IN&@81A'F8HV[&,$,N/7(K@J^I/C?^
MTWX2^('PZU+P]I=GJ;W5YY966>)(TC*2*^3\Y)SMQT[U\MT %%%% !1110 4
M444 %%%% !7T#^Q/_P E4U7_ + LO_H^"OGZOH']B?\ Y*IJO_8%E_\ 1\%
M'VO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M\_?ML?\ )*]*_P"PU%_Z(GKXHK[7_;8_Y)7I7_8:B_\ 1$]?%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'V!^S)\6/"'A#X60:=K.OVFG7JW4SF"9B&"DC!Z5\W_&#5K/7?B?XEU#3
M[A+JRN;UY(IH_NNIZ$5Q]% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Z=^S_\ %M/A)XR:[NXFGTF^C%O=B,9=!G*NH[D'MZ$]
MZ^M]<\0?";XQZ1!%JVKZ+J=O&?-C2XO/LTT1/7'S*ZYXSTSQ7Y]44 ??FB:E
M\'?@Q:7-QI6I:-IIF7,A@O#=3R*.P^9W(SV'%?*?[0/Q@'Q=\717%I%)!HUA
M&8;-)1AVR<O(P[%L#CT4=\UY?10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5] _L3_\E4U7_L"R_P#H^"OGZOH']B?_ )*IJO\ V!9?_1\%
M 'VO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!\_?ML?\DKTK_L-1?^B)Z^**^U_VV/\ DE>E?]AJ+_T1/7Q10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >N?#S]F3Q
M1\2O"UMK^F7^D06=PSHJ7<TJR JQ4Y"QL.H]:Z7_ (8G\<?]!7P__P"!$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /G[]MC_DE>E?\ 8:B_]$3U\45]K_ML?\DKTK_L-1?^B)Z^** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KZ&_8E_Y*5K/_8(?_T=%7SS7T-^Q+_R4K6?^P0__HZ*@#J_VZ/^/3P9_OW?
M\H:^3J^L?VZ/^/3P9_OW?\H:^3J /T6^ :"3X+>%$/1K$ _F:XGQ!^TUX+^%
MFOKX0M=+NY++2PMK))9*OEP%1@HH)!;;T)]<]:[?X ?\D9\)?]>2_P S7Y_^
M,;EKSQ=KEPS;FEOIY"Q[DR,: /:OAA\0O!FL?&GQ!XV\:WRVSO-YFE0SP22*
MISA&.U2 415 SW.>H%>E?$W]L/3O#.L1V/ABRM_$,8C5Y;UIRL63SL4 9) Q
MD]CQCBO$/V?_ ($O\8=2NY[VZDL="L2JS2P@>9*YY"(3D#CDD@XR..>/=->T
MCX%_ Z=;/4M-M[W5E0.;:>-[V8@]"0V43/7!V^M 'I'P=^*%K\9_!<NJ'3A9
M,DSV=S:2.)4W!5)P<#*E7'4>HYKX<^,OA>W\)?%3Q'H]C%Y=K#=DP0J/N*X#
MJH]@& 'TK[F^#GQ)T?XF>';N]T+3)=*TVSNC:1PRHB$X16R%0D*/GZ9[5\D_
M&>6-OVGKYYL+"NIV8?<>-H2$'^5 'U-\*/AUH_P0^'AGN4CBODM?M>K7S#+$
MJNYES_<7D >V>I->5I^W#8MKZQ-X7F31C)M-S]J!G"9^_P"7MQG'\.[\:]D^
M/,<LGP<\7"$D.+!R<#^$8+?H#7YR4 ?;G[2UOX&\:^ [B>;7-(B\06D)N-.<
MW2":3'S&+;G)##@ ]"0:\Y_8>_Y&KQ-_UY1_^AU\_7OA/7--M(KJ[T;4+6UE
M02QSS6KHCH1D,&(P000<U] _L/?\C5XF_P"O*/\ ]#H [OX\?"'4/BY\7/#=
ME!NM]+M[ O?7N.(D\UOE'J[8( ^IZ UVWC_QWX;_ &=?A_:VMI;1JZ1F'3=,
M0X:9AU9CUP"<LQZY]378>,_'^A> +2TN==OX[*.ZG2WB#<EF8@$X_NKG)/8?
MA7D_[6?PL_X3+P:OB*PBWZKHJ,[A1S+;=7'_  '[P]MWK0!\;^+/%>I^-M?N
M]9UBY:ZOKEMS,>BCLJCLH' %9%%% !1110 4444 %%%% !7T#^Q/_P E4U7_
M + LO_H^"OGZOH']B?\ Y*IJO_8%E_\ 1\% 'VO1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\_?ML?\ )*]*_P"PU%_Z(GKX
MHK[7_;8_Y)7I7_8:B_\ 1$]?%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5]#?L2_\E*UG_L$/_Z.BKYYJYI6M:CH
M<[3:;?W.GS,NQI+69HF*Y!P2I'&0./:@#ZE_;H_X]/!G^_=_RAKY.K0U;Q'J
MVO"(:GJE[J(BSY8N[AY=F<9QN)QG _*L^@#]%_@!_P D9\)?]>2_S-?GQXB_
MY&#4_P#KZE_]#-6K/QOXBTZUCMK77]4MK>,;4AAO)$11Z !L"L9W:1V=V+.Q
MR68Y)/K0!]8?L4>-M.@T[6?"T\R0ZA)<_;K=7('G*456"GN5V X]#GL:Z3XR
M?LKO\2_'$OB*QUU-.:[6,74,\!DP44(&3!'\*C@]QUYX^+89I+>5)8G:*5&#
M*Z'#*1T(/8UU4OQ<\;S61M)/%VM/ 1@JU_*21Z$[LXH ^[/A#X:\-_#[2+GP
MAH>I)J%[IS+/J!W R>;)G#.!PI(3 7J HSZGY!_:ITJ;2OC=K<CH4CO$@N86
M_O*8E4G_ +Z1A^%>9Z9X@U31)99=.U*\L)9>)'M9WC9^_)4C-,U76]1UV=)M
M2O[K4)D78LEU,TK!<YP"Q/&2>/>@#[Y^"OQ7TGXP^"([6ZEBDUA+;[/J5A*?
MF?Y=K.!W1NO'3.#7$G]BGPO_ ,)"+L:O?C2O,WG3B%SC.=GF]=O;IG'?/-?&
MUG>W&G7,=S:3RVMQ&<I+"Y1U/J".1752_&+QU-;B%O&&MF/&.+^0$CW(.30!
M]A_M$_%C2_AOX$N]%LYXQKE];FTMK2!ANMXRNTR,!]T!3\OJ<8Z''D7[#W_(
MU>)O^O*/_P!#KYMN+B6[GDGGE>::1BSR2,69B>I)/4U:TK7M3T*2233=1N].
M>0;7:TG:(L/0E2,T ?0G[;Y/_"9^'1DX&GL<?]M#7K?[+GQ/7X@^ 1I5_()=
M7T=5MI@YR9H<8C?GKP-I]UR>M?#^JZYJ6NRI+J6H76H2(NU7NIFE*CT!8G I
M-*UK4=#G:;3;^YT^9EV-):S-$Q7(."5(XR!Q[4 >A?M"_"UOA=X_N(+:,KHU
M_FZL& X52?FC^J$X^A4]Z\QK1U;Q)J^O+&NIZI>ZBL9)07=P\H4GKC<3BLZ@
M HHHH **** "BBB@ KZ!_8G_ .2J:K_V!9?_ $?!7S]7T#^Q/_R535?^P++_
M .CX* /M>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Y^_;8_Y)7I7_8:B_\ 1$]?%%?:_P"VQ_R2O2O^PU%_Z(GKXHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OH']B?_DJFJ_\ 8%E_]'P5\_5] _L3_P#)5-5_[ LO_H^"@#[7HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?OVV/^25Z5
M_P!AJ+_T1/7Q17VO^VQ_R2O2O^PU%_Z(GKXHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OH']B?\ Y*IJO_8%
ME_\ 1\%?/U?0/[$__)5-5_[ LO\ Z/@H ^UZ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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M%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6BNZ_X4?XV_Z O_DU!_\ %T?\*/\
M&W_0%_\ )J#_ .+H]E4_E?W![2'='"T5W7_"C_&W_0%_\FH/_BZ/^%'^-O\
MH"_^34'_ ,71[*I_*_N#VD.Z.%HKNO\ A1_C;_H"_P#DU!_\71_PH_QM_P!
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MH_QM_P! 7_R:@_\ BZ/^%'^-O^@+_P"34'_Q='LJG\K^X/:0[HX6OH']B?\
MY*IJO_8%E_\ 1\%><?\ "C_&W_0%_P#)J#_XNO:_V2_ASXB\(?$;4;S5M/\
MLEL^E20J_GQOES-"0,*Q/13^5)TYI7<6-3B]$SZSHHHK,L**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y7XC?\@2#_ *^%_P#06KSF
MO1OB-_R!(/\ KX7_ -!:O.:]O"?PCR\1_$"BBBNTY@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJOAS_ ,AN?_KW;_T)
M:Y6NJ^'/_(;G_P"O=O\ T):Y\1_"D:TOC1Z-1117SY[ 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!ROQ&_P"0)!_U\+_Z"U><UZ-\
M1O\ D"0?]?"_^@M7G->WA/X1Y>(_B!1117:<P4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5U7PY_Y#<__ %[M_P"A+7*U
MU7PY_P"0W/\ ]>[?^A+7/B/X4C6E\:/1J***^?/8"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"QESLG@;<I(ZCV([@\BN-^*?QOT+X17&G0ZQ::C<M?*[QFQCC< *0#NW.O\
M>'3-:N48KF;T(46W9;GH=%>!?\-H^"?^@7K_ /X#P?\ QZIH/VRO LJY:TUJ
M$YQM>VC)^O$AK+V]+^8OV4^Q[O17#^!/C3X0^(TYMM&U97O@-WV.X0Q2D=R
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5\.?^0W/_P!>[?\
MH2URM=5\.?\ D-S_ /7NW_H2USXC^%(UI?&CT:BBBOGSV HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?B-_R!(/^OA?_ $%J\YKT
M;XC?\@2#_KX7_P!!:O.:]O"?PCR\1_$"BBBNTYC,\3>(+7PIX>U'6+TD6MC
M\\FWJ0HS@>YZ#W-?GOXA\0>(OC;X_220-=ZGJ$HAM;1#\D*Y^5%]% Y)^I/>
MOKK]J_47L?@SJ,:,5^U7$$#8[C>&(_\ '*\*_8WTJ&^^*5W=2J&:RTV22(D?
M==G1,C_@+,/QKS<0W4J1I=#MHVA!U#T?PC^QAH5OI49\2:I>7>I,,NM@ZQPQ
MGT&Y26^IQ]*XKXR_LI'P;H5SKOAF]N-0LK53)<V=T 98XQU=64 ,!U(P" "<
MFOL2HYX([J"2&9!)%(I1T89#*1@@UT2PU-QLD8JO-.[9\:_LJ?%ZZ\.^*+?P
MGJ%PTNCZD^RV$C<6\YR5"^@<\$>I!]<^Z_M3_P#)$->_W[;_ -'QU\0^8WA;
MQ;O@<A].OMT;]\QR<']*^WOVI_\ DB&O?[]M_P"CXZY*,VZ,XOH=%6*52,EU
M/A+3]0N=)O[:]LYFM[NWD66*5#AD=3D$?0BOT0^$'Q(M_BCX(L]7CVI>*/)O
M8%_Y93 #=^!X8>Q%?%?PI^&+_$W2O%4%H"=6L+1+JS4'_6,&(:/_ ($.![X]
MZTOV>?BF_P +_'*1WLC1Z+J)%M>JW B.?EEQ_LDG/L6[XK'#S=)IO9FE:*J)
MI;H[S]MK_D:?#7_7E)_Z'7KW[*?_ "132/\ KM<?^CFKR#]MA@_B?PRRD,IL
MI"".A^>O7_V4_P#DBFD?]=KC_P!'-75#_>9>G^1A/^ CU[I7YY_%SQ/<?%7X
MMZA/8YN4GN5L-/1?XD!V)C_>/S?5J^Q/VA/&_P#P@OPLU:YBD\N]O%^PVI!P
M=\@()'N%#M^%?,G[)O@O_A)OB?'J4T>ZTT6(W3$]#*?EC'UR2P_W*,2^><:2
M"@N6+J,Y?X)^,9/AI\5=,N[LM;6YE-C?*_&V-SM;=_NMAO\ @%?H77P=^U'X
M+_X1+XJWMQ%'LL]647T>!QO8D2#Z[P3_ ,"%?57[/OCG_A/?A=I-W+)YE]:+
M]ANCG)\R,  GW92C?\"HPKY)2I,*ZYHJHCT>BBBO1.,Y_P >^"K#XA>%+_0M
M17]S<IA9 ,M$XY5U]P>??D=#7P##+KOP4^) 8C[/J^CW.&7G9*O<>Z.I_)J_
M1ZOG3]L'X<V>I>&8O%\3Q6VHV!2";<0IN(F;"@>K*3D>Q;T%<.*I\R]I'='5
M0G9\CV9I?&#]H2PL_A%8ZCH%SC4_$,)CM@&^>V'25CZ,IRH_VCD9Q7@?[.GP
MF;XF^-%FO8BV@Z:5FNR1Q*W\$7_ B,G_ &0?45Y;:P27]S;VJ.H:1Q&GF.%5
M2QQR3P!D]:_1GX5_#VS^&7@NQT6VVR2J/,NKA1CSIC]YOIT ]@*YZ=\54YI;
M(VG:A"T=V0?&=0GPC\6JH"J-,G  Z#Y#7PQ\(/!5K\1/B+I/AZ]GFMK:\\[?
M+;XWKLA=QC((ZJ!7W1\:?^22^+O^P9/_ .@&OA+X5>.$^''CW2_$4EHU\EEY
MN;=9-A??$\?7!QC?GIVJL5;VL>;85"_)*VY],_\ #%/A;_H.:Q^<7_Q%>+?'
MOX$?\*@DT^ZL]0?4=+OF>-3,@62)U .TXX.0>" .AXKU0_MO66#CPE.3_P!?
MR_\ QNO'OC%\:M3^-NH:9 -+%A;6I9;>R@<S2/(^ 26P-QX   '4]<U%5X?D
M?)N535;F][8]W_8S\77>L^$-8T2ZE::/29HVMRQR4CE#'9] R,1_O5]#UXU^
MS!\+K_X<^#+F?5XFMM4U659I+9OO0QJ"$5O]KEB1VR!U!KV6O0H*2IQ4MSCJ
MM.;:"OFG]LOX@MI^D:=X1M92LM[B\O O'[I20BGV+@G_ ( *^EJ^ ?V@=6G\
M7?&W6XDY,5RFG0J3P-F$_5MQ_&LL5-QIV74O#QYIW?0^H/V6_!J^%?A187+Q
M[;S5V-]*3UVGB,?38 ?^!&O OVQ?^2M0_P#8,A_]#DK[2TVPBTK3K6RA&(;:
M)(4 &,*H 'Z"OBW]L7_DK4/_ &#(?_0Y*SQ$>2@H]K%T9<U5LZ+X0?LOZ!\1
M/AUI/B&]U74K:YO/.WQ6YCV+LF=!C*D]%!JG\7_V4D\#^%;S7]#U::^@LE$E
MQ:W:*'V9 +*RX!QG)!'3//&#M_!;]I3PEX ^&>C:#J<>I-?6GG>8;>!63YIG
M<8)<=F':JOQE_:LTSQ=X1OM \.:?>(;Y/)GN[U50+&?O!%#-DD<9.,9-8VP_
MLM=[?B:WK>T\KG-_LA^-+S1OB0N@>:S:=J\4@:%F.U940NK@>N%*^^1Z"NG_
M &WO^0IX2_ZXW/\ Z%'7)?LC>$+K6OBA%K*Q-]@TB&1Y)2/E\QT:-$^N&9O^
M UUO[;W_ "%/"7_7&Y_]"CJ5?ZJ[]QNWMU8Y[X!_L\Z+\6?!UYJ^HZE?V<\%
M^]HJ6I3:5$<;9.Y2<Y<_D*]&N?V*/#C0.+?Q!JD<Y'R/*L;J#[@*"?S%>6?!
M#]HNW^$7A2[T>;0Y=3:>]>[$R7(C #1QIMP5/]S.?>N[O?VWX_(86GA%O.((
M5I[_ .53V) CY^F1]:JF\/R+GW^8IJMS/EV/G?6=.U3X8^.KFT2Y,.J:/=D)
M<0G'S*<JX]B,'!]>:_1?PIK)\1^%M'U8J$-_9PW6U>@WH&Q^M?G_ .'_  QX
MC^.7CZZ>V@::[O[DW%Y<JA$-LKMDLQ[ <X&<G&!FOT)T;3(M$TBQTZ DP6D"
M6\9/7:BA1^@K3!IWDUL1B6M$]RY117 _&UO%K^ KJV\&6DEQJ]RZQ-)#*D;P
M1')=U+$<\!1CD;LCI7H2?*FSC2N[&KKWQ1\(^%[I[;5/$>G6=TGWX'N%,B\X
MY4<C\J;H7Q7\'>);I;;3?$NFW5RYVI +A5D<^BJ<$_A7RE\-/V4?$'C$WLWB
M*2?PQ#"X1%FM]\LS8R2 6 VCCGG)^E<O\</@K-\&M2TQ!J0U.SU!':&;RO*=
M60KN!&3_ 'UP<]_:N%UZJCSN&AUJE3;Y5+4_0"N=U'XB^%-(O9;.^\3Z-97<
M1VR6]QJ$4<B'K@J6!'XUQO[,_BR^\7_";3Y]1G:ZN[662T:>0Y9PIRI8]R%8
M#/?&:^2?VA?^2S^*O^OD?^@+6M6OR4U-+<SA2YIN+>Q]X>)/&>A>#X$EUO5[
M/2T?.S[3,$9_]T=3^%5?#/Q'\+^,9FAT77K'49U&3##,/,QZ[3SCWQ7S7X;_
M &<_$7QJL/\ A,?%/B5K*[U5?/MX_L_G$1GE"1N4*N.0H[$<BO$O%WAO5OA-
MX]N=-:Y,6I:9,KPW=N2N> R.OID$'';I64\14A:3C[K+C1A+W5+4_136O$6E
M>&K9+C5]3L]*MW?RUEO;A(49L$[06(!. 3CV-?GWX'\5W6J_%[PWK7B#5&FD
M&J6\D][>S8"() 22Q.%4#Z "OJ_Q[X)O?VA_A'X5DM[R#3+F80:C*94++DPL
M&48]W_(5\6>%= D\5>)M*T:*58)=0NH[597&50NP4$@=N:RQ4Y.4;+3IYFE"
M*497W/TFT/Q/HWB:.631]6L=62(A9&L;E)@A/0$J3BEUWQ+I/A>T%UJ^I6NF
M6Y.!)=S+&"?09/)KSOX"_!V]^#VF:Q;WFH0:BU[*DBFW0KMVJ1CGZU\^>,/A
M-\4/B?\ $KSM=TBYLEO9RB3R.LMO909)"Y0D *.W<^YKKE5G&"?+JSGC",I-
M<VB/I^/XY^ ))_)'BW3 ^2,M-M7_ +Z/'ZUV5C?VNJ6D=U9W,-W;2#*30.'1
MA[,.#7R1X]_9 ;PIX.U/6;+Q&;Z;3[=[F2"6T\L.B*6?#!S@X!(X]JS?V/?%
MM_I_Q"DT$3NVFZA;2.;=F^594 8.!V. P..N>>@K-5YQFH5(VN6Z47%R@]C[
M1KDM=^+7@WPS?-9:GXDT^UNTX>$S!G0^C 9VGV-><_M6?%*]\"^%;/2=)G:U
MU+5RZM<1G#Q0KC=M/9B6 SZ;N^#7S[\%OV?]2^,$=UJ#WZZ5I,$GE-<M$97E
MDP"55<@< C))XR.#SBJE>2G[.FKLF%).//-V1]NQ^,=!ET)M:76M/.CK@-?_
M &I! I)  +YP#D@8)ZD"C1/&.@>)I98M'US3=5DB4-(EC=QS%!ZD*3@5\6_%
MSX2^(O@;ID]M;ZP=1\-:WM@F9(S&"Z,)%5T)(!RF0P/(#=.AZ[]B7_D:?$O_
M %Y1_P#H=3'$2=14Y1L4Z,5!S3N?7E<QX@^)OA/PK<-;ZMXATZQN%^]!)<+Y
M@^JCG]*\D_:J^,M[X)LK7PWH=PUKJE_'YUQ=1G#PP9*@*>S,0>>H"G'4$>(_
M"+]G/6_BSI\FKO?1Z1I)D*)=31F5YF!^8JF1D Y!)(YXYP<54KM3]G35V*%)
M.//-V1]G^&_B#X9\7N4T77;#4I0,F&"=3(!ZE,[L>^*Z&O@#XJ?!CQ!\$-0L
M+XWHN+263_1M3L]T;)(.=I&<JW<<G.#SP:^H/V;?B[<?%#PI/!JC!M;TMDCN
M) ,>>C [),=B=K X[C/&<4Z5=RE[.:LQ3I)1YXNZ/0]8\=>&O#UY]DU7Q#I6
MF76T/Y%Y>Q1/M/0[68'%2ZEXNT/1M(AU6^UBQM=-F57BNY;A!%*K#*E&SALC
MD8SFOC;]K_\ Y*\?^P?!_-JT_AQ\#_$/QWT*QUK7->;3M(M($L-.C$/FDQQ*
M(_E7< HRO)Y)(;ZU'UB;FX1C=HKV,5%2;/J'P_\ %?P?XIO5L]+\1Z?=W;?=
M@68!W_W5."WX5UE?G1\6/AC?_"'Q<-)N+M;M6B6YMKR)=GF(21G;D[2&4C&3
MT![U]L? ?Q;=>-OA3H6IWSF2]\MH)I&.3(T;E-Q/<D*"?<FKHUW.3A-6:)J4
ME&*E%W1XYJ7P.^'-SXTNM0E^)5C#?R:@\[V9N[8,LAD+&/!;.0>,=:^HJ_.#
MQ#_R5S4O^PY+_P"E!K[3_:*\;7W@3X6ZA?:;(8+^X=+2*91DQ[S\S#T.T-@]
MCBLJ%2*4Y6M8NK!MQ5[W.G\0?$KPIX5N&M]6\0Z=87*C+6\MROF@>Z9S^E0Z
M)\5O!WB.YCMM-\2Z;=7,G"0+<*)&/H%.":^+O@C\+='^+&JZC%K/B9=)GBV-
M';G:9KHL3N*ECSC'. 3\PZ=^U^)/[(.L:#]DE\)3R^($FD\N2VF"121<$AMQ
M8*5XP>F#CKG@5>K*//&.@.E33Y7+4^QB0H))  Y)-?%_[6WC]/$7BS3K#1_$
M$6IZ"M@DCPV%TLL'G^;)DML)!;:$Z]!CUKZ.^"^E^,-+\!KI?C((=0MR8H)A
M.)7:':-H<CJ0<C.3D8KXK^+?PMNOA)XDMM'O+Z&_DGM%NQ) I4 %W7'/?Y#^
M=&*G)TU9:,="*4WJ?6'[-OC3P_#\*O"^CR:[ID>K$2H+!KR,3[C/(0/+SNR0
M0<8[USO[9G@Y=2\':;XCBCS<:;/Y$K#_ )XR<<_1PH'^^:XK]GW]G[4-0E\*
M^/%U:V2T6<W'V0QMYF$D92,].=M?1WQ@T8:_\+O%-D0&9M/F= ?[Z*77_P >
M4545*I0<9*VFA,FH5;Q9PG[*7Q";QA\.QIEU,9=1T5A;,6.6:$C,1_ !E_X!
M71?%+X(:;\6=<T2[U:]GALM-216M;< -,6*GES]T?+C@9.>HKYM_8^U]],^*
MCZ?G,6I64D17_:3$@/Y*P_&OMNJH-5J24M2:J=.I>)\;^%-'LO#_ .V%#ING
M6R6=C;74L<4$8PJ*+1O\Y[U]D5\AZ;_R>L__ %^R_P#I(U?7E&&T4O5A6^SZ
M!11178<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS0@B-KZUCF* ]=NX'&<#IZ5K44FD]PO;8S]%\/:7X;M7MM(TVSTJV=S(T-E
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M"M<7=C%+(0. "S*3Q6]13:3W$FUL065C;:;:0VMI;Q6MK"H2*"! B(HZ!5'
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M2DY-R844459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5\.?^0W/_
M ->[?^A+7*UU7PY_Y#<__7NW_H2USXC^%(UI?&CT:BBBOGSV HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?B-_R!(/\ KX7_ -!:
MO.:]&^(W_($@_P"OA?\ T%J\YKV\)_"/+Q'\0****[3F"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\ ?;?_ !-'_"N=2_Y[VG_?;?\
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M31_PKG4O^>]I_P!]M_\ $T>WI?S![*?8Y6BNJ_X5SJ7_ #WM/^^V_P#B:/\
MA7.I?\][3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\ ?;?_ !-'_"N=2_Y[
MVG_?;?\ Q-'MZ7\P>RGV.5HKJO\ A7.I?\][3_OMO_B:/^%<ZE_SWM/^^V_^
M)H]O2_F#V4^QRM%=5_PKG4O^>]I_WVW_ ,31_P *YU+_ )[VG_?;?_$T>WI?
MS![*?8Y6BNJ_X5SJ7_/>T_[[;_XFC_A7.I?\][3_ +[;_P")H]O2_F#V4^QR
MM%=5_P *YU+_ )[VG_?;?_$T?\*YU+_GO:?]]M_\31[>E_,'LI]CE:*ZK_A7
M.I?\][3_ +[;_P")H_X5SJ7_ #WM/^^V_P#B:/;TOY@]E/L<K175?\*YU+_G
MO:?]]M_\31_PKG4O^>]I_P!]M_\ $T>WI?S![*?8Y6BNJ_X5SJ7_ #WM/^^V
M_P#B:/\ A7.I?\][3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\ ?;?_ !-'
M_"N=2_Y[VG_?;?\ Q-'MZ7\P>RGV.5HKJO\ A7.I?\][3_OMO_B:/^%<ZE_S
MWM/^^V_^)H]O2_F#V4^QRM%=5_PKG4O^>]I_WVW_ ,31_P *YU+_ )[VG_?;
M?_$T>WI?S![*?8Y6BNJ_X5SJ7_/>T_[[;_XFC_A7.I?\][3_ +[;_P")H]O2
M_F#V4^QRM%=5_P *YU+_ )[VG_?;?_$T?\*YU+_GO:?]]M_\31[>E_,'LI]C
ME:*ZK_A7.I?\][3_ +[;_P")H_X5SJ7_ #WM/^^V_P#B:/;TOY@]E/L<K175
M?\*YU+_GO:?]]M_\31_PKG4O^>]I_P!]M_\ $T>WI?S![*?8Y6BNJ_X5SJ7_
M #WM/^^V_P#B:/\ A7.I?\][3_OMO_B:/;TOY@]E/L<K175?\*YU+_GO:?\
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M175?\*YU+_GO:?\ ?;?_ !-'_"N=2_Y[VG_?;?\ Q-'MZ7\P>RGV.5HKJO\
MA7.I?\][3_OMO_B:/^%<ZE_SWM/^^V_^)H]O2_F#V4^QRM%=5_PKG4O^>]I_
MWVW_ ,31_P *YU+_ )[VG_?;?_$T>WI?S![*?8Y6BNJ_X5SJ7_/>T_[[;_XF
MC_A7.I?\][3_ +[;_P")H]O2_F#V4^QRM%=5_P *YU+_ )[VG_?;?_$T?\*Y
MU+_GO:?]]M_\31[>E_,'LI]CE:*ZK_A7.I?\][3_ +[;_P")H_X5SJ7_ #WM
M/^^V_P#B:/;TOY@]E/L<K175?\*YU+_GO:?]]M_\31_PKG4O^>]I_P!]M_\
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M 'VO_P 31];I!]7F><T5Z-_PKG3?^>]W_P!]K_\ $T?\*YTW_GO=_P#?:_\
MQ-'UND'U>9YS17HW_"N=-_Y[W?\ WVO_ ,31_P *YTW_ )[W?_?:_P#Q-'UN
MD'U>9YS17HW_  KG3?\ GO=_]]K_ /$T?\*YTW_GO=_]]K_\31];I!]7F><T
M5Z-_PKG3?^>]W_WVO_Q-'_"N=-_Y[W?_ 'VO_P 31];I!]7F><T5Z-_PKG3?
M^>]W_P!]K_\ $T?\*YTW_GO=_P#?:_\ Q-'UND'U>9YS17HW_"N=-_Y[W?\
MWVO_ ,31_P *YTW_ )[W?_?:_P#Q-'UND'U>9YS17HW_  KG3?\ GO=_]]K_
M /$T?\*YTW_GO=_]]K_\31];I!]7F><T5Z-_PKG3?^>]W_WVO_Q-'_"N=-_Y
M[W?_ 'VO_P 31];I!]7F><T5Z-_PKG3?^>]W_P!]K_\ $T?\*YTW_GO=_P#?
M:_\ Q-'UND'U>9YS17HW_"N=-_Y[W?\ WVO_ ,31_P *YTW_ )[W?_?:_P#Q
M-'UND'U>9YS17HW_  KG3?\ GO=_]]K_ /$T?\*YTW_GO=_]]K_\31];I!]7
MF><T5Z-_PKG3?^>]W_WVO_Q-'_"N=-_Y[W?_ 'VO_P 31];I!]7F><T5Z-_P
MKG3?^>]W_P!]K_\ $T?\*YTW_GO=_P#?:_\ Q-'UND'U>9YS17HW_"N=-_Y[
MW?\ WVO_ ,31_P *YTW_ )[W?_?:_P#Q-'UND'U>9YS17HW_  KG3?\ GO=_
M]]K_ /$T?\*YTW_GO=_]]K_\31];I!]7F><T5Z-_PKG3?^>]W_WVO_Q-'_"N
M=-_Y[W?_ 'VO_P 31];I!]7F><T5Z-_PKG3?^>]W_P!]K_\ $T?\*YTW_GO=
M_P#?:_\ Q-'UND'U>9YS17HW_"N=-_Y[W?\ WVO_ ,31_P *YTW_ )[W?_?:
M_P#Q-'UND'U>9YS17HW_  KG3?\ GO=_]]K_ /$T?\*YTW_GO=_]]K_\31];
MI!]7F><T5Z-_PKG3?^>]W_WVO_Q-'_"N=-_Y[W?_ 'VO_P 31];I!]7F><T5
MZ-_PKG3?^>]W_P!]K_\ $T?\*YTW_GO=_P#?:_\ Q-'UND'U>9YS17HW_"N=
M-_Y[W?\ WVO_ ,31_P *YTW_ )[W?_?:_P#Q-'UND'U>9YS17HW_  KG3?\
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MW_WVO_Q-'_"N=-_Y[W?_ 'VO_P 31];I!]7F><T5Z-_PKG3?^>]W_P!]K_\
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M %\@]FCZJ_X7;X+_ .@U_P"2L_\ \11_PNWP7_T&O_)6?_XBOE6BCZE3[O\
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M4?\ "[?!?_0:_P#)6?\ ^(KY5HH^I4^[_KY![-'U5_PNWP7_ -!K_P E9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !"_X53\.-;\5_V?_:G]FQI)]D\[R?,W2*F-^UL?>ST/2OE'_AY?_P!4X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .&^-O\
MR3#6O^V/_H^.OE6OJKXV_P#),-:_[8_^CXZ^5:]O!?PWZ_Y'13V"BBBO0-0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"YH^L7F@ZE!?V$[6]U
M"VY'7^1]0>XKZD^&WQ)L_'VF_P -OJD*C[1;9_\ 'U]5/Z=#V)^3ZN:/K%YH
M.I07]A.UO=0MN1U_D?4'N*Y:]!5EYD2CS'VO17&?#;XDV?C[3?X;?5(5'VBV
MS_X^OJI_3H>Q/9UX$HN#Y9;G,U;1A1114B"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6IV&EVBE8+9+)&" L6(RT9/4D\GO6M_PU!\<O^AFU7_P B_^-4 ?J=17S/\
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MGK4TMWK-YX:NWN))$"N[F*0<J .>G05\#_LP:/?P?'_P/)+97,<:Z@I+/$P
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M\E2\,_\ 8&'_ */DKH_V1OC=\3O'?QCMM*\5:U?7VDM9SR-#<6J1J74#:<A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGF;</$3T#CICMD?D.*\^K>$XU%S192:>J"BBOI.+]GOPN\2,9-0R0#_KU_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KB@"Q1110 444QIHTE2-I%61\[4) +8ZX'?% #Z*** "BD9@BEF(50,DDX
M%,AGCN8EDAD66-NCHP(/XB@"2BBB@ HIC31I*D;2*LCYVH2 6QUP.^*?0 44
M44 %%,AFCN(EDBD66-NCH00?QI] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ,E=HXG94,K*I(12 6/H,\?G7Q]X)\/^+?VD/VCM,^(NN>'+GPMX3\
M,CRK."^!66>2-G*@9 W'S&W,P&T!0N2>:^Q** "BBB@ HHHH **** "BBB@
MHHHH **** &2NT<3LJ&5E4D(I +'T&>/SKX^\$^'_%O[2'[1VF?$77/#ESX6
M\)^&1Y5G!? K+/)&SE0,@;CYC;F8#: H7)/-?8E% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <-\;?^28:U_VQ_\ 1\=?*M?57QM_Y)AK7_;'_P!'
MQU\JU[>"_AOU_P CHI[!1117H&I;TG_D*V7_ %V3_P!"%?7?CN:2V\%:[+%(
MT4J64S*Z'#*0AP01T-?(FD_\A6R_Z[)_Z$*^S-9TN+6])O-/G9TANH6A=HR
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MCSX_ATW27\/6<H>^N@/M.T_ZJ+K@^[>GIGU%?/-1@XN,&WU"FK(*U1XLUL#
MUG4 /^OI_P#&LJBN]I/<T/ISX#7]UJ/@=Y;NYENI?M<B[YG+MC:O&37E'Q=\
M1:K9?$36(+?4[RWA1H]L<5PZJ/W2'@ UZA^SS_R(,G_7[)_Z"E>/_&?_ )*9
MK?\ O1_^BDKS**7UB:,8_&SEK[6=0U-%6\OKF[53E5GF9P#[9-=MX/\ @MJG
MC+08=5MKZT@AE9E"2[MPVL0>@]J\]KZC^!7_ "3;3_\ KI-_Z,:NC$S=*%X=
MRYOE6AY;X7^ FJZ_!-/=7D>G0+(\<1:,NTNTD;@,C"DC@G\JI6_PUUG1?B&F
M@:=K4=OJ!@,R7=O(\95<'@XY!('09X(YKKOB9\:=7T'Q7<:7HX@B@LRJN\D>
M\R/C)'L!G''/!YK#^%.OW/BCXP_VI>;1<7,<K,$SM7"8 &>P  K)2K.+J2VL
M3>5KLS?B?X.\2>&;"REUS7GU>*64K&C7$LFQL<G#]/PKD_"WA+4_&6IBQTR#
MS90NYW8[4C7U8]J]H_:4_P"0'HW_ %\O_P"@UP7PT^*\7P^L;BU.CB\^T2>9
M).L^Q^!@#&TY Y_,U=.<Y4>:*NQIMQNCI;?]FF\:+,^NP1R8^[';LXS]2P_E
M6#XK^!&N>'+*6]MIH=4MHE+.(05D50.3M/4#V)/M5F^\<^/O&>L276AQ:E!8
MLW[B*VB.Q5[;FQ@GODFO>/"3ZK+X;L3KD:QZKY>+A1M/.2 ?EXY&"<>M<\ZM
M:E9RDGY$N4H[GQ_I/_(5LO\ KLG_ *$*^K?BI_R3S7?^O8_S%?+\MNEIXN>"
M,!8XKXHH'8"3 KZ@^*G_ "3S7?\ KV/\Q5XEWG3?]=!SW1\CT445Z9J%%%%
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MD9)YH ^Z:*Q?&GB_3/ /A74_$.LS_9],T^$S3.!DXZ!0.[$D #N2*_._Q?\
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MWQ?\:?V9X&:\TJUFE9;'3-)@#W4BC.&D?!). 2<$*.?3- 'Z245^8/B3Q_\
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M;3QQX2T;Q!8AEM-3M(KN-7^\H=0VT^XS@^XH V:^<_V]_P#DWN[_ .PC:_\
MH1KZ,KYS_;W_ .3>[O\ ["-K_P"A&@#\SL'&<<>M?K=^S-XR_P"$[^!7@_4V
M??<+9+9SDG)\R$F)B?<[-W_ J_-/PAX/_P"$@^#?Q!U6--T^AW>EW)8#GRG:
MXB8?3+H?^ U];?\ !.'QE]L\(^*?"\K_ #V%W'?PJ3R4E7:P'L&B!^KT 9W_
M  4B\9>7IWA#PI&_,LLNISIGH%'EQ'\=TOY5\,=*]Z_;"\23_$7]I'5K"R)N
M!8O#HMJ@/5UX9?\ OZ\@KSOXV>'H/"7Q5\1Z';8^SZ;<_8X\#&5C55!_2@#]
M1?V@?#>I>+_@QXMT;1[5KW4[RR,4%NC!3(VX<9) [=S7RO\ L<? #X@?#?XQ
MKK'B3PW/I6F_V?/#]HDFB8;V*X&%<GG![5]4?M ^)-2\(?!CQ;K.CW366IV=
MD98+A%#&-MPYP01W[BOE?]CCX_\ Q ^)'QC71_$GB2?5=-_L^>;[/)#$HWJ5
MP<J@/&3WH ^ZJ*\L_:*^.EE\!O ;:O)"M[JUTYM].LF.!++C)9L<[%')Q[#(
MR#7P99_'?X[?&+Q1*N@:SK=W>8\S[#H2&**%,\95!@*"0-SD^Y- 'UI^W_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&_.O ;:)9KB*-W$2NX4NW103U-;X?5SJ/JRH=6>M?!7X5IKCIKVK1!["-O\
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M*>J6NL^/=6O+*=+FUE:,I*G1L1J#^H->;1BUB)MHRBGSLY2OJ/X%?\DVT_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%:GAKPU?^+-6AT[3H3+/)R2>%1>[,>P'^>:3:2NP#PUX:O_%FK0Z=
MIT)EGDY)/"HO=F/8#_/-?5/@/P'8> ])%K:@2W,F#<73##2M_0#L/ZY-'@/P
M'8> ])%K:@2W,F#<73##2M_0#L/ZY-=-7A8C$.J^6.QS3GS:(****XC,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG6X_9X\#,AR!8[/Q61@?U!H ]8KYS_;W_P"3>[O_ +"-K_Z$:^C*^<_V]_\
MDWN[_P"PC:_^A&@#Y_\ V(/"2>//!7QD\/. 3J6F6UNA/\+D7.QOP;:?PK@?
MV/OB5#\*?C$]SJ;_ &?3[G3KNWN_,.T+L0S#.>^Z$+_P*O9/^":?_']\0?\
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M1@<!?X03GDX7H?\ @H7"TOP)LF4<1ZW;LWT\J8?S(J3_ (>#_"__ )]]?_\
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M^<V7&Y\_=&,+C/)QM^L_^'@_PO\ ^??7_P#P"C_^.4 ?3->+?M)_M*Z3\!M
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MN ;JN<#D8/O78?LTNTGP$\"N[%W;2XB68Y)..IH Z+7/BKX*\,:G+IVL>,-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '#?&W_DF&M?]L?_ $?'7RK7U5\;?^28:U_VQ_\ 1\=?*M>W@OX;
M]?\ (Z*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%:GAKPU?\ BS5H=.TZ$RSR<DGA47NS'L!_GFDVDKL \->&K_Q9JT.G:="9
M9Y.23PJ+W9CV _SS7U3X#\!V'@/21:VH$MS)@W%TPPTK?T [#^N31X#\!V'@
M/21:VH$MS)@W%TPPTK?T [#^N3735X6(Q#JOECL<TY\VB"BBBN(S"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAM?V>[W7+BW\03:V=4CBC*RVHA\O86.1AFSG?^E>WT4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^W;\)M#O/":?%))M4AUJZ:TM/L<Y5(4C*L?FC*;U<=P6X.>*[/]D/\ 9O\
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M^N>G_P#I?)1^UU\,M4^"_P 2-,^,G@I3:H]VKWZQK\L-R>-[ ?\ +.895O\
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M3[?NY!) Q[ 4>(_A]X>\7:UH6KZOID=[J.ARM/IT[NX-N[%26 ! /*)U!Z4
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MD'@.P].:Z*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .&^-O_ "3#6O\ MC_Z/CKY5KZJ^-O_ "3#6O\
MMC_Z/CKY5KV\%_#?K_D=%/8****] U"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***U/#7AJ_\6:M#IVG0F6>3DD\*B]V8]@/\\TFTE=@'AKPU?^+-
M6AT[3H3+/)R2>%1>[,>P'^>:^J? ?@.P\!Z2+6U EN9,&XNF&&E;^@'8?UR:
M/ ?@.P\!Z2+6U EN9,&XNF&&E;^@'8?UR:Z:O"Q&(=5\L=CFG/FT04445Q&8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '#?&W_DF&M?]L?_ $?'7RK7U5\;?^28:U_VQ_\ 1\=?*M>W
M@OX;]?\ (Z*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116IX:
M\-7_ (LU:'3M.A,L\G))X5%[LQ[ ?YYI-I*[ /#7AJ_\6:M#IVG0F6>3DD\*
MB]V8]@/\\U]4^ _ =AX#TD6MJ!+<R8-Q=,,-*W] .P_KDT> _ =AX#TD6MJ!
M+<R8-Q=,,-*W] .P_KDUTU>%B,0ZKY8['-.?-H@HHHKB,PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI6W3<"@.01@YXXH ]*HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  "B_P#B:/\ A!/#7_0O:5_X!1?_ !-;M%'/+N%V87_"">&O^A>TK_P"B_\
MB:/^$$\-?]"]I7_@%%_\36[11SR[A=F%_P ()X:_Z%[2O_ *+_XFC_A!/#7_
M $+VE?\ @%%_\36[11SR[A=F%_P@GAK_ *%[2O\ P"B_^)H_X03PU_T+VE?^
M 47_ ,36[11SR[A=F%_P@GAK_H7M*_\  *+_ .)H_P"$$\-?]"]I7_@%%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!*D\J?IBL+P9\!_A]\/=134/#_A/3M/OXP1'=B,R31Y!!VNY++D$C@C@XZ4
M=[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<U?1%% 'SO\ :_&7_/;7?^^YJ/M?C+_GMKO_ 'W-7T110!\[_:_&7_/;7?\
MON:C[7XR_P">VN_]]S5]$44 ?._VOQE_SVUW_ON:C[7XR_Y[:[_WW-7T110!
M\[_:_&7_ #VUW_ON:C[7XR_Y[:[_ -]S5]$44 ?._P!K\9?\]M=_[[FH^U^,
MO^>VN_\ ?<U?1%% 'SO]K\9?\]M=_P"^YJ/M?C+_ )[:[_WW-7T110!\[_:_
M&7_/;7?^^YJ/M?C+_GMKO_?<U?1%% 'SO]K\9?\ /;7?^^YJ/M?C+_GMKO\
MWW-7T110!\[_ &OQE_SVUW_ON:C[7XR_Y[:[_P!]S5]$44 ?._VOQE_SVUW_
M +[FH^U^,O\ GMKO_?<U?1%% 'SO]K\9?\]M=_[[FH^U^,O^>VN_]]S5]$44
M ?._VOQE_P ]M=_[[FH^U^,O^>VN_P#?<U?1%% 'SO\ :_&7_/;7?^^YJ/M?
MC+_GMKO_ 'W-7T110!\[_:_&7_/;7?\ ON:C[7XR_P">VN_]]S5]$44 ?._V
MOQE_SVUW_ON:C[7XR_Y[:[_WW-7T110!\[_:_&7_ #VUW_ON:C[7XR_Y[:[_
M -]S5]$44 ?._P!K\9?\]M=_[[FH^U^,O^>VN_\ ?<U?1%% 'SO]K\9?\]M=
M_P"^YJ/M?C+_ )[:[_WW-7T110!\[_:_&7_/;7?^^YJ/M?C+_GMKO_?<U?1%
M% 'SO]K\9?\ /;7?^^YJ/M?C+_GMKO\ WW-7T110!\[_ &OQE_SVUW_ON:C[
M7XR_Y[:[_P!]S5]$44 ?._VOQE_SVUW_ +[FH^U^,O\ GMKO_?<U?1%% 'SO
M]K\9?\]M=_[[FH^U^,O^>VN_]]S5]$44 ?._VOQE_P ]M=_[[FH^U^,O^>VN
M_P#?<U?1%% 'SO\ :_&7_/;7?^^YJ/M?C+_GMKO_ 'W-7T110!\[_:_&7_/;
M7?\ ON:C[7XR_P">VN_]]S5]$44 ?._VOQE_SVUW_ON:C[7XR_Y[:[_WW-7T
M110!\[_:_&7_ #VUW_ON:C[7XR_Y[:[_ -]S5]$44 ?._P!K\9?\]M=_[[FH
M^U^,O^>VN_\ ?<U?1%% 'SO]K\9?\]M=_P"^YJ/M?C+_ )[:[_WW-7T110!\
M[_:_&7_/;7?^^YJ/M?C+_GMKO_?<U?1%% 'SO]K\9?\ /;7?^^YJ/M?C+_GM
MKO\ WW-7T110!\[_ &OQE_SVUW_ON:C[7XR_Y[:[_P!]S5]$44 ?._VOQE_S
MVUW_ +[FH^U^,O\ GMKO_?<U?1%% 'SO]K\9?\]M=_[[FH^U^,O^>VN_]]S5
M]$44 ?._VOQE_P ]M=_[[FH^U^,O^>VN_P#?<U?1%% 'SO\ :_&7_/;7?^^Y
MJ/M?C+_GMKO_ 'W-7T110!\[_:_&7_/;7?\ ON:C[7XR_P">VN_]]S5]$44
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M:C[7XR_Y[:[_ -]S5]$44 ?._P!K\9?\]M=_[[FH^U^,O^>VN_\ ?<U?1%%
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M^,O^>VN_]]S5]$44 ?._VOQE_P ]M=_[[FH^U^,O^>VN_P#?<U?1%% 'SO\
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M &OQE_SVUW_ON:C[7XR_Y[:[_P!]S5]$44 ?._VOQE_SVUW_ +[FH^U^,O\
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M )[:[_WW-7T110!\[_:_&7_/;7?^^YJ/M?C+_GMKO_?<U?1%% 'SO]K\9?\
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M #VUW_ON:C[7XR_Y[:[_ -]S5]$44 ?._P!K\9?\]M=_[[FH^U^,O^>VN_\
M?<U?1%% 'SO]K\9?\]M=_P"^YJ/M?C+_ )[:[_WW-7T110!\[_:_&7_/;7?^
M^YJ/M?C+_GMKO_?<U?1%% 'SO]K\9?\ /;7?^^YJ/M?C+_GMKO\ WW-7T110
M!\[_ &OQE_SVUW_ON:C[7XR_Y[:[_P!]S5]$44 ?._VOQE_SVUW_ +[FH^U^
M,O\ GMKO_?<U?1%% 'SO]K\9?\]M=_[[FH^U^,O^>VN_]]S5]$44 ?._VOQE
M_P ]M=_[[FH^U^,O^>VN_P#?<U?1%% 'SO\ :_&7_/;7?^^YJ/M?C+_GMKO_
M 'W-7T110!\[_:_&7_/;7?\ ON:C[7XR_P">VN_]]S5]$44 ?._VOQE_SVUW
M_ON:C[7XR_Y[:[_WW-7T110!\[_:_&7_ #VUW_ON:C[7XR_Y[:[_ -]S5]$4
M4 ?._P!K\9?\]M=_[[FH^U^,O^>VN_\ ?<U?1%% 'SO]K\9?\]M=_P"^YJ/M
M?C+_ )[:[_WW-7T110!\[_:_&7_/;7?^^YJ/M?C+_GMKO_?<U?1%% 'SO]K\
M9?\ /;7?^^YJ/M?C+_GMKO\ WW-7T110!\[_ &OQE_SVUW_ON:C[7XR_Y[:[
M_P!]S5]$44 ?._VOQE_SVUW_ +[FH^U^,O\ GMKO_?<U?1%% 'SO]K\9?\]M
M=_[[FH^U^,O^>VN_]]S5]$44 ?._VOQE_P ]M=_[[FH^U^,O^>VN_P#?<U?1
M%% 'SO\ :_&7_/;7?^^YJ/M?C+_GMKO_ 'W-7T110!\[_:_&7_/;7?\ ON:C
M[7XR_P">VN_]]S5]$44 ?._VOQE_SVUW_ON:C[7XR_Y[:[_WW-7T110!\[_:
M_&7_ #VUW_ON:C[7XR_Y[:[_ -]S5]$44 ?._P!K\9?\]M=_[[FH^U^,O^>V
MN_\ ?<U?1%% 'SO]K\9?\]M=_P"^YJ[CX43Z[+K-X-5DU%X?L_R"\:0KNW#I
MN[XS7J%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7QQ^TW^V[<>#];O/"G@'R)-1M6,-[K,R"1(9!U2%3P
MS*>"S9&01@]:^@OVAO'LWPT^#/BGQ!:R"&^@M?*M7/)6:1A&C =R"X/X5^<'
M[+_POMOB_P#&;2='U,-+I<0>^OD!.9(XQG83Z,Q12?1CWH =%XU^./Q&$FH6
M6I^.-:@R9"^F-=- N,@D+%\BXY' %:W@?]K;XK?##6?)O]:O-:AADVW.F>(2
MTS=>07?]XC=>_'<'I7ZAZ;IMIH]A;V-A;0V=G;H(X;>! D<:CHJJ. !7A'[4
M/[+4'QX72;[2IK/1_$-K+Y<]].C'SK8J?E(4?,RMM*Y[%AF@#TKX/?%G1_C1
MX'L_$FCDQI(3%<VCL#):S#&Z-L?4$'N"#WKMJ\5_9K_9Q;]GNQU>#_A)9M=_
MM,QO)$;80Q1.FX;E&YCDAL$YYP..*I?M)?M5Z3\!%MM,M[(:WXFNH_.2R,GE
MQP1DD"21L'J0<*.3@\C@D ]WHK\W[G_@H9\39I2T=CX=@4]$2SE('YRDUZ_\
M!OV\V\=>+-.\-^,M&M=,N=1E6WMM1TYG$/FL<(CQN6*AB0-P8\D9 &2 #[!H
MKD?BWXQN?A]\-/$?B2S@BN;K3+-[F.*?.QV7LV"#CZ&OE;X9_P#!0B;4[[69
M/&NEZ?IVFV>G/<VZ:8)#<7-QYL2)"H=R.0[D],!2<X!H ^UZ*_.S7O\ @HEX
M^O-4EETG1]$TW3\_N[>>*2>0#_:?>N3]%%?0W[+_ .UQ#\<[^XT#6=.AT?Q)
M#";B/[,Y,%U&" VP-DJPR/E).1DYX( !]&T5S_CSQWHOPV\*WWB'7[L6>FV:
M[G;&6=CPJ*.[$X %?#GC/_@HQXKO=1<>%_#^F:7IZM\AU /<3N/4[655SUP
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M)(Z!/+1<$NB'.5/:O<:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8O\ XJOCFBCZC'^8/9H^QO\ A._#7_0PZ5_X&Q?_ !5'_"=^&O\ H8=*_P#
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M_@;%_P#%4?\ "=^&O^AATK_P-B_^*KXYHH^HQ_F#V:/L;_A._#7_ $,.E?\
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MB_\ BJ^.:*/J,?Y@]FC[&_X3OPU_T,.E?^!L7_Q5'_"=^&O^AATK_P #8O\
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MU_T,.E?^!L7_ ,51_P )WX:_Z&'2O_ V+_XJOCFBCZC'^8/9H^QO^$[\-?\
M0PZ5_P"!L7_Q5'_"=^&O^AATK_P-B_\ BJ^.:*/J,?Y@]FC[&_X3OPU_T,.E
M?^!L7_Q5'_"=^&O^AATK_P #8O\ XJOCFBCZC'^8/9H^QO\ A._#7_0PZ5_X
M&Q?_ !57],US3=:$AT_4+6_$>-YMIEDVYZ9VDXKXJK7\*^*M0\'ZO%J&GR[)
M5X=#]R1>ZL.XJ98%6]UZB]F?9E%<[X(\;Z?XZTA;RS;9*N%GMF/SQ-Z'U'H>
M_P"8KHJ\N47%V9BU8****D04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\F5AP?+C0J2OHQ89].Y]?\ _"K4D_9,TOP7IEZFBZKJ&B!7N70MY+W'[R4$
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MLQ_&+4_CA\-Y?$6JV5I872W\MH(K/=LVJJ$'YB3GYCWKY?\ ^"D?_([^#O\
ML'2_^C:]B_X)\?\ )!KC_L,W'_HN*@#Z9HHHH *X+X[>/=0^&'PF\1>*-*AM
MKC4-.B22*.\5FB8F5$.X*RD\,>A%=[7CO[7O_)N'C;_KWB_]'QT ?)7_  \8
M^)/_ $!/"O\ X"7/_P D4?\ #QCXD_\ 0$\*_P#@)<__ "17)?L3^&](\5_'
M.UL-;TNRUBQ:PN'-K?VZ3Q%@HP=K@C(]:_0S_A1?PV_Z)]X5_P#!+;?_ !%
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M(((R#7R+^WA\$O!/@7PGHOB3P[I5KH.I7&H"SEM;)?+BFC,;ON$8^52I0#(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_/B?#<Q2-<:!M5PQQ>OV/_7.@#](**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X;XV_P#)
M,-:_[8_^CXZ^5:^JOC;_ ,DPUK_MC_Z/CKY5KV\%_#?K_D=%/8****] U"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7Z!T4 ?E1IOPV^/>C645G8:1XXL;.(8CM[8W,<:#.>%! ')-6?\ A"?VA_\
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M:]BHH _,W]G3X&_$'PY\;_!VI:IX-UFPT^VOEDFN;BS=(XUVGDDC@5^F5%%
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M[:W[.4_Q/T*#Q7X;L6N?%.FJ(I;:!<O>V^>@'=T))'J"PY^45Y+^Q]IGQ/\
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M@M]<2&VO(C'(%+#!P>QKW:B@#/U_0;#Q1HE]I&J6R7FG7L+07$$G1T88(_\
MK]J_,3XD_LG_ !"\">/M0L?#_A_5]<TRWF$MAJEA;L^Z,\H2R]'7H>G(R.,5
M^I=% 'ROX]\8?$OQK^R=)9'PEK<'CB]=-'U"V%BXD>+!,DZC'W9$7:3T#.P]
M#7QC'^SO\4X9%DC\">(4=2&5EL9 01T(.*_7:B@#\H_^%6?'3_H!>-/^^;C_
M !KZ(_8B\&?$?PY\2]:N/&.F^(+/3GTAXXGU82^69?.B( W\;L!OPS7VI10
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MQN7/U%3>$O'/A[QY937GAW6;+6K6&3RI)K*82*CX!VDCO@@_C7Q[_P %+_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X;XV_P#),-:_
M[8_^CXZ^5:^JOC;_ ,DPUK_MC_Z/CKY5KV\%_#?K_D=%/8****] U+>D_P#(
M5LO^NR?^A"OL#QC?SZ5X3UB]M9/*N;>TEEC? .U@I(.#P>?6OC_2?^0K9?\
M79/_ $(5]D>(=)_M[0M0TWS?(^UP/!YNW=LW*1G&1GKZUY6,MS0N8U-T?,R_
M&[QHK G6 P'8VL.#_P".5[A\)/'MQX\T&:6\B2.]M9/*D:,85P1D-CL>N1[>
M^*X=?V90&&[Q&2N>0+'!_P#1E>G^#_!^F_#_ $-K2U8B,$RSW,S %SCEB>@
M Z=OS-9XB="4;4UKZ"DXM:'@GQ[TF'2_'\DD*!!>6Z7+ =-Q+*3^.S->\_\
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M6>!^!^I-/8****](U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH U_"OBK4/!^KQ:AI\NR5>'0_<D7NK#N*^JO!'C?3_
M !UI"WEFVR5<+/;,?GB;T/J/0]_S%?'U=%X"U;6M(\3VCZ"KRWTC>6+<<K,O
M=6'IWSVQGC%<>(H*JK[-$2CS'V#14<#2/!&TR+'*5!=%;<%;'(!P,_7%25X!
MRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>T&\CU"2YU.W>W:>2-MT<<2. SY=1E@-H .3G (!^J5%%% !1110 5A^.O\
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ML-W%X>FMWCF0HZB-'C4$'GHHH ^!/V3O^3B? _\ U^M_Z*>ON3]N#6]1\/\
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M58EU/7:N 1C<"#@ ^9M;_9)^-FCZ%=:Y<PO,8(C<S01:J)+@ #<W ;YF R<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0.=WD12*5'LI*DX_.BI[)S?M8\K\@?+?56.C\7> -"^(.DM*(H/M,L>^WU&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^"/C/XBM];\2P7LM];VJV:&VNC$OEJ[N. .N9&YH S?V-?\ DVKP7_USN?\
MTJFKX\_;_P#^2_-_V"K;^;U^A?@#P+I7PT\(:?X:T1)4TNQ#K"LTF]P&=G.6
M[\L:X+XH?LL^!/B]XG.O^(;>^DU$P);[K>Z,:[%SC@#W- %K]EK_ )-[\"_]
M@Y?_ $)J^$_VY_\ DX_7_P#KWM/_ $0E?I-X+\(Z=X"\+:;X>TE9$T[3XA#
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MZ1M/=F1,.I5LKCT)KV2@#X@_X*7_ /-./^XE_P"VM=5_P3B_Y);XF_[#)_\
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MN8(HP,GN<4 :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+2-%L_"^N!&-K>Z='Y,:OU DC7Y64G@\9 Z$5[U10!\A?L*>,O&%C)KOP_\
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M(7[*'[+&E?$_P99^,?B ;K6+-PUKI.EM</'$D$;$;R58-@N'PH('4G.[B/\
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M_P"28:U_VQ_]'QU\JU[>"_AOU_R.BGL%%%%>@:A1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!\+?%_P#81\;>-?B=XB\0
M:-JN@1:=JU]+=HEU/,DD>\ECN"Q,.I/0GK7JW[-O[&]A\%]8'B/6]1CUWQ&B
M%+;R8RL%IN!#%<\LQ!(W$# )&.]?2=% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 <-\;?^28:U_VQ_P#1\=?*M?57QM_Y)AK7_;'_ -'Q
MU\JU[>"_AOU_R.BGL%%%%>@:A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M5:TO2[K6K^"RLH&N+J9MJ1H.2?\ #W[4MM6 :7I=UK5_!964#7%U,VU(T')/
M^'OVKZA^&7PRM? =AYDFVXU>9?WUP!PH_N)[>_?\@#X9?#*U\!V'F2;;C5YE
M_?7 '"C^XGM[]_R [BO$Q.)]I[L-OS.><[Z(****X#(**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M * O_DU/_P#%T?\ "DO!?_0%_P#)J?\ ^+KN:*/;5/YG]X<S[G#?\*2\%_\
M0%_\FI__ (NC_A27@O\ Z O_ )-3_P#Q==S11[:I_,_O#F?<X;_A27@O_H"_
M^34__P 71_PI+P7_ - 7_P FI_\ XNNYHH]M4_F?WAS/N<-_PI+P7_T!?_)J
M?_XNC_A27@O_ * O_DU/_P#%UW-%'MJG\S^\.9]SAO\ A27@O_H"_P#DU/\
M_%T?\*2\%_\ 0%_\FI__ (NNYHH]M4_F?WAS/N<-_P *2\%_] 7_ ,FI_P#X
MNC_A27@O_H"_^34__P 77<T4>VJ?S/[PYGW.&_X4EX+_ .@+_P"34_\ \71_
MPI+P7_T!?_)J?_XNNYHH]M4_F?WAS/N<-_PI+P7_ - 7_P FI_\ XNC_ (4E
MX+_Z O\ Y-3_ /Q==S11[:I_,_O#F?<X;_A27@O_ * O_DU/_P#%T?\ "DO!
M?_0%_P#)J?\ ^+KN:*/;5/YG]X<S[G#?\*2\%_\ 0%_\FI__ (NC_A27@O\
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M * O_DU/_P#%T?\ "DO!?_0%_P#)J?\ ^+KN:*/;5/YG]X<S[G#?\*2\%_\
M0%_\FI__ (NC_A27@O\ Z O_ )-3_P#Q==S11[:I_,_O#F?<X;_A27@O_H"_
M^34__P 71_PI+P7_ - 7_P FI_\ XNNYHH]M4_F?WAS/N<-_PI+P7_T!?_)J
M?_XNC_A27@O_ * O_DU/_P#%UW-%'MJG\S^\.9]SAO\ A27@O_H"_P#DU/\
M_%T?\*2\%_\ 0%_\FI__ (NNYHH]M4_F?WAS/N<-_P *2\%_] 7_ ,FI_P#X
MNC_A27@O_H"_^34__P 77<T4>VJ?S/[PYGW.&_X4EX+_ .@+_P"34_\ \71_
MPI+P7_T!?_)J?_XNNYHH]M4_F?WAS/N<-_PI+P7_ - 7_P FI_\ XNC_ (4E
MX+_Z O\ Y-3_ /Q==S11[:I_,_O#F?<X;_A27@O_ * O_DU/_P#%T?\ "DO!
M?_0%_P#)J?\ ^+KN:*/;5/YG]X<S[G#?\*2\%_\ 0%_\FI__ (NC_A27@O\
MZ O_ )-3_P#Q==S11[:I_,_O#F?<X;_A27@O_H"_^34__P 76QX;\ >'_"-Q
M+/I.G):S2+M:0R/(V/0%B<?AUXKH:*3J3DK.3%=]PHHHK,04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45QWQ3T2]U[PY%;V%N;F87*N4
M4@?*%89Y/N*\H_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&C_A6OB7_ *!4G_?:?XT ?1%%?.__  K7
MQ+_T"I/^^T_QH_X5KXE_Z!4G_?:?XT ?1%%?._\ PK7Q+_T"I/\ OM/\:/\
MA6OB7_H%2?\ ?:?XT ?1%%?._P#PK7Q+_P! J3_OM/\ &C_A6OB7_H%2?]]I
M_C0!]$45\[_\*U\2_P#0*D_[[3_&NX^%'A/5O#^LWDVH6;6T;V^Q69E.3N!Q
MP?:@#U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37_4M_^3W_ -KH_P"&FO\
MJ6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\ D]_]KH_X::_ZEO\ \GO_
M +77AU%'U6C_ "_F')'L>X_\--?]2W_Y/?\ VNC_ (::_P"I;_\ )[_[77AU
M%'U6C_+^8<D>Q[C_ ,--?]2W_P"3W_VNC_AIK_J6_P#R>_\ M=>'44?5:/\
M+^8<D>Q[C_PTU_U+?_D]_P#:Z/\ AIK_ *EO_P GO_M=>'44?5:/\OYAR1['
MN/\ PTU_U+?_ )/?_:Z/^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37
M_4M_^3W_ -KH_P"&FO\ J6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\
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M^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37_4M_^3W_ -KH_P"&FO\
MJ6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\ D]_]KH_X::_ZEO\ \GO_
M +77AU%'U6C_ "_F')'L>X_\--?]2W_Y/?\ VNC_ (::_P"I;_\ )[_[77AU
M%'U6C_+^8<D>Q[C_ ,--?]2W_P"3W_VNC_AIK_J6_P#R>_\ M=>'44?5:/\
M+^8<D>Q[C_PTU_U+?_D]_P#:Z/\ AIK_ *EO_P GO_M=>'44?5:/\OYAR1['
MN/\ PTU_U+?_ )/?_:Z/^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37
M_4M_^3W_ -KH_P"&FO\ J6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\
MD]_]KH_X::_ZEO\ \GO_ +77AU%'U6C_ "_F')'L>X_\--?]2W_Y/?\ VNC_
M (::_P"I;_\ )[_[77AU%'U6C_+^8<D>Q[C_ ,--?]2W_P"3W_VNC_AIK_J6
M_P#R>_\ M=>'44?5:/\ +^8<D>Q[C_PTU_U+?_D]_P#:Z/\ AIK_ *EO_P G
MO_M=>'44?5:/\OYAR1['N/\ PTU_U+?_ )/?_:Z/^&FO^I;_ /)[_P"UUX=1
M1]5H_P OYAR1['N/_#37_4M_^3W_ -KH_P"&FO\ J6__ ">_^UUX=11]5H_R
M_F')'L>X_P##37_4M_\ D]_]KH_X::_ZEO\ \GO_ +77AU%'U6C_ "_F')'L
M>X_\--?]2W_Y/?\ VNC_ (::_P"I;_\ )[_[77AU%'U6C_+^8<D>Q[C_ ,--
M?]2W_P"3W_VNC_AIK_J6_P#R>_\ M=>'44?5:/\ +^8<D>Q[C_PTU_U+?_D]
M_P#:Z/\ AIK_ *EO_P GO_M=>'44?5:/\OYAR1['N/\ PTU_U+?_ )/?_:Z/
M^&FO^I;_ /)[_P"UUX=11]5H_P OYAR1['N/_#37_4M_^3W_ -KH_P"&FO\
MJ6__ ">_^UUX=11]5H_R_F')'L>X_P##37_4M_\ D]_]KH_X::_ZEO\ \GO_
M +77AU%'U6C_ "_F')'L>X_\--?]2W_Y/?\ VNM[P9\>]/\ $VL)I]]8_P!D
M-+A896N/,1F_ND[5VY[5\X44GA*35DK!R1/N.BO$?@]\8?-\C0=>G_><):WL
MA^]Z(Y]?0]^A]_;J\6I3E2ERR.=IQ=F%%%%9$A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45AZKXY\-Z#.8=3\0:5ITP.#'=WL<3 _1F%7]
M*UO3M=@,^FW]KJ$(QF2TF65>1D<J2* +M%%% !1110 4444 %%%% !1110 4
M4A( ))P!52+6+">18X[ZVD=C@*LJDD^PS0!<HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .&^-O_ "3#6O\ MC_Z/CKY5KZJ^-O_ "3#
M6O\ MC_Z/CKY5KV\%_#?K_D=%/8****] U"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *]U^#WQA\WR-!UZ?]YPEK>R'[WHCGU]#WZ'W\*HK&K2C5CR
MR%)*2LS[CHKQ'X/?&'S?(T'7I_WG"6M[(?O>B.?7T/?H??VZOGZE.5*7+(Y6
MG%V84445D2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%1SSQVL$DTTB10QJ7>1V"
MJJ@9))/0 5\C?'+_ (*;?"KX4S7&F^'9)OB'KL1*-%H[JMG&P."'NCE3_P!L
MP] 'U[2,P5220 .23VK\@M:_;^_:1_:#U6;2OAWI<FE1ME?LGA/2VO+A!_MW
M$BMM/N E%O\ L-_M6?&J1+OQAJUU:1R\EO%/B224@?\ 7&(R8^F!0!^KNH_$
M7PIH[E+_ ,3Z-9,.JW.H11D?FPJK;_%KP/>.$@\9^'YW/18]4@8_H]?FEIW_
M  1P\97 W:EX_P##=LYZBVTZ:?\ 5BG\JMW?_!&KQ"L9-M\1]$E?L)M&D0?F
M)30!^HMG?VVHPB6TN(KF(_QPN'7\Q5BOR*U+_@EQ\>/ ;"[\)^)-%OIDY7^R
M=6N-/F_#<JC/_ JS)_BS^V3^RXQD\0'Q--I,)"L^NVJZO9$#M]H7<5'_ &T6
M@#]B**_.OX,_\%>-%U9X++XF>%9-%9SM.LZ QN;;ZO"W[Q1_NE_I7W=\/_B7
MX5^*OAZ+7/"&OV/B'2I.!<6,P<*?[K#JC?[+ $>E '34444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 R65((GDD=8XT!9G<X"@=23V%?F[^TO^V'KOQ%
MUN\T3PCJ,^C^$8&,0FM6,4U_C@N[#YE0\X08R#\V<X'U[^V)XKF\)?L]>*9K
M9MEQ>QQZ>K X^65PC_\ CA>OB']BOX<V7Q$^.5BNI0+<V&CV[ZI)!(,I(R,J
MQ@CN [JV.^W'2@"IX._8Z^*OCK28]6@T);&UN )(GU2X6"24'G=L/S 'KE@,
MYXS7/>+/AK\2_P!G36++4-0M=0\,W,C?Z-J-C<@HY'\(DB8C/'W2<X[8K]<J
MYGXE> [#XF^!=9\,ZDH^S:C;M$'(R8GZI(/=6"L/I0!X+^R#^U5-\7$;PKXI
M>,>*K6'S(+M0$%_&OWB5' D7J0.",D 8-?4%?C=\,O$]U\._B?X>UJ-GAGTW
M48GD53@E X$B'V92RGV)K[7_ &W_ !_\1_A1JOA_6O"WB2YTW0=0C:UF@CAB
M=8[A#N!RR$_.AZ9_Y9F@#ZZHKP7]C;XRW_Q?^%\K:Y>F^\0Z5=O;W<S*JM*C
M?/$Y"@ <$KT_Y9FH_P!LWXT:A\'_ (9VPT*]^P^(M6NU@M9E56:*-,/*X# @
M\;4Y'_+2@#WZBOD[]A_QW\0_BG)XBU_Q9XCN=3T6S"V5M!)%$B/.<.[950<H
MNT8SC]Y[5Y-\<_VT?&?BWQM<^'OAW=2Z;I$=Q]DMY;*$27=^X;;N4X)"L<;5
M4 D8SUP #]"J*_,7Q%J/[2?@'2VU[6=0\96.GIM>2XGNGDCCYP-Z[B$&>/F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <-\;?^28:U_VQ_P#1\=?*M?57QM_Y)AK7
M_;'_ -'QU\JU[>"_AOU_R.BGL%%%%>@:A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7NOP>^,/F^1H.O3_O.$M;V0_>]$<^OH>_0^_A5%8U:4
M:L>60I)25F?<=%>(_![XP^;Y&@Z]/^\X2UO9#][T1SZ^A[]#[^W5\_4IRI2Y
M9'*TXNS"BBBLB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\M_:#_:0\%_LV>#SKGBR_(GFREAI
M5MAKN_D ^[&F>@XRYPJCJ>1FA^U%^TKX?_9A^&TWB+5@+W5+DFWTG2$?;)?7
M&,X_V47J[_PCU) /Y:?"3X1?$S_@HG\:-1\1^(]4EBTJ&11JNNE/W%C%]Y;.
MTC/&[!X7H,[W))^8 N^/OCI\<_\ @H+XWD\*>&=.N8= +;QX<TN4I9V\6>)+
MZX. _P#P+"Y^ZF:^L?V?_P#@E/X*\%P6VI_$R\_X3?60 QTN M#ID)],##S8
MXY8A3_<KZX^$/P:\(_ OP;;>&?!ND1:5IL(!D8?--<R8YEFD/+N>Y/T&  !V
MU &9X=\,:/X0TF'2]"TJRT;381B.TL+=(8D^BJ !6G110 4444 %(RAE*L 0
M1@@]Z6B@#YQ^.?[ OPC^.,=Q=3:$GA;Q#("1K7A]5MY"WK)&!Y<O/7<N?<5^
M>'Q,_9O^.'[ _BAO&?A75[F?08W'_%2:(I\DIGA+ZV.0%/'WMR>C U^SM17-
MM#>6\MO<1)/!*ACDBD4,KJ1@J0>"".,4 ?'O['W_  41\/\ QZFLO"?C&*W\
M+>/9 $@"OBRU1O\ I@S'*2'_ )Y,23_"6Z#['K\OOVYO^"=B^$K:^^(WPDL9
M%TR#-UJGAFU!W6@'S&XM .=HQEHQRN,IP-H]%_X)Z?MWR_$L6?PS^(FHB7Q4
MD>-&UN=N=4C49\F4_P#/=0,AO^6@!_B!W 'WY1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>X4'AI52/RL_@TM<S^PA=_"ZTT'6I?$CZ+!XOBO-\4VLF-2MML0(83)P#O\
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MCWKT&@ HHHH ***Y3XE?$_P]\)/#JZYXFNY+/3FG6V$D<+RG>P) PH)Z*>:
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M* "BBB@ HI54LP !)/  [U],^ _A+HOA+1HKW5[>"ZU$1^;/-=8:.'C) !X
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MG_><):WLA^]Z(Y]?0]^A]_"J*QJTHU8\LA22DK,^XZ*\1^#WQA\WR-!UZ?\
M><):WLA^]Z(Y]?0]^A]_;J^?J4Y4I<LCE:<79A11161(4444 %%%% !1110
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M?M3?#OXH>*+;P]X>U:XN]4N%=XXI+*6,$(I9OF90.@->M4 %%<!\5?CGX/\
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MJP_W2: /:Z*X[X??&#P9\5(IG\*^(+35VA ,D,>Y)4!Q@F-P& YZXQGBNQH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)MX(490$7:#D\\U[5X!\(P^ O!6B>'+>X>Z@TNTCM$GD #.$7 ) XSQ6_10
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M5_:3_;3M?B_X%E\)^'M$NM.L;R2-[RYOW7S&5'#JBJA(QN5223VQCO0!J?\
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M+?:3?@QZ=)=.6>TF4$B,,>=C %0O9MN,9->R?\%!_P#D@UO_ -AFW_\ 1<M
M'F7_  33_P"/[X@_]<[#^=Q7.?\ !1W_ )*EX9_[ P_]'R5T?_!-/_C^^(/_
M %SL/YW%<Y_P4=_Y*EX9_P"P,/\ T?)0!])?L0_\FU>%_P#KI>?^E4M>[UX1
M^Q#_ ,FU>%_^NEY_Z52U[O0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '#?&W_ ))AK7_;'_T?'7RK
M7U5\;?\ DF&M?]L?_1\=?*M>W@OX;]?\CHI[!1117H&I;TG_ )"ME_UV3_T(
M5]<?$'_D1/$'_7A-_P"@&OD?2?\ D*V7_79/_0A7VAJ%Q;6EA<37C(EI'&S2
MM(,J$ YS[8KRL8[2@S&INCXDKZ1_9\TO4=/\)7,EXCQ6UQ/YELDF02NT98#T
M/'Y5MIXZ\!1.'2_TM&'(98P"/TK.\1_'CPWI-HYL)FU:[Q\D42,J9_VF8#CZ
M9J:M6I7CR*#"3<E:QYG^T/)$_CR)8R-Z64:R8_O;G/\ (K7N]E:/?^!H+:/
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MT]Z].\>>"O'?A[2VDEUBXU31[= I^SSN B 8!:/TQWY]S47[.VG1W?C2YN9
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MXD^)ND^$?B!=0:W9ZU.MI;Z@EK';S6\[<1@B,*K*S$*?ER,@YX((!^B%%%%
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MPY]RC(3[Y/>O@S]JKX\VWQX\>VU]IEG)9Z-IMN;6U,^/-FRQ9I& ^[G@!<G
M'J<#[2_88\&WGA#X!V4M]$T$NL7DNII&XPPC941"?]Y8PP]F% 'O$>KV$LHB
M2]MWD)P$6522?3&:SK_QUX:TK5ETN]\0Z59ZFV-ME/>Q),<XQA"V>X[=Q7Y!
M:?XIO_!/C\Z[I;I'J-C>R36[NNX(X9L-COC.>?2O8+#]B_XM^+8++7;ZQ3=J
MD\<D[7=ZINT21@3-(K'L&+$$[N#D9H _3FN=U7XC>$]!OC9:GXHT;3KP';]G
MN]0BBDSC.-K,#T!_*ODW]LOX\7GPNT_2?A=X+NI-,,-A$+R\@<B:* +MB@5A
MRI*J&8CG!4#J:\B^$O[$GC#XK^#H?$\FJ6.B6MZIDLX[P.\LZY^^P4?*I[$Y
M)ZXP02 ?I59WMOJ-K'<VD\5U;2#<DT+AT<>H(X-97CK_ )$CQ#_V#KC_ -%-
M7YF>#_'7CK]D#XL3Z1>O)Y%K.HU+25E+VUY$P!WIGC<5(*O@$=#W6OTG\1:M
M:Z_\,=3U.QE$]E>Z/+<P2KT>-X2RG\010!^8G[)W_)Q/@?\ Z_6_]%/7Z,_M
M!_"F'XR_#F;PW/K:>'XWN8I_MLD F V$G;M+IUSZU^<W[)W_ "<3X'_Z_6_]
M%/7VO^WO_P F]W?_ &$;7_T(T 6OV8_V:;7X#ZMKMW;^,(?$QU&"*(QQ68@\
MK:Q.<B5\YS[=*]YN=2M+-PEQ=00.1D+)(%)'KR:^%/\ @FS_ ,C3XV_Z\K;_
M -#>N<_X*,?\EMT3_L7H/_2FYH _0R\U>QT_3WO[J]M[:Q1=[74TJI$H]2Q.
M *H:!XU\.^*I)4T37M,UAXAF1;"\CG*<XY",<<@BOSN^%GP6^(W[4_A:P%QK
M<6D^$/#\2:?8+<J_E,RK\QCC7AFY^9R>X Z8'E?C?PCXH_9V^*,NFM?FRUS2
MW2:WO]/D(#*PRKJ>#@@X((]0: /USU76+#0K-KO4KZVTZT4@-/=S+%&">F68
M@55T#Q=H7BN)Y-$UK3M9C3&Y]/NHYPN>F2A.*^ /#?PB^)_[:IN/&>O:_:Z;
MI4;M;V:S*_E;E W"&$<*N<!G)R3_ 'B#CQ36M/\ %?[.?Q8N;.*^.G^(M$G7
M%S:.=DBE0ZGMN1U894CD'!% 'ZXZ_IPUC0M2L&F%NMU;20&4C.S<I7=C(SC.
M>M?*/PA_8EL/AM\2=!\2Q?$:WU>33IS*+)-.6,R_*RXW?:&QUST/2OH3_A)1
MXS^"1\0+&(AJOAXWOE@YV>9;;]OX;L?A7YJ_LG?\G$^!_P#K];_T4] 'ZO7%
MS#:1^9/*D,><;I&"C\S3;:^MKW=]GN(I]OWO*<-CZXKYZ_;W_P"3>[O_ +"-
MK_Z$:^*?@*OC_P 8/JOP\\"W'V$Z^8YM1NPYC\NWB#@[W'*QGS>0!ECM'<@@
M'Z?3_$KPA:ZD=.F\5:)#J 8J;23485E!R 1L+9SD@=.]=&K!U#*05(R".]?F
M!\<OV.O$_P $_"B^(Y=3LM;TI)$BNGM59'MRQPK%6ZJ6PN0<Y8<5[%_P3Q^+
M&J:C?:UX#U&[EN[*WM!J&GB9MWV=5=4DC4G^$^8A"]!AL=30!]O5S.H?$[P=
MI%T;:^\6:'97 ?9Y-QJ4,;[N>,%@<\'CVKYM_;F\0_$FZ@LO#?A'1-;?P\\/
MGZEJ&EVLCB5B2%B+H"0H R>@)8#MBO&_A[^P)XO\:^#K+7+W6+'0);V(306%
MU"[RA#]TR8QL)'..2,C.#D  _0_2=;T[7[476F7]KJ-L3@36DRRIGZJ2*MNZ
MQHS,P55&2Q. !7Y$1WWC#]F?XLW5M;WILM<T:Y$<ZVTI,%RG#!6'&^-U(."
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M0!T7[/\ ^Q-)\8OAVOBG4_$,FAI>/(EA#%:"7<J-M,CY8<%@PVC'3.>:\O\
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M>H5"N/=V]J?\%OV#%^(?P\TWQ+KOB2?29M4A%S:VEK;*^R)ON,[%N2PPV!C
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MKG.QB5\PC_MK/)^5?M+7XI_" GQK_P %)[*YN/G,WCR_NSGUBDG=?R\M?RH
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M!<VV3Z1W4RC] * /H^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"/KG\J\G^"/QZ^.'Q<^*T6FZ/KTO]GW=X;F^1K.&:"QMB^6PS(2H4'"C<,G
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M? W_  LOXA:%X7^V_P!G?VI<"W^U>5YOE9!.=FY<].F17ZU?%?\ Y);XQ_[
MUY_Z(>OR_P#V6O\ DX3P+_V$5_\ 06H ^B_^':'_ %4?_P H?_W37H/PS_8%
M\$>"M6@U+7+ZZ\6W,#!X[>YC6&UW#D%HP26^A;;Z@U]/44 (JA%"J % P .U
M?C':V$6J_$&&RN 3!<ZH(9 IP=K2X.#]#7[.U^->A_\ )4M/_P"PS'_Z/% '
MVM\1?^">'ABZT"ZE\&:GJ%CK: O#!J$RRV\O_3,D*&7/0-DX[@U\>_#?Q7%\
M'_B&9?$GA*PU^.TF:VOM)U>W#M&5;#;=V0LBD'J"/;N/V KXE_;V_9_,\?\
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MBD%RO0G<N"".<5YU;:U^U7\:+<26:7OA_2K@962..+3%53T96;$Q'NI-?/\
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MM/\ [6G@'XO> I]"T7PS=W.JRO&8]5U.WBC-H%<,3&59F)(!4CY1ACUZ5O\
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M1_\ Q5?/?Q+\#Z_^S%\:D:W22)=/O1?:/>RKE+F%7RAST/'RL/7/J*^F+_\
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M/5O$DNMB7=+'#+-(Q0#@,58D#.2.#V-<!6AKVO7WB75)M0U"<SW,IR6/0#L
M.P'I6?7I4TXQ2EN:K1#D1I75$4L[' 4#))]*^K_AC\/K?P+H:*RJ^J7"AKJ;
MOG^X/]D?J>:^8/#>K1Z#KUAJ,MM]K6UF6;R=^S<5.1S@XYQVKU__ (::_P"I
M;_\ )[_[77)BH5:B48+0B:;T1>^*GAKQQXWOVM;2S2'1(6_=Q_:4!F(_C<9_
M(=OK7F6M_"/Q-X>TJXU&^LXX[6 !I&6=&(!('0'U(KO_ /AIK_J6_P#R>_\
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M5I5I>1S2ES!1117,0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M74IUBL=#2&*X2- ,?,70]@69N .>0 ,??>OV][:_"_4X=2NEOM1CT>5;FY1
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M\F]^!?\ L'+_ .A-7PG^W/\ \G'Z_P#]>]I_Z(2@#[E^'/\ R:KH'_8HQ?\
MI(*_/?\ 9._Y.)\#_P#7ZW_HIZ_0CX<_\FJZ!_V*,7_I(*_/?]D[_DXGP/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR-N1+RZGN(A_VSDD93Z\@UV'C#X+^!_']U:W/B'PU8ZI-:PBW@:9#^[C!)"
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M^&_7_(Z*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%=[\+OA=<^.KT7-R'M]&A;$LPX,I_N)[^I[5$YQA'FD)NVK#X7?"ZY\=7
MHN;D/;Z-"V)9AP93_<3W]3VKZ>T_3[;2K*&TM(4M[:%0D<2# 44:?I]MI5E#
M:6D*6]M"H2.)!@**L5X%:M*M+R.:4N8****YB HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "H;NUAOK6:VN(Q+!,C1R1MT92,$'Z@U-
M10!YQHO[.GPU\.:O9ZIIG@[3;/4+259H+B-6W1NIR&'/4&O1Z** "BBB@#S>
MQ_9Q^&>FZO;ZI:^#=-AU"WG6YBN%1MR2JVX,.>H(!KTBBB@"*ZM8+ZVEM[F&
M.XMY5*212J&1U/!!!X(/I7CVL?L=?!_6[YKN;P;!!*[!F6SNI[>,^PCCD"@?
M0"O9J* .0\!?"/P=\,(9(_"_AZRT@R</-$A:9QZ-(Q+D>Q.*ZF[M8;ZUFMKB
M,2P3(T<D;=&4C!!^H-344 >>>'OV>_ASX3UJTU?2/".G6&I6K;X+F)6#1M@C
M(Y]":ZGQ=X+T/Q[HS:3XATV#5=.9UD-M< E2R]#QZ5M44 <CX(^$O@_X;7%U
M/X8\/VFC2W2JDSVRD&1020#D]LFH/&OP8\$?$758M2\2^&[+6+Z*$6Z3W*DL
ML89F"\'IEV/XUVM% &7X9\,:5X-T.UT;1+&+3M+M0PAM81A$!8L<?4L3^-<U
MXP^"'@3Q_K']J^(O#%CJVH^6L7VBX4EM@S@<'MDUW-% &?H&@:=X6T:TTG2;
M2.QTZT3RX+:(86-?05R?BOX$> /'.MS:QKWA6PU34YE59+F=278* J@X/8 "
MN\HH SK+P[ING>'X=#MK..'28;86D=HH^180NT(/;;Q7&^'OV>_ASX3UJTU?
M2/".G6&I6K;X+F)6#1M@C(Y]":]#HH Q?%W@O0_'NC-I/B'38-5TYG60VUP"
M5++T/'I67X(^$O@_X;7%U/X8\/VFC2W2JDSVRD&1020#D]LFNNHH S/$GAO3
M/%^B76CZS91:AIETH6:VF&4D (8 _B ?PKG/!GP5\#_#S5GU/PWX:LM(OWA,
M#3VZD,8R02O)Z953^%=M10!@>,_ 7A[XB:0VE^)-(M=8L2=PBN4R4;^\K#E3
M[@@UY[H7[(GPC\.ZHM_:^#+:2X1@Z+>7$]S&IX_Y9R.RGD9Y!ZU[#10!Q'C#
MX)^!?'^H07WB'PQ8:I=P0+;1RS1G*1 DA!@C@%C^=;NF>#-$T;PJ/#5EIT5O
MH0A>W%BN?+\M\[EY.<'<?SK:HH \_P##/P!^'G@W7+76=$\)Z?IVJ6I8PW4*
MD.A*E3CGN&(_&O0*** /)O&?[4WPT\$)JT=[XEMYM2TUY(9=-@5VG,R$J8P,
M==P(R3COG%?FGH6D:C\=/C'':V\"07WB357ED2W7Y(!)(7D8#^ZBEC]%K[0^
M)O[ EM\0_'^M>)8O&KZ6NJ73W4EI_98FV,QRP#^<OOVKTWX#_LK>%/@3-+J%
MG)/K.OS1^4VI7@4&->ZQ(.$!XSR3[XXH ]=TK3+;1-+L].LHA!9VD*6\,2]$
M1%"J/P %6Z** "BBB@#R_P <_LR?#+XBZK)J>N>%+:;493NDNK:66V>0^K^4
MRAC[G)K8\+_!+P+X,\-ZAH.C>&K*RTO4(F@O(@&=[F,@@K)(Q+L,$]3WKN**
M .(\'?!/P+\/M7.J>'/#-CI&H&)H3<6ZD,4)!*\GH2!^5=)XB\-:5XNTBXTK
M6M/M]4TZ<8DMKJ,.C>^#T([$<CM6G10!XQ:_L<?!ZSU(7J>#(6D!!$<MY<21
M \_\LVD*GZ$8XZ5VOBGX.>"?&MEIMGK7AC3KZUTU62RA:$*ENK8W*@7  .U>
M/85V5% &%X.\#:#\/M(.E^'=,ATG3S*TWV>#.W>0 3R3UP*YSXB_ 3P#\5KD
M77B?PW;:A>J@C%XCO#/M'0%XV4D#L"2*] HH X'X<? ?P)\)+N>[\*>'XM+N
MYXS#)<>=+-(R$@E=TC,0,JIP/05)\0O@=X$^*LL4WBGPW:ZI<QKL6YR\,VWT
M\R-E8CV)P*[JB@#S?P!^SK\.OAA>K?>'O"]K:WZC"WD[O<3*>Y5I&8J3_LXI
M=0_9T^&NJZS<:M=>#M-EU*XG:YEN=K!VE9MQ?@]23GZUZ/10 4444 >7W'[,
M7PLN[B6>;P3IDLTK%W=E8EF)R2>?6H_^&6OA/_T(NE?]\-_C7JE% 'E?_#+7
MPG_Z$72O^^&_QKT/5_#NFZ_H5QHVH6<=WI=Q#Y$MK(/D>/&-I]JT:* .#\*?
M CP!X&UN'6-!\*V&EZG"K+'<P*0ZA@58#)[@D5WE%% '*^.?A9X3^)?V+_A*
M-"M=:^Q;_L_VD$^5OV[\8(Z[%_(58\$_#SPW\.+">R\,Z1;Z-:3R^=+%; @,
M^ -QR>N !^%=%10 5A^,/!.A^/\ 1_[*\0Z;#JVG&193;SYVEAG!X/;)K<HH
M \K_ .&6OA/_ -"+I7_?#?XT?\,M?"?_ *$72O\ OAO\:]4HH XCP=\$_ OP
M^U<ZIX<\,V.D:@8FA-Q;J0Q0D$KR>A('Y5VLD:31M'(H=&!5E89!!Z@BG44
M>.:[^R!\(O$6I-?77@VWBG=MSK9W,]M&W7C9&ZJ.N> .E=]X&^&_ACX:::UA
MX8T2TT:V<AI!;I\\A'0NYRS'W8FNEHH P_&'@G0_'^C_ -E>(=-AU;3C(LIM
MY\[2PS@\'MDUP_\ PRU\)_\ H1=*_P"^&_QKU2B@#RO_ (9:^$__ $(NE?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P! 7_R:@_\ BZ/;4_YE]X<R[G#45W/_  I+QI_T!?\ R:@_^+H_X4EXT_Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEV*FRL ?1B"9)!_P)1[5]O\ A'P;H7@'0;;1/#>CV6A:3;#$5EI\"PQ+[[5
MY..3U/>MFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HJO>ZA:Z;");RYAM8B=H>>0(I/ID]^#5'_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
M^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M16
M3_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_
M / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_
M^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_
MXT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H
M?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&
MC_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G
M_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M1
M63_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\
MP*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_ $&=/_\  J/_ !H_X2W0
M_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_
M (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^!4?^- &M163_ ,);H?\
MT&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_  ENA_\ 09T__P "H_\
M&C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\ _ J/_&C_ (2W0_\ H,Z?
M_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/_H,Z?_X%1_XT :U%9/\
MPENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0!K45D_\ "6Z'_P!!G3__
M  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?_09T_P#\"H_\:/\ A+=#
M_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_QH_X2W0_^@SI__@5'_C0!
MK45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\ ^!4?^- &M163_P );H?_
M $&=/_\  J/_ !H_X2W0_P#H,Z?_ .!4?^- &M163_PENA_]!G3_ /P*C_QH
M_P"$MT/_ *#.G_\ @5'_ (T :U%9/_"6Z'_T&=/_ / J/_&C_A+=#_Z#.G_^
M!4?^- &M163_ ,);H?\ T&=/_P# J/\ QH_X2W0_^@SI_P#X%1_XT :U%9/_
M  ENA_\ 09T__P "H_\ &C_A+=#_ .@SI_\ X%1_XT :U%9/_"6Z'_T&=/\
M_ J/_&C_ (2W0_\ H,Z?_P"!4?\ C0!K45D_\);H?_09T_\ \"H_\:/^$MT/
M_H,Z?_X%1_XT :U%9/\ PENA_P#09T__ ,"H_P#&C_A+=#_Z#.G_ /@5'_C0
M!K45D_\ "6Z'_P!!G3__  *C_P :/^$MT/\ Z#.G_P#@5'_C0!K45D_\);H?
M_09T_P#\"H_\:/\ A+=#_P"@SI__ (%1_P"- &M163_PENA_]!G3_P#P*C_Q
MH_X2W0_^@SI__@5'_C0!K45D_P#"6Z'_ -!G3_\ P*C_ ,:/^$MT/_H,Z?\
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M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
MA3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?
M_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3
M&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J* /#?^%,:_P#W[/\ [^G_
M .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L_P#OZ?\ XFC_ (4QK_\
M?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\ A3&O_P!^S_[^G_XFO<J*
M /#?^%,:_P#W[/\ [^G_ .)H_P"%,:__ '[/_OZ?_B:]RHH \-_X4QK_ /?L
M_P#OZ?\ XFC_ (4QK_\ ?L_^_I_^)KW*B@#PW_A3&O\ ]^S_ ._I_P#B:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%9/BGQ);>$="NM6O$EDMK?;O6  N=S!1@$@
M=6'>N _X:.\-?\^.J_\ ?F+_ ..5K"E.:O%7*46]CU6BO*O^&CO#7_/CJO\
MWYB_^.4?\-'>&O\ GQU7_OS%_P#'*OZO5_E'RR['JM%>5?\ #1WAK_GQU7_O
MS%_\<H_X:.\-?\^.J_\ ?F+_ ..4?5ZO\H<LNQZK17E7_#1WAK_GQU7_ +\Q
M?_'*/^&CO#7_ #XZK_WYB_\ CE'U>K_*'++L>JT5Y5_PT=X:_P"?'5?^_,7_
M ,<H_P"&CO#7_/CJO_?F+_XY1]7J_P H<LNQZK17E7_#1WAK_GQU7_OS%_\
M'*/^&CO#7_/CJO\ WYB_^.4?5ZO\H<LNQZK17E7_  T=X:_Y\=5_[\Q?_'*/
M^&CO#7_/CJO_ 'YB_P#CE'U>K_*'++L>JT5Y5_PT=X:_Y\=5_P"_,7_QRC_A
MH[PU_P ^.J_]^8O_ (Y1]7J_RARR['JM%>5?\-'>&O\ GQU7_OS%_P#'*/\
MAH[PU_SXZK_WYB_^.4?5ZO\ *'++L>JT5Y5_PT=X:_Y\=5_[\Q?_ !RC_AH[
MPU_SXZK_ -^8O_CE'U>K_*'++L>JT5Y5_P -'>&O^?'5?^_,7_QRC_AH[PU_
MSXZK_P!^8O\ XY1]7J_RARR['JM%>5?\-'>&O^?'5?\ OS%_\<H_X:.\-?\
M/CJO_?F+_P".4?5ZO\H<LNQZK17E7_#1WAK_ )\=5_[\Q?\ QRC_ (:.\-?\
M^.J_]^8O_CE'U>K_ "ARR['JM%>5?\-'>&O^?'5?^_,7_P <H_X:.\-?\^.J
M_P#?F+_XY1]7J_RARR['JM%>5?\ #1WAK_GQU7_OS%_\<H_X:.\-?\^.J_\
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M ,<H_P"&CO#7_/CJO_?F+_XY1]7J_P H<LNQZK17E7_#1WAK_GQU7_OS%_\
M'*/^&CO#7_/CJO\ WYB_^.4?5ZO\H<LNQZK17E7_  T=X:_Y\=5_[\Q?_'*W
M/"/QCT#QCJ?]GVWVFTNF&8UO$51)ZA2&//M2="I%7<1<K70[FBBBL"0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .&^-O\ R3#6O^V/_H^.OE6OJKXV_P#),-:_[8_^CXZ^5:]O
M!?PWZ_Y'13V"BBBO0-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%*\,B2
M1NT<B$,KJ<%2.A!IM% 'T?\ "/XN)XGCCTC5Y%CU=!B.4\"Y _\ 9_;OU%>J
M5\/12O#(DD;M'(A#*ZG!4CH0:^C?A'\7$\3QQZ1J\BQZN@Q'*>!<@?\ L_MW
MZBO&Q.&Y??AL83A;5'JE%%%>:8A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#AOC;_ ,DP
MUK_MC_Z/CKY5KZJ^-O\ R3#6O^V/_H^.OE6O;P7\-^O^1T4]@HHHKT#4****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IT4KPR))&[1R(0RNIP5(Z$&FT
M4 ?1_P (_BXGB>./2-7D6/5T&(Y3P+D#_P!G]N_45ZI7P]%*\,B21NT<B$,K
MJ<%2.A!KZ-^$?Q<3Q/''I&KR+'JZ#$<IX%R!_P"S^W?J*\;$X;E]^&QA.%M4
M>J4445YIB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ'*>!<@?^S^W?J*\;$X;E]^&QA.%M4>J4445YIB%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)WPTO/ </A%-"^R:7'<K>&6WE9;B29590SRG+-P[<'CG@"@#@/\ @GE=Q3_
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M@F3[LD; ,K#V((-<CXQ^-G@7X?:N-+\1^)K'2-0,2S"WN&(8H20&X'0D'\J
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MJ0"/2MNOSM_X)Y^-K_2OBIJ'AH2NVEZK8O,T!)*K-%@JX]/E+@^N1Z"OT2H
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M4\"Y _\ 9_;OU%>-B<-R^_#8PG"VJ/5****\TQ"BBB@ HHHH **** "BBB@
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MP]\#M93P[:WESJ>HLE@&L86D>*-\F5\*"0-BNN[L6%?&'[*/[,T?QC\5ZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM"3><0&SVPW.:^JO^%*_M4?]#E=_^#YJ /(O@9\2->_9H^-KZ/J<S0Z:+_\
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M6UE)'Y$D\4"2),",'<_(!/X&J/P T6+5/')N)E#+8V[3H#_?)"C\MQ/U KZ
MLI[/QIX7BFGMF^Q:A;AF@G&#M8=#_C^->#_ #48=.\?7-H9@4NK:2*(GC>RL
MK#_QT-1"IS4II1LUV!.\7H>E_&6T\3ZIIEG8>';>:2.5F:[D@D"-@8VKDD<'
M)S]!7,_!W0?&?A?Q +?4K.XCT:=&$@EE5EC<#*L &."2,<>M='\9_$OB/PG8
M6.H:+*$M-S1W),*OM)QL/(.!]X?EZUP/A#X@_$3QO?36NF7=NSQ1^8[RP(J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%=;\.? >H^-]91;5GM;6W8/->CCRNXV_[7H/QIGP^^'U]X]U7R8<PV41!N+H
MCA!Z#U8]A7U1X?\ #]CX8TJ'3M.A$-M$.G=CW9CW)]:X<1B%27+'<SG.VB+L
M$7D01QEWE**%WR'+-@=3[U)117A',%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?$\DH'RK);VZ*3[D3G'Y&OACX3^$[3QW\2_#'AV_DGALM3U"&UFDMF"R*CL
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\_?M$?M?Z!\$KE]$L;8>(/%.P,]HDFR&UR,J9F&3D@@
MA!SCJ5R"?4?B]X[7X9?#+Q'XG*K))IUHTD*-T:4X6,'V+LHK\N?A#X"U']H#
MXQ6.DWU[,\NIW$EWJ5^QW2",9>5\G^(]!VRP[4 >B:O^WO\ %?4;II;:[TO2
MHR21#:V"LH'IF0N?UKK_ (=_\%$?%&FZA##XRTBRUG320)+BP0P72#NP&2C8
M_NX7/K7V9X/^"?@7P+HT6FZ1X7TR*%$"-++:I)--[R2,"SD^Y_2OF[]JO]C4
M>))].USX::#!!J4T_D7^F6KQV\#*02)P&*JI!&"!UW @9!R ?5W@[QAI'C[P
MU8:_H5XE]I=]'YD,R\>Q!!Y# @@@\@@BMJOGG]CWX,>./@IX?UG3?%-QI[6%
MY*ES:VEK.TLEO)@K)N^4+A@$Z$\K[UZ'\8_COX4^!VDP7GB.ZE,]R6%K86B"
M2XG(Z[5)  ''S,0.1S0!Z'17Q=<_\%*=,6Y"V_@.[EM\G+R:DJ,../E$9'7W
MKU/X+?MF>#/C!K4&AM!=>'==GX@MKTJT4[8SMCD7JW'1@N>V30![]17._$/Q
ME#\//!&M>);BWDNX-+MFN7@B8!G"]@3Q7B'PP_;B\)?$*_UF.^TZX\,V.E::
M^I7%]?3*Z;5DCCV *,EB95P!DD\ 9- 'TC17QUKW_!2+P_::DT6D>#M0U*R5
ML?:;J[2V9ASR$"O[8R1U[=*]M^!G[2?A3X\V]Q'I!GL-8M8Q)<:7> "54R!O
M4@D.F2!D<C(R!D9 /6**JZIJEGHFG7-_J%U%965M&99KB=PB1J!DLQ/ %?*W
MC3_@HGX/T6_EMO#V@ZAXC2,E?M4DBVD4A]5R&;'U4?2@#ZSHKY2\#_\ !0WP
M7X@U**TU_1[_ ,,I(0!=EQ<PH?\ :*@,![A37U1;7,-[;17%O*D]O,@DCEC8
M,KJ1D,"."".<T 2T5X]\;OVI?!OP-E6QU*2?5-== ZZ78 -(BGHTC$@(#[\G
MJ 1S7BNG?\%)]%EO0M_X(O[:TW<RVU^DTF,==A1!G.>-U 'V717)_#3XI>&O
MBWX<36O#.HK?6F[9*A&R6!^Z2(>5/Z'J"1S7)?M _M":?^S_ *;H]YJ&DW.K
M+J4TD*+;2*A0J 23N^M 'K-%?,=S^WEX0M?AQ!XFDTF\&H75W+:VVBB5#*XC
M"EI6;HB?.!G!)(. <''1_L[?M767[0&LZAI4/AJ]T6[LK?[2\AG6>#;N5=I?
M"D,2W V\@'GB@#WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *\=_:]_P"3</&W_7O%_P"CXZ]BJ&\L
MK?4;9[>Z@BN;>08>*9 Z-WY!X- 'YI?L$?\ )PEG_P!@ZZ_]!%?IG67I_A?1
MM)N!<6.D6-G. 0);>V1&P>HR!FM2@#\WOVV_V?O^%;>,/^$LT6VV>&];E)DC
MC7"VET<EDQV5^67WW#@ 5ZM^P+\>#JVFR?#C6KG==V:-/I$DC<R0]7AR>Z?>
M4?W2PZ**^P[_ $ZTU2V:WO;6&\MV()BGC#H2.G!XJC9^$="T^Y2XM=%TZVN(
MSE)8;6-'4^Q R* /SV_;1_9]U7P-X^U'QGH]C+-X9U:4W4LUNI;['<L<R!\?
M=5FRP;I\V.PSK^%O^"B?BC1?",>G:EX<LM9UB&(11ZJ]RT0<@8#2QA3N/KM9
M<^U?H,Z+(C(ZAT88*L,@CT-<A)\&?A_-=M=2>!?#3W3-O,[:1;ERWKNV9S[T
M ? _[-VG_%?XS?$PW]KXFU_3M":]-YK%_!>RPP$,^YXU .TNV2 H'&<\ 5]U
M_'/X6P_&/X8ZQX8>5;>YN$$EI<."1%.AW(3CL2-I]F-=O96-MIEI%:V=O%:V
ML2[8X8$"(@] HX J>@#\DO"_B;QY^RK\39I19MI>L0*UO<V5]&6ANH20<<$;
MD)4$,I[#!KJOC5^UWXO^.GAZ#PU)IUII.G22H\UO8!W>Z<'**22?E#8(4#J!
MR<"OTNU_PKHOBNU%MK>CV&LVXY$.H6J3H/P<$50T+X:>$/"]RMSHWA71-(N%
M)(FL-.A@<9&#RJ@T ?/7[#'P!U/X:Z'J/BOQ%:-8ZQK,20VUG,A6:VM@=QW@
M\J7;:=IY 1<\D@>/?\%!/AAJNF_$6#QK#:23:)J5K%!-<HI*PW"?+M<_P[EV
M8)ZG<.U?H54-W:07]M+;W,,=Q;RJ4DBE4,C@]00>"* /SC^$O[=7B7X:^!+/
MPQ/H-IKPL8O(L;J6=HGC0?<5P =X4<#&TX YKROXYP>-[_Q3;^)_'ENUGJ_B
M*#[=%;.AC:* ,8T7RSR@PF #S@ GDY/ZF:/\*?!/AZ_2^TKP=H&F7J'*W-GI
MD$4B_1E4&MG4O#FDZS*LNH:79WTB+M5[FW20@>@)!XH \N_9=_Y-H\'_ /8.
MD_\ 0WK\Z?V<P#\>/ .1G_B<VW_HP5^N5K96]C;);6T$5O;H,+#$@5%'H .!
M6;;>#M L[B.>WT/38)XV#))':1JRD=""!D&@#8K\X?\ @H?_ ,EST[_L!6__
M *.GK]'JS=1\-:1K$XGO]*LKV8+L$ES;I(P7TR0>.3^= 'E_[(( _9P\$X&/
M]'F_]'R5?_:4^#__  NOX5ZAH=OL75X66\TZ20X43H" I/8,K,OMNSVKTVSL
MK?3K9+>U@BMK>,82*% B+WX X%34 ?E'\)_B]XS_ &5O&^IV\NE,C2XAU'1=
M25H]^TG:P/\ "PR<,,@ACP0172?&S]KKQ;\=)=(TS1M/G\-6]O.)H[;3+J26
MYGGQM4[U52< G"@?Q'.>,?H_XC\%^'O&$<<>O:%IFMQQ\HFHV<=P%^@<'%5_
M#_P\\*^$I_/T/PSH^C38(\S3["*!L'J,HHZT >;_ +*G@CQMX1^'9G\>ZUJ6
MI:UJ,BS)::C=O.UE"!\D?S$X8Y)89X^4?PU\0_MO?\G*^*/^N=G_ .DL5?J/
M65?>%-$U.Y>YO-'L+NX?&Z:>U1W.!@9)&>E '.? O_DB7P]_[%[3_P#TFCKX
M@_X*,?\ );=$_P"Q>@_]*;FOT3@@BM8(X88TAAC4(D<:A550,  #H .U4=2\
M-Z1K$ZS7^E65],J[!)<VZ2,%R3C)!XR3Q[T >7_LA?\ )N'@G_KWE_\ 1\E?
MG1\9=%U+X<?'+Q+%-&8KNTUB2\MVD7AT,IDB?W!!4U^N=G96^G6R6]K!%;6\
M8PD4*!$7OP!P*R_$7@OP]XO1$U[0=,UM$^ZNHV<=P%[\;P<4 >#?LI_M0ZU\
M??$'B"PUC3-.TU;"TAGA6R#[G)8K(6+,>,[< #C)R37TG6/X=\':!X0A>'0=
M#TW1(7.6CTZTCMU8^X0#-;% '*_%?_DEOC'_ + UY_Z(>OR__9:_Y.$\"_\
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MQ1);Q)%$BQQHH5408"@= !V%9VO^%]&\5V8M-;TBPUFU!R(-0MDG3/KM<$4
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M,T73M%1UT^PM;!9""ZVT*QACVSM S0!\A?\ !2;_ )%;P3_U^W/_ * E:O\
MP3B_Y);XF_[#)_\ 1$=?5&IZ+IVM(BZA86M^L9)1;F%9 I[XW XI=-T>PT:)
MHM/LK:QC=MS);1+&"?4@ <T ?%G_  4O_P":<?\ <2_]M:[[_@GDH?X%:FK
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M?\\]0_[\+_\ %5\U45C5H0JM.1+BI;GTK_PT-X6_YYZA_P!^%_\ BJY_Q_\
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M7%S"40R1 +G(ZG=7@U%%52I1I*T1J*CL%%%%;#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJOA]\/K[Q[JODPYALHB#<71
M'"#T'JQ["CX??#Z^\>ZKY,.8;*(@W%T1P@]!ZL>PKZH\/^'['PQI4.G:="(;
M:(=.['NS'N3ZUPXC$*DN6.YG.?+H@\/^'['PQI4.G:="(;:(=.['NS'N3ZUH
MT45X;;;NSF"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %8?CK_D2/$/_8.N/_135N4V2-949'4.C AE89!'H: /R)_9R_Y+SX!_[#-M
M_P"C!7Z\5CVW@[0+.XCGM]#TV">-@R21VD:LI'0@@9!K8H **** /R ^&_\
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MV5^M];^"?#L%ZK;EN8M)@60'U#!,YKH-3T/3M:$8U#3[6_$>2@N85DVYZXW
MXZ"@#R+]C;7[?7_V=O"GDR!Y+));*9>Z.DK8!_X"5/T85^??[1WAG4/ _P >
MO&,-U&\$DNJ3:A;.00'BED,L;*>_#8)'=2.U?K)IVE66CP&"PL[>QA+;S';1
M+&I;@9P .>!^54O$/@_0?%T*1:[HFG:U$GW4U&TCG5?H'!Q0!\Z_LM?M3:Y\
M?_%FKZ!K>F:=81VVE_:5:Q$@>1MZ(Y)9C@?., #CU-?$VN:#XD_9Q^+T NK7
MRM4T.^2ZM7F0F&Y1&RC@\;D8#MZD<$<?K#X=\%>'?!Z.F@Z#IFB))]]=.LX[
M<-]=BC-2>(?"6A^+;=(-<T73]:@0DK'J%K'.JYZX#@@4 ?$?BC]N;Q3\6-$/
MA'P5X*DL]>U:(VK3Q7)N9%##:WE*$7!P3\['Y>O;-?/?P=N7^''Q^\,?VTAL
M9-+UN.VO5<C]R1)Y<F<?W><_2OU:\.>!O#?@[S/[ \/Z5H?F_?\ [-LH[??]
M=BC-27'@[0+NXDGGT/39IY&+O+):1LS$]221DF@#8HHHH _,S]O?_DX2\_[!
MUK_Z":^Q?#O@X?$#]CS1_#VS?)?^$H(X1Z2BW4QG\'"G\*]:U#POHVK7!N+[
M2+&\G( ,MQ;([8'09(S6A;V\5I!'!!$D,,:A$CC4*JJ.@ '04 ?B7:V<U[>0
MVL$9DN)I!$D8ZLQ. /SK]0OCQX8A\%?LAZWH%O@Q:9HMO:*P_BV-&I;ZDC/X
MUZZG@SP_',LR:%IB3*V\2+9QA@V<YSCKFM.[LX+^VDM[J".YMY!AXID#JP]P
M>#0!^=W_  3G_P"2VZW_ -B]/_Z4VU;G_!2/_D=_!W_8.E_]&U]TZ;X;TC1Y
MVFL-*LK&9EV&2VMTC8KD'&0!QD#CVIVI>'M*UET?4-,L[YT&%:Y@20J/0;@<
M4 >%?L(?\F[:5_U^W7_HTU\I?MC_   U/X;?$#4O$UA9R2^%-8N&NDN8ERMK
M.Y)>)\?=^;)4\ @@#D&OTIL-.M-*MA;V5K#9VX)(BMXPB@GKP.*DN;:&\MY(
M+B))X)%*O'(H96!Z@@\$4 ?G9X7_ ."@OCK1?"D.D7.DZ=K.J11"&'5+@N)'
M/0-(@.';IR-N<<Y))KPSXK:!XLTGQ+'J'C6.6+7M=@_M>1;D;9MLDCJ"Z8&P
MDH2%[ @8'0?K%I'PJ\%>']234-+\'Z!IM^ARMU::9!%*I]G50?UK7U'PUI&L
M3B>_TJRO9@NP27-NDC!?3)!XY/YT <7^SE_R0;P#_P!@:V_]%BO1JBMK:&SM
MXX+>)(((U"I'&H55 Z  < 5+0!\^_MN_%"Y^'7P9FM=.E:#4M>F&G)*APT<1
M4M*P_P" C9[;\U^9NEZ@^DZE:WL4<,LMO*LJ)<1B2-BIR RGAAQR#P>]?M/J
M>B:=K2QKJ%A:WZQDE!<PK)MSUQN!QTJA_P (+X:_Z%[2O_ *+_XF@#\VO^&Y
MOB^/^8]:?^"V#_XBOI?]BKX]^,_C-JGBN'Q5J$-]'80V[VXBMHX=I=I V=@&
M?NCK7T=_P@OAK_H7M*_\ HO_ (FKNF:!IFBM(VGZ;:6#2 !S;0+&6QTSM SU
MH ^+OV]O@'JFHZM%\1=!LY+V#[.L&KPP)N>+9PD^!R5VX5C_  [%/0DCR3P3
M^VOXY\"_#%/!]E!83&VA-M9:I,K&>VC.< #.UBH/RDCC R#BOTZZUQMY\%_A
M_J&H&^NO _AVXO&)9IY=*@9F/'))7D\#DT ?!7[%OP*U/X@_$>P\7:C:RQ^&
M]%G%W]IF7BZN5.8T0G[V&PS'G&W!Y85]3?MN_%"Y^'7P9FM=.E:#4M>F&G)*
MAPT<14M*P_X"-GMOS7OMM;0V=O'!;Q)!!&H5(XU"JH'0 #@"J^IZ)IVM+&NH
M6%K?K&24%S"LFW/7&X''2@#\6-+U!])U*UO8HX99;>5942XC$D;%3D!E/##C
MD'@]Z]S_ .&YOB^/^8]:?^"V#_XBOTE_X07PU_T+VE?^ 47_ ,31_P (+X:_
MZ%[2O_ *+_XF@#YQ_8J^/?C/XS:IXKA\5:A#?1V$-N]N(K:.':7:0-G8!G[H
MZU\D?M3_ !0N?BE\9M=NFE9M-TZ9].L(LY58HV*EA_OL&?\ X$!V%?JEIF@:
M9HK2-I^FVE@T@ <VT"QEL=,[0,]:IMX'\..Q9O#^EEB<DFRCR?\ QV@#\I/A
M?^T'XS^#FG7EEX5N[2PCO)1+.[V44LDA PH+LI.!S@=!D^IKMO\ AN?XO_\
M0?M/_!;!_P#$5^DG_""^&O\ H7M*_P# *+_XFC_A!?#7_0O:5_X!1?\ Q- &
MEI4[W6EV<TAS))"CL<8R2H)JU2*H10J@!0, #M2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S[^W9-)%^SIK"
MH"5DN[19,'HOFJ?Y@5\S?\$[(8Y?CAJK. 6CT"=D)['S[<?R)K[3_:+\!3?$
MKX+>*M!M8O.OI;7S[6,=6FB82HH]V*;?^!5^</[,'Q/MOA#\9M'UG4G:'29
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M!)9>>N?N?X0? /PK\#WUH^&8KF-=5DC>474OF% @(5%;&=OS,>23DGFO"O\
M@F_'CX=>*Y-N-VJJN[UQ"O'Z_K7UY0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '#?&W_DF&M?]L?_ $?'7RK7U5\;?^28:U_VQ_\ 1\=?*M>W@OX;]?\
M(Z*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5\
M/OA]?>/=5\F',-E$0;BZ(X0>@]6/84?#[X?7WCW5?)AS#91$&XNB.$'H/5CV
M%?5'A_P_8^&-*AT[3H1#;1#IW8]V8]R?6N'$8A4ERQW,YSY=$'A_P_8^&-*A
MT[3H1#;1#IW8]V8]R?6M&BBO#;;=V<P4444@"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GKQY^P]
M\/\ XA>,=1\2:A?:];7NH3FXN(K2YB6)F/7 :)B ?K7HOPF^!7@[X+6,T'AC
M3/(N+@ 7%]<.9;B8#H&8]!_LJ .^,UZ!10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHG606@88:1V&07()4!20 3R2?EO_ +=_PT\4?$CP]X3@\,:+=:S+:W4[S);
M$QJ44 G)[X-?4E% 'S9^PO\ #SQ)\.?A[K]EXET>YT:[GU0S117( +)Y,8W#
M!Z9!'X5])T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PWQM_P"28:U_
MVQ_]'QU\JU]5?&W_ ))AK7_;'_T?'7RK7MX+^&_7_(Z*>P4445Z!J%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5U7P^^'U]X]U7R8<PV41!N+HCA!Z
M#U8]A1\/OA]?>/=5\F',-E$0;BZ(X0>@]6/85]4>'_#]CX8TJ'3M.A$-M$.G
M=CW9CW)]:X<1B%27+'<SG/ET0>'_  _8^&-*AT[3H1#;1#IW8]V8]R?6M&BB
MO#;;=V<P4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .-^+]A<ZG\.M6MK.WEN[E_)V0P(7=L3(3@#D\ G
M\*^:O^$$\2_]"]JO_@%+_P#$U]CT5V4<2Z,>5(TC/E5CXX_X03Q+_P!"]JO_
M (!2_P#Q-'_"">)?^A>U7_P"E_\ B:^QZ*W^O2_E*]HSXX_X03Q+_P!"]JO_
M (!2_P#Q-'_"">)?^A>U7_P"E_\ B:^QZ*/KTOY0]HSXX_X03Q+_ -"]JO\
MX!2__$T?\()XE_Z%[5?_  "E_P#B:^QZ*/KTOY0]HSXX_P"$$\2_]"]JO_@%
M+_\ $T?\()XE_P"A>U7_ , I?_B:^QZ*/KTOY0]HSXX_X03Q+_T+VJ_^ 4O_
M ,31_P ()XE_Z%[5?_ *7_XFOL>BCZ]+^4/:,^./^$$\2_\ 0O:K_P" 4O\
M\31_P@GB7_H7M5_\ I?_ (FOL>BCZ]+^4/:,^./^$$\2_P#0O:K_ . 4O_Q-
M'_"">)?^A>U7_P  I?\ XFOL>BCZ]+^4/:,^./\ A!/$O_0O:K_X!2__ !-'
M_"">)?\ H7M5_P# *7_XFOL>BCZ]+^4/:,^./^$$\2_]"]JO_@%+_P#$T?\
M"">)?^A>U7_P"E_^)K['HH^O2_E#VC/CC_A!/$O_ $+VJ_\ @%+_ /$T?\()
MXE_Z%[5?_ *7_P")K['HH^O2_E#VC/CC_A!/$O\ T+VJ_P#@%+_\31_P@GB7
M_H7M5_\  *7_ .)K['HH^O2_E#VC/CC_ (03Q+_T+VJ_^ 4O_P 31_P@GB7_
M *%[5?\ P"E_^)K['HH^O2_E#VC/CC_A!/$O_0O:K_X!2_\ Q-'_  @GB7_H
M7M5_\ I?_B:^QZ*/KTOY0]HSXX_X03Q+_P!"]JO_ (!2_P#Q-'_"">)?^A>U
M7_P"E_\ B:^QZ*/KTOY0]HSXX_X03Q+_ -"]JO\ X!2__$T?\()XE_Z%[5?_
M  "E_P#B:^QZ*/KTOY0]HSXX_P"$$\2_]"]JO_@%+_\ $T?\()XE_P"A>U7_
M , I?_B:^QZ*/KTOY0]HSXX_X03Q+_T+VJ_^ 4O_ ,31_P ()XE_Z%[5?_ *
M7_XFOL>BCZ]+^4/:,^./^$$\2_\ 0O:K_P" 4O\ \31_P@GB7_H7M5_\ I?_
M (FOL>BCZ]+^4/:,^./^$$\2_P#0O:K_ . 4O_Q-'_"">)?^A>U7_P  I?\
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M$$\2_P#0O:K_ . 4O_Q-'_"">)?^A>U7_P  I?\ XFOL>BCZ]+^4/:,^./\
MA!/$O_0O:K_X!2__ !-'_"">)?\ H7M5_P# *7_XFOL>BCZ]+^4/:,^./^$$
M\2_]"]JO_@%+_P#$T?\ "">)?^A>U7_P"E_^)K['HH^O2_E#VC/CC_A!/$O_
M $+VJ_\ @%+_ /$T?\()XE_Z%[5?_ *7_P")K['HH^O2_E#VC/CC_A!/$O\
MT+VJ_P#@%+_\31_P@GB7_H7M5_\  *7_ .)K['HH^O2_E#VC/CC_ (03Q+_T
M+VJ_^ 4O_P 31_P@GB7_ *%[5?\ P"E_^)K['HH^O2_E#VC/CC_A!/$O_0O:
MK_X!2_\ Q-'_  @GB7_H7M5_\ I?_B:^QZ*/KTOY0]HSXX_X03Q+_P!"]JO_
M (!2_P#Q-'_"">)?^A>U7_P"E_\ B:^QZ*/KTOY0]HSXX_X03Q+_ -"]JO\
MX!2__$T?\()XE_Z%[5?_  "E_P#B:^QZ*/KTOY0]HSXX_P"$$\2_]"]JO_@%
M+_\ $T?\()XE_P"A>U7_ , I?_B:^QZ*/KTOY0]HSXX_X03Q+_T+VJ_^ 4O_
M ,31_P ()XE_Z%[5?_ *7_XFOL>BCZ]+^4/:,^./^$$\2_\ 0O:K_P" 4O\
M\36WX1^$>O\ B36([:ZT^[TJT'S37-U T8"^BA@-S>U?5E%2\;-K1"]HS.\/
M^'['PQI4.G:="(;:(=.['NS'N3ZUHT45Y[;;NS(****0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MW=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^W=2_Z"%W_P!_V_QH_MW4O^@A=_\
M?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\ ?]O\:/[=U+_H(7?_ '_;_&CZE+N'
MUI=CV*BO'?[=U+_H(7?_ '_;_&C^W=2_Z"%W_P!_V_QH^I2[A]:78]BHKQW^
MW=2_Z"%W_P!_V_QH_MW4O^@A=_\ ?]O\:/J4NX?6EV/8J*\=_MW4O^@A=_\
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MI/ .I7=YK$R7%U/.@@8A9)"P!W+SR:SGA)0BY-[%1Q"DTK'?4445PG6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <K\1O^0)!_P!?
M"_\ H+5YS7HWQ&_Y D'_ %\+_P"@M7G->WA/X1Y>(_B!1117:<P4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U7PY_P"0
MW/\ ]>[?^A+7*UU7PY_Y#<__ %[M_P"A+7/B/X4C6E\:/1J***^?/8"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .5^(W_ "!(/^OA
M?_06KSFO1OB-_P @2#_KX7_T%J\YKV\)_"/+Q'\0****[3F"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NJ^'/_(;G_Z]
MV_\ 0EKE:ZKX<_\ (;G_ .O=O_0EKGQ'\*1K2^-'HU%%%?/GL!1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/RK)@$,O?:PY&>G(YQFOF3X\?%+Q?H/Q:\16&G>)-2LK*&5!'!!<LJ(#$A.
M#QR37U[X3\!>'O T4T>@Z3;Z8LP42F%?FDVYV[F.2<9/7UKX9_:._P"2U^*/
M^NT?_HE*O$N<:4;O4F@HRJ.RT/I+XRW'C6[^%7A*?PE)JLNJR^0]S)IQ8RLI
M@))8KS@MC\:^,T_M'^W5V>?_ &M]IXQGS?.W?GNW?K7Z2^"?^1,T#_L'V_\
MZ+6OSZM/^2N0_P#8<7_THK+%0UC*^YIAY:-6V/I[]FG_ (6)_;FL_P#":?VU
M]E^S)]G_ +5W[=^[G;N[XKP[7/BUXT@^)VH64?BC5$M$UB2%85NF"A!,0%QG
MICBOO*OS@\0_\E<U+_L.2_\ I0:K$)THQBF31:G*3:/T1UO6;/P[H][JE_,(
M+*SB:::0\X51D\=S[=Z^*_&7[17COXE^(?[/\-RWFE6L[^7:V&F9%P_H6=?F
M+=^" /UKWO\ :VU&:Q^#MU%$Q5;N\@@DQW7)?'YH*\D_8JTJVN?&.O7\B*UQ
M:6:I$6ZKO?YB/P7&??WK2O*4JBI1=B*45&#J-7..U?4_C)\,$M]2U34/$-A!
M(X*R7=TUQ"7/.&!9ER>>&'/-?2O[//QM;XL:-<VVI)'#KVGA3/Y0PDZ'($BC
MMTP1ZX/? ])\3^&--\8Z'<Z/J]L+O3[D*)82Q7=A@PY!!'('(-9?A'X7>%?
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M%92@Z=:"O=&D9*=*3M8ZW]I_Q'XS\ _$%9--\2:I9Z1J4"S0117+*D;K\LB
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MHUJ/W%C;I IQ][:,%C[DY)^M%)NI6E.^B"HE"FH]6:M%%%>@<@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !75?#G_D-S_]>[?^A+7*UU7PY_Y#<_\
MU[M_Z$M<^(_A2-:7QH]&HHHKY\]@**** "BBB@ HHHH **** "BBB@ HHHH
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MD?PY%XE36AK&J&X6[%YY9,>W=OWX^[G&:JO2E44>7H*E4C!N_4]UK\X/$/\
MR5S4O^PY+_Z4&OT?KPJ]_9(\.7WB6XUI]8U1;B:[:\,8,>T,7WX^[G&33Q-*
M52W+T"C.,+\QV'[0'@V?QS\*M9L+.,S7T*K=V\:C)=HSN*@=R5W #U(KY&_9
M]^*=O\*?&[W6HI(VEWD)MKGRURT?S JX'?!'(]">^*^_J\<^(W[+OA3Q[J,^
MIP//H6ISDM+): &*1CU9HSW_ -TC/).2<TJU*4I*I3W04JD5%PGLS!^+7[4?
MANW\%W4/A+5WO=;NT\N&2&&2/[.#U<EU'(&<#KG%4/V7/B%X\^(6KZB^MZFU
M]H-E#MWR6T:EIF(VJ'503@;B>3U'K1I?[$^A6]RCZAXBOKR%6!,4,*0[AZ9)
M:O>O"_A;2O!FBP:3HUFEC80YVQ)DY)ZDD\DGU/-$(UI3YJFB[!*5.,>6&IK5
MXA^V ]XGPBQ:LPA;4(1=!>ABPY /MO$?Z5[?5'6]%L?$>DW>F:E;I=V-U&8I
MH7Z,I_4?4<@\BNFI'G@X]S"$N629\:_LI:SX+T?Q#JS>*'L;>^:.,V%UJ.T1
M1X+>8 S<*QRF">P.#UST7[6'Q?\ #_B[2--\-Z%>1ZHT%V+R>ZMSNB4JCHJ*
MW1B=Y)QP,#GTZ75?V*-$N;R233_$5[96[,2L,L"S%!Z!LKG\:ZG3_P!E#P78
M>%+_ $@BYGN[P*'U64J9X]K!OW?&U1D8/&2#R37!&E6]FZ=D=CG3Y^>YQ'[$
M$JG3_%\8/SK+:L1[$2X_D:\^_:__ .2O'_L'P?S:OI'X4? 72_A'JU[>Z9JN
MH78NX1#)!=%-APP(;Y5!R.1_P(U3^)W[-^A_%+Q,=;U#4]0M+CR4@\NV*;,+
MG!Y4G/-6Z,W05.VI*J155SZ&Y\ _^2.>%/\ KS'\S7S[^VQ_R.?A[_L'M_Z,
M:OJ?P;X7M_!7A?3=#M99)[>QB$2238WL,DY. !WKBOBQ\!-'^+FJV5_J6H7U
MG):PF!5M=F""Q;)W*>>:UJTY2H\BWT,Z<U&IS/8H?LI_\D4TC_KM<?\ HYJ^
M0/C!"UI\6/%PP8V_M:YD&>O,K,#^N:^]_ASX#L_AKX3MM L;B>ZMH'=UEN,;
MSN8L<X '>N"^*?[,F@?$S79=:%]=:1JDP43/"JR1R;0%#%3CG  X(Z=*RJT9
M3I1BMT73JQC4;>S.N\#_ !B\)_$:_>RT#4FO+J.W^TR1&"2,QKD#DLH!.6'3
M-?%_[1W_ "6OQ1_UVC_]$I7U1\'OV=K#X1ZW<ZM#K-UJ5W-;M:E7C6.,(65C
MQR2<H.<^O%4O'7[+'A_Q[XLU#7[S5M2M[F]=7>* Q[%PH7C*D_PTZM.K5II-
M:W"G.%.;:>AVW_-&?^X!_P"V]?G[X/\ $=QX0\4:7K=J@DFL+A+@(>C 'E3Z
M C(_&OTA_P"$>A_X1;^PO,D^S_8OL7F<;]NS9GTSBO*O!7[*GACP9KJZB+V]
MU1?)E@>TO1&T4B2(48, H/0T5J,ZCCR]!4JD8*5R]!^U-\/I?#W]I/JLD<X3
M<VG&!S.'QG8.-I],YV^]?'5RVH_%_P")DK6\)^WZW?DI&HR(PS=_95ZGT4FO
MI?7_ -BWP_?ZA)/I6MWFE6[DG[-)$LX3V5B5./KD^]>B?"OX$^&_A1YEQ8)+
M>ZI*NQ[^[(+A>ZH  %'TY/<FIE3K5FE4LDBHSITTW#<9\:OAV_BWX0WN@Z9$
M9+JTBCDLX@>6:+&%^I4$#W(KY'^ _P 4U^$7C:2ZOX)9--NHS:WD:+^\3Y@0
MP![J1T]">]?H#7E'Q'_9L\(_$6]EU!XYM(U23E[FQ(42GU="""?<8)[DUK6H
MRE)5*>Z(IU$DX3V9F>+OVKO!&D^'Y[C1M0;6=39#]GM4MY$&[L7+J  #U[^@
MKYB^"_@N^^*/Q2LMZM)!'<B_U"?;\JH&W$'T+'Y1]?8U[E9?L2:1'<JUWXGO
M9[<'YHX;9(W/_ B6 _*O<_!'@#0OAWHXTW0K%;2 G=(^=TDK?WG8\D_H.V*S
M]E5K23JZ)%\].G%JGJV>7_M=^#KCQ'\-X=1M(S++H]Q]HD51D^2RE7(^AVD^
MP->+?LQ?&C3/AG?ZEIFO.\&E:@4D6Z5"X@E4$?,J@DA@0,C."HXY)'VS)&DT
M;1R*'1@596&00>H(KP+Q?^QUX9UW4Y+S2=1N=!65BSVJ1B:%3_L D%1[9(],
M"JJTI^T56GN33J1Y'">Q@_M%?M">']<\%S^&_#%[_:ESJ!5;B>*-@D40(8@%
M@,L< <9P,]#BO-OV1O\ DL=M_P!><_\ (5] >"OV6O"WA#3]062:XU/4KRUE
MM?MTX4&!9$*,8DQA3ANIR?P)JS\-/V;-#^&'BB/7+#5-0NKA(GB$=R8]F&&"
M>%!J/959U(U)%>TIQ@X1/5[VSAU"SGM;B,2V\\;121MT96&"#]0:_.Z\.J_!
M'XI7T=I(4O\ 29Y8HI&_B1E*JWXHX/XU^B]?"G[5FNZ1KOQ8G.E%)7MK:.WN
MYXV#+),N2<8[JI53[KCM58Q+E4NJ%AGJX]"]^R1X,/B7XF-J\Z;[71H3.21D
M&9\K&#_X^WU2OMVO&_V5/!9\*_"RVO)H]EYK$AO7R.1']V,?3:-P_P!^O9*U
MPT.2FO,SK2YIL****ZC **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MJOAS_P AN?\ Z]V_]"6N5KJOAS_R&Y_^O=O_ $):Y\1_"D:TOC1Z-1117SY[
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ROQ&_Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5\.?\ D-S_ /7N
MW_H2URM=5\.?^0W/_P!>[?\ H2USXC^%(UI?&CT:BBBOGSV HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?B-_P @2#_KX7_T%J\Y
MKT;XC?\ ($@_Z^%_]!:O.:]O"?PCR\1_$"BBBNTY@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJOAS_R&Y_^O=O_ $):
MY6NJ^'/_ "&Y_P#KW;_T):Y\1_"D:TOC1Z-1117SY[ 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!S7CZTGO-'A2WADG<3J2L:EB!M
M;GBN"_L+4O\ H'W?_?AO\*]BHKLI8ETH\J1S5*"J2YFSQW^PM2_Z!]W_ -^&
M_P */["U+_H'W?\ WX;_  KV*BMOKLNQG]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
M"C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z
M!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&
M_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH
M^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57
M<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O
M^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?
MAO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^P
MM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_
M -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *
M]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[
M!]57<\=_L+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_
ML+4O^@?=_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=
M_P#?AO\ "C^PM2_Z!]W_ -^&_P *]BHH^NR[!]57<\=_L+4O^@?=_P#?AO\
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MGD'U:!YE_P (#JW]R+_OY1_P@.K?W(O^_E>FT4?7*GD'U:!YE_P@.K?W(O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PWQM_P"28:U_VQ_]
M'QU\JU]5?&W_ ))AK7_;'_T?'7RK7MX+^&_7_(Z*>P4445Z!J%%%% !1110
M4444 %%%% !1110 4444 %==\.OB+>^ =3WINN-.F(^T6N>&_P!I?1A^O0^W
M(T5,HJ:Y9; U?1GVIH>N67B/3(-0T^=;BUF&58=1Z@CL1W%7Z^2OAU\1;WP#
MJ>]-UQITQ'VBUSPW^TOHP_7H?;ZFT/7++Q'ID&H:?.MQ:S#*L.H]01V([BO
MKT'1?D<LH\I?HHHKE("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!PWQM_Y)AK7_;'_ -'QU\JU]5?&W_DF&M?]L?\ T?'7RK7MX+^&_7_(
MZ*>P4445Z!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5UWPZ^
M(M[X!U/>FZXTZ8C[1:YX;_:7T8?KT/MR-%3**FN66P-7T9]J:'KEEXCTR#4-
M/G6XM9AE6'4>H([$=Q5^ODKX=?$6]\ ZGO3=<:=,1]HM<\-_M+Z,/UZ'V^IM
M#URR\1Z9!J&GSK<6LPRK#J/4$=B.XKP*]!T7Y'+*/*7Z***Y2 HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKJFI0:-IEWJ%TQ2UM
M(7GE8 DA%4LQP.O -6JYSXD?\D[\4_\ 8*NO_1+4 >=>%/VO_AAXU\2:=H6D
MZS<SZE?S+!;QM83(&<] 6*X'XUV?Q1^,/A?X.:99ZAXIO9+*UNYC!"T5N\I9
MPI;&%!QP*_,/]F;_ )+]X#_["L7\Z^M?^"D'_)._"?\ V%6_]$M0![O\+?V@
M? _QDO;ZS\+:LUY=V4:RRP30/"^PG&X!P-P!P#CID9ZBO1:_''X2_$O4OA'X
M^TKQ/IA+26DG[Z#=A;B$\21GV(S]#@]17Z[>$/%>F^.?#&F:_I$XN--U"!9X
M9.^".A'9@<@CL010!Y_\0_VHOAY\+?$\WA_Q%JT]IJD4:2/%'9RR@*PROS*I
M'2O2/#VNV?BC0--UG3I#+I^HVT5Y;R,I4M'(@="0>1D$<&OS6_;O_P"3B=5_
MZ\K7_P!%"OT!^!?_ "1+X>_]B]I__I-'0!P.H?ML?";2[^YLKC7;I+BWE:&1
M1ITYPRD@C.WGD57_ .&Y_A!_T'[O_P %L_\ \17YQ>*K87OQ%UBW+;!+JLT>
M[&<9F(S7V2__  36TXHVWQ[=!L<$Z8I /T\V@#W[P5^U#\+_ !_>Q66D^+;0
M7TIPEM>H]J['^ZOFJH8^P)KU2ORR^/W[)OB;X$6J:K)=P:[X=DE$(U"W0QO&
MQZ"6,D[<X."&8=L@D"OI#]A#]H#4/&EG>>!?$5XUYJ&G0"XTZZG?=)+;@A6B
M8GDE"5(/)VDCHM 'U[1110 445S.J_$[P=H5]]BU+Q9H>GWF[;]GNM2ABDSZ
M;68'- '3457L-0M=5M([JRN8;RVD&4F@D#HP]F'!J:218D9W8(B@EF8X 'J:
M '45E6/BO1-3N4MK/6+"[N'SMA@ND=S@9. #GI53Q#\0?"WA&98==\2Z/HLK
M %8]0OXH&.>F ["@#H**JZ9JMEK5G'>:=>6]_:2?<GMI5DC;Z,I(-6J "BL'
M7O'OAGPK*8]:\1:3H\@&XI?WT4!QZX=AQS2Z!X\\,^*I/+T3Q%I.L2;=VVPO
MHISCUPC'B@#=KQ7Q1^V%\+_!WB+4=#U36KF'4=/G>VN(UL)G"NIP0"%P>>XK
MVJOR'_:-_P"2\^/O^PS<_P#HPT ?KM'(LL:NIRK $'VIU86H^+-#\)Z5:SZY
MK.GZ- T:[9-0ND@4\=BY JUH/B;1_%-I]JT75;'5[7.//L+E)T_[Z4D4 :=>
M)Q_MC?"V7Q$NAKK5R=1:[%D(_L$V/-W[,9VX^]WKVROR L/^2]6__8RK_P"E
M5 'ZS^+_ !7IO@;PUJ&O:Q,UOIEA$9IY40N57.,[1R>O:N"^&_[3?P_^+'B0
M:%X;U6>\U(PO/Y<EG+$-BXR=S*!W%=-\7?",'CWX:^(?#]SJD>BP:A;&%[^5
M ZP#(.X@LH/3U%>"_LW_ ++>C?"+XCC7['XC6/BB<6<MO]@M[5(VPVW+9$[G
MC'IWZT ?5-%4M2UK3]&1'U"^MK%'.%:YF6,,?0;B,TMCK%AJ=J]S9WUM=VR$
MAIH)5=%(&2"0<# - %RBN7M/BGX+O]3&FVWB_0;C42=HM(M3A:4GTV!L]_2N
MHH **0D*"20 .237,1_%/P7+JG]FIXOT%]1W;?L:ZG"9LYQC9NSG/M0!U%%4
M-3U[3-%,8U#4;2P,F=GVF=8]V.N-Q&<9'YU/8:A:ZI;+<65S#=V[$A98) Z'
M'!P1Q0!8HHHH **S-:\3Z-X;1'U?5K'2T?E6O;E(0?IN(]16=HGQ)\(^);A(
M-(\4Z+JL\F=D=EJ,,S-] K$F@#I***^+_P!O_P"+.J:38^&]"\-^)/(L;];M
M=3AT^==[[#$%1V7Y@/F<%<@'N#B@#[ T?Q!IGB&.Y?2[^WU".VG:VF>VE$BI
M*H!9"1QD9&1VK0KY6_8$\1:5IWP2EM+K4[.VNGUF?;!-<(CME(@,*3DY-?3F
MIZUIVBHC:A?VM@LA(1KF98PQ[XW$9H NT53TW6+#68FET^]MKZ-&VL]M*L@!
M]"03S3M1U6RT> 3W]Y;V4);8)+F58U)],DCG@_E0!:HJCIFNZ;K7F?V=J%I?
M^5CS/LLZR;,YQG:3C.#^1JZ2%!)( '))H 6O-OBC^T+X(^#FIV>G^*=2FLKJ
M[A,\*Q6LDH9 Q7.5!QR*Z&/XI^"Y=3.FIXOT%]1!VFT74X3,#G&-F[/7VKXE
M_P""D'_)1/"?_8*;_P!'-0!]O?#[X@Z)\4/"]MXA\/7+W>EW#.D<LD31DE&*
MM\K 'J#7GOB[]KOX9>!O$NH:#J^LW-OJ=A*89XDL9G"MC.-P7!Z]JQ_V&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#XK_ /)+?&/_ &!KS_T0] 'YJ?L:_P#)RO@O_KI<_P#I+-7W=^U9X@\=:/\
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M&C+G'=@@8_6OS:^-6I2:/^T1XSOXE5Y;7Q)=3HK_ '25N&8 X[<5][?L,?\
M)N&@?]?%W_Z/>OS^_: _Y+G\0/\ L.WO_HYJ /?M._9&^)?[0MA_PGGBWQ1;
M6.I:M&+BUM;Q'D81-R@(7B),'(49P#R <U\]6]WXI_9^^*4@CF?3/$.AW?ER
MB)SLD ()4X^]&XQP>H-?K[IUJMCI]K;(@C2&)8P@Z*  ,?I7Y;_MHQ+#^TQX
MS51@%K1OQ-G 3^IH _4#P[K,7B/P_IFK0J4AO[6*Z16ZA70,!^1K1KE?A1_R
M2WP=_P!@:S_]$)754 %?G5^WQJ_@+7O'=G<:!J/VOQ9;@VFK):H&M]J9V[I,
M_P"M4_*0,\8!*E0#]1_MD_$V_P#AA\$[VXTJ8VVI:K<)I<-PC%7AWJ[.ZD<A
MMB, >Q(/:OCG]C;X!:;\;?&>IW?B /-H&B)')/;(Y4W,LA;8A8<A<(Y.#G@#
MO0!XSINKZQXBM=(\)2ZX]OHWVP&""]N66SMI)"%,C#D*.Y../F/<U^H/[.?[
M/&D? /PS-!!<?VGKFH;7O]2*[0^,[4C7G:BY/N2<GL!\@?MD_LQ+\+M4/BWP
MQ:;/"=](%GMHAD:?,>@]HV/3T/R\97/FNN_M*>,-<^&'AGP>U_<6QT*Y:6+4
M[>X>.>2,)MA0D8/R!I!G/(*_W<D _6:BO#_V.F\4WOP3T_5?%NK7^K7VIS27
M-L^HRM)*EMPL8W-R0VTN"2<AQ7N% !7XN-J1T7QJ=06,2FTU#SQ&3C=MDW8S
MVSBOVCK\9=/LX=0^(UM:W""6WGU58I$)QN5I@"/R- 'U;_P\IU+_ *$.T_\
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M_P#HPU^JGBO6-2T#P#J&H:-ILFL:M;V)>TL8ADS3;?D7J.,XS[9K\J_VC?\
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M !@5\@_MSW_Q-U^ZM?#GACP_K<WA..$37MUIEM)(+J4Y^1BF3L48X. 6)SG
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M<;(' EN),'U6UE8'\",_A0!Z+XP_8%\<:9X2O_$4OB&QUG6XHGN[JP02,\A
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MR-%3**FN66P-7T9]J:'KEEXCTR#4-/G6XM9AE6'4>H([$=Q5^ODKX=?$6]\
MZGO3=<:=,1]HM<\-_M+Z,/UZ'V^IM#URR\1Z9!J&GSK<6LPRK#J/4$=B.XKP
M*]!T7Y'+*/*7Z***Y2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPW\3=)\7?$"U@T2ST6=;NWT]+J.XFN)UYC),99556 8_-DX QR2 #]$****
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MX5>/[7XI?#O0?%-HGE1ZE;"1XLY\J4$K(F>^UU89[XS7Y66'_)>K?_L95_\
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M$6CV*6O%JL$8B_W-HV_IBO@+_@H[%;K\4O#4B$?:GT<"08_A$TFT_F7_ "H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9TJ1K>[L+D$+-$PPRDC^%A@JPR/NL,U^MNGV%OI-A;65I$MO:6T2PPQ)T1%
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M:A4C10JJ!T  Z"@#Y._X*._\DM\,_P#89'_HB2LK_@FS_P BMXV_Z_;;_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#AOC;_R3#6O^V/_ */CKY5KZJ^-O_),-:_[8_\ H^.OE6O;P7\-^O\
MD=%/8****] U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBK^AZ'>^(]3@T_3X&N+J8X51T [DGL!W-)M+5@&AZ'>^(]3@T_3X&N+J8X
M51T [DGL!W-?57PZ\!P> =#^R)*UQ<S$27$N3M9\8^4=@.GJ>_M%\.OAU9>
M=,V)MN-1F ^T76.6/]U?11^O4^W7UX>)Q'M7RQV.:<[Z(****X3,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^N1DV8]MN*Z_Q7\'/!/CBVTVWUSPUI^H6^FHT5E"\6U+=#MRJ*N !\J\>PH
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MTK%W=E8EF)R2>?6@#\Y_@I^T7K?P'BU ^']"T"[O+TCS;_4K>:2<(.D:E95
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M%IHLEVJK.ULI'F!<[0<GMD_G76T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <-\;?^28:U_VQ_\ 1\=?
M*M?57QM_Y)AK7_;'_P!'QU\JU[>"_AOU_P CHI[!1117H&H4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !115_0]#O?$>IP:?I\#7%U,<*HZ =R3
MV [FDVEJP#0]#O?$>IP:?I\#7%U,<*HZ =R3V [FOJ7X=?#JR\ Z9L3;<:C,
M!]HNL<L?[J^BC]>I]CX=?#JR\ Z9L3;<:C,!]HNL<L?[J^BC]>I]NOKP\1B'
M4]V.WYG/.=]$%%%%<)D%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ><?&?X!>$_CII
M=O:^(;>:.ZM<_9=0LW"7$.>H!((*G R&!'I@\U\WWW_!-2UDN"UG\09H(.R3
MZ0)6'_ A,H_2OM>B@#Y@^'/[ 7@?P?JMOJ.MW]YXJG@<.EM<(L-J2#D;HQDM
MVX+8/<&OIX *    . !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '#?&W_DF&M?]
ML?\ T?'7RK7U5\;?^28:U_VQ_P#1\=?*M>W@OX;]?\CHI[!1117H&H4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%7]#T.]\1ZG!I^GP-<74QPJCH!W
M)/8#N:3:6K -#T.]\1ZG!I^GP-<74QPJCH!W)/8#N:^I?AU\.K+P#IFQ-MQJ
M,P'VBZQRQ_NKZ*/UZGV/AU\.K+P#IFQ-MQJ,P'VBZQRQ_NKZ*/UZGVZ^O#Q&
M(=3W8[?F<\YWT04445PF04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <-\;?^28:U_P!L?_1\=?*M?57QM_Y)
MAK7_ &Q_]'QU\JU[>"_AOU_R.BGL%%%%>@:A1110 4444 %%%% !1110 444
M4 %%%% !115_0]#O?$>IP:?I\#7%U,<*HZ =R3V [FDVEJP#0]#O?$>IP:?I
M\#7%U,<*HZ =R3V [FOJ7X=?#JR\ Z9L3;<:C,!]HNL<L?[J^BC]>I]CX=?#
MJR\ Z9L3;<:C,!]HNL<L?[J^BC]>I]NOKP\1B'4]V.WYG/.=]$%%%%<)D%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX5V.E:C:ZQX,2-[R]N!']GGW[<>7ABW\0Z@4 >R4444 %%%% !1110 4444
M%%%% !1110 45XW\+_VG=!^*GQK^(WPTT_2M1M-6\$/&E[=W(C\B?>2!Y>UB
MW;^("O9* "BBB@ HKQN7]IW08OVH(?@>=*U$^()=(_M@:B!']D$>"=OWMV[C
M^[CWKV2@ HHKQOXH?M.Z#\*_C7\.?AIJ&E:C=ZMXW>1+*[MA'Y$&P@'S-S!N
M_P#"#0![)116!X\\>>'_ (8>$-3\4>*=5@T70--C\V[OKDG9$I(4< $DEF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?+W_!23XV7/P0_91\37FFSFWUK7F30+&56PR-.&\QEQSN$*3$$="
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MA_M]ML_\>Q7H/['D5S#^RC\'TNC^]_X1/3"/9#;1E!_WSMH ]@KX _X+5_\
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M<$,#B@#8UC]L'X^?L[>,?"\/Q^^'7A=?!FOWZ::GB+P5<2LMK,XR-\<LCL<
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M%Y[9QZCS/,_6@#ZL\>>*H? G@;Q%XEN4\RWT;3KG49$SC<L,32$9^BU\)?\
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M[)/PE_:"^ _BK5_B!X.@\1:G;^(I;&*Z>[N('2$6MNX0&*1<?,['/7GK5O\
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M&<U5O?\ E,58?]B,?_07JO\ LJ6,,G_!37]IJ]9<W$-I!"C>BN8"P_.-?RH
MO6O[:_QM^"?QD\(>$OVA?AUX>T;P_P"+;M;'3O$/A>XD:&&1F11YF^60,%+K
MN!V$ [@"!@_=]?!7_!6 ?\2OX%'O_P )S;?^@U]ZT >4?M6?%&Z^"_[.?Q!\
M9V!"ZEI>DRM9NV,)</B.%B#U D=#COC%>"_\$K/@WIO@[]F[3O'UU;_:O&GC
M>6XU#4M5N?GN'B\]UBCWGG:0@D/JTA)S@8]F_;2^'E[\5/V5OB9X:TV$W&HW
M.D23VT"KN::6!EG2-1_>9H@H]R*\^_X)C?$W3?B)^Q]X,M;2=&U'PZDFC:A;
M;LM#)&[&//LT31L.W)'8T >V?'CX+:!^T%\*M?\  _B*"-[/4K=DAN6B$CV5
MQM/E7$8./G1CD<C/(/!-> ?%WX-O^S__ ,$W?'G@$^(KKQ1#HWAR[B@O[R%8
MG\LL6";5)PJ[B!DD@ #/%?3'Q.^(6D_"?X>>(O&.NSI;Z5HEE+>SL[A=P1<A
M%)_B9L*HZEF &2:^5OB+^T G[3?_  3>^)7C^'PW>>%[6^T:^AAM;V993((S
ML:1&7&4WAU!(!RAXQB@#QW]DGX\?M#>*_P!G3P7HGP1^&.A76A>&[%=.N_$'
MC.Z:*.^N58F1+:-)4)5=P&\D@G(X((KZ4_8R_:_U3]HJ^\;>$O&?A5?!?Q%\
M&W2V^J:9%*9(7!9TW1YR1M9"I&6'*$,0W&O_ ,$][**P_8P^%,4*A$;2C*0
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MC=ZKLAA3(W.V#[  DD $CNO^"1%E;Z;/\?;.TA2WM;?Q2L44,8PJ(IG"J!V
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M.NL_''XO2$S:'X7U[3O 6@.?F0^5YCW;*>GWUW CJ+@_C^BWQA_:CT_]E?\
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MU-^VC;_'7_A(81:1:"=&_L7[*?,)PP\SS=V,?-TV_C6M^V%^SQ<?M1?!#4?
M-KK<7AZ:[NK>Y%]-;F=5\J0/C8&7.<8ZU[910!\T_M&?L6:=\?OACX&TA?$,
M_AOQIX)2%]#\3V<19H)42,-E-P.UFBC;A@RE%(/4'S/Q#^R/^TK\9=!?P=\4
M?C]ILO@:X:-=0A\/:''#>W\*D%D:38FS=CG[R^JL/EK[BHH \I\1?LR> O$W
M[/X^#5SI;Q^"H]/CT^"&.3]] (\&.5'8']ZK /N(.6SD$$@_-F@_LC_M1?#/
MPY'X)\#_ +15@O@B"-K:R?5M%634+&WZ)'&Y5R=JX ^<!<#:%& /NFB@#YV^
M '[$/@?X(_!WQ)X%O&F\8R>+%?\ X275=3!$FILRLO3<=@4.Q7#%@6+;B3FO
M'/"O[%/[0?P8L[KP;\+/V@H=)^&LLDK6MOK&CI=7VFHYR4A8J1W)RK1C.6"J
M237W910!\L?LF?L/I^RO\3?'GB2U\6W'B.Q\2VUM$L=_$3=B5,M--+*6(=I)
M&=^ ,;L<U]3T44 9WB/2CKWA[5-,600M>VLML)",A-Z%<X[XS7C_ .QO^SC<
M_LK_  4MO =UKL7B*:&^N+O[=#;&!2)"#MV%FZ8ZYKW&B@#Y]G_9<NIOVT;?
MXZ_\)#"+2+03HW]B_93YA.&'F>;NQCYNFW\:\:\<_!WP?\>_VE_%7B;X'?%^
M\^&7QN\-K]@\410:9)+%=*/W:^9#+L20?NU!=#(GRQDKNP3]SU\V_&[]@[P)
M\8OB ?'UEK7B;X=^.GC6.?7O!VI?8YKD  #S1M8$@ #<NTG R3@"@#X<_;3_
M &=]>\+_ ! ^"W_":_%'4OBM\6/%'B>VM(5DMX[*WM;)9$!6"V0E8P99%R_
M;'W1AL_>?QI_9<NOBQ^T9\)/B=%XAATV#P,\KR::]J9&O-Y!X<, F,=P:SO@
MC^P9X!^#?CY?'EWJWB3X@^.HXS'#K_C#4/MLUN""I\H;0 =I(R=Q )P1DU])
MT <#\?/AC+\:/@SXP\#0Z@FE2Z]ITEBM[)$95A+#[Q4$9QZ9%>;:3^R/;_\
M#%Z? /5]>-PG]DOIS:S:V^S$GFF6.41ECPK[<KNY (R,Y'T/10!\<_![]B/Q
MEI_P8\7_  C^+GQ$B\??#^_TZVT[1;2UM/L\VE+"S,DB.03E2(2 2P!C Z<'
MGO"/[)_[4WPQ\-VW@;PC^T)H\/@BRC:UL;B^T!)+^TM\81$RK?=&0,R?+QC
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M[(QR6R><)(_-<.0Y  !("YY/'2NX_8W_ &1[C]F./QWJ>N^)8_&/B[QAJO\
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M ^*=>@^!'QIM?"7@36[MKN71M9TE+Q[-F7&8]RLK,,  _)E0H;=MYZWX'_\
M!/V7X,_M':=\5Y/'UWXHU%](FMM;DU2 FYU+4)F8R7(?>1&F"BK$ <!!\Q.3
M7V)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cntx-20211231_g10.jpg
<TEXT>
begin 644 cntx-20211231_g10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *""^$"<CA"24T$!       +!P!6@ #&R5'' (   (@"1P"-P (,C R,3
M Y,#D< CP "S$V,#@P.2LP,# P.$))300E       0^J?1#3F_36!^($EZOG
M#>6#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M   %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<'
M)I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M  #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '
M4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6
MY0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !
M)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F
M]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M  3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F
M)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W
M5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M           $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M               %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&
M%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$
M8C4FQT                5&]P(%5N=$8C4FQT                4V-L(%
M5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F
M-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M     -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M      .$))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M             _@   .$))300-       $    'CA"24T$&0      !    !
MXX0DE- _,       D           $ .$))32<0       *  $          C
MA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M   0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M      <   _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@
M  _____________________________P/H   X0DE-! @      !     !
M "0    D      .$))300>       $     #A"24T$&@     #-0    8
M           ?\   =D          $                          0
M         '9    ?\                      0
M     0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   ?\     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',
M !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M  !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6
M=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&
M4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %
M1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   '_
M   %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4
M   0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M    EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6
MQT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M!.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M        QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F
M<      #A"24T$*       #     (_\        #A"24T$$0       0$ .$
M))3004       $    !#A"24T$#      ,Y@    $   "@    *P   >   %
M"@   ,R@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (
M0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01#
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MP?Z57N==>ZO]$RL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ I )= P$1  (1 0,1 ?_$ !\
M 0 " @(# 0$            ("08'!0H! P0""__$ &(0  $$ @(  P0""PH(
M!PL- 04" P0& 0< " D1$A,4%2$6,1<X.4%1<7=XL;:W(C(U-V%V@9&U\!@C
M,S1YH;3!"B0V<W6R\24F)RE'4E979VC1&2A%2$E866)C9H:7IN'_Q  = 0$
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M@QG&<\4KSQ2G%*<4KQG.,8\\YQC'X<Y\L?@_3Q2O&%HSGRPI.<_@PK&<_?\
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M+>.Z:.U2.30^&2_.M@I69B+R;!+#'J]L9JZWG>=<)4XI6F^Q?VOF]OR-[/\
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MZD'B-:L8YK7=_(-0C J0N+.C-SH%<DPI:&GFU)3(B/O,.8QZFW%)SC/,'O\
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M ,DX&T,2>F <]\]L8.?<"1T!-1P<@=R2!@8/4@$=O;N7\9 [UE-<[-]?+<7
M *SN+7QLY:)$R("$#[(.?(SY<&7/@NQ<0TO>WC27I@HI''L2T1W2CHV>D8B7
M[H_[.;!R!@]5W#IW + D>W!1@1W!5O\ );$H(.3Y X/N. >ORAE(]S*?,5O/
MBHTXI3BE.*4XI7P%9PL6+)$C<R ."CH$R<7(%9$>(+@BXD=R00F$I4M;<2-
MC1&W7YDB4XB.S'0XX\M+:5*PI59'1SL]L#>&[^PU.NY37Z4T(Y;X8NL4C6U*
M!)$"Q.RCE= 2Y>Q@/9S;%AO+A*NPALZ8H_I[4:VR,N0M<*%(;R$:?/\ LI5H
MW%*IOI6O#4+Q*\VK8?=_KV4VA)/6,TCK/3[ILH)M=6L7]%NUFM:SQJH]V)LM
M,321KT*+OXS-9TTQ8"-UP1M$.PC@+Z8"5/F:LVWV1O8G2&W2>KD3%[)A:VND
MBA?#@B;+/;N#=>(9KLB'7%.L8L$B,6]TD-!,.H456UB"CU*?2E5O=&00.(F*
M2$!5<1F4IN95,@C&2Q0'<% ))'8U6MQ&9X^:H:,-ET+B,. "=A<]$#D!2QP!
MG)([U0?-W%XGPW1D1$(AVI+SQMPW_ KFW!/7 *O8^V[0&TKKHQUUA']'VW1C
M-AU!IJR;?); I]R)V6J17W9M3:,KV17J99AV(]W+M+H8EC60VMRT,#/NB>Y7
M6K6* 7<^56..32GNY5!>W9"BEV>4('H1CUE65BT1FM!<SJA6:&W?3[R2Y]&A
M)Q--'?K9(65'1UE955565A*[Q1K+VR5T:[*#R&H=$9UJ_I\3])+FO?MYA;#A
MNR&*T]:W(.K6.NY6L2) RQ.$X B K<3<<H-C1",DL,?E.CXJX$2RSBW9G@$L
MH@=^CM#O;ELX(!#%-I(QT/2J=L9C#;M. LYBB,ZKU42E%,BKU[!\@=^GY:ZW
M>SOXG^Q/S_\ M,POX_G6=Y_7G[_S^OG<NE?57AW'_FVF]W_A&B]O9T[=>_G6
ML[K^CWWWR?\ ]<O\,5F':+_+>*O^>_KK\'_I?V9_O_\ ]\N6O#/Q?"[[RM2]
MG_(^&OG[#V/<8CJ/;B/[J6G^O>5DF\OGCQ8L?+^$^N/U^?E\]H@/[^>/Z<_+
MY6^A_P#%3_HN(3^/X+FZ=O=\ON[9FO<9XFSGOI^/EYT?\/(]3Y>563^%]]U%
MWC^9-HS]F75OFN/$O[&>B??GK?[RXF\Z]S1?J]??<VS_ %-G4Q/'7^TUK?Y<
MZ9^JU\YPSXQ_6G!]V;/]FOJ^CW^#R^SMJGX.]>_?'#E5#]G?X;\4_/\ [0NO
MO]6+D_Y?I^?-8\0GZ?XEC_KNA=^^?36S^C\E=K^$GU.^@^^]KQ+_ '%'G\]<
M#?OX7[]_FD=7_P"T.JG*%]_.<<?>WP[^MX<J^X7^IWT-7X9_%K]C\8J[1_1K
M[3/JM^;_ *F_4D-SHG@_ZU.'/N)IG['#7R,^B ^SGXP?A*XT_P#>&_J4ZOJS
M^+/Z.9'6H:J+ZX?=1^XG\Q!7Z-;<U1P[]DSB[O\ T)._RZ:.GN^?NKGO@W[/
M'B8/_1%A^>/1/GU^3RJW7FUZZ$IQ2G%*@9XGGVAG9#^: G]<JUS*N"/KKT7[
M:;]1-62\'_7)I?\ I9OV:>NN/'S_ -]-1_T5=G_!C_R6WK\6/Z_K^_Y\W*?Y
MBZ_"!!^VV=;7?^:F^^^'S'_*H_Q?E[=C78>\*;[0/KW_ -%73]I-RYI[CSZ[
M=9_TT'[';5JWC7ZYM3_[5O\ LEO[A\_;WJPWF(UBM.*541VL^W(9_-.VE^I.
MVN<7>,7V;H_P,<8_N'C2NT/!_P"P?/\ ADX1_??!M1IZX*2C;?15:L^E*:[L
M3*E9SC&,)Q=-LY5G.<^6,83CSSG.<^6,?//U<U-X6$+QK]#X2<#X/XG))[ #
M6N+R23Y  9)/8 D].M;5\4<G@OZ(8#J3JG#( P3DG0>#L 8Z_/%=@6++BS6\
MO0Y#,IG"LH]JPZAYOUIQC*D^MM2D^>,9QYX\_/'GCSQ\^?26&>&X3F02QS1Y
M*[XG21-R]QN0LI(\P#TKYNR120MLEC>)P 2DB,C 'L=K '!\CCK7T<JU)6F^
MQ?VOF]OR-[/_ %).<4K^=MX?'\)^ -^#_# [?^?U_/\ [YM2_/\ U?>_3Y\5
M#IGRSC\>/[*R/PZ>R.]]#]<_#TK6G-J7'7('<_C076B;5%5<HL?#OE.D@NG\
M)^NV)I"58FC'8IDHPIA64^;<^2G&<>T5Q4:_I%<4IQ2G%*<4IQ2G%*<4JAG4
MMKJUD\6X^Q<]@7?5.[)K%GM8K1%HKLFS62TTD'J,3KJ14H6W-9;WV%IV+U[B
MRQV-ZU^D7+5VNMFYVF5<(.RTK9(CIRH?[>WO_3_MK0%)K=97XGK^Y9>]1L\L
M]V9LM;@:IK/6D-IHU%8/;3[#:.B#K?LC3?9ZG_9KP,/:%M)>9:M[:NV=/D@R
MM7-)J0HF7>@5Y4:[,O%*C5W.^T_[5?FY;M_9M9>*'L?/W>VM:^&9]SEZ%?F<
M=:OV.4[BE3?XI3BE.*4XI3BE.*4XI3BE.*4XI3BE:8V?L"^TVQ:X"5.E5&SQ
M]AV>546IUBV 9J#PLO%IUQO"G%PAFM[JB8.6'I9!A,G$V+(P2DPX^87NN7IS
M/K:;8V=Y!J,UU>75J=/MENRD&GPWBRPM=VED 'DU*R*2":\C8J8V7E*YWAPJ
MM2D=T:-516YCE,ERNW".^<!&ST0CN.IK<OSRGY_+/E\_OXQGR^?]']_+GD#.
M!D8/F!56H]:P+B@1OLT7-DH <2-W3F81*%);$ = B,:4TVMZ5-FRG&HT6.RC
M&5.OONH;;3C.5JQCY\][48Y)H>&X88WEEET<I'%&C222.VMZP%1$0%F9CT"@
M;B>@!-6\7JO=,Q '.!R3CH(8<DGL/[*K@:[E[HV/XB<K2.LM#V(/2".OG:N)
M[$EQ1TO6VJG#<>MS^U1P9T0&"%JX3+,NTRK2,VQ0V45E#S"GBZ<KJ\K83<(:
M-I_AZFN:GK]M-?)J"W,W#L,L,%R;IE%J-)DF$TT\-U%$PO;I?1.8L*O$%AZ7
M*^2-2N9-7-E'8RB'E$>FL'Y6W <R@%%1D8_2E(EZOUPP&TVR4?6M<H>)\V&J
M>:LQO+3EGN]DDI*6ZS2&O5EM10I[%E#,",MQ[(NOB8PRL@6WG(H$,,B9PQC5
MM[J%Q>F)7V0VL&Y;:QMTY5I;*PZ\J+)8R-@"6XF>6YG(#7$TK^M7MJBIG&2Q
M^,S$EF^4GL!Y*H"CR45@?6K#"NLFCDRD*=CJTQKU,AM+3CZG6<TT5AQM++27
M'7E+1G*$MMH6XYG.$H3E6<8Y><1DKQ#KK D,-7U!@RY+ K=2D$8&201D 9SV
MZFI;8;H;=<KDQ1#+,JKDJHRS,0JC/=F(4#)) !-?3J&)I9B4;=U14%UM[WF?
M%-R$:\M=+8D3V";R"D9Z2>KX:--)M%4R%$6&W'IR9.'79:?5E2\^0^N7.K@+
M/>WMTMNQC474=R@C:(\HHIN(XP60+R]JD[0,@ 8Q[>I\.WV@B#TU-/B-W'%<
M0K::MI&H2/!<1+<03M'IU]=21PS1.DD4LBI&X8;6).*WKR6O)KQG&,XSC/U9
MQG&?+/EGRSCR^6<?/'X^*55QM'P@^HVWMBW7:-O3L[-HOMC*6D]D9=&(0[)0
MO)7+E^Y1% W\QHWM7%>R9R\[EM'DGUJ\O/FO-2\,.%]5O[O4;I;_ -)O9WN)
MS'>;$,DARVU3$VU<]ADX[#I76_"'T:WC7P1POH/"&AR\*C2.'-,M-(TT7>@&
MXNA9V40B@$\POHQ+($4!I.6I8C)&<U+3J[U3U9U#HAG76H_I)BNG+7,N4W%F
M,(-3L&9PD*%D98DHA0<-Q<PP,#TL9:5Z7O;.>O.'/2G)>'>&]-X8LI;#2Q.(
M);E[I_2)><YE>.*)L-M3"[(4P,=#DYZUIKQ;\8.,?&KB*RXHXV?3'U2PT:#0
MK?X*L?0+<6%O>7U]&&AYTY:8W&HW!:3>,KRUV@(,ZF=\/_5DJRLV0A=]G$E!
MU7F'3!4J=3FQE&K.P*CNRIG:B#S I<(B0$H^SO;3$&?:R%CL;$X76(BSCP<?
M.&E/;* HT?8-&L1;NVR,;8QDG^HN5'MW$MDUJ\,0ZR="RRM*.G0.[*\AQ['=
M58CL" %  Q6IR7AH"QFU:EM?7N]-J5VRP+X<.'#<YC518^,J9BC[D"I!52<5
MU,4R6D03NT401?V1'+3% 41F0$K^1L@>&<:F8EB<]0\AD<  9/+N$ R<D9-P
M2<8)*CJ.M0R0I QG:%4]>F'A;/3'7$0&#D=3TK-COAJ:/*Z]J&M1EDOU:K]#
MAW@=5'(*=?GIX>#>]@D-A3$PW;S0K8Q') IQ)X;5K''C,V8)%9AD8YE5@C_&
M%CDL[DG<Y4DCI@KSNH(ZACSF)(/4JO<#!@.BJ@ VJ" ",]"(< CL0.2N 1YG
MS (^HWX=6M3XR[5R=M/<RZ?L1-@^E]5<*4.7$-/$[CLG8=?ER3<^@2K?B92;
MSM>W60)):L;3QB2L3"NR[4+&I@OQ;U@1VR93T& #*AB? '3!B(CVG*@*"H#%
MB8 8P,YQR\9ZG$;+(@/MQ(N_=T8DX)V@ 9'CH'IG'89_LGF?8'[O/L%?L18>
M2#ZU.")LNG^]OTUF$0/:_*7"JM5PL1)&F7Z5::V0*3I:&SLTI @#H<4I*]L8
M^F'L <RR2RMU&"?6F?&<].G8L#$]0 >N-G7)_J"-1TSYB),GW>PXJ<7%*<4I
MQ2G%*<4K!]G3R K6VPB@@*!LA4;1[9/&5VU$H@:KGB$,"0D0@MD+D$K@"@)2
M2VU!,$IJ%Q((]^1*DI4RTO&5*JL\-KM-;.Q&W=YP3.EM.:SB5@/"E$)E-J--
MI=^0:G6@I%@1K$L!N?:9&_#+D#AMWY9WX+3 E,)$6Z7$+;/DH=N65*E1K#N;
M5MD=GK-UH'%@,^RT\?M8V=4,K>Q8T-H=4-B1-?5T7#M1D!"J$^TPB8B]Q[T'
MB$G51GA8R97E$!:YLI"E0>I)0E6_& VI#28)OTJ_;#CC\$89_;X>F1MK#^E.
MORTC4A"N#*'&TY:-GHU_68^U%$CMIEE&J+*'-I/O&ZT,J0]\_G^>E7AJ4E.,
MJ5G"4IQG.<YSY8QC'UYSG[V,??S][@]CGMYTKA7K+7(\%DI(/!F!LES+4<B\
M3A-09#N/7C+;,MQY,=US'LG,>A#BE?XM?R_<Y\H9!VCIZWQ?\[WCVCV'S\J9
MR"1U"]6(Z@8[Y/ECS]E0/\5I:'/#F[:+;5A2%ZFG*0I.?-*DY*"<IRG/U9QG
M'EG&<?+./JX88!&,8!&/9[J*<[2.H."/?GJ.V?S9KJ5;._B?[$_Z3(-^K.]/
M+_M_IYW3I7U5X>ZX/^+:;K[^?HGMK5UUCT>^^^7\^R8?W5F/:+_+>*O^>_KK
M];^S/]/]_P 7+7AG.WPN^\K4O+_J?#7X^V?=YG&*CJ/;B/[J6G^M>5D>\OJ\
M6/\ Z3ZX_M0 _P"O^3\7X>6^A]_"D^V+B'I_^&3?/L.U3WW?B;SZZ;^+Z=%[
MA^/OUSD]ZLG\+[[J)O#\R;1G[,NK?-<>)?V,]$/MXSUO]Y<3?VU[>B_5Z^^Y
MMG^ILZF)XZ_VFM;_ "YTS]5KYSAGQC^M.#[LV?[-?5]'_P#!Y?9UU3\'FO?O
MCASY]O[JB.SOE\;\4_\ *%U^_7)_S_U_U\UCQ%GG^)>?^6Z%^VMCY>GEY5VM
MX2?4[Z#[/_-KQ+_<4>/S5P%^_A?OW^:1U?\ ]OZJ<H7W\YQQ][?#OZWARK[A
M?ZG?0U?AG\6OV/QBKM']&OM,^JWYO^IOU)#<Z)X/^M3AS[B:9^QPU\C/H@/L
MY^,'X2N-/_>&_J4ZOJS^+/Z.9'6H:J+ZX?=1^XG\Q!7Z-;?T?W^7W^:HX=^R
M9Q?[[)/];3?]E<^<&Y_Q\>)>?_)%@!\G*T3^WV^?85;KS:]=!TXI3BE0,\3S
M[0SLA_- 3^N5:YE7!'UUZ+]M-^HFK)>#S_W2Z6/^EE/Y;:X_LKKCQ_\ E34?
M]%7:/P?^JV]?A\L<W*?YBY_"!!^W6GS]W;RK:\G\U-]]\/E_UF+V_P"P_)78
M>\*;[0/KW_T5=/VDW+FGN//KMUG_ $T'[';5JWC7ZYM3\_6M_P!DM_T=JL-Y
MB-8K3BE5$=K/MR&?S3MI?J3MKG%WC%]FZ/\  QQC^X>-*[0\'_L'S_ADX1_?
M?!M1#U+CSM74+'_LVW%_;^Y.:-X.^JG@S]['''[=QK6Z^,OJ1XV_?3P1^[N"
M*L#\-^Y5*O\ 7H*%/6< &,6/9%NCU\44+P(!(Y(0@"TI@1"E/M22+J79##:F
MXC3J\+>:1E.%.(QGI?Z%S6]'T[PULK#4-6TZROM3XIUB+3;.\OK:VNK^01Z:
MACLK>:5);IPTB*4@1R"Z@C+*#S5]%#HNK7_B;J%[I^E:C>V6F\,:--J-U9V-
MS<VUA$?A!Q)>S01/%:H5BD8-.R K&[ X4D68?7SJRN6:TWV+^U\WM^1O9_ZD
MG.*5_.V\/C^%/ %^_P"7<#N!\OOY\[-J7]/SQ\O/^OY<A[>O]WS[T\_R?Q^?
M^VM:]0_XCO"F_P!.;;O[,Z6\C2OZ>_%*<4IQ2G%*<4IQ2G%*JAT7MVM:B[O;
M2Z@4C2G6VCT4Q;91H-?=:.VVD6V<9DZ=K&RCE(O0IC2+FM-@;L=-3;'?"D%K
M?3%\3JD\(NA&DYB"YQ HI_?\_G^7VQ[KG33M$SX@$;?A#4FC0E.%]C;;8VK<
M*UGU3;,6?75HE;0FS[B9M$77:-\M&!5,;TY7*Z]&L[5ZG[JL.W;#;2<C5S=;
M;FJ5?%Q2HU=SOM/^U7YN6[?V;67\7Z>*5K7PS/N<O0K\SCK5^QRG<4J;_%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*U*YM1Y.TE:L;UW>7Y: T6Q+M3<C7^*LD%*GJ%
M_$LX>OK-IRVQ/0['>C)JZI_FTIUB(^PIMUSTO@W_ 'M&IF_L1&9FMQ;D7_I7
M/5!)RL+8-:Y,9!5S="/)PS*00*?,/,Y?+?L#NS'MP21GX^[N.VW/NKB-MYQB
M\=://.,?^'$O]?YO.^^7&ED"RXCS_P"18OW_ *&:EE_G+;_3-^SSU]5LVHYD
MM/HFL@WT^V#&3A@HPS/P-J-$7(80\S*V#;4Q2+8-[,=YJ5#K8P<=N1)M^+*C
M5Q(5<LU I6NFCE)?:E+Z#I[>M$Q3FWE^ 2I73[,M&TP# J]S*\-G&59#<&<+
M \6D.2L8WN._7"I_VVP<''4*,L>G0 YJM;H!T1LFH-H=B[-NG>]A[(.P]E1!
M(D3=1I-P#%MK=5IET>V6X(/6JU0?IEF#9H-:@3VF,3!0\2[[L26U.9BP-B<=
M\;V^LZ9P[;:/H-OPVKZ8\LLME)$)VM3=7=D-,$L%K;.+,26KW,D9<I+)* T8
M*,\GCZ5ILMI->R7%[+>L\RX64$*C!%?F!3(XWD.J9 &U4 '?"V-XQC_"85\L
M?Q%H\OY/^_\ <\_E_+\OZN8 ?K<7[N-^[Q_9^7%>O_P^/^A_^/I\_+\=;2MP
MV08KA49%@"";\MA+3< \Y):#R<^U;5E$]R&Q)E)9]*<JQEEAQ?M$HQZ?3YYQ
MXP2!R$N=_H[9$O*4,^S!/JAF1<Y '5ATJ[@N;BTECN;20PW,3;H95.UD?! 8
M'#8(!/D:T1T\KLJM=;]1CI@RO#5KH-,D-IKKLUZ--974@;:)\WWZ-&<;)R<M
M*S*::2['3A#66WEYRK";B\U"RU>ZGUBPAN((-7EDU3DW7+YL3W[M<&,F*21&
M"*ZKN! )!PH%>MQ'9:AI6M:CHFI7@O[G0+NYT+TI0RI*FEW$MJKQHX#I&[1L
MZ(V616"EB16PM0XQ\(N'RQ\MK;4QCY8^6/IR:^K/E_?Y<\?3OYJX^W]0_:YA
M^@5?\7?TS1_O3X5_<EIY?W5MCE_6*UXS]6?GY?+/S_!_+_1P>@-*H)WSV3\2
MVM[HVC7]:5/8TS7X:\6(=3I8_0B#T"178A%]D6[#-*ILS)2,Y%2VIJ=F7(S(
M1G#F'EXSZLZ,USB'Q&M]8U.#3K6_:PAO;A+-H]$69&MUD;EE9C:N9%*X(?<V
MX=<D'%<D<7\;>.%CQ1KUGH6F:U)H]MJEW#ILD'"'ID+V4<K+ T=U\&R^D(R
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M/EC&<D]L8P<GRQ[J8Z]NN=OOR#U'MR"#T]M<0>V5KBJA@]BL]^I-;K]B>&L
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M"^?SQ\O.L[T\OO\ R\_GY>?^OG<^EC_?3AT'S\-IOVC1!G\60?R>1K6-T/\
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M<R&,97C+K?JX7\8\GA2# S_OS:?FMKW^W\7XZ^CW^#S('CKJA) '^+S7ADX
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MD0=U#2.1DLI&0PJ3-;OM+MX$99ZU9PI< 8$J.C"D2>QF+,#(SE+A1I:UH5F
MVK&4N2E)2RVK'I6M.?ES)K:\M;RWCNK:>.:WFCYL<J,-CQ?Y8)P=O0Y) QYU
MFUCJ-AJ=G;ZAI]W!=V5W")[:YA<-%-"20)8V\TR#ZW;I7-NF@["'G'RPUEN-
M%9G2%O3HK2(\*0IU#$QY2W4X:BOK8?0S(7E++JF74H6K+:\8K[ER!N&3V&1G
MY]*O RDX!!.,X!&<=>N/9T/7MT/L-06\3J9#7T3[+QD2HRY$2I TRF$/M*>C
M*DV^LKCID-87E;*GT9PMG#B4Y=3G"D85C/GS+."/KKT4?]:;]1,<_)@'K63<
M' GB72\><LP_):S_ -OXJZXK) >FTU/"YT-/H\+6R0%^<EA/IG.ZKNJVH2L9
M7\I;B7F<MQLX]LYAUO*49PXC.=S$'D7/0_7_  >1_P"76@\_>#[NGEV&UVR8
MI1COQ?"<=^AN8B3V[8.>H^7VU?#X9&X=65/ICU;H-CO]5"W.TU_9T\!6R)F'
M&*D8-<OEX)')K<5;GK:B#!\>1,ER'\-,ML1I*_7G##WHU1QOI]_-Q+K]W#9S
MRVT%Q9)-,D;-&CW%K:I"A8 @M([!5 R22,@9%:WXPL+V?7M9NH;:>6W@ELTE
MF5"45Y;:W2-,@=6=RJA5R<LH(&Y<V+T+:>N=H5P7;M>W.OVZM&G23(@R%(,R
MH1)P/*>A%$0G,93F1F!*CO,RO9I5AI;>?7Y8\LYP^[L[NQFDMKRWEMIX@ADB
ME0JR"10Z%@>P96##..AS6*75G=64SV]W!)!-&$+QR*0RB0!HRP\MX(*Y[YK+
M&3(>0AAR.5&OHE0GB45;4Z,XF2.C^[^WGL*0[G#T)CWJ+[:4WE3#?O+'K<3[
M9OU6Y!!(((*X!!!!!.< @@$9P>_L/L-6Y!4D,"".A!!!!]A!ZBJE.U$F.]W"
MB26GV78SW4K9SS,AMU"V7FG:/ME;3C3J<Y;<;<0I*VUH4I*TJ2I.<XSC.>+/
M&(__ "WI[%\&.,-Q\ESH/&A&3C ST )/<^5=G^#_ -@^;M]F3A$]_+X<X-&?
M<.AZGIT[XZU#[59"!&L_4=R1-B,(CZWV[B0M^0RTACV]AW$ACVREKPEKVZU8
M0SZ\X]HO.$(]6<^7-'\'JPU3P9+*R_\ <OQN3D$8S?<:8SG'?(Q[<]*W5QB0
MVD>-H'<\4\$=,Y/U.X(QT[]:^32DEA3_ $O0EYK*V=X; 2[A+J,J:6LGK1Q"
M7$XSYMJ6A:%I2KTY4E25)QE*DYS0X#5A=>!9*L-O'W$'4@C!-[PN "3V)["J
M_'?Q?'L'SX X8 SCN+/BI2 #[VP??TJPKP]]E5^NZ0,OWVY1(#Y[>)FN '+
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MA/FT][)SV:U>A7E&E4J:5V+J[L)X@M?W-J7M7HUP3,>MV9NC&.U5VL6[[1\
MU:4U^5KICJ?*)Q*3KB16+*.?N,TP.P;GX%U[XA.#QB%BFDPJH=,^_P"3Y//\
MGS%2@O?9>^53OQ4=%YJU; TZT5:E,Q;K+T;MFWV&[LEW+I,(A(FXP!$/KN@0
MZV4&1DM"K/!L<=V44=DHD,SB684)4:L:<;;=0IMU"7$*QY*0M.%)5CZ_GC/G
MC/SXI45^V( %5^E/9T#60HFN@AO6[=S(X*"'0Q F RK75H>4U"'0&8\.*TIU
MQQU2&&6T9<6M><>I2LY>2CR5$C4>2QQH(XT7V)&BJB*,*B*%4  "G<L?-W>1
MSYO)(Q>1V/=G=V9W8Y9G8LQ))-87X9GW.7H5^9QUJ_8Y3N*5-_BE.*4XI3BE
M.*4XI3BE0I[7;_TKI6_=6$;7V;4*$Y-W,7*QV[(68@N9$XTGN*IK+O-J]2XH
M=FQ6NO"9)>4ED=$F%HB),IK"U*3F'#&@ZUK-EQ,=*TR[OQ'H\4;&WB+CF_#.
MDW0A4] TS6]K<2I"I,CK"Q53@9L+R[M;62V])GCA,DI"!V"YQ%*N>_1074%C
MZH) )ZUJSOWW=Z[Z@ZO[1ES;V(N\ZW@3.MA '6Y<!;S*#]N"&A\*258A&$1P
MX6$N-*<)$R,F.VTIA,**B64DPX$CU.!.#.(=7XFTR..QFLDM9H=2EN-1BN+2
M$P6D\+R)$SPEI9G#H(XXT8D,7;9&CNM+5-1MK*SDEE8N&S$JQ8=B[A@N1D!0
M,9)8@=,#+$ [SU'V)M'9C7%,V=HV@/5^AWD5@H,NNXI,0<\W%RZ[$<>%4"H$
MSA8^N+/C2H<ADU8Z%$D>Q]^$E2@]V+)D^%JV@6W#>HWFF:U?<^_L9!%)9:,C
M2KN*AP);^[B@A@#1LC(8;>^<;MDL,4BLJW%O=>F0Q7%NA$4J!U>8;3@_]&I)
M)'7.64''JE@0:@K&\/6:2\2D3V2O&_+)<; &JHC93U6DU2-"K2WXDEZF0ZR+
MCYLDY0>MCO=$'!D3RG/1RZ6)4F1-DI>D2LTDX^=/#B7ARPT2SLH)[]].6ZYT
MDMR+=BE[+-,>7$)KR96>W:?,:"-\"'8%B%JNEVAUE=1E>\D=+,_2A<(L7I12
M6&.51R&*VR>I(;7UG9U8^E*7RMA&](5L?OO6C->L ,1'^S*7;RR5K$TXY[Y]
M@3>CGO.'XMI I3'Q"3(C>Z994OWEUJ9[WEMA4-_7.FB8V?$?*EC0#0XAAH3)
MA_Y0Z#ACB6,;=H9=F,[BK;L*5;((9=+3D"_L;ZZD-TS+):ZE#9*L7H=TNPI+
MIE\6D,QC?F!U7EJ\7+W2++')7"<Y1E*E>KSQE*E>7EY^?GC/RQ]7]'EY?>\N
M>5\G]M6M10ZY:=U[K:Y[_(4T-+&2I6SF!,AU^Q6@RER"WK36!-#7L3IHFRAW
M$V9(=5)0VF4I"T,*>S&:99;E75;S47NH;HV9CTZY]$LEM].TZS:WM3:VUT;=
M7L[6!VA%S=7,PC=F3FS2.%#$DYAQ0'73^#Y#<7DKZCPVVIWIN;R[N1<7_P#*
M'B'3?2V6XFE43^@Z?96AD0*3#;11GH@K+&J;3H_8UTNU5:TP5SK#XO\ %&P8
MMHCDO*M<N'))^_)BIDY(R(:W(KTWVOO+L9:V%N*:4I&?)$$(UPR"&(2?!_,W
MB--_,:Y96<L%SO9?5+9R1T)QTJ_DU;5'\.4M'U._:U_E0;/T9[VX:W]$BTF&
M:*UY)E,?H\<H$L<&WEI( ZJ& (POM#.OFT-7[-TQUW,S(6X209H?%NPPZ0K
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MW=WQ1INM:K+?ZC##OU*SVSEK5UU*.&TU2X9&6>0+'&HV9TGZ8:(ZUS]BVW5
M(R)-&[+<J(1?)64N::=KM6NI%H/'1'(27FFGV40V<.RD)P](SA675*\\^=_P
MIPGHO#\E]<Z9!+#+-/<VDA>YFF!@M[IQ$NV1F7(VY+#UCYDUB_CKX[^(_BM;
M<,Z+QGJ=E?6.FZ;HVOVL=KI-AI[KJ6JZ);F\E:6TAC=T<R/MA8F./(V*,"K
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MS3$:.TVM+;+:4S<R3MS),;MV-[8W9SNQGXV>H/<'M4_-E_\ &2?&W_';X_\
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M#05GC""%MKR0@P&_0M=EHISI&EGVZ=9G_P!GCK)_$7)X_P"-\_\ .SB#W_\
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MHGE*JM>[BE.*4XI3BE.*4XI5(=.^[G[2_-QA?J[KK^G^^.:BM/LPZK][T/\
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MKT9;C;<X.9@SQ1.&I6'QY.',@RFVI3#S2'0#W8]OET']@S^(4KY:]5Z]5!F
MM=%Q10M$\P33"C87EE)"PEIYTS*QAU;BL.D2Y2?.?_=>G+TIS"$H1Z4)AM4
M>P*%'7IM50H7WJ% P#GM3^))/RDDG\YKF\89RK*,>SRM&$K4G]SE:<*PI"%J
MQ^^QZL(6E*L_7Z%)QG/ISC$< >[N3_$FH$#SQGI\O?I^>O/H;QY9]"<>GR\O
M)./EC&,XQY>6/O8SG&,?>QG.,?7Q@=_S_/\ )\G3M4:PZC;$H6RA3IO7ENKM
MS"QWH,9XG62L(O :?)  UH',+DP77F4N3*U80)R,C*L9=%%QTQ&,L2F5J#J
M<=Q\_P ]",'!Z$>7R]?SYS^.LTY&E.*4XI5&GA>6!!'LMV]$E;M M-P'7'9[
MAB&W>ZY>R(P>[O.W9!L3"(GNQO@DE$,,L:/:8+==]"2QK;#8B8TF=">$<5#S
M'X\_/VYQ^+-6=4?J3H77&[;OV-IU-DB=T[,0:8V+?,VBUSB5YA&)0.3%&6>*
M0-2AA074FZX*'Z]'O0?==?"<$A5.:#03QY@FJ-0:AW_4;GBLEJ%GJ%=8VT8T
M4;*C=B5G-A*JLYZ9H,E,+;71KQ0;&IHL.)61X+KDC=#)E[890W/?U>^B'7A"
M(TY\_EI5L9D(&L8N<#L(D:="DX[D,D',P8I,61B.X\G8L\?-:?B3(SN,>3C$
MAEQI>/DI&<<E(4_& (Z=^HR#D'!Z9!Z@]P>U 2"""01G!!(/7H1D8Z$=".Q\
MZPJ%IW40T.U7QVK=<#P#!MJS,!(-)K,00S8X[;++%@9&QQC<)LTPU'8::*H9
M3.:;990A]*6T83-YJV3N7)4Y(*Y[E3G*D],D8)\ZA@>MT'K=&_SA[&_RA[CF
MH>>*[C&/#F[;X3C&,8U-/QC&/JQCXH*\O+D!CRQCW5'M5@L?_-V/^9:_ZB>1
MI7NXI3BE.*4XI3BE.*52'3ONYVTOS<8?ZNZZYJ*T^S%JOWO0_P"IIU=^:W_W
MO;A#\*EU^\^**N\YMVN Z<4IQ2J'>Z5+N+G;W:UU;J5G<IC/3W88]^WH E%U
M=B=]CBYL8A/V!,7(EN7EYYIK$9<O#^7'6T>S]2T85H[B^SO#Q9JM[Z+<&S7A
MB^0W0@D-ON.F7";>:%,8;?ZA4MD,0.YKE7Q+TO4V\2->U5=-OSI:>&&N6[ZH
M+.Y.G)-\$ZJ!"]\(O1EEW.H$1EWY9?5]89CGU(^V1\.W\D>P?U][+_W^OF/\
M+_5_P]^YVH_O#7JPOP[^O3P:^]?6OWIQSBNS=SI!>P^0?HKMZG(TIQ2J$?$/
M^Z,]0/R2[*_LG87-K<'_ %F\2?="P_76E;,X4^M;6_MZ'_\ QUNKP/\ [2EW
M\L%[_P!@K'/-\3_KH/W/M/TS5YGB%]7U^T+;]9/5PG-=U@U.*4XI7Y7^]S_1
M^G'!Z>_Y*5!'I#KN\:_7OWZ:5@K6\67<1HX!^)L)9^*B)&7\LD(F<+7ZX[GJ
M3Z5_N<_/&/+G//@%PSK_  V/$4:]I5YI9U/C:]O]/%U'L]+LY-X2XAP2'B;<
M-K=CW&1UKH/Q[XHX?XE'AP-!U:TU3X*X)L=/U$VKLXM+V,)S+:7<JXE3:=PZ
MCH>M3PYT-7/E.*4XI3BE.*4XI72JWG_F';[_ $F=7_V/M)SCO6?B\5]/^,BW
M_%TX@_A_;[ZZ/T[OH/WE3?ITFLM[2>?MO%$_.LU)_5\>W/\ A_D^O_5^#GH<
M3=O$S[Z-%_:-7_OJUT,$R<#^[1=5]G;DV&?/W]O?TSUKM[:Z_B^HO\S:Q_8D
M'G5&G?4^P^T[7W?\ GEY5H*\_I=U]L3_ *UJHNUC&=LGC!E;8?*6^DW2*8-2
M;'K2Q;JU-=QP^/(Z[2JU1:J!JX#:I"=7F2X$)8MNSZ\/H$FY.()B3I1^OUH:
M7EV6\JWKL!\4K0W9O7]LVGH3:FO:4$UO9[7;:R^*KH/;[]BC:QEDG'HRV$WI
M-4BSSI6N,N-9ED046*IBQ,-9KY%30PC+?11G1G5 @3*S029D57"B*9)=ZHZ2
M1O(FP-$LL<D)D"\U'CW(:UNZQR%I#)L,<Z$1'8YYD$D80/D-&KEMKRH1+$C,
M\)$JH:J[W9TQWA1/#QLE/%]H;]H5G4W6+>K-YUGI^)I_8&N-C$)@V\6TF[(/
M[&Z_A+#7@Y9DB\+BUG7X+7E?IH60W7JF-B1 XV=F\GD1V3EAA''!;0('):0)
M;01P())"SO,^R-=\SG?*V7*ID*+6-77FERA:2>:9N6JQQYEE:0[(E55B7+=(
MUW!!@%Y&W2--[PS/N<O0K\SCK5^QRG<HU4J;_%*^2?,;'09I!YN0ZS!B2)CK
M42.[+EN-QF5O+;C16$K?DR%I1E+,=E"G7G,I;;2I:L8S,B&1TC!4%V5 78(@
M+$ %G8A54$Y9F("C)) %0)P"?8">G4]/=YUI"A=F=,;&J)F^ [E"'4T"<G5L
MC9K7CZ(A6S8R9('$(#9*P*@0WWH<Z*Y'>RT\I'FIAU"EQY49UWV+_A[6-/NH
M;":SDDO+B!+B*VM0+N8PRHLD;F*#F. \;!E! /1E(#HZBC'<PRH9$<;%8J7;
M*+N4X89;'8]#Y9JO#K?XI\;L?V-VCH*@4HA<I]-^D3U6GPJW&IXBQ"*[/'B"
M-B,V4WL@V[71$,O-]W:::J)<L7@/0"$0=&FOR D;/^(_#)^'>'=+UZ_OH[..
M^]'%PCW#7LUO+<1O+';P6T&G0BYE>)"Q9KN**%P\;R,@6<^99ZPEY?7=E''(
MSVI?+&/EH0CK&26:1F'KM@#EY9?7 [J,7\7>I["M73BP+VGMRL:T#/V(7(BT
MJFA#A48>.C =C-AJD9NLUZ%//9*EAL5F#)75JB&;D(9>F"IDUN IKSN ^*.&
M^$N([;4)HE$2K);G5-9NK>U"+*4$LL-J#R+61+99I6!NKN0QHZI(L9?.;<-^
M'G$WB??2\+\,Z/J.M:I-:/=K9Z2R":WB@F@1[J<2H[7%K"\T:S1Q+%)APX;"
M$-N[I;6M;Z5\.('+JUIK=GKXJCWHH6V4Z0M.NXEE0/.61"R1NU5R$7O >.'B
MM)#,%Q$8B0$CAK"0,;$:/"CH\#C/BNVUGB2]XDN+F.+34ECN 5$&HVMI;V\,
M?.,5O(WHDP#QR231L1'-*9#,2SN3=IX=<0Z+Q3:>'5YH6KV?$OI=AI3Z))R+
MC6&OM0C@DAB0"2UA,USZ3');Q--%RHY8XGE4H6K[>DG9G3]FH=HF!9%: MP#
MLP="H]2VUN#>-D?^'E[##5+@5V[U<>9A,&$PU6&(U481-F4-),SK#\,FLY83
MC6K\5Z!J]P)M/UZWUMHHTYDMKI=C9SL\L43K"L&FF2:[DB ,4A>,F%HR(R83
MNK-.+_ [CW@2\M;'6.&]8TM+F 7/IVM^@V&EQ1-';OODU635+BPM@AN%CD2Z
MN;9N>&CB69]U5.^*MV)W'?-M:=+:'J5_F5$8"DQA!X'0QU[$EKI+F'QJVQYX
M:&M%=?G-@R4^(\-&V,GF&E4QLQ%%F8$B)&T?XC7&K-J&CO;:O8Z%$ZB-(-2F
M2.9GD,_^[WC2UNQ':HOTD[I#(DK(>0&]9>MOH5]4\ N$>%>)[/Q-U33M5UC6
M.([#2[![>35K2WF6>"RFCTK39WNM*;4+SGVDM\[VMMS&M;2Z-I/=6JR<R0?B
M1T#ME)ZCU<H"U=U_G6!ZT5=R_6_:FT1^U;D)HV:;87K#/H5=V5K&C4BHVIAQ
M#"XX/7BB<[U(?^#!YZ\2R4;*^*K#1EX;EGU?5])M)1:M):W6NO',FHZ@ME.U
MOINFK/972+>7C;O1(;>&U9]C 2Q'(?DBW\4>*^#M:XBXGX.U[B#@_2.#X-8X
MDFT[@&S%JVLZ%H-P=0FTK6I$2ZENK*]AAC2ZU/6[B\D@PBF\2,@&>71:O=P'
M.J&FX^R[!UPUI;&@<A)&MZNUA]):V/&I/&L"VA1.J[4!TA,Z8'^'$)Z@ -0:
M"5D3HK<65[-3RLLT1;!-*LDTR_T[5+!8%]&U#2>5\&W49)8R6G)@MHS$'+)E
M;>$%U;U<Y)U[Q!/K=SK%]<<1ZWK?$FN32I+J6N<1QR0ZYJ5P\,1](U**5(W2
MX*;4(**"BH5RI#-4R<Z==DYOC)C=L3>^>TGL/E1D^50P>SZC61.=2Q8@H68U
MQ$UJT=EQQD.1@B0(0PN03YM]],JZ16G2S2SC5N_$%_'JZ:(. -=ECD3GKQ*N
MO:8FG&PWQ03:J-.:Q-R;:TNIX[66W-VMU))AHE:,EE\<FY74;?3C96'*N.'[
M_7TU!M4U]9%BL-1L-.DM&L5X'EL3>O+J$4T 77SIC6Z%;C5K2[DBM&VGXGGA
MQ]*MN=@^J=EW%6>Q]LL\^QR*K82 +L$TXBYT %4-DW*%3"[VW=F-DQV8UL&0
MR6)%=76A7P,A:H4<O]*2@>,YZD[Z"L=]/JVK:-IQTNQBU&<:G'=M+'8S:E9:
M3'<QFWL;M3&^I:C96NW>LG,F4E.7N<9EPU8<37EG?R:'JEU86\3J+N.WNM3M
MQ*^S<I:.QBDCF<)V#YD"*S!0B%JO:#:)T=7VHRPFG-7"<P8/N$9V!0:I%D,0
M&V5,>ZHDLBD.^QRSE;:D>U]"TK7A?JPM6<W .1GM\_T5AO3\7M/;_954/AY]
M=/#GSLOMD[I'J[J@!-L.S$%5+GU"G&6VJ6W4J1&4&%0I1BS_  $.C82KL28'
M@X8^O+][:7$<6VQ#BPYVDTYM@LM<T/57>-9FBTG4X+^6&)RRJ\Z0DF(,RE1N
MP<X! -4H[S1KH[=,XBX=UJ10&FAT76++4YK9&R US';2.T +*4', .X8([5
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M@$YV,PSNV*SG Z[5=8\ 9ZON<>J.I 8_U340-P!'FZQC/0;F5V!)\DPARQZ
ME1_6%:"N'BD#JE6[-97]'G7(\)N6=IL)=IE3"]LI 0OOX19ST^OU2CVRSUXL
M)7UVMY%(2*!L@V*%-UHS<+/2QK-PE5%A@S*>I0*TFWJ%5@P# ^8+J5RVU1E<
M,2VT0'K*C#H)"RIN]7UEVDJW?'JN""-Q.U_5PA-2A!=NAYH)V1L3^IMF@ O7
M@*3L&2EB&Q!0V_BQFKP&RUYKI!^3[HQ)E1S2X4)#[K\5R$Q&,O36$35P8<6R
MH?.,H[IC/<HJL2/=DGMGH ?/ =]GL>-9 1UZ,SKCWXVY]^2,=,U$K;'BCN:X
M@6T.[I]*+W37% [6U MLN]5FJV&W5\07U'.^,T^J/"R-=LCED$LG9=S-:H81
M.$W6N44C?K%5Y<!<#Y]>@$A'0Y)C,P/? _X!_P"MNZCU?5;$ZH6,>1TD9,'<
M/BL8P3TSA@9 -I'8!L[60MSU:\1:U.R8-3.Z@ D;W;KUN0'K=8K9H4)4SE8U
M!<]\#3Y.[D)\0Q*UN8C5K1IO(@=):L,>WG7FT^]U6+%M+=.F?U2_?;&(RX.,
MX<-@H>@=LHV8P0RC!/02%)%!*QDD9?(&>F&'+)S[%Q*NUL>M@@#. ;+:-;AN
MP*33[X&9G1P]VJU?MHJ.4C>Y$V!MC$Q#$%DC#RMS,2<U%F-(EQLN.98D)<:]
M:O3ZLF4JS*>ZL5/R@D?PJ56#JKC.&4,,]#A@",CR/6LIY"IJ<4K$[\[,8HMT
M?'O6F-/9J5C=@R*- %%;JQ,;#S%QGJ>,.Q9H,E:6GL(77X!F%+%3"R8D<C%D
M1''FEJ561X<VD.P.N;WO&^[DT?JO7XG9"H!*O;!F5JA4[M9>2,DP5-G/LW5?
M2MCN^BQ<261+3;+[37MA K*6LP;*GJ7$+2Y)&0J'Z/G\R3_LMCXJ-4<U2P6@
MOXI@V!MBV3;*FI[ M-2J2 .>P<33=7V^_P!72-T'T:M@36[2>NX>T$=<[.NY
M64PYJ=RE38M@LZ!-AB; F)@0U/[ZNFM=LJ]$K9NXW:Q!*C4JV.DE[#9K(4A!
M  ,5";R[,)%RY)^- '0(K2<N2)<N0RPTC&5+6G&//DK,J#+,%&0,L0!EB%49
M/F20 /,D"IE1G;:BEF()"J"20H+' '4X )/N!J/N>[W37%);V5GM;USQKQZV
MO4%F\YW1KK%1>O,</BP2*:U8OI%\)<M# '.#+P%,O)1H7G$]<5,7/M>3'*\O
M*M]-#M%T_G%C8([1Y^.J.0C%<A7(0X;I4@(/,QUY6WF?YF\93=[-XZJ#\89(
MR*TAXJDJ--\-[MA,AOM2HDO4$N3%DL.(=8D1WR(AUE]EUO*D.M.MJ2XVXA2D
M+0I*DYRG.,\B05)5@592592""K*<%2#U!!!!!Z@C!HK*ZJZD,K ,K*0596&0
M01T(((((Z$=:L+C_ .;L?\RU_P!1/(5&O=Q2G%*<4IQ2G%*<4JE>I CC?C<;
M.L"PI9 %WKS"B-&UCIB1#LKX!KU&8[9++.(:W\+;6C+*7LN86A>,I\TJ\M3V
ML$X\7-2N.3*(&T&)!,8WY181:>2HDQL+9!R 2>AR ,D=W:SJFF-] +PGI2ZC
M8MJD?B?<S2::MW;M?I"=2XF82O9B0W"1%71A(T80AT(;UES=1S;%<(TXI3BE
M.*551NNC78CXG_6B[#Z?:9],"ZTEPS%MA5\M*K(J9EC;N,1"1YB(X*@RE9(0
M,)CRY;+RLS8F,(SF0SZ]7ZW9WDOB1PQ=QVES):06,B37202M;1,1J&%DG"F)
M&)90%9@<L@QEAG0W$FDZI/XZ<$ZI#IM_+IEMH%Q#<ZE%9W,EA;RLG$F(Y[Q(
MS;PR'GP@))(K$RQ@ [US:OCYXQG\/-GCH /8!6^:<C2G%*P7:'\6FQ/YBVW^
MP"'+JQ_IMG]M6_ZY*NK+^FVGVU;_ *U*JU\#_P"TI=_+!>_]@K',Z\3_ *Z#
M]S[3],U9?XA?5]?M"V_63U<)S7=8-3BE.*4XI3BE.*4XI3BE.*4XI3BE=*G>
M?^8=O_K^Z:5?'G_+[EVCS_OQ_O\ ESCS6AA.*^WV2+?IY]N(1V/R'_;71^G?
M&T'[RIO_ /D_/_8:R[M'_EO%$_.LU)_;VZ/P_P!?Z/P<]#B;MXF??1HGG[+C
M5_G[NU6NA_SG _W$U4>7_B+#'Y^O7V=.HQ7;WUU_%]1?YFUC^Q(/.I].^I]C
M]IVOZA*T'>?TNZ^V9^W;^=:LQY>5;4XI3BE1I[GX\^G_ &JQ_P"[ENW]FUEX
M^0X(((_$<^>1^6E5$>&1X3?4)WKKU![.G0%IM]QV!UHU1=[!4+:6#FM:+-[&
MU(%EG/=ZP]742\1(<LU*E!&I1F6X,D-0WTO.NQD+YD&N\5<0\2\+Z=PAKFIR
MWVC:<T)*M'!#=:@MJC)91ZA=V\44LJV896B:$V\DLD,,MU)<2JSMZ6B:I=\-
M:W=\1\.L=#UJ[@CMS?Z;+<VTUN@,+7)MMLY6-K]X5>]W!TD+2+&D,;F.MT[/
M\%;2-^W%-V2&L[-&JTDS4R#6L@U,0X#C#P$<<T8$XFIL\-;S=G7"?7+E/05O
M04SG&HR7$LLJ3SQJG@Y8ZCK@U)-;U&UTTNAET<\R[$D:)$C11:E<WC:A:HQ2
M1U%O(HB>8F+9BNF=!^B_\5=$X!U?@*2YM-8MM8@U"VFU35;6RN[V.VU2WDM;
MRWV2V3Q7"/"X1#="8IAAZRL%66=_\.GK5:*%<:O5:7$I%CL08G%#W%J?:#S]
M</2Q3HP?8D"9]F9B$I Q"T)1'?>9]M&2N'[=IIU6<9%>>%W!]Q97-O!I44%Q
M+;-!!=3S7M^UNVT\N01W=Y()-C88J7!8@DODECS-<:I-=QW4,L.GVJ7\4\-W
M/H^C:#H^HLES&T,TL&H66E)-!=A'9H;K$C12A9 I(VG5O5/PSJUU_B;%BWS8
M<O:R+[ #BO9B!=BU:S!&#7ITF7!G-U^_$E'6"<F3$>6W-<;984/:4EI:UY6F
M;A'@&'AA]0FDOVO9[Y;9.=;Q3:=(D=L9F6-GCO9GE7=,656=40YPN6)K$^$^
M&M'X&T^XTGAN;7GTZZO?A&6TXAU2VUR&*\,*0/-91C2[&*U>>*.);I^7)+/R
M8-T@6)%$:^HOA'6'0'9N=NNV6*B3:^F)?&16*01.A;QEZWO.9]9 X.J=5)*]
MZ3*F2#*TV:3F9)=4F8T56\Y-3Y/#7 >MZ3KIU#4-66ZT^,7/HMM%=70EC,JF
M*(L>3#\6)BK?36&/5(DZ$9/\'\&:?+>ZGH.G:Y;Z[JHA&JW6I<1:]JMC>; N
M6DTS4]:U#3VDBV*EFYLP;2,%;7T=#L&^.^?A[2MXZ=J50T(VT*ME:O-.)M)N
M.U=E#0#-0IX&Y00X%KW>58<NB0LZQIR+J^8+05J-,)X;Q'PZZW)]CC7A6^UC
M2X;?1W22Z2]28IJEY/-;+%Z/<1,T:W"W:Q3*TB['BC215+A)$5G#>?JNFV'%
M&EW^@:S?2Z7I>I6<]I>3:7HNB7=W+#-$T30*-0M7B@)#\U+N+;=6\T44D,BD
M'.(T+H'M[6WA_&M%";<MS=*0=_;!P89\*=KT:5;[+[_,$Q+_ ':GO75$4Z(B
MPD%'%%1;#CZ61CN,"X:%KLX>$M7AX&O-#%RD>IW,5P6M[0VD=B7DG+")7]"B
M(66$#F.0AYC$,VS.;E[73ELGT8"#4;(Z?<:>+N^M&T5IDN89E//MN%Y-.2U1
M&FY3R::L-R\:<]76Y<N/SX=74#L]H0!L@5MQ6O@\4O8Z4>K08L/@[)C_ !&N
MQIRUF83P*QUQH%.B$<PI<=UQF9(3)PAZ(N/[OA2K;P]X5XAX>^%3?M;VHO&L
MS'$6%Z'Y"W =@8+F)(3F1=Q*,THPI8)&@&,\&<)Z5P/H0T&U2RF@^$-0U(2Z
M5/K4*\R^E!5)8-<EU#9Z-:1VEC'Z&\23)9BYN5ENII)6AOXM%*[()VIJ\=0M
M-1=B5N/KP\Z_+UYU_=M(6,1L=M-3;,/)Y=#7%UG%@=>9)G 4LDX*-2%L%)PV
M3-0F0GQ/$J_XUL]3TI-(BU"Y@CA],4Z5:7IBAOHY)XDF8Q"?9<"!RJ[GZ(Q.
M &R<[MN!]*XPCLKF?C&YX7;1=7AU"VM.3P[<^D7<=M/#'<R/JME)*\2QW4L3
M01E(&.'9&D0%=O\ BDM[]B]2-1N"=<C!1T_>Z.1NI77CA@W;)YAO4%@KLCZ2
MA(FO@;4!MT7[4%*=42G);AQ8H%#'N/I0W=>)MUQ(O"FFBW@E$D]S9I>/927,
MUS(KV%P98[BW2TC41238YBN[J7"@H&QBZTS@O@SC2YOM$XHDO+W3%AFE$0U.
M]T!+ME?T9A-=:-J=E-<0RV\\XDLV9;:8.&>([(PLKO#Z&[8/=.].+N^G]=DR
MKM4+5B;,V":,5VSSZL+OUB?"0"]?>U4=4U :8;C$A\1PL]#EN*9*M-0ERO0S
ME' =UKT_"NDO?6JM<<N99)+Z[N8KMPMW.L;21O9R-UA$94M*=RD8"J M6VK:
M'P]P]?3:/HT]Y\&V AAM4>>;5753!&\BOJ-]J$]W<L)GD!>>6208VEL *M>!
MHUW9C^)^Q)QJJYO46-N9 Q@D-H1!=!^AEAC"&#B6-BKHL<=B :$Q8T$Q9WV6
MB#D9I<"=*2RE]C.!W.H<:CQ&0)8ZDVG)?PV:RI#<>@G3I'AF>'TIK40BW=TW
M-(V"K G.X$U'^0&C2F+C0<<30WL.C3V*: ;/AQH_1IKBWNKFU;=;G5#--=6,
M4BR^DFY1<QPRJA K@O%8[*7'3V_]*5*KZ_@4!FH4.IV\? <<"Y0N<).7RN59
M0_%6GR(K0VJ0'BZ*OAY4*<)ED)K\."/0K"IEYX@>(.K<-Z[HUI;Z58MZ(HU9
M&OXHKIY)KF#5-*=/I<C*UN+>=W6(E&])$<I5=B@W6G>&=SQ>NDZU9\2:=IYX
M=UFZO((+CAPZN)KJ31KW2CSYIM1TUD@%EK-RX@CC<+<QP7 F/+Y3WL3-@:]A
MTR99)6H;5E;=7M1YZ+]B0Z\T]]*H>35MBN3HH"6VE%FE-(</R'4Y06<0B603
M)4C&<;6?6(X[5YS::AZENTY'H%SAB$+[-RQD9.,;B<>9->4-.D:<0K<6AS.(
M0QN8 1Z^P,8RX)QGXHSYA21@FE#PI>W;6TMU;<JE^IKZX)H,G;;,P>.M5[=B
MVFOV*H@Q;\D:.$&'XRQ<.?&P,LDIMG(K$%J$F:WB3$;QK'P_\29^(]3U73KS
M2;&R25KK6Q-IUK</()Y);2V>%Q'SF]'"N&1F"A'4JSY95J_N?#36^#[;4;V]
MUK0-3AUG7IM0Y6G\/OP_+!=7EL!*G/NM?U%)[=(K&)8K9(8Y%=W?FN@"CGJ[
MVNT_(\1PQK::"MF QBPVK2\P<3%PF*9\)FF+6>,-SA<TRB4JO'#1/$XF F5Q
MIMT@S\3E1'9KF<MW$'B3!+QY+HITVT0.JZ!Z7Z&T<ZK97-W=)=&4S;Q-*\O+
MF=H<&-=H"%B:LE\.>*X[NYXU:;A-]*N.';#3O1(K6^^&$M+.^OKV*=;@YM#J
M$TFH".ZD#<MX(%5"S-BK->X&]=%:GT#L/9.)H)XS%G"B@^55(U17;LW NV.U
MY&L4)5@KEFB9+PZS-4$E%)=?+S8]7:D#VFTQVV_8YQQ)Q1IW#^C7>JS1VVHI
M (T%E-)*L5PUQ*ENJ.;=TG"(THD8Q,#ZO?!-2VFA:OJTQL-.L;.YO9XIQ##J
MTUQ:Z<[+#([>E7%K!<W$:*JLRF*"5F=57;@DB-/0GL-HRZ]3K"3.&JRT0UL,
M71%O[';H+4Z:'IE5!6 5%'C1M4J4Z;68IEUXF/%$HME,ME79+CUD-D'4NM^'
MP3QAINJ<+Q7*VUE8+H=O%ILR1W$R>F&PL8&:[D-T99(YKO<5D6%9(U9?I*-\
M4V>F\$\1\)Z7P_PWJFG:1Z;8:3INGQ'0KJ_N;&^6S@CLTN[F>\L;>2UNKJ2%
MGG2."2&",QLC.=R+QOAL]CX78?9.V1):UT'8$B+(([892*HEF"S@1RU('U O
M+C3+2 '--QY@AOX8XQ ?R\['ER6WF\QW7<*AP5QCI/$-UJ]KIUK'#(]Y-K#L
ME]?7)CBN>1;FW(N])L%;8\>_FK)N8.%Y";-YH0\%<3\)KJUQKVDZ180ZYKUU
MJ=K)INO7&K21FXM;6,V,T4VDZ>,1"T,OI:OF1FY9MT"AVM_A4^IC4LI'5D!
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M,!Y;62,F0H-Q7!*[F6K'#)(\"*O](%X5;!VJMBEO)<%B!V2*Y23U=QV@Y .
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MF9G8N[,69F.69F)+,Q[DDDDD]23D]:E55151%"HBA450 JJH 55 Z     =
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MKC-5Z*T]I'%F1J>A@*.FX%LFK"@*V^A,V6E3ZX[#29$B1@<''JES,B:^,Q#
M!LS9OPH;#]]E>V*2L4<"DB*+XB#.T$1Q0 ]<DLL-O! "Q)6&"&($1Q1JLC -
M*\S8,LA.]SC<Q:229LG_ #I9I9F_RY99)6R\CL<MM=$J%X<J[UJ"0S3M+M@V
M\59R4I_&0UL#Q2$,:;B^P>9QF7#BE"#3:7O:L>B4YE;*E>E290!S(YEP)(Q,
ML;]RHN+::TF ]G,MKB>%_,QRN.A((, Z-&XS&YA9U/9F@N(;J$GWQW$$,J_Y
M\:GW5I'5%7ZF:9O=THNI)&I:ALJQE!;MQI86V"';IB3+@'K17@RZU),RS($*
M@:NUV2LU(;!&U^%#D64R$$,-22\IV:(DVXBA):W@<KM0EDC>.*&'#L"?7BMX
M[:(!R3' D$:[8UC4'7$O-E&)9DY@9QM+H\TA+H#@;'N&E+,@VO.TA8M*7)RO
M8G7+36U=A:^VI>:O**[!U6F:B@V.';[K7I->:)3($\I':AUJQAQL^(6D"Q^"
MT0K"GQBL6(S!(-2(2?=^03Z7(\R;5D>(02,P#!X0Q<1.K91DWD.592&8(Q!*
M(1%_7C6)^J)(947MLE*<LR*1AE?9E P((5F (#-GVZ\T]HCK:#N$_7]3J&JZ
MZ5EO6FX$&'TBQ+*($12$/RYQ.6J*%KP(>AQH6)CO0:Y7('MF1<$?&6ZE40^R
M**#=B*+"Q(2, LL<*C)]9VV10PH6+,(HH85(CBC18D&25Y"&>60L6;J6;+R3
M/@#HH:66:9PH :6665@7D=C\UQZY:5V1M"D[OM57>+;)H0AX-3;5#M]R$I'
M)Y%@S.%9%@K&/KY<28G1H<@O"+#"$,RB' 8)-2XL*(TS!5Y;SD##3(()PPR)
M(U#@12(^5*KS9"%*^J7+ !NM0+F6*)-VZ*.3TB$J<;9'"9E1TPP9EC0;@WQ
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MULKRVC<'&R>)E"L'Q7NG2X:U8H6"2:<;M)6#1W%O86NJVS6B@(&6"Y-];RS
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M6(EAK=TK5[TK.%71R%7JE=(S *\TVXNYAQRPV&^?LI4^>OX;5U4TIJZB:6M
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cntx-20211231_g11.jpg
<TEXT>
begin 644 cntx-20211231_g11.jpg
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M4W9WD[:W)3(W5'*UT0HS0D-A<7-XHKCA-#92D2:"H?_$ !T! 0 !!0$! 0
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MN)0%"-J<4I2EJK17*^7&->+[">VL1:&[7&MIAMNVZ!),UYVVMO2,!;&^)4^
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MK;9G%LKD^I[';.0+CLE+NAV:8VBNC>T!@):D7IZS(;@]KX[Y4'1-B,+4AY>
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ME L>5(B^\3TVI1R8("A1KC$:4Z0MW:9LO=HD06JSN6"\&;N76DS5R;.]"<2
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M[#;:,ZT'T]F#JK4=K@*,@S1QJZ6ZJS3-@G $.V)NH5V.1+X!M.SUX1AMUMO
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MR2,E*D04PI>VD;;PIKNV@F6E]47:TV]Y+;,Y+;T*1:U*<C:G%1E)?:4\H*=
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ML!+2NQ+W:0BK[M%R#KZOC0I #F(!-V\3?R;X$4]7:]5I!JP*/!I SS#I/6>
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M^AR]$5*6L36NO6D-BA*4BV66JOZ6>.%;1>KY*GF$U1;QD?2R8^NQ!"LI4-G
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MX.?1_K!..GGSU='5D8])J?M[VZ38=;=2;\U?[#K\19=S:.-G"JH *H*F#K2
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M5 U%3]>!#H4>T0/JM=@7:[<8M\WY0F+38E# P-DH7>DM(A^:""KE>!C(0^#
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MUHNTK:E2UB+:J.U4F-=DLW;7%YV&'LK&P)U#"S'10UBA&!UE;ATV:]#RE4H
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M.OT#I^(?Y<:QMKN_%,50]L:JZM+$]<ZUI=7NNZ2Q>SC0=DH\8ZQ.GF@M>K3
MXU#O!RAAQLLS:T9LE:%/0\QF:H6LY%Y<%ECKX?%\'P8!S3/DZ,GCQ\V//PXX
MX@U/&H=MVC;"-DDD:\8K=<I]^V/KJIEI]P8G2KP:UAL*ZZZL,YX5"!975PRR
M]2;7"D2912>]B=*1D:EH<Q**",>@'T\: Y])'HX5J=1.[=YA:T 6O9FL1\W
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MCBEX"2B@ Q!E.@39$0,G('97A(:=!CSJ^X*FI5(5%,#U\OQ\_M5D#77W5;$
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M2MQ\4R4UL%ZV;5_262?$6*PM6-L!(  ;3M:RFFY(FL#2I@=%!@)*HB(I4D<
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MNJGSB_3_ .M9?\%7W\L\?46[(_B!'OM9_P!OIWR/8;^VQ?O#M%^ZJ?.+]/\
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M_=5/G%^G_P!:R_X*OOY9X^HMV1_$"/?:S_M].^1[#?VV+]X=HOW53YQ?I_\
M6LO^"K[^6>/J+=D?Q CWVL_[?3OD>PW]MB_>':+]U4^<7Z?_ %K+_@J^_EGC
MZBW9'\0(]]K/^WT[Y'L-_;8OWAVB_=5/G%^G_P!:R_X*OOY9X^HMV1_$"/?:
MS_M].^1[#?VV+]X=HOW53YQ?I_\ 6LO^"K[^6>/J+=D?Q CWVL_[?3OD>PW]
MMB_>':+]U4^<7Z?_ %K+_@J^_EGCZBW9'\0(]]K/^WT[Y'L-_;8OWAVB_=5/
MG%^G_P!:R_X*OOY9X^HMV1_$"/?:S_M].^1[#?VV+]X=HOW53YQ?I_\ 6LO^
M"K[^6>/J+=D?Q CWVL_[?3OD>PW]MB_>':+]U4^<7Z?_ %K+_@J^_EGCZBW9
M'\0(]]K/^WT[Y'L-_;8OWAVB_=5/G%^G_P!:R_X*OOY9X^HMV1_$"/?:S_M]
M.^1[#?VV+]X=HOW53YQ?I_\ 6LO^"K[^6>/J+=D?Q CWVL_[?3OD>PW]MB_>
M':+]U4^<7Z?_ %K+_@J^_EGCZBW9'\0(]]K/^WT[Y'L-_;8OWAVB_=5/G%^G
M_P!:R_X*OOY9X^HMV1_$"/?:S_M].^1[#?VV+]X=HOW53YQ?I_\ 6LO^"K[^
M6>/J+=D?Q CWVL_[?3OD>PW]MB_>':+]U4^<7Z?_ %K+_@J^_EGCZBW9'\0(
M]]K/^WT[Y'L-_;8OWAVB_=5/G%^G_P!:R_X*OOY9X^HMV1_$"/?:S_M].^1[
M#?VV+]X=HOW53YQ?I_\ 6LO^"K[^6>/J+=D?Q CWVL_[?3OD>PW]MB_>':+]
MU4^<7Z?_ %K+_@J^_EGCZBW9'\0(]]K/^WT[Y'L-_;8OWAVB_=5/G%^G_P!:
MR_X*OOY9X^HMV1_$"/?:S_M].^1[#?VV+]X=HOW53YQ?I_\ 6LO^"K[^6>/J
M+=D?Q CWVL_[?3OD>PW]MB_>':+]U4^<7Z?_ %K+_@J^_EGCZBW9'\0(]]K/
M^WT[Y'L-_;8OWAVB_=5/G%^G_P!:R_X*OOY9X^HMV1_$"/?:S_M].^1[#?VV
M+]X=HOW53YQ?I_\ 6LO^"K[^6>/J+=D?Q CWVL_[?3OD>PW]MB_>':+]U4^<
M7Z?_ %K+_@J^_EGCZBW9'\0(]]K/^WT[Y'L-_;8OWAVB_=5/G%^G_P!:R_X*
MOOY9X^HMV1_$"/?:S_M].^1[#?VV+]X=HOW53YQ?I_\ 6LO^"K[^6>/J+=D?
MQ CWVL_[?3OD>PW]MB_>':+]U4^<7Z?_ %K+_@J^_EGCZBW9'\0(]]K/^WT[
MY'L-_;8OWAVB_=5/G%^G_P!:R_X*OOY9X^HMV1_$"/?:S_M].^1[#?VV+]X=
MHOW53YQ?I_\ 6LO^"K[^6>/J+=D?Q CWVL_[?3OD>PW]MB_>':+]U4^<7Z?_
M %K+_@J^_EGCZBW9'\0(]]K/^WT[Y'L-_;8OWAVB_=5/G%^G_P!:R_X*OOY9
MX^HMV1_$"/?:S_M].^1[#?VV+]X=HOW53YQ?I_\ 6LO^"K[^6>/J+=D?Q CW
MVL_[?3OD>PW]MB_>':+]U4^<7Z?_ %K+_@J^_EGCZBW9'\0(]]K/^WT[Y'L-
M_;8OWAVB_=53)I[LSI7?<XV-U5;U6:978D2<79R"L0CW6+.>=CQG/.;%#FWO
M4=9<3Y&%.K1Y?%:4ISC.>:VEV&VGV1:BOW^W)@M37'&HRA,A2MXXTE*UI(B2
M'U(PE23E82#G )(-=IL9V4-B.R _.C;)WA5S>MK++\Q!M]RA;II]:VVE!4^'
M&2YJ6A0PV5J3C*@ 03.ZE93X>'A]/C_/_9SD:[^OUQ2G%*B[>'_0KM__ %7;
M _W3+<W^RGV4[-?W_9_^XQJY/;W[!MLO_P#%=H?^TRZ^.CGZ0U^-=.*4XI3B
ME.*4XI3BE.*4XI3BE>V'>_\ Q#>IO_9U1_P<+\^8>Q1_*SV0O^;:#_W*Q7VY
MV>?Y NQ%_P NR?\ [-EUXG\^GJ^(Z<4IQ2G%*<4IQ2G%*<4IQ2MM^B/^-OI/
M_2,C_NR<YY[V5OY/=J/["U^>1:]<[ _\KNP_]Z/?]NFU3=Y/\;+=W^EC7_<H
MKE?8L_D^V6_NX_G+]4=G7^5O;G^]T_F42M4>=_7DU.*5/AGKCL4;6]4GH,1B
MPR]LN+C"JX$]>0<"$'XD,P$'GV'&FF8;]BK!"%:1:TO.,9"NNR9#K'NLC#?*
M1MLK,_-O\1UQ<-&SZ0Y(F2M#<62REQV-*>B+"U*<1"G,/0) *$K$I(;0E>\0
M5=[,['.T<:V[*3V&6[B[M:I34.W0=X[/A2%LLS(4>X-*;0AARXVN3'NT-27%
MMJ@K4ZXMO=.!->>ZQ['!C14C$9HJ6+0:G.8!"6WYCR&[9!OQ.,VHJTE01QV,
M.U\5G_R!!UN?#?9DC7);3,E35N)MM9I3TA&\5'8C.W!I<J0I#22JWNVAAPAA
M2A*"5O7B.UX;*5-.H4V\EM2FPJ_<.QEM) C0W=RF7)FQ[3);A0D/2%I3=F;_
M "&4*DH08)6W'V>F2/ DK2^PM#L53R$/*;P"+IS9\V.$EQ*87?C6)4!(9]M#
M"FYGQ0+.L8]?F]?PCM2P0PD5:>E>@SF$/G/97A,21Z>U<VBLC2Y+;ERC(7#W
MW*4J40IHQY34)X$:?"4W+?8CJ2C4K>O,IQEU&KGVMC]IGFX3K5EFK:N!CB&X
MEM)0_P JA/W&.0K5A"78$63+0MS0@L1GW-0#+FFZMZ!W ]@>MJC$EMDQI O'
M>3)%YCLCQ,<5,*O$I'O_ * 98R$<$3B$<NY!DPH)"/-DLM15Y>Q8.U>SR2\%
M71@*9>9CK04O:U/2%R&HZ6$;K5)#[L60TRN.'4.NLK:;4IP::RD[![7+2PM%
MCE*1(C2):'$KCEMN/#:B/RW)3@?*(7)&)\.1)1,4PY'CR6GW4H96%U3W72>P
M=>54;;;>*9#1"5ML=+P-D3(^34,U6(XV3.Q-'H6I3<1]LDG,*4TMYM]+"WE^
ME'DCGIU5LVFM%XGOV^W2%27&+?"N9?0VODKD6>M]MDM/$ *<2I@[UM24E!6E
M(U+0\EJ+UL3M#L[:8UWO$1,)F5=[E9!&==1RYF=:VHKL@/QQDH:6F4G<N)4L
M+"%+(2VY'6_$W-_7)4XI7M=T/_Q$^V/_ ,/9_P#PB'<^9.RO_*OV._\ GL7_
M +C=K[;[ O\ ()V7?^3:O_V;&KQ1Y]-U\24XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE>Q/L@/\ ]\;I_P!%*K_WN3Y\W_\ B-_W5LS_ 'A/_-F*
M^RO_  =?[]VV_NFT_GDJO=MS^K^W^[GR?7WM79Q2G%*B[>'_ $*[?_U7; _W
M3+<W^RGV4[-?W_9_^XQJY/;W[!MLO_\ %=H?^TRZ^.CGZ0U^-=.*5L=J+7E!
MMVLMJG[F:;K$VM6?5(\+8GH)TLW&9LKMU26&Y%!7/Y911(B#Y9<F.[[E[IGT
M7&<ON>IQVT%XNUNOE@B6V*9S4Z%?WI4)+D6.7%01:S'>Y1)'@!CE+V6T+3O=
MX-85H3I]'V2V=L%WV5VMN5YF)MDBU739*/!N*V9TI#3=T7?!,CF)"4=X9(AQ
MR'76U[G<^QJ;WB]6QVP>J5-=L=R:K:2P<-5K%NI48'3P)>Z74H,J&PZ)2@0R
M% +VUIDHV,Q;_B4V6RD?+C"84YR<X6?6P]%XRS;?7'D-J5.Y/(E7"'LR')=Q
MEQK9:V'[E:+M<Y3[KL:W*5'4_P!K2PTVHO-N2'60TF.@+0YZ/M'V)K.;G>DV
MOE4.!:[CMJ68%HM\V]7N5%LVT6S]DA1669EY2W*3'%Z$IYYM$9UF)'D*D*FK
M4VMBP;"ZKT>N "@.!9R#%YID7=)&45DB<-@[6/UM?0]=0Z7=?L3N*P_\/)JS
M&;&CI[&5,.K(R<YRVYS+L^WESG2X\IV"RJUW->S#+3").J5;WKW:9$U08"(*
M>7HWS("U//,K 6 RC@4G7[0]BFRVV!+@L71]%]LC.VTE^4Y#TP;O'V9V@B6U
M*Y2G+FOM4X8TE1:3&C26RII1D.9(6,LUAH/46:)7HEMAT6\6TO/W$IUZJV>]
M%+-;1](K%8,P8&I9@(R-UY+/BU&I#TJ%9XCSI+++T6#&(/Q'(R]??-K-H>VL
MQRWN76U6^.SLWI3/@VEB!;WKK/GQGG=HFY<5^]-0WQ%0AMV XA+&M#CRV4.!
M8VNRVP.R*K#;6KLQ8KY=IDG;(N+M=TOTF[7:/8[5:IL>/L@[;YL?9QZX1E37
M5O,75EQ<G=N-1VI+K195'V>JHD_4R5B%FI<$R,UA2;3!K8NOR$0S$LAJ>+L$
MS)?/VFT-"ES4XQ)R2&"R22#+"7RPNLHAYB"%[H[=O1+BQ#?BMN17[Y=+>[.?
MFMER,VSM"Y9HJ$0X%O5(#1]CW#\A@LJ6I$>1/+N\DCF_J61I]JE7"+.=:FQM
MF;)=F+9$MKJ6ICDG9)K:*8XNXW:[HAE]"0\9,6+*Y4&TN3(=I2P&81PGM1I"
MMZC, Y]3FXE!;4E:FX(]3LX55I< '7),JMSC,TA*(OVG.2S9XD/D16(P\6:#
M8ARYWK2&X6QV#VHF;11935P9+<J H NO!++\]IV5-;;FLQ6F4,H@?P=41A]#
MBUO/Q96]::TMJ>U'94V&MVR$R!(M+^^@W5.4L1]<B+:WV(%M>>MK\YZ2[(<N
MN9B9\F*XRAN-%FPMR^_O'$,:F\[ZO)Z<4KVP[W_XAO4W_LZH_P"#A?GS#V*/
MY6>R%_S;0?\ N5BOMSL\_P @78B_Y=D__9LNM'] 5/1:]8$KQN:)7<#V-KA*
MK.(&96S\%TUF35R1<G"I</7SBH"[8MR(E\;(M\?(%.49:EOI0O"<^J;6W#:H
M7QFU[-.3-\K9^5/:9C-V$QC/1.9CQW+H[>$A\6X!PI?1;%\L(.II!4*\*V M
M.PJMF)5\VS9MO)V]K(%J?D37=JA,[5NVN5,E,61G9Q1C=MU*9"XKMY:-N!3H
M?<2E6*K*[URHQ-E@=%LQ2::LFJ:-L)"BU<RU&JL.^;8U]21:1<L;<(OQ<Y$A
M'BKA#)42H/F*M#4:)[^\V0%4S-L[DPI;JX#+<:'?[M:"(\T*<GN6C9Z\W5\O
MMOVQSD\5UR&PED1I(D[T:W'=RA3$F];>QM99:&X[5UD/3+CLK8=H<R[6I+=J
M9V@VLV?L<1$1Z->V>53F6;A)<DJF0U0RT4MM,<H=3)A]Y7J96%BY;E2OMH.'
M40GIL$3,I0@:B>D9O:!H@E':D_+60VF;--$V# 1I_,>,N$RN.3FP77DNLT1^
MR!,#[:;A:8,2*IY++LENZ2']R7]DWMK65J;[5-DM-18ZXTI:=2TNJ#C+3J$E
M*JY78EMQC/*M-_N<^<F,Y)CPW;'$BB2(NWC&P<EI#W;QU*7WILEN;!0X&VE,
MI+4E^.M06A>NJE*UX),6BP[ MK=?'5FL&&8T:EAY!Y1.Q7:\458^6VFX)$HB
MP9U-R2<(0"1%#\*8IF(B2IEF3+6O;VXW>3'@0[1;U2WI\Z*I:[I(1$#$.U6J
M[!YM1M9D*6\U<PPEEYAA2'&@MTH"U-MTWSL56?9^%-NEQV@NR($:U6N:AMNQ
MPW9YE7&^WVP&*\@7P1$M1W[*92Y$>7)2XP_H8#I0AU[!;;H,5K3:VIJ,<.IM
M'RVML-Z7%C1U08DC7I*]8K]3,-S8L]R2AV[@HDL^W';RPZ.%SA3K4I]<KSM;
M2W;6OWNP7^Z18BH/:R XAMQQ8=6B\,VH3+A&+3C*4$6N4ZW#4LZTO2&I"5-H
M#>E6EO&P$79C:O9.Q3K@FZ"^75E;K331CM.;/2;[VNM,U+[4E;@5?(#+UQ0V
MD-KC1'XBT.NE[4B=+3H.D38]BG9UJWJLD#.=C@@4'+?OTJ%<JQK361>V@;G"
MAV2SJ-)GCBD.-"<)PBKU8F2IL3+X2:S&E#I/,6[:RYH7#:-Z-_8E1-BY4F4V
MBT-.VV??+['MTNW.N08(BEEYAQ;J8[L9,]MMIP(EMJ6V^WW-WV LCR+@^G9Q
M.RDF%<>R1!A07E[0/L7BU;+[,2[O!O,=BY7;EPD,2F$1U2F9;EJ=??84NWOH
M9?BOV=WI*-2=AL,7L[*K?R3.GI9--3'Q34XF".4L%+#":N2L\ W$F1%W@<3*
MQ;+""OPA\=W$/)5]W.(U]/9-=,5Q2[5%;FBX18B&#<7G(K+$N+<Y;4J1<&+>
M]$<:=%J?8CN0792'7EIWO)DIRY@K[";(F-I1?)[MM%IFSW90L[#,Y^5!G62
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M3,:DDNQU-,QVW$2527%%$=N=H+VW%M X0&J8$39M<!M9)%CHAE^.!"@H)(+
M)@I!8X3(Q[%\G#MAKCY67-FJ?$GRB%M>\/HD-[<;#VE3D%^1(N$J1"O4F^[]
MYV,A<J5+=8E/,2T1HD=E<+EL2%-1';::"),..H*T(*#SJNRA?TLW.-$B6F!$
MN>S<+9CDL9B8MN!"@,283$J Y,GRI#5R[6S[C;')CS[Y<AW&8@HWC@<1>+'V
MVO5BK#]2S5Z.)$R*_8Z[ED3&LK;<6):A59$EEBX4RS3!H=.6:H.D1!XJ%#$1
M9;T]] Y2Y;F>8T+L?VJ%.1<>7723)1+A3-<ER"I3CEOD3Y,8/NM0&GY)"[@\
MAQZ0\[(6VEE!> ;369<.RW?[A;';3VLL4.&[ N=O+<1FYI0TU=H=KAS%167K
MJ_%A HM$9QF/#88A-/+D.",2\JL!V7O.Q;5#H%6,'6V'6+@3N$0H+:,1YT1\
MU7JW72@EMN09E0'!<MFIA)V<R83Y%F;'<]WGLQ)#T5>VLNR\*PR52(4J:H+M
MT>W.,/JC+:<1%F39C$A11%;>3(;7<)37@.H84RM(6RIQ"'!H=I=NKGM5"3#N
M4*V(+=XE7EF3%;F-/M.SK=;+;*BI#DUZ.J(ZW:(+V'&%R6WVUEN2AIU;1A3G
M2UQ-.*5[7=#_ /$3[8__  ]G_P#"(=SYD[*_\J_8[_Y[%_[C=K[;[ O\@G9=
M_P"3:O\ ]FQJ\4>?3=?$E.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE>K]/ZRZ
M,+T.B7>=7U+RYI94:RB\V,ZTZ5VM8Z6-N]2LK:$$DNQXJ0L:Z.NC8>612WJX
MTAZ)E,A25>"7/;;:F-=KM:V9@&G:4.07^0Q%)C[/0KD]:[E"43'*5NF4NUI2
M^[KD!,Y10X"@8^KK-V,MA9E@L5\?MZE%6Q:V;E%[93T*E[67&RQ[[9[FD)DA
M;;0@-7M2XK)1$4Y;$!;6'"#%(GJ#2Q#XA=HMEF/Y*:VN5A^'5NN->$H_#TN]
MM (]62"3*VC@Z#ZF(K\*5\*(DYT<;AN*V*,/RAV_D=D.Y2$2.06Z%%W%[MD+
M?39QRW$=VH38)29S/)@N*\[I+B'6^4L,-+?U.&3&0V_R43L0V>([%%TNUSGF
M3LS>KF(]MMB2'9S.Q"]JX*[9)$Y;<^-'UI9=9=,.5*?;C:&4Q)JWHM)%Z6"\
M-4Q\U=K(!^-0K%BP0I]-BR'Q98'5JE9V&6IX2PF@T03/:M6(ZS)F?!BB_<VL
ME,Q)4[W*'<<[)3Q5<D1;7#F<E<A&(ZS<UH1(CR[A<8"U*:E0HLER2RJWZQ&B
MM/./AU7)]ZVSO7<=OL,QTM69V?>[C;C-;N8N##]D;=7$E0+39[LA*9$"YS8;
M4.0B[!LSITB*S$W*#,W#SYC,=J^HE=S$K(ER1L**;A6/<T"_E8P.KD(D(?0;
M&! AO(VU=\CF)3F#$!^1#$S[#-DO$);<!!%J'%<<@=D*7O)LA*+.N(["V:>M
M#"Y<]EUYV\0I<R1DJM6^4V.3NH:<D,PFD)90I\L+<<2FI78E@;BVQ5+VA:GQ
M[EMI&VBDMV^U26H\?9ZY6ZWQ-*$7[DZ7B)T=;S$.3<'W')+B8J9:&F5.7$WU
M.I@ 61"12DN?9Q4+=PHM9[".EPJM@MK[<5;UX')#G!MC8^%/X'3W"+\<HR9B
MMQ94MY^)+4F"[%L1=O[C+>8DN1FV8,EW95^-"AOM.W#<7K9J;>I##Z7X*Q(3
MOFDL(7'7$<4XVVE#C0+P<RYO8FL\"+*AM3'7[I":VZBS;E<8KS%JY5LWMG;=
MFX<F*N+=&C$68SYE.HF(GLH:>=4MA[#"VH1L.CPE(WEK:@3$74D!.[!'U4PN
MXU)RD*,-0+\FI&WP"XATH[.!D6V7789)J1"EQO7RPI&'V,/JZ>'M/(N>R]YN
M[1MC,N+9WY\=-NN*;J(RG;1VQBHF!R)'2S*94M*7&%MNMN! 6"4+*!Q<_8>'
M9-N=F]GI";U*@3]H8]IF+N]H58C,0QM!VHG+MRFI\M;\&0E"E-24.LO-%PME
M(6V'%;);.ZPZPE^[31(^5K82#);W<LDX( V M^:%UA4X5M#Q!U<VQ8D33A25
M$C%HTBR@C<:K9>D0F5M-N*0M7%V/;F]MZVI#R+W(E,;)"$U*EV=*6I5^N#MN
MDN/3=GH*F8L=MQ<=:(,N(Y<-*'5I6I.0/2-I^QALR]H?B1U[,Q(,O;]5Q?@P
M-H5K?@;*VEF\0F8UNVMN@?G2WF&I;;MR@3FK5O'&$*0A1251=GI\.=&:_)C;
MD?+8MT0$<FQ858$XRU7+!1+!L+$D41EVR('>(5P.!7"LL(M/%+Q-7,6"292+
M?8>WH[(C@?N[#]MBQNUSLN*TX]/?\.9#N\.S:)##5N<E(9FR98=@NQV9(+0:
M$ODID(6GE3V(&51K%(CWB?+-U8@7!YIBU1,)MMPL%PVB+D24]>&8+DFV0X"F
M;FQ,DPEAXOJMZ9R8CB%U-DZ="*\-V//3=[ 4=HRHY-F Q48@U^95OD72[T0)
M.23UA%#)4\<)MC[$\0&GD2T!T6Q)?&K8,Q$M4P>R*_,D65DVR)'3=M<<O+N3
MCZ&Y_;2Z6EE@(B0I#[;3TFW)4S)E,L1GDOK;2\%Q72JY<^P]&MT?:-Y-\GRW
M+%NY:8Z+,W%6[:38[)?Y$M3UPN42*[(BP[NMN3"@R)<V.N*TZY%W4]C1:%Z4
MH0SLQN#7L(&?LH/7@"^FZ91S+DT>8O1BLAL315>4\&EI+SX,G*I)=#@63#+'
M X[.86!STS"8]X;375_8C9R\.2HD&5>)5HC7.Z1@T]&M4:=)W4B8!*;,9EUO
MP(Q$IMV/$E/^R[Y#7AXYV(L,7LF;8[.L0[A=(.SD#:";9K'-+T:;?IEKA[Z)
M;BN"\)DAAS+DP+@N1Y=PA13R<17'QNKO6^KZMJV0NJ;2S^ADX!U-4.OL>2VB
M6;!8:S83T5^4R?LK-VKXTS&KJYT0),8L1 9%D/RB1:+&3 9E6)VW*;#!C;NY
MQ-JR95P#LM7_ -.D*B0YT*(XAM4. NURWXKDU++DEM<%E]Q"&V(SBR\MO)MO
M8P5M7<Y>]LMPV"3R*TEF C_ZO$;GW&UW&X,K=1<KHW?;?&GM6U<AB&\W=)$5
MI;CLJ6TTF.A^A&]2*^80,:'[ .NDF(]!(6B#BG1'',1;YH^Q[IACJ>AJS+?L
M)Y$:KS:W$@S6 R")4@-]%Q",.X7=?[($N,7U.VB*EA2[NS!=[9N %=HVJA;+
MN/7$J@!$.(I=P9G./-+E%B.R^%)4=)%N-V(H4M,5,?:&:N0EO9]^YLBR-$AJ
M_;"W/;AF/: FZJ7<9R6K2_:V6'D0DRIDB*4+0DK35 KJ>/51;?=LVFVAT"5G
M5! MFHB1AAI@!2*O=UHN,&-8)\H"Z;C6=@>!D1&24)W+#94BZ/'RL^ZWAMZ[
MVVMUJ$"WR3($0294*[[^,I4NZS[5FVNKA,MS!$7 6],0XN.ZD+,=E#SS>',0
M]BJ.;%=KX;K=X0B*G\BA739XQ9B46^Q6J^D7EAJXR7K<9[5U;CV]UEN7'66T
MRI3D6.]EJ!-W4*OZNV9:=>U\\6LJ*>4G@"I8L&B@LOFAD^7%F8@0XI<SYQR4
M-1_1DR)#$AYW+_FB--I:4YU.S%VEWVQV^\2XC$$W*.S,CQV)2Y>B+(9;<:WS
MJXT7#Q*EZT(0I"4Z,.*45 <+MO8(&RVT]UV=@7"5<Q9I<BW2YDJ"U WDV+(=
M9?$=AJ;.U1@$(T.N.MN+47 64)2DKB?F_KDZ<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2O8GV0'_ .^-T_Z*57_O<GSYO_\ $;_NK9G^\)_YLQ7V5_X.O]^[;?W3
M:?SR57NVY_5_;_=SY/K[VKLXI3BE1=O#_H5V_P#ZKM@?[IEN;_93[*=FO[_L
M_P#W&-7)[>_8-ME__BNT/_:9=?'1S](:_&NG%*[T29+3+L9N0^W'?6RZ^PAU
MQ#+SD?U/=W'6DJPAQ;'JN^BM:<J:]1SR93YU>-)0@J2LH25H"@A92"I(7C6$
MJ(RD*TIU $!6D9S@56''$H6VEQ:6W"A3C86H(6IO5NU+2#I44:UZ"H$IU*TX
MU'.;U+9ENIA:09&RX1&7+ASX4ANSB!EKB.,E'HTB>XF)88I%EB7*>B,*>G1D
MLS74I6RX^IA]]IW67"RP+E'1&>0ZRVVXRZ@P9,BWN!3"5H927(3K"UMMI<6$
MLK*FDDA80%H0I.[M6TMVL\M<R,ZQ)=<9D,+3=(<2[,E$I3:WU)9N3,EMMYU3
M2-<AI*'U)"FU.%MQQ"[38[I:K:<-6.P')Y Q89Q4@7DY>S'1*DFY:II3_!8N
M&8C#$V5GU78D=AJ+G*4)PSA+:$IOP[; M\6-"B16F8T-J.S&;"=9;;BMAJ.-
MXX5N+4TV-*7%K4YQ)*B22<6Y7JZW>=-N5PG2)$RX/RI,QTKW8==FNE^4=TT$
M,MH>=.M;3;:&L@ ( 2D"R,$B,;,3,:?-CY'O.28&6)3[684AW+>77XF6W$^[
M/.99:RXZSY%KRTWYE9\B?#*4RRO>:VFU[U(0[J;2K>H3JTH<R#K2G4K"59 U
M*P.)S@HDR&BR6Y#S9CK4ZP4.N(+#BM.IQG2H;M:M"-2T:5'2G)\$8JDGSJ&9
M<=!LNB//C,0YS"24Q+,V)%3A$:++:P]A$F-'1C"&&'DK::3C"6TIQ]'*#%BE
M3:S&8*VEK<:466RIIQPY<<;44Y0M9XK4DA2CQ42:N"=-"'6Q,E!M]M#+Z!(>
M"'FFAAMIU(7I<;;'!"%@I0."0!5+()$9B%-RY\V4VM_$E:)$I]]"I.&41\2%
M)=<4E3^([;;&'<XRYAEM#7F\B$IQ6AEIL@H:;00G0"A"4D(U%>@$ $)UJ4O3
MS:E%6,DFK;DB0ZDI=?>=25[PI<=6M)<T);WA"E$%>[2E&KZ[0E*<Z0 *+ERK
M-.*5[8=[_P#$-ZF_]G5'_!POSYA[%'\K/9"_YMH/_<K%?;G9Y_D"[$7_ "[)
M_P#LV77BK[Q(Q'S$P^][KEY,C,;U5^[YD)0II+^6?-Z>7DMJ4VEW*?/A"E(P
MKRYSC/TYH1KWFE.L)* O2-802%%.K&=)(!*<X) .,BOB;>.;O=:U[HK#A;U*
MW9<"2D+T9TZPDE(5C4$DC.#52@J4:4E39*>VI,=B(E2)DA"DQ(S[<F-%3E+F
M,XCQY++,AAG&<-M/M-NMI2XA*L4%AA0(4RT05J<(+:""XM*D+601Q6M"E(4K
MZY25*2202#<3*E)(*9+Z2&T- I><!#3:TNMM@A0]C;<0AQ"/K4+2E:0%)!'Z
M^,%LI4G)0CE*D+;4GWV3Y5-N34D7$*QZOAE"R"4SUIS^RJ:E,I6,OXPYAR=C
M(.Y:R"% [M&0I+1820=/ ADED'G#1+8\#A4\KE$$&3((*2DC?.8*5/"0I)&K
MBE4@!\@\"\ Z?#&JJI^R'ICWK$#!$IG+S+[K929(),25L/JDMXEL3''FI3>'
MUN.*;?0XA2G7<J3GU%^-M$.*TG2S'98 2I*2PVAE2 I(0="FPE2#I2E(*2"
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MHDDG)-=/*JHIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*]B?9 ?_ +XW3_HI5?\
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M/SMWM(/M;[/_ 'J[^!<W_<9LOXEB?A?G*T/=AM-XWD^AGYJGSMWM(/M;[/\
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M3BE.*4XI3BE.*5]*GL^/Z"_VE_\ I99_^'^KN>6;2?R@[*_U#7YS,KU#9S[
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M]BMY_L[?YRQ74;%_9-:OZYS_  ':HO:[?TDG;7_61'_W4KG*]C/L7LO]D_\
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MKPBML.R='L"))(8+H(*%.E*5*TH4 O"1DE( 4DG4,J$IA,IDRG7VHX5[,N.
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M[MI]AFS?GMG_ &IZODTY[)7D527$TSMN?4&=@0M:7B72)+C#<>U1ZP7>!/\
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MA4VO:MQO;J_L*H@(B!_N#,66*JFNMOQFHRE.YBSK0N*F>MJR%)#4*L,Y49+
M<!#D!IJ4ER5(6EV8+?=HSSA*M1*5O281*N!*6M6G+2 2+] 3)5(*""B<ZY'*
M(K*%-P^7VJ0RV-.G!2S&F@#)TJ=QJ]D41:0O:30U>B,R)$;-N>@5>+!JX&?I
MZG(C5;9@NAWH-8-J22TY^2_9$;+N!<78)8(HQ(0RV:>;,1DXU]5&YU;EHN+J
MB$J# 4\I3SB9KY+T5<B.XW#"$@!HQ&$+:2X@C.CV,XDO%-#=XMK0!4"\4LA#
M+:H302S*2Q(0[+UDDN"4ZXEPMK"N"_9!F.UJQ:1VLU7)K00,_76I+QNJ7>!M
M5;FOJ@EZR'"O5:EZ]KCK1%+/OC#$/>(<Q<5N0%CO='\P;2TRX5;:88O"SS$N
MN+#A ;>85# E/X:;3=WY+H*2=)*K>MMC"M61J9SH))M&\PBTT@HR5M/)EYCM
M#>K5:F8[>%Z20!.0M[*=.DZ7L:P,?CO(9H<ZJ:]C5>PU K/D[9WO9A8&LB]9
M1W:)J8\(TXSK.F++ZU/V*,9! Y NWP:^\7E0I6<QRDR,+C-3W'9$[/MR$/2B
MZT^A(AVYI3KJY:A(F-KG&4^$2FVBVXX%L*<#:5#B@*62D8C:%R,J/'2TZPM:
MITYY"&D106(;C<01V=<9QP+;0I#J6RLI)PI00 <GSDYT]<I3BE?67[8K^AO]
MG#_V^M__ -KEKYXWL/\ 9OM1_P#E/^[M5Z[MI]AFS?GMG_:GJ^33GLE>15N^
MO:^G2TZC[+)7;: *TU;5>K-:2-9UH)&BC)<_70VM5=V8NVJ.YB/Z^/#*^NYF
MP"@;9@A;9\T)B.U$D?*UO0<CG(3(B(CPW&7IDR6);KA4I*92G70D,[O4)3:W
M0PV[O"VAA*7,E0W!Z+ET!:H\M<B6V\U#B151&FP$%<9+315OM928[B6R\XWN
MPM3RE(P =]6R->[HZ(*6.S6N^5:!-O!:PVUP9=">KPQ"-"H<G;#MP&U%\%7"
MU;S*=)U>?)&Y<>=4PEB FDDY*:L;F31^J<L5R0VTU'?4F.AI@+CIEN)4J2(8
M96_O'4.X"'DA?#CX1?;&^;2E>S;OMN6MUZ0T%2%NO%+ZXJ5!,<S%/(9*&UM%
M6IE6G!.G"0RL[M:E)PH?W#U'"D5X5%I@P;1XEFT5\0KS&KJ4_P"A1Q4?8[&]
M 4660R3+NJM<8Y3!?GDFY<XT,!1(<TLAH3%RYD*LDQ0=6I]:Y!:N.ATS) S(
M6J*;>LA.A'L);?7_ !82VMPJ2C*SBTF^04J;2&4HCAV %-"(P<1T)DB<@%06
MH[T+8025E;B$ %?@"JJL]K-+UL.F*-D%13Q77,ZD5YH;K&LPW].-ENJNR]17
M2&DO$G-SKI"V!MNT5*[DI"EYD/P*Z^>)MXLDQX6Y2[9Y[KFI24+")*9#I7+=
M4)Q1>(DV.2@ITL*BPF7HZ!C 4Z&T>Q)"Q+5YM[2"$J6@KC%AK3$;!A!5IDQ'
M@'$J"WTR)CK+ZNM+9<7ATE)OS?<[2EAN=SL=QKK1 S*LNWL:PMA.@"TKH]<M
M3VF955=((K$P4<F2<1:?LH6^XU+($1$^\S#K3LV06,9<MFPSVF&&F'2AL,PN
M6,HDK_A#K(G!X)WJ5MA.I^*L I2E:8Z6R$A#9%SM];G'WW7F];BG9ABO*C)]
M@:=Y$6=0;*'"<,RD$@J4A3Y<!5K7FQ1>V6CU7>-+@A6ZA3@U6V).#"0FJZL.
M@N[$L_8:RV^-,G,LS#5L@#,Z:(P@0V"%NL98PHQ'IN3D2G2#<V7=59KAR=25
M.%]];T5+CCDMY2N2M6QIA24DA#*E\O0IQ2G&"%(47]"GTH2*!>[=OP4HW+"&
MI"D(1$:2DR7;DX^%*P5O)1R)24)2V^DI5AG6&BLG.;5O71*9U(5KP;3[..ND
MXD2J6G"5'UU5 M;($N[%^MT,G>;S,*ML5R3/T/&5K.0'+3$($UJWC\IELUZ#
M G\QV;?<-,CE*GF5L(2E^<F1*?6\A-@CLJ1'CI;)=";B>5AQ RMUA6075J35
M]VX6\*8,=+#J)!4MB"N/&:;;4J]R'@N1(4L;I2X"51BA9\!M]''=A*J\\^QI
M2B3-LV$+JW+#VM*(B#KVC$VF(C+ME"4^.D2[<YJXF5HDSKR8:*7&2ZM^3EM1
MW$-E[,2+&0CI;6B2F&TY,SRN1JDR$DJ(:<?.L,)"N*4QT%#"1@?Q>HC4HYYB
MZN1US7&XF.21@F-'4,>R(9&@O**>!4^L+>)R<:PD'2D ;<>QY_I*^IO^G9K_
M '#MO-+MO]BMY_L[?YRQ6VV+^R:U?USG^ [5%[7;^DD[:_ZR(_\ NI7.5[&?
M8O9?[)_\KE4;8?9-=_[2/\%JO.'G3US5?KS*\<9\RO'&/#&?'/CC'AX>&,^/
MCC'AG./#'T>'T<4R>LUSAUQ.<Y2XM.<Y5G.<+5C.<K\/-G.<9\?%7ACS?Y?#
M'CX^'%3D]9])KGU7<80G#CF,-JRMO'G5X-KSG&<K1CQ\$*SE*<Y4GPSG.,9S
MGZ,<8''@.//Y?/34KAX1X<1Q/ ]8ZJXRXXK"L9<7G"U96O&5JSA:\YQG*E8S
MG]I6<XQG*L^.<YQC.<_1Q34H\Y)]L]//6:T;8]NUR5D&:I.@1YLL<D3)28KU
M<M@]Z W/@%66G!%L$G!.5Q20P?/A2?<?>H4N(R_$>9<3YLX\B*Q*0&WDJ*4J
MUC0ZZRH*TJ02%LK;7@H6I*AJTJ2HA0(K)C3)$1:G&5I"E(T'>-MO)*0I*P-#
MR'$9"T)4#IR" 016-%3)8X3(F3!*:3*ER4PR4(39#K\N>5(R')4XC*><5E;T
MR7)=<?D2%YRXZXM2U*SG.>7D(0VA+:$I0A"$H0E( 2E"0 E*0. 2   !P %6
M%NN.+6XXM:UN+4M:E*)*EJ)4I2CTJ4223TDU;<YSGP\<YSX8\,>.?'PQXYSX
M8_R8\<YSX8_KSG/]?*JHR3SG-<<4KZ5/9\?T%_M+_P#2RS_\/]7<\LVD_E!V
M5_J&OSF97J&SGV![3?UDG\UC5\U?/4Z\OK9'5UAUE*TSM+5U_N)FD3K1LK3=
M[!%A].=M\.1&H%9W<!,CIC$<T'D0I#SNR@\F$]CWAIQN).0YAM:6O4U<QJ6)
MT.7&81(2S%G1W$*?#"@9+MO<;4DEM84 (C@4/!(*DD9XUM8;L0P9D22^N.IZ
M3"D-K2P7@1':FH6D@+04DF2@I/$$!6<<,[FL]O=$#*[6 ]3#HIKV-2V?7RR0
MC77G/5!\]U=N.J34>24?MKD N(MFV3 *XE_A8;WTK&%IM).1!L+Q,$4T9LMQ
M6Z\MYS?CEK,D(7*(:?#=V8F-J" QK;6Q#0XPC6X4H*]RA*F@EQ&][=6Y+32&
M4[A7)78^I$8[QG7:W8BP5EXI6AZ4MMY>A&5A!>64N%2%VJP]LM'VTELV3-'?
M!P!.\=ALB:O#T_1LHN6M[Q2HM=Z]A7IT)R"JJ2=*VILE<7_34[(;DEG# B>3
ML3?DY4U9I[*882H+<1'MF\>,Z3EB7'?+ES<2E04'A/9TL#.!A&AQ*6C5MR\P
M'E2BH:$*?N 0T(3.'XK[(;MZ"I.-T83H4\>&H*65H4MSA60$>TFB$G(4>%=9
M\\17YFMXP6WE-!U,M;35!JA6Q$=K52Y02L[X>0-[OFG A168[V0%=&489KIZ
M7FNSYQB5;1:;CNE%4="7'4RBXRBXO(81)>0VF&\P4(U(;MZ6W$#(WKJY"Y0&
M]2E";J[O;MXD)D*6ALQ0AY5O:6\MAE;BI;3P<.E3DY2VU</8VVV$1B=V5+50
M%.V_6HGKRRA(NNHT,U-HD>L*9L-.=LJR\&)UVI6LZ;61Y2+; V8#.M[^!/'A
M9<MZJ8[9>);1<.4?%H"2JD6:ZHE,N&4I3:)!>!;?#6A2KF_+?=4A3*]1EQG&
MVEH;QDH4RM0:7O$P;S:E1G6Q' <4P&O9&"Z5I%N9BLM)6'4:1&D-K6E2\A.M
M+Z 74Z#H]KK=(^B:OVSKJ3K>F6>5LD<*A1+2:C$G# !4 T*)YRTJ,5B,.LQT
MCEOBD8CI7%+/>]27)D7&86=_*@*D2X4H2GVA$6M19;*-V[K;6CCJ0H@G4 OC
M@H& $J\*N?BW!$:',BF*P\J4E 2ZXE16C2M*N.%I!"=.6\ %*SJ)4GP:SZ@;
M U22UOJNJWR[;&UR1TWLRZWQF1KT&R2)6L=;V*(\ERL&5'A*:CL05,I"8$,X
M4BRQ:1\H/.P^E\ H83QI,:8B7,>CQXLI,Z*Q'(DN%"65,&0,/(#:R_%6']2F
MT%*RH.)QAP+1E194)42&S(D2HJX,M^0#&;U*>0\(Y!:7O$AF2A3&E*U@H"5(
M5G*"E4OQ-_Z4 SAFP85CO!>RR^ONI]*$=?NU"-'$PIM4&T,18#QBU/65+9F(
M,:JDHY68L*OXD2[(V#D2<BFHCKO,)=MGNI5&4U';:3<ID],D/E2U!Y<E;;:&
M0SELK+R6W2IP@-%P#62!6<FYP&EIE)>?6ZJVQ("HVXPA*FDQT.NK=+@"P@-*
M<;TMY4YNR=(!-9!?.Y6I+GM$?N:;03S=DJ1[9E:IU7IY*-1:^$IMFMA&T4G:
M-:7.'7F*#VF#8-6 99FW0\E9L[(KVQ63R;M"*$Y%N-8IC$-4%,EO=/-Q'GWG
MT&0ZX^RREI^&Z$J8+D-PMM+:(<&[;#D4MEA2$IN2+[!?EIFJCN;QEV4TPTRH
M,MH8>>4ZS,;"D/I1+0E;B'04$N++<@.!Y*E&NE]MM.NV_=<2M0)("J;?+[.N
M,0[?*& VKFO6VZ;_ *=>U8,U$HB('/#26NM9UR$PAR!+^ V4JG#:'EC,6%JD
M6:<&8"G5!UZ$B&R6XTEV%O&6+:_']C?1J<;4F5+=4?" <:;!SX9:-1O<'>S4
M-!3;,Q4IX.2(Z)>[>>N#+WALK"4N)<BQ6@,@[MU>!]9O:\]=HGJ[:MF;$L]1
M&S@]4L=YMAZLB2DAR62%U\N>GD P\A*>ESWI,Z&.D1H\M]V=-<=?;<6N9)4K
M+Z^EB-NLQ8S3RDK>:CLMNK0 E"W4-I2XI*0E(2E2P2D!*0 0 D<U<Q-=:?F2
MGF$J0R[(><90LY6AI;BE-I425$J2D@$E1)(R2>>O03V,G])EU6_THM__  RN
MW.;VY^Q2\?U+'YW'KH=B?LGM7]8_^:OUBOM:OZ1[MQ_K2>_[A"<N[&?8O9?[
M)_\ *Y5O;+[)KO\ VA'^ S4,5KK*Z:Z]HWW)F[*DP)1?805F)2]2*N-9"RJ&
M-JTW#]YNSEWK[%3A&'[5%9:?2$+JB1(<V<IJ3EM$5S/=NH;N7:X)B!81&<)?
MF[AU:9*WDXCL".Z7E(#*B1O$:E*2D$9)&&Q:0[;1<%+E$*7)0$L0P\T@QTM'
M+[Y?;#*5EU(!T+T@*5@\ >FL]0-P6*+L#"A#0\Y2C1BH00#DX1(DVB_5K96M
M]9V6F#I+19,9@D,*[. .Q9#F78IUY;8T*N9*D84U+MZA-&,0LK;?0AY3@2L!
MJ,[$ERVI"DE&2A:(;H(X*; *W-(3QH:LLQQ,G*0ER.XMA+>I!+LAJ5&BNLI(
M5@*2N4V4GBE9\%!)/#&!W5_=Y6KYMT2H-X"*K[EG@8EV.L029@4S547J8JO@
MIIE@R=GP:0[!MQ 6)@2R<.O%01.1%1'.AE3KRKM 0]N"^=YO=TK#3JD-K+QC
MIWCB4%MM*I 4PE:U)2IU#B <MN:;:;1<%L[Y+(W>[+J0IUI*UI#0D*W;:EA:
MU!@I>4A"2L-K0HC#B-4A"NDF^2Q6SU>1&J<&ZUR-4V&*7)V'29-@*G[;M"H:
ME&T]N-$L4A FPQ;);!B9X\VX/5$93'PO&,S8.7<9=_MR&VG@IY4=TO$OB-(2
MTAMF(]-6^5*;3J:+3*M*D!6I6?Z*L9*;#<5K=:460^VED!DR65+6X[*9B)9P
M'"$N)<=2%)5C3P'\Y.<6%=2]Z'G6HM:$U6SRB%AKM81#JVTM9V*2]/M5RAT
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MN-J4 HN)*=(45:FRVH.I*04:DA7UU67;=.8B,3G&'D1GU+#;A0L)RD-J"M1
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MH=<#3;;KB''72AEU0;:2M>$'P:.RF&%(2XL@N)*DD(6I(0%(25J4E*DH0"M
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M+=[7S23_ #1%G".\L@\#NT+'42"#7D.T'8NV_P!F2X;MLM=4,-YU3(C';&"
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M/M1DX6EF(;EC<^#ELNB*#O\ @<.GV'B/#X44O:3M."A%E[H,)RVI^?VGSO\
MPL/!CEN.2Y*<L9W_ ()PWX5*RU?E0".;E&IC13"L_"$UF4;D0%)]%7A\165A
M1I#:O>/+C/NS;F/1\V?^?X)XGHL@>8[6*N:H_P#_ +)GM1$/ ZA_$)CNN(5X
M&3[(I/A8'-DTM:]I#'DF]HLJ)8/\#%K?GNQU#0<<I5+89<2=Y@>Q(6-&3]=@
M5;JJWM-1)>+O$UXR(]T=RTNJSK)()>_>HSZ.%MEQT6+B)EKU\NJ2YE[#F&<(
M3E.5YQ>N"-G P.U2[RN3O$ZA<&(#;&ZTJUD*C/NN;S5HT@ITE.HD@@ X]I7M
M>9*A?6MG40]RK0JTR;H[)Y1J1H"D3(K+6Y*-YJ4%ZPH( 205$=.6]M_*7RXA
MZV^1_P 4QCU<S[/\I?@GK_2OT,#?A?Q3W;Z<-^\^Z9?_ &?5PW^URK1LSR'.
MN]]LN3YT[BW\AY7HYM?*.4<GWG#5N]YHXZ=7"J"YMIVTP&MFNTO*P-9E77MI
MR'><5;KDG).5[KB$;W<[SAKT\:[[4WM))%O%(B:]>$>Z-Y>7:IUDC$??O4>]
M5+;8@=*C9B89]#+:E.X>RYE["D83A&546]&SA85VU7>$2=XK2+>Q!<8W6E.D
MJ5)?:<WFK7J 3I"=)!)) KNZ]KQ)0+$WLZY#W*=:KO)N;4G?ZEZPA,.,\T6=
M&[*5%865%8*0 DFOLC5^2,&YJ$:F.F<Y1\839)9M@8A/N_\ *?#7!D*3*<S[
MUXX1[TVWC,?]I7@Y^SRU!19"^_VR5<TQL'DQ@LQ%ODZ_!WZ9#K;:1N^?=J5X
M? >#QK(N:]I!%BFS(LJYI*>6)N;\]J*!N_"Y*J*PZZH[W@G>H1['Q.%<*--7
M[Y)+4]&IF+WX.>FRU+-YJ65>^>#7GDKA8,8QD?\ M.>6)G.)G["?%C]OA2+)
MVQ2$*N?:CP=2U-1!<<;KPM+8=,;^.X)R[_%<3X?@T0O:3M.HN(LHO^%:6T/S
MS9\[_"-3RHXF@<FXJPP2'_!&6_"I4VK^IHA\N8U,9?QEGX5BIRSDEI6/*][Q
M\0R8A1%HSA?N_H^[8<\R<O>?RYPC"EQ19 IGM2JYK1X?*.V+41M0.4Z-R(SK
MH5PUZ]93@Z<9!.%H7M*42>WR+*VX"CD@M#\]U"AA>\Y29K#*DD*W>C=!>05Z
ML$)S:ZRWMA15.+E$UPT$]![SKK,^S2"OO/ACW?"6RHV-$RQG/F];.7<.8QX>
M1*L^/+\]&S0CGM8N]*E:TX$]B W'T<=9*H[[CFO&-("<'CDBL2UN;9&6!>FM
MFD0-"\JM<JZNR]Y@;L!$N*RSH)SK)7J QI!KB4WMK%DPF##UOFG_ !&-C+LJ
M?9TV3X1ZC7OB\,,C5"_B.&O7S&;]Y]V4YAK#KB4Y7G$MHV:Y#EU=[%RW#G@M
ML6\P>4Z5;H:U2!(W!5HWBMWO G44I) !/.;9]L\,-;-&S<I:!6]*NJ;GR/4C
M?JW2(JHO*0C>;I.]W2E! 6M(*B*JV-[-3-C8HL6@O#?=<9EJMDVPQIN)OK.^
M.(R \"6PJ+Z'HYPIU:7O6R[C*?)A&<V[<C9XM+[;+NZ']X=V+<S!<:+6E."L
MR7FEAS7KR$@ITZ3G.15V\+VL#[7:!O9]R-NAOC>)-R9?#^M>0TF%&?;+6[T$
M%:@O65C3I )JSS5^2#%YK$:F.67.8OQIL]+-L@T8S#<S.^%O#X3\]S.)_I)B
M^]L-85#RXM[RO82C-N(FR&7($]5S3!]DY*J(U$7+/L@W7*$/.H93EG47-VM6
M',!.4Y-7K@O:00(IM:+*JZ'<\N1<'Y[<!(W*M_R5R/'<D+Q(TAG?-(U,ZE+T
MK 2>8;5]S59*B$:FINWED>YLPY9M55RKU,>Z^\R7X2"Z4Y9\<R/2BJSASPPW
MYD_3R'463M@@,JN1M64;Q;K,07 #3[)H;0Z8Q.KZS4Z,IXJP>%&5[2=J73(1
M91?<.;E#+\]5I)U^Q;UU;"9@!1G>:&5$+^MR*_%0:V"K,_Y>QJ4RG&(WPOY(
M2SDK*LYR_P"^>_X,PHF$8QCW;W;,?+F59R_ZN$>5OS3<D6,;GM.JYK_C.4=L
MF8;>/K-UN>2O.ZL^R;S7IQA&G.58BS+VF/*.Z!NR-XW7).TTBX/:C[)ON4<M
MCL:<>Q;HMZ\Y<UA.$YME?;VTHTWBU1-;MUWPD^JY7Y]G>-8SAMSW/TVB(V/!
MSC+WI8D^9['E;RYEKS*PG&<B8C9D15&WKO:IO@:4S&+>B+]<-[J4P^MW@G5H
MPCBK&K S6+;G-LS.2+LULTBV^RZE6Z5=7)V=*MSI1)BM,'*].]RX,)U%&3@'
MDHWMG%B4D+$UPNI^]0\(=*3[,W8O<LH8]_RIB(-=&XE)7[S[FG$C+2D88R\I
M&<N8281LSR(&4N]BX[MS*6&+>J%O<KW("W'TO[LC=[PEO4"5Z00$Y2W-LQ<B
M(+6S2K1O6<+ERKJFY;C#?*"6V8JXN]"M[N0'=! ;UJ22K%7<$[-:>BYU[$H<
MACT',S,7 C8H#WO7J8]),500801Z&6_I<6ZGU,.>&$HRGZ>6[8G9\I7VX<N[
M:]8W1MC$)Y.[(\(K$J0P=>>8).DCG(-7;VO:L+:[GF=GWF]VHOB]2KE'7OM7
M@!KD,62G=E/URE@*"N9)%4%HV<(UD J1/:3[011V<+ F#0J*3(4ZOGI\56<.
M%#;L1G(>O/DD8&03)MJ$RN3*A(E^Z^JYEK(M]ADWV9<F+ E4H1&I$R-&DN,,
MW.9#9<'@QXJ7%<IFH8)?>BQ5.J2AMTME>E(5BW7:F'LO;[/*VK<1 ,]^+ F3
M8C4N39;=<)#).J5/4R@PK<N4!%8G3D1VRXZP'MSK5HE!*DK2E:%84E6,*2I.
M<*2I*L>.%)SCQQG&<9QG&<9SC.,^..:$@@D$$$'!!X$$<X(Z"*ZD$$ @@@@$
M$'((/$$$<"".8USR*FG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KK<_J
M_M_NXI79Q2G%*A70<*[0:'-QL'XPFQR]@;1(>D;E.2Y3(2;L.R/UAJ.IQY_T
M1F*XH6H9%;4EJ-!4PTVTTE/DQU.V#MK=N[7:?DQA-V>PLZHC:6VURFK-"1.4
ML)2C4^9H?#ZU J6Z%*4I1.H\/V/F;XS8'^Z+EHN3VT.U4C1/=6ZZW!?VBN:[
M6AHK6O1%%M,4Q6DD(;8*$I2D<!-7.6KN*\IK+T/VQ:Z=KC4TV\T0/0-(V6RF
MJ/:Z^NWP-DW\=;[7E\L$V(Y$:@Q@;#U++6.-:GP)DXO8E[37;A)34F!\D/)?
MY_Y?!2H*W7[/'M J%92^L=IBI$2IT#L.%UK4 Q\Z"//@K[7^ST*@:MC$2$'$
MR!$ O[=ULV-(P-CU.L#DZ]@1)-3FSA%<MXM2IPK?0+8\<Z5MT^^UVNS72>JI
MM#I]6/[#G5'40BJ;W>V;?:Q39<B4#(R1UXK#,,=(G9BB)GQ><7@,X&UY$)&%
M*A^I>S+W97%U0H2O6M;9+K44N$E5XZ6M3,:T45^Y:6M_Z.+-;J_30,@C7;.3
MH=U)V"8W3HLI,HV"CV2+LF4NY'K,I63S?9K[K72",.'V'D-;'*X#C#-V26M^
M91Z@B-::#KSFJY;QQ=I;:J1>V:IMSDE\H*LSC0:]2RQ$;8C<L[$**5*YSH7=
M;5JG2M!L6S')L_5E1V:.5+>L5H_D+'=MR:IO]:E"B-?BU%+T6@T:G6W70*4@
M  3#&GHS0,$ %.2!D52M?[5[/GL16C=GN@/9T@P"J\'<F=;5'7963"O35>.
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M]Q"5,6/?+R!!:X+I!8J)8B2*_65N/)S"4J6>J'=<WM1NATVY:SK%=OM@T_\
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M):]G+A;IJG%)(84F9(OT]I*6U8+B3%)< *4E!.1^3(3L ]<5S0.P=9P*)DE
M=; DM='2%C2*;Q&^(Q%6!B]08*ILG*9?NLS 1+47#S'J19'HK]68LO8Y%L#4
MNS7UZ[[AY*IC%ZB,PC(5O-PX(:K2ZZ&F\M[QOE14YI5AQ&H:8FP>R&N]*?M^
MT.RT>P<JCJ3;Y6S=PDW,1$AKE+)N+=_CL%]TA[<O""$-:VPIIS02NY["$[I(
MSQ[FL+K0:N.;B+03C6^C&+7*DS<O*4V_$E#;A6VXL=+&4MJ8<CR5J<QES#R4
MY\F+%ED[+L,O"_6J\7!]3@+"[;=HUO;;:T@*0XV_;9RG%E>2%I6@!/@Z2>-9
M6T<3;>3(CJV5O>SUJC)94)3=YL4V[/.OE9*5LNQ;S;$M-AO"2VIMQ14"K6 =
M(KK.,VS*J 2'4;;2A%Y8R.^4)TW3RIFND,-CWFRN!8"):14T;F434Q)AYD&I
M_ND1MR*[B2XXF0BU ?V=;N<MVY6ZZ2;2O?\ (HD6YQXTUG4\E4?E$QRWR&G]
MW'UH=T16=XZ4N)T)!0;UTB[7NV: S9[Q8X=^;Y-VRGSK-+FVV3ICK3+Y+;V;
MK$?B[V46W6-Y.D;EE*FE[Y2@Z. HS;+%&*03]MI1#8CJ2& ]B&T\J.JT-3C:
M,#,SJT_:9Q";B*[AQ<O#1^)[TA24-YC93E2DJ1LZN[1WH=MNC-E26>4PG[DP
M_/="2=_NIR(#++6\3I#>J(YNR"5:P<"8,7:]%AEL7"[V.1M&L2.17*+9I<:U
M,E24B+RBV.761)?W2PHO:+@SO4D!.[()/1KL5N,=(**VC<J):8SK,9(=JGTH
MO4WH;Z5O9EN3G2=MLJ9K;S>6$L-M-Q%,J0XI:W<.)2BN]2-F7T1Q8+7=K>XE
M3ADJN5UCW%+J"$[M+26+=!+2DJ"BM2E.!0( "<$FWLY$VTC.2CM5>K!=6EH:
M$-%EL<RT+9<"EEY3ZY5XN8>2M)0$)0EHH(42I60!:*P$W]%MK4RW; UJ7I27
MR*G@@/79T-8'([C$E(MI!V7>BL-MR+(7$=F.Y#+3+;9>:;;C9?2XUDSY>Q[E
MN4U;;-?(UU*& B7+O465#"TK;,A1B-VJ.X4N-AQ+:>4@MJ4E2BL)(5AVN#V0
MFKNAZ\;0[+S+&'))7!@;-W"%<5-*;=$5"9[U^EL)4TZ65/+,)0=0AQ"4ME84
MB_#=2TT=L0UM1R-/+W<O&;'Q2QTE*+)K 9,:.P\$J$24M42MC)KS"YQ%L<RT
M_/F27U2Y#K'HL,X;^T5S?LL79]+C,:U1EJ><C1&&XQGR2XM:95S<; <G/M)4
M&F%/J4AEMM&[0E>M:\^+L?9(VTD[:U34B;?9K:8[4RX2G9@M4(--MK@65ETE
MFV17UH5(DIC(2[(>>=+KJVMVTW)?-%744XI3BE.*4XI3BE.*4XI3BE.*4XI4
M3V"%7=5)V%M4/3;-8#5F76YEP&T]IPL8+M@6&@;!2!7Y!"-$?F"@CJG9R1C>
M"Q6".9CH:(28T&/CHH;LW:#M-L_)N<"%%@"<U;7[D4QHT8RUJEKCO36V''4M
M2)0"6=^HQX[KRUE3*''5GD+BQ;=DAM'M="LETN,ZZ&V/7J-9DJF39J;>VB W
M+CVYV2TRMZ)!65R!%2)DMB,AL)D.-,-B\T;:5 V36I%NIEG&EP,)V1&*2_.Y
M!<"3(3#<F= /0R#<68$GP8[S3TR&48BR(S3B'74);6E><6[;/WBQSD6ZYP'X
MTQY*%QV\!T2VG5J;9=AN,EQJ4T\M*DM.,+<0M0*4DJ!%9M@VLV=VGMCEXLEU
MC3;?'6ZU+?U*8,%YAM+K[$]F0EIZ"^PVM+CS,IMIQI"@I:0D@UD@NS5PXZZR
M$L 0P\PWAUYH65@$'66LJPC#CK<20\MMO*\X3A:\83E6<)QGQSX<PI$"=$2E
M<N%+BI6=*%2(SS"5* R4I+J$A1 XX!)QQK9Q+K:[@M;<"Y0)JVTZUHB3(\E:
M$$Z0I:67%E*22!J( R<9S72Q;:I*(8$Q;-7I)3+SL? U@T->(9D,^?UF,0VY
M*I&7F?3<]5KT_.WY%^=./*KPJ7;;BVSRER!-;CZ4KWZXKZ6="\:%[U381I5J
M&E6K"LC!.15#=YM#TGD;-UMKLO6MODK<Z*N3O&]6\;W"72[K1I5K3IU)TJU
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M+4[C#?BVE"E+\,)SG%;MMN+#6_?@366!I)>=BOMM +("#O%MI1X1("?"\(D
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MK=N%UO=V]3)BHT.DN(TM#2LE8PHYK]5W6^O:@&)URJ4:H5FOFE2%& @"N"!
MDJJ7%3!E*(CH$2/$FYD0D(B/YD-.9=C)2POS-XPGD3;Y>;E*8FW"[7*=,BA
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2BE.*4XI3BE=;G]7]O]W%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cntx-20211231_g12.jpg
<TEXT>
begin 644 cntx-20211231_g12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %B"^5F0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!N#8E
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              <P   7L          $
M                 0             %[    <P
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   <P     4F=H=&QO;F<   7L
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ',     %)G:'1L;VYG   %[     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      +N0
M  $   "@    ,0   >   %O@   +G0 8  '_V/_M  Q!9&]B95]#30 "_^X
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MM,\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MH20@RGNIO5BJM*M"%A:GC*_"6G8L1%VBB)LI/R,!.R<PDF[CYL3"]5CIRMS
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M1FJBKIN@V78KNP,>X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'*B[,7\#;6W_C:_?KU/X!4
MCVLWX5Y?XKZ9_P"G6/ ('CL^T#2V]#\*/]H6T42&3#R3^S!9)W-]>@ SCQO>
MK[>2#@1."8?V)XMOT_@B<P'I<;*M#C9:^V?'M4;>XMRMV461:E"/]NUY,TLL
M7R%0ZA#L%')SIJ,E3*)JM3&;JB<IC=0/KFW+>?;>?G$WC1M*6*]U38CETU9D
M0%C8*4K/*5LL2D0X(L8R-"PO$$8\J9TBMT&+<@D2; 4X&X6W(:\I3<K8';&J
MRTD]N*>P(8TG"G50I5O;M46#.6J+5N]:MV:3&/91;%M#R:<K BWA84'$6NK%
MM%4P-F5'9$E5FTY&N82LW&$L;N/DI:"N,<ZD6*TO%"^]KIA!S'2$3,,9)L24
MDD#*LI1!-XV?N6\@B[1,0A -_O=[2\A1=EQ+QP[<6C:MDJCB>,G&Q;&O0]7I
MC8P1D9 >3JG>ME7:B<1%J,T&[!DR@:ZS9G5E?+/ C@/F,^0%^9R<_)%"#7"T
M7"U72PQ[B,,>/E7UTAWL#8XU=--TDX1AWT9(ND4T6CEN^8K"B]8R#9\W;N4@
M-&.[Y].P5]^=G'04-"W>F7%*/I[!M'.F*E-:*1;)*+<S 397"YHQR[\>ZL99
MY>3D%?*YI61\8X*L!EY+D?5*]8JK,TV'D(M/7M)OT;6&[*KP%?CY>VWA>042
M=S4*G8+ 2/AJ\X=L9E XRUED9&4A&Z"18>/79I0@$8X.ZR5=G*78XIG%(35'
MEV<['OS-#J+2DFPG/;YHYGC&<",B9%R";4O@^3B+!%- PB<#*F ]=>N<S6+"
M[LT6+4LF]CK5%K>/0\<W\DN,!+UN9 B/AD\%08R;? U/X0^(7%)7H?Q?@F!<
M=>)^IS?9I_7:?6)-*-E8ZC24B]KQW[0RKUNQE739\]KJ[PBR:KFN*2""\@E&
MJ=/(WLG+K,UVXR3H#@9#BN2>V(RR3MH6G2S3R?L<1;7#&>*XDH9A8(*V,[C%
M2,+&*.B-XA1E(-#L$2,@22)!OY")(0K=P'BP/AUO=ERK$8WB&2,"Y8M(*1@&
MR4C%^5@DB_ND7L!)]T%=,JC^,M<-&2,>*Q56?@-09OF;YDJX05 R8QY,2<Y*
M+-KW&QS>JR/NY=2["O09IT)26OB=:-,NIYE:K)Y=/L5G=1@73>/0M==7@W;!
MD[KLE%D8HLS@?GL_)J;=VIS+UJ K[>-BY"%DZ ,U#HFD:--0=(K-$)9H!K%N
MVL/'R,C'5.%?'B';><@HI]'QIV+=1Q%MGYP-AQ&]KY"32$^Q4B?;!LVUPT3,
MM'BJD9+5D:SBJL)R>/*)C@T8HA)&\(/+5/#4Z(B80P#Z\1R*N\%&P<3%1=29
M,8AXQ?/FJ,2\(RLR\?5IFF)&FHTDJ6*:J.:[8)=E*NJRPKKV;</3RLRY?3":
M$@D!\ZA;XM^NHQK$P<=6G32-M;JYPQ9=C(NR1,X^8L(UXLDU1EFC"23481C)
M!J$^TF%891(S^!6BI-99ZH!^6*WI?X226EHMU&M7ZS+6;#QWM:BN!&VIH^*C
M*H0$7!ED% %G#M4IA-PFLA*%.X(LB5-<Y, _+([?GG4]KV=C82J5L-7NFSNH
M0\#%ND(EHLVLJUM 7I7\C(R$F*TVX7764>R"RODZA6*)TF;=JBB!]A+D'L=*
M)AH3RR,4CH&&L,$P35C$S* RLMJB;=(G<+%5(JY<IR$'%,F2RQS>1P[)O&(E
M*@D02@?JD=_3+VQ^[!C1-:5ZUGEY6:=3\%!3"#]\\FV<HSE2N@>6)^U%!X$N
MZ<'32;)>"Z(W.F8A$S)G QI+W::GJM5:G*^2.V5+]M4:\_4;_P"'#*+EW)7[
MB!/(%. N85M)B[DXUDND<8Y[)RIVBJ:3]9' -^36^[]/2Z$V_4AQ?-W5]>)"
MC&^*2!;8]785"R>$3QYA$IH>-; Q*!O[%<^,6ZJ ?P"@>#+?%\8/9E^@>(\H
MGG]>DGXGCO#)Y36:38]?QOB2^/+XM/W/VF5*X)U$57@MW0&**(IG ^JIR+O/
MCV[QG&5"*D 4AU9>0C815%W95:[4I"DP!YP57ZZ!O:F E9!-(L8WC"/7S@9.
M7+(OTD'"0!IR*NK52*7/#TY\Z@1I[V!<OX9VNI"V:C0#.L0%S8IEE4VPV%.$
MBX=F_1=-W-=E3PL0\D(%=ZR3<"!BFTVZ9N+N-?3BJ2[J+@8BNMU4DA3,HPA6
MP-69W B<XJNC)AX3A<1 5E!$XE#KTP#;. , 8 P!@# & , 8 P!@# & , 8
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M7RQ?:< >:QX?_-2W>OEB^TX \UCP_P#FI;O7RQ?:< >:QX?_ #4MWKY8OM.
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M_$ _%CDB*N%ULE[;DOPNN"7P5< JHF*K;KR2Z^29KNWYH#+$( B8>@ '41^
M Z=>\?@_+]/3T9$5%XXI>UEO;IQY9DO^\L.H\>GZ>H].[OZ>GKW!T_1^W7%\
M;?UAGCRW]4+^MZ?]LEZ<P*Q"E\,PB!0Z=1$.@  ].\1'H  '4.HB/=Z1[L7R
MLBK>UD1%NMUMEGA=+X8)F151,57#CN\5W 5DP$ $P (AU !](AWCW!\/3H/4
M0[@[NH]^.TG/.V6^SEMXHUUNA?FZISM:]N-KI>V28FH*E,4#!U$! 1 0#J!@
M#KZ!] ]>G=T'X0'X<N]4QNBV7!<%(BWQXWMSY]."F@K)E$H"(@)O1U#TCZ>G
MY@$?Q (^COR73GNQM@EU1$15W*JJB(B\2Z]+X<<#7QI!'H ]1Z /3X>@B( /
M0>_H/3TX145+IEQW>8NE[7Q3&V:VXX'F @8.H?BR@UP!@# & , 8 P!@# &
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M2.)(W.NYMT3M*C41;_/WC9.7%GI4^C*PVR)6V5RK;&K36YUC6=H93D\?77:
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M;.01$O42^"/=_!]/0>@"(=>[T"/Q!^+KGP^]<,,++QP/I$R3"W)-QY92C &
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MLD4Q.\-:L;GD;-78=D>2EYZ'BHY-X$<=_)2;)DS)(&6\F!B=RY730*[%Q_@
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M*>T#D3UPHI<8 B=Z.H*94R5,XOP+/&4.LBD0(T7'AK+)(EZJJD(8#*0&*(B
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MC:G[@X:;U[H6H7]I9M\;AEI&27FJ&,UJW5=YGK1(>Z37S;8R;B!<[%FX67)
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MZ\>[5;O7+%PH=H=9F*B+A1(5$!,F8HC3&_'#KKACR-ZX*, 8 P!@# & , 8
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MN-8,7<F\65%Z$>>QQ*4G9]ZB*0I2$+:]YE(0A0*4A0WML<"E*4H 4I2E "E
M        .[ +/%/\C4_[PW^U' *JNQL_ WDOHY.<MP__ )#[!_HZ!^3 +6,
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M% %#)D&QJ"0AC@82$%102EZ%$YQ 3"&N![?W\G"_^ZQXY?[,^O?A]'^B#X<
M?OY>%_\ =8\<O]F?7OW@P!^_EX7_ -UCQR_V9]>_># ,RZYVWJS<$4\G=3['
MHVRX2.?FBY"7H=JA+9&LI,B*3D\>[>P3U\W;O2MUT%S-55"+%2624$@$.41
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M@: =(U4AVR;UV@K'QA$H2M^3&;.4EDW[!>!BG<?)%>,7K-)VW6# UK7,S1U
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MZ_'@'+]]A]***<J>6'C%%#^#H:L] ,<Q@#K?6O4>@B(=?0 #Z0]'PC@'8#8
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M_K/.WN.I$'7N4W"AAN/32-?9VXUJN[_<.NTHQXTV5(^U,U$HU.0;R!EDV\(
M6 SCH[*V\2 F XS'LO#\.G0GU:V'\X%RP1-_7X0XG."C .S#]BL^]5QG\?\
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MXR%-1&-E9YXJV; B"8-T#I-T@WZUQZ>)*7 /SN@#R9R/3_K"W?W=?\C-\?\
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M299QK.0V3L*(C7*81[&39$I4/-,TE7AK<N)S>7";L41/'=SO@GAZG(GP48!
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MOU31#>015 DIQ=AFE>T+KB'8Q,#!-6,.LDC%5@UY/ LBC)/5/%1IMDMFEW%
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M8(F:]?A#@[^RVO?']:_57HGP_P#S_P!G?!\']/Y,%.+;@# .P\]B'?@/[_\
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MLT[9-2L4\Z:L41<O5T(J*E73U5)H@4RSE0B(E02*8Z@E*41 "0Q3D.'4ABG
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M=PCZ.[Z?T8+I-=;G%MP!@'8=>Q#S%+P@W_X1BEZ\C''3PA .O2B5?KTZ].N
M;K]EM&(?L]]6>"<IA#DA6>H%, B >Y"W]X]!'H 8!US6 , Y8'L10Q2\Z=["
M8P% >.+T.IA  Z^[FK]W4>@=?H^@?BP#F)]LHH0W9<<WP Y3".AK7T # (C_
M )5'N !$1^/N^# X>GDOQ<ZBS & 3Z[*\0#M(>$ F$"@')G4@B(^@ "W1O41
M^CX_TX!W!A3D/_C3E-\/\$P&[A] ]PC@'E@# & , 8 P!@# & , 8!H( 8!
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M-9^-.K]U;,V7>;/=]54&W0_BWC!&RR$<QB*%!.(H!\CH]8<*&-&-SI/K++)
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M2\FZUK0X*G.)I%NWE58=%9([Y%H=11LFN*JROA%1.JH8G0 $!./?TZ!@&5<
M8 P!@# & , 8 P!@# & , "( '41  ^,>X, K:YH<F:T9@XXXZZV53H#96P'
M[R@SUDE9><8MM:*RT&Z-%K*RE:D8F4C)^2G'$# LY:)>22U%D)R-G[%!N8PH
M-G :UKS0^7Q8X<&/7W%AY)U6'MDH\L41;X2KW^#@;#<*Q?HF*9UVTW:?N;%R
M]8V.Q71:"CW4E+024'7;2P8Q%A=5"!FGTFQ("XWW9Y8>7GZ%G
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M@]DD+!831E+5N%9>U]IL:A)6BM-1C1?;6LOU:AZ/1@&@B!0$QA "@ B(B(
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M"MD-%S.R9%1G%M[Q=$' H6=[!LY9LQCEG#X'0$VL #W (_%@$-.97,6D<4*
M_D7[EJ^V',0<XXHM=<H2ZT6I(1Y8]HE*VY[!1LN]K]18RTW"(S,R9@OY(W>^
M4F3*S0>O&8:QUGI+D%..W$9YR;D8W?&]KM:KP1>T3%I1E5!LM&<SJLU"C'MV
M]7;0=K,6AI4D_E%?A[7JZS2NN=Q:OE(]62924DDC,-GCK7/>3DG+JGZ5-Z\"
MZM@Q:1;%G&QZ";5C'M6[)DV2#HDW:-4B(-T$P$1$$T44R)D#J/0I0#KW8*?K
MP""7+[EC4].&8ZQ\DC)VT7-HV0?**;28ZVC]=QTLZ%E%V?85E9I2=EH57EGB
M9HB&N2,$\B1LJT;"R+N,"40=8)K+V7WSSS0C%Q0XT3&\F<KM7D P@;;7K1>7
MNPJP_<GA7EH>SY%V]>L29INM.'<#9]07N'AF;>2H<XA(0C>6BCS-4<*UV0K:
M-?#CN\-7+@VK5LQ;-V;-N@T:-$4FS5JV2(@W;MT2%310013 J:2*292D33(4
M"$(4"E    P4]^ , 8 P!@# & , 8!6%OK3^R)O9'(2<E=.O=UO+UK8:=QMG
M#SL:XI&O!FM?258M%.O%.E;76B1$?,61V\GIRX,&LLO.04JE$'=,GD'%LW0F
M>%\L_=,;];HJ9=27''S0S/2M71:O;':+I:Y"-KK>7G[E,I6.28(0,(A%1]9A
MY?VMCGKBNP*0.6T4XEQ?S[Q)8[B:EI)VH9;!=)K6!(7 -NVNV5ZD0,A9K3+,
M82$C$@5=/I%VW9H 8YBIH-TU72J*1W3M<Z;5FW X*NG2J3=$IE5"%$"F&VW:
MR]H!M.FUFOGEJ=K67U;L*8K4,N:DV!Q!6F M5>B'4_O2AO9IO(N8;P'*NOKQ
MHFVQ+=XC[=C+Q$F\FXM=W5"^?49%J6A=%U+0E+&K5IN07,C(JSUAD"II))O9
MQVQCH]<&#9))%*.AF#")C8B$C4B=6</&,$'"SMVFN[7$MBB\-^_?ATQ,W8*,
M J.YO<XF#"P)<8=,WU[5=AV:0D:U==A0M3?6R6IK):GC-"PUO$G!C$7?8BH2
MT"H%:8SK>RC#.I5W28VSV:&7AVB]O<F?3GQXIOTEN>5>*G!BI:NLO[LUH:RX
M; E6M?=,8)U;K/-IU%Q'0CR(5C9&<<329-F1L>9Z^7U_*WR"<7"F04D%</*+
MH,&*,>+[8W_JWX\2QS -!'H'7]OR_$ ?"/P!@%,_+'F0VV!(W#2NJ58]&1BT
M7]?;WQKN2%@X^\+6%\-'L-6U[#QPNVE_GX8SP\->8%:4A[QK56<A;56(B9DC
M0PNGAKAKT!+/B]Q.AZ!&5:^;2J%+=[JC(*+A#SD5$1[9--I"-/:VO3DA#,CN
MJQ&[01KAF]:M]NIA6#6U(Q;-84T6"$;%Q8<=:UX3FP!@# & , 8 P!@%8^\-
M3[/D-A<EYEWJ9_N"9V5K%:A\;YT\NT>T2CQL]KUQ6[52+[5Y2SUQI Q<E;E7
MEEGK,U;R+FPP<LA&HNDY&"CX]1I!^[ZY);UY$J^//'.L:(A7JC:0L5FN=E:U
MH+3:;?.'LLR<E9KS2OP< QE%FS588*N1J QT4=RFK+/$1.\G)&4DUUWJ@9X^
MV6/IK D;@&V;?<JS1(-Q8K9,QT'%(*(-BN9%ZU9%=/WB@(1\6R%TLB1U*2;L
MZ;*,8)&,Y?/%D6S=-150I1 I7D[58^T%W-(04(A8:WKIQJ)E(5=HHM5GSG6E
MC:V^W0SV5W9KF2>)HVF,N7DCVAWO3-O*TL%3".(\BH^0>2#BP5)\>B_TNK@M
MBT3HBEZ#J2];J2"ZCF7E%;#99AZJ5=[,3SIC&QJSC_ TD&[-BUCHB+BHN.9-
MF[5E%QK)N5,ZB9UE ,V8!H(@ =1]& 5%<X>8Y)&28<6-/6)6N7;8L[)TZP7=
M[ V1XU0B6D6L>6BJ-[0J,GE@F'LHHUK\L:(F(R?90I;?*T1&S3]2D8]@'&]L
M->G'CP,P<7>"U*UC;C;JMU9,WV&_2AGD+69"U3%U+K%ZPA9"#<13:WN9%$FQ
MF44WDI-IK^S6^O!=:G599Q5BR@QJ;5C'@NMWL6+>C  CTP"DOE?S+';1IG1>
ML(U)K)OYAS1&MH;;:2:1>QR6FTJ:UE*YK[]SMZ\DYUZT2>HEO;DCV.N^D#3$
M3<O<A8F+)0CQZC>F>OZU<FCQ9XI1^NX2KW/:U8J$KN6+A(N(;3+6$AR#!,XA
MC[51T@V;-$G$5"WU_7THF&V#.4Y9A#7![7F$PE',"F(S;AKS]_&_(G'@# &
M, 8 P!@# & , 8 P!@# & , 8 P#;%TMT+0:E8[K8USMX.KP[^;DU4DQ57\E
MCVYW!TFR(" KNE_ !!J@40,NX421+_".& 59;NY(;9W-84.-L5KG8''V:OM,
ML*"[':%2/8(Z[#8/)6%7@'=TU3.6*-I=/MT:6S0<K>XFT>Z"@V]2O,YV&:EE
M8=*>#=?AK+,W]QD[.BB:U7KNSMDJ/9O<$;?%]G5P[!9*'C-5O96./&/J566L
M.Z6BS1"\*HVK]L+&IQU<M_M)#RQ*Y%.F344HB6_/7/S4<4W>_7U+-LH& 8;W
MC0-@[-I3FG:_VO(:<7F"2+*<MT! 1\U:DHIY#2+1)&LN95<&,#(DE%X]XK+G
M8OW1&+5TUCO:Y^Y;RS$""&J.&SV^*6)YN!A<:J61FC1>TJO*S;^3?7*V4RL1
M=#@KYJK:C&S.+7&:?O="-(M)C7$^L_\  5EG38R<++,9)Q*AK7$M"B(B+@(J
M-@X./9Q,-#L6L;%1<<W2:,(^/9(D;M&;-J@4B+=LW03(DBBD0I$R%*4I0 ,#
M6O# ^@(@ "(B   "(B(]   [Q$1'N  #O$1]& 0@W!S)K\+66B^FQ@KG*RFR
MFNKO=9:GD_3M2UR6<0%@GSS$ML(:O+QC^'$:\O764I HS$,-M?QD5(OV@**]
M UKH12X8\3F^U:H;</(*'LE@E;M8?=X1Q;;8_GG-Y=/(\T.65GXEUU]RJ:5>
M5D]<6R@0+YYIK85<:Q%EAZS&-72$>R#C\:_!<(R9,XUHVCX]JW8L62"35FS:
M(IMFK5L@F5)!NW;HE(DBBBD4J:2292D(0I2E*   8!^G & , 8 P!@# & ,
M8 P!@&(MO;8_<LC(,8VE6?95OM<NI"U.@4U>N-;!/.6L:]F)-PF\MDY7*_'Q
MT1%,'+R0?R4NU1)_8[5'Q[UXT;K 5.7U_M;M!I>ST2.8.*96ZC=E8YWJW:FM
MI>,D*I#O*ZK2I+8)IEPY95JZ6ZHSLM<(FRZO<R!T_:5]6[WK^U-%U*E99N>'
MMZ\O49)SW6X^%U3KNYEB?''AYJCC,=66I/MZ_N4S2ZU3KQ;YJ5=.Y"]DJAEO
M:6:L2*JBB3R<C6SA2&8RJQEI,E=0CH9X^?(1C-1.C6M<>)*W & 0CY1ZNWG9
M'#?8%*O%DGJYKXS:8:\=Z6HC27VRVJ\-/05R:/=BEFF$F-K)'39)C6R'EL)6
MHRRPK()UO(J/6TM"")O^<;=/*Z=<D/G:&X742B&I-CGSR5E]P#&%;ZFB9YB:
M#>5:NQL.X)6$]BP<?(+UNY;1IJEAM$<WOZD<TD1:2!?')*R[=68=!NQ\>'//
M=K,G;@IMJX7"LT&MRUON,RR@*Y"-P<R4J_4%-NW(=0B"*92D*=5PY=.546C)
MFV36=O7BZ#1HBLX622.!51S1Y27JZ0*FJ-&M92OLK95-6V9Q<Y%]:Z#?IZ*V
M%L5[42UZATY>NQMMEDHQ6$,CM=O$3U-V%7JA8TIBI'4D442KA_5OF_M;QW$H
M.-7#K7.J8FEVF9I94-@0U;@(UG'SDZ6\A1?:2-78Q4<PGUFK1O9YNK-9*;KL
M-LY]%-[W)5!\C"3LJ_2;@."8*G%-:LI-S!1@# & , 8 P!@# & , P9N3>T3
MJ-S4Z^UI]SV9L*^*RY:;K?7[2(7LDRSKK9!Y8IE9Y8YBNUJ%@H-%VQ*_E9R=
MCVWE<C&Q[47+]^V;*!KB5+6=ONCM)5[30W\O'Z\I4+L>4,CK^VZTDY2-3UJS
M,O5%95]9F=@@$IR\-IAG;M>[:U;).XB<IKN;"2K3SR&/A+%;)?7'GZ^8POU]
M^%OQXEI/'/B[0.-4,Z8T]_9)B7G(6JQUPL5EEUY.1MDE4HY2)CK%*^.$WAS0
MQ(M8=5\=15VO$1$(R=N'1HU-P>@DG@# (.<I-<\A)28B]G:YL![K6Z BX.;C
MQ$+O*'-7:-FX&;KUTD8C9+&P,SEV*PC95-[K5I,MVM4:2#-TVD!3E9.,L]<
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M,22-BF"SY))FQM=FK$:N^J;3:;V'97>?JID(Z??O2D$3!KD3#P!@# & , 8
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M6=M0B&]@EY0D487PG7'YXX+^5)\         '0  .@ 'Q  =P!@IK@# & ,
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M<FX[Y7M@[2NM9IE$%>GTYS1J="4^A.[/(PZ+&"D+';)!S/2,G<9U],S+R8.
MI*LXN/:LV3+^R!,;\K9+G>_+#!,"4>"C & , 8 P!@# & , 8 P# ^[-!0.Y
ME*;.!9[=KK8FMY-_+:_V90GL>SM-:5F&81\]&F0F8V9K\]7;"Q(BWG*Y8H:4
MB7QFK%YY.E(1S!XV W7J35=?T]3DJC .9.4.O+SEFL5BG%T7,];+?:91S.6B
MTS:S9!JS]LIR7>.7BZ$>S8QK,ADF,8Q91[9JU2$MGOUEX+D9-P48 P!@# &
M8LW+KJ0VC0WU9@[<^H5E0DH*QU.YQ[!G+K5RT5>993T'(K0T@(,9F/!^P20E
M(ET=).0C5W;4KALHJ1PD!MC3>MMAUAU:;5N&Y5.^[!M*\*BK(TVF/J36HJ&K
MK%PRBV4;#2UGM\B#Q91[(/9-^M,F!=1VFU1;HMF:0'#7B9Z .G<& , 8 P!@
*# & , 8 P#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cntx-20211231_g13.jpg
<TEXT>
begin 644 cntx-20211231_g13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1PJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ' Z^<8(X0DE-! 0       \< 5H  QLE1QP"   "( D .$))300E
M   0KR]7_,-/(S&XDIJI^;[;*CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              Z<   =C          $
M                 0             '8P   Z<
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   Z<     4F=H=&QO;F<   =C
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   .G     %)G:'1L;VYG   '8P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      1IP
M  $   "@    3P   >   )0@   1BP 8  '_V/_M  Q!9&]B95]#30 "_^X
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M[<4_VY>P39DX.CK [^=:8K'OV,<'.LLK]_Z--4<]H#R.I/VV,<&.=C
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,CEWD96AL\;5V/ F0U*!@I/!\1DV0D1&8V=VAH?AM__$ !P! 0 " P$! 0
M           $!0$#!@('"/_$ $(1  (#  $# @0#!@0& 0,"!P(#  $$!081
M$A,A!Q0B,2-!\!4R46%QD8&AL=$(%B0SP>%"0U)B-%."%R5C<G/Q_]H # ,!
M  (1 Q$ /P#^O'L]<MZN^QM%]1NO<EB%926SH-8UMSFW)C$LSW>+P.O7T=")
MAX7#E3(,68E,@/R1HDNX-O<CQ =LY=:M'3E1+"75\+QW&5P_*<_RR=&U&+5B
MX_+@SZ:R>OJUBYI,T:*4UBT)2@NU*"C8TQ&B&JNY0\ELVWR&'BL#4YFZD:=;
MM3DWHI:<]J"@4GS6)M8QM=[,ZH0&[JBO[:[[>\1?N5384A7R,=@MNWG1W=>-
MTG/LPZ+.@XV]J@(T3);V1WC0!V8**PVS2D;"JC7; 40+M6L@;-T131]H_P!&
M&W7<=T=TYR+0V'HU<=Q?*=,MY3+\SHIA<3R <HKB_'0X$A6G"#V4=,( LD$5
MG86-W.>V=1<OC&\XJ3KW8N:5AT>DJUCNRGB+=W2!F7I:"6-CX"1UZ@B(]Z/V
MFA;Q/=WE+]][WAQJ-R^&UH0I<)U40]WHL5#4DNZEJZ-Q())<;N4EWSQ*S9MM
MK(62^[9Z%&CRP]U[/N+<*)UH]$^/)=*\5H6[-IW!R+N=+R(Z4CC.3VJU.35#
M=4/R.2R20^0N,@(>]%52=_S+WQ\[N22W)REC#C.U4/J,W8LS$K9=E7E?S.BJ
M/O8^ T0WVL"NIVZC]^8<=H8F4[<7%25=6O5MRS?K[94B>S6+0VO)7.XR\=%0
M!: OSA=HS)"9A EQ$C$ZM5LJ.L:EMD6R:3);1&KY_I70OE17T]QW)Z^/W<?G
MY?$D,S]&S/D=5 U6NEK(@/-I$T,\ZKQ_#HB[G5W,XKG5%@LN7V8L^S+K;Q^H
M[<M6=VE=V0'GLRJB%Z?%H#7O^]55V&0;%^WO:,OWM=>'VYD-9[22&6$4M^46
M^@VCV')GJAL $&XW7;6%Z%-]F=Y.S$A: 9"^]W-6[&*LL3AB$78.TW"MF[IW
MA Z5KJX4[/0TY0XU''7;^RNH*:Q;]IZ? :+C*4KUU!ZMV6EE9".K Q&&OE^2
M+G2X F9_40Z]K=?9?=G%$(DO.*?+Z=MM/TV7XU5(#UQ&[+VJW4?B1=J)Q9%<
MQV/VC%;*L>8=G)97#_JZGU=FP'&E*1*USD0EEA#.PZ)AG"M]X="QJ,C*N_5D
M&XPBK@648K.D5FN]]R?1O!9,FQAX7XL>7A,^NN=OF\SCOD]''JT9\C.(M9:*
MK5J.TA5>'J"/FLQ&ZNJC!U)RNC2A8Z5:=#N2=G_9E<7H4/R2=C$-TAR/G2/P
M4!32N_*A*_3(;.ZJ;P;G[-P6A9W4$1L9F7$ [A7GPT;8V^!^D)C!V!0LA8"H
M:5NUWR+]@YD$:"2%S'U6K%Z@[< WK1=1LKLVPM\PX[A]?*9>1?CM;&\=60V9
M*\[T-3KU!CIJ*H; Q2]J ;1&!5ZPV(W5%V[G7R*<3\BGT0!KMXCHNQI*S0DM
M%@R[*BJV*6T@NJNKM=U=U=UWH4?\9SK[%V5?E)!7UDAADJK*"7)+UC!.K09*
MM:WM ^\#P$T1CAJPV$BFQ$N);-YP0CE9C)>:!0D@T+D&NKC;8?KU2OAWS#BU
M"K3B9:=NOC<WIAN:&W;@2+-2UM7C)6=:V%>4';3S*;I$@ ^PD0T1]7\>NDVQ
M.@*/-GV/\BSB63/K9X9S8LGBUI,'\:UY@<:T_4RA[C19K._%0@L#:W_(7U$7
M*[KWKW:3FCY)9V'=7BH,5MC661&,,XVU+&[!'*@@ZK68,9.1FTM:@8D$!(*Z
M/RF#*S02XBYNB-ND^(2')\;6SF, \HG#0[SU+PWGT/)I K&P6,HLYI',@VZ&
MMNO!=KHF5N=U/F2'(-+'KO/QVN\+=/?,*#U>LI-+$C>-@/9PM)S16D%U=DRK
M[5)AK#OG!++)=9PZ$&E0<CV=(W2+B:B<AK69 !"U'@M9!('[F75[-Y7&3X,^
MSVU^%BT4)&4GN=L9?I#/+?&E?LZ6V9%\VV]69@<&'&,T5Z.[.UE<HVDJ 4;,
MN=ZF)._Q@>M5U5=@(^]7<Q'-H>?&!26B7*'L!/XF9H!>)9,81,SO<HP,1_#)
M1G5W[7VE<7/C%TIAK0ZPVKK&>NKX@2MD@QA:34S!WK2.I6(=K7W<+WG]GQ@?
M.9IL8CI EM#H4_,%40>S5ZMZ"KI-MRYKX>\I1<J)[<0CQ6NL336KDM(DV\:M
MGJ&.3#H/+F]-HC\SI%2[9Y#7>@(JKO\ F[%=8;'/HN]R"T+$CRJ*ECI9FL1]
M;0NG.\UD5)3;#L;'V[E52R_=V^[.J410\!I3$6'6IV7O.-4G%Y;.ACTS%Z_:
MD@<@E$AF3X R?B5I$2%A8XY;@X^H4'MWY9XWV=N-FS99JYINFN*Q<@?*Z^3]
M<L'"\4[E-&?*8*?K('(SHS"XQ,4@QSP]5M 9"JC\:\BHAL>9WZ,@X49/3'5R
M6Y>%+7@;%(\EM<QIK @([%23I868"3+&B*A[S7SV+[E]S>K ;M#29R8UK:UR
MP"HZ+O"D+=:UXG#F94#9_8B-T>?B5C0/60DP2)9@1?NE Q8,39M5Q;O1T[1T
M>M=O1ZSA>F^G>=;P?)AGV\?QFOD.5XWE./+9\R:G8.'=RBM.+32E-M1@->JM
MB[OS"QHO _;G^2YGF>+7R6.VYMFU&7!MP:O0]$35KY!>$TZ4>H8TP"LK P,:
M(;KO7D)7)8I+Q-M+)LR8F)AAE ZRJ?H\6NB[X(0'Z:S&J[UKNUY5";:A9=XL
MJF]QD&VCWJ0XER@@N2:NQ!?337)5%+E?R71%XL&5>:SU;>0ZGKC.-U 5_+<A
MQ6O!FT\?J4/C8_BV^K8=7?IV+%WVM=R7BZEK1LT6[LC-DX3YW:D@[-R[4ZGI
MUI85]KKTZ3V ;[4=71UWHAG'T \1DU840N+/=>;4[5\I@S*K[?''L2,!%(.-
MI:^@05W"!1@T5+:#D)/#9DZ?U[*?;W;9YI(UA8Q9'=XX34=>NJND%9-/'?\
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M65O.A".Q@!K(V#X3-ZKF,VAA=!-EART+H-C.'H(N/?BB;=!TV4UQ7<]TULX
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M>7E]):]C&-M_<]-M+\-O:JH:[&#+[W//[!P>NS0-- F;\7(6($ K%^!-(SB
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M1E$*;:,X;)'\0C[P_$F:6NVJ;6,F' Y0B!;)Z[;:Z("G+1+37;;&NF,9SY^
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M6)$I(RR-D1%^1;BDWCQ\>'9RP-.W"RC@HRSEJ^470_P?,'R&]BQ4S;K-0"L
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MO/O?_>.M_P!__P#O_P"]]_\ _P SY8[_ '^_M_+_ $_7^M1'S>V[^;][>?\
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M)8Y6;QN0O1Z 7 3K!80 J#)-A,I&%'  CD2XCQA@5<HEKX9V"!%J4)W_ &6
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M])V8H[K28)SH U<V]9Y0>M(&P4P"9J$FAJ6$]5V2#,Z0]>R0RU1)Z*;#C&"
M-T2%/IX<MK!6E(CCH=><LSK'!A _1)@,*@-><"$K)8]B[]P_?"Q8(D,2^.SV
M:666F[0SU0HMFI@V= 059"QQC=51E]/;L7V+N/<;XNTW7\+VDHF:T3(R+<8
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MJDG ES+)!KO/("IJI$'RLA'@YT@L)*JFF+<85#,FB)7P_P!^KXF+Z>1*0W7
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MNK&+5#8P:U*S-V?"I%&8')IG*X$?$L8O9%6'04OBI*Q9PV46W/DPDB#G$V)
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M)%6,5)DV!%"<5 $I>T)!9T2(X9F0R$)/B6C=^?8*B^(D[WQV8K_KQ!@5JS=
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M6<(3JJPC1B2C5G<;0BD7(RI8F@%15=)HGZ']U>LY4D"#,K%<*%C\D!Q)$:K
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MG[7^*&A J$0IV@U*$)"?-2F2&)Y)S!@><-22<:$-@9LB5?"!P<2FX;ZA&@A
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M 40C\G$E03_W5OA$LMU7KF\XNT[,5_:\KF80T^F+;6NY8 ,S>:Q$9$3-?"&
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M(-M8:4,RWC=FR2P@3]W'VY)-B8E4" Q)Z;&[ &LB5+%HVU-HDY6;V(I:G2*
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MO:Y$*;XV5;AE4'^NB>5,*;.]5DVK#&GMY'/NYLZYHT")K\2JK[FNJJZ._?U
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MIRB>?%^@\9@Z[?>,75<FPJ-R K8-<P<_]RTA!8-;CRMW-:"[*U0%UB"F<L(
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MG8]=RVF9;8<H<2542JB!8!K1AA65L!#T5$F*#T>N1>(FZ#B(XB.(FNWQ9_\
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M@T?:CS-@V!/Y6*;L6<DU;:(F$1[H=U5+%S)H/)YY+9<V>4\1'2M2Z3TIF$"
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M346CNQ<EU$JK>VPU8%?>FO"KJO4[_28G175=D^-6NJNRNVUWKTQL;.Z[WI/
M+^$ZNW>5K9@XEI@95BI94Y+\C$T1,_:%-:O27@"%WC,1*]3!<&03R'L23#!*
M1LL\=/#(PQCT6?R-&0&'B0X<(+Q[U9F//G#Y713#7*!]B,V052T4<X<>JPU3
M4<Y2TS[Y=J4<9M>]R\ZT9S?ZS3I8*-->HHR.Z*@\6B%B7:RHO&PKS\9$^'F+
M?R76_3'&<;QVOE]7*<MFXR^,PYCV:MV7D;O%R&964&*O1ZN!^D34; 2:_,7E
M2;9.[2EXU;V$@K&Q*BF N9Q9VNLQ4?C/:$MV!1KHCN\%$F+U!J_&D&N%T=U&
MCUJ@KE!9!REKNV<(+*9XOEN.YK(&[C-:MF8BL/55Y50L'MY 8&(,68]ZNP8
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M8S][S^_GB/Y?G^OU_.5_V[(3K.V<IT/9FVF?ITVQ%CF<;:Y^K.,X9??Q]/\
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M[#175=R]K]J[][]OM^4^FE?B)%VLO$;OM7W+M7?M7\[^U?SG\[[&_.U0KI1
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MZ TO';SAPFH[+DMDCI/%3MH#*R),R,@94X.;OU8;DGB8R205"SN"+KQL>73
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M56A@K.C8W3Q'%HNE-*K$R4DO:"VQ 3A#0,D>T%']\^6D<E#$E$9$IGS3QGU
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M<=!HMWOV\:NNUTKO^9V'<_I[UV'[WW[R\/GCZO/Z<_5C\/E]?.,N^WZ_7?\
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M1ZC=U7T>T^?Y#B0XSEM"N+!V;D4YTZ/VGPANX;C=/R.5O#[0<EXIY5:M3 J
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M$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$J/W0_:==_P 8(?\ /C/$Q^=?TO\
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MDM[(N!51]ENPTDKNT[E@+6;W])>OU;Q:8GXE NJ=AS3X49Z2:@0-:"A.;2"
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-.(CB(XB.(CB(XB?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cntx-20211231_g14.jpg
<TEXT>
begin 644 cntx-20211231_g14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &.B^8W8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!ND7C@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              HP   8&          $
M                 0             &!@   HP
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   HP     4F=H=&QO;F<   8&
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *,     %)G:'1L;VYG   &!@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      .@@
M  $   "@    1    >   '^    .9@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M<\GU5)<ET;ZF](R<09&?A8Y]6'X[\3(R7L=4YK7,?NO?6[<Y='T[IN%TO
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 0 "70,!$0 "$0$#$0'_Q  ?  $
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M*=GTZ](#6V59H*U8),,6TNJFBVF;"HWM+1ZE$0QWZS5LB;OH9@J]BTGQ1?\
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M$31%1INOP=D:E86"&B9UB54JX,IF.9R;,%B 8I%@;/45T@5(!CE(H!.>4#F
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MN62U1KN@2455UJXF\*QPY8'$K+-;<[F659F:A!EHP3-YK<VM7+&:.LU.8SD
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M!Q%[$AH%SF5DG5FJZ:(FB)HB:(FB)HB:(FB)HB:(K9M<XO7XTCY!%)<YG2:
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M.9&Y8ZC,@ EE"TR23 !E75/JK9T10XA'E9-9.R&:&;\# Y[I,JLY!ST@="!
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M":ZH=&Z9K)B!N)DQ'F\..Z<4-/B6GNBU!6,;)354/%2QDO8"SCIW$> =8"X
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M+9E:5I'HS5XS6PU5/44\;8X#$6S<8#?7OD8V./D-L[K7%['2W,]?YNF#//\
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M*<P3* 0AM=TJX3<+Q[ Z_"H,/Q&.6L9&ULTYI!$PMGBDS$;G/O9K@"#?.UK
MWRF#:(UV&XC35DU51R,A+R61\>9""W5LTN8UEAML1D;F^Q>E(.H ]P-<7'D\
MGR+H*YU*)HB:(FB)HB:(FB)HB:(FB)HB:(L?9)_0^G_RBW_Z)QV^C61PO\*/
M^RD]05E7 &$7%_MC/6>58'#L#W ].M@!-MI]7L6*;^^_UBL8YFR*?%.-;+>D
M(D)U]%!#1\/#J/!CF\G8+388BI5QF\D@0=#'1RT].QI)*1!JY,PCQ<NR-W!D
M01/#GN:TN!!-B "=^XVOUZ%Z &L+DV)L=F0WG.VX99[>E1\ROEG/F%J>I+W
M<4R02=TQ=6X6VURIY"?LXP+Q:S5^P,9/&K"PS-JGEZ\T,SD(F5@[*@:?4>+-
M%:[%FCA.^HR231MN1K$EMK7)L>4#Y;<O,O;0V1Y =8-:2=PRM;/VYK%)]Y=I
M5BJN9:5H-;%W?LL4Z?N;_&F5IU@+/'%=K-A9RA\6LY6*R'1599&P*@Z9V]RJ
M5M'L&M@;K.8.P0[Q;P:F36C%[$NS&H3<6R!L#;;;ISO95>*&J\V#O &J0\-
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M@6SY I9IKC+I(6N[##9)FQN^T/%@0"2?"Y]US\J]K)!$Q"&'@(B4HB(=@B(
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MM7.C=#R]M*;/_P %;FLEH5^VT^_[CJ<O15HSDNN1?_\ E[WR=?4X/[_\WF
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M47G7*2@)K%0Z)%'F(E/SS'U_1G3_ !+1BBDHJ6CHYXY:EU4YU09=82.:UEO
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MFDD:409-I1=JH50Y54 0BGC*777<)I-D(AZSE55B1[MNY4(LQ ("'$!X@/6
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MHT@Q'":Z*"C,?%OIQ([6C$AXPR/!&9RR Z+]"U5>ON<H*'[-L<#[N,:_Z?\
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M5YQJP,W8M#LF\M:4&AFL6J9Q%MQ:ID*@9"-<&,LP1$@ILU3G4;%2.8PFO6\
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M%I3;A0<A"@,(:K&N@.1D JHQQ7'@Z0SOO:=V64!T'><603(A'B14@^Z7"*<
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M3TV>4NK)G(UQ ]!R$BB[:/W+QHU4=O5ZJFQASG<,'1#H33F/<(%(15=)))=
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MG]-IVLJ_Q6_"_0G9T%[?;/@'S[;IXR*WYWWU,3^FT[65?XK?A?H3LZ#^</\
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M.WS=NM*X9?VEPC/_ *T=_P M)Z^CE6<T#MVSKLOXD-V_CX[[1<=&Z]NGV#\
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M]Y>SR^?54@;=8;=][^46NO#6D"W("2<K;?ESV6VKD3!Z!ZA^U_)U#U\.'VM
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M$J2+",6ML>_B[8JW024(7I;2PE)!O8SJ<\\X#Q=24,Z5.)].QY]T$W+^Q/\
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M?F&63*?F$ IC&YHF W-*4Y#&-PX !RB(@!@XD70CIZ'ED!<1\@V<) YDVG.
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$B+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cntx-20211231_g15.jpg
<TEXT>
begin 644 cntx-20211231_g15.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M+6M1H_+AZ[*#)F0"J&>S/GAZ%> . . :J5.YO8'WL.OS6)4O,YC9<UIL.ZM
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M%(\XD-)"SX/T49U^!+JR)X,-RW;U]?!=2CDIBBJAJG^.S$?^4-X+_P!RK?\
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M1&RTC+PY: U\1T>KWI"A,1SUQ<J*Y<5._P#!X\+WZ0-??>,@OXGS"^87B_\
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MU/#^.5[XLOJ__P !./K>M_)<?,+Q?_8VMZS?\(=]#QJ>,6%ZFA_''Q9?5_\
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M5!,PG8+0K&SLKG<WD$/,(!9,P0+PF1R:RIB1D<*(I.8J?T(,1Y<0\&1Z-LQ
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M'Q,?:_Y34C];I?\ I]P+BZTZ]P^)C[7_ "FI'ZW2_P#3[@7%UIU[A\3'VO\
ME-2/UNE_Z?<"XNM.O</B8^U_RFI'ZW2_]/N!<76G7N'Q,?:_Y34C];I?^GW
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MGA3&-L"S7*JXTS;C=CP7' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MUA3;7;.F@^/@89&A:&NFNFF@^*P.)1&&",9UV<J"(VQ7(N'I15Z_="#)/ '
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M4G7O/3GP>HX X X X X X X X X X X X X X X X X X X X X X X X X
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M;5KX='A$XM!&9]A[#%SY[9#263M>-TB(['AHE%'T>)QIUHA&R.:"D)N?#E9
M+V'RGW%X4=F]9-J.A\\$I3&N&K:M%]Z8\^@Z >W/$(8-X^M.X+!DAA<8R7E)
MZ)T;.S9"O7&U=T/*7"S6 C[L+'K V=6#8=GUAJ($OQCT.RKE29NG!% 289%
MPT>W\DV=LU#-6'XA4]< @#BLF]7(J6Q0C$@<CH%^]_\ D[-G?+>KAV03LE77
M5.)KMB\#;+(M6+@E&18ZXHT2UQ8@8#7X8:]'7T9LZ]6&F[*IM[Q!),A!2%A5
M76L937E8E">AA,*L3=XV#$I9UNCYX0Q)2>3QG#!W"&$\[ E\RMB'F,7EK2L
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M%9XS/B5]B_C$_?E[+NYG[QWA>]K^PE6^DJNCP?N5N"M](1M"YCI[F:T#>UU
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MBL_#.$T5,Y5PV+0Z;Q<V@FXT0?,]2>1Q5FP+,GS!L(I3MYB_N . . . . .
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MN4I$L :*K1]JVIQ"#J[ABE.E//\ R\W.40M#NI4K1"P$T/GQ&,%:_2AR6ZS
MT('DA$IN:1TS#99'IH%<!!X]+$@MN>,!PJ$[:#1D LH>L1 1^.-8Z-T#&NU,
M?.E*X>U=--)L#KZ#L:]CJT>8.EWJ;J4SR7NG"^N-,[EK$G4CL YHBGYZNZ3)
M S)WZ Y)9=RX18)-DG+MVOHHY5$%[< < < T,_M#_P#L5UA_S10K_I/=G!1^
M9.?W*:=/VR/_ /)O#J__ '_;7_\ #ZT\[S@3_P!9_P#LO_MG)<+/^@?^Z_\
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MA0$<Z!)MA14RL%MV(CG*K:NB)>HBIBVK=2DGOV=KPE._'0KN?:5N=IZ49UO
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M4438ET1KLF-+CV1:(J43'^>!-/@@< < < < < < < < < < < < < < < <
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M#JA"49$J.V9!811->BN=,]/<N%,^E%T%,J/N/XC_ +G^M\<N?KA*@3Z4S(=
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MU5/1HK1%/3TBZNZZRGFZ2;77SUEE%%E=_)YRBN^ZF^<[[;9R!R^VB7R1D/\
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M!L&HH.)9H#QHYDCJ@T9,VJ>J2#=!+3&-=$TT]<:XQ_3G]^VV<[9SG(%2X X
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M"]'.KY[HMJZ5$&7^ . . :&?VA__ &*ZP_YHH5_TGNS@H_,G/[E-\W!<< <
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M73N^2F]2+4DV6BK=!LHJ$$84VUIGS]?N\YL>X(' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M=-24C'2V70YV^Q&0\9<% D5)EQ@.2*'T!TJDX3841R(7MVHA,'@@< < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < U1=</_K/.]7_ -G*[_\ ^)JG@LOU4\WM>;7>"I;.?_SRT_\
..LRK_ /[5'@%S< < _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cntx-20211231_g16.jpg
<TEXT>
begin 644 cntx-20211231_g16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1UT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '5B^=1(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              I$   ,6          $
M                 0             #%@   I$
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   I$     4F=H=&QO;F<   ,6
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *1     %)G:'1L;VYG   #%@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      2\@
M  $   "@    A0   >   /E@   2U@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MUQ_O#\W_T>RRW?KM_P#7*9KD/-=^O9'_ !@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  #_X4%.:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO
M(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM
M<"YD:60Z-$5!-#1$1#$S1D$Y14(Q,3DV1D5%.#1!14%!1C4W.30\+WAM<$U-
M.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI
M:60Z-3%!-#1$1#$S1D$Y14(Q,3DV1D5%.#1!14%!1C4W.30\+WAM<$U-.DEN
M<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M-3 Q-S@X,T)&-3=&-S-$,C$P.3A$,C8P,D8R1C,U0C<\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C1$030T1$0Q,T9!.45",3$Y
M-D9%13@T045!048U-SDT/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3,P5# T.C,X.C,R*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HT
M14$T-$1$,3-&03E%0C$Q.39&144X-$%%04%&-3<Y-#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-"TS
M,%0P-#HS.#HS,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4P030T1$0Q,T9!.45",3$Y
M-D9%13@T045!048U-SDT/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3,P5# T.C,Y.C T*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU
M,4$T-$1$,3-&03E%0C$Q.39&144X-$%%04%&-3<Y-#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-"TS
M,%0P-#HS.3HP-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M4F5F.FEN<W1A;F-E240^>&UP+FEI9#HU,$$T-$1$,3-&03E%0C$Q.39&144X
M-$%%04%&-3<Y-#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T
M4F5F.F1O8W5M96YT240^>&UP+F1I9#HT14$T-$1$,3-&03E%0C$Q.39&144X
M-$%%04%&-3<Y-#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#XU,#$W.#@S0D8U-T8W,T0R,3 Y.$0R
M-C R1C)&,S5"-SPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H
M;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @
M(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-
M;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#
M<F5A=&5$871E/C(P,C$M,#0M,CE4,3$Z,#$Z,3 K,#4Z,S \+WAM<#I#<F5A
M=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP-"TS,%0P
M-#HS.3HP-"LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C$M,#0M,S!4,#0Z,SDZ,#0K,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ T@#] P$1  (1
M 0,1 ?_$ !X  0 !!0$! 0$            &! 4'" D# 0H"_\0 61    8!
M P(#!0,&!0X)#0   0(#! 4&!P 1(0@Q$D%1$Q1A<8$5(J$)%I&QP? C)#)W
MT1<8,S8W.$)28W.UMN'Q"B4T0U-D9:*E&41%56)R=82&E<+#X__$ !T! 0 "
M @,! 0             $!0,' @8( 0G_Q !=$0 " 0,"! ,%! 4$# D'#0 !
M @, !!$%(082,4$346$'%'&!D2*AL? C,L'1X15"M?$D,S4V-T-2<W:BL[0(
M%B4F1&)D=8(G-$53<H.$5&-E=(62DY2DP\32XO_:  P# 0 "$0,1 #\ _;?=
M\ZJTZYR%3+622!6*+%8'PRYFWM/?FB3L2BV^S5P)[/VOL]P6-X@#Q?=W\.ND
MZMQ<VEZI-IPL!-X21/XWO/AEC+&CX*> X'*#C(8YQTK8V@\ C6M$@U@ZK[L9
MI+B/W<6?C<G@2F+/B&ZBSSD<V.08&V2:]66=#O/" ULB>_?_ (V,80_\/+M]
M?Z=?8>+6E ;W' )Q@7(/3?K[OO\ ' ^%?)^ ?!&3JO-CK_8>/_Y1^_X^52=M
ME$7  ;[' N^W'OYC#Z#MNT#S^G8?AJQCX@YQGW4C.X_2Y^9Q& /X^=54W"GA
M9Q?<^.N+? ^OC'[\5?4+T"^VT>!=_P#K6^P>O]@+O_NW[@.I2:N'Q^@QG?/B
M@8^/V#^>G2H$F@,G_2,_^Y/7_P#$^?PJZIV<%  0: &_^7W_ %I!VU)74 1G
MP_H_GZ<OWY(J*VE,NWC;CJ/#Z?Z_YZU5%GR#_P QL/\ G [>O\G7/WU3_,]/
MUC__ $K&=-;_ -:/3[!W_P!:O7[:+_T1?/\ YP?+O_@:Y>]X_P 7_K__ .:X
M?R>_^7_J']]>9IXA=_X$!V]%.!_[GXZXF^4#/)G_ ,7[U'WUR&G,?\8!_P"'
M\?M?QSU%4REF*3?9L [?Y;;U_P F.X\<A^.N!U!>T?\ K_7HI^7X&N:Z6Q_Q
MP\MDS^#_ #_CM5K<7<J "(,"F] %R)=_K[ 0_< [ZCOJZIMX.3V_2=>G;E/G
MCKUJ5'H3N1FXQZ"+)_VG:K&YR=[ !$(@IP#_ *\)1^?_ "7M\=17U_D7/NV3
MV_2^H_ZF:GQ<+>)C-X5\_P"QP1WZ?IAG;T ]:C3S-QVG:ND5 /65,3U[_P 0
M.(?CJ!+Q6R9(LLXZ9N -AC?'@';?'4[U:0<">-C_ )4Y<_\ 8\^?3-RN>GIW
MQG;,<9]1*[ZQP,"6HID^V9J,BA=!-G-[N60>)-#./8!%E]J*(*^T]E[4GM )
MX!.0!\98-OQP9KZTLOY-Y?>KJ&V\3WK)3QY5CYRO@+^J6!(YAL",U87/LV6W
MTR_U ZR6-E97-YX0L0/%]WA>81A_?#R\_)R\W(V,Y*G<5M"'8-; K5M-*4TI
M32E-*5BW+.20Q= QTZ:%/.$?33>&%JF^"/%$7+-\[!R*PM'@'*7W$4_9@F01
M%4# H'A$IKO0=&.N7DMHMRMJ8[62Y\1HC*&Y)(H^3E$D9!)E!SD[ [5USB;B
M!>&[&"]:T:\$UY':>&DPA*F2.:7Q"QCER%$)!7 SS==JQA&=2*,D4I@J*R(#
MZSI3[=@_]5E]?7;CXZO9N"I(3C^44;/_ &9A_P#O&NLV_M%BGQ_R3(F?^V*W
M<C?^QAY5,6>9D70@'V"H3< 'F2*<.=N=_<0]?4 W#RU6R\-21$CWM6QO_:FS
M]#(?Q-6\/%RS#/N#J.IS<J2!D9V\ =/KZU(V^24%P#:*.3<=N7I1#RWY!J'Q
M_1VU$?173K.I\OT9W_U_4?GK/CXAC<;6Y!WV\09^G+Y]=^V/A=TKHBKM_$3%
M_P#F2CMY?]"'[_7; VF,,XE!Q_U,=?\ Q?D[5)76$;/Z+'E]L??M]W7Z57IV
M9$__ )L(;AO_ &8!]?\ )AZ;?/6(V#C_ !@/_A/[]NW7!WZ>><:DI_Q>W_M=
MM\=O,>7TQ52$ZD(?V$?JK_\ SUP]S?\ RO\ 5/[ZY_RA'V0_-@*^#/) &_L>
MW?\ A0X]/\#S_<-?19L3^M_JG]I'XT.H(/YA_P#O _'H-OVU2J6A(F^S43;?
MY< __4/[=<QI\A_G@;?Y)_?CIOU_$9QMJ0&2(\@?];^ ZGI5O6NR*._\0,;;
M_K(!]/[ .LJZ6Q_QH QV0D>6/UA6!M91?\42<'^> -O7&/+OM^%E<9.1;[_\
M4G/MV_CI0W^'_)QY[:D)H;O_ -(4=O[6QW^3?'K_ %1I>(HX_P#HS-Y_I0//
MOX9P-M_X5&WF;$FNX#7U#[<\2A"_J8&'CMV'M]=3(N&))3_YXHSTS"3U_P#>
M =QW..]5\_&,<!(-@[8\KE1\-O!/7;TWZY%0J5ZG$(LAS#3EU_#Y!/E3$1VW
MVYB3 ' >8"//.VK.#@=Y\8U)%)\[4GOZ7'[*I9_:3%!_Z(D<Y/2]0# SOGW9
MOS]*SY0;6%XJ$):P8C&A,MUEP8F< [%N"3MPU\(N 0;@KXO8>TW]B3;Q^'8?
M#N/4M4L&TR_N;!I!,;9PAD"E ^45\\I9B-F _6.X.]=ZT74UUC2[/4UB, NX
MVD$+.'*<LCQX+A5#?J9SRCKTK2S-P &6YL>PF:PH;[?]EM@#?]_/6A^+1_SF
MNB>C16@__3QC]U>FN!!S<(6 Z8N=0'7J?>22<=-@<?*M4L]=5]>Z93T ++BW
M-5];Y$LT)2()_BNK5VQ,DKE9I5I"5>L2:DW<:NHUE;)(NR(Q!4DG#50$EC.W
M3,"E\<C2;9[M).2:"-HP9&69W1N15+LZA8G5E&,$@G<G;(.<&MWPL7C5[>YF
M$T@C5X(T=?$+!$B;G=2'=@,#E./QSJRZG,#QU>CK%9\O8TH[1ZQE'CEI=<AT
MB >PCBN6Z&QW<8F;%>Q*,&<K2,DV"&QK<FZ;YPE7\@23"HOER33UFU7MX(;C
MG*)&[<I RBNP/,"ZD?9QRNBET8_KI@X&=J*>XM2@D::*/G!R))(PR,A"2*_V
MR T4C*DBAB5?KYF^U?J_Z5K+#6JQUKJ8P#/U^B5R.N-WG(3,>.Y2(IU4F!,6
M)LUJDF5C795V!DS$.5C+2RS-@[.02-UU#_=U8K%<H5YH95)8J%:,Y<@#(4 $
MDD;XVZ$]-ZII)K1PY6X@8*H9B)5(52=B<-L"=O0[>53FN]473K9I/'L'7,^8
M7GYS+46XF\5P\)E&D2LIDN&9DG#O)>@QS"=7=V^+:%K5D%V_KZ$BU;?8$R"R
MI#1CT$)@$R!B8I%"?K%E("].IR "00<>H\Z@.]LY0++&YD&8PK LX.1D# /5
M2//8U4/NK7IEAG&2F<MU%X*BWF&1:!F!I(9;H+-SBHSZ02B6),BMW$^16E&>
M2RZ,4U+9"1IG$FNC'I%.[5(B,E?&^P?"DP_ZA"'!P 3@CR )!QY[>41S;@L/
M&CRGZPYA]G<]<$8W\@=_EF"H]=>!WV:Z;@J$EY6S66_NJ2WJ5EK*$/.8^FVV
M0<49@S-6)>.M<?-JH/X5]2<(W%P238-G391ZX@$6IG+634>,\W*_AO*1@(2&
M#'#;,%SCXD?QK 9(3,D*Y<R<O*0/L'F0N/M#_JC/?'3M@;:G?"("(#P/QV#?
MOZ@'U'GUWVU%:< 9'X']H\_2IJVYR,[#(V!V[8P!MGY=JM;A\(@(@;<>1VX^
MNX[]N1$0^@;:BO,/M;CX?/T VWZBI208Z#OUW!R?@?3IMOO\(^Z=B/B 3#Y\
M^@<^NWRW 0W\AU$DD+9)(P!V&/EN3W]>ORJRBA!QM^WICI\,?'L#42D76X&
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M5YC=O=(S+T<+S>'R-]EL9.!A1L%TW=$-7Z?\J/<S?GY+WF^3]*R!7;4^DZ]
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MM^P>8W.WGYU>D'H@&WB\7'GL \\^8^@!MMOZ=^-2DFZY;<GT_)Z=1DU >#R
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MFU8=_'C/UMX3_ ?"O4/L_/-P=H9QC^QI!Y]+J?\ JZGXUHEU-K^#-]G+MO\
MQ2O;AZ[P,?Z?[.X_ =>3N/7QQ;J SC]'98 Z[VD1SCY8^&0-Z]U>RN,MP)I9
M[&;4NVVVHW0Z^?U&W8UB=DZ$ #GGC81_$!#;\-QW#D.0#778I#@;@==_+O\
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MY[[;CIT[8QM5V3? (?RM^P]]MQ[#N [\;^GE\PUG$OGE=SZ?#OOGSVW[5#:
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MG(W(\]\_&HX\?#][[P;B&X!OV\@';U'X<=MOA-CB"@; [#'S_/3ZYJNEFP<
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MS'D?0-^?7?SWW#[O;4R*$GJ-^H'?MCL1]?A\:Z:XW('7\_=UZ_/)VJ)/WW<
M-L(AQSV\M^>>?+R'Z#JSAB  SU^!Z^7;I\O3KFJ]WZD]3ZGO^P;_ +\UWKZ/
MSB?IQQ@<1W\45*\__4LV'[->3?:$,<9ZZ/*X@_W.W_9CM_#VU[+3S< \.'.<
MVUSO_P#:%W7,7K,<^SZD+P7?8 :57D?C5H<1_1V]1#?OKPC[5G(XZU0=/T&G
M8^>GVP&?B!W[],'.?TX]AT7-[,M"( R;C6#YD_\ *]Z"/]4=/+.VY&O39V'
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M6>O7Y^9_"HH]>@ &Y^\(>NX[CSOW'COP/'KJ6B<Q7(P/VG8[;?7X]*A2R9R
M<^9^&"<$;#L,]<G &:_0CT9J>UZ9\5GW =XN8Y#S\-HG"_'TY^.O(?M'7EXV
MUX8Q^GMO7K8VI_::]Q^R@@^SWAHCI[K=?=J-X/V5RLZVG8I]35]3$>"-:B <
M\!XJA!F$=O(1$P\_[1#P![69/^?VL+DY$>FC?I_<RT./O_.U?J;["H0?9;P\
M=LM+K)Z;[:WJ SY'<=/3X5KBT>B&WWMP[[".VX^GS]/,.?GKH*/G';.Y'7.^
M/+?XCOL>V-GR0@G!Z@;G^L@=#Y@@#TWD+=[N&X#M\./KSQ]![<^8[ZF+)G.0
M/3/SW&X&XQW[=<X%5\MOU&,>7ED>6,8\CGTZDXJZIO.VP[;^O<0#COW^'&I*
MRMG)/U./,Y  WQVSWZ=14%X#V!'7;&#V'X_#MYBKRQ5=/'"#-F@L[=N5"I(-
M6J*B[E=4XB!4T$$"'55.<=@*1,AC".W&X<S(#--(L,,;SRR'"1HK/(QVV")S
M'/4]!GR["#="&VB:>YDC@@C4F2:X=8HD49RS2R%44#J?MYQZ;C;/&W2;E:["
MW=SS8M#A%! QW$\D<TT=$=A$S2OD%)R"@[@'@E5XH-MU"F4V A]FZ#[-N(M6
M"2WR+HUJW5[M";O&W]JLU97+$\PQ<FW50 ZF3/+6FN*/;'PEHG/#IK'B"^4<
MHCL6Y+ /O@3:BY:,J, YM(KLN<(Q38UT.Q?@#'V+4TW,7'#*3_L_"M8YGV;N
M3\0@'C]RV3(WBTQ'Q!X6"**ATQ CA=P)0/K=V@<&Z+P\JM:P&>[ //?W9$ER
M2?UO"  BMU(P"($C+*%\0LPYJ\V\5>T#B/BURM]<BVL V8]+LN:&S4#]4RCF
M,ETX_P NX>0*Q/AJB_9&;@  [!MR(_4>^NUUTFONE*Y?=26 <GX'RG*]</1M
M FF[J[;-_P"N=Z;F*PLH7J8ID6F836&N-R(KMHK/56:%,K6YE!K[:U-RK0C[
MWQPZ.PG'Y^/I3[O7R_/YSTK=K &?L7]36+:YE_$5@)/5*Q)*$,19,&<W7IEH
M)4I>K6J(.<[F"M$"[$S.7B'?\*W6*55$[AFNU=+J5F?2E-*4$ 'OKX0",'<4
MKR(@BF)Q323(*AS*J"0H%%10P !E#[ 'C.8"E 3FW,(%* CP&WWL!V&PWZ#K
MBOF /V^OJ?7;K7]^ OH'KZ<^O&OF!T_/]?KUS7V@D*/ A^O]_KI@>77KY?3I
M2OH  =@ /7X[>OK]=?:5]TI32E>#ITV9-G#QXX0:,VB"KETZ<JIH-FS9!,RJ
M[APNJ8J2***13**JJ&*1,A3'.8"@(@I7'ZR66Y?E2K5+XVQE+SE(_)Z5*8<0
MV6,O0ZSJ)L/5W-Q#T6\MBS$LJ@=!W'839.45F%\R+'K$<6YR@ZJU>-]FC(2!
M_A&=NW?U\OX_+UKZ/OS]WG\>F/+?TKK)3Z?5L?U: I-(K\35:C5HMI"5VN03
M%"-B(:*8)%0:,6#)L1-%N@BF4  I"@)C"90XF4.<QOM?*DFG6E1NTU"LW:(<
M05JA6$[%.N5&C] JI2* 42E<-U.%FKI,IA]BZ:J(N4A$125(([ZE65]>:;<)
M=6%S-:W$9!66%V5L9!*MOAT.!S(X9&  92-J@ZCIFGZO:R66IV<%[:R@AX;A
M ZY*E>9#^M&X5F"R1LLBY/*PS7.G+/0<]3,ZE\131'"0F%3\T[&O[)PF4>?9
MQ4\!126$!$I$FTNDAL0#'6ECF I3;@T#VJ)F.WXAMFP  =0LU!!ZY:>T R#W
M9[=CDX"VX&2-"\4^Q24F6ZX6O 0S%_Y+U"1E*YR>6VO@3D9("QW2C R6N3RJ
MHY[W*IW.@2 Q5SK4Q6GH&.5(DHP602=> /O'8.O"+201#?\ L[)PNB/D<=MM
M;ATO4]+UB+QM,OK>\CZGP)$+)G<"6,GQ(6QG*RHC9ZJ.^A]8T;6-#F]VUFPN
MK"4D\J3QL(Y ,_:AG/-%*N1LR2,#G8X-0!>1[AXA$?GL ?0 ]?IQ\M7*0@$$
MXP1L<_#KN!\<=]JIBX[YSG&^>8=>H.#]WECUM+AZ)@'<P 'P[@(?#;?YCQW'
MMN.I"1@;KMD>I.^.V?//F.G6L32>N-^O?IW^N?I\:L#I]L @41\P'O\ 3<>=
M]^P!]>. U(6([$XWP/(D]>G;KOCOMUJ*\AS@=!Y'<CU'IU_)Q%G;P3;\CN._
MKN(CWWY^??X!QY38X\;]AN >F.W;'D"?(X'K%ED"[#'[OAMG&,9&!CKN>OZ-
M^B8_CZ7<3&[[Q<WV^%KG@_9KQQ[2P1QQKX/7Q[7^C[0_A7NOV2'_ ,G7#'4X
MM;H'8]1J-YY9^5:#=673QF[(/4'=;-3<>3$Y7Y!O6"L99NXBD&K@6=7AV#H"
M&>2+8X>R=H+H'\1"[&3,(")=C#X@]I/ O%VM<::IJ6E:+->6%PNGB*=)K5$?
MP=/MH9<++/&P*RQ.IRNY![')_1_V0>T_@+ASV>:)I&N<0V]AJ-J^J&>U>UU"
M:2,3ZM>W$66M[29/MPRQR AR & .#D#%L)T2]2STQ 6HS2*3$ $5).TU@H)A
MQ_*39RSUR'&X@!4#"&P=AXUUVU]DW'4X^WI<5KU(:?4+(  ^?@W$Q&,8.%)\
MZ[A?^WCV7VX;P]<N;Q@#@6>DZF>;R -Q;6ZYSW+#;."<UFZL?D]<KO#$-9K?
M2Z^V-MN5B>6L#](!'D#MACX9F80#L4DH8H\ )@#G7:K#V)<02D&_U72;1,Y/
M@+=7SC;8A2EG'G.Q595"]<OFNBZI_P )+A6($:7H6MZB^Q!O&L=,B).Q =)-
M1DPN,J3"2V2"$QD[*4_H$QM#&36MEELEQ5*!?&U2%&MQ:A@Y,)D&1GDH &Y^
MZ29)L [;B(>+7>],]C'#]HROJ%[?ZF0 &CYDLK<D9R>6$/<8W_5]Z]2>U:PU
MG_A#<5WH:/2-.TK1$(PL@1]2NE&W^,NN6V)R/UC9\V"023@C;2F8OQ_CU $*
M=48."V+X!=-69#R2Q1[^]2K@%I)T(]A]X=J\<!L'&ME:7H&C:+&(]+TVTLP!
MR\\4*^,P[^).W--(3U)=SO6GM:XGXAXBE,NM:Q?Z@2P81SSM[NA'3PK5.2VB
M P,".)  , 8J>[ '8 #5Q5#32E-*4TI32E<F^I/%ETZ+\@W/KQZ8XH)*ER*)
MK#UH=-[5VC&0^2:O$MU%9?-^.$W2B<3!YHJ,:D=_+M?XBPR%$MWA7SA.?%56
M:^>O;OG\?X=/V_=B,;Y[$=?@>WS_ !Z5HS9O^$@8#:]0%3IU2Q9:9CIZ6>MX
M^ZYDEEUHFT-!?IB3[:K6."L'#IU P+DZ"LD$I*-)^69A(?9L&W<,V*<RR/W^
MGY[>?4;5]Y#@_+ \_OVQ7Z+*M::W=ZW!7&GSD79JK9XIC.5ZPPCUO)1$S#R;
M=-VPDHY\U.HW=-';=5-9%9(YB'(8! =]PU]KC5^TI32E-*4TI32E-*5^97\O
M?^4:R[@B0@^C_#:SBE.LD8T97K(&3HU^9&R&JE@GK95TJ16!23(M '?&JSUS
M.V%NY^TE6#MM&1@L"G?N%_ASV_/[_J*Y*N>O8_U'?;J/6M&>@_KCR!URGPQ^
M3PZKL[_F3A_QO&<Q9&ZTG'Y'ZEHV//%)TGISM&0"OT2P$;)E&22DY]$Z%@OD
M:PC*6=V>=DO?Y5D9(Z=/O_..QWV[5]90OVOCWV'4].G[L8.17[,:K5:U1JW!
MTZFP,35ZI68QG"U^NP3%O&0\-$L$2MV<?',&B:3=JU;HD*1-)(A2@ ;CN81$
M?M<*O^E*:4II2FE*M,S PEB8+14_#Q<W&. \*\?+L&LBR6#80#VK5VDJB?;<
M=O$01#<=A#6:"XN+659K6>:WF7=98)7BD7H?LO&RLNX!V/;IFHUU9VE]"]M>
MVMO=V\@(>"YACGB8$$'FCE5D.Q(W'0FM0KYT'X-M_MW$*REJ'(K")_:UE^8T
M<)QW_E0\J20:)(CN&Z$=]G%  V3,0?O!L#2O:EQ7IW*EQ/;ZK"H Y;Z+,Q&
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MJ*(LY<3 U=BUF_=WDIU5EU;V07YEB6ZU;V=WUQ^E@'-/>\.SRM@-%G=[<D
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M>ORG4M>U-@SI;VZRNQ2)26\./G\*WB#W$[-(TLKP+!&$+OG2\M.J#J69^!T
M%7Q'BET148NFP_M@<1TM),' $\3XP@5VS;NT1<+N#$FI(I' 1S*,M>)^)--X
M8TR7@G@N4&,DIQ!KZ,/'U.XY2DUO#*C,! -T=HV"A ;:$E/&EGI^$.$]7XNU
M>/V@\?1<LWV7X:X;D#^[Z3:Y#P7,\$@4F<MF2%94#LY%U< N((H.DNP!V  U
MJ"MZ4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI6L/4-TUP.9VC2P1+Y2FY5K?@<U"^1AE6KUJX:G,X:L)55H8CA
MS&^\??163'W^)6.9U'J"4[ID]Z%QKP+9\510W=O.^E<16!632M9MN9)X7C)=
M(9VCP[P%\D,#XD#$O%D<\<FS?9W[2]0X'FGL+JW36N$]4S%K/#UV$DMYHY0$
MDGM5F#1PW03 92/ NU40W*D".2&-QCO+TKTQY:8YWKT;'7&&IF188SYFYCWS
M6UQD?5%SLK,+=B*C5BJ]7.NF9$ 1]HHR"0(S8INDVB$"*7B:;V?<21<865O!
MJMKI.N6K2PRQ31:A!#ITOA:@$C+)"TK%@8_LY:/Q1'#X@B2REAX-@]J?",_
M6H7=UH=]KO#=XL%Q#<6\^DW-QK$2SZ49)PLDZP1B-Q,ID4+-[OX]R83<2UG0
ML0I.EG%PE*4OC)<3&\)0#Q&&_P!JW,80[F'@!$>> UD]D:@>SSAP@ 9CU$G
MQDG5[_)(&V3C)]:X>W9F;VK\6\Q)Q-I2C))(5="TL ;GH -OX;X9Z&6R']4?
MK*?E:H&?CG:;;>\BF0KD[<DS:52-A<B4RGL 5$5"IB82%4,8_A\6^O4OM.9A
MI?L\CYV\,<)V<G)D\@=H+4%PF>4,0N"P )  ). :\9^R*-/Y9]I\HC3Q#QC>
MIS\H\0H+O4&Y&DQS%"Q+!22!G._6O;&G3UDC,>676>>JF.;-#5N1<,\68@*\
M:RL'7&C1T(H34B=FLJQ?*'52!T@"OM%Y5Z!).1309M8F,1P:OQ7H^@Z"G"_
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MBS^];B3_ +@UCT_]'W'Y]>E=HX(_OTX0_P!*- _I:TK"O0Q_>L8L_P W</\
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M5\$-Q >>!W#GX"'(>??S\^=/S^?/YY%*^ 4I>P>H!\A'?;](>?/QTQ3%?0*
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MLL9<N6D%Q,K7<C2\[BYEE,<B1,L2\[73XK6>XN(WD9[LEKDNRE99 S%).4*
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=I_$TIK[2FE*:4II2FE*:4II2FE*:4II2FE*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cntx-20211231_g17.jpg
<TEXT>
begin 644 cntx-20211231_g17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &"B^880X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              T\   4R          $
M                 0             %,@   T\
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   T\     4F=H=&QO;F<   4R
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   -/     %)G:'1L;VYG   %,@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      -P@
M  $   "@    9@   >   +]    -I@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M/4LR[U&5VX'53:PFH'?6*1AP[5OOV[ZV6LL_P?Z7Z:Z6ZIMU+P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( 0\!J@,!$0 "$0$#$0'_Q  >  $  @,  P$!
M    !PD%!@@! P0""O_$ $,0  $$ P ! P(# P@'!@<   0" P4&  $'"!$2
M$PD4%2$Q%A=1(B,V06%Q=[<D,E:1D]/P&#-R@:&Q0D-24U=CX?_$ !T! 0 "
M @,! 0             $!08' 0,( @G_Q  ^$0 " P$  00! @0$! 4# @<"
M P !! 41!A(3%"$Q\ <5(D$C46%Q@9&QP18D,J'1"%+A,T,7-4)$4V+Q_]H
M# ,!  (1 Q$ /P#^_C$1B(Q$8B,1/YT*SYZ?5&D%2+C_ (Y3ADD)TOKT?4ZP
M5XS=;@6N@1\(%Q1RM420L1A385#U7H^Z]8LR[K)*(B+4=S9%'B9R:EA94H]'
M]_/_ /R6\^)/5^DWGQWA+]VP&>5:56GH,.D]OD-XY_-VFL0?0[%7J7;7.120
M<C<ZNJPUD&*E' RP_:^P]^/#M"Q$@*AI$Z?@IZ+LL8U+P[[I +I$@'I3X9L<
M0T9$R)43)B% 20PAX98$D"6$4,6,R^R0.XVMO6TXB9?$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(TY/_1:5_Q+[1_G%>\1)+Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2-.3_P!%
MI7_$OM'^<5[Q$DO$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1(TY/_1:5_Q+[1_G%>\1)+Q$]*WVFU:0M>DJW_JZWM.MJ_+:MZUK
M>];WO2=;5O6M?IK>_P!-;SXLQ&_%W57Y\>+NJ\WX\_CS=>?%>+OQ^E75QXN_
M/BKOQ^OBO/CSY_7_ "_2_P!9[$+2O7N3OUUZ[UZ_W9]5?G]/]?\ 3]+\?W_M
M_E?Z77YKS4?O]_Z_YU^M7^+GZSF(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$C3D_\ 1:5_Q+[1_G%>\1)+Q$C:T\^;LLB<8HL=E$E%C11"
MR(L>0/CVQG"7$EUP]Y]M<,=O92E?-MDQIHED<QD=!*%K<Q7L>F1ZVG0^]"EC
MKR)QN^;$O7HS F]5CHY.HV@7-UW>LKMU+>-&M3@6#5^X[WG=P^>E"J2P_KZ&
MZ I>H\Z-%M^OY3T\X+*M^:OK^*7;$E[&,61DLJ$)%9;^)M*-;WO2=:UK:M^[
M?IK6M>N]_P!>]^GKO?\ 7O>]YE #0#0UY\5^GF[N_P#C=W=W?[\5*+S=_F_'
MG^_BJJO/^E5557_"JGLSZB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$I]C/K2>-<G$%6=% [&Q4XLJU&SLXZ%SQQV$HL$3S"*@NA'UT?H;UH;AK
MS/\ 7Z9#UJ'_  ;]J=)=E)J5A(^O@(E"D2QG@/:XSOW.6.@QU7LE)>19;K3I
MNHVU< _/0%CH5LF*?.@EEU6;L=<.95(0SQ8!L1-GC$QY(KCBARMD"#HF>Y/_
M $6E?\2^T?YQ7O$22\1(WM6K[LX[]G=EZ9W&C?@>Q?V=_#42^EE[)W9M2^OQ
M54?O>@=>D%I9&Q-F;;1HU(^UXKV/_$EZM-<SYJ7]-/\ +;1?*^K6_P!S_E_G
M%;Q^Y]7S]:K_ );[VVFW>SV/H+N_YM\3X4??I7N^T?WOE_F%Z+Q>$>S^6?4\
M9:T^/LW_ .?NE4P57=DLB"2(UMS:-?+K6E^FO=[?7T]?37KZ:W^?IZ^OI^>_
MR_KS*:]WC^KQY_'YKSXO\5YNJO\ -5Y\U57=_BJOS^90?NO/Z^/[>?Q7Y_X5
M_M/9G,1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2L[ZHG:NN<,Y'RZS\HZ&?SA
M,KV0.OWF3K9G&1K[*U-[GG0I1N(H8_<:S=JI)RS=CB8&<FP@:C*S+-+A;/*H
M*AXR,DY%I'[_ '_\?_$[FXO+R-@X]RB>EYEZQRTWS6BR\I82)*GS+\](R58B
MS#9E^7YX.'0)5V4)>=.<DJ,(+3SEOJ)K([,*Z$VE$DO$1B(Q$YE%\+_$H*0%
ME1?&_C+,@'9++;AB4<^K?O;L5P"CXZS26T[ VVXJ7"AX=@D9Q"P])AXA3([3
MD6 L='_'_I_\23ZGQGD]&Y^!RJI\YIL'S:,<+?"HXE?C=UEH@^6)GSRE1+P[
MHCQALZ87,F%OMN$DRI+Y[[JRG5NJ1/DXP #%THJ-C A(Z. Z'V(0$  9D,((
M0?K]Y:8&$%'0VP..RVE+;3++:&VT)TE"=)UK6(DK8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$2H#ZO%G,J/.^/2NK6Q4Y,CK 4/R,ZK,]4 Z\3UR7Y
M_P!/BT5FB63G/7N2#B'=#K1Q7/8N-L$ON(.D[&I)[H2E 3]<1_?]_O\ 'Y_Y
MRP+Q2,JDCXN>-LA0Q(H"CG<$X^9308.,F(6$#JA//:Z]7A8>'L,G-S\3%CQ"
MPV@(V<F9:8!%0T+)R9YK3Y3J)/N(C$1B(Q$8B1IR?^BTK_B7VC_.*]XB?79[
ML[ 26XY(D4WI,:B00;/S2X((Y;CI#28V*>3&27WTDU]OMPP?6FMBM%1ZM?/L
MO>F<<ZO=/G:BS"G(-!@O=]CI;_Y?G>5-8OZF1E9M/S:!I='H_ _7!^6_8WYK
MH+G!RJV9QT$U]^[963X<66MCE5:P/[&D+>CX4G9V*+N[IUIT_P!2_A_KW&-.
M_$(\$]0Y 2C1!B]A&MZ8-$^X90[]L6S[E_"4QM?Q/M:4K3;J5(]RO;Z[N\FC
M[67-IM3<]Z$*?]?0/QZ$_* G2GKN[L'+]WL:'F_:=$/F_'F5>A7P/<CY%.^%
MK%?,DO>EOQF0?(H_%>]1^/<LO%>X+J_%>9\)%F@!9%$41,QK,@MT=C0CIC"'
MM$&;3]F,I&UZVV29[D[#'7[7B];WL9MWVJ]([.KS5:JQ-W9%ZK-2_KF]8-^7
M1=4A=B15=,?=U2%W_B/_ #\0EXN=P8-S$_97DT&CV,9\PI9:[6F_#F45#?N6
MG_\ >8/D%?\ [A!,[EA(D8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1O>M?KO6O[\7=5^M^/\ >)XUO6_TWK?I^OIOU],?]OUB><1&(C$1
MB(Q$8B,1&(C$1ZZ_CK$1B(Q$8B,1&(C$1B(Q$JD^K1/-0_,?'@(CK,[RD2T^
M45$J<B74ZQ(SMPF(:P5B[1L_JH3<67&E\]M%<@2).UP70VI:+)J<E##2L42[
M/CQ 92)T'RWOW.>1^'/C#>>@7Z>O@MEX;R#<)8J9RKH%LNG5S2>:0,HY8:QQ
MOF]4L_0'GYT7WV$F"B*J0[ #E_ :R(AGT2B3SQ[NO..ZPQTSSXVSIW$O##S=
M?O?.NB\EO, \:RM\'4_SSJ]5I5ZA&SVFGUQY$I7A1I#0Y.PGB-#/_&B2_B(Q
M$8B,1(TY/_1:5_Q+[1_G%>\1)*VG2O3U_/TWZZ_LW_U_'UU_Z>G%UY_7Q?\
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M)I)M/5/YS<2M!'N5;5VAH)*ET^D:"H?B>68F)'0(>"KXB8(T1"PA:*[0WT5
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M28J[)9VLR"R KJKL;L;\>:J_\YE\FR/&(C$1B(Q$8B,1&(C$1B(Q$8B,?O\
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M<K>M:]=_EG4YZ<X6S0Y2%U=5;',!85=WXJK([$:N[_UGVM;''[%+-IW5W0+
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ME=))(T9IFSISLXP* =B3]0]/)Q7XDFA3'"E(*1NS<AK\NO4IC\>C0G3JS/)
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MU&,%H=L2I)EP\F=]@\C-CYG6Z?81NZW/?J/=Z?8[K!IOJZ,9+ "Q\SE=]/\
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MX-WHO=A^71D8P=?(V,W\Y=4O/1F=;^;LS,K0:[)N?VIZV02"C@51LR%H$6=
MT^*6P))E0\;,[;$+"*-$*&<#E R676"G=:;?2T[O3[;J4^M?3/:+M\X7O1>7
M?G^NCI9?>IH(UNPY.A0J<AVA#E'FVYW+)3VT(MI1G\BSJO-?<Y8\K<:D.^SB
M=;VX-%@Q3'95;-6'RU+E(:IH/QN4P32OR06P:L#&YO.9%*>,1&(C$1B(Q$T.
MX[ ^[@T;9EWIU:SMPWX$Z,Q(H:0.G<HM3L@^/%J"TUL;YF)%:F72=A*8:68V
M.IO'>W>2]'- E[6](KUWSPYS5*U^P5!]P_.ER,=Y@ E6X=16%M^M\8&_X1NW
MYM:;3N]K,B\'C-]TMPF:**V%]7V@A;M?S^ZFTL\R_>*K?1F*2;Y@>-OS+^JX
M@ B-AZX:W:4%Q#]Z(A+1%V=N4V2M^YK,BF20BT&L30\B%^)$M?B9+FQV)L9M
MI]K7.+U*MX\8<K$<_D:E]JFX'>H"Y_:Q=8-UN8SOGKQ@U+:>/15K2.E@UK;?
MQ!TDT+EYKKX)HOK5JIFSJ9F<BTZ5<4=O+U\P\@K6/&K/H,&K-!<]F1UY5W>,
M!LV8&W:6;K+,.(TXW)&RDK-MT2,:NQL,+5G BH)Q^:TV4VFQ[&2A11+4TK>X
MYA0SK32') )E6HQO5_O$ZHEZM&S;T%^F<M^H=&+/R3SMYAEOJG*KIDJA8]B]
MYW>--K,5+O7G"ZRC5+E,?(,SIRY<+.YJOB+ULZ0/5N&L5V!W@%QD"%GA"AU.
MM@&PJ0XZO013?$_:_A49]CMQ0/X>%]FIW;NW5"_;-_;[<V_K3VW-L^S:]O:T
M[M7K\FM+]<V!B^&\>2\UD6>\R/@(_?[K3\0?%9?+_B>ZU^VR^3^OSY]_]7F8
MIJ^7[.CYZ&G_ #N^:AH*&F_(7R4-+_PZ&C]U52_Z*KQ0_P!/B9#),Z(Q$8B,
M1&(C$1B(Q$8B,1/"OTW_ ';_ /;$2 NF5IR7W*AHFH-9]D'C08F/F'&=2\:@
M4A")%VGME',1ZY1UAQXD-)(Z$?C&A=2AI,6ED,/6OK'DWNO6@>AS2U]9&/-B
MS=!JZZ&3X76&EG 4[2O(6UHFPT6U0#_,!0.M[LPJ3GS;TQU0PWE>S)N^MS6Z
M7:G8@*\>LFI*\RNT:\YZ*QBP1!]*;9UAM]Y4JT6;6\_=1YP\(B3E+#*1\#!2
M4R"F-E[9-_8R5:!:CP=R\NX'52=1#CHR8TIEJ:;*;>=&EDQ]@C7@0Q)(;5_K
M+TB:ZU;.MMS<W!KZ.6L&OM;QS;./F#-F/I;KS\-X\ZS&LSE*Z &3+#7]?IY6
M9DHU9MA>D_4P&>7+S,;]^_+@TWKQ\K&6I'6T%I?6'"MO65>WVL^=!EA(+H68
M[T<S4K3H?G=BZ)6S&-[KHJS$L$D;8EI%F.FB6K11!QFG0+4S7$;=EYR9%D-0
M->3+"OCGU8I#Q&D*CGVQDPO37)<D?Y.ANHU-9[.AL3DZ+5]GTVE*3S]M7)^3
M1T>GO3MOF<W[RV(9RM%-;0%F92Y)[W42SW=-P*)BET>+*>G'3.3WV/<#N0SH
M>!R<["_)?4Z=XF U/4S$E9'3UL=.@^5UTIB:T>98TE6$51[,VX3-E$6">AF'
MY)F#9F:FI[4?4A652#<P*$TR^8$ZZV C<6RLH#>U/1O)<G?>K1U:?U$'J5T#
M=T7MZG2P);K7SPZ''^6LG&6H]5ZPS@ICLQ&O,'U08[/-=^INBEF6\^?G4GG,
MK.W$",2 YV#:U.4MQ9.K2[T]-ACF'(;K:*M()O0?V3%;YTAFTY@48B,1&(C$
M1B(Q$P]@<B6H627/(8<A_MEID&B6=D,NCKWI"F=CZ0XLA;NU);:':;<>?>4A
MIA"WEH3N#TBPAAU%TZ46"E7]D7+MJS7=U7L^*A,FF96(*6 DPVD K$CL:N3B
MK66I%828&OY!M!J/XS Q_J]],NQI=!561F1"(!1$5T-7<T:,G*= #R)$>),I
M.V3"B%#28LUJPFNRQCD=7A].VEQHQT-\MPD<!UXQ$2$[H_2WA-LF_'CV3H<+
MFJU-R)Z'V2=STN3L7T;Z^EF[4S)RU6?:->DL[M5O3D8YU8DE\_\ B*$&W5OI
MP]78U //':?BV.6W(>'^7)#$@-/09[>51(%R4"IND 46I@_!?L;9I]^XPMB'
MF7Y$/[,Z-D(ET9LX"02+MYK1H^B1'D/ %'!/LOM;W[5,EN*0MMQIY#3B-IR\
MP=->YNO/:-&35B-0:<VFD68UH4+D,!N9^C.U;0+^FUN(A(2!@ 0W4K->%F5>
M9_RIT9]8M)#T$?M*T,M3EFMRTO6Q9U7FC4-$)"8$8%138,LY"C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$2)N<J;329Y3KCC3>NC=LVMUG;FGFD?O?OON<:4TE;B7
M$)]5(4A*E)5K6TZ]?3.C3[?@=[C(!^,_<878F%>V_P"H"&B(3']1(:LA*JL:
MNZJK[%45M50B)G; $ /Q8$1%5")T7]/L*[\'[O ^V[]UU7FYR/*\@BRIP23C
M(E3:I&FFS=6&W3XLJ-N,P(;%F"[NC4#-2!*XQ!VX*3*5+HCHPIV6-97N/'0_
M'+\O;_0.1W31NR8R7>OT^_H\1(\+(_)ZAVYVXG('U$/,W:V7C)]\S6XMHX\;
MKV/%GUE@_,S?^#UKK5RW9=>NVUE[:</59?:U*V</(W/N0W^0??QI2&N\Y=#*
MFLEZ-2:QH,:>?P:5\^VJB.6682XS&A $N2A#K6T% +6W-NJ/(D(NW6&HZ9@A
MJE+NA18\8@M$%HH0]DR,F7!F)QV2UEVO2S.ST!%>).=Q:6&JULR-(>D=:W:^
M?W.CQ/BYP<+H'FQ+P_*&&W(:O7DUDI72M^P^-ZI'DX75>UNE(9U*/W"^A+!5
M9E9]?#YO8IG0OLX T[6Z+ ]_QZ57GU9%VSG?7E:9Y*(W'Q$D+54QHAI8X,*1
M78,*RTR7_#YV-TL*9K[&F2Y],U*M2,C$G;$!A$UZ+@'8V,:^XF'1,RZ/H;-6
M7!LS\;ZN?3H7GYQ\GGY^UZ?W_5ZF3SFW8$B&CK5T=BM.S!H^NCG#R\?*9EPE
M?WF*Q+!ZSTD[7G?UBV.SH=IWUOZ#^9W<E:.?I$=//Z+#-/,9ARLS(W9KT:-Q
M]'5TE:M3"#$!]K<-BP(>GKCPX]<$0R6)N5J_V*XX>L2"X&&5^%!BJ<?U\3H>
MPY1\K112CSY$PYYUL@AT0;T/_#S'FP<,LJ,Y<]Z]"?O\CZY9%<G6?-YYUD0@
MB97L9EO-L8X7/^SJTZ'L;\S&K7I7UKJU;>O6G3H'>!I=6/J_/]IG5RCTM]#K
M=H]J_>8.^;(L+2GX,^9"17\8 QDSYGDQ",1&(C$1B)XWO6M;WO\ +6M;WO?\
M-:_/>/TB8R1CXB6;0Q* A'MCNZ(:0:.R1IA[2'&TOM?*E6VG?C6ZWIUO:5^Q
M;B/7VJ7K<37DQ;0%>S.C2(%3 %RP98,JC"C"BJR [$F!1#[;L2(?/@KJ^_/K
MTY")F5[LYD/L,E,(+(/<)>T_;=40>X0/P7D:(1+Q1#5UI%AC:[&GPKHIY5=D
MPXJ3CHX2 BQY%S<&\_&OR26X1$5*I9!8)'COE.:$99&=<'9(>4DA##M!T\O*
MQ:,)KT,YFI&'9ERIYV->DOY<QN5NKVX QZ_8E3DY+O12!4#+6IQ$+_B.UQ.W
MZ4; -*]V=NO)ITMW:CSA6T!T+S>=9:LM&UJV:1I!-,S7\S5B)*MH8(HZBP\8
M#'LP8%DB:I4A9YF1)<KI P-;7]PVT:+(S9@S3R74Q;[SJQEH"80VPHDD;3P:
M%UCM7IO!ESY P9>IBX_#3U%ZGLY1IS\@J8(Z5:N@]0M OIDQQI*T*&L]M-=-
M14GJS]S7J:\M>C!KZO6;AO.H-X.?T_ $269\:FM"Z^Z"UTT;<PF-%8,]KKJ2
MX2Q1$^SI<85\BT#BD.BO,OB'#LF(4L5P@$QI@QALA+;OP..L(0_ME[32E_$Y
M[<MY_4P])='C;972DM-#5,S:E+>)6DW9'@K0D&T!_&1J$&>P_CLJ&_&/Z\.K
M"?QZ5^W^MBQ8!@Y)FFQIHK>HC4PE^X+.A.R&C&RJO=7G.Y82)&(FF6JQ$P9$
M8TV@1E@Y9"7Y26*=!AX_0[/R(044T,1K11JU:;#9?4(PYIHE6R]/MCAFTG7Z
M;><>,0#."]).%FW:T\^'+:E^\ <X5LH&Z+NQ13?B27QMHGT[Z^?39\["&VM-
MD;R-(KL,F10NUZ+85T1*6;%^Y:!'W.^/Y6C[UW2OB^9R=9W)7*<&AY4,:7CX
M\B/D$E 1+D.U*(E4&MM EJ=M(([3\&0,T^2*XD<,Y:'QG"HYQMY3(=3>ON=%
M>#:A.O+E;DU?-FQLQ+V_>!XAD?YZZ%@7.>E;6INEI?=.3>G+5V2TSO@Y6,M>
M5CL^C0O3F^+1I#4>6\A)(]"JKFN,AV+:Q2FU1O3=J;6?2-C1.D6%;E6XP%,V
MZ.]+:#$U(N!^[0BCM,(^\4+I:4+T.HGY=LZ6E*OCVC6])]/:G)L%;!Q9*Z))
M/?69-;#S^ZD%J]E6^TT5#=*^2RI?D1+V57D:N4NJ\]ZM-XZ:.2]#;RBZQMPY
MK._A%MCY&V4OV^_Q95[O/@KK\S*9+G1&(C$1B(Q$\;_/6_[MYQ?Z7Y_RB<I]
MH66RFV+@G)5N*=AQ_P!Y4B,!&R345'BCLD"-M.%*5-1J7X3<D23)0$?/;A74
MBR(L-^)%E&LZ:]?MTK_G=<PM8XF84_\ B_:O'EVC@RJ31(^'YF7TLU,Y_P!Q
MK]?+Q=>N>2UZ%8!TZ'Z%[-]$JSL9RJVAD/6.MO\ X:RNT/S7LTL80,)GQU6#
M3:]WU03DZ&GG5O$VYW;OKI3G. +5+R4<\Y;9$H85/WXCD]-D$PL@N-BHK\(>
M*C8RVS3$ZER1)VB(,,B &+0' "E38Y=C?;<;A M8]O;L03NYH<I87H2[I=)C
M>?K#-SL%XR9DS=W>O:!ZVC?/T.RY%=?'S,[>DA_59[JY@;!Y&+/I%?&S)<UM
MYF+Y_-6G?G+5OVAK!>K5R<C,5ADS@6U*=>AG)=TM"N>:N>%^[>[-5H6,%AQ=
M02%19 !6[560;*Y'0%CGX1N,VPS!2W1*O)2: R8*4DG5(JD63$''0P@D*MT9
MO<T&)/Y"\&?GIOGC>%N9S.WQ4==N3E=3I\X<1@GG[_5W)U:ZS/YV[:R_Y7DT
M9=6G A.!E@-;LZ8G4/4[H,O?[=@:%#R>L_FAHWX,'1/59MZ.+TUU49KT*WXL
M@#?4UY]*,^Y[MZJ:RL;FS-QMU]]^OHF390V$&?D'^?2JH(F%BSSI%F?)DHUD
MJ43^U4TR!"*V_'SLXS&M61K;YSS<E(1[<AF?>@&-9?/#>_5IYJVO;Z6W7S78
MLFE^P.BW5B'3LHNQT0QX*]^7J=$,2NJ#7,)>S0BM!85ZR6H/NGD5DS=%JT*]
M19 WKU:$KS%A7GUVG)=<G">K;Y'1S.>S8SF$I:O=DSO^N/5>OT_C_;^7Y_[L
MW-7Z5_?_ %_S_P!?^/ZS6,\YS$8B,1&(C$1B)K<]*U=MEV)L4A#LM2#"VG 9
M4P)C18Z]Z:7_ #!3S>W6]K4EOW)UOT7M/IO2O3*OI:N.*SQ=73SP7J40GFW:
M,ZZ>DK]I?X;V!9AY\C[JKQ1U^+HJJ3L6?I&=:><C:;$'14_&A[+2RJ\U=FD"
M]A55T7B[_(W^?QYGH8K58C@9+3P;) AS:%2KTV63,[*&#TMUI!IDV2<\X&%[
MWG6&77]C";6ZXRAI2W%*ZAY/)RY]8L0MF9RZ^\WHO;OMB,]F:QTZ.@[0RT9R
M)A* V6M%^ZP$/-W/HNCT-#D6#2!JSNLR\*5XQ!KA!9DA&):5TY]  L,%_*[P
M/O([_7(0(\ R#\M;9BT1YCJR-OQ&A5#%O^B&'"%OB[V@E[VLH:6\I;B_:REM
M2OYO24R><KF)1YY2\@9G,([/%2K4YH^%&9,3Y%IU2Z61D1%5+H+NJ"JKJW-W
M&_V]$M-Z5"*_9K^2FI"_+!"EM\$L+MELH:&JNV6=5Y.[O-Y82)&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(D5<T>0/3)PASW?&QT;MKSOL0IQ?QM=>OKB_8A.MJ4K
MVIWZ)3K:E;_).M[WK6=;CI:F'8F= !%8K"V&555W= L:LC*Z\^T!JR*_ U5W
M=3Z ;,P"K$;(A&K,J *LK\59&5T(#5WY(BNA&O-W=57FJ<.W^<?CA)VV>&@^
MR^/X4?(U(B$ CX/H'+Y_3*U*,(E96UF!3X[<?,?;'[=:B(AVQ.F,@K$0DB<%
M=&"\>?Q&T^IMG<Z2>9Z0V(Q;N$?-QYN5P5].A)MO?MV=;2A2ZQ]"UZ:,,?.9
MTFO^*LX_+T5&I'J+T%AX.?C<Q_0]2Y;U8^XGHZM'1[!<PV?%25X\?(SO-]Z\
M=GD(3W[1Y@93<IYVOGF+G0-W;S.Y-*7QA(GDES8V')J=>KU5D?WI\W?EHL.+
M<*0B<DB(6;_#8\J4DOO23&U/MGO1:V-&O*C2 WCM;_Q(S_Q'W>H@I'']7:.:
MWA\SF\/3?-:>S.C(3 7NU'@56/,W;LI[](68Z2QD(OL\;5,T;&_AQ7\/L_IL
MF:-_IA>[-VNIT^OFOH!6+6_6K,P^=G7O;]G2G!A/*A#;&\R]5DQ-?:%HYY1M
MWF=PXB;.=5W?B#,G([I2SI.,Z#2M5:I7**=!2PH!H&UO,O5J1;"&FW)90R#4
M.&$B2(;NEQXZ,L[Z/7.CI:FWZ;[B]>NO3EZM>7A=*N/P>[S_ (%T2 S$P+X^
MI>1/3O?::>!F>/6F[^LJ8=P[]'KP9;7W>4S)EKU .?+IZ^-?7[7!UUI*RTEH
M$##K9+T:.:&&WT@A2O3C< UK;=R?COU:@]AHCUIYY)4V7BV);4;*GT*UQ%VK
M;M@W"PTL:T/9896V9 P826CV)%)B&9$4M#@A+>TLLO.^OO2S7-YU_:X5>G]=
M&J]>0+)F=KW9,VB]&?0Q&9NH/8X,[&N0MR]&=^4O<.8#+S%Z@2E._P 9NM?8
MRD#/K:3$5.6E6K3GI+\ZW:%9RLDEH4M+F+/-H1H&ZMQ",\YDLHXQ$8B,1&(G
MY7_J*_\ "K_VWB_TOS^G]XG(DM.QE8G:U*N$1L3"G7RTAL6V7$&;DDRS M@<
M(CK(6%)ZDB8A3C)@X+1;$:XV@*+_ !9]M;(X\AI#=TL?*Z/'U_+DQX=7J?M9
MU]K=G36ZMZ4=1C,O6=FU_?T8V&+DYE/#*8ADS?=,!K,MVTLG/U]/#U<P*;JV
M9^!R7ERLKVGF^FS1S5*T<Q3<]Y UA1J8\TMT!9:]/TP,C>Q49379#RS(Q1$@
M8S/)#DZ[*2@LS%M?(5.&1P$8Y4H6(9CYY$20:0!(AN6Y0;[30A\>!&6&S"[1
MO#]_\0-+&XB/3I7U!1OY&W;GVY1-CNB_*K$[@\[*M>_Z+-#<NK/?:^N8(SZ\
MJ$=7L((:RO%Z(2"=MJ2EO/)F3HY,NG$_VJSX$ZG[ Z^_2QV$M@(#1G8'(O0!
M,?GTZ=/,YK?SFJ_/1,K#E[,B(,&%JE+;#EH5D6RWAHN<?0.:YMB0ABRS:W+Q
MHPC0XY_L<L)1DH6P2AZ3KCPP=AR^CCW<]QOQ<K-S.+Z<7EZ'/2KK>I$:ND5)
M:PEZ^:]^CE[<8)7G7ML3Z;7=!ZM"F[N62$P>A@U8]J SZM^CH]CN&[%M8[E^
MGBS\\#8D*++K2*>CBU,:369?<.!*,"V),,70![NJJ2Y"DDE%M[G-61Z+BM2;
M-E8DA946/]2W 1VF3P8YI8;13LBWLL,7>B2D.Z+(>?:2EK<_ 9@>UKP_F-=5
MF/%]U775J1MSY_\ '-"15JS91- O/55OSJNFM]U-:5K %ZN["]J%K05XBYH:
M]=YF<UN9^-VGVH%[+9G?HL7$D<M_"YM$I=C[%A1D1R-F42AGYVM.M[UO?IZ?
MK^6_3_?Z>G^[./-?Z_\ *[_Z5^G^OZ>?Q^L3QM*'/SWKU]/R_7>O_3UUKU_M
M_7]=>OIZX\5Y\^/S7G\_[UX_Z?W_ +?GQ^MQ_P!_'_M^_P _Y_W_ $GG2$I_
M37I_#\]_E_=^?_ICQ7Z?V_/X_/C\_K^/^W]O[1/UG,1B(Q$8B,1&(GC?Z;_+
MU_+?Y?Q_LQ$XQ\F3R&&&'"8\.*&BGXV0B9PBJO65<[-!KV7#P1+NRP8H6)(.
M44DMF7>,8"("8ECP$1;NRTZ$_C#I8I*S>A.#-SSQ:\?4;QSZ]]#H9R)^#FON
MM&;&'.8^G?8#>QJD.0K3K3]%Q%>W_P"&&9;7D"GMUZ-B]F33A'JKY0X<.A5J
MW;UW:'ZV;%HI)(+""W:%FS-F<6I5JG-MXMLA78UYP00:.L3EJBI Y,8+7R2)
M:PD1P[]* KE(CVY^)#K1\.5N3E9,HR0F(V52^8Q(_/'UX>=U)ZB[C>9A<].5
M6?I?S[%LUGE5R7'OZK,ZRX.7C\++72PY^5LYVD=N[6>K5KR;;)Z-7OS<974V
MCZ>XN7IZU+8]C^;7&U(SWK?T4IP\U6JP[FGI][2>#6_I(VH^GDRHSHQZ<5BA
MN4AT]-O/Q'-9^=C@U&.02R9[]X93HE67%'-/PM[2',"()-@S 0@I5@R/^_/'
MBV2DL@S+#K\384RDA*AQU?Z1Z_4S(K6[F&_H7ZJ:Q''O'H67.]4"C>@FZ.?H
MRY<^\=&.]#L^1;A#/TE,/)T UZ-N?%,]5\SGM>&1/2 , >EDB[L#JSD'2]/?
M8Q,^%&Y#]>C'>?96?,W6U1M;A:L-G.^EFQOU=<\!GR9J2(4/",&#MRLZQ)G.
MUAR%DZQ+$ER\C.1[DLP4_!&CLEJAA6!XH2+(.;EM$;:*1#2!+F]/X8=5G1TO
M)'/2Y-;NF&W47'/!KY70<_5LZ.6]JFLYK4K:S$M:\J<;=5[R,5N'G:W%IS^(
M',K E%/V&MK,.!N3.'3'9FZ6!:,F?G:*S, =Z6FH=Q./6W2"3QT%6FM>=8]?
MYO*OTK^W^G^4U-&(C$1B(Q$8B8^6W)ZC#]PVA52V@RMQJ#MK2$L_0[GV:"U-
M?SJ!E$_%HA;6MN):VO:-;5K6MQMGV_J:KPTF]M9W7CK195GO32R^"GV']=)M
MOMIMA_70>[V_U>)W9JSWISUKMPY+>JM19Z"WUG]X_-::9=!;:7[OCH_Z+/Q1
M?TW<@Z2KUT)U8)9YNQ*^_I[,7+!F;J""I<D8@K;(@0\"U)JV"P)*S2WFV7PI
M=Y;@8H,@6\M+H.N]7,]0N_FNP@ZMUIX(Y->?1?!IV[0#76",P\P=A_43GU[?
M>('EZ+#K.M&IYG[TYIFW<=5\[.)<ZKS]<M69R![%IR 8+LW./>S+7V&.RX@"
MS#1B6%.:Y"Q$AT;,"&=:P3X&00^S&1VX(F(E]5Z4KFW#Q25FZ!7 V59;QPT:
ML",==*(TZ >D]8:=),!?>1=HSZ.QFU<S33%X\E\MV#H5SM?-N].=E:1S7S^K
M>@]*L=Y\9&PJO/H!Y9KL=&=YC3N:GFNS[L]K9IT_S%>S&>S/OJDN"D_8K9SQ
M2"&:;=II8#[7I+..C^I&A0WNE;K;<!^*/K*<,.F3TR$@_ME@1A;[88H#7P!B
MI2TSI(PC*''%J>)?<TIQY]:=-(:N^5RJYOW6&^]&GH:1TZG4I><"8M"<J_C0
MFJ$*%"%"9$36M.B-C2JQ$*S=NO964*5\*,:"SYUVUCC%9O;I/WM9=D5VU[+J
MAH%@-T(+&_=9;/EO($8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B17S)+BJ=-:96EI
M[?2.U:9=6WMU#3N^P7S3;JV]+;VXEM>]+VCY&_?K6T>]'N]VNMM%:SH"H#L;
MH#L??0'?X [#R/NH2NBL?->[QX\UY\SD;&B&S&R"KJR&B]MD-7Y(:+Q?MNZ\
MU1>+\7?GQ?Z2H;RE5(1O3"VI:ZPITJ73=.ER*+0U*_9K8.=VFNH"8CP10EF/
MCRY2P'M#L+V:V>4*C[(%AS\Z_P"--;<GJYX;O47/U;=/#IC-0]<==9[7H+QS
M*4K&A>;YFAK?>0QI9_:!S!+X4!?NO^$'UM/I-#,? Z"\:O4-H5E'E-0+:T)5
M\G5<\M&ICAS"S&FG+(B6.=F93:^UJ8/.O=226+>^^/86$B35(I<BF,;E!QGD
M1!D>TXS55,51S\!T[$;3LEYB6'%=<=1HDAEDQ]03VLOXA-<'<-@=017O]/<#
M4O*+@62\FG(HT\8AY-?3^3!1"UH[1SL(QMKE+TF2BVO_  V2IW!!;>:QC.?Z
MA]09?NWD)P,VHUF+.S\G7$NA[=Q?X8GA:T &_A B6OYUR'T68E!;^6&5/1Q!
M"$T>'+E]3$''!**.K\&XJU OU98T!\D>$Z$.\0V.IUW[ @XDI;Z_@#OO5._5
MD]4-R.Z6-NBE^GL3.@G9S\V<WZ>;SK_G"*Y!AS5&G.Y*S<8F9WG=I:\7,,4X
MKZ6P9-GIQ&M7-TK O_$F]6*L&_7I%>7J;PKB/_FP,Z)UHTAINETX1&GKS+4(
M?XCKR.4*FUU5IR;LHUL4MUK0,TP5&G.$C,QX(Y*RS(=.HUU]Z6:DBDH%<*2.
M,0.,LQ]QI?L_1OT9>\N,L]W73V_<2[R=!3LF@G9JR9J(W/P5],V-UUJT"*&:
M 4ER5?8;87=>!_4WTJZC*Q<QO(NJ.].)B]"04XM.@EBE.N_L@L,EYE7;:63'
M+:VE+HZJY,S+)CT8B,1&(C$3\K_U5?\ AW_[;Q$YBZ!T7GD5:/4-!6K3 @R,
MB;8(\* 8&8CV6W!943<E:'! [ :,P$\M<7 N'2HGV!#*G ]*(8)U%ZH]6^EL
M?9&@IW\WY2-.IW0SIYB,XYO;8;D?<[!YLG4>I6=IMR<QFC=G^NP:;G+Y4LV-
MP?3/J+9S"J_BOF]%^;,K ]N]V@]'O6W(RLO,%^CG(:S0N@T[P1C?;@.A:0J8
MOE#JO7><T%-*KM?D#K746Z7/'.MR18X<?%JM RR1 69.&$ -.D3 W985V,1)
M/"0[![*=C%;>%''TEZV]>>D?3(^G.7R-#^YPO_#O5UD.IX9\N0>RFV(S*U8\
MJ'Z->G.W8GZ0ZA3A5L75BP32"MP>D/0_JCU+?>Z'16CE]HN]S4#6=1Z-6N^0
MVE:-#,NM[TY\J- XW#K/-3=SLY%\R16YQ[?']+A3ZE4C330Y&4DJ3,UM$)-6
M0'FPE9.C'VRK$DQ$9!L1,L),B,Q4H*',-%1VVH0EH)1!$FMEZ^S>K^=IXO#T
M:M:=6[;Z<Z?)'!U.HGTGFY#\3!;TB?\ 4YB\>[/OSKP;$9MXZ4?'B<"">]]I
M91:_2VW/U>WFR9GIRX^YBZ?WN=S7>I7=5.L#3S!7]GH,T878]!;LCGY&)T_+
MN63Q4A%,5U_R*>JUDAD2D.U+LS3@ #4ZU94S"+ VL;9(R4.ZFR#']QB3FI/[
M#<>63#[=V:H)Y:U$*5O/T-T^+U><&O!6L>@67*OI!U*VCTQ)%O30G6]KVWCK
M4&R\WU7OP4=O^!EL^81U!ZKP=/F[SR[/JEC![BP%SCR%SR!H(9[@^FM(5JO.
M62M/V$)W75*^PL?Z),&9S,5FH6N (GV@&QRF6M R2#GPC&'R8V79T$8)^'R0
M[!(JGA/D*:-0E2W&DFAB./#D-(6RJE['.9T@RBMU!678&IF9HDS)O ,^I/U-
MBUM2=H]^A>D+]Q .G/G-B7K$EE8<[:&)F@C3;/GS6@'+(5Z<1V_.W[.4R!HB
M[V)-!?T41(>X :HRIE:QIR:I04?%I?:>8..F"R)=\"2)AX%"W4$"1(\>(\6:
MT.[\KC(*S)(8$?8S[2'F-O14.NJLM_ 1FR!_CAKU=!Y[2R;-&/FB1_.C$O+G
M:[3[#HS!-MT*SJ^-U_*%EDQ-L*'+UST:?'Q,S(Q*7C%^1.KH>T+2[8>AH)SV
M86 $T4YV:&4U=V!^S7K'=ZU*&R\0,?(@N1I;^R/>&ZEY"DH9)?89?0V4,(6V
MT:RTV:RR8,P6PR0VT4TV^A:-7W*V/VX$ZM64L3F6WW(/Y*N@!S%J;5.6EPAH
M4 :%K<E3UK:(.6#!(:J^AF3DV.SHTAK4NE>'!:['W&E;&*]RF-41(81H,U-8
MHS61J8:R&[S^6,AQB(Q$8B,1&(C?Z;Q$XA\GY<ZO;2;#RF]6*32/'A2KY3XH
M/.HA36WYL\_:F#H7XI@<)1  IXHQYI@CVU'FP@1$>QY[_C'NT\H@T\[3[NMI
M%>;)M:]B,OI3%\8MZ&C0=JUX?&]6?Y<X:$*U,<AA_._#G8D-T_PLR9>A9(Z*
M*OEYCO2_GI2#=?JC;1$.#*@%FGH7]5KK5H;F:[,I+0&DIV-!I\>7N8G7^??<
M.PSTG'RTE,[IZ'-%ZW!5=Q\<JP7[=2K3@D4:"=/,2*(<W:9 Z49><D(MAH"*
MBG-Z ]2[][O30/;C/5DW:-__ (?*KUKOE\9C4MZOJ8N+R[RXWY]'3'0K#J.F
MZM5&3,F9:\N @W7Z:P8%^I:5]].35DS8_P"=B!Y[OI=H1<GE^G![G3^;7G<K
MF-S'T<]"C-E(?KZV$_3LJ_QS6<G)6@R<0B,(+"]@3LYMC[%V+L=''DTO@7!F
M)LCA4Y'S$;+R+$@0ZZ(WLU@V;L)4L>T0\S%/2?2W[/3&S$G&YV:KS?S(D%F^
MEUO3Z-7S9>RK+T3/;BZ.3=I6]QVGW.'5T^D_7H#YUY'JWG<W'ZC5L^\&;40:
MJPUHO0.OD^H&9;1HXK-W+%7-TX'X\S,Z16\JSM3@YBL:+4LM76GC$4Z5,.D&
M%Z:=^Y0(Q:8I,B]!]-88BY?0:'BWEN@KF01&U'ONJ,E='1<7#/5(L6LH4$G>
MG\'S:S=H-[/#/F6M?<QAJ/!ZN0O/T*336FQV:N@E/LT/*]6T7Y,W//D.7S!]
ME:=_BB"E94KSA8KI;6%Q=99%[O2CCTXZ>"U  .^@YU,2I0(Q%FUOW*ZZ#Z?E
MQ]X?]?PST=7Z?_'Z?\/W^?UFC8SF(Q$8B,1&(FCV^_0M.^S9.1)'R$D^T,!%
MPT<1*'O./.;;0XM@=&T#,;6E:$.E.L:)=;V*%HDU2!EX[W/4O/X/UPU#LT:=
M;!5FQX,;=FAEF7M$[!56*0N_(B;S7\S!M.<&Z"!)7')X>WL6\LY9D9\JR;IU
M[-*LN=0C57=43"HF'571$"A.UA=-;\::)@Q'=>YUMVD2+U=FX_<\?(,UV+&_
M'X89M$D0*+):(*FPY$@./AOPTIETV<8-0J,T0EC;@4NWMIC"?47\1N07IO4[
MC]!%]+3K#DXE_?PK6.EN=&V]#^@G6>;+S@Q.%FGI!I$,M&P/GS[$V*LLX7H?
MJ?SW,KI87U@3F/I:6?0V.(LZGNR?$C$S.M^G;>M1+3A-)?8L!.U.R,JV1EQ#
MM[<I)R3\K)L"5L])(0+A<PR4 [8X1I1)&J^3)S#\L4/*B?B@Y/R -0H\G6=,
MA6&:,E77-XG_  ]_B,O=MU,WZE9N1JK3ERDW8+,]];F!>A_\N/3O=J:G4B]J
M6G>5?.#7QZK/TMVK>=7D?K;T$WGYLZLN8F]//:M6FE936Y?*WL%*"Z(9\(95
M-S']+0/C06X\W7"G8,:<8^)OJ_;8BQ2PT>AIAT0M Z6YF&-<G8P XPJ.&$B)
M\IB.%8BY(IV4'$86P](Q>Y-D^)7)(D E,N;"Y'\0<'4V)S4FOA>*A^]B<?0Q
MX];W95)YW3<&9 Y-;BVH4LPO3BK8&K >L=6:P9A'2]&[^=F:XRL'(([+%L6&
M+7HS+5K:W;A2;V&_.H,3F-%HY]-9SRZPSLSZ!,9RS84P^,1&(C$1B(Q$8B,1
M&(C$1B(Q$T#J]LFJ#RWI5ZK=9+NMBI= N5L@*:!\WWUMFJY79&8BZR%]NR21
M]W/'!L10WP#OO?,6CXF75^U"D2"O%7R#E>N^/,3U_IA%2 >>M70*]NS5*/FH
M:C6R(JW0[#3ZY=*M'3TI8)82#MD;%@202'IR;9<<)<= E3HYT4E:)G^?]0YV
M+4Y@&2LP0KA%]ZX7H=_1HQ+L?+=2NDC'ELH^!LC;,A&FBG /L_F0,2.2*I:'
M6EJZ-7Q_7=\UW2OB93;&SHJ78%3+&UU;/=065U\=>_S7@?S.Q7O^57QU5L^0
M/CJZ&ZMGNJP\T?\ 1XLJJK]_]/\ ]WX\RD_S"E:3)],!>HA$P0!NKQFC7I9B
M)80X][R%"K W$*^!\9,<H9O;Q"6G4K1MI"-,):TK\N/XZ_R.O6PAQ1Z04OE8
M:V?S!.!5DZZ8>>\]\Z[4U58CS#;"H64P6!850U<_2W^  ]:_1;V=8L)W?9V?
M3O"S8RP70)'0O1>VJ8#+V"XA!?N"Q+WV9%97(D[&7$F7$8F*=E'5NU6G*F7)
M=#2"GI_5<C=2RDI:6M2V=%^]*%$[V2OT7LE"'=J;1@GK(L+>N#,7V[L^1PBV
MEMH::72OC8KVF-T1W\)M_J61V+2J_+1 [(:S_P!!*V*X#EZ_I^T.YZA'#6(O
M<D.</9VUD"[NO8)BJJHJ55*JZJEV0>#O*=-D*^OK8ST8N<74VVZ&E"3&1&I=
MN-1 P6Y$=AAA6XYI6GU2"!61_:"K:M>B$H4I*9GJEO++U<#,]=$>(M7I_P"%
M>BLX[@Q5RN<6L%K65Y +Y2TVD *D5Y"K\5[JD+T=GZ-^AVCH_EY=EC/4]F:2
M:6(]M=3J+S,:PJO28T 9J<QGNTT(?DB*JN[[^1].XK#U;0T)9W &5.Q^WV;&
MIAN2VIJO0@L?[D1S:H]+:(-B):2D;T4E2%),U]_HK/U"_AY_(_Y#5\&MU9K+
M'\M=$,X:O=7'Y=8_>.,1R55\FN<7A-5XN[IM4[Y*GYD^M*Z]=@OYQ].]%UJL
M"PVXL]^.GT!V6):?_,D7\S'?[K=^OXM7^#\<E']\G+]_I=87?]SKO_)S.YB4
MX;NWU6/&^DW@.@NU3OL[,GQETF!GX;C-G9!<CZ&V>[.$-[L&H(XA&FXTI3"A
M 24-[3IJ16 ^E]EA_I^_W_\ %Q(>>^N)XA(<AVAZ9Y(&.S-5U;F6VN0/"[8C
M]%["<'<5)SP""BFWM?\ ?1:I"+>3M*AI)Y+C6W$3,QWUJ/%&7CDR452/) YM
M//9#I9C2..',. 5R.U)*=V\\7+#@DON-Q1;R"HPP^$9;3_ILP*XV4V.B=B<2
M\U>'=VK+5JKAMJJP)$?%R8XO1:C-4R1)"EE2#+#X8\DQ[#FFBHJ0$(?">(&2
M^/\ S;[K3C3BT29U=CYAM*O2Z0N][3OT_G7=_P!6_P#]6O7]/XZ_OU^N<7^E
M_P"U_O\ O_TN/S_;]?[?[_\ M*.O.[JMZ.FZ^!SN-Y<N/CK/:96.D#)JVDM%
MQR2S0A]O1I406#'F_?*D"W0Q!VQ632"W@_13ZW%^&/\ ZANWZ++1Q.<"N]EU
MYMG6VV[+DP[,+?.AF5E*S='H5\2OO#O:*KS*6IS&/6OY&M(O9O\ ]/GI_P!5
MN7WMI,XNO,_#R\%JTZMN38NC4K6NV.P8;MMEDO&#'7H:34K5G8SXT@(\<=*N
MG:IZ@\;B-C<Y<,AH*QN2:G)ZU;&=>+L9+,:MMG4"C>WQH@$,!+[VG'41S  +
M+B0Q&&&])^I>KZ,W^G/1.%FOU?[^?S>D3K/!R[6TG=70I!^RMX5[TY,J,P'9
M,(<J<R**EH6-;P]*<CU=S?4OKO8G'Z2]FWH\H%C6KJ@:J3R4.>/O'GL+V.TZ
M6:3'^BBU,T/(/E:9W]'4;]VN=B.6MB!\U6F/YA%PYNCYNV/*5*"2\FP0<RK<
M"G:B'6 HM+9*EO%Z%"CQUNI;#8;:Y]6=?T;T\?I*JU^K_;C]*9L+";BY1DS1
MGZ&T':?ST0$6,%&==,]SC^%*5V54H #K](\/U7S]OK$JQ^E/=H]7:=@_#KZJ
MZ!+L&)PYCH<1U:0O1H*EW2UVW1I;\5$T[.]/Q.[1$$TP<F^/TNKG[KE70$J-
MFK-+%FL:1*,FJ/7/,*^Q;U*C&$"A N(2MXL\P@=M9"'7_?W\*.QZ<['I_!HX
M6?I),N-S2<SK%;-;DBW;G!GO^[N%2V;,^YOUA:%4TVO^/R^S/P7_ !)Y?>Y/
MJ#HY>R[ RE]?H@*^95!D4_VY7$%#]3$3##([$OYR6?E8 FC]JA$>L_WQ\P_V
MTAO^*[_#U_\ L_PS:E_O_P"/^/Z374X*\E?J0\WY<>S5*C&],G+(BPHCRI(3
MDO3$U H-J.+>(_"KJBBS,(?O9VA&4D1C!S)"&#66315J'*WI7^)O\2-WIP,F
M+@9LCNB[H&EC.CW_ $WQ,IH0C2+P6[J]#[*VCL%2_P <Z[8"W@#D6W.\]L_P
MY_A_C]2NUZ>UKTY<.?!3Q##P^_V]=/:W/:+9FY>+X;260G,]Q;P%9DJR4TJ8
MBN0KU]5*JSE+HQ&JGU,RPNR=E7+Q,KS'N<+67PQG]"19#D]6*A7'YPP-*7M(
M%T*/$IV4TX4R7*!!F:TWZB_BSZCZ' ].L+G<5_5K;V+W8]7KOTQEY#\X,%6!
MI[N3ZGY3NB[*('5)M2\/NT"QU.UY\S9MST]_"GT_D[_J%)=7L9^<&/ECBW9/
M0OJ/9UDZ#&VZU5SNKZ=WKYZ=%^WR^W7L8*;K.2L>C2F\NQ]6.#B*5SH&!J_5
MS)4D.P:L3\UR_K0S;+X,IK[ 6.G[!SNPKF8X.-?^UV49O\9<<'0X>0\][EDR
MP_C+ZMP<#TOFYV/D.UDCH_S=V_UWZ.70L7O\Y4Y.CT.MUF;\V7"=9R:ZAZ)D
ML&O,V4=NB7_"'TSO[_JANWH]+/D4_G_RQ6+T-ZM:1KT9:%SM7/P<SECSM+]0
MT^E*K^7>US!RBM%52+"_'GSKX[W6OA$(5=JC-,P0)\JF\<PZ%188@S?QCR+4
M#,VBO1\9+I8*<;6A@0QPW[1]I]8Z=()T/Z*]"^LE^K>1ATM0&;H,P@[4E6WD
M[LYZ%4I>Z\KN3TNBNT+T.7:[<:C)3E7[??3A7H3UCZ6/TOU]^-;RU8D[6)S.
M9CZ6%](9;3QUJS]/!SW+T,0H_D 5$(M4RO/LM1,Z/_?)R_\ VUA?^*[_ ,G,
MZF(3DKO7U)_';Q^D!(NP!]0N!1DU#5]I5 Y])RP"I2<4"D(=F9EGH&%+TC\4
MC=$*"D2=)<-2,QI\L61'"1(!L'UL/$RM+=%DJ?Y!IEA;G^PA\.GF0C90$\L)
MJ082^:5:!H-P<@1Y#J-#2[YK2=Z64".TXTZXB>RO_6K\4;(^V!'4OR%W-$W9
M-!!@W>8B[,-L'V1$@\AHT>SD03+ XPSBW$E2XYR_]8<)YIMYUI$Z$\?OJ.>/
M7D25(AUL7H].>C)&:BGU]$I1, $L^!+?"-%:E03)F)4^MT0W8X_W^B5(")V^
MR.OX$/HG5?[X^7[]?2ZPO_DZ[_R<XO\ 2_\ ;_3_ +_C_G^(E9OGTOA]RIMM
ME(VV=?3>9B,KT+K?/.W=@H-&,%_%&]/;LE0J'0ZQ6I4AR&:/CW)=^M2!A.MA
M NF/M1?Q1WG/^/\ ZTR>F_2/;Q\\&K[>\^?E)W\NY6[GM)S,Q-5TT=-;QU47
M+%BEW65PT; $"HD-^OOO^!'I%_J3UGQ&[C N3A'?K^(=V[)O6"DZA2SFOP&I
MJ##I6MIU]E)50,,J\-5\]4>J)2'N/VL0ZS=P78#+Y!ZC6]>0O>C8C4>B))U+
M[?<=ZQMAUXIP:-3[_L#U*;%'1LP1O3"'/(8?Q,[+/1'63J_E3>FWU%S?K6/I
M#TL>->:N?I'8+2^A2K-WU\M+KZ>@KI(^')6"Q9ZT_P#X9<97KSB7F'I+YJO3
M'4;IJ_4WJ).P]?\ ,,_U2!8;/E&D#IT?_P!QG&K<WPAUDPJ^N*I50 XE&Q0%
MT[^).@=4V3]F-Y(]WBZXW#$UQW8ZQ5-]4T,'(H/V8ITQ<>.YH<A>D&NHV4RU
MVYOXJ=[-Z!S8<CL2.EE]7_/[5^E_2RL 8&<JZ1\%#SO8C<&H=!$WZ:RI3;L=
M3!)RQZ=G\+>$_P#B'JT:DZW\W1Z*H2MWJ#U+MZ1[E=;_ !2>+.@3M68LU)$,
M_P!AR_E4N[S@5(8=H/@*]Q6K5VN3,_:NQ/\ 08%^VQ?W]][QV>^TS0\P::4W
MH"IVOI=CJNR=1;>V?QE-49=');>2D]@D]A<AZO\ _I]]=H]4>F>?AZJ3=WN9
MNZ.:]@\WFY,(-UGMWI7D##2A2P\2M%N>O&H;(3![J+0G[/EG^//HIGI?U3T'
M<LQ1Q-V#FZPQ7LWZ-I!G5DQN;K/;\C3&M[@M>=NMQ"+$DE5!G96>T+]\G+_Z
M[K"Z_LVZ[_R<]*5_K//DA#K7FSQ;D6G='ZN%Q6/#$3QB:)7%3+08 \?8I/\
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ME.U;WO65M^B/1EK%)>D?2Y) K($WZ?Y5K B_]1"%Y; 2+\>XJ&O/B6=>L_6
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M\EC/Q-K;$E^'\XIP?X@QMWY]LG?;0S?W;6WOY[;9'R(V[_.>GO\ SQ$^2O\
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MH[W4^A?NNYO)]'LS36X2JKOUS%FJCSLJQ.-U-RZ@B[Z!*U.DIE+&*B1[X3>
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MWMMKAF>8P7?8BH#6GG/*NYWVN.V*A\MLT_J0;'@NK6FJ;;LU:K,HJODS,/(
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M\>1[$+-\'9ZZ;7(7G3O:J[%V2DPO5(YVYT*GUN<B><]!EV1N>'RCSDG1H?I
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*1&(C$1B(Q$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>cntx-20211231_g18.jpg
<TEXT>
begin 644 cntx-20211231_g18.jpg
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M<*8:L$MDV+8*J+5.W01Y])$?VB:G J' !P < ' !P < ' !P < ' !P < '
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ME&H_-CC5+2!+-;$+N5HXY;G#B M1^('DY$&1$5[G?+*V697*QWSZ<BSR%NW
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MY@R2(F39PV3(F31@@^*%7[Q^[<.% DS,SN>\QT;@0' !P < ' !P < ' !P
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M ^<X@WU0O)3^P'V)^R7 !\YQ!OJA>2G]@/L3]DN #YSB#?5"\E/[ ?8G[)<
M'SG$&^J%Y*?V ^Q/V2X /G.(-]4+R4_L!]B?LEP ?.<0;ZH7DI_8#[$_9+@
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MZ5$635U67',E9VVO1625>LI#:THZ7Q[[F!9]4H_[ILW3=]@8S[[ RXJ)M%%
MK)MDTHC.@RK(!%NWF1F7"W._'HW[M^>0D_&^ZCV10/M',\U6X9[]4H-.7,^'
MMI*H7W<W%73RU=Y14XK7Y."UW&$(I!H+/Q,D62:[G(C<L&?M@:&JRN^X1;=T
M[O?]G61EP$=))WOMFDM;T"RL?7EIF:F82:58D$MFS6D(>_C-0=-.JETST,'.
MBH/.42$ZGDXNB1&H4!>#VK)O$A\F=N#:;"((M7H3:]CW7Y%?>9D79ETF/>#[
M:3U]-8/)I/:D@CS:Q^U]F=8]Z4 QZ@B,=KM@)GDEK:KGAK25GXSV!WLFPA#.
M+WH-E(9M8=?(P8TIJ_JU"..PDM> ,BZ-Q'?.^=CZM^7#K%A76^QC-M476-A2
M1NT;R2119HI(_AR*C<2ZD Y18.<)A$%55U4@!<H/=E0&BJZZF SQC[1=;?TJ
M[!![SW]N_M';>! < ' !P < ' !P < ' !P < ' !P < *TO$9^! !_.1[\?
MO\]FN!=STSZD_LD++>!00Q[H7A9]%0D1)8"YA@I!Z[+H."AV 2*X9$Y< (I)
M)\8' *Q&690H5=F+KZ%S>:G94?N^/:BAT56%AXK+CAD:PP$D5S\>VQVSMP'4
MNN$[L"Q*Y3D-A[P]X71.R..[E8@$D4-T=DH@>)1*6,#M>R,W-5H(?C,S!R"+
MD XVSK0"O-@^IL5,730FDT:!!^/'\.H=\X . #@!6M2'XU'R"?FN>//_ )E[
MK\"Q^@GZRO8@2/NCN9U:Z].6C"XKO@T-*/"R(34*H06-GFI!=ND[TP5 QML8
M,A66K5=NX7*F&+$6V2<-E'#U+5PCG?"U+$=#I"DHJ-3BQG%.$ULC6;CJ5F1*
M+:-,DXXTG5,C-QQ*6TDI)J46L5_5\!Z"M+VDUI^1@?1_B&NQ&(3E0.>B,B!3
MGHS;JF5>1U&J.P8,^0;K;C;<.#(D3'5M.I:86;;A)Z,3NZI!U732Y_N@18Q5
MU?QJ32V7S&,EFDK#"0,0!K2.1N5%HZH3RX6&A4-WRK!KJN^W2V2U2;*;KHZ;
MY./)C2V]K%D,26KFG:1W6WF]8B(S3KMJ4FY$9&97N1&1\2'GE9H%=PY-\VX@
MHM6H51V:7?(*S3I=,F;):UMH=\FFLL/;):VW$)<U-12FUI(S-*B*+,>EO6(/
M!IA&;6ZK,NKM>FR,8DS^,715U+"(-9YJ5*E70QZS0K:1V'#)%/6:L4=OSD3/
M.&MFQYHR9GBT;9AU&93?G&*[;]5^7?N[+#8K"[0=%8Y'IU\J9_1TC&QV,JRN
M7QX5F)S!=X!.P>+(;N,B&.CY$UN=K*80_/NFF'#@I7I\*OE):+O6RFX+'POT
M>.O=T](VH-8?2QE-).H#/]>AT\TE<882P@Q3@XT^XFB15>#15$L83;MW+^0#
M)"]7@@_=9XX>A9*^VAWKLC3S M4&>6_F75S(8J(7CU$(P>[IY -8$_A%%;1<
ME89B(Q(2J-7TB]5PNWH 5CVPQCA*5I"X/(XLK W@OWG*#Y!(9'MM%F:&,@SN
M6^Y_:9E[;CX(]V8ZM30C+=-&\/;60C/]ZPGL&DF:S&V'@LUN2&]?R"YW#^28
M''! V7NH!HHFT/%RKP0\@#4.')'9!!H^7!8^1^"O[!B2=N>.<V)8KFY1U3*!
M31PL18Y,-:Y=L'Y@0]$S8S(]4WS+=+=)BYM -/'LKWTP/3;3YE-E"GN,D3+.
MP6/=8_X_P]70-O.69TAV)7"ZD!_KRZ-*:CX5=JKYK"GY>18T,.(6.B$Q]9HX
M?S/+:1L7<+1CSC!G9G)&+N*Y9HF&BXY,('% =_\ 3R+=A8>,@3)H1EA> L85
M 2,(DU2I55%ZUGD\Z]O??XHT0L$2,"M[8EE[56:48#A*LSGVD.9O!D??X4@&
MLV"<\[W[;]/LL?4-^1D74"Z2,DA42D@:7)]B"4R&&)= 9(V=,-IFUK:%+DP
M^0CB.[P.7L&I8H-EK$<+;*P^Q8;7\A-$\%&:CC4^#,MY;K'8R]9^S/G8==@W
M4_KU 8+"J['U3"CD>KV1'9C$,3",@)0\ 3"3'WLH.R<(L5&+(QXJ]./W#IOB
M.-Q# ,VU9" #(4%&#!S,%SYGGOZ>L=6B%?Q*"+29>+"$!2DO-M#YWW?TZI.'
MPV,1Z%"4FS;7U6HX<'B<3CH$8,'HMF+5D+2VT0RZ6=N' 0-SX . #@ X . #
M@ X . #@ X . #@ X . %:\9_' W7_EM]8_WG>VO L?H)^LKV(%E' J' !P
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M3SB&R49$:C2C6,C6JQ&9(21J.V1&(?1[R0]"[PK61'(]:T4L8:W+BXTI53X
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M,:C@9GC?#02"!,&XL2-;>TW44]@Q8-6[9+VBBBF4TM<[[[[>G;(!GN #@ X
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MF[L$J>! < ' "M:D/QJ/D$_-<\>?_,O=?@6/T$_65[$"RG@5#@ X . #@ X
M. #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X 5KQG\<#=?\
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MF1_)\9(1"B11H2$$-R\BD^<,PBWR;V*_KWEPOUENX$+P.!4. #@!6IY=_P
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MD)DY!)2/8$XB3)==X\>/9GR)39*C-1),RR(]YEQMUVMWWR,?INX'&' !P <
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M5P$F^! < ' "M:D/QJ/D$_-<\>?_ #+W7X%C]!/UE>Q LIX%0X . #@ X .
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M7]I/_&8=_P 'L/\ S><?Q\Z0?[32_P!&-??'+_)@T4_V*M?IE_[@?.7]I/\
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ME'BL3=)NWP#9/W9T_=[[XWP$GZ*;9YJ[[(R[!;?P*AP < ' !P < ' !P <
M' !P < ' !P < ,')I* AD</2Z5EV(",Q@01/R X37U;#A 82T5?$B+U??\
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M6CY\ B(BR,[FDSM8N7/6X;]VXKV(6J=^+J=T/3(*8KRYA (40L@#%K-G#N(
M9TZC,+- I1E%V*C<K+"(P]=OYFTB )_N;4>HMX^6-+CA9 [H);[!4BN?LW_8
M1\+CLW6:R =NT575B1J<KV4$D@AVHQG+F/#(HK(=1Q@D(6=YCX;_ +)&Z).1
MZS-%,=G9FLBVT<MU%$U]=]@@QW;@ X >,:ZZYVSKKC&=L^MMG&,8SMMZ,:^M
MMZ/Z\^KKKCTY].?1C&/ZL8X 5KTA^-1\@GYKGCS_ .9>Z_ L?H)^LKV(%E/
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M6I#\:CY!/S7/'G_S+W7X%C]!/UE>Q LIX%0X . #@ X . #@ X . #@ X .
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MZ4D_H.O_ (6'Q-Z1?H.)^LF%_P :#[[[KY_?4I^KRS/L=Q\9>#/I23^@Z_\
MA8?$WI%^@XGZR87_ !H/OONOG]]2GZO+,^QW'QEX,^E)/Z#K_P"%A\3>D7Z#
MB?K)A?\ &@^^^Z^?WU*?J\LS['<?&7@SZ4D_H.O_ (6'Q-Z1?H.)^LF%_P :
M'&NQ/=0*!H:X377)^QFE]BJYES^GXG+839(^-R&Q&H5VK%1)AVK'A"&C-X6U
M;([Z.3(1HOMMJW=FPS954FT?&7@SZ4D_H.O_ (6)+0WI$N5Z)$M?/_M)A;=^
MFA3)UW\C/D7O'K&A2EYB(I2?:N=V[)X3.;ZB4<P]']9NNVL<C9/%D&X%&7\M
M4*7W)G;Z6QFF(L*03!Z+L1,WGOP,4,U^5CXR\&9_Z5D'8^%$KV7_ .,Z#%U:
M&M(1*.U$BFFV1?E'A<KGT&=9W;KGTV+F5SM 6+TQZRU#"J1J,T7!P>##=F3#
M1U!;0(F3!%XY6(GI5*#+B'9>2"7RPX[(2*52%_MN^-GB3\BZWRJXSC#XR\&?
M2DG]!U_\+%#T-Z13._F.)^LF%O5_IK=R'9-.WO7K95!+:=NV^7#ELT35>0:P
MV+;"[QPFU;:+.WD30:M]57"R:6%7"R26NV^/7WUQ]/!:2\%ZR$G5W6]=QMM*
MG:16V6R6ZM+;9*==IJ&T$I:DIUEK2DC,KF0@]#>D8DN*30&7-FTZ\I#%>PV^
MZ;;+:G730RS5W'G#2VA2]1M"UF23LDSR$E>;V/, X . #@ X . #@!6EXC/P
M( /YR/?C]_GLUP+N>F?4G]DA9;P*"NSR%K(E0=&Q@5OJ3F#&YF,X0BP9C2TC
ML-Y%1]?V-$3A^"P7L!)HS6<QR&)3($PE.A?8NYCT;.O38$<E,DHD^;A9/'AE
MOSR/A>U_<)&=7Y=&I-48!@!-ZEG\2PM')6R59U@+,1N1HK*O'$>DP2F21>MH
M[(6K1VS=.P4<(*Z-&KQBY=II+O<^N$'O_C]N8D/P(#@ X 5K4A^-1\@GYKGC
MS_YE[K\"Q^@GZRO8@64\"H< ' !P < ' !P < ' !P < ' !P C/V'[ +54G
M'H%7H%&Q>PMG[.Q]3UEJZV017V;8UU*3N<O4,;JQJKX9HIJ_E,A5UTW7]5 "
M%PY.DF2',+5ZL<#8Q(C13*O.UD0(6M8CU?ZR5*46;,&,1DM]T[&K)IK6=6DA
MZOHRT;(QBJIXDQ-47,,:,\(DS)QEBPV4N.-DZ9G#PYAYAPTHJN+J\I"HU'IB
M#4EJ[E2G[*G1)#@Y.+^YKT2K O-K:EI:Q+ON*1M7<QD0D/DO:G8"W7S;W4)!
MZRA;7*CQ8:'0VTC]>0<;A,##(TC[X4<,T,GSB^<P9@V=,>>9C*1*G/WGU^MS
M%%&AQVT%9R7.DJ_FX5-AMW:C,D?R&R)IA#LAPR<Q6EK2FC&$ZGM0Z>G#>",,
M154+1[@B$XJ0W1J4;NT--\EU3$=:D?Z1Q'6WDG)JE1<6\\MJ&Q%8C13\<_CI
MLJG3KV_>V-E2FV+2,O7TFK^!3B2%)HC2A61;O$S4A=DG1E]&BUK& *@P(:/Q
MT0T:@DT"XL(8+CR/O6OL&D/2%3:PPB@X5IL6E4ME#<:?.A1FH:JRU')!L1T-
MI91):I3+Y.O,L2'5K?-3+K[++C>H?B-!H4B*LYU3D.RI*U*<89><6Z4-3FL2
MUF9J-M4I;9I0MQM"219:$*4E5Q<YSQT;8' !P < ' !P < ' !P < ' "M>,
M_C@;K_RV^L?[SO;7@6/T$_65[$"RC@5#@ X . #@ X . %&L'AU$&/+99UBR
M)OUZ7["QRQ-8G%21[N;+X9V&:Q//6*'JH,X]TT!P5Q7=B#=1A@^BSFQ>;I27
M:).BSPALW<170(H%S]$M]K<LKW/B+RN!0. #@!6IY=_P"K*_WI]2_P![^A^!
M9'I%V^PQ97P*AP < ' !P < ' !P < ' !P < ' !P < ' #TN7+=FW</'CA
M%JT:HJN73IRJF@W;-T--E5W#A=7;1)%%%+791553;5-/37;??;&N,YP 53S#
MMS:O<@^8I/QPOF6D18$7D=M_R!F Z)ZE:R]V4]U,QOKHR=[:C>Q=TM\>W22?
M#5%Z>@+S5NZE<A/$,ZQ14+6U;&KKU>)ET\B/OZ-QB;?6GK)5?5&MD:VJP>3W
M3>EB,KG$WE91:261:UA'E-7$HLNT9D]UP3F$YD[S7#@H7>YU201T:B1#08#'
M#!;,(,S,[GV<B+D1<"$@^! C9V[_  ?)S_\ K8+_ /Z)$^:)I+_]"JO_ .;2
M/_W=-'I^AK_UC4#_ ,BO_P#\U6!)/F]CS . '+K:NRIJ)C&\QM^P(U7\>]K[
MLU=R @FW<EGV<8]F*CXE+"QB2&E\[:ZM0@!@2+.]ML:-F:NV<8YDZ51:K7))
M0Z1 DSY%M92([9J2TWG=V0Z=F8[*;'K//N-M)(KJ60Z\F7&AM[64^VPW>Q&M
M5C4K@E"2NIQ9\$(2I1\",5F=F9-Y NX,"0&=(8\<ZNQ9B<8E][:O NM6$^M$
M8EHJCH'AU=I1*6S.(1G99RW.N3LWTA1LTW8(CF@3+)R[T=^DX;C8"PC.4[C5
M]G$\IQAQDJ31&DU.!3'#L9O3*B<N)#ER;)4PEB$<UAE3ANJ?)Q*#1KU0<K=5
M8)-'0NFMDLE>53%''>D)+(DM,$TZZTV9F2S6\3*U$DDDBQG>T2IQ$^ 5?7@.
MU9*/F5F"(5&1M@2T2RP.&229,@[-O(S;!EJW9ZMVA,LF[=H::LF&OLU==M6#
M'7;#1'S*JNP'ZG4'Z7&<ATUZ;)=@1'5[1R-#6\M49AQ9J6:EM,FA"C-;AW+-
MQ9_+5L45+Z(T=$EQ+LA#+:7W4EJI<=)!$XLBL5B4JYE8DEGDE.XN@<Z YPX
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M5HFU:?*/4*;)=B2VDOL+<8?0AYI9(>9<6TZC5<;6I"DJ/;^=@80. %:7B,_
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MVJX12TE5B1Z FDU&RN45<.XS/'D;DK#&=\>E'=\(;Z.4MM%VVRJ"B:FVRS,
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M=)VFW=-E]VVZFJVB+A!7;3&BR>VP2?HD7'65EV(%I? J' !P < ' !P < '
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M(=)#)WR+6=DLD5S,\DEK].Q9'EF]&V-YKVL^G^K*?C9ZE:9U_P#Y]]U<9_\
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M587%<"H< ' !P < ' !P < ' !P YG;U8C;?@SJ%$BQ,#MK(H',P9X/JQ5(
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M#'PU*(^W=#\,?>7K,))2L^.71ET[NSMYV'=X/XIO$[9$+B-APGJ-39V&SR,
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MRNV<F'(6&@!\=%N"KEFT'LW!)9B-04?+M6#)LJZV540:-DMM4= 'F9GS&\<
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M-7N;PK].>LF5:D7\:U,Z*O1P^XS :/56^(J(IJ-![2?'I''0T7<O7*")4I(
M;%MOLY+CDW(+'RY^K?W>-QC^;SZJ5;?B:2LJ;O!QA(W'#:Q9DRB\B:E=HLB3
M1$"Y)#+&C<YKJ4!&^2SAXB/D,.(X8&VP>3B%ALGCX$R- 1F7K]?CWY#J]65T
M#J&M8%5D9<E7D=KN) (8$=''2#PNN+CHUN+8JOUVC5@Q]XV;MD\[HC1PT6UQ
MZ&HL:/'HMF2 0>9F?,;[P < ' #C(NAZ^!S*#S$,U(CON>B+$'QJ,)OL.(JV
M*6<0C#R13!5B^0=O]Y@V:1M<"$,)E$=!4>EDU%(M=D9&[SJ#]WJ\>P=FX .
M#@!K4OA\;GL>(127"TC4>*9:9?C%U7*"3G+%ZV(M/659KMW&OL7K1LOK[-;3
MUMDL:[^MIG;78 @*9\7'6N0OB*Y=]96HU>1322B D9D@:O$0+NP)K(9_)VNQ
MVMXS$9C,V2\CDK]43K9DFF[F.,\>ZQ]R-^('%"X6UC[[7Z;%;B+'^!4. #@
MX . #@ X . #@ X . #@ X . #@!$?LKU)8=BYE1-D,;IM^BK&Z['IX?KN:5
M"C4+\@FXL>%.J_E#4R(N>I[>BA)FYC+Y\T;8S'D7+19UN[1<ZN$FZB(21VOD
M1W*UCOS(^!D? 1BE7B@J^;$I([F]VWI84?FT\#W=8=<RQ>I1D)L[L1'Z894>
M/N*7NZ]J2$SD2_(142'?'897,O@U=N9",;$AL1%H9=#W03K'P(BWD6_(C.]L
MS/*]]]SSW[AHO2?QYWQ0S;L>]N.V@\T+VGUHHWJY7#-,ZTE^L0A%#Q^X0D;=
M$Y((I.ATUF;A*TFS5F$6A4@D0QH"7=R"R)X7+J/6H%*(R(B(BL9GETVZ3Y;\
MNHK##1_P]16<!Z$D%_VO8J=ATY NO\1S&*WD<,D56LB?72*%(%'C4%(V/3"M
M@Q =/H\]R8L",Q\F!8/I$ZVRJL4W&MRSP&MOL19WSSO8^!YVRMR'9FOBBHT5
MO4[P#95V S%,0/I# (29;%*X>.4AW0MS8BU4$R;,K6;\40+RE&SI(TL;;+!$
M:223&*1@;$W#599T#6/D1YJ/C^<1$>X^C(:,"\-5$QMHC'A-V=BDJ])B* C]
MBUPL4I]>/6F$ZTW#-KUK%A)RVU.8FP7*$_G))4ZY@,KAZYD&V;"%=D?2L[4!
MKGR*^9D>=RN1%SZ.-]YCTI>&.A4AT2&_=H[#JZ4T%"Q_JVNJ4J7*W6 7';U@
M78H.C ?9U$DG.%&MBUC!4=W-Y:6HY7B<?0CZJNRCTN2(O%N'CP7$-8\\BSO<
MK9'>Y=F\[6M:XPI?Q(@=KAZTR=K8!Z81&M^P%W]DKUEEBF0NEF7+)[1F\*N@
M?6KR,UW6D(KA>M4>PU:UE;[E%UHPT!NZ\91\/'GK>0NR(@)U\CR(LB25N%LK
M[SWE<CYWOU],7Z+6;)NL-P5S)9+ 0EP2_N,_[JUX^ OI&=@49L"/]@(OV#KF
M+GR)&/ 390 H;B+&+R\BWC6CG0.3(OQ(U=\W:);!4CL?89'VE8_:=O6--E?A
M7ZN36;3RP34TN]L>LB03J6R-D-E,*P%1DTY[(G.S>A5@U7KC;91Y"I/,K#@L
M)>O_ 'EPPK:Q)<)(_$CK]K(6 22C+EP]16]=B,^DBZ1-[JQ0)6B1%T/Y.8&&
M9O?78NUNP4QV!>]_)\2[FSL6"BD:#*/V[1Z[2C%:Q"# 2A1RT9;')"/,G$F
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M #@!%3MMVR@_42%Q&:3?0:NRE$\'1=1(E*1443&QUD),S&P9;JZ*)K_$UHA
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M2T!7>"[30.4&LE5R3..QXAI[Y*HM)Y- E8Y*Y* BOQ+=?U[O'4,($\C-!&T
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M4>UB2'PE,;Z$6*S,%_'CK$D<8QC&,8QZ,8QC&,?V8Q]&,< // !P < ' !P
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MP7/?[^=^/(['[=YWZ_OU]C;PS%#;CNK=;F<Q H]K6+R/65]>5B#!YM''8M]
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M!IAVS?- 3)FN$EN,^1%NXWN6?>)V(]*8TWM,K9"$R>IMY!8X"QS03$:"9?\
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' !P < /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>cntx-20211231_g19.jpg
<TEXT>
begin 644 cntx-20211231_g19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    * "^$"0#A"24T$!       +!P!6@ #&R5'' (   (@"1P"-P (,C R,3
M Y,#D< CP "S$V,#@Q,"LP,# P.$))300E       0;F(:> 58=)+&2<A\C$
M?:QCA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M   %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<'
M)I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M  #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '
M4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6
MY0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !
M)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F
M]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M  3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F
M)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W
M5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M           $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M               %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&
M%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$
M8C4FQT                5&]P(%5N=$8C4FQT                4V-L(%
M5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F
M-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M     -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M      .$))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M             _@   .$))300-       $    'CA"24T$&0      !    !
MXX0DE- _,       D           $ .$))32<0       *  $          C
MA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M   0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M      <   _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@
M  _____________________________P/H   X0DE-! @      !     !
M "0    D      .$))300>       $     #A"24T$&@     #-0    8
M           @T   =D          $                          0
M         '9    @T                      0
M     0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   @T     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',
M !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M  !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6
M=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&
M4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %
M1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (-
M   %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4
M   0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M    EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6
MQT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M!.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M        QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F
M<      #A"24T$*       #     (_\        #A"24T$$0       0$ .$
M))3004       $    !#A"24T$#      ,Q0    $   "@    +    >   %
M*    ,J0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (
M0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01#
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MLVR"SZ6M;K&;?[2J_\WNCO#2*G;=FQK6VVAFWT_LW\VVST_P"8]F_:J;PX=
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M[V^K9M_P""K_2V,5>W!Z9TS"J9=B4Y^?;+*F"FIMEUIE^UK6L9776S\^S_
M-#/4M1^B?9O4RMV_\ :>\?;O6V^K&OV?\ F_9]DV;OLWI?H?Y[_M1]I3=/^S
M?M;+]??^T]=GK;9^R[OT7V/9[?LV[;Z_\ AO7_ *5_VG24A;T_IO3<$Y'5:,
M>Z^QT[&4UF'OTKP<)K:JK+O]'3ZGZ>W_"?R&QNG86-BV]0ZSCXM =#_L_IU.
MKQVCVLJ;:VIC[[G_X7Z?Z?]'CHS?LO_. _;-_VK8?V;ZNWT]FT?:OL>W_M3N
M_G_4_6/L_\W^@]5+-^R_MK%_:&_P!+3[!OV^A]I]WA[OM?I_T7U_\ A?L_Z5
M)2'#Z=BO%O4NHXF/AXI;^BQ+*Z0&5@[OM678ZK?7D6M^G3ZOHX]?\ PWJ)87
M3<;/R1F_8Z*.FAI%%!HKWW$Z?:;_4J]2BK_N-57^D>S]+D?Z!A^M_8O6POVA
MZOV/U?=&W[-ZDL^R_;Y_2?S^W[+_@/M'\]_@5K)*8UUUU,;74T,K8 UK&@
M#AK6A22224I))))2DQ( ))@#4DIUD]>]#;1]OW_LS<?MD;?2Y;Z/VV?TGV3?
M\ SO\ @?\ N7^KI*:^)@XG4LK[77AT5],9/I$U5EV42/Z0=U6YF*SZ6,]EF_
M(_G?YCTO59N#@]2RPS#Q**NG8[OTV2VJH^N]IVOQ*6OJL;]F;_ -J@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MXU+0XRAS2VUW$N8QH<VS8A(#)>^G-M^UO9'%4 RS6 JO[$5GBS![KCK;?@]
MW$=Z_+GPF&]:.R^9K"%#UH"W%,YFLG-O(Z&798GY$7B/G0K53Z',B$D36R%[
M"#ON&ZWG7&N?!'NN-VT_.T,;J[[\7-C#.:>XF6,KK9O&.1SP&N(!8!VW-.%-
M'+*TV-JCFIWBG#H=P2;W.-'WJ0'X8MVE[:$9)&V).G'3MN^DQ!D]"-*(MZ-.
MB"VB,#W*P!M-I-)-(A%W==Z'I6\WN63:XK6X,QO83!V(=ZW)+Z=40:]K2]^Z
M>;#CVI8'?P:65TH:_MH@VH8RE['D+I2Y_.7W18]TP:QSVQN#MV8L!OO#=%0(
MV:BV_P [3DU >T68&[K@>GN'3KM^5[2O.P$9EU$S7KS8_6ZU ]3V% 9O*Z_F
MCU,R>K&"VR*?L)!6I^2QAXQ=1:P06^<-BRZJ#G9=NOA-9%1+0N'5T^+V_:IK
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(N:70V-O*=MEI&M"B
MLC=5I.VT?3![.]3:AM>+%4A6@?9AMJ^U*;O]F^H_9EMJ[P[RCEMMA;&F<$51
M@^"7"F;C"H^,WX@Y1F,-6]>L+N)JV1;(RH.J^5>.'R"3%%CHQT<;/MWJFC/#
M3"_NK/J,J>=-?VCS^'J%_'U: *E_'Z"/GLI>]M.O5V7U;-8M*^L,G6$%&4W>
M@J22]F:M!K@-/))):62@18.'JZ[Z:(.9H(##IZ1C!L_F4QX/AN2:NAR*IA'#
MMU]&@L>D<;V^3B#\ZJ>C2^IO\EOF/2+>.RKH*]<>_AT[;L2%ONPH(5+I]<(5
M_8>MJ*QA?X#R?NU74KK^;PXHEV:FK4F?!4",D^@8;'J4H9.)Q$A((NNY+O51
ML:.':FX:UMWL-NV('WUI=?6Y#67L+Z@ =-Q5MA^%=P$;QXW<RYK. Z)-T@V-
MCKT+I[&M^^<AMIY:U]PZUS-72X=26UH4#35PLPV&CV&QWM- S#.O/<]I0U-2
M.+RA:FK=FXQK(8X0EXZ8 6K_ .$B]?$8>D-K&P(N7. )!()+2 2-.U:-PD:%
MW;@:W7&Q!O<7L 21<'C?0\+NL0.@ B_7;S2K(N.JN$LC@&7Q8BW#::;1NP)Q
MK9,Z!,\N%]A8J83G0D<UDDE8B]F;<T_Q(I3_ (P3<(?"V5Y1^$9.O[!Z; ']
M_"YUZ57]IX^/3^SHX+J'")PB<(G")PB_F<8S\>,9^_CA%!VV_E_=*_F,[L?E
M/JIPBG'PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*CSO1
MXK-D]3NP9FFXS4T'E@H5'(P:U-'3IYD076/,=GJJ.6X]'9MHBW_O4TLXVVWW
MQC.^_HYSC77$.>]J+\EXS%A0P9N("6@@K>?-::?=,TU3#S>X*:8:<Q<.WM=Z
MUM%-3D]\D>#;ED:KSC+G>;+KJ;,-?@?8,>!LQ%KFT='AU4*DU#L2I"#(:\LY
MOFK-$8.^XN(;(^D.]\OM/H-<O<$K7T=&2:K8O=4@9PL:5+. AE:K(P\D(]LN
M_5:J$VVA?=NFU=Y;MW*J.NVRC;57?.J>+WRCF(YHR]18Z:449JS4#L82F<1\
MQ4RT_P#&<W$7;W-[_P" +;UM;+ >VG9FS9)M*QW9_'B[\;9@S,*>,3?2-H75
M!Q+":+$R.QFU%2V,0FK,(//.WQ'OD-+BT<CF/B =H(AENQ_N>FI9SM$+CL$6
M5S6W8^/;3H%4HBGG;T0'KR15^RLN&**&+/7!/)[*03N")JCF#D>Z(*/';%C<
MYT)N0+!QZ[V+0->C5W ZZ$=*Q.-1?PM ZNV#SQX?R1TVUOP7F4/$_>NG[T&P
MK,*8.NNS=85]&6H&4.RS<AUKL"QQ]6.;Y<K)"D]MWK&>-CT.9@!^CE@Y-%ZZ
M6<E&K24JZLJAI(!X?QI.A)M'(Z/0#B7$:#B;.TL%Q<; G2^ZPZZ"[P#:_@!O
M>U@"!QNI:=<K]L*U@L2FL['U &C%LTT)O6LXW!9P:DUGL(D33"O%AI^+. +?
M,JU%CY/'$24PAV^@Q"3$,1C4(IER'+%J'2XXD<;:@\>'38V-CP<.'!5O>UNF
M_'0CS?(1?0KQ*W<X*=Z_S"ZX)!)=HY!6\I1PL%:L;F=2,EY@YOQOU\&GC!"5
MQ1L09PAK(GK>12DJ-#EGL;#-RPI^QTE E^(;T%R&VM=U@+\+FWL.LZ#5+VO<
M'0$Z:WM?AZ/-=>;K>][#?7B.H*QF-2/9,E#+@E!\[54O+&VPUQ7C[K5L"$G(
MT8'HDX2=-A>P.2KV-EB99TD(&1J2,"+H9,$6XX#<D6X;MS<:WW[V_P#E'I(_
MDW7+H!\)!\%@TCTW^10Z;>(5V %5O1LT+T?74X.]BZVKFX*YA==S@ZP.MHS(
M+4HB"2V'&TY2%U8;33WHO44^K@DD4:1V5R./FP9[X)#T$SBM1<VZ20"=VVGW
MM\AXD'@PV'3?2^J?Y_&S20-.)YQL8N;V )(OTMZ5Y*"^)VM:5M!(M7U?BBU6
M:S*)BI5:3M[*6S)A&[4NR84356R3%"-.78F6D9E"WH\X!.-$U1AXH& &-(VP
MQ(Y5&>1:1N\#O-N+>!TC?/?FR1;H7#>X^ @:Z<6,=YB"\#733JU%N/.*Y)PB
M<(G")PB<(G")PB<(G"+^>CK]K'\F.$7\]'7_ +77^3'^SE+ < ![?N'H1?WT
M=?\ M=?Y,<JBJSZ%_+ \87XOEJ5%_)_<(=4O+^;^WA4'VGYU:;PJKZ!5)^X&
M$4!3Y 6478NT1I)TR]\FP\@JW4T9OG [W4Q]\$6CC9-PJR]VM/=2:>R'NIOZ
MSUNA%'_J3-K"LKK[7%A6@<CQZ7S0+I('KB+Q=>(AFB+S?;#<<V$NI#)W&?<V
MJ6V=GBI3;9QZS'^ 2]#^^(I'\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(N?6S+WM>U994]'-&S\A"(!,9<R8O-E=6CQW&XZ2,MFCK9#;1;5NY79)HKY2
MWU5PEOOE/;&^,9QY^+5IPW"L2Q%L8F=08?65HB+MP2&EII9Q&7V):'F/=+@T
MEM[V-E]N&T@K\1H*%SS$*VMI:0R ;QC%1/'"7AMQO%@?O 7%[6N%4H \2JY"
M,EB8E["*R]Q'9A$8\\V:M94BZ39R&2B@CI9LHK)'*6CE%N_450V5;K)86TT]
M8EOIZ6N81Y)Y8N)9NS?EG*\F1:*B9F#&\-PA]8S')YWTS:^JBIG3MB=AL;97
M1B0O#"]@<18D J5N:N3)09=RWCN/1YNJZE^#X578DVGDPF&)LYHZ>2?FG2"N
M<8P_<W2\,<6WONFUE8'=MN6< LB'5-4[:L6,B/5G9EMDY/;KV0-HJE'ZS,0
M$YC[!O'-V[W+TH^L!@N7DRSQ1C"!+30@X R18FT8)SJ)L";:  Z\=;]'@MJ>
MBXXJ(O5KQX6U^WIOH.FQU7&$^X,[E77H]:<$"UDI)U.T%=]>X@Y]_2\TK9\-
ML&\*TJ=I.-#038"^DXM(;/5I".7$[BFQQ-FR41V9MWFV$^72+Z7,@U&O:%X
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M[@4R5<E4)#&I2R=H-6F9[<>%B #_ *I-K>9SAY]%BO70= )(\]K^G='H\:C
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MN>/P39O_ $@U?ZNY>5AG@'?6@[!_.J _,H=S(>PGO/K?+]9ZCAJC+[H/\-.
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MPTG@,+PPG_SU8MR7(6!/)WS"!J3G#-@ ZS[PX#UZ+3/0/?/I[<3JNZSK'L!
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MY H>?NI(14?L1.BS]X5)NBRKIPLHZ?.'/I.-[HRWC5164&#8_3DT-5-!28E
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MN+W"G9RWE]:SG^/]_DNI_P"Z7G_1I[]?]W,#[?.X&">6'^I3K8=[G7\(6?\
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MZ\^FS+@U55TE#%43"JKF224L4U#7TW.MBC?+( ^HI8HVO9'&][HGO;(UHN6
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MAYU[KBYW;#<,%5&VP(<R:6FFBBEOO$.YJ5['@%MVN&^+N:T+FPL:T;S"\\Y
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MHY7WUV5V]#91628ERB\AXA*UK):[.N"UDC&7#&/J3%.]K-YSG!K2\AH<XN
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M9OA%?M>U"?OJX?T[6=R6NSGO'RUY+A_KR+3=RH+?W?\ :G;_ *3R^GL2DO\
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MAN%A((YT20FH88K@;P="'/Z" Q[7!KVN:/%B>\U+%'XUMNWFH<>_>:[N9(>
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M/[>GK*TS<CVKU6<_Q_O\EU/_ '2\_P"C3_,#[?.X&">6'^I3K8=[G7\(6?\
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MY\L$QBMK,7PV!\CVQATK7-;4UKA(P4]0\"5D]5,QY#K&Y;O=J "  !O[LJP
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M=UK**SY]A?K#)_%]<RC_ /6"KW[?]GV/X^:E:#\I[-OQDVJ_4F:_;YEL<G^
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MJTH<0CY65V%'V9$:-CLV,G44X^RJ0)(C4>3G"9+1V'WF!2H0KP;:8":V'#8
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F"?V5L6GI<R46(I@<(G")PB<(G")PB<(G")PB<(G")PB<(G"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>cntx-20211231_g2.jpg
<TEXT>
begin 644 cntx-20211231_g2.jpg
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M              $$!08'" ,""?_$ %81  $# P$$!08)" @$! 4% 0$" P0
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MDC:[BR):>!RH;5F+%9&(V1[[0YA3/$'N]I/XU:UOZ ZCND)(\I9]@QHOP;:
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MV9*3^G?8K_%!V#^\?D9/AZ![*8'CZ3[:?9DI/Z=]BO\ %!V#^\?C)\/0/93
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M]^],ZWT9TXTJX'(VK , %%[MF'"4QW7&LY</NG9-PR+5!U=G6SQ"W[4BZWB
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M]7\9S=I3MJ^,K)XUXHCL-NNOML,H?D;&_>0VA+KV[!2WO7$I"W-VDE*-LJV
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M541UCUWBEGZA((WB=/L^P:_MDSL";;B#VQ).RZDU4H=5N2+"G#;+$\ )H=/
M1!K(Y%=F5T$T#,!28R>8C$5,G.?#&.S';Z?MXU8T_H[H\M-:EEW=D&64E85E
MDCC.S;>7A%+K$UM&U$]>S*B1&5.+VTCKR ,KTXD0FR&O2'-S(<2&0G%Y1)3/
MJ_G[:JEPZ6Z"O!2J&3M9GK*4^V;(MPR=&,RV9;DG;>P8.T;\,D2E>I)9%FKJ
M*%E&U#71Y83'AK$!BH\,3-0":F3Q\1CT#'V>^>-5\-U5U!7BFKC00<='$]/
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M.E:V")50,#'1Y$:64;@SQ4 H<&F5,GV>'/S]O/.>WG5X-^SZZV1#QBRB -G
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M)(P2. !R._B>'CS%>'JX=4/4TF ]E?U1Q0/DPIOQR8;7YEP<8]3YO83X_/\
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M2U<./P;,TR/>6Y,IE7'Q4I6UXO383CV94='BYC'J,X^:_'.$_E8\JL^9/B!
M(\"?6 ,U&#A0QV)]0XUS3@ S)E7%;$)UQ!$G0W864K;\'VQCD7X@XCQ<QX)C
M>167,J\N<X3G*?-C'CR!^!]8/OYZ^B.?#M2>SB!CV'G7F6 ,N2R+B(3N4.[*
MKYAM6%M^"QD5F!B1,Q_S/'TFLH5A6/#S^*%8PG/ESX3GAS_JX_\ -G'G%1@]
MHS\<GS8.#YJ, #*)<)Q4)W"$;0-FUJ\S?@D5)8FX8F9\%^.&G,K2E./#S^*\
M8RC'FQXLCC_T@>?(S]A/\ZD Y_\ Y$^;&!0& ,Q9M.<D0G6VQQJ\R)RE+;SA
MEDE[[B ZO&',Y4F2I:<M^7"L^"L*5A.,^/&1Q_Z0/.-GV&@'+AR)/9P!S[1R
MJ[:+ F"ZD%@$&%QYD:,XA]ES*5+;4J2^O&%90I2<YRA25?)6?S^&?GXXX402
M2/?A1(( !]^-7;SYKZIQ2NO[^$![:U]J336@">P>O6MNPT(MLZQP!X/9)G88
M:!7Y355S(<*C7=>6VI3GIDAG&8;C9"3+B)95E3;"'O!S&W^B"W3+C<[PW#O,
MVS+;@L+6[":ANK>29&R&UB9'D("0?C H2E61Q)'"M;=),V-"@VU<FV1;FE<M
MU*6Y3DIM+2@SG;28KS*BH@;)"BI.#P /&NK%]M'K3_\ 65U6_CKLU]]/-^?D
MQ??GU?\ _*6/^&5J#X>M7S3L_P#F+M^_T^VCUI_^LKJM_'79K[Z>/R8OOSZO
M_P#E+'_#*?#UJ^:=G_S%V_?Z?;1ZT_\ UE=5OXZ[-??3Q^3%]^?5_P#\I8_X
M93X>M7S3L_\ F+M^_P!/MH]:?_K*ZK?QUV:^^GC\F+[\^K__ )2Q_P ,I\/6
MKYIV?_,7;]_I]M'K3_\ 65U6_CKLU]]/'Y,7WY]7_P#REC_AE/AZU?-.S_YB
M[?O]/MH]:?\ ZRNJW\==FOOIX_)B^_/J_P#^4L?\,I\/6KYIV?\ S%V_?Z?;
M1ZT__65U6_CKLU]]/'Y,7WY]7_\ REC_ (93X>M7S3L_^8NW[_3[:/6G_P"L
MKJM_'79K[Z>/R8OOSZO_ /E+'_#*?#UJ^:=G_P Q=OW^I7T-VYZ]V'>6F  ?
MV=_6NEESFU]=!Q5Q W+L'+.5,D3MX>%!LH:+8-KF ,DL"E/M%!T<V(*B'ID5
MELD-G0E/17;;>--WIJT75Q>M;X^ANVSEK9<BV4(>2B*ZI32RBW)6$. %"BA2
M5@$E*@<$5ULO=K<N5O0G2]I:4N=$0EU$BZ%;:E/M@.("YJD%2"0I(4E220-H
M$9%=]OZK-@?M*;A_AOKY]QW..-H?V$^E?^JNF<'O/J]E/JLV!^TIN'^&^OGW
M'<;0_L)]*_\ 53![SZO93ZK-@?M*;A_AOKY]QW&T/["?2O\ U4P>\^KV4^JS
M8'[2FX?X;Z^?<=QM#^PGTK_U4P>\^KV4^JS8'[2FX?X;Z^?<=QM#^PGTK_U4
MP>\^KV4^JS8'[2FX?X;Z^?<=QM#^PGTK_P!5,'O/J]E/JLV!^TIN'^&^OGW'
M<;0_L)]*_P#53![SZO93ZK-@?M*;A_AOKY]QW&T/["?2O_53![SZO93ZK-@?
MM*;A_AOKY]QW&T/["?2O_53![SZO93ZK-@?M*;A_AOKY]QW&T/["?2O_ %4P
M>\^KV4^JS8'[2FX?X;Z^?<=QM#^PGTK_ -5,'O/J]E/JLV!^TIN'^&^OGW'<
M;0_L)]*_]5,'O/J]E/JLV!^TIN'^&^OGW'<;0_L)]*_]5,'O/J]E/JLV!^TI
MN'^&^OGW'<;0_L)]*_\ 53![SZO93ZK-@?M*;A_AOKY]QW&T/["?2O\ U4P>
M\^KV4^JS8'[2FX?X;Z^?<=QM#^PGTK_U4P>\^KV4^JS8'[2FX?X;Z^?<=QM#
M^PGTK_U4P>\^KV4^JS8'[2FX?X;Z^?<=QM#^PGTK_P!5,'O/J]E/JLV!^TIN
M'^&^OGW'<;0_L)]*_P#53![SZO93ZK-@?M*;A_AOKY]QW&T/["?2O_53![SZ
MO94V\^:FG%*<4IQ2G%*<4IQ2G%*U^=LMM/\ 778=:VU5:K9K)93U'*ZX.A8M
M3M<BIVCWYTO/U&Z2N0T4_7!Q:J;)\P>0+(%H15NF[.LYN#$GY&LM)^@,@C('
M:#D>?QY>;A7R3@CQX>GEZ/Q..VM@*//Y$>IY?4\J?/Y/'R>?PQYO)YORO+YO
M'R^/S\/#Q^?/FOJOUQ2G%*<4IQ2G%*<4IQ2G%*<4K'/0/_IQOL54U9\N:SV$
MLLMEK/R_Z;8=-H>U_61C_P!VGI][(IRO'CC,AJ2C.?.VO&)/''DX^8D?9BH
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MKMFI4J=!$WJL6JHR&9-:N=F")AF:V63 <*X*B,C[&-#EQRF3W]F/,#G'I%7
M%Z::NKX/%3K-HV<$H4"Q ;;3Z"-N+:J;1;0#VU4MW/GJ^+E"I2BI(SLRE##T
MYZ\2K>D2V0M0>HHK(:WV8>44R3Q[>W[/L[OMJU;UTYZ\]E+<+WJ0L=DL*;6&
MA6BM$*R?KRA,B <U<9U\*LM4LR:],N0\3)I]KR9$"0=NBTMBTIB7T> 9M<XN
M8*J9QPQZ??GV9YX.*NR)UQU/-O,?Z0[#O6P=@00E,L-CCW"W"3!*S#JWM"U7
MJB6 Z&BA(, 8(%6LK=P84/41U7I> D\B Q7W&A8C(I3E[?M^VK,A>SZZ_"W-
M2X$3+K BZ?(5:;4H;QX,?RZ6I6UB6XQLQ\K:Z\?L(\C*MI,M'M+U4,5M^WU]
M<$+;,F&*K4%5U3)X^/JSSQV<??C5,J71[KB3H03-/N%X)4FTT1JK3RXJYB94
M':&EC>M-,ZT?H1V<T#5&G4L_0]'ZR@NF*_@+<,-PRKHVW0D6VRH+J9[\'WSG
MTD\.7ARJ<(?5K3\2L7RE+'EY=?V-J"%I.VP))^:V]*U_$*;2+,QHTV$J'/&$
MER]N73'QF%(8FMI6/S%=8?&-/94R>'@<CR^XKG:[Z\4?7UR^L=HY;;=L4E'O
M7QRZVTL,D%;8[?X>EQ1@@5@  ]?K;3\&NZ!U370Z  (- A":^I;L243*DB4M
M3/9[]OM[:_0KK;J,%1=<ZX'A<QZ[K*QU.SUYKUHR9\XU3LRW DBP2DQ4+.9Q
MF1)7)Q*1YY/Y2LK3Y59XJ*IEAZM::M&I2NDRXR>Y0"NQK3L63 BEE#YD<_>=
MGG=IVL7!(P6X\B "L)FV62MD@\=3>)5'L)6HN.J'3G4J5.>W[>/9CMJ,#G3W
MK[6]FU'=Y:R6*O'*QLEH\"^(FJRZ'3L'9NW=C6*)#BRCM:('AGTQNG8&VU)N
MM #P@2>:/U]N2-FV8!63@U3.?1Z@![/M[*N*U](^OMTV;:-OFA!M=VMKI-HY
M,B629''N1RVM9.KI8E E/F'M#\CY>+0W"RPK#>PH\*YXSDQ&:=PH%$#'X=QS
M]M0"4U3TZHVPF:#&NVUT'FKD!L]QUC2P]TOPBU6"@[<1V*J\O8<*LZ[M;\$5
M5KONEB9EUDK6Q!078A0.U.G,5@(@ IGR<L>K'V=_"J%=*3TSW7B1K'7%O":T
M&WIC6%&,4^#KRR4.DV?7^I.P)$_,1JEKX#1A39J?L7:YW7$^^TPV4J[9;<4
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MJ1LEY2),8_K"H;+:&&' TT3D)0%*4K*$[.VM:E!3A63*6NNXVW=K[^)1>O\
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MIO\ \A7KZ)N/W-ZKC9_E:U_2,+[RU7U0><"UU_3BE8(]B>FTW>FTFM@,6^J
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MG478<4K!L@I\51Z15:4/=V7:)FP[3EK:$NUG%S]HQA$>>A J,3?7$AJA0HC
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M:ZXM<[\[2JVNNM>O E;:&ZTT6.@56\,"5P A_<@V/V$LO8=ZL3]LA*P/V?1
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MY!D6J7:RRK"<U2( @Z+'OT78FXMAM% !$? )JV=7Z:O7XZYD(VN2-?;H,G6
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M=#Z/> =XI1/-6V +9CK7[RY #VJ._'BS,MX1)'RQ,[&<-$HN7)/ _9Y.SU5
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MK7'CR$L]A_I]4KG1NMVJZO?VY4>SC@LUR5 G95[Z*@$#90D#$2TK_P"8Q(%
MY@Z [#<PE<!<?,!24YC>&.V>C*VW2T:%T];[REQNX,172XR]G>QF7I<A^)&=
M!XH7'B.L,J:5@LE&Y(&[Q7YP],MXLM^Z3-6733RF7;7)G,):D1\;B7(CP8D6
M?,9*?BN-RY[,F0AY)*9"7!(!.]R<E>9W6L:<4IQ2L%=VHSO_ ']1^N3&52-?
MZ^9@;<WBE&<YC$ELNI^@=#G9QG"5I)R5H+DA[OCB2*?CS8ZDR!OBG4.JQ^6>
ML[3H9!*[+94,ZDU:!Q1(*%#X(L[N.8?<*9,AE1_61UH=00XP*WWH8_F]Z/+[
MTEKPWJ+43DC1^A"K@[%"TJ_*#4#',A45I*H<62C_ ,*6VY'=!;E8,&^U1H]X
M/T36ECK\(B0I=-+6)5QAC&7'TC72D8,T".S(K.%83"A,PC _,YU*8\!TFTRM
MQ&)_SQ+^D-:;M,M%AG0VGWK5:Y$XW1J.E2PPJ0W%3$F.MISAII#,IDO* 0PI
M]*2H!ZL\_HG7VQ6^_P"I[9<7XT>]WJ);197I2TMF2B([-7/@,.K(R^^M^%($
M=*BY(3%6M*3U>L%>NM'=MG:O5LO1L9A8"J6R%8CYJOMW3$(53!Y^8[(Q:9MN
M0AR.=.59&0\Z,.RV#G2R#,(<UZSDUM&HM$6E=RZ1-/NZ2;285NN+4Z;+A"Z[
MF-:V9KJG!<'KD I$N5;D]6=0SLQ'G'T-,)*U.I&_.DF^HL_1+JMG7;C@N-VM
M#]MM\*XJLA>F7N3;F4-&TL6=2DN0(%V4)K#DD*GQVHSC\E6[0PI79&YW17YF
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI76$_"??Z .L7[X;5_DI?-[=!/
MRQ??HV/]Z%:EZ6_DVT_XY[[N:Z87.FJT33BE.*4XI3BE.*4XI3BE3OU:_K.=
M<_W[ZA_U!KW+3?\ Y"O7T3<?N;U7&S_*UK^D87WEJOJ@\X%KK^G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*QGWE'EZ\/UG
ML:$C2)#5$@RJUMT;"9<?DF]+%I3<TJ7:C,I6Y+)ZL,MLWP<E"').:XF^!AS2
MYMB;3F1QX=_+R_SY>CNJ#PX^GR?RY^3-9'PYD0C$BD($J/-@SHS$R%-B/-R(
MLN)):2]&E1I#*EM/QY#*T.LO-+4VZVM*T*4E6,YBIKD\4IQ2G%*P-[I^SUU!
MWO'5"N[DNFV@])J)Q-HS1==6"LUFMV6S-M/0V3UI5+IIDX3)1A,J<&ANLFH;
M<*!/EYAM,37E3.9%I_4]RTRZ[(M28K<EYLM+DNLEUX,DH5ND%2PE#>\0EPA*
M1MK WA6E*4ILUWL4&^-MLW#?N,-J#B6$.[MHN *3O% )RI>PI2 5*.RDG8"5
M%2CDEJ?K]I+18&OUO4>K*/01E8 M5D.JNUT9")M!FUH><BRC:8^3))4V4WB>
M3E$9\J44(J<(D'I,UUQ]5NGW>Z71UUZXSY<Q;SI?<W[RUH+I! 4EK.Z1LI)0
MA*$)2VCXB E ":K(=N@6]MMJ%#CQ4--[I 9:0A0;R"4E8&VK:4-I94I2EKRM
M94HDUYW!8[[21(B\5 5BT JN1<F;&ID(>Y,M!RDNQG&B)*DJ:<PMZSU1STK
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MVAN2$GE@;>Z;[C&9U!:]"VIP+LO1S9HNFXY0,(D77=MOWZ>I(.$R9,TI8E8
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M;I;*Y<=B[EJ!&I"+**URBV#=)$U5+%T>@=BFB4U#;.O[:,"$9P<*=-.U/$Z
M]3UJ;/'!/:!P!/#.,\=GAV5DWL3MIL#6>\:S2W)&O#8>TZIZJDQU)L1Y5:V!
M9+?MW<.Q=<7.7J\7  3G;A/#"6JW:CX23-C0A(VL-1F&Q,:T%K0!5&.&>/,C
M[,?C[*K/VI-K; T&9V+2:2.I%Q";WZ\:6^$G2,@D,EW8MN/3>O>P-5E$\UJ1
MZ=>IENME^TU,M0L3/GMEZ79K"+B,NQ17F4P,^8GQX9Q]@/G\]0U</:17>DQK
M@DGJVA2+'KU&P0Y"AM; ,Q+[LLO0+CO6D&KOJ6MOU%Q\MJROS=+8.VPK,>60
M"5\S979669%''(ORF.'OW _CCR^FKHO?=+L=1GMF^^:5U+)9U@/O\LJS%V3=
MWY!"5KCK5J[LN8@BWLZT89D-%!^P96N!4YUN,I)D5BV/P51EKJ?%2!G''F/_
M /6._CPX^^:YL+O5L6R;!1K>H:\UJ3/G=@GZ1&CYV =ES]0JK^RC^OFF-^"(
M%07*K-JMXD*]?Z-6H+N&C\ 9; 39=N  AW@\J,#!.?5S/#@/)V^8]M0\S[4;
M91!N2]$Z]U86VC6>J;DXFR[TUM790A[8M%TE=9MF("[6>JISZNA3^W"=1&V0
MP)J=<*6>I#(9.Y5[%N)?0-4[/CWCD>S/L\WFK:'HC9N-RZ>UYM#W6!"<NE:A
M&),45))31+$Q?G8G-B2!82$EE!6)C#_PTLD<B"5A98(BI1$7)AD9:H(P2.ZI
M9XJ*IADV&K@R8;L)<8"##VO7GES,^*+&06?,E'K3)\YUB+&:\RDI]1YU"/,I
M*?'QSC'%*C%[;$HI*F0*!KV[75\3<$5$_/E#<T&O"%,+D(+FHYF^X JMH<4Y
M%=AN2J!!MJ'R2F8B%):]XEQIQWGLSW^;A^-1GN!Y^3S\:,"=W&GHCQFVTBD1
MH=M<FO#*>"G6V49IT=454,++L-J6)8&DYZFY?Q:= JCGHQY3488MF1%R2D.'
M9D\.WO\ -ZN/IIQ[<>;VGU\/)CG2#I@/AP/*LURV?>20"TR+<+G6"_&A339-
M[(Q3$6;7Z(Y3:B9##EB8[HL,;KQ$?!>?(O,L8<)SU2&>X <,<O+WY/;3'EX>
M/OG'C5P574VKJ-'C1*;KJD5=B&2(&8R057"C%,F"S<)DH70[$A-._%23(T:R
M0(Y7F9,:'P6Y+[B(D=+<9/?[CE4U=9X $M(4I7+*(&GP!N%(&F IB''(BR<"
M4WEJ1#G093;L>3'>;5E+C3S:T*QGYX\<8XI6-C83:G7_ !A-/CG=UZ8C_P#;
M2)1'$[<.MX*<^/HTLV9E-HV?58#6,IC56S$HMY%QD>@$LEL3@=6H_P!<#SX'
MO[#Y>X^(X> YU''/AW=WDQS\G^U3?0-ET;:(=PY1K#$.1(LI8\I%PB3 -5\J
MSCQD!+/7B;$,[63L7QQB6%/#AQ2-XXR]%1A2<Y^2,5.<U?7%*<4IQ2G%*<4K
M"+LSU>N6W3P\YJBU5?4QJ8NNO7>VJ@&"9"W)J-@'6"KP3U6B28%>L&0! 7#G
MU^Q$9#%IKDN,B.%*Q14@C G?0..?'N'9X]_/WX@5\D9Y<._U8[N6*S=QX^'S
M_/\ ^_A^;QY\U]4XI3BE.*4XI3BE.*4XI3BE:Y>P7L_W=U%IAV/O6_QWW"YD
MT.!7?"+L! N'GTOD!-77F4'(UL$OTV6F1S3Q&.PU'CHRR[Z2/+H[6G0R=527
M9C>K[RA:I,J4Q$NV+M#AJF+VWXUO)<BOP8APA*6$K>;0EM V%;*<=*]'7](=
M.AX;-O=T%IYQM,.#!DS[%FQ7"X)M[9;CS+L-U-C7.>-IQ:Y*T1G'%NN';1MJ
MSL1AQ68,2+!C(PB/#C,16$8_,AF.TEEI&/\ ])0A.,?_ -<W<TVAEMMIL;*&
MD(;0.Y"$A*1Y@ *YN>=6^\Z^Z=IQYQ;KBO[2W%%:SYU*)KTE1D V,(ABD9$P
M87@3!A&(YE6&Y4"?'<BRXSF4*2O"'X[KC2LH4E6$JSY58SX9Q\2([,N._%D-
MAV/)9=COM*SLN,O(4VZVK!!PM"E)."#@\"#7I$E2(,J--B.J9E0Y#,J,\G!4
MU(CN)>9=2% I*FW$)6,@C(&01PK4=KWIOV(%;JLX3&RC]-U#7 @ZC =A"9[#
M-]-:P;-JN JC54@SC,\,["FR6X)TRZF,W&7"Q#'MD!?B-5S99.B_6T?5=PB?
M#TVUZ:@Q&+1#O<=Y";Q+L"99N<:T6Y])WT4M.K2U+E*W:6RT&F$O1_U%=A:C
MZ:NC>7H>U3OR7MU[UC<ITB_7#3DN.XO3\'52H(LTN_7:.O\ X><E]AM;\"$@
MNK=2\7I*HTO$H;?DI\B4I\5*\J<)\R\Y4K/AC&/%2L_-2L^'CG.?GG/CG/.F
M , #). !DG)..TD\2>\]M<;$Y). ,DG   &3G  X =P' #A7ZY-13BE.*4XI
M3BE.*4XI5CF=9:YL4X<5.T*G%RP=LDT&+D*V'E%PR3+$F,6^#E78:B I9*/,
MEM37!\F,Y)1)?PZI7JK\63RSP[J8'/''OJTX>DJ\"2%13+-L2D1Z\-.C18T+
M>#10$A)Q!)6)<NN7%VT5\C,#SB2B(1<\9(:A/1($%;+X6*D7F<\^7'MQQJ,=
MQ(\.SU_AY*\1@V\*V@6U#N5.V5 '5X\@DU<Z^]3;=9+/C!F76GE6VFKD5,&)
M=<= A2[<;54N1&C12)V+F9(E,A67#NQY.0\QR3Z:<>_U<?5@>JI&JQ \4 #9
M]HKS=5/R&G,DZ^R8C6!D=(;?=:PA@S%CPV2$=YIMN4P_[I$=]%]")$6-(0ZR
MB*FJ_P 4IQ2G%*<4IQ2NL)^$^_T =8OWPVK_ "4OF]N@GY8OOT;'^]"M2]+?
MR;:?\<]]W-:2=7]9-&'NL=0MQ+5PTW3S_6C?FRMK]NW=A6D>4TCV&HTW:3>K
MM(QZA$MD2@);LKM6U:(35+12C5YV$C:KA^FGAD(;&1$V?/OMV9OTF,W<%M26
M;Y:(-OTX(;"V[I9I28'7KJJ2J.J82P)$]SK#$IJ+$, -26EK4=K 8EHM[EH9
M?7#0XPY:;E+F7LRGTKM]SCJF"';Q'2\F-ATLQ$!EZ.Y(E=<*V'4(2",L+U[/
M+I09M!HOK<R.KNO@';#4]#V>/.;%*_%=0ZSUGI;?FS^S+?OQ,Z\W.J6PZW2-
M>6RAW@LJ9/&V4R1H8R<TZ&GLD[!%UEJAIAMN:VM^6]I^XRX"VH3>[N,V=<[1
M L9V6V04R8;\J;'EQ6]E"V&FY:TD.I+=YDZ8L"WG%Q7$-Q6KU"C2TNRE[<*)
M$@7*9=AM*=PIF4U'BO1Y"]I:'5KCH4"VL*Q5D]-M#([F@(0>P:F-===BM5/8
MH'5Z]F[-48&:1O-6>E[+N-:VX(J\VHK%=8B<2_K=-7^]0I]B>U9C$^KVQ)I(
M8O?TZFN_Y,O*=9N+5Z@F1#>N @P0TY=(D@)A1G[<X^F0'+ZVJ( U#B+0R)_Q
M'XY:WC=F58K=\/-I;=A.6N4&93<3K<LK;M\ADJE/M36V5L[%H6).7),A*G3#
M^,R]O-VO*>D=0.BHRZ-UJXTJASJ1<>RW7+2NG[[8+]O4@1VUJ39NIG#<7:=5
MG4"_UNKU6][3.M(-XDW8'(UMJTQ(ET<Z#;S7R*WL?E:EU8Y%+\:5+1*C6.]7
M2Y0V8=I0BW7&#<0TJ ^B9#>D2(D!H[K$5T39[03*:>_7(Q>(]DTZA\-/QXZH
M[]UM<"#)<DW!:YL*7"W@F,JC2FF69,UP;S+[9BPW"J.XUEI6=>W5;J)KO?=,
ML.+4;(U$N/WI*I<102OVFZ7UX:.TYM"[,U^*+JDPVF5 ('ZH*@ER0+4ERL<!
M6<DX&,"8Y 9)S+4&I)MGE,]7:1):7:4RE!YZ/%AI<7<H,4OJ<D)9*5H:D+4V
MAVXQF%_^&O\ 6J0M.-6>R1;BP[OG%,K1<2PDMMO2))0F#,D!I*62X%)6XRA*
MUMPGW4_MI&P%(-T]>O9UU[<>_P#L-IHYL>P @VF=G#=6P;B%"5ZRM*FV&R6\
M$'LMJAUJQ67W /$14U**2!SDBFPR4]D38MCT^7) IL/A>=:/VVT66Y-0677;
MG!<GKC.NO,D(99C.N,1U/LL;;BNL?JTK DJ;07&84E*72S[6O2[4^Y72"Y+<
M:;@2TPTOH;:=&TZZ^VV\\EEU[8;&XRLI)82I00[*84IL.VOINB]7(G1@QLC:
M-=J,S<ENWYLO5%/L%E>V_,F"0XS5&K3(.2&'4':M%J ::&L-N,%VCM^KEO"S
M7DMP2(^6.A.PUU%SEW]6JVH5O?D)MD>T0;C*98%M2EQQRX3VG0XN7;Y<EU+K
M,=MLM0WX[J1E:%I6L+'C CV=.GERIC3"I[]REPF'7C-4IMM$.&XVIM$:9&8;
M4VZ^XYO9+3[:B E:2E)2<XM8>S#TA0+5:0>\'R%R2O;Y.GU6.?(DJ$\[0JQO
MIB@BKQ$Q7K-#=GC-K427$M Z4ZIV&R+E0RM>G284R.2=Q2X:\NLR/'=M(1&(
MMS<F0IEM$L"7(M)ENQ5;]A80NW2TJ86D847 IMY"5)*!D$/25OC/O-7 K?S.
M6PSO5+C$QF;B(R)"0TZG:1-CJ2\E1RD(4E;2BE06=-'5K^LYUS_?OJ'_ %!K
MW-FW_P"0KU]$W'[F]6"V?Y6M?TC"^\M5]4'G M=?TXI6.&T^T6N=0VQZJVF!
M;Y"!(S7Q6W60(%CSZW1V-NW$YKW4[-B?=)Q"K\K85ZKA>L"&JT(L. TQB//N
M2ZP#(#BLI3'X^JJ!8>WU KFK:1M653=IRH%^I]KV2%J4.K#L7R/K"E!_I)9-
MA%Z_-L$) X- K4@*:P&<GKN\G-E 5^-4W;?,=KD94XXXR!Y^'O\ [\JM6/WR
MU!+1/FQ:QM9ZOA">P&K':,U"'&!URK:MV G5E[V,4S-/1BBZ,#OB9H/$P6+(
MG"K(:Q6 * (UBN'#0]3!^SM':,CU>SGPJT;5[1W3 ZN6F;1ZY?=CW6J#J43)
M:V&"X "PQ(USK^;)YRLVR$8 40FKQT*"V[WF:M8:WN0JJMMXI/C(6ICOX#W[
MO?TBI5TYVJ@;7SL,8[K:[5JST67MAP<&F9 /Q[^"U?M[8FH7R=.)J,QFT2IA
MN@Y:E0K6Q5V(TTS#6*('JSEJTR%,>_H/JS4*T+VD6LBX'7+6P:E9:7L?8&MM
M?76+1!$ZL6UY^T;-&Z\(U'6E?S'/#[(5-&5[5I L5;"M3KNN9YDG*%+M\(L'
M.#1:F/1WX/+CQ]1]!J17.Z4")L6;K4EHO=<"QNA]>NU('('TIFSW&VW5WL$^
M5I\ 5+N<0./^BE>ZX;!L_P!+2=F8IUM#C7I5/-&(Q"F2;HICMX=OX>T?CBJ"
MGVB^@)*@\L;!V).JQ\U1@(B^2:X+K%-)3[[KZE;1&11A&[V*KS"Y:)2MC4<H
M]51 Z?=#+YN4)IU;LY>IWB#65,'PSW9X\#CCW<B?)Q/,9STXJ*<4IQ2K:J%/
MK="KT&JU(6T'!#W"$AB&V]*E..3"Y*89,$ITZ<_*(%"YHR0(&31@G+EE#!>?
M-*$I<J=+D2'%*N7BE.*4XI3BE.*4XI48RM5 #5H+V6XRIU[8E3J^0K=4MS0H
MI3J%+KL1QJ(1J5?R-:BQ[ _.E$24BUDLDK,A4WX;"*Q \2(/:G/F[_'W_P!Z
MCMY^3PJ3N14TXI3BE.*4XI3BE0U?M'5*[&&[D/E&M?;-B141!^SZ#+8"VU,5
MC/FCC3J7HLT%=Z^ROQ4BLWD/8P+2EK?C0(TS*)3<@D<.8[CR_EYL5! )SV]_
MO^-8Q[![*;=T5<-<ZQO(6L;.-VBX5&.FQ:R@3Y-DG:\+FW )L_:-1-$Y=CIL
MP2WB288M "9=Z<:> %13D.K29D2-&G .2. \>7DSV^?&,]M"<=A\W=XCGP[<
M>'?BM@//FIIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2M?YKV@%,!G"%8G4&RQ[!"WN3TU%'RR0QC!P)!L5JJ+&
MT0<A"9#<RLR+32;7798M[W4Z(*!7%$8C0PI729I4@9\P)]'9Y:O@EVM*2]G[
MFU;0M7MVHOH!<(GLJ6<V"%HD/Z*$J73[B*EU269%RA)2S%V[ ?@0A%E+TRI#
MU4^9-MFP:O%,!LR5.SW]OX?97!N7;]P)5]8'*WKQ1HAL[9&V->01Q8K<VXHI
M>I2=Y&E"LMS6VJ]M620V672'W8+#%1]UC)(,I(DXN6L9?4 SG^7XUZ;1W*^!
MUX00$:ILEI/&S^^*W#KX644*N-3-#]C*SUW/E'V*Y4[%:Y@%Z;8UWV<NNTVP
M6494 I5,&K'C:8HN2ICO\/6,^GN';WUDCI_8\?;.NP%\CQ1T'XLX;A2X0FP0
MK0.B%*Y8"M8,1XAJ&Q"<?;9+!IK>8A@37K2*6E0FX56J6N"9K8M45)?%*<4I
MQ2G%*ZPGX3[_ $ =8OWPVK_)2^;VZ"?EB^_1L?[T*U+TM_)MI_QSWW<UHKUA
M[.C6U[T-H+:)_=Y.CV/> <28&0"P_72JY*GD.TD_KQF@5R')V2/V:;N3X8=.
MV# EC=?$JQB,-GC"I4:S'E%(6UIVM)T2[W>WLVMN4Q:G'&UJ;7-WZ4(L*+QU
MQ]:82X+49+JTPUI7,;?RM#C;;A(0K7D32\61;;;,<N"H[MP0EQ"5IB[I2E7=
M=LZLTE4M,MR06T*DI*(RVME"T+6@ K3'';'H;"TG8=)5S5%KLVQ#FZ]G;-U(
M#KAB#0GICMFU_;:;41DL98=97_8=6EM6XI<6HB:P3(!KQ5)(S.;/7X<8T%>D
M5NGM7*NC-U?N$=B&S:X$&XO/M+EI2&)D>3)6E;,Z)#?28S<8J+Z$.19 7^H>
M66G0FEO.G4P';>U">=E.7"7+A-M+3&*B]&?8804.Q),EE0?4^ &5J;D,E'ZY
MM(<;)F#<'L?]K4[<D_75%O\ 6I=9D.ZH!T>U;8$VW6)&_P!VVF0VA4!%6 UY
MNNV20PZ0V%I>_"0A V\)&OU^13K03F#!!]<J%;;;TD6^3;439<-]+X%P=E1[
M<Y'GHAQ8"($EQ]YXO,)(1#N<-QU#0<6'DR6$)6XR$JKINB)C$Y46/):4R3";
MCO34/Q%R9$Q<MAMEMH-.J!5)@24(4LH26BP\LH0X2F(IOLT]C$X""NMMDT:^
M#V- T#>)-U0'9@%+#]RTZ?W7-HT8@ND%*Y&*"ZC6"LD67MQ^GB;-ZPF##7$L
MDV37!]R1KB$A9;G09<-9N\RU-C>P7<B-<F;6F4I EH>4A<E]M+C<=F2XQAQ:
M@IA*7ET2M*2EIVXDN/)2+;&N"SNI;6R7X+D]4<*,=;25H8:<*''W6$/?$2G9
M=464T(Q[-[<5=B%"M@V%I0.!IV;C&VN>DV.ZOC].EJ' U5*LX.\L#]>S2T\E
M!G[KUO7VE:\&7L=..'U1X1!^(-*38?JUK>VOJ;;8A71UV3U8V]I+,0+N3<Q=
MP2P[%*YJ6T(6BUS73UU<1:&F<K0E2VTJ\UZ6G-!:W)5O0VQOQ,=+L@IA+C)A
MEYN0$QE+4M*KA%:'5D2$J<=PE12A:DW_ %GV4N]7KG4:K<K'KH5/,W4%7SE2
M"V:61O0RME^QQWJXJYPT/U]FFS N=I@'H$-2+8N=*&$A1EL<J"HDL;1O](-I
M$63(BL37$M177FI#K"41%OMV5F_=564O&2AWJ#P4K,<(2XVXT5[80%U+.C;B
M7V67W8J%./MMN,-NJ7(0RNZ.VCK"<MAA3?7&BE/Z_;4A2%A&SME%F@O9SW9V
MC?6+<=K:YK-4(]?KMO2ME!0^_P!P'$I%/JE.N*]?3#XNH1ZK](EB;G 0=?JM
M@N+%0)P28,\RP=B+%YJ7=:Q1+ZE%M\U^0B\1+4^VXJ)&6A,F1)C=<0TY)+^Y
M#D999$AF,9*%(=9):4'*IV]+R#'ZT_,BM,JMLBXM+0F2^E9898?ZLIQ#(9WN
MP^@.%EQ\,+"FW '!L5KJYFM8Q4[]6OZSG7/]^^H?]0:]RTW_ .0KU]$W'[F]
M5QL_RM:_I&%]Y:KZH/.!:Z_IQ2H>O&@M1;(M$*XW:F13I^' $#%O/$CD4>7@
MUPF2.51BS@1Y.(!MV*6?,E[%17+2,,.T>QE"%@J2PQF9(G.*9]_?U]]1MV'Z
MDT/L-KFMZP(G++0JW61Y2O0U4;X+&)JJ!RH3J*8JJ29<05G,!IM=GYCRAC<C
MX,:5$AQ;<)M 1#X:2J0<5=L[J[H8C'K,27KV J+4B-G)"HK!6PP8TE=UNK6Q
M[:/LD:"7C1[C7;%?8\6WE:I;FC=8EV"'!).!_>(,1;*F3^'X?9PKU.=5>O*Y
M-PFHU368I&_#KX*MY0>F>-+FX6S+='OMW2^6'S8Q)B0;N42+8_?H<J-.&E(T
M>0(DP,LMX2J,GOJ0:WJK7M0F.$*Y6((R>[#L4!Z8V[,?DO1+;;BE\LK3STJ2
M^X[DS<#94_-<<4IUR?.?5A:6\I;2I4./]+>LLB4S+7K%EO,6&)AP8D6UWF$*
M%J!4VMT .4#A8=G8$![&-JM,I,"):1<&)96I5(I)I);X[3ZV2%JG)QCL\WV\
M^T^FJM(ZE: D-1$_0>9$F08@^+$.C+OL$1:V7QQJ_P!A:.XN JUP[4JWS"VU
MMH/FKLLPJWV!G8][@'CA(?;3T6>ID^_'N]@]%<LCU5Z_$@3%75K44.K3*L-K
MK]=(GZJ%G"E5*JT.352XRM%Q,(W1"-.HU.KAC7QAF=2#8NM!HY>OS<0&,H4R
M??WY\>?.L@^*BG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4JQ]C7T?K2I$;B4!W&Q0AKL%IX30JF:N]G?]_G1X"'(-<K\
M685FM1ER$R)SD>.M,2$T_+>\K+*U8#C_ #I6LFA]B"UDV/;MI=9MH%.P%5/>
MC:]A=;KM!)U'9]<"*PS!:LFJAE@&"<E@\".RQ!82&C28<M*(8R:Z;,R(Y"%J
M>[V[7.E;Y/U+8Y4K5ECN+_6+KI:4XD3X82E* [I]Q*0TK<,H2A$0(0X\VVAI
M:9CZDR&=[6&[=&>M]-6O1^IH,/0FI;3&ZK8];P6E*MEP4I:W-SJII2E/)$E]
MPN.3E..-1W75OMN6Z*%Q)&PU6^]4C]:A]LVVW#-=4LTSC+$W9+[5&DQYJ79$
M=X1*B6!R$[@LS)B2F,0XWO.9>6%/CES(BV9#NQ[/=(U[ML2Z0T241YC1<0W+
MCNQ9312M3;C3\=U(6VXTZA;:OVD**=MI;C2D.*U!?[++TY>)]EGN0W95O>#3
MCT"6S.A/)6VAUIZ-+84IMUEYEQMQ'[+B O=O-M/(<:1QM:=C]";CEO#M7;?U
M[>"K"5N/!@%H%S#:&6\94N3D+[P@KF*G&,YS+Q$S&^2O!W/ESX7+![CZ*L^1
MWCTU9F[=_%*<78U=J2HR]F[P-CT31]:C(6T J8R4I;,>T7TTI<>&)#I=0K,>
M(Y,C2B2T(9]>"U)8E*U_JS64BUR4:>TW;7+_ *MELI=8@("DPK:PX2A%PO,K
M*&HT4*!*&U.MN/D)1MLI<0Z=J:%Z/8MZAN:KUA>&=+:#@R%,2;HZI*KC=Y32
M0XY:M/P0EU^9-*2 X\EAUJ,DJ7NY"VG&4X]:[[=ZOTBW8M=]@^RD;9NV1I<C
M8+OFET*[VVOZS:F*91+KD\_2:H7$C18.:A_#N2ZQ#@=;[L)^ /BQ6T(NVC[5
MJ6V6I2-47I-[NLJ4[,<<:92U'A!\))@Q5 -J=C,J2I32E,L[.\4VAM+24"K'
MT@7K2%YOB'-%:<7INR0X3%O99>D*?E7$QBL"YS4%3J6)DAM2$/(3(DEPM!UQ
M]QYQPUGS3+O3]BUP;;Z'9P=PJY=K+PT]72<0L+EI3GRN);EPW76L/,+QEJ3'
M7E,B*^E;$AIIY"T)RDC' UA'.K8VANS4>E1D8OMC8U0H$&:IQ _-E-0QTHHX
MSY<O-"1SCF2)5UG"T*>:'193C2%86XE*<^/) )Y#-*I>K>P^C=V9DMZHVM1[
MW+A-9D3A8$]"D&X,?"TM^\S@3CC1F'&RXI+:9,F"TPIS/D2YE?CC@@CF#^'I
MY5 (/(^-3'G.$XRI6<83C&<YSG.,8QC&/'.<YS\L8QCYYSGY8QR*FL#MC=^N
MMD85?0E?VA97'0,>=7C6SM?:JOVRZ9KX]-:S"A3)UDKU=G56;*A2I$=]B-'*
MRF)#WI1U+RM>6^4T^-*DPI<>)*,"5(C/LQIJ6D/JB/.-J0W)2RXI*'5,+4'$
MMK(2HI 5P)JMMDJ'#N4"7/@IND*-,COR[<M]R,B?'9>0MZ&N2TE;C")"$EI3
MJ$J6A*]I()Q5A]<^VQ2 . @=M6<-L:AER3=<H?9:GY?EULJ3RXAB)5=IP7&&
M"U$NV,N,,.-V4>,F.NJQDBRZAMZP3=56;4VI-(RH^GND1&_C/.HBV?6L5"EP
M)JED(CQ;SLIVH,U9(0E]Y*$O*SO"X$+FN[PU#HS2&O84O5?1*X8LV.PY.U!T
M<S5H;NEN0VDN2INGMI6S<K<WA3BXL=2UL)V=REI3K5M9S'VCV+T3I1V-&VOM
MFBT2?,93)AB3U@@QCDN*I2F\2XH)#KIB1$]1"F\RV82X^'$Y1EW"_ES;X!/(
M5H$D#R]W,^@5<6MMO:NW$'</ZLV!4K^)8<0S+EU8Y +^X/N)RI$8FQ%>7)&2
MEH3E:8I!F-(RC'GPWY?#/!!',8J<Y]_-^%8EW[;^U]_$"NONK[J:O21LF2.O
MO9(TTY& CO<UJ;*BM<8<PVZ<)1<(=:DG(><,1G$_]-,&,NPK#G3EWU)J76LA
M^Q]'N8-L:=7&NVN)*%(BM*0HH?BV%) 7-D)PI"I30V4*X-N1PIF:>@;#H_1_
M1S$C:EZ6 +E>7F43+%T:Q'$+G/)<2%QINJ% J;M\-8*7$07SMN(XO,RE(?MU
M2_I_M!IG9]C5JVA['>VQ;:F(PQ:K?7JF?53)!,3'AL$'G;G"$?0'!(F\][\P
M*$'IF%(<=Q#2MEC.4[<BLOL18S4F093[3#3;TI3:&5274-I2Y(+*"4-J>6"X
MIM'Q$%12G"0*T/-?C2)LQ^'%$&*]*?=C04NN2$PV''5K9BB0Z X\F.V4LAUW
M]8X$;2_C$UDUSVJFIQ2G%*<4IQ2H<L77K1]NQ&Q9]64HZJ&YL5Z&Z3!Q);\-
MW;<A4O9:X<AU"GXJKK,4F:>RPXW[Y-9BS%>63#BNLJ50W^K6@94,=!F:U#SV
MQ[IQUZ00F&YY.PMV>6/GV:#>#$PH^6V$(LDP0'D6 +>IMB$&W P;).%*^$CL
M1E3D^X'V=GF\:]#W530KTA<OZ#O1Y&;$8M;"X%NO S VPV)\W*/DPB!UEBM@
M73DBQFWB[05,".2<(O*F,O9PWY%17*?ZO:#E2STZ1K4*[+L2Y;\Q]<DQE4"<
M2M@2_%3%8Q@EA-,/FK_6JY?SEAJ"09PW?*^$NA8A,LPJ 5CJG)]_1]G#'MJ5
MZA3JS0J_"JU0$1@8* \2E,P8RGG<NSS12:<-E9TN4Z_.)F3IPD2.'C)*3+*F
MS1&>7*S)9&;)DNJBKEXI3BE.*4XI76$_"??Z .L7[X;5_DI?-[=!/RQ??HV/
M]Z%:EZ6_DVT_XY[[N:Z?^-I;#P[K5_%P.>MIQAJ-JUSWM7FHL=BWE;\RU7L^
M'_0H;N9PO9$X3X^!4C*D_G<SC'1WP?"Q.'5FL7,DSQL__-DQFXA+W]HF,TVQ
MG_\ ;0E/96DNN2LQ#OW,P1B'\;_Y<!]<D!K^R-^XMW_K43VU<4'?VZ!I6KG(
M.R;5%,4K8%KVK4231%6)E<V/><@56VZ!W\IRN#8#SE7KK\Z>QE#JI 8?);RV
M_&;<QXKL]K6W(:7!CJ:E0X]ODH*/BOPHF]$:*Z,X6RR'W@A!R EU:3D*(KU3
M<IZ%LN)EO!R/)>F,+"OC-2I&[+SZ#_5<<+394H<<H21@C-5>N]G>P52KM6J=
M<V]>!%<I%R%["J0F*:?Q%KUU"32!$18QGJ>=R,1&D"Y6=#6ESTX\LE/D-MI=
MER%N>;]ALTEZ1(?ML5QZ5%<A2'%-C:>BNI0AQE>, H6AMM*^&5);0DG"4@?;
M5VN;#3+#4V0VU'?1*80EP[+4AM2U(=1VA:%.+4DYP%+40,J)-<&=P>S@>LP:
M:.W5>(]9%UB/2Q@KXBTZR-JT8";JC00>Z_'=DPH6:K8S56>3%?:7(K,U5>D+
M=#L1H3/BYIJPNOKE.6N*I]Q\REN;!!7(+K4@NK"5!*E]89:D D$)?3OD@.E2
MCZ(OEV0REA,^0&D,AA"-H$(92TXP&T$@J2G<NK9.R02RK=$E 2D2Q>_:+=F[
MJ-UP-AVE%)3K6"=@P)59)W8I*L*;+6:54CF+/]8=PO4:0,G!]?UK&*D'C!*-
M$(1GBL&KQ2+^9*;?$T58HJYJU,&5UY;2EI?1%;2SN'Y4AK<=2C1%)<0Y,?\
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MV=@!K;/%&RMS P'-VLA)M<6[,2[C<;8AB6AZVB.7GG6"B,[UA!6CJ[NT2O9
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MX"37;N/T@V4CZ]D7&S;,MI(=<":"U6&T(?0;#*R[-N+HH<J=GLX]F.SGGO\
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M\<!CRYQV=_(^YKG5JU6[LF3[)WOLJ$AL[3UQU;N[833YJKD!L+14J3!&*C'
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MXI3BE.*4XI3BE.*4XI3BE.*4XI76$_"??Z .L7[X;5_DI?-[=!/RQ??HV/\
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M=8_U(A/XXG_RURD_22G?-.)];/?N-5_Z']M^?4[ZAC_Q2GXVZQ_J1"?QQ/\
MY:X_22G?-.)];/?N-/T/[;\^IWU#'_BE/QMUC_4B$_CB?_+7'Z24[YIQ/K9[
M]QI^A_;?GU.^H8_\4I^-NL?ZD0G\<3_Y:X_22G?-.)];/?N-/T/[;\^IWU#'
M_BE/QMUC_4B$_CB?_+7'Z24[YIQ/K9[]QI^A_;?GU.^H8_\ %*?C;K'^I$)_
M'$_^6N/TDIWS3B?6SW[C3]#^V_/J=]0Q_P"*4_&W6/\ 4B$_CB?_ "UQ^DE.
M^:<3ZV>_<:?H?VWY]3OJ&/\ Q2GXVZQ_J1"?QQ/_ ):X_22G?-.)];/?N-/T
M/[;\^IWU#'_BE/QMUC_4B$_CB?\ RUQ^DE.^:<3ZV>_<:?H?VWY]3OJ&/_%*
M?C;K'^I$)_'$_P#EKC])*=\TXGUL]^XT_0_MOSZG?4,?^*4_&W6/]2(3^.)_
M\M<?I)3OFG$^MGOW&GZ']M^?4[ZAC_Q2GXVZQ_J1"?QQ/_EKC])*=\TXGUL]
M^XT_0_MOSZG?4,?^*4_&W6/]2(3^.)_\M<?I)3OFG$^MGOW&GZ']M^?4[ZAC
M_P 4I^-NL?ZD0G\<3_Y:X_22G?-.)];/?N-/T/[;\^IWU#'_ (I3\;=8_P!2
M(3^.)_\ +7'Z24[YIQ/K9[]QI^A_;?GU.^H8_P#%*?C;K'^I$)_'$_\ EKC]
M)*=\TXGUL]^XT_0_MOSZG?4,?^*4_&W6/]2(3^.)_P#+7'Z24[YIQ/K9[]QI
M^A_;?GU.^H8_\4I^-NL?ZD0G\<3_ .6N/TDIWS3B?6SW[C3]#^V_/J=]0Q_X
MI3\;=8_U(A/XXG_RUQ^DE.^:<3ZV>_<:?H?VWY]3OJ&/_%*?C;K'^I$)_'$_
M^6N/TDIWS3B?6SW[C3]#^V_/J=]0Q_XI3\;=8_U(A/XXG_RUQ^DE.^:<3ZV>
M_<:?H?VWY]3OJ&/_ !2GXVZQ_J1"?QQ/_EKC])*=\TXGUL]^XT_0_MOSZG?4
M,?\ BE/QMUC_ %(A/XXG_P M<?I)3OFG$^MGOW&GZ']M^?4[ZAC_ ,4I^-NL
M?ZD0G\<3_P"6N/TDIWS3B?6SW[C3]#^V_/J=]0Q_XI3\;=8_U(A/XXG_ ,M<
M?I)3OFG$^MGOW&GZ']M^?4[ZAC_Q2GXVZQ_J1"?QQ/\ Y:X_22G?-.)];/?N
M-/T/[;\^IWU#'_BE/QMUC_4B$_CB?_+7'Z24[YIQ/K9[]QI^A_;?GU.^H8_\
M4I^-NL?ZD0G\<3_Y:X_22G?-.)];/?N-/T/[;\^IWU#'_BE/QMUC_4B$_CB?
M_+7'Z24[YIQ/K9[]QI^A_;?GU.^H8_\ %*?C;K'^I$)_'$_^6N/TDIWS3B?6
MSW[C3]#^V_/J=]0Q_P"*4_&W6/\ 4B$_CB?_ "UQ^DE.^:<3ZV>_<:?H?VWY
M]3OJ&/\ Q2N:/]K>3Q+9^*Z/@J@Y7C$CX??)#<M",YQA3C.)-6<9<6C'BK#2
M\M8<SC"<O-8SY\>K/])*1O$]8TDR6<@+W-X6EP)[2G;MZDJ('$).R%<MI.<C
MPD?T/XI97U37;X? );ZQI]M3*E <$KW5V2M(4>!6G;*1QV%XV3LTT)V)UQV+
MJ[UCH4Z0B2-<9CV&M%FVHQ^O2Y"%K81/C,O2&78LM+3JH!&&_(A2\,OMI=1*
MC2XL??>CM;V/6]O5.L[RPXPI")L"2E+<V$XL$H#S:5+0IMT)467VEK:="5I"
M@ZVZVWR]T@]&^INC:ZHMNH([9:DI6Y;;G#4MVW7)ELI#BH[JT-K0\R5H$B,^
MVV^R5MK*"RZRZ[.W,OK :<4IQ2G%*U@^T_\ 9P9]I!K_ %A1L;CQISZN+B5M
MGQ3.OL[!^,?$PN0_N'N6+M2?A_H>/O'O7O<WU/\ Q>[M_P#EYG>A-:_D5,GR
M_@WX2Z[&;C[OKG4]UNW=YM[7596WG]G9V48YY/*L2U=I8ZIC1(XG=1ZJ^M[;
MZMUG>;;91L[/6(^SCGG*L\L#G6E__A:5_MR)_P -6?O\YLW\_?\ RK_ZW_[3
M6!_FA/S@'U4?XC3_ (6E?[<B?\-6?O\ ./S]_P#*O_K?_M-/S0GYP#ZJ/\1I
M_P +2O\ ;D3_ (:L_?YQ^?O_ )5_];_]II^:$_. ?51_B-/^%I7^W(G_  U9
M^_SC\_?_ "K_ .M_^TT_-"?G /JH_P 1I_PM*_VY$_X:L_?YQ^?O_E7_ -;_
M /::?FA/S@'U4?XC3_A:5_MR)_PU9^_SC\_?_*O_ *W_ .TT_-"?G /JH_Q&
MG_"TK_;D3_AJS]_G'Y^_^5?_ %O_ -II^:$_. ?51_B-/^%I7^W(G_#5G[_.
M/S]_\J_^M_\ M-/S0GYP#ZJ/\1J_-6?@SZM:;.USL;/=))K% OE0NWP?[.V1
MWQ;Z*V >=^&?$/KRG>X^_P#N'NOOGN4SW7U?7]UD>3TETD_IQZ]!FPOR9W77
M(DF+O/AG;W?6&5M;>Q\%IVMC;VMG:3M8QM#.140^BDQ)<65\/!SJTEB1N_@P
MHV]RZES8VOA!6SM;.SM;*L9SLG&*[47-!5N&G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M$7M7[<9D[4UU1%O/(KX
M:A)M4>-A2DLOF+"?."I<E:,>"'5L0JW#9CK7YE,>M+2WY,/N^IR#_2,N4IS4
M-DLY6H0HMG%Q0WDA"Y4V;+C..$<E%#4%I""<E&TZ$XVU9[[_ *(]GA-:2U)?
MTH0JXS=0FTN.X!6W"MMN@2V6DJ/QD!Q^YOK<2G <V&5*VBVC9U2<YUKK6LKN
MJNLZCL>=MA=KKL*T*INL95J BBMU3KX0\9:LM=&(^*6AZ<.A#H?N9*7A3L^4
MW&PYEOQSA?DYL7H\L-MOCNHS<835P-KL#EQAQI%U%FC+E)GP8Z>L7!;S#3#6
M[?<!4\ZEO:(_K;-:EZ6-47C33&D4VFXOVL7K53-IGRXEC.HIB(2[7<I2NJ6I
MN/)?DO;Z*R0B.RITI"L#9VJR2AZ&Z^K@;7L 014;2[5!6CUN@C.^8(*CT^V7
M=FVXNU7C;3:FCPMC;&N"1BH,A<F4MR4Y(@-/N.M.XYG3>C]%EG4<V)'MEP5;
M8VDE*B2M8,P[3;+C=D7+X6M[>H4NL19X85&CEE9<=*G"XRE:E)4*UF_K_I%3
M(TC;ITR\6E-WEZ[2B?"Z/Y$^^WJT6)=G^ KJ[I-;$B=;%2DS)0D-):92EE+4
MA3:4+0:QMV?I"IP^T4O2]5.1J179<^O1FRUU)9<& )!:J#3T]ALW*:&X,C,3
MI3\*L$WDQ&CK#PMS$Q3,M)%W!;_I*W-=(+NE;=+;M,)QZ$VF1=7]IB&N3;H\
MQY EN)8ZTQOG%M6]]0:3,0J,=Z4.!]6R]+:ZN[W14SK>[0';[<FH]R=5$L<7
M9E7!N'=Y5OCN*@M*E=2E=79;?NL5LO*@+1+3N0XR8J+ZC]/BJG;/5(4MB>>D
M%-&PZT:L8BS5!\:C:%CM )Y2QZU3 I:&RH&IV85#D+0)<BM-I!%'R6"$&/=T
M=&4@JN%N:<0],7(TBU E3HT^VK8&H9T^(K+)+L22T@Q"IV3%?N$8H2!#D+?W
MS3=A<Z98@3:[L\RY'M[437C]SA6V7;+PW).E+;:IZ F0 S.AOK3/2AF'-C6J
M8AU:C<(K<7JS[M!C]3A),:U9 FX0\ZH_"MN%YAR33K$.?@1].-5IZQ(>$+=?
MF/.SF[%AT6F*I_U68[7K>C*DNQ85&CHYC/L(G1-31GK:8NI93LM=KFLK91I=
M,!4X*C%:W%J=$X*CALKVDH3M[#CBFVK@YTN2XLI=LG:,FQ[QUS1T)F U>K;)
M1(<UHJZ(MRD3$I;90B.JV%$LO!O96XLM[;32'GZB#Z9RCEM2 B[#0\'+1-7S
M:G98=%L<F&5B[8$8+UV4<6^]"$51N.TI+<Z',/S#KRUX4(#%$MRO=_>'T7KF
M7(0V[V%1I+6GWK=/;M$Y;4AO4<;K4)R6I:FHUN#:"$NLNS')BR?^%B2-E>Q3
M3^FIJ!9S<7=.*1-B/:K8N]K>OUL;?B/:0F&'<F8"6T/S+NMQ0*V'V+>S;T $
M3)T0J:WE8QU+#'8^O!$.SP*S9']?6 S9F$*</F+?8A6W[30<HIM>FDPJI[<$
M<*C3)\6!);F8@QER(HR?.D>[*J1T<19B++&:N#$"<NRS)4] *IDFYSH^I[C9
MMFUPGGXA>2TQ&0Z\VTM+NZ;*VX[SSF[JC/2]-@.:CFO6N1=+8WJ*WPK6XH)M
M\*S6V5HVTZ@"KU<F(L[JZI$J6XQ'=D-*8+[J6G94=AO>#'NLZ3G'MB7VD3[!
M& C=9#+D?N%FG@S[*X5?I3WN\^;&JY&"+L:R$V0Y#CP@A&&+GH?F(;()@^D_
MEO"[?I1V9>[Q:7IJ(;%@8NDRYSWHDQ):A6E6P\ZW;WVH\XO.K4TAJ(^U&>"W
M0E\,[*]G8EUUPQ;]-Z?OL>W.7"3JB59;=9;7'G6]8?N-\1O([#MUC/R[8F.P
MVEYQ^=&?EQU-LJ5&,C;;"Y3U]U1C;).21U;V=&(!Y):J!:Y8X=$MJALZ;;1C
MA&*BP2B;0@765CW$I'$("2QDT[,4IP.**CT9G9R*R]'3=]F.,0;^AZ*N3;HD
M&<U9[D6'G;E',AH37'TQH\!3) 9?8$F5++A*HT>2PDO5BFHNEMW3,!J3<]+.
MQYC4.[SKE;7[_9Q*88L\I,9TVYJ*N9,NB9*2J3'D&%"@H8 3-F0Y"@P.+*ZH
MRX]7?()V"&?N+>J96WV*2V$+^:161EOE4XHW](59P-:G-SXV7!S&6E*GHPZE
M](]"&GI'DYT=.-V];WPU%5=$Z=<U,FTIB2<KM[%R<MDA/7CA@/!YLJ81LDO
M+V]P$I4YZM=+3+EV;C'3LU%E5JYK1B[ZJ=#PW=)5E9O417P:,RE,*8=")+FT
M!')06S(*EH;Y?V2E2[\QK )M.M%;N*-DPFP!.05BA,U-0*L$K0=(C)[T=<:U
M#1K <@*\S&1<Z49Q$9CP%#Y*R4?T_-N7+RC3\34,"3=HTJ1%O4;JDYI-N,.
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MU6T"2++2FVF9#;;#"6K-"U?J.WJFJBS@#<)JKG(W\"WRTIN2]YM7"(F7$?3
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MG%*<4IQ2G%*<4IQ2G%*<4JT[A>*U0AXXK:ITD<.*V$#58DQD09+,I-V<DR'
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M,7A1R4=$EF.2B(?99E(0O&4^?W>3*BNI5C+<B'*E0Y"'8TEYIQ2L-+WTDB;
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F@T2'U,'! PYY9^.Q%CO$I<> V_-<CQH["Y+CBFF&F\I;2J*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>cntx-20211231_g3.jpg
<TEXT>
begin 644 cntx-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &D"^9R X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!J CV
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              J    4@          $
M                 0             %(    J
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   J      4F=H=&QO;F<   4@
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *@     %)G:'1L;VYG   %(     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      /V@
M  $   "@    4@   >   )G    /O@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MNOJ?7+7BNO/RW/() ^T6#1H+W?2L;^:U&-_UH]1M(RLXVV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MSW7FFNTAV<00T[$C2T/W0N*#?"8(:@:M>*+MKM_/EUY7HGX2#U(_D(V;^?\
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M_";4^)KR=_/^(^V'Q_W/+3Z0GQA\8_-\%_93_O=$_"/NJC\C.QB?_)9K[_\
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MI'V96RQN(S !ET*H?%8K"X;#XN)C9,0R-\.$F>T1AYA=B6.<Z)S=@<K6R$$
MU6^ZN'5#MOM!MWN%38_LKG!F<59^#[6VI\,M-*,ZON\FVMP3(K-L%DZVMVV4
MUKD%W;DSU$;()<5(:[&IW&$ +/K/ ,=Q;&X)\G$\'%@7LQ4T4<K9/ES$,;(0
M,DL,FF9D+F/M@D$9>#1"O$</A(<0R/!8A^);)"6EQ;$QK)9H79'$:EV4D@@4
MYI-:ERWRS2IV*KMSK?II@*VVRDTS',)Z;,=P?&]C*BIRW'=[UJ<4P*\W-R+>
M>QHZJU<^BW @R++#WUU]D27[E;0E #5)1I07U##3\5=P\\<=%Q&"!TV)XIB,
M5B^+=M#B.'=MB9H>'P\-9.Z(.Q,3L/ #+!&8OQC7@@-/SDS<#\+/#W2X:<G#
M8?"QQQX1T,T&+DABCDQ;IC'1;&0YSB)6M)!N/=PAZAZ8.GK,+?!XL37?*QQ?
M<K=7<7:RCR]]_AKP,+I]L8Z4G(=YL\8+M].*V@6MRFKNI,#'L:Z>KQS';^V+
MSPF2UKH*WY23CO&(&3.Q(X;#B,#A.&\0['LI'_"\1Q SQPX#"0NQ<SGRCX,(
MY\5((XGR.A:,.S(7S>1O#.&ROB;%\+R2S8O!NE=(R41_ X8G/QA[**)L#97/
M:^*-YD?E[1YE>UX#>]AO1+@&2ARXX<?NC394W&NFXH#=,IM5'LW?YIU)Y)@
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MN[,N[LJXRS?$5#\/AN!X+#8F?B)D?B)98L1AX7XP1/9'#C2#-F)9%/B7O,8
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M;<W-=@0"WFW6[=Q1.#LJ8_%:6VN<;O9TE;'Q$'KVX/@6%XIP;BF'9/POAL'
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MM[?VF:_F1?M":(O##^*#O]PE7?/O9@OP_J1E?S>Y/K\^..VOU?[C?_:O$_\
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M\'^.?HGB'_*3'ZF:*GZ%EZ0;R_C5=T>%7^IH7/"_/[=PG'P\NZ^6GX:^2?\
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M%Z,CTJ-9:T-[6;&[MUUWBU?%58Q<@9O1!6F.5D#BGP5]$>/E["J@*%YQKXQ
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M96D@.()!SAKG#F-@36]L#]%%Z2ZO>!*!TX;BA2U<\A=;()DN+#25Q<OJO6E
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M;OH ^U/5K^G7[$_/W)IE;\T>UWVJT==?1H-/?E^W6^2,5%3\951%YXX3\_\
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MNE?]4.Q%"-$0_<S&;-\Y.(C0A4=@/<'/3-\@QK&: MHP3Y9%!FM,PQI"R_\
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M^(O*\_M19<1N,2G",.H8!$@N@-P:V<VO0''QI*AP=?N-:A5-56/&H*L6LIH
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MEM0LUI9B0E@OGTQID>R)A[T\K(&WIWIY>RL4+#0YQ%CS=,M !-39.S0VS0H
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M;,>@R"9V-RVB2<[-][1O8/(.@)DS1Y "XAN8C-0>0UQH$V0%7$9'9:S=HRZ
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M=]./MO=1A9/?MMK@LJIP<@.VS21<OM+6G$-L\M46U/QL+ ,EM0OD:8O'BH!
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MJ_<+$HPS 4F9.?;#@QHZ>2)LE-AH<00"XL/]!X>YF1W(.);8HD97-)(ND(<
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M:]A0M',.7"+$6ZS(W#R /;F+*(#HPX 97-=-WR='90 !>O28AY@H "-LF8L
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M_P!GX?7HBE%ZN1KE8WQO1KE:SQ(U'.1.6M\2\HWQ+PGB5%1/-=$4<_=)N/\
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MQ LE\4>8@G4$FB0XG3B>WFF+0XNGQ;"V[ D^$RME% T<DKZ)RV:&N4"N]4=
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M_)/B?!?*+&<3QGP6/"<2FA=@6-Q$;L5,QN'C#I#APUL@C:YKFODRAK30+N\
MMN]?I"_)DT1-$7%_/A=QY^%>/IX74.QWV.V_J\>GBGL]>WKKEU7E'T.V<=;O
MCO!3V%%D%4?D R3B$08-G50%.1599F,YT&Z^26^!T%!?[P,$*%(ER2ONC:NU
MQ@BI$KDF?"PZTU%F=@X]6M#3A[:-& =D_+V />!< WX3FS9B(@VBQY.\50Q5
M'O9G8DL<22YPN 7+N"UI!&$V+(\S'ESB"/5[46%%^Z_]!\5_LH;7?X]4>B*4
M-$4%[N[Q3[69'M=5-Q:ZR<3/KC**LR/'*LRYNP4H<3L,B'G%KA%1989I@4&*
MDD5&P,D:].7<(N"XA^6M!!+*7<AV;X& 'T]J:]%<]*6C*UUBS,(P#XX;%3NY
M;Y<,0!S) WI:9;!]<^X.\6<;?TMAA5!55.<6N*U+:^"BS4:<-+CIYQ+>VYM!
M]P+&7[B3CJ8S)ODAF",'9DYU.,3=CROCKK!D?5K;?,TN [-\[6\\W8]B/59D
MK;4C32ZZXF(0N8&N+\T;9"-\MSXJ$C2KKL!IU)NM%NQB^^.-Y7N5E>UU?4WD
M%YB$14IYY4F..JB&B3BC/]CC!R$V[:KY"XG1H?3 IX&O\;F/6)LG,$F-TF@I
MH=1O4%SFC:_F.UNOIKD00675//L%;GIS&Q.ATK4X?3[TY7:[2[@YU;TN%X+>
MX9G6:XF0/D>4&%XM556)9>ZAEOK:W"JQR3BF4['6[Z.M&A0^V2/' ;9B$1W.
MDH(8PBB9&,?73,+(TZ;++=2\<FN< :W#=COS'N.6';7=2&X&5Y[C>';@;708
M )D=8@U9;$6=B0;<Y;#B\^9E4\-'\E>NQI4Q6);OY/RDT*V%C:2"1$XP>)A.
MLK2[$;D1EH!TUTC)TWT#W:ML]W;<H0:B+=0\N#C6@(+@&W>[@ 1[A1C<];>1
M5=A26S-N%)PO(H&34+XWVSK2^2SO=TJFK>RX8%]R^-25(>W-5:7XF1&02S0Y
MFQ@#XVXT;+99 (:PZ9GX?MP*J@,+)BB"!\X!D3==7-(UTK9CITV9V5D,SX'N
M) !>)8H3E/\ 0J:4C4AF7Q5Q+ZO]Q*VNJS[?:^GJW,N;/"LS8ZYM28,,SOY$
M3(*ZN/F?6!%V -=2%4F0W3J:NLI#L?M22Z>52Z(X C79M,K6AP<US@QK@;#W
M"9F'%'2RZ9XC&E9\HLYQ6?R'./=<QN=S#NUO9F6ST&0.=Z IXS;>:X?8[=TF
MU?W%V,VX6'9MN"%E.9GV@&*,QS!F8FI(D:5T2'.M;J3, 70OG="REJZ^\MBQ
M;"2M;5D\\S0]Y.@8SM"2=FUOTK?,?12TUI):";)<UI WU-$UU'(5KX;+'Z+J
M<#^]UG.XN2TL,]9B.>MP^)F%VU5;P68\U+B]F-9!VEX=CE86-+-?O;"4A S"
M@HARH(5=-ZI-.MC(GNMG:NQH.85E,'$<;@X@;L@O;A0X76_0A8C[[Y&V*8S#
MOO>^VP.$QAVZ?"<H.VUZW62YEO?:U>-;-9=BN(Q6E!NEGFWV,6D]W="UYV+T
MV=V@58/81AU7RR-=6C)CHHV!BV40$;4F)?92MBB'*T03.W#D@%\&-D#KTS8;
M XC%M8--3(81'MH7#P4S 122G\B3#LRT27=OBH,,2#5 ,[;.;TII4;Y]U-9'
MB&Y5KB =!B7W/UF0D84^XR"YM:^82]'V1R#?@K)K26OK+-@F&BX[CQ5#-Z@
MRP?<2^U,D08=XLN&?*!^31V:<- LN#HFP.H#FYXF<YK=,V7*=25T+0UH<7;=
MGG!&ISR.9I7S6M!]=&J7TO\ JBR';[;;93/=R-LG5[]SSKQ,@J\?OX[!^'4X
M6 YGN!23L^6@<>(M;:V QJM *JWC@1T]C:%1$GR#URE$Z+6LD$>:RU@S.-!H
MDIO:,:0*(:^VCF6M:X@%U*LC=)GJM'-:T:]X..6[UZW>QO397W/^I&QI-C]Q
M-U,1P20[(-M[BWHLGP_*;D&I^2#L?D@6\DGM:1V1 6D8M>3"8%%43D)8RD0
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M4>H[LKN\JS=@YC#FB9+;0I4/GB'2"!Q./T0-/0V#!W>,D>$ZNGCC.>T[\8N
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M+!@Z'HYPUM#N#BA65Y988SN)A=CMG8U9$="UU5MR>=N)=MQFI,AJHITF%O\
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MBJ>LFN4AIS#K;7!S=:[P#B-M] ZVGNG2]:72-V42:U<9!-70#F.)/@ TDDZ
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MKBVRMQS-\WNK([(K7*<&Q49X(U/B=3840-G;QQ11%6-G>Y#0%V]F&A)CG B
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MN,Q10DOC5KYP1K&"T]6R.15>-"=+8^!K6-)>6J/<_';X(/L8#,P&\C\5*0X
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M$T1-$5OM:^.UK+"LF(-%AL B0Y2:TXJLL8(R87POF!L0I83 "XFO5XY8LT1
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MQ[N>>W"=^._*\_L:E^L].===:"E^SKI2X.D:Q'.<J-:U.[G*C43Z5=Q_V]M
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M$T1-$31$T1-$31$T14<O#57X)[UX_9T^GT(HMS_=K'-O) !+5'E6=E"2;"%
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M?"W'9VN=%#B)F-<6B5D; R1P<6D,S2M?33YSLE  G:UR&(W>OXO;'1X?@0Y
M8[Q:FP"/S6YA)E]>^9;0RONL:JQ)QF.$C>#7_+(Z$M+]7;DP)!(_J3PF Y"S
M&X]P)S2Q318*-I!H!L;X<3)(PZG.YT)JODQK6#]])AF:[!X,<F212XMQ;5YC
M(R7"M8_890V0#?,>6,DY+1X[.RFR?J1H0<B%BCAL0C3-LZ@I"XX(9"'_ "0:
M+.:$QWK8YVCS/E=!"1"U\TGC;(_B_$85SCDX9"UMV+EQ#WU9K,YLS =ZT:+-
MG2UMF%Q.4!W$,07 :ED6':R]CE:^&0@7_3-==;4<"'NS_*@IMN;3+\TNY!6-
MEW:RJC=1XIMSBWRR%!9?>W%M<(%QG*,HRP+Y10"QJ:^V'(%K82;O)(*F&BK;
M*RXTNA^#P0Q82%SFNGC@,O\ *7-)+.V?+)(\AF9P:QCF,&8NRYP'!%@6LG&)
MGEEQ<S0YL#I^R_DP=ES]FR**)@<\M;F>]CW4T-%,+FF><;VFQF@O)<K.GMLO
MS"2K&I&95EY(MK;A5 SYIG5U4D 00%0*841.78MK 17V,SH4-DGB" C%\6O,
MV==::";-@'*&BFCNMTV&MG5>X@7H,HT[H+BT:4?.+CKN;.^U#12<B(U.$3A$
M\D3R3YOS_:T55=$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31%%^Z_]!\5_LH;7?X]4>B*4-$31$T18UE.5T^'UDEM=$R0BI**+#$,(
M78'&'&SM%" KJX" DZP.-(DC@&#$'FGE>JJUGA:]S>V&PN(QDPAPS,[W,>ZW
MEK((VQ-+Y))IG%K(8VLU>^5P8*:!J3?FQ6+P^"C,V(DR,!:T-:UTDLKY'98X
MX8F!SY9'NT:QC2XZDZ!8HF:Y?8E2PX_MQ;2B0J,U]GE-F'B8\LDS^9F"!+#<
M74T84/#B2)ZL6)\SV0!.*5I+Q^PP^&:T.EQT322X%D,4N(E: ::XT(H'!^[<
MLYH DUH#Q=BL42X0X"5P !$DTL,$1)NP.]),,M=[- -2*S V.9]KN8L2MAKM
MOL?1T@L;;"WR*XNF1^.=%+<VL'I,=0A\8;7J- MP+ZXA?Y)-%#&JR;:SAC2#
MVV/Q(U)8,-#@W> #W8C& >),9_JZZ9+^*/:0(<#ASRD=B)L6W?FQN'P9/2@\
M:G0Z68&RK)L;(.A%R++C=^<RH+,&SJMI=L:0-]+#DT21MH3,D%KIKM:" .RY
ML(+;<++1\?JY616GJ5-JAIH]#'##B5F!@?@^VC=$<0^1TV(,;B0\"4,C9&9&
MVR0Q11YFES3W7$&? 'XAT3L=B&8H1/$K8&1B+#=HT M<8RZ1[^S?3HQ++)E<
M [< J3ZO;#,,EIQ)MU-QLKGM390K2UQK ;C[B<3J2825/CHJ:TQ\.MSHVI"<
ML )1EGE+I[]@DDI0H8-A/3Q_';$'0D7RTUYT?VKY(:;?;>G\?;ZBKM]X':"9
MPLEKA(&3R!-(:-)FIEKG+X7%JU2IF.R\^[X))\#6SE?[(D8U(W2JQ/#JV=K)
M'0Z].MGEUZJ.:'58NJH; 5M0&@KT*6H1AQH81QX8X(!XXX8((6-CAAAB8D<4
M443$1D<<;$1C&,:C6L1&HB-1$UFO3^WW]RE#IZ?'TK[ZM?1XGW/K531$T1-$
M31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$4:L_
MIPD?V-0_\:#M$4E:(FB)HB:(NL^=L;7.>]K&M8KE<[A/"J+[^53MQQ]J<?/D
M&P<N9U;TUQ<*T_%AF8[=+K8;%0FM7$ <[('_ -5Y1^SFH4SK??$,9;D=+4'1
MWN;5N-36];3BP$RUQ%B3%8Q4M<9=,C^2Q7F6(#X"X9#4+KQG-++@@'G&DF^4
MPO#)I1AIL48\)@IYXXG3SO;$X,<Y@>]L#SVYRL=8IAS.&4$D$#XW$<2B8<1#
MA@_%8N*"21D$+'2M,@:XL8^1C2QF9[0TESFT#F(K51C<Y1#D%E78\3EMQO-=
MTAK\AN<$VJQ^D'H)$AK;)*BKR_(#+%]75U_M1 AD-=892-:6QX@1<=?-51FC
M:OPV##A[\'@NQ,P=#'B9)3+( TC,X-/<:YQ%-<&C*#0U-F#!8F;(W&8T2")P
MFDP[(VPL<YP):W,VGN:S-9!<0[+K6@6<89M+>VU16VNY5Y>T]E-45D86W>W6
M47F$X/MY T.!9*"L?B=E5V.2EB2^(8R^NCB8"70-6DJJ(!WL:_&O<Z1YDE)E
MD<27/DM[G623F<ZRX6; )-'4:ZKY)C&Q-#(VM8P"@UH  %5H.6@UK?G:RR?9
M#"2H)A2S]Q2Q28I8"12=W=TYQR1YV+%,.1#)F#F3031N='-$]%9*QSF/1S7*
MFLT+T%#HW0?1[UIR"W9\/8*]E5?CNL]Q_$L7Q,"*JQ;'J7'*R!'I"!1U@=6)
M&DKT?*K8 H88T65Z>.5WA\4DG+WJY_XVIE V%>(WUOGZ3?I0DG<D^DZ>FO?8
M+(>./SY_;U0*YD^DVI[^_L351-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31%BV29SA6&OKH\NR_&,6?;SN&JF9%?5=*^R(:K$=  V
MR*&4N5JR1HZ,=)'-5[$5$5[>2+%]UE1U-BBHO*+N?M<J*G"HO\W-)QPJ=E3Y
MT54]Z<Z)[]%*.B+KSDP#,]9/-'#'PO,DKVQL:O'*(KGJUK57NJ<^?"\::G8$
M]:Y#KU]BA(',#P) ^DZ#734_5I"6=]0VVF$'U^/KDU!;Y?;P*568P+DN/!%O
M!8^-DUM8G6=B)6TU/ LK$<=8$P^TR*@E7!8V#HPI/;#@)7Q.Q6(>,'@6%K'8
MS$!PC[1X);'&P R32EK7$,8UQ &9V5MN/BFQS&/$,#'8O%$.<,/#3G9&D!SW
MOOLXHP2T&1[@W6AF=33"\>;EY1E8N1!@XYO3N,/&:/@&'X-:QVVVFTC_ ).(
M'MLARO<D@*&OCL;*S&DI9K>&K7)TKWRU&*8L3"F1DD=I\9!'AO@7#>W;#+0X
MABICV<F.HYF,$37$,PC006Q9G]I('22.-,:SC#@II<2,;Q+LNTC!."P[!G;A
M0X4^0/>&E\[C8,M,$;>Y& 0XNG(3"]WSS;4C(=X(*@&>1(J:JV\P6AK&@!K7
M5T3WV-EFZYZ9967RI';$QD"MJ1&"%@BN ?,#,49\7I9IN4 T!0&G( #0#H!H
MOE-!0!) WLZYB->MV==:.R[H&R.#-M/EW)H#]Q+MH0X MGN*5%E;ZP>!"?6)
M3 F#,J*64YQA#[*>JK@YSD=%"3)(,,+# H$40"/'7ZU02#8)!Z@D?4?!295T
M]32", IJNOJ08N$B"K QP1(N$1J>K&%CBACX1$3\1C>R(GN35  % 4!H -@.
MBA))LDDG4DG4^DJY:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)J'0:"_!%KAAW4-#EVZ]QM>W LJJWU1F1A+>%
M^QR11+CA+QE.N:R)WMM#47WJW38M8E.FCNH)!'HP9Q<;-5MEI<>Z01H=SUH>
M',<@;OFATY@]*OV>)]'HY+-["RKZ?=*PLK4X.LK@]L19C+ \F ,(6%N4FHZ8
MDHF2(>")JJGBDED:Q/$G*]TTU.@%GTF_0*!^WT<QT%^-<J^DCWK7DKS%NEML
M3(L(NXF#D2^!7K%!E=!+(C6\(Z14CL'N1J*YJ*OAX15;WY5.>L>'Q,SLL6'G
MD/\ NX9I!>FEM95Z[78WJEPDQ$$7XV>&/2ZDEC8? ]YPTT(!V)O732.KOJGV
M#QT@RN-W*I+"W!^4DEI\=:=D]H^6J54-@A$H!+!\DD$JQBN7M&A<L(RR)-*Q
MJ^@\,XDT][ 8MN@)+L/,P '4><SF#8UVUZ+C]\>'BZQN%-<OA$)=[ X'Z*&R
MQ5>I@V[+.&P7:S+,A:&',0TXR5(ZR<EDTD< CR<,KMP9JY\T?LI<L5N+7V<0
M1<4T-47)$3!#H\-Q30UTIBPP<X@?"'MA):+[P;*YCR+!U:T^&MK XEA7%PA,
MF*(;9&&:Z:B:[ML!830OSB-]1:M(^.=4VY]2RSR3/J+8J"T&":/C>&8\N09?
MC@DC(YK8@S(;:\,QPO)IE\0M.YU"=14,2>UV-3D)DS@P>DDV P@$$$#,;*?Q
MV*Q!>8'.#=1A&M[)T<;762^8ETG=+0UO=/.*/&XHMGFEDP48%LPT>0RUFMIQ
M!<'@N+1JQA%60==6YC#TN;>V.-E8QG-[NCN?6GJ,XS[O]TLVMG%)",\>6*4<
M&XJP/9#$DED, 8$P"=\KFJ,V)L<;,-XIB8FY<.R#""[O#Q,=(=!1$\C9,0*Y
M99!0VT70\.@E.;$NEQ)Z2O>U@_\ 2C,<1WYL)OFL^Q[8O9;$I8Y\7VFVYQ^>
M$%]9%-3X9CU?-%72/%DD CE%KXY&!R/"#?(.UR12.%'<]CEAC5OBEDDG=GG>
M^9V^:5QD=UW<2=U[8HX\.*@8R'D>R:(R0>1+ TD>!O3392+7U-74Q/@JJX*M
MADE=,^$ 6$2)\ST1'S.B@9&QTKT:U'R*U7N1K4<J^%.,5J7<S5ZGEH--AZ@+
MYK="@*T%@>@FR.JN&B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FH=CZ"BTCZM:*6X+IFB;2Y7G9)6)9/5/NL7R_</&W
MN@-E!3[BR1<"H[X4];MZ(9%-FL &+C>QOC)/9$46S1OXRCME!UV\\#ZM]M.H
MM7D=M]M+]7/W]*FG-< S[+JVD"H<ZJ<*J*Q<6M ZXC!(LAN +K&RQ[,.1]DF
M65]3(/&6*(R4%M+) K(96,)5DK'1]HS")+FCDECUID4H@==Z$O,4O=ZMR"_G
M!<9.VR$1/B8\@ &:)\S1IK3630N+OFNSD [M<HBGK\>+@979QUMWQ-[5N.K[
M"2ASC:7;EL1J$-B-@FJ<<H@R(20IQI18X;0P\D!4FA<Y9_72/];L=A&O'9\)
MP=#S3)/Q"22S5%]8UD$@UV^#M!W  L+S?!,66=[B&):21F[*'"-C(UH-[3#2
M3-OJ)B[<6=U8+O9SHFS":L*W%S+%=TK"J?ZZ [<O?:SS%LI"C60;Y9:NVS6:
MA8R06WL('A#5(]:D,[88PXXAA&09^^>);*R6)N%@?'^*?#@\'#+%=9C'/' W
M$60 "YTI.@-DV2^]\98Z*1V+F9)0D;)B\7)'+1/XR)TIAH$DY6QM:+(#:H*?
MZC,.F_'PAJZCRO92I!#$% %#K<@P8,> (*+U 8D,4!D;&#C0_P B@A:B1Q,5
M6L:U%5->::>?$.<_$322N><SS)(Y]NU))S$B[)-T%Z88(<.&M@BCA#&Y6"-H
M9336@R@4#7K5^'WBV58QT0NZ6UT<<3W1NC'S?$VLCD3\9[%9%:(UCT5_B<U4
M1?QO$J?C(J\CKOKZ=5U79^_+M!^5;;;]?.+_ +Z:(GWY=H/RK;;?KYQ?]]-$
M7!^]6S<?@23=G;-BRR)%&C\\Q5GCD<CE;&SQ6J>-ZHURHQO+E1JJB*B+P1<_
MOR[0?E6VV_7SB_[Z:(GWY=H/RK;;?KYQ?]]-$3[\NT'Y5MMOU\XQ^^FB+YQ[
MU;-S-<Z+=K;*5K9)(G.CSS%GHV6%ZQRQN5MJJ))%(US)&+^,QZ*UR(J*FB+Z
M??EV@_*MMM^OG%_WTT1/OR[0?E6VV_7SB_[Z:(OF_>K9N-T37[L[9L?,]8X6
MNSS%FNFD;'),L<2.M4621(8I958SEWJHI'\>%CE0B^GWY=H/RK;;?KYQ?]]-
M$3[\NT'Y5MMOU\XO^^FB)]^7:#\JVVWO7_;SC'DG=5_HI[D[KHBX1[U;-S-5
M\.[6V<K$DEB5\>>8L]J2PR.BFC5S;541\4K'1R,Y\3'M<QR(Y%31%S^_+M!^
M5;;;]?.+_OIHB??EV@_*MMM^OG%_WTT1<';T[.,=&Q^[.V;7S.<R)KL\Q9KI
M'MC?*YD;5M45[FQ1R2*UJ*J1L>]4\+'*A%S^_+M!^5;;;]?.+_OIHB??EV@_
M*MMM^OG%_P!]-$3[\NT'Y5MMOU\XO^^FB+A'O5LY*WQQ;L[9R,\3V>.//,6>
MWQQO='(SQ-M53Q,D8]CV^;7L<UW#D5-$7/[\NT'Y5MMOU\XO^^FB)]^7:#\J
MVVWZ^<7_ 'TT1?-V]>S;'QQOW:VR9),KDBC=GF*M?*K&^-Z1M6U1SU8W\9R-
M1?"WNO"=]$7T^_+M!^5;;;]?.+_OIHB??EV@_*MMM^OG%_WTT1/OR[0?E6VV
M_7SB_P"^FB+.ZRTK;JO$MJ>P!MJJP@C* LZTL<^O.%E3Q1$AF"23#DP2-_&C
MFAD?&]%Y:Y4T1=[1$T1-$31$U"+!K1%K3BVUV[H.[A6997N0+D&(06&6%UE)
M)&Z:1 KI\T>/5@E2^K&"Q67%JZ9@$]Q5V]D7D[()9+0>"0Z11S=&TZG.Y.Y^
M/+U4/:A_8/HY^M7K.=MME,8H+;);G:C'\AC;-41D5L%#3V!UN63? PU(K8KD
M@2NE5MX6*3$AY< @\R*6Y\:QJ[7I@Q6)PP(P^(FA#C9$4CF D"K[I'+3Z-EP
MFPN&Q!!G@BF+00#(QKR!J2!F!TW-+J50E%1E*;2]+=M4&>J? I=;4[)A$+!(
M^-\D*S#9Y'+ZN1\43WQJ[PN=&QSD56-5-/QV-E;EDQ>)>T&PU\\CA>UT7$71
MW6&X+!L-LPN':>K88P=[Y-ZK*8<MMQG*X?8G.X'.;X%=#+M-$JMY1?"JLW%:
MJMY1%X\N41>.4[<#)(="]Y&^KG5?MW-GZ5W$<8-B-@/4-;?MI=MN>9(SNW9;
M<5G?S0[:Q/K_ !=Q_P#KU@V;)U)WL[^WZ5H #8 >@ ?4K%B^\-CF&/5&44>S
M>YDU1>!1V%?+,3M>/-(-.BJQ\D,FY'CB<[A45COQD]_;OI6_COXUIJKT\-O#
MT=%D'W?Y1^1C<A/_ )PVM_SDZFVP]E(GWP,H_(QN3Y?U0VM^S^F3Y_L?/JHK
M/9;MW%2;CX!FSFYC"<GMYZ.I:PO:^1LU@/0W>22LE>W<CB"-*K'[.5)9.&K+
M''"GX\S$4GO[^Q7C[O\ */R,[D?JAM;_ )R-$3[X&4?D9W(^GY0VM_SD\_L:
M(GWP,H_(QN3^J&UO^<G1%:*S=NXMC+\$+9W<QY&,V\5';->7MA&V*PFHZ7(H
MV1.=N1Q-&ZKOZV3UK/Q4E?+"OXT2JI%=OO@91^1C<G]4-K/\Y.B*OWP,H_(S
MN1^J&UO^<G3U?5]OJ_AJBM=WNO=X_36M[9;-[F1U]-7&6ASXC-KYI6" #R$D
M.CB9N0KY7MBC>YL;.7/5$:G=431%<TW!RA>%39G<GA?)?E#:WC_[2>?V/IT1
M5^^!E'Y&-R?U0VM_SDZ(GWP,H_(SN1^J&UO^<G1%8G;Q6;<DCQ-VT&Y27<M'
M+D48RF[7>%]7!805DLS9/OD^%71EDP,<SW-D:Y5[M17J^KV[_P ?!%??O@91
M^1C<G]4-K?\ .3HBI]\#*/R,;DI_\X;6_P"3<E=$5?O@91^1C<G]4-K?\Y/O
M_P"WC1%:J;=B[OJZ&TKMF]S) R)"XHW2&;7PO5X1<X4Z.C?N0CFHA \K6JO\
M\B([LU457O[^A%=?O@91^1C<G]4-K?\ .3HBI]\#*/R,;D_JAM9_G)T16FWW
M;N:1*U3]G-S&);6X-('ZLS:^57GV+GL&8]&[D?B1N5CO%*[\5B(JNX3CDBN_
MW?Y1^1G<C]4-K?\ .1IZOJ^WWOTT3[X&4?D8W)_5#:W_ #DZ>KZOM][]-%3[
MX&4?D8W)_5#:W_.3HBL];N]:VQ^0U@.S^Y,AF+V@U/<1*=M<U1SBZ.HR(=C>
M=R?QXY*N[ E25/Q?6.FA_GX7HA%>/O@91^1C<G]4-K?\Y.B*OWP,H_(SN1^J
M&UO^<GZ_^OMHBL64;QV>'8UD677VS^Y@U'BU';9'<DPD[9%2P55( 19V,T0T
M&XSYR)(@Q9GL@A8Z69Z-CC:KG(FGJ]_5:>J_?93:B\HBI[TY^W1$T1-$31%A
MVX>2D89@>99<)727!6,8S=WPU5$YS'V,]37$'1!(YD<KV^T/@2-7,BD>U'*Y
MK'.1$7#S0;OWI(V:<NTD:S-N-&9LYUV:4Z^ )]- FO2:H>)6!=/N1CY=MG67
M,0=4,R2ZS01KZ4LFPI+1*W-\BKG9#2&&K(3/39(\5U[5J^:=K K"&.*>>)C)
MI.KFUDO6XXW:UW2Y@=E-"@YMBZZ[ VLAQ<762:<\4=QD>^.SKI^+(Y7EO8V9
ML\#/TC?[5/W-9H=%I?.2-BIQX6IRCNZ(GP^CWZANP>AOG^S7_%0[$=00/8H?
MV4NB<AI<R/LL;#QFRAW2W!J30 [8J[')?1WTU,/:H:8#7.;+: @B&$"0BL%#
M(EE'&E)B8TJ8PYHXWG\MKC5[5+(W_P#Y6G:2R,&H9V0!JMX(G'3IWM_3>MJ9
M/ S]*W^U3]S543P,_2M_M4_<T1:U;U[A XUN!L3AC_N2+L\SSA\]=36]R759
M!,E*@8I]S01Q^JKIAZ&NO22CVV9$BFFRTU%75Y1]U$0!EG?E,6MLC,IJSH+'
MK'4=/ (X?)Y]='Y=ZOP]:V51C.$X8W^U3]S6D3P,_2M_M4_<T1?*=6Q032(Q
MBJR)[T147A5:U51%\+'NX54[^%CG<?SK7+PBY><K'.Z"_?G[->BH%D#J0/I6
MNO3)GD6X.$Y!:_)5(!+#N#ET))&.6DUWCMV38$#9)->TEE-*2DX%BZ^\21,(
M28(B.<&Q HK8:PQZIZ$=UCK\YK370F_L^GP*RZNT<VO- '_TL=RT/G<O!;'^
M!GZ5O]JG[FLJIX&?I6_VJ?N:(M:-WMSJ_&=XNG' 9\-N;B7,,ZR"=N51UN2)
M08A()MCN&P6:6RK*DNF)M[5%-JXZRX/!&%K23+B61LPU>DI@SO<S4969KY'I
MKUTVNZY72CR6LS::N#1J#KI?B*L5IK:V0BF$F5J0RCRJ^%A#$C?&]7#R*J1S
MM1JJJPO5%1DB<L<J*C7+QH@-UXBU]_ S]*W^U3]S156VY,2JJ+2T:,A3JVO,
M/09KX8'$*&/(0D+9IU9#$Z58_ DDSVQ,5R.D<UB.5(30)Z*@60+JR!?K4%=,
M.=B;D[5AY7%C8V+%6.0927;T@=Y!E->)?65V7<W?L&2A3%55X+)8V9#T-IRB
M*QDKI0QW1O%D&@M'+&[D]F;_ .HCK_1V(NC>@(O-C/(T?D.RDUX CTU?+2]E
ML/X&?I6_VJ?N:*IX&?I6_P!JG[FB+5?/MUDK.I':7:HC%4G%,%=DXF333R,<
MEK<5.X=&@E2&,6PDUU174QBY"]]795U?!DM'/8%TDD@$EA83VG:C09&D[B]-
M?6#7*O05'C*QKOG/:-O'37UWK0'TC:CP,_2M_M4_<U%4\#/TK?[5/W-$5NMY
MGAU5B8.T-"!0BB8%.DD@!26&"21BF3P0D30BHK>9Y8H)I&1>)S(I'(C%R\AH
M)) &ED\F_E'U-LJ@60#U'U\KY]%&&PUM89)M3B>36N,B8B3E(]CEC: :P-M6
MAB95<6.0@3S$V0->;$98A64%F=6S"L^1RS)JECYXP63R:REE-/G4"\?->0,[
M:L[/S 'H L@V7>!(N@/3]/32JI3!X&?I6_VJ?N:*IX&?I6_VJ?N:(M3\VW3<
M)U4[4;3R8D,:(3CMI?P92ZQ>.;56-I29NUT8]4TB.6Q"]BQ20,TME<=6@SW
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M5>6<3$4!$58$MBBC&&:5ZI306><<SBUU#9O:3D.)J@*R'QS#6B%U#(+?WW:
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M L^P GT:KJU67XG>ER5])D^.W!\,1$\H55=5M@7%"(8^N*FD&$)FF9$-812
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M00:!HZ&CL?0>2ECJ-R-QN-QZ1SZ+5[J(S2@P++=GK_(\ZO\ &*L.VR0TR@J
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MUW/F6D>) %78R\MRO%979V$-)U #HSH>8H$\AN>2]9F]FM1.R(U.WP[:Y@4
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M $3C1K&6 %@_,L:\O#F@AT60YM&N#GAKF6-0',<X.<-6,+G-+7@%;:XM;8<
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M/42 CEWAI0H>V^&69MSB.,6]E3RX]86E!4V!M#/&^*:F*+!@GGJY8I(XI(Y
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M!.#(\*6*=KXY!'O&>U87.8L+0[ND"G L_P"%U6/18!]0Z*%V747IJ/2-!_\
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L^?Y_;HB:(FB)HB:(FB)HB<?G^Y\/JT1-$31%141>RZ(JZ(FB)HB:(FB+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>cntx-20211231_g4.jpg
<TEXT>
begin 644 cntx-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2=R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )U:^$ <#A"24T$!       +!P!6@ #&R5'' (   (@"1P"-P (,C R,3
M Y,#D< CP "S$V,#@P.2LP,# P.$))300E       0^J?1#3F_36!^($EZOG
M#>6#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M   %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<'
M)I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M  #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '
M4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6
MY0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !
M)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F
M]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M  3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F
M)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W
M5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M           $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M               %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&
M%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$
M8C4FQT                5&]P(%5N=$8C4FQT                4V-L(%
M5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F
M-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M     -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M      .$))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M             _@   .$))300-       $    'CA"24T$&0      !    !
MXX0DE- _,       D           $ .$))32<0       *  $          C
MA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M   0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M      <   _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@
M  _____________________________P/H   X0DE-! @      !     !
M "0    D      .$))300>       $     #A"24T$&@     #-0    8
M           H4   =C          $                          0
M         '8P   H4                      0
M     0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   H4     4F=H=&QO;F<   =C    !G-L:6-E<U9L3',
M !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M  !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6
M=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&
M4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %
M1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   *%
M   %)G:'1L;VYG   '8P    -U<FQ415A4     0       &YU;&Q415A4
M   0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M    EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6
MQT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M!.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M        QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F
M<      #A"24T$*       #     (_\        #A"24T$$0       0$ .$
M))3004       $    !CA"24T$#      ,'     $   "@    -P   >   &
M<@   ,   8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (
M0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01#
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MQBZIY_#N#MX2<3H'4,NCJ>/6RQ[ZKW^G947%S2'#Z8:Z=KF?27=+,Z?]7\#
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-#4V1U*&MK?Q)B<H,T135%5B8V1G:'.%I<;_Q  = 0$  00# 0
M    !@$$!0<" P@)_\0 8Q$  00! @(#"@8)#PD$"@,! 0 " P0%!A$2(0<3
M,106%T%15F&5T_ 5(E5Q@9$8(S)4E*'!T=0()"4S-39#4V-UDK'2U>$T0D52
M=).6H[4F1%?Q1F5R<X.%I;*VQ6)DI,/_V@ , P$  A$#$0 _ /OXX1.$3A$X
M1.$3A%'&U=KT?2]*+7_81N.#K8=&,/R',*=E3);OCB(+%PFL9?(E)SF,MQ(4
M=*G%YPXZO+;#+SK>"U'J3#Z4Q-G-YRXRECZH''(_=SY)'':."")H+YYYG?%B
MBC!<X_&(#&O>W/:9TSF]89FI@-/49,ADKCB(XF;-9%$WG+9L3/(C@K0-^/--
M(YK&-V&Y>YC7?/YO?RK&[;R2FC].M1]35!+JD0YN8@\U=R,;'BGTI">0:GAQ
M.7L>#GJ@>!F3$5C+:#DQ.,+5XGUG^J3U7E[$U?2;(].8P.+8K#XH+>6G8.7'
M+),V:M5XP-Q%7C<^,DCNF3D5[UT-^I8T=A:T-G6<LFJ<L1O-4BGLTL)6?MR9
M"RN8+ES@=OO-/89%*T-)IQ[N::7S.V'9^<\X^]V%W*AQ:E+RF'L>VCV<9SX?
MN41X!6+';3_Y*4-)3C&?W*<8YJ67I.Z19GF1^N-4@N.Y$6:OP,WY[[1P3QL:
M.?(-: -N2W-!T4=&%=@8SH_TDYH&V\^#QUEY[.9DL5Y9">7C?MS/)<7WT?9G
M'A_\(?>'P_'M:]>/YO8>\/\ H_A\>=?A)Z0O/G5O_$.5_2EW>"_HT_\ #[1G
M_#6'_+3/Y4]])V9SX>'8?>&?A\?#:MZ_)X8]I[PQG'CX_P#3CCPD](7GSJW_
M (AROZ4G@OZ,_P#P]T9_PWA_T->/?2=FOI#[PQX^'_C5O7L\?B_[_8_P^W/Y
M\X\7A)Z0O/G5O_$.5_2O2JCHNZ-#V='FC7>ANFL03]0I$[>G;9=I/[$]KQ<,
M,0([XWQ#AV$>\5"2']I7MMLF.8*$0KLZ)G)[Q<CME11$?ESP\W,F%(;_ +GG
M/+F?7G295BISV-9:PBAR$#[-*1^H<J&V:\<\U5\T7Z[W+&V*\\).WW<3QXE:
M5^CSHIMSW:U70FB9Y\;994OQ1:;Q#W5;+ZT%UD$NU+82.J6J\X )^US1N_SA
MOUGOI.S/TA]X>/AX^S:MZ^#XL8_L]G'CGX/C^#^.V\)/2%Y\ZM_XAROZ4KKP
M7]&?_A[HS_AK#_H:>^C[,_2'WC[<^'C]]:\^S_\ O?AS\'R>.?@^#Q>$GI"\
M^-6_\0Y7]*3P7]&?_A[HS_AO#_H:]D=I>S2%8S[X?=V58SC/@K:EX7C\V4J.
MJ2KV>/AA2<^/P_%QX2>D,'?OYU;R\NH,H1](=:((]!!'EY*CNB[HS<"/!]HT
M;@CEIO$ \_&"VH""/$05->M/*+=KM<3XSS^QG]@"6E(]: [#CHL#$M'[G"L9
M,8]5L\9SS,9]&M@VAI+G]<>COI\Y"I?I[IYZ2<#.QTN;=G*K2.LIYN)ML2#D
M-N[&]7?C=RY%MGAWYN8\;@PC4OZG;HLU#7D9#@>]^X0>KOX"9]-\;N>WZR>9
M<;*W?8%KJG&6@ALC''C&^?J5W6USVF$O0H#3E3V.'A8F6&C$I3<E[U;"V&7#
M%>G)0S@R$Q(D-,..YCQ9P]]QIDA"9;D09,[V=T:=+.!Z1JKHZX..SM6(27L/
M/(UT@8"QKK-*4!HM5.-[6%X:R6)Q#9HFAT;Y/"_2KT-ZCZ+KD;[;F933]R4Q
MX[.U8W,B?)\=PJ787;NJ70QCG!O%)!.UKG5YY#',R&Z'-K+4"<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(J"=\O*+Z$Z!4>*;V7-D62_V-A]5"U+6GXN;=:E,K]"X2D*D9S&KM6AO?N"%
MD)IRSA:'(@F(8*I0,<E6EM'Y;5MLP8]C8J\1'=5^?B%:L#V#=H+I9B.;(8P7
M$;.>6,^.L!GM18_3]<2VG&2>0$5ZD9!FF(\>Q_:X@?NI'<AV-#G?%7R,;\\O
MAW[VZ7EYH-NKO7VIJ<<3"KVN:Z(*%\Q<JSEK!:XW* >+R9Z$Y\UR6!:J\1WP
MPI QG/CCGH7#]$>D\?$WNZ&QE[/(OEMSR11!P/\ !UZSHV!C@ >&5\Y&Y!>3
MS&H,ATA9^X]W<TD6/AYAK*\37R;$\N.:</<3M_G1LAY\]ME4E?E2O*'N+4M7
M;[=F%*SE6<(M3C2/'/\ Y+;3"&T8^1*$)3CXL<D7>#H[S>QW^YW_ *RL1WW:
ME^6+?UQ_5RC_ !]OI7K^%'\H;]+_ '=_*Z1_H^.\'1WF_CO]S_BJ=]VI?EBW
MX_&SZ/\ ,\7OY5SWO*9>4AC#H!>1VMW['$E7I\864?L1!H<2D"_5?=-B!-<C
M)C3'AWKL+UYJ.ZXN)ZW%]82WZPUY_6W0^B7220MP>*=+"V-TL36-,D;90XQ.
MD8'<3!(&N+"X . )&X7)VJ]3M8R1V6NM9(7-C>0T->YFP>&.,?"XL) =MOPD
M@'8\EP/PH_E#?I?[N_E=(_T?.SO!T=V][V.V[-^I_P >W\:X]]VI>7[,VS],
M?,;?^Q]._E^?9/PH_E#?I?[N_E;(_P!'P= Z.\>G\=Y/VG;M^GM_&G?=J7Y8
MMGZ6>+M[&?3Z$_"C^4-^E_N[^5S_ /H^.\'1WF]CO]S_ %<^?SA.^[4N_P"[
M%OEV\V?U\'T_4GX4?RAOTO\ =W\KI'^CX[P='>;^._W/^*KWW:E^6+?UQ_7]
MQXUV(SRK?E%Q$IN9$[=[==>:5A:$DRHXY%SG&,X\'(!P81@/)]OM0]&<1G/A
MG.,^&/#@_H^T9(US7:?H@.&Q,8DB=V@\G1O:YI\6[2T[>/MWJW5^IF.#AF+1
MV.^SA"]O9ML6NB((\>QWYK:9U%_JC'>5,-":YV]JPG;U'=<1'G[ I0<=4]FB
M4+SA.2,@)!<'4>TL1\83A0V&-J$Q2,N/^ZDI]"8S\#U#T,XV>*2?3MF2C9 +
MFTK<CYZ<A ^X9,X.LP$^)SW6&[[ AHW<)5A^DF[#(V/,PMMP.(#K-=C8K$0_
MUG1 B*5HY;AH8_M(+N35]>6G]Q:UWYKFL;8U%;A5WH%P@^O@K (<6IE]"'%L
M2HDJ,^VS-&E1LMIZ 6$$8T4D*(1Y$$A%CRF'6D^>;^/N8NY/0R%>2K;KO+)H
M91LYI&Q!!!+7,>TAT;VN<Q["',):05N&I;K7J\5JI,R>"9O%'(P\B.P@@[%K
MFGXKFN <UP+7 $;*2^6:N4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A%XSGPQG/R?T\.$7R]^4I[$$MO[X,44=/=Q0=1$)=6&CVG5>JSK9$SF-;#
MDII.?,<EL$D/@(BE>>EF ,R[']$LC-2Y\\>G_7=G4^L+6#KS.&$TS-)1A@:X
M]7/E(R8\C<D:-FN>R4.I0NYAL,'&P@S2<7TN_4W='E72>B*FHK,#'9[5]>+)
M33N8.MK8>7:7%48R=RUDL1;D)MN!SYK#6O#FP0D:ZOB\/'P^3&?DQX8\/CQG
M_#\/L\?9S0J]%)GV93X>'LS\.?'V>/CX_P ?CCP]OMSX>SA$^'V9QCVX]N<?
MG]F,>/\ 3QS[.$7G/C^?V_%C\GM\?'Q]G_L\>$5SJM59@75%#L]5UM2+M72M
M6V+:-QW.\ H9(.&EB#=@ CJ"FV2&\S:&:C A8 ]7H=9(!;?93]Q&88D$H:QL
M5C<>*QDE32V$R&+T_A<O2MXS.Y+5F5S-6*>O6DJ6KE2##-R#VF7#VHZD%6W1
MBH2P9&[<R4.SI8S'&W2&8RM>_J[46)RVI\_@\I2R>FL3HO"X&Y-!;LLN4Z-^
MUG9,3&X0YZG)=L7*>3FR<-O%8ZABK.\4+Q*]\HUC58^/;C=:%:_B$I *M:;U
MM-M5?US5-M+INPI%3$6&[V*^:V.QWFWZL<L1$P#)7U2628%BNIA#)#KF9 ]Z
M3XW3U6/*VJ%?"PV'TL?I;3QR5/"X[43L3FG8VM?REO*X2XUS9,?<NV;%6?,@
MLLU14ZN&0D.C?$,MJNS/AJ.3M:BL5&Y'):UU6S$7M1972C,U@/A6WB\-CL'J
M.E('QY7'TJ56]7P(XJ60DOMFL0[$2MH1>/5DW2WIAQ:_"B(LYYN-$J<F;,JT
M9ELG+0VU6I1)^7/D $)1C =^;)D271_JZWW5N*4K.B<V(QF<J(HJ,$0R-QL<
M.,?+)C8VML2 -H/G?).^F /UNZ61SS%P$G=>B,"978+"NGFOV)G8K'NEGRS(
M8\K-(^K$]S\G'79% R^2[]=MABC8)^L ;RW.+9SGV_GSCV_%X>W&<>.,?!\'
MM]GCX>WX\XM99/S^W\F?9^3V_+[?D^7V8SXXX1/RYQX9^+&/9X_'[?;C\OP_
M'X_+PBS?6^PK3J>\UC8E+(+&V6J%&"8Z1XK4T[E/BW)@3&TJ3F0.)1''QQ&*
MI242H,F0PO.,.>=C,Z>SV2TQF<?G<3.ZO?QUAD\+QN6O .TD$S=P)()XR^&:
M,\GQO>W<;[K":DT]B]68+)Z=S, L8[*57UIV;-#V$D.BL1.(/!8K3-CL5Y>9
MCFBB?LX,X3]CNHMC"=N:RH^RP>%(&W2N#3K4=:DK=@/RXZ<SA<A2,Y0J2*GI
ME#I.494CUB*YYJE)\,Y^J>FLY6U+@,3GZ>XKY:C7NQL<070NFC!E@>1R,E>;
MK()".7'&[A^+LOD!JC3]S2FHLUIN^0ZWA<C:H2R-!#)Q!*YL5F('F(;4/5V(
M>+XW52LXN>ZD;F<6!3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X11MN+:=5T?JK8FX+O)5$J>M*;8;J>=:PE4A8
M^O#)!%V+#;4I.'I\[+"80^/C/G29LB/'1XK=3C-W1I3Y*[4Q]5O'8NV(:L+>
M?.29[8V[D=C07 N/(-:"XG8*WMVHJ56>W.>&&M%)-(?(R-I>[;TD#9H\;B!X
MU_,T[.=C=C]L-W7O>NTB;DZRW4L[)8@(?>=%U>OL+6U7Z@ :>4K,4'7!OHH$
M)O&,.R%(?(S5ODITV4_[=P.#I:=Q=7%46-$5=@$DH;POLSD#K;,IV#G/F?N_
M8\F-(8S9C6@>8,ME+.8OSW[+B7S.)8S<EL,0)ZN%@[ UC>7(;N.[G;N)*@/F
M86.3A$X1;M;=@/3].4*7LO4--LE1Z]>3MU=<-<#[%18P@'=MU]I-M 38<V^7
M%L!I]Q'U^GW,].-,QB[K$JT4*QIG.I.NF)&-1U1+;RMJ/'Y:[!9S>L[]>Z^*
MX7RU<9@J,XE:(WAPKNEFA9'%QM+F5I86M:(RSCV#,60T:[[5&O-7Q6FZT]9K
MZ[6Q3WLM9A+"'C82LCBE<YY:1O,R4O)>XKN6M'UMO2NTK!?M/5)H?%Z?V3?T
M^S4SK0* T OL#;U?'GM3+U]V+GWF.;CE:%9MBT@(2UMJ6A0-:#H5,LU>*PS#
MK!D_-Z#E;)RV/BIY2PW?4D6(CBLYE\UR*CCI70WQ;P[*ABZJS%4L2LMW[+[4
MCIXWQEA#(F]WP?"<?;DL4J^WP))??)7QS&5W6KC ^N^#(&<2<==\T#3!6B;7
M:V-X>'NXW"-=CZ\UN,8[::5&ZKU2*;T3I_K9J,=<'Q8\=;RW;,S==(TNUVXA
ML0O):?KD*1D?O!XV#B315/EBQ;Q0Z,DE&I)EO(T;F0<[3N6ER>2D=E\CF\H^
MH)7R5HM/0U<C8BJQU(V[3%I=CN"0M?-UC@V)W5<,:LK=>H&YG'QT:3!CJ>+I
M,L&-K)GY>:>E$^5UJ0@L _70DV+(^'BZQI<'..+=X=7AJ5IP*8&:0%:59:VL
M/UXQ3+MJS[W>Y*:;IM#E)N0^OW\3-?&=G-0V0C(@&W-J65*[<%/,A(;+0T/9
MVLE+C2-^>UEY8Y<K)DB['R738JWN[,;;BL6QW/)-4D:),)D8&M,8I1%L,D1D
M#N)T8 Z-15(H*$<L=&.D!=95$$U45[M=\,!ZYD<\;W-R-24N$CK,GQV2=7M^
MV;#5)S92AB<(G"+?#Y!GNZ?T#V@#]=K*7?=T[V-*MUYH9*D_["K&VWXR8],L
M@]MS*L,O6=^-&HI=F/AO)%9*OS92UIK\=O.I.EG2T.5PLF<@B:,EAXQ(^1K=
MG3XYI)GBD([16!-F(N^X#)F#<S<M@]'^>DH9-N,F>32R+N!C"?BPV]MH7L!Y
M-$VP@<!L'.=&3]RONOYY:6]TX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A%X5_M5?FSG^+V\H>8/OS\6W9SW[.8YHOA]/$)98Z:*D%+<GDRQ(A-<<
M\5.+ES)K\F2MQ7BKQ6IYU:E9RK/BK.<^.?'QY\@\A/+:OW;,Q)FL6[,\I/:9
M)9GO?OZ>)QW7VLQU>*ICJ%6 -;!6I5((0T -$44$<<8:    QK0   !V !=1
MGY,_![?X?9_!CY<Y_C_-:*\3.,_%XYS\/PY]GL^#'MQG'\7Y\8^(B[<& .V:
M>@57Q,\R16R])Q#'1G9+Z8\9O+LF0XAI*O11F&T^>_(=\QEE'BIQ:,>'+RCC
M[V3L"KCZD]RP6/D$->-TCQ'&.*21P:#PQL'-SW$-;RW(W"LLADL=BJYMY.[6
MH50]D77VI6Q1F64\,432XCCED.X9&P.D?L0QCG;-.4YU;?VQA,O.J=A%P1R)
M*<.D*\?;Q-G0[./J$T3%4R+>;:(PCI#U"8@BY CQYD=X6N3[LNP!LW)]Z^>;
M6L6YL7>KPUQ(WBGI7&]=-#D(,9-6BX*[VB>*W.(I!,88VR,=#UG=#HH9<2[5
MVFC:K4Z^:QMR>PZ,N;6R%!_<]:;%VLQ!=FX[3.*M8H573P.K=T2/BECL&-M-
ML]F'W1J/:3DN8/:UY<79D"/#F3(S0 HXZPS/R3;@NN);C9SG,MX27BQ<)\Y;
M\L<0A,I7+B26&^P:3U29)JS<#ES)#'%//"*<Y+(YNO;"]S0T@B1U:Q''MN72
M0S1MWD8YHH=9:1;%!;=J3",BGEFKP3/OU6M=)7[E,[&'K#P=2RW5FE^Y$44M
M>:3ACD@>[VGZEV.,;??<J!M^)%K86US)L&#)EPHP,_6V;9#DR)++2FT^A NJ
M($6\JRJ Q#GOR4H8A2'45L:2U+4;*]V*NOBBH5,C--7BDDBCIW:3,C$]\D8V
MW;5<9)V<S"(Y#)LV-SAPKZRTM<,3?AF@R:;)W\3!!:FBBLR7\;DI,3+'%$]Q
M?]LOL[GJ2-VZXS0"/8S,8NQ)Z2V8--R:VFI&BAZ!)GQ9XH,*+D7X:QZP[:EK
M?:@8A2&Y#YT7&A^I2I3CLN9%BJ;;>G0&Y7=:T5J6M=DQHQ=NS>A?.R:M4K6I
MW1" P-+S((! ]DCK,+8C#+(7/>QC@UTL0DMJ>OM*7*,65=F*=/'V8ZTM>W?M
M5:[9^ZN["&B,V'V(WQ-HV9)S/%$QD<4LC7O$,W5X@1I-Q$!(5E+5<^-KY%V*
MU ,SA<N*-F.3&9,B$F/*>:2TYB:Q!GKB*PO*)6!\_#"G,PI6&<3:P>8I4H<C
M;QEZM0L.C;!;GK2QP2F5DCXN"1S0UW6MBE,9WV?U4H:28GAN;JYW!WK\^+HY
MC'7,C69*^Q2K6HI;$#8'Q,G,D;7<0,#IX.N !=&)X"\ 3Q%^,>W\F/;G_JQX
M_+X_P?%CQ\<<Q:RJ?P>W'CX?'CQSCQS^7Y?9\GQ?!PB?#\7P^SV^S\GA\N/'
MP^3V^SX\\(OJ/\EV2F$.GU*8EY6IL39+T-@*7G.<YA_=//(8\W.<Y_<IE$)2
M$X^#&$^;CV8QSZ,_J>)YINBW#-E)+:]W+UX=QMM",A/*&CRM:^60 ^0;>)?,
M3]4U6AK],&H'0MX>Z:>$L2CG^VG$U(CON-]^&)F_;SW._-;"^;O6@DX1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X15.[%]K8F@+?JO7P
M[3&X=X7O;T2^D:S5M0Q*$^0CC-<1ZU)LI J]?KY1![##2+6*Q&1%F3'WL^L^
M>TUAI&7<QB\.[)07;3[]#'5:#JL<T]]UOA=)<,P@C8VG3N2%Q[GD)+F-: !S
MYK%Y#*-HS5:S:EJY8N"=T4540%P97$9E<XS30@ =:SL)[3Z 8L]^WMK][D[O
M?4^MG^L7R[^ :7G5IX?1G?R80JW^%[7R!F/JQW]X)[]O;7[W)W?^I];/]8OE
M?@&CYU:=^K.^3^9/H^?T<T^%[7R!F/JQW]X+Q[]O;7[W)W?^I];/]8OE/@&E
MYU:>^K._W(GPO:^0,Q]6._O!/?M[:_>Y.[_U/K9_K%\? -+SJT]]6=_N1/A>
MU\@9CZL=_>">_;VU^]R=W_J?6S_6+Y7X!H^=6G?JSO+_ .B?U;I\+VOD#,?5
MCO[P3W[>VOWN3N_]3ZV?ZQ?*? -+SJT]]6=_N1/ABU\@9CZL=_>"UN>5Q[9[
M0NWD_-\U*?T_[/:1'G\:W@3[]LUC33-5B0E;7H[LD5(<I&XKB?3).-M9%L);
M!O17$R76Y3\=I?I.3;H[PM*'6&&F&<P^1?$^V]E6G\*=>7BA:X7M[KQE2+[6
M2' ]<'!X80'#<*-:OREF73N1C=BLE3:]D+736!3ZH--F#B8>IM3OW>-V\H^P
MGXS1N5\2_/4ZT0G")PBS@+K+8]CK).ZUZ@70[3PLY@88M0>L&B5=%D)+L%AB
M"0-0X3PZ)+<?*"V$QWY*'?3%!C64>?/B8>LI\ECZUB.K8NU8;,K'2QUY9XXY
MGQM#RZ1L;W!SF 1R'< [B-Y (8\MN(ZEJ:%]B*M/+!$>&2:.)[XV$AI <X#A
M!(>P[;\@YI<1QLXL[D==M^X)P:K]ZO9\NVK@D)3U$;H=ZS:PHL6X'7F62"2
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M6JLT0)DBLPR,X=N+B9(US0.(@;EP Y^7L*_HN>_;VU^]R=W_ *GUL_-](O\
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M(Y YL390^23L[XQU#*_<,+8@U[7M9+P<7'1DIDM+8A\;@+)>*02OW:6AXCV
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M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7JK_:Y_I\?"*M'3[^U]I_\
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MEMBZF(R80F><<?SA]V\4PE1ME9>;CK^[5;49J-PBAK7EJ[%:!L.:/<Z1MG9
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M#H#KP1H-.VMW&WJ<U2/VQM&KD[O2]65FD:DONW[<>32Q5EISMMN1872$UVD
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M:AIBVD*6G8>*G9[I0ZA':IXZY6D,:M$VHYD5@N6( YDR#((H5ZK>1?Z==>-
MTO3MPJCN[+.#UQK'7=IV39;!LD:L_!U5LD%N2O8J-2?V181FH@4K;-9 [&/U
M'74T0"M%M'I+VI@[(?DJ>(K5;*Z!=4]L6&[7&V:[-Q+OL.[!MB6J]4?:NWM8
MWB7;@6LV=-0R0ZWZWOE5L%>C2=6L(I)H-72 H'8@N7$'QI*2ZY(418>1\E_T
M6(Q2 _&AAXH61U=J33Z@]:NFR*H'@4_0I6*:TK,!BJU<14"O7W5I&&P[1]K
MXX_:%=:S)B#K>S$G3F))%W-?\F_TLK &171&D1Z(1#5.\]*G)DVW["*6"TZ_
M[,%PA_?46XVDE;9=DM]EV@:K@0E9;_92I2_KD#VLP;-";4ZAPBR"D]"NJ6N-
MNC]X4C5[M<OXIJ"N"J#>]D9IK9D=01^JXUS=UD_;WM:R]C9UP*'4F3LF74W[
MY-KT-F!,L3[>%943_'\?YO$K@<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G"*@5B\EQT)MDX\3L/76N$R5FKFUJD;GO6;8")DVN[OW*]V#VB-
MQ)8MK3T5%IW!)F7%<B$N/+$.SB 8!(%5R?,#OD^D]FWO[[>A<0]H3R>]>VPX
M/M%0I#6RK5L'=MOG0K 6N1(85OO932YMS>*C<8D5F4O*KWH_41>;8*X8;0'#
MU8&V2A"0ZC\&27(JZRO);=,]Z:YZS$-(&;A6M.TS?-;[*HG(V!OBQ6S9X6I:
M3V1I+782G[6N&SX.U=9UBH![J(.ZI/4@ZV(KXBLB%T4=&'&HQMLBLQKSI+T*
M'B-N:=UWJBM1Q<;1\/IIN"KC;!?$*SIX] L&SDZ[-S'[#B2]./L;QL=R+W.'
M-7=C)&\S2)FTR2N4JBD[/1X_J\?T+L)'D\^F NZO[8=T]+)'!4 _)CU]5ZVM
M8J3&*F-7N:CL-I Z:?N4[73.S+!JI+U$(7D336K\9"2)$%\W(>FR''B?3]/S
MJC-?TKY';+>I93NO[/!1K*@:$CT4+?IO:/#%LUO]_F;1^O$&\UBVFWX.\J[K
M[=!%<:A"]HCKPSJ:)[F3X46L4V"+?C$5WA/1_HAMS7%45 T[5+MK24%[#YK<
M2>5ND\2X,[<V5=O["L2AI<[ZPB7>[8E<\K",QDE*49BJ@UYBJR("HC!%8?1/
M7G576ZJ$Z=J<.>'"SEBF6VP$;;?;_L^W6.R3H0X8\7L5ZV=9[A=#DM L0*%Q
M/=0]*:@#!T(?!;CQ(S3*2*:^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A%Q9TZ$,A3"1*7&@#A\61.GSIC[<:)"A1&EORI<J2\I#,>-&8;<>??=6AMI
MI"G%J2E.<X(JZRNW_72%9J]49>QV8Y>RLTER,Z[6+HD $E;*C096O MZMN:Y
M]RFMK1>&2HG[DZEL(U6+.?=+"8XL1)D%(#4@BGK[H1/N\JM>L/>ZZ!&#JVO4
M9_J:1N9F8&'<E?5?<G$CUG&4Y'^O>Z.&O"3F+B-G#V2*FO>&-TRN=6I>J>X(
M:;9!YHQ-V;KH?7JSN Q=JR>U6Z&CS=H4^SZ/%RK[K,C25WH/ >OXLQ65CF;6
MD6LQZL8DQ7R+&>MG5WR?"Q6N[+UNI]0/Q=$;8M>U:A>0EQN]J*??AW'J"%!M
M>R+)>3=D)EMMV:]:<V8+;=MEW+W5,H <$K@3FGAH]0\GY?H]/8LPK?DZ^DM4
MDSY 30E2;@EA&^:Z_6YY6U&Z,BL=GC%?L.^*J-H!NPD:0)J6Q3=6#E2=6$U^
M'7Q\UH@^"'"E&CGNB3\G+R^_)9)ULZ0]6^H\^U'-#ZZ56#UQ%5X ?M-AO6P-
MEVEVHU-,I-1I,"T[/MEQ/ Z%5T3)>*Y20I$?51.7G7(0IIU2G,D]_?YEFE^Z
MM=>]I6G8EQV)K(!<;!MK1R>N.Q7CL@K-@VS2"#5CL.*&2!+)8!>YN#5ML,_)
M&,-8-Y<)*;44RQ'AM1R?3M[\C^91Y7>A'4JMZ#M'68=JM$K3=ZN,#8EX!'+Q
ML.RG[O>1EDJ]K'VVW[$/VXEL:RG(QJE5%31 Q;)CON;71 #.<@8;0S!/3OR[
M58^F['I&PHONA2;%"LHI0\:5CFA29,@%/'%GR<:!+%'/0)$%VGGQ!!"LBYLO
M,?T3:I.&42HBGR+L;1<*U2AT<O:"\8..EV.G5&/*D8=6ARQ[ MH2B4T5A,=M
MYQ,@_;K&$!PU+0EE,HBRJ0ZS'2Z\V1>Q6W5L(9JU?+%XH\O=B!(15(DG+C>#
MQ@0%(60@''R,M^JNEV:\(,G4"\OIGR1 0V1BQWH@8F]%(LCX1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1:D-T>3W=[,;(V16=IS2\#51?M)-["RB8"P&J\8ME
M,NO0QWJFQ41Q@&\TZP>I6P!*K&2"&$OUDI3\ HI2*9BF2019%C%]\GQV$VL2
M)G]B7;1IG9I\"/'S=_C@EG#[(JT,!IJW:BEZYUX):%OLUG5>WIQ.%LG85?9M
MON?7S5TV@!@ +@J36+6+(N#L#R>Y:LG*_3M/C(%0J6U=QB@%X:UI78("K5OJ
MF:ZXZ[USV4HUD=;DAD R.UK-J\/8JV7KL V6E7A8$@1BI2NQE89/?\RR6K>2
MX#U>^0MDPHVI8UUB7[76P<6V%5%,VCW>K/>>P]CK2:2<P-21P?L.CCKNCTE\
MR?75"')55?D(H[RH:R*[Y'IIUO*DJ28(:Y:D$]<BP06G3,V*UH>#BJT0M)81
M 3EHXC$V/')7(]-=;GIE>N27H+TOT[@<0J$1=OU;I]DIFIWF;6,D 2UNVGOK
M:J:W,4RJ=61.X]Y;#VI7Z\33&?DQ6#0D%<!T6P18DF3$BGD$HT23(CM-/.$5
MB>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X103VBUK8-R];-_:DJD
MYD;9]F:;V31*].DO*CQ6#5JJ!<*,S,?0E2V82YDUEJ:ZVG+C<5;RT8\_&.$5
M0+9U8VUL:N[XI(*73JOISN9;J9M79#]R]WHFZM09G4#5=-V!1JY7Q0V?5;(8
MF@=90(U4LQ&VUES6=A+2IF0]X@5L2-FD40->3!) ((-8!C2IQMI48WM#7MB"
M31M#[#V3&]BVRY[&W94:M'I!B%)JTFNCHI8S7[9)B':)3HTD,1JX=@;@BLS.
MZ7/7 GU@>MUGE4T+HS0&VM4&@/7Z][;TPRZ5V(7Z^S!(VHF:O<(EN9US7!FH
MS8I((S9G''<R:O/9C,OBVTCB>_O[]BK-;/)8L!T;*FZ'B:4UZ:MARY@PTB74
M5NN9T$6ZVZOTE6]&'R+H4TY/J(@OK:(<CA#<"VTL:]@8=F4^US(L\(3(H[I?
MDB2\:NV<5?)^GCCJH)4;K&-D!&(1M7B[9V!QMJXBJTH3K^@@0"3%-)677Y*5
M1:328!R.:+>-?"!; 3"MD7<W3R3TZ.Y#;U- T!7*X5M.Z).SJ8Y2*^+'; I%
MLWY8-IZ5K#N3>K=H4EA6DJR3$5NK)M6K;V)K0L40JM!&U'W5$W2JD6.C_)3[
MGC:==U=.V#ITK<Y6J-=T7'8@D+MDW;%=!T+KS5-*DM"T]+T+$8?HK8-EJDG8
MMF9/%K*$;3?[\$>T^:L<T3L,:19O2?)O[OH 8?7JY<M8MUZR3Z*FV@B),RJ#
MK>O:^[3B>PT,-K6#4];TBI6!JRBV3M=)PHE*TW7 M@,KLL&ODF%SQ$TBZFJ^
M2VN=-IE%JJ1G6Z^5B@Q0@-.EKH(/L:6N4<"#[&UP7=K ''U.6W"MT"3N&N7^
M*.; %X[5BAVP5%L,(I)K^Q1I%W=?\FON*-OHWMTQ>=31T%[0",&GZR#4)(76
M-5.ZO6SLK4)9YB#21EK=)5;7>EK+KR!]\#:^YBC1ZSK*5^UU.M$YU:@$7=]?
MNC.TNOXK5>N41J0^#8[.T;;TPI1F(26Z$"UUJ>SBK/9)MG<IE L5F+;3,HK>
MN(XBWYV5LL=5;2>D6[<FSXD&9,&$6XKA$X1.$7'E2HT*.[*EOM1HT="G9$A]
MQMEAAI"<K<=>=<4AMMMM&,J6M:L)2G&59SC&,YYQ>]D;7/>YK&-:7.>]P:UK
M6C<N<XD - YDD@ =JY,8^1[(XV/DDD<UD<<;2][WN.S6,:T$N<XD!K0-R2 .
M9"@,EVPZVB);T&=NK7N)+"LH=3%L,,DVA:<XPI&7QJY;'GISGP4GTGG)SC.,
MXQG'(A/TA:'KR/BEU7@Q(PEKFLR%>;8CM!="^1O(\CSW!W!V(V4]K]%725;A
MCGKZ%U1)%*T.C<<-=9Q-/8X-DB8[8CF"6\V[.&X()Z_WX?6'YZZ/^D'?YOSI
M\).@O.O#?A;?S+O\$72AYAZH]4VO["\^_#ZP_/71_P!(._+X?_1_E]GY^4\)
M6@O.S"_A;?)OY/)S^9/!%TG^8>J/5-KR;_ZGDY_,GOP^L7SUTC](._%\/_R?
MXN/"5H+SLPOX6WQ]GB\:IX(ND_S#U/ZIM>/L_P SQKQ[\/K#\]='_2#O\WY7
MPDZ"\Z\-^%M_,J^"'I0\P]4>J;7]A/?A]8?GKH_Z0=_F_'A)T%YUX;\+;^9/
M!#TH>8>J/5-K^PGOQ.L/SUT?](._S?CPDZ#\Z\-^%M_,G@AZ4/,+5'JFU_83
MWX?6'YZZ/^D'?YOQX2=!>=>&_"V_F3P0]*'F'JCU3:_L)[\3K#\]='_2#O\
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M8L?#NND?I!W^;\IX2M!'LU9A?PMOYE0=$72>?_0/5'JFU_87CWXG6'YZZ/\
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MK:M[%O;%4CL&-D4;!';+ZD]4FCU<9<.&M:E;-OS#@>):6NZUPC;![8[_ +S
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MS"D ]Y&4Y@?Z:J?W>GX)[8'L_P#?;IWY?[ F_P"/']>_P?X>/L<,KV]\V/\
MP&QS.^_\;_5]7,I]E[A0.(Z(RGB(VS53Q[=N^/3\$]L#XMMT[] FOX/[M[/;
M^?C['#*[_OFQ_9M_D-GEXN7VWGR\OI3[+S#>9&3]=U?I_P!'_P#GZ%Y_!/[
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M'MHV3V\OXWR?F\93[+S#'MT1E#V[?LW4\>^_^CSVCM/CY\D_!/[!^=RGY_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>cntx-20211231_g5.jpg
<TEXT>
begin 644 cntx-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2E>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *4*^$%8CA"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  0$L
M   0 !.$))300F       .             #^    X0DE-! T       0
M >.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M        H  0         !.$))30/T       2 #4    ! "T    &
M !.$))30/W       <  #_____________________________ ^@  #A"24
MT$"       $     $   )    "0      X0DE-!!X       0     .$))30
M0:      ,U    !@             "NP   ^@          0
M             !              /H   "NP                     !
M                       !     !        ;G5L;     (    &8F]U;F
M1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&
M5F=&QO;F<          $)T;VUL;VYG   "NP    !29VAT;&]N9P   ^@
M &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&
MEC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6
MT    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6
MT    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M  4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M!"=&]M;&]N9P   KL     4F=H=&QO;F<   /H     W5R;%1%6%0    !
M      ;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&
M%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497
MAT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&
MEG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$
M%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94
M)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&
M5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W
M)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P        .$
M))3001       ! 0 X0DE-!!0       0    ".$))300,     !]E     0
M   *    !P   !X   T@   !]) !@  ?_8_^(,6$E#0U]04D]&24Q%  $!
M ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M  245#('-21T(                  /;6  $     TRU(4" @
M                                                     18W!R=
M   5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<E
MA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M!P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _
M@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3
M@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@24
M5#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                           %
MA96B        #S40 !     1;,6%E:(                     !865H@
M      ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "
M2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M           !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                          9&5S8P         N24
M5#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W
M!A8V4@+2!S4D="                             &1E<V,         +%
M)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
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M(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q
M33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B
M<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K
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M/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*
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MP,#Q48$Q,5$Q,8$0P,# P,#!$,#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M" #@ 4 ! 1$ _\0 'P ! 0 " @,! 0$           @'"00& P4* 0(+_\0
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MCD'34TKY337$CT)?I_N(-Q#<J/?Z7)6;RTE!@G/X/P]'@>,CQ^%\?-G/X/\
MXW+QXXXY$/6S_$/U8_1''O[1RWN..3/MG^*V*_68TL_;'H?E,<<<<G."!-^Z
M8V'%D!>",P37\)9F!"R:(X.;:R> 8<Y\F"P%B3B*$$.!"&8=@><X"# :,XXX
MXXY-SI<DAL!4LC.NC8URI20:K0.UPR(M4934/6I%9:%80D.0*T#I;$D0&"5B
MQ&(,N3,):UJ7LDNL6".0D9:KM]?TM'84\KIJ[.+Q85GNY2Y,YV5-C4SA(D[6
MXJ4JM1%8F0G3)6F!P4H] @&3#XBA:FI4H0)WE^"^2<U>_KLQ<<@GM2^C*["O
MJ4[/?8Q,^4_0WXC:8_1/77Y_Y(,_Y_?_ -/O_/S*_'''''-/N\/TH?2C^D+>
MW]D-\YN"Y'N[WXIZX^N%H9^VI0W+"XXXY DT^E"UR^HMN']O&D_+[XXXY$/6
MS_$/U8_1''O[1RWN..3/MG^*V*_68TL_;'H?E,<<<<GJ"Y_NCM@<>&?=#:(_
M)[L_@K.^;\_*%XXXYC:PK7AU:X9DCZK5+I+*5"E%#8/'D9KW-9FX)"@'*DL=
MCZ3Q4J"419I)KN]+!(8Y'$IP'&2O+.V8,6@Q*&M['N["9PO10*$0 T"507KU
M$7H"T#R 19XCDEW3YN G'+DYN#DI2^MX8-OK_!J5Q:Y*_P!MQ]R)"FI9N;6Y
MG0(VII0(VML;DQ*-O;FY*0B0(4B<L)2=*C2)@%ITR8@H(2R2"2P%%%A"  0A
MQC&.;QQR"NU'Z,KL)^I3L]]C$S_O9_[,_P"#E/4-^(VF/T3UU_F@S\ROQQQQ
MQS3[O#]*'TH_I"WM_9#?.;@N1[N]^*>N/KA:&?MJ4-RPN...0)-/I0=<OJ+;
MA_;OI-R^^...1#UL_P 0_5C]$<>_M'+>XXY,^V?XK8K]9C2S]L>A^4QQQQR>
MH+X_='; ^.,>'P-HCP]_CG./16=\^/#'A[_''AC.?=[_ !]_ABA>.>%2I3HT
MYZM6>2E2I23%"E2H- 0G3D$@R8<>><:(!9))181#--,$$LL 1#&((<9SB;#K
M2G%O&&-6OZ1(AB9F529QV!E;>:IBA B1!+,Q5,2-,0K;57&8%X(I6:I9ZL3>
M?#D@D$\/;5\149&KNGXC7"AU>D67623B2!3_  NLB8K@/DZE(TP?P)3@[>KI
M$K8S)C1&GMD/BS='X0P&*%(8[&6@D\PH64^....05VH_1E]A/U*MGOL8F?*>
MH;/C1M,9_/4]=9_Z8@S\ROQQQQQS3[O#]*'TH_I"WM_9#?.;@N1[N_\ BGKC
MZX>AG[:E#<L+CCCD"33Z4'7+ZBVX?V[Z3<OOCCCD0];'\0_5C]$<>_M'+>XX
MY,VVF/&K(KC/C_&9TKS[LYQ\VY%#YQ[\9QGP\<>_'S"QXXSC.,YQFF>...3U
M!<^.QVP./?[H;1&,^.,X_P#16=GW9SCPS\_SX\<>/N^?&<<H7F(K%N:,5\X-
ML8*0O<WL9_)]/&ZRA"1,ZS!V39&<7EV6 5K&]FBD7)-3GE*YE-'B.Q1,H*]1
M$\"<ST:%3T1+3TKM(XA[V07LSNUA&4I;:&BBA:KJ5H.2N)+BVJYLX.*5M=+E
MD2 Y*F, ?(&I@K]&>6G4-M;%/C>3*%5+XQC&,8QC&,8QC&,8QX8QC'NQC&,>
M[&,8^;'/WCCCCCD$]J/T9785]2G9[YOG_$Q,_FY3U"_B,IC]$]=?YH,_,L<<
M<<<<T^[P_2A]*/Z0M[?V0WSFX+D=[P#""IZV\V?#S;B:%@Q\_O$+=6AL8Q[L
M9^?/Y_=^?.,<L3CCCD"33Z4'7+ZBVX?V[Z3<OOCCCD0];/\ $/U8_1''O[1R
MWN..3)MN/R57%,Y$$/CLWI0#Q%\V?2;ET*# <>(@_?"R+R@]_P#O\A\ BS][
MFF^...:A**WM:Y-V,;VT',*&NNG6^BZVK6336[K5^+AAI,498#Y05&Y"RRE+
M/7!8L:+!99 ;)6$\QI(&TH8](TDQ!&WA!AM,ME3,K3O$OU*GQ+*KK17D\E7=
M\E82AS.0H#$IA.#Z4K^2)#$J3.59GIV^R;39%4;&%O*5Q^M;&C3^@D:/+]>5
M;"ZO0+DD4;#0+WI0G7RF3NZY8_3*:.Z9$G;BWR:2UW.5OTG=P(4J9$2L=ERD
M2) G3-C>%(V)$B,C(?'''''''()[4OHRNPKZE.SWV,3/E/4+^(RF/T3UU_F@
MS\RQQQQQQS3[O#]*'TH_I"WM_9#?.;@N1YN_@.:GK?S8QGPW#T+SCQQC/@+&
MZE#>&<>/Y<9^;./?X_-RP^...0)-/I0=<OJ+;A_;OI-_K_KGE]\<<<B'K8_B
M'ZL?HCCW]HY;W'')<W , 54\2$,P)6,[1Z.%X$,!IF,C-W6U_*++P$DPH>!'
M#&$H \BR46,83#RS2 F%#J/CCF%YQ=+5'GLR"0UF7V;:N2V\SX!QD].7[ 2N
MHC HGZPY(IP)F@$8P62H6"6O S7IV2)%),.CDL><)F=5\:6G_0EVAU[WHO.Y
M^P5HQ674$FL9]MZ56PJL,Z5G7:W.WHG:,5#FOUJDF5%FP9],CN$*B8L+3#8\
M*N&AYB8SU+=&$&/N5XXXXXXXXXY!7:C]&7V$_4JV>^QB9_Z_-RG:%_$93'Z)
MZZ_S09^98XXXXXYHI[2[;9Z,WYZ<;.?8K9,V;H]8VZA(XO4=?R2SY^['ONL*
MF/I0,<-BB)<[N $RET*7.JO!92)I9TJ]U<%*=&C.,Q9LR[&ZZA0[' LUXW?>
M\UI< *7<<Q746WI$&3/H_AE_MM@0VYE-#,JO#\"E>!V,SY.C!67N+8-6@^$"
M'S3)O+O?7P:U?T(Z.V^/S2&\^E4;=E).JUN*4DW<8WM9#Y8J7U*<7'Q_&(QJ
M4E8.K8SR-@":SND@D<#942XQ;-&,"FD9GV20"$EVN:KUHWL?L5%9C75[N&):
MBVG(1RQR=C)F65*:U C08%/J_29A*H;C,X_A2T(2W^)9/-#F0),8_J3]D==1
M15;Z9?KCO0O#3<O:8:[JV#4"W9 FF:YX-DI"=VJWV0T*E%A1E.?&3RW*11].
M>V-@'9@6+CB$#H6K![&0=BE;QM9;"1?0.["D%0+8R@>UK-J+<CZEE1LI5*4:
M4RL\-$?6J[&2M9Q!8I"JBJ5P3L296G6KS"D851Z;D2CL-K6*J[,1*:*W1=CJ
MJ98V]/HX[J+=3TF?2Y.YQYK1-U?K$D9$EL-X0&R1&J?FZ''/!S WHGQ:[Y2$
ML3H)+&<ZW=KI/V(0&:FU5M1ZC4N@MZ.<A9R]7+J.E3V3:UU:'KV<BOHV3$1N
MMCN$9 \%)[$;H40]+H"M0NB.2$(3T!P.6FN[!ZP;Q2X!U*[DF&0FM(3:3N!)
MJ%>RW"QGG0:^&W1V-')8><FEU@LV+&;<2V QDYUE$6%'YN!X;TPXB\!(\(NQ
M"JBLO6#Z7W.)$P59%;<6XQIOL$I],PR]'"UC='6H2*#J@/5CH SEN3R*N&D2
MR81M6T2PEZ:4?P6>1I?#\HO4N%#D0.E]T@>S*U;+3-.^XQV),(4,3LACZY(Q
MHA$0,T2N?@!(DR=;7A0,S%M5H'@A>SIA-BC./8)^P6JE U(/B?W$)]6JC-PY
MR?I[L&'!L<P668&/E9!!#/-9)N#0!+J\6 3S(\YP)@#X9SB3-!MV*UAFF6M,
M8<JUV@<EK;JBBMLY=&=6KTDS$<PM*M\1G1]&^,D)6MBNQ%)C2>8VUV2H%+W-
M,I;5:%I.3N2(PZL2>PFIC_9'DJ+<4.7FK)!;J?!NFVQ964L?C>),)9'G3SU\
M'#78RT,4798ZV79(FC[EPCP&MF5&2)G K\9'8?41_P '_"H]R"L2.KI9;242
MC3+9 @+>P0X,V&XL+]DRNP^PK"<<0-U^#=>.GJTODN76)896E;F71[#ASD78
M!4J[,&P&K-MTOP_KV=62U9<-0MA4&&AGK]/.5+NR3#*J %_ Z;NI5?O'P0A$
MC]GR:8C<HJ7'&YQ'+8^%?(>S_9#2DAK2D$*.KMOTBJR[\U=E+&!\TNV2:RVE
MOKK=2KP/J.9C<Z[1DP=^<<0MVS$&B4&MCG)\JX\ICR1S"_,P5U*Q+LOHF:*:
MS2-59;AI#;6%+PQW+_I?LM'"6K,)PHRZYFQ[U6Z(F"A6X3#^#PI48U!D?F*]
MC96>F+\WK\]I&M29CJ62OD5VAB#!<;G)VF/.\VU)V&B""-*8JZIF98.S5$@K
MY 76*5T7*R0QA5-Q,I,H*%DYA$O+QG/,*8[&&^]I'6,5CT$W#H^L[>G3S6[-
M*E6G>P22U)*Y-9T<;U2QR4NE<'1[6>N5*Z4(DZ:R[++S('U"BDZB.HH$)A3S
M7&2:5WMU6:8W4;#65*[<Q9IN.U7.M6$#]IIM"T.P9N09"B7.8W$\2VOO;L?:
M78R:LQZJW;1<"6Z0&(9(M4R5:9&GXY%W2/=EU#R9OKQQ0UKM^D*LRVEE,L*=
MYTRV595[;)T/P3].]R]"Y5NG4PVO,YF34$BQY(6W0Q2)*_!(>3,QUYPB_MI[
M*J)>2X>8FK;;TCX;W(MHYJ+<---DV\U#+$ HR$]]D12NN"AQVMLYEC9Z"SW?
M"6#*/5WCT#X9ED=,)>&P]G>O$A:6-Y2P#<%(CD5B8K!K"ZZ0;7-JW,CRB9%W
MK[@WJ:E"M9H=Z-^2%8G3P0@B E*9T) \B$UK?0^P1]E>O*Y*D6$0S;'"=;9)
M-5$9.TKVL).S)SRBC@+AI#*C"K+A00' ]+88R,08H?X,R0!,R$ N>7V-Z_&M
M.7HN)[2C0XM@JF@X#IKM-ZX9+#DYBH#H4WYJ7"XVO_1%"P.S"TXH"6:(HDR0
M@..* /PNW9'KTS!E U<2VI-#$;12U"YY;],=JG/*R5+ R41+C'@(*C4&2B"A
M#%'02BQH\!R@J7![+E2_E?"!D]?\DE['M?(H7/S'.*;2'@K:SD=2/^6;3;:1
M]$XRI=B7B)6PTMHJ989/88 $(>QJI_#0O<+1%FL9BQ\(+DC )Q\\O[%]?H29
M:8'F,;.G_$_/V^M968PZ>[024APD;B=*2"U4%/8:H<"K&BZ84/>1N4R@HW^+
M-9 FI0O=DY#XSF+?1S?LZUEKY9:2&0LNS0CJ?E2&'RX;)IWM'(TJIS<#Y.G*
M60Q8Q5,X); CI)D0?!+I/"37U@;R2DJA8X$$."$P_A37M,U6@#G9;3(4.R(E
ME3O#"Q2O#'J#L_)4ZA=(\*!-V8HL8*H<4LV2  F&8Y+HF<\)&< BLNIR/TQ>
M!?LT[3-4( X6BV2(O8,*NGTT*5S+#3J?LK("1DS_ -D_!WX+J6.KEZ>:G9"]
M(1O">)FO"B.A];R_%-WL]=A/('9_V%ZYN^@_936J0N[<2>-:B3R/N?K.MM^)
M6+VA>M1NZ& B12@^NRXZXH/32)MS+71$YGMT")RL.FBIB+;UHB-OU"_B,IC]
M$]=?YH,_,L<<<<<<T^[P_2A]*/Z0M[?V0WSFX+D>;OY+Q5-:8-$, !;B:'X\
MP,!%G!F-SZ*$0'(1?\0T\)1(\A^^ $S)F/<#..6'QQQR!)I]*#KE]1;</[=]
M)N7WQQQR(>MG^(?JQ^B./?VCEO<<<TW=V@KP*UIJU10N[%+:42TG9V@3U4FO
MH%3EP>9M[59L9DI1"=?:GHDY;_6KDP(K@3,K$J]>F;+!7^&F-[D)\2@)O!LM
MQU1MS)5->."C8^W8Q'X\T3B>J M<4@:-X(;2DSE+++ED793(BP/;TJ3FNYM<
M5ZRO4I)-=$(DT09HD:-_;>SPZD"RG]KL:W'TFV;8:\J369_5M'L>&U\)>E D
M7(ZD@1SB]IH60H(P<0JD"]VDUB.R56H;GR<.;.!O:V_/7'''',77?))9#:8M
MN7P-,TK)O%:TG4DB"1^&K+9%4E8XPZ.;(0[C;TJU=AN-<DJ8"SU-(H4Y3B,P
M22,S(0Y^:?3'MDW$?[%J%9:BFIKJK:Y&7K1KN1J(Y*R6]7!+*V;H"YII+97#
MB8U6R%J=%BV45TG-LR,/KNC2Q"1!<8E$DY21N&N.[C67?%L/)9MK7'YMJ74,
M>2;#511EWM;>V[!KB'<5?[$9GB>(ACSK-8%$6A_D,#+KEUDUFH6],L(1,;RG
M;F@Y4ZL*@UZP!\NEM;='W.LIJV(5+#I=&[%V$.N.FT<S>9/ +!AD5T&FVSL.
M8WJQT5;2!'A<W.#,<<R.%-S*4MTG4-C$Y/[C%D#\=&D66MA^]FVUU2WZ?656
M0ZLW %'S]I@6,6/F1[+PJQ73K6D>\41V'(J=R@&8F[Z]1-V3HZ\#*'%P4%.[
MXC&^K429. R)**@UK[++OV*[$*_U_4#K*%5?'5^[D DT$9YLDDMRRMWUTQ2;
M#&[#M:'+H.W*JW9)8Y2B22ZM<1F3&H9#%GE*:Z$N."4*DN32NVK:_7:8;MR&
MV%536$UQ6^-[W&M8[:EOH:L@K95&D,@@,<(H*DE#!09+])]@K3Q9:%2QH);(
M9CASQ&UB[ &[)@TA^ZK0S;6V-P0;"S2653#JNJ^MKZLFBJR*23*0R&S9&OJ2
M:R6*3![LB.N,-CS%!S%&$D>$TL3(_P N/+5"?0.3@0$E" WG]J/T9785^7^X
MIV>]WY_]QB9\I^AL>%&TSCW9\*HKO'CC.,XSX1!G^;./'&<?FSC.<?F]W,K\
M<<<<<U [O9*QV@]*WI F"'F?;VX(R P( @-^Y(>,Y$:$18\FE^AP<#!8!%"P
M:(LSTF0%B*,V_<C#>H_)%554+!PB?2;GZ$D9P P163L'[G4:7DG.0A%Y@B\W
MF&7GP"8$&09%C O'EG\<<<@2:?2@ZY?46W#^W?2;E]\<<<B'K8_B'ZL?HCCW
M]HY;W'.C3^R896+.!ZF3QAN*5'^HM#:D1N#U(Y*["+&:2Q1*+,B5QD<K?U0"
MQB2L4=:W-U4A ,9*08"QB#\NG>OTF;<]T#A1EH5Y8D)U_%4R5;%6:E+GD#\O
M3JHS*#SWB1V1(%U=(9C'8W8^%J5CCZ6%LI$I1+HVB+<72QT#B $50?1-I9K4
M@TYU/U]U;;94NG*2BJNBM<AF3D@*:UTG.CS>6F5/BAM(4+"T G%5Z90!&%6K
MRF*&62)4H$#)HZ>XXXXXYZYW=$;(TNCRXY/PWM#>M<UV4J)8Y*L(T"8Q4IRF
M;F\A4O7G^A*'Z%$A3*%BHSRD)B#CA@+%H:/[O=0TI-4O51TC94PK=WL.^H79
MR.-5(M)LVKWBB-?VC8XQY;*Q8VMRQ($BJ#S$AT=#LO3(NBR94[IW @$H2+8R
M/-+OW(];+ !VE1KR^G0BM(=:;W#K?;J6DAU>2,RG*T:K1MZ 5!*_8I0W2:P>
MNG5,[R",-Z9M :6D>&= I<'6.O[<V3BW=TU#*I1.(Q#=/[ B+!6MW0JOQ$69
M5LJKJ73=5:^IMP[(*EM?U^V5A(5*>?O$9K@MH;HU+%T<,E\7D?MY2]-Y2MA9
MY#R:'[L-07^I*!L';2KRJ%M.]-69+=13:VUA*)7#FJFD< GES-]>-LT>89'9
M',%#A2\'723V5'(LO@[TXB3M+(Z*U;['4;E0$@[6=8ZYG1LCF-926J68-165
M.9>.Q*HF<"V)!/H%=-(Z[M%?MT%70<#/)B)6_6U"V=FE)-EX;%F%<< TX<HX
M2_/,8]6N[B>N!\65H@)89Y-3YL*"6*U>RM=WZ2$0N963:]FT/$<2P\IH4$QJ
MRG:]*MEE3$!(&J=U$Q-;/5%BED<?;1=R:$;11O=/4ZHMI8I6K_4C-=30X3$F
M$29#ZH[H3E3RXICURA3AL:"GL#P8ERZ$2%,BPD>250%J90K), J.Z7VI?1E=
MA7U*=GOL8F?*KI?\3M3?['&D_P!S2"?[$,QD(TO^U9J_V.,(LY$$9/\ P8L"
MSG.,ASC.<Y]_,E\<<<<<T^[P_2A]*/Z0M[?V0WSFX+D8[S"4!K"I1)B#%!N-
MSM$PY++ $S.$YFW],%+#Q8%C/E+2HAJ%1@\8R( "1#QD&<><-G<<<<@2:?2@
MZY?46W#^W?2;E]\<<<B'K9_B'ZL?HCCW]HY;N<XQC.<YQC&,>.<YSX8QC\^<
MY]V,<F=3=,AL]2NC^MB%FDA*40TSG>,G(6+*785A"XM(N;X[AJ7-KK<,D1AP
MKR:UPYS;(>@5(E;9([(C[ZG+9%G<Z\I&-P9[6SAU<WRQ;4=T9S>[VA.5"9PD
MOLI0I*6&1N-)$:5#'X%#0J4Z8X,1A#0PLJM4E)=WE.[R$:QZ5YFXXXXXXXYT
MZQ(O$)O7\YA=@ITJN R^'R:,3=(N7&MB)5$']E6M4E3K').H1GMR4YF5K2U"
MXA6E.2%"&H*4D#+":#Y[VS4SH18Z-95++L[%X_5ZFQY-"V*SFC?";,2LZRY'
M0L2I::15+.T-GHQ&*WW7QJB,9>8MD_+"7"C&US2M*(EQ+<5'4HY6_13>=KW'
MKK%_289!#V-HB5,8;M4Q:DJCGSLCI;6VV5M9P9ZLM(IAMBW0*S8G6C394.A"
ME+,7A#+$Y+XE6R@9\VR?L8IZ=*JV1(L"WYXZ-3[85H42Y!E+/>.%E/.-[1U+
M:>@48+61]!.S1L\NKN'E6)'[/>%S W1=D8XDO<'AV42>/.+>7WV =2O3W<3U
M%5E;+2+. W:TU9&F6/P_8N1R5B<Z+2T/.=0Z[GQ[<QR8_*X,BI_,I@#5/0GA
MPN<(RI>&)2EE"!X<E%*+^G?3I\:W$B69O"<REUA<FAZ^S)U>E@RVRS5<DM>N
M;L#.BY2]N:PQ)/8Y8U1UL\Q-Z1I4Z-C3Q!K:"&H;5E6C4]J:^J'3MM61=S.C
MD_?'B*QW7*-IGN26?,GMX=4^K5WR+8JK%[^O6N0SG1T!;$J?'^1JC,@+>T:H
MM@$0F8DB1O)J#5S6>N=0:5BE 5(KF1U;P83D1#V^;RQRF+C'&1:O/6HHLUNK
MIG*DB-1\H[#:P-N<BPA;R2@&G*50E"L_!W:C]&7V$_4JV>^QB9\KNKLFYK.N
MLGDEISLP6(Y.3E#P:40;F/M^3"2S, +P864/Q  >"R\#"' O(#Q\N.]<<<<<
M<T_;O!P/M%Z50^;RB*G>]Y_WP3?*,.-2G4G( F! (K!V1'@&$LP8!"+ :('C
MY,XSN!Y'VZZ<:JN*G++/&F$'<'2=1DP L!R("3:NI%9I&<B /&0*BB1I1A\N
M,C <((1EBS@P%@\<<<@2:?2A:Y?46W#^WC2?_7_QY??''.B6A(I?$*XG<KK^
M"#M";QJ)/[]%*W*D".**)X_-+8I7-L01R5Q1KVYD72%406U(')Q2C;DRQ408
MO&0DP<>5J3ZI]KWP?7GK?FZ*-F=-V<I9G:%5M07M1'-[HL-KAA)8?A0=$43>
MQY@"5U6GFX'\.E3.PQAI.8GV8REA02!)DK8>*K9Q<"C"^^5J9JA(51:EKH:'
MNJA1'G%&)$,K)%T2<)")18YQAIYARF$M1+56J800MKNGL<"5(_CH]$B1MJ-(
MW-R1*@;T"8A&A0HDY25&B2)BPDIDJ1*0 LA.F3D@ 4002 !118 EEA"$.,8Y
M/''''''''.G6+$/C"KZ=0'V^^13X<0V3Q#X41@].EDL;^$K(N9?;\>4JTRQ(
MG?&?UWVBTGJDBI.2O3)S#DQY81%"T35ET-(:F8 9B>XMD8LA=*)LY2.QY'5]
M>V&-WB]J4Q3=+69'2XC:8YY'ANCNTT7!9#')3)2Y6HCCX%Y3+6V1QYT$RDY&
M=^C^KI/86Q4IE=Y3YWB][-FTP&J,)(W&&-[KB5;7/5(3"53AIF;7Z$YT?H)/
MJ%ALMK7 F1K1,2HL29:G=/1^L&^V=^EBN$T=HU'7UT2J*2J@8IK0BBLH>X;'
M)>5)+"UXV,DFS*^T)VS#5,@7Q\MVPIG+5D^1)%[408J>C%Z-2'(34RG,W63I
M ]ZE(-D)I-FE!&99?UW2:2Q.NFF3D3!EH^@&9[D"VGZ/C[VE8V!")GC"V6SR
M6@0-B(3<U+)XJ:"%:_+<)>IVD<<<@+M;5$(NL/L.5*1Y+()THV=$8/ !F9#C
M-,S(.,X 6$8Q>_.,> 0YS[_'YO'/+*K?\7D"_P BXO\ ]QH>=SXXXXXYJ1W/
M;_7>SSIK/R8(L+5*M[7$. XR+)IHM6S6T)0\8!G 2O1N)IHC,C#X&%%%XP+T
MGNVW<DG<L 3*^JH(L9SC&V^FH\> A!^^+V>JPP&?$.<9SC P!SD.<^46,9"+
M @YSC-;<<<<@2:?2@ZY?46W#^W?2;E]\<XJY<B;$:MQ<E:5O;T"<Y8N7+5!2
M5&C2)BQ'*%2I2>,LE.G(* ,TXXT8"RBPB&,00ASG&N+<!->^ZVK-_4MIO(4]
M8G6C4LQB,5V@E2M_864;P^-K@WIBJK0,04TO>4+B$O"0ZV"A-<2;&I\1R2 F
MV><G6-B+2I_!B.H_?7K4*V:DFXCNSPUGM0V,LL2H]IE\?L'(G6/>5P66NLD<
M7=GAC:\N*5Q-BB9E)6"=EN6Q6O>DZ5,E8#%GUI<<<<<<<<<<<<<<<<<<<UX=
MN2_V9U9=C"[T %/J^DVS0O0&>7 #//3TN+\!>8!@?#'G\WO +'CC'N_+RW*X
M_%Y _P#(R+_]QH?\'.Y\<<<<<U([@9]+VH]/Z<P)9A))._3B4$918Q%+2J!C
M*(M068(&3"S I5ZLCQ ,.!%GC"+&?''-MW)+W(_%_5?UM-.?VFJNY6G'''(B
ME*8@?8[1JL0 Y4)]+-H2"3,A#D8"E5W:D#/"$>0Y&'!@DI&1A"((1Y+#D>!9
M #(;=YABP;K8X>[EPB.-#O95KKT(U[36D. 0>Z%I/$(2WB8/BPU/&ZZB_B+(
M_A#,W1J)<O0G-L72R62#01]=U=!2SS/UB"3;$.C9,52-4V.[-4;")9FEX8[-
M_F4)U)J)P3HG&V']O7C+4HY58" EJ1N#6SR&&U] 'M.<>?1V,8QC&,8QC&/=
MC&,>&,8_-C&/FY^\<<<<<<<<<<<<<<<<<<<UP=P_T479!]239C[(I7R[*X_%
MY O\C(O_ '_^0T/Y?R\[GQQQQQS4AMY]*OU"?XLW^^PN'?\ AS;?R2]R/Q?U
M7];33G]IJKN5IQQQS0G>&\\@K#O'HS7B1UW5;9!3]-;9<SK>D.RT2C"ALALL
MG-52%Y=W*MW6(AD(IBTR"K#(Y':_:E[J*9M$A2S1+)6IN8I4@9-J)CM;EWY]
M#$_;='5.J)$$V;.[64FNJ8E>L8\!0J)O:54BK!B6I ^ 9+/FQ?.E!:A6G15]
M#U)+3+C\TPBOXA7+2<S0]E):DRQ<H=G14,]6Y/+\]+/)Z\_260.JA:^25_7^
MC+]>?'UP<'57@LO"A68$LO >Y<<<<<<<<<<<<<<<<<<<<<<UP=P_T479!]23
M9C[(I7R[*X_%Y _\C(O_ -QH>=SXXXXXYJ0V\^E7ZA/\6;_?89#N;;^27N1^
M+^J_K::<_M-5=RM...8'E=TC,?7* 5!'<VE8[:>8WOA1"_V37M<KLH2EY0K2
MG@4J].QJ,DJVTPN'1UNE-CK"'5N<B(>7&A.,C:_E%M[^#&;&6MW#QOL*<=S(
M\16KE;L.V#GZIG0S..W5'9[%5J1X% :I;CQ2EA0U[A>QM+/%'1ZG^':(PY6-
ME,9Y H84ZU\^S+CCCCCCCCCCCCCCCCCCCCCCCFN#N'^BB[(/J2;,?9%*^797
M'XO(%_D9%_[_ /R&AYW/CCCCCFI#;SZ5?J$_Q9O]]A<._P#YS;?R2MR1!Q *
MIQG.,9%MKIR$.,YQCS"^Z9K 7AC\^?*$6?#'O\,9S^3E:\Z//;)A59-25XFK
MX6TD.3BG9F5 G1N+U(9*^*PFF)(_$XLQ(W.2RR0*RB#SDK#&VET=U!*=0<4C
M&4G.&#$0&:U+N3EGR_,BH^M%A7FQ!&9Y)0W')B0KS,!#,YK&7%:FKMH<6\DL
MP4>KMZ43'T2TH:V?QU64XQG&=8M$XQ!V%OB\.C[/%XXU%C*;F1A;TK6V(PFG
M&*3\DHT91) 3%*DXY4J-\GI52H\Y2H&8><88+L''''''''''''''''''''''
M'''-</<-C(NJ/L?#CWY%I+LOC'^'-1RO&/\ KY><$2'H(/#4*D/D4HXI'DB@
M'S^4].T(R30^.<8S]Z8 6/?C'S?-CYN=KXXXXXYJ0V\^E7ZA/\6;_?87#N;;
M^:0N]B2+H%KG2UC?*%QOKVC<,V=IQWE\SEL!9+*0SMF:)6WRL#3%8F;7-BRE
MTL^)+8NGFL(1LJ F.+L,[TAL$(8PI.=V2ZJRVG9MF:\A\BTO?V:Z(;*(\C6)
M-D)&F< U(A)]30ARH$F1$Q=[LB<^E4B]K0B*$QIK8W9ND,>FTPKR1MJ=@69T
M@%.,D.=#9B]NKM8EH+T'LUULN8^I'ON6\9@#S&.--[>E1,,&BN3RRC?@U$6Q
MJ0+#R"G)\R]/PE3PJR_QQQQQQQQQQQQQQQQQQQQQQQQQQS7)W XQGJG[&\9^
M;.E&RF,^&?#/AFI95CW9Q[\?X>;"&0@"5F:$Q?FR6G;$!!>1C&:/("4I18/.
M8:(9A@O*''F&8,8QY\1#$(6<YS[/CCCCCFI#;SZ5?J$_Q9O]]A<._P"G_7/-
ME5@VE$JW3HPO1S@Y/SP,:>,PJ,MRB0S:5K0^7&4L?CC?@:U244(8!.3PJ]3C
ML?2"&ZR5X9F9,K<4^DSMKZ>Y9W1TO XW;%K U=D%8RM1+ZD8V.+M=I>P@R%*
MF;901;BHJ0,B>1OS@RI492%JK^0M<<A[N0K\TBLM(:D<$^P[K<T,K?K6T_JS
M4>L7Y^EK1 4SFY/\QD9@@N,OG$H7FO<PD8&P)ZE)'FUQ>5*@31'4)QR=F:P)
M$AJQS7 6.JZZN...........................:Y>X#Z*CL:^I3LI]DLJY
ML-;?_-R#_P"B2_\ Z"^<WCCGR:["2/9.I)%VDL-H[-;$RNJ4&[_5R1:5J,KA
M(8$XU!J+;#M%7R_VFH_BTPB/K2$Q2%OAL7DLCAYH9'\'R7:3RA^4OZE>[!B&
M!7QLRIL#1M._7_MD.5*WG6<G1)M<9A;!:;8FI'SM2NR W$^6ZU#"4R6:Y%:&
MH:I7O;I;Q.7=+7RY+,#QD.*[+F9N>[5Z\V,K_8.";,4SM#:L8<9O6KU0\$U^
MKQDD\F<2W-MK?8&0VO:C1'2Y61 %^896,C5W WADL.6.+M<=%TC"B7XENEPT
MI&)VM\VCWDK_ *[=V.O&LJGPZZBF;%4RM@^PE\R)S;'1CFM80FNVV71FW6.O
MI499#@S-[:(+TN?FA HS.2G)N=@O FES,5U]7;AVOUR8Y.J+0?4*23:0D("I
M?9,O["YT\SN7B;2Q!28=G<.EB1,B:TIAJE0V16.-[%#& U:MQ'8ZT$JCBAY0
M^.SN*_F":7_K )]^YKQ\=G<5_,%TO_6 3[]S3CX[.XK^8+I?^L GW[FO'QV=
MQ/Y=!=,/#^]O_/L__?P^XUQ_VXX^.SN*_F"Z7_K )]^YKQ\=G<5_,$TO_6 3
M[]S7CX[.XK^8+I?^L GW[FG'QV=Q7\P32_\ 6 3[]S7CX[.XK^8+I?\ K )]
M^YKQ\=G<5_,%TO\ U@$^_<UX^.SN*_F"Z7_K )]^YKSR9NSN%^\\-!-,\_@Q
M>?QW_GF/POW_ )?)_<:^\O\ X/Q\? 7O'[L>[GO$=U]K_H<>OZ#ZHA4>87CA
M)OU*QD^7QQY?#)VGA8_-X>/FQY?#'N\,YYROCK[4_P"81JU_7XDW[G_.&=>G
M:R7G. =?&LRC'B+'B5OX[AQG&/'P%X'ZF$Y\!>&,8]WCC(L>; <>.<<7X^^U
M_P#HZ];_ .O^K_=6X^/OM?\ Z.O6_P#K_J_W5^/C[[7_ .CKUO\ Z_ZO]U;C
MX^^U_P#HZ];_ .O^K_=7X^/OM?\ Z.O6_P#K_J_W5^/C[[7_ .CKUO\ Z_ZO
M]U?CX^^U_P#HZ];_ .O^K_=7X^/OM?\ Z.O6_P#K_J_W5^<U+??:9DPD*[KN
MU^ #TH/61I-^AF9PGR(6!Y3X.U<*P,\(<8S@!F0 SG.,9'C'.RDWOV.Y**RH
MZ^*A"?DL&3@D[UMPR@G>7'I,%"'K: 8B\#\< $, !9#X9$$.?'&/)\>W8Q_1
M\U+_ %ZFS]W#GY\>_8SXYQ\GQ4WAC&,^;[NIK\N<YSG'EQ_<X^;QQX>.?$.
M^ L> LY\V \!?L'V0HR!G)^N.M74P AX"E0;W1@L\W 4XS\" )SH)N38"88
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M:139\^E(9><VDC2C9VAS/:'AWJ>#-C6XI\M[8RN*][:F8!:(:)N9\_Z.=?\
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MG6F;)FTOC<ZD%5 5:?E4[B,1>.1&5.Y.UVM;ULDQYG+_ &[:4'KYD4!BS$J
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M!4=(I(_4M_V+$HTLA5',#W#ZY^$C$-S<F^9NK/"9+(H@<IF13^D7-3TO6*D
MY",M[*V/4;2M<:X4[6E"U PBB]7U%#&& P2/C<7)W-:HS&T!3<V)#W5X5KG5
9R4!()")0N<5BE8K/$8>><,P8L\RKQS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>cntx-20211231_g6.jpg
<TEXT>
begin 644 cntx-20211231_g6.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %F:^5S0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!N;?/
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              =@   7_          $
M                 0             %_P   =@
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   =@     4F=H=&QO;F<   7_
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   '8     %)G:'1L;VYG   %_P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      ,
M  $   "@    ,0   >   %O@   +Y  8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ ,0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ ]'MIRC:]S,_TPX@BO8P[0(]ON47UY<L%?4 "(W!S*S(!
M&YVD+SOJO^,#*HZQU#&_8^!:S'R+Z6W6 [W^BY]8?9H?<[8@4?XP<S):P8_0
M^G/L.CFQ$.EPV^YH_,:HC>NW^-)9*)&IT&^LI;/I)QLP@C]I1,\,9W';\[Z2
MF:LPN>?V@&-+B6-:QA ;/M;+_<[V+S?_ )Z]6AI/U>Z=#@2#IP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( +H"70,!$0 "$0$#$0'_Q  ?   !! (# 0$
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M?Z#=HFEKWM8WL;V)L.F_+'+ZUIBV5O(J$-324ME3J9+2FTA\#P%*6%]J0[W
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M=\=L.RVZ_ NJWZ)<M+1.;IM?I4"LP&ZG3YE*J*(=2BM3(R9U,J#,>= E!EY
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M#SI?>1 BQXB'7U?G/.)CM-AQT^KBP5''GYYZ1P0P@B&*.($LQ$:*@+,;EB%
M!8G?403?F=SC''%%$"(HTC#-J8(H34WBVD#4?,W/AC?]W3_PEY]2"E)5Z85V
MI2/+C@ _;KN5!MSV)(LQ N>MKV)\+\L9 +;]?&PN?U>7+H.N.7@HPH<DJ&"H
MG*L'/&?3SXQY>FA4&][[\]SOY>SV8>_V<MO(;6M[;XR&DI((*N#D#/'EV\X
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M7+CR[?WH-OBYWQ81\5Y;+NB56XN+Q1CGU_/B_A;GUY80I/TDCV:,3/C5O>S
M&24[23U#R^RK$?L)U)CSV@D^BTG_ $ +^[5?ZMK'$Q,^H9+6$P)%[%$!%^5[
M2'GA$D?2:/9>QN';@WPSZ)3L]4B3Z?\ ?8#]^I:9A3R?1+>\ ?5JO\>6)29E
M3/RUVO:Y5;=?!CX82GOI07LKV/\ 5+CWT'W;-5(_/Y5?[-9UJ(FY$GW8D+50
MM:Q)O[/V]/+]N$>1]*?]D[%5V/71ONA6 <?B6JJN"2!RFK$>AXSG SC696#"
MXY8S*P87'ZO+P]HQUM_2I/9-.DI1=6^Q(\_[BU6X_P#Q;U]-<XR*C.;*+G"@
MU]*0]E,\GN1<V^I'V[,51)_8:L/Z\>?&L32JHN;_ %?M^S]N)45!42_04>\G
M]0.-]OZ3_P"RP=_-N3?/GY[-U,?/_P K'Y?O'SUB:LA7GJ]P&WMWQ.CR#,)+
M:5C%]A=F%_=H)\_81UVQN(^DV^RZ=4 BY-\LXSV_B=J*?VA=4^W]WV:QMF5*
MH.HM\/;R[P'CSVVQ,CX0SJ5M*+"2>0UD?48R<;[7TE[V8;N>RX=[" 2,G:.>
M#Q]GUM@?M'V:C29Y01WU.^W^(;>77K\?+%K3^CGB6IVCCHSSYU)!VYW'9;8W
M6_I)WLS'?S*]O4><<;25#@^7_?7'[_MU$?BC*$^E,X/3YICM[AL?+^>UO#Z'
MN-)P#'!06/+56A?#?>.]O8#A59^D:>S;?[?#K>]!*L=H.U$T>?ED*JZ?Z?/C
M.>-1SQCD@_LLWG:"2W.W.W[,6">@OC^2VBGRPWV ^4$!'O9 /A>W6V^%ACZ0
MO[.V00&JKO(HG'YVUTA'F,^2JSQ^W6)N.,A4[RU%AS(IY#Y=0#\;?"Q,R+]S
MWZ2)3I2CRL];G-(1M[- /U;],+#'M^_9]2 2W5=W\<Y[MLWQCSSR:SQY>GE^
M_6!N/>'UYSU0_P":/\+AC^W;R.+"/]S7Z3I!=:;)=N8.;1@__<GP/PPHL^WD
MZ"7\%FH[O+!\O[G"OL/]]7/ER>,_MUA;TB<-ISGJ[WZ4DIL/'O,![]_('?$R
M/]RYZ5I;:*3(S?I\LQ7W\NQ/ESMSPI,^W/Z&'R U)W?5\O[G21GRYYKHXP<^
MGVZQ-Z2^%UN6J*L=?X%)T_Y77S]V+"+]R1Z8IOH4.0].>=PCGRYQ>SEMO[;*
M;?MN.B9W 0[NUS\[!:!&?L57^?/RY^W (UA;TJ<(H"6J*VPYD4,I'U$_SXG1
M_N-O3;,>Y09!<\@<_I5^V*]AC9'MK.BP\!W=K//G8+.?WU\#US\SCSXQK%^-
MG@X DU=7M_P"?]N)2_N*_3FQ &6\/7/+_9#3?9V=_OY''-/MI^B]61XF[61_
MYA, ^O\ Y?/^+]PQP/2WP6/I5M6!YY?4<_<&^S&5?W$OIW:^G*^'C;??B&E'
MVQCQV^LX[4^VBZ,5>3F[7IYV&P/WFO8^_G[]#Z7>"1_NZK/LR^I__)?]7UX[
MC]Q%Z>2;?)7#N_4\1T@'_4^K]>V.0]L_T9^?C;L#RX-BQ?V<UX_KY_7KC\;O
M!-_X?66_^KJFW_W=]_O;'?\ J'_3W_@OASV?A'2?_DM]>,_PS_1G_P ;NO\
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M/'E^'M]@?=_MW_Z-<'T:\$G?\'Z/_I5/\HQU_JK?W05__E'S0_\ B[A_?_\
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M=R;S'?WI2O)Q1B. H?+R/'&3)CFU1HY NX)L+CE?D"6\#UQ*28M%&Y NZD[
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M?V]&VSJRE:D<[E7F,]N>>*,?0>0SY^?&NRS@VN.8ON+?7_-8[VQV6IU6VM<
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MLHX(6H8ZX:S.[Z)Z]Z"EATQ0N!453QM+ C,H:(:F9;-IN),[A69H$@GE=)C
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MZ5;\_MI"NUGPH41+3RE/( *BT<AOU4"E0P2D>?ISJ/4UL [52&U.]U[I)VL
M20;#QM>Q'UQLBX.SF"JES%Q3>K".<EA4)JL],UAI()^B;&PMR-[X5]X_[(W@
MY,8!+3*:4X>X%!"6Z/3TGX#ZDI( SP"==,B[M&$/,F4'KL)9+;]1]9QY_E2]
MAPKER/;4]9F9 !N+M5GJ+7%CT( ZWPVMKKFI]J77'GU?WCP#,]X CM!U?@J>
M;6?A[VP5 H)QWYY2!W'REYK2R5M&8X= 8!3WC8;7L+V-KB_2V]KC?$/.\KJJ
M^A:GIQ'VCP,5U.54#0P%S8VW;F1U Q.MZ$;G;_7)<]LDKI5W5*E(I*IP]T?[
M8-#CQ'O>6"75,_QT1[L)*BM/:H8[CBDB=:'):>EJ 1-3)(9 G?6[S:AI8V!N
MK#E:U[''7AG(J_A7T3O49IV6B&B82&GD$NPS2=@0 %)(+KS /.W(XV9FRE\5
M:I0*7%:I)F2ZC&B-!VI-M-EZ4]X+65J:40"M0!."!SQC72+.Z&)&9NW 6-FL
M(P20%'@UM[7M>^-37BC*J>FFK)'G$$-/)*Y6!G;LXU+L0H().E;@&US;KMAZ
MU3I#W@MRYJ#1*DW:J9U<9GNT\,UX.H4B"V5/AUQ,8)01Z?"0>?OUA3BG*IX)
M73UHB,H#>$+>Y%K=^_(^(OTOBCI?2?PM7Y=7UU.^8-3T#TZU!>C(<&<Z8]"%
MB6%[WM8CP..[;'HYWDO-%S,T=%II7;-,JM?J EUXM(5 B2$MNADIB+[WR<D)
M44IQDE0\CBS7C#)Z%J0S"J(JYX:.'1!J/;2*UKC4;+<&[';:W7&;-/2-PY1F
M*24YBRR(C=VEL54*K%RKNE](=.ZNIR>0.&74NF+=!I^J-+;MPKB5$1G FM)[
M?$#WA802QDI[@KD < >8U8Q\0Y>5C8"HLR"WS8ZBX!&H;[V/U7MB3#Z1.&V6
ME8-7@34YF0&C:Y309">9((4C;<7'0<G*]TW;DT9FK466S03,<AI2GPJPVXW_
M !R \C"O=LG*%IR<  Y'VZB?+M%,\$R=OH1]3 Q@'2-CL9/$';>][^V#'Z0>
M':KU>KC>N[+M3]*CD#74Z6N 3;O GW[##'K>PFX%N4R/,J#='2RNHPV4"/56
MI#G>Z<)RD,)^2B>>[Y ^6IJYY12.0!-NDFYCV-A<"X<^%AT'UXMLOXUR+-*I
MZ>D>J>1:>21A)3/$H":;F[,+&Y %QCOW2HTVW*+:DFI)9#5)-3<EEIPN'M7(
MC8"  %+.7 3Y8YSSYP\JD2HFKHTU!JCLA&"!^B&)O8V&R[;;WY#&Q<"9S1P\
M0K5L9&B6:)S9+W AD7K[CX;VWPC6SMW<EPR4,T]N%WJIK-4'CRTM8B.>$4G\
MQ>%?QB<I \P0#QJ5/F5+"A#]I='>%M* C6E[V)(OTWYD>%L0\YS[+Z::HJIF
MF[.6OGC73$S=YY'90;';NBY-_#>UAAS2NGO<*Y%NQJ:S1E.E7'CU9ME(P0HG
M*F#CA)]!R,:QP9[10@%NV%@+VC!YW\'^(YVWY7Q2/QMD67*LM4]6JD  I3.Q
M/3:QZWY'EMAH5+I9W4HD6CRIR;>+3];3';\*M-K67 5E04GP., *R3D9&, \
MZF?A+EK-(H$X(BO^:(!OR_3L>M^?C<[XF4?I"X=S&2IBIGKB\%*9GU4K*.S!
M"['QN1MUZ&W)R4C8J^XLQZH/IHR(\9;D9TBJ(4H./-^&TD!+'YI6I(4K((!)
M^PQ*C/*%X>S7MBUU-NS'1@2/I^1VW_7C'4\790R10*U69)D[5!ZJ]M*$LQ+%
MMC939>I&Q)P_6^FS<RD[A[?61+;H K<6Z(:GD,UIIR($SVH\MG$@QQW?Q3K9
M7A [2HI\P2($G$&724>95"F?LYJ4A"T)#7C#J;J&-MP>=]A<8IQQ[P_4Y%F^
M=PM6&A]1F:[TC+*3 S1O:/5SU@A06%^MMAB0*QMQ<E*O2=39:8(E4YRH4R4&
MI(=:]ZC2'8[O8X&QXC?BH4$+&.\?$.,8IHJJ*2C73K(D*3*2+=QD!%P=P;6Z
M=WSWQ7TO$66U.505L32B"=(9X]<15Q'+&LBW35L=+#4+G>X'*^(GJ^V=S5=O
M=RE16X!DF#;*<.3 VVI:V [@.%'JEL\$#*N$D9SJ[IZZ"G.332%@D#U+266Y
M"LQ ( .^YMXCKYW=/Q%EL!X=F=YBE3-7!-,1)/9N5:XN" "=CN;?7']!VLNN
M@]]-J"*?[R\QXS:6IR7D>"M#322I:6P4DN(5Y\X^>,:G5><T<S*\?:V!%P8R
M-P6)-BUB+'8?9B[GSNAJP)H3+H5]!)C*FZ,6-E9M^GV^-^;'3'NA6JJX_ ;H
M"17%&1#\6L):5F.V?$+B"PHHRVV2!DYSC@DDR!Q'EL4*!NW.@%3\V-P3:P[P
MN ;6MXF^VPAS<?</4<4BSO67HM*3E*9B 9#90K<CN=]R.=AS."J[+7L_2*G,
M;12BQ"A34/D5%).8C#@="!X63RVKMP1W>GGG6.'/*$2Q@]L2TBVO&  2P )[
MU_@-CS\Y$/$^5I54T+&</4/$T8,#<IG71<WL-R-6VV^VV$B_:1-I=L;>Q9#:
M/$%J0R2VX%(&&HZ?,E.22%>9'D/73+IXVK,S<'NO5LPL.A9_?;<>SXXON&\O
MJ,YJ,\J*)5,=-F!CD+L([.YE90-72RGH+XB:VG#0*_"JD])]T1+COJ#)2XZ$
MQW M7P]P3GD$#N&<$$ZN*NU72S01D:FB9!>X4%@;;[FU^HZ<P<;%FF0UXHRF
MF/6\<BH.U7225%^0ZWV-O8.>%VY;@I]<KB*G"\8QHX4P[XS2$.%TO%U20@.J
MR!D?$%%./UC6&BII:6F["33K:Q7220 %"WN5&^W@+WM?EBLH,CKHJ.1&$8*R
M!3:86-DTV%U!.WE;?<89U<6:Y="'8??VRY)2TAX!"O@92%A9&><@D'/GCRSJ
M9#:GI '-RBG40=@-5["]C?EM[QYVF2Y?4^L4] %45!;LRM^Z2;DW/Z("WY"_
M(^6'YLA<,*V+PD?6*)!2VB2VKW="7"GNFPB5]JEM]R4=JB<=RC@ )/I7Y]!)
M4T2=GIVDC8:MN22> VOJVN0+7WZ8JL_R&OS6&OIJ01&2BCJ*N822!%$%,DPE
MTL0;GO"W4]ZQVMB6KJONA39>XT2,):G9D^E)8\2+V9+;<9:DJ*G0$'M02"<Y
M/D1QBHIJ"H497*=&A$EU6>^S$A; #>Y(]EM_$ZKDV25\@R2G7LA*(IUVE4+?
MYTCO%1M;>_M-KB^(=K5<AN5-FK]KHB/MQJ<G+22LR64I#B2VAQ9",).',X^8
M'EJ[I8'6%H+@NI:4V8@!6)/,@7M<7%O"QQM[9!7T66B:98Q&:J:)2LRO=@&8
M[6!%K&_.]C[1PM.*[>.Y5&I='(5*+-80D2#X+1\*G2Y3H+@[BDI;95CX<*7\
M(QR=<UC"DRV>25>Z.Q/=W-C*B@V)\6%_ $GPQ49C+'EN45-35&T2O!J* LW>
MFBC6P%B3J=;^_H+XM%MEMA<U5W!W*I<9$%4MBU[:2X7)12C$E"@DI5V*)402
M%'MXR",'.M7S&LA^3<M?O6-35'<;]UKVL-CSY7Z&Y.-%X@XERR@RG):F9IA#
M-75BH4B+'5&23<:A8 ["Q-^5L0)NY39E#=J$&<EL28DZ3$>#*PM'BL2I+"BD
MC&1W-$YP.!GUXO<EE28!DO;2"+WN+JI/3_&VY]<;EP]+'7QP34Y)CE@2:,L"
M&[-XTE!(MMW3RN+';IAJ[/T:H7S=EH630D,JKE7F/QH@EN>[Q X(\J8I3C^%
M%(+3*SD(/Q82<#RGYK*E'25=5*#V2(K$)WB02B"PV W;<7V\,2>(JR')LJS'
M.*TN**DA229D4N]NT1-HQ;5NXWN -[]+/CJ"LJLT?<JW:+/3%%0B6_26GBQ(
M+C07'JL^(I*5]J>X>*V0"$C(Y. 3BMX?J(ODZIE%]#U,KC;<*\4;#8$W[N_\
MXQ#X'K(,[R&NS"AUM3+4ULA:4"-]"4\,I.@WYJZ<SO?8>,>U6CS#4*_;* V*
MI%E,M.I4O^)[T$RCVN\93X9R"4CXN,<:FQU$0CIZPEA$Z,RG3ON=.X]MA[<>
MJ<-QMGN1BAR_>:>.#3VA$:$I)+*W>/(:58W.Q]F.ZMV/7*DS&#(C)#184HKE
M(0%%MOL)3A+N0%8XS@\GC.#BI\YHE9P3(;ECM&>18\[V\/9RM<&^)U/Z,.)X
M@7=*%0;V'KB-])M7TE4J3N-@;CD3<;.MO:JZH$&DN24TT)J5.5+B=LQ*UJ9"
M%I)7\.$J/((]",\# U4R\3Y6TLZ U ,,O927A-@P.^FQ)(!'[!L<>H4GHDXO
MIZ'+))$RW164(J*<)6J6,;(1OL0"0>5R%OXXCY%EUB,BD)>3&!3/<4>Q\+_.
M4M9 PG(!XQDG& /,\7@S.FD%0%+W$2WNA&Q%ASZ@\_?X"^@C@_.*098)EI^_
M6.%"U",02=1V47 N!;PN!??"/)I,Y^4XVEM ]WJ12M1=XRAXCX1@D@G(Y &#
MG/ &IJ5$2HFY[T08;="!UY7M[SY[G&H5N2UBSYE,533#/5]KWA<:&D8V!M<;
M6V%C<XEE>VMS2:_:"&VX8549DY$7NE 94RVT%>(>TA(&?/!!Y&/352F;4G85
MC R$0HFJR<PQ(%KG?<=2+8\].<T4=)7NQ>T,<32$1W(U:[V%[,=AX>(OA]2>
MF_<F0IT-MT+.%R?]EVA_% $XR8YP>1ZC)SJ,G$&7@*#VQL+&\?AU_.#P/3]5
MZ)>/.'T"%Y*L7=8!^22'YPVL+7N.O2P'7"!/Z?=PE4"HY;HW\7[NE9%6;./Y
M0D8P&1GG[1GG'IK*O$.7]JC?/@ L3\U:]P>A8D^8&V)\7%^3FL@C#U1:82%+
MTSVL$N23<@;#XV&(XN",[1(D&E3<>]MRO#6&UAQ 4M ">U0 ]02>,^G/)U/I
MG6I=IXQ\VP!4$6-P3MSVZ>7/D0,;1E52CO6SK?LY:25%N"INQ4'8W/38\O,7
MPET.@5&KPZ\Y"0VI$>J-MK+CO9\3G>L8&#D8P,X!],<@ZRU%5#3O LA8-)$Y
M%AMW2!S]_P!1\-\5360PO2K+J&J$[*"U[$7VWL?/H/.V&Y)M:JM2%/K3'!_B
MTG+ISA 2%<!./[T8.<GSQSJ2M3&RV!/+P\;D&_MV\.M\39*ZGF?4NO<"_=ZZ
M=)^K?D/'#ZO*RJY":LYYY,8)E6K1IS)2]GN9?\?PRH=A[592<IS^W!Q!H:V!
MFK5&KN5DZD$?VNGEN;C?F-]N7+%5EN:4DJYC%&7U19A/%)=;?.(!J%M[CO B
MQ]G*V.X;;71)CTI+3<%1N4RV:852T#*X*@'P_P!R1X0\^Q6%E0X  \^C9K2*
M9K]I:E[,RV3I)]'3OOTN+#SO;$FFS^@IXLTB<RAXDIQ):%F U,66Q! :X^'7
MRV+HM*L4BV8#\I,8-HN2'2%=CX6KWAIM7=V\#N0%-J[5GA?'PX5KK25T%15N
MB:R32M-NMAI+#8F][V8;6(%_$&T&CKJ>>L=(R]_5'GW! ",P&]R;$"VQ!M[L
M2#0K5JU\V\BVZ&(_UC%93'=]\?$5GO<=7*20Z4KY#;*R?ASW<8^5=-514%::
MB?5V<I+(4&IK!-!!6ZVWY;GW8J*[,*?*ZAJ^J[3U=F,A,:ZW MV1[NQ-V91L
M?/Q&.VD]-&YL272I[PM_P:A5&:4QBM(*O>0ZV4A8\#*4X'F>/UC66;B/+GCD
M4">XC9A\T>H(MNW6WCUQBGX\R"2.IIE]=[2DII*V6]*UA!H.X)(!-]K7N>0Z
MX<,WIFW-F5F<RPBWBXQ-DH<S6DX*TNJ"L$Q^1P2!QY<:PP\09>(DN)]D7;L@
M""0-MWW-[\_/VXKAZ0N'(*6"65J\+-"C):D<[,HM?<V.XOOA0JFQU],5)EI;
M=')84VI934VU\%(Y&& I6<C@ 9Y\N=1DSFC6-P>W!((MV=MSTOKL.8WYV/NQ
MQ2<89/4TQEC>J".&"DTSK]$G8[FW+G?E[\1K:VU]UUR3=3L)J!VTRX*K2I7C
M2TM$RTK_ +P=BNY 0/SCV\CG5C59K1P+2!NTO)!#*MEOW"+;W(WOX7OS&V-D
MS7-J/+AEJU+2JU90TU= $C+@T\B@H6((*M9@--[]//#'G657:1*?H$T14U!E
M:FU>%(#K?<I ?&%@)!'8XGT.#^Z?'F%--&M2FLQ$7[RV;8E=QO;<&W/$Z+,:
M:>)*J,NT+ ,"4(8B^G<$D_2!&YV'+:]W18M%GIH;Z2&LPZU(4[_&8^%IMKN[
M>.?+@9'.><ZK\QJ(A4J"3\[3J$[IYL6M?[/?[<1LUJ8FJD)#=^E15V!WNUKG
M[3]0Y8_3#]F+MI9N\OL4NF';V][FJ%ET>O69!>IEXT>KP*'7+4O2B;VSZ_MU
M<=OU"J,RJ8+AHM_TNVJA08=2A5"!5*O'ATR93:C'F.07[Z@%J2$&U['XW)]^
MWWZXNLN%J2(?Y7_6.)1NOV0>TUY0X3]=WIWGEWJW=M#W"K.XJW+$1==Q7W33
MU'3:I7J@(]H1Z/#B7)6^IF]*A5+:HU*IUO-4ZE4.W:? B4A,]F9,Q,^_(^T?
M?^C$)=.WL1+(V@CRZ)<F\%W5JV;.O&]U;.TNGP;-#].L6[MC4;)O+O.H.V5!
MFU.\'J<XBJ.+8DO4:E3:!2ET)N'&J]?@RF&^_3V_<;?K]F[MH7L7>G&!7IB[
M>WLW5C56WGZ4?J&ES=O&Z3;3@M:2W"D/6A#M--(@5BNW*]3MPZ[4GJ<P_?$Z
MEM-74W7H=7N-ZMOO]^O3"_/;]7C?[V]^^-ZZ/8A=-]VBU'*G?^Y;\RTJW?MP
ML2)4';JJ1:S5=S;6V0LZ]?PCHE8LJ?;U:I53H>RX8AT&;2'*'257G6138+,>
MEV['IK'/W]GMQ[+4ZFQ*53:?2H389A4N#%I\-I 0A+46'';C,-I0TAMI(0TT
MA*4MMH0GM 0A*0$C@B_PMT\OV8>'EB MV>FK;+=VZ[4NZYZ'%>K-L34&2XN,
MV_&N2A^[R$+H-=C*6A$N&V]($F$\<R84AK^+4N._(9<TWB'@7A_B3,LMS3,J
M.&2LRZ4-K= XK*6Q$E+4@FSQ=[4FH'LV!9>=L;_PIZ2^*N#LISG)LGS">"BS
M:$JHCE:.3+JS5&R5]$X[T<A1&BFC6T<R278:U5ALCI2Z<<#.SEC_ /W0@?N[
MQ@>7H/(:[?B^X)_BODV_/\CC_9OS.'XU/2/8 <:<0 "UK5\NP%MAX#88R.E+
MIQ&?[C=C<Y\Z0V?/[U']OGY\ZX/H]X(:U^%\G.D@C\D06(Y';[_# ^E3TC$$
M'C/B"QYCU^6Q]N^_V8FZ-1:9#I3-$B1&XU*CP6Z9'A,=S33$!F-[HU%9\,I6
MTTU& 9:"%)4VA*>Q0(!UMT$4=-''% @BBA1(XD466..,*$11T50JBW6V]\:'
M/+)52S3U#M--4222S2R$L\LDK,\CNW,L[.Q)/4DXBIWIWV9>V8;Z>7+&I_XF
MVJ!&MEJQVYE69@M4>'(:F1&&Y[-0;K3<F-.89GL5-%234V9[2)K<Q,I(=%DF
M9UZ9B,U6I<5X<R"H*QLVME"$E'1HVN@T69"-!*VL2,06H:1J3U%H5-*$"=E=
M@-*FX[P8/<'O7U7+=XF^^$>Q.EC8/;6I0ZQ9NW=/I=4A*O\ <;GR*G7ZU*>D
M;IN6P[N',GNUVJU)53GW8JS;935IU1,J6XU2FF&GFF79+;^:ISK-*M)(YZMS
M'(:0NB)%"I%")A2*!#&FE8!/+V86P&J_,"W2'+:*G*M% JLO;$-=F.JH""9S
MJ)!>18T5G(+$+8FQ(/5:W2GL)95DWOMS;%A)I5F;C4?\'+OHS=R7=(%1MM%-
MET>-;,2?+K\BJ4*VH%*GSJ=2K>H$VET:DPIDJ/3(41I]U*DN<YE-/35,E26G
MHY#+3R&* %)B58S,!$%EF9D1FEE5Y&90S,2 <=8\KH8H9J=(2(:B,0RH996U
M1#7:)2SL8X@'<".,J@#, NYQW5KI7Z>[@J5'JU3VKMI4V@T2V;<I:H2)M)C,
M4*S;PH-_6O2W8%*EPH$V)1+OMBA5J"U-C20V] 3'/="?E1G^(LXS.$,(ZR9=
M<D\K$Z7;M*FGDI9V#.K,O:T\TD;A2 5<FVJQ'+970.P<TL8(CCA&D%!V<4L<
MT:%4*J0LD:,"03MIOIVPCW)T==-MW(0U<6U]-J325;Q*=;76+FCMS1O]*$[=
MUJJ(B5N.FK,7E.;C3I,>IB6Q2YL"ERZ$W2Y%*ISD7+!G^;TQ!AK74CU K=(7
M"_)@"T&D/&P7U=046P&I&=)-:NP/$F5T$MNT@U6]:W[24$BM;75!BK@L)6L2
M&N%TKITA5M6?>WV8NT.Y]$HEJ696ZCM1;#3U_N79%IL!=WU^YU[FP+<I-Y51
MN]+IK$FZZ;<%6H]LQ*=+?G52O6Y4"Z*I6+5J==@4FJ0+?+N,\SHI))JA17RZ
M8%IM9CABI_57EEIK4\<0A9899I)$THDBL>Y(JW&*VNX=I:I(HHG:FB76'"AY
M)9%D01R 3M)VJET558:F1@NZ$[XLI,Z-^FJH7<Y?4W:ND/7,[";AKEIJ5PL4
M_P 9FT#8+%;;MV-6&;;8NR-99_!B)>;%(:NN'14HI\2L,1VT(341\09S'!ZN
MM<XB[02!=$+.H[<5/9"9HS-ZN9U$KT_:=@\EV>-F))L?DJ@,IF-..U(-V#R
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MP+\P<?-4,,L7#&2O-')&CU^9JC2HR*^FH[X5F #%38L!< VU6VO#3:2:JV$
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M*PI0YP#G@D#SX/.O0( =%03<7A 4F^Y%MAXD=1SVQ\[9DRM+E>EU8QUC,X#
MZ$8'2S6/=4D[$V!N+$WQ'7":A-'EW5-U22<?$#(5R#Z@^F,@CR/'-]<]C#S/
MS* ^5@I-_KY^>/*<Q%ESS;3>?,6&UM2DRV(\18W',$ 'PQ;:*RM%Q[:*6VM(
M,ZM%*E(*02&V,]I*0,CY@DCC/.M0C/Y+F>_]CI[;\[,WV7Z8^9YV4T&=@$$B
M&$D @DB[G?<FQ\Q[,6A:KE%;+JG*O3$!,1R,2N?%0 ^0<LDJ= \88_U+\_U(
M&.*?0Y_1;=0>6]MM_P#)/+ZSN,>63T%<W9A:*K;\M27NT\I^;!W>P4]S_&Y
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M7\^>U Y-AY $#KOO<\F41FELCC(=F#[3@1\<#)],\\#/GJ]B-JV;I\U +D$
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M,\^A_9]FN#N&OT)M\=_/RVVN=_$=(R!64 OWO5)-N=MB1L/COOC?IR5"YYP
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MRY([*Y#[BW7ELI0 EI3BU*66QGX4D]HS@#&MGID19JI$541:8L$4 *&U&YL
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M))&2M6,<@8Q@ #5M3TD#YM/4LA,O8TMFU-MI!46%[<K<P0;;BY).@-G>8P\
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M)Y.,U#$E7'4B<:Q#1R/& 2NEHT!0W4@D#?9K@WW&+7+D2K@D$_>[.A:1 "5
M=8QI(TVY:CLUP223B89-H4.O27Z)5([CM/JZUN3FVGWFE+5&0J2P0XVM+C?8
MZT@X0H!8':KN!.:F&JGIW2:)],D0.@E5-@P*L-+7!N&(WN1TY#&NMF5524YJ
MZ=E$U-H2(LBLMI)!&]U*Z3=7;<@6)!VMM1VO=XJM'HW<3!C78VAE! "^U,A;
M225@!9^!*1R3DC)&>3O\ '83U %I'H[L1RW0-]$FW,D_5RM;TJFW@GJ+ 2R4
M5V(OS*!CMR N3R]WCAP35*70;MB+451V*_"::1@#"$+[0,@=RCA(Y))./M.8
MJ?PS+Y+6=J25F._,V/VFWOQ'C %30N+!VI9&)\25N>>UKDFW+GC0IEL4AFW*
M?.;8=2^_+E(<47GNU24*64_"5]J3Y9( )QY\XUEDJYC631%AH2)&7NK<$VO<
MVN>O,_7OC)+63FLEBU*56-" %%[D"_2_7ET\.N'14,R+RM2F.#,-%@LN!L#M
M5WLN2$M'O'QGM">1G!\SDGF!"S)05TJFSG,W%^8LQ2XMRWO[>F(4+::&ME79
MSF+;['Z6F^W+J=^?COCIJKSE+J%HU"$H-26W*@XA12%@* 2WGL6%(Y0H@@@C
M@GSYUDIU6>*OAEW1NR4].9+=-]F&QN/=OC)"JSQ5T<@NI$0(O:X!)YC?F+^^
MUCM=7%*B3:O 9DI4M$E^)/=2'%)S)?>2IQ0*5)(R5*(2G"1D )X&L#321TTK
M(0#&LD:&P-D12 +$&YV N1<\R;WQ@[9XZ>1D-F021+L#952P%B+'Z(WW)\03
MM,%72EFWJA1VP1 [&$AOGN[4267 /%.5_G'/GZ8].=>II':KCE)^<+,2;#<E
M66]MNFYM?QVQ0PC54PU#?G5+D'I<HP-P.Z>O0>0PZZ%!88I5+KC22FHM53M2
M[W*4"(W:MD!LY;RA: 20GXAPH$'F/*YUNGZ-MA_E<_/?H+FV]CBLJI3+4U5%
M( T#TIN.1^=+1N-0L1=386(MSN+8;-S7Y<M5J:X4V8RY';?D)0GW6,VH!MTJ
M3E2&@HD$#))QY_;J?!20F$2'66*J>9M<C>W2YO>WCY;8E9;DN74$&JE@:,LB
M%OG97!.FU[.[6V\_KPJ6]<E7JM7JB9KZ%B)!@O1^UAEOL<44I4HA"!WY&,!8
M(&. ,\1ZB".*&%T!!9Y5)))N%(MMR%M[V\?+'6IH::"G@$26$DLJN"SG4-]K
MEKCSM[L0)0JI.$O<*0IU)=1>-6BH(;1PRJ0X2,8[<]Q/)3GGS]#?U$$3+EBZ
M39J&*5MR+N$6Q\O, VO?VXW',)7JX\DCF.I(,JIHXQ8+ICB10B$J 25%P&)+
M&W/KC<VSCHN"YJE2:BCQH4?W4LH2I32D>*'UN?QC1;6HJ* 1WJ('][P3CMF[
M-34]/+"VF21G5S8-J"A;6#7 M>VUM^>(.=.:2CCJ(CID<N&-@P.G2%V:X',\
M@.M[[#&Q<4Z53*#*BPW.QE5Y.4I0*&UDP5!U"FNY:2<E"!AP$.<9[_/.*EBC
MFK8Y)%NWR<)P;D?.!A8V4CQ.UK;\NF%+"DU2CN+L*!9QN1\X-)#6!'4GNG8G
M:VUL?I/>RBW!H^SWL3>GC<&HPX-3;L;8C<N\*;;TZHQZ>JXY]FUG<6[V:'!E
M26I1$V4BB/*9=9B3'XJ6G)J(SPBJ&MPI26IXF)N2MSR\3L+ "PZ8VZC<M31,
MQ-S<7L!R8@>6_D+\^@N-C:GVJ-N[EWC0;/I/30TBM5[>2V-IX#U)OFU9(H@N
MJU]ZGZ8]>"*E0J#-MRYJO.V,N>-0+6CL56/.L>LVS=]0K])@3I%.C2,2K;6V
M^&WP\.GLZXN[T5W/:&\.V5R[TP=H+7VTN/<;="\U7O\ @S<S6X%K7E<^W3\;
M9Y-[6?>RJ/;Z;CM2HT';^D4R@U:-;EOPY<*E^-"@R(KS=6J;'-OV??[_ &XM
MXFAT5!RBDTU',<_#!C)YB,*BQ3@- 9C15JC1_P#B8ZE,M]K9*=,,'U'12@M_
M5%,\,M^"4>XQ>TLAJ-'#13X6"V&(<1D(([0U%C-@!##00PMA4TPQK/PHDDMF
M1':?+3K;[7BH#@:>:)+3S87D-NMDGL<0 M.3VJ&NC1QO;4B-I9774JG2RWTL
M+C9A<V(W%SXX[*[IJT.Z:T:-]#LH:-B"R,%(#*2 2#<&PQL^6N_+'7&" ?//
MZB0?V@@Z88T:BN:W"FJIC,>144PY"X,>9(<B1)$U+2S%9E2VHTQV+'=?#;<B
M2U$E.,M*4ZB,\M(;673K0.2$+ ,5 9E6_>8 D E5N5!(!8 $@''5RP5B@#.%
M)56)52P!T@L 2 QV8C<#<"^/%B7[/;JIB3[JW%@;X[>U[=C=S:OJ2MG<QRIT
M.7;M(MZ\-_*%9T>$Y:ESTFA5*ZKFM>RIUE6[0J$S<;--D4^UK;I1IL2)(>E0
M]>AIQ9D)2"C?+:N*@H*W)ZJF$<HJ))8<MEJ79YJ:HF2&&2I-1+).L<C)(TC1
ML#''$JZB<AS$-+4+60R5533YC%,3&L:Q/61PJJK(D;22)%V2!2Z @(& U,]U
MV?[-JO4>XHSUE4O9^59M(ZB]L-S*%9]QS+@52X]K[8=-E5VMHU>J\<VO6$52
M_P![=>L*W!N"(E<471 I<"+,O*%/\%Z!C'&,4L#+4O7^LR91F-%//#'&',N8
M9TM=)'%:8:*=:%/5D8)W)&*]DT=QC(W#\BL#"M*5CKZ:H@CEU&,1TE(\2=J2
MKDOZTW;,HOK%U;]&U5+HZ.>H38:DMWC?=G6_O7'O'<O;:XKTV<VZI%VW?MY>
MLRPMK]WF9LO<"+MULG0*PVY7=SKVIEST!VKV)=<*;*H=NT?<"^(HI%,N,7<?
M$.39H7AIY):$TU#7I#75DM/!4PK4U= P]6-76SHTD='2RPR:*N%E[5WI(#J,
M.*N7*J^@433!:D2STKRTU-#+*DAABJ0PE-/3QD1FHE62%64H0.SF<?2$RV![
M.S?)^T]B45=ZPXM3A[=[!2JM=]UW3=[NY_3Q?%N[FUW>3>AC:FC0Z)5J-6ZS
MN)4;A%M5"X9MZ6S+8C4\PZ@*_1XD*&N!5\894E5FQC2>4-79EHBAIJ;U+.8)
M:"/+LO-=)KBD2*E$;S1PI"ZR-+KTQ3:W:;3Y#7=E1*S0QZ::EU.TTR3T4JU;
M5-4*>)5>/YX,$DU2J4W5#I L[JM[.#=JJ4ZZ9C%R[<4J^-RMN]\;6W/NN%5K
MG3.N2K=0G4I;FX%RAR>+:3*DT*QMFJ54;5L2.L14Q+EJ#[;,.FQID^M.Q4XN
MRM)(E:FJGIJ2JH)Z1"L3&*++<EEH8(RC.Z_.UVF>8ZG^:47+D!#E;(*LI*RR
M4ZSSP5$,[C6G:&KS'UAI!I1.]%2:8H[(FI]R.;%$W,]F_O=?=<ZDY3$;8UZB
M;O\ @)IU'N2X*M6:C4D?CFL.\)D,W>C9^'=]B6W)VYL^10V;3J5=W>I5O7/-
MAO68Y;=$@JC2\U'QAEE,N3L5KQ-E^OM)(8XXE"^H5,4!:):IH)YTJY]?;I3T
M;O#?MNUE-\8ZG(*R=ZX#U3L:DQV!=R[$U$+U&EA"LL2/#%I*/-.5E ,1C2^/
M;FBTR'1:53*/3H42FT^E4Z#38%.@-I9@4^'!C-QHT&$RAMI#42(RVAB,VAII
M"&6T)2V@ ('G#,\DDDCN\C.Q<O(;N[,2S._^,[$DWOO>UAC<$4(JH  %55 '
M(!5"@#R  'CXX4],=L&F&#3#'PO?2\*3]9;R]$Q+P:#>VF\0Y25$G\*K&4 D
MY&"2D>A\L^G-;7U)@TV743]F]^72U^9QL_#>1#-IFG-08?5F "@ AR1< DD6
MOJ/0WTV\<?)="IPF04MEY2>P+0#@$**1VY\P ?NSG(YQC6J5-7ZM,&*:NT*B
MP-K7)/GL!?SZ<\>ZY7E!S3+S&:AHA LW>*[/H0(% N-V8@>5QX83=JWS1+^J
M\I +QAS*RTE)X[_&IDAK(\\8"N//)SK+Q&!49) I&D2+2.;]/RB,VOM;<@$[
M?785WHN8Y7Q[FDBD2FEFSJ);]W7?+ZM 0-QN-[<_9TZ:/9PNZUYY7.$ 49J7
M+&(QD&0'.\%"B%H\).4)PKXOC/EZ:S5F:G+,QIU$';&L,4)/:!.SL%(M=27O
MJ)MW=AS&*7A'@]>+N"ZN1J\4'R*<SK4 I^W-1KGJ=2O:1.R560*K ,23N-MX
M_I%NBHS)!]Y4RJE)D0T@)[C($9*L%0RG!)'(YPHC)/EJYJ:T01H>SOVVASOL
MID;ERWM?X"]ML:919#\H25X]9[,Y=#60BR;S^JQ2-WKL-)<K:POOSOU<FVMQ
MJLW=RC5%,5$]4">%^"7"R72NER0E(7V+P 7,#*3@@#R.==<QA-5E4P#%"5!\
M0+2(=Q<"UKWW-O/'DV=0_*?"N9Y4S"(5\"Q-,!J:,)5)(6 ) 8G0!S_5BQMW
M[KN71?\ 0*<NBL04B319GC)E%Y?;]9/I "2P@=H\3'))':?/.M9ILL[.BJ*D
MS$D1S)H"6&R!@2=1-^FWMYC&BY1PXF59-5Z:R2<E*E;.@4:NPC7^V/\ : ^\
M[[ 8EFH7$M%_V&V8:28\*ML@EPA2_$CJ*B0$$)(QW%/.<YS\ZJ*.]%6-?Z,E
M.;6V-W;G[?$>&XQKR96&R3.P)ROK$M*Y.D=S0ZA0O>%]U%N5[VMRP[^DK<V0
MB?NA#51V,56R;AI*EIDJ"F1(J,1L.X\'XR@I_,[D]RO[Y(&L'$.4HOR<_;L1
M%5TU0!H&Y5&.GZ7(W O:^W+PH_2IDJM2</2^LL/5LYHY[E.96"4D<R0/CM8G
MD<(E1:\.E[DQ@5$2;M:=R1CM)?87VCUQ]I(P,<:[._>@N -,=N?.Q;RMU.UM
M_&YMB?0J7J>%YCLR9-(NUMPT0!)-]M[ =/:,:L%PQJ+="!R'J4XD'RX*7<'&
M#G.01\S^HZQ#=TORU <]N8//?;NV_7BPK$$U7E3$V[*J!Y<R0-NEK#8\[>WE
M']>IGX"4N'N"T^JHN/F)013%MAIEMNLI*U2 ^%.*)9(P&_" 4#GO1Y:LZ2]:
M7H.[&.]4&7<L3$FR6N 01UO<;[$;&TI:H9M639&T?8K$LE;ZR&#,QI'550H5
M%@Q.YUD^1YX;3UNINZV=T'3*7 -N4^C/MA+8?3)$Q]"BA9*VRA(4SD$=V5?:
M.9-,YI9\K>RR=H\Y:^UB+IL;=-5S>_U#%@N;')\UX;58!,<PJ*Q"S/I,?91$
MZK6;6"&V!*V.+50)BHEB+I(;2L4^Q%5'QU*(4[[O0D-!OM /:%=G<59.#_>G
MUI6&NI)Y:Z@@B_\ ;O?ZK[>.UQSOY354ZR9VF9-(UZCB$4G9!=E+Y@TA8N3O
MSM8*=[&]A;'G4SN.^_&JU--*;'OTB(KQE2E$->[Y5PV&?B"\ <J203G6Z/E0
MC:";MC\TK#2$ U:]N9:^WL-QUZCZ)R_AU:ZOI(O6M'<G!;LM5SI9C<AMB+$V
MY>SD)F_&0\Y;]":^J6$I9J#;H4)*LGLCI21CP1C.3G!/EJD^2AV\Z]NVR%AW
M/%M@>]R]W/PQJ+Y*L=?6.:AV/9-$1I%N[(QO?5N;6VVZ#D2,+5O;C/1JZUBD
MMN!TONX][*, MJ&0? 5GY_/.=1YLN"0/)VWT2HMH\6L"2&-OAO[></,,F2HH
MI$-04L$6_9AB""+?I#8VW.V%*O[E.US<7;%!HZ(WCW=&9[A*+P&4--\GP6^#
MDD??C('EFI:*U'F,G:7(I=04*!OJ)WW.W=L3[\5E-PXF7\.<0(M4TH3*J@DF
M((1J+-< &P(Y>?C?"_+OAV@7%<,5-.9E!58JKP5XY1C,EU(3@MJ]4?JR".-5
MZTHEB6365N%!&D==(V(.X%QT'+?<8Z092M=EF7,T\D96BI$%EN3:%3?GSWO:
M]K@W\,0+)N!<R[;]NWW9#:X;=!?$(.$MJ)@&,07NP$8([\]AR3@CC.K]H!ZI
MEM$6VF:I0R6W&EP^R\C>UB"??C;H*,09?E>7B0LK-5CM2+,/G^T^B"1S.GF+
M#?GB6-NKK<;IKE!]R;"*Q4G92Y/C$*8^L4LLJ2EL-GN\/ ()6CN)&>TG(JLR
MIPL@?66T(L0!'/LP;&]_TK'Q]XY:_G66J]2M>97#4E.$6,*-$G8,\@)-[B_(
M@#;"Y2";?O=SXC*339DAKXAV%:'8) .!W=H07>T#XLD 9 .!#>Q@CVL74-SZ
MAR#YDD#?ESQ%JT^4\HTGYKUJ%&:Q#:=,H-ARO<*!;;GR.&-=.Y[UMV_4K1;H
MR)8E+JLGWYV:6U-&HQWD@)9#*@?!*BH'Q/B\L#.=6M#EWKCQU)E"*CIW$2^K
MLRHM?4#O87V\/#%OEW#25^;TV9&K:%BM)2]D(KJ1#.K:F;5J[P(OW; "]R;8
MA:]Y:JO3+0?4T(ZX]M0F2"KO"PHX*P< I'<D@)P<\9[<8U;4([*HK@"&!JI#
M:^VV]N>YL1<[;7MOCU_@?+C >(U[4'L\T2*^C38GME)U7OT MOX^QG5.S@:8
ME)J"OXWO&"RE6."H@$+ X_-\L8U+AS,M.R]B 5L+A[<C;PW\R=MKG'IV8<'B
M++(6]?8B4MW6A#!3;40#JZ#F+#ROC2H]C(P3]9.93'=3Q&&,! 4#D/(.,$<D
M?9Y $9*G-&0"\*D&51N_6]M^Z>6G>QZB]N0B91P3'-VA^49%/8SOW:?4+",6
M_LZ#<&_+GMOAQ6'MBU6KFMN&:P[',R3*1XHAI66REAY0(3[PWZ(P0"G.?/(&
M(6;YVU)0UTHID?L44Z2Y )+J/[4D6#7Z^7AB_P""/1S%F^?</4K9M- *R>K7
M6M*&,?9PRR7L:A02Q2UMK F]SAQT&P16[GO&.:HI@670KFK:,1D*]_-LE;@8
M6%2$%D20T25I4X6^3VKP=1:O.6I:'*I%IU;Y3JLOI3>1KPBM"W8=TZM%R #I
M!YFVV,>2>BR+-,\](-$V<RQ#(\CXNS,.M(C&I.6-*!$P:H 4/LS$%B+6L>>$
MJ!M@W==M5?<I597!=8=@._5(BB0A7O,CW,A4LOM*2$)1XG=X0*OS2D#D]YN(
M6H<TAR,4BR@]HGK/:%>49E%H]!N"=MF'Q%L.&/1!'6< -QF<^DB>C2GD% *%
M65Q-7O3-KE%6NG2O?'<O^B>5\-N18"'&D1/K1W^((G=ZHO*E.C)20'. .\CS
M)^TC(U.CS=B3(:=1K8PV$H/T"1JO8<][[#Q/E"JN D*FB&9L>R05A9J4@GM@
M&9;=HVXO8$,1SZ85J?2?P0J--N-#YGN0XDE'NBT%AMSWR*_$42Z''.SP_&*\
M);PHI">!SK$:LYDD]$8^Q#2@=H#K-HW64'257Z6FW/D?$#&L<;<$1T'#D4_R
MDTMX*)RGJVFVNIB33?UA[V)/Z/Z/.YQFT*H[%J:;G2A"EL.L/IB**^WN@.Y"
M?% R/%4D J\,X*O(XPK-7KJC%&#LX*A[B_? N2#S*[FP-S]E!!P&F<95*3F1
MIQV=2=J7M.=TL?G4MWBH!N;W QSNFV/?HD^J*G=@K-6-76TF-DL+FK5*4R%E
MU/>EM3A;"R$%6.XI!.!$R_-B:I:+L+>J0M"',E]8A(BOIT[:@ UKDJ+#?GC>
M*KT2QY'D>6YLN>O4EX*&(P>H]E;MZ99"=7K+$Z2I4D 7Z>;BVAVF3>-_6C!-
M;53U5FH*:#JH/O;<=+46622TF4V72X&\!"E)!4I*<]OG%XBXC.697F$JT@F-
M+$IT]H4#F1XAN=!TA==R1N NP\-IX*]#$/I#SG)<AGX@FRM.(9W@-0E *HTB
M015#EDC-9$'>7U< (VD N!?8$ZVZD4UR2ZVXL1_J:\&[*[T([DR4TQV7&-2"
M?A\-3Q<[S&RKM3A'C+P5:R9'/V#1J%U>L92N:W+6[-I^S/8\KL!;\YM>Q[H-
ML>>5W!:<)\*\4!,PDKODCT@YQD:AHA *A<LII46H%I)>R:3LP6CU&P;F=..=
MY;6MV;$I-4365U!2(KR_!]R# )=>;9[0LONG_P"4X^$$XQCRUEI<[]=G-,:?
ML^UWUB0,%""YVTB]]/,<N9'7&N>CN,YU0<19X2*;Y"J,OA6F%Y6JO7DG747
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MU=0N6(,E1$IM](=Y;'X<C?EOAXNV@A=#DW']8%)8N%F 8WNW?WI>27@YX_>
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M_.Q]Z30 $4ZN\UR>Z+M?8"^V-=XNS/+:C/,I,&8T$R"MRT%HJNG< @;W*RL
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MZ="$J2VP9DZ45!B'&2XH%Z4[V++;+84ZL(40DI2HC#)/#"8Q++''VTJPQ!F
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M2J)ID;US,X-<<T@++J@&F][%0%V-@"X"4WSN9&:)2T=HKL<7'"AV%TA\>(4
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M:$K2X]VE!'PDCL&",@A (.,$^NT<CF7)R7;?*LN!N=B"5%FZD[VY7N>7,8^
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MO[>6/?S^ORUSA@TPQUK23CC/"AZ<$XQYD<>><'75A>PZ=1;GNO7F"-R#[3S
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M2W:174K:Q4"$#>VX(/@+8UP>B_AE:*LR\#,/5J]X'J5-4A+-3,'A*L8"R!6
M)"D!A<&XVPS6_HZOL\6I%0EML;VI?JC+D>6H[H+*5LNJ[U)0D4)(0KOY"QG
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MWS4Y5)DN;*4-V7O]7FE7C^&/J'"$'O4$HY"1CDXUL4>1T41@([4FFBB@B)8
MB**VA6LMF(M?41>_PQX_'QOGL<6<0J](4SS-<PSFM#TP-JW,[^M&$JZ&.)@Q
M 3<@<V-L=%>^C(^S)N:@6U;59@;[OTNU(,BGTA#.[+C#J8\N0B2^)#HM]2GE
MK>0DA:CE(RGD:RTF44=#5UU; KB;,)EFG+/J74BE$""P"@*3>W,F_/#.N-LZ
MS[(N&^'J[U09?PM134&6>KPO%,89Y$ED-0YF=97+QJ051 !<6-\-B)]%B]E=
M!+GNE*W^;\1)2>[>)]6,D9\[>QCX1CCS'W$6$D226U7V-QRY@W','E]][8UB
M&IE@CFBCMHGBDAD!N3ID !MO:XM<7!\+$8>5'^C/^S3H5NUVU*="WT11;CJ,
M2J59IW=AUR0],A*;6PMM\T$>"@%M/>A*"%8],\0:C+(*BIIZIVD#TT;1HJE-
M!5E*DL"A:^YM9@ 0-N@UVKR"AK,RH<UE,RU67T\M+3Z&0((I@1(&5HV)+ \P
MPMTL"1AK5'Z+9[+.J///RZ9O\M<A*&WNW>%Y*5(0  ,?@\<>0R002,@\' EQ
M0)$ J@Z5-U!Z<[C8#8\_&^+2&G2!51;D+<C4%N2>9[H7ZA_.JGZ,;[,5JGQ*
M4FG[]"##G0JDPG\;SP*)=/[4QU*5]0<M@!(6C&%#."G4<Y? 9Y)^_P!I)#)"
M3=+!)"2UAIO<W-B20+&^^(IRZ#M9)PT@>6":!]T T3 ZB.Y>XOM<E0";J1BW
M5%]C3TA46W/P:@2=UTTE;;C*VEWO"><4VX^Z^K^4.6ZIWN\1Q6"5$]H"<\<:
MA-Z.\BJ:M*Z2?,3,CEU*3TX0W70 0:1C8* -B"=[DDWQY?/Z#^":BIDJI!FP
MDF,9E"5Z(C&.V@!!3E5"VY@[\SA6H'L@.E&V0[]43=U62\5%Q3UX4Z3W%?85
M<.VV0.6TX(QQD>NH]?Z,.'<R"+43YH EK=E44R'8$ ;T3"UF:]P>=^F">@_@
MB*;UB$9M'+V?9:O7U8&.ZL05-/U9000;BW/<X=#?LL>G!I8<16-S@L9P?PCH
MQ R"/(VT<\'R.=4TWH4X1F1D-5G@5K7M5T72WCEVVXO< &_7$Z+T0\+0N'27
M-=0O;\KBVO>_^YR3[STQE_V6O3J]XX56=S2)+18?"KCHV5LJ':M"5)MH%!*<
MX6,D'G&ND7H0X0A[#359Z?5YQ.NJLHK%AR!MEP)%[7W!MM<#':;T1\+SB<23
M9J14PM3S?E<5VB8$, ?5NZ2"0& N.>$:5[)3I=G1VXTJH[I+:92E#24793&B
MD-J2IL%:+;!5@I&21SSY ZMH/13PU3RR2I/FQ,K,S!ZFF(NX(-K40-MS8>SP
MQ5R>@K@>9((Y3G#)31K'$/7T&E5 47M3=X@#F=^O.ULR?9*=+DUUI^5/W16^
MRX%H6B[*8V 4@H1\(MO! ;."#PHY)\^$'HIX;IXVB2?-2&5E):IIB=VU7'Y'
ML18#KL,=9O01P+/*TTWRRTC "XS%5 "Z=-@M, " BW/B">IQH5'V0G2M5*/-
MH$F?ND:547ER);"+NIZ'7'E=J>Y,A-NAQM/8D H2<9)(UWC]%O#L-=%F$<^:
M=O# 8$#5%,8])8-<CU*][WW!'/R%LT'H0X+IX!31'-EA%0M5I-<CDS+8*Q9J
M:]@H4$<B;FUR;Q]#]AKT3P?J/W9>[R/P<>E/4D&_V5> J:M2I/B$V_E_O)^$
M.$A)R0.=74G!64R>L!IJ[\I"K*>UI[D)8+;\EV(&U_U\I<GH;X/E];UC,SZZ
MD23VK$74(=D(M!W2  .[IN.=[VQFJ>PSZ(:RM]VH'>%YR0TXRX4[@L-)+;GB
M=R>U%OX&?$5D^? ^6NT7!F4P@*DE;I4@@&6 \K 7M3"^PY\^=K8YIO0[P?2!
M!"N9+V;K(H-8A&I2"I-Z<D_1%][^=]\)9]@[T+*I\.EE.\)AP6U,QD?C#:"T
M-EP.X+@M_N4KQ!DJ5DX 'VZ[CA#+!(\G:UA+V)^=AY@$?WOX>>Y)V&)!]$W"
M9J):JV8]K.YDE(JTLQTE18&G( %^0 'UW<+OL1.BU^)'A/.[OJC17?'9;%^Q
MDE+O;V]Q4+>[E# '!]<GUU@7@C)U=G$E;J=2K'M8?HWN!_!^G+KY^&(">A7@
MM)7E"YIK==+GUU#J%[G;U:PU;$VWN  ;<]-CV&G1'&==>85O AQUTO*)W 84
M"X23DA5O$%/)X_9CG.1N#,I=0K25E@I46EA&W('^#\P+"^,S^AS@Z10K#,RH
M72!ZXFP'+_<]]O;?'1.]A?T1U.\%7U.5N\Y<:C"69+=_LMQ^ZG--L1#[F*!X
M![&FTAS(_C% J4,DZQP\$91!1"A26M[&TH),T>JTK,Q_L-MF8D;#KORQFB]$
M?"L.5C)U?,S0@S$1M4P,X:=R[D2FE,ER3;=C8;"V(UE_1V/9[3;=NRUGVMZS
M2+VOT[DW A&YG9(?NE2G%K?CR$T +BQ"MS(A-Y:3SCG!%D.':%:FEJ@T_:4>
M7_)L(9T9?5]-KNO9B\@(!!!"VVT8V8<'90M?D^9#UH5.19!'PW0?/ QKEL>P
M[1&1@\Y4*&ENO(V4:B,,^H?1G/9HU6IS:Q-A[[KGU LJD*;W9=;:/@,(CM!"
M!0"4@-MH"CW'N(SQG F1Y5310QP*9-$6K225+'6Q8W.BW,[;7ML;\\6=/DM)
M34T5+&TO9Q&33?LRUI'9[&T8'=+;&U[#>^%1'T;7V;[;/@(C;YA'@^ #^-9[
MN+?;V<GZC\P/(X//G\M13P]0%M5Y=6LN2"@W)O:VBUK]/KQ@;AZC9RW:U NV
MJVJ*U[WZQ$V'MY;';'L1TX=/6WG2ULEM]L!M>U5Q8&V=-D4JV4W'436JRB-*
MJ<^KNKFU-;+!E/\ OE2E%+O@ME+:D-@81DW$,2P1+$FRJ+>WJ3M8;G?D,7$,
M"01I$@[D8[M[7OO<FP OOT Z[8FY++*4]B6FTI!20E*$A(*?S3@#&4X';QQC
MC&LN,V!+32""AIM)&<%*$I(R #@@ C(2D''F !Y :86'A]^7V;8[-,,&F&#3
M#"!6;:HU?>I;]7IL.H/4.I1ZS1G93/B.4RJQ4N(8GQ' 4K8D);>>:4MM:2['
M==CN][+JT&+44=-5/3O401S-2SI44S.H+03IJ EB8[H^EBNI;$@E6NNV)=+7
MUM"M6E'4S4ZU]))0UB1N5CJ:61E=H)X_HRQET1M+@@,JNNEE!PO!('H/+'EJ
M38?7?F;_ !Q$QA2 1@<<YXX^?RQ\]-(V\O,_MPP)2$@X]?O_ ,9.@ON3:YYD
M"W( #X 6'E@!;&2/,CS(//\ 7[AII&]MB>9'/'%CX^[IY^?+QVOCK\/[L#D>
M?)YP3@^F<#SXX^S7%O GH+'E:Y)VMX&WLMX8YP>$GG@'UR1Y>6/7'I^WT\]&
M!(V.X%@2 ;7-]MO'QOC@;7\^>Y/M^_U8XED*R%!!2H=JDE(((((((( ((X(Q
M@C/')UR 0;@[^/4&]P=O=?>VPL!OCGRZ7^/M'+F2?KQ'MA;0;7[5L5B/MEMW
M8NWK-Q3_ *TK[5EVI1+9;K-0 6E,RIIH\.&)LAM#BT-.R M3*5K2UVH6I)E5
M5;75IB:LJYZEH4$<1FD>3LT%AICUL= *@#:_(7)MB/#2TU,&6G@BA5V+.L:*
MH=CS+6%R;^>W2PQ(/@D !) ((.",I.,@Y_43Z8S@D'&HMNEP!X  >/MZG5?G
M?J1B1UN?J/,<K?#:VX]^.8;X 405 8RD=H.,<$#T)Y(^[Y:XMY^'+;ET]GD?
M?>^..@OO;????QWZ^>.24 >@]#QZ'[,\X_7]F,:YMR/,C8$^!-S8=/Z+G'-N
M=][[F^]\<]<X8-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#
M!IA@TPP:88-,,&F&#3#!IA@TPQQ7^:K_ /=/]!^_^C0\C;<]!ROA[[>?/%'+
MDW)KVR74'N95Z]8N\%[V;?MJV!(ME=@6Q.N^F4FI6_'JU-KL54=,Z-$ICTCO
MB270SVO2"4NNM$*;<7Y37Y[6\+\99Y4UV5<2YIE>:9;DS4+950BNIJ:>E6IC
MJHQ'VT1A9]2.Q-RQ%SS!Q[9E?#F7<:^C[ANDR_.N$,CSK(,WX@3-?EW,ERJJ
MK*3,7I)\OD5_5I6J4A[.>, DB*]E(W7#@_++M[]!74]]G]Q^3_SUS\_N^W4K
M\9]!_%;CBWC^#VW_ *9B%^)W,+_[>/1G;_\ NP7_ /0,8_+,M[]!?4[]N=GY
M/V^GUWD>7KS^_'/XSJ'^*O'/^KW_ &S#\3N8?QX]&G^M8_D.,_EF6[^@OJ>_
MP02?^>O3UQD?L.'XSJ'^*O'/^KQ_E>'XG<P_CSZ,_P#6L?R'!^67;_Z"^IXG
M[-GY/ _76OO_ ,FN/QGT'\5N./\ 5_\ [9A^)W,/X\>C3_6P?R#&?RR[>\OQ
M%]3V?_4_)_YY_K@_+7/XSZ#IPMQP?9P]R]OY7CC\3N8_QX]&?^M8_D.W7QQC
M\LRWOT%]3WW?B?E9_=63]G]2-<?C/H.?X+<<?ZO_ /:\/Q.YC_'CT9_ZV#X_
MP#V[?7@_+,M[]!?4\/\ W/R?V?[,^?[=<_C/H/XK<<?ZO?$_POIUQS^)W,/X
M\>C3_6L?R'";4>N7;^C^ZBN[8;_6XNH/I@TA%>VP>IZZY5WE(3%HE'"ZNOWN
MK3"I7NT4% <[% N)/:%1Y_2UD5)V?KN2<741F81TRU.1F-JN=B-%-3@5+:YW
MO=$.D&W/$BG]!W$=;VIR[B7@+,EIHVJ*UJ+B59A04B F6NJ[TB&.EBM\XR"1
MQ<:4;>RD.LRW\#NV*ZG@?LV?D_XJT?U\G&-26])U I(_!?C<VY$</&QY>-6#
MU\!^V/\ B=S#<#CGT:&VU_PK^O>@6_NV\^@/RS+>_07U/$_^I^3SQYC^S7E_
M7RYUQ^,^@_BMQQMM_M>_[7A^)W,/X\>C3_6L<O\ ,?K^K&?RR[>_05U/?X'Y
M//V?[-?U_HX_&?0;_P"Q;CC;_P#I_P#[7]N'XG<P_CQZ-/\ 6P?R#&/RR[>]
M=B^I[/\ ZGY//VC^S1T_&?0?Q5XY_P!7O^V8X_$[F/\ 'CT9_P"M8^WU'Q\L
M ZS+>_05U/>?Z'Y//G_Y:.GXSZ#^*W''^K__ &SS'QQS^)W,-_\ 9QZ-/+_9
M6/K_ "'&?RR[>_07U/?X'Y7_ #SI^,^@_BMQQ_J__P!LQQ^)W,?X\>C/_6L>
M/_$?#Z\'Y9=O?H+ZGO3_ 'GY/F?_ *YUS^,^@/\ W+<<6\?P>_[7CG\3N8?Q
MX]&G^M8_D.$>O=8-,F4BJ1Z9L9U,IJ+]-GL05/;23&&DS'8SJ(Q<>;JSCC38
M>*2MUMMQ;205I02 -1JKTF4KTU2L/#'&R2O Z0E\A* S.DBQ79:MF10Y4M)I
M(4'J;C$BB]$%5'6TCU/''HV-.E33-/HXH#MV';1F8JIH0KD('.@G<6!M>^)W
MZ>:/<= V1VRI5W*J)N:/:=.<K8J[S[]4:GS$KFO1Y[DE:Y!E1C($=Y+RU+;6
MT6U$]FMOX.ILPI.%\CI\U:1LQ2@B-89BQE$\FJ5U<L VI"^@@BXTVZ8TGT@U
MF65_&W$U5DRTZY5)FM0E#ZJJ+3-3P$0)) (P(^SE[(RJ4 #!]0YXF76RXT[!
MIA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@
MTPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP
M:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88
MXA" 00E((& 0D @'&0"!P#@<?8/EICBP-K@&VPVY#P'ACEIA8> ^ P:86'@/
M@,&F%AX#X#!IA8> ^ P:86'@/@,&F%AX#X#!IA8> ^ Q"V\>UK^YK^U3S$Z%
M!_%[NQ:VXLGWR.[(]]A6^W/2_3XP:_,DR52VBVMT%D!M7B X2#K'$O#[9\_#
M[+,D/R+Q#09VX9"QGCHUG5J<,/HB1I48@W4F-21=5QN?!_%2<+1\5JU-+4?A
M%PCFW#:=E-V(II<R:F*5;V_.+"L+CL]BPD(O8G$SIP!@# ''WX]<>G/IK9_O
M]_OSWQIEAX#'+3"P\!\!@TPL/ ? 8-,+#P'P&#3"P\!\!@TPL/ ? 8-,+#P'
MP&,$ ^8!^\ Z8YL!R%L9  X P/D-/O\ 'GA@TPP:88-,,&F&#3#!IA@TPP:8
M8-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,
M,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F
M&#3#!IA@TPP:88-,,)=:K='MRESJY<%5IU#HM+C.S:G5ZO-C4VF4Z&PGO?ES
MY\QUF+$C,H!6Z_(=;:;2"5K UWCCDFD2*&.2:61@D<42-)([GDJ(@+,Q.P"@
MDG'5F5 6=E10"2S$* !S))(  ZDX0+*W&L'<FCBX=O+TM:^Z"93L(UJSZ]2[
MDI*9C !?B+J%'E3(B)3(4@NQU.AY <;*D +3G+4TE512=C64U1236#&&IAD@
ME"DVU&.55>U[B]K7!'0VQPU$%2@DIYHYXR2NN%UD6X%R"4)'\^V%FKW);] -
M(37:W2:,NOU>-;]"15:C#IZZS7IK4A^'1:4F6\T:A5I;$24]&IT0/3'VHTAQ
MIE2&7"G"D<DG:=G&\G9(TDNA2W9QK;4[V'=0%E!8V + $W..[2(FG6ZIK<(F
MHA=;M?2JWYLP!( W(!VPK>*C&<D<XY&/3/W<C]_&NEQO>XL0+D;&X!V\M[7Y
M7N.F._6WWVQ'E=WAVGM>Z:38UR[EV';UZU_P/J.T*W=U I5SU@REJ:BBET*=
M4&*I.,EU"FHXC17/&<24-]R@1J9'05\U/+5PT-9+207[6JBIII*>/2 6URHC
M(I6^]R+=<1WJJ:-Q%)/#'*Q4")Y460ZR G=+ ]XD6VWQ(B7$J!(S@?9CGGC[
M^/7'[]0M0VY[VWY<[VYV.]O#$C^?ZC;;Q'GRQ@.H5^:<^7(!QSCUQ@XSS@\<
MY\M P(!'(BXZW \"+@^R]\/'R-C[?V>?+SP*=0E7:5?$?(#D_P#7_D.N=0W%
M]U )%C< WMM[CYX>'GR]W/[,(L>Z;:EURIVQ%KU'DW)18=/J%8M]BI0WJW2H
M%6,I-*G5*EM/+G08E25!FI@293#3,M4.2(ZW"RYVY&BE2..5HY%BE9TBE92(
MY&C ,BHY&EREQJ"DD7W%L8Q-$9&B$B&5%#/&&!=%8D!F4'4H-C8D ';?"FY/
MB-+9;=?::<DN*:CH<<0A<AU#3CZVV4J4"ZXEAIUY2$!2@TTXX1V(4H= ;AB-
MPOTC_:]X(+^%W(47ZD#F;8[D@6OMJ%QY[7^RY]QQL%:0"><#[#_7G_KQKB^X
M%C<_5RV/GORYG>V.<!<3G&<_=_T^HQR/3UUQJ4DB^XM<&XY@D#?F;#D-QUPP
MC5^YK>M2DS:_=%<I-N4*FI;74:U7:C#I-)IZ7GVHS*IM1GO,1(J79#S+#9>>
M0%O.MM))6XA)S0Q35$B0P0RS3/?1%%&TDC64N2$4%B%568D#95)Y"^.CR)&C
M22.J(I 9F(5020H%SM<LRBWB0,+"76U)"TJ!2H!04#D%)\B",C!XP<\Y'SUB
MU <P1Y6)/A>P!/Q&._+ '4$A(4"2<8&"?^C(R1G&<'Y:7VN 2-N6_/EY6Z^R
MYQQ<<KB_M'W^'[<9[QDCG(R?+SQYX^?^32_](W^S[^'7'/WWVY^W&>X'RYY[
M?U_KQI<<^7MV^W#&"X@#N)PD DGT';G(/VC'D/LQYZ7%KG;]77?[]1CBX\1@
M\1. 2<!6<9!'ES_1D_+C7!8#G<<^>VPM<[GEOCG]?+W\OC@#B22 3QG^]5Z'
M!]/('U\CZ$ZY)%K[[\K _??SPOCIDS8L1'B2I#,=LNLL!QYQ#3?C2'FX\=KO
M6I*?%?D.M,,MY[W7G$-("EK2D\CO&P!) +$ 7*J 6)8#D  22=K GD#@2!8D
MV!( )VN2; "_,D[ >.V.X+20% G!\L@CTR.#\QR!YG.N P-K;@BX(W!&VX(Y
MC?GX;\M\/<?9U]GMQCQ4$D9/&?3_ (/G^SU^7KC2_MZ=#OJN1;;P!QQ?]=_*
MQL;^P['SQD+23VC.?M&,\XXSY_9\]+\]CMY7\=MK[[&X_:, ;_L//VVPCR[E
MMZ#6J7;DVMTF)<-;BU*;1J%)J$1BL5>'1O=/K>73*8Z\B;/C4KW^!]9/Q6'6
MH/OL3WE;7O#/?D6.5HY)EBE:&(QB298W:*-I2PC5Y -"LY5M*L0S6-@;8X+H
M'6,NH=PQ1"P#L%MJ*K>[!;C40"!<7M?"E(F18C8=DOMQVU.,M!;RTM)+LAU#
M+#8*RD%QYYQMII )4XZM"$@J4D'H+L;*&)L6L%-[*-1-K7V&Y\+&]K'')(47
M8@"]KD[7)L!?ES(QV>,@#)) ^9& 1\\^7RQSSD:XOSL"0!>^UB.>QOT&Y/+
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MTXK;J2J$^9_ASQ37TJBU(QBOZNFK3#F^!+<2TJHCR3.99JBDARNO>HHS'ZU
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M9.RL$9VB4D_.'&W#M2D6FFDI5,M!/23)4BHGB5YZ@3M41DS&0R ,ZB[ DBY
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'TPP:88__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>cntx-20211231_g7.jpg
<TEXT>
begin 644 cntx-20211231_g7.jpg
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M5&-VHM+4U>)8>)(C)"4F)V$R0E)B@:&U_\0 '0$!  $$ P$
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M-X.;O-:\ENH(U U!')>/+6WT,7DK\36/DI8^Y;C9)KN/?6KR3,:_=+7;CG,
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MPN_A[^^/1?YCO?\ 44]267_HU_GQ^ZG_ %1=%?O^>_4[OO"?X7?P]_?'HO\
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M:CMUY:$:*[G#/'GHU9[!?O(WO'1*;?NQ7BA5'E,2+S'GY'F_.Z?SJF'K-9X
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MM9:QBKNF3C&)H6LCL]9J8TR,JNGK&.MC[L?!J,EKP[HABD<RVXG@-/@DMU
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M(B(B(B(L!ND^F!X,]=OEFZ9T+B&QZ[7&P9M5B,M=-["$U(6/,5F%[XU%U_H
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MDMM2R(I]R2-FRVM-]=),F"^\^[$?>QN['<?>W9WTV=WSM2[H=:X:.SS#HUS
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M;K6!O2RO(7N$X+9J]-ZE<Y8NXV$E:[-I*,R9$TP?,F!-B-$)19W;<MC8W80
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M9US^FNZ"Q/6D$M:>:O* 0)()'Q2 .Y$!\;FN (Y$:Z'QK@@$:$ CN/,+K1]
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MQ)>QOV29"_,7.FNVY7/;(QYDLS/+F3;O%:XN>2YLNXSB-.H?N-W@=T:- .P
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#B__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>cntx-20211231_g8.jpg
<TEXT>
begin 644 cntx-20211231_g8.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2104&AO=&]S:&]P(#,N,  X0DE-! 0
M    )#2^DF@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              M    =D          $
M                 0             '9    M
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   M      4F=H=&QO;F<   =D
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   +0     %)G:'1L;VYG   '9     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      9S@
M  $   "@    /0   >   ')@   9L@ 8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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MHF'U8@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5&)G=(6EM$B"@X:5_\0 ' $!  $% 0$               $" P0%!@<(_\0
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MX!\MO_&&NM^8T]^NVW']NHX?=)YQ^2^76[>^%3OYNY_-L=L1[Z!;?\T5:WW
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M#WT&VCR^A#6Q\@]U$ITV\/U)Z?ITT^ ?+1_UAK1V_N&G_P#7WZ_8X?=)YO\
MDOEWC_MA4^K]S]6]O7B/?0;9U^A#6N>_^%,G]_\ 4G?3X!\MZND-;_L, _\
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M &^CJOA]TIF_Y+Y=\HU/V?KZ^SJQ/OH-MZCB*M<M]M[3*[[AM_S3R'<?O:?
M/EH_ZP5N_/\ <%/_ .O\]AU8C[I/./R7R[G\85/+_9O;MQMYPF<4TSQ)/[PT
ME*?&55.H-*\X1&/E7<D+X9M6:3.54'+1J"((>U:8E$O>=OO3@(!L Z\V]T7H
M#3]"8\IDILRFK^^+UJ.)J>.'A&E2F92NB1]6L3,K7M8 $=@]9]RSW3:SW0I<
MZBJ\JILM&51T$B&"HEG,W=;U88-Q(XPF@TRZ=(.K4;VQNSKS/'L6&F&/%[V4
M#]\#%W^J$QX]?U8(/D.WWO/X?IGW"/Q3G_\ .5-_PI]/;ZL?(']DG^/>C7\T
MU7_%GQ_7]./,+Q$!WZ '/ETVZ[>0!Z_#??7NQ'9U;]OS_6/*,?-V #Y? 'CU
MV#R^'U<QV !ZK<O+<[<_JMMZ+;X>W[3R'G\F.0$,)A I3"(=D>R!=S?5[=D=
MMA'81$H!UZ@ <QU3K2U]0MOOJL/!)N ;\Q8WMV&]L5:2; ;DD6 (.Q ()L20
M+$&Y 'CQQVW$"@ B.XE]8F[0 ( &X;B&Y0$-M^8"(!N74W %RPMSY@ "P)^O
MF=K8BQN!:Y-B+;WU*S"UKWN$>UN91AS4@-AW'ZD=PY"'9$.>P<@#;J&_,-N0
M[;\Q -3<6O?:P-^>Q%QN>T;CK(Y8G2=6G;5J*D!E)!63A->QV D\ DV&KP;W
MQ]!25*8"&3.0YN9"B0Q1'81$>R AN80 !'EVM@^+5 EB8$B2-E W(=2.=N=[
M#>ZFY&^V*C#,--XI064, 8W#%2-2MI*@@,INMQX0#$7"M;@ &-N <QV$WB;Z
MD YB(@ [   .X\@V 0'ETJ)46)( N!<D#<WL#>VY)V',D\L4A68V4%C9FLOA
M'2A(9K+<D*18GER[1>/7MRY=.?Q\N7,/$=@'J&IWVW[3RV\GBYW',[<\4^<>
M2XN;;;"]S;D;<N1MB!WWY\^7F/3;?QW'U_S:GU>KV]K88SCPT[?3 X9W#G]$
M>J=/5+-NH^>X>'KWYZY#I[?WF=)>SO35\^=]/+ER]N6.V]SC^/?1/L[_ &7^
MGC#V]&-C?9(OX0C'GMOCJM!UV_OK9?R\_/D&N1]Q7^)TG\\UO]#1X[W^R#N>
MGT0 N>\.6]5S^_9D3?;:PN;[6YWZL:!B0X$ XD-V##V2G$#;".X\@'H([^'J
MZ:]:$D9<QAUUJ-T!&H#J)7F!X[ 6/C&/#S%($$I1N&W*2W@$V!L'_!+6-]-]
M5@QMX+6C81V';D)A / !,&VY0$-@$0#81V'D'/EJ=0N1<:M-S8B^G?PK7)M>
MXO8[X@JP!.EK E20"0&TZM.U_"T[A>9Z@3B!';GTVVZ^ [#\@CL(AXCL AZY
M-@-^1-N1/,FP//R=AY==L0%+,%479A< 6)(!4$^0:@2>06[DA58ATW#?;GMU
M\N0CU\.@^ ;CS#EH#>V_._EOV6L.7(WL1;<7PL;%N2Z48D^"-,@#1L;V\%P0
M5/)NK<8Y%*8X@4FYC& =@+N(F /\7;<3 ( //;L\A#J'*&95!+,% M<D@ 7[
M2;"W+KW^>51V-D1G.^R*7((TW!" D$!E)4V(#!K6()"0=S@)1*)-^V40'<@[
M@'U0;;E !$ YAR$0 =A$-0'4A2&5@_X)!%FV)&G<ZN742+;\L28Y%+*48%#9
MP005.^S _@G8BQL=7@_A;8@?(-N6^_/?;;F(CTV#KUZ[_P"CJ00;V)Y[]G+E
M<7!M;F.7([WO20PL&!4D JK>"Q!MNJFS,-Q<@&UC?\%K VZ<QW_^$=M^8 (C
MU -P'GR\!W#3<[VY>/>W7;8B^UK=OF)$6 )L W*[ 7V4[ F_)E-^PC .8]0#
MGU V_KW\QY#MX;#R'8=PU.VPL/):U_)Y]SS\G+"QM?J^;RCF+\Q?F+D<CC;?
M@7W^FDQD/@);G\8^X2R\QY_#R ->;^ZU_$3-_P#2Y;_^1I?;?U<L>K^XEM[I
M60@VV3-?/_:FMY$;$=8()'9C&G$G_" S(([_ +X]L\>?[<.O'GKH.A'\3NC/
M\R9=_P -'CE_="_CUTO_ /\ 8LX\GXQJ>7T^;&$@]7Q<@\.?7SZ?#T]6NH\1
MWOSY]>W+J'/R>G''X"/(1$P!MU$1VZ;;#N(  ;>8COUTY<N7S<S[>UIMR\=[
M6YFVY^?F?(.S&Z,OPO%5J^,&\,HXC[E(S-<A<C.7[YH_81RE]CPFX)PE$QRB
MTI'%KI2+5F6;NT4U7TZ=HBVW,Z+MY/2^Z(5S#/WJ56HRN"FK:K)$@B,4LRY5
M,*6I4U$MHYA6EEK:=XRZQ4@E=_!C-_9*SW,0V6=&8Z1WI\XJJS+Z+/I:B59J
M>!\Z@:MHI%HZ=Y*BG-"H?+*M)%0SU_<R1@&4 ]=OP\5JPQE-0JTNY36M$#CM
MP,_-,G;-<7USR+E&L^E%@"/W"+<A8ZIQ22['VP=$!5,[EFZ-Z08XW6Z:YC1S
M9E)7TX(H*O.U[AI98981#EF29#6K$:TTRR,QGS"H=9="$:N',G@*N+*] LMK
MDRR'+*DJ<QHNC[I7U\%1!,U1G'2/I50,S4*5)6(+19/21\(,RO*'DBE DVL&
MN</$G96-==-+,R07EZO"WF3;.H]9,(&DO;/;:Q.V-98CH_I2%86KC%\_2!-'
MOFL\U!)0OHJQS;BNZ<P44M8DE$[I!75>4TTD4ZL:S-8J#+JZDHE41D1M7+7R
M1POKD*R4C@HQD4#2T'N?SYC%0205\2-/EU!G=8L]/.@HLDFS?-,LK\Q<L(S,
MF7'+(Y*B-(H2\681.FD0L\G?C>'-:2B:_*C;0CPE3*>V;62A$4WD2@?&]@R;
M'._06L\\DE$7\)7E" 6280:QCNVCJ.1DHY0KDV/)T]$-56TARLRM3 =SR15;
M&.I9<[H\CG DEHXHAPJJL!O!+5 ".2.=H)U,>,B+W.7GHJ"K&:I3]UM()H9Z
M5'EIU;H]7](Z5UC@KI*@K+0T$BZZN&B:1I89J>*6GD2842X8EK54QT_MB=GE
M)624G<>$@$PAD8]D\KM[H[FX(GE432+Q:.F$ 34041;N9!HF=@)"++ED07C\
MO*ND^89GGL.6FAIZ:G6DSGNT]TM-+'793FL>7,*=^YXEFIFN&!>*"1N,6(4T
MY2;!S?HKEF5]'JG-%S&IJJJ6OR Y>O<<4$+9;GF1RYU#W0HJ)S!6)HDA<)/5
MPE(56.21I^-%@#?\&WE^GKW\ VWYZ[GK]O7[=?+:^. Q/AR'?GX;AOY#UZ]/
MC$-]QU3M??;;KMY2.O;GXMC:UKEZ!Y?:_H^C'IQ[&&(_1#R?O_D3%>KK/%Y_
MS^.O"?=X_$V1#J[YU)'B_<A.WH'DW Q](?V-WX_Z1?S/3]?_ 'U/1[>+'G;=
M_P!VEO\ ]:+!\GML[_FU[+DMN\^5?S=1<^WN:._T^;'@N>6[\YO_ #KF'/\
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M.YZMKR4=2%961BNH+(K1MITLU]+A38JCL-KD*Q&PQR*FHIVA(0Q@+^R$I1,
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M'(=3[?/YO;<#"YY7V[,!\-O/D/\ /R\?, ';;4 ;GU^/]@[#;GMAO]> #S\
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MPL=/?C-/DZB^SX? ?[F^W]J)]O\ XKF'VG$_2-<)V_[0+^7[NYW^6=A^'?\
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MZ?"QT]^,T^3:+[/\^(^ _P!S;XHJ/E7,?M/C]K#$?2-<)WV 7Y]?U]SW+_\
M,_@YB/7ST^%CI[\9I\G47V?$_ ?[FWQ1/\JYA]IQ/TC7"=O^T"_7_+R=]?\
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M'S#@:X3N7Z@+\O\ IY.^O_GGGTY;^?@/(9^%CIY\9I\FT7V?$_ ?[FWQ1/\
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MJM=5456M:=I3#^_R2%=)EE_!MJOX5[;9[US..RPTPQ^3+^B)CG)FWAW[!S%
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MWZ=;$7W'7U;]6V-ATE);.:L6Y+"N_P#H(6%KW W-B;&^_7OCRB](6^N*>?\
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M;ZXI]T4_/]8Z7'8/7]> 4><>)?,>7MY<?I>_H<@YCV/BV$QC#M"86#<QA-L
M/\GCR[0CL'/I\?P>6>Z8!HR<V NU:-AOL*4C<W.US8<@=^W';]# 0U?OL13[
M6&W[\2=MK[6^NV/U*:\IQW>&F&/R8_T11^_9P[_Q6V?R_P JR^>^_P"'X->O
M^YK_  '-/SN#^A?'GG3+^%T?^A?JO_?$]'L+=OYU=>DXY'ES^?Y_/MU^LX:8
MG]?M[>+#3$ VMU<]O$#;Q\NV_C\C3#?:_JOX_;?Z19IA?LWVN//YOU]OC:8G
M#3$>;JYV]7ZNKT8:8=GKZO;?:WCPTP]A]7F^;SXW,]CO_AR\*7\>F//]H&GJ
M';[WPAK2=)?XO9U_-U3_ +F-CD]^^V7_ )S%_2+XNSV'/&^'L_/\.""_B%H7
M^T^0-<_[G?\ %]OS^H_HJ;&TZ6#^VX_-(>6W]\E/;Z>W'B'KN\<UROU\MAU=
MFW5Y_4,-,3C8_ACMI*;>+ _"Q5NN/).@S\&P5L\G::NUE%Y![# YAHO(5-?1
M\WC6>=1B+]S%6SOPAW!F2U/L91K]JD]:K.:<STD2F.5T%3%(S11Q3F$(LHXD
ME-/=*Q%=T80V#QV$L1,L<:G)H9!#-*2\:W@D2TC2)Q QC)431^'$VA7 8*02
M=#W1F.-A;>'#_<9NP6:8R!!V&9C/HBNK-)W&Q2<M8[ Z>\,-7CL>P\+/L*Q7
M R(I6\XQ<]#HV\T&P?S"I6=GMCJ1CI0\Z]U],<Q@AB@%)/&':$1QTR+"D*G-
MYI:DR1-)(*9I*"2-C$9'5(M**2RA,9DJT<DS2R31N4#B3B%W=SW#%% %<(HE
MT50-G(6[79U4$D9'94_!]_/E*<I6.,9-Z!79GB5C!F5([))4UJ?1\+K67$DO
M3IL';N*]TQK4K(2MD&5>M%%BJ5=K),$:VLF@? EJ:^E6CBJ:JM[KFCRQS$LM
M(0\]37B',(ZB'A\3@F$\.G*W%E9U-]6G)6&CG:H>*& TZ-66=TE%HX:,R4K1
M22-8R<5=4H!+$L 5( O;62I?@U@(ZY2V.*MCZ9?1M4M9,6LYB;L4T:;;.+AA
MAE47=K@&+&%3;6MG5G.2I+NK!8/;Y1^VG4+!#&@FU06?7Z*//9)$2KGJ$1IH
M35M$*>$<1(*LRK'-*TD<D;&.DC"I%PM#0LC*S/HL5+98$=J>*$D(XIA)(9+Q
MEX!&7542Q774, Y8AU>]PJ:]:.)FOX_J4M4HFEP1(.1LD(EE:S1"R,NWDJ*O
MDIA$RL-B5=*9$KD[*B1C0KZ.?*)&=2#>U=XY=NRIMQ2V^425,J3/43F6.!NX
M8'&ADJ6HG>*6O$B$J34/<, JC5&;*!8G#KTAC>-88PC2+W3(ES>%:E1)'2@7
M-N"@# DWL^^YMC6#6VQAG]GEL>5_/SPTPW\]O';KYCEY;;^3;'J1[#%_;&L!
M_P#TN6/]S.0=<ETY_BS7?Z6B_P"*BQO.C?XZI!_[$_KA?ZL:_>R%_P ./BN_
MCWR-_M"[UL^CGX@RC\QI_P"@BQ@YI^,LP_.ZC^FD]OKQIQK=8P>?/U>FV_4>
M1[?%AIAYO;Q_JOAIAU^WB]'ZCAIA[=6_B]NW;#3"^W7:U]OHZ[X:8>WS^,'V
MV[<-,+\^OQ=?9SO;>U\-,/K]O5ZL-,.L >CQ"_+JYGK^C;]"7]#Z_OG\4H__
M "4A]_@]T+WX^H!X_P WG/NC6[ERCM[M;_<;]?H\F.NZ(_O^8_FZ;^5M[>/L
M\9Q^?);^RJ?Z:G_C-KT4<E_S%^=L<@.;>,@>@#]>/EJ<5?K]M_V8:8@7V]?[
M3Z^OZ6F _;Y>?KOAIB<-,1Y/;??E?VY^)IA;R[^:W/;:W+S[^G#3$X:8B_MR
M/H-O+AIAOOZOJ]K<^9PTP_8.OT^CK^<X:8>G?TCKZO1])ZP<Q //3#D.VUR?
M-]/J\F/T,<6?]HMX(M_\Y\/Y '_JN=/#EX^7P>.VO-LE_C]GOYM/M_XE!\WT
MXZ_,?XKY7;;[[#Z--5MZ,?GGUZ3CD/8_LW]O6TPW_5U]=P>KR>/KPTPN/1;Z
M]^P=M[=>&F)QF.B80MF1H8\E6).IN)=526")I3B>*WN$ZUK[=@ZL$FP8>BJ1
MK&/AVTD@NHK8Y>"5E2(2):ZA,J1,H1G@5.8P4L@25*@1@1\2J6%GIXFFN(8W
M*_?C)(ZE-,4,AC8J9N&A+C(@I)JD7B:)G.HK"742NL=M;H+Z0@N""[@FQT@D
M6/8E,#7ROUBSVN>+7V$;78F.ED2H6>O3+B=;2,Q2HDJL(C!R<BHZ9MAOD,NZ
ME.R$8DH5Q&B[]LT3M"Q'F=-+-%!$)7>622-@T3Q\$QI,YXNL*%9A3S*B7+L4
M)*A"&-+TLJI)*Q15C57MJ!+JQB4%=)-UO*FY "EB#9@1BUY#&-EBY]A7'8L@
MD)+'\9DIL+87[]'W.2^.D\H,^]!A'N7*;SW,JIB[*+864>\%3T]\VCF[F21O
MK5QM&TH#:$JFI"&T@\5:P4).[CP.,=0-[F/?3J\#%#0R*XC\'4T"3K;40(V@
M%0+V79A&0"/P0P.^D:CVE\*YB:S,577.*<CMYZ<1D'$+"KTBRI2LLA$&[,JM
M'1YXPKMZC&#M[8*MD5$V8&*+@R8& =4K7T+1O**RDX494/(:F#0A?= SB0JI
M87*W-B%8@G2;5&FJ%=8S3S!VUZ5,;(6T&S6X@0FQM?KW%Q<B^.G;1TP=.6+Y
MLX9/6;A9H\9NT5&SIJZ;J&1<-G+=8I%4%T%B'2615(51-0AB'*!BB 909656
M1E=& 974W5E.X96Y,K#=66ZL"&4D$'%G<$@JRL#9E8 ,IZU(O<$&UQN;[<^7
M7U.&WT]G+K]NKQ'#3 ^+S\NR_CMY[#GXCAIB<;-\%?\ #!X6O^T+AO\ WA5[
M6MSK\39M_-M9_0/C*R_\8T'Y[3#_ /50]7T]@.-Q?9K_ .V&Y;\O<YB[_=Y7
M_P"?6DZ#?Q;I/])4=G_::CVW^:V-CTD_'57Y(;_[/!CR?UUN-&.KGY_I]K8:
M8'ZO)XNK]G/#3$_-Y?;Y_-AIB.6^_+K[-^L_2?+S-\^-N'#(<G"0D]7G5-LS
M68 B+E*&ML656 EUXZ$E6=<F',L:*BUK ]9V2$*A'U^1G03E'P5UXLULK5]#
MM=9WVIEDDCE2I@*'P3+ WWY TB/+&L9DD$2-$X9IDB)4!U5HV#8RQ13LJ,AB
MD#7#:)D/#?8\-R2%+$.A B:0 MHOJ5E% ?89M#2Q*U=%]7G\BVQQ*9-=+Q\P
MVD(LL#"U&0NLF@VE8T7S%\_1B(QTFDFU6.@J^*5J9PD;O!3O)F$+Q<7ARHK5
MB4(#)H<RM,L(UI(5= &(9KC4%OX);;%HTTBOP[IJ$!J-F# 1K$TA"LH(8Z00
M-R+FW+PL4>O8GR'<&,:]IE1LES4DU9<B<?5*W8YY^V)"JQ2#MPZ)'Q"S;N#N
M)I@@F=JZ=&264*D](T.NS!S7+6TL#.L\\4&@1G5-)'&C&4.RA2[J;A4)8$;#
M>Y4,5I2&:14>.-Y-6KP8T=B "@N3IT;EAR:_B%P&H;JC75E7$KB\J-F:5):2
M4ATK.Z@91O7U)=$RY%8LDRLU)''D$CM71%&97 N"':N2&3 R"H$NK44[R\!*
MB!YM.OA)+&9=! (<QE@X6Q%[J" 02+$7I,<JIQ6BE6,D 2-&X0[VL'TZ3O?^
M4=[XM;5W%/L.9V]-M^H]7+#3$^/R_K]NK#3$=?/V]K^PPTQ/M[>WIQ^F+^AQ
MOW1<6VWV%PM_^]D_7EWNE_O>3_Y]=_NTF.VZ'?A5W_E_FGQ^I;7E&.ZPTPQ^
M3'^B*/W[.'?^*VS_ .U1?T]6O7_<U_@.:?G<']"^//.F/\+H_P#0/_2ICPYX
M?J;4[_F*AU*]^WON.EY=4+*%8=,F5A/#L8U])O4X9W(LI%BVD%$F1DVRSQBZ
M;D4. JHG* [=WFE1/2Y=65%,(S411C@\;48^(Y"+K"D$A2;\['D<<S1Q1S5=
M/#*6$3O]\T6XFD*S,%)N+D*=^?,XVD5X+&2%+DD5YV7"_IYFD(6*?,V2TQ5Y
M'"K.I9;E(J[-(V-CSR"CRW2^)YLT+)2$M#UAE#^B2,Z_C(ATO.,--[X3W0K+
M#&U-W 9)8F81RQYB:JCB>FXC-;1!%60AE6-YS,S*$<H$.P[U?>6NSF451174
M&2-J413L)0BB]W:G8H[,D9C8EF47865+\'9ZV,W[H\N4Z-"-:6R98$:Q%EFA
MF*U3*-CC(\K*-W,4Q<QJ3QW5LEQ 0S )!=H^G&,C'N)=A&^ASCG)CSP3+ T5
M%.ZS/#!J,\,>F:HGJ*:('6/"4S4S%FTQVB=7"E[PI9;*WCXG$JH@8XYIR%CD
M<F.%()7N%'@MPYQI6Y!D5QK8 .?A*\(85MO<7%HRW4XH*6WN4T]3;5ZX2BK^
MJTJ^UG'[V8C@2BT$Q>2\K;X5:!AWIV:BJ 2GMT\@Q9-COT>>\=HUAR^=VF-,
MFEIHH^%45-,]1P')'X,?!D65PMT)0 ,6L(?+C$I,M5&@19G)$;L'BAF6$R)>
MQU.9$,:D@. UV73X7=^DANQK<?&Z=VI9LCG?2AF%>,2P$BW]<A\YN>'YY/\
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M-K>?R]>&F)W]0^GT>W.V/TP_T./^Z'BWV^PF%_\ ][)_Q_)SUY=[I?[WD_\
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M'$JX9HS'9])5@A661I#?=\N2/@HM/)$98X5#DAV5<PJ+RRZ=#G1 T9#DK<,
MX9$"XMYE1^"N-@ZDX7=0%@208HNWDB^OA8R2L-G1KUO=6*L6)I$9/4G&4"UF
MF44P@I)KC+'R#DJ4"JPN=F&P*I2-Y:GI%+)-<20EB40)3ZHX5=Z9(980:0Q"
M1DD8,)*FI=26!ACT@M:,65HD5M,@"ZFURZ6D=5E9HY#QA(5+J+<.*)2 ")&+
M$+5<8XJX9;]!TX743BT;C.+Q]F+6H7(<Y%(K-Y"EY,L%EJ$NH_S78[='0])E
MVM0CY%]*4>B/XEO'"Z:6J^1:LM8WU-769O3/4!)*T0*)H1-)3)(R,DU+%%.H
MAHDA;N@R2R(4FG5]?AI"^E173P9?*D998#)<2<-964.!#([Q.6GDD41.%7PX
MHB%!*LZC4<735!P&M3;W;486NLYW&-1KTW:("I7*=L5.F+CDFLR--CZA5;,2
MRV)E)(8[OB-0OSM)E9Y1:3CYF_PPS4M$UEBDSS8JG,NZJ:#6[PUM1/%32S0Q
MQU$5+1U"RFIGATQ$=U48EIU!B2SK$P0-(QQCR04?"GE 424\,;2+&[M$TT\1
MC$,;G4"8:DI-^&;IQ!<B/>PL65K",CB\CVXDI0OE6V4E;98)>]O(;(=5G8JM
MM7.'HBE4A.RQR%F@;?;!;Q=EE2U"VF8QS^P+/I*G(PC*8+D5TN8K5E8#4:/W
M%W/"E-$]-*LCGO@]34-&6BE@74T0$T9!5#''*SE19IXZ,P S<($=T"65I625
M"J TBQ1@E764@!R8R+LPD9%56.&,XK493+>0V^-(2#@:!%VZ?A:<VKTK.SD:
M^K</*NXZ%FPEK%-S[^0=3<:W:R;MXD^3CG+ARHM&,(]D=%HEL: 5 H:4U4LD
MU1)!%+,SI%&1*Z*[H4ACC5.&7T@6)(%R;\\>IX1JIA"B)$CND81G<%%=E5@S
ML[$,%U;GF=ML8HUEXM>U_;V[>K'Z8OZ'&YV+BV_ZDPO_ /O9/UY=[I?[WD_^
M?7?[M)CMNAWX5=_Y?YI\?J6UY1CNL-,,?DP_HBGGFSAW_BNL_P!ZUE'7K_N:
M_P !S3\[@_H7QYYTR_A='_H'V_\ $3Y_HQ^=;7I..1]6_I\>WGY^?MQ(#L._
MZ>0]/'RYAIV^3EV^+Z?*!B#OL.T7\7(^P\>-\S\9[(T>1+W!.5)A*E3F-B2K
MF<06(?'DA@J5Q\QIRS,(PG>1".4YR2RF_3%QL]W:1)"-W#8)(_.#(6#2$52A
M'E$Y4QL3W3WP2I:IN&MQ#211TH!!'X;$V:V-OWT!T_N?<(([ZU!X/<IA$5].
MH)QGDG/,E@J]IQ\+QQALYJM95@ZI$7V+>95=7BPN9R>NR,G+UB=R#DS"M\EX
M&">Q\1%KFIL>TQ$>+;(J';O9-S.E>O$VR4<+5X@R$B:EDJ)*1DI>#'PH*7AI
M+%!35L,;R*[2*9F:L+27N L=E8DJ5IDS*\<R1+.K3-+)Q&G#-&TDU/*40A5(
MC7@:5&Q\.YY$&[9+CCK\I89&:5H=G8H.+ YGFC>)M[-D[;KR.3^)JV.E4GAH
M%P5I*QM<XD')JU,HME58B\TB$GCLW;%P=BVL#HY(L,,8J8"T<"PLSP,X;13Y
M3"&*ZP6627*^)(I8$QU#J#K4$W&S56>5N!(H=R_@3!&!,U<]P^DV(CK+*=/@
MR1AB-)MBU5.,5DQC:-6(6 MRE:HSAHD9:8M2"L[<V$?2;76X]>W*M(U%BZ?Q
MLA;%QA4^Y<(0M8BH6O)*NUF'MJO>.0-(U3++/"9:E.4=.1%#(:N"=C&&8L%*
M0#\'2QFDE<D*Y3$=]+<)4CET0G^^3!I)%$4R 2-ITM8S$ 6LJ)&N^@'%?J_%
M' WF1N]5NKN0JD!>F[Q%"R25IF$GM28)8]J=43BZQ*1=2MJ\*_EUZ9'LG*WM
M >(D*P[?U615BD'Y9N/HFR62%::6!8ZB6 ^%$(%9)V>HDF>2>-JFF,JJ)I64
M!BRRNC ^ 0T1Y@CM*DI>(26*RF5@\(6GCA"QNM//H+\-%8A1="RG9KC6'B2N
M5?R!G'(]MJLE(3->E9U,L3,RB[QU(3#2-C&,266=.I".AI!VK)&8F>^ER$-#
MOW15RN'D5'.5%62&XRN"6FRZEAG54F5"TB( %C9Y))"@"LRKIU@%59E!! 9A
M9C@UDD<U942PW,3, A;F5544$W .X6]R!<$;#EC!VL_&./;V\?KQN9['?_#E
MX4O'^OICS_S]K^#K]_6DZ2_Q>SK^;JG_ ',;')_QME_7^Z8NK_VU\WC\6_BQ
MOA[/S_#@@OXA:%_M/D'7/^YW_%]OS^H_HJ;&TZ6?C<?F</\ 22X\8JG9)&FV
MFM6^([CVVJM@AK)%^DI]\V]L8*1;2C+TA(#%%5'TEJEWJ8&*)R=HO:#?<.WF
MB6:*6%[Z)HWB;38,%D4J2I((!L=K@^,6QSL;&-XY%W:.1)%U<M2,& -K;$C?
MRXV/:YFQ)3YN8M>,J!?(6U62,RJT<3,[?6[UQ4T<C8NOE!1@*F:#@8(KJ/8R
MEU)/2,Y.)+SC]I 1,5'%A#GFG\UJN]];-&D%;44TT,)HRJ1TK**@4E93U&NH
M5Y)+2O'3&((A:-#*[AC?0F6*N"*1I((ID>05%W:H#&+NBGFAM$0BG0&EXFIR
M7;2JD@6)R2;C-:K8_>59:KS",T%67K[:535I4F$ZXG<"8ZPE9'MD>V2FS<VC
MWA:(O.)*0;]F^?-)<L.=Y%OX]*Q'P6Z.L:KN@3H8FE1S&T<BF+AUU5711QF*
MH5'5EG42!XPMTU(M@$Q?7-1P.$8I-81TU*ZD-KIH*>0OQ%<J]HF9"EVTM8E2
M2^.K,<:TI+62S3CR$FY9A-W?-UQ0KL_9EI.%[.4K=1;7"1$HR4;E1>L:XK2R
M-G)"II%> Z349E8"W #74R"...- T*E(,OA+Q0A9#W)#51SNK +9JEIUD/-K
MJ TAMA)FKN23&Y!DJI"K2'2./-%+&"=[B+AD=EFN$6UFK\#QEU6N3"2C2L9(
MF8A&R)7H'EGOD;*VQ6RFS?B_+R\*YEDZ\V07J+9/'*\4U3]%2?J3EIG;4;T<
M'ZT(6V^03R1M>6@20QM3G@TS)!P6H:VB,@0REQ-KG61V-DT1Q1@G3JP3-8E=
M3HJ9(PZR#B37D+"IIJ@J2$TM&!%H12 =;R2$[A!T<:<:X4ZOUR(G8"P2DM76
ME9=^ZUN_JDI8W\Y3\H9JR#&-C.KU4K>V9Q+Q', M%7:;1S(QLM6V4FBG(-'*
M\6$UG1YJB61X7IXA(TH,&F>&)8YZ2DA=@*=T)DCDI"RKJ".DS$N&&\TV:\**
M-7B=V14 DO'+(Q2:>4 F5' 5EF"DZ6(,8\'2;+RQKQG0]3MT9:K-4K1/&K;7
MAS2K4<VLL>,8Q2P?3R5N7BF\+-0\M68E"W20GFV$XT@',U5$A?1D,9NK/R4J
ME35='Y)H6ABJ84+OF1D=X7,A[NG2:-N(DHE+PA2AC:;@R7U%1;>J/-0)>+)"
M[%5I B+*I0&FA,;+H9"FF0GB7X?$0@ ,02#78[B)QN:T8WK[>9FBUMY"\/T;
ME&8N\M)/J1&U7'V!9?'5_J-3K<-4GMACW]DC+K<*DLX32D&?MD4RK%9:+L!Y
M&,H.4U:Q54K1Q<6-\S:CCIH$2JGEGS!ZFFGFE:7AZ(Y(X94!TL$V87%C4:^!
MIH(U=S&RT@J#+(SPA(Z=H)XDC$:D:XY'!-V!95 VWQHWDNY#D"^6BWE9%BV4
MQ**&AH8A@,C 5MBDE&5>N-S!U:5RN,HN#9^ -8](-=%20"FIX8=1=D0<21OP
MI)6.N61O')*6<CJ)MU8U4THFF>4*%#,="@'2B+X**+W(L@ Y[VQZ'^PQ?VQK
M ?GZ+EC_ ',Y!V_'KFNG/\6:[_2T7_%18V_1O\=TO^9/_0R>WL<:^^R%?PY.
M*_\ CVR+_M"\_3I_-L^CGX@RC\QI_P"@BQ@9I^,\P_.ZC^FD\U[VYXTYUNL8
M?M]6&X^>A)/,WVMOV;[>3<[>,]N(L.5K;WM8>8_2#XNT'#4W/:>1'F-[CR&Y
MOVW.%AV"VQ'M\Q\W(##<?,=1<[[\^?C\O;S//MP  Z@.S8"WM[>-I[?/]9])
M[<1X["U[]5O+R._7Y!N1OBK04].5B5:3E;FI>O33 RAV4Q!2+R)E69U4CH*&
M:2#!9N[;F415414%%8@G2443-N0YBC2\<<JE)45T)!974,IL;@D$$7!-P;7!
MW&^*@SJ0R,58 V()!WY[C<;7Y'?R8Z3QX[D'CJ0?NG+Y\]<+.WCUXNJY>.W3
MA0RR[ITY6.=9PY75.95==4YU553&44.8YA$9550!4 10  % 4     #8
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M((6EB"K',U.'$#2H$0+(T98:5-[C$K4U"HL:RD*$,8)"&01DEF192#( 2Q+
M-8W%[VQ4K5Q#YAND;+P]AMY%XR>7G'DTTCJU4*\G*2%GL%,M5CE'QJY 1*CF
M7G;'CRF3$M+JG-)OWL U5<NU.^> YI@RRBIV1XH2&3A!"\LTI188IX(40R2.
M5CBBJ9TCC4A$5R% L+5RU=5,K*\I(8L6"JD89G>-W8A% U.T,;,UKL44D[8M
MB]Y4OF3%FR]UFT9=9L]E9054(2OPJCZ:G3-#3MBFCP$5%FL%HG3,&)INT3HR
M-AES-&PR,FY%%/LWJ6DIZ._<R&.XC4 R2R!(X@XBBC$KN(XHQ(X2--**#95
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M_P T'GY=/?-T?^.*']+_ %<.\V<?%]1^C/UXCWN+CL^U5S/\T'GY=/?-T?\
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M57,WS0>?ET]\W1_XXH?TO]7#O-G'Q?4?HS]>'O<7'9]JKF;YH//RZ>^;H_\
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MS)^@4QS(J*( DX260.HD>Y%--"Q>&0QL4DC8@ DI(A1UW!V*D@VW\8Q2R*X
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MVEX=2N@ZJB&"+5QI-*M3T\5.D[1&Z23+PN+'(=+1RL3=E 7%H4JW0ZOP"Q_
M759I>)I#VU*I_!90;,-[ DWNC&_!NRQQ<KC)QF19=+'%\IEOK=CP_"Q'N;I@
MR]HG%C-;'$LV$TI&12M<H:<)CV*(C"'F31L TD'5C55=2#5S;GS%IXXE,2B>
M&6*1*ER));1Q*IC9F4,RO,K3LNO3=RND@(RUK"%)\(Z&5E9!<"Q/@D&YTE5\
M';Z!C#R?L:T%.!04<F9AL]Y9XO@<8X_I:,= -* Y0Q=BMK;D(2$EY2I3#62=
MW245M*#B:O4.ZKS<AX&/" JD"+J4.]S#GTJF9J>GC@:HEJJB4EC,IJ*MH6D9
M8Y5,0B40A8X61[!G#N]P!;[E#$<1RP 10 -%T3645BIN;%SOML+6OOCN4'V-
MFET*RXZNC7(<M)6G&#_$_N?<N*Q$-(&1@<61%GK:4?9J;'NV]7E)Z=AK($FI
M<VD9%SD#?(QK<H S$'#^$=4SYY-/#44Y@C2&I[J+J&8E6J7BD&AR-:QQM&5$
M)+1M$W"9=*H1"4:J8VU'5%PM&QL!$ACL1>YN#<$FX8!C<X]*M:/&8-@!V8:8
M8:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:8
M8:88:88@Q@*&X[_$&^F&,<WS*M-QVS.M/R6[X4A.UA6!/3)=X([]@$FB9@!$
MAQ#LE</%&S4#<A6WY#H<ZZ293D,1DKJB\I4M'2P#BU4M@2 L8("@VL))6CBO
MS?'2]'>B6>=)YQ%EE(3"'"RUM0W HH-P&+SL#K* ZC%"LLQ )6,X\Z<M\2.7
M;ZFZB*B"^/ZZMVDS'BUS*69XB(B @YFBE2,P*H4=^ZAR-ETQ#L'D7*8B77SW
MTOZ>=+L_62CR=_>_ES@HS4TI;,IT-P=5851J96&^FD$,HW#3.+JWT[T+]RCH
M=T?,5;GQ3I)FB6?AU,>C*8'%B.'1EF[K*$$:ZPR1N#?N2)@"-:Z MDS&$V>>
MI5AEX9XX5!601*J=S'RQNT)A"7CW7?-)$#B([J.$CN"=HYD%DE1!0/,^CM)T
MEZ*UKU^1YG4T4\[B2J7BB6GJWOJO64\HDAJ23?PY$:5=3%'1B3CU3I)2]$NE
ME F79YE-%6011\.ED6,055"FD*!154/#FI@+ \.-UB;0@DC=0%QZ28NXKFDR
M1K%Y,BAK$L/83&=CRN'%==G#8.TL@85GT2)^>X*'?-@V,=1TB4>P'TIT8]TQ
M*T1TO2*D7+:L*H:MIBTF73-^#J*-JFI-1-]+F95L2TJK8#Y8Z7^XW59<TM9T
M6K3F]$"6[WU&B/-(4)-@KJ5IZW2+_@""0[*L#MX1W#9OF4@W1>,73=XT<$*H
M@Y:JD7063-^Q.DLD)DSE'P,4PAZ]>K12Q3QK+#(DL;BZ21L'1@>L,I(/IQXI
M-#+3RO!/%)#-&Q62*5&CD1AS5D<!E/B(&.UUU<Q;PTPPTPPTPPTPPTPPTPPT
MPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPQP4532(=14Y$TTBB=0YS 0A"%#<QS
MF-L4I2AS,81 "AS$0#5+,J@LQ 502Q) "@;DL3L !N23L+GD,2H+,%4%F8A5
M4 EF)-@ !N23L !N>6-/\E<:^(Z#+MX6/-*7IT1T5*86JB;99A$HE,)53^V+
MQPU9R3DH_L6L>JLF(D4(L[;G I3>.=*/=NZ)='JV*@IEK.D$HG$=<^4")Z>B
MC_EOW1,\<-5*I("PT[NI(</+&Z!6]HZ+>X1TVZ2T4F83)2Y! 8#)1+G+2PU%
M;(?P$%+%'+/31-:YGJ8T-BICBD5BRY_Q[E>@Y2BRRM)L3.82*4HNV9>VWE(X
MY@ >ZD8QP5-ZS-N.Q3*H@BKL)D552;&'T7H]TIR+I31K79)F$-9$5N\8)CJ(
M#UK/32A)HC?8%T"OL49@03YSTDZ)=(>B58:+/\LJ*"4DB*5E$E+4@?RJ6KB+
MT]0MMVX<C%.4@5@0,B!S^_\ >';70#< ]N.<PTPPTPPTPPTPPTPPTPPTPPTP
MPTPPTPPTPPTPPTPPTPQQ[0;B'/EU'LCL'WOYM1?MV\MO3S_7XL+_ %>W9BQ;
M;E''=#2,K;[E7X'LAOZ.^D4"OC\NB,>F91\N8>@%1;J&$>6VM%FW2?H]D2,^
M;YQE]#I!)2>IC$QL+V2!6:>1K V5(V8VY8W^3=%NDG2%PF2Y)F69$D>'34LK
M0K?KDJ&58(U'6TDB@=9QJA<>/G$L$N+:LQ-MNR@&W,Z9,20<8  82FV7FSMY
M P[ )B 2*%(_U("L4!$P>1YU_9 ]%,O8QY5E^<YZP(O+%3K04@%S<)+7%*AG
MM9@.Y>&01:0;C'L&2?V.?3?,D$N9U.3Y A%Q%5535E6;K<$Q9>LT"K?9@]6D
M@/\ >R.=V4GC;P=:2I(RDI,4I\IV2BWM,2X3;]L2@)A"3BAE(U)+M;@51VY:
MB.PB)"AK<Y%[N'0?. JU5169%4-L8<WIG5 0!X7=5(:FD5"20&DFB)TDLB[8
MTV?>X-[H63,[T]#29[3J+B;)ZN.1R/"V%'5=S5A>P!*QPS#<!68WMM%!6BMV
M=J1]7)Z(GF9P Q7,1(-9%#8>?U2C554I!\P.)1#H( .O4Z+,LNS*(3Y?74E=
M";6EI)XJA#?EX43.-^K?<;\L>3U^69EE4QI\SH*W+YU)!AK:::ED!',:)D1M
MNO;%;[91^7;H/CM][GUZ:S;CV^OEOZ=QC!QRU.&&F&&F&&F&&F&&F&&F&&F&
M&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&.D]
MD&L>D*KE3LA_<D* G5./D1,NYAW\^10\1 -6I)HXA=V [!S)\@&Y\V+T%/+4
M.$B74>LDA54=I8[=8VO>W(8Q!:+/9Y5-1G!$4AFI@$HN]@/(J%'<!$AP R;0
M# /_ +,#K%'F1<H].<KZ[,)PT5(#3(1;C;<=MCX2\U3MZSRL>9QVN4Y/E-*R
M3YDZ5T@W%/<BF4CD'%U:8>)K(1<,I'/!+G%QGBZKEVF=TY7.919PX,JLNJ<X
M[F.HJH8RBAC#S,)S"(^/AKC7Z-B1VDE!DD<DO(YU.S$ %BWX1)MOO9AX+ I9
M1Z+%TN$$:0P.D,40"QQ1!(XT4"P544A5 '( "WIQ\/H2H?\ NA/^X;\NJ?>R
MG^+\W7YL7??I+_V@_P"L/^;#Z$J'@T)_W#:>]A+WT"X\2_5@>FDO(U#?ZUC_
M +U\3]"9$.0-2!OM_<&'H.X#SW !^#KML.^H/1B-N<:GMV OM8$V -P.79B/
M?G)UU!/E;Q6M?5>WGY[C>V+OJL%8Z8MVX%XNU;F/WBT>?MJQK@>7:%9HH84P
M4,&P=\EW:^P; J :VV74=?E3#N29EC+7>$E3$][7^]VT@@7W72=]R=K:+.:[
M*L^2V8PQRS!=,=4NE*J.U[ 2K9F0;GAN62_\G<XV%@K:#U,B,JV&/>;  G*(
MG9K&Y<TU! #);[[]E4.R4.0*G'7:4N8"4!9TX,G(V.J,GJWYJ3O8';QG'FE?
MDS4[,U)**J"YML%G3Q.@N&[ R$WYZ5Q>8" @ @(" AN @.X"'F AR$-;.X/(
MWQH]QL001S!Y@]A\8Q.F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&
M&F&,277+L'5"*H,D5;#,$ Q2Q\>8"H)*?W(/9$2G1;@ AL8B)'+D-^;<"[G#
MF\VZ2TF6JZ0HU=5C9:>!E4!K7^^S,"J =>D2-R\&UR.PR'H9F><LDDSQY;1-
MN:JJ5M;KM<P4P(DE/.S,8HC:PDO8-HIDVPY0RF*S2;D58^!4-L%<A@49Q9R
M;<H/A XN9,X;%$PO5E4"J%[Q!!#?8/&.DL_27I0KP5E0:?+G(/>^F5X8"!_E
M['BU##KXSM&&&J..,G'T/T2RCHCT0X<]%3I69FHWS2N"S5*L0+]S+;A4B\P.
M"@E()6262U\8.^@R;_W4VP<MNP _AW$>OP??UQ'O#2P&A;#Q';EXSSY_5CT/
MW\K_ )?UG%6A,;SM;DF\Q7WDC"RC0V[9_&KJ,W20[;& JR)R'$AP^I4(8PIJ
M%^H.4Q!$HY=#T2J<LJ4K,OGEHJJ,AEJ*:22&6X%OPT8,01LRMX+#P2"I8'!S
M#I-EN;4DM#F<%-7T<PM+3U<2SQ/O<$HX(#*=U90&4^$"&WQNSCO.MNCTF\7D
M&.]MD2 5(M@C&Y$9  #JI(1Z8$:.1W$1,HR]%4 @ (-%SF[0^S9%TPS2!8Z;
M/8!5*/ &84L8CE%@+=T0>#$[G<ZH>'<6 B9KW\ Z3^YWD\[RU?1>J[C))<Y9
M62,].223HI:IBTT=AR6I$JDFQGC7EME#SD5/,ROHI\@];F_NDA$ITQ'F!%D3
M[+(J '4BI"' =_J=>D4M73UD8EIY4E0@&Z-<B]]F4@,AVY, <>.UM!69?,U/
M6T\E/*+^#(M@P'\I&%TD7<69&9=^>*MK)QB8:88:88:88:88:88:88:88:88
M;@'4=M,,=1X_91Z0KOG;9FB "(JN5TD$P  W_9*G*'/PV'5N66*%=<LB1J/Y
M4CJ@\EV^C?;%V&">H8)!#+,Y_DQ1M(WH4$XQA.9FIL.4Y4%WLTX)N'<1#)14
MIC!R#9TY,U9]G?J)5E.7, ,&M#5])\LI0P5Y:IP!9*:)WNQY#B-HC'EU''5Y
M?T'SZN*EX8:"(\Y:Z98RHMS,,8DGOXN%Y;;VPE9.(>[N .C5:C'1Q! =GDTN
MO)+B CN E:-18(HG /[DZKHGK-KD*_IMG$MTRS+(*<&ZB2L=IY2;<Q%%PXDM
M^%<O,AL5ZPP[_*_<QR..SYSG<]001>GH(DITVY@SR\=W4[VTI$W7<<AKM:)_
M-%O!9.6NL\DU6W [&&5)!,A(;?\ I1DHDK,ZZ8 .P^E'7,8/V9C>' YG/TOS
M<,M5G5;'$U[PTC=P1, ;V*T?!9UO<#BL[&Q#&VV/3,GRCH#D@1J3(<OEF3E4
M9@K9C.6 MKU5AFC1CV0I&HZEON<-GPXLHH951%114YNT=0XB=0YA$![1CF,)
MS#OXF$1Z\]<:W08.69UU,V[%P78DWN;L22=SN3>_6<=ZG3:*-52-T1%%E1 %
M50 18*  !8VL /3C@.&3]?13#N/^* C\8B(C\HZI]X<?(1+RVV.WBY^;>^*A
MTY0<I@/)MR\0 &'T&#;[^C&]6P &P^?(0Y_#RT]X<>UXUV((N@._;?GMUB]O
M$<3[^EM;C#S[^;?;'?C<72T*Z(^B'$C%ODS 9-['.G#)TD8-Q Q'#95-0H@/
M]T!MPWVWV$=9%-T.GHI1/1334DZWT34SR02KN+A9(BC7-N9)([1RQBU?2R@S
M"%J>OAI*VG9=+054$=1"X_\ :CE1U/;N+>?&?*OD?.58%,@65>?;)@  ULS1
M.5 VVW[)\ MY8V^WC(B7GOV1UWN6YUTTRRRC,>[XQ8:,QC%0+"^W$'"J-^TS
MWVZL>:YOT3]SW-M3#*URR9B29LJF>EW/_=V$M&+<Q:F!OL3:UM@Z]Q$RABD3
MM=-42,  !WD [!=,X_XP1\@""J0 /4/3UQVWVW$.?<T/3BH.A<RREXF(LSTL
MH<:AL3PIA&+$[C34, -B;X\US/W,(%9FR?/8I$YK#F,+12#<[-44W%1B .8@
M2Y.X YYHA<GTV:[!49<C18^P>CR:2D<J!Q']CVG)2(&-X?TM8Y1$.0COKK*7
M/\KJ](CJ0CG^1.K0MZ&%N=A^%Y]P<<'7=%<^R_49J%IHU_OU(Z52$=MHB74'
M;\)!SY8OY-1-4A5$E"*)F#<JB9RG(8/,IBB)1#U@.VMPK*P#*0RGD5((/5<$
M$@XT#*R,5=65@;%6!5@>P@V(/EQSU.*<-,,-,,-,,-,,-,,-,,-,,-,,-,,-
M,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,="3?M8M@]DI!VWCXZ/:KO7
M[]VLDW:LF;5(Z[ITY<+&*D@W;HD.JNLJ8A$DR&.8Q2E$0J2.6>1(88WEFED2
M**.-6>2221@J)&B@L[LQ"JB@LS64"YQ1+-#3Q25%1)'#!!&\TTLKK'%%%$I>
M2261R$2-$4M([$*J@L2 #C'=<O6-KR]7:56[56TR*+87B[6#L,7+NTV@'32,
MY418N%U2-RJKI(BJ8@)@HJF&^ZA-[U9D>8T*B3,<JKZ-&8(DE92S0*S,I8*K
M31J2Q )TV#^"W@[7-C+NE649B[4^4YOE=?)&AD:&@K:>ID1%<(SND$LA"JY
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MOYNG>5?\EZS]>'OG?_'/^OA]#M+ZRG]S+^;IWE7_ "7K)_\ W8>^=_\ '/\
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MP99*28P].3?9)-2?ZKW(W.P##;KVQ<2,IVNR5PV41,(<Q*(*DW^'8IPW_P!
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M$N,JKFSI*:G:AI,NGJR4[JAJLPJJ:GC!C)?@5$.754D^F4*BB2FI]49:0E6
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M(I)=6)3AU;MX-B'53>UP>9SW.:G*\QZ+4D$<+QYYG<F6U32I(S10IE68UP>
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MZGU':V.2R/.*VOZ1],\LJ.%W+D=;DT%#H0"7AUN2TM;/QW!)=^Z)'*WMI0J
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MJCI:@<-@" )HI%4\F U+X)&.0Z#9/6Y'T?CH,P1$JES//JDA)%E BK\ZKJZ
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M(%=F*B8$68N%CBF1,RA>CZ)P9=4Y]20YKP.XG@S)I>Z94A@UQ9762P%Y'DC
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M-.B$E M0::DS^2HS8PS<*-:$Y-FD*FH3B(9XNZY:=>%IE^^&.319"ZYB -@
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M:O*1TE&,T[)D:&")L;MO';XO'[=O+LWY8@*2&(M90"UR ;%@HL"06-R+A02
M22+ D>DG#MD6P9:PICW(=KA'E>L=GA/3)B)>P"M740?-WKM@LNW@EK%;O08Y
M^9I[8Q(H6NRLG<6Z9O8^>EV#EL_<,4V]7M['&:3?L3? /X-#R-\,83QU4Y^%
MRCG>RR;0B$/=)NB/*XN#ELL=TWA:-'0LD8[=)0R[3NI)LLF4CI)$RH *R8'3
M-VQZ/-:^BJLBZ*T=.Q-5EM'F<5<IC9"LE3FU550#6RA9+T\B$E&8*Q*D*P-^
M.R#*J^BZ3=.,QJ8E2CSFOR2;+9!+$YFBH\BI*.H9DC8R1%:E)$"S*K,JAT+1
MLMLUG$0*/9*)AZ;!MX^/,0_#KFSL">S?;Q;X['&/,4R5,EZ/'2&/V!(RJK2-
ME38LDV/M<1)ZULTNTG3@TW-V/29Y"3=&4W_IYEA<<N]VUN,]I\SILSGASB4S
M9@L5$TLAE$Q,4E#324J\0<]%(T" ?R NC^3C0]&JG)ZO)X)\AA6GRMJC,$@C
M6$P*)8LQJHJQQ$=U$M:E1)<[OKUD#589%UJ,;[#3##3##3##3##3##3#&H7$
MGF[(6+;EBNN5-E%,H.Y,[2[E[+,T#(602R4W"V+',/"8PKS;'JY'->MMPB;?
M:;)%V2;9SL7'LZ')G6KK]@65D(9ACSN8\:_'+C7&.&XJTXKBL@6^9Q[CBR3-
M\7QED".;24K/8FIME1Q9/P[6T \;9/L%F?6ADZN<&S=M6[F$<L8["SJ77;0Y
MV!&_7;V[.OSVQE&T<7W&W637.?9X9IMM@X%NM*PU/B,;93:VN7:S%WXE*+ 1
M)9X+;*LG$A!)X3IUZL3EA5%EYJ&R2R@HJ#B5PA9^<FQ) %MP#<E0-QRN6L+7
MWN=NL W O"!GE6*-D)81D%Y88D!=4.\CRB)5#/8EY%(4$R+&0ZK: \27&KD+
M,57KM/G:U$4U[+5Z#K5S9X$R EC[)24?D]O'VS)1(V:MQ+)'5%I6YIG5I"JJ
M7)$7TI$C;86Y(P$LB4L?-RYCQ]7.VWIYVVO;TFQ;:P8+^&M[D,19;ZF7P3X0
M!4&P)!9<=."]D!XT+4X28-N'&&J4O*U##3AE&62DY'D0AY/(T9@M:;OKU:,G
MFKV2I,//Y+NM9"L.HJJ.V2]%=N%[](2<;9:]%R00;&U^NQ!M:X.XN#N/.-QL
M1>7C:-BK%206!TO'(+JS(?"C9EW920;D,NEUNCJQ[TY[(/Q"064;%C^<KM+I
MU90R03'L=E:U82RC[10Z\1.9/A)YPXK$!E*8F+4>8:TRNV: ;&?T:3C*_8DI
MB1BI*L/H>SNH]'I%_1>XOU'D=[7L<4V.E6V(8LH\)2UU"DDJ"6 \(68J%<A@
MA)1M.VO"YQ+9PS+?7M'R?B)MC%_6\64;)]O05;3J:T<GF"L4N;QS6&RDHLG^
MKT+-L<Z5._M';5-^Q>X_KK\T=#HV9)J$;[;>OEXL0>>Q_7X]_3C?74X8:88:
M88:88:88:88:88MVWO(F/JMD?SS3T^"8P,N\FF(H)N@>1+:/<K2346RIB(N
M<LR+(]PL<B2O>=VH8I#".LJBBJ)ZVCAI',=5-5TT5-(':/AU$DR)!)Q%\)-$
MI5M:W9;:@"0!C!S.:FI\MS">MBX]'!0U<U7#H64RTL5/(\\0B<A)3)$KIPV(
M5[Z2;''RI+Z&DZ=59*N,@CJ](5V$?04>#=)F#&&=QC5Q%M :('40:@V8J((@
MV14.DAV.[3,8A2CJK,8JFGS"O@K).+5PUE5#52ZVEXM3',Z3R<1@&DURJ[:V
M&I[ZC8DC%&43T=3E.65.7Q<"@J,OHIZ& 1K"(:.6FCDIHN"G@Q:(61>&O@I;
M2-ABY]8>-CAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAC#V3;
MA-5JTX9B(M1N1G=LA.Z[.@LW*LH>,0I-KG2%;*&$/1EO;"(9&,L4IC=T"B0
M'>"8.AR7+:6NH.DM34!S+E63QUM)I<JHG?-,OI"9%Y2*(:F6R'8-9OY..4Z0
MYO6Y;FG1&DI3&(<YSZ3+Z[6@=FIER?-*T+&UP8VX])"=8W*AE',XS  ;!MKG
M1R%^=M_+CJ\:3\1O!_\ 1[R;0,B)W"!A JBF.49)C8: 2Z2;9EC?-=0S6R>X
MQG36> -C:US\I4T:[9+$,?9R2$(,4)8Q%U M5%YPY>W;M[?3C6_&?L5E:H%5
MJ=86R:=R6OVVF%L3R%K4^P^B7AZK0<3$3F++VSL^1;JV6/DUQ6:@_P B3M?"
M!BI="KQ<2TJ3%D@D";#S>WB^;?T8HE8]B;BJW7G$$3+R;LZ(,VS-\]IMAF"6
M5A!QL\TA1RI%6/*4Y%7-_..9UP3*1H!K18G(,"K(0!(>O)/R.V;#V]N>*<_]
MB_L5CM5Y93-WQO#52U4A$BMGK&(46%LC[I/7CBHN$]!XP[R].#XNQA%*YX8,
M9"K+*6YU=*\64@UIV(5D9206;7W\5[;$@=5]_;Q7&)4BXU E01<!@I(VOI)#
M!21<7*L!STFV]5RG['3)5TD3?\2M:?>[Q$7.[VB7IUAI-:1K.0U[_E#*EZ*\
MR%"RMF@XS(9*0PRH\BZ_%3MJKYV4K#Q-ZCICTN$;TF:8IW]O8?-^N\VWL=DI
M+5[AP:6&\TB-D\1\/'#?AFT+L\;>Z"QDD<!6%G>"O\7WUQ98):EQ5LLC)O!V
MEFXJDJ:>I*;B-*$4]>).F#$]?[/5V>C;%GRGL3M;(X(%.R+!U9BUQ''X^B6R
MN-W<JA#33#!3_!+ARQKJ>08S'B] GHN4E+A8*++T65DWMRFI^71NC5Q)(JL!
MW/7YS?;D!?Q#R<NS;%3-J8GPK;!=1#,%&RJ6L+Z5 6X518   ;"AK>Q)$>QB
M,2^S' %0=57-U8G7C;%<P_D7#/,:N<WGH,+[K\M6V*C(RNR&=)Q9N]D(J9NZ
MS9@Y8L+I"MK-,D%8=G/GBG'K_6XYU#UV!B7RD8J]BX6+CG:L+&*0L,JY8L4&
MRZD3#*OY16)C3JI&,QC%).1.P:BDU._=F2%PHP]O;<^W5BSLMURK6RDOH*Z3
M(U^N.)&MNG<J5^QC!1=Q=GAI2(0],D4EFB8/IAFQ8BFHD)W(.?1T#$753.7;
MY%79AEV:05F60"IK(XJU(X3#)/J2HHJBGG/"A*R-PZ>662ZL I0.^I%93S_2
MC+LKS;)JBASBJ-%02SY?))4">&FTRTV8TE32IQ:A7B43544,)#*2XD,:%796
M&2BCN #Y@ _>UJ!N+_-N,=!B=,,-,,-,,-,,-,,-,,-,,-,,-,,-,,8TQ15:
MY2JI[05674G(D;!<)@)!5VR>F&0G;5+3,NT!>/22;B6/E)!VP*GV.^0!L"+@
MYW!%3:V^>YC69KF+5E?3"DJ329?3F%8IH0(J2AIZ:GDT3LTEYH(HYBQ.F3B:
MXP$(&.?Z,95E^392M!E=8:ZD6MS2H%0TT$Y,]9F555U47$IU2(]SU4TT&FVN
M/AZ)"9%8XR7K48Z##8.NP;^?WOP<M,,-@\M,,-,,-@\@TPPV#R#3#%BPN+\:
MUNWV3(->Q_2X*^7(B*5MND/5X6-M5G30! J))^?9LD967(F#5KV2OW2X?U,W
MWW[A+L/;T<L223N220 !<DV %@-^H   <@!8;8OK8/+3$8  !R -@\@TPQ!O
MV)O]$?P:6OMV[>G \C[?5\XQA7'EDLLME'.T'+.5UH&KS=%;55!5HB@DU;2M
M%C965(W<)MTE7@*RJZZJAUUG(HJ&%%,R292IATF;45!39'T5JJ8**ROI,SDS
M$B4R.SP9K44],70LW#(IHT"@!=0&H@FY/&Y!F.:5?2?IU0UC2&@RNOR2+*4:
M$1JD-5D-'5U8CD$2<8&LDE+L7E*.2EU "XS2<1*41#J'3EO][<-_@W#7-'<'
M>VQW\V.R/M[>O&/,4U> IE(CZ[6)8\W"M)&R.F\DH[9OCK.)>RR\S(I"Y8)(
MM3@SDI!XR*0B8'1*W!!<3.$U3#N,]S"MS3,YZW,*84E7)%1QR0+'-$$2FHJ:
MF@;ASDRKQ8(8Y26)#%RR> 5QH>C669?D^3T^7Y75M6T4,^8215+303EWJ<PJ
MJJH0RTZI$W!J9I80%4,@CT27D5B<BZU&-]AIAAIAAIAAIAAIAAIA@( /4 'X
M=,,-,,-@\M,,1L'D'R!IAB=@\OT#I\FF&*9(PL/+JQ2\K%1TFM!R9)J%6?LF
MSQ6(F$FCQ@G*QBCA)0[&138R+]F1ZU%)R5J]=MP5!%RL0[#'1A:E5:X_LDK7
MZW!0<G<9<E@MLC$1+".?6>=2C6$,E,V!VT017F)1.(BXV+3?R"CAR2/8,V95
M0;MD4R,,7#IAAIAAIAAIAAIAAIAAIABW;?'QLM5;'%3+OVOAY."EX^5?]\BV
M]"C7D>Y;/G?I#DBC=#T9JHJMWZY#HI=CO%2F(4P#E4,T]/6T5131\6IAJZ:6
MGBTL_%GCG1X8]">&_$D"II6S-?2I!(.,+,H*>JRZOIJN7@4M1154%5-K6/@T
M\L$B3R\1[I'PXF9^(X*I;4P*@X^=*C8J&J%6AX)[[90<3786,AI'TA!WZ?$L
M(QJTCGOI34I&SGTIHDDOZ0V3(W7[SO42%2.4-59A/45685]35QB&KJ*VJGJH
M@CQ\*HEG=YH]#W=-$C,FAR62VEB2#BWE%-2T64Y91T,QJ**DR^BIJ.<R)*9J
M6"FCBIY3+&!'*9(41^(@"/?4HTD8N;6'C8X:88:88:88:88:88:88:88:88:
M88:88:88:88:88:88:88PEF]M;R1]#L-.1EY!S4\E5>7G8.&.8'<Y5'AW5?G
MVG<@=,CDK)K,EF@16,"/:BP44,0$^V7HNCKY>9,UI,Q>F@CKLEKX*6KJ0.'2
M5\*I64<A<JQC$TE-W(SI9[5!4&Q(/(]+HLU$.25^4I5SR97T@RZKK:&C>TM=
MEDQEH*V(H2JS+#'6"L,;,!^YM8NRJ#FI/?L!OR'F AY;"(;<MNG3H'P!KG0;
M\_'\_P _;X\=:+=6.>F)PTPQB;.U;R!<,/Y"K&+)\M9O\U7';&LS1I1[!&;/
M5#)BJ@C8(UH_D:XYD&97,:ULD>Q>/Z\Y=I33-JX<L4DCL,>7>3>&WV0*S2B9
M\77EWBV#2I&3X:':/>)O+EOFXOW68YSY$5!C.S,F5Q'3-AKF0K?B6PM9P*T^
MF*TQJHD99)LQ8&,8/79Y_/?M\G5B=6RKI%UN-0!!:]C<F]O$.76-\9(LO#5Q
MALYZ[L*'E.?&O.(VVQF")V<X@<G&<X=EI29L,JC;+_$R4?9%\W-WC"7AHF(K
MEU>SZ=7]S@LXQU$LY/VQ8,1\WS^3]GFQ?/"SP\\2-*R#%VS-F2KG,U6#@+DG
M7:2\S?>;JUCI^>4I;%HK/-WP($MS5LTC+I)1!;G.7A2!=V8%XMQ' 2*AZFOS
M\>W(=M]NSES&]KCD3B02 P %F%C=038,K74D$J;J!J6Q*ZEN49@?1S3$8:88
M".P"(^ ;_)IAC$F8Z0^R94F]18/6+)!Q;*5*3:KL5S'/ UZU15@D6[(&Z2VS
M]V$25LU%P!6P&,<RJA * ZWO1W-HLES%LQDBDE=,OS2"E6,JMJNLR^HHX))-
M9'WJ(SF1]-WLH"J;D8Y?I;DDW2/*H\IAFAAC?-LDJJTRZRS4.79K2YA/%#PU
M8B>7N58XRX6/=M3J-QEHO[$OP!^#6BY>/Q]N.HQ.F&&F&&F&&F&&F&&F&&F&
M&F&&F&&F&-?^&J.;PV.'<0C+QLT=GD/*HNG<4+[T5!VZR-97J\<H$BRCW0/(
MX716CT/1NX])25%JNY;"DX5ZGIC4/5YV*EZ6HI!-E.1-%'4\+B/$F44<4<Z\
M&65#%.(S)"0Y)C*ZPCW4</[GM+'1='6HTK*:M:GSOI(DTM*9>''.^?YC/)3L
M)XH9!-3F413 II$BMH9TTNVP&N6QW&&F&&F&&F&&F&&F&&F&&F&&F&(-^Q-\
M _@U!%Q;?S&Q].&,84F_*6NZ96K 1B+5ICJ=KL$A)I.Q7&5<2]3B[*\*J@*"
M96BL:>53:&3(LY!0O95,=,YC)%W>890N7Y9D-?QV>3.J2LJVIS$$%,E-F%10
MQV<,>*)A3M+JTII)T@$#4><RC/7S3..E&6=S+'#T=KJ"@2J682=UR5>5TN93
M!HPJ\!J8U2PE2SZMF)!)49../9*([;[\O@WZC\ !S^+6EQT>,!\,J#5EB*,C
M6LDTE1CK5DMHY<LDWR*)'A<DVM5TU%.29L'956:JHME^\;$(95(YVYUVQDEU
M>JZ;2O-TAJ*B2"2FXU%DDB1RO [<,Y)EZQR:J>6:(K*JAU D+*K 2*CAE7AO
M<Y2*'HI2P15,56(,RZ0PO-"D\:<9>D&:&6+34PP3!X7+1/JB"ET8QL\95VS]
MKE<=SAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAA
MIAAIABU[O#.+'3;976BJ*#N?K<Y"-5G';!!)S*Q;IB@HL*93G[I-5<AU.P0Y
MNP!NR4QM@'-RVJ2BS&@K)%9XZ2MI:J14MK9*>=)65=15=15"%N0+D7(%R-?F
M](^895F=!$R)+79?6T<;N2$62III849RH9M*LX+:58V!L"=L?*@03FK46FUA
MZJBN\K=5K\ [7;"<6R[F'B6D<NLW%0B:@H*JMSG1%1,B@IF+VR$-N4*LUJTK
M\TS*OB5TCK<PK*N-)+"14J:F295?22NM5<!M)*W!L2+'%K(Z"3*LDR?+)G22
M7+<KR^@EDCU<-Y*.DAIW>/4%;0[1EDU*K:2-0!N!=NL#&UPTPPTPPTPPTPPT
MPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPQ @ AS^]OX\O#GXZ8'T^V^,(N:[F*
M&R"I+UVW1%AQ_8)-HM.U2VMEFTK5$011;.G-%FHEL*3AN9-$K@8"?:'*9V==
M9*93!<Q"] *O(*G*#3567U5'F])#(M)F.7R"2"O9G9T3,Z6H<:'4LR+54D@L
M@0/3.5UGDGH.E5)GW==#FM'7Y%7SQ-799FD3Q565HD:Q229-64L965'TB4T=
M=&0)#(Z5:A^&.Y=;OE.O3!&-1PI(Y BC,4')IQM?*?6R$>**N"+1XQ\XX2>&
M.W3206%R4OHZ@.2D3,)TE-4Y7EN35=,9<PZ2093.)704TN5YG5L8PJ%)A+20
MR1!7+,N@MK4QDL+,I-S.,XZ14-8(,JZ(5.>4I@20UL6=9/0*)F:0/3\"NGCG
M)C54<RZ>&W$TJ25;%9N%IOT%#0[ZK8P>7B5?'3+*P3>UUROJ0A3M16444D9E
M9-D_!)SLS$C,QQ.8>^)NB7<<?+J++:JIGBKLYARN"(,8:J2AK:I:DB32H6*D
MCDEBUI]\^^JH .DD-MC+S;,<YHJ2EFRWH[/G-3,0*FBBS/+J%J,&+62U16R1
MPSZ)+0VA8EB>(!H%\&-JOSFCNK"\Q>]CK>@1R+;'Q[97'+IX9%P*3<A;(W6-
M H>F(;.2F56 J)?Z4MLJ&VHEHLM3-$HX\ZBFR]C&'S@4-<D,8=2SDT;1BL?A
M, C:8O"+:E!4$E#F6=/DTM?+T=F@S5!(8\B.9Y=)+,4?3&HS!)30IQ4^^ M)
M9 -#V?8?&A6[(=D7DB73%#['*+1-H=@LZM]9M 2QUCKE<ID)7UE3,Q:%31.8
MSKLE6!P'="(I'U7FU#E=$(#EN>19R9#()5BH*^B[G"A2A8UL<8D$I) X>HIH
M)>P8$T9)F>=YBU2,WZ-U'1]8EA,#39IEF8]U%S)Q549?+*83"%2YEL'X@T7T
MG%$KU\RU*69K$3N"I*L5]5P\2<6U7(-+ED&J#=NZ4:N30T:X/**E?+HMVY4D
MB=XW%T51;9-)7;*K,JR."B>HI>E%-6U:K&RT"95FL#R,[(KQBHG@CIUX2N[E
MF;2PC(4$LN,*ASKI-4YC%2UG0RIRZA>29),T?/<FJ8XDCCE:*0TM-,]4PG=$
M155-49D#/8*V.-NON6H6PNXNL8*D[G"(^BBVLS?(-,@47@KMDE')2Q,PX)(H
M>AN#JM1%4H L9'OTMT3D-J*#*\CJ:*.HK>E%/EM4W$UT$F4YI4NFDL(QQZ>!
MH6X@"N+/X&K2Y!!M&:YWTGHZ^:FR[H559O1((C%F46>Y+1)-K1&D"TM7.M0A
MA=FC)D4!RA=/ 88KU_M60:X,2-*Q<^R+Z8#L9(&EMK57]IQ1]&]&*I[H%D@>
M^F=ZN)#-.UW -3 KV152WQLIH<KK3.,SSR+)N&$X)EH*ZN[HU%PX7N**3A\,
M*I/$TAM=EN5.,W/\SSS+5ICDW1F?I&93+W0(,URS+32!!&8]7?&6$3<8LZC@
MEN'PR7_"35]'%HOQ*$G8T<9/5KH9),RF.PM5=3=)*&D2M5$QLQEO: PIL1&4
M$Y5Q*<A?1"_U0/9"@466MFC49SJ),O#.%S@T-:86 @9U?N%4-: TMH=.@,">
M(;(,5MF6<KDBY@O1R=\V(!;(!F66B=2:D0D',6E7+SI@/=1(EL5!B75+8#XT
MZQY%L\7-&L^/%\9RB13(0J<G8H&WHNU%6JIB/EBUMX4"-VKGNB+-%5VZ[@O:
M[M9,!$Q:LRH\KH9Z=:'-TSNG;PZEZ>CK<O:,!S>)>[8E=G= "'5&5">3$6Q3
ME&89[F5-6',<@DZ-U2#11K55^7YLDS/&Q$S#+:@A8XI-(>)Y(Y)!?2R ZL4S
M%F+EZ6O.6:T6&1NF0[8#,+)9Y A637T9CWQX^#KT(BJLT@J]%F<N#,V)%'#@
M[A=R[=NUUUQ$M[.LZ3,EIJ2BH(<KRG+Q(M#11D2S7E*\6JK:M@)*NLJ D?&E
M8(@"*D<:(HO8Z.]''R=ZS,,PS*ISG/<UX1S+,9[PP:(-7<]'EU CO!04%-Q'
MX,"-)(S.\DTTKL2,R &P;!T#D&M%CJ,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,
M,81AX:J8.4R':9ZWM8:J7J]-K(1&;,DPC:_8+(A%1,@BE(J+&*=*>FD"R)N_
M(W29+.5Q,8$N^6UT,]37])1D]#39?)45^592U!KIA)-/6TE&\]1"[0@;/2TS
M&&R:W=(TOO8'D*6CRSH:V?YE69M'297G>>)F2Q5AC@ILOK\Q2FIJA(ZAFN8Z
MVL3NDA]$<#RRL;*9),9G1<MW"9%4%2+(J$!5-9(W>)*)F #%4(J7=,Y#E$!(
M8IA P#N41#7/D%258:64V*G9@;D6(.X(((((N#CK4=)%5T8.C@,KJ0R,I (*
ML+J00P(()!!N+C'U[9?/\.HO[?JY^;%6';+Y_A^']/7RZZ<_;YNWS87^K$]H
M//Y.?X.FHN.WV&^&&X>8?+J;V_83\V&':+MON&W3?3#V]O3B.V4>8& ?TWY^
M0^H>>HN/HVW]/9Y\+]?S[?/AVB^8>?Z?IY^0ZF^&)[1?,/EU%QV^G;Y\,8MR
M?EFKXMC&[N:5<2$M++ECZS484A'UIMDJIL5&-@8H#E5<G,<P>DNE!28L4A[]
MZY02 ##N<FR.NSN=HZ55BIX%XU;F%06CH*"G47>:JJ K*G@@\*)0TLS@+$C.
M;8YWI%TFRWHW3)+6&2HJJEQ#E^54:\?,\RJ6(5(*.E4AG!9AQ9G*P0*0TSJ&
M%[MK<!"0X2TC$P:,(\M<D%DL1"IID=/9QRQ9,EG4B=%5=%5Z1FQ9LU3H*J("
M#4O='.7^F'P:JKJ:D4\4]2U3'00]Q4A+,T<=,DTLJI#K5&$322R2J&16^^$L
M+[#94%!1T9JYZ6C2CFS.I&89@%5%DGK9*>"%Y:@H\BM.(8(87*NRVA722-S<
M2I>T00[/:Y@(!Y" [@(>L.OAK$(!Y]H/G!N/6,;#&$6#:CX&3L4C-VHT-!9"
MR4XF6Q)LY$(6%L%J;-A=1C5XFAW;!C)2D>]EA7DEDFJ3Z162%PGWA 4Z&1\U
MZ4R44-/0&IJ\HR9*5S2AWJ*FCH&?AS/&S%I)(*>6*"T"LQAIPQ4D.<<A#'DO
M0E,QJ*W-%HZ'/ND4M;"*TI'2T5=FD<9FIHID0)##454-15:ZEU59ZEDX@01J
M<VI+HKD*JBJ15,Y"J$4(8#$4(<.T0Y#!N4Y#!S*8HB AS =<^=B0000;$$$$
M'L(-B"+&XZB".HXZT,K ,K*RL P96#*5(!!!!((((-P;;XY]HOF'3?ESY?#T
M_3;47'.^WU?LQ5AVR^?X?TW]77IYAJ?HYX8G<//3#$=HO/GTZ]?O>?Q;ZBX]
MO-R[>8PQ J$ -Q,  ([ //KY?#J<,3VBB&^_+<0\>H=>772_U88=HOG^'3##
MMEY#N&P]!\/+KH#?EOY-^6&)W /']/T_"'GJ+VPO[>WK[,<04(([ //RV'?D
M.W3;S_%YAI<6)ZA>_/JY^7S8>WM[?/B>V7S#]/T_#Y#I<>WM[';GAB>T'F',
M=OCY_D'2X/(@^?##M%VWW#;X?T^32]Q?V]'/##M!YA\OGJ;W^;# #%$>R \^
M?+X-M_PA\NG/V]M]N7/"^&X>?J_3]/PZ87ZNSZ<!$ ZCMIA@(@ ;B/+2_M8^
MP\^&&X;;^'Y-,,<3*$+MVC &_3??Q_!\>GMOM\_/$7'HY^+R]GGQA#,D5?;E
M&5VFTA9U&Q=HL+4ESNT=*IL'E7J46H26?$B>X<H22TO8?120+!S'E4(Q*\<.
MG9T@*F8>AZ.SY503UN8YH$J)J&DE.697-3M/#7YA.#!#W2&5H1347$-9*LMC
M-PDB0$EACDNEE-G6:TV7Y1DS24U-F==&F<YS358@GRS*Z<"IG%(4>.H>JS!H
MUH(I( P@$TDDA4!7&;DBB5,I1\ VY[[\O,1$1'X1'7/>7;'6CVN2>6W7['GU
MX^FF)PTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPP
MTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPQ
M3I:)C)V/=Q,RP9RD6_14;/HZ0:MWK%ZV5*)%&[IJZ35071. _5)J)F*;8-PU
M=AFFIY8YZ>62">)@\4T3M'+&X-PR2(5=&!Y%6!'4<6*FFIZR"6EJX(:FFGC:
M*:">))H98V%F22.0,CJ1<%64@]>+%@<3U*I52:IE.+*U*%F32*I2P<N_3<PK
MB3:HM%5ZXN\6>^TGHQ$"*L&K$B;%BX[:S=J0RBG:V-7G5?F&809EF+Q9A4P"
M!6-5!$R5*0.75:P1I&U3KN4E>1C+)'96DL!C3T/1K*\JRRKRG*%J<JI*MJAQ
MW%53"2CDJ8DA:3+VG:=:/AA%>&.)!!%)=UBU,VKIT/%"5$?O'Y<@Y0MWI;0K
M3T.\V]2PL&H%626])9MCLVP(.Q[KN17 QA[E11,"AV@$+F:YSWTAAA&4Y)E@
MB;5Q,IR\4<LH"Z0DK<60.@V;3I U;]EK62]'.\U1/4=_>D>;&:,Q\+.LS%=!
M%=U?B01BGAX<G@Z ]S][9DM8[4QCA9-C;26T,H9B=F)+N)<:Z^O"KBJ'%PJJ
MJ,:>%%@4@Q*/>BDW9=^ )(II)]LW8 =7I<_$N7G+QDG1Z*\"0]W0Y;HS"Z*J
M\;NDSD<=]%WDX?A,S'2-1QC0=$^!F@S/WR]*YM-4]4,OGS=7RSPW9NYC2BE4
MM2*&T)"9?!15&HD:L=BZ8>3NDT::-DO+E6,9DW9#&4NZJP$. -S*F]*!@FQ7
M*#Q;O=EU^\W4*1,.R7L\Z<LSWO;3&F[S9#F%Y&?NC,\N[JJ?""C0)1-':-=-
MU4+L6<@^%M<S?HOWWK!6#I%THRNT21"ERC-11T9T+*I<P&FE!D<2W=PP)*1D
M%2@Q6;IC<ETC8B-/=LA5<(@_;!]3;,>!DI+^D%0[,L[(U7%Z7ZGOMA*GLN8Z
MH;";;6/EN:][9YYSEF49AQ@1PLRHNZH8;NS7@02Q\,@-H%B?  %L96;Y#WWI
MJ6F[\Y]EG<QOQ\HS 4=3.>&$_=,A@E$PN-=B@!D+,0;VP;8W*VHB]%]V^0G!
M5RN"^ZYS9CJWE('#X7PBA81:@=,R.XLVY@;#W3$ ;AN =H8;- V:IFG>W*ET
M%#WN6CME;:(A%9Z3B>$K6XCCB &4EQ8XE<B*Y(^2=^<]8NC+WW>O4YVFJ;C:
MTKA  KK^]*1#X,/@6Z\?.A8S3H0RHDO.1K?[:$:$VO5H/8@CO1?2/JHL%&C8
M&AG/I ^EC]7W_<MM^SW0;U9MFW?80CO9E&6\$R&^4T7<9EXG#VF^^R"01\/[
MT"!I+N=]6*<CR#O)W1?.L_S?N@1@=^\P6NX C,A_<^F"#AF0.!*3J,@CCN05
MWH58PLG6;&SL9<HYDGC,S.C>TMFO:TO7G7I3=RW[#R+.Q1*N1OZ2*[4O>E!%
MR@W5#<4MC95=T@[NHGHN\G1^C#\/]U4.6FGK%X;*UTG$[:2^G3(=!U(S+MJV
MPLMZ)=[:^*N]\O2NOX1D/<>99NM50R<2)HM,L I8S(L>KB1 OX$JJX) *F;/
MA9.SV%W8390S%!"[4:J#"UJ\JQ%>;^BMF[;L-(M-@H5!-SZ/Z0[*54>^<K.%
M=R]Z)04/2#N&C6C&2='JO2)!W56Y;W16-Q'9[M/QUN4OIC.CP5"C<B^&9=$^
M^5?)7'I)TLH1(T;=PY=G'<M!'PX8H;1TXIG**_#,D@$EGEDE<[L N3%JU!.)
MIG8W$3'+ST<S<1["968M5)1DQ=G24=M&C\Z1G+=LZ.BF9PBBH1-42AVRCMK2
M+4U*4\E(E1,E++(DTU,LKB"66,%8Y)(M6AWC#,%=E+ ,;''1O0T<E7%7R4E,
M]=3Q204]8T$;54$$Q#2PPU!4S11RE5,B(ZHY4%E.*V4O9WV'EX!X 'D ?IOJ
MSC*QRTPQ2IB$B;!'O(F;CV4M%R#<[5]'2+5%ZQ>-U-P.BY:N2*(+I& >9%"&
M* _5  #SU=@GGIIHZBFFEIYX6#Q302-%+&XY,DB$,C#J8$'F.1.+%32TU;!+
M2U<$-533H8YJ>HC2:&6,\TDBD#(ZGG9E(O8\P,6.TQ168:B.,>5)Q.4B"5%<
M6BU5F';&6B!<2 22P0\BY,]58)F6[:*;=(!;-V2AF;9%%N5,A-C)G594YHF;
MY@*?,ZH",2"O@66&IX49B7NF).$LQTV9F)#O(-<C,Q).FBZ-9=1Y))D&5/69
M+0L9#"V5U<D-31\:?NB04<\W',"F0L%C53''$QBC1([*)H.,R4(\J<MYR-</
M;4K(HA?+0>QA' R]+YQ7>-&PLS._2Q]-$!4[_P!&:;@44 $TYMFPS;@?VKR?
M+3!Q/Q51=Q\;B&,_?_OLG$$?#^]VTZ-;\RUPR/(.\AJCWZS_ #<57!VSS,>[
MQ3\$2 ]S?>8N%QM=YOPM>B.UM.]"JN%TJK86EA+D_,5A%H9T;VEM-Y5F*^Y]
M*;N&^SN,.P1*L#;T@5V@"J'<.$D%0[0I[#E5W2'NZC>C[R='J/7P[55#EG<]
M8FAU?P)C.X&O2$D.@ED++?>^,'*^B7>RNBKO?+TLS#A\2])F><"JHI>)')']
M]@[FC+!#(9(P' 65(WWTD%9L+IV6R.K(.4<QP)G2C0_M)6KRK$UUOZ(@W0[#
M6**P6*BFY]'[YV4%3=\NLX4W+WH@"BZ0=QT2T7>3H_5Z%D7NNMRWCUK<0N=3
M3\9-3)KM&2G@JJ#<#><QZ)]\,PDK_?+TKH>(T;=Q9?FXIJ"/AQI&%B@[F<HC
ME.)(O$.N1W-P&L*Y?,9)WPT68UZR/4/:PCPG9HEI4KA)'TST;<\H5-HY],.V
M!MLT$1)W'?N=@-WP[8V4YOWI$X[V91F7',9)S:B[L,7##BT'WV,1J^N\@%PQ
M1#MIWS,]Z/\ ?PTQ[]9_DYIA,/[29@M")^,8C>I#03B4Q\*T)\'AB26V[@CZ
MN\<)NZ*WHHW7(38K<K8H6UI9CHWA;T9X#P#.+#Z*8ZIUQ#T=R86X"JT$4!V#
MZK5$>:</-'S/O;E3ZS(W>^2C+98G$CT62EXHTK'N\:\0A9/"Y;8N/D6O)H\G
M&<9ZAC$8&:QUX7.7X<W%O)6F AR_[U(3#X4(";6!QQIV-B4Z(F(DEXR'9@F#
MJ'&2N%F-.RT:*C7T7LQ+T[1 S(A.3DA0(?LN@!;F.Y1G,LU&95$%1WLRB@X
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?3##3##3##3##3##3##3##3##3##3##3##3##3#'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>cntx-20211231_g9.jpg
<TEXT>
begin 644 cntx-20211231_g9.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H64&AO=&]S:&]P(#,N,  X0DE-! 0
M    &?J^9E X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!R1(,0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              CL   <S          $
M                 0             ',P   CL
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   CL     4F=H=&QO;F<   <S
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ([     %)G:'1L;VYG   ',P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      /E
M  $   "@    ,@   >   %W    />  8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ ,@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ J9&+UA^9<\49SZ77V$&MMT%A>[^;?!9]'Z"7V/J$_P!%
MZK';VV?^07HHRLVCIU%E+F&AE(W!O\[N8QUKZ_<+*F_HV?N*?5<Z[I]5%C+W
MV_:'%K=PK  %;[]Q_1AWT:E9/-$:<.WBQ^SULOFPP^I3KB=4(^%LC3^I[O<G
M^Q]0[8O5?\VS_P @N]'7,H>EZCX]2"[:6R ?W6_9W;O9^E9^D_FOTGL6A5G8
MEE8L_:)KG4ML-+7"20W<TL_.VI?>C^[^*/9\7SOH./UZKK6$\57UN]0AKLMM
M[:-Q98!ZI_E?F?\ ")L_&ZQ;GWVMHS[0^Z\VNH;?Z1=ZCX.,[_0;OH?\#_PB
M]"R+ ]V,:\G[34ZYFHV$!S7L;HZEK?WDL<91Z32,6PUV>H[W#;]'U'[]WJM?
M]%ON]C=Z1Y@_-PC]U/M:5?B^;_8NK2?U3JP&D0+2?Y4^Q/\ 8>K[A&)U<M\(
MMF([0Q>EOLZHW:VO;9Z.UNYQ:TW.+8?;9M_H]%;G;]M;?7M_D5_SM>VK+:+3
M987;GM#=UOI^LX_1$M_H>)5N_F:/UF[_  F__#C[R?W1]JO9'=\[^Q=6C^B=
M7)[ BV/^H1>G8W7J^K8=C,?-K8,BO9]J%XK!)VM;D6[=NQS_ .0O2Z,W$I%C
M;<QMMN_](7$ -<[Z-3&?F,;'M_Z?O4<S*Q[\<"FQMFS(Q@_:9B;JOI)?>2=.
M$:Z*]JM;.CYSU7I_7+L_)MJQLRRQ^1;ZCJ!:ZB0=KOL[X9[&V;FL0JND]<$/
M?CYQ,>ZM].00#/YI8[W+T;&R[JF>A14+;;'YEC Y^P37D[-D[7_2]?Z7\A66
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "\ ET# 1$  A$! Q$!_\0
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M]N'J3E_E$Z^'[[EU6UPWR5SLI/:K>Z5\M_IXLA:,>R3<^_?C\MQO;]OICO\
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M9UC";\.UL4<MY)PJ4A@FM>ZX+,BVYCZ5/JB-$2Q&4TVXM?FW);N$9PC.$X^
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M<Y%)*'C>(.V:C8<B1T(O"$AW13QHQ"B$[:.N+><#K";A,OUS%*+S76ZRY>2
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M>4XCR,*QC.<6; 5!Q/A!BI-35%3-&>=EG&]QJ<DWH!A#J#I;HLWT@XDI*?\
M"238B./BBIT:O.R;C-04R)9MY"MUE)A865J0KI=S MHZ)TKVUBVV*_9NC^7C
M:=,HNN>7*^D;AS*URJV G8&GP9RNU7>DAVX6TK'J]$@VAB(4&[/JM,];Z8 M
MQM(C8L1$D4&S!M@:)#N=M;JU;ITS.3U=E$2M#>?:;:"9IB9FJ6%---"8F3+@
MMNR#T[NJ%$$/2IW+=+MN$L\)4C3IIAEBG/J?J+;+CBP6UL-3EG%_:VDNG=4O
MM,A"P/P<PB^Y@.)(, E)6A2D+3E#B%*0M"L92I*D]RDJ2K&,H5A6.BDY[\9Q
MG&<<70$$ @I(X4FX.HA7$""+:XKJ@ ;9Y#.XMTPN% <0(M?;&.$1"J"T6[V0
M62.5VFVJP! V'5&"X2OEB@P3AB/B6^HF0@PY$. EF)GTIW,M]GS<?J\OR6\>
M5QYGIV3EW&VIB;E677;;DR],M,O.@G1NVAP@K&ETH(UJRV&-S<L^ZE2VV75M
MH'3K0@K2D\"B-1Y82O=G/3KTZ9[\>[W=>[OQ[O3N[N_CTD'5Q@7O?;JN,KG4
M+:SJM&H7N#8G,;+YC//7JUFVP91*J+S"RYFNZ!K2'4KB18H J/'Q6\;&/R-8
MVR"(O1G:!UZXZL&!XC15D@X2*(+RD6*.]$'QHTM$IE(IGR*PY04_9.;J;DU+
M,F96X0\:>VB>E7'95,FT&*DIQ2FMS2$]#@-D%SI+9WCM)J9Z$8E$LK6&=SN@
M3;@E7TI=6^X7)=*0%%PDJ4"JQ5TQ&4*F9SM; &-PG]=PIM).CUTUENZR+69M
M-\*!*E8#=I15+39IS4)^SU:2:( 6XH<HPMB$%J@P,_ZI,O3'EZ$83DW$.IGW
MD3DNL3*DR:9-#,JQ,S,LU+]%2\NE:TLS32-T6G<BE*GGG5!*-S%\S7)A"D=#
M ,+262'5/J=?<;:<+^Y+<6-):5:2$!*[C02$DD"$%<W-M7,*H3$U%>QXG9VU
M;%M8(\H+<SDRVR#H5+X 2,+DQ[LNU-5L&NPD(95IZ;/)Q39$G+7YM.75^R37
M2I)[=C59%3E-I\O3'6]TE9<,"7F%AU;K=SN"G'K)6RFR$% M<J 'GF.C7V]S
MZ#F$B<FG)UL[F\X5EY!6E*5(&BJR2I>D;DA15D+&)($><K<C]S8K1'2&,6U\
MCCU0J+D.V,6@\P]L !L8>+G"4QV3+KHX.%S60;S41$J&"(.RF,.*0C"^)+X9
MI;4HJ8:K ,JEMS0FT.2ZF6E+DG95;Z5EPI%WW.BGDDD%Q):UJTHZ#M8G"^EM
M<B=VN3N0:>TW 9D/I0; *) 2B7!).0!&0-V\8YRXT',&#\ABLOB:\/%A:T,+
M&I!G J"*H50HJESV#H<F).$IC5 KDV3)(!?18KCMB;%CQI&: ,53VNX76\F_
MV6>2XXZZX^XEEIH.$SC\\-R+;J766THF9A 2EVY<;9.DI"%MKTBM)38=!-Z*
M4A+22ZLE"4ML-I*TNH6E14EAI9*D6S5:Q(4E4&.;_:EG-V#<4S43S]0)EYL4
MO(BYL^*G"R:V9MG8DX1&L/H;PX=/<>W(:$0%/+==C>BP)JX<QU^3'D:F\-4Z
M72W3T5-"9X(26R42YF5!,G3Y-MUUD+*U-MB2;F-8*5*6T"+A4;#5YI:C-&3O
M+:6BLHW;<4J5,3\PM(6L$!0<FU)20+C<R1K(B.>[]]2]U0Z)&EU48 <I(J4.
M64:DN$3)U<R("AJR5+/1H\PA&@, F/4MPZ\=LC.9A!@A9R8YL/!#]FC41%'<
MG7&YIV83..-*#);++##2 M12E&Z+"7+K*7 TEILZ)*&DW45<Z?J"I],N%LI0
M6$*&D'-)UW2L+DZ*"H ) "E%2CK*B;$,A!$%B>'<C19(BEE:&WE08,F7AIQQ
MJ3(;;<S':<\A;C$*8\VE73*V8DIQ/5$=Y2.PMUMK\*XAO*_3J" <TI.:B-14
MD<I2+9B.>EM:_O$E68%D@DWSXM9L38&-=^/\O3/=W?O<;.6,"+:XS]O\>OA_
M)_MX0C'\OX^_][IPA!X^YC/=_/CIX?5Z^][W"$>I'LV.V$Y2N5'DXU1HG:,3
M;#MWIDO83QA=8I@LL$4BS;(MUL&XAD)-I&//JP*-PO2,+AM8:E>=93EQ+>'5
M_!\9>QSB*O8DJ%4D3(=#370VY!Z8=0Z-PE&&5Z:4RZTBZFE6 4<B#?6F/J&'
ML6TJETB5DID3)>9W73W-IM22''G'$Z)+R2390!ND6SRM8EG.U!Y^>27M"J]I
M\(#V'N+6"]8&;@4D2"VDA]G2839X("(VRPW#VB'S#5#R&4MQ:UOX>Q(2E*49
M;SE75P+A/$V$'JBZ])2$Z)YJ7;2ENHK8+>X+=422N17I:6Z   "UKG9'AQ-7
MJ+7VY1M#\Y+&66ZLE4HV[I!U*$@63-)M;0UF][\45L%=1\M^ZZO4]>\KIFV&
M-]T'7QDL?<M5;33QG,*L<=N=I-QZH"58;/ZV+_1Z,D/Z'!D&7!NQ!(R:Q!2)
MM B)"MUO:J5<I#\U-UYI@4><GTH:++_1+E&#B)1EC=W$MM%R3F)AXI4I#0<E
MW"A2PIA:UR_ 7)TV>::9I1=Z.8EE*6IYL,MU$ITUNAM(6YN<PRBQ&FK0>0EU
M*3NJ$;K'SEPH #85OL8ZPU\U9FP]))'!HL-&+DF5%FC $<Q+/!JH^B_&*[#B
ME);Q-C7\0K8QZFV#KXYVM";"\SV*_//R$JRXP\RT7)EMI;JU(2DM%EQTEEZ8
M291MPE MT66VUB[:%I>6W;GTR6:F7U)=:<6E+1<T;*R4'$HT5I:6'B@:1)4T
M%+0;+4A2 H1(.5R=U)PY8YY"\S:C5AMPN%,>$BA_KX.A+/609_8CX)ITRYKR
M64B1]9B&9ZIYP-4S$6SRTU4Z!$SXD^0SQFL3S6@VT)5J9>5*R\T'G'#*-.,/
MOLR:75;F)IMH]&.*:5H+>:W-M3Z%+20(]YHS!<*ES"F6MV<:+:4%Q:'&VG)A
M3?VPL*/VA"5V6&UA;B6E64"85%7Y!JO:10(U%W(5C0K=9-7#:^TYK(P0>'"]
ME!])&XRKC.!DB=>K)AN+N)R**BD#;$(S/K+;3$U#9[*@NF:QC,2;RY=VDI4X
MPS/*>6F<2AIQZ3=J$NKH4N,H=>E]UD-(K0TM:4S"0L MW7FW0F76TO"<*4+<
ME0E*V"#N;J)5:RO0=<2AP]$E* IQ*?M2M=[A#B.3^JV.H"[4"NVP<Q;.X"B5
M4N3UJ.C4R<9N-[M.NJM69]LC7>7&AV-D^$$/6H>Q$EI"#C$UU#LOU#;<->A6
M*)AJ9##LI*:39<7,LHFUJFFV)66:GIF8#!90=P7+K<1+.*4-T6RDD)W4I1@*
M-+J;2XE^8 66@VM3"0TI;SSS"&2ZEQ8TTJ;;6Z$@Z"'+@JL+IZF\L-4,'=U5
MXY>YC,/34]Z&>L(*MMF9DB=4].;MV)=AX""_:0XN9%]<6HY=9%3YLG&",.1"
M.-N#$IDBY?HFJ]--LTIYF505U1M1:;=>W-IL.S]*E95<P4L//!PL5#=W6T$!
M"DEOIK!0U,TMA:YQMUY:!))(=6EK3*WFI:=>?2T5/-M[F');<VU+!*T@*R*C
M&THG+;74;*W6!F12VPP.NM?5.QU7*JU>%++%[^3U[* 1K)7]7O'K/&S$I]FL
MLN2V()N0FS01G+Q!P<M27M4_7IEN0ICP#,H]-SK\O,!,Q+)"42J9G=5,O3X;
M8Z9UMD)W1 44*("0LY92],9Z*G6UA3[<M+M.-$(?67%OEE2 6Y0J=44MNYAL
ME(4G-12"86].Y9:U?JNZN-K0F%-G+G)%1S;I2\!JV.%3]CUS5%8S2YY:#81Z
MC$"VNG57C6NUWZ]L1X8Z.G5EZ.AQIE?CF,03,J\C3G6G$M2R%JETHEGWW7N@
MGZ@Z'T,[BL,+9#*)6H2(>DTKRF4@JC>W2V7FG"F74VHNJ =4I]#*6U3"91G<
M"L9N)=2ZI^6F0'RC-DV3'T-:>Y8IUMUK)#Q"\W7UG>WU9UDZ ;L,2#)HFIQL
MDM$#6 QL2.2(1=@#QU?,F+5'" 8 B6$.4Y85R.NPXGB,6JMB)$K4=V$NW-RO
MV)9#4ZVE3J)B?6E)6VF12EE4NZ'VTLEU>Z(=9?0X 4!#F;LC22]+%O=%L.B?
M<TY8N66U*@Z*5=$++B7@6GE+"4E):4RH:.D3"=Y;^6W6&VM55>VV1T]&.PMY
MVA5VS"*-1(4G1&OZWJMZTCAB'8K^(=R)VO:-9!U\DO+C"'#2E2HKZ8K25>FN
MUZH4VIO2C"6U,N4I EE% 7HU>8FIY#*EE)N99,K(S#ZT$:7VD7("[CST^FRL
MW*(>6HI6B<6I[IK7I[+4MN@ S >4_-,MI(!)T\ATIA50.2, P?MQHQ*O$J@,
M8*0Z4D/7%+78S<[5G,=;X0H0<D3VXIJ93[+I@8 +0X*7Y1*44?A2D"I3:&7\
M-];BVF&FTR:9RS?11=>4&V4HJ-'EENJ2&P4HF&*FM:"2 V&%+&F 0=HHC06Z
MM?1)8U,!"4E3CBY6I/A 42 =P7([DHY%94G(%0$=XCV?M;K2:0_<-FW,&S<)
MHNMYAM:W#32PVTD+]KFCJRXW\D*.&F &D[#9+HGBS9!3F!#XQ&5O2LRH.I&,
M9F83,="R$JZN7#CI69YUMA;#,E-S;EBN2+R7E*DUL(:<;;4%K ((0%N2J@L-
M*9W>9=;2\0FPEVUNI67VF-0FTA2 '@Z%BVD$D 9VA*5+ECU89V^/UW/=M4<4
M?Y7ZE=!AN9(8'QV=L7(+6 \0Y&D83(9(T@3?3SJ"47.&7DLCBP9;K,N#F1G?
M-U^HL4U4X$RQ=9Q"_)NML*W8BG2[TVMQ+R5!!:F#*RX*% D*T@L7T@(UM4V3
M7-)9.ZA#E,8?0I1*1T6^VTA%E9W1T0Z 1;( C6#&_MW)-3FZ^/( K%:A1$+K
M6?FZ^0$CVFO!MDTC&XFKP7NA]!4/BCT N=U:_5Z3/9''5SY3DEYS#C\'$8IK
M9Q5-!Y2'6)52'9MM4L%.K9>>E)AR1#3$FUN:NBIMAJ>2],I4I!0A(4 I*CHY
M.45@M!3;KJ5MRZ@Y9L.)$PPJ;#RW5::0RTXMA++) 6%.!0RUE6P^SSIY).1;
MVP;[5I(6R7,$2,G-2FY\^TL#+15:H'M]3J%6,6.?-U@TJ:2-.W-MS"9F"8@-
MEEG*V2KWB=QM-,G=>@I69;=:DUMM2T\FTNIV6=F7F)E]UE 3.Z6A+F5* 6UM
M.$J)N!Z4X=EUW3T1,,Z#KR%J<8!6M*'66T+;;2K-@@NJ#V04E2#HI&8K^W53
MPE%N8D& 2^B!,U3H>W/8DR%25Y,[!T;KN^V-:'%I0I,9RPV0HY#CY3CT2(IB
M+WX9QG-VI4T[.2BGG]$."=J;%D I2EN5J<W+,IL<[I99;"B;E2@5'7%<G66V
M'DMMWT>AI)PE1N5+>DV'G3Q N+79/]T6&R&EXZ,>2/9S^1P_:=[B^R7L'X+-
M3\?FCV8^N:3[32_G<['V3V/>HTSVP=_@2\4+]MEU]DXYF/\ Y,^[X8_*_:I[
M_M>][_'UOV,NL>B?^)?.\_%#QGURU+_@_,)6*K>G3'3\?WOU^OO\7R*O&?>^
ME^/\_"$*43=;D"C-P@MMLH:&R\V^S$%GBL",T^R3$G&7FH\28PTAYHT!!EVW
M4H2X@F%$D$JQ+&PWF?,Y)RKY*GY:7=4I 0I3K"'5%(86P$Z2K$H2V_,,:!R4
MPXI!L%J3&Y,P\@!*'GDIO?10ZIM(5?=-()3<72\E#B3EF@$Y@6W</;.U!V:^
MH?LO8$'-2@D1E4]#N5CC9K0PNA+18;7\M$DY"0"K2&VB4,;F-'G(0E,EIQ..
MG&HTRFKW?3I\BKHEQ+TP#*2ZMV=0;H4XIQM2E$9**C<Z=U  DDYIG)M.A::?
MNTE3;2B\Z2TA9-PC1<0,DV2!ED,SJCHA]C[#KLY!.O7RY B3*1R6B :T&QDU
MOU("SJV(\B7"G,2$^I5=)3P(WHO'H(2=,%1?-0)3\=>3DA)O(#;TI+.H!>.@
MZPTZ@%]Y4PX EQ"DV<?#4PLZ(.[-)MJTCBB:F&R%-S$PE>BE)4EY220T"VT-
M(9V#-DF^K,"XL8^;M_OC\]TH_=K:\2D1UQ'R+UD,N3WHKI1XVY&=EJF^?=CK
M,2'RRV''%-+*/.D%)S+<6ZH*?(A(0F2DPTD@H;$HP$HRW&R4I0$V1+!#*#:^
MB@)-DQ)FI@J*NB)C2(L5%Y1)%R;7.S2)5;5>.T2V?LLTN*X8V'>2SD*.+BPW
M"=M/SEPXH)@K%"1HBI4]U<>.%C'#<82PVI+0^.:+,PTM-D):7H;IM.:#@:D9
M5O=2Z5Z$NPG3W9:5N!10T@JTU-MZ1).EH D$@6E<Y-+T2N8?7H!(0%.K4E(;
M2M"-=\TI<4!8"US;(QTY.P+W+K[]3EW6V2:K)D#9C]9DV,R_7GY@8;"#!Y;X
M9Z<X-=D"0XT<)&/KBY<@#1\&!%6U%B1V49"1DTS'1:).43- .!,PF70EY"G7
M"XX0Z!ID+6I2U Y%2SRG$S4RILLJF'E,&P+)<.@I*1HHTAD+I2$C(96L./$J
M^7F<+&@IMSM<T(%%S 88/+L9F2+$!2+S,DB'&#GIKD. *GR8T=^8.B--0Y3K
M#+C[*UM-Y21(2*'77DR4HEUYUM]UU,NVEQ;S8(2XH@7*@38$DD#O1)FIA24M
MJF'E-I24)05DI0@F^BD7M8D ZM8O&OCV>R1<1TQK"=C)B!YM=BICEB#.(M?(
M29LT@"C)1)QA@-.FDR,N8,;PF#*DSYK\AAQV6^XYM7+2[A47&&EEQ\3#A4VD
MZ3R0V&W;'(/-EIL)=-R6VFV[!.K$/.)MHNNI(06P0HC1:*B2V "#HDK6X>F'
MVQ1-L[PK)>Y-O3W#;L[:FR)CEFC"X=C<E7BS2%GX8/SF0D4XMXDI1>,(RZYD
M6S/S(:'9<<]#0UAQ?7RHI-*1N6C3I).XK4XRE,G*I#"EF[A:(9NDN'IED6)6
M;YV$;3/39T]*:F"7 D.?;G0%!) 3>[BK@)!3J&2CP9_%W;>U9"(+<C9NP7T"
M81H8*0]<[(ZD8.LB<HL, >E9-284(\G*DF8D;#;!5"U)GMOXSG&9%*I@+I$A
M))+RFUN$2K%UK8(4PM=D)"EM+%TD@Z(&W.(,[-V2.BIGI 4H^WK&@A5])*;;
M%7).K68^)K:6S;'.P4L6QKT>))5'6D@:MU@*S4JB)+(BJQ+G$'GTYC(/&TL9
MPYU928*I:RC!&9YZ6Z;3V04LR$DTVI)2IM$I+I0H*4A2@0AM&2BS+E0S!,NV
M=@(*G)EPI4Y,3"U)5I!2GEJ*5 *2%)N3TP"UIO?4I7)'U1MG:C3B7FMEW]MU
MNK)HK;K=RL2'$TE.,I33L+22PM-50G.<)KR5>I*<=R8F.O#[%TPC153Y,IZ(
M7-6,K+D*FEFZIA22U?=3K*@O2TM2A$=&SG2CHJ8%FPR"'U]*TD6#83JT   $
MW MLAOL?K]>F>O3I[G3IT]SIC&/IY]WCW9FY)N2;DVL+V L$BX  $><F^>K7
MEQDW))RS.W+@C/X_2X1$&,=<]V>_N_\ ]DXS_-G'NX[L^YT:L[D$%)!&PA:;
M;1SXXF]@3^D".+<U\_IC]#_EEY0>5(WRV\OQ@SRR<OA8N7TCJHD5*DM-Z[G$
MB1*?1 ,J>0GSI-<<E3)TR4Z[)DRY#KC[[[BW7G%K6I2OQS5\18@15*HTBNUA
M#2*A.H0TBHS:&T(3,NA*$(0Z$H0E("4I38)  %@(_0-/I%*7(22UTR06M<I+
MK6M<I+J6I2F4**E%31*E*.:B=9S-X\VW;#["D<L?.&_K'1^N^7RC4=.LJ/8$
M@V.6+ET-MI+E73;9&9B;9=6F2?62F&QU9].S';RWA332,J5CC[1[&\D*[AU4
M[5)ZKS,T:I--%]=8JFD&T(922$)G&TJ6$N+L5&YN$DA,?.L8/BF542LE*R#+
M/0C3FB*?)JNIP/-K!TF38$ 7&?<M:*O.:'F7@[K.D@>LJ&(TQI!%K*W$3K*L
MQX@Z(4MIC+B2-WMC8QMB#,/.,.N#@ J(TU7:'6U(K54AQF5EB!F]8?H*Z2RA
MV>FW:I5"R)=R>F%K=4U+H5I-RLLIR[B6D_?.K6=TF7#NCMRE 36JK4T3KBVY
M5A,G);H74RS24H"W3<%YT(Z4JT3HH1FAA/2-6"EE48P%@/54O!L%7-EZV>&/
M>D#3@$E-#F!S^6G&LOP"0]^--AO*;<6RIV.^VO+3BT9SE*U)X[[[#$TTN7F6
MFWV'0$NM.H2XVM*2% *;5TJK*%[*RCEM.N,K2XTM;;B"2A;:BA8*AHFRQTPR
MX-NT0N7=W[HD%21U_;VT'C9@.W72QEZ_6QTL3K[3C[S8(D1<,*F3@Z'9<IQ
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M*,=>F%9Z]^>[.>_&<].(T&;DZ#6DK)2M!%R+BZ>0C(#8!KX9#JAH@.*"4WL
MZ+7)VYYWUV[^<9RXYW8\O.<8Z=/*ZYSCR>G3IGKW=,)3C'O8QT\,8QPW-D9!
MIH#4>E3F+9$CCOSO$[HO:XO4#^%'</WQRV"U\QP$1CRE>.%9QGIG'7KG/DIR
MK*O)3USW)\K/E93TZ=>O=WYSQ)0T=*Z4'2-R"A/("<S?*ULLKF,0M0 &D0$Y
M AQ(L#QZ5[9\%\^00>6OIG'EY^6QT5CPQG'7KC'3KWX\K.5=,_\ &SE7CW\
MAJX.YMZ2<VSHI)03:Y3P$VL<LQEQQ.Z*-QIJL?OANHLO: JRCJ)X.'/A/..^
M.7%=<XZ9SU5CKCITZ9[^]/3&,93^=SC&,=.F,8QCN;5S]J:N5:2CHINI8N-,
M_P#:()%\R"HY:[BXNUMT6+=(+.IN4[4Z^3*W!EE''Q\?I?4QTQC&,8\>F,8Q
MC&,>YCC8"D"PL!P9 9DDY G^=[\(&)5?._QEH)RX[CO;+CCC'?X=._/AC&<Y
MZ]V<^]]+B;@ZL^3D)[FHZ["(%CM3;:=)-ARV)/>!CV=?D<+OY.]Q?9+V#P^M
M9J?C\T^S'USR>8/W&E]1!'NN>VBXC[)['HM1YGM@[YO+QI[]V9FAN?;M!.?V
MQ[AM.VJ].UY:>7 (%:UN>J(>+*B'.6C7<^6LHBRT6WNO2&W83:8[D5Z$VVTI
MS#K3RLI6C=*XXJ^$\)X3EZ;+TYU$W+5AYU4XS-.K"T5R=0D(+$W+I"0+FQ2I
M1*B2JVB!@_AJ0KM=KKLVY-(6P_3VT"7<:0G153)91*@XPZ22<KW L,A<&ZO_
M #.?R0=W797--U]W^W?57Q*<>?VY<4^\*!W92I#O_=.PC9[7M$]\U/\ UY7U
M.#\SG\C_ ,)7--^WC57Q*\/;FQ3[PH'@E3_YG#VO:)[XJ?\ KROJ<'YG/Y'_
M (2N:;]N^JOB5X>W-BGWA0/!*G_S.'M>T3WQ4_\ 7E?4X/S.?R/_  E<TW[=
M]5?$KP]N;%/O"@>"5/\ YG#VO:)[XJ?^O*^IP?F<_D?^$KFF_;OJKXE>'MS8
MI]X4#P2I_P#,X>U[1/?%3_UY7U.#\SG\C_PE<TW[=]5?$KP]N;%/O"@>"5/_
M )G#VO:)[XJ?^O*^IP?F<[D?^$KFF]_YN-5?$K_V</;FQ3[PH'@E3_YG#VO:
M)[XJ?^O*^IP?F<_D?^$KFF_;OJKN_P#\*</;FQ3[PH'@E3_YG#VO:)[XJ?\
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M![$EV<_T+%'_ &8O']:N'M@8R[/3?Q);ZB&]3#W8MCXSWUL'L279S_0L4?\
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MW^J.2QB[)52PXA*\N"P8$R(A5D88C3$RAC"5:U()6A1S2DZ*T$7"DJ(TN,+
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M;K%'<;'A[*:&06W'J[$6\MN)"FL,(6ZO.5N*2WA2UYRI6<JSG/"$1SY2-B;
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MQF-ZGMQE2_2,99\SYS&4\9.TRI,H6X]3YYI#8*EK=E)AM"$C6I:E-@) VDD
M;8A$]).*2AN<E5K60$H1,-*4HG4$I2LDD[  ;Q+KCPQZHTEF^9RP?I(5_P!
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M?H+_ '%=[F-L0U[+KYWQRF?6A!^/_P!O-\<<67'/7=7OAZ_W41R,.=0*6?\
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MD_RP0:MJ_,,;':LDH::K=$KNR3$HL58<?C)N&Q;A#C19DEIN,PM$+,-"/;H
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MIYCTB.I6'6?/,NM><0GSC3B.J%(0U'+@1H4N#=(5'YHW^9K->*U^KV:;+O\
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MZI5Z41E%:T3L@QYA]$9@ABN'@S1:# APYK;C:'\R$(9\1R/:_ 7'6%L#WK9
MV-JTL,-"JC#GUN+43! 35QM3B/'1<>LMN25>@#L2%N1941U$V3(<B.16GY+,
MA")DD1\0L/G"R#.)$ E#DP)L=2E)2_$F,KCR65*0I*TX=9<6C*D*2O&%=4JP
MK&,X0BOW9>F]3 ;/KZJ[1ONW+[:;0.F@J%.DA:?-S6:I6!LVGY1)D@*8&&PV
M0ZMM)G2K,9:EGYDGT:1)GO0!K\?"(SY_UY=O!"HUKH/0LR'O/52KX>W8.V_$
M$W>Y,6@P$LL(8%L<8H(KT:O%P0F#$B,,QARYHN,I^5*'MI'$(7HT"3!;X1,3
M9&C8 <= $"H<<>,%PHHX= B-)9BPH,)A$:)$C,HQA#3$>.TVRRVG&$H;0E.,
M8QC'"$=S/A]M/W\<0=:>7T&(.KNI\HBMWL_/F][1;[/O8WX+M0<6[%'N;"7[
M*2'GD_'!H?X>O=NYCS>5B%V^B T7:NU^FE) \>RUN;L]$Q#!)X,ABO%WJ#HI
MD)9FXMEL52JIB=6B[D(Z-KMLLP2J6,B/C [)/:#$)N%*[UMX'SSZ"K.5@?\
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M:[QIK?5JK]M*AQ?C;VR,Z;U.D/@4K_ ;B-6J?GF'.#]CERJ_PUNOCL3UMY-
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M*LU*._$=>:+\[R\_92:@_P Z<X0Y\^??B4G"$([80B<?H=V!C&DOD3-0LHF
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MQ#>6<7<'AW"UYZ(3AO)'K\MG/3&.G7/T\]<\0-GWW!8]S6>YP[2.*'<'/O\
M/:(<6Z[IH=$I;%YMU^KM<J4C$935D-V"$,!N8E=,1\H*2Y34/.'\],-9\_G"
M\]R>OAPS).NPU<>HV-[</!EPQ.SEXM7/A!X08;:C<VVA;Z:@A*?O#7%E*D7L
M1X(\)?:^6ES'E)RO#,:-")O.O.J1C*DH;2I6<8ZXQX9X&YR(L.$&_<.0/>[\
M1&CW;SU\KO+[9X]/W)S":QUM99,%LDP"N=V# BKL!YQQIJ8B&0FLOJBN.M.M
MMN^;RA2VUXPKKC.,3GM\7/7QV'%"%EI'FNT/S"-E5Z9W10=G9"M,NE4TJW"K
M$Z.;D85EE<U R9(7'0_A.?-*=2G"\XSY'7ITX'+5?9Q^7AU7X[PU\[0S.UNT
MGY--,6$A5MF<SVIZ=8ACRXT\(;O(:(4A/MXPI3,B$N;Z2V[C"L9RAQO&>F<>
M_P!\=^^6VUQGLS(X[ 9ZK;)OQ=_N9[."'2U!SC\O>]*%8MCZGW11[]3*FXZU
M9+'6K/ *"@3K,5,UUHK+C27&H3C<5:7UHD*:7AI25Y3C&>O$YWU9'A-R#X\M
M6K(9PR[O)ELY,]=\C>&!QVK/(1Z>F#GG T5B0MY+/D9V?64JP[ESS7D92HGC
M.%><QG'3/NXZ=.[B +#4<B3:XVWX[6SU?UB(MKUK9!)BD";!%*PY8DJE<X>3
M3+:<B3(<AG$MB1&D^7EIZ.Y%ZR&W$+4C+&,N>5Y"5*XG9GX^?=] A"W'&1)B
M##*""4$J,(,IDP"0V4S/@38ZT^4A^)-BK=C2&5IQU0ZRZM"\?G59X7%[;; Y
MY9&UCXQ\9/"+M7?([HU@\!R.O@/ 8^@\H-+1DS!<^&2B+4XA$J#)9EQU+9<4
MRZA+S"W&\K;=0IIQ&%>4AQ*D*QA2<XQ-_IU'B([X((X1F,H7&>=[<&?#P<A!
M&PY'..]PA!PA!PA"3OOS#73]2=B_@>9QNE_=#'ZYK]],:WOP3GZM?[BHAKV7
M7?V?'*;X?H0@_J?\/-_>XLN.>NZO_#W/W41Q\.94"E\4FWKU[=<:.^9__*A\
MN?7NZ\H/,3GW>[^Z3I[^?W^O$R/6/6_V@H?F-4C5,]<M.[45'SB3Y8L2XJ<6
M&#A"#A"#A"(\D^5_4YC;+>Z2 XJ_>6[E7KOZ3ZK/H'.E*M0C.O@<)\<E.&7P
ML*$:784C'LK9S<A@*R=<3 \+#:(MQGG]'];PEK%R<:HL3_+](<<)Q7>6NO1*
MKKIU\%K*V26PD/%/0AJ1.V'KVY$ Q1;='!MYLU%ETZU,8]+5#-Q7'6EL('O0
MX&CN7?5'+B$,5?3E8A4FJFYPHO+JX2&.&5]LX-K0:JR3L,6-@PHT0K8!U?%2
MK*\PE+!<VS*//1T%RI>9/1,/?PA#%<P'+W1>9"IA*??LNX&U^UQ+D,RFNZ\M
MC"3,,(?K[:IE=VE2=A4LHQD992B$()U>8[$E*C$![T2?$C26T(UVN.5W3NJ;
M;<+Q2JS#$6C9$ Q#V>5B#@4![9<DM;3ER8,W9 L./9+F0)&TVF  F8;CI@@;
M!+".,R8$,,T+0ALB7(?I:<E],,C>@"7-4C-,LI EP</T>BQ!-$KI<:K+]:EJ
M)HM%;UI2@9>(<45$C6@V"U/&5>RS2)R6A"T.<I.K#I*F$7I-NBII>P5[+CCX
MQMA^$8LR#%?-BY!514:2GQW #]5 # Q>NS@%G8J\*3391^943=@"%D(D_P (
M0<(0<(0<(0<(@^D>4177V6/M.ZY]>#FB_P!9O;?%NQSUQ/\ :^A_,E/CA8;Z
MDM_"JA\X3-_ICGS,^WP[-#].^;?\ :N,:/UL8O\ T:#\X.1%2ZM8>_3JGF8B
MQ'BIQWX.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(.$(QGP^VG[^
M.(.M/+Z#$'5W4^416[V?GS>]HM]GWL;\%^H>+=BCW-A+BPI(^=S^J.#0_P /
M7NW<QYO*QL.5_OYY.T\QX?W0>5;O_P#X6:5^/CQ%=ZV\$? *U_YAG(BF]6<2
M?":;\U2^OBBP]UUIAIU]YQ+3++:W775YPE#;3:<K<<6K/<E*$IRI6<]V,8SG
M/%3BP17ELWF*U#N4-ROEZ3:T9]<G-EK>  #64>2IUH,.!8,D],?'5:TQ1)^9
M#S6S@*SQYC ]R._738HPA?H4UIS*(/%Q=Z_]8=B5SM:)$V"QUFPE;$&*UTA8
MH;O]IEN*CIC5=N-AHKSL8T&"3PJIL\]4;6L>"P06<?"@)YU<!L:C+V$3"#-<
M^]2#7\AKW.JME3BL&53I;+T9RFLH)4J^66M4FKW>#'(6>%)5 )W"XU@4D3(0
MP8C1BCDV?%B/"3< <A#X:)YA@V\V9_H57/5.= $1#F89F2&)1YXN7<;_ $9N
M>(,U\@4#&![IK7)R1#(C)TJ 0"S 9>')=CE6\-H1(7]_A$',$<(B&.H.7^GV
MG5FK#MLB7L#;H^M:W62>:]L+96N9RX :06G#QQD?4;+7427!LPV7<C^J49V3
M%S/DMH4AMQ2,[Z_+2TW6JA,Z:U;HZ0E;#[S(6V%.*3?<EH!L7EVN3KXHZN&L
M3UBCT.5I;*:>Y*MN.329>I46D50,S#[4LP\MDU*1FE,[HU)RR5I:*$G<D]+E
M"#M/+V#"T[F4, ".[8MA#HL!*ENQ-W;S=DRI\'5%8DC945G-\<2=>2::7&:\
M\U-RXY&2.SE;3"8R*A+T\)775 3J5=&[I+JZ+F@I?W-D@%(.ZW79QM2;*N
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M">T7(#I).N!(EB?KLAF;.?A%$(=CEWU\>U9IRG46RJ%H+!4GG%C04^:5 UN
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M,L1,&MY$GA.S.&PL.G.S%+ !M05<S1:L[A.[&O27JC>+V5!'7KGA=TLQXQ+
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M/K0@_P#/S>++CGKNKWP]?[J(Y&'.H-+^!HV<NST6C1WSYZ)RZ>'M0>8GN_\
MF3I[][B9'K'K?[04/S&J1JF>N6GV[$5+SB3A4\VEGY*ZL08/\UDYF [6ZD4:
MBOET[)4%: 7VM['KA%]B'5\*!$C*ZZ-OP2,4Q'EV6I(L"(8Z6$DWD0DW4XL'
MH[ODB+8/F![-"Q,V0+"J[<ZI6RW3G&C+U/VR<"[738]1Z,Y@K"<J[\0 7<M1
M_*JOIX$>HJ746]JS  HZ4%3*/CQU@0SY\^4]V-E5)?9BF=ZTG2#]>37MWYLZ
M+5K:L7*5N(;<+I,LP2I\P;MIM4:PSFB,DF4L$=1N:&W%_; ]>J:6DS!6#3"?
M.H<[<Q?GMC;;:]C]U%#N6J+K13S3:%V4$!I<0UMR='NAO76D!5KO(:KRA1R:
M.K+1?6FSH0+8Q<A/KD+9B[-;85_>LL=BR2G$+^6W>YF%1<-V\J^V=ATJ_P K
M4;%R];-GUU0Y.U+W.$:A)4:ZJW'9 U4I ^K[7+T:W&K;3MBT@X?+ D!8DU0M
M/DT[%U*E7JP\AW-F7T<')GY(8K3?,ORW5$/I.YT/EG<J6-B1\6B@ F[X13:V
MAU2!URL0H%%IUNBBW;3;O4CF:LB8]0IB)8DL\5MYILZ2+2\S%H?3M\>JVS5L
MU&)+3PW)",KM"EW"G&88^7L>^I$T_"=OWJMU*VZ_O$37UZ=/ *W(L52J^K]:
M; @"HT$E88(K4&OC+H*P@L5R9,@SLHD<_1S\L("U1^SRG!=$$['JF\'Z5=:7
M:;5K$J_0M_%HYL29VQJFH,P+55G(SMOM4W86P=TU,G4&[Q63;!:*4+V*+)C#
MB#DLDB-O/+GSR&3;B=S=D1-&5RWU<G%NBW[Z8J0,R,A;VM1FV[!'' >SGZO8
M#Q!,J1;)=FN%JJUU&#KX3G![A</4"R-8(EZG$G@D+?UV\^9A3&]Y]F%:"E/V
MC?AEA E];:^CAA!BUZWYAZ[7:E6ZGK_=LF+7B,YL!'UX6.5RI1-]UX#F5*-&
M_5!=UJ]8ER2Q1V!,1//GS^F%IJ/?79[BK]7+=H,>>.W&^-":0'*TZB[DDUIT
M5L.TZ.K]BEQIAP9'UY$D0B!S1R]H3!SV+9!&PJDBS)<CAX<>,A&LO>P.0[5#
MC%8*4<]FR41.TI5#J@1G:!8K<Z[JB!3Z-LN*W,$29\4S4ALW5==J3M'N\^0)
M/&=:5%V#7IQ--->DHC@Y\^'N1'*=M+D0I.+*/UWH.PV,'43588@%:YM/9(?9
M<0_;*3JQX?8;)59YIG;] K(\):!&JG;,4C.&ATUVQZF@UW VZG!!E$\^?#$O
M-)2N5K:5 M]J:T>1KX;=%+,;/.@ITBQ'HEY Z.W'<Y;[E."NS$.Q:^/OE@^2
M36((,'6(-F<VQ'/-!5%BQUMM$:N'BYV/?-X2VE[SR%6QC2<L#JT]1[I85U2)
M0:BQK;=C2HQ<H==V_)K\$K K,:KV>%0KK6%']G2XTDI5==7.OQV+K-$$80U*
MD/YVOW;<.R)=\O6TZG8B-_TK4Z.3UZ*Y>'0M  @34.Q#)4VF!Y]IHU:L(.&?
M C6I]&GO:[,0*G909NU"S3(F<P\4BF1A4;$1,2;X0/'Q>7+QQ77V6/M.ZY]>
M#FB_UFMM_C]3BW8YZXG^U]#^9*?'!PUU);^%5'YPF8Y\S/M\.S0_3OFW_ &K
MC&C];&+_ -&@ZNV+G,\48U/*M8>/ JJ>9B-;S% .T-G;-V7-T7L5NOZSQKVO
M.:W!@M>:5L4YRSQBX!VR(?.;/N@">U>""&+#$A1"PE[6351FPYF#<2YQ\1LU
M.+!KUB&[+4KM)QU:VC,KMXMC=I(KK$ZHB(=BY=;,.@';.5"2KL[7)MYUB/R5
MK-!$MN!PP.P9UW@ME-G(0V52':TEQ"$$SKOM0IEE$7DV:()LL*/28UM:$FM
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M5LA@:_#M8"IT1B#C,]PV//MW7)<<Q/8&#T1?GSXH[&I=M\^LN4;-[1U()=K
MW6E^F@Z^.I2:G=+/? <F=*J'G\.;4N(P W9XK,0*S6UKG^0^M1Z38H;,ML-
M0]/=MXM7&8:JDRNTC$:AVX%V*R4SMFD5?28>L66K8KMW#7TDYNC8)[8YZG9E
M"J6Y/G_(:.T:K'<S@(-4<S7):P<&0\VW*FHGG;A@";,[5>!9*[12NLM:$Z]%
MK5$;*[93526214I+V&+C72<JHN[ 9%0Y0BA/2(;,"3:V<S"F5VYEV3#9F5V
MAP<^?=XMMH:43SE]I6(8-3;[H*NC9U2KM9+%*J]2" M!]^V["N (",#VY_8C
MS:;H>@#ZH#"TMJMRV\2RD\[/L"(\9$/*$2FVG>N>>!LRS@=20:R22&QKR(04
M<HLX[79 (B-UM#G66NQFK]4W8<F58+3N@G+6[-*+5$U6#".QHZ<KEE4/1#.V
M7;?:L6*F[+R$U%5J0:AU?87K<9BTR.2.N6><X.$TP54R$_:4P,3:K$(D[;D7
M V'C0[>0B. 9-1K30N=F:A'4)[6[22K#)X6QTSU0JJ*[MHS"V&.J#8VZ0BT6
MD>NO40<A&:MQH=*?7?D1* 389#8D6-HG'AQ02FL$Y@Q#CYF+FV,N*994\C"'
ME--Y=1C/E80YE&,K1A7_ !L)5UQC/NXQUX0CZ\(1&KG-]J!S6?8V;S_!C9^.
MUAOKBH';JE^?2\<^K=2JGVOG?-G8V_*A[5OEL^L'I[\'M=XTUSJU6.VE0\[>
MC.F]3I#X%*_P&XB/6< ,]H'SU8M;^8E6_*H<N'KEE8ES(&8P#,G>F#$C$X<Z
MP0A>:'YD+]+@O,S(WD^>BNMO(;6GL3W63A_M]7]6?XM3.6.=+=<55[6TO^+/
MPR-*HG9,U.KI'UG8<<8-]?=%+0R,J^;*'%Q=^C1MW#:/81<V7F%.#S*\NU;8
ML:#41,875'($:UE7Q@\('FLU(7L+Z[9\L=Z%:_8N1&VVG6NHE;&MS%)TC4=Q
MP84:3;[1%K.Q1H]K7.V;K$L%D58FKCLVMQ =:Q:2C$^ <HUR#XF3"1(C'=KJ
M#<Q%]7/DY\-N&%AJG4?9WWJR3]::XLDZW6R-&LK$H7.O>SB9? NKU$;J></C
M%+-+5Y\74Z4:#4T+&A376(P\<A<+TF>',3F43'9KVUN1J:T($'"UHIR^7D[?
MM<4R)?WK5&GK'Z\WM3CDM81,:26F%1#^T>786Q1!)_T6WGJUK>R+$5V14HQ>
M8Z@.?/R>+*&\K&D>0LUL[8_*X.K^SPKVO]:5RRG9)39Q\551%( :^,QFQD.!
M)ORK?6Q;(+FUL5C,N66F@*I;K7:+0]$*V0YKVSCJHB.>OC_ER\D:W6U;[,86
M)&5RL&[)51H.YV]%6)%K)M .N>5A5[2NQ;-/&G5R<2H4)^O:9ICL>,=?#$2(
MNFW=8D=(&-GYSJ'/QY\.W7#VC.7CD.WWJ,KR2UZ6_;*'IL^4*6*F@;;=!TP&
M;M>;=@NP0LD-V B6LA'O)R7@5"GNMBH!ZOG1D4:Q(JA+*%N7CX\A_+5],-6@
M[R$8N),^_%V76KQKG<)<7"".V&WUZ;L$]JS:XAIPA%$1[*P)L=*3M34!*?6Q
M5R4+E6E>GKX<K0 I5PAJ?-0SN>>>>1\1]-HV)V;V8?,',L.WKU8 *C&RJ6TN
MX)L]IM 'R0M_UQ&UE+&RFH1/%;00A &9%3)NUN?-: 7>O6%C$]BUULRN$AS^
MCGW[QH;+7.RM!U-8.>>!FH^EBU=VO%"B;!:R=@<+-4?$>/)"1XJVTGXY.F.M
ME+5"$J<# !<R#;[ JLP&QQJ,AW;=X<7!WNYKA9^H7+._SFVJZ[ V?9X]GLH'
M61JF:M/-'Q5&B&]FHUF/9)#I48X6KA:TV.1JBEMS!30RM2VH,&PD""+.*C$C
M(-$\]<=\WI'LZ:V/U^2M]APMF0*"7*E&+?LS8I6?8:\H4(VC5GU3RYB3,/B(
M&O\ E0>'!X4Y<KS.M*Y=*@XTX(OUF@V5#AY\_)XXZ[MO[-^#2(]5&WX>?"TV
MPVN^C0-;-W0\<<,Z$T$+UG8"4-H>AZ<0%B]1R0(N!.6[FN6@H9"/A)Q4^:@*
MDHCNY_UV<7?RSC8V#9'9\&]?U^OSMLD*T&U5#D5='K8MNTZE<P@"\UHO=+;3
M+%/J:H=GEU>=7M>GR6Q(,M]\769>N2KMBD@CU%?=$(GT\]7=C5W9OD>%D*U:
MR-VVO%7NJ!L,Y0[F$V7MD<S7L4.XP*M<==A77C\.5KMDY=MOR:PJDF( VM.6
M"6JJRTA2HZHBL(C._%SVW]$23U3S1<M,I&H]2:P//NK+^I6NZ?51P<[.Q5V@
M6NK?:( HX5RS,'Q80P)J^X5=1K)<D.<NE2L%0R3?L8,W$@H9^/Q7] YF)(WW
MYA;I^I.Q_P #S.-TO[H8_7-?OIC6]^"<XD.?N*B&O9=?.^.4SZT(/_/S>+-C
MGKNK_;!S]U$<C#G4&E_ T>GD\HC1WSN[4/ETQW=W*#S$?O;)T]]/P^W]OA(]
M8];_ &@H?F-4C5,]<M/[45'SB3A6<UM\Y8 -LIH3=E'G7BS3 <^OHF#:G;36
M:!0=@$6IQ,Z3L-='2(]746*:H1+K*D3X-M*&J:\BDJ65AO(<J<6&(]%=M]ET
M<UVWL$Q''&*L*A'R^",RK;1)6&)"GK'\KEEMKZE0W[$IGT[5PK6A*]/NN(BE
MZW!)*.M3G6S,A"UHG71N7O080W6MGT6C0!1MH"&:$'Q\VQ0GB02/5X=>KWJ]
M">(MM6)8FMMHC!'+5#(SP;DXM,@+A$S)F3-0CXW3E8T?L8R8,WZG(MV#=E;N
M$H.7)$U5_%F35:W37"V0\25$B3'70E.J:FXY5)""-,UX;9 T4;8D/%'T([4[
ME>T*1.C;)*UP)R7%FI5@;>8F&8D8D6EW<SLK$FR#(A)@7;6X&P+$=N0.):81
MB%7;(6GEP$<;,DN.Y0AQJ_KFDU5-117J]!%)H5+5KNGIC>=Q@!2E>MWRJ[!\
MXZOI SZTZYC^R^=>Z"8N//?\)Y:!SY\_'" E<MVGBP>H!['5&;.FE6DU=A)
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M.GO6(/8IN1_X.MC?=,<T'QR<1OVQ)[\EODJD^HPWM4C\C,>'SWK$'L4W(_\
M!UL;[ICF@^.3B=^^)/?LO\E4GU&,=[=)R^TS&8!/]OGN$#+^TY:S![%-R/\
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MZV-]TQS0?')PW[XD]^R_R52=NO\ $8G>U2 ;;E,:B<Y^>.JW#,<<'L4W(_\
M!UL;[ICF@^.3AOWQ)[]E_DJD[=?XC$'#=)_(S&?^?GN$#9,<<2:T#RRZ5Y7Z
MR?J&DJG,J0*T6J7=K S/MUTND\M:)PP4'E%I9N]V&RFW'G1H07&RSZHXC(3%
MPMMA+KCRW.)5:M4*V^U,5*8W=UEE,NT4M,LI0RA2E);2VPVVVE*2M1%D#7'3
CD:?*TUM;4HV6T..%U>DM;JE.%*4E16ZI:R2$I&:CJ%H__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233442328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-04321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CONTEXT THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-3738787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2001 Market Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 3915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Unit #15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">225-7416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CNTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive Proxy Statement for its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001842952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233411416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">CohnReznick LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Holmdel, New Jersey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233517432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,635,197<span></span>
</td>
<td class="nump">$ 290,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,620,164<span></span>
</td>
<td class="nump">8,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">51,255,361<span></span>
</td>
<td class="nump">299,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">50,389<span></span>
</td>
<td class="nump">50,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">51,305,750<span></span>
</td>
<td class="nump">467,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,829,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable&#8212;current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,826,294<span></span>
</td>
<td class="nump">2,707,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,207,121<span></span>
</td>
<td class="nump">955,989<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,033,415<span></span>
</td>
<td class="nump">9,548,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable&#8212;noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">69,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,033,415<span></span>
</td>
<td class="nump">9,617,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock and redeemable common stock (no shares authorized at December 31, 2021):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,771,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#8212;$0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;$0.001 par value; 100,000,000 shares authorized; 15,966,053 and 331,789 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">77,510,809<span></span>
</td>
<td class="nump">1,876,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(29,254,440)<span></span>
</td>
<td class="num">(18,797,570)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">48,272,335<span></span>
</td>
<td class="num">(16,921,079)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, redeemable common stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">51,305,750<span></span>
</td>
<td class="nump">467,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock and redeemable common stock (no shares authorized at December 31, 2021):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,400,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock and redeemable common stock (no shares authorized at December 31, 2021):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,341,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_RedeemableCommonStockMember', window );">Redeemable Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock and redeemable common stock (no shares authorized at December 31, 2021):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cntx_RedeemableCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cntx_RedeemableCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233543032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">331,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">331,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">210,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">210,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_RedeemableCommonStockMember', window );">Redeemable Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cntx_RedeemableCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cntx_RedeemableCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233535000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 3,087,832<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">3,805,067<span></span>
</td>
<td class="nump">1,641,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,632,920<span></span>
</td>
<td class="nump">930,667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,525,819)<span></span>
</td>
<td class="num">(2,572,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(64,240)<span></span>
</td>
<td class="num">(661,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_FairValueAdjustmentOnConvertibleDebt', window );">Change in fair value of convertible promissory notes</a></td>
<td class="nump">9,317<span></span>
</td>
<td class="nump">9,877,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">123,872<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (10,456,870)<span></span>
</td>
<td class="nump">$ 6,644,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic (in dollars per share)</a></td>
<td class="num">$ (3.69)<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted (in dollars per share)</a></td>
<td class="num">$ (3.69)<span></span>
</td>
<td class="num">$ (3.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">2,833,674<span></span>
</td>
<td class="nump">348,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">2,833,674<span></span>
</td>
<td class="nump">2,054,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_FairValueAdjustmentOnConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment On Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_FairValueAdjustmentOnConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098226881624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Private Placement</div></th>
<th class="th"><div>Warrants issued in conjunction with series A preferred stock</div></th>
<th class="th"><div>Issued to placement agents</div></th>
<th class="th"><div>Issued for services</div></th>
<th class="th"><div>Issued in connection with IPO</div></th>
<th class="th"><div>Series A Preferred Stock</div></th>
<th class="th"><div>Series Seed Preferred Stock</div></th>
<th class="th"><div>Redeemable Common Stock</div></th>
<th class="th"><div>Common&#160;stock</div></th>
<th class="th">
<div>Common&#160;stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common&#160;stock </div>
<div>Private Placement</div>
</th>
<th class="th">
<div>Common&#160;stock </div>
<div>Issued in connection with IPO</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Private Placement</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Warrants issued in conjunction with series A preferred stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Issued to placement agents</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Issued for services</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Issued in connection with IPO</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,537<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,178<span></span>
</td>
<td class="nump">2,615,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 529,902<span></span>
</td>
<td class="nump">$ 6,291,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrants', window );">Fair value of warrants issued in conjunction with the Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue', window );">Change in fair value of redeemable common stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (97,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,715<span></span>
</td>
<td class="nump">2,624,324<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 7,771,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,935<span></span>
</td>
<td class="nump">$ 6,341,288<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">(23,960,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,480,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,442,035)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued in conjunction with the Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</a></td>
<td class="nump">219,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Change in fair value of redeemable common stock to redemption value</a></td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">6,644,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,644,465<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="num">(16,921,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,876,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,797,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,982,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,728,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices', window );">Temporary equity, stock issued for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices', window );">Temporary equity, stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,837,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrants', window );">Fair value of warrants issued in conjunction with the Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees', window );">Fair value of warrants issued as placement agent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43,797)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue', window );">Change in fair value of redeemable common stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares', window );">Conversion of convertible preferred shares and redeemable common shares upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,212,543)<span></span>
</td>
<td class="num">(2,624,324)<span></span>
</td>
<td class="num">(16,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares', window );">Conversion of convertible preferred shares and redeemable common shares upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,641,005)<span></span>
</td>
<td class="num">$ (6,341,288)<span></span>
</td>
<td class="num">$ (82,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued in conjunction with the Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,593<span></span>
</td>
<td class="nump">$ 43,797<span></span>
</td>
<td class="nump">$ 371,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,593<span></span>
</td>
<td class="nump">$ 43,797<span></span>
</td>
<td class="nump">$ 371,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation expense, including vesting of restricted stock and issuance of common stock</a></td>
<td class="nump">511,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible securities</a></td>
<td class="nump">137,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">137,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares', window );">Conversion of convertible preferred shares and redeemable common shares upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,853,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares', window );">Conversion of convertible preferred shares and redeemable common shares upon initial public offering</a></td>
<td class="nump">21,064,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,059,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Change in fair value of redeemable common stock to redemption value</a></td>
<td class="num">(53,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock in initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,428,626<span></span>
</td>
<td class="nump">$ 28,880,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,750<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,422,876<span></span>
</td>
<td class="nump">$ 28,875,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(10,456,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,456,870)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 48,272,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,510,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,254,440)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Due To Conversion To Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityDecreaseDueToConversionToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177168-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098238355752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityOfferingCosts', window );">Offering costs</a></td>
<td class="nump">$ 310,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_StockIssuedDuringPeriodIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">4,321,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_StockIssuedDuringPeriodIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2,369,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_StockIssuedDuringPeriodIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_StockIssuedDuringPeriodIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233217240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (10,456,870)<span></span>
</td>
<td class="nump">$ 6,644,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">3,087,832<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants for services provided</a></td>
<td class="nump">371,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">511,079<span></span>
</td>
<td class="nump">219,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">46,315<span></span>
</td>
<td class="nump">661,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_FairValueAdjustmentOnConvertibleDebt', window );">Change in fair value of convertible promissory notes</a></td>
<td class="num">(9,317)<span></span>
</td>
<td class="num">(9,877,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="num">(125,577)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,611,492)<span></span>
</td>
<td class="nump">4,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(866,007)<span></span>
</td>
<td class="nump">556,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">252,655<span></span>
</td>
<td class="nump">757,701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(8,799,487)<span></span>
</td>
<td class="num">(1,034,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from the issuance of convertible bridge notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from the issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from the sale of common stock in initial public offering, net</a></td>
<td class="nump">24,428,626<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the sale of common stock in private placement, net</a></td>
<td class="nump">28,982,575<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">58,394,036<span></span>
</td>
<td class="nump">1,149,054<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">49,344,549<span></span>
</td>
<td class="nump">114,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">341,037<span></span>
</td>
<td class="nump">226,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">49,685,586<span></span>
</td>
<td class="nump">341,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_WarrantsIssued', window );">Issuance of warrants in conjunction with Series A preferred stock and placement agent fees</a></td>
<td class="nump">309,390<span></span>
</td>
<td class="nump">78,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of warrants in conjunction with Series A preferred stock and placement agent fees</a></td>
<td class="nump">2,837,832<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_DeferredOfferingCostIncurredButNotYetPaid', window );">Unpaid offering costs in accounts payable</a></td>
<td class="nump">102,071<span></span>
</td>
<td class="nump">117,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue', window );">Change in fair value of redeemable common stock to redemption value</a></td>
<td class="nump">53,330<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock and redeemable common stock upon initial public offering</a></td>
<td class="nump">21,064,623<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_DemandNotesToConvertiblePromissoryNotesMember', window );">Demand Notes to Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes</a></td>
<td class="nump">5,866,290<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_BridgeNotesToSeriesAPreferredStockMember', window );">Bridge Notes to Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">529,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember', window );">Convertible Promissory Notes To Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,291,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the sale of preferred stock</a></td>
<td class="nump">4,982,835<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the sale of preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_DeferredOfferingCostIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Cost Incurred but Not yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_DeferredOfferingCostIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_FairValueAdjustmentOnConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment On Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_FairValueAdjustmentOnConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_DemandNotesToConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_DemandNotesToConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_BridgeNotesToSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_BridgeNotesToSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236267464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">Nature of Business Context Therapeutics Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#8217;s operations are located in Philadelphia, Pennsylvania. In April 2021, the Company completed a reverse triangular merger, which resulted in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger, all common units, preferred units, options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock, options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. As this was a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities and equity of Context Therapeutics LLC. Further, as a common control transaction, the consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098237147928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_RisksAndLiquidityAbstract', window );"><strong>Risks And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_RisksAndLiquidityTextBlock', window );">Risks and Liquidity</a></td>
<td class="text">Risks and Liquidity <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $29.3 million as of December&#160;31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its product candidates currently in development. The Company&#8217;s primary source of liquidity to date has been the issuance of convertible promissory notes, convertible preferred stock and common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first half of 2021, the Company raised $5.0 million in net proceeds related to the sale of its Series A convertible preferred stock (&#8220;Series A Stock&#8221;) and warrants for common stock (see Note 7 for further discussion). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2021, the Company closed an initial public offering (&#8220;IPO&#8221;) on the Nasdaq Stock Market, in which it issued and sold 5,750,000 shares at a public offering price of $5.00 per share. In addition, at the closing of the IPO, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent&#8217;s warrants have an exercise price of $6.25 per share and a term of five years from the date of issuance. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and 480,415 warrants converted into 9,816 shares of common stock. The Company received net proceeds of $24.4&#160;million as a result of its initial public offering. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company sold 5,000,000 shares of its common stock together with warrants to purchase 5,000,000 shares of its common stock in a private placement and received net proceeds of $28.9 million.  Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. In addition, at the closing of the private placement, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent&#8217;s warrants have an exercise price of $6.25 per share and a term of 5.5 years from the date of issuance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its cash and cash equivalents at December&#160;31, 2021 are sufficient to fund its projected operations into fiscal year 2024. However, substantial additional capital will be needed by the Company to fund its operations and to commercially develop its current and future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to secure additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#8217;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#8217;s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#8217;s product candidates, length of time and cost of developing and commercializing these </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#8217;s financial condition and future operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. </span></div>In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks And Liquidity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks And Liquidity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236268296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of Prior Year Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of warrants, the fair value of convertible debt, and prepayments, accruals and associated expense related to research and development activities performed for the Company by third parties. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, the Company&#8217;s level 1 financial instruments included cash equivalents and accounts payable. The carrying amounts of these assets and liabilities approximate fair value due to their short-term nature. Convertible promissory notes are recorded at approximate fair value on a recurring basis (see Note 4 for further discussion). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains approximately $50,000 as collateral for the Company&#8217;s credit card program. The Company has recorded this deposit and accumulated interest thereon as restricted cash on its consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s cash, cash equivalents, and restricted cash as of December 31, 2021 and 2020:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"/><td style="width:51.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,635,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,685,586&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations.  As of December&#160;31, 2020, the Company had deferred offering costs of $0.1 million related to the Company&#8217;s IPO and the Company&#8217;s Series A Stock financing.  All deferred offering costs related to the Company&#8217;s Series A Stock financing were recorded against Series A Stock upon completion of the financing in April 2021 and all deferred offering costs related to the Company&#8217;s IPO were recorded against additional paid-in capital upon completion of the IPO financing in October 2021. There were no deferred offering costs recorded as of December&#160;31, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock and Redeemable Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its convertible preferred stock subject to possible conversion in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Conditionally convertible preferred stock (including shares that feature conversion rights that are either within the control of the holder or subject to conversion upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. The Company&#8217;s convertible preferred stock feature redemption rights that are considered by the Company to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020, the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible preferred stock subject to contingent redemption are presented as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development Costs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expense consists of the initial up-front payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company&#8217;s acquired IPR&amp;D expense of $3.1&#160;million for the year ended December 31, 2021 reflects the fair value of consideration ascribed to the collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) for gynecologic cancer therapy. See Note 9 for further discussion.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of prepaid/accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the prepaid/accrual accordingly. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients&#8217; service payments are classified. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. Until its IPO that closed in October 2021, the Company had been a private company and lacked Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted stock awards based on the grant date fair value of the awards. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to April 2021, the Company was a limited liability company that was treated as a pass-through entity for income tax purposes. In April 2021, upon the completion of its reverse triangular merger, the Company converted to a corporation and is subject to federal, state and local corporate income taxes which have been provided for in the financial statements based upon ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 740&#8221;).  Context BioPharma, Inc. has always been subject to corporate income taxes. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under ASC 740, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting. Deferred tax assets are reduced by a valuation allowance if a determination is made that it is more likely than not that some or all of the deferred tax assets will not be realized based on the weight of all available evidence.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an examination. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50&#160;percent likelihood of being realized upon settlement with the relevant authority. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s consolidated statements of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income Per Share </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes net (loss) income per share using the weighted-average number of common shares outstanding during the year. For years with a net loss, basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which includes convertible promissory notes, preferred stock, warrants and share-based awards outstanding, would be anti-dilutive.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was in a net loss position for the year ended December 31, 2021 and therefore basic and diluted net loss per share was the same. The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020, as they would be anti-dilutive:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:67.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,006,691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, the Company was in a net income position and therefore, used the two-class method to compute basic net income per common share. Under this method, undistributed earnings are allocated to common stock, the Series Seed Preferred Stock and the Series A Preferred Stock to the extent that the preferred stockholders may share in earnings. In periods of net loss, losses are not allocated to participating securities as the holders of such securities have no obligation to fund losses. The total earnings allocated to common stock is then divided by the weighted average common shares outstanding to determine the basic earnings per share. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants and share-based awards using the treasury stock method. In addition, the Company considers the potential dilutive impact of its preferred stock and convertible debt using the treasury stock and if-converted methods, if either is more dilutive than the two-class method. The two-class method was more dilutive for the year ended December 31, 2020. </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net (loss) income per common share calculation:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed earnings to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,573,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders - basic</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - basic</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net (loss) income per common share calculation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed earnings to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,573,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: change in fair value of convertible promissory notes and interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,216,633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders &#8211; diluted</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,145,726)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - diluted</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.96)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt&#8212;Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 470-20) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminated the beneficial conversion (and cash conversion) accounting models in ASC 470-20 that require separate accounting for embedded conversion features and simplified the settlement assessment to determine whether it qualifies for equity classification by removing certain conditions in ASC 815-40-25. In addition, the new guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments and to include the effect of share settlement for instruments that may be settled in cash or shares. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its financial statements and related disclosures. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2016, the FASB issued ASU 2016-02,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,&#160;in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a)&#160;the existence of a lease, (b)&#160;the lease classification or (c)&#160;the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases (Topic 842): Targeted Improvements</span>, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098239357768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2 &#8211; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3 &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Active Markets for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets (Level 1) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant&#160;Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Observable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 2) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unobservable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 3) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents and restricted cash (Money Market Accounts)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,051,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,051,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Active Markets for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets (Level 1) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant&#160;Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Observable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 2) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unobservable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 3) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (Money Market Account)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Promissory Notes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described in Note 6, the Company issued convertible promissory notes from inception through April 2019 (the &#8220;Junior Convertible Notes&#8221;) to various investors and from October 2019 through March 2020, the Company issued convertible bridge notes to the Co-Founder and Chief Executive Officer (the &#8220;Convertible Bridge </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes&#8221;). During April 2020, certain of the Junior Convertible Notes were converted into Senior Convertible Notes (the &#8220;Senior Convertible Notes&#8221;) (collectively, the &#8220;Convertible Promissory Notes&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the number of embedded provisions contained in the Convertible Promissory Notes and Convertible Bridge Notes, the fair value option, as prescribed by ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was elected and applied to all Convertible Promissory Note and Convertible Bridge Note issuances since the Company&#8217;s inception in 2015, in connection with the preparation of these financial statements. The fair value of the Convertible Promissory Notes and Convertible Bridge Notes was determined using a scenario-based analysis that estimates the fair value based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the noteholders, including various IPO, settlement, equity financing, corporate transaction and dissolution scenarios. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adjusted the carrying value of its Convertible Promissory Notes and Convertible Bridge Notes to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as change in fair value of convertible promissory notes in the consolidated statement of operations. The change in fair value of convertible promissory notes within the years ended December 31, 2021 and 2020 consolidated statement of operations also includes reversals of gains and losses previously recognized by the Company upon conversion of the notes (Note 6).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Convertible Notes at  December 31, 2020 was calculated using an option pricing model (&#8220;OPM&#8221;) framework and utilized the back-solve method for inferring and allocating the equity value predicated on the concurrent sale of Series A Stock. This method was selected as it was concluded that the sale of the Series A Stock was an arm&#8217;s-length transaction. Application of the OPM back-solve method involves making assumptions for the expected time to liquidity and volatility, and then solving for the value of equity such that value for the most recent financing equals the amount paid.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of the aggregate fair values of the Company&#8217;s Convertible Promissory Notes (Note 6) for which fair value is determined by Level&#160;3 inputs: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,842,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Convertible Bridge Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,877,857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of Junior Convertible Notes into Series Seed Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,291,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of Senior and Convertible Bridge Notes into Series A Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,866,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236147320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098237121064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Promissory Notes</a></td>
<td class="text">Convertible Promissory Notes <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Junior Convertible Notes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December 2018, the Company issued Junior Convertible Notes and demand notes that converted into Junior Convertible Notes which, due to certain embedded features within the Junior Convertible Notes, the Company elected to account for these notes and all their embedded features under the fair value option. All of the outstanding principal and accrued but unpaid interest associated with the Junior Convertible Notes converted into 2,615,553 shares of Series Seed Stock in May 2020, of which 840,363 shares were issued to the Company&#8217;s Chief Executive Officer and an immediate family member (&#8220;Related Party&#8221;). At the time of conversion, the estimated fair value of the Junior Convertible Notes was $6.3 million and was reclassified to Series Seed convertible preferred equity. In connection with the conversion in 2020, the Company recorded a non-cash credit of $7.7 million related to the final decrease in fair value of the Junior Convertible Notes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Bridge Notes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From October 2019 through March 2020, the Company issued convertible bridge notes to the Related Party in the amount of $0.5 million. On December&#160;22, 2020, the outstanding principal and accrued but unpaid interest associated with the Convertible Bridge Notes converted into 78,178 Series A Stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to certain embedded features within the Convertible Bridge Notes, the Company elected to account for these notes and all their embedded features under the fair value option. At the time of conversion, the estimated fair value of the Convertible Bridge Notes was $0.5 million and was reclassified to Series A convertible preferred equity.  In connection with the conversion in December 2020, the Company recorded a non-cash credit of $0.1 million related to the final decrease in fair value of the Convertible Bridge Notes. For the year ended December 31, 2020, the Company recognized approximately $30,000 of interest expense in connection with the Convertible Bridge Notes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Convertible Notes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, $5.1 million of principal and $0.6 million of accrued interest related to certain Junior Convertible Notes were converted into Senior Convertible Notes. Of the Senior Convertible Notes issued in 2020, $2.5 million of principal and $0.4 million of accrued interest were issued to the Related Party. During the year ended December 31, 2021, the outstanding principal and accrued but unpaid interest associated with the Senior Convertible Notes converted into 844,824 shares of Series A Stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, the Company recognized a credit of $2.1 million in the consolidated statement of operations related to decreases in the fair value of the Senior Convertible Notes. For the year ended December 31, 2020, the Company recognized $0.3 million of interest expense in connection with the Senior Convertible Notes, including $0.1 million payable to the Related Party. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into an original loan agreement with Pacific Western Bank as the lender (&#8220;Lender&#8221;) for a loan in an aggregate principal amount of $0.1 million (the &#8220;Loan&#8221;) pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Coronavirus Aid, Relief, and Economic Security (CARES) Act and implemented by the U.S. Small Business Administration. In June 2020, the Paycheck Protection Program Flexibility Act was enacted, which among other things, extended the deferral period for loan payments to either (1)&#160;the date that Small Business Administration remits the borrower&#8217;s loan forgiveness amount to the lender or (2)&#160;if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower&#8217;s loan forgiveness covered period. The Loan was set to mature in two years and bore interest at a rate of 1.0% per year, with all payments deferred through September&#160;5, 2021. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The outstanding principal balance of the Loan of $0.1 million was forgiven in July 2021 and was recognized as a gain on extinguishment of debt within other income in the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236120792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Redeemable Common Stock and Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock, Redeemable Common Stock and Common Stock</a></td>
<td class="text">Convertible Preferred Stock, Redeemable Common Stock and Common Stock <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company converted $11.7 million of principal and interest related to certain Junior Convertible Notes into 2,615,553 shares of Series Seed Stock at prices ranging from $4.28 to $4.56 per share. In May 2020, the Related Party purchased 8,771 shares of Series Seed Stock at a price of $5.70 per share for $50,000. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2020, the Company sold 132,537 shares of Series A Stock to the Related Party for $7.168 per share for proceeds of $1.0 million. The Company also issued 33,129 warrants to purchase common stock at an exercise price of $7.168 per share to the Series A Stock holder as part of the Series A Stock financing. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, $0.6 million in principal and accrued interest related to the Convertible Bridge Notes were converted into 78,178 shares of Series A Stock. The Company also issued 19,544 warrants to purchase common stock at an exercise price of $7.168 per share to the Series A stockholders as part of the conversion from Convertible Bridge Notes to Series A Stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February, March and April 2021, the Company sold 738,445 shares of Series A Stock for $7.168 per share for net proceeds of $5.0 million. The Company also issued 184,597 warrants to purchase common stock at an exercise price of $7.168 to the Series A stockholders as part of the Series A Stock financing. Additionally, the Company issued 24,134 warrants to purchase common stock at an exercise price of $7.168 to placement agents as a part of the Series A Stock financing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company converted $6.1&#160;million of principal and interest related to Senior Convertible Notes into 844,824 shares of Series A Stock at a price of $7.168 per share. In addition, warrants with a fair value of $0.1&#160;million associated with the Senior Convertible Notes were reclassified into additional paid-in capital.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company completed its IPO in which the Company sold 5,750,000 shares at a public offering price of $5.00 per share. Immediately prior to the completion of the IPO, all of the Company&#8217;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and all of the outstanding warrants converted into 9,816 shares of common stock. The Company received net proceeds of $24.4&#160;million as a result of the offering. The Company issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per shares and a term of 5.0 years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock and received net proceeds of $28.9 million in a private placement. Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have a term of 5.5 years and an exercise price of $6.25 per share. The Company also issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per share and a term of 5.5 years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants for Common Stock </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At December&#160;31, 2021, the Company had the following warrants outstanding to acquire common stock: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:47.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration&#160;dates</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued in connection with IPO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued as part of December 2021 private placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During its evaluation of equity classification for the Company's common stock warrants issued in 2021, the Company considered the conditions as prescribed within ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging, Contracts in an Entity&#8217;s own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The conditions within ASC 815-40 are not subject to a probability assessment. The warrants do not fall under the liability criteria within ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Distinguishing Liabilities from Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as they are not puttable and do not represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company effected a one-for-6 reverse stock split of its common stock and convertible preferred stock. No fractional shares were issued in connection with the reverse stock split. Any fractional share resulting from the reverse stock split was rounded down to the nearest whole share, and in lieu of any fractional shares, the Company paid in cash to the holders of such fractional shares an amount equal to the fair value, as determined by the board of directors, of such fractional shares. All common stock, convertible preferred stock, per share and related information presented in the consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236239800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">Share-based Compensation <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Context Therapeutics Inc. adopted the 2021 Long-Term Incentive Plan (&#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units and stock grants. The 2021 Incentive Plan allows for the issuance of up to 1,266,092 shares of common stock (the &#8220;Share Limit&#8221;). The Share Limit will automatically increase on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (4%) of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of December&#160;31, 2021, 742,706 shares remained available for future grants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Grants</span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2020, the Company issued 7,512 shares of common stock to members of the board of managers as compensation for their services. The Company recorded share-based compensation expense of $0.1 million in general and administrative expense during the year ended December 31, 2020.  </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options generally vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4NjE_01118990-dc7d-4e7f-96e0-43c8e460d916">one</span> to four years, and stock options that lapse or are forfeited are available to be granted again. The contractual life of all stock options is 10 years. The expiration dates of the outstanding stock options range from January 2028 to November 2031. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock options at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Stock option compensation expense is allocated to </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees and consultants based on their respective departments. All board of directors&#8217; compensation is charged to general and administrative expense. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock option compensation expense of $74,000 and $404,000 in research and development and general and administrative expense, respectively, during the year ended December&#160;31, 2021.  The Company recorded stock option compensation expense of $75,000 and $29,000 in research and development and general and administrative expense, respectively, during the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option awards granted to employees during 2021 and 2020 were as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.06%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.86%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.78</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity for the periods presented: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(years) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,059&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The weighted average fair value of share-based awards granted during the years ended December 31, 2021 and 2020 was $3.84 and $9.34, respectively. The aggregate intrinsic value of the options outstanding and exercisable as of December 31, 2021 was $0. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of December&#160;31, 2021, the unrecognized compensation cost related to outstanding stock options was $1.5 million and is expected to be recognized as expense over a weighted-average period of approximately 1.73 years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues restricted stock units (&#8220;RSU&#8221;) to employees and consultants that generally vest monthly over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwNDQ_d169f036-bec1-4a91-89bb-ca2c7da81f4f">one</span> to three-year periods. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the service period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to RSU share-based payment awards: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date&#160;Fair&#160;value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at January&#160;1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded share-based compensation expense of $33,000 in research and development expense for the year ended December&#160;31, 2021 related to RSUs. The Company recorded share-based compensation expense of $2,000 in general and administrative expense for the year ended December&#160;31, 2020 related to RSUs. As of December&#160;31, 2021, there was no remaining unrecognized expense related to RSUs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236063064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent License Agreement with Drexel University </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the Company entered into a patent license agreement, as amended, (the &#8220;Drexel License Agreement&#8221;) with Drexel for license rights to patents for certain intellectual property and know-how related to certain technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Drexel License Agreement, the Company issued Drexel 16,666 shares of common stock. In partial consideration of the Drexel License Agreement, the Company is required to pay to Drexel certain milestone payments, ranging from $10,000 to $0.2 million on the achievement of certain milestone events for each licensed product. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to pay Drexel a royalty in the low single digits of net sales for each licensed product on a country-by-country, licensed product-by-licensed product basis on issued or pending valid claims. The Company may credit against amounts payable to Drexel, on a country-by-country, licensed product-by-licensed product basis up to 50% of any third-party payments which the Company must make on account of third-party license agreements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration of the Drexel License Agreement, the Company will pay to Drexel a de-escalating sublicense fee on a quarterly basis of a high single-digit percentage that decreases to a mid-single digit percentage as time passes. In addition, the Company will make payments of the fair market value of all other consideration received by the Company from sublicensees during the quarter, other than: (a)&#160;royalties paid to the Company by a sublicensee based upon sales or net sales by the sublicensee; (b)&#160;equity investments in the Company by a sublicensee up to the amount of fair market value of the equity purchased on the date of the investment; (c)&#160;loan proceeds paid to the Company by a sublicensee in an arm&#8217;s length, full recourse debt financing to the extent that such loan is not forgiven; and (d)&#160;sponsored research funding, paid to the Company by a sublicensee in a bona fide transaction for future research to be performed by the Company. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a strategic review of its pipeline, the Company recently notified Drexel that it is terminating the Drexel License Agreement, effective as of April 27, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreement with Tyligand Bioscience </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a license (the &#8220;Tyligand License Agreement&#8221;) and process development agreement (the &#8220;Tyligand Process Development Agreement&#8221;) (collectively, the &#8220;Tyligand </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements&#8221;) with Tyligand Bioscience (Shanghai) Limited (&#8220;Tyligand&#8221;) for the development, manufacturing, registration and future commercialization of onapristone extended release (&#8220;ONA-XR&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Tyligand Agreements, Tyligand will be solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand will be granted the exclusive right to ONA-XR and will be solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#8220;Territory&#8221;). The Company will retain rest of world rights to commercialize ONA-XR. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tyligand Process Development Agreement, the Company is obligated to pay Tyligand $0.8 million and a certain number of warrants exercisable for common stock upon successful completion of the manufacturing development plan, $2.0 million upon the completion of scale-up of the first cumulative 100 kilograms of the GMP-grade compound and $3.0 million upon the Company&#8217;s completion of scale-up of the first cumulative 300 kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#8217;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand 1% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i)&#160;the sale of a generic product in the territory and (ii) 15 years after the date of the first commercial sale of product in the territory. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, upon successful completion of the process development plan with Tyligand, the Company issued Tyligand warrants to purchase 111,576 shares of common stock at an exercise price of $7.17 per share all of which were cancelled in connection with the IPO. The Company recognized an expense and liability of $0.4&#160;million to account for the fair value of the warrants upon completion of the manufacturing development plan in June 2021. Upon issuance of the warrants in August 2021, the Company reclassified the $0.4&#160;million liability into equity. The Company has expensed $0.8&#160;million related to the process development plan as of December 31, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, while the Company&#8217;s license agreement with Tyligand was signed in March 2020, the parties acknowledged that such signature was premature since the &#8216;successful completion&#8217; under the process development agreement had not yet occurred, and as such, the parties properly executed the license agreement upon such successful completion in August 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and Licensing Agreement with Integral Molecular</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) for the development of an anti-claudin 6 (&#8220;CLDN6&#8221;) bispecific monoclonal antibody (&#8220;BsMAb&#8221;) for gynecologic cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The Company paid an upfront license fee of $0.3&#160;million and granted 418,559 shares of Series A Stock with a fair market value of approximately $2.8&#160;million, and these costs were expensed to acquired in-process research and development during the year ended December 31, 2021. As a part of the agreement, Integral will be eligible to receive development and regulatory milestone payments totaling up to $55.3&#160;million, sales milestone payments totaling up to $130&#160;million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company leased its corporate offices in Philadelphia, Pennsylvania under a month-to-month lease arrangement. The Company recorded rent expense of approximately $10,000 for the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 30, 2023. The minimum lease payments under the sublease is $0.1&#160;million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div>Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company believes no matters existed at either December&#160;31, 2021 or 2020 that will have a material impact to the Company&#8217;s financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236230680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2021 and 2020. The Company had also not recorded any income tax benefits for the net operating losses incurred in each period due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,874&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,802,828&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569,489&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(527,181)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,275,647)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,569,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2021 and 2020. The valuation allowance increased by $1.7 million and $0.2 million during the years ended December&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense/(benefit) at statutory rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable partnership income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes carryforwards of federal, state and local net operating losses (&#8220;NOL&#8221;) and research tax credits: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;Federal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,030,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,030,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;Local</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,926,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits&#8212;Federal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL carryforwards begin expiring in 2037 for federal and state income tax purposes; however, all federal NOL carryforwards generated subsequent to January&#160;1, 2018, are able to be carried forward indefinitely. Local NOL carryforwards expire after three years with the 2019 NOL set to expire in 2022. As of December&#160;31, 2021 and 2020, the Company had federal research and development tax credit carryforwards of $0.4 million and  $0.3 million, respectively, that will begin to expire in 2037, unless previously utilized. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception. State and local NOLs may also be limited. </span></div>As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s consolidated statement of operations. Due to NOLs and tax credit carry forwards that remain unutilized, income tax returns for tax years from all years remain subject to examination by the taxing jurisdictions. The NOL carryforwards remain subject to review until utilized.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236077464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions Since inception through December&#160;31, 2021, the Company entered into various convertible note agreements with the Related Party. The terms of the convertible notes and their subsequent conversions are further described in more detail in Note 6 and Note 7.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236124152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events In March 2022, the Company issued 360,000 warrants to purchase common stock with an exercise price of $10.00 per share and a term of 5.76 years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $0.3&#160;million was recorded in general and administrative expense on the consolidated statement of operations for the year ended December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233464600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification of Prior Year Presentation</a></td>
<td class="text">Reclassification of Prior Year PresentationCertain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div>Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of warrants, the fair value of convertible debt, and prepayments, accruals and associated expense related to research and development activities performed for the Company by third parties.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments At December&#160;31, 2021 and 2020, the Company&#8217;s level 1 financial instruments included cash equivalents and accounts payable. The carrying amounts of these assets and liabilities approximate fair value due to their short-term nature. Convertible promissory notes are recorded at approximate fair value on a recurring basis<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityPolicyPolicyTextBlock', window );">Convertible Preferred Stock and Redeemable Common Stock</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock and Redeemable Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its convertible preferred stock subject to possible conversion in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Conditionally convertible preferred stock (including shares that feature conversion rights that are either within the control of the holder or subject to conversion upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. The Company&#8217;s convertible preferred stock feature redemption rights that are considered by the Company to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020, the </span></div>convertible preferred stock subject to contingent redemption are presented as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development Costs</a></td>
<td class="text">Acquired In-Process Research and Development Costs<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expense consists of the initial up-front payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of prepaid/accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the prepaid/accrual accordingly. </span></div>Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients&#8217; service payments are classified. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. Until its IPO that closed in October 2021, the Company had been a private company and lacked Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></div>In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted stock awards based on the grant date fair value of the awards.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to April 2021, the Company was a limited liability company that was treated as a pass-through entity for income tax purposes. In April 2021, upon the completion of its reverse triangular merger, the Company converted to a corporation and is subject to federal, state and local corporate income taxes which have been provided for in the financial statements based upon ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 740&#8221;).  Context BioPharma, Inc. has always been subject to corporate income taxes. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under ASC 740, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting. Deferred tax assets are reduced by a valuation allowance if a determination is made that it is more likely than not that some or all of the deferred tax assets will not be realized based on the weight of all available evidence.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an examination. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50&#160;percent likelihood of being realized upon settlement with the relevant authority. </span></div>The Company will recognize interest and penalties related to uncertain tax positions in income tax expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income Per Share </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes net (loss) income per share using the weighted-average number of common shares outstanding during the year. For years with a net loss, basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which includes convertible promissory notes, preferred stock, warrants and share-based awards outstanding, would be anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Debt&#8212;Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 470-20) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminated the beneficial conversion (and cash conversion) accounting models in ASC 470-20 that require separate accounting for embedded conversion features and simplified the settlement assessment to determine whether it qualifies for equity classification by removing certain conditions in ASC 815-40-25. In addition, the new guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments and to include the effect of share settlement for instruments that may be settled in cash or shares. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its financial statements and related disclosures. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2016, the FASB issued ASU 2016-02,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,&#160;in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a)&#160;the existence of a lease, (b)&#160;the lease classification or (c)&#160;the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases (Topic 842): Targeted Improvements</span>, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent Costs, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098239226024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">The following table presents the Company&#8217;s cash, cash equivalents, and restricted cash as of December 31, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"/><td style="width:51.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,635,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,685,586&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020, as they would be anti-dilutive:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:67.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,006,691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text">The two-class method was more dilutive for the year ended December 31, 2020. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net (loss) income per common share calculation:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed earnings to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,573,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders - basic</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - basic</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net (loss) income per common share calculation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: undistributed earnings to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,573,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: change in fair value of convertible promissory notes and interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,216,633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to common shareholders &#8211; diluted</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,456,870)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,145,726)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - diluted</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.96)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236131848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Active Markets for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets (Level 1) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant&#160;Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Observable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 2) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unobservable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 3) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents and restricted cash (Money Market Accounts)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,051,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,051,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Active Markets for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets (Level 1) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant&#160;Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Observable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 2) </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unobservable&#160;Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Level 3) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (Money Market Account)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Promissory Notes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Roll-forward of fair values of liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a roll-forward of the aggregate fair values of the Company&#8217;s Convertible Promissory Notes (Note 6) for which fair value is determined by Level&#160;3 inputs: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,842,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Convertible Bridge Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,877,857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of Junior Convertible Notes into Series Seed Stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,291,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of Senior and Convertible Bridge Notes into Series A Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,866,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,829,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236036632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236229352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text">At December&#160;31, 2021, the Company had the following warrants outstanding to acquire common stock: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:47.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration&#160;dates</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued in connection with IPO</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued as part of December 2021 private placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098239140904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option awards granted to employees during 2021 and 2020 were as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.06%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.86%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.78</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-Based Award Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity for the periods presented: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(years) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,059&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSU Share-Based Payment Award Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to RSU share-based payment awards: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date&#160;Fair&#160;value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at January&#160;1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;13.55</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098239213080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of tax effects of temporary differences that give rise to the deferred tax assets and liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,874&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,802,828&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569,489&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(527,181)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,275,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,275,647)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,569,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense/(benefit) at statutory rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal benefit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable partnership income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of operating loss carryforwards</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes carryforwards of federal, state and local net operating losses (&#8220;NOL&#8221;) and research tax credits: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;Federal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,030,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,887,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,030,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards&#8212;Local</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,926,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits&#8212;Federal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098236133304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business (Details)<br></strong></div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=cntx_ContextTherapeuticsLLCMember', window );">Context Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cntx_ContextTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cntx_ContextTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098234607672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (29,254,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,254,440)<span></span>
</td>
<td class="num">$ (18,797,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,853,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from the sale of common stock in initial public offering, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="nump">$ 24,428,626<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Shares issued upon conversion of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_PlacementAgentsWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember', window );">December 2021 Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember', window );">December 2021 Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issuance, consideration received</a></td>
<td class="nump">$ 28,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_PlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_PlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098226815928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 50,389<span></span>
</td>
<td class="nump">$ 50,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">3,087,832<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Expensed interest related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098226777992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,635,197<span></span>
</td>
<td class="nump">$ 290,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">50,389<span></span>
</td>
<td class="nump">50,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 49,685,586<span></span>
</td>
<td class="nump">$ 341,037<span></span>
</td>
<td class="nump">$ 226,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098234534856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">6,006,691<span></span>
</td>
<td class="nump">184,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">506,691<span></span>
</td>
<td class="nump">24,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">160,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098234992808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net (loss) income per common share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (10,456,870)<span></span>
</td>
<td class="nump">$ 6,644,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: undistributed earnings to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,573,558)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common shareholders - basic</a></td>
<td class="num">$ (10,456,870)<span></span>
</td>
<td class="nump">$ 1,070,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">2,833,674<span></span>
</td>
<td class="nump">348,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic (in dollars per share)</a></td>
<td class="num">$ (3.69)<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net (loss) income per common share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to common shareholders</a></td>
<td class="num">$ (10,456,870)<span></span>
</td>
<td class="nump">$ 6,644,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Less: undistributed earnings to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,573,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Less: change in fair value of convertible promissory notes and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,216,633)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income attributable to common shareholders &#8211; diluted</a></td>
<td class="num">$ (10,456,870)<span></span>
</td>
<td class="num">$ (8,145,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">2,833,674<span></span>
</td>
<td class="nump">348,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Convertible securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,706,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">2,833,674<span></span>
</td>
<td class="nump">2,054,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted (in dollars per share)</a></td>
<td class="num">$ (3.69)<span></span>
</td>
<td class="num">$ (3.96)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2740-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098235722904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash equivalents and restricted cash (Money Market Accounts)</a></td>
<td class="nump">$ 49,685,586<span></span>
</td>
<td class="nump">$ 341,037<span></span>
</td>
<td class="nump">$ 226,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">50,389<span></span>
</td>
<td class="nump">50,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,829,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,829,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash equivalents and restricted cash (Money Market Accounts)</a></td>
<td class="nump">49,051,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash equivalents and restricted cash (Money Market Accounts)</a></td>
<td class="nump">49,051,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash equivalents and restricted cash (Money Market Accounts)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash equivalents and restricted cash (Money Market Accounts)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098226751576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Roll-forward of fair values of liabilities (Details) - Convertible debt - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning balance</a></td>
<td class="nump">$ 5,829,292<span></span>
</td>
<td class="nump">$ 21,842,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustments</a></td>
<td class="num">(9,317)<span></span>
</td>
<td class="num">(9,877,857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">46,315<span></span>
</td>
<td class="nump">660,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,829,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Bridge Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember', window );">Junior Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Conversion of debt into equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,291,288)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember', window );">Bridge Notes to Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Conversion of debt into equity</a></td>
<td class="num">$ (5,866,290)<span></span>
</td>
<td class="num">$ (529,902)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_ConvertibleBridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_ConvertibleBridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_JuniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_JuniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_BridgeNotesToSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_BridgeNotesToSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098226765176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 436,990<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_ClinicalTrialLiabilitiesCurrent', window );">Clinical trial expenses</a></td>
<td class="nump">339,072<span></span>
</td>
<td class="nump">126,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_ManufacturingDevelopmentLiabilitiesCurrent', window );">Manufacturing development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">345,530<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses and other current liabilities</a></td>
<td class="nump">85,529<span></span>
</td>
<td class="nump">269,816<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,207,121<span></span>
</td>
<td class="nump">$ 955,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_ClinicalTrialLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_ClinicalTrialLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_ManufacturingDevelopmentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing Development Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_ManufacturingDevelopmentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098228352472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,240<span></span>
</td>
<td class="nump">$ 661,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,615,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,824<span></span>
</td>
<td class="nump">78,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Junior Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Convertible debt beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount', window );">Converted principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_DebtInstrumentConvertedInstrumentInterestAmount', window );">Converted interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Junior Convertible Notes | Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,615,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Junior Convertible Notes | Series Seed Preferred Stock | Chief Financial Officer And Immediate Family Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Bridge Note Qualified Financing | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes issued to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Bridge Note Qualified Financing | Series A Preferred Stock | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="nump">78,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Convertible Bridge Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Convertible debt beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Convertible Bridge Notes | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Senior Convertible Notes, April 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Convertible debt beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Senior Convertible Notes, April 2020 | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes issued to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_AccruedInterestRelatedParties', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Senior Convertible Notes, April 2020 | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cntx_PaymentProtectionProgramLoanMember', window );">Payment Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_AccruedInterestRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest, Related Parties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_AccruedInterestRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_DebtInstrumentConvertedInstrumentInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Converted Instrument, Interest Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_DebtInstrumentConvertedInstrumentInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_DebtInstrumentConvertedInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Converted Instrument, Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_DebtInstrumentConvertedInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_JuniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_JuniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_BridgeNoteQualifiedFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_BridgeNoteQualifiedFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_ConvertibleBridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_ConvertibleBridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cntx_PaymentProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cntx_PaymentProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098229359112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued in conjunction with the Series A preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cntx_JuniorConvertibleNotesMember', window );">Junior Convertible Notes | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted amount | $</a></td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cntx_ConvertibleBridgeNotesMember', window );">Convertible Bridge Notes | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member', window );">Senior Convertible Notes, April 2020 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember', window );">Issued to placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued in conjunction with the Series A preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToSeriesAStockholdersMember', window );">Issued to Series A Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,445<span></span>
</td>
<td class="nump">132,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare', window );">Temporary equity, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 4,982,835<span></span>
</td>
<td class="nump">$ 950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Convertible Bridge Notes | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Senior Convertible Notes, April 2020 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_DebtConversionConvertedInstrumentPricePerShare', window );">Debt conversion, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare', window );">Temporary equity, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock | Junior Convertible Notes | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued as a result of converted debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,615,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock | Junior Convertible Notes | Convertible Notes Payable | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_DebtConversionConvertedInstrumentPricePerShare', window );">Debt conversion, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">4.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock | Junior Convertible Notes | Convertible Notes Payable | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_DebtConversionConvertedInstrumentPricePerShare', window );">Debt conversion, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_DebtConversionConvertedInstrumentPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_DebtConversionConvertedInstrumentPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_JuniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_JuniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_ConvertibleBridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_ConvertibleBridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cntx_SeniorConvertibleNotesApril2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToSeriesAStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToSeriesAStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cntx_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233001112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">480,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedInConnectionWithIPOMember', window );">Issued in connection with IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedAsPartOfPrivatePlacementMember', window );">Issued as part of December 2021 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedInConnectionWithIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedInConnectionWithIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedAsPartOfPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedAsPartOfPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098228221336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock', window );">Annual rate at which authorized shares of common stock increase</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of grants during period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="nump">$ 9.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,861<span></span>
</td>
<td class="nump">14,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based award contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cntx_StockGrantedForServicesMember', window );">Stock Granted For Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares of common stock authorized for issuance (in shares)</a></td>
<td class="nump">1,266,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense related to RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 404,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cntx_StockGrantedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cntx_StockGrantedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098238213928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">97.06%<span></span>
</td>
<td class="nump">97.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.07%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 10 days<span></span>
</td>
<td class="text">5 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098228288536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-Based Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period ( in shares)</a></td>
<td class="nump">24,830<span></span>
</td>
<td class="nump">24,830<span></span>
</td>
<td class="nump">10,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,861<span></span>
</td>
<td class="nump">14,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at period end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,691<span></span>
</td>
<td class="nump">24,830<span></span>
</td>
<td class="nump">10,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at period end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,059<span></span>
</td>
<td class="nump">130,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at period end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 17.84<span></span>
</td>
<td class="nump">$ 17.84<span></span>
</td>
<td class="nump">$ 20.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.05<span></span>
</td>
<td class="nump">15.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at period end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.68<span></span>
</td>
<td class="nump">$ 17.84<span></span>
</td>
<td class="nump">$ 20.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at period end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at period end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at December 31, 2021</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098235674312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of RSU Share-Based Payment Award Activity (Details) - Unvested restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">50,096<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(20,915)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(29,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 13.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.74<span></span>
</td>
<td class="nump">$ 13.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">1.77<span></span>
</td>
<td class="nump">13.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">$ 1.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098230309000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Sublease minimum payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,445<span></span>
</td>
<td class="nump">738,445<span></span>
</td>
<td class="nump">132,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices', window );">Temporary equity, stock issued for services (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices', window );">Temporary equity, stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,837,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_DrexelUniversityMember', window );">Drexel University | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent', window );">Percentage of payments as to credits accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_DrexelUniversityMember', window );">Drexel University | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_DrexelUniversityMember', window );">Drexel University | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_DrexelUniversityMember', window );">Drexel University | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Redeemable Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity new shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember', window );">Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Maximum obligation amount</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent', window );">Quarterly sales payment due upon completion, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod', window );">Quarterly sales payment due upon completion, period of payment</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember', window );">Integral | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Maximum obligation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum', window );">Maximum development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum', window );">Maximum sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty payment, percent (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember', window );">Integral | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices', window );">Temporary equity, stock issued for services (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices', window );">Temporary equity, stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember', window );">Scale-up, 100 kilograms of GMP-grade compound | Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember', window );">Scale-up, 300 kilograms of GMP-grade compound | Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Payments as Credits to Accounts Payable, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cntx_DrexelUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cntx_DrexelUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cntx_RedeemableCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cntx_RedeemableCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098235715160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Expensed interest related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=cntx_LocalJurisdictionMember', window );">NOL carryforwards&#8212;Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_OperatingLossCarryforwardsExpirationTerm', window );">Local NOL expiration term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_OperatingLossCarryforwardsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_OperatingLossCarryforwardsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cntx_LocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cntx_LocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098234581000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Effects of Temporary Differences That Give Rise To The Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,983,415<span></span>
</td>
<td class="nump">$ 3,199,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">421,880<span></span>
</td>
<td class="nump">326,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">249,874<span></span>
</td>
<td class="nump">43,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accruals</a></td>
<td class="nump">147,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred tax assets</a></td>
<td class="nump">5,802,828<span></span>
</td>
<td class="nump">3,569,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(527,181)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cntx_NetDeferredTaxAssetLiabilitiesGross', window );">Net deferred tax assets</a></td>
<td class="nump">5,275,647<span></span>
</td>
<td class="nump">3,569,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(5,275,647)<span></span>
</td>
<td class="num">(3,569,489)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_NetDeferredTaxAssetLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Asset (Liabilities) Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_NetDeferredTaxAssetLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098235000824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax expense/(benefit) at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Non-taxable partnership income</a></td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(25.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(16.30%)<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098233221816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Operating Loss Carryforwards (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research tax credits&#8212;Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 421,880<span></span>
</td>
<td class="nump">$ 326,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">NOL carryforwards&#8212;Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">14,887,383<span></span>
</td>
<td class="nump">8,030,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=cntx_StateJurisdictionMember', window );">NOL carryforwards&#8212;State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">14,887,383<span></span>
</td>
<td class="nump">8,030,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=cntx_LocalJurisdictionMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 13,926,879<span></span>
</td>
<td class="nump">$ 15,399,777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cntx_StateJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cntx_StateJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cntx_LocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cntx_LocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098234746584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants for services provided</a></td>
<td class="nump">$ 371,895<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember', window );">Issued for Professional Consulting Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants for services provided</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember', window );">Issued for Professional Consulting Services | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>cntx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cntx="http://www.contexttherapeutics.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cntx-20211231.xsd" xlink:type="simple"/>
    <context id="id3806566135d43128a2459f8523168f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87bc250d89df4abbb4e488707f760dc5_I20220318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2022-03-18</instant>
        </period>
    </context>
    <context id="i7d018297e2234b888007658079c886f7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5cce182d571042c98e5effd7fdf6c2e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84f30e1e4d284ef4be016484aa57c1cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic683c6b9022b4f92a00ac3868a3f9346_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a0d98182ab34ee7baec49057ce8676f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68f213b55483406f9f85d99b2a65fa12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51367b5fc58744139f31963837e98df8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i285ef89c1ae14c19928c2e368283074d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1bd11c091e024a7a92541bbe11337dd7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadbb65d9f6724cb6a5cd710b45cc033f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibb93a595192045d2ad7ef4eaa1b20c05_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfe019d635614547bf06c09e991419b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f8740cca1c745199eda7ed1a4c1f483_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47d1bf6b4dac47b7984ca62205cdf5ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4e33079a371457f957e34b3350067ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ce49c28af0b41f0ad1acb06f7f428c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3f2f9c93a454fe2a0edbcc51fd35e05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f0d5097ed154ff1ba3d972352d2867d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iddeb956fa4494216b6ca445ac804fd36_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b7ed393336144da884a7c61ce2da7a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i625d9f20831b4f60bfb06856c3aea35c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2dcdb9bd37f420e9dc8c7b39ea998eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07db14fa05f64cf3bdaba6c0231f7ef8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i117b2aa3311747edb244e9aeee8fc1de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3251068f24e94754a128ec78c77f7334_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1b71ff94d7e42dc8077cc9688deb3f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf1ad6b33cea4855b42055c26af30d02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i449ce80766bf4e398973559957e68f41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibfa7323ee88a439a91a0ce98d394f1b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14b6d70f7b20444b83ad2461cd950758_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic77193cc910d458e928d0612bcad6229_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i243e310d4e9f4b44810d72c76300cb01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5ac1e9d0f1a4ddbaf6c8ceda2b4372b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a2f3ed31f33425492aeff13156184d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9bd53ac676234dc686b2453d0815dd41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0843156761eb42e38470d03cf3e6bf74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2caaf4d5a53246158004742c606c9ef6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i045d90f6713c40aca3bb010b300e93c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25b12ba6b5674eebb227199023ca61fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie50b1aaa60bf499993eee4785c15824f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaa6d7d44de0047f1bb1cbadc0b046365_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1aeee7d03a0640068206aa28850aa627_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69779aa1bd2d45a6ae2b2ae5627e59df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i000327aebd1d4982bbd9d962da1fdf97_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:DemandNotesToConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1870092b17d54844b0aa4cbcc3f8ca0c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:DemandNotesToConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b39b2be197f4335a69486c43230e142_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:BridgeNotesToSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f53e07ae1ec473f8c5c078ea26659c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:BridgeNotesToSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae8e22b696e144e3ac3f230b33279167_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i001e36ae235344e082b79a6dc0a8bcdb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">cntx:ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7d9b23ad16c43aa8572a0ac6ca614b4_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cntx:ContextTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i4173532c9b754389b02c47c17758a39e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib574e9442de340bba7e8df59de0aa8ea_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="ifaec33cca2ed463caf5a7211bdf75d02_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ic9fe5d1cf7064523ac856ef87a48d0ed_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i536b13a96232407dbc13d841f1fce5a7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6affe466c51c4622a311e2ed55837af8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5177f9964b244a76b68f2abaac086c21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i839fbb147c914876bf372cc7e6439da1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc8935fc9d464f29836a2a16fe277e98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id255264c0c894b67a64f0a3ef3d68e1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5f9e0e12992402d90ec7a6af875e1fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5aebf98410d2455caa4d29b128109b43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d242a6318ef4c6bbdd7b8627be0cff1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i887b64939c5845d2a4612345d96858c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ce232c5ed264fc1a5e2e91833604312_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcee81aa26da40c7aa01c8ed07319386_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81d84cd8ac404ffb9652dfeadc1a177f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68566af59223448eb22d5006be5194ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77004ca7aa1445119a9a78b5703984df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37c0a790ca1c4e73b5def12d29757201_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c39b33c88a8458686857dd42b2e64f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic199b723275d45d2bc21be1587aae664_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia34409531cae4268bc173922ce57ac3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib510cda252c24e72b8fa50da53cf17e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16b5edd019244d8c9ac599aebe563739_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i908727eba5bc4358b2ac0822d99cd9ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id55d52b883b8439db64cf84da4088ed2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie62db008cf5d41d287747c3ee2afb05c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i58cb9ed855944a858084c633831e74b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id0dff24cca894323a3974079199c467e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98b4298623094156bda38964f2ca6d72_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb6e5f4b103e4e5482b8dc8b7527a3cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4cbdfcd435a84616aec15c81c9bb7b06_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89d4008efcc04a669ef14e103f9a6a6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia686afec9e234c72967a01ae8d98a108_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:BridgeNotesToSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie234c0a724cd46029a0f0307bcf0e78b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:BridgeNotesToSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4296ddef4cfc4b709b45e518ab9c281c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2c5ebbe3b814fed872de2b6750f3337_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i969ca1b809854daabd8f8995c295fec4_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cntx:ChiefFinancialOfficerAndImmediateFamilyMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ib2e45ef9fdc642a0ac8a1d88dfeb09cb_D20200531-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-31</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="if5bffb2e3fd7430997f0e5cd07ec38b3_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i3a7a5cded79d49a4a18179828d3d9f12_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:BridgeNoteQualifiedFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0f07fc75d54b479cb5bf55f32da7bf1c_D20201222-20201222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:BridgeNoteQualifiedFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="i1b93a5662e8a4c92ba2e140ae85fb825_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i453801845a4245559bdf44e3c243247b_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00def9c120e34dfd81ad8cc464be10c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee6cc68e23a644ccb73a6bd8317cac15_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i00ba2e7eb0484b1295d941578acf8031_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i4cdb9eb262764bb9ad359f4cd6409d95_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="iff833741a565408283759dc258048916_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ica3de374ebb14eb283c5fa464ed31769_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2caffc25ed4f42e195b906a4eab85ec8_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i3bcdc4632b004d2e82615143090acd9c_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i06a8b2942cc1406a9a317b357d09884d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cntx:PaymentProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i60dcae9af0d042a6808422ea713c8707_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="if4ebfb8391004e768936ed5a183ccbe7_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:JuniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i7c3d5bf929d841bd8562efa81175ada4_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i5785bd98b84141148e297a25af4b1ae4_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ifd17b8baad484309af4929360d734817_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5007a2b8df544622bbb6844a27b85941_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:ConvertibleBridgeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70476cf5f23e40b7a8e694276c179049_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToSeriesAStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee66bc4c666546b5827d8f9046ce2e6e_D20210201-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i1de5d059a75a4d8e960f6f97b1e4b44e_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="if041032296804b76bd219f45c1d66fab_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToSeriesAStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ib058079deb3c476694d758a0ce02221e_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="id1de2115c90540ebb9bb07d72b519bf0_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i1c63a7c492b249a2823508e305461100_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cntx:SeniorConvertibleNotesApril2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i8d1cfe7096e34e6ea497fb994bda8378_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="id4631fd77028469dbd1afde77f30a01b_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i8f3867dedb684f8482d09a62b1bef50c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ba1a5fd4aa54bd18b6277a18720bbb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedInConnectionWithIPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36c3e785908e44e893746fd8fb714979_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedAsPartOfPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7f73c1e9e5a43a7aeb2e6b60176ae83_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf6e09006c2a4e438d001a5d8e06267e_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ib1e1c00a5a0c46b7827110eaaccd2bde_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i10ff1ceb32174558b92e60058255b0fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92b4d526304e44d59c45f6d02124e335_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cntx:StockGrantedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71a428ef7a1b4d19bf600eeaf6b76bff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ad2696d269b4e0593b847bc2847d326_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e63271831534a1c9f0c9dafdc78b906_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88a6a22c984641faab12a3f3aecdfa8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76aea4c250d247f696a873ec46ad8c83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89568e4239cb4b4dbc069d2edc09f071_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0abf375441494967be6030dfc54f96ad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16167060dd4a411bbbf08ccef55b90ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87304bb5deed428b929244468618ab9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice47411318244bb2a350092f360fd3ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a6d5e19e9c2468da79c3794e7c72abb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i572c857cebbe4fc1982b32de57c0220a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i992c3c31612041b88458293caef78ce6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied12b91ed1cb4150a7ff06c8518ebfab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic066948fc7ad43b0956073d48292abac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i090b28e5ec1a4e8eaa2a115e3b70282b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92dfdc8947244a08927a080fc1dfb72b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifce6960f11854815999679040b558ff7_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:DrexelUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cntx:RedeemableCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="i78fbe4d1c3214a428e35dd1f8055123c_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:DrexelUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="i1a58857b70524568849add997a11e677_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:DrexelUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="i3a7d7b9cfd5348869e9ddcb95a366ed4_I20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:DrexelUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="i91e81531d0aa47a7b6d49a7c6551bbd4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5037d579dc114c0484a17c0cae6d7468_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp100KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i72e8fa04e6e04b7499dd9509fedc5611_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp300KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if9ae36474bc442648e5731b2aae1cdd7_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i32152868968f47f78b1854b4910902e8_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i0a5ea7538cec4d73a63f42512b7cb189_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if9f956c8b3ce4d38a8596ee10f01e3d5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69aa76103ac748efb2f5d056d2cf8104_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1bf28a7fb38490592f0eae3e1f12ce1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i760a27b106d14efc85f77118941e7eec_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i5c01fc0d079243d0863dab34c442d2d6_I20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-01</instant>
        </period>
    </context>
    <context id="ibc572ca47de84c2097d086542a0002b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80101d4b12c34ca8aac0080981f8868e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71f59721c4e142388846035376f047f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cntx:StateJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb11fc45a9024916b87e1c43f8c7f43e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cntx:StateJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10821272b4754a39be917949dd892095_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cntx:LocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae70c994731842459a8bf4cb62e7db3d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cntx:LocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73cb300b7bdf4e6a842303015e1050c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieae15c2289054f01bddc88f4e06f1c45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8661fa5883274943a3502b6df99bcb33_I20220323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="i2661b361222b4e279fdb7c4c8e9cc8cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>cntx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV8wLTEtMS0xLTExNzU4_0950ba9c-9a76-48e9-8595-7a74e4250407">0001842952</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV8xLTEtMS0xLTExNzU4_d01ff163-1377-4a1c-addf-80ed0995d677">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV8yLTEtMS0xLTI2MjEy_9d8ef5e3-c381-4fa8-b8b8-c473e4ec3727">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV8zLTEtMS0xLTI2MjEy_d2210b5c-1e0c-4b51-af3c-8dce718a9d09">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityPublicFloat
      contextRef="i7d018297e2234b888007658079c886f7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF80L2ZyYWc6ZTRiNjA4NzY0MTYwNDIzYmE2ZmExODA3MjZkZjNhNTIvdGFibGU6ZWQzNTM1NDA1YmY5NGFkYjhkY2UzYTg1ZWM4NzA2ZDkvdGFibGVyYW5nZTplZDM1MzU0MDViZjk0YWRiOGRjZTNhODVlYzg3MDZkOV80LTEtMS0xLTI5MDgw_84ee0607-92e5-44b1-816b-ea90c757b2ce"
      unitRef="usd">0</dei:EntityPublicFloat>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="if7f73c1e9e5a43a7aeb2e6b60176ae83_D20210601-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjcvZnJhZzpkMzUwYjYwMzk4NTI0OTA3ODg5NTczN2RkMTE3ZWVmOC90YWJsZTozNzA1YTU0OTNlZjY0YzgwOTViYzMwZWEyZjE1ODlkYi90YWJsZXJhbmdlOjM3MDVhNTQ5M2VmNjRjODA5NWJjMzBlYTJmMTU4OWRiXzQtMC0xLTEtMTE3NTg_20d900f6-f979-4a8d-ba99-de2ed3ea71d1"
      unitRef="number">0.1667</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i71a428ef7a1b4d19bf600eeaf6b76bff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4NjE_01118990-dc7d-4e7f-96e0-43c8e460d916">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ice47411318244bb2a350092f360fd3ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwNDQ_d169f036-bec1-4a91-89bb-ca2c7da81f4f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTU3_ee3b8787-194c-4dcf-8e8a-b4cb94e88f43">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6NTRmOTc1ZTY5NGVmNDNkZThiN2U1ODBiZWI3NTJmY2YvdGFibGVyYW5nZTo1NGY5NzVlNjk0ZWY0M2RlOGI3ZTU4MGJlYjc1MmZjZl8wLTAtMS0xLTE3Mjk1_f1be4109-49cc-4100-b263-dde05ccf9738">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTkx_3ae41e00-2e2a-4783-b4fa-32f6febbc474">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTkx_77748eab-86c2-4779-bad3-4b30ce5ece6c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6NzljNzA0YmYyMzJkNGRjMGI5Y2I0MjU4M2RkNTJkY2IvdGFibGVyYW5nZTo3OWM3MDRiZjIzMmQ0ZGMwYjljYjQyNTgzZGQ1MmRjYl8wLTAtMS0xLTI2MTMz_c762e371-2459-4475-ae31-35875db49c4c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTU4_7d0bbe7e-c283-412a-b80e-822d06f063f4">001-04321</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8zNzQ4_b8d2b665-2182-4feb-bf09-6f1790f1ebee">CONTEXT THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZGNlYzA5M2MzYjY4NDg1NjkyODhiYjBiMjU1MGE5ODEvdGFibGVyYW5nZTpkY2VjMDkzYzNiNjg0ODU2OTI4OGJiMGIyNTUwYTk4MV8wLTAtMS0xLTI2MTM5_1fb76b2e-5373-491f-9504-8252b5545cb2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZGNlYzA5M2MzYjY4NDg1NjkyODhiYjBiMjU1MGE5ODEvdGFibGVyYW5nZTpkY2VjMDkzYzNiNjg0ODU2OTI4OGJiMGIyNTUwYTk4MV8wLTEtMS0xLTI2MTQy_0187197d-df14-42a3-a102-ebbce063673f">86-3738787</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTU5_774aa62d-471d-4c09-90ad-6365b3618e6c">2001 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTYw_675231ec-256b-4d7d-bc4d-baf0f8c40ba1">Suite 3915</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTYx_638137b5-e5e3-48d4-afa6-39fe7d21991c">Unit #15</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTYy_821bfd12-b38d-4303-bd91-ed7496ac1d2a">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTYz_6bf1472d-d596-4fd1-8da1-231d4fb36335">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY0_0c8d5007-b9c0-407f-b1af-788417c22a95">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY1_5d1f9621-4984-41eb-9c0d-a65db582316b">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY2_32d7a5e9-b455-47a6-bbc4-041110c6147b">225-7416</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZWI2ZWFmMjc4ZjIzNGI5MDhlNGIzMmQ1NmFjYWQ2MTIvdGFibGVyYW5nZTplYjZlYWYyNzhmMjM0YjkwOGU0YjMyZDU2YWNhZDYxMl8yLTAtMS0xLTI2MTYw_91bf4309-7711-405b-bd03-b8f6959fffbd">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZWI2ZWFmMjc4ZjIzNGI5MDhlNGIzMmQ1NmFjYWQ2MTIvdGFibGVyYW5nZTplYjZlYWYyNzhmMjM0YjkwOGU0YjMyZDU2YWNhZDYxMl8yLTEtMS0xLTI2MTYw_391b8085-1ab7-4b33-b582-da8af7f00ff3">CNTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6ZWI2ZWFmMjc4ZjIzNGI5MDhlNGIzMmQ1NmFjYWQ2MTIvdGFibGVyYW5nZTplYjZlYWYyNzhmMjM0YjkwOGU0YjMyZDU2YWNhZDYxMl8yLTItMS0xLTI2MTYw_03d55012-2b4c-4a40-8919-2a0d45c11c56">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY3_ce001a0b-d3d2-443f-b470-0966b19fa6cc">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY4_b96ba7f9-e618-4375-8309-700b29618b15">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTY5_ad72677b-e725-43bb-abcb-30cd2af86d53">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTcy_f7729cdc-4ecc-4850-b324-dbf49e4c9030">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6YjUyZmJlNDkyOTI3NDgzMjlhODI3NWEyY2E1MzIzZTkvdGFibGVyYW5nZTpiNTJmYmU0OTI5Mjc0ODMyOWE4Mjc1YTJjYTUzMjNlOV8xLTAtMS0xLTI2MTkx_d62a0d71-4a16-4f73-aba0-4f4a23c10c96">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6YjUyZmJlNDkyOTI3NDgzMjlhODI3NWEyY2E1MzIzZTkvdGFibGVyYW5nZTpiNTJmYmU0OTI5Mjc0ODMyOWE4Mjc1YTJjYTUzMjNlOV8xLTQtMS0xLTI2MTkx_f7e7b2be-9c87-4922-a8f4-5a23cbcd9f0a">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGFibGU6YjUyZmJlNDkyOTI3NDgzMjlhODI3NWEyY2E1MzIzZTkvdGFibGVyYW5nZTpiNTJmYmU0OTI5Mjc0ODMyOWE4Mjc1YTJjYTUzMjNlOV8yLTQtMS0xLTI2MTkx_28571e69-55c7-4411-be5f-72329e8a61e8">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTcz_a0a8d791-62db-4ca3-9953-0ca27b8b8f90">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTc0_88d24d0f-7154-4ea8-8d08-381f38fbf08f"
      xsi:nil="true"/>
    <dei:EntityShellCompany
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTc1_05fdf7ce-ced8-4d0e-89bf-4545783d85c6">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i87bc250d89df4abbb4e488707f760dc5_I20220318"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTc3_6e723a11-d671-49e7-b6d3-ac78d67a1840"
      unitRef="shares">15966053</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xL2ZyYWc6ZTZkMWFlYmZkZjMzNDg4NmE2YjRhN2RlMzQ5MDQ5OGIvdGV4dHJlZ2lvbjplNmQxYWViZmRmMzM0ODg2YTZiNGE3ZGUzNDkwNDk4Yl8yNzQ4Nzc5MDkxMTg4_b9c0812a-01eb-43ab-8528-12122213c485">Portions of the registrant&#x2019;s definitive Proxy Statement for its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDE3L2ZyYWc6MzA0OWE5MzE5ZjFkNDU0Y2EzZTFhZWU0ZTQxNjQ4NDgvdGFibGU6NTA4NTNlYTc5OTk1NDU2YmEwMDUyNTcyZDQ3MzUyMjYvdGFibGVyYW5nZTo1MDg1M2VhNzk5OTU0NTZiYTAwNTI1NzJkNDczNTIyNl8xLTAtMS0xLTMwMDM5L3RleHRyZWdpb246Yjk5NzdiZjVhOWI4NGRmMTgzOWI2YWM2YTUyZWRjOWRfMjc0ODc3OTA2OTU3OQ_b0fa9113-180d-44bb-ac42-2c327d86da0b">596</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIzL2ZyYWc6NDAzODI0Mjg5MGY0NGE0Y2E0ZWJmNDU2MmE3YmRkNjQvdGV4dHJlZ2lvbjo0MDM4MjQyODkwZjQ0YTRjYTRlYmY0NTYyYTdiZGQ2NF8yNzQ4Nzc5MDgxNDg3_3da35103-ef19-48d1-b5b9-2c119b5c1abc">CohnReznick LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIzL2ZyYWc6NDAzODI0Mjg5MGY0NGE0Y2E0ZWJmNDU2MmE3YmRkNjQvdGV4dHJlZ2lvbjo0MDM4MjQyODkwZjQ0YTRjYTRlYmY0NTYyYTdiZGQ2NF8yNzQ4Nzc5MDgxNDg4_543a60ae-d5f0-4b16-b79e-515a2c0ec913">Holmdel, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNC0xLTEtMS0xMTc1OA_12930f03-53c0-4b00-a2c5-33f739d942e0"
      unitRef="usd">49635197</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNC0zLTEtMS0xMTc1OA_079ac6de-df8f-44e9-aadf-3a5164383814"
      unitRef="usd">290670</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNS0xLTEtMS0xMTc1OA_17bc2a40-a0a3-461e-9b27-adbc29de902d"
      unitRef="usd">1620164</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNS0zLTEtMS0xMTc1OA_3844a98b-3d76-4e9d-9151-c66773932928"
      unitRef="usd">8672</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNi0xLTEtMS0xMTc1OA_84875f08-e7bb-419c-a267-3019440c42fa"
      unitRef="usd">51255361</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNi0zLTEtMS0xMTc1OA_ce78cc9f-be37-4d32-9472-e4ee64a9f911"
      unitRef="usd">299342</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNy0xLTEtMS0yMjQ1OQ_76a594c8-65d5-48f0-a585-b77afe6959e0"
      unitRef="usd">50389</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNy0zLTEtMS0yMjQ2Nw_f1637c5e-acdf-4c17-ae21-4e0b9556e156"
      unitRef="usd">50367</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredCosts
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNy0xLTEtMS0xMTc1OA_612e505e-fdce-47c9-bfd3-c3fb8ca9ab8a"
      unitRef="usd">0</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfNy0zLTEtMS0xMTc1OA_809ebb46-a13c-4a1f-8418-38bfb713a903"
      unitRef="usd">117631</us-gaap:DeferredCosts>
    <us-gaap:Assets
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfOC0xLTEtMS0xMTc1OA_b48cbdc9-b828-40b1-9fa4-74c8de7914ed"
      unitRef="usd">51305750</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfOC0zLTEtMS0xMTc1OA_cc000052-83dc-4cc6-8e0f-9b0bdd9bde0f"
      unitRef="usd">467340</us-gaap:Assets>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTEtMS0xLTEtMTE3NTg_cfe517b7-63bb-4da5-bf1f-10735fa2d389"
      unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTEtMy0xLTEtMTE3NTg_f4b4848c-bb22-44a0-822b-c7a938c58ac0"
      unitRef="usd">5829292</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTMtMS0xLTEtMTE3NTg_bfcfd7e0-b6aa-42cd-ae97-44210aaf9d89"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTMtMy0xLTEtMTE3NTg_e8394ba9-856a-41f4-a0a0-11e2c957fb25"
      unitRef="usd">55014</us-gaap:NotesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTQtMS0xLTEtMTE3NTg_0f60cc57-13d3-4f1a-94dd-bdfd67bfcc2c"
      unitRef="usd">1826294</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTQtMy0xLTEtMTE3NTg_5a1644d1-2cdc-4d1a-ab59-81b2fc10058b"
      unitRef="usd">2707861</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTUtMS0xLTEtMTE3NTg_826cdb05-00d5-471c-9476-e77978761d8f"
      unitRef="usd">1207121</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTUtMy0xLTEtMTE3NTg_697d3ebc-f428-40b2-aaff-e3ffd84f7bab"
      unitRef="usd">955989</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTYtMS0xLTEtMTE3NTg_c39ac748-1f6d-4bb4-8578-6f4cc1f40eb1"
      unitRef="usd">3033415</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTYtMy0xLTEtMTE3NTg_63636d8c-9c10-4300-8a9d-694bc3539d1b"
      unitRef="usd">9548156</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTctMS0xLTEtMTE3NTg_87a377e5-4952-45b0-bf00-ae3bbb5f117b"
      unitRef="usd">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTctMy0xLTEtMTE3NTg_b1291fb2-eb99-4da6-9ed1-569f449bd5bb"
      unitRef="usd">69040</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTgtMS0xLTEtMTE3NTg_151f939a-5921-4ab1-a21d-9bb2d701ab97"
      unitRef="usd">3033415</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTgtMy0xLTEtMTE3NTg_557a9b5a-4f28-4ea8-b048-dba4bffe9be9"
      unitRef="usd">9617196</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTktMS0xLTEtMTE3NTg_d16a37d5-9c66-49de-930e-12a997a662d4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMTktMy0xLTEtMTE3NTg_dca0bfb7-482d-46d6-b256-9468886a81ae"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjEtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo2ZjE1Y2Y1YTEyY2U0ODFkOTAzNDQ0N2M3OTU1NWYzZF85MzQ1ODQ4ODM2MjA5_03b859cc-9817-4c69-8ea6-554dcc6e70ba"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2MzMx_187eae98-b604-4e36-8dc3-12725995651a"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2MzMx_2f8f2675-255c-4b9c-8bd5-0f3201490e9b"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2Mzg3_04784901-2883-4134-90de-a030dd4c9aaf"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2Mzg3_09c07840-4115-4dd9-b516-382bfcf5fbf1"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2Mzcy_18c1729d-388a-45e0-b2cc-99e2b7873e45"
      unitRef="shares">210715</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo3NzJjZjdlMjE1ZGQ0MGRmYTIyZDVjYjY5ZjdkZGQ0Zl85MzQ1ODQ4ODM2Mzcy_36279a38-a871-4de6-88f8-99a408e2378d"
      unitRef="shares">210715</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMS0xLTEtMTE3NTg_514313cc-13dc-4e17-97f0-8547855ea109"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjItMy0xLTEtMTE3NTg_0008cd16-a9e1-4daa-b602-9d228fc3f011"
      unitRef="usd">1400935</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl85MzQ1ODQ4ODM2MzI3_7075dbf2-9499-4fbe-989e-1fda7838d986"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl85MzQ1ODQ4ODM2MzI3_aaa76190-956b-454b-852f-aba5723e604e"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl83MTQ2ODI1NTgwODAy_5129dd91-7457-46ff-b522-e589ccbbf97c"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl83MTQ2ODI1NTgwODAy_a6301993-38d1-4a9a-bcd9-06b0cc02e432"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl85MzQ1ODQ4ODM2MzQ2_204efed7-d2af-4e74-bb1a-36c132f3871a"
      unitRef="shares">2624324</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjo1MGMxMDY2YWM2MjI0MzE4OTIwNWMyOTg3Yzg4ZWU3Zl85MzQ1ODQ4ODM2MzQ2_371feb37-84a8-47f2-9930-8c3f45fdeecf"
      unitRef="shares">2624324</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMS0xLTEtMTE3NTg_3c7b4f3e-5bfa-49e9-84ee-8a62cd903928"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjMtMy0xLTEtMTE3NTg_a9f594b3-5435-4a40-b95e-3770ab1925f7"
      unitRef="usd">6341288</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl85MzQ1ODQ4ODM2MjYz_6a5efece-cceb-4e9f-ad24-c180536d40b2"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl85MzQ1ODQ4ODM2MjYz_ea06823c-7ed7-45ff-9244-8b560397a95a"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl83MTQ2ODI1NTgwNjg1_06efb1a1-b862-4ae9-9033-9e2feddfb707"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl83MTQ2ODI1NTgwNjg1_1f93ac99-14d1-414a-8777-2e8d99b8a249"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl85MzQ1ODQ4ODM2MjI5_45ddcbb7-4bbf-4e57-8e5a-1dbcadffbb42"
      unitRef="shares">16666</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjpmN2IzMmJmMGI3MjY0NWZmODZlYjM4NTJlMTM1ODc1Zl85MzQ1ODQ4ODM2MjI5_b103d400-cdb8-4b5e-9bbe-1b184c01e77a"
      unitRef="shares">16666</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMS0xLTEtMTE3NTg_3511c860-1938-4796-ab00-422ea12037ea"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjQtMy0xLTEtMTE3NTg_8c67869d-fe38-4a07-9144-ad04f420f619"
      unitRef="usd">29000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjUtMS0xLTEtMTE3NTg_df27d363-90ba-4ce5-b093-8ed80bcd9df0"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjUtMy0xLTEtMTE3NTg_694572c5-3700-4798-9bf9-35b30917f299"
      unitRef="usd">7771223</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF85MzQ1ODQ4ODM2Mzk2_0ac163f5-1d62-4740-9670-39da330309a6"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF85MzQ1ODQ4ODM2Mzk2_396a6c8d-55f7-4a16-9a27-ad66f6ef5975"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF85MzQ1ODQ4ODM2NDEx_98dcfd23-ff6d-49b4-bacc-a9cb75924dfc"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF85MzQ1ODQ4ODM2NDEx_a9344ca1-c6fe-4920-9333-592913d240ee"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF83MTQ2ODI1NTgwOTA3_0b2f60ba-4dc3-4073-b6ad-2deac96f24be"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF83MTQ2ODI1NTgwOTA3_3997e419-d8e6-4568-bdff-213f435bafb4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF83MTQ2ODI1NTgwOTA3_8f6ea2ab-1926-4dc9-89d2-29a1ea187bb0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMC0xLTEtMTE3NTgvdGV4dHJlZ2lvbjowYzY0ZGFlYzRhMjU0N2IyYWI5YzQ5OTI2NGQxMmUwMF83MTQ2ODI1NTgwOTA3_c178a2f1-dfed-4910-ae40-c155dc281a2c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMS0xLTEtMTE3NTg_699f439f-c7e7-421f-b4dc-6ca67cc2b7be"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjctMy0xLTEtMTE3NTg_465deb1f-c14e-4cd9-a665-f6217b4fac44"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2MjU3_55b92f21-3d61-4d99-96a2-71d4170fa7ca"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2MjU3_f361ba4e-79ce-41f5-a011-661781bbba26"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2Mjcx_79d6ce06-9bb3-460e-811a-cd748cc6ac49"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2Mjcx_b6265676-6c6e-4ab7-913e-6646cb377747"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM183MTQ2ODI1NTgwODA1_0acb6cc9-ff8b-40ca-bcdf-14f44ec264c3"
      unitRef="shares">15966053</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM183MTQ2ODI1NTgwODA1_5a28ab2d-4801-4154-8509-5257479deff3"
      unitRef="shares">15966053</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2Mjk0_18a431a5-3ce3-4c1e-8953-65a37eb7a831"
      unitRef="shares">331789</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMC0xLTEtMjQ5MDAvdGV4dHJlZ2lvbjozOTIxYjg2ZDYxM2U0OTEyYTk5M2I2ZTczZGU0NTYzM185MzQ1ODQ4ODM2Mjk0_5d54b5e5-02bf-401c-82c4-ad0db48fae71"
      unitRef="shares">331789</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMS0xLTEtMjQ5MDA_281b3b5c-7ed1-490c-951f-c712bd993a58"
      unitRef="usd">15966</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMy0xLTEtMjQ5MDA_5adffe74-6e65-4bf5-9df1-53888bd9ab1a"
      unitRef="usd">332</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMS0xLTEtMTE3NTg_2627eac7-c0fe-45ef-8ebb-74ee681eaa2d"
      unitRef="usd">77510809</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjgtMy0xLTEtMTE3NTg_d0de9355-fa5e-4ef4-8c26-912b8eb8629e"
      unitRef="usd">1876159</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjktMS0xLTEtMTE3NTg_a723bebc-2a7d-4f59-a13a-765c161978d8"
      unitRef="usd">-29254440</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMjktMy0xLTEtMTE3NTg_75e43be3-2357-4cc0-9d53-cc722180a2be"
      unitRef="usd">-18797570</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMzAtMS0xLTEtMTE3NTg_c8535dcb-7301-4850-920e-9ad43953072f"
      unitRef="usd">48272335</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMzAtMy0xLTEtMTE3NTg_0b285caf-6e43-4319-a31b-3c6b967ffc5e"
      unitRef="usd">-16921079</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMzEtMS0xLTEtMTE3NTg_096dd00b-e6e2-43e6-96e6-de1a788ba76f"
      unitRef="usd">51305750</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85MS9mcmFnOmIxNTJmOGE1MDhlOTRmNjVhMzI2NWJiNWIzNWNkMmRiL3RhYmxlOmE1NzlmMmViOWMxYjRiMzI4YjUyYjBjZDNlNjU4MWM4L3RhYmxlcmFuZ2U6YTU3OWYyZWI5YzFiNGIzMjhiNTJiMGNkM2U2NTgxYzhfMzEtMy0xLTEtMTE3NTg_4b5b5860-a565-431d-a43c-7f622be7a7d8"
      unitRef="usd">467340</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMy0xLTEtMS0yMjQyNw_460b1c63-61cc-456f-a9e1-e44df60558c4"
      unitRef="usd">3087832</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMy0zLTEtMS0yMjQzNA_3c89a410-7863-4da8-8b06-e6fc883b61fa"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMy0xLTEtMS0xMTc1OA_9ebcb735-06d5-48b7-bb88-35ce28742dd3"
      unitRef="usd">3805067</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMy0zLTEtMS0xMTc1OA_50d25c78-7ba6-4f82-bf1d-f20e1fb94970"
      unitRef="usd">1641501</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNC0xLTEtMS0xMTc1OA_1e28d671-e4e7-4534-a1b0-329135e1b3d5"
      unitRef="usd">3632920</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNC0zLTEtMS0xMTc1OA_6c69d996-8c74-4803-8b6b-82072f56f02c"
      unitRef="usd">930667</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNS0xLTEtMS0xMTc1OA_0641488f-c6fe-4c91-aae0-71552818453e"
      unitRef="usd">-10525819</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNS0zLTEtMS0xMTc1OA_5f2cca4b-8044-4a1a-b3df-418d5c1ab5c4"
      unitRef="usd">-2572168</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNi0xLTEtMS0xMTc1OA_5a806be5-6f71-47ec-8b51-8e6af7eb2fe1"
      unitRef="usd">64240</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNi0zLTEtMS0xMTc1OA_64880c12-1b43-43f5-ad05-b48e66027287"
      unitRef="usd">661224</us-gaap:InterestExpense>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNy0xLTEtMS0xMTc1OA_cb93e9ed-925b-4c12-b0c7-09bb310712f4"
      unitRef="usd">9317</cntx:FairValueAdjustmentOnConvertibleDebt>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfNy0zLTEtMS0xMTc1OA_3b4dc549-1bbb-4ffa-b704-e72f9c421cf2"
      unitRef="usd">9877857</cntx:FairValueAdjustmentOnConvertibleDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOS0xLTEtMS0yNTA4Ng_dcc55c0a-617c-427c-85fc-240fa6771a4e"
      unitRef="usd">123872</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOS0zLTEtMS0yNTA5Mw_8d428c72-500a-4793-8b43-c71e59636938"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOC0xLTEtMS0xMTc1OA_b61b4a52-030e-4e01-a13a-c5cf14b9003f"
      unitRef="usd">-10456870</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOC0zLTEtMS0xMTc1OA_740535c9-b250-406b-938b-46f17093fcfd"
      unitRef="usd">6644465</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOS0xLTEtMS0xMTc1OA_58a4253e-711d-4fce-a3ab-a966582dd845"
      unitRef="usdPerShare">-3.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfOS0zLTEtMS0xMTc1OA_37955766-93c8-450e-b949-df54092b3054"
      unitRef="usdPerShare">3.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTAtMS0xLTEtMTE3NTg_86dcb69f-7c9d-4b88-853e-ea4df1137302"
      unitRef="usdPerShare">-3.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTAtMy0xLTEtMTE3NTg_cf124d86-1ec1-4cdc-8673-0a38fe901d53"
      unitRef="usdPerShare">-3.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTEtMS0xLTEtMTE3NTg_76051f47-f817-4c34-98ce-946b7ed3c8cc"
      unitRef="shares">2833674</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTEtMy0xLTEtMTE3NTg_4ea3f75c-e8e3-4bbc-a2cf-85a5342c92a5"
      unitRef="shares">348368</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTItMS0xLTEtMTE3NTg_bb42eb86-dc70-4a39-a174-48c3f952f1b0"
      unitRef="shares">2833674</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF85Ny9mcmFnOjNiNWZlODA3NDI3NDQ1YTA5MGMwNWZkZGJjYzQxYzVmL3RhYmxlOmFhYWU0MDVjMDM3ZDQyYTliZjk3YmZiN2FkYmU4NmU5L3RhYmxlcmFuZ2U6YWFhZTQwNWMwMzdkNDJhOWJmOTdiZmI3YWRiZTg2ZTlfMTItMy0xLTEtMTE3NTg_50e75fd6-1260-4ee5-8478-f04eaac397a9"
      unitRef="shares">2054875</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i51367b5fc58744139f31963837e98df8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMS0xLTEtMTE3NTg_27275dca-1553-463d-bea3-c666f739da91"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i51367b5fc58744139f31963837e98df8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMy0xLTEtMTE3NTg_88309c6b-4ef1-45c3-8335-ff985ae08c1b"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i285ef89c1ae14c19928c2e368283074d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtNS0xLTEtMTE3NTg_feee1a42-d8b0-40cf-a6eb-12f413ca7794"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i285ef89c1ae14c19928c2e368283074d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtNy0xLTEtMTE3NTg_bda91b5e-b679-473a-ba90-f59b138e2fd4"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i1bd11c091e024a7a92541bbe11337dd7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtOS0xLTEtMTE3NTg_de4675aa-9341-4296-9fb8-c00fb9d79c54"
      unitRef="shares">16666</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i1bd11c091e024a7a92541bbe11337dd7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMTEtMS0xLTExNzU4_fe6f1e2a-2e2d-406f-875e-c1e833778be3"
      unitRef="usd">126000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="iadbb65d9f6724cb6a5cd710b45cc033f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMTQtMS0xLTExNzU4_347723d0-10ee-4cab-9ced-fd163f32fb59"
      unitRef="shares">324145</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iadbb65d9f6724cb6a5cd710b45cc033f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMTYtMS0xLTExNzU4_cb567107-991e-42dd-b105-3d561fbc409b"
      unitRef="usd">324</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb93a595192045d2ad7ef4eaa1b20c05_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMTgtMS0xLTExNzU4_18384050-3946-4504-bc85-55a457a34ed7"
      unitRef="usd">1480955</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icfe019d635614547bf06c09e991419b0_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMjAtMS0xLTExNzU4_bf1cc7a0-179d-460d-a997-b62504422f50"
      unitRef="usd">-25442035</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f8740cca1c745199eda7ed1a4c1f483_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzYtMjItMS0xLTExNzU4_dbd5ae82-3c96-49bf-8938-2468a2de69fe"
      unitRef="usd">-23960756</us-gaap:StockholdersEquity>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzctMS0xLTEtMTE3NTg_788866f1-ceba-47d0-9562-83077ef46ce9"
      unitRef="shares">132537</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzctMy0xLTEtMTE3NTg_d3f4fa5c-38f0-4fa2-bcc5-460ba06083d9"
      unitRef="usd">950000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzgtMS0xLTEtMTE3NTg_ca23ea9c-85f3-409c-b9f0-23524f3395dd"
      unitRef="shares">78178</cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzgtMy0xLTEtMTE3NTg_f6a36e0e-daae-4e94-bb7a-b669b1874613"
      unitRef="usd">529902</cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <cntx:TemporaryEquityDecreaseDueToConversionToWarrants
      contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzktMy0xLTEtMTE3NTg_a531e757-c429-40b3-ad2a-abb83603d3fa"
      unitRef="usd">78967</cntx:TemporaryEquityDecreaseDueToConversionToWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i47d1bf6b4dac47b7984ca62205cdf5ab_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzktMTgtMS0xLTExNzU4_6a6f4b1b-8d18-4475-9b96-8accc557aa7b"
      unitRef="usd">78967</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ie4e33079a371457f957e34b3350067ba_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzktMjItMS0xLTExNzU4_6008c9da-6581-4f6d-aa1c-55700e6f5224"
      unitRef="usd">78967</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEwLTUtMS0xLTExNzU4_b1631cbe-0165-4b00-907d-2254e472c156"
      unitRef="shares">8771</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEwLTctMS0xLTExNzU4_03b1c3bb-0bb6-4bb6-bc16-f58d45b386ba"
      unitRef="usd">50000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzExLTUtMS0xLTExNzU4_446fd917-a335-44a8-a8a3-d361eecdc782"
      unitRef="shares">2615553</cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzExLTctMS0xLTExNzU4_ef5b6616-b030-4780-b424-f42f56de110f"
      unitRef="usd">6291288</cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="i9ce49c28af0b41f0ad1acb06f7f428c1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTE0LTEtMS0xMTc1OA_64e79fba-37bc-406c-a708-9461280d51eb"
      unitRef="shares">7644</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i9ce49c28af0b41f0ad1acb06f7f428c1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTE2LTEtMS0xMTc1OA_f55ef17a-2609-4de6-85db-e0ad4fbb9f57"
      unitRef="usd">8</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="id3f2f9c93a454fe2a0edbcc51fd35e05_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTE4LTEtMS0xMTc1OA_dbb3db5c-056d-47ac-82b9-ae2f07359fcb"
      unitRef="usd">219237</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTIyLTEtMS0xMTc1OA_673f66c6-fb0f-491a-a29d-284284ad39a0"
      unitRef="usd">219245</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue
      contextRef="i9f0d5097ed154ff1ba3d972352d2867d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTExLTEtMS0xMTc1OA_82d36b69-7aa5-444a-9867-bcbfee340bc6"
      unitRef="usd">-97000</cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="id3f2f9c93a454fe2a0edbcc51fd35e05_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTE4LTEtMS0xMTc1OA_77e91858-509c-4486-a19d-1b73d12cbef0"
      unitRef="usd">-97000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTIyLTEtMS0xMTc1OA_733bddb2-7fe9-4cd8-8a49-7eedd7c36465"
      unitRef="usd">-97000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="iddeb956fa4494216b6ca445ac804fd36_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE0LTIwLTEtMS0xMTc1OA_73712e6e-84d2-459d-b0f2-92b491758a89"
      unitRef="usd">6644465</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE0LTIyLTEtMS0xMTc1OA_210e1ff6-a39b-4ba4-91dc-0cb1a354da64"
      unitRef="usd">6644465</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTEtMS0xLTExNzU4_30d938e9-70db-4bd9-ae31-beaee624deea"
      unitRef="shares">210715</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTMtMS0xLTExNzU4_6c48b0a1-3434-4102-b962-cd351cb588bd"
      unitRef="usd">1400935</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTUtMS0xLTExNzU4_c93e61cf-b23f-4771-94bd-829626c7d1a3"
      unitRef="shares">2624324</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i68f213b55483406f9f85d99b2a65fa12_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTctMS0xLTExNzU4_59425f06-adbe-4177-acb7-207802bd16a6"
      unitRef="usd">6341288</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTktMS0xLTExNzU4_66825d03-6297-4dff-bc85-d04bdc15c39f"
      unitRef="shares">16666</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="if1f1bd90ae8b4358ac44e2086f22bf89_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTExLTEtMS0xMTc1OA_0785e87a-d452-4ed9-8f7d-4fbb1787aea7"
      unitRef="usd">29000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i2b7ed393336144da884a7c61ce2da7a2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTE0LTEtMS0xMTc1OA_191f5b8c-79fa-4639-91a9-7023ba147919"
      unitRef="shares">331789</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2b7ed393336144da884a7c61ce2da7a2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTE2LTEtMS0xMTc1OA_dc85f3b4-305d-4436-b5e6-000b32592860"
      unitRef="usd">332</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i625d9f20831b4f60bfb06856c3aea35c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTE4LTEtMS0xMTc1OA_1777aae9-ac12-49df-b2fe-0d05ffcc5301"
      unitRef="usd">1876159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2dcdb9bd37f420e9dc8c7b39ea998eb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTIwLTEtMS0xMTc1OA_60bdcea9-ac13-4f7c-b18d-787e2e709b6a"
      unitRef="usd">-18797570</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTIyLTEtMS0xMTc1OA_b0c66080-3f24-496b-9a02-2a1ca170e3a3"
      unitRef="usd">-16921079</us-gaap:StockholdersEquity>
    <cntx:TemporaryEquityOfferingCosts
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTAtMS0xLTIyNjMwL3RleHRyZWdpb246NjFhYmU5YmE1YTFjNDg1MzkzNTJlZjQ3ZTE2NzRiZDJfOTM0NTg0ODgzNjE3NQ_6f9b77ae-9318-4a6e-9a4b-c33fb6dff122"
      unitRef="usd">310021</cntx:TemporaryEquityOfferingCosts>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTEtMS0xLTIyNjMw_7586df95-dbf6-4166-b886-123d5a38d0b1"
      unitRef="shares">738445</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEyLTMtMS0xLTIyNjMw_26358f8f-bc96-4d09-b50e-bb6ffc25dd43"
      unitRef="usd">4982835</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTEtMS0xLTIyNjMw_f6995407-6f94-4d7f-8bf3-88512fb24456"
      unitRef="shares">844824</cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTMtMS0xLTIyNjMw_7eba5a40-88f2-4490-88ac-36219907225f"
      unitRef="usd">5728793</cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTE4LTEtMS0yMjYzMA_acb51cb4-39fd-495e-8eb5-515dae6c018b"
      unitRef="usd">137497</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzEzLTIyLTEtMS0yMjYzMA_2605e48a-f51e-47a7-9d72-5fa4c1479c7e"
      unitRef="usd">137497</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE0LTEtMS0xLTIyNjMw_b27921ce-dd8a-47ec-a1c3-702f33908353"
      unitRef="shares">418559</cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE0LTMtMS0xLTIyNjMw_43c4b90b-ce29-4c28-95f7-d63361b3ad6b"
      unitRef="usd">2837832</cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices>
    <cntx:TemporaryEquityDecreaseDueToConversionToWarrants
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTMtMS0xLTIyNjMw_2c7058ac-5421-4182-a010-34e18828ed71"
      unitRef="usd">265593</cntx:TemporaryEquityDecreaseDueToConversionToWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i07db14fa05f64cf3bdaba6c0231f7ef8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTE4LTEtMS0yMjYzMA_24120b6c-2245-40f7-b4cc-cdb08982c524"
      unitRef="usd">265593</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i117b2aa3311747edb244e9aeee8fc1de_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE1LTIyLTEtMS0yMjYzMA_16e758bc-d78f-4530-875b-ef38274e40a0"
      unitRef="usd">265593</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE2LTMtMS0xLTI5Nzcz_bb79b69f-b146-4767-afff-e8223dcb7e1f"
      unitRef="usd">-43797</cntx:TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i3251068f24e94754a128ec78c77f7334_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE2LTE4LTEtMS0yOTc3Mw_8ac203e8-aaa4-44b3-8575-54c5220075da"
      unitRef="usd">43797</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="id1b71ff94d7e42dc8077cc9688deb3f4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE2LTIyLTEtMS0yOTc3Mw_83a4d851-5dfa-433e-ace1-c2c0b5530c5f"
      unitRef="usd">43797</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ibf1ad6b33cea4855b42055c26af30d02_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE3LTE4LTEtMS0yMjYzMA_1d374784-7164-41fe-87aa-0ac590979606"
      unitRef="usd">371895</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i449ce80766bf4e398973559957e68f41_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE3LTIyLTEtMS0yMjYzMA_49a87dbf-f40e-4569-baf0-41ca38009af9"
      unitRef="usd">371895</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue
      contextRef="ibfa7323ee88a439a91a0ce98d394f1b9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE4LTExLTEtMS0yMjYzMA_acf542e1-425b-4037-8b6d-83a2f10bf843"
      unitRef="usd">53330</cntx:TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE4LTE4LTEtMS0yMjYzMA_53ac4ea7-95b0-4359-b84d-f6cc57aabe44"
      unitRef="usd">53330</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE4LTIyLTEtMS0yMjYzMA_c971a884-60d5-48a6-abb6-be21253e1cf4"
      unitRef="usd">53330</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTEtMS0xLTIyNjMw_b71a0984-839f-4ee8-a60e-36db2d3b72a4"
      unitRef="shares">-2212543</cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTMtMS0xLTIyNjMw_a812bd68-ac21-40af-a60c-8c75f8d64a0c"
      unitRef="usd">-14641005</cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="i14b6d70f7b20444b83ad2461cd950758_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTUtMS0xLTIyNjMw_893a43e8-00c2-459b-9d37-d51a8d330b36"
      unitRef="shares">-2624324</cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="i14b6d70f7b20444b83ad2461cd950758_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTctMS0xLTIyNjMw_10bcfa1d-7eba-4a73-ac3d-d07ed13d74b3"
      unitRef="usd">-6341288</cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="ibfa7323ee88a439a91a0ce98d394f1b9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTktMS0xLTIyNjMw_2986e945-8d4a-4d1b-8f98-eb531073b576"
      unitRef="shares">-16666</cntx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="ibfa7323ee88a439a91a0ce98d394f1b9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTExLTEtMS0yMjYzMA_3b3c2ba5-6d27-497a-8488-88a3cd18ec6f"
      unitRef="usd">-82330</cntx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTE0LTEtMS0yMjYzMA_6939c148-d0ca-4c75-91c2-3290edb6f78a"
      unitRef="shares">4853533</cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTE2LTEtMS0yMjYzMA_af9e08d3-b91f-4f07-a78a-2822f0d1ed5b"
      unitRef="usd">4853</cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTE4LTEtMS0yMjYzMA_f225e124-c409-4bdf-8a4c-daca636bf247"
      unitRef="usd">21059770</cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares>
    <cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzE5LTIyLTEtMS0yMjYzMA_47e45a91-ef13-4fc2-9abf-fd67120ef2fa"
      unitRef="usd">21064623</cntx:StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ic77193cc910d458e928d0612bcad6229_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIwLTE0LTEtMS0yMjYzMA_04e83f5e-0086-4cc3-9a58-bbbe011c68ca"
      unitRef="shares">9816</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic77193cc910d458e928d0612bcad6229_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIwLTE2LTEtMS0yMjYzMA_a6bed914-5e5b-4c6e-a0eb-c22d2262032c"
      unitRef="usd">10</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i243e310d4e9f4b44810d72c76300cb01_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIwLTE4LTEtMS0yMjYzMA_6f2ba0d4-81e1-4e38-bb18-215d669a048e"
      unitRef="usd">-10</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie5ac1e9d0f1a4ddbaf6c8ceda2b4372b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIwLTIyLTEtMS0yMjYzMA_dd5059de-cf12-4f5c-9257-38cf21005b53"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <cntx:StockIssuedDuringPeriodIssuanceCosts
      contextRef="i0a2f3ed31f33425492aeff13156184d7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTAtMS0xLTIyNjMwL3RleHRyZWdpb246ODM0MTk4OTM5NDkwNDQxYmE1MjE2MDYwODY5NDZlMGNfOTM0NTg0ODgzNjE5NA_6ac68844-8daf-402f-9743-4e1589ca3139"
      unitRef="usd">4321374</cntx:StockIssuedDuringPeriodIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9bd53ac676234dc686b2453d0815dd41_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTE0LTEtMS0yMjYzMA_398b4775-c4ad-4cb3-bfe0-1ae9f7fa72af"
      unitRef="shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9bd53ac676234dc686b2453d0815dd41_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTE2LTEtMS0yMjYzMA_f5f73b3d-61ff-4af5-bb28-53e0a3b52981"
      unitRef="usd">5750</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0843156761eb42e38470d03cf3e6bf74_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTE4LTEtMS0yMjYzMA_7a77ee2c-451a-4153-8de3-049878b8493c"
      unitRef="usd">24422876</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a2f3ed31f33425492aeff13156184d7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIxLTIyLTEtMS0yMjYzMA_8874b99f-4838-4d53-b2d2-8128217345af"
      unitRef="usd">24428626</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cntx:StockIssuedDuringPeriodIssuanceCosts
      contextRef="i2caaf4d5a53246158004742c606c9ef6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTAtMS0xLTIyNjMwL3RleHRyZWdpb246NzFjNDRhNmZiZTU2NGVlNTlmYjk3NWUxNDI2MmQ0YjhfOTM0NTg0ODgzNjE4OA_7e305489-fece-45ae-a59f-174a8a3ce75e"
      unitRef="usd">2369496</cntx:StockIssuedDuringPeriodIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i045d90f6713c40aca3bb010b300e93c3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTE0LTEtMS0yMjYzMA_97ad3446-803f-4002-9a63-ee29c720028b"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i045d90f6713c40aca3bb010b300e93c3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTE2LTEtMS0yMjYzMA_1b72ad29-8ff2-4a19-90c0-b58142c53499"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i25b12ba6b5674eebb227199023ca61fc_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTE4LTEtMS0yMjYzMA_2cf708fe-0835-4726-ac39-7211278abec5"
      unitRef="usd">28875504</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2caaf4d5a53246158004742c606c9ef6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIyLTIyLTEtMS0yMjYzMA_caeded41-c333-4de4-bda5-7dcd3e114f2e"
      unitRef="usd">28880504</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIzLTE0LTEtMS0yMjYzMA_99ec26db-79c4-4ed9-9098-6146e25cf4a7"
      unitRef="shares">20915</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIzLTE2LTEtMS0yMjYzMA_9fc380bd-22cc-4c0b-baf0-fd5d046a8bb3"
      unitRef="usd">21</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i6454fedcbf114eba8c4bf21613b5bc80_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIzLTE4LTEtMS0yMjYzMA_8fcfd107-2d19-4a6a-94b0-58719fafeb80"
      unitRef="usd">511058</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzIzLTIyLTEtMS0yMjYzMA_592221f7-1362-4fc6-a400-f2ece3eed5da"
      unitRef="usd">511079</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:NetIncomeLoss
      contextRef="ie50b1aaa60bf499993eee4785c15824f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI0LTIwLTEtMS0yMjYzMA_014f404d-2cb4-4f7d-99ae-97c89d892cad"
      unitRef="usd">-10456870</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI0LTIyLTEtMS0yMjYzMA_e870d914-e33b-48b3-b8ea-7ba8d2f4a320"
      unitRef="usd">-10456870</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTEtMS0xLTIyNjMw_bbe73ed5-5074-42f7-b713-17356267e5ab"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic683c6b9022b4f92a00ac3868a3f9346_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTMtMS0xLTIyNjMw_d6a542dd-34e2-4cb1-b980-749085c37955"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTUtMS0xLTIyNjMw_b1acf9b9-a56e-4566-8621-15fe4f6c2fc3"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6a0d98182ab34ee7baec49057ce8676f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTctMS0xLTIyNjMw_217a3f88-10dd-41d1-acce-bc97035a7768"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTktMS0xLTIyNjMw_6c112f04-40b6-41a9-9895-18557fe994f9"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iad7dd3b0ea034392adfa47808bfbdbc8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTExLTEtMS0yMjYzMA_2fccfab7-b177-498a-be46-20db83ba6c39"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="iaa6d7d44de0047f1bb1cbadc0b046365_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTE0LTEtMS0yMjYzMA_1aff104f-15ae-402b-bdea-fa2062342059"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaa6d7d44de0047f1bb1cbadc0b046365_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTE2LTEtMS0yMjYzMA_a0cd8d5a-0193-4b90-a1c1-005ff8fb6963"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1aeee7d03a0640068206aa28850aa627_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTE4LTEtMS0yMjYzMA_ec7313fb-dde5-4865-b060-bf84f598aada"
      unitRef="usd">77510809</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69779aa1bd2d45a6ae2b2ae5627e59df_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTIwLTEtMS0yMjYzMA_1b2f4bd5-1119-41df-8837-5ed3e20fa182"
      unitRef="usd">-29254440</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDAvZnJhZzoxYjc5NWFkMGI1NzY0ZmZmOTI5YWExMjJiZjJhODY5Ny90YWJsZTo1ODU1ZDNlNzEzNmQ0OTRiODIwMmE2ZjgzYTU4YjcwNC90YWJsZXJhbmdlOjU4NTVkM2U3MTM2ZDQ5NGI4MjAyYTZmODNhNThiNzA0XzI1LTIyLTEtMS0yMjYzMA_294348f4-7d09-40b3-8b3e-3b77ec07210d"
      unitRef="usd">48272335</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzMtMS0xLTEtMTE3NTg_38569b1c-00a2-41ab-8bf9-94424c882454"
      unitRef="usd">-10456870</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzMtMy0xLTEtMTE3NTg_f0d79cbd-18f4-4967-bfda-c9ed5f7d8ff9"
      unitRef="usd">6644465</us-gaap:NetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzUtMS0xLTEtMjI0OTM_b42de82d-1259-4472-a917-e19317746a3d"
      unitRef="usd">3087832</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzYtMy0xLTEtMTgwNjk_90252981-618c-49a4-975b-44c951c1930e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzYtMS0xLTEtMjI0OTY_14cc4dcb-7e5e-4157-b728-3491975be036"
      unitRef="usd">371895</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzctMy0xLTEtMTgwNjk_36b05c05-8db1-4ae5-9644-a96f7b12d877"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzUtMS0xLTEtMTE3NTg_92a0b571-47ce-464c-a326-341efd90a3d0"
      unitRef="usd">511079</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzUtMy0xLTEtMTE3NTg_56449f69-ff4e-4294-8897-24347e23e660"
      unitRef="usd">219245</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzYtMS0xLTEtMTE3NTg_47429286-2221-46a5-bff3-e7855facffcc"
      unitRef="usd">46315</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzYtMy0xLTEtMTE3NTg_f808de09-b475-4d5e-8610-633e87432f43"
      unitRef="usd">661224</us-gaap:PaidInKindInterest>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzgtMS0xLTEtMTE3NTg_f97a979d-b7e1-4030-8ffc-127d84527af6"
      unitRef="usd">9317</cntx:FairValueAdjustmentOnConvertibleDebt>
    <cntx:FairValueAdjustmentOnConvertibleDebt
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzgtMy0xLTEtMTE3NTg_78931868-8efc-49c0-aeee-fd13abc97f3c"
      unitRef="usd">9877857</cntx:FairValueAdjustmentOnConvertibleDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEwLTEtMS0xLTIyNTI0_0583186e-6e5a-4040-a4ad-d513070d3470"
      unitRef="usd">125577</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEwLTMtMS0xLTIyNTI3_ce3cd741-3a14-4429-8443-31e97223085d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEwLTEtMS0xLTExNzU4_17decdc3-c91e-4deb-a93d-0db9d06a300d"
      unitRef="usd">1611492</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEwLTMtMS0xLTExNzU4_e4ce556b-5e47-41b9-8ade-3ffee27db568"
      unitRef="usd">-4332</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzExLTEtMS0xLTExNzU4_95831726-7498-4ea5-9de0-e63c6905c52e"
      unitRef="usd">-866007</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzExLTMtMS0xLTExNzU4_60e7bcd9-ccd4-4806-bc46-bc75357b0054"
      unitRef="usd">556270</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEyLTEtMS0xLTExNzU4_5461d46a-9154-4096-b8b0-c34a59ea5124"
      unitRef="usd">252655</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEyLTMtMS0xLTExNzU4_20c4707a-8ccf-419c-bb4a-ac7a9d236473"
      unitRef="usd">757701</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEzLTEtMS0xLTExNzU4_767f0773-8fd0-4fe5-afa1-bb58df7d9256"
      unitRef="usd">-8799487</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzEzLTMtMS0xLTExNzU4_77aa4c43-22f3-4847-9161-cc436a467f87"
      unitRef="usd">-1034620</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE2LTEtMS0xLTIyNDkw_94b45272-f259-43ef-85b9-51398cc26708"
      unitRef="usd">250000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE0LTMtMS0xLTE4MDU5_06d23e59-08d9-413c-a4d6-3aa94f104a7c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE1LTEtMS0xLTE4MDU5_c13c3de7-d07d-445b-8082-197c82986934"
      unitRef="usd">-250000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE1LTMtMS0xLTE4MDU5_6dd7bb09-47f8-4ab6-b228-6afaf8364aef"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE2LTEtMS0xLTExNzU4_ba446cc2-33ec-4157-83b6-5f4eb17e5973"
      unitRef="usd">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE2LTMtMS0xLTExNzU4_204d8c1e-7e93-4dda-99ca-3b1d74dba3e1"
      unitRef="usd">25000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE3LTEtMS0xLTExNzU4_1f52f014-c7e8-4378-b9e8-47dcc2413c76"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE3LTMtMS0xLTExNzU4_e3db9b74-a18f-4f80-b81f-e2f726d3ffed"
      unitRef="usd">124054</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i14b6d70f7b20444b83ad2461cd950758_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE4LTEtMS0xLTExNzU4_22f3b4dc-b013-42a8-87f9-124e55610484"
      unitRef="usd">4982835</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i1552805dd5f94eebbc3388e3b82fe5ff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE4LTMtMS0xLTExNzU4_159097f5-9653-4614-82b6-9c0b330f18d0"
      unitRef="usd">950000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="ie40b623eecb24132bdca7f1c38c82114_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE5LTEtMS0xLTExNzU4_9dd449e9-142c-4005-8ab3-57f53501332b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzE5LTMtMS0xLTExNzU4_e59e63aa-2c78-4764-9ec9-b20383cf6189"
      unitRef="usd">50000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIzLTEtMS0xLTIyNTAy_724f24b0-62f6-4145-84ac-70a4407e1389"
      unitRef="usd">24428626</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIzLTMtMS0xLTIyNTA4_0cf5b6f9-0ebe-4314-b7e0-661663461b2f"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI0LTEtMS0xLTIyNTA1_fd65f675-56db-4940-9a9b-7ae0ead7fe2a"
      unitRef="usd">28982575</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI0LTMtMS0xLTIyNTE1_df1ca1a0-57de-4527-b561-1e8aa82ed629"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIwLTEtMS0xLTExNzU4_8532b4a1-7e3b-445c-8eba-2179b8c3703c"
      unitRef="usd">58394036</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIwLTMtMS0xLTExNzU4_18e2d5ac-8cfc-4c62-af04-c7fb328a2195"
      unitRef="usd">1149054</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIxLTEtMS0xLTExNzU4_85c4cd18-aac3-4b9e-930f-46a8d89a0dd2"
      unitRef="usd">49344549</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIxLTMtMS0xLTExNzU4_f6acc2fc-5dc0-4c98-afb2-44e3733f1406"
      unitRef="usd">114434</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIyLTEtMS0xLTExNzU4_3957d2aa-3bef-4661-b604-874a5e30fc85"
      unitRef="usd">341037</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2f8740cca1c745199eda7ed1a4c1f483_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIyLTMtMS0xLTExNzU4_6bbc2251-da00-46a1-bb20-1807b5c98c68"
      unitRef="usd">226603</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIzLTEtMS0xLTExNzU4_1ab4e205-fc6d-468a-b068-95fc3350f17c"
      unitRef="usd">49685586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzIzLTMtMS0xLTExNzU4_2fd4f0b7-b260-4c2b-9c0c-93ec520e3982"
      unitRef="usd">341037</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i000327aebd1d4982bbd9d962da1fdf97_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI1LTEtMS0xLTExNzU4_a0af5c3f-375d-4443-9a04-ccc32c332203"
      unitRef="usd">5866290</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i1870092b17d54844b0aa4cbcc3f8ca0c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI1LTMtMS0xLTExNzU4_ce0b2935-db3e-4093-8e79-805bddddf7e4"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i8b39b2be197f4335a69486c43230e142_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI2LTEtMS0xLTExNzU4_5f1451b3-182b-4d03-9064-1fb82f02533e"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i5f53e07ae1ec473f8c5c078ea26659c1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI2LTMtMS0xLTExNzU4_b7f4b470-6d71-4736-b113-f575b7b0b20c"
      unitRef="usd">529902</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="iae8e22b696e144e3ac3f230b33279167_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI3LTEtMS0xLTExNzU4_c09d2110-c3ec-4319-8acf-217afad03e05"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i001e36ae235344e082b79a6dc0a8bcdb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI3LTMtMS0xLTExNzU4_0279a08e-b4ec-4185-a2f6-901b2fa1c90c"
      unitRef="usd">6291288</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <cntx:WarrantsIssued
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI4LTEtMS0xLTExNzU4_a5f40bc4-ea9b-4d78-bb61-ae627a628573"
      unitRef="usd">309390</cntx:WarrantsIssued>
    <cntx:WarrantsIssued
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI4LTMtMS0xLTExNzU4_24a55514-7554-4977-b5e1-596318cac325"
      unitRef="usd">78967</cntx:WarrantsIssued>
    <us-gaap:StockIssued1
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzM1LTEtMS0xLTI1NjI0_db0b999e-b945-483f-9a06-1440233d1ed0"
      unitRef="usd">2837832</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzM1LTMtMS0xLTI1NjI0_2a35987d-ab13-4a11-be3e-4e5876f7ac99"
      unitRef="usd">0</us-gaap:StockIssued1>
    <cntx:DeferredOfferingCostIncurredButNotYetPaid
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI5LTEtMS0xLTExNzU4_ea520afc-1b22-4186-86df-4819983ee97d"
      unitRef="usd">102071</cntx:DeferredOfferingCostIncurredButNotYetPaid>
    <cntx:DeferredOfferingCostIncurredButNotYetPaid
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzI5LTMtMS0xLTExNzU4_4c7f7a53-a299-4fb2-86ee-b557afcee125"
      unitRef="usd">117631</cntx:DeferredOfferingCostIncurredButNotYetPaid>
    <cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzMwLTEtMS0xLTExNzU4_e4ec53c7-8eed-4c59-8c26-8ad4822acc64"
      unitRef="usd">53330</cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue>
    <cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzMwLTMtMS0xLTExNzU4_bb2c497c-7980-4d2e-afc7-663511d6a80a"
      unitRef="usd">97000</cntx:IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzM4LTEtMS0xLTIyNTM1_d7d32327-32a2-40f3-aa10-27855c1054a8"
      unitRef="usd">21064623</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDMvZnJhZzphYmI3NjFkMDkzZDU0YTFmYTg1MTIzMzI1YmNlZWZjYy90YWJsZTpiMThmMzkzZTc2M2Y0ZThlYmQ5MGIxZmZjZjQ1NjRlYy90YWJsZXJhbmdlOmIxOGYzOTNlNzYzZjRlOGViZDkwYjFmZmNmNDU2NGVjXzM4LTMtMS0xLTIyNTUy_1836d37b-776b-48f3-a884-bf6ba9c80f51"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:NatureOfOperations
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDkvZnJhZzozMjg5YTg5NDg1NGM0NmZjYjcwNzE5ODY2Zjg2YzI5NS90ZXh0cmVnaW9uOjMyODlhODk0ODU0YzQ2ZmNiNzA3MTk4NjZmODZjMjk1XzE2NDkyNjc0NDE5NDA5_4e3bae1c-7ac2-429e-9efe-0bc46d92dc36">Nature of Business Context Therapeutics Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#x2019;s operations are located in Philadelphia, Pennsylvania. In April 2021, the Company completed a reverse triangular merger, which resulted in Context Therapeutics Inc. becoming the sole holder of 100% of the membership interests in Context Therapeutics LLC. In connection with the merger, all common units, preferred units, options, warrants or other rights to purchase common or preferred units of Context Therapeutics LLC converted into common stock, preferred stock, options, warrants or other rights to purchase common or preferred stock of Context Therapeutics Inc. As this was a transaction between entities under common control, the carryover basis of accounting was used to record the assets, liabilities and equity of Context Therapeutics LLC. Further, as a common control transaction, the consolidated financial statements of the Company reflect the merger transaction as if it had occurred as of the earliest period presented herein.</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="id7d9b23ad16c43aa8572a0ac6ca614b4_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMDkvZnJhZzozMjg5YTg5NDg1NGM0NmZjYjcwNzE5ODY2Zjg2YzI5NS90ZXh0cmVnaW9uOjMyODlhODk0ODU0YzQ2ZmNiNzA3MTk4NjZmODZjMjk1XzE2NDkyNjc0NDE5NDA0_b71bd307-219a-4801-ab49-c3bb44b96ae8"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <cntx:RisksAndLiquidityTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzM4Mzk_0ff5aba5-d4fb-43e6-a57a-28c0d7873b07">Risks and Liquidity &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $29.3 million as of December&#160;31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its product candidates currently in development. The Company&#x2019;s primary source of liquidity to date has been the issuance of convertible promissory notes, convertible preferred stock and common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first half of 2021, the Company raised $5.0 million in net proceeds related to the sale of its Series A convertible preferred stock (&#x201c;Series A Stock&#x201d;) and warrants for common stock (see Note 7 for further discussion). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In October 2021, the Company closed an initial public offering (&#x201c;IPO&#x201d;) on the Nasdaq Stock Market, in which it issued and sold 5,750,000 shares at a public offering price of $5.00 per share. In addition, at the closing of the IPO, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent&#x2019;s warrants have an exercise price of $6.25 per share and a term of five years from the date of issuance. Immediately prior to the completion of the IPO, all of the Company&#x2019;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and 480,415 warrants converted into 9,816 shares of common stock. The Company received net proceeds of $24.4&#160;million as a result of its initial public offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company sold 5,000,000 shares of its common stock together with warrants to purchase 5,000,000 shares of its common stock in a private placement and received net proceeds of $28.9 million.  Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants have a term of 5.5 years and an exercise price of $6.25 per share. In addition, at the closing of the private placement, the Company issued warrants to purchase up to 250,000 shares of common stock to designees of the placement agent. The placement agent&#x2019;s warrants have an exercise price of $6.25 per share and a term of 5.5 years from the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes its cash and cash equivalents at December&#160;31, 2021 are sufficient to fund its projected operations into fiscal year 2024. However, substantial additional capital will be needed by the Company to fund its operations and to commercially develop its current and future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company plans to secure additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#x2019;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#x2019;s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#x2019;s product candidates, length of time and cost of developing and commercializing these &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#x2019;s financial condition and future operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. &lt;/span&gt;&lt;/div&gt;In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#x2019;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#x2019;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#x2019;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#x2019;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.</cntx:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzYwNDczMTM5NTY2MzA_7bac54d1-3de7-45b0-bb6d-af8b3c1c6e3e"
      unitRef="usd">-29300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i4173532c9b754389b02c47c17758a39e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzYwNDczMTM5NTY2NjI_03470299-36c5-4431-8661-2de05ee0ce5e"
      unitRef="usd">5000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib574e9442de340bba7e8df59de0aa8ea_D20211001-20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDQ1_bea5e9c6-31de-46cf-a726-438667d90470"
      unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ifaec33cca2ed463caf5a7211bdf75d02_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDU2_5ceef92e-0b44-40bc-807a-925505ea73e4"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic9fe5d1cf7064523ac856ef87a48d0ed_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDYz_229b565b-9612-4c8f-b0e8-c03c45b3c583"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic9fe5d1cf7064523ac856ef87a48d0ed_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDkw_c21ef994-d0b6-4689-ac95-8fed74d07c55"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic9fe5d1cf7064523ac856ef87a48d0ed_I20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTA1_e47a7a01-a431-4cfe-acdb-e14bead803a6">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDc5_fb9de2a5-058c-4359-bb30-921ef8d4552a"
      unitRef="shares">4853533</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i536b13a96232407dbc13d841f1fce5a7_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDk3_644138b9-ff89-4e25-8415-77be358e0d79"
      unitRef="shares">480415</us-gaap:ClassOfWarrantOrRightOutstanding>
    <cntx:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MDcy_e90355df-3bbd-4eb1-bd1b-ff1eb630fa43"
      unitRef="shares">9816</cntx:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzkzNDU4NDg4NTg3NTQ_9fce6798-a28e-4a1f-a532-c9fda99a4b25"
      unitRef="usd">24400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTIy_02841ab3-5fc2-40ab-a618-8b830ab134ac"
      unitRef="shares">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTMz_9c10140d-bd38-41b1-8884-630f5432de35"
      unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzEyMDk0NjI3OTI3Mzk5_6b262aa8-e907-4587-b76b-ee1e38c1222a"
      unitRef="usd">28900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5177f9964b244a76b68f2abaac086c21_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTUx_8e864815-b73e-4143-8d84-eff0599373dd"
      unitRef="usdPerShare">6.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTcz_7d61c121-6941-4bf7-8ac2-7fdc12a1bb3f">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTQ0_f3c42900-95cb-405c-96db-4d3e6841af51"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTY1_b315ff77-e5c4-49e3-81f3-1295bbfe423a"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTU4_c6641284-6895-497d-99b5-6dcbc9cdd6fe"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTIvZnJhZzphYTNjN2NiOTc1NTM0ZTgzYWI2YjAwMzllNDFlMThiMi90ZXh0cmVnaW9uOmFhM2M3Y2I5NzU1MzRlODNhYjZiMDAzOWU0MWUxOGIyXzE2NDkyNjc0NDM5MTg5_538bcd98-a0b7-42cc-843d-8d20485058ec">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTM3_2f7a1fb5-54d4-4afa-8b26-6fecae5def03">Summary of Significant Accounting Policies &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#x2019;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification of Prior Year Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of warrants, the fair value of convertible debt, and prepayments, accruals and associated expense related to research and development activities performed for the Company by third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021 and 2020, the Company&#x2019;s level 1 financial instruments included cash equivalents and accounts payable. The carrying amounts of these assets and liabilities approximate fair value due to their short-term nature. Convertible promissory notes are recorded at approximate fair value on a recurring basis (see Note 4 for further discussion). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains approximately $50,000 as collateral for the Company&#x2019;s credit card program. The Company has recorded this deposit and accumulated interest thereon as restricted cash on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s cash, cash equivalents, and restricted cash as of December 31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,635,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,685,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations.  As of December&#160;31, 2020, the Company had deferred offering costs of $0.1 million related to the Company&#x2019;s IPO and the Company&#x2019;s Series A Stock financing.  All deferred offering costs related to the Company&#x2019;s Series A Stock financing were recorded against Series A Stock upon completion of the financing in April 2021 and all deferred offering costs related to the Company&#x2019;s IPO were recorded against additional paid-in capital upon completion of the IPO financing in October 2021. There were no deferred offering costs recorded as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock and Redeemable Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its convertible preferred stock subject to possible conversion in accordance with ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Conditionally convertible preferred stock (including shares that feature conversion rights that are either within the control of the holder or subject to conversion upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. The Company&#x2019;s convertible preferred stock feature redemption rights that are considered by the Company to be outside of the Company&#x2019;s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;convertible preferred stock subject to contingent redemption are presented as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired In-Process Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expense consists of the initial up-front payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company&#x2019;s acquired IPR&amp;amp;D expense of $3.1&#160;million for the year ended December 31, 2021 reflects the fair value of consideration ascribed to the collaboration and licensing agreement with Integral Molecular, Inc. (&#x201c;Integral&#x201d;) for the development of an anti-claudin 6 (&#x201c;CLDN6&#x201d;) bispecific monoclonal antibody (&#x201c;BsMAb&#x201d;) for gynecologic cancer therapy. See Note 9 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#x2019;s research and development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of prepaid/accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the prepaid/accrual accordingly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipients&#x2019; service payments are classified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. Until its IPO that closed in October 2021, the Company had been a private company and lacked Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#x2019;s stock awards has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted stock awards based on the grant date fair value of the awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to April 2021, the Company was a limited liability company that was treated as a pass-through entity for income tax purposes. In April 2021, upon the completion of its reverse triangular merger, the Company converted to a corporation and is subject to federal, state and local corporate income taxes which have been provided for in the financial statements based upon ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 740&#x201d;).  Context BioPharma, Inc. has always been subject to corporate income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under ASC 740, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting. Deferred tax assets are reduced by a valuation allowance if a determination is made that it is more likely than not that some or all of the deferred tax assets will not be realized based on the weight of all available evidence.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an examination. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50&#160;percent likelihood of being realized upon settlement with the relevant authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net (Loss) Income Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes net (loss) income per share using the weighted-average number of common shares outstanding during the year. For years with a net loss, basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which includes convertible promissory notes, preferred stock, warrants and share-based awards outstanding, would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was in a net loss position for the year ended December 31, 2021 and therefore basic and diluted net loss per share was the same. The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,006,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2020, the Company was in a net income position and therefore, used the two-class method to compute basic net income per common share. Under this method, undistributed earnings are allocated to common stock, the Series Seed Preferred Stock and the Series A Preferred Stock to the extent that the preferred stockholders may share in earnings. In periods of net loss, losses are not allocated to participating securities as the holders of such securities have no obligation to fund losses. The total earnings allocated to common stock is then divided by the weighted average common shares outstanding to determine the basic earnings per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants and share-based awards using the treasury stock method. In addition, the Company considers the potential dilutive impact of its preferred stock and convertible debt using the treasury stock and if-converted methods, if either is more dilutive than the two-class method. The two-class method was more dilutive for the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net (loss) income per common share calculation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,456,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,644,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: undistributed earnings to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,573,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,456,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net (loss) income per common share calculation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,456,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,644,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: undistributed earnings to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,573,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: change in fair value of convertible promissory notes and interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,216,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,456,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,145,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,706,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,054,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Emerging Growth Company Status &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (ASC 470-20) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (ASC 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminated the beneficial conversion (and cash conversion) accounting models in ASC 470-20 that require separate accounting for embedded conversion features and simplified the settlement assessment to determine whether it qualifies for equity classification by removing certain conditions in ASC 815-40-25. In addition, the new guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments and to include the effect of share settlement for instruments that may be settled in cash or shares. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its financial statements and related disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2016, the FASB issued ASU 2016-02,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;,&#160;in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a)&#160;the existence of a lease, (b)&#160;the lease classification or (c)&#160;the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQx_d2507a54-693b-4f05-b66c-adf02cd5b8cc">Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTM4_f16a10bd-d843-4a15-8023-cc1d6f68af09">The consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#x2019;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMTQ4OTI_15f1bbe3-245b-4d0e-8b13-817b22ab1ade">Reclassification of Prior Year PresentationCertain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQy_1628e52a-76f9-4538-8299-b774c48a7afa">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the fair value of common stock, share-based compensation arrangements, the fair value of warrants, the fair value of convertible debt, and prepayments, accruals and associated expense related to research and development activities performed for the Company by third parties.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTM5_bf01e21d-fb38-4294-8312-1ea7190c68ec">Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTUw_118d4f8a-e19d-47f0-83bd-d5dbea7cee11">Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzYwNDczMTM5NzA5NTI_4090d2b8-bf1d-46c2-a1f0-a901ff0c9a11"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQ1_5d08da13-138c-4818-883e-6a4e30a274ae">Fair Value of Financial Instruments At December&#160;31, 2021 and 2020, the Company&#x2019;s level 1 financial instruments included cash equivalents and accounts payable. The carrying amounts of these assets and liabilities approximate fair value due to their short-term nature. Convertible promissory notes are recorded at approximate fair value on a recurring basis</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQ2_fe920f94-9b8f-4130-b9cb-702a230c4623">Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDU0ODA_d38ec7bc-b8a2-4e00-b48c-7b5cf4661100"
      unitRef="usd">50000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMjExMDc_4113f1de-ba13-4da4-b886-5ebd3d56d33a">The following table presents the Company&#x2019;s cash, cash equivalents, and restricted cash as of December 31, 2021 and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,635,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,685,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzItMi0xLTEtMjk2NzY_0497eab4-52a0-435a-931b-af5dd562cf64"
      unitRef="usd">49635197</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzItNC0xLTEtMjk2ODM_a9a5f0ba-1178-447f-b98f-eae2825630e8"
      unitRef="usd">290670</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzMtMi0xLTEtMjk2NzY_c55c822b-0991-403b-83a6-8932ffbefb23"
      unitRef="usd">50389</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzMtNC0xLTEtMjk2ODM_ad5e3611-dbc4-49ec-b3fe-1198082bda75"
      unitRef="usd">50367</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzQtMi0xLTEtMjk4ODk_e1945a6c-a2ee-47aa-98dc-0c9dd895141d"
      unitRef="usd">49685586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZToyZDMxZGRmZjNmNDU0ZWY1YjFjYjczYTYwODMyYjk4Ny90YWJsZXJhbmdlOjJkMzFkZGZmM2Y0NTRlZjViMWNiNzNhNjA4MzJiOTg3XzQtNC0xLTEtMjk4ODk_204e15d8-a40f-4734-9eec-dd700b960d10"
      unitRef="usd">341037</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQz_aa932e5c-684c-48ea-980b-7cda9dc206bd">Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCostsCurrentAndNoncurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzQzOTgwNDY1NDA1MTI_2b5b4ec8-0a99-4eee-915d-b9de0af1d280"
      unitRef="usd">100000</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:DeferredCostsCurrentAndNoncurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMTY3NDY_f747db5f-7132-439d-8039-0500388ad591"
      unitRef="usd">0</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <cntx:TemporaryEquityPolicyPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMjExMDg_32c506dd-428a-478a-ac92-dd1e4e961963">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock and Redeemable Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its convertible preferred stock subject to possible conversion in accordance with ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Conditionally convertible preferred stock (including shares that feature conversion rights that are either within the control of the holder or subject to conversion upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. The Company&#x2019;s convertible preferred stock feature redemption rights that are considered by the Company to be outside of the Company&#x2019;s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020, the &lt;/span&gt;&lt;/div&gt;convertible preferred stock subject to contingent redemption are presented as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s consolidated balance sheets.</cntx:TemporaryEquityPolicyPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMTQ4OTM_7a534eba-91d6-4188-9512-a519c800d2b0">Acquired In-Process Research and Development Costs&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expense consists of the initial up-front payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxMTQ5MDA_ca4d7f11-ce2f-4fe2-884c-ba7c4b9a5030"
      unitRef="usd">3100000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzE3OTQ3_d07fe6e7-31da-48de-813b-e87f9c07ebfe">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#x2019;s research and development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of prepaid/accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the prepaid/accrual accordingly. &lt;/span&gt;&lt;/div&gt;Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cntx:PatentCostsPolicyPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDU0Nzc_20c2004c-0e43-45f9-b91e-8785505374d9">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;</cntx:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTI_f2bf962a-c72c-43e6-8901-9479aa169669">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipients&#x2019; service payments are classified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. Until its IPO that closed in October 2021, the Company had been a private company and lacked Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#x2019;s stock awards has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;In addition, the Company measures and recognizes share-based compensation expense for advisors, officers and director restricted stock awards based on the grant date fair value of the awards.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTM_ed25594d-7145-488e-ad9b-f04559038abf">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to April 2021, the Company was a limited liability company that was treated as a pass-through entity for income tax purposes. In April 2021, upon the completion of its reverse triangular merger, the Company converted to a corporation and is subject to federal, state and local corporate income taxes which have been provided for in the financial statements based upon ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 740&#x201d;).  Context BioPharma, Inc. has always been subject to corporate income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under ASC 740, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting. Deferred tax assets are reduced by a valuation allowance if a determination is made that it is more likely than not that some or all of the deferred tax assets will not be realized based on the weight of all available evidence.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an examination. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50&#160;percent likelihood of being realized upon settlement with the relevant authority. &lt;/span&gt;&lt;/div&gt;The Company will recognize interest and penalties related to uncertain tax positions in income tax expense.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzkzNDU4NDg5MDQ1MTU_25b65691-0af3-423c-9d47-39ab19c1c537"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzkzNDU4NDg5MDQ1MTU_c6cb5699-852a-411d-b823-4aad573902f4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzkzNDU4NDg5MDQ1ODg_98687dac-eb39-49f4-9953-a17f6e1256bb"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzkzNDU4NDg5MDQ1ODg_ff272b86-0df4-4273-b566-48cbe451e414"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTQ_90f4bae8-dd6c-433b-bc1d-9f5e033eede2">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net (Loss) Income Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes net (loss) income per share using the weighted-average number of common shares outstanding during the year. For years with a net loss, basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which includes convertible promissory notes, preferred stock, warrants and share-based awards outstanding, would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTY_60f85450-db54-4528-8839-9706cd0039fa">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020, as they would be anti-dilutive:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,006,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icc8935fc9d464f29836a2a16fe277e98_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzItMi0xLTEtMzAzMDY_01deb4e6-b3c1-4d72-ba3b-98074a7d8648"
      unitRef="shares">506691</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id255264c0c894b67a64f0a3ef3d68e1c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzItNC0xLTEtMzAzMDY_29dd9127-bb0f-44d3-8b7c-abe7084516a3"
      unitRef="shares">24830</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie5f9e0e12992402d90ec7a6af875e1fc_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzMtMi0xLTEtMzAzMDY_f73989ad-0cb8-4a9b-98f0-1365e5875a48"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5aebf98410d2455caa4d29b128109b43_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzMtNC0xLTEtMzAzMDY_6542ae7b-a79b-4e90-88c2-1a248e8c5c88"
      unitRef="shares">45</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3d242a6318ef4c6bbdd7b8627be0cff1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzQtMi0xLTEtMzAzMDY_57bb7617-791c-42c4-a3a6-8ea284dc99bb"
      unitRef="shares">5500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i887b64939c5845d2a4612345d96858c2_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzQtNC0xLTEtMzAzMDY_5b7698a9-65e5-4895-9b69-7c25d8b52d1f"
      unitRef="shares">160108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzUtMi0xLTEtMzAzMDY_fe500906-b9c5-4b40-ac81-09f52338ffce"
      unitRef="shares">6006691</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpkMjM3NmI1NjQ3Y2Q0OTJhOGE2YmQ1Yzg2NzE5YzZkMS90YWJsZXJhbmdlOmQyMzc2YjU2NDdjZDQ5MmE4YTZiZDVjODY3MTljNmQxXzUtNC0xLTEtMzAzMDY_fa02bb6d-b176-4a5f-a297-f716cf00272a"
      unitRef="shares">184983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTc_5c33de48-689f-4585-ba28-91d62e2d4d6a">The two-class method was more dilutive for the year ended December 31, 2020. &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net (loss) income per common share calculation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,456,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,644,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: undistributed earnings to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,573,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,456,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net (loss) income per common share calculation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,456,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,644,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: undistributed earnings to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,573,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: change in fair value of convertible promissory notes and interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,216,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common shareholders &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,456,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,145,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,706,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,054,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzMtMS0xLTEtMzAyNjE_42cffb12-12e0-4632-9404-4ce793554ec6"
      unitRef="usd">-10456870</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzMtMy0xLTEtMzAyNjE_7841d148-b318-448c-afe5-5c44d4486af6"
      unitRef="usd">6644465</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzQtMS0xLTEtMzAyNjE_794cf4c5-9e5c-48eb-af74-ef00ab81a9a5"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzQtMy0xLTEtMzAyNjE_1d8a3dc7-c247-402c-ac4b-bd1a0e8f2fa2"
      unitRef="usd">5573558</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzUtMS0xLTEtMzAyNjE_ee7836eb-9058-42ff-ae39-6e7bb415d0cc"
      unitRef="usd">-10456870</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzUtMy0xLTEtMzAyNjE_1fe22436-a09f-4474-aef7-19ae090564f0"
      unitRef="usd">1070907</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzYtMS0xLTEtMzAyNjE_b2e8ede6-0c7c-48ac-9e07-fc2211965a5e"
      unitRef="shares">2833674</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzYtMy0xLTEtMzAyNjE_67602241-46f7-4f45-8a31-a6372e78f73c"
      unitRef="shares">348368</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzctMS0xLTEtMzAyNjE_ccf26cb3-c077-4f92-a6a6-aab62125ed8e"
      unitRef="usdPerShare">-3.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzctMy0xLTEtMzAyNjE_10b2aa1e-0395-4e96-9bad-d5ae6b8e8ad6"
      unitRef="usdPerShare">3.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzktMS0xLTEtMzAyNjE_30fcf021-c648-44cf-9c1b-edad9cc4c929"
      unitRef="usd">-10456870</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzktMy0xLTEtMzAyNjE_7a22689a-cadd-48d3-b9bc-383f10ab9fbc"
      unitRef="usd">6644465</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEwLTEtMS0xLTMwMjYx_e0c71af3-7e86-43ad-b29b-f6686148370c"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEwLTMtMS0xLTMwMjYx_94036e09-2dba-4790-b68f-87fe5f3bae76"
      unitRef="usd">5573558</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzExLTEtMS0xLTMwMjYx_a9e7c68d-2f54-4e7e-bd29-af0c8ef48487"
      unitRef="usd">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzExLTMtMS0xLTMwMjYx_97d7c567-9a7b-4838-8cca-c21183687732"
      unitRef="usd">-9216633</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEyLTEtMS0xLTMwMjYx_b06df87e-0b40-439d-8325-51e3035ae39d"
      unitRef="usd">-10456870</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEyLTMtMS0xLTMwMjYx_e92f74f1-681d-4590-a09a-a87e1332ae17"
      unitRef="usd">-8145726</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEzLTEtMS0xLTMwMjYx_a472fee7-6053-4456-b1de-49592afe03d1"
      unitRef="shares">2833674</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzEzLTMtMS0xLTMwMjYx_97298817-b26b-4086-8cfc-7c02d3187553"
      unitRef="shares">348368</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE0LTEtMS0xLTMwMjYx_5b5e3e87-d3d8-4485-89c4-163b79b83074"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE0LTMtMS0xLTMwMjYx_8f396a93-9a9b-4ebd-bde0-dd8ff0b5e77c"
      unitRef="shares">1706507</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE1LTEtMS0xLTMwMjYx_d7e08134-10ca-4323-9ccf-d9dbb579fd0d"
      unitRef="shares">2833674</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE1LTMtMS0xLTMwMjYx_4aa60bef-ca8a-474b-ab80-14e7ec10aac7"
      unitRef="shares">2054875</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE2LTEtMS0xLTMwMjYx_bead1cf0-f622-481c-90e8-3df6902af998"
      unitRef="usdPerShare">-3.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90YWJsZTpiYTFlOTI0ZGRhY2Q0NmFjOGYxMWYxNTk4Nzc2N2M5OS90YWJsZXJhbmdlOmJhMWU5MjRkZGFjZDQ2YWM4ZjExZjE1OTg3NzY3Yzk5XzE2LTMtMS0xLTMwMjYx_5e849307-c397-411a-b8e4-9285ee618e50"
      unitRef="usdPerShare">-3.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTUvZnJhZzo4MjVlYmI1NDljYjY0NTQwYWNjZTUzNjBkOGRhYmZlYi90ZXh0cmVnaW9uOjgyNWViYjU0OWNiNjQ1NDBhY2NlNTM2MGQ4ZGFiZmViXzI3NDg3NzkxNDUyNTU_10ee73bc-3eb8-439a-a619-a24aed06ea57">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (ASC 470-20) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (ASC 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminated the beneficial conversion (and cash conversion) accounting models in ASC 470-20 that require separate accounting for embedded conversion features and simplified the settlement assessment to determine whether it qualifies for equity classification by removing certain conditions in ASC 815-40-25. In addition, the new guidance requires entities to use the if-converted method to calculate earnings per share for all convertible instruments and to include the effect of share settlement for instruments that may be settled in cash or shares. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its financial statements and related disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. The Company adopted this standard on January 1, 2021, and the adoption did not have a material impact on its related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2016, the FASB issued ASU 2016-02,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;,&#160;in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a)&#160;the existence of a lease, (b)&#160;the lease classification or (c)&#160;the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous GAAP. In July 2018, the FASB issued ASU 2018-11,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this standard on January 1, 2022 and the adoption did not have a material impact on its consolidated financial statements due to the fact that the Company did not have any material long-term leasing arrangements as of the date of adoption.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90ZXh0cmVnaW9uOmQ5YTA1MTY4YjY4ZTQ1NDRhZmQzZjhlNmE4YTRjYzFmXzQwODY_2fef9c9a-2c6d-4f6f-b9f4-73285b95ae8e">Fair Value Measurements &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1 &#x2013; Observable inputs such as quoted prices in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2 &#x2013; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3 &#x2013; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the fair value hierarchy described above, the following table sets forth the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Active Markets for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Assets (Level 1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(Level 2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Unobservable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(Level 3) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents and restricted cash (Money Market Accounts)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,051,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,051,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Active Markets for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Assets (Level 1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(Level 2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Unobservable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(Level 3) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (Money Market Account)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Promissory Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As further described in Note 6, the Company issued convertible promissory notes from inception through April 2019 (the &#x201c;Junior Convertible Notes&#x201d;) to various investors and from October 2019 through March 2020, the Company issued convertible bridge notes to the Co-Founder and Chief Executive Officer (the &#x201c;Convertible Bridge &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notes&#x201d;). During April 2020, certain of the Junior Convertible Notes were converted into Senior Convertible Notes (the &#x201c;Senior Convertible Notes&#x201d;) (collectively, the &#x201c;Convertible Promissory Notes&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the number of embedded provisions contained in the Convertible Promissory Notes and Convertible Bridge Notes, the fair value option, as prescribed by ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was elected and applied to all Convertible Promissory Note and Convertible Bridge Note issuances since the Company&#x2019;s inception in 2015, in connection with the preparation of these financial statements. The fair value of the Convertible Promissory Notes and Convertible Bridge Notes was determined using a scenario-based analysis that estimates the fair value based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the noteholders, including various IPO, settlement, equity financing, corporate transaction and dissolution scenarios. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adjusted the carrying value of its Convertible Promissory Notes and Convertible Bridge Notes to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as change in fair value of convertible promissory notes in the consolidated statement of operations. The change in fair value of convertible promissory notes within the years ended December 31, 2021 and 2020 consolidated statement of operations also includes reversals of gains and losses previously recognized by the Company upon conversion of the notes (Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Senior Convertible Notes at  December 31, 2020 was calculated using an option pricing model (&#x201c;OPM&#x201d;) framework and utilized the back-solve method for inferring and allocating the equity value predicated on the concurrent sale of Series A Stock. This method was selected as it was concluded that the sale of the Series A Stock was an arm&#x2019;s-length transaction. Application of the OPM back-solve method involves making assumptions for the expected time to liquidity and volatility, and then solving for the value of equity such that value for the most recent financing equals the amount paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a roll-forward of the aggregate fair values of the Company&#x2019;s Convertible Promissory Notes (Note 6) for which fair value is determined by Level&#160;3 inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,842,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of Convertible Bridge Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,877,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion of Junior Convertible Notes into Series Seed Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,291,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion of Senior and Convertible Bridge Notes into Series A Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,866,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90ZXh0cmVnaW9uOmQ5YTA1MTY4YjY4ZTQ1NDRhZmQzZjhlNmE4YTRjYzFmXzQwODc_ec821465-5841-48a6-8347-7ecb08a86338">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the fair value hierarchy described above, the following table sets forth the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Active Markets for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Assets (Level 1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(Level 2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Unobservable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(Level 3) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents and restricted cash (Money Market Accounts)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,051,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,051,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Active Markets for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Assets (Level 1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(Level 2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Unobservable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(Level 3) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (Money Market Account)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Promissory Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7ce232c5ed264fc1a5e2e91833604312_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTpjNTA5Y2M0YjY1YjM0YWIzOWU4MTQ2NTQwODgwNjhmZS90YWJsZXJhbmdlOmM1MDljYzRiNjViMzRhYjM5ZTgxNDY1NDA4ODA2OGZlXzMtMS0xLTEtMTE3NTg_d2a82c12-3fd1-4bf5-b728-aaa464f60ed1"
      unitRef="usd">49051061</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibcee81aa26da40c7aa01c8ed07319386_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTpjNTA5Y2M0YjY1YjM0YWIzOWU4MTQ2NTQwODgwNjhmZS90YWJsZXJhbmdlOmM1MDljYzRiNjViMzRhYjM5ZTgxNDY1NDA4ODA2OGZlXzMtMy0xLTEtMTE3NTg_708908f2-868d-4249-919d-e83e92c16efb"
      unitRef="usd">49051061</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i81d84cd8ac404ffb9652dfeadc1a177f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTpjNTA5Y2M0YjY1YjM0YWIzOWU4MTQ2NTQwODgwNjhmZS90YWJsZXJhbmdlOmM1MDljYzRiNjViMzRhYjM5ZTgxNDY1NDA4ODA2OGZlXzMtNS0xLTEtMTE3NTg_b81de7f8-cc0d-4554-b828-ced336df0b8b"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i68566af59223448eb22d5006be5194ba_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTpjNTA5Y2M0YjY1YjM0YWIzOWU4MTQ2NTQwODgwNjhmZS90YWJsZXJhbmdlOmM1MDljYzRiNjViMzRhYjM5ZTgxNDY1NDA4ODA2OGZlXzMtNy0xLTEtMTE3NTg_7a16833e-8998-4258-a775-2f3fe359f6e2"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash
      contextRef="i77004ca7aa1445119a9a78b5703984df_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzMtMS0xLTEtMTE3NTg_a97a320e-fe6e-4e48-8770-f4a3c85fd569"
      unitRef="usd">50367</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i37c0a790ca1c4e73b5def12d29757201_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzMtMy0xLTEtMTE3NTg_14340175-8616-443f-a6d4-cf8d730ace1c"
      unitRef="usd">50367</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i3c39b33c88a8458686857dd42b2e64f9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzMtNS0xLTEtMTE3NTg_6602d7b4-44ce-4d90-ab44-57a4633bee91"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ic199b723275d45d2bc21be1587aae664_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzMtNy0xLTEtMTE3NTg_2caeb5c3-f946-45b1-a2ad-577bce9dcfc3"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ia34409531cae4268bc173922ce57ac3f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzUtMS0xLTEtMTE3NTg_dd64e2e0-599c-49ef-bd79-89ed99eeb4e4"
      unitRef="usd">5829292</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ib510cda252c24e72b8fa50da53cf17e1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzUtMy0xLTEtMTE3NTg_0f418563-37ed-419d-9294-fcf76f6ae960"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i16b5edd019244d8c9ac599aebe563739_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzUtNS0xLTEtMTE3NTg_94110193-c2f5-46be-8277-863f99ff0563"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i908727eba5bc4358b2ac0822d99cd9ba_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTphZTljZWMzOWFkNzQ0NjE2YmJhZmM3NGU5ZTgzMjU0Yi90YWJsZXJhbmdlOmFlOWNlYzM5YWQ3NDQ2MTZiYmFmYzc0ZTllODMyNTRiXzUtNy0xLTEtMTE3NTg_15dc1384-6238-4ba7-aef5-479993e8d411"
      unitRef="usd">5829292</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90ZXh0cmVnaW9uOmQ5YTA1MTY4YjY4ZTQ1NDRhZmQzZjhlNmE4YTRjYzFmXzQwODg_8fcf473e-5e5f-4d92-8538-2af0301ca1d3">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a roll-forward of the aggregate fair values of the Company&#x2019;s Convertible Promissory Notes (Note 6) for which fair value is determined by Level&#160;3 inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,842,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of Convertible Bridge Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,877,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion of Junior Convertible Notes into Series Seed Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,291,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion of Senior and Convertible Bridge Notes into Series A Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,866,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,829,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id55d52b883b8439db64cf84da4088ed2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzEtMS0xLTEtMTE3NTg_e216fc79-d41b-49f4-b900-b609753762d9"
      unitRef="usd">5829292</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie62db008cf5d41d287747c3ee2afb05c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzEtMy0xLTEtMTE3NTg_12beb84b-a3d3-4a11-8786-edd71e808f75"
      unitRef="usd">21842931</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i58cb9ed855944a858084c633831e74b3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzMtMS0xLTEtMTE3NTg_d2cb5f0e-460e-418c-9e9e-4b8b8386617f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="id0dff24cca894323a3974079199c467e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzMtMy0xLTEtMTE3NTg_b40ecc38-1e2c-47c8-bf6a-261e6ee080ae"
      unitRef="usd">25000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i98b4298623094156bda38964f2ca6d72_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzYtMS0xLTEtMTE3NTg_abdad9f6-58f0-48ad-96ee-2b45678820fb"
      unitRef="usd">9317</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="icb6e5f4b103e4e5482b8dc8b7527a3cc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzYtMy0xLTEtMTE3NTg_dba8ad76-8969-476e-8371-caf90688e389"
      unitRef="usd">9877857</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <cntx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest
      contextRef="i98b4298623094156bda38964f2ca6d72_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzctMS0xLTEtMTE3NTg_544055e2-9193-4123-aa35-d60aada42965"
      unitRef="usd">46315</cntx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest>
    <cntx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest
      contextRef="icb6e5f4b103e4e5482b8dc8b7527a3cc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzctMy0xLTEtMTE3NTg_9451333d-49d4-408b-8d8f-ecd25bdcca77"
      unitRef="usd">660408</cntx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i4cbdfcd435a84616aec15c81c9bb7b06_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzgtMS0xLTEtMTE3NTg_d1ff7312-4487-49aa-b991-5bf73effebe8"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i89d4008efcc04a669ef14e103f9a6a6a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzgtMy0xLTEtMTE3NTg_5de86270-9a50-4546-9156-c4e1a0b3c3e6"
      unitRef="usd">6291288</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ia686afec9e234c72967a01ae8d98a108_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzktMS0xLTEtMTE3NTg_9e6e33d8-8584-4ab5-bd3b-66e4a44a24ed"
      unitRef="usd">5866290</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ie234c0a724cd46029a0f0307bcf0e78b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzktMy0xLTEtMTE3NTg_3d0acfc4-1a9a-4b94-9361-1e5188d6ca6f"
      unitRef="usd">529902</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4296ddef4cfc4b709b45e518ab9c281c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzEwLTEtMS0xLTExNzU4_8a7d0e03-0a5a-41c9-9ef4-4e6f2a6c2745"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id55d52b883b8439db64cf84da4088ed2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMTgvZnJhZzpkOWEwNTE2OGI2OGU0NTQ0YWZkM2Y4ZTZhOGE0Y2MxZi90YWJsZTozNjg5NTMzMGM0YjA0NGJjOTJhMWFiMmM3Njk4MTg2Mi90YWJsZXJhbmdlOjM2ODk1MzMwYzRiMDQ0YmM5MmExYWIyYzc2OTgxODYyXzEwLTMtMS0xLTExNzU4_fd708782-9e08-48ec-a2f2-e0e5541a909c"
      unitRef="usd">5829292</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGV4dHJlZ2lvbjo4ZDNiNWRjMzUzMWI0MGY3ODBlYWI1Mzc5YzFlNzM4M18yNzQ4Nzc5MDY5NzU0_095f6ac2-304c-4724-930a-4fef006b431c">Accrued Expenses and Other Current Liabilities&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGV4dHJlZ2lvbjo4ZDNiNWRjMzUzMWI0MGY3ODBlYWI1Mzc5YzFlNzM4M18yNzQ4Nzc5MDY5NzU1_bc5153ae-5e03-48e9-ac88-d9c4c532c65a">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV8yLTItMS0xLTI1MjA0_86d52454-1d28-42b4-849c-29222f99c5e2"
      unitRef="usd">436990</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV8yLTQtMS0xLTI1MjA0_7d76dfbd-bfa3-4b75-8f79-9f385956aac4"
      unitRef="usd">0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cntx:ClinicalTrialLiabilitiesCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV8zLTItMS0xLTI1MjA0_800a0d86-5062-4b04-ad3d-194290a52fd2"
      unitRef="usd">339072</cntx:ClinicalTrialLiabilitiesCurrent>
    <cntx:ClinicalTrialLiabilitiesCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV8zLTQtMS0xLTI1MjA0_0af66e0a-2cb3-42c3-b801-e80dec0cebcc"
      unitRef="usd">126173</cntx:ClinicalTrialLiabilitiesCurrent>
    <cntx:ManufacturingDevelopmentLiabilitiesCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV80LTItMS0xLTI1MjA0_af6f1092-6cd3-4a0d-8033-1cdf2ed3379a"
      unitRef="usd">0</cntx:ManufacturingDevelopmentLiabilitiesCurrent>
    <cntx:ManufacturingDevelopmentLiabilitiesCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV80LTQtMS0xLTI1MjA0_edb0fc2e-1234-4bef-9c7d-2684a494804f"
      unitRef="usd">560000</cntx:ManufacturingDevelopmentLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV81LTEtMS0xLTI1OTMz_bba45393-f0c1-466f-b3f1-39c8ef888396"
      unitRef="usd">345530</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV81LTMtMS0xLTI1OTMz_2fbfaaa3-c27a-48ca-a609-60a59feba5a9"
      unitRef="usd">0</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV81LTItMS0xLTI1MjA0_d1fe9526-2757-47dd-b365-dc664ea49937"
      unitRef="usd">85529</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV81LTQtMS0xLTI1MjA0_736d938f-5de9-41a7-b29b-20797eb27658"
      unitRef="usd">269816</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV82LTItMS0xLTI1MjA0_641d650f-c32d-46fb-9905-34dc6dbd3253"
      unitRef="usd">1207121</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDcyL2ZyYWc6OGQzYjVkYzM1MzFiNDBmNzgwZWFiNTM3OWMxZTczODMvdGFibGU6MDFjOTUwNWYzYWI1NDEzMDhmYzAwMGFlMzg3YmUxYjEvdGFibGVyYW5nZTowMWM5NTA1ZjNhYjU0MTMwOGZjMDAwYWUzODdiZTFiMV82LTQtMS0xLTI1MjA0_d15f2141-0c00-4215-92b4-09933c6a09b3"
      unitRef="usd">955989</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzk0OTE_37d755c2-1a4a-4163-aea9-b30d5d7ce676">Convertible Promissory Notes &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Junior Convertible Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through December 2018, the Company issued Junior Convertible Notes and demand notes that converted into Junior Convertible Notes which, due to certain embedded features within the Junior Convertible Notes, the Company elected to account for these notes and all their embedded features under the fair value option. All of the outstanding principal and accrued but unpaid interest associated with the Junior Convertible Notes converted into 2,615,553 shares of Series Seed Stock in May 2020, of which 840,363 shares were issued to the Company&#x2019;s Chief Executive Officer and an immediate family member (&#x201c;Related Party&#x201d;). At the time of conversion, the estimated fair value of the Junior Convertible Notes was $6.3 million and was reclassified to Series Seed convertible preferred equity. In connection with the conversion in 2020, the Company recorded a non-cash credit of $7.7 million related to the final decrease in fair value of the Junior Convertible Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Bridge Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From October 2019 through March 2020, the Company issued convertible bridge notes to the Related Party in the amount of $0.5 million. On December&#160;22, 2020, the outstanding principal and accrued but unpaid interest associated with the Convertible Bridge Notes converted into 78,178 Series A Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to certain embedded features within the Convertible Bridge Notes, the Company elected to account for these notes and all their embedded features under the fair value option. At the time of conversion, the estimated fair value of the Convertible Bridge Notes was $0.5 million and was reclassified to Series A convertible preferred equity.  In connection with the conversion in December 2020, the Company recorded a non-cash credit of $0.1 million related to the final decrease in fair value of the Convertible Bridge Notes. For the year ended December 31, 2020, the Company recognized approximately $30,000 of interest expense in connection with the Convertible Bridge Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Convertible Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, $5.1 million of principal and $0.6 million of accrued interest related to certain Junior Convertible Notes were converted into Senior Convertible Notes. Of the Senior Convertible Notes issued in 2020, $2.5 million of principal and $0.4 million of accrued interest were issued to the Related Party. During the year ended December 31, 2021, the outstanding principal and accrued but unpaid interest associated with the Senior Convertible Notes converted into 844,824 shares of Series A Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2020, the Company recognized a credit of $2.1 million in the consolidated statement of operations related to decreases in the fair value of the Senior Convertible Notes. For the year ended December 31, 2020, the Company recognized $0.3 million of interest expense in connection with the Senior Convertible Notes, including $0.1 million payable to the Related Party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Paycheck Protection Program &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company entered into an original loan agreement with Pacific Western Bank as the lender (&#x201c;Lender&#x201d;) for a loan in an aggregate principal amount of $0.1 million (the &#x201c;Loan&#x201d;) pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Coronavirus Aid, Relief, and Economic Security (CARES) Act and implemented by the U.S. Small Business Administration. In June 2020, the Paycheck Protection Program Flexibility Act was enacted, which among other things, extended the deferral period for loan payments to either (1)&#160;the date that Small Business Administration remits the borrower&#x2019;s loan forgiveness amount to the lender or (2)&#160;if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower&#x2019;s loan forgiveness covered period. The Loan was set to mature in two years and bore interest at a rate of 1.0% per year, with all payments deferred through September&#160;5, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The outstanding principal balance of the Loan of $0.1 million was forgiven in July 2021 and was recognized as a gain on extinguishment of debt within other income in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ic2c5ebbe3b814fed872de2b6750f3337_D20200501-20200531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjI5Mzc_5953571c-8291-4b8d-b874-c9c10935be27"
      unitRef="shares">2615553</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i969ca1b809854daabd8f8995c295fec4_D20200501-20200531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjI5NTk_e6005ab6-7b58-4140-a487-96c1c42286b2"
      unitRef="shares">840363</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ib2e45ef9fdc642a0ac8a1d88dfeb09cb_D20200531-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjI5Nzc_42d474b1-4354-4285-975e-f86adcb849b8"
      unitRef="usd">6300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="if5bffb2e3fd7430997f0e5cd07ec38b3_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMwMDY_c42eb2c7-0bad-4912-8924-58a4b6a6288f"
      unitRef="usd">7700000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i3a7a5cded79d49a4a18179828d3d9f12_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMxMzc_de9a8559-8ef9-4e44-8858-9bfdeaa2bc7f"
      unitRef="usd">500000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i0f07fc75d54b479cb5bf55f32da7bf1c_D20201222-20201222"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMyMzc_065cb55a-2aad-4c83-93d1-d852eff91aa3"
      unitRef="shares">78178</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i1b93a5662e8a4c92ba2e140ae85fb825_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMyNTM_c9ffe1c9-bc97-4a0f-90c8-ca87efb74175"
      unitRef="usd">500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="i453801845a4245559bdf44e3c243247b_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMyODI_58458cdc-ee90-4ca0-8468-a8055f0e9482"
      unitRef="usd">100000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:InterestExpense
      contextRef="i00def9c120e34dfd81ad8cc464be10c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjMzNDA_7e7793d4-f250-47bd-8ddd-2856bbfcb8a9"
      unitRef="usd">30000</us-gaap:InterestExpense>
    <cntx:DebtInstrumentConvertedInstrumentPrincipalAmount
      contextRef="iee6cc68e23a644ccb73a6bd8317cac15_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM0MDQ_a5945e54-7b52-4f51-8010-1d7bf58d8d64"
      unitRef="usd">5100000</cntx:DebtInstrumentConvertedInstrumentPrincipalAmount>
    <cntx:DebtInstrumentConvertedInstrumentInterestAmount
      contextRef="iee6cc68e23a644ccb73a6bd8317cac15_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM0MzM_9954b41f-6128-42e5-961b-f457d75f9d73"
      unitRef="usd">600000</cntx:DebtInstrumentConvertedInstrumentInterestAmount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i00ba2e7eb0484b1295d941578acf8031_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM0NjI_61ad03e3-05ce-4846-b6a8-6dcfa586bfed"
      unitRef="usd">2500000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <cntx:AccruedInterestRelatedParties
      contextRef="i00ba2e7eb0484b1295d941578acf8031_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM0OTE_ab2e84b2-cee3-4a22-9903-8c1c16f394d2"
      unitRef="usd">400000</cntx:AccruedInterestRelatedParties>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i4cdb9eb262764bb9ad359f4cd6409d95_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzkzNDU4NDg4NTgzMDU_06ecb544-f630-43d4-8eb1-10e3816243da"
      unitRef="shares">844824</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="iff833741a565408283759dc258048916_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM1Nzc_8b15fc68-2fae-4756-b302-debe71659a0a"
      unitRef="usd">2100000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:InterestExpense
      contextRef="ica3de374ebb14eb283c5fa464ed31769_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM2MDY_12eb10fa-29f6-4b54-902a-3dc80ac90fe2"
      unitRef="usd">300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="ica3de374ebb14eb283c5fa464ed31769_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM2MzU_64ffcedd-7dca-4724-92fa-57a325de5ffa"
      unitRef="usd">100000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2caffc25ed4f42e195b906a4eab85ec8_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM2NjQ_e10fb9ac-5e22-42d3-968b-1122f8cf5528"
      unitRef="usd">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i3bcdc4632b004d2e82615143090acd9c_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM2OTM_9ab6079c-580d-478d-a5a0-991c608245f1">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2caffc25ed4f42e195b906a4eab85ec8_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzYwNDczMTM5NjM3MTE_74983698-7a80-429c-bba8-4095a5b95b70"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06a8b2942cc1406a9a317b357d09884d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjEvZnJhZzoyYWUyNmJjYTZkYWQ0ZGIxYmM0YWE1YWQxYzM1YzIyMy90ZXh0cmVnaW9uOjJhZTI2YmNhNmRhZDRkYjFiYzRhYTVhZDFjMzVjMjIzXzEwNDQ1MzYwNDg2NTE2_a194d60d-363e-4fc1-9f06-e68f32e74c81"
      unitRef="usd">100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzcwODA_fc9ec707-6607-4088-8027-5b0bf296b7d1">Convertible Preferred Stock, Redeemable Common Stock and Common Stock &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company converted $11.7 million of principal and interest related to certain Junior Convertible Notes into 2,615,553 shares of Series Seed Stock at prices ranging from $4.28 to $4.56 per share. In May 2020, the Related Party purchased 8,771 shares of Series Seed Stock at a price of $5.70 per share for $50,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout 2020, the Company sold 132,537 shares of Series A Stock to the Related Party for $7.168 per share for proceeds of $1.0 million. The Company also issued 33,129 warrants to purchase common stock at an exercise price of $7.168 per share to the Series A Stock holder as part of the Series A Stock financing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, $0.6 million in principal and accrued interest related to the Convertible Bridge Notes were converted into 78,178 shares of Series A Stock. The Company also issued 19,544 warrants to purchase common stock at an exercise price of $7.168 per share to the Series A stockholders as part of the conversion from Convertible Bridge Notes to Series A Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February, March and April 2021, the Company sold 738,445 shares of Series A Stock for $7.168 per share for net proceeds of $5.0 million. The Company also issued 184,597 warrants to purchase common stock at an exercise price of $7.168 to the Series A stockholders as part of the Series A Stock financing. Additionally, the Company issued 24,134 warrants to purchase common stock at an exercise price of $7.168 to placement agents as a part of the Series A Stock financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company converted $6.1&#160;million of principal and interest related to Senior Convertible Notes into 844,824 shares of Series A Stock at a price of $7.168 per share. In addition, warrants with a fair value of $0.1&#160;million associated with the Senior Convertible Notes were reclassified into additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company completed its IPO in which the Company sold 5,750,000 shares at a public offering price of $5.00 per share. Immediately prior to the completion of the IPO, all of the Company&#x2019;s preferred stock and redeemable common stock converted into an aggregate of 4,853,533 shares of common stock and all of the outstanding warrants converted into 9,816 shares of common stock. The Company received net proceeds of $24.4&#160;million as a result of the offering. The Company issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per shares and a term of 5.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company sold 5,000,000 shares of common stock together with warrants to purchase 5,000,000 shares of common stock and received net proceeds of $28.9 million in a private placement. Each share of common stock and accompanying warrant were sold together at a combined offering price of $6.25. The warrants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have a term of 5.5 years and an exercise price of $6.25 per share. The Company also issued 250,000 warrants to a placement agent as part of the offering with an exercise price of $6.25 per share and a term of 5.5 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants for Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At December&#160;31, 2021, the Company had the following warrants outstanding to acquire common stock: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration&#160;dates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued in connection with IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued as part of December 2021 private placement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During its evaluation of equity classification for the Company's common stock warrants issued in 2021, the Company considered the conditions as prescribed within ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Derivatives and Hedging, Contracts in an Entity&#x2019;s own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. The conditions within ASC 815-40 are not subject to a probability assessment. The warrants do not fall under the liability criteria within ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Distinguishing Liabilities from Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;as they are not puttable and do not represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company&#x2019;s own stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company effected a one-for-6 reverse stock split of its common stock and convertible preferred stock. No fractional shares were issued in connection with the reverse stock split. Any fractional share resulting from the reverse stock split was rounded down to the nearest whole share, and in lieu of any fractional shares, the Company paid in cash to the holders of such fractional shares an amount equal to the fair value, as determined by the board of directors, of such fractional shares. All common stock, convertible preferred stock, per share and related information presented in the consolidated financial statements and accompanying notes have been retroactively adjusted to reflect the reverse stock split.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="if5bffb2e3fd7430997f0e5cd07ec38b3_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NTk5NTk_e755c17a-41d1-4325-9e7b-c00ad243d53f"
      unitRef="usd">11700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ic2c5ebbe3b814fed872de2b6750f3337_D20200501-20200531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NTk5OTA_027177b9-5553-4f83-abaf-fb14877eda0f"
      unitRef="shares">2615553</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <cntx:DebtConversionConvertedInstrumentPricePerShare
      contextRef="i60dcae9af0d042a6808422ea713c8707_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwMTI_46936c3c-e442-4f5b-ae67-535b04214efb"
      unitRef="usdPerShare">4.28</cntx:DebtConversionConvertedInstrumentPricePerShare>
    <cntx:DebtConversionConvertedInstrumentPricePerShare
      contextRef="if4ebfb8391004e768936ed5a183ccbe7_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwMjY_81ffb0e6-1f7b-41b4-9048-2f93e76d0fcf"
      unitRef="usdPerShare">4.56</cntx:DebtConversionConvertedInstrumentPricePerShare>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i7c3d5bf929d841bd8562efa81175ada4_D20200501-20200531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwNDA_0b048f15-b6e1-481b-a978-341925b9639c"
      unitRef="shares">8771</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare
      contextRef="i5785bd98b84141148e297a25af4b1ae4_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwNTQ_f1370bc8-4ed7-4a7e-8123-bafe21ea2ea9"
      unitRef="usdPerShare">5.70</cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i7c3d5bf929d841bd8562efa81175ada4_D20200501-20200531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwNjg_bc6d1933-2a84-4870-bbce-75c6b8c8669b"
      unitRef="usd">50000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAwODY_802907e6-fd2e-4130-8a6d-eefc7e8eea62"
      unitRef="shares">132537</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare
      contextRef="ida6f7b4cb3bb49de8ab1c6b508adb33a_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAxMDQ_fbb9341a-da42-4577-b881-33cfd36eaae7"
      unitRef="usdPerShare">7.168</cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i1c5d23d450264f54afac81eebccfe6cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAxMjA_f7139f83-7244-4dba-9c90-15f04a1ff48a"
      unitRef="usd">1000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ifd17b8baad484309af4929360d734817_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAxNDk_7a7d6fae-8680-4af4-9e68-e898674b5d75"
      unitRef="shares">33129</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifd17b8baad484309af4929360d734817_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAxNjU_7358e475-99bd-4355-8d8e-da382925add4"
      unitRef="usdPerShare">7.168</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i453801845a4245559bdf44e3c243247b_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAyMDA_66ea354d-6143-456f-9e33-4fcfafc1cd8d"
      unitRef="usd">600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i5007a2b8df544622bbb6844a27b85941_D20201201-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAyMjk_52d238ba-46af-40e2-8eac-82173bafd436"
      unitRef="shares">78178</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i70476cf5f23e40b7a8e694276c179049_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAyNDU_90b326d3-0b15-43af-8d98-881c7902a6ba"
      unitRef="shares">19544</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i70476cf5f23e40b7a8e694276c179049_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzYwNDczMTM5NjAyNjE_360f7d0c-30bf-4dd7-be5f-56487cab9c0d"
      unitRef="usdPerShare">7.168</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="iee66bc4c666546b5827d8f9046ce2e6e_D20210201-20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc3NzI_a51c1f7d-1e00-47c3-9485-44cc68a79aae"
      unitRef="shares">738445</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare
      contextRef="i1de5d059a75a4d8e960f6f97b1e4b44e_I20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc3ODE_7a0a661b-779d-4494-8126-84f2bd0a9a0c"
      unitRef="usdPerShare">7.168</cntx:TemporaryEquityStockIssuedDuringPeriodPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="iee66bc4c666546b5827d8f9046ce2e6e_D20210201-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4Nzk_70925a23-f3ed-4a5e-a281-c65476d09159"
      unitRef="usd">5000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if041032296804b76bd219f45c1d66fab_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc3OTc_bb31e473-980d-4fa6-b247-acdb6649b885"
      unitRef="shares">184597</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if041032296804b76bd219f45c1d66fab_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc3ODk_5533e973-9c01-4840-925d-f4892775cd44"
      unitRef="usdPerShare">7.168</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib058079deb3c476694d758a0ce02221e_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4MDY_527e7791-cc80-4d23-ae8c-1162db4da0ca"
      unitRef="shares">24134</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib058079deb3c476694d758a0ce02221e_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4MTQ_8c09ae83-f0f0-4e95-9ce0-7227a86e2295"
      unitRef="usdPerShare">7.168</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="id1de2115c90540ebb9bb07d72b519bf0_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4NDU_697248b6-2e99-47bf-b106-93f8184882d9"
      unitRef="usd">6100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i4cdb9eb262764bb9ad359f4cd6409d95_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4MjI_c94ac82f-069d-418d-b1ec-b687aa6551d5"
      unitRef="shares">844824</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <cntx:DebtConversionConvertedInstrumentPricePerShare
      contextRef="i1c63a7c492b249a2823508e305461100_I20210228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4NTk_eeae1371-5014-4440-a207-3af3837c26a6"
      unitRef="usdPerShare">7.168</cntx:DebtConversionConvertedInstrumentPricePerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i8d1cfe7096e34e6ea497fb994bda8378_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODc4MzE_d38ef3ab-d2f9-4d08-99d9-3f851e86b5a2"
      unitRef="usd">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib574e9442de340bba7e8df59de0aa8ea_D20211001-20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzkzNDU4NDg4NTQ1NDE_c078a8e4-be8f-4115-9336-c47db456fc1a"
      unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ifaec33cca2ed463caf5a7211bdf75d02_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3ODg_5ceef92e-0b44-40bc-807a-925505ea73e4"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares
      contextRef="i671c0f3f11484a63a807f265ef485cbb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzEyMDk0NjI3OTE4NTU2_6939c148-d0ca-4c75-91c2-3290edb6f78a"
      unitRef="shares">4853533</cntx:StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ic77193cc910d458e928d0612bcad6229_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzEyMDk0NjI3OTE4NTY0_04e83f5e-0086-4cc3-9a58-bbbe011c68ca"
      unitRef="shares">9816</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i9133735e066c4f4ea8c7871915a16053_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzkzNDU4NDg4NTQ1Mjc_9fce6798-a28e-4a1f-a532-c9fda99a4b25"
      unitRef="usd">24400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id4631fd77028469dbd1afde77f30a01b_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY4MDE_96015c8c-dd6e-4016-8c05-373685eaeff9"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8f3867dedb684f8482d09a62b1bef50c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY4MTA_271addad-57d2-4954-8062-9b96b23e9a02"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="id4631fd77028469dbd1afde77f30a01b_I20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY4MTY_4d0c8076-f464-423c-b0d4-44e684d04c85">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwOTU1NDk_b288ba13-dfa3-426a-ab2e-fa6f2e912b50"
      unitRef="shares">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3MjI_9c10140d-bd38-41b1-8884-630f5432de35"
      unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8498d6f77f2b4445808bffe07dc299a9_D20211201-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzEyMDk0NjI3OTIxMjU4_6b262aa8-e907-4587-b76b-ee1e38c1222a"
      unitRef="usd">28900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5177f9964b244a76b68f2abaac086c21_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3MzA_8e864815-b73e-4143-8d84-eff0599373dd"
      unitRef="usdPerShare">6.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3NDI_7d61c121-6941-4bf7-8ac2-7fdc12a1bb3f">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6affe466c51c4622a311e2ed55837af8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3NTA_f3c42900-95cb-405c-96db-4d3e6841af51"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3NjA_b315ff77-e5c4-49e3-81f3-1295bbfe423a"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3Njg_c6641284-6895-497d-99b5-6dcbc9cdd6fe"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i839fbb147c914876bf372cc7e6439da1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzI3NDg3NzkwODY3ODA_538bcd98-a0b7-42cc-843d-8d20485058ec">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90ZXh0cmVnaW9uOjM5N2I1MTRiZjNiMTRhYzZiNzgyYjY5YWM5N2Q4NjRjXzcwNzk_e673902e-33cf-4833-95f6-376d7d4c9646">At December&#160;31, 2021, the Company had the following warrants outstanding to acquire common stock: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration&#160;dates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued in connection with IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued as part of December 2021 private placement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2ba1a5fd4aa54bd18b6277a18720bbb6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzUtMS0xLTEtMjMyNDk_bb5cb1bb-d363-45d0-b947-49c97e12a039"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2ba1a5fd4aa54bd18b6277a18720bbb6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzUtMy0xLTEtMjMyNDk_0252383d-c371-4bde-8a38-7154440c048e"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i36c3e785908e44e893746fd8fb714979_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzYtMS0xLTEtMjMyNDk_01e96f18-6bad-4dff-9b21-004dbd6acf4c"
      unitRef="shares">5250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i36c3e785908e44e893746fd8fb714979_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzYtMy0xLTEtMjMyNDk_6869578a-58f4-476c-ae7f-eb766969acf5"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMjQvZnJhZzozOTdiNTE0YmYzYjE0YWM2Yjc4MmI2OWFjOTdkODY0Yy90YWJsZTo5ZDljZTBhOTcxNTY0ZDA4YmU5ZWUzNzA3N2YyNzliZC90YWJsZXJhbmdlOjlkOWNlMGE5NzE1NjRkMDhiZTllZTM3MDc3ZjI3OWJkXzUtMS0xLTEtMTE3NTg_43fd57f1-3943-4549-97d4-590be8590984"
      unitRef="shares">5500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI4ODM_7fd7b16c-cb24-4aa4-bfc7-6d883a536872">Share-based Compensation &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Context Therapeutics Inc. adopted the 2021 Long-Term Incentive Plan (&#x201c;2021 Incentive Plan&#x201d;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units and stock grants. The 2021 Incentive Plan allows for the issuance of up to 1,266,092 shares of common stock (the &#x201c;Share Limit&#x201d;). The Share Limit will automatically increase on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (4%) of the total number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of December&#160;31, 2021, 742,706 shares remained available for future grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the year ended December 31, 2020, the Company issued 7,512 shares of common stock to members of the board of managers as compensation for their services. The Company recorded share-based compensation expense of $0.1 million in general and administrative expense during the year ended December 31, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options generally vest over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4NjE_01118990-dc7d-4e7f-96e0-43c8e460d916"&gt;one&lt;/span&gt; to four years, and stock options that lapse or are forfeited are available to be granted again. The contractual life of all stock options is 10 years. The expiration dates of the outstanding stock options range from January 2028 to November 2031. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures stock options at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Stock option compensation expense is allocated to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;employees and consultants based on their respective departments. All board of directors&#x2019; compensation is charged to general and administrative expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock option compensation expense of $74,000 and $404,000 in research and development and general and administrative expense, respectively, during the year ended December&#160;31, 2021.  The Company recorded stock option compensation expense of $75,000 and $29,000 in research and development and general and administrative expense, respectively, during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option awards granted to employees during 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.06%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.86%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.44&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity for the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price Per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The weighted average fair value of share-based awards granted during the years ended December 31, 2021 and 2020 was $3.84 and $9.34, respectively. The aggregate intrinsic value of the options outstanding and exercisable as of December 31, 2021 was $0. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of December&#160;31, 2021, the unrecognized compensation cost related to outstanding stock options was $1.5 million and is expected to be recognized as expense over a weighted-average period of approximately 1.73 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues restricted stock units (&#x201c;RSU&#x201d;) to employees and consultants that generally vest monthly over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwNDQ_d169f036-bec1-4a91-89bb-ca2c7da81f4f"&gt;one&lt;/span&gt; to three-year periods. The fair value of an RSU is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is amortized straight-line over the service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to RSU share-based payment awards: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&#160;Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&#160;Fair&#160;value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at January&#160;1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#160;&#160;&#160;&#160;13.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#160;&#160;&#160;&#160;13.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#160;&#160;&#160;&#160;13.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded share-based compensation expense of $33,000 in research and development expense for the year ended December&#160;31, 2021 related to RSUs. The Company recorded share-based compensation expense of $2,000 in general and administrative expense for the year ended December&#160;31, 2020 related to RSUs. As of December&#160;31, 2021, there was no remaining unrecognized expense related to RSUs.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibf6e09006c2a4e438d001a5d8e06267e_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIwMTE_c2a5e7c8-606f-4ce5-91d6-cf2efedc71bc"
      unitRef="shares">1266092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock
      contextRef="ib1e1c00a5a0c46b7827110eaaccd2bde_D20210401-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI3NDg3NzkwNzczNDU_b12b9023-a082-4798-a025-e4082e83d1bc"
      unitRef="number">0.04</cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i10ff1ceb32174558b92e60058255b0fb_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIwMjE_f47b6336-dc04-498d-8ea0-ac9855b14db5"
      unitRef="shares">742706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI3NDg3NzkwNzkyODg_bafbf3d5-2fb5-43a6-8378-b5c3c35410d8"
      unitRef="shares">7512</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92b4d526304e44d59c45f6d02124e335_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzEwNDQ1MzYwNDczNTky_7d7b879d-1ca9-4497-a97c-9f11c146d4ee"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4ad2696d269b4e0593b847bc2847d326_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4NzE_ffecce64-ae3e-4981-9b6d-561e932d0286">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU4ODg_99901803-7913-463a-bdd6-53adc9173e0a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e63271831534a1c9f0c9dafdc78b906_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzkzNDU4NDg4NDE4MzE_691fecbd-4b14-4fc6-b195-93e3b0a71dc4"
      unitRef="usd">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88a6a22c984641faab12a3f3aecdfa8a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU5MjA_5cca054c-eb9a-4dda-9a76-9af2d008cf2e"
      unitRef="usd">404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76aea4c250d247f696a873ec46ad8c83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIwMjc_0a257cff-c85e-420a-aea0-20afb48740dc"
      unitRef="usd">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i89568e4239cb4b4dbc069d2edc09f071_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIwMzE_fdd67453-f833-401d-b9e2-c5df802e6d8b"
      unitRef="usd">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI4ODE_fad636fe-3bc4-4d59-b9b1-fb260d68da8f">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option awards granted to employees during 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.06%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.86%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.44&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzEtMS0xLTEtMTE3NTg_74c39282-6a35-4c68-9368-6fac0f74fbd5"
      unitRef="number">0.9706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzEtMi0xLTEtMjM5NjA_613ba24c-7830-47cf-9afd-fa87316c0b95"
      unitRef="number">0.9786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzItMS0xLTEtMTE3NTg_726be605-b32b-4ba4-af54-6dd2c74fd9ab"
      unitRef="number">0.0107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzItMi0xLTEtMjM5NjA_bee18f99-6fac-4f5a-9834-44a7a2daeecc"
      unitRef="number">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzMtMS0xLTEtMTE3NTg_17b07c38-f657-483e-b259-67c72a3e67d2">P5Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzMtMi0xLTEtMjM5NjA_7500e6d4-dedf-4d14-8b33-8ce7cf555bdf">P5Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzQtMS0xLTEtMTE3NTg_0c2eabba-0424-4071-8861-883b8bb724f9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7de6ad1ddf8546a6af2eea2ff1ff1546_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo3ZDNhNzlmNTRjMDA0MzBiOGM3MGZhOTU2YmNlOWM2Ni90YWJsZXJhbmdlOjdkM2E3OWY1NGMwMDQzMGI4YzcwZmE5NTZiY2U5YzY2XzQtMi0xLTEtMjM5NjA_db517272-5834-40dc-a492-fb99363936fe"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI4NzY_0da07e6b-646b-4a20-a418-61c07fd61b4a">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity for the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price Per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2f8740cca1c745199eda7ed1a4c1f483_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzEtMS0xLTEtMjM5NTA_7cc70e8d-9ddd-439d-92cb-e821e767f608"
      unitRef="shares">10414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2f8740cca1c745199eda7ed1a4c1f483_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzEtMy0xLTEtMjM5NTA_94456049-495e-4a56-8587-00458e974b36"
      unitRef="usdPerShare">20.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0abf375441494967be6030dfc54f96ad_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzEtNS0xLTEtMjM5NTA_db838477-48ac-4389-82f3-b22488729c6a">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzItMS0xLTEtMjM5NTA_e15a42c6-bc21-4aa0-b01b-814a613d1bfe"
      unitRef="shares">14416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzItMy0xLTEtMjM5NTA_bd3f0fec-f7c4-4721-985e-11bdda77c69e"
      unitRef="usdPerShare">15.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtMS0xLTEtMjM5NTA_0fc830c6-bdcf-4ef1-880f-1a05664f2a02"
      unitRef="shares">24830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtMy0xLTEtMjM5NTA_81670d29-b4b1-40c4-9782-7b76f0318e08"
      unitRef="usdPerShare">17.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtNS0xLTEtMjM5NTA_84402abf-9dbf-4df9-a4d1-d75897bfe0c4">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzItMS0xLTEtMTE3NTg_cb7122ce-0014-41ed-b688-470b1b4b6a57"
      unitRef="shares">481861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzItMy0xLTEtMTE3NTg_a3dce039-0570-4ad4-ba79-8ef8f56a1baf"
      unitRef="usdPerShare">5.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtMS0xLTEtMTE3NTg_e66567f4-6a25-4691-a60c-473b2173be4f"
      unitRef="shares">506691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtMy0xLTEtMTE3NTg_23a224f4-5b31-47f3-b9fc-f974f7c15ba4"
      unitRef="usdPerShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzMtNS0xLTEtMTE3NTg_8ff7fd88-8a16-483e-80fd-1002b85fe6df">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzQtMS0xLTEtMTE3NTg_ada10bd2-7baa-48f5-80d9-1d724b6f4fab"
      unitRef="shares">130059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzQtMS0xLTEtMTE3NTg_cf91cc94-d0c9-4fc0-8b75-d2f1990ce303"
      unitRef="shares">130059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzQtMy0xLTEtMTE3NTg_c9a6c2bf-d0f8-4e4d-8ccb-6de8717df205"
      unitRef="usdPerShare">7.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i16167060dd4a411bbbf08ccef55b90ca_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzQtNS0xLTEtMTE3NTg_f00a7bba-e804-46aa-aafe-6849a15d8ba3">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzctMS0xLTEtMjQ4MjU_790be4c0-07aa-43b5-8263-5023e1378945"
      unitRef="shares">506691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzctMy0xLTEtMjQ4MjU_6a69c15e-d808-4322-816e-25d2cb2492ef"
      unitRef="usdPerShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTpiYzk3YTBhZWE1MmQ0Y2NmOTY5ODU2YTY0M2RhNTJkYy90YWJsZXJhbmdlOmJjOTdhMGFlYTUyZDRjY2Y5Njk4NTZhNjQzZGE1MmRjXzctNS0xLTEtMjQ4MjU_e93486dd-9465-4051-8585-d9c9c5ffc0ce">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDQ5NTM_61523ebc-784e-44ed-9343-68b8f5633a4f"
      unitRef="usdPerShare">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDQ5NjE_08c084a0-5ddd-43ed-8cd3-9e54534119d7"
      unitRef="usdPerShare">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDUxMTQ_4d0a6c79-b20a-4d22-b6af-04ab4a946452"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTU5OTk_1ed68680-4594-4a27-ab06-118032fd7078"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i87304bb5deed428b929244468618ab9a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwMjg_15b7d991-4796-4353-9231-1c7b195ab3e4">P1Y8M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6a6d5e19e9c2468da79c3794e7c72abb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI3NDg3NzkwNzczNDg_cf33e4be-4eb8-41bc-ab9a-0f1235cd99ed">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI4Nzg_05b57e9a-6e39-43e5-8da3-45853e96c484">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to RSU share-based payment awards: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&#160;Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&#160;Fair&#160;value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at January&#160;1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#160;&#160;&#160;&#160;13.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#160;&#160;&#160;&#160;13.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#160;&#160;&#160;&#160;13.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i572c857cebbe4fc1982b32de57c0220a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzEtMS0xLTEtMTE3NTg_834824a0-55fc-43cf-954f-2e63f8e7c2c0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzItMS0xLTEtMTkyMjc_e7d5dac8-f0e6-4f45-9298-31140c281868"
      unitRef="shares">177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzItMy0xLTEtMTkyMjc_84263482-06a6-45dd-aa0b-c257849637c3"
      unitRef="usdPerShare">13.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzItMS0xLTEtMTE3NTg_ee78a9cd-2290-4c57-85b4-1489f2a19e2b"
      unitRef="shares">132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8d92ab4958ae4886b434000e2b01cc8e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzItMy0xLTEtMTE3NTg_9ed0a91e-c7dc-466d-a5b1-94a2b2e653a4"
      unitRef="usdPerShare">13.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i992c3c31612041b88458293caef78ce6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzMtMS0xLTEtMTE3NTg_daa79f21-8a76-4ab8-a89d-f67f527a8cb9"
      unitRef="shares">45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i992c3c31612041b88458293caef78ce6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzMtMy0xLTEtMTE3NTg_e36b1777-72b8-490e-999a-760b9b843b28"
      unitRef="usdPerShare">13.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzQtMS0xLTEtMTE3NTg_49439773-d48f-49f8-9e90-4fe5650ca447"
      unitRef="shares">50096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzQtMy0xLTEtMTE3NTg_95cc6ee2-f314-4f60-87ce-4be8c54d5aac"
      unitRef="usdPerShare">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzUtMS0xLTEtMTE3NTg_070cb96d-ca32-4487-b2d0-3ab6c6bb9a89"
      unitRef="shares">20915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzUtMy0xLTEtMTE3NTg_e50e37a8-77e6-4d9c-a7df-998fa4f438da"
      unitRef="usdPerShare">1.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzctMS0xLTEtMTkyMjc_4663e139-f2aa-47d3-914d-dc80cbcda2cb"
      unitRef="shares">29226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if9afe8474ec74164a85da5072d3912d1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzctMy0xLTEtMTkyMjc_d42c3417-85a8-4dec-8881-fd14d317fbba"
      unitRef="usdPerShare">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ied12b91ed1cb4150a7ff06c8518ebfab_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90YWJsZTo4Y2Q0YTBlNTQ1NGM0ZjcwOGVlZjg1NTk1MDgyZGY5Yi90YWJsZXJhbmdlOjhjZDRhMGU1NDU0YzRmNzA4ZWVmODU1OTUwODJkZjliXzYtMS0xLTEtMTE3NTg_5341f44b-a7f3-496c-b2a2-9ca68467976e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic066948fc7ad43b0956073d48292abac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzYwNDczMTM5NTYwODA_913fbb9f-f0be-4581-ae44-9238d1bbefca"
      unitRef="usd">33000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i090b28e5ec1a4e8eaa2a115e3b70282b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzM4NDgyOTA3MDIxODY_e6f6b9d2-690e-41fb-bb45-81e30aea2b48"
      unitRef="usd">2000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i92dfdc8947244a08927a080fc1dfb72b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzAvZnJhZzo1NzU1OGE5Mzc5YmY0ZTkwOWFhNGQzYjZmYjRhOTExZi90ZXh0cmVnaW9uOjU3NTU4YTkzNzliZjRlOTA5YWE0ZDNiNmZiNGE5MTFmXzI3NDg3NzkwNzczNTE_c703a30c-03c5-48db-8220-c92b37354887"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzQ5Mjg_3c2a0b91-ec8d-4cf4-bc67-311e972aa03e">Commitments and Contingencies &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent License Agreement with Drexel University &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2015, the Company entered into a patent license agreement, as amended, (the &#x201c;Drexel License Agreement&#x201d;) with Drexel for license rights to patents for certain intellectual property and know-how related to certain technology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Drexel License Agreement, the Company issued Drexel 16,666 shares of common stock. In partial consideration of the Drexel License Agreement, the Company is required to pay to Drexel certain milestone payments, ranging from $10,000 to $0.2 million on the achievement of certain milestone events for each licensed product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreed to pay Drexel a royalty in the low single digits of net sales for each licensed product on a country-by-country, licensed product-by-licensed product basis on issued or pending valid claims. The Company may credit against amounts payable to Drexel, on a country-by-country, licensed product-by-licensed product basis up to 50% of any third-party payments which the Company must make on account of third-party license agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In partial consideration of the Drexel License Agreement, the Company will pay to Drexel a de-escalating sublicense fee on a quarterly basis of a high single-digit percentage that decreases to a mid-single digit percentage as time passes. In addition, the Company will make payments of the fair market value of all other consideration received by the Company from sublicensees during the quarter, other than: (a)&#160;royalties paid to the Company by a sublicensee based upon sales or net sales by the sublicensee; (b)&#160;equity investments in the Company by a sublicensee up to the amount of fair market value of the equity purchased on the date of the investment; (c)&#160;loan proceeds paid to the Company by a sublicensee in an arm&#x2019;s length, full recourse debt financing to the extent that such loan is not forgiven; and (d)&#160;sponsored research funding, paid to the Company by a sublicensee in a bona fide transaction for future research to be performed by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of a strategic review of its pipeline, the Company recently notified Drexel that it is terminating the Drexel License Agreement, effective as of April 27, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreement with Tyligand Bioscience &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company entered into a license (the &#x201c;Tyligand License Agreement&#x201d;) and process development agreement (the &#x201c;Tyligand Process Development Agreement&#x201d;) (collectively, the &#x201c;Tyligand &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreements&#x201d;) with Tyligand Bioscience (Shanghai) Limited (&#x201c;Tyligand&#x201d;) for the development, manufacturing, registration and future commercialization of onapristone extended release (&#x201c;ONA-XR&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Tyligand Agreements, Tyligand will be solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand will be granted the exclusive right to ONA-XR and will be solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#x201c;Territory&#x201d;). The Company will retain rest of world rights to commercialize ONA-XR. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Tyligand Process Development Agreement, the Company is obligated to pay Tyligand $0.8 million and a certain number of warrants exercisable for common stock upon successful completion of the manufacturing development plan, $2.0 million upon the completion of scale-up of the first cumulative 100 kilograms of the GMP-grade compound and $3.0 million upon the Company&#x2019;s completion of scale-up of the first cumulative 300 kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#x2019;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand 1% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i)&#160;the sale of a generic product in the territory and (ii) 15 years after the date of the first commercial sale of product in the territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, upon successful completion of the process development plan with Tyligand, the Company issued Tyligand warrants to purchase 111,576 shares of common stock at an exercise price of $7.17 per share all of which were cancelled in connection with the IPO. The Company recognized an expense and liability of $0.4&#160;million to account for the fair value of the warrants upon completion of the manufacturing development plan in June 2021. Upon issuance of the warrants in August 2021, the Company reclassified the $0.4&#160;million liability into equity. The Company has expensed $0.8&#160;million related to the process development plan as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, while the Company&#x2019;s license agreement with Tyligand was signed in March 2020, the parties acknowledged that such signature was premature since the &#x2018;successful completion&#x2019; under the process development agreement had not yet occurred, and as such, the parties properly executed the license agreement upon such successful completion in August 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration and Licensing Agreement with Integral Molecular&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#x201c;Integral&#x201d;) for the development of an anti-claudin 6 (&#x201c;CLDN6&#x201d;) bispecific monoclonal antibody (&#x201c;BsMAb&#x201d;) for gynecologic cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The Company paid an upfront license fee of $0.3&#160;million and granted 418,559 shares of Series A Stock with a fair market value of approximately $2.8&#160;million, and these costs were expensed to acquired in-process research and development during the year ended December 31, 2021. As a part of the agreement, Integral will be eligible to receive development and regulatory milestone payments totaling up to $55.3&#160;million, sales milestone payments totaling up to $130&#160;million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company leased its corporate offices in Philadelphia, Pennsylvania under a month-to-month lease arrangement. The Company recorded rent expense of approximately $10,000 for the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 30, 2023. The minimum lease payments under the sublease is $0.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company believes no matters existed at either December&#160;31, 2021 or 2020 that will have a material impact to the Company&#x2019;s financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ifce6960f11854815999679040b558ff7_D20151101-20151130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc3NzE_a8f1e6de-f4d4-4ab7-a83c-f41d6bf1bba0"
      unitRef="shares">16666</cntx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="i78fbe4d1c3214a428e35dd1f8055123c_I20151130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc3ODc_affc98bf-2b7c-4a37-a7fc-da14b40a90fe"
      unitRef="usd">10000</cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="i1a58857b70524568849add997a11e677_I20151130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc4MDU_29e2b5fc-3fa7-4425-9fbc-6a4d454fca8a"
      unitRef="usd">200000</cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cntx:CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent
      contextRef="i3a7d7b9cfd5348869e9ddcb95a366ed4_I20151130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc4NzQ_1ae5dbff-cdac-4e80-9f82-d584be20878a"
      unitRef="number">0.50</cntx:CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent>
    <cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i91e81531d0aa47a7b6d49a7c6551bbd4_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc4OTk_49d8d35c-0e6d-44c3-971c-65f18ed8985e"
      unitRef="usd">800000</cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="i5037d579dc114c0484a17c0cae6d7468_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc5Mjg_85f88420-927e-47be-ae71-4a8e7de2883f"
      unitRef="usd">2000000</cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="i72e8fa04e6e04b7499dd9509fedc5611_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc5NTc_1351a1f8-7d07-4421-9973-c30cbeaae449"
      unitRef="usd">3000000</cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent
      contextRef="if9ae36474bc442648e5731b2aae1cdd7_D20200301-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc5ODY_a826367c-558b-411e-88a1-4a5257fbe99b"
      unitRef="number">0.01</cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent>
    <cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod
      contextRef="if9ae36474bc442648e5731b2aae1cdd7_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTc5OTY_967955cb-1c13-4138-8d96-f17ecd6e2acd">P15Y</cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i32152868968f47f78b1854b4910902e8_I20210831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyMjk_d4ef3d67-a0e8-4d27-b081-74b557514599"
      unitRef="shares">111576</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i32152868968f47f78b1854b4910902e8_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyMzg_fd40f892-c68c-47f6-8c77-ca33511e7840"
      unitRef="usdPerShare">7.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i0a5ea7538cec4d73a63f42512b7cb189_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyNDU_2d28494b-823c-4eea-8692-96b5f6241063"
      unitRef="usd">400000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i32152868968f47f78b1854b4910902e8_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyNTk_8fa05ea6-ec35-4e98-b212-cd88ddf045d3"
      unitRef="usd">400000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if9f956c8b3ce4d38a8596ee10f01e3d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyNzM_0b590c51-e719-4fb4-a2ca-83791540b63f"
      unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i69aa76103ac748efb2f5d056d2cf8104_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAyODc_7670795e-6add-463f-890e-b61a02ca5b7d"
      unitRef="usd">300000</cntx:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ia1bf28a7fb38490592f0eae3e1f12ce1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzMDE_ed7ed727-2142-4734-80b8-3347d7153988"
      unitRef="shares">418559</cntx:TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices>
    <cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices
      contextRef="ia1bf28a7fb38490592f0eae3e1f12ce1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzMTA_934b733e-0c5d-4eb9-954f-a54b70d5717f"
      unitRef="usd">2800000</cntx:TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices>
    <cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum
      contextRef="i760a27b106d14efc85f77118941e7eec_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzMjQ_7135b31e-d7db-4bec-a40a-f157224c7724"
      unitRef="usd">55300000</cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum>
    <cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
      contextRef="i760a27b106d14efc85f77118941e7eec_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzMzk_31505b8d-771b-4ea9-8b69-b92a252fa4d2"
      unitRef="usd">130000000</cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum>
    <cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="i760a27b106d14efc85f77118941e7eec_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzI3NDg3NzkwODAzNTM_02cad234-606b-4e31-b815-85719c64f21e"
      unitRef="number">0.12</cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
    <us-gaap:LeaseAndRentalExpense
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTgwMTA_590761bd-eda5-49d8-b63e-d56c7ff93cbd"
      unitRef="usd">10000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzYwNDczMTM5NTgwMTA_d126f772-054f-4f19-82ca-e9a5f875acdb"
      unitRef="usd">10000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i5c01fc0d079243d0863dab34c442d2d6_I20220201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzMvZnJhZzo1ZDNkMTg5ODMxMDM0MDZjYmNhOTA3MDMyODBiYTNiNi90ZXh0cmVnaW9uOjVkM2QxODk4MzEwMzQwNmNiY2E5MDcwMzI4MGJhM2I2XzkzNDU4NDg4NDc2MTc_c4287b2d-a942-4c5b-9dfc-27878b57e47e"
      unitRef="usd">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI5MjU_1756db34-8804-45e0-a8f9-3e5f15733add">Income Taxes &lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2021 and 2020. The Company had also not recorded any income tax benefits for the net operating losses incurred in each period due to its uncertainty of realizing a benefit from those items. All of the Company&#x2019;s losses before income taxes were generated in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,983,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,199,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,802,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,569,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(527,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,569,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,275,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,569,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#x2019;s net deferred tax assets as of December&#160;31, 2021 and 2020. The valuation allowance increased by $1.7 million and $0.2 million during the years ended December&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense/(benefit) at statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable partnership income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes carryforwards of federal, state and local net operating losses (&#x201c;NOL&#x201d;) and research tax credits: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&#x2014;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,030,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&#x2014;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,030,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&#x2014;Local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,926,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,399,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credits&#x2014;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NOL carryforwards begin expiring in 2037 for federal and state income tax purposes; however, all federal NOL carryforwards generated subsequent to January&#160;1, 2018, are able to be carried forward indefinitely. Local NOL carryforwards expire after three years with the 2019 NOL set to expire in 2022. As of December&#160;31, 2021 and 2020, the Company had federal research and development tax credit carryforwards of $0.4 million and  $0.3 million, respectively, that will begin to expire in 2037, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception. State and local NOLs may also be limited. &lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s consolidated statement of operations. Due to NOLs and tax credit carry forwards that remain unutilized, income tax returns for tax years from all years remain subject to examination by the taxing jurisdictions. The NOL carryforwards remain subject to review until utilized.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI3NDg3NzkwNzM1MjI_2b1731ac-b80a-4a82-81cd-0a75cd4989c3"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI3NDg3NzkwNzM1MjI_ff03a8bf-2e1b-47e0-a473-044495af5396"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI5MjE_c362a798-10bf-4346-bd8c-53989b4df32e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,983,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,199,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,802,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,569,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(527,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,275,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,569,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,275,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,569,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzMtMS0xLTEtMTE3NTg_32031c5e-e94c-45e5-8f31-5c6fc0b3ebd0"
      unitRef="usd">4983415</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzMtMS0xLTEtMTE3NTg_c79b9a54-e31d-4bbf-b79d-618961bc0d66"
      unitRef="usd">4983415</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzMtMy0xLTEtMTE3NTg_e535398f-f23c-4bc4-8207-4194eabd340b"
      unitRef="usd">3199412</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzQtMS0xLTEtMTE3NTg_a62c9f49-79df-4934-8685-50c8d5b733b7"
      unitRef="usd">421880</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzQtMS0xLTEtMTE3NTg_f413ffd4-4439-4e0d-a29f-cbfd1ea4a28a"
      unitRef="usd">421880</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzQtMy0xLTEtMTE3NTg_b2b1045b-24a3-4507-92f3-1f718df9b7cd"
      unitRef="usd">326551</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzUtMS0xLTEtMTE3NTg_1af72eb0-5bd3-4492-8d33-e47a4e81773a"
      unitRef="usd">249874</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzUtMS0xLTEtMTE3NTg_474f1518-c498-444f-9373-7ac55dc0609c"
      unitRef="usd">249874</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzUtMy0xLTEtMTE3NTg_7d7ee4b4-55f8-4ad3-af63-af61d51ee68f"
      unitRef="usd">43526</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzYtMS0xLTEtMjc1NzE_feb2f465-f3f2-416b-984f-5732a1dfd2b9"
      unitRef="usd">147659</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzYtMy0xLTEtMjc2MzI_7f0f8ab1-c6a4-428c-b47a-6430968b6722"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMS0xLTEtMjc1NzE_2ff00526-4ea0-42b4-8546-d7a09db269d9"
      unitRef="usd">5802828</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMy0xLTEtMjc2Mzk_f7409749-811f-44e8-af9e-e5649f69b240"
      unitRef="usd">3569489</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzktMS0xLTEtMjc1NzE_d4cbfe7f-9247-4c02-923c-ff7873f47fa5"
      unitRef="usd">527181</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzktMy0xLTEtMjc2NDU_4c01817a-24ae-4963-9229-1e8b0e13741c"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <cntx:NetDeferredTaxAssetLiabilitiesGross
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzYtMS0xLTEtMTE3NTg_d2cc13ea-a74d-4ea8-b42f-f1a6278128b8"
      unitRef="usd">5275647</cntx:NetDeferredTaxAssetLiabilitiesGross>
    <cntx:NetDeferredTaxAssetLiabilitiesGross
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzYtMy0xLTEtMTE3NTg_4de040e9-3642-454e-851c-13d6845a52eb"
      unitRef="usd">3569489</cntx:NetDeferredTaxAssetLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMS0xLTEtMTE3NTg_70464d39-956d-4c22-a603-abff59399a37"
      unitRef="usd">5275647</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMS0xLTEtMTE3NTg_78ecb3ab-2264-401e-804c-e3c461bb1666"
      unitRef="usd">5275647</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzctMy0xLTEtMTE3NTg_16623e33-f7f7-40a1-ad73-2c7898815134"
      unitRef="usd">3569489</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzgtMS0xLTEtMTE3NTg_238c8c77-91e2-4cf4-aba0-d2bd68d2a031"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0NTYwOGI5NWM0MTc0NjM2ODc2ZGU2NTU3NDhmNzA4ZC90YWJsZXJhbmdlOjQ1NjA4Yjk1YzQxNzQ2MzY4NzZkZTY1NTc0OGY3MDhkXzgtMy0xLTEtMTE3NTg_d6e8ecfc-a157-44d8-ae21-a0361c913231"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzM4NDgyOTA3MDA0MjE_76871ca2-0bbe-4ef8-915d-70dc70161bb9"
      unitRef="usd">1700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU4Mjc_ef576e9e-30cc-4787-8f23-45ad01a88e60"
      unitRef="usd">200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI5MjI_33416e80-4bac-41cb-a64e-1ab41bac36fc">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense/(benefit) at statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable partnership income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzItMS0xLTEtMTE3NTg_b4612eb6-9483-4a49-94e7-125735a78e2c"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzItMy0xLTEtMTE3NTg_4982f9c7-0f01-48b5-a98c-1fcbec437bf9"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzMtMS0xLTEtMTE3NTg_0dde9b1d-e808-48d8-8404-264994e1d928"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzMtMy0xLTEtMTE3NTg_e2bfb66e-d051-4c75-8458-384fb223463d"
      unitRef="number">0.118</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzQtMS0xLTEtMTE3NTg_f6a99200-3bac-418d-b614-5af6e0a11a6a"
      unitRef="number">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzQtMy0xLTEtMTE3NTg_98604e64-33c4-4bb2-aa0f-fcc3869bcdc9"
      unitRef="number">0.255</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzUtMS0xLTEtMTE3NTg_a4627652-a192-452f-b4f9-a00dee180f61"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzUtMy0xLTEtMTE3NTg_7bfa2b1a-3ad0-40b2-a6db-bc7f07dae4ef"
      unitRef="number">-0.092</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzYtMS0xLTEtMTE3NTg_1b772bef-b532-4f98-83f9-a1e9d72f58c1"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzYtMy0xLTEtMTE3NTg_cdebbc86-d9db-4a01-8832-cc5345119aa5"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzctMS0xLTEtMjkyNDg_56545541-868e-4a5c-9b0a-f4827e17d25b"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzctMy0xLTEtMjc2ODU_09902872-cfe9-4a06-94f4-ef81fd3b17d3"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzctMS0xLTEtMTE3NTg_0404eea6-625a-4ae0-87ff-64186a7d16ed"
      unitRef="number">-0.163</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzctMy0xLTEtMTE3NTg_17b2d53d-d1eb-41c3-96d6-e232b2fb64e5"
      unitRef="number">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzgtMS0xLTEtMTE3NTg_00168abd-21b1-4c99-9ee8-ddaa0f58300e"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTo0YmUwN2VjZWMyY2E0YTZlODI5MjEyYjQ2OTU0MDBlZi90YWJsZXJhbmdlOjRiZTA3ZWNlYzJjYTRhNmU4MjkyMTJiNDY5NTQwMGVmXzgtMy0xLTEtMTE3NTg_66aaa890-29d8-4213-9f0e-bca46497f4ed"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzI5MjM_efdf4b3c-ad5f-470e-aa87-2c0bec5baf3a">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes carryforwards of federal, state and local net operating losses (&#x201c;NOL&#x201d;) and research tax credits: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&#x2014;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,030,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&#x2014;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,887,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,030,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&#x2014;Local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,926,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,399,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credits&#x2014;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibc572ca47de84c2097d086542a0002b6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzItMS0xLTEtMTE3NTg_c0626a9c-b2a0-43cb-b200-353cee84fd8f"
      unitRef="usd">14887383</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i80101d4b12c34ca8aac0080981f8868e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzItMy0xLTEtMTE3NTg_65c74f21-08ab-43aa-98e8-61913fe6f191"
      unitRef="usd">8030123</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i71f59721c4e142388846035376f047f3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzMtMS0xLTEtMTE3NTg_0a4654c9-210c-4874-826d-7eee8fef6c5c"
      unitRef="usd">14887383</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibb11fc45a9024916b87e1c43f8c7f43e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzMtMy0xLTEtMTE3NTg_9c2411f0-d87f-4e15-91e6-4df395bc064a"
      unitRef="usd">8030123</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i10821272b4754a39be917949dd892095_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzQtMS0xLTEtMTE3NTg_0c5e8ba7-4ce4-439e-b581-738fbfa7e726"
      unitRef="usd">13926879</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iae70c994731842459a8bf4cb62e7db3d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzQtMy0xLTEtMTE3NTg_514890df-21b2-4f49-9a82-e60c7a1d87e6"
      unitRef="usd">15399777</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i73cb300b7bdf4e6a842303015e1050c5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzUtMS0xLTEtMTE3NTg_34f62f2c-acfa-45cc-9256-c5e9c0a013ff"
      unitRef="usd">421880</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ieae15c2289054f01bddc88f4e06f1c45_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90YWJsZTpkMjBhOTk4ODM1MmY0OGFkOTgzOTg2Y2MwZGEwNzg0NS90YWJsZXJhbmdlOmQyMGE5OTg4MzUyZjQ4YWQ5ODM5ODZjYzBkYTA3ODQ1XzUtMy0xLTEtMTE3NTg_995e4bfd-7fa6-438d-8afb-21116e9332ae"
      unitRef="usd">326551</us-gaap:TaxCreditCarryforwardAmount>
    <cntx:OperatingLossCarryforwardsExpirationTerm
      contextRef="i10821272b4754a39be917949dd892095_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU4NDc_def11d26-e9d9-4dc6-8bf6-141ba7401bf6">P3Y</cntx:OperatingLossCarryforwardsExpirationTerm>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i73cb300b7bdf4e6a842303015e1050c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU4NzQ_53d5b4ef-d79c-4711-958e-e9bc5a236cca"
      unitRef="usd">400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ieae15c2289054f01bddc88f4e06f1c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU4OTQ_7e5b3acd-59ee-4d85-9e04-4fd2f6fcde5d"
      unitRef="usd">300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i5cce182d571042c98e5effd7fdf6c2e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU5MTQ_52fc6e82-13aa-40f0-bef3-7c6d6950ba8e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i84f30e1e4d284ef4be016484aa57c1cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU5MTQ_6cf647c0-5cf1-4370-b432-680f54984993"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU5MjQ_850e49a9-b9de-464b-9ad5-4b7c591377b3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i428581bf313b4667a64bafcdd1f92f3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzYvZnJhZzozNTYwM2ZiMmU4MmQ0N2Y4ODgzMjg4NDNhNjgzZDZhMi90ZXh0cmVnaW9uOjM1NjAzZmIyZTgyZDQ3Zjg4ODMyODg0M2E2ODNkNmEyXzYwNDczMTM5NTU5MjQ_8d86728c-abe8-4c2d-a458-6e6ada1c1dcd"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xMzkvZnJhZzo5ZTk1N2I1YTdjOTI0MjY5YWNmMGYzN2VkYjRhZmI4Yy90ZXh0cmVnaW9uOjllOTU3YjVhN2M5MjQyNjlhY2YwZjM3ZWRiNGFmYjhjXzI5Mg_8f83b41b-007e-4b4c-ac9b-8b26a3bbe862">Related Party Transactions Since inception through December&#160;31, 2021, the Company entered into various convertible note agreements with the Related Party. The terms of the convertible notes and their subsequent conversions are further described in more detail in Note 6 and Note 7.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="id3806566135d43128a2459f8523168f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzIzMzk_e68f5d19-fe1c-4164-b952-8f38ab0b55df">Subsequent Events In March 2022, the Company issued 360,000 warrants to purchase common stock with an exercise price of $10.00 per share and a term of 5.76 years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $0.3&#160;million was recorded in general and administrative expense on the consolidated statement of operations for the year ended December 31, 2021.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8661fa5883274943a3502b6df99bcb33_I20220323"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzI3NDg3NzkwNzY3NDU_cd12958d-c4af-4bce-8950-4b5a87b080b7"
      unitRef="shares">360000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8661fa5883274943a3502b6df99bcb33_I20220323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzI3NDg3NzkwNzY3NTQ_b04ca3b0-2de4-4545-b9ef-43b37547c58b"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i8661fa5883274943a3502b6df99bcb33_I20220323"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzI3NDg3NzkwNzY3NjE_d4156410-1eaa-4958-aea5-516ed7ef8e40">P5Y9M3D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i2661b361222b4e279fdb7c4c8e9cc8cb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwZTBlMWZlNGU2NTRkMjBiZGUwNGY0MmM0MDlkOWRkL3NlYzoxMGUwZTFmZTRlNjU0ZDIwYmRlMDRmNDJjNDA5ZDlkZF8xNDIvZnJhZzpmMzY2ZDExNDEzNWE0ZmY4YTI3ZWE4ODBjNmJmMmI5NS90ZXh0cmVnaW9uOmYzNjZkMTE0MTM1YTRmZjhhMjdlYTg4MGM2YmYyYjk1XzI3NDg3NzkwNzY3NjM_ffe999de-ff3e-41ec-b8c4-2ff2882a683d"
      unitRef="usd">300000</us-gaap:FairValueAdjustmentOfWarrants>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1@$ W+%U&N?SV&T/B9"&P"G(J($P*,(<$M)G@%KEUQAA +I[LU7>+WJV_:+
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M,0JZ8V^ WU=2FOV)?<#AR^#@?U!+ P04    "  Y@G=4OV=-GQT"  !K!0
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(U4VV[;, S]%<'/1>PXEVV%
M8R"7%<W0%D&*;0_#'A2;B85(HB?)<]NOGR0[7@8D7E\L4>0Y/*1,)36JHRX
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M#!_P&<8$JH5"T-JOQ04B>(IQ^^?&[@+U$04:MX5=*@1SLS:0!^!FGW\[7$G
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MQFEN.LIQ=DN\VQ/NH#DR\GDD0S,?[:F=AH?2>QB6H0A<HYX>6DH*44Y/Q_3
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MG!8@83=<UWGC\6SF]4^3Z@]EMJJ>]K_.RC);5F\7+.1#DQ#@W]]D6;GY('Y
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MTC";N>AMTX\&;61CW+CN%/PJ85QWO6H;W5:RY)THT;J##_!1A]HM6G&]0Y_
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M4B@C +]O6Z@(QR]F@?&=E.O_ U!+ P04    "  Y@G=4HBT.9@0$   ["0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;-U8VV[<1A+]E<9L$"3
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MV<OM)&G8#Z)KY//+SL7H*OE9DL[)\P:L%PYOHF[ %PS?XZ[_!E!+ P04
M"  Y@G=4J;[/L&X:  "*3P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6S=7%MSVSB6_BNL;->44T4IDN])7ZIL)SWCKG3'%7=F:FMK'R 2DC"A"#5!
M6E;_^CG?.0 (RI*3[IW=AWV((XD$<'!P+M^YD-]M;//9+;5NL\=55;OO7RS;
M=OWFU2M7+/5*N;%=ZYJNS&VS4BU];1:OW+K1JN1!J^K5\61R_FJE3/WBA^_X
MM[OFA^]LUU:FUG=-YKK52C7;:UW9S?<OIB_"#Q_-8MGBAU<_?+=6"WVOVT_K
MNX:^O8JSE&:E:V=LG35Z_OV+J^F;ZU/<SS?\W>B-2SYGV,G,VL_X<EM^_V("
M@G2EBQ8S*/KO0=_HJL)$1,9O?LX7<4D,3#^'V7_DO=->9LKI&UO]PY3M\OL7
MER^R4L]55[4?[>9OVN_G#/,5MG+\-]O(O:<G+[*B<ZU=^<%$P<K4\K]Z]'Q(
M!EQ.#@PX]@..F6Y9B*E\JUKUPW>-W60-[J;9\(&WRJ.).%/C4.[;AJX:&M?^
M<"^'D=EY=F\6M9F;0M5M=E44MJM;4R^R.UN9PFCWW:N6UL.H5X6?^UKF/CXP
M]_0X^]G6[=)E[^I2E\,)7A&AD=KC0.WU\;,SOM7%.#N9YMGQY'CZS'PG<?<G
M/-_)@?GV;#/[KZN9:QN2EO]^9H'3N, I+W#ZO\+>?]?<V;5RQN'&NT8[7;=*
M-*(NZ0=3%V9=:;Y\8VM'8TJY_NM2D]84=K56]1;S%?&R+K.YJ14-557F:#Y-
MBMJZ;*D>=#;3NL[(1*Q50_>9FB=I2KI;DW2WR^S3^'Z<+72M&U556US6:TRI
M>M+7/5U'?_F/R^/CR;=_O;JZXX_3;U^.LZMZ"Z.@&XUI:9%V25O+:MO2D-9F
M:KVFS:M9I;-%9V1QXL%*@T=TG<?B Z;-E,OFM'3I)TJ9>-\2GU13.N).R4QF
MY@2JKNYO E',T+TC/ZW!,Y<,^A0'K1N[ZJH%\W2VY=5_C*S=.]NUI?_B7#]>
MW5_W;,&9??F8B+=55VI>S#.=SQ_?;^2\<PA#JQ];3-FHM>Y:4[CL_?N;_LJU
ML>NE(MN89[<U:2;V'Z[=-KK"]_=M.<[3B4'K].);EVV6%J=O-S61Z;J9,Z51
M#8DK'6Y5$8VM;KSP]41B2M+.VBFVZJG$Z<J0@>1-TRD6J2B/LX^ZJ)1S_?FQ
M,AC;9/^I53/4BQO=M.3.((-T?8OK:B7+]ZLU<4(PF>[#@L:U)(Y;D7+LN>@:
M$M!6)EDGB_!)D;PV.W1AB9*D.-/S.3FNS(H\DC+9!CNC*<C?\&&18VYDS#C[
M1%/13^]<:U8L:9 #4<&XW:\1"]P$3V]:OPG6CD;_UAE:F1Q/39X:-T-S5NJS
MSG1<$D=#6^E6:]E(NU1MIF0;@ST$9A)-=+_VIUH9-3.5:8V?JC2NJ*SK&NV)
MAQ9@Y61,\NM@N"R(G0:I_O+F6;(.D*D?"00YFKGL&NAB?Q_;*DV"4I+4%FU'
M<X8C(HFML(TY#,V<M)R&69=P;)R<UR[SR'3Z>4DPH":-?B!$ K(\G2(@46UQ
MW<6A9-V >W0T:'_0COM10@$^;GG:4I-.DI+1,#K_&9E;76CGR N-!S[HL%"L
M5*G_-$ULM/)LUK5,#=GZ##K?,CEB9.;*--F#JCHO-:L5"3^AJ.)SGCFR57H$
M# ?)6>%(O2-LR**(7+M]TVSXAOW7B.X'LA<&CJ;4LS;G+;/J;?V$M,^&!",R
MP]+.0+.7J@R64O8 V2%+42Q% _0#@>8UJQNC5Y%N.A2HJ#<[B645]V'(-Y#:
MMVQ(R1H7--S;"7;QY)--FWTT[G/B9TQ-F*<3/K/>KLF/DFZQZ)%M_F=0XK 4
MT>J2 R^>K%/(.@W6\:81!I40BZD8LQ3*R3;Y RP,\10$B!,+"R&P@#4FW2.%
M<T:$<ZY+#Q[H2M<,1 9[,6TGE-"]^A$RBB6?CF+QV5EQ26  HH7C(7=$&X/2
M;3,R1C !-*/K<$*I2TH,XXS\$!V<YV/*,Q/GM4Z.>\#"A&$ER19=9FF+^^+=
M>UO.YDWX89OMDRUOEJ98>G,3V0:56>J*#-6]7C"IM[5$=9CT@W@3TD0G5YW7
M^#FKNW*L,K;6P7(38^&AZ4QI$36C@,\OZ\3K:+;@#5D,HJA?AYB@'I2I&)E!
M@#542:YY^%,LC8[NC0@J=<&FC1U.DV<T*/PTHI]PRZ*QW3K'UG&EQ$]+0NK
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MF1"*IC\]7]J1'/XXNU-M;PUN=L5_3D#2[W_=-:[C=*6,\!7NOEZ4@FI?79?
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M"<P=",K)YM"Z$0J+VVC)!,?!D9$,Q3SYFBSZJ%TVMELL47OF-#@["5Z[58^
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MT\@11HA42>YZN^3;A$.#^F ?W)==F'5HM(U*X/4G+!F2K;MJ0I[ SBJS$(U
MH-%Q:.%<J'BTW C6<_(0%[W[KGUX&HOC0;6RH%J'C36P>$@2\%B1@;AV- ]B
MQB,ZY=[O"B4_Z>[U2AU-2KIB:&BJ+0,=@;!B9CD7_ =)#I+QU!?M6G5@6ZD>
MTW+.VQ\^DX,CHJ7HS?+;8.\.#DJM8RC9?<DC]$ZV#3D6F5C4ZIEL0M_+*J R
M^+9HEPW=5[0A--[M0_"/W R>=SA,#8?%\U$?. MY* _-0Y=*" \B 8P5]QD;
M+]Z[)@B&;#C#5_BXR9B?^O+/I>XQY4\&\!.4Q0'HD\I;+]JV?B/8:G#_;C2;
MC@W:_TUV-)WDIV?G^>7%Y"5])6M_>IJ?GI]E[[5S;PZ9S><,3' M1^1/+D[R
ML[/+EW^2NI'7\R=43O/)Q21_/;G(_O'U&AEF.R8'>9*?7YQF)Z>7^<GYY1[J
M>KR1T' R/G^-U4_&M/#;!*+\_SDGF:Q8XADEKF@>? #I:5-]G<0>(348UWB=
M'T^)YI.3/RL+/-/TVVC#GW#DZ#*?GI[E%\?G+_\]4I&V!>YAVS2_(&QT]D=E
M,-#?KW><3\X(M%V<?4$.DYT'2:0/KVF[[Y!%Q/1_;>R&7%6PP?>$9[MA/S6>
MB2%H$08L9$ 1'L25!F=.Q?M0[Z=NM2;RFS;[T#5]J] ]?NK6:*EB&WX\F1YG
M1TE%X:</U_>XV*<! RBC.?VU_  A8'.A4+6HD-XN@7'IGEIO,DXE/QAV47W'
MMXL/+".HTO*,+Z?U8@L=1<)%&QIYAD3LJ>?(\TS]M"B <QO?L!+VI/L#V0CM
M'X=$J,TAH'&"__@Y!#Q0+-C75V?E@=X5S<\=O8@]OV:C_3,@(<W7^BP@/),\
M SYG+(2JDG]2<(=VOW-FCVHJ(S@E%D]"8NW(O)0'R@@XD5UHGI$@D'UDZ'XU
MGQNN\3UPQS=L WGW!XO'Y+<(6E@OPG+/L"?FIX,\^F/C+$GH:&?HX;[FT5L@
M;)_?8Y*;Q.9XIDB!E$^D3PD=/A(BL+;(J?B*L+3\"-<#5W8.AI\1I[MI@2L(
MMQX\RW\WG!#EA6Z!%IH^MN(N/B_J5_>?^,J(K!&AB5GK#10^"OTW?<,M#N(#
MPZ$//FX\XM;BB\GH>/+2]XVQF)@';]/_IDL<M)\5N?R&>X[H/-YQ921F@3YL
MZM!_S+->3L]&IS1K\BJ"0&GR<H7^Q_2Q>@;YG.<K)",2MW 4'V7I?WR9'@A7
MO9F^?FMRJ#XMVS\VF(SBYP,)B)7\0%N_G._[]0@YEDDE!]'G#N4)O_"X>A^L
M;)9:T&<HG8:LNG^X8N=5 5S_7)'$HWW=9^F*T,D=]R2,'1V?[<'?$-3X%HKX
M-#W7L(R\KB+DI?8 9E8$CU;TGO!*2GU5-4 "Z2.!'/78P4L?PML%YGZ*A&E2
M)]AY'!@:.@NW2<,L/W_E2=@QN,KK#UO98!V1J_])U1V*(!YGYWVEHO1=$J4I
MV12P$55X@DYSOU@(3*0KY> #_"&CVK\\0"+U".C));[>KZZ_V#%?'4V/=VMH
MTI9[06KS)KL7:=N&H.=J**WI0# %'3WAX%5H4^.G4OOCYQXMLW+R #AJ+DFI
M\M$W)'#98)_/V2P-*AWUTC^1T=>#!DP8D@+O%\V?U),<ZI.2'9MI,BY<OI""
M1N3>],R'0Q%7FE7,@G#*"'U@[\AM;?LC-2RK*].VO@HES2HUZOEA+'Z6-.KA
MU\J(A]!U.+1G:?@_%<>]4A>]R:V7L>><R8]ZUC I)('GA]S)]'PT(=E\KU&(
M#%)Y>7K\,N,GG]'[UWA%1R2NQ7'C+3QX)XD$[^)=I=RN" \O:-B"7.SOOI-K
M!KPIO[.)9$_/[Y7(8\D!6ZAX@;1 R3^D94I?FQLVT4IT#AQ7R3:&CX3TCYWY
MR](@OX:+MX2:\3H25N@>D^2](L%*J<I907O<,E!\!O;G?E\T>A:^];0TB6WK
MN'SEU;,,G6^8M='M-JAKH)?""!V>O.,,^5!@N-^VJ_GA7JZ/,5\XSU'R-OT+
M(E@CACX @H:#@],BC_K2HS!YJ8QOL^'I\NQH]C*9???5-@3WBI<^<Y869Y'6
M\4]#2 ^(--[E24O;SD9$)Z.I@%HCKS^DFTO7Q INXTEL%%X*(<FSP^?X4U>Q
MT%\>%/K+T72Z3^C?D)%M%AIZ=[N"F(HV[7MIUZOD_6C<VX&WP/$+6NI67I46
M?XTOFKN2]ZOUM\M;ZGY60-AX"'].0R?CB[,7\LA1^-+:-;]M;6;;UJ[XXU(K
MVCQNH.MS2X&Y_X(%XNOW?O@74$L#!!0    ( #F"=U0!R+KLJ0@  ,06   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;-58VW+CN!']%9222ME5M"71
M-_E:97MV:IW:B9WQ[N8AE0>(A"3$),$!0&FT7Y_3#9"B/)9G:_<I+[9( 'TY
MW7W0S:N5L2]NH9077\NB<M>#A??UQ7#HLH4JI3LTM:JP,C.VE!Z/=CYTM54R
MYT-E,4Q'H]-A*74UN+GB=T_VYLHTOM"5>K+"-64I[?I.%69U/1@/VA>?]7SA
MZ<7PYJJ6<_6L_"_UD\73L).2ZU)53IM*6#6['MR.+^Z.:3]O^%6KE>O]%N3)
MU)@7>GC(KP<C,D@5*O,D0>+?4MVKHB!!,.-+E#GH5-+!_N]6^D?V';Y,I5/W
MIOB7SOWB>C 9B%S-9%/XSV;UHXK^G)"\S!2._XI5V'MT/!!9X[PIXV%84.HJ
M_)=?(PZ] Y/1C@-I/)"RW4$16_E!>GES9<U*6-H-:?2#7>73,$Y7%)1G;[&J
M<<[??)3:BE]ET2CQ24G76 7$O;L:>@BG+<,L"KH+@M(=@L:I^&0JOW#BARI7
M^;: (:SJ3$M;T^[2=R5^4-FA.!HG(AVEXW?D'76N'K&\H^^[^D&[K##DK1/_
MOITZ;Y$=_WE'QW&GXYAU'/]Y.-\51+5XX6J9J>L!BLTINU2#7=+%SPLE[DU9
MRVHM&J\+_1O\DF*)G9)S?Z&5E39;K(5?2"]JJXW5GK?-2.:2999]F93JN<!9
M#^%^76.KF0E=U0T6&UH#(_#B4D)<XWKJO,H6E?[2X(Q5A?38[(W0.#C3E:PR
M+0LAG5-X(:N\][+0<@KSO5;ND+WR"ZN4*-12%=_HA\AH<=\)B<=<N<SJ*?9(
MJ#0%F,==B)](BAB+O_UEDH['E^)Q2K#*::%:L:[)%G3D2V/(9L"4P07=<@?J
MSK[ Z,,H*NU$/?#Y1!C@0:#( -MWY"0A&F2QV=BB- O)M05Q%6L!E'75/K6J
MCSK5OU3F&S^@:;70\(4DX:T#L-YC';(J$]6+''R1Q(U6?6F@@JVVJC;6ZVHN
MD C:KPGHG+2:FF-H5A5%KREK"C;0>"#',F-S1%&!OSPK[@=EDW^]T$S-4B5A
M)X>(-'IV@S,#Z14%Q=1FC\\N73]U>@G3)@,D^[YNHG[XE#76D@;DM48R@%Q4
M.07.+<&(GXU'!OXSA.RI"]EM"-FG$#).^H><@,FP^S98LA=3:U\\ZWFE9UBK
MO'CD./:R+&1)NSO=WKT5Q^V=1_OBX^NZN9=N(2AH<)+KE=  47@83@YDM+X'
M1E;K:#L\R4R#K?OBK^+X/!F=C)/1Z?CU Z.<7O9^O89J]'\&U>??@PJ!<C)*
MCD[/^C^^!>.G7L+=FVJI4"EDQI,UI7;.V+7X!V!Q)"69I.=)>IZ^*:B_?@NP
M&AO*OJL/ $J2Q&G2+P(4LVO(DY[N>J.[8MTSO,#Y3-6!CA?6-/.%N 41 <S1
M^%SLD4@R)1U=_KVI<!UL><,N\/+X<I_JO^5XC3WH26PD;M+SF'E#V<%R6U6?
MJ-HY6;YK_=3J?*ZBY5 5MA]\1%1RB"4]]^"/F?CA*XJ8,^QQADS 6M^+OOEW
M0>26%X?B0\,$T*) ID&(1^-*-PN)VH6$6!&-1J,Y-+#S6>W8W+=JUZ8.VSTT
M<-RA(GO7 :LW''J=77VG5 M:U7"5PA<JUSSGF\<L-?7/CJPG5T-B!8S?R5Y&
M?0>BR6MV-YQF"=V<U*O$_)VNQ>WSO9B,3Q)0B 51D9-!](\JGU,L</W@$+?H
MQ-M8D75=Z'"YRZ)XS\CW;.0\H]L(=SK5P9O7R*9 @ BR%W;B!W"JXL30W63P
MJI8V]#8A59SJ=2W.H\7AKBDT+7UH9G\.:\8G5U[9DF/7.()-"I>IBDKR(+1I
MLI+%&O=::"A0H1KS"I73MC5;/1UR8QJX;'VPXN&%$P:N@6([Z]77.@1GUGCJ
MM (!D+.X;?"F0CH ,J=1J]PR2-1]]+HVSK%'& 8S4Y*K2ZD+INTV9^'DPA0X
M[ C]K&ARDM+2S</38T+= 'H74IGPC8>.)&)?S4FY1;L";P6:^,K)..P!TYQ0
M+AI^;O&*$6KI2.;_Q8A%Z8:7F;1V';1'YZG;^>.A"RX"_#8>^5:?Z@-6FVX+
M_1CZ(4XZLJWMG($*IFU'_3==#^U#K.*>1/0XZ,%"TYNA!9U3M%XEX[O71A1)
MX32%SEE[E]MTVM0J5$&$\0]I(0>CIK62N$D4S8MO-&0$+K<;O\<@L(4S,8-X
M[( !3H:A80[>B^TB,E(Q2RTIOXHU@X;.XK= 6/VKJJE-%3UQF\*/3NR%JWE_
M5\'OO!P0]F_[*2IR]$A9$R(>B[R*Q,KS [TI38X69R_>#X]/G[I;9&9EJ>CS
M!WL91\"0U5.9O1P /AH[E%^8,+?I:J9"/\RDB_8[DYR$="0667 (6.5HN_R&
M.( )-=,4 B#,+C^C^.'<K7CV)GLA4+1KU9%SKJ-X9)D/_IH0JSQP%@ENI04
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M"VG<VK5W"L?&23J9[+^2&(GCW8NE+[PMD#W =4I21_#G!,"=CS U]2 &R_;
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MIO"O3S Z:_T*S;X=<+XNC7+=%.A/^QFZZD;''W@W@&^YV0ME06)!U/AZ/ S
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MLQ301:?NXH]I8@V;C_S@1\*TTIY+)6*Q)3QN9I=F0%[@L.R*S['K 4Z7IWO
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M,<!409LMK+=H66:K[QGRKN;K8+&(ALD[R-,"3)>KT==P-5PO@NAR]=_#^V=
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MIMATNP.710X4" DRX03!/ADL=. 14"H=!&-/T*T9*B12-IWT$ZK_/++2@6?
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M_JR6ALWUOBS8%WI4\8D' H0BH@??MPC+V8R?.O,*@(JZ;,L0\IA]VS8>+8!
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MS&7:HVJSXT_X+HR3ZV^U6 R2;S24<8ZI9UKO?$6]HXIJMWO71 E!#O'I^&W
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MZGAT?)@ =8/>&>R:.%RY8QG5N*SD;D0* >)?.]'9&Z' <-LN?P)02P,$%
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M"LW3D^,$7#];^DVP;>SGE0TT'>*RH7&,CAW(7EL;]AM., SXQ4]02P,$%
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ML(\(&&1%'X %V844& D3>IO7/1 (V;^VW.,@JK]V$%3&!)T<JA KQ9%)3&W
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M![3;@.MSA0193YR!_G]J\C=02P,$%     @ .8)W5#[JG[A,!   \0H  !D
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M.FIG0/>E4O:P<03]3V+^%U!+ P04    "  Y@G=4*I>B0L0"  #*!0  &0
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MY>N+CM]Y?O"#+99*/^B.SU=D06^INEO="+CKUE82EM%<,IXC0><7G4O_[#K
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MZ0!J+LHSY_)&\94Y(YUQI7AF+I>4 ,RT /P_YUP]WV@']<G_^#=02P,$%
M  @ .8)W5/$$4)L# P  @@@  !D   !X;"]W;W)K<VAE971S+W-H965T,S N
M>&ULI9;?;YLP$,?_%0OMH96V0J#Y5261DJ;3]M"J:M3M8=J#8XY@%6QJFR:3
M]L?O;"A+$T(G+0_!-G??^]P9?$RV4CWI%,"079X)/?528XHKW]<LA9SJ"UF
MP#N)5#DU.%4;7Q<*:.R<\LP/@V#@YY0+;S9Q:_=J-I&ER;B >T5TF>=4_5I
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M?#_UH/?KP2-=;Y1YX,\F6[PF3T1]V3X(?><W5E*:D5Q2G@-!5E/O#KY;A,@
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MFK)JK:N!%EO7G2Z%-KVNN]V8SQ&0UL \7PFSC>J!7:#YP)G^!U!+ P04
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M!CB?":&/'7,YM/\%9G\!4$L#!!0    ( #F"=U3PY?;M8 8  (LC   9
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M$QK;7@(8/OJMG(OZAH'^H?(Q8)8C4?\@Y<I#@,/MMOTS-/3M-/R=B:CIU.&
M& (;1H5M:^,;[OD'7O1(6C]R!$+=-L;*K@:>>-[/C5TY6FZ[([572G:^?LED
M*FD\S_?GU0DNF-%0[=F;>O11ZSN8U6[M57O^,Y7/5"QYG(*0+92@=])7>D3Y
MRX_R1B;KXNW[+)$RB8K+%:-S)O(&ZODB45-*W^0O]*O?WPS_ U!+ P04
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MEKV6F%WP>)V^YS6/.8_#]..*DB5E4D#<?XA%\=2%?'4L?SGT_%]02P,$%
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MIOHJ!,($Z/=SSM7CQ!RV]G(5_0-02P,$%     @ .8)W5( /H!A0 P  VPH
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MI1L/.USH[A.%,=#O9YRKS<0XJ/K9X3]02P,$%     @ .8)W5#>PAH$> P
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ .8)W5*LNK+HT!   [R    \
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M/K\;;Y^_+*\W$>?A!>< 1ZWOOU!+ P04    "  Y@G=4G"O3#[T!  !W'0
M$P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=DB8CR4#@(V;;<M
MB_Z FSQ(1!);MJ'P]W7"(+6BJ(A*O9M$B>UW7VSI;#)^VUKRO4U=-7Z2%"'8
M!\9\5E"M?6HL-7%D;ERM0WQT"V9UMM0+8F(X'+',-(&:, AMC60Z?J*Y7E6A
M][R)KWUIFDGBJ/))[W$WL<V:)-K:JLQTB.-LW>3?4@;[A#2N[.;XHK2^'R<D
M[&1"._)SP'[=ZYJ<*W/JS;0++[J.L]BF8CYL*_+I^1(G>C3S>9E1;K)5'9>D
MWCK2N2^(0EVENZ+]\\DA[C#MKOSJ_*[,N< X<^:,]?'$'%T>=SB2=O7 QD+D
M0GG^$X^)L?35WT?M:>>4_S([;N^'<<ON/#SK;M?O\=<S/M:_L \!TH<$Z4.!
M]'$#TL<(I(];D#[N0/JX!^F##U$:01&5HY#*44SE**AR%%4Y"JL<Q56. BM'
MD56@R"I09!4HL@H4606*K )%5H$BJT"15:#(*E!DE2BR2A19)8JL$D56B2*K
M1)%5HL@J4625*+)*%%D5BJP*15:%(JM"D56AR*I09%4HLBH4616*K.H_97TW
M9OG7OP+;>UKKLCGDL^Y_Z_034$L! A0#%     @ .8)W5 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  Y@G=4R<K7=.X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  Y@G=4F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #F"=U2C
M+)]=[@8  "4<   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  Y@G=4OV=-GQT"  !K!0  &
M    @($Q#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M.8)W5)5Z=Y$C!@  K1H  !@              ("!A!$  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #F"=U1B+);LBP,  ,,0   8
M          " @=T7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  Y@G=4*6\UQ?H#   $#0  &               @(&>&P  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ .8)W5*M]\86L"0  +#8
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M965T,3 N>&UL4$L! A0#%     @ .8)W5*F^S[!N&@  BD\  !D
M     ("!3D   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F"=U05 :_#VP<  +D5   9              "
M@1-V  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ .8)W
M5-,YE97_"P  G"$  !D              ("!)7X  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  Y@G=4XR+",@8(  "B$P  &0
M        @(%;B@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( #F"=U165%$<9P(  'D%   9              " @9B2  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ .8)W5&F7 4_& @  [ 4
M !D              ("!-I4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  Y@G=4Z4V< DH4  #S/   &0              @($SF
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #F"=U1YDA2-
MW00  %L-   9              " @;2L  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ .8)W5#[JG[A,!   \0H  !D
M ("!R+$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  Y
M@G=4P1-+5M0"   P!@  &0              @(%+M@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( #F"=U0JEZ)"Q (  ,H%   9
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M970R.2YX;6Q02P$"% ,4    "  Y@G=4\010FP,#  """   &0
M    @(%VS0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M #F"=U2]U2#'@ (  ,(&   9              " @;#0  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ .8)W5%DIF>,> P  QPL  !D
M             ("!9],  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  Y@G=4SW"2AS($  "1#P  &0              @(&\U@  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #F"=U0Y5(2E_ ,
M + 2   9              " @27;  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ .8)W5+YJ4O&R P  [ P  !D              ("!
M6-\  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  Y@G=4
M;61UH=T"   7"   &0              @(%!XP  >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( #F"=U3PY?;M8 8  (LC   9
M      " @57F  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ .8)W5!:H>2U9!P  *"H  !D              ("![.P  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  Y@G=4#0%!(M<"  #+"
M&0              @(%\]   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( #F"=U2O(_H@X04  %(=   9              " @8KW  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ .8)W5,T=A?[@
M @  ,@@  !D              ("!HOT  'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  Y@G=40IN*X4($   /$@  &0
M@(&Y  $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #F"
M=U38VTH87P,  &H+   9              " @3(% 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ .8)W5!T_^'3.!@  2R0  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( #F"=U2 #Z 84 ,  -L*   9
M  " @04= 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M.8)W5#>PAH$> P  %!(   T              ( !C" ! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  Y@G=4EXJ[',     3 @  "P              @ '5
M(P$ 7W)E;',O+G)E;'-02P$"% ,4    "  Y@G=4JRZLNC0$  #O(   #P
M            @ &^) $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ .8)W
M5(YA./J] 0  >AT  !H              ( !'RD! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ .8)W5)PKTP^] 0  =QT  !,
M         ( !%"L! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #D .0"&
)#P   BT!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>186</ContextCount>
  <ElementCount>291</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/RisksandLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Convertible Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotes</Role>
      <ShortName>Convertible Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock</Role>
      <ShortName>Convertible Preferred Stock, Redeemable Common Stock and Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2206201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables</Role>
      <ShortName>Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/NatureofBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Risks and Liquidity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails</Role>
      <ShortName>Risks and Liquidity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Fair Value Measurements - Roll-forward of fair values of liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Roll-forward of fair values of liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Convertible Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails</Role>
      <ShortName>Convertible Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails</Role>
      <ShortName>Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-Based Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Share-Based Compensation - Schedule of RSU Share-Based Payment Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of RSU Share-Based Payment Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/CommitmentandContingencies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences That Give Rise To The Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Effects of Temporary Differences That Give Rise To The Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Income Taxes - Summary of Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Summary of Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cntx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Subsequent Events - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="cntx-20211231.htm">cntx-20211231.htm</File>
    <File>amendment1tosahmoud-oncost.htm</File>
    <File>cntx-20211231.xsd</File>
    <File>cntx-20211231_cal.xml</File>
    <File>cntx-20211231_def.xml</File>
    <File>cntx-20211231_lab.xml</File>
    <File>cntx-20211231_pre.xml</File>
    <File>contexttherapeuticsex311ce.htm</File>
    <File>contexttherapeuticsex312ce.htm</File>
    <File>contexttherapeuticsex321ce.htm</File>
    <File>exhibit231cohnreznickconse.htm</File>
    <File>levitemploymentagreement10.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cntx-20211231_g1.jpg</File>
    <File>cntx-20211231_g10.jpg</File>
    <File>cntx-20211231_g11.jpg</File>
    <File>cntx-20211231_g12.jpg</File>
    <File>cntx-20211231_g13.jpg</File>
    <File>cntx-20211231_g14.jpg</File>
    <File>cntx-20211231_g15.jpg</File>
    <File>cntx-20211231_g16.jpg</File>
    <File>cntx-20211231_g17.jpg</File>
    <File>cntx-20211231_g18.jpg</File>
    <File>cntx-20211231_g19.jpg</File>
    <File>cntx-20211231_g2.jpg</File>
    <File>cntx-20211231_g3.jpg</File>
    <File>cntx-20211231_g4.jpg</File>
    <File>cntx-20211231_g5.jpg</File>
    <File>cntx-20211231_g6.jpg</File>
    <File>cntx-20211231_g7.jpg</File>
    <File>cntx-20211231_g8.jpg</File>
    <File>cntx-20211231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="560">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cntx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 186,
   "dts": {
    "calculationLink": {
     "local": [
      "cntx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cntx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cntx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cntx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cntx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cntx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 463,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 8
   },
   "keyCustom": 41,
   "keyStandard": 250,
   "memberCustom": 30,
   "memberStandard": 26,
   "nsprefix": "cntx",
   "nsuri": "http://www.contexttherapeutics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.contexttherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cntx:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Risks and Liquidity",
     "role": "http://www.contexttherapeutics.com/role/RisksandLiquidity",
     "shortName": "Risks and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cntx:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Measurements",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Convertible Promissory Notes",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotes",
     "shortName": "Convertible Promissory Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock",
     "shortName": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Share-Based Compensation",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Commitment and Contingencies",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Income Taxes",
     "role": "http://www.contexttherapeutics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Related Party Transactions",
     "role": "http://www.contexttherapeutics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.contexttherapeutics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Subsequent Events",
     "role": "http://www.contexttherapeutics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2206201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables",
     "shortName": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.contexttherapeutics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id7d9b23ad16c43aa8572a0ac6ca614b4_I20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business (Details)",
     "role": "http://www.contexttherapeutics.com/role/NatureofBusinessDetails",
     "shortName": "Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id7d9b23ad16c43aa8572a0ac6ca614b4_I20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Risks and Liquidity - Narrative (Details)",
     "role": "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
     "shortName": "Risks and Liquidity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i9133735e066c4f4ea8c7871915a16053_D20211001-20211031",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details)",
     "role": "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails",
     "shortName": "Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "ia34409531cae4268bc173922ce57ac3f_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id55d52b883b8439db64cf84da4088ed2_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Fair Value Measurements - Roll-forward of fair values of liabilities (Details)",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails",
     "shortName": "Fair Value Measurements - Roll-forward of fair values of liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "ie62db008cf5d41d287747c3ee2afb05c_I20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Convertible Promissory Notes (Details)",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails",
     "shortName": "Convertible Promissory Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "if5bffb2e3fd7430997f0e5cd07ec38b3_D20200501-20200531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
     "shortName": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i8d1cfe7096e34e6ea497fb994bda8378_D20210201-20210228",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)",
     "role": "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
     "shortName": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock - Schedule of Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i2ba1a5fd4aa54bd18b6277a18720bbb6_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "ib1e1c00a5a0c46b7827110eaaccd2bde_D20210401-20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "ib1e1c00a5a0c46b7827110eaaccd2bde_D20210401-20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails",
     "shortName": "Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i88d6ced734aa469b96eb303e5f33e8a9_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i84f30e1e4d284ef4be016484aa57c1cb_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-Based Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i992c3c31612041b88458293caef78ce6_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Share-Based Compensation - Schedule of RSU Share-Based Payment Award Activity (Details)",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails",
     "shortName": "Share-Based Compensation - Schedule of RSU Share-Based Payment Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i572c857cebbe4fc1982b32de57c0220a_I20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Commitment and Contingencies (Details)",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences That Give Rise To The Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Tax Effects of Temporary Differences That Give Rise To The Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i73cb300b7bdf4e6a842303015e1050c5_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Income Taxes - Summary of Operating Loss Carryforwards (Details)",
     "role": "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes - Summary of Operating Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i73cb300b7bdf4e6a842303015e1050c5_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i5cce182d571042c98e5effd7fdf6c2e4_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Subsequent Events - Narrative (Details)",
     "role": "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails",
     "shortName": "Subsequent Events - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i2661b361222b4e279fdb7c4c8e9cc8cb_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i51367b5fc58744139f31963837e98df8_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "i51367b5fc58744139f31963837e98df8_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cntx:TemporaryEquityOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cntx:TemporaryEquityOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statement of Cash Flows",
     "role": "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business",
     "role": "http://www.contexttherapeutics.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20211231.htm",
      "contextRef": "id3806566135d43128a2459f8523168f6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "cntx_AccruedInterestRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Interest, Related Parties",
        "label": "Accrued Interest, Related Parties",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterestRelatedParties",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "cntx_BridgeNoteQualifiedFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge Note Qualified Financing",
        "label": "Bridge Note Qualified Financing [Member]",
        "terseLabel": "Bridge Note Qualified Financing"
       }
      }
     },
     "localname": "BridgeNoteQualifiedFinancingMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_BridgeNotesToSeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge Notes to Series A Preferred Stock",
        "label": "Bridge Notes to Series A Preferred Stock [Member]",
        "terseLabel": "Bridge Notes to Series A Preferred Stock"
       }
      }
     },
     "localname": "BridgeNotesToSeriesAPreferredStockMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ChiefFinancialOfficerAndImmediateFamilyMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief Financial Officer And Immediate Family Member",
        "label": "Chief Financial Officer And Immediate Family Member [Member]",
        "terseLabel": "Chief Financial Officer And Immediate Family Member"
       }
      }
     },
     "localname": "ChiefFinancialOfficerAndImmediateFamilyMemberMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ClinicalTrialLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial Liabilities, Current",
        "label": "Clinical Trial Liabilities, Current",
        "terseLabel": "Clinical trial expenses"
       }
      }
     },
     "localname": "ClinicalTrialLiabilitiesCurrent",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum",
        "terseLabel": "Maximum development and regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayment",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Payments as Credits to Accounts Payable, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Payments as Credits to Accounts Payable, Percent",
        "terseLabel": "Percentage of payments as to credits accounts payable"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPaymentsAsCreditsToAccountsPayablePercent",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent",
        "terseLabel": "Quarterly sales payment due upon completion, percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "terseLabel": "Maximum sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Payment Period",
        "terseLabel": "Quarterly sales payment due upon completion, period of payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "terseLabel": "Tiered royalty payment, percent (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Maximum obligation amount"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_ContextTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Context Therapeutics LLC",
        "label": "Context Therapeutics LLC [Member]",
        "terseLabel": "Context Therapeutics LLC"
       }
      }
     },
     "localname": "ContextTherapeuticsLLCMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ConvertibleBridgeNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Bridge Notes",
        "label": "Convertible Bridge Notes [Member]",
        "terseLabel": "Convertible Bridge Notes"
       }
      }
     },
     "localname": "ConvertibleBridgeNotesMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Notes To Series Seed Preferred Stock",
        "label": "Convertible Promissory Notes To Series Seed Preferred Stock [Member]",
        "terseLabel": "Convertible Promissory Notes To Series Seed Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesToSeriesSeedPreferredStockMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_DebtConversionConvertedInstrumentPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion, Converted Instrument, Price Per Share",
        "label": "Debt Conversion, Converted Instrument, Price Per Share",
        "terseLabel": "Debt conversion, price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentPricePerShare",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cntx_DebtInstrumentConvertedInstrumentInterestAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Converted Instrument, Interest Amount",
        "label": "Debt Instrument, Converted Instrument, Interest Amount",
        "terseLabel": "Converted interest"
       }
      }
     },
     "localname": "DebtInstrumentConvertedInstrumentInterestAmount",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_DebtInstrumentConvertedInstrumentPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Converted Instrument, Principal Amount",
        "label": "Debt Instrument, Converted Instrument, Principal Amount",
        "terseLabel": "Converted principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertedInstrumentPrincipalAmount",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_December2021PrivatePlacementAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2021 Private Placement Agent Warrants",
        "label": "December 2021 Private Placement Agent Warrants [Member]",
        "terseLabel": "December 2021 Private Placement Warrants"
       }
      }
     },
     "localname": "December2021PrivatePlacementAgentWarrantsMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_December2021PrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2021 Private Placement Warrants",
        "label": "December 2021 Private Placement Warrants [Member]",
        "terseLabel": "December 2021 Private Placement Warrants"
       }
      }
     },
     "localname": "December2021PrivatePlacementWarrantsMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_DeferredOfferingCostIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Cost Incurred but Not yet Paid",
        "label": "Deferred Offering Cost Incurred but Not yet Paid",
        "terseLabel": "Unpaid offering costs in accounts payable"
       }
      }
     },
     "localname": "DeferredOfferingCostIncurredButNotYetPaid",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_DemandNotesToConvertiblePromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Demand Notes to Convertible Promissory Notes",
        "label": "Demand Notes to Convertible Promissory Notes [Member]",
        "terseLabel": "Demand Notes to Convertible Promissory Notes"
       }
      }
     },
     "localname": "DemandNotesToConvertiblePromissoryNotesMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_DrexelUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drexel University",
        "label": "Drexel University [Member]",
        "terseLabel": "Drexel University"
       }
      }
     },
     "localname": "DrexelUniversityMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_FairValueAdjustmentOnConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustment On Convertible Debt",
        "label": "Fair Value Adjustment On Convertible Debt",
        "negatedTerseLabel": "Change in fair value of convertible promissory notes",
        "terseLabel": "Change in fair value of convertible promissory notes"
       }
      }
     },
     "localname": "FairValueAdjustmentOnConvertibleDebt",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Accrued Interest",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value",
        "label": "Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value",
        "terseLabel": "Change in fair value of redeemable common stock to redemption value"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_IntegralMolecularIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integral Molecular, Inc.",
        "label": "Integral Molecular, Inc. [Member]",
        "terseLabel": "Integral"
       }
      }
     },
     "localname": "IntegralMolecularIncMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedAsPartOfPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued as part of Private Placement",
        "label": "Issued as part of Private Placement [Member]",
        "terseLabel": "Issued as part of December 2021 private placement"
       }
      }
     },
     "localname": "IssuedAsPartOfPrivatePlacementMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedForProfessionalConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued for Professional Consulting Services",
        "label": "Issued for Professional Consulting Services [Member]",
        "terseLabel": "Issued for Professional Consulting Services"
       }
      }
     },
     "localname": "IssuedForProfessionalConsultingServicesMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedForServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued for Services",
        "label": "Issued for Services [Member]",
        "terseLabel": "Issued for services"
       }
      }
     },
     "localname": "IssuedForServicesMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedInConnectionWithIPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued in Connection with IPO",
        "label": "Issued in Connection with IPO [Member]",
        "terseLabel": "Issued in connection with IPO"
       }
      }
     },
     "localname": "IssuedInConnectionWithIPOMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedToPlacementAgentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued to Placement Agents",
        "label": "Issued to Placement Agents [Member]",
        "terseLabel": "Issued to placement agents"
       }
      }
     },
     "localname": "IssuedToPlacementAgentsMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedToSeriesAStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued to Series A Stockholders",
        "label": "Issued to Series A Stockholders [Member]",
        "terseLabel": "Issued to Series A Stockholders"
       }
      }
     },
     "localname": "IssuedToSeriesAStockholdersMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_JuniorConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Junior Convertible Notes",
        "label": "Junior Convertible Notes [Member]",
        "terseLabel": "Junior Convertible Notes"
       }
      }
     },
     "localname": "JuniorConvertibleNotesMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_LocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local Jurisdiction",
        "label": "Local Jurisdiction [Member]",
        "terseLabel": "NOL carryforwards\u2014Local",
        "verboseLabel": "Local"
       }
      }
     },
     "localname": "LocalJurisdictionMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ManufacturingDevelopmentLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Development Liabilities, Current",
        "label": "Manufacturing Development Liabilities, Current",
        "terseLabel": "Manufacturing development expenses"
       }
      }
     },
     "localname": "ManufacturingDevelopmentLiabilitiesCurrent",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_NetDeferredTaxAssetLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Deferred Tax Asset (Liabilities) Gross",
        "label": "Net Deferred Tax Asset (Liabilities) Gross",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "NetDeferredTaxAssetLiabilitiesGross",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_OperatingLossCarryforwardsExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration Term",
        "label": "Operating Loss Carryforwards, Expiration Term",
        "terseLabel": "Local NOL expiration term"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationTerm",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cntx_PatentCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Costs, Policy",
        "label": "Patent Costs, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cntx_PaymentProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Protection Program Loan",
        "label": "Payment Protection Program Loan [Member]",
        "terseLabel": "Payment Protection Program Loan"
       }
      }
     },
     "localname": "PaymentProtectionProgramLoanMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_PlacementAgentsWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agents Warrants",
        "label": "Placement Agents Warrants [Member]",
        "terseLabel": "Placement Agent Warrants"
       }
      }
     },
     "localname": "PlacementAgentsWarrantsMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_RedeemableCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Common Stock",
        "label": "Redeemable Common Stock [Member]",
        "terseLabel": "Redeemable Common Stock"
       }
      }
     },
     "localname": "RedeemableCommonStockMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_RisksAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Liquidity",
        "label": "Risks And Liquidity [Abstract]",
        "terseLabel": "Risks And Liquidity [Abstract]"
       }
      }
     },
     "localname": "RisksAndLiquidityAbstract",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "cntx_RisksAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Liquidity",
        "label": "Risks And Liquidity [Text Block]",
        "terseLabel": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndLiquidityTextBlock",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scale-Up, 100 kilograms of GMP-Grade Compound",
        "label": "Scale-Up, 100 kilograms of GMP-Grade Compound [Member]",
        "terseLabel": "Scale-up, 100 kilograms of GMP-grade compound"
       }
      }
     },
     "localname": "ScaleUp100KilogramsOfGMPGradeCompoundMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scale-Up, 300 kilograms of GMP-Grade Compound",
        "label": "Scale-Up, 300 kilograms of GMP-Grade Compound [Member]",
        "terseLabel": "Scale-up, 300 kilograms of GMP-grade compound"
       }
      }
     },
     "localname": "ScaleUp300KilogramsOfGMPGradeCompoundMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_SeniorConvertibleNotesApril2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes, April 2020",
        "label": "Senior Convertible Notes, April 2020 [Member]",
        "terseLabel": "Senior Convertible Notes, April 2020"
       }
      }
     },
     "localname": "SeniorConvertibleNotesApril2020Member",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_SeriesSeedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Seed Preferred Stock",
        "label": "Series Seed Preferred Stock [Member]",
        "terseLabel": "Series Seed Preferred Stock"
       }
      }
     },
     "localname": "SeriesSeedPreferredStockMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock",
        "terseLabel": "Annual rate at which authorized shares of common stock increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_StateJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Jurisdiction",
        "label": "State Jurisdiction [Member]",
        "terseLabel": "NOL carryforwards\u2014State"
       }
      }
     },
     "localname": "StateJurisdictionMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_StockGrantedForServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Granted For Services",
        "label": "Stock Granted For Services [Member]",
        "terseLabel": "Stock Granted For Services"
       }
      }
     },
     "localname": "StockGrantedForServicesMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_StockIssuedDuringPeriodIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Issuance Costs",
        "label": "Stock Issued During Period, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodIssuanceCosts",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares",
        "label": "Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares",
        "terseLabel": "Conversion of convertible preferred shares and redeemable common shares upon initial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "terseLabel": "Shares issued upon conversion of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares",
        "label": "Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares",
        "terseLabel": "Conversion of convertible preferred shares and redeemable common shares upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityDecreaseDueToConversionToWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease Due To Conversion To Warrants",
        "label": "Temporary Equity, Decrease Due To Conversion To Warrants",
        "negatedTerseLabel": "Fair value of warrants issued in conjunction with the Series A preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseDueToConversionToWarrants",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees",
        "label": "Temporary Equity, Decrease Due to Conversion to Warrants Issued as Placement Agent Fees",
        "terseLabel": "Fair value of warrants issued as placement agent fees"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseDueToConversionToWarrantsIssuedAsPlacementAgentFees",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value",
        "label": "Temporary Equity, Increase (Decrease) in Fair Value of Redeemable Common Stock to Redemption Value",
        "terseLabel": "Change in fair value of redeemable common stock to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityIncreaseDecreaseInFairValueOfRedeemableCommonStockToRedemptionValue",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Offering Costs",
        "label": "Temporary Equity, Offering Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "TemporaryEquityOfferingCosts",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Policy",
        "label": "Temporary Equity, Policy [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock and Redeemable Common Stock"
       }
      }
     },
     "localname": "TemporaryEquityPolicyPolicyTextBlock",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Price Per Share",
        "label": "Temporary Equity, Stock Issued During Period, Price Per Share",
        "terseLabel": "Temporary equity, price per share (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodPricePerShare",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible securities (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Preferred Shares and Redeemable Common Shares",
        "terseLabel": "Conversion of convertible preferred shares and redeemable common shares upon initial public offering (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfPreferredSharesAndRedeemableCommonShares",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, Issued For Services",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Issued For Services",
        "terseLabel": "Temporary equity, stock issued for services (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Temporary equity new shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities",
        "label": "Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible securities"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares",
        "label": "Temporary Equity, Stock Issued During Period, Value, Conversion of Preferred Shares and Redeemable Common Shares",
        "terseLabel": "Conversion of convertible preferred shares and redeemable common shares upon initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfPreferredSharesAndRedeemableCommonShares",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, Issued For Services",
        "label": "Temporary Equity, Stock Issued During Period, Value, Issued For Services",
        "terseLabel": "Temporary equity, stock issued for services"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_TyligandBioscienceShanghaiLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tyligand Bioscience (Shanghai) Limited",
        "label": "Tyligand Bioscience (Shanghai) Limited [Member]",
        "terseLabel": "Tyligand"
       }
      }
     },
     "localname": "TyligandBioscienceShanghaiLimitedMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_WarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued",
        "label": "Warrants Issued",
        "terseLabel": "Issuance of warrants in conjunction with Series A preferred stock and placement agent fees"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued in Conjunction With Series A Preferred Stock",
        "label": "Warrants Issued in Conjunction With Series A Preferred Stock [Member]",
        "terseLabel": "Warrants issued in conjunction with series A preferred stock"
       }
      }
     },
     "localname": "WarrantsIssuedInConjunctionWithSeriesAPreferredStockMember",
     "nsuri": "http://www.contexttherapeutics.com/20211231",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r249",
      "r366",
      "r367",
      "r368",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r43",
      "r45",
      "r82",
      "r83",
      "r182",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r181",
      "r219",
      "r251",
      "r252",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r428",
      "r429",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r181",
      "r219",
      "r251",
      "r252",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r428",
      "r429",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r181",
      "r219",
      "r241",
      "r251",
      "r252",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r428",
      "r429",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r181",
      "r219",
      "r241",
      "r251",
      "r252",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r428",
      "r429",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r44",
      "r45",
      "r82",
      "r83",
      "r182",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r373"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r287",
      "r373"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r284",
      "r285",
      "r286",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "auth_ref": [
      "r216",
      "r232",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "negatedTerseLabel": "Change in fair value of redeemable common stock to redemption value"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r177",
      "r232",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Fair value of warrants issued in conjunction with the Series A preferred stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254",
      "r281",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r139",
      "r147",
      "r151",
      "r155",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r325",
      "r329",
      "r347",
      "r371",
      "r373",
      "r407",
      "r419"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r42",
      "r78",
      "r155",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r325",
      "r329",
      "r347",
      "r371",
      "r373"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r255",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r27",
      "r67"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r67",
      "r72"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash equivalents and restricted cash (Money Market Accounts)",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r348"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r75",
      "r78",
      "r102",
      "r103",
      "r108",
      "r113",
      "r117",
      "r123",
      "r124",
      "r125",
      "r155",
      "r165",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r217",
      "r218",
      "r222",
      "r226",
      "r347",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r239",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of securities called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants prior to conversion (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r239",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r162",
      "r411",
      "r423"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r163",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r373"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock\u2014$0.001 par value; 100,000,000 shares authorized; 15,966,053 and 331,789 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r129",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of preferred stock and redeemable common stock upon initial public offering"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible promissory notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible Promissory Notes"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r176",
      "r178",
      "r179",
      "r181",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r207",
      "r208",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r13",
      "r408",
      "r417",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Converted amount",
        "verboseLabel": "Conversion of convertible promissory notes"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued as a result of converted debt (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r195",
      "r202",
      "r203",
      "r205",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Promissory Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r77",
      "r84",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r207",
      "r208",
      "r209",
      "r210",
      "r360",
      "r408",
      "r409",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r206",
      "r409",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Outstanding principal balance"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Convertible debt beneficial conversion feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r178",
      "r207",
      "r208",
      "r358",
      "r360",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r77",
      "r84",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r207",
      "r208",
      "r209",
      "r210",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r37",
      "r77",
      "r84",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r233",
      "r234",
      "r235",
      "r236",
      "r357",
      "r358",
      "r360",
      "r361",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r12",
      "r406",
      "r418"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of deferred costs.",
        "label": "Deferred Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCostsCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "cntx_NetDeferredTaxAssetLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r308",
      "r310",
      "r311"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "cntx_NetDeferredTaxAssetLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesThatGiveRiseToTheDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Less: change in fair value of convertible promissory notes and interest expense"
       }
      }
     },
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "NOL carryforwards\u2014Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r54",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r99",
      "r102",
      "r113",
      "r116",
      "r117",
      "r120",
      "r121",
      "r332",
      "r333",
      "r413",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic net (loss) income per common share calculation:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r54",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r102",
      "r113",
      "r116",
      "r117",
      "r120",
      "r121",
      "r332",
      "r333",
      "r413",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income (loss) per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted net (loss) income per common share calculation:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net (Loss) Income Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r79",
      "r297",
      "r317"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax expense/(benefit) at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r297",
      "r317"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r297",
      "r317"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r297",
      "r317"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r297",
      "r317"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r297",
      "r317"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "auth_ref": [
      "r297",
      "r317"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent",
        "negatedLabel": "Non-taxable partnership income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized expense related to RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r51",
      "r86",
      "r87",
      "r88",
      "r90",
      "r96",
      "r98",
      "r122",
      "r156",
      "r232",
      "r237",
      "r284",
      "r285",
      "r286",
      "r313",
      "r314",
      "r331",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r430",
      "r431",
      "r432",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r65",
      "r214"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value of warrants for services provided"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r339",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r193",
      "r207",
      "r208",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r335",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r337",
      "r338",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r193",
      "r242",
      "r243",
      "r248",
      "r250",
      "r335",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r193",
      "r207",
      "r208",
      "r242",
      "r243",
      "r248",
      "r250",
      "r335",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r193",
      "r207",
      "r208",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r335",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r339",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Roll-forward of fair values of liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Issuance of convertible debt"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Conversion of debt into equity"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value, ending balance",
        "periodStartLabel": "Fair value, beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsRollforwardoffairvaluesofliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r193",
      "r207",
      "r208",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r65",
      "r211",
      "r212"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r28",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development Costs"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r298",
      "r301",
      "r307",
      "r315",
      "r318",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r80",
      "r97",
      "r98",
      "r138",
      "r296",
      "r316",
      "r319",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r294",
      "r295",
      "r301",
      "r302",
      "r306",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r52",
      "r137",
      "r356",
      "r359",
      "r414"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "terseLabel": "Interest expense payable to related party"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r78",
      "r148",
      "r155",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r326",
      "r329",
      "r330",
      "r347",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r78",
      "r155",
      "r347",
      "r373",
      "r410",
      "r422"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock, redeemable common stock and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock, Redeemable Common Stock and Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r78",
      "r155",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r326",
      "r329",
      "r330",
      "r347",
      "r371",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Note payable\u2014noncurrent"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r41",
      "r56",
      "r324",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r126",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r46",
      "r47",
      "r51",
      "r53",
      "r66",
      "r78",
      "r89",
      "r91",
      "r92",
      "r93",
      "r94",
      "r97",
      "r98",
      "r110",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152",
      "r155",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r333",
      "r347",
      "r412",
      "r425"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r99",
      "r100",
      "r112",
      "r117",
      "r139",
      "r146",
      "r149",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net (loss) income attributable to common shareholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r101",
      "r104",
      "r105",
      "r106",
      "r107",
      "r112",
      "r117"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net (loss) income attributable to common shareholders \u2013 diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable\u2014current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Fair value disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r81",
      "r367",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties",
        "terseLabel": "Notes issued to related parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r146",
      "r149",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Sublease minimum payments due"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r34"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r373"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock\u2014$0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification of Prior Year Presentation"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from the sale of common stock in initial public offering, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-term Debt",
        "terseLabel": "Proceeds from the issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from the sale of common stock in private placement, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from the sale of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from the issuance of convertible bridge notes"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r249",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r249",
      "r366",
      "r368",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r364",
      "r365",
      "r367",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r291",
      "r387",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research tax credits\u2014Federal"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r72",
      "r405",
      "r420"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r12",
      "r72",
      "r436"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r237",
      "r287",
      "r373",
      "r421",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r86",
      "r87",
      "r88",
      "r90",
      "r96",
      "r98",
      "r156",
      "r284",
      "r285",
      "r286",
      "r313",
      "r314",
      "r331",
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Stock issuance, consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of tax effects of temporary differences that give rise to the deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r255",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Share-Based Payment Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r261",
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r239",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based awards vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total shares of common stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of common stock available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at period end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted during the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of grants during period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r263",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at period end (in shares)",
        "periodStartLabel": "Outstanding at beginning of period ( in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at period end (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at period end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r253",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofRSUShareBasedPaymentAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share-based award contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r276",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at beginning of period",
        "verboseLabel": "Outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r75",
      "r78",
      "r102",
      "r103",
      "r108",
      "r113",
      "r117",
      "r123",
      "r124",
      "r125",
      "r155",
      "r165",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r217",
      "r218",
      "r222",
      "r226",
      "r232",
      "r347",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePromissoryNotesDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r40",
      "r49",
      "r50",
      "r51",
      "r86",
      "r87",
      "r88",
      "r90",
      "r96",
      "r98",
      "r122",
      "r156",
      "r232",
      "r237",
      "r284",
      "r285",
      "r286",
      "r313",
      "r314",
      "r331",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r430",
      "r431",
      "r432",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r122",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of warrants in conjunction with Series A preferred stock and placement agent fees"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r39",
      "r196",
      "r232",
      "r233",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible notes to preferred stock (in shares)",
        "verboseLabel": "Conversion of convertible securities (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common stock in initial public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture",
        "terseLabel": "Share-based compensation expense, including vesting of restricted stock and issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r40",
      "r232",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r232",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock Issued During Period, Value, Initial Public Offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture",
        "terseLabel": "Share-based compensation expense, including vesting of restricted stock and issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r22",
      "r23",
      "r78",
      "r154",
      "r155",
      "r347",
      "r373"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r218",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r237",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock, Redeemable Common Stock and Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r355",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r355",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r355",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r355",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficitParenthetical",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Summary of operating loss carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesSummaryofOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock and redeemable common stock (no shares authorized at December 31, 2021):"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r165",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Temporary equity, carrying amount"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]",
        "terseLabel": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r10",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Temporary equity, par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Temporary equity, shares authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Temporary equity outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement",
        "verboseLabel": "Temporary equity new shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofChangesinConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit",
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r111",
      "r114",
      "r115"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedTerseLabel": "Less: undistributed earnings to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "auth_ref": [
      "r109",
      "r111",
      "r114",
      "r115"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "negatedTerseLabel": "Less: undistributed earnings to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Expensed interest related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual Risk or Uncertainty [Line Items]",
        "terseLabel": "Unusual Risk or Uncertainty [Line Items]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the unusual risk or uncertainty and its financial impact or potential financial impact.",
        "label": "Unusual Risk or Uncertainty [Table]",
        "terseLabel": "Unusual Risk or Uncertainty [Table]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant fair value"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants, term from date of issuance"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConvertiblePreferredStockRedeemableCommonStockandCommonStockNarrativeDetails",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Convertible securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r101",
      "r117"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r99",
      "r117"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.contexttherapeutics.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 3.C)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r442": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r443": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r446": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r447": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r448": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r449": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r450": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r451": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r452": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r453": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001842952-22-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001842952-22-000029-xbrl.zip
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M693.DW[@0:+/0''DE)]/IN$8QJ6YSG0>TS([43I)'.1Z.0TR'@>Q*O/^QEL
M/D8>Z&U$^./YA)TMP_1I!O;P5$B(W-!D6GN[;F#?^PS)OB+L/@68*<PK(Y1S
M%N.!L4<SGJ-2&%PO##?'_F0"Y+']'V"2)4O\B"9]9N,/>!"B,,*),.PN_Y+X
MEDL(HWF?)S2V??]X6-_=,JPW,QW!FJUMYV2!X<YC3<D0YP!0B^ A4 ^*-\:4
M@R&/, Q%<*9BF"<4Z7@R3V9[EH,RI0&&P,68A389N."(W'-A^DH[%LM0>N@V
MKF$85&?@O%(D8WGH#C@]K"V/W1^=%EQIWK-'-1^?OEEV>'-\:G/Z"O64B,'U
M/GKE.XOQ8"4I-@>!^RWA00N0X$F^16FSPY6&Y,[C8/8:R:E.]5G1@ZCAMDA#
MT(0ZC8=TI KK..8[I]\N+O[XB;33>G J=DYWM]PQK3.]>M8A-V>]3OOZFIC-
M@>[I>O<-YQ*@F/0QR1V?FCP4)4&&Y,KZ$DQ233R1,6/&M]PS'\S3PVV$+T?K
MKT>(GG,8?*)(VB2;)V89MT2*>)2!IHK5QQ\: 5=I3$=UGACAFI<:\RTN.&!I
M1FJ+I_I=JE@=US!6'8Q[SHM+IJBL@\=EM6K)W:LN+:Z4W*5E7VBVNG?P(LWN
M+R^>;;9L)&&E 0)7*4T^%6J%!Q:L7DWOB3MOK-"H/9*Y2 O++6"UM+_[R ;F
M#]=@SQ;;CE;WXK+9^>OIG89OG];3ZK*%8A-?."?X!N:XS-5]R05N(7RV%YZ+
M??!OHSF%?OTA/!43+T?1SGY#F2LFUC5/R#F+Y-?"<!/9X1N 5H<.F '7*FOT
MAN;=PV]?VHF35L192-J&I2+U[.+Q /;52'T#TGF?XC:ZI45!?<Z@W\DQGMZ^
MZOYY=M*^>F?'SY/;[->NG-GO76VA[+:]_7?J^4SJV:.2W9)K&@U$%KR3SXT"
MUX1\/D?^'O5O^Q(/6A;S<8;FK_%JU'$649N(D.]U?4-(F]+]K8+:Y?A;H..1
MUB!>.17&!/XXR%N!Q%:0PC[("C_89G6K-FF_>CLO4]6,KFRV 5;\39KWO>3W
MO>3Y(567[R67[2])F=^T.OX74$L#!!0    ( #F"=U04#.^2KRD# *G2&@ 1
M    8VYT>"TR,#(Q,3(S,2YH=&WLO6E7&TFV-OK]_(J\]#WG5*V%<$R9$>&J
M\KNPP6ZJ#;@ VPUWW>45(R1HH#,E0/[U[X[(E) 87& +D'#V@"7E%!G[V6/L
MO>/W_W/1:2=GKBCS7O>/);R"EI+_\^KW_Z?5^O?KG??)6L\,.J[;3]X43O6=
M3<[S_E'RV;KR)/%%KY-\[A4G^9EJM>(U;WJGPR(_/.HG!!%RY6#QDF0ZM4*@
MEG36M!B#3X(ZTN*,*2D,S[ FRX<OC<@\]LRV.$IYBTFN6U+AK*4]%2G2G JJ
MENU+C!QRV#OFLI19@K1UB'E&#$/22FO#8X_Z\';PAMWR95[V&,'\CZ6C?O_T
MY8L7Y^?G*Q>Z:*_TBL,7!"'ZHCYCJ;X@',R_=7JW[*NN<:/S!V7K4*G3\15>
ME3J>71^ JPAN(=RB>/R(=MX]F7K$.8V78"GEBWAT=&I9]*_?&7Z\X:[7;CH]
M[G!8JW(T[ML?'R9O=$_K+J<BWJYT9N6P=_8"#L0A_(>-3C7=_L7434VOVW<7
M_?Z1*]2I&_1S4\)OG7@9)I?CSB_Z-P\[[\*870#DBWZANJ7O%1W5!\"&6Z 6
M(BU,+F]RVZMC.G&CB6>VX%6FKAF]VK<>B],6$I.4+/.;)A(F'+_X]^;[77/D
M.JIU%3)A=/;*Q-:792^J@_'4EVW5/?QCR75;'W>7 -5.V5>_=UQ?)>'*EOO/
M(#_[8^E-F.=NO[4W/(4GF.K;'TMA[E]$6KYX]5__]5^_]_-^V[T*5&J-*/#[
MB^K'WU]4M]8].WSUN\W/DK(_;+L_EFQ>GK;5\&6WUW4P@/SB93C1%=7'W%K7
MC1_A^!8(C"(W24WU'>?_6,HM%2A+LPS3U#**B5"$I=*+%!Z>"9]]60M#0?#?
MUB4JNJH3'NWRE^M=&-_P#;Q.H=H;7>LN_N6&2TENXZT_#?5:[^P]V3G;IYL#
M>[Q^=O!.'F\?KY\?[+UN;WX^:&^]^TBV]G9.-H]?YP?O/IYOO=M'FYU-M+G6
M/MG^O'/RGFZU][_V+C;AV,'>V\[!WDY[Z_@C.EC;.-_O[+0WUW8Z6VM_'F^M
MK:8'<,W!6X'>DX/A_F>3P;GYUO$JV_H*]]S;/]]:V_BZWUDG!YWUB^VU5;IY
M?'!R<+QUM+6W<6;?O<WUNX_9P>>_OF[M;6*X'][O[*=;[]Z>[!\?G>R3CU_W
M]P[QP>=-N-\J.5@[J:_Y!,]*NP=[I^V#M4V\^?4CC/U3?G!\@O8_[^3;[W:.
M#_:VCK;7/L%['-+-M8.3[4_B_/W>>G]S%UW OQ=;7S^R+TB" %72@$#E68L)
M)ULBE6F+*\X<(REBB"^]0H!:P8A,R>\OIHCZD#1>!3UC@ZYYVU:'2TG%;'#;
MB_Y+GU\XV_*J'8160_1O$_WB&M$MPM[CC+8PY:!/%38M9:UO">0LDC*U&0>B
MOUU]O[O^B/0>F19O\]*H]KY3Q5OXI6P(_'<$'EX2>(-L'J\/OT@KG$\=;1DJ
M<(MY)5I::-$RC%,PCPSE! @<B/!D]/T ]^_9AL)WHO#7:Q2V!&9:IZ:%'0++
M6:>XI3PU+6&-XU@H"8P,++Q_"WW?%LH$PR49=/.*NH/2+DV3FX.8$$1R1PAE
M6H"9CGB6"L2E$6"0\R\;D=P9!0_!.I-W0!S_L=2BU_7TAX%NY^9MNZ?Z2TD@
M/AQ%#=7_CNIH@NKIYMKA^1?!G$,9XBU)7 K^DL8M@3/=<DHBPU.N"9B2K]"(
MZ",JWT[U[J"C77&%\)Y[3@UVTJ6*4<65T\1E.D.89\H)6O-Y5O/Y502P$0!J
M-^?E;K]G3HYZ;3 /RW6P3/O#K5[?Q5]W3]MY'\S4VM_<"=8TGA>,7&P>F[.#
M[I]'!U]/3X!FY_O'^^>;7T\88 %M[ZW2[;7#=&O/?-TB\-R]=7KP^5-G^XT$
MFOY9'NSUO@(&\/[>1SAWJWUPO(^ MN?;>Y_R_:^;YP>?UX<'Q^MX&YZUG]?7
M_/O/(]VQ[>WC3<# )\#<7^DF^=39.MXY!BRF6Y__/-[\^KJ]O_=G9W/O(X/W
MRO_]]:_^YAM4*7D8P];>X1>"K$3(9RTON03]+FP+;#S9LHXX2YWBV&* R0K.
M,GX;5F[4 !PK1D"U<(4ULUAJGR'DG/*9YIGV_AL:8 R&(U6XU^!MVC>]SJGK
MEM&!6BW GSIT03V\'EZ>\D$-PT^KYZJP\<\G5_;S[F&E//!3P^/K:@V/'@:[
M"F^_6T\WOYH41 (ZV#LYW_[\]FCKW5]?]X\/.OO'.T?;8'\= *D/_GV$3.=3
M5WV6@^WCCT"RCVQ_[P3@T@:1L-,&:*7[G]?AV5OY5N<@WPKWA3']^VL03^;K
MYMYF&J[9.E[_@C#&0DK4LH;;%G/<MV3F4(M1(QS+  @X6WKU =^F"&XDLW&,
M,XPIB'^0,9HHFB(DB:<9\H ?UY#Y\<@</O_UQ>),>D2SEG8&##HE0?!+K5M&
M$:"[$M@S?S.97TS[XX7SKG!=X\H;P@@A$/2RC)$) $(2PTTO^\-3H&N9=T[;
M(4P1?SLJ DZF(@8K%V! P..F[U$]__*A]1C*WJ"(WV)([64-OA&9[V]ECF[D
MHKDQ^I;;\-WGKDCB@-R-09TW&_^:=G"O7OQJ]-/TW4\C.$??RKXJ^FNJ[UZ-
MPF\(CZZ[/#8>IKT\%9,6Q9>/J(Z,OH\>\F)JHFZ<-\&U 7_="FD]4UIK\-^%
MX B4.8@!DT9SC2!@ZCF8KBKNU0\S0%H('%$QOE%]Y&XS$ R9^/IE$";E^,TZ
M3I6#PKVJ"1 /CFXQ.C;Z'NYQXXS>PP">JQD%[&4MBGYP1@>1GZ>GK Z(O_RX
MNW;OV4R-<3"=-N48,6*D<*GSWG)O?6:(8]5LS@D[3\WF%(?>;S:G.91YBAQV
MS!(PY#W3#N&,":94R@TV.LX FK\90#.; :N ;30SFH)XDM8)I;')=(J$LII2
M]7@S4 L&=Q@,C^JKA8==@#]B\OZF"VY18G,X6JV#7?HR()[#-6_:JBRW??1B
M5B]R$#WC4V ^7+GZ(6J]PMEX2G7'WU_<^*#QW(W'\X@$FF1X,+BB53:>?9N?
MP:Q-GAH-"]7O%=\I&ZY='WY<<]U>)^_>=-N[2O"I6[R8'OW?B2:3"0HPE*",
M-/.2*(24H2(3BGI)6?9XHNE9P7)VDC-3X,@(T!Y*4^8<U\H9)A&(32<RGOF%
M)E PHVOJ[#IPAA:20,(33'6:,D$9RGRPUZV4X#IFJ5>8++1@?SH"S4[S>NRQ
MMA(I)S2CJ5"&,4<0F+$@\[R0BT^@'6<=.)VZ[=[T.IU>=Y&HHRRWEFKD%**,
M@@*R7C$ND-!>6VW$XLNWQZ?.[(0;(R(56'L*$HYE&5<9T\H;:[$/03$3(Q)H
M%)&8%P-^*B*![AZ10#.+2*289ERGWJ2",X:IA!F4&164.RFLCZC&<D%1_61F
M%98S S;@VH'L-U@YS R6D@CPQ&DFB*"(,[O0!'HRK3U# H'*QM@@B1TB3'$E
M2<JPU@YC2D%C\,4GT*/KA1E21UFM,S!S?<8),SI3J;$<(\U28Q"E?H&H4RW+
MAJ6:7A>^EM,R;O%(H[6D*I4IE@2QU()!Q9UG3BFL"3(H?3:D6;4V#RMKJOU!
MY7:C^T:=YGW57A R&>_@=C:C:899RKCV* -QYZ3$#$N-G@V9=EQ?Y5UGUU71
MS;N'Y8+0AWBPW) Q"AO.@)FDLXH[BQ58"QY<_<>CSY-I8 /2@UJ6(I(QGS+E
ME1'8.6T NYG13V#[+[XQ^_2N">,6'+I,,ZL,B!TN!3,J(P2!"O>I6DBR/H2B
MN/,H:DQ]5B'#H[]=[(2BGPD[KSY0;I3EP(7'][K'@V[,./J<]X]^&N YYBCX
M5E)1#AJ/>YER1YFF(<,&G&6U0,!K2'Y'%9*F1*#4VM1+!II#&TJ%<%0+XEU:
M)\TM!LGGQ]U^>K)*XY@T1"@/'A_V2(%99#3*//>,"(,7D:Q/Z 8^/4$M]<1+
M XXCN"+>$86<!3,OQ=[2U('/^.P(^FC.X],35WID4R2#\P+$]5@K:B4G-"66
MB(S;123NTX;4GIZFUCHMT\PKQB0C.-.9@8\I.&B( <]FBTC3IPXC/#U5B08F
MI9)2FF$&_ID03'&38>.(55PM4BK!7$159[A,G9$0[29(4*R9SY#V8.^(-#-4
M.453\VQ(\P11U1F221-KK);:TF"*(B>M$89K*IV24KA'S#-=>''X(/1Q#.F,
M4.>,)@Q3HJU1W&-#A1$$8_8$%0X/8(L\94SQ20HPLN@V6*,]T-!I)0S3'LR2
MD!>GP2991++.B9A\>N(B;C5F7J'49\QXJJW2*C,(B.BY\Z(A[O,/&#\)\##F
MFBA%*7Q@8!F#RF!.*N><\ ;;&VLQYQ1X#<GO1G)*4HQ"1C40FO&4*4R$,QQL
MN%"83Q?2/IAK65,!;J_WH:U,'.WJ81CC<\26Q9IC[R6SW#'P$P3BW!B9"6&=
MIGZ1L-50]=+C\UC93%-JG&(B336X?6EJ2*8\11:1!:+J(DF,M[T"E-)9;MRS
M1!5CTC@0$%FF/7-4"LEIFLJP9 W:B>$%0E5#SR@E%*<A[B"$8E0JB14R(16?
M2N:QE@M$SWE< WD:]X#IS'+DP4E C#$MJ+*$9=A8F2*>+J1?.E_)!4\32^+8
M($]#)$DPE5$%8MB3+'4>U+O1>A').B_)!4]"4/#=L*1@:6-D62J<),*B#!-M
MP' C9"%E[ZP(.F,M'@,'73>.&VQ\V'Z.B"*,.AK0Y*1GFC$!GSDQ/*,(&8V>
MGW5V?[K.A].QD.ARJ0H=("T"SY)9JY7/C##.*J(9Y621%% C-2;7,13QU%F*
M/:6,I$P2Y;S'%*<93+WE"T37W8$N<YNK8KBKVN[&M<=G2D2I;4J5R7A&*+,F
M$YDF+*46"9Q:NU".^=,9$S\O?)!@@=]YAIUFQ%'!.+*(&A ,F?9\D6+ ,R%B
M8R9\OQ%JE/+,IBJE(>J0"H089\1D*#/2/4FSS@>$TH<B/X.)&B\H/$>*AG)I
MB7S&,34,*:.H!F<":? J'#BP]*>FZ-.IM87$$DDU)EIE&I1-K'PBA&,I$:%&
M9=B;!DN-UOD^YQ1IK)0*&<A,PG^H<XYQD1K00(3=V(9^7G$U+YFN3T]5H*?E
MEC'K@A'AL=;8:&4-THAE-$L7J G:?"3^SZX#&@[Y9AQ\!(4RAE F",J4(D*D
M"*A&^+,AS5,D_L^P"Z?D7(8>-Y98EJI,.:*)<BE0R*72+E*;U*<6AP]"'Y@S
M2L)V.A9;)@71VDHK,V(5]M;+10J^K3D]L6_/Z^'';OZ?@5MSI2GRT[C5QV6
M=<UU5->&/7_*O5YU43_7;?>AZ'7RLNP5<3^@9ZG3L.!AYQ2-N4V98$R#O&1&
M&T.], H]1>O(GX?B3U*^*#25FFB')?>,4I#"DHG,,$I"[W^V2*EX]Z'XZR*W
MAZZF^$^3J9WZE#H$$AV[L+4B\'1J$!=.D2Q+Y4+U@%@H8C\)9RLG'"$ZDQGP
M,7-4@1 'IM84=+K$V7/5WK>+[Q'M?XZ4+""$H\&DIBD%\B,PW\#8SL _54(;
MNT@MPQ:<_$_3;();T.M461R4N5(BY40A9;(0RF2ZWKX(L8??#.J^5"^+_LOM
M\RX0^R@_G:9L>+V](U>H4S?HYZ9\__[- [M2B/WXSE3UIJ6CWZ=WBCF%CZ,;
MW'EO*H8Y<#4Q4O.442$U(J#/#>8\%8K*JT5VC['EU_?R]G.HR)[:ONQ'$MY3
M'DKH&+&.,J2UXDY8GTKKP T#*ZTB*T8CC8WF5V3/2;8"1G?7NV@V@M<K9R@U
M1A%G64:-\JGB0"QM/4]#;=-&0[N[Q+#0;&)81GJ76FP\1QE+02$:D6;."ZZ8
ML,C9^2?'W^4#7JD7'%4E+PA]9-@:(/2KR\!."2W/A>&"8XE3A3.4TB>0>0LA
M9E*::4R5S @E+'1[,)A:P;#'WCB0.+5])^=PLT_YW2;5=.2*26$SS[DGFC&6
MQNV'O(.Y,$1*59<H8+( _NT\YO* (_+H540*Z,= $*38L(P013$.6\"GJ:!<
M^0785NKO9/6:,_':\!Y7*?I8@GM&BT,I>!M>RHR%#A^*9SIT@%!:*8-$9@B>
M?V+-!=<]S,Z]5'JM,;B$$C,!M/&4$V.XRQB55BT ;7Z$D:(=-/_<=+D7>/7P
M:P&"^*+UP7N'"(P1DJ;>2'!"F"=2T$P1,*F\(SSL9[9 T=]5N(/-VX-^?N9V
MG1D4>3]WY?J%:0^LLV^+7B>LNP_Z*H0"M_UHD?U#O3GPZ^'--YCF]/7.:;LW
M="X*@>T859RG$,/,PH(D34G&# )X,!WW!O1(4>>IS83#B[3 ^TQA\33;/*1>
M.N0P&,[@31 KD3. #;"Y>.H6*_/U46"QX\I^D9M^'8S\"%*XW-G]^!PE1JJ<
M]A(\2V0)2U.C%+-$:DP$>)>:T49BS ,TGD1J4$ $41G%PGEF,JVMY5IDA&N'
MC/>+5-?W*-"H;=+G*"6$X#ICDDJ3BKB!(<N W*$V)Q.I,*21$D\!A2>1"MPX
M0HE)G0U;T!FL4D><Q(+2##&*R0(XGZH\6NW:\$_(ZSU3;7<MI7>SUW7#356<
MN/[;0=?^G9]YYV>_57GQ2;4'@*/-RM<+@W];N/\,7-<,IP<Q/GGBU'(G0*X
M2,ZOZSN]ZFF<$U@IDEG%$)B="F$CG$6<8DE%UN!E/O#R/4,:?_PG3+ JS-'P
MO3MS[5M&M=$%L5K&,_""@%=@*YBQ0AF&F/=:9BFQWBD+<B\$2.<?O+.@%ID5
M='X.3IH7\(:]4,#'3R4!4XT)IPFQ85]'[5(LF58_!WAI ]Y%!"_G"#&CP%S
MC*482R45%SKEB$K!ZN*QN78T&KP\YBXVE!NDN$1A<W#F.-6I=1X32R1/.0"E
MP<M\X.49F9DS!*^A,K1+%T()EHH,_IMR:QG1Q(&3+><?O(V9^=-*7H.EU)Q0
MPE,;8H/:$*P=3@7H;I=E[.< ;V-F+B1X%7A&2*84&^48R80VF%-PF(Q+>:BH
M6RCP_B0TTRE&QBJ2$D/ U"-:>)4BJU)J/.9N 4R]QMQZ4@#A3*?.6H0E8<P*
M(Y5)I51.NS2CP/X+!:"G-[=^/@DDD>"$.ZU2;1A-A28A+980*Z6QLHZL/7L
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MJ0%-!KK+\E0H9!PBA. %8*)Y-)5G1Q\+4HY@G!J)4H:<UE)KQ"TG.L52>[1
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M'TN5K7(I$C:,+U;#=/>*U4NTO6VKPY^;]]$7(2QA%H$Y@E/68DZ)EK!(M*C
MG@JO/1+^.N_?EK^R4&I(?-]R9GGDVNV1_9+\<D/J_-2R'TB07T<IIQ-+X.R[
MEL ?TMVHBM<?/&H19N\;7D:CD W^@E)O/3>N99P5+6!/UQ)2^Q9+6<H%M2(U
MV=^[#$_/@W_?&2D:KZM1A_\YZ+J$HFJ[KN27P#OMD/JHZQ!72( <,=4E3X)]
MT DY0B$-J=MO#RMCWP6SI'0 7SO:J^\_@ZI9__+U&YBJF+6,%5,A&2FX%^U\
ME)05V-R-:[6+:%>TX":MJ.I!2G1BD=5*LO?-&VMW"%/;K\O?@ZT3BK54:=5_
MIHJUPJ%MT^^%'51(/1WQWH4#=G%7QQ^$TJ ;<P# >((W-2&3J_*+U.$AG!B^
M54.LBW1K@^FL%^V48(*%C(OZ:SWFD([5'R; K=&^BRD9/J2IPMV"27:-8BL+
MA;N8@E/A#F;=U-$C+.*[D&MS?*3&.SR^C8EA,$.#;EX)QECH7"Y-"TO!M2$I
MLD):SY36FCDF!$?<\PQ9DW[9" ]"%(LET!\F[X#<^V,)W9",&^D1 ;(;'[0]
MZ$?/%(@U+4"[@T[+]F+K@7"[I23@WL6;_LSBE'[)'"=48=RR65B<DHZW=&9I
M2QDNX">%!0/_!J?+,LN643KNAC<B]:NJECVB99*EE\?E[N/Z]W'A^W+2NZ33
MO7ECSLHKHY1>VW[S<7-]:R_N[;*]\V%[9W5O?2UYO9_LK+]=WUG?>K.^4"+@
MH2MD1OO<E9=;<3C[>@CW!DG>-6X/'O2Z#3#ZJ=GS,%3-&"3"CE4H]'EC-&SX
MF1+1P@030C U3*1+B0-I=NIJU^[5A^#*UPE^T[)ZW(5KE 9XYI(/1>]BF,2^
MKS&,$(*"00,&$9Q4FW,GF\Y%_0<WC,+VJ->VKBBG"E)B^/!*[4E0G^.HW\1&
M:%.IUI?IU9BM5N:%ZD?_0H5JY*JX(U&^7_L<#FY:O]GD5L,FF!Y5P"4F9-=#
MWQF'4]Z".D@P:OTK]!F;V*&@NJ8802]X*A_ '$HV-C:6DPV8E3)<A=DXU?OV
M.]]]5Z=K3/_HR8H8!?F,OB=;4<YL5Z+Z+:O=8T_[2=EKYS8)HNVW^E"]B>R-
MQ\+^"%>.S$OCB3MU!UO_]X?WJUNK>]L[^\G6]M[Z30NCHR'5%](**;.<S!L7
M0^]&MQIO-S_L>\=Q ^F^N4MF9*TGH-YV-UD]+?)V0FAEY2\GYV["Q0JA7!AS
M6(8I<I" (.7 '7+%8<C7!HMIT(XR%<3-FTJS1C\&Y/@ 7K-,0#.N@'2%^XW*
M26"N7%*)WEC(!Z,8"<).W.6Y/,I/JU"O*V/0]^8[OW__9@5N'Q1ZMX[SCH7W
M:'RQ +&^>6W6!9N^7 X!6Y"40=+&'ZHH=3CY-"H=F 15!%U31G<P1HHBN:.V
M ,$/VJ <WQ-.N7H_>.AMHPXC#BB(X:3@T$W9FY<WJGS*V0VLNM]M XN$BBYY
MG0)?N,G=;NJ\]U]7KO3T_)Y5R^>M).XOZNI7@3,3VQN$B?D;B7;K5-?/C'O+
M]JJ%L9>%"W;)F;N<B_]>FKJH?CRZO$1I8-)!__9+[FSLO_I=%R^NV ^3?\,]
MHVF,D4,.>\=<EC)+D+8.,<^(84A::>T7'->GXD5'XSD^58>NI0NG3EK1LGJI
MVN=@9BV]F!XM#+6>&1XR7A[PK;YYMXG]D!YGE]6[-=796WW]?CUL<!QW^0S>
MWS.U]\B*Y ^PN>6*H#.W(E%H^35A5EPQ%V\Z?$_#H]II[%M6A_</XY7_30/-
MW]7<C"4Y*D*8X!]WD$Z,\I#WW'?!$U1%# "#0P7*VK;>]WHGL1_JR#LM?W^A
MKHJ/V]/8[HB+RAI]1.",QG</.=9 ZKZ0RO-;L-((DV=,^90LO=K)RY/DK3+]
MT.AHT %=.6S$1@.>NX$G/VO$QD](>5 8U0KS,OCS=E#VBZK]R':,$X1&%XT(
M:8!T-R#]C02Y$G+ [(XAW1^ R1WJ7!X+L=\196YDZMR,Y>ZL(,/^>=4ZVEQ*
MS@7 X95JK.KY5*QP_JV4@ :D=P<IRY9>A17>!*\DHVK1N41KH^?G#C=XH?R$
M1I8\-"8H'LF2U95D(@11CC+6&['20.CO(42S1JXTH)A:OB5R)%E>KR0?NX4#
MTITY&U9%O(]I=6%EI!$S#:+N@RB.&D'3P&(*%BRM!0U9"6G!IX$4KA$L#8+N
MA:!&L#2PN *+$!6/@H6N)._=H6H'\6)<[(W>!%P:"-T10HUD:6!Q%1:DEBQL
M)=F$BY-=Y5U_F*SEI6GWRD'1V"\-G.X'I^<@94@C9&:(BBP;+64V:YF-+IQ;
MF'):Z\)T9=0N(Q3S[DQVW:CWIE^/'2R6X5@[%L!.5/7"I?U^*.X-Z4_5#J3)
MA[HZ*E9G5==.E/DV"K;!Z'TPRINETP86T[ 0J!9=V4KR_^TX&,J9L_]_(U(:
M[-P-.XU(:6 QG:$SLH5XL(4F&J:&P,"@ZD(2#)S5KFH/RSP:-F_'[5#?]+JV
MZI0<SMF)M?KQE.U35PVJ,7H:*-X#BIPT\JD!Q:3:HGBT)L)75Y*_0C>DO!_;
M#429 S^T1]\G8IG)JNX-^B/O+F29-7*H@=Q](">>072SD40SA(48)7V(E0D+
MZ++B/HJCW<'I:3M^5\6P*8=KH'5G:(G&,VM ,:6&<,IJB2-7DC>Q-V3L51;D
M#)@ZZK!PM>3Y'+J2K5:[1E2-N[JCKZ/FS)<2JUGQ;<#XG6#$*&V$5(.+*5QD
MH\02">Y9Z/M7 /FCR(FI:[:1,PV>[HNG1LXTN+B&BU%QCWR]4G<;V>A6.Q?
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MQI?WD'?34>?LB@1L/:$(C/C,?AN]RQ-8\U-S@UD(C"R]"FRN=-[.*[,O(-/
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MS2U4@#?.^*6_SB! YP04@%Z9]JO>.,"EG]$1*=\MM)VFY$GC0.4-<($72XX
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MP-.)<]UBAZRH)?GW\$(__%'9W,/H;[$A\V4@70E>?@=X[AJ=N[KHW'4P=;G
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MKNF0-1^H!2*3[V00["PW"'8:#8+^BR\S"+;ZNT\6/',A3CA88")0LBH.YL2
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M.#H[75(M:JK>ET\7S%F(L.6 \UY5'MF$$_Q'',%4AK+&8=>-O@HL_"8P5V+
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M1-1\(?5>#P,".7E&_\-X._P; \>U<94%LCT;4E%-OF .;2@OANFLZ ](DYA
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MUKWH>J^31+B(CM%R[7"$8D'A@"4[V'0:;'N_AME_R'(1I^A_@_2O( X30XT
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MS3'&AUR*BV*0SV?!>B%L0Q98/JWX+HF=I[H4H!_B57CV(Z\"4BSK57B3^J/
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M6CT&A.6*:9TOQ/[?=:UNT^ -:_48]/3N??5T\YGX?MKX!]Z;O2>R-4\+Z>B
M1Q4JND:0?HMUO3P_B4<,']W[2J/H:SJ&/,3,7__V94;10W=7>7Q&T=^S8BNF
M1GI[VP\=IWILFG?["Z,7*Q>C>()[\Z61I97;FT?2\>BN2LS/PW$1+!;GKI?N
MCK4S6VS\[/QX$2'O9^]+3:!U7&@U5VS%=,;6]I=Q:_S P8?=IQ)]>()[T[MO
MLG15]^9I13 6(T.[Z\C0WV$?_1BUQ60CO?2NBNB:*P_C?%UM_+G^/7_<N7^/
M.YVMW8<H_NOU,7C3:P!;YO6V-[VLX"8)6=GPPL]IRU$W5#802;+ U![1E'UI
M^4.;-?$F@1_ED[EWG40%76K3:D,JCKB@#45K)!_&$^^8WC =!*D(J:U>V^MO
M]GM=[QU*F6=X3UJ,4>^'TF5NMX-B7?2NJ5?<<M4>U[2-4'1+LD]*VJ32E,N]
M]*4H3JOT5= O,&*>ZQ3]:;?<1/>O*/0LVYE(53+Z6$S'7CCE6E(N6XVD606:
M%PW]659$0=<[C-'4B(5&92)>J[<Y'=.\=^@ITG^!SD5 QV)4/ND/>E+35_M=
M?*OMR?_E@4BE6W^3G\;EDUK K(LB=:_RL,Q9M;*D3[NXF)W6]])2AK&4F-.^
M<.$XPR)0=I8,<C^4BF<42N,)=#[\L1;9_F'G/?&U[K! *24>$8\3E!!J@3C/
MWA2.HP0[#+*N.6,[O,ZO3H^]%K<6Z\R"M#/RYQM>*%60=%P3V@5>.CZ?V/^D
M2.U;G'XY='0B/8S==3^+Y:*MM[_N9_'M:C91UN[T,-,33N=RF*2S))4^3C&]
MS[WE3[-(L[?5W=]]+$6:_>WNYNYC*=+L[7?[._U',MCM;N^.]7D//]9'U;*$
M[M>+S=WO7/FH7EO%G=E?%!P/6@'(1"YG:9(G]$8C2UF4/L!H6A?,2G%W&M&G
M6FTDVW+,M#H_<-'5^Q]X[H?CX >>_3$[2&S PNLY#\;T\!_Y*IS$HQEY:7GV
M38!8]ZOI8!.^GGS[G%9[P)JZ\]Z+SM%E9_,[5X/]*+41%TY,Z^Q73[C?$%]*
MR4E;$MAQ/+3U'GR+_%+?^T4#AU?!U*?ML/'#QUDYNG(+_&+=>>1;8L&F8S<6
MWO:N_ SA&_DCJ73Y1U_^PUV%/1(7IJGU59)PB])K!#)I;IF_WIQOD;;[%1'\
MJS#"AF"):6;!,&]K@/E[P)P>LP'QI>7D/V9.F)-2'1F5,.]V#/6N2\F;WR2=
M+$>#;R61E3313!EY@T\T=*8-!>5A$B.OY#)F,M4DL_0A)>>GH1^W(2E '#L-
M\C1,Z%[Z=*B2H9\.PYCFM=[#>U3K"<6PYW ,B[V1M9% TJ;IU>;1V!+)7ZY7
M^KO;&S_H:G%R\X]SSF_VW1^VW!^VW1]VW!^$1ALYYO\Y7J_[W5T_M@O:WOE9
M_[CMG6CNN4UN8-M[%2;^M1^2B ^C\&N-AULJ AZM\=!_:)OU$1VT#S 7;K46
MQ$#HJ=6 H&"3T1#&%0IC,2X&(>!53(<-D :TF?QEZ O#,[H&!%D(?F#&N$"Q
M!5^CTW[,3=S:=1>W:H0A8&16=KVDCRDL\9A6ZRO-A/52?Y%E0.; .G1@61%_
M/_0J>?0OZ(7Y8QJ;#0&$6RV"&SH!R0UG(F:@PBIB;H8 U.+:Q+^/S+0>_BP-
MIWXZ7WOT:X_^NT>:OE;M_IC+9M2N<<777G<E1ZT\[M[I^^/,:QU%21:,UG7O
M]U[&6;F,U795\.N@'#3R_CT"[S_FPO>_>YC]QUS7M?_\MRKE'W/9/J^4GTXY
M+)V,EQX7F'FS(/5&_OS .SU_N8@#._#.?GV)"&TZ]8?)1WH<;1;]DC[;V*#P
MP/N?8Y3*N@_^@SY<+_>[I2;VX4M&-_>0 >#J2U.[Z9FR3;0L3/-Y!_WT; UI
MJ]]_MF$[[26Y'U7*-K7P+PMRKQ5[_^WUMK<WN/EB&@;<[!6=:7/;T"B8!ND8
M__!' ,T$7G"-GUJ7)X<G&UWOT/VM=H^DCW.!ZYPN9XP0.']=ZE51H3P*KD(T
MEL0=G66H6*1)<&]$,P5W.-HP!)I+_KGMX=V9M)?D%XX"&B7OIJ\-)+6 D8V+
M.*%QI%)$F,1F(*,$6")G#&A7BCY]R71*GT(5;,<\4-X7QL.HP*FY$A*DMN</
M$$) 7>/,#V.I _61,!BF#%LD.V?L3Z=^9QP5N3^=1ZCHSJYH<3(IU"P7SE^V
M;CR%49CQ ]T6J/2RY]R9,TQ2:<VH=X#>6JY?6X>-N3JG@/M_0BI@2=K2,].T
M_K35<C00% N$D$!(8B"+SXC-X<2/QU*1RJTF4]AGHY#K>.G\G1R]R3;:WC6J
MN?D)&<,I].!%_@!U=TDZ1ZEZ$>6W-7!=6<GU)*KHSS0V4VG2O9(3^UPS7=]M
MQ5WMT7U+2*_MO0HB5$F;.:_&MM" RG#C0RPH*#CZO8VR7V]ODX0%+7#-;3M!
M:UGN+\M,5;56IY"&OX:=W3WOIW^^>+&Y<^#U=IYUC3_M<!VHL#85\K139>$Y
M"LI]=$-/(9J+5#@0RI;>I@?N0%K^9@4IJW1.>HE;AK,&,YJP5&F,4,R86X"$
M6A:B@-<TXZ6I5EHI9P49CUEV58A<-A7%W+=72]QLIUO^+A?C9_Z4:_9;L.8,
M*P IBOE?X -XYY<>,(1IZ@_1V)=$]U!5*%HH>PA([[Z0?LI>7DPA0VD72?-W
M^[2DO?V]@^FT[4GD^M1K;>-5&,N8]61?W][UO/=).2E_. D#IICPCHZ.SKW6
MD.Y 9S@?1H&WT B<OGS)+Y:-)+UBU,\H$"4W:O,Z9E(&C;<;]<=T [OH,L[]
MP9V^XWBZM(>/YFCS3=,C?87+RQB^8F;?0GLG;^;6X/O=G1=T@BQ_1LS]=W->
MN 5U)4J*OY@,Z")<RX#D<8,@OX'%4=^NV7_3VFYMT[1?T0RX-_?I+T?>V?@<
MO<K<^1N3PK!2R'/-JGBME$RKSF9W=W/CCC/D XBUULMEWNN\4^_1_N8SK_7^
MO[=EL\'$J+_9W>#I=G;[7?H%_OCSB^[>L_J"7X2?O-8N#LNLO(O2^*-JY66@
M(8$YR >*Y@$#:<W=L%QP]C?7W W?9B75#!=)UH/YV*^?31:4,$HAB,E3*%)K
MB(_(J)DF!1 C= G>O+GT6E5#W',L\8U28G6MMY$&>!=K!GP=CSF\H,?X&;JU
MPR>E6<=)XV.\9,CA-N5;L;'/Y;0GC\AF)(</ZIW$_KD-*KXK(XH54W(UC>2O
ML"7/%#"FUN,1#;]8&X^+QF/OQ894X5@+<J??:$$B "U*SW54^YNUCU4,2\>$
M9!%09O+A^5^1LB'E#(,Q<^BR'..RMXG@2=O;HO]M;T*T6'.3_=3%\D-%^O[/
ML5>0GQV5;CB]RKCFS-:4)Q') @&OD@T:1<X\,-1)X%_3BM,#@@[;H\'H0#UX
M:YXZ@08>1TRV!"R9C9=DT@33Q%B\VV3>D4'0[_4.>CURMQ=MXE[YB3WZP""D
M$S .A\^S*:(P4QKKL(@:/][?D& &"<,P:?C[%B(_))_';/;2=C5,K.8-E-8?
M66UD=B)T09*4[E')6,=K9(RUMK=7KM[$'WD7Q^X9V:H=D8MCNJ1<#R8^@^%/
MZV][4@K6(N^CF71O0\(_<<&Q-085AN(-T+S!%@2C:@OCP9KL5<VIMO$<LL =
M$U."J>M1_0NF$H5@?M-$##DJ&.Y #4X9C$)2287!(!PFYDAPT N+#LXB.M<N
M;5&-GPVCOB';WI-3R=8=]I2#+J*<X%G0BI%SL[@R]&=G5\VFWGHO,? DCISP
MH0VA09@D1=:HP]]L>6]?7R*4=*U,<QR8W#[P7H!8$X?5S[)DZ'# -07$E ]-
MUM:'37L=!C?*O^9JY3(":"7%2^648ZXS*'IK$N#>1&%:#,(RL#?::"L4D#]/
M@Z>)#6+:"C_2F[-=_KGI^UVX9"8DF4W"&>_6%7(6UC>IF^+Q2$\%,_216Y"0
MMQOPDQ;7>T2_F!@!J<8]>4ZE,4)+J(M) ]O:1'"<I2,ND2Q-"\<\U% =+7B.
MA?:R>3Q*DRD)O@+1Y8HLC JZ?>6IEEFR_*AX9@L^!JG302$.)#T1FS@-X+Z%
MV11#(N^8@=<RER&J)D=/@\;R,\;4FWD<#$5HJT65K>:T;Y^DFDVG<JR"C*2,
M""Q;]J]*FDZBJ<.S$ #863CZ!AY04R=Z9SBMD$"2YL@"L24PD%P'?[LJ!]LB
M1'8V]8I6F!@3"<&[U(:^L!V>:6D 7K28,5B\@[5S;GWLP=SA181X;_TTS@]Z
M-E 4^P5)M[;),PB9)XF)/)SQNG'PGA6!65A>2+)HMIZQ$M"E8AVT\\P$S'0Y
M%U:0WYE!XM"B,3UE5F2@EX0843E+K\_)DEO16W?K\7N=#(M,TA^\B[6#U(K_
MN[>U@=33+)FI)A6=XX)2OJL9UU>K:E=U1QFIQ&PR4=16*&1!SE8.OMCI(;RT
M:&?., ^R9SQ;@N+2JX(C-\P05+VA"Q=$R<U]]O6!R!R-ZU7;OM&MA+]WBQ2%
M(!9(AS27./_40>B[U]_J_;]Q;[O[YVS\#SH,^=*_56-?_=W>[-.7T#KN]O9F
MGQ  6D?5&J)JO2<757M<)LD;DEQ%E&2^=P0]*AD!3:M\N$8&\?&IA7).0[8-
M)/+>>G-T:;$3"4\M!#-SBOP\?"U7OSIN#XDF?8(_'))%PJS17K\CVA?:Q'QI
MRA>*O@G'DM,E.5X!:V JZ 7U\) QPO]F9&%_XK^1QMEITZK4G+ 2W&>TM7I"
MOUWP"TY^>XQJ^S!BXPI+1WMB5S<-FJ$^7NOL?,,3:7<=D(&'!02I]@#DXSM(
MAZ2P/7-\.7:^=N)\K;:5"8F16*G0G>]B3=TQX&7A$)6?.!)DNI&/-*6'3S,D
M#R=,[:W.H7?MCQDO0JY.()B,U#C1#$E*2=]G7>]UD>($(+GJYG_";"'M=)-P
M2K3(R0H54P&K90Y(UUT[-NU\C]2]-PWS!+8$%ZKRA*YHU\3/8C=L6N3BFIK)
M12%]1\Q@.I$D2C3*A>/MV#-!@<?*"@7#D$<-\V>(N!0?99\^3>,Z4PNE,^!,
M8<4D"K,FZ_LJ3#.QB/A^6AOI*G%L63WYB^82K6D2T=2QYF[0@$Q>Y\-Z@=KE
M _/Y3'.+DB$U-/KN@-L,OYG0#BO'N3$!Q9P;SNF@!:#3#Z]-AII9UB_M)=<+
M3&^)$^_U\:%K1F)^SBZZLJEMMJ[MA5=(U&FTVL9RE&[]$5[_-[16ZN34KK^L
M,_H4X"-ME9]D\1:2KN'OV$2V^?0@2H8?D=JY#GW>KA(L):@MVF]SP<TYG/HP
M\9/K<(1[XQYP$R/+$^>JD5/6W^SMM\F#I\'"T[J($EJY7^D$TB+0P=.LR!$;
M4TY; _K0J>,0=C@<BC/C7?)SZ#7:5"&H1/@6VQ:((XU4%$D&.C\B)+""%9T&
M8 /BD.8FP.TM6PW4XY^/QCOHBSM@&E#0BI>!!<A,D1X+J_'X;L?KI!#$9-42
M:-:,1KM!1?Z\T7 8((5LHD8EJ &5: 2&'Y\;G"9_';$<^WJ];UAR&WG'( ";
M4<GI"NW[2Z2[NFP[M[AL.XTNV_;NE[IL+Y:X;"M];,S>][;+W6OU]Y]ML$!8
MR *8G,I"/D5TSXX%D?I.#**UN_VLBBE6>) Q4+DI"3W,9'Y(>$X1'/.A [D>
MUWE8#P]+@ZG/V71'\[.;Y_7Z'DGX? *%FD  ! (,<@+.GPW-E4U90NP1?<^T
M;?FR"%]3&*_=$,=;N 4/TY#HE:\:P(URTHRM1<9B%68H[M\(1C5L;+_"B^*3
M<Y31R<!I@<)B@8(F.Z6,@B4,*\B@M*U2X^9 SK/*D# +GL.4K,]1\,EK^3'H
M5;@1%H)E],)($G&TY3%+OG!$)]%/:5%R<84FX8"L77+3#A=_*1:%;"\97]PC
M)]=TBN-7C1M]Q8%9-5C4E:Y;&1Y2,6FQ]1-H[52MR0DMOWZ6)GMR_KQJZ6M>
M)G?<D:[W2W(#5 H9>0R3QZPKKY7$9[E">FDR'B!'P6V.2<+C_2[YI[" 6%D
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MZ&:SCE<(@;JH954]) .)TSQ>8 TTU^0$$O#*=%KP(9AOD,4AL6'J;W;^6WJ
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MB"F75,/C%/K*AW<5PLT05F6)H!FK RS"0'(DFIG]!8R(K(9!03Y+ \+L#DD
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MA#?%VR&JFJ&A7/HB+]+_I_579AR=T&=Q:8?@&XU4-\1I-S :R<1IX]I4H?)
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M&@WUC BTZW0:MA;H[[ ?FG[;W4I7[G?9GW<SXC>A0#URLSGB/8&@J#F)4<@
M=RNRV<\@R" 9AM>O+Y]=VNWO=]D"K\Z'"MW"O#]EY""?S!Z!G[;U0$2[BH+9
M!5+QC63]4C%FOW=B*B0]DK/A>2QT=L(!$C79DXS[46;9WQ:0F?9K )FAC5+8
M-LXD17_V!R;S#E'-R+]PXT [093J2C"6J*0-VFLQQ3P'-X8-QAE"1;-(S25Q
M E.R1)9I'2^7$C,.$EX%"19<?).%ATWR7N_R#[-GO>R5O]7SEM<BFVVCT8N3
M,_]P-L\I*=RNJ5EPZ-QM\QW3*N!,"$XJ/V)MZ;+C">^/=^I0+9-0B"6N=\8Q
M4=Y@AN(PI(TI0"F_3\3*0B3*"7"03 W*;_0H0DYCDG:21#X7LIK9C]7LN7=J
MR:.3U-67ZOWF4K4HQ#-[YBU -_M;O[P*=!4_U$A&5?%#_OG>^:G@(@8&G/XU
M>9$,-15INDU=%WU,;AU:T*&MWK+?UI  )5NR<GGDSTR6&A;8"G1KRD5&J:^\
M%9^>$_TZH@<6!LH02,@)OFD0?_!D<UE U)18,/Q\]M.Z*-VM8V#TQ?U'J[.M
MEB]F[YI^LPTUJ4M3CQ2K^NS56Y6:[V31RDCZ@:7'Q0;#!RHJ;:)LU&G8HZ(N
M@_E_^ICG_Y8'5SZYT!KD'R&PN7B;<26Z[-S]FF]IT.$XZ]WH)M_N6V3]=DVT
MR+F^2'@Q;'ZD1HGXI^AZL1NTRV#'.G^ND:\JDWYP$^@>2):%W\1J./"\/Q#U
M+3\OI8[I@F_[+1V>\JR3G,I^&S?D:-&B;:[ZC:5\YL$0QI869;OSF5DMZ>5E
MG.GM9##\92C33 ]TD05NX%4AC<8Z5,R;X-W7L(3*?$%ZLRA](8/#Q'F:9Z;\
M,)XH)AD<G=LB@JF66</BC*M:G,J4N<DTSRR4N8OHQBCA$:UM4JP.UME_XZVK
MT.N ]<IG<YAMX8",@H_'=\Z^BZ>=I529LVQKW=*YX)>=1N+0!>_8N[%P$0-A
M(<[$-HLNG8;AD0#(GTWT:U Z@7N,/<0;K#)_"O,2L";7^%ES5[E506[>,SG"
M>)&W<4;%!QU%0X!OY$FT[AVR!:NVA -?1-7]Q9HK>%C_CO.-B^:R7O%I_XRH
M3%(-.-\-&4%;-;)%4-&0-=W5-?0&I#>*/+H.A91@_+2> G9_7JUF!!H.' 85
M%/C?%#Y&PRJ4W%%3QD?#C5(HW^FZ\%GUPCRLG,WS9LH[Y$+YR(F(4-=*6'B$
M*H']K@>Z0>X/35LH"\0;5VSF)-Z#(^5!OMUA)9M]E/C<F-9.X&PS '!#0U4"
MS0TUY<:?I /ZI@#:EO)]T-@D..\>1GD<22-A"CODDI6([#]L7"BY./Q=Z&:*
M89FZM"F@RF9C0$:84\S'42YGM!IP2G$L%\KK-J3C,:N;J[R2,#5034U80G;1
M-$_+<28.M)BCU&B/0HDBY"[)<)Z=*G('*G)/3A6Y3S.2:1NN +T6D>I8,CR"
M$QN A&SU)E+H"Y<V( H20J>;FSR*OI4NCW(7%9ELWBEH&4BS,)Q"^@OXI2E+
M$QT-W3.W/O\,,2XB):[E4TN"D!TR/TB@"VV[7N5N.-H8D'^&?3H:P=1;^'&Z
M35=IP.><G"?C0\8HN2#!]Q82^Z5R+V"W[@)4+F>/AK)#/?\Z'?#@^7':GD81
MJ(T:4CYE7D&[B)2^@4'S#UU-&+3@U"_EJ7C@2.(CGR*\9NT49D-CZ1(MS.#/
MRYKAC!' JISL:C]Q>K!FG;22)SD*<[%S'ZL*S99]['04S) ':6@&T.(GSEY&
MA6?89G9[9VV_6I&WQ&/9.):W8,E2$.;3G:'TT.MWB($=KIAUO"Q#O:1RVH.<
M\\?G>KQ3Z&D\CK,00_!(@!W/MI?;)B%.+JRI1<^:%V2*2<FKJ%)P./8]Q3A^
MTE23$(+%-%,1V7W5U#<=\*GQ9GZ5% '3#:N#B,46[7@5"'4@PI^T-)BN, ,!
MCU.+5+.D#5A."_WR+26%HYFXI!JZ?,(X,GIGJ=KFM%.T:9X&W552X P/=NVB
M:U]4@YH]ZK"A=6[/Q>^R2*7,R^ZD\>(^G>M(NY6V'0G"<+K##,N>T%.SG"/N
MO<1*)G,V.-%(3S!6UMUFNP8HES79HK\X*3E%>#NMD#!L8A1_AP(*VR[7<HM!
M-3RU[*&%-8@:\(,T!O>,LB[]8)S]O5B\G^>+]TQVYRV\FSUC]L,C;06:BK<T
MD=LZ$GL?L)]G YI<+/F4?W",W$@90=QUJ+4:.&*$4U!^1X7=)9^CAA@0$2;Y
M, 7J(FX$0[0]U!]\!K^?-_<KK%K_ /]WOME^)_\LEK:M .<Y)7R2%/9]>A-F
MC]SYU3F/YH]T#"/Y_I+)0@AGPUF8+[)]5_Y;WU)96E_^,G0 _$554$?HYO%
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MS9N$XM>^XW5#QN!*U"0,4$?*J3XV98+,/CJ)Z<J!NDW=Z?*E52%@8]HFU4Z
MDELSL 9%&-8)GI&)N-A7NA_=1&;"3ZIE%Z%>IL5L>GKSY ]^/3Z3#(*SVCG'
MMR1_XCH^1?SZ0A8A@@*79 98?L/_X[E?AS?21'?IC5$)5B'VU\-5)LR_7U5/
M'C^^H$"5M)7?^B#"==GL;5_XCS_]]N*K#'FFV?]%/PT.BLO9Q;<7CY]*U.,C
MI>V:XE&I-?N;/'KR]3=?S)X\^>KLFR\OOI;V<,W+5'Z2R%@Z B[,VP(R(K.;
MFYOS!3M#E&/+MZBZMOYW&TZ,6#B0E)0YJ**EK1<JN <Z&<"Y$*LA.PAU 23
M20YV=O'X[._W,+</:*&@2A_/E!6E",@79$*>N&@$(/FR\E$7>(:XN<P_2*MX
M2;BE3[[3C[Y0X[#O V^_?S9[45!%*'RB51[753(=.7< X4CG+\1HUU_%9ON
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M[ A1OH,18#4+QP[E1(Q/^B;ZI#\&GU3/'4"1<+J,ZRGBT;(L)/56MD0E2C7
M@$-(N%<*3.[4S+*C$]WG23=YVJOF;@ AU&4W7L$F!"X3]V3/M(?6"_)I)*GO
M5PH5\_'$C)10"&@,*D* *E_5N !XT@C0T_L"(N"_5E-Q+QN$"O=XUX3%+B*K
M#-+#</*7NR"V)YH4E!RX5@9CP9L)8TA(/)G=QM<7!"HGD'=^@PG=!D@-4];=
M'5V")YGS3^\.+W+5&,2V (K:^]G+L[*NL7C,0N,^3M[]^R:3UY# ,710Y1W
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M25CU B4&V&-U5KU*'4^N )E0G%ZF:>F0<0N$'VK0;M:NPM,0Z?8]K9="'>J
M"OHHX_7OB6K7[\!^!0U!.Y4,&_53M4\^L&]O.5VF9S:LH#"UNFJ@RDBVCH"Q
M+#]&5L/'>M=^XY@[Q&FW?)1FK_@+'%@&UE4;'F(F13V%@;EU^K'AG<@7,&]J
M>&5ZS]!P/C-.>!OE.P8^WAX';V!2N)V\Z2K)S3.39*Q\*>JL%Y%ROP+\+[QU
M;^@Q6^5PL+G'Z5Q],'*XPPUMT4@E'Z\;5$850!UGWZ1WS'FDSXPKRDYGISJ"
MXVNTW/=5H"5=NI:FWALL2V0*8++B=0\X@@,P>HJ-#C?]**GO!^,U*MHR#YI
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MX/)0NY?TATN4B*<:?IF %12$:Y%B\9=7KULM4YS6WJ]H.BQ/IV(F_8G0KO(
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MKQUQ 4%H#._25Z9]+W2%B:&3WC%P3@U:P_J*<FP@WO*G"36&^&^VE*/WYT&
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M@6P2)<4[YW9RT-YDKT>)/S&V0[MG%P=6<./ZIQ?TCDQ2GE6%XLX0_H 4LEA
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M@T'TXV!='4[7K_-&>_C 987MV#BPWN7BH, 7H@8YT,#!K9[-\[H&NQ1=:NX
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M';0>1,= 7ZS:!CV7\1<D^3NZ-[#,=R3_NAS<R.+1+-)^Z:@;1268&3<]#MZ
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M-D<OZL_8;F3NEXF;W:BH%<%#FFKCHIJ!3@J6 [PB_0U61G,#JX<M6]ARAZ2
MC;<Z9NO,N82C)[E__Y0PV5A&'ZTGKBJW3[ 4\FY]6B;+U*5 *2RC$:XNSO5-
MWQ<I =A"H<$;5X)"-G"9-(8P\0#7HF"T$MJP*FYHD5UDB?HPOT>YGE=J,J+0
MT=+/:I4=+*_.D\_' 4KA9_"$5,!C-*XU0!?2#TG/4C,U&YY5"3)X[UV[(!$G
MJ]SNP5-9[D!9[IM36>[CC*1B,R*A)^SGB/$7J^3BZ<F5NJDSOHZZ5$JEK<L[
M6#0?]G9U8L$VA26!"L<0LPUH6?WXK-2/X2W\2(T?-@7<QD5=,$A$/?2%&W71
M14&I2;6OLO1#)CD/[*E\5;Y$8,_HTI#Z'_F)#)@TWXPAN> G_&AV35OO(>U-
M</3&2.C5_C'J($PR?,O$KXMS&YQ  S4_D6O=9V=$DL87;PBJ*2'\,(ZNJ8BG
M5(F1&?Y,]SNOM%,WTGU/GO('5N*$C -963TFD!]..;JKQ(5GYU.PTF;'QL\D
M>_8TU_>^4;OYQIX@"MD/>S%1)4H]7DIY6BJ!)*=VFKK[)\*2_-1X F3"PEXC
M44?%ZP)Y&U*I:%9[P8V.7O,TE?>]"V,?'IRX4%ZA"0N5CIXC3=_[)]K\49H1
M@;>.>?;'C;%4C&*2B_%(D0%:_.!3]^BGF/38*V7F/-K@7HAT?)')BY5VE8IV
MR/BB#+)BE&R-2'H51JMML<U$<)$BP^2RC0M1U[E0,B,;3\CK'3/C4 XWZ82(
MZ9J)#L.^3M -R9LCKN,)=BSEFJ$!BTTYXWUD\=CY6]XNUF>_YN_]0\XN%JUV
MF2;ZKN"JX>\H<,'*HM].74Y:*4GZ1"$BQ-U-#QJ(E?'L?D_%RDA?R6%"C2M+
M(V-9*I2).\[FH?'VK="DA5V(:!QPY!^>7YR%[MAEW5U*-Q#A#A<Z&,Y["&C8
M9I;:WC(),K*0;FU:[AIWELPV=L[ANQH;;(@:UTKDU$Y2WL/F( E$*-U)$QBS
M#OX-J'BE7;7@R<""*!C3&EKX!.JRC(+5_JMFO00)^ A*&RZ55).4/C8F9IL,
MF#2B36RRN)^>T^B_JJFU_IEIU:+'%HGEM_35UQAB?B7:=?XQ'G[SYZ\R+37T
MMZ5FF+FWOS$K(7T0PA[NF$;9VV?NW1-68FGPU*9P0C'V&JH)?9.(H:TLXWQR
M1SOI^FT;7"@&F29G<AD<\<;\OJ,#T=_>[U# -<<%-<=64CIC IFA0V_$M"+7
M*C*]EB<LT\;*S+9!U&[A&!1N[7]2DV4Z$C+816DUI)8N7]++^MV1?C1 R=)V
MT:#<-,I-HY?0:,6*51D"WV.<?T,'0;4FS93A6 J#G@W:CM._)U!Y;T=+(?W[
M5^?-@I;1TU*65DS'][W110IG:*["/&8M-..WS*RIEUT=<#Y$CS#)""*EV;P-
MJU\U[TA?FD$%:-YTVN0PD/+*]^'EU';'XOM(U;2IO/VN634N!EE1@=J_.ML]
M+%,_79W4@LTJ-/5\ 3PWW;PA'(SW2H[2(?QUHALJ(F8/"TQR(R7U*]-2N*[J
MS5'Z33^ 9C^+12;I4XY*,\%@E:."("7XK:/7.S8PL:/&7V%=S OI+0AM.1$.
M<'#0B[*O"3K=7"/R@=B^LJ&!=B'N$N2"QOS\7D]!VQ<C'3KYOUV4=.66D*%$
MW8F>8EH>EIH2?/CH31#5Q9.C;*2CKP>UHATM+$91MS2D8@;S.#FR&=-B$%;$
M<<\2!['>9B5F9YNC(7SB7J5!ZZ83%_ L"<_G>? .U0:J FY"QN0OG=*#AK8A
MQ-\Q^#/=[$:8-B(:F)^,<,B)Z-V*E=F9@- OWZINS3$NQ8)D&!A55:-IS_6?
M9_ (5(=L]?38"KW$"= P;;^>/C@!&C[.2$)6SWL+;5W1&2"8UW$S)%1)<:LK
M^Z:+,,=DWXRQ,AXVEK;C/T14R&=8Q8MHZ]PV,$JP W2,I_%/RF/*2IBP$1"U
MI!WF4LB:'S!O\+>L$A()0M+#^Z;C5 ^TGJTE5Q&XB%FS;UJZ"2$LI.TZG!$9
M'RX+'ZS61$"FLF!L0IE(+7Q4#LI5?J7@0&/D0E:X&?1EWB P:$UG\C1\R%LE
MOGE1F3)OI#Y*2=K>@24\MH*N4'4(U$OTY%80K\<+SYUZ!J4\XH_W>T<FQ"D#
MJ=#Y[!6%_XXF-&$-' 874S,J;Q?9KHSW[O_6R$#[+>+J-N%\1'=;VTKV'CM,
MNE!3 G;-)&9R*R)=M^.2M]SZXS_.7%D]AJR B? _,HV6]%Z:ETR(ULP%:5T1
M>$*7OSR!#XVJ=R-=5GG3T%L*<Y<E6S0Q 1D6"LKAJ^SADG6%-@)<TQKP1R?4
M'S5SL\RWRC<LI65J=05I^75>+YWTS)7[S-JVA.8X<I><SRZ@8>U_V@AV>X0V
M\D:'6<01HB,^Z%E/0F5K7HR,9B!3CI6YP[6.(6[V*$/$M\G* 51K8NF0[^PN
M>5FGMH']R(2\=*3KE^'[MGM"6N$$K88*0UR#E5CX<>Y1ZG3D#)B_OS5NA[8_
M394JC[.A0@G!VVUMD#!'[2!S:>M'P:Z-,EI)_(?'E6+N1&<JG?7YAC\QX.)B
MYOB>B1GM>->=P.;B&)V"&T1MM8.7Q6W3*F+0VS8MLEGLTU@BA!L+ZZ^%BPWK
MFBVTM)':!4Z=0TULI90:/<]!OSWRACW GS+[[7SV8VRSM\=XNL/JD4<8@?G<
MY ?A :GZE2]<)PI!J;_ X,\M^1F&TU<H .TCZ3;-5'>7FQ7JE??@T&WEP_WB
M2GIX:^?>YVBY80_&[\4SI$@E\Y_Q=X,1DGH 7FP7^C%WQC\0#C@X[6]>O7TI
M^[.F<F,5G<*:;TFCD=!H'N,&(6]5N]I4.3RT+'F[NMODI27P[+5)K6K.J$@'
MGZ:*-G;Y*39W:&L.K:P^=T_JW4\Q&)T%]@I%#!<#Q<[>XL2>2I9O\E6.([3I
M>ZKI,;PN43;!%\%1<\F-1\8+4+GD(DE,'^/*^;GS5I6632_#]?TO?;BN;A=J
M.4_9B#'VT[I^&E_0HF-*Q;[<1,8-GZ$3M'";9;J 8QG =N.@,SW&6E.,%GES
MUP5#B2WF.EIRS3>\:NWD[;/8S&_[^V.S^T1ASVP[<:* #AKX3(<-]O"L.+ZE
M9_@V0S?KR&G"HY0)2;"/"!R*BSZ*+IB,*OI&H]\3MW*QKB@<IBC6N7>X7*\I
MCG^?I]V /38V7I#,N()O:K\P5^RB3\G=P]*\OG*2--8O<3C-QUP^6]3>[SS3
MVT8@[F'#>GP3SCDS><\DOQ7H?V<X:_*F*B.2"ZX7'+'SF=92XRQ)E2/DM$<N
MH%LU9-6(K:@J%2?D=%JY1G.)-%NOY)CP>G+]XH9C;Z0@:SOBP_-/0==&VP\7
ML8J$4(3X=L=(9"U<913.4L\0,V'=;ZLE*=!,PZ1JIAST%HYK0)SXZ.<]Q+FP
M%O^6S8W'MY)_G6H/11LY2&OGS@RQMS"LU8A)P7#W>BY&1;EF1'XK&86R\N&I
MMVUU;,@(##K"$WAH1::F*T3!2;JC033!X2ZX>#@LQ_<&;R"G>UR28%=@?8]*
M7DW8?_P#^\53@'S.@"' @&@DC"29[2U!IHV!W.:/I1XS>-:$2K[.6MZ5CR5*
MSMJ@5[S,Y4 PC<TRIKSA8_7*E!"]6U&U@_ZY8URK/VC!KK"4[?:DI& -3#RH
M6[<FJY.-K''E$38+SS_9%<'7A.ZNEN\E'!8Q_I:"J9!:Q$8%&^)*4S/VP]C6
M"%!":7'YIQBD4Z'P0*'PX:E0^'%&DA==T:HS 9/).:+ '[+LA;ZQ(L5<].S[
M$SFP)E_RI@V\4JEH#Q/RL<63OF=C\!A#XB(K702Y:RW"7L [K,G7-6L?$6HK
M3IE7G"</!?W$%0ZT6TGYY1CM(WNE.@H6:,[Y!A?BNV7XE-2$JKIT^T:& E[^
MV"@B]Z &=VDY0(!\0R_"^>P-8#VT*G(%%..+9JK\(UV"I*U.S[)2@/VZ>,PQ
MUOB -@^Z,0U'CMKW?6,:!(ZJWG+IJ,V,,2#(E<,9801@$W0@]'&P[GI;0);*
MNMHL56.*\T!,WE0MND:)82K@48'5(:1>"*8X8]NV&VG\ &DC^5DF]V <_=8O
M.G>L,F*_NA%3D&80["&L)1GPN@A5),B:\EKJ!B%#BJI4F.6B'(,;F90?QZ+#
M#$4ZWL.4A/IZUN#1SM#4N@]9BI;9_+JZC;5BNJA]%HTC_+KAI6+HJ>3E;7X&
M5=4L44E@L)7LP%BPI"LZAGT&Z&L/T:\;:;ZI%N^8J&+$\5<38 H/@I.Z@2!F
M@"\U+DY7,B^VB^7)-$?0OX+6OJA>[PW&)GTA44@10D?RDKD'2LAYH\''^/%%
MS!@>XPYZP_N ZL=<>!Y=,XA#H$_EK<G-BQ$T95?#^G_*VYT*Z!$7:+?1X-BH
MZ-&F(?O*/K)$];'3,[OK,AVK+C(.Y/:/=\MGBX6N'F.YH<[&KE$3<LN-<T-7
MWN$=TUOULNAA\2!#=<=%S[\(VW LY._OS6/<)WU@:<@PF.)RC\-GD+0>$JN&
MU"NI?R4IJ8EJH22-.*%W2+#@?'91!JK5F,T(F\,<;O;8,[B<83O7;6 ZF?S*
M.L@]33N1T=&O3D!ZQA!"MP7W_"=.$B6I%0;&::W!P%D;#)4@!'1:)3] 8Q%%
M+^6$MW%"%/R*M#XA?0Y07%D*BA@(R)N\2]7)+% &B*3(Y <K2?@4HW)(.I$=
MJZMMT7!5R?#XAO;" D34N&:\^3'NTC?)R*0[]J.Y_-@2UH0'AQ[;DE>'O_3M
MHI-> '#SDF"G$P:7+ R+AQ .B"%C?/O273(WR0[<)BRH&7A)95=0.\=.0+,^
ML/!SR=3HK.DJ1P<Q,L ((8)O)-7$)V@G'0-)XBJSV$;;OS;(P!O\;Z8),O;.
MC[OI_\(;V:X4I*OD[0:T%8(---VW"3\L\(1]"8G;46D;1Z'.:> -M_"J(S10
M,BUWX^?.Y%W85&HY(S,IY=!'#'\^;]:SU::Z/DY"@&?K'"JPWE:87F8ZCV.$
MI+T_RG ?P,P\9TOJM2Z:M9Y!G3- 9KJP0'AC(S]S/>@.,;/94VHX6A75MX-V
M'LKQN3)'[[J2Z 51Z(+L,ID@UA]8NC.BM;#9#$(S;=,.W]>.$LD\:V\ZZIZG
MUG$*6^IN U>'>WU$C'>6$+8-FWYB]96.<<6X%_6BVS:@$6R$;)O4K^1R,>A7
M]!08;NP5O-O!6SX]!B2)21DUUO!26[)75@@Z K3R8BD=4PWU)"^2\4'OK?!<
MH&10,N;"$4T JQLLQVX72"C&%C&U_B]B>=DR#H "82&"$D)*@"EY5I7^)&RD
M[JS=;2R&E45<6MQEHI.5I^JH.?$T"4QJL/_"YC1?PH-<DF=66J26I("QV^E:
MB:;7C)+[4A##YWB6)\8>,JT1Y]\#8@?6]@08E!O)<@H(4"*5Z_6HWT_5FP/5
MFT>GZLU=1W+\W'OM8XW&V]# ,4M+\"=&!%-FF]#&SP!T]1:<LGY'>+8K8IHX
M(O .$B1< 9(<=6.] :,O]_QN1(GL_M!N=C4B+V\'C_5 %KSW#B0KJY#',>,#
MX?!W D,P Q6$:6)H3.4W$@*24W;NG$B2+24@V>R%0 4T!LA=C+15)\\4P[IT
MRE:;CJ*EUJ68&7HHAC,KI.T*9PS%*= VV0+,L4HH&2B/(*3A)ZK<3T0#]Z_.
M+QU'W7@$SXXZ.>D.TZ@#%3%!(\KR8'F3$TWC_4^5AH8AJ>#]'ZI2=>)M&70P
M(>K1:5F0=\.P5/I[<54L*;714$HZWYPF['XGS%NT3F0%<6R1=UKYP+[6(F?:
M+$QV-G"^P&/OFIC3#_FTTZ3=YZ3QT<:381R+D;SF:1[N<Q[4L= #25V.Z)-P
M^.;]H&Y[XF2_W\E8Q$Q<X\J")<'R6%E[Y_:T61JJL&Q.4_&)IB)F?5W#(&4<
M&D0251>"1LHW^Z8][8Y[IU)FPQ1 AZ0>H[E$)J7SQWJJFYVGW45<D/4OA)=\
M\*W?6S72K)=U==VN!8P&6..CA]\:@,W?7W[WAN@T3W-\GW,<2GHN1_+2D$BD
M;M[):_L]IF?I5CG7Q2AGNW3SUBVY8 8X<NW$A3/%N/1CP-\T'1<3T@\N\AVE
MM=@#.4WC?4[CY:::TW&VJ,IJ6RPR83CJU1TDB>1MH-'A0EDN^NLG 8%/HAH!
M ZCSL2D:EOCF6I<<9)3-GOW ']'3J^'"WC%F:__!>=>B#<#G6^5)E9J%.!8;
MC!:P"'+J*S*&J#ZX:U\2N#G<ZWQ>L0PL\=1TM7<! 1$I*-]MFI2SV;[J<#=B
M8*.320AC2OI#+?>F8^HHX0 DO1I=VRJ*M04W-U!]4H:L0>G4']>D'U6'WWF?
M>;'H0#(!2"#8SH3&63[-:;44=S&8:-5OU8D2$7B:3@Y)%8' !8QC7.I4F-!W
MVL;RTV!]@QZ9&3%",4*X[N.8PH3OF!X+,+H;IE+G2W.<ZE+%3L<7*WOY= 7X
M=9[+]ZT>;Z#4"E\$3A",&2";[N$N >C52U^O*]4G(&WNZKJ\I*)*,QR0N-P0
MJ'V\!3<<>E;^Y<)06&HOQEZD,:_"O=+QW6-N"WVM=6 [CSN)IPZJXG(6U\)O
M:]2'KXJFF"?&,<:H0OLB*%J4K=JN+M,.L*$]K?O;:G0< ,N^\T;[;$S;KXXW
MD?8.CWB?Z-@0DA';R [ 3L*''Z 0U&-']$TR!P0.'*<C!F\,#S;C,$5=_%8<
M8N-L(L=H[Z@F+5U,--1<^(K4_MG,/_+:CRLU+I5+-)B=$4X_2RP@J/#+?2QU
MADHF,P?3V*OR1EN=JIOWZ:-&F"=X[13T) (LD573H"J]HT9V!'P[3=LMM:DO
M_+(EG&;3HQ@#V:TK23R>*:%+!OKKAP';^/GB[+]>9[-G/S[_^>G[9\\?S^;-
MQ1S^'1E==J5Y^0WWTRGNO->DJDZNM7C$2892:G0F#DPCLS']EGD\8<C^\O3Q
M'PY#=MJ,=]V,4?>382;O").YH:BY=)FT6G.74DG2S/)SD)%UK!FT:Y7YJNDW
M(@?UR4CW&SFM1C2 3\;W?E/KW7;NV*5:^&":<.@UX707ENK6D@X%#F-I\^(
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MKPZO-GF>K[_(O_SBT9=??/=EL+XQ!*6'TZAFLV?R4:#OKUFG\@J4VC[.I70
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M?Z,386[N2EIL\ABSA#Z:XU^RMUFMUH!QK-#3&#?]CR'LZB5ES*EF)913;?9
MB0BVKGS;9,'*)WUAH:$X&VM,%1,ND&0Y'L@>.UQ1B4(&1ZI\;^2*%,Z5?2!U
MTO6)]8W-A+\EGZ[\P=[3L>;:LW2*B&_AXQ. 4[;<J#4,NP-FHO#G4[X_:ZNS
M)66QS6@<R&WW.@64]._.0WYKS^,S\-T>?$.*P*G.3FHLVXJFH.I:U*Y1Q):6
MOCH:)[+!-/3^9SJ!"?8G*[RIT$,C1E0<9-L@J1CZ-]HWF"<^C)#?T)'+MQUS
MJ[7*Q %PZ "(M)FQI9-]<_)^O/.=(=NG877H0BZ(O13Y:K?9#)WQZ1#(&+??
MWY1A:N]I5-&'.0,69J_R>*N!2P^^YE )T>#(U2B)RAE&?S&]3-3K75^ZX0/&
M%EF^Z%#8_O8O<:=@3046$_F^XUX4%QBJGV#4'OY9JRU O_@E[__OX9/LFZ=/
MLP=/'H]M_-$R[C\$>(S/Z(02(S#0% =6F: DZ/>*X?#/\U 4R#<Z<]HW [,3
M28;Z!H@6A_34%$E#>^[?] %. X8"Z4F 7M^(LT![%O^3/GOA5\=F]O!K'2-;
MZ[!MN1O_)F?=SCIQ(6.(_/:UCQ/05Y8<<MQ%;%N%U=7RK^N791V>ZYDB0D:,
M[H%W?OSTR>0[\]Y;; 349+:$GYL>G.:CO/I;+JK2>0IJE*O0)YY\D$Z.3/8M
MO4^U25JMX=%'PP,R9ISZDG_&?P/TAET1$\32K]*50%?HCY-T'_I'I,9WZHXF
MO(XTEX+M(QZ2B#MC)&BJR,.A.9]=!">2KLPP"W.@ F[H'<'+0FBZ.*2E$24*
M;,[VBIO-E=#7G?_[PZ^^RNR=A0H:L'N-A!+$?\0UP7(+_75T<,TCT0FNV><"
M%3,UX<M@PO<A9.9/3UM=Q8K<TNQ^H*']7)2*_XJTS&9F-1Z.$?'RJT2,)N86
M'IV^2).?RK%2H/;-,XC4?R0N8PW*Z\N\%-IL0#-KTK<[*"K^V0:02 Q/U4(E
M]%XF3C=T7#)3NZ$]U'0U12"9Z0U&Z-VD338Z$TU%I!INR?:W-_[C:!:@SF!S
MTD<+15J>]?$['$"PJ.X,HUA"[99;P/&][Y_Q6RGH3QL0] 5IL2Q(+H_+:[%W
MY8Z+Y^W:V6O*^_FGZ /P)(6Z$>WG%**UJ.I=A?SJ)96_.&_J3T3*OR3  -X>
MP+T8N"PC8T<1/7UVA"CH8[E 0H74L%=)+SMR!2;X! */#L$S/WQ-A]UXJK,=
MJ+,]/=79/LY(*KTI.38!?"WUX.BQFUJTH2UH=&ECHY/!LM9QZ9 \BJG(=H_$
MJEQ!G-]PC75US?61:[I/]4Y(1=BV1FM@Q+&,K1VQQ*$DR'O0II,,H"\UT,!*
MQ+=6RP.#U("69V@+V/.!.<;6]M[6E@DY*!K $5O+",-&<35,Y"PT<FCW._:K
MS3O%LT*C#3:^'&1X-S$/HB3)F1,3E40%*M@Q9D[0QK-=Y:WHGCU-+0(9Q1@<
M'R96]T^^]DO&Z9D2GY_+-^S0-_YJF[P.E_J-HQ;'2D#2<@W<]U\^B&$H%PNT
M-IQCJ*\B.]V U2DSOR??E5KS..^7,[=2[+_20*X7^14CU'G4I-6LF"(EJ6%,
M>!.AF&P<_Z4CQ*?D[?NN-?BEP$7CI[C/.F(Y"1<AT@IDPG[B%G[5^WC/KWQ^
MLJ/$;@^QOESL?S]K\_=R1O,!2$:E&B%4@S=+<+%&*='"3%&FRU\%(#2W1%F4
M)TE(;@),23&'3C+/9>\^H_1@ Z] &$[.?[\VQG_[RQ%ZY\,EX,T4O"BAS)<?
M_51&JI=?2C2POVFU@#)[0<ND7 Y W;0"1@V5.6]0FA,8H#=N_AL&M=4[;BKO
M;Y1:)FS"<@6:59;D/[OE9> #1#UR1]:-.WR;6&4JRL!ZIVA!-!^"W&C%]CJ^
M>;0->*4B<I[VWEA2"R$A,C$ W.(B1@OWN?T4T.]^>>-?M"Z:9:AE"C+;+R&9
M#'VR7MD5>D/I=[$CEW0$;+13<"4,A8$[1/-E"1<Z)8'P<8&H:A\VSRT)*- (
MS:7G93GK&/]0;P,F=./*2PK0Y%9232;#0Y=2T427EV+&L5CP0!S.](9;='3&
M7\#Z)RM<GW*SL&TTM)F/9ZHESQ2=>5"-E[\PD>/(4G"HD(!1$D[P;+%1R:?H
M,-AF"EK>,)B)98VO)793FJ#F_@AS5RX")F%2)=+0LE/N3VHZ-[- TB.&EQ=S
M4"VB<UPR:RIMUXI*G>3QE"P_.$$<$VLN+KIP],+FK9" #&]VC%F*OZF;K*0A
MWL)M&VU"FSO;5$3IU$4.^5*<0EPY!E:^T2FG\C$^T&B^U@7P!&=:"VU50<HP
MD'F:G4H??J&(T]=2F'[#*S.":?RX8U,9R0*N"3=<90Y])F'9]&[CWHN7I+8J
M0R]P!Z8^V3I)WPVE&):,EVJBXQ5,+6&$N,_'_V-;+=FAK&K>JS0FH=B,8O?L
M"_]D33&/- YM74DW'?L$7VI>]N!P1$$E7HIQ/%#'\5N,-.Y6W0;IE+6W7=[V
M!-.O@X/L[F\;$DX4CPX(MP7RD%CL VTXR7&;Q#/>@QQ/YW]JE84K8&S"&4K%
M*G+/:FN78.]BHAMY:&K;;4*#;C )@?);+^:?PZ(#Q&.S46CA7>_HK*F+!OO3
M\]%X=P1PT5$ZRB]M1;SWDHS$$A'=HD==V>R]F=BB/5(!0E(>\=/N3<1B?9PP
MS.>NV15"LCAD^ ^OZ _NACLUM2FR(^IC'I6FYRV&VEM11]\!%B'PQF,A\KGI
MAWY=[.@:U&3;;2A?*;'C,M]2R(U*6+CG55%WR!7[&)--PW\S'0%B#-!"!NF(
M$LS&9$&IFX :W5Q=^V\TI-XHIWM++<4^GNQ*=3_0ODI]QC54*'3.M4<#-<CX
M<OL;7XW-%O<I^%D"/BWOK2CD9M#],;*T!/16RG*T&!#8D+J3?F;I#F%L0I%*
MAI(CK-^-<$.P8 0,5 CE_)"%BTK,G8CZ)HIY@B!BSCGW/J=EQ(<>"U&O6!"1
M6,?S.)D;MJ>:*R=XT8;:2Y8BGSCUJ(5:JH':0(!2P?&SR(8>5Z\F:?SIKTI2
M5,(E<).PD?LG'87LDK6-8S,V53K7\;GS, P$,.8ES1SL>3A,%W:62KR0]WG)
ML;,<2"O)YE J3\'^</,8F^6_X5W_>F^[^$U.A=-6,2VF\%\[EY/*KM$]P#0<
M)TD.Q1F_G+\YGZW<TJF54#\1M"E\THF.%%=%N/K/K"UE#H""##>:OI+6J<A,
M!11"!64AQL@:<EYON@@P&5:.$!BI*+/.\2;TL+%/8;D98NB"960C$&)/NBJ6
M'11(Z7.#-^8WY4(*@BL?+G!RC /<VFGKH_AY9+J@F^2F0G^T]Y6 %-FW[E28
MS<?US@(6>(,)/S1[7'[=^C56-Z%^'A-'UTX6ZUT.%'V0,+Q@12?G\(HWN,T@
MC\I 93WY5_F6W6D176>WG,X@3PX[?C?/J>8VTWM*<,9&S7FS6>T=G7Z8ODT+
MW#3G5AB](N+#?&NN08FG0^+0[755OY.(FPG&.:_7-*@)H"_4<2$P+R6#L/63
M%U A1<H1XG]<D&^^8*WJM,?E?*;>!4"H@>3#8(@E?3#E:"1T)(K9U;+[JLY#
M253=[]1_R-LV7[P#%?O:_\/53=(>.\\/$+^=BHA_>?KUJ8CXD8J(LB\U4E 1
M(-W/,[BE&:]Q;"9=R)*<I*VY6?F]H8KM8ORCFQ;3^' 6Q1L15S'H!:7NH=J#
MX K8_0:3*6%D//W9SR;'+3 ABX="O]M !Q)X61^3'Z.+<*$#J %%]+\R2I;!
MI90!9_HJ8.$6X\GP?. >AJE3G] .>=_C9=B$J!FRTZ$EF,PX<@R9P]D-)U4.
M=.4HNJ(&4.-7#!P)FPZ ;VQ/1N-GA^R%E-SP97[&B.#!!4?"%5FJO2,BDS"F
M4\P(/'MNP.<1P>.(U\Q^OP\#X[/SUZ.+G?; =I'NG%8E<LK6B=#CQS1(4 $*
MKF]?^=V*,8QV6?2>C/D%;QDY'6$JY5?'AF3$)_,1WKA+)J?TL#D8S'02NB,.
M'43N.H_!XR*'IRBU>3-\5(.ZO2BY*\.#9LHW^[ _.J&7IEW*,8!>Y!@MU\\'
MAD^6;4.9<;?93VQ&)A?Y&$7=4<TGI3(!")FS*7F8='U4?ZY4UQ#E;@5M(0@4
M3L0M!.HF=@Z_13F*9U+*4H)H/M0 M,H7X6C%Q=C$+-7MM+XEECF5;4+;EXR?
M6R;O7(3^((MM@3<>FPT9YKB53+DS, Y9T"Y=Y@QY3QJ@!>"]DL9IW1F39L;@
MZ"*ZPK5SZ _6QQ[0#S<^O?^8F2"#\$7SI<&LTJ\6'#R ^I=R+UI1ZV> AU;"
M@GKP,139I&DZ10A%!%4/6XPLF?#(IY(V=WNOW@%UUUW\&9_:IP/[XRK*I65L
M<2Y#67HBPU"E_#PFV<!+[;JNRLM51_F-KN$,60@+TE1E+^.1^@_!TMHGN<4=
MJ 1XR8B')1(;M0NDAC[.H3NZ<,7Z* LUORI9U;7M.M"2-=[,IO[0I89<M"$X
MEP% JU%74J]Q$WI[^9B=%Y7)LU#(L<[];"U<QSF>43T,+0FYMM"^\(A ,'\(
MYG%Z"7)YY3<L1#+@U$/-Z(:D5WNX;":R?O'->NLITEY,Y-JE'BL67%\A8&1Z
MZ]#4>>TN.)_]&-"(.EREHVB4[@<XY(HZ^O)+[U$T"L3G4=0:%6A<43-9"1-E
MR SP!^&5:(5:=$)!WE"5_%YLO",U*SKJP,G&><N1D5.>CZJ66+-TFRDSK&7G
MA 7N>^E;#C3*MM!O7D5>/'F=B. <A-'V'(ZM!O.@("C(4/0>A*9[TYT2#)'D
M674Q'N4I\,.+GU]?" QJAU=?]/C?,-M0&<QMXW-D_S,2U9U4+ZCV^T<0_22'
M\H<0NKSPGH5?'_O9ZY@$N1 XRG[VA2A\841%S^M+;X4:%A0(C4(\N(5(>V+C
MU:@XAYTY,R+!D 9?^-M66Y AS>9U]<[59TOGIZQFD6*)K!4N1@QT'76_4JS
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M&6ZR1F*\8W!4C@1%IEU\)>TD'T+R?JH=_>7IGT^UHWL,Y,:Z9(RY\$Z1"!E
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MCVXFW^:R,^J$_&(A*WE/V<9,Y8PZ]ZVC[H6Y3+*81HT'#OTLR8657V TBB@
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MA$4Q779:[@KI](+-C&+NR@BX<EY3Z[(:/<#J/^C)K+5(&WG&A$24L+M9 YL
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MS[JI"D@AHPZLKOK .T/;=&GY:"-NG(>7FW^ZTNFU(#OD.R68)S'70-$\!D3
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M#6E3P8U]PBB-V%IUOJ]%9&3]^EE6:XB\<$RB%9DH0:4]I$H[GJY[P8S+E&0
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M)6#4IBY2B(1B#'.:E=;%&J$+!.R0]4PS3@MOD,_EY/-J7#ZI16FS8U@2G5!
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M$2Q)\UQ2[8:M, 2C.)T.Q=S>Q'DY&*?K9_RTFEPT6\U!4_>C18#QT3RT>%?
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MPP7BFJ6<I"L1X1Q3Q@*)>79K'M6LX/]WC@$6]VY!N;5Z[$=LM78SRI7HU1T
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MM4\Z('BX?&5$@)XWFSRS*+"CPH6O/A*J@WO8JM2D-^I>9B8XU8]AN=$#I@M
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M';9[]5D<24<EM58CX(PY044KY'+-8HPD,NT)I=GDI/J5N3%R_*K5>FO]2>-
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M(H\D#,@8)Y ,WGGC YA%<96!Z-M(OO"?U8CY6!P)IIT/V36*'5A.L.)(<Q:
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M%\.Z6CO?4%7(^ZWY)<&-]P&<JNV6;2K8L'!CM7<F9^R?-#4XB\DN"U5 5:,
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M365N,+KI.[+#,[^OF<M6#6!= H_7LX_X$YM]M%X8^@9VT58OY/^\O=Y+Q:0
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MM2H-H!:U:T1M?^?X2"NI"F\<"I9IQ'7D2&O!D"%%E(%0D3.@GRZQJA: )Q:
M&&E!K9((>UA[3@N& 'LDXLK9P 7H"G)CK*F,OZG;:)GQ7IFQOK:"X),ZQ-^8
M?K(P!N]"/X<XU7[Q>;_X^R.-@3J8H)#W,@7%,8NL R6EHTA5(T+P8:EA_:;8
M"[?T<^^%8>.7?_<&@U\;E>,0Q**1Y>*%!\$DQ_,HQ7$DY]$OG?R*E7T"&Z^*
M<9B&LY3W!00U*>+U.#2ZHYQ*F3,ER]/PLFA0RA : FM(%_HRJ'^<AEG:TNEO
M@]+R-/GAZ=G-')?FJB.V= ;M)]_-C"?];Q(6!?:;&0W"N.!054RH":85F,+M
M07;TM >#T3BA)'EJSGLI,+B=/=\S9_@S?6 FH6YE#M1B-:#>&=RRU[](GH0R
MJV&N( A<;?KIT*_*E)@Y::S.!V?FIUEY*5+9UI38F5^\_?6Z4( -+*URL'"8
MDFIXS:S?U,ER@YS<RI=8QA[=3"R^E3&%62RV&H\=2.U.@A]UPG[<AD4;K]F'
MX$#8$Q%Y\ST+CG\+LO)GWF1EI'5<5"RU2AFKE,,CB6$-N,#(6P$T1%"%E )&
MJ@LLG<>8Z>6P!POL1 58-B4)U]:K2+&QFFNJG MZJ9#W08Z[&;OY)DC0N6B,
M%S'5UZE6<8;%A&I!IZEF;KJL"5C&DKF$D6-(C/-H,PN1LUMB<.6>*+T^X^C9
MU<CQV]U+GJSSEET[RZ__3WE2,HDJRMT+<H+\^2#\-O[+[[X]..^8B]_:W8P?
M^:+?YX<ASI>:%V3-67Y=Q>%HO8692MZ]JEM9]> J2F<K._X6.C&4W\EB"U.Z
M]FN\1>[XG69WN^M5@R5LJU#RY0Q64G6CVU[39^[:EI"W^*E>^NF*CCUEU-HS
M]:=9(ITYQFQV_\^U%GG"N9MIOG33=B0;/JL)2&_2T._:U_VYY@S?1@)_B"Z1
M9:W>,F)_<!.)N6UWLANUM[U5J_&7WOBV)$H+KD3GE&8B.NVYY)%JQ:2AAL@8
M:%$$K6[K2KPG7=_.[JV?H1G7.8REQ?;2-:?OV2%]C_</_G6R_]<;>GCVGAQ>
M'M.]RS?B\/+SE]:'A69<9^\O6I>.@AE ]W;\Z>>=]Z)U]H8?'GQN?][YYW1_
M!V;AH'.Z=_;^.Y@!TXZ'E]N7K9W#(TQ\L#Q(9)DCB/N"@O',;&KJ4W!3>"6Y
M2KUS95/J=06@[MB,:[,;&M:0<2/(2 &[5'*' 3JXS<=/$1L6(O,2C)A;'S_5
MD+%QD#'IWU=!!M7>:T(+9&WJW\<]0\H6#AD;"JRX(-(P(#*\J1A^$8AQ:XJU
MN@GX1E.LC]V4.!S\<A9%VM]W(UT+TW G!%TQE3\D3@81=<"!4*TIQ]1K'!R
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M;?_[^G=N<OSXF"92Y?VJ0C;8>6JU,DH!(-D#]C,[GQ\X]+W&H W#H(_+GI4
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M)@/(=796:=<GS#5;)-M_)"!/[0]+23U(#*E.*!LGE+DCX1CS@2LDE8Z("R5
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MDYM3(V2-D!.$#+ 1+,;*1;"^B:>J*'CA6 A@\%DL7$)(HFN$_ $0<C%ZAMH
M6M$BPSQ#W!""5*$D"MX7)"BL8B& >I(F&%)-S>[=0.I)(')3<@.9W)S<P-WJ
M*"_QYG4G%]>DZ]+;S>!*W?"B85(H9W7P2@C-N5$"M@=WDC'%2"BX92N=E(^
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M''&L+%)>112<I\)ZYTQ1O'HM)6["=QN$"+4;:5WMS7'"R-KLU2I=-6<,? C
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MQ5TC(*)BK.#$""DX5E2Q0FCOJ%"@"C21U[DN:H?;4RD'DL)VE"4B@M&!:#1
M% HA4Q \A;FRH2!2:(--(@I7V#S5B4AJ?9>21C(8 Y0/<S?G)#Z]\] OVS;/
MLMVQ2VXPOL&R7VX]M[V7:-]&G)UA/H \!VL)_ 'B[$0T7/+@P2R3>B'UXOIS
M]CMYXGYR2:4I5H=0@'$<#:(Z2L0!XY'&U"#FG<+&:1Q#IC%7!)C=PAVW3O2:
M*5R_,\HT99/D:(8<7]0R=2.9NOQX)'F,+GB/"N],U1@7@!")PC J?! QFFN.
M&\Y+XW4-!5[HZGQ5E_"ZN_=K+==W]][@-MTKT[5^@/2KU<F*[\R%.PGN2TIJ
M&U:P"7\][INS%\B1=V<3,>9"-S*^5J8BC*O7;Q_GH\1.#_YECONAY#=98[PS
MK@U4M/$) #GTNXT_3/<+V*;YAIV0(SC&4?;_SO\<A]?G<!!3WK.=SMWASG#K
MXQ2E/V,%WRDRD#H#Z$9%\"D7-A MK,;2\&"L$L&IR@=SRQ#DM\:%VG5\<S6S
M=_K^* !OL=HX) *EB%//D);*(D(HC<I%(:BZ1LW\DD1I+$(@+1,!.A_U!R,#
MTE$IH*NVY^Q-WKU[-[G'-,;HSUZ_US5?V_T16+YMWTSZK!UB,SMBWH!X]<Y
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M#:"CL =NJSPRPF"D-7$2*\I%)*]>#[_ULA$]6,Q(+SL-]_+:CIVM\/^-?MH
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M!^'LO-<W_8O2ELC852J2,L[R7?;2E@H&V%S^ZH91LC^[)*5$+YQ"E2,1R,H
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MB^T=#R\][(T#5^@-_/&<B<A%+$L7A$P.X.7ZBY>5L#>RNH:8#Q*4D]CNO'S
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MW6N<6Q;GSB=QSG N).8&<9.K!U@AD19:(8RYT-$H[IC,I]HVY6P&Z^U@;H7
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MDB=&4\=HB/ 2IA3;A^Y'_?9_!\"RWK>!BP]*<<,]<".[^\>V76]1C*+*\W+
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M[V@L$ORQ(!,PGCW7:AZ5^>CM#$=?AX;7@KN(X.YM^T.;DC?:)42=\B"X3.4
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M2'#")+(@;JI>,B,Z'^N$,Q"=L3C 4B4A7KSL7.P<8B<,]H*@J(A!/#F.+/6
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MO+"42>]MKAK%9VQ5 ^"[50J7@)PL)0"WXSAK ;AW =C;_W"HHG#,^H"$B1&
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MY/3_;^]*F]LVFO1?0>6MW9+RDA1.'O*NJR19SJO$.B(IZSA?7$-@(,(" 1H
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M\2S;[_@=EV+/OVGY5/*R<J)OK5AZE#)O3R+ME,6?,9H]*76"-$5/0J4MF Y
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MY+J"GJ$CZ*$#!C3,QFS@F*M11W$"NBMJ\;^AUH_*%MU4D7;-_%MSLNED;D>
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M2QV_G)1(1<!#](57@+MQ;*K\HH5?M/,B?E'3[BF_Z&OZ1?_OR6AKZG.58NR
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MHH1^CP+WU@5EDA;)\0P&\/BO073);P"UY$)I'ENWG2U#;>?-WLXN-Q.RDI6
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MT9^+->,@8%+S4$_B9Y,)#3P6/8!'JA7/DZ9\)%[BM3+N<05>]?_.,7<X\]>
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MZH'-KN^?;V+$>93^1;5A(,5]*-4-$^IFFI^#JT(BF;%FVU9F7;HNK*4G%(F
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M[,YZ"^U2FLC;P\7O342_%[Y)H;Y($7^91EM578;_A[YM\+>04^%2[5D^DO%
M74Z/!T)R<#87!Y*'Y$!_4@.0D%<\H+ZOYK%)<?TEGG,892AS^_I>?#?D<8J
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M09EK,LC'2S'BQNJ>>+@HIKI5DO\W#/2*WQ<J1S ] ^SW%@]ZF6< FW!LPH3
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M#8U80KDFCK9?I]VQEA/<=,)+L229TFR:@)8[!K%Z\<L4<HLW09?,MM6Z(-=
M\+-CW'F^#?0@GWH4AJ;(&07#HIDZ^91-L%:2FI)>?+P-5/Q!W,M0@@+_(3#B
MT/QU\A(<&ANPE#V_-4O'7? L-Z3XSMI&530USC;YWLV]=Q,==W^JQMC O:1,
M.%1=K/@T@H%XA.D='0/O-4LTA<D;H6NUY.,?M"?]5SRR/3O$\,"91X30&V2@
MHPA]E?52\MZ08DQ^*-+T95/"&8%5WKWZ/U!+ P04    "  Y@G=41=(5SK45
M  #DRP  %0   &-N='@M,C R,3$R,S%?8V%L+GAM;.5=6W<329)^[U_A95XW
MFKQ?^DSW'#?0<SC+-!R@M^=-)R^16-NRY%5)!O[]1I9LL(V-9:M2+M@78XER
MU9<17T9&1$5&_OT?'XYG!Z>X[*:+^<^/^(_LT0'.TR)/Y^]^?O3'V]_ /?K'
M+S_\\/?_ /CWKZ]?'#Q=I/4QSE<'3Y885I@/WD]71P=_9NS^.BC+Q?'!GXOE
M7]/3 /!+_T=/%B<?E]-W1ZL#P82X^K_+GX2).CO'P&-.H!3]YB0*L$H%[Y(U
M/(K_?/=3<J;PHC)8IBTH;R/XP W$(IUFT4HG-S>=3>=__51_Q-#A 0UNWO4?
M?WYTM%J=_/3X\?OW[W_\$)>S'Q?+=X\%8_+Q^=6/SB[_\,7U[V5_-??>/^[_
M]].EW?2Z"^FV_/&___7B33K"XP#3>;<*\U0?T$U_ZOHO7RQ26/4ROQ77P8U7
MU$]P?AG4KX +D/S'#UU^],L/!P<;<2P7,WR-Y:#^^\?KYY<>F1;S%7Y8K8YP
M&4YPO9JFCKX[?ERO??QD,>\6LVFNBOXUS.H8WAPAKCH:27_GU<<3_/E1-ST^
MF>'Y=T=++#\_2O/5!T(D.!<;/'^[^6://T--89;6LUXR+^CSV2TKF,%1T]_C
M/.-&4.?/GRW2I8MF54V+Y?E?SD+$6?_M9-W!NQ!.)B^F(4YGT]44N\-Y?K-:
MI+^.%K-,,^K9_ZZGJX\3D2PFFQ08FP4HK31X'S1DRP2ZY'RT]K+LZD [&FFO
M[!*ZV&O\[(&/JU ?XVS5G7_3BQD8/U/\W[9%MI'[(".?,&Z$E\H"$ZJ *CJ#
M*]%"2"(R);/,KK0>Y.7Q7&#2X3(=+)8T<#)PCP[>8S5'9[9N@R@LTQ<4NSS3
MSJYXW*V/C_M[PG2%Q^=_7PU?0U:L%L,(?J-8&LJNFG^R.#Z>KNHR4$='\VU%
MRP4M&Q40=T'D4A *2P1(L$ #XV28LD.N?$J>Z29,^ JH;9@AO@=F#*68P9AR
MS?@"R\)CDH#:$X[$.7C%',CDD_8J9BMC$X+<9@&OYX7\'GBQHQH&H\-;/#Y9
M+,/RXP;$D[!<?B2&'AXOUO/5X6JUG,;U*L09OEV\"DNB\40IZR0WF=P]KT!A
M,1 T&;GHDS ZD_53N0E;[@QU&S*I[X%,;94X&-<NK9+.,Q%4@N(L 4@Z@;.>
M 04361>7&2JY7_=DI_$\62][N<:2"D->IZ_FH(SRX)D7X$64#@./G)O6PSK#
M,E+GZTZ:_XJ?=1^)#\?DQ?S=6UP>_[Y88?<J?*QS:\*3]$%0N(RT=A,<FEU!
M2PM)HC)::ZEUH[#B&C0C=;!VT_ZN4F_I1(E ?KUR%JRM ]-10[#*@)<F&?+Y
M V-MXJWAP\A7! ]I=FV6J?\.LS5. NG-2%F -.0HJA$"7"XTX4JRV9F0:,1-
MAG<-F#%9MAV9<)7BNXI^T(!R,;^ PF85I!8%0JC/3N0V1!XSF)B]#48EU&W<
MOJM(QF39!M;^3D(?3/6'.4_KV,/L59CFY_,GX62Z"K,)(]N*61O(GM/(.(TQ
M>(-@,1?&"_?:B"8,N '0F&+%@8DPA H&X\-K7(7I'/.SL)Q35-$=IK0^KJ+&
M_!3+-$U7DV14+B(R*-%H4$PQH'#% V;C<K:11=V&&K=C&U,0.#!+!E9,BSCO
MW$LWC/3GHX"4N 3E''EIRAK0RBK/2 "AI >)B^ZS,LY/<;F:DO/Y%./J?(0\
M<RXM&G"*[+6J;\QHA (P>LN9D$Y;U6A]O [/F'RD'?GPY2JYLP*&6RM3JCF6
M\VCD'(O*$AE&25@HME%!>'!:4U :2F <9>:V3<K]>CQC<ID&)L, "AB2#,LU
MYFM&**W(J"6"28%&J#D">?6&AJD=,9-;7]IDNVZ$-";G:7A*#*"&P5AQ,5MQ
M#B2$*)@C,\6,)7IB=A"$(><^IA*$<$9(;,*':\",R4$:F F[BGXXR]!UN/I,
M0Y=]*<%#XLG6E8J>;I#<LQ!+"&A,-FUR*9=@[.P'A>ZHOM*D?ZHO>QIF_4O.
MU?G;ATT$&Q.BCBA!ZVA(?33,8$CZ)EG&7=9!HFOC%FT#;TQ>TOTY\H6#-+AF
M!IL(KY9X0A'MLP\G..^00+ZL%4.7A\Z*0%E*@1P##3VP *Y.>YE1"L20,N.M
M4HVW@1N3)S4<88;6RL!V<Z)SEL85"I)EXJ LS^ C1;%"B4"NO5#*-'*?^N?O
M.HJG9SG=)XN.!D/K2_)*:2CT&ZB(M*"E1'&*8U$%+[*S;5X47((Q/LMW)RU?
M9?#]13Q@FJQ;+:=IA;WA_7TQ3^=O*+5*4A<.Q7E9W[73S$G"@:&?S,@@N&MC
MSVY"-#XCMI/N!Q%\(U>/QZA]$19R4@0A9PN1%PTH')*XG&&\4<[\KJO6OH*]
M 11^?Q%?T?+?'U\5R OZ/'"9]IL5_>P+ !?EY0E=79^S<[WV#7=M6+B]S3@&
MJN#^'5?/YP0"7RRZ;H+%*"62!B>U(*J$"#';"(A%^YRT++S-ZG\)QJYVX3F)
M>4F6ZLS)FF@ODXHID?OMR)_*F,A?2S0!G&,^,HV8VF3$KP"YHR, 38W#_15_
MU4;L(N[!UH*S:3)_=V%0@67/T2?@5I-ODF2 &'( 9HOD3EH151N]7P-F3([
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M,MM@M#,07:W%)1,'+AE-+KU.+!G/M ]-K,KU>+8AC/Z^%J0!%#/<JY)+Z=_
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MT[MC,V>L-+)%CNDRHY?MIB,E/*2'Z2!S:7&].H>X2*9*U@AIR%*.EHQD@J3
M&?*BA/!&6L><SFW26%> .<3M5C>Z>IB>M)>@F]Q87%R,1W,\'S[39C4]NYQ]
M'D^&_P?SP)/;+5!9*,80-$;XHG)D0!<=F0N))=$F:/T(J)/A0E>";^"KWH&V
MX"B7)6=.AV5F9"PKA0R\3@4T]RB%]]Z)-O??RTA.4?O;B[A%R#KGN2##^;LP
MS&]&K\*7X2R<#WC.12>E@<5<K]*\ 9<,$A.E*-X:1+.BEJ>+@/5J0"=#@"X$
MWL E?8\S$@KFG\)D1";M]"RERXO+\UH1])J$G8:S@=!:!),5I& %V;*1CJZ<
M&*3"1,X^& QM-H.GL9T,.SI60P,O]>'"!Y:IF"R7I+_H"1&W$!TBZ&"8]8YS
MZW5/KL3)$&%/,3=P%I[RE:JO&US2%F241$RM,P1%5JW.R4DE4O"VC>?P%+(3
M]2L[5<A#PMC]=XJK3,&/\WL8VILRVI*@R*1 2>\@1L\A!.7)TD4B=YM<J/LX
M.B3#G9+\YGF2>PASE?/XW:+ ^B_I?#S%_-?O9Y-+O/WFH@3YI_/Y __Z_10_
M73R(X>W!AU?G83I]6^:,/?MC.!U(K[1"VAXM*@<JU+QNPS+MED;KD&/6C;(C
MUD+JD"6/-$EXA#4[J'D=8_82=XO(PQT\K^?[Z4:(!DO]&KKU-Q]@ZO+06-=R
MXA'][Z>T9:>S&XGWPP5M:Q:G8B"M(<Z[3*=6GN?O>"1K5]K(\K/FP+TV'@>D
MP#:";G$W@9-JN=P/C?YM;E@-"IV$,@@RBXHARR7)!$X)"244--IPQ56;Z,,C
MH/JW(O?5V?*!T)' .^RR4#NI7.'Z@)A70DOD1=7+>G !);%>2XC:TI&8G8I"
M1=1F*7'J87^6#9[S;-7;M0P[?-7GT-YC1KR89^G>QCZO<$47T6".0)@MK=<C
M>')Z((7@R4&V42J]D6X?><CS5FQ7TEM[6_#O/RS)A?R5?[3LK[2X&?^,].MA
M@Y9F6S1;NO_)/75>>F0Y2VV8>$I>E41KL45IY#[5@I1L O?&^9C7MV&Z_XSN
M>S*AL\X1+XLPKG;^*^"XE&!%<IY;3G1Z+CV9EC(T'ERP6<N$XHD6&+(F%]P)
M"%Y$8(&1=<5UD*&-<?D$L..HX]R"!T^DQNPE^ 9MG);@T0OU=C*70)[?PKW#
MR1SQP'N3@Y<.-$\95*P7,+6 )-8W-!CDRK8)4FT(\-1XTHDB&C@G*^G\9CJ]
MK%0.Z(M0"A@Y8Z"4) \L*;*H% J),DL7VT2K'@%U:KS86> -LB)60GM[.:L=
M9VL3WT$1,=C:<,J2L49VF*UEIYFH:X7*G-L@<QMO]2EDI\F*747?('OBOK.U
M=C,3M%:M>*GE9Z&Z7[29!6; <I68S3ZWLCHVP_?L:=) #0U2+.ZC?& A\<RT
MT;7]5:DU<$(2E9FI"6#1RH"%6=XFF?MQ7"=&CKW$WB"=8A6ZNQM<D@Z]$A[0
M:08JUY5;D\ +[I300H1&J9A/ #M)6NPJ^.:IV??,(9?0.%;[+\6BB+$E0BAY
MGD(<90DJH"F]4>)$S,^.Q-T@B^).V&_MP<95=LB,A\0-[6&)/"9G8H D64Y9
M2\YTFT9S&X![]M3H6@$/.>(ZS^6_HJXI C.3!I+G->PO% 03(TG!A2*]-M:F
M?O+X3V2;Z$+0#_7O.]?_W8.,N11B-A&XKB5H+GOP$1UD6JH.)BA?>BKF."7S
MH3.1KPA>[1WM7,HBDLP$PT0"96E/4LDSB)S\'N$#,O12M.HZ<CR9=WMH>@]A
M'G_F'7>62^X0G+"ZMDO60!8-K28XCMHS%7.;G/YCS[S;2LT;9]YM(^Y^LJTV
M0?3",^^V4MK3:5>[2+P?+ECF@C3.0>$VD\O+:KV"KY7R"F4@;UCJ1I;"L6?>
M=4R!;03=<^8=5NO$D8IXM5]43A:\C04X(M,JT"$:VK2I.O;,NZUTMD7FW38"
M[SGSC@7F,$8&VL[-6&O!J<*@,)N-3<HEO]0BXOEFWNVBWJYEV&?F'7+-G=!(
M2T4/2KH$O@[+R%XG9W3-S1 ;Z?;8,^]V5FQ7TCMHYMW-D38=EU>?P^@33H>C
M.]V3[W-VY9+#JMJRZ[K;>VO</GVO-;QV.8"]"G8ID3"9Z+2W3IA0TV!B0(E*
M"%8PVZ19&?0)M/-L1%^X-^2PUVO9VC(I)G"29Y!.1*TL\<@WCE;\TE4VXIM1
MFF"8XFM<_/^;T5)"P_OQ^?G/X\GO89('SBER,QTAJQ-.5$H<HG 6C"75THY2
M++:QO+9!>11QNVT8LFR*-5-)^Z3%AW'&^8OOM )I'=F.K"9&\810DK2:AY!"
M:E-X?WR)1^WTNFU*TC9*:9^YN%&/.H<VR0@\N#J,1UB@(\7,IRH%Z0TY(;WD
M,QYC%\%#T:ICM768%3FWC9=?@FH=+*["7E]."/8[<HK&>?%N_(J_SW\T'23+
M<Q990G0D&L(7(##ZFTU&,EE\U(%MY'/L]/@3)$]/NFB0.+D9Z/DE^RUFYY,M
M03+P*=@:*C$0R=D"70*Y>"P+)?O)L]T$[0G2K3?E=9A\N?4KLG"-:KSX;;GC
M)GW 1+\Z;R]>'&."9492"S6B4#($G@L8)0+MR=Q:\:03W#VL$^3;@7778;;G
M%BN9OS9/+T0(+G0V'(RV==*-=!!<88",Y6(<#U;F#DFX&:J7S<$&FNLPL73K
MEVGQ?9+=!YQ\'2:L_2=$\8D)X#'6+1P%N& MD!>N;21/)\G-JK7W@O&R2=:%
M;CK,4MWV]7@(W =OO=0>)*NIDTIJL@MB ,NM$C+GXE!VO9']R:FN-=-A4NLJ
MX-=2>GU)_N_M%OMQ_'?RD\-H1F"=3BI;2=NHE_6:AT,PJ("S3*LH1N7,=Z'1
MDT]^(=3I5@,=YL#N!'9!]K/IN_.0YL'ELT_TQ\](K.<B*>6D %J%J1NI I]M
M@IB<K;.B='9MB+0>TY\4ZU1K76;<KEK'0^']'(:3^2;[MJR\8/LXKM^^^%*5
MNN@*CDEQZUB$I'3M"AX-."<RR!RST,+R(LHN+.P VPMA8]]:7,'*_;(_=G6<
M;R^$%Z62H_Q@M?,?#*(VBB64$&2MD&.!053:@4DQV<B5-J[[<.XN2%\(8P^K
MX17\[>..X8'3O?'B5##"9LR092;S%CW2RQEIA5FF;!BY4VJSOG*-@;YL]O:C
MWQ7D[?R*X\%%L588!8\:Z(2HJ8$E@(NA0' :Z>4RNO V59O;W=[W<05MM0B*
M2P<B!%\G=@J($A,P)27ZE!DNOXO'<07=14K0P]2J>Z\7JZDMQ4#0/-+KI4DR
M425(+I,''FDGMFTNY[<$>H*)0=TIID4._\.B0\VL\HB )=6Y(,'21FPST%<^
MTOL3T+4I]CW*[)\.E;><S+^7Y'L9\C@(3*J4,X>L$[G#LF@(L5A(T@1A3"%[
MKE'_Y",8OM$K&?:3?8-N96?YOR^GB['''\=KADU=!51NBM>1%T('ID1)@$FQ
MKA0!1DOZ(G.1&C5<WQKJ:7.IK>8:)/$\ZG#.__R11);)*O^"HVFHR_G/R7@Z
M'22E8RPI@M"E@!)*0RS!@$0N5+*>MM-&168[(CYMXO6BQP8-U1YS&1^#S4J1
M6EL)OOA<PW(97%8"//-<2Q$PQ%;]CG<"_"+9UZD66\W!VST1*= +(I0)( ,2
M>A,%.,8"Q$S.+C/DL(0VP]*>?Y;9@3;";G7:H&7<?FE)/'FFLO,0D4BC..WJ
MT60'3.<4 R):W\8*?/899X?9&KO5:-<I0=W?13!F8Z[-]XHVY%8)-. M1N!%
M<5G')(JRV6W325XO=<_!(U!CUTE%G5\Q1!^]1A[ !!1D@@1-BV$,2@H\1JF3
M\)OEBISBG5&_E.Q'B0UZ]VWB]5\+MW[C[@7%W42$^W7<])[1(ISEX.O25%2Y
M3HGVX',LPD64C+=QL=NLYS0)?40<:-.&<*-2-"VB9M)%"+F.=]""$'+% ,F]
MX\S1>VC:W(,^G[K! [D\N^FHRTRF32SA6Y3!6^YC1@@E*$+)/8DD:C"R\!P9
M4]KYWGV8ETVD/33494;1-<I?<49"&5_@+S6$%)2(RM8,]^)472]Y2'64'J_-
M>[5.)C1JC7L/QFGS8G>)MTC*>7AYFT/1Z'("79BHAZ0 Q[.H$V0B]TDK8QL%
M@[M.NUEQ%TD+4PZ+@^C(HE4A6XA*,N"^D-/ET8IPF'O@759WKS]KY,5KKR7D
M$)#41J=2++2O>.M8T$')8$Z\I_$^R2Y["//H>AI?96Z-+[Z,1]6"7HS*+K84
MY0VPZ"THSB0$6SAM6Z48Y$G;1C,R'H5U)+V-MU+W.N;L+?8&F3!+F*Y'W6\
MJFF+XY6P#MSE>'_UC5O)OC=B,)<*M[4_DZBG8\P&Z%U08+-D+%C#2VZ3,=<C
M(39M>=P3'[81>8NFUP\Z>9+;X9+4&6A%"12251N=L> LT]DZ*9UL<P][!-U2
M.U#1^JD8.\BW00N]-<&T*W#>VE3'1T+6FOAME %GA(92.R.1?2PD;[,!/ KK
M%(C0G=P;[ +O<4;KP_Q3F(S([YI>HY+.QX0&M%*T7C*?P948 +E.D2?%C6KC
M+*W&<PHTZ$#2#5)DU_?YEZ88(6A[XJZ09<QX A\\6<8J,,V4#<F[MF[#D8Y#
MZ<1EV$O<#7BPHEOX)HA>^#B4K93V]"R,723>SSB49)A7S O(.=94A5+;"9B:
MK\!BQ*!%%O%9<V#G<2@=4V ;0?<\#B6Z&$WVD51E)%DJ/(+3%@&3CLHJ'T1L
M,Y3YV,>A;*6S+<:A;"/PGL>A2)%T0*O 1!E!!3)8HJM#Y.@%$"%8+]5F(S.>
MP3B47=3;M0S['(?",AFR5DB@?8W<5&4M!+)LZZ)E<A))')ME<AW[.)2=%=N5
M]-K9<5>U46\G[X>?/L_F!U7VTEAO!-"R B@L'%PV"K++#KVV16'3B68/(9V
M/=^-N!O4HZT$=L7[3:#U8=BO G<8"[\C-6Y"CCUTT,[47PG119E1(^UD*FHR
M/^HK4:(@\]8:5(%>B]BF"J)W>CQA_/?/CFU$W[5I<+_#W)LZ'^F_+T>I2OGO
MP]GGQPS6Q$P)61A@*!V=?46#SUD#F3*>9XEHY6;]2W?'<###8G\]COM70M=>
MPP+NQ_']KH37H<X2=,GDN$!6;C[_ST!(,8(QWJ'515BV62._1Q]S(@SH3I1=
M;Q /NN->85(QE,AS EM7J0J9OS'2[NXLQV*U9'GY"OE1]3YXP$DI=C_Q=3W#
MYLXV,\*;7>;-N[?7D8B0C&9D(DN5/9G(FH-7TI/N>"&7IKB2S!:J7?N@DU)Q
M-^)LT:OB,DZ'>1@FWSZ$<[P;S(Q*^R1$ <]C[=Y#.TI@/D(D-?+,M!6Z4=^D
M=9!.P$?L1MPM>D;<PODU7-!?/]([, USPEZ] IL@;.HJ/HWQ0'="W2AUF2IM
M--+BHN!II(J+6(2RM6.JJF.U++AB'3"6T-L@Z?T))\69I^Z0#D69;131@"JW
MYUZ**AMI)(AY;-3P#%%$1JZ)#AESH9^VB2@<T,#H6C_+K1IW$FZ#[+)WD^%7
M.C)OW)4K5$8I8V@-P 62#262@B!\@"@U1QV-+JE-3N%J/">G_P[$OO:5/X&A
M[(M&M9^1 (3S^PL^N@GM][$^VW'MCXA\:79[42)[7VR(R:H0F4>7(]-:2^ES
MM*G/V>WW47<^R%T[DW.9-[2NB8/DZ$%TT9.O[Y-V(O/4:%QG=X/<5S4J?UM(
MYL/1IU?CZ6Q*_G()#E, SI&<),\D^4=DT&1:?33H!/<[=9&_]Y2C:*Z\C3H?
M:_2^N_PZS_=87;)<OQ-&"1< 649G@I-0I-=U!D*"R"0#01]6.#I9]&8!W$V>
M]KP5W;D\FS1+OA?C, H-K\/:Y\U3E6+DC]BLR82(7DJ>A&YDG1]-&>DNVNY
MF$=31KK604V96ZE] 4RQT&JT@5H.3JY&,J(4YH1IE M^Y''!K=2\<5QP&W$?
M)K:S"<(_XX*[*W7[(,\N&CD,=QQ7(F9;/5U,H*) </7N,N3"E*9--F5Q4IS9
M.2[8F#+;**)I7-!C\"HS"]DI6J?--1$3+>@8ZWQH)[5NDYIXW''!K?2S-BZX
MC7#[BPL6BUKI:FH51P=G*@P\HH>HA$94GLSB-@[Q,XH+[J/_#L1^'''!<7D5
MII]_/A__/NTL?G?W,WN(LZU=PG(\+ AZ,Z,,5B52>78VB>1R#*9X5I1<'0^[
M^^F=QZV2,5%B'1YKL@3E1 0?DP;)M"1<UJO8JA]A5W&KZT_\%6=54.\FXZ]#
MDOF/WWZ;UAR-MV3\AUEM(4FOWM=YM^BS.)U-Z$VDK3-%88(&IW2IZ9T2(KTD
MY!D&I8PD;?$V56_;8SV*:,DV;%G1&ZVE>AJ<;/>[N17E8DHI I]OUL(%@I44
MZ,*S33*6$MHTF3UP_[S6>GNTA=XV0F]@P=[K5?L>Z61(PW.\!_'C>&OI"&%Y
M*@I0FRH3H2%:R2!91<Z (G--M=ET6JSFY/EX< HTJ"%[CU.D#_Q\-LJO\2N>
MC[_4];T9T1(2TEN7G2FF6 $L6I)73F1$UI>0[-* *EL3DF["T"> ]4^VPVO_
M09.1[E378,.\&1M_*[B;W-OI(-#BI$1"8TU-LA0&@L$"O"06@LO!8YN6Q8_"
M^I-5':JM10>;E7.Q!ES'$I,CJX";^5U.3:=#!E9Z&:)5VN9&<_56XOF315TH
MJD$R_*(GU_\['-&?,YS@=#;($9DJ9$8R3$1H$Q \UE[(Q>3:1-BK1OUT'V+Y
MDS;[*JC#O/GYQ?ZJO?!N'M)KC+,!2TYF5B?[).9 ,3:?[.- **48.BD%;I8)
ML\G37C!'VFBDP83$_R2Q3JM<</IV]-,?5027P^GGQ4DZ!ZBRXTJ*4K$I.D4Y
M@R!"AL(#2<4@\D:]UY^$]H+YU49]#>8=/IQB<".*JW:3-W((RI@498"LA0#E
M10)?._WGC#7UV/G V[0#WQSCGXQKI= .9QNN1_IN@E_HT'Y]E9#[TQ_5V$-R
M2=_62Y,S>HMJLJ-!(WPQH(LDVX^9 "%X#T8&ZR33*32Z6=@-[S$,)NF& 4\2
MK7/UM<@=>(#Z+*4Z FSZ+GQ;5&RB$(EG!]YEVI4E8^!E=("J,.D%RSRU":,^
M">T%46D?I30(%:P$.+G$_,LPQ.'Y8E2LB9XQE/5B7-.NK9D'KVP$QZR,D7.G
MEMN?M23.$KJ7Q9U]5-,@5+#YU<) .$MXM(3 $JM=X"3XE#-HF>@;61M9#GUS
M?/)7,XW4U1^QWI +.UTC&.:C=)S>-4;;)M#V&< SU*"Y4=*5%*UN<P>S/=93
M34WH2CT-S",Z;Z\GJ*9_7@XG>',#M/J":(!&HLC!@DZBEAXI!C$4#\7%H!+3
MT<8V=-H6Z='L6IUI_T&XLZ'J&E!M<_$,F V$SB+A8S7<'VB_#4P!*\4)7^=?
MY#:1A\TQGCR]&JFK@;&^!NG/PU$8I=6"B2(6[I,#9LD55;(@.$]&8@I9!4:X
M8^F58(]@/=5#L2OU-"#4?!O%//V91/,>SVL2[;LPJ17@<380W'A?- <A3*WF
M\AJ"88*P":]XE"RE-LUJ'D-U-+M19UI]D*7>D4I:V%!WL%V7[;XM\QC8+^/1
MIX\XN9C#-"Z%4)@F7#+7OGVL3@="2,;:P+D)QK<)9&X(\$61J"M%-=Y^;F'>
M;52QII?%0":K<W:\5O"0A1<T@Q"E!R.\M$9GEF2;8VUGR"^4<UTKLT6ZRPK@
M;ZIRPOF[RW@^3-<M*0:<.6U-II<D<'I=4B0S(9A '''H+;TX+K8IT]P8XHMD
MV?[*:M!)<O7KL%R#-N#9Q\RS@EQG=2NT'KPV F2BTSS*Q!AO%&78"-^+Y-.>
M:FJ0*[.Y4 :<*,]3R1!5'<HK)3DPLB@07-EBK(ZI-"NZV1#CR9.JD;H:),E4
MF/5_M??2UW!>HVSOD20P3.1WU!^<C?+];]SYS:O^/0^NJ=+Y9:95_O1'FC<E
M>T]OTD^T*Y-0,[*L3-: 6==:6XX0BY(@3<Q&1Q]9H]:'_:[SV4<RCI@6+08#
M[;/: 5D3GIF<(0=9+_!I&4Y: 1ZC$G6\5;9M&@'M!?ME4W0KI34P#O<#+Y14
MBKM26Q_8^KH4"#DD8))68Y45*-L$YCIDW Y%+9=?OBRZ>X7SZ_+^JW9?MZ>V
M4,()3*32HLA.$U* "V2L\<2932++5!H-Y-P W;-_YSI700.+IL:U%J&&VFGH
M*NA0K2^"=SD?&G-1\Z_XP,88A&,!1,KT%C&1P2>;P>08"D]2(FL3I-P4X0'H
MTKE^QSTHI^VTK]H!T4N.M-MR4>,(S)&%;B/8%'W(3K!LEWI ;C3!ZX2TNZ_4
M6E1 WO8:)3))VN82.>]H6>U(J 0$6P(4'IW'$!G+K;IXWJ(X(7WO+>0.;?@Y
M]Z[SLN_V#B9_X[)^[\?+V:_CV?_&62V:&QACI& H(/LZORB&VN?)(BF02<^"
MY2YLUJYWXT>>D-X;RKKKDL2'WN=-2=S].XF;3NBUQB7CQ9>JF_GO#9(H2B B
ME,#H# J%W .1#4AKHC:&D]7D-^)*!V!.C45]ZZ=!3/;6CKGN3SFW76Z,&C[@
MT8:40H#(,-3Q(X;\2S%/IM71!*GR\D3XKORTIZ"=$)W:J*.!8[+4)MGRXK.N
M$PV9BJ"D4^"M%N26>9M<]H:S-L6M1]-:?"]/='=A'DUK\>LE7,U;O.UQRW44
M&H,#]":!LO/+IBB!1:\]IH#,-)Z,L0SI2%J+;Z7F=8S92]SMYHW/\5QU.=T$
M41_3Z.]@.E#K\&Z4MGK,^+X2[X<+3F9%NR2=A'7"IBI.@]-5:<XG(5TV*;3I
M -47!YYJ!=X7!;81=-<AI\7P\@^(>>7\<LZ$505)174.XMR3"H)VP.QK,9A.
MF:/;R!-Y_#D'&S6\LQK&;638H#/J8^/I&9UA4E= F64R>ZV"Z#('X[E4HEAD
MHM%YOQ[4L^5"UP)OL,O?CX+_^.VWT?"?E^0*3]-D./=O%Q-0O6!22PU1&;T8
MIN*-9V"2E[5_"LN-$GDV@G<"%F'W:F@0R+X/LK;%OQYZO &NIC;B.F2'L10;
M*/-1NNRIB>:[RAU\7',C/%JPO+XCS#'P;CY#CWNI>73)]+&1M&;($W;D 0FR
MC0*ZMBQ?XT48Y5_',ZS=FNZFX(\OAM/I>/)M_K.K@S%Z:0P/&;0*A!0-TA&I
M#3C% BU 8':;W75N]=C^;8UN5#7N1<Y=C[7\<3+,G_ *Z6-6DLDY"3I'Z5UP
M 92+A(]\*K#%1!YS\E9M=O^QZ1-/@0=-I-OUIK">G]>8U[I1PI.!C,Y#*I9,
M9R/)=.9> (\VDU-E"P:Q$2EVQW *-.E) VL-TE;SBGX-L\L)CLN/E]/A"*?3
MUS@+P_.=QA2M^ZANIQ-M!'AI*!$I):-4.1?ME34Q>HP9N3*<WET7\V#=A^YG
MX/UM.!I/AK-OUSU_;V]2,O&-.V&!Z]IY+MD$O@@%1FBKDL&H8YO62FLA[6O,
M+G_PV]]']/)]'GYY1ZYBO43\A#]^6PPH'YB8BHS90-3U,*U]UIW%")@X1X[)
ME=2F-_46(/O?L[IAR[*-VTHO#2)NRU 7 0,RK(P(M$4[EVL'#QG &5<3O[/U
MF97 &]W)KX33U^UK/V387L*'OHN=3F:#&PK/'4 C@Q*R3KE6EH,*OD!$U.!B
M=$R[K O;J+"</OD.-^BK95X\>/2A(FH=:''<A30[-'+O ;DRU3:!LDV\;#L%
M'R(TMJ<Z5BEU#UDV5J\B(TP$HJID-6&<!P*7LP-).YAUJ*/@&^WKQZ/6-?&L
M=EK=1H0-/-*ZKW^\8Z/_\LNK*X]GGD5:(H-4T_M4*IQ<Y=KZQG$;I$(5RV91
MJ<>>TI^%MK?LQRT$M]8":^4JOA]._S$-H_S+\)^7PTP'T*^U@F V_(I[.(U/
M?VBW[N.6BUAR),W\&$7AA6$J"3IOL_3.LY0U2BG4X.F/W\]&_FUT.;T,Y_4Q
M;R>_C1).Z%-'LV^W]J'2M6^Y(\Z$HD'96*]@%0>3@I48N/.^377KD]#V'^E7
M/Q#S3V$R&HX^3<]2NKRXG#?<>DW$2,,Z5$=$E-Q#4+4QC741G,\%3$C9RA*3
M=*G)XI_&UK]#V2U7'D[IZU0;+3(X;J>3UZ'3PSSOF3P>O<>$]$+FMZ,[X\H'
MDA,H&QB=Q[$./Y'U(LEF\#D'[YD-7+2ASE8P3XU%[734X,+V[KC[RRHU^J+.
M@[LJH7MS#ZLPQK.<$8JIY-=UF(Y5$;C+OC 30A)M]N%M4)XPG;K54(N*QUNL
M[R;#A.]P,L<Z<$H':\GJ8[G49LA&55P%-)?*!Q-4MFVZ!:Q#=,(LV5WR+=J:
M+!+JK@ISWT[>#S]]GMWP&-/E9-Z"Z%4X/Z\]BJX+>*]^<3H(B6%(TD*4A7P2
MHP5X&>9UO%RE.K$I-&ILLA_P4^-7GWILT>MD%?R?_L!)&DYQ_L+<#LZ]QLP'
MR1IKZF$<T'!03"IP5F4P46!&RWR2;6JV=X+[(BC7J<X:%&1> ZI-:.:(WE[.
MIC/RGH>+CK<#%7@1T@4(#&N@+!@(+B;(0J58K XZM<FS?@K9J=&G4TTT*<6\
M:5SP^K(6L2]:EBULN[N%I'?2-&XWV@&/W'$1'4C&R'G0H;H,R4&2S#OFBA.-
MYI+NA_O46-:C%AO,B%RYQ=YY3P8"3?+*\=J1N][,9@$N)02I8DY<QJ!=H^KQ
M)Y"=&H\ZU<1#IKC^^E-;:4R660*7K-0>++K61;C:<8,K#($ O[C^U&VYTT8W
M#TGD]RLO?&RGO#;K;BVZ@3;T'^$+9 )5F])Z\$;GV@#7Q9B"MV8IHVI=O>%V
M#SX5=C07^HIHY-[Q[76B6.2#.*.B\9SL-.EE+<4+$#DYD<:4I&4NM$.V23%\
M%%9?^5-M-Y'N)'_H?*H;T^PR3H=Y&";?[@3'YLD*A6.(DGQ$:]"2U25MK7R0
MX(+S:+-C(C7JQ;8.TJ'RKCK4^H,VG5U(O_&-1[B@O]Z)GU\E0FR"L&E9X],8
M#]0*HQNE/G+#T:%&#L,=9(Z%:!4PH\-B#XZ"S'87K-.Q"*-"FUD:A^+,4ZTS
M#D69;131@"IOWKV]2H JC!8I<@3O:T.QF 1X32:632)*'\GP5FWF#=Q .$"G
MM8[ULSR5?"?A-LC'6)[1<IWSYE5*09!W;D6L$]<C!%;($+-<%,F1>]5J]MPJ
M/">G_P[$WJYQTOT8SGRK4SRB=S5XHSD94MEZ")X,*<U<XJ4XE5RCD2/K()V>
MP=F-]!LD1:P$=IURNP&T/IJLK0)W&!.S(S5N0HX]=-#7[G'=W:-H)A,+8',=
MMB&D@E 6%P;&9L6ST3WN'P>T)OMGQS:B[[H@X>9\._M46]1>1^FN3CL7>$R8
M,KA85QRY!\^T 4[?CM8[KLUF;<0??<S!>G#MKXUQ$U%VW0KC-:8YB*J79;MF
M":;AWB>F.$3F:L>.&IAEG-[;%+V2]'62:2.-;_[,$U%_(R%WWRAG/<PY<9>P
M9B&MD3%#Y@Y!,1L@B!#KS#)#%A0:N9R@M ,A5CSX!;!B7W'WWO7BP^7%19A\
M&Y</PT^C81DF GZ64NT_7N]]QN?#5#MZI,^8+\]Q7,[H^WEX?ED+>6XS$G[Z
MHT[(PUPU\&I\\>5R-L]='Y?KFHCKQ-(]ZJ,.A+3;HJMC$/=2)9=PHMBLC4Q<
M*:]4%,)%R42-BG">R^! F/>SBQ\'\?-]$&\?@+B]'2/?TFJ,!8J7GM[>H,!I
MET'(X'7B'DUHTX*NJQ7LZV'LB6,QRV @-??9S;>^FF#I:MJ<$ 6\L-(G1"]*
MF]A6)_#[/[D.PM]E#Z=_U;<H?KO:F-X^L3$]N9Q%L"D)EDS4')Q, A2OYG]1
M!7)TRCA>R"EHE$'9Z3KZ2C\X"AX?D +'DM:PY\)__+;Z ^9!E&HND*V 1-J<
M065/\E J@<N,Y10YR:--8D3#11VL2?0!J=KM[M\991I$35<CN],=<1-\32/L
M3R$\3)C]:"BQ$57WU.<A>)>*E8%.,@@*(R@=.03C$'2.IF"BESCTN94>N/'U
MLZ7;-FIL0+.?+KZ<C[\ASF_2W\Y;A%_%HG3.3%HA05BFZO@(LLJ-(:-*I)0T
MX\&;-OQ:"^E87*M=M3=N(?H&;M#M</LYM-](RM/W'WZ[OLHH)N;($K!85&WI
M["%*H\%8QZ-FQF?>IM+^45@GQHWN5-!@S[@*6E^/F<DVU!8 Y%X5L^C4')BW
M@$+(G,AI=[?C+%O4FYZD_G<7<>_7 C<C;?^&87HY60P[O0WQAND49[6[U_DP
MQ.'Y7$@7B]_,85;H'W^M_W@\HE.XSE>F4SF&Z7"?GMJ-$74;YN]3?$OA?,LB
M+X:YP*)1+(=8&[AD#)E;7I-C!XVQ[;<+W8 [F\,XJ_WC;F!< <YO:U.DQ://
MZN"*T0V2'RN2VY@10U0L! 4%0P%5HT?.)0TE.,N+)3LOMVD#TNDR]G8ZYAAN
M(+T>3FO@B1#<#"_66%AA*D#R6=2:=@0OM 0;8W+6LSH2H(W7\12T_D^ PS'P
M@9?1J=X:F)1U&';]WT__O!S2IE#WD5L3I_Z@-E&X]XT[OSG@Q2N=M8.<315-
M('LGT)=%B9)%YH*'C=I5;Y^=M@_L Y@DW=)@.8FM-QTVL%GO QM$GZU%4CB]
M68E<^B+!23*K)&,H72P2EQ.=.G=B*HY3H\@>4FZ0%WUG-WYLP4XH9%$Q6F%-
MZG<L0^16@ A8M"63B/$VN:^;X7O)YUH##;9(K+[MO%)G**U .AWHZ+DJ)8,V
M) #EI:N970;(%62F.*FD:=1F[FEP_3.LA5Z73ZN.E=* -UV\9XN[.S3<TI$:
M 8VCA7!>6Z ;,4\O-L:E;!OU_.IL"7TE&1S/WG88[1]+DL'-ZG_\=B>X\/,$
M_WF)H_1M?N_"' H>7804>0U[*5O-APPHHN&.<\U<F_R9#< =ZM+_0*Q9Q]V.
MM-=R<UT%\"I"NPG$IE?W&X \S.U]YPI>1Z".M7,@(CGFHTST!@=>6"TK=1"U
MUX!)2^<P.Q_:] TZ&(&>N(X_!OYLHY2>>#.]V9>O;G:"11T#*R"\#.1LVP+1
M1@6&,:E#R2I@FY3Q3= =T//L2JT;T&8OG30*E=*IO10_F[\Q00A,2@G((:4Z
MMYW\(29("#)(@I@S^4O-XJ"K,;UL.Z@C736(?3V(S"YA7/W=ZS=@ ^Q-[:)]
MT!^HJT!'3'@TH-J#&IN'WK=<@P^<,<,C!%\<>=AUT*XR#A!3,99+CK+-U<_Q
M4?"IS@5'R,!MM-> >7\;C_#;W\+D'SC[^7*4KU%I1<\-)H%E9M[%TI$MP3V)
M@ZOHI2M*M GXK\;3OYG5GTZ79RGOKY &%M<=9^7FK_]SB!-ZR.=OO^!7/)^_
M161SFLBL .4S87.N]I-B K3U16:O5-)M[@PWP_>R+;$&.FPPK&BE__$0[W4"
MX09@>P]/K85[\$!59WK?Q&GL5&E]11_6@HZ:V1"8!&ES'3JI$D0R&N9=+EP1
MT6CM3Y5AFT>RCH-@V^BJ);'>C+Y<SJ9S"?#K]B4Y1*>T!160SG%N KB< EB>
M=>8Y%AO:&%:/@#J.(%9'ZEQ'G#UUT=*FN@--7$&S,BB#5D*2VA T.NR#MQ:\
M9YATD!(;=4=_!-1+H\DNNNAI-Y'7T#2&.FL4(EKR5:U$\$Y'* :C";2C$O#>
M:")?)DUVT<5Q5*"\'Y^?E_'D]S#)XW)3BS =ESO%"EW7F&SSS!ZJ2'86P5*=
MB)>)98O,^2)4-LDS(0RZXN@LD1G]FFN5+9[>:1[5"I]S[F3^-AK'*1(,\C7G
M%*<?CT>)H(0KV5]E]12+.8N$P&,MMU(B@G-U6HUC06,RC RZ/K*I]EU(9YOS
MXP[])IA>A?-4Y]S7*>7$BY\7O!@4DZ4,,D,P28'2J8"3+ (6$6C;4JA*FUK2
MYDL[>-9NKV_!VJ/D*)C3TKR]L^/]?3C[_& QT_NKF;Y?RB1<B.?;_+,&HH2H
M2G+@M75DC$FRPUQ68'0@/U(:2S_NS0W?>SD'? 6.@W8;N/G]<J:G.-,FBUJS
MIODDN>G FT)^2<VK#>A!)5DCP9Z#R"YQ%;73N7'F9Y?+^?-%.#;.-$BXZ'A1
M_TEJ_F4\G;X9+3K8O!E=MZP99,D+"L/(^5(<5#V=HR@"<O2,>6O(3VMS)=[;
M$O]\89X#MSJ\'YLWR^YXE6<I32[KXF8XP>EL(!13I0@-SD<$5; VYI#T93&F
M6%FT2>(IK[\'G']R_S@I\9#MZLB.C \XFRVJ=*8#Q@,W0DAP1M8[J<0@%,P0
M'=)/%$/?.G;:^9K^?#&.DCT/WPM]G,ZU9RJ)@APTK[5ZEAD(V3-:'@^.&\V-
MZJ]&HV/G^E QTT7>CA',\D@$)DO;U$97 GRVI7:[,I%'%Z1KTP&LPT4<J/[T
M.*)T/7/@"&M0;UZN^1B8>48'ESH)@P;0:C(.9(H0, 0PR5DA;+*!-V;U*EA'
MDN77'U?6Y_GMJ;.6P;#]#8;EY5W=[VZRP'Y2 ELM\>!IA/O2JMU52(><>);D
M+[IPYEGMH%GS@TVA?<,[5]N!<,\L2X$UWI&?%^DWSVQ\=IS?A@KM._Y<)<G$
MDHK(A,*66(<+<W*; B9R.#@*DVLGFS;\7 GG6?O+7:C]\89 .^BLP3UR1?)F
M-"5K=SX2</[BL8 %1081:PJ7JLXW9XJ<[Q TTU;PV";[Y"&6EVYL[JF=!K=,
M]Q'=:3:]":ZFAN$Z9(>QY_;5W*-$V%/L#<ZCM?@$QZ)"\9",E76@**MSAQ&,
M+JSN>SSI-@E6_=+A"4NG+S9L(^VN)_O>.=Y^G SS)_QU/,/K LO$N>/&"! E
MA9HDPB!R+\BB,ZF$6EH7EBR3-7=?CSVE?X.C&T6,6TBQZR'>_\_E:#B>W(%W
M%QB3T;&<-(12JV9M-O4>"P'1EB23-SFXC=3[V%-.0;V=2;'KM_<.V3Z./^"D
MCAYZ1YK"R>1J!,@5R.*3RL@U2$_[K@J<Z*<$>6E>UFD01K@-)[1O^L134'L3
MZ?9>YG"'MN](:,/I=#SY-E_4'G4,3W]HMX4*6RYBJ1+!E(16>2XU1H5:!Q59
M(@-><>ZSB#AX^N.[-+1NKV$8+Q:-]D!^*#FFL5H2DO:.X)04T4<TMDU)VQI
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M[/6Y#OB1!BS:Q#2WS,CQ;R!L0_)*P(::V\*[O0O:?LG8Y?6I/5_AV;4;15)
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MNR=B'V"O;64'*K!W ]''2'_2MK)%*E&\<F"4H/.+>SHA4[;@,6<78@E9^>=
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M5U$"$0^$V7P&8XZBVH3%AN F)??7CU.GJI4/.?C/.#W2OSH'TE0%5&E@[\D
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MXL.TR<#FUWJ-3T!FRA&)-X]-&9_DE!VV-#+KG7";^)BHAK31OF7HM5)[5R"
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M4Z*13^1TFYO\Q6HZ!SXEQ>^02IUV%E W?^V7D@U)K[K7+'-9_3EA&H40;^0
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MY1\L4P#<=#:Z@B<^.4#Z?YVS-3D!J<&)+/9/L,H&N &1OZ'+( 9"\0-L6J>
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MX5*:0(I5'\"S*R '.(04A/5>Q-&30\O !UG%F(3I!(H^/((*6(#_S9E$0'#
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MT#_UGY*((>>H7UL_W4"J]@XE3K5I\AZ:SU/CA";F.E/U!$2<1'@]C_G!#E1
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M$0)#R3F0X,GD>Q-#' ]&#(%3Z:B"*G=\R;>IO"J"412A^_!.[9SA#]%DRTX
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M[P+-*K*2)_KB4(A4?E-'MOF&KY=9=W;D@^)",.3&FYW@S35I5. S7'<D2:D
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M_)U?EQBZD  Z<,OT[DGR$)X-QE6!?S>H* >/V&2R85Q&O2A8^]V/W\UYIGL
MF>#IX^YMZ#4;_M.-/^SA:<_:KJN03Y=-\TNM1OSAR!_VR,=H+<!>4\!2P%+
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M;YSWWC&^'_//WFLG:^T]YWR>9^ZUUD[RP!F3 JDHG[.(?(H4(L6C%J>T."B
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MDH@[059JFWFA&P,_+TKZT6I&7KNRJ@/RGX6U(LZ48M,N#KB_2+^SF<BB]W2
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M_*<#DRUPEF,*D#!@_/A+E.QO94:9P#-F2\<S/+^ZQ1ZJK8=X0O3A;5H$:W*
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M,KUO-N&6\E40!<VCAR:@-#:MUR*Q9[2_-(41KJG&9+E^QEIL:3?;G^9I  Q
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M+UJ['@[\R4L=>2)_53Q^X/T-;CT6R5_,'RI%/]BECQ#XB"+Z6/F><D)23[?
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M\-ABM364_E*5F_K-FHJ)/S%I+I<V\]^%,0*PO!3BETY<HM_M'MU[)&;<.2J
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MI<DCSG?JU=N$[<GMLW5T'Z[\)>X4T"Y*L]2Z2<Q".%I!P_,NYMH,\A_%^4K
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M5Y=8V?">9@&SW3PU%?9<MOG)+XWH5(-,YZ!HTE?_*@.!Z(MB3WE?7,=DI6E
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MUX>_&B]KVW+J#UIVQFR=:"T5$]('_4G?4O;9]]1"';$Z>PSJ8->RVIX!MR'
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M^%^ B1!>_V;#6/T5[H;PFIJW#XO>W&/XP1WAHSY;GTWAAD?!EK@ER'N9<]?
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M\XSF6VQT_MI:FB;#<MC!-5EG)][<AG(]A=CC.D9'D^-)3$"IIC>(I 1I!AV
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MIH6.5YJPYQ8_$35D 'U)0Y6@:^?0W;/SJDGJF:-K-=O?7V_FF]'48?I^;1(
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MMCT*;KA[SV9-:^/_CJQ(E033FKK:JMPZIO%V.S06JC$4&[EI@K0( %@[)__
M=SJP4A"\&39/>U2T,8<9_'@L;]1?6KG5X?7>U3D+Y;FW:TKV<ED<B$8R\ )Y
MJHCDAT^J>A%O1(:I1\X^KFUQM@G]Y.+$=_4Z-=NIN4P!EN=GAN+7%PJL'!L3
M2FV[BO4J;TWZ$(8%;Y!]K&]"4/%BD[)0B24^YKK*%=>) 8-/4_E)]_*;$LE
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M15ZA180_G--!Y;#(#D.+;C9\IE;3\(O]+W6N<2-A8J_<5/[!L< ?GJ[B%LA
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M,U+RVWR;TVQ<$^=ZW&%%!00U S[4)\%1Z!GP4WI?9NO7&2"XV@;!<M:18K=
MI*4P^:^*4 A:=X$2IV58/R9-T-GMCE=N'YEXF41O9#5H0?:L4S'BZ<&ER3&7
MGMB>RIYL9F5#0PZ R9_._2(9;A4EIJ1HMLP497V=]DK#9';PC\@=QM=DX#)X
MC_$*=2?B6 ).8BN5*9-GP(,D)'2-?"\!B_1:(>3@[9TTQ<4OTV?NT/!/GP'1
M2RVI'1!FA-VV3$>*6$84ZN;5&&<;!B.=1K=77)11]Y_SSN&S7/41[<I$1LLG
ML'+0.V^_YH3UF;=VCD5RC!VTPRIJ VNE <:*M]+2/I= SB&<%>7;B, H_LX2
M@5N_)54KP+%,PFU!['NE<(=H^%;3 W_V2VD!HXK*"I-+R1V[T9D<"@\;C][Y
M@KQ/WM5K.4Y,?+WP_E'7<ZK-?3YX(G:HDU'$^ ?2II]7QJ(FI=>P^D>YV.^Z
M- "S9<)ZM_?TLL/R-,1!(N(,8%$2K8%3-G^IM'C@'MY[3^/9%XT?#+[=/["4
M'[^09RB3@_TVL4=U2/I#67>1O-8QZ^%?9JGOE2-$/[&T!$8#0D*\A>3[[%B=
M/_7NT1 "O)X8[GT*_?O<X)AI>:*.4-L9<'BR<')M<QLQNT#4WMDE=MQ&GC!G
M@=C_84)X(P1W=0@?I?3GT%7$F<"XF4;Z223BJ^,P9,LRB+123B_)-S*GZJ;%
MD"\JJ+< 3LJQ2)>QU")D/C4*>HFX0-I-T%1BN]'"P.869&J2J%W2CC@<7"7]
M,+\B!D)RI\<2 V? TQ+GWP=DV-"MCR^3H-45 <NJCQE?C%AYV_SR$,*(:OM*
MG[H"D)=GP/GSP$!+MA*)?*Y#/8C]T#UG."5IKF]('VA#:8ESI']S.3D#"#XS
MB+6W6: &.,\9\+5X#8P5[CX#<@.1BF? \]UCV4QR$G_81*P55/R("87LV3=2
M$\)O(M8O50PA_D9?:^1_J[ *9M+D'6=R<),]Q@*@6XI*'.V]LG:TD!.:"B="
M"\F?SN^< 5O\#F= -A<&\;>*6R-?!\W2":9BG3#%]7<I&'$1[]X15'W_U %
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M_HD1AZBL4+DL!\4*^0YD6A[[*&CQ,!<NB+G0Z[[,_>%S9>0MD@V]-_C9A_J
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M[?T<_B+]KZ_[QZ*L*:X$4\0K<ZRD)>C\IPU^K4JM*H>_T.WI/1&&0$5&N7!
MYWV-OC*E]#-5C]?AO)4-_BO+^79C_PM Z?]>X[_Z,Q>,UOT6##A 6E%>)W2;
M/<'+TMQGW#5,/T94>0WDC0;A'EE*G0%9$D3MNZ108[(B*(U?NTBJ5B9_Q#1-
MFG7N#.B(QQ00R!![]B"B>,S??=NSK@#?ORO]VV*0*WP'@=*$C1+]D<?2U&<
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MW0B"2&_2"0H*BH!(KP$5$)$N(%*BTD&J]!:*5"DB"HI2%!&4$NF(0*0WZ55
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M02I_%F#8\_-]+$S@O>#2,-EW,X6%XZ-VKRS6O!K#?D80GT0SMSPK\ P6SD&
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M_<VGY4B/$F$.@:LXU'>^ OFW"@JR^D*!YYOZ@I\.AI?E#33&8Y"M]O->4F3
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M ]D_1WX7#CQ@[O7V:Q?L.,M)Y9!/+K/)3GU5/O*2G[,A%:JF)KYNV;FT-9_
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M*I8F:! ^.J,7NKZK"WIPEI=1/ N;]1"PXPT-L5X]X'3B5T7]C((7V(A@,D)
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M_L_C@L4WZ[5"3AA;ZXZT^,:/3NQ5.>VFC;6WYY!AEP3_)K/=# 1P*2CXN_:
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M5+OP-;"-1657(F"#AFUA=^?4+@-_KSEY8I9N>A[_=6%)G7VD/8*);9"/!RZ
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M32UN),A+7,WI[_^P5^#_OX:WJRS0S2].X+,^/$"E#_Q@=AK\+T[4!>-83O$
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M;<Q*/Y7/.EK<DQ]IDVX%!DC/0+CW]!W\F!6YEL3A[IV^?Y$%)6N#&MPL<_&
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M(.SXCF68#2JIQTPE9)\:;=86H57M:T0END7:O$4H'X0I'D_4-#-G=:@^61I
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M&Z#"YF$*KAG%I,AD7AZ'7#!?NIZYCSN_ X=DL-/W_RC+DM"7/O7VXDPZN,6
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MOQ/4DADVUVV83>&^DS+*&$[/@5ZC-O&WH;"8;56B-N].>/:1U?Z'(>4+7C8
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M1!6"=752N:7S(F+D4M#OM^Z;YUXZ'B?EEMCSST2/W*XN9\S&[M(SO\]_ZNY
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M+J][TVCI+-[)Z_,78"A3-+O#U'WFL(6-:@>&UH^-X.F*;)! @<ZM'Y;/E7Y
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M(:5+/N.%$\^8MD(KW0@I,!!T_,4*&=#D ;!PAH >,#/"H>2JDC<JEK7%1J6
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M:AJ-/PBV_Q@'%7"1_JY[:#NX*@.\>6,#610R?<3 B]NG0[1+T)VA/#D_L.D
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MUW0@"J=Y)0Q;J>[%.JRKTIK[D25:%@C_7IYXXB+L4;BF"8UCYT-'&%XQ]%K
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MA3SB"5(.\1VYFB?.P3>&'%8_0 D56@%7+UJ>IWT'LPVOT/9H_%KG4QZJ#KT
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M#NG[0FQL8(,2_&\P@N#C,LVA$+;6^";T-XS('2F)+?G2R\K,VUYL61C+T^0
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MRI!B:)QU!/?QKPX7AS6%Y@O>V7ZI7$*45$[[35)?H_S-I XQ4\>DN;'2N-<
M$7Z4-IY7R[;Q,[!P'0R"B06YT4 0.X7*[F:,]5+:+@KJM5.093 S[5LK\>,V
M<P@?3H[LX-'*1D ^TQ:EG,+_BDENE0H:'JI3N#P[P[Y+DH]HYHIQ=E:LD$H-
M%]$_\C8C')J],+Y!)>N3D%BEV$O><7.U2N&>FCR!)]S*[-QMY%5-)8^^2ZSM
MNG=RYY#CHM^SV3?S6Y-R'7!^RFG\W>OX+92";,?<B18Q[(J"OY;35:01R+0Z
M675BE?/;Z0M>/'&":=$^>LSQP,08V!.4DE?3D A5XD-MQ3@(0U@]]E:+2V);
MA'SE%"KZE=50\LDHX()DU#>+<[>G04T>.]Y=2'&P!V(B>GC<EE3-%P.3AUY.
MWM3PJ'0RD1.:/K?,%5'.SQWBO!#0S^1H*+MKTO$:AXB':A6M6YR>0IG5Q6\?
M6J]+?"(9\&W#QT"0J0"2BSP&_G41S@K>N,,0W</V-LBKY3OC\RA*L3<&18VW
M!!T8EYNRK9C#/.%MKG5\XGS1HH?3W4+,2)X!<D9Y=R^JH;M+/N&#=2\V?-_^
MB*[.F7Z$-%K'($GR>%FBR9 ART)7UD,RO,!^D.W3+&TH]P*)GZP9]&9>&$7E
MNCZDXJ6.[W N(CG\*K8=?9BH\RPG6=J-.W\GZMY,,D^P3 SY)FQ<K94_9=Y\
MH,V$RP@C_-R=N8.X-US5,F;%_?#.PS.VCZS.)EY86,19Y^&M5G[!G\WQ/9;A
M/6"!G6]0PW)TCWAK#X<ZB76;/-'RV$IPNY\[=59A1OK9X"5O_L/6AIB(RU*"
M3/MT@ ZPP,;R"4H1M ONQ-Y3MA!2NW%CEBGS\Z .X.O1BQ$7^V 1XVU(_ W(
MQA9#&*> )F@0H@E%-A#BM%U=TX/:)"XD>G5?@ 2;LK59(K=?EO.1^5-H$;\W
M&&9UFPF=M\39$^!8>V)FB<T*C3M9N.9+P]&P]V%DOR7G>#K OW(XZ-<6I?A<
M!ZW3B0[D?]$C*\:]H7&JD.\F/+K7J%K?KGH_58P?D^<YR*8WSX?6F\_K5DJ4
MD,8+;\QAPOZW]M[\'>H__/L>V;).9!=#B!)"2#1C*6M2"I68RFXLB5#&C"7[
M3A1B%-)"4]9"QC(H:W;&,F:4[&:B\:Y9W//YWG_ ==W'<1W']</MA\=O<\S,
M^SQ?K^?Y?,Z\WC-@O/Z\Q',7!/0D]=9OS9*:3<_C,MW+/4M.''': 6EF"SSG
M>-LR";L].<@(&!?K+&!@1TG,U-*0O3Q<+\3O%65T+=E<^YKP8&]8CR)O\&"W
M@UBT[- >Z'\I(JUU5#1>*Z%$!L"2SG'B)1_=DH=-*#T85BH9[6_.Y@D_^.-@
MF+#+.Q JZ!&("DY'-ZBFP4AA?13O!>_8#>,'BS,"P>%51+]&'@U=&S,. 44G
MAX'M5RC/=L\KGY,%AE9P#09=F%C88:0>"4Z M1&$$\LB2DC^=4-2$39DB]'%
M3QK1N57O^\OROJE829]1,D(%,0N0*M0B/+'>>0,&Z<Q,NBD9JP>T7-'UR_;[
MYS!_;@R.:/Y-T.BU>;G]_ %1/M+Y)6L,7:O%]D+)$.'JT* T'#LS#1AT#+RY
MH-'2]*I(N#!A73E&7$51I^LB1LU0R3C81+Z8NDW;I%JV;Q%R[!\38#%EU,>[
MA",&,BK%V1[-S6,52.7 GPW*BH[318$F;O5?D:;,NCV0+W@:PZ[U'B@=S<?0
MP0C_$2BO+]SN:+QO'>+1ST=8'SV;#Q+E&7<BF-RV%]>HZW[*XO]%LL 5&JW-
MP#A.8GQ3-ZVULI7]U];-&Z#URS"*TS!FJADO3RC![('*ND!L;8/3;^R!.A(H
M0[$O*:\22O2HF(RMW$N4P:)?2:6?PJ>37?= GP0_"@IZ?/II844-DF>-P^MA
MZZ1R H C3W80N5?GN6Z\2+V,:9\,T1C/RFY0NW-RD&_VFJ#FB)5LPH(EG.WB
M%\*C<3Y:<1!>AL%[ADD#$+5(C[0UPO+!4Z<66PR.2<6(F+G*W\J69DX+2E^+
MU8[[4:)!!6]4TV4!U"Z^<*F6-)0N#QJY;/OPY*+G#XF%Z,$>__L_P@V?"?Z(
MY6CC): /PWSL#R)/ )!@JO/UST\ 3W]%7/3YLJ&F[=AG[NG6TN&:I0=,_L>!
M+ 6 :7',C]"C$9=@\A'."UNQ54C5</",_VG7NRRO\<V-I)-IY39) H*'I*\]
M3Q.4V88 QRN[U%K/HMKW0 +(\+).O82X]T#LR"J9KWM%XUM]LVMUQHM;9[ZN
MFF5/?,': 5?H\%G?B9HI)))R+5]+]#28-YZL7><A5''O6;=V6EBI\/9"XP9N
M82@%SM%B3U5R;/Q$*0(L!U/Q31HDH> [QHB<E#.:1QAOLBJ>B;<II%!Q7*QQ
M2+UW-Y/''L(P LZ1SJ#DOP[^>Y"/0Q_U*WQB8S5W.-E1['GP9^VL>]=#X'J,
M0$"$#$G <,!\!\(6R=AXJ"*BD/:B8H <"1:HJ9H(%UDU##%6(S8;_42^X>0R
M.!+\+X2N8U\YRQJ$"7B,3,O:0R5'N8P.*JC5I[EG+$I!%[[SXHG_N[D/9JV^
M0/Q?)#O$U@E0/]7BW;%$4K6+0[*$M?_&L4_GT4U=AS[PRGW"#L(3893+.((Y
M+8X2\(6],N%Q9U63M.H^_,([APNO^&1X!&D*/(A\U@=[(I(A/0C?!'' 7N .
M[8%^F% -F'&:Z)VKSE]A%,LO9P6TIFC'7[K6N"%V1_O1+0N64K#=?C\8/VBK
M+I.0V35$]UK&<>NY@JWJZSY1RA_-_>P74AH0G^AP4[X[8\/#=<!9V5F;&D[K
M!6*J&>%C4&'4$(M_U/@.N5A46[.Y&K&MX]OT<%$[*R,^:9;#:+OYA/B'X*_S
M>Z#>NU6P=0O8/X%Q>^!8D4IB3R:A]N+X$;!8IJ1TH/&\<KY6G1MHT3AOUGK(
MOCCJ L@+R=Y_L;'(("9&#RX<84[6ZA3BO$1%8=^TY1.J'_\>*(=?SW'P2MTM
M&KD6EOKS;@3*Y*^M]QZHW0IZU)R"H>&8SQFN^@4/JS6?/ W1+*Y\M99:.9^2
MK;#9WU]&77[D;+X'X@[[/#+9">>N_NF#:R!V7['V+\_472=IZQLMAIAB '"]
M'=WWQ@4T^X$'F$]>%IB_G!M0X^+<5GZ]BN:Y[,.!4D9-0.HQ[4'\?=3#W7 >
M8T7)Z-*(^:U+-6/E49=Z5>^5]BGD/56H>:,NW:Z0Q7,/1V'GG12W8T 976 F
MXEU;H5?10\H6OLGU"ZOYP>M>!UJ7S-)P=8Z8$V%@2=*:8U"?"C=#S9D8K$=1
M_0^!&5::8)@I_!CPK Y#.?\U)!\VE5_"$+H)6U;C',-Y;66@C  MNF3/(CH5
M"AFN,CY,PAU<KHGPW5'/S]ERB*G&!R=W?KR67>O'<TI7Z9$3-)MNQOK/\:M@
M\:X")-5H#THQ\^UJV,TC3T=;JU6**I]ER Y>4W[#)?0BPV2Z1'VL196=A@]$
M]+#XUA:$.,D6'SU?1!A=HVBF^CY\#8=;>F7E^G)8B'XU>Y?HJ%ZR<.^1<S2
MIH4QJ_= WIG@E0V*"WDBE6K>=J^MQK=)OBFIBO:#)_FHK\X+_2R>;]_=I4"A
MH'];M&O,LM-$0N["4M%B,<RNR"+?VJ/NRVAEP-(\2?NS^4*@@_1U?5Y!'8ZO
M6#CV.>RN%J%UFU9!T6\^AB.12)G2$=Z7SWK5WA%Q/_B45TB>?..A,[=43H6]
MJL+D\ ['WRO473A @C#$>=LD)>2E*'6MFO6C#Z20Q[WU9F,G=B]VOQ1U>37W
MY G>4\64\_[K'KT_C1M@^FT_3.UDK#%'^2W@)D2,X4\-/60:0-(X%O*C>N9H
M<A%:XT=5I=\N^C+GJ=^X=+@60WQK@5->#+BT<^"1]]=Q--[1/AE[!$:YCHZO
M=-%F%C,@1U>.F1U(UH?_HS:'%V4PL/4@OX@^6BGS'91C^4H$D9S9$<3K!^5*
M.'_VN=OA+T]69?PO=MD:/G25E7:[%O#'<]!RBB@$/;H,EV!POXCHZ32X2S>?
M"'!:G?"_TU#RMA-PO2[NN=YKZ=<+;$,+ B@PLF#AJ$63"86Y!R+T5QWX"_>.
M:LOMN3@Y"*-87\#!IQH[B?Z""F=+2OUW!3DE2Z9[7F\;#TU$0ZNHOU)>4%1C
M6BZ079YL:^P$G/UU)5LWO4_03E'Z'SMWL]T=%O#FQ;NJ=A'K#-(5$EVHN\E_
M^O+J<9]-%6OC[QWI?/[7L[CXS'+VV[0#IO1<<OAC&.DV0X_J'=_2E4@/LFH>
M->X>E!R,7_S6<Z>I]21[LYL!M'E(7*LJX/AV<[3%=V$C\-?&([NV:1US)7 1
M[_MIIVM!F\6?Z1W1T(V)TPCPH16#0K<WGCQEK^;/?[]%<+503O&9NI,]]N.4
MPD(<O 3R<:"6U0]KG.S*C"X,W<9PKC:4N0UO*$>M!:D^%2O5?$@VE-=YA%'4
M?>Z%LTAN^[;@_(MW_2=:<H./O>%M@$JJEFE(^ )[O/G&V21>OO+L1U%OQA3W
MG7;!X;FS):NENZ5@18!.-^BCV[-%Y\(>R"=(<&72SIML9]31\&@B\5362V:#
M;(#*E>LTX1JK I9H.RY1G(9C'*;3*C\Q7Z"D;OF4G-#PI1JU_Q;2Q4LX"]3X
MWK"^\.G$(XD3O8MU*;,@IQ;, I'QRG:QD9F<3_RG:E%%G EOD]E:+Z-VGF>^
M11VYT=*@<>(Z0+2,WLA8DCQ1@N!H \<[H!,NQ%.LW4UDX#581OD:[=D>"*N&
MWE%_M&,/'-\#=<MF)N!JV=U+W$D(IQID!%[M;#ADWI^6@^YIYVQUYX%5];GI
MT?F W0M V7_"!_PE$X7G4N<.WQC1"-(XULUGH?]+T.B4(9>\*5?8>V]:7C.0
M3+^*;C<]&0J)/[7<]!C#NR'Z!YSDVEW2..\1H*[?9GUO@Y][L<CK'$<I-S!*
M^<YJDS=D/D.I72^UT[+YD-C.TLP!(3^'*YVNR8)2@W16>EJT)U?%="U#!.]W
M'>T32Y&3$W:,^7'(\@K\.:8.UAXT8[2XVQ'EWB&O40NX1)8/U*QYY>\>#U-.
M?ISZH_8 9W'%PU6I#%W7R75;*K8;(P>[PU<WQ./GE(\3;U'GH#!T5Z.E1JPZ
MF(76G.H>4C9O5"[=D(^&_L >9-:P!_,75=I[P#"*5!0G7IGDO_WPA5^@87T3
M9S0^Y.>GOT="V@5Y'!$=# T29&9>Z_ *^#TPTY;KD_I0 -[#I<TG/WMF^\ >
MZ&6&S6:/4LF?37@#?,.N M6+/AC88GJB*XH<^=M_1TXEX^;F<F:+R:^^3,5G
M3$F%FN^\;31X_:_NH#08?QUV^GZ?U=C)5H,AM%:BWH#?HOH/WX\@>=\C]X^\
M^ADNW=O=S^<K"2DGUC:VV0NC!C#\I]&<$7[&,]/8@@>/5KD:&T_R%AB7K%MR
M%K\5M^17WS; HVNTNNUC8(*A6H0<H<!_],5S)2^TDEKL7MT2FO&O #V;MN!3
M:V[YL<"5'=WS1 !5@!K$R+><HULS5(:1(:2>&>Y5_Z8:KSF5O-Z8I3;6JCTO
MY_V\.YW\(,";=9#*]NTEO,P2AHLG&2;IXP9I>=HE.B#7^N:->8!2Y;1&].WW
M;=E9%H\\(#;_G&GES+<L+A^V<+2X>V*!T0Z6JLN<9F3$CH"0F<!,:D_H'9FJ
M*[4B^3U;!SFL!BW4%V& "G8]E_*4%@N R=5P,F]<*56B,HA\W/]N4V1SDIRB
M1,/F(:GR6\C!GG,/UYS8J0 ];6_"C&$I >A%RSBD="4P1 HG+-9/,+2P,QI_
M1V\\\\_G\Q3L*TE9M[ZA'WO]#(AS10M0[GEL?($$F>:TVP,]CN7;N'IU/+!>
M3E\VVERC**GC4&56U8I21H$PV(R/KOD9FT \% I)F>?\SG EI7:U?G\0Z?BY
MKL!">+3="=+1:^KDUF6UX:H!0LX$TR^M#:/FG(B<W7F5$' ?:;1*[GPR=$*Y
M4PX7&3@/:\8\^ATD@B+"V":-5-:JQ)"AH#N+8)(1[RXV)1 [J5WJIB*9?<3@
MX$CUUO'S@M'<,Y\^2 \XLKW?DZ[KZ*DT]([DVSU0346:#KK=#NW[;N+6K+DO
ME]I\RM*!SNUT] G0%P0=P0@ 5*FY'?*B;,61BXBTH.R!4@,G>BY1P?&;RCYW
ML@O$'A;]S#KEL/9)[C'GIP,\X+D_%&>&>#0:CUVXLK4'XAMH9,7!'WWG?8(:
MQX@%M@JP!M&'D-ZWS59ONN6JWVAVY[L'9$@H_#E@:9X!=$5H,41K%^:+%K:F
MFR]1_XSC""V^BP\#]81L'3__W937.C>AMEL2EA5KOCHB&A*3Z<6L:Y5W8UQC
MYK4>BT#8/9[U,SA[/G?&Y-WG5_D\-T;T(/->26J[1UOH++YTJH$=6V@@$3H3
M(Z$!EIUOCJ6_=@GL,U<.[#:FG[:3%9[-GOK.VX", #1*4=_A_.QDR FD')P?
M<FCT2/CY4O1<7O?HSUL6PM!0]^RO0PH4NPC>+F)<$!W&UFX#Y,.%PV1UK)AY
M6<3]336M+<7KF+Z3UX^-J_(W)TDK1X.&Q'=Z\%M)-^T[T(DE1ZD9S6==5FZJ
M/&FLK?WDVBZI*(8A>W6\7KT1+7VLU0E(I9NH;ABP%_D\D+<(( T>DB)=-F3^
M204$>=VX&*O[L=SBEJ=!XF4K7K6(;C7.'K0')A-29Y#"MDGVW,L8+I34LO--
MR81UYTO-5-ZTS4*UK?>.R=D:9=:7\US;@I1C[Y]12/EWE:;#Q/ZQ)YR@=\^+
M4C'QSNUH$:1L:,._5P5BKZQN283.R=^WF# K]TQ4,S\TBV!?X[GUEQ^8:5"Q
M+O['%B-IY2#>_FVK=;3$700[OWF:-[+X@^@77Y/LGBO'?"_^'O(/,QA]#D&[
MS:Q"7J#V60###]_Y_/., R#.3:/K^5^MDT=4LA)R0^0OM1=_6G/3I;C0?@.[
M='O@Z%RK.$.=POS%CHMEKN-_4I,51C0\-.?/'\(6*N?UWW']0-0DM0WZ81F'
MAU@7X 0<JSO <@]D4M*<"2AMI.EC/O[0P3>[K;FU%EY=[>R[N <BJI512H43
M:<[,FA9/JL B)*E5"'F;XHB-1:GXZK_Z!UM?L;TQ?UX_<$IZ]I>PG%6X8'.3
M^$_<89P_.,E- 6!6(^6 PPL!6EV/V!-OP;I^(!POF2Y1?+=?+(GR6%>DA3-A
M[M,I_K"<,ZGMF<!)QTQ<3"8K=H?.]DKP17 //(-X""E./P/ .V0N9,9K6F#>
M WWX52+NDW.VV>M4Y?=_,$%]Q\SRC<)O1U\/FH$L5K8%I98(488VN!>T^ D1
MWEV-[UY- 9GMVP,_375UWGO<\,C*$GBC\-C(6KW95WS7$76!-0OE 89)Y\(7
MZHE=6RF$\+2?K=2+ZIXO?,]>#,NGQ<MH_'X77:WXMX/1UTT:.H.=_'^/B#(^
M,Y^T&D5P+J WRNB.0XM#8E,1=^4L\0X5943M UZV?2])]\!V?7\GIX@4(J9V
MB"F>"697<W(/1$;\@$T?7IB,:=5B$=#UH5!]2DDN^36[T^J$5^_\<I-LW>9X
MU#\%%[_#E&+KT*04Z 'TL"(%S>*_NP?B!_UU9_$)O799'6$@6VL+ C4TD9=S
MS4]$35IL]WZ@*<3=,EB/H4YVP&JQ>.*,?;>;SAAW27$ ^6N.VF&>R&_I\^]J
MI*XJA32 /X!R3+@RUEA\(IY!KX:HM,$1L<;Z1JI-EYAVVHFC!1VOY:)!_+_1
M4YVTNY2G/9DS+K08JE;:T;,53^.,78+U&E)/)#0T?2JA[7KD<N[FPQ2RGG5*
M2B\<:I./H1L@#<?0"V7$0_!%;->[9B,<QW)CS71$4)O$Y &?VZ$GK)LX5]/,
M02//125.O2664[NSNC]VOTTJ/?$V#<1KPHVZ&]$[L<OB"Z=?4TW9>>?[@XEA
M*=XZ6"\@\.!DH6.W[:&4LU*_!^. ,AT%KE(_IL[( X1&I&WM6-W::VP=_:L#
MF; ZU]ES.O!%WG@BUR%3KD??N9O47D;#9'"^F+@-:BZM@UFUOG%W6R\=W)$_
MKS#:F_G,-D"^<%.R=>EQ?YS<K//*Y'H1-09EC!ILY:*^LU'Y@AO-,?H-MOU4
M*]XSJJ.4O7X!^9%R3&H3ML#.5G7*#B^_'0;<N#V"\VZ[CW)PA8NW(:6 SCV0
MX#D2AM!,BO^QQ(>4-"[<BG>XFI^C/I UDQ')F_/UN7?!D>^\":PYS]:S:[ C
M*"VKBP1(_)\-H[:;G)@"<-[2N9GC*[N3]Y1>?X)E+C=V0PB9]LR\/9 7&K06
M5#9 AA_RHX7)N*6_F/GV<7-39LY>E>LQZ+Y9;KXCZ^1D#[$.U_X7RH]N/]8B
M^=+M_/":<U-]QL>WTK )V7?9)ZL@S'(GJR%F"+8<YV-/"+./9L\9%A\0WHD"
MUU!Q^$S)F>F;$9&7QD!T8YVJL 6;7PIQ2]8'+_-OYWX.N\QCF0;59<VX"5'2
MA]("6R489YY:U#0B9KX($S;)KI>D',-A_:HBM=Q<)$[Y,UQ4-PQI:P;;?C9S
M/04C7V^$2->UO3Y_O"XT6*/MRPU!N)=%1\))0/$#SX1@<%RF$G627;D923Q$
MN,7N;<0,>3>6P?UR9B7<P#G?36:$>ZS$QFR=6G#,M%;A=LWGME_G3(%,MPP2
M;N$)E//^K94K#.LL8KFWX+<?LQR ]Q_U%1-(H ^FSGGC*96SW9TLF0 % T<G
M.YPO5],P+U:=G<%5KC?S9J4/%HCENSFKE6]*72VD8>+0#;BXUA.H_J;&;J-G
MQ[ZOATH%PAI/-P8K3X0?*O6*M^\]\L%CZI[!PY2#O J1K&*5*D)47;Z&P/1I
MF^]ZGWET__N&+[A1JOM,%W*%O$7 +/1TXF(@(L@ TO6=+VP#\&5R6D](UZI.
M8D6_=.2DKT@OMW+SL5L\';&SY&CCVG9T'7K#E[K=H0T028T=6QS+4-$O<\<*
M)%.#-E5:6AYK<XQ=4+Y]P+3]=ND?:2G5!N93G/]<^*)\ 56K<UZ/\H1]A9B%
M@[.K-ST<"C0JVW(%G^> ?"@62UPZ-1^%>C!(PU9F+=0XPL""*I'^EG$.T"/)
M.8P8I6OV"IU[OZ58%\IS^&?3-\CLB3;1+Y:]9\''F6FAQ8CSS-<X/Z8N7EX5
M>GJR^K2O!O;!4&T5SZ:GRO6_?E8711I]C -*P36P.VS95KK)?(WBN@G\@H_Z
MGRXV0]"+S ->;?V.[6[CW*X]\GQ[P!W=Z<">B)0Y-F6PFE B8(G[@*['U06K
M$A@#10W,C:(0UB B^K\\:H6E'[G.?=L&$;[:)I]X_SFD+7/PL]K[NQB6@(:.
MY='F3G8\U+QP-2>==F\*"GC"S-0X=T3_K]\OM,\^_V< %\(67N*X UEG6+UN
MZB,[S2$/WJ_PG NYE&QQHZ+QVX,K8[5FHR=BQCZ(+Z-K?G4M0XU00RQ>:IU#
MLO=8Z'+7+\/CX9#-33&FLB7C5.3D6^=\A@03$PJ+)E2FNW1*-F8MHU3&A3^<
MEM:/>GKID^>!JX$'8M_^.'["FM-'(,9$=@\D X5\H\))DNG&DN*K*S5 G&73
MR 1U<5N"\[2=U/W2]+; 01W=E$YF 4K8C@Y#"E PG6OI#N?\ D3Y%!' BU-5
M,Z]R+CY67I2ECNU@[5]&0U78N[K(U8UA^;U5%LE#H4M2)?$:**43+X:R[P1L
M#ZC',$YT04J&H;HI=%VS87^&WDO??Q;%!QM&=^@1&QHOW++Q*>)B4: #+70+
M@/.E[QY(OIZ8&C[96#B4C-T!0HO$OJC='M$X_#1CVBRVU5VT'Y^;$QQM!<68
M<".WZ,&LWD9X_6Y'@&K[!.IH8J?.U-J]U:7-2/-[1Y0E1?P)<O?L2X1#&.<,
ML2_52@_Z+] UR@_E?NI.*?C3UG678=;P/0C)3;8-$FO1!KP"])?.7=F4]4?X
MW;VC[3[EKU&XK/X+3?"F*5$2-^S)YV2O46%)+?85G7>":-9U3-$_BHU?DHS.
M)CN6^6?USV;@,\"G.;;1#)&^A9IE-TXJ&K^&@2ZL3:*G9?2Z"&3[=;J7X9UO
M;0^%1SXOS*0YCXRR^IY>11'T]T!R:)+BXYL72HMEZ9+KE?VJ@L9#!F':VZ$S
MP&1=A&X[P:"3R._K)D/9Q$CDO?0-6T'X>H,ZNF32.(:4=Y5_Y%@KY[I<X]C>
MZM":OK]&>KIA2'4FM[0J)EYNI+XURU[Q];NRH1^P=HP,,8KBO4G1$F (#K=J
M(:VHE5W@:>?%"F+G@!GM;W7+U7+]E$D);-2G9EV7V?4I:R]#M;4<NM2!CO^.
MV#YA'46WGV4(D;&0U=;3%$RJL3?E'5ZFN>"!*L6MFG8F2"[YY&:1M:"U\H;B
M?>N9'#L0$D-&1V\#8!:_-D72MI6Z](8*(ZO,CB#<CHYO=70[J'76G<B*=3HX
M<<9#T4"^Y;8XYPHN'?(1G:',?+$)-4 >!F(0"YG2?DX(SW=3JQ->Y-Z_CE?N
MWY,%55WQ#,,4<!X PRV9)3"V@4[< ]5F-+X!4JVBX/@2[;'1OA:J07(0=#+J
MJ*B 6M1;,5&>>SIA:;DQ;G],(#P,1_9Z#6.8,<L91E$&75OI#HA6Y81334(-
M!14J[_,J#+-E+'VN)107B.<&$TP";6]SK!3NK@>] YZ2+=?IY#6B!$$@,T'F
MT8VY3KDX]ZL/SCLL7\0T#?8O;*Y-M+YZ&7T&DHD1] 2&*=[=\CR)E^U.N$9>
MRND*\DCJ_9 /B7BM=&;G:Q4X'EW+3O1[H.E*2P!&]E6@6N0%E>MG(Y<.B[I:
MS#0>^JP2$7C0D.N ,&+2IQ3\F*%.%V-]1_.<W&R1I=328A.M <3)G/KJUH]E
M%>.TPHS[#A(G+._?KY8:O'XBQ^Z1UGH!'5RYCJ4:])0HUU,#>I+6D;8! :(]
M:!&#N]?Z[$[7Y"L2K*6)T=K-1R;'=BYSW/+NSDS\C70&+BS:<W<]:O)O51C>
MK*MOB6!T10\<MCCR6NF>;&U:&KGYK!KG]F0;G&(?1. DA3]>1VJ3[ F/%LV_
MGT0.U5Z_N8RWE/@K8]FF4_)^G>B >/D=MU#8-)3>$O(2R%WLZ;9#D'^VIBOD
M#YD63LU,;W*)*@LI)3AU;#I>TZ@[@ ^&AUXQ@4!1D_":\:$- ^^%@QK&IN#$
MQ/@_R_7Y.@1I_&J<_/5.S=&MH9%*YKL]D$>Q*JUH)-3VTX/F(=Z(7YTALM6\
M^']!_]:L^:XF@-YX]+XA/8GEX'T-_7L!A#Q.#IH:I:4!TY4])' JI(Z[8JMS
M2$>_I8'"RI2K7WJ98LJGSF72DO%S4D&TRJ3G%3*2&6>L1'4F6<8PU$F(:23G
M6X OWUY@3<+*(_*8K+6PP0$ZX?3]::$OYMZO8?;#)A!A()%FR:Q Z2QK+6RE
MP"!UTTBA>\/O7X 3Z\Z0ON#BK4ZF'\-/-Q]A_OSC!-&(DL.R!N0YJ9+K_YWI
MX/=;O!C!$&T*?11ZRE)UZ\5UBGN>:PR3W)0X:]IWW_2;^.J3R[P=_^#K\?1+
M$08=B__=<(CVZ;."0GH.W[@YZ^;S]E]%<27'W8R+$KVOKHD<W6@3J',/>KN,
M^VB0V")$5P*>+CQ]7"]9PYJK*];\,S/5,NW=]$0-D2QB-<3_5DPDWE'ZS+=_
MEU) E"!AUK="P3U0C=M3BFZW,R=>QK7U6<-AN(OE#^B?^RNG33:G5J>4#*6/
M_!!5[]R!3$-H+P%OTE?&X04TX40[4H0K(,#C7T-*C9^$/E/TS.R[W/I[O(,'
M%@+X3_'.G;[,VRO/SXRN@R7":B4S6Z66YQ5*UO HO8;L!V@)OU-/<Y;"N-2?
M=5)2/W]H3N[3/FE][ N6]A!PU&IC[]B20Y0C_U+\MGV<U'TFA_%W;R3=#>=2
M7L1>+-RQ4>/\17P,K_DYV:E%""%CNQXBS85?!"U>BU<:&1DK(_C/3-CAH6'_
MA.M_H<XRDUM"%HBI;DI .AW*L,DDS5>0O7SK!WBO?G2IUO^-S!=]FQ?PN-8H
M:D*A.4!!^R9=)@7TUV7!<AU1#2 6E7%2+$U@I549:>/B53OZ,^7[S6G?>UG7
MDMSE:+5I)!-1&%?.> 7]"JK["B.8FIC8>C3"J*L1+0P] 3P\[P15K$FRR>G*
MI7\N^WKRU";'X*GU*KE+O",[[.:V'F4FH0Q8WYUEW+*IOQ8]7WU><!&H:,H]
M3YG(;PAXK8-Y.O#@O$"6O?<,0T'>\@5J> _T80=V6 _'"?20&I-=2$_Q6EP$
MRSMEJTXT%I)GF$.D_>CAW6NZT0^YC-35#VC_N2#&06%]IHLS_)BERJ.G,9D8
MZ:H_0YPWW 0^MQB1HC3\6?/.1ERUW&9E,T(9P7$)$']?FL0_Q_CZO.?'@WP#
M1#L%M=-.^I1R7SX' CFFJ(&PZ7L@]K">"NI&R\!\BL%D8BQ*#=NY@; :'K5M
MS#EG6%D@'&C0A'M6RF.;<,M]<J+U*]LLB+-7KAX[>BQOZ($9AS$L(S<,-95F
M.LXR1GTCA'?@I(#- -NNL"!Q(D,E"($YNV1P7XX\EU,AE\L1LQS2#1X-O<S;
MC^)CYAD[DH>FM_!$ =8Y8 *6K.T7 OZXJM] YEN_>WU1Q/]N2Y-5?.>AD!S9
M>\K.!4 X39]9'@H1MJ3\1/O\A,=3NS4DKH?&R_1._^+A*HCQ8=GGN?0;18 "
M9!&;*>SE9#_51[.TGY8TI[Y*#WBO65N)N-GGI^^CH%U?)6NF?+$K@\;/XY+V
MSWGX?R1KB*[I:D?WF6$\V ,]3A#QE8@-#5J'UV!./3^U;3PWU3,P&K1H^;\U
MG?_QIX" 7SWPCP892%DJ H\6P7D3DZ\PC,9:+@[H?RY=#5-_\&K>/J?#T:'Z
M0[YW4!->,J"<1]T%=P#F[AK4"9=6 7JHX3UV5"6RPXQ>">:D4^Q$G^WCV')S
MJ:WZY][\H&Q .1_[ECU3<EO/LO!-N&2HCE8WY+$\M(B$QB??D2"D$3U=BC1L
M3I6"]96Z+TUM9ZTBZXW,A<:_$5 =.!&6;L0>J+/D*+.L];A+Q)H-91WG\Y'2
MFGA;XV3Y4\,Y=5!1H@ F5SGXDV <;4.,8YNM;C4_QX@-Z;@>.&!U1R+;1]6"
MU44_OLW7"=8=F$M#SNFS]*KI=U!#DI!ZR78ARS;]IEDW^<+-U?D?<+M ;\??
MY>#TF*>&W6<G&]B5/LT:QGST*J;229DQ=?%4098LM3+60?([P]Y;Q"OVFE6G
MIP%G?:':3()@A5C<&$27"E[/I-LP/+_#VXEB*)AO#2!#*G,U@X!]@CLCT?Q9
M-V3LDFO##.E]JU70F_24%-!OC BJO^0 U6"=!16ZM1($B2T;71Q=2#"$18$R
M>0RO3$'FWX'H28;^/PY9P?1]8#6PC0N4H<YL0)6M476.L<#1@P3"MS\!XAYC
M)P/^*0=_=E;U6P _YVXCB-T&-['+7MP*0N&AO( 2)1Q?PMWBV^*NFLK>$R25
M\0>GSA<6Z=3LS(9Q"W?=ZXJY.Y-LB#U"P:Y?I9LRI&J;*$$=0P1^.55258W-
M1,._[HRGS@0_PV]6U]_(?>NM<S>\_=9:;]=3C.-WS_^WZ7_%1'I>:23C"VGC
MZL4;7!J1"(T/66F/Y^-#,H !=K/7@^AG9EF]>R!NC1;>!^^[R,=?M'YJIH?J
M=W,?-1.>BR]Z=7;I2S=;(VGHZ?NK03,6Q$4L0_E4JE7=X3+T7>:3OX])B05+
MF]W0P"*T#!5[A"%'0??@"/ NMV. '!6U37K:O26$G3*^(B;CD=,56K:+6#+7
MQ&>A-DQ#=53[I-6;N9A#<'U&(#.NA8^:2N:@_LFO)P<EHLY&3!C^V>+U@[L7
M_@"!MBTFN*)!L\W6;=_.'(B&'OGO.)MW5&3''N@05 #=@:!:.@#55/<N>=6&
MNGB/QHS>^8EO'B9. AXJ[CPW)+7:_*.&$X;FT3)HSSXLVQUX=]@G#T<DR.F#
M.8VQQPIIKRQ:YDU)G:!G/?<01@N9Z](+D#@4%"[ONCJO#,0MOE[4[L0"G9?I
M_A,+L96]LB:\ODJJP:#G(KEPZ^^\G-1M4AI.!BH(=+9]7^6KL,7ZCERO7L^6
M=A+MW!+G\I8O$%\BV*]G!NV!!-TPH#]1$;.J--N5@2K"S#J^Q#??\+QG)C_]
M?O-G4%K:CR@PV\R$4")I2M1\#,6]:P]TD*6)/)_:0P1O[:P%&%VHJZ^C&Q,<
M.OJ_'37D^FGU.-H6Y,Y9R5M"R5S'T*\BM2ESC3$M2G0S'PIPM%>__N.GUN^B
MMG1;Y!T1G>I="Y-^C)94&PC\>;D4+,7,AWDR>6DW*$+=\17$N;6FULK[#X2\
M77&P5ES3;4Y#:2/GX?O!.=9WK:%#[.GRNW(CF'Z$;?02\9E<#&L@:I$(F+0\
M)$4HU\=NNL"A!LFI(IF;V4LVPN8\X#3A7>AI5'<X'((2!X3!HL#@XB7@"TD@
M8KZGI_ \]!H&P6'0K'#"1E?!_[B#E(?(U__Q6/P11;33S#*HOB\5,"?W;'#X
M1E*V^].Q&BVPLIZ AZ]?9IG9M!_24OK\X"O7NT/:-.?./1"'#UJ@1;PLPK[3
MZ7BES\T+-02"BZK1E<C<\6?/<WIRK%5S787$0,[?,'7>ZP)WJ)9D9;085"ZB
M@4Z"=ZDEP*^/BM5)EJM=]DK3>9XG:\L9"_W])<J;W021:E0WL=Z@"\%GK$<]
M3'L2#4#O_)CM>N%[7*BK_]QPKZ5P>*A100+?U\#$5>+T'H@620E:'Z709CKD
M^3]&(L309Y=628R^U&]?.5[E473P'&T<)B 0J.N1(ULW<;$X3Q<L'XHP#P,V
M64<3ED;Q_Y1OFOFD^CC9WD_V:.YO_GH;U1U!@ *_,J(F\2R9$88W:<[>=&+]
MY5A=E W!UK;9NMO!I]BF)GO95*^2_7:#Z$?0[>Q^9K4J S/XF^&IY,FZ#:^!
MJAWZ\?6T^RZJSY4S!^[], 2!K 1*[.74/S'9X]TC,G,Z R:W^F@KV9V:F=IR
MY^T>R&=5INFF;%2OP2F[BF>_^O.]5(VWC@3#K:ZPXW@GA9-VMI6)@?D,);N=
M'3:^R@D8=&?LB@*W;SQ!^/:7^)W]AN-2?#BF.?S[6\;XSA]VV7MW]T ?V6,3
M#R%,$!<A>+2$*3E _?RM"$1'UO3IL'\/G?HOK0_.NQ_O?[PA6TZ(N"8 OW;%
M1+!0:O-.SG'W&W>S;<Z>Z?U@?,AT5?TG>GJ2=G(,YP7)@&I-,F07#[H#[F1+
M7T_*+9J_7?FSWM-7'SZ3E:I)PVH75ZHX)HZSK<0@_,/D>G$X'<+0F6@Y_I!L
MA;0_5E8%?:U96J??SFDN&*G_U!\SYVVXY;:XF,GMLP<284"J #A>POJU3].7
MJOSPL*'AQ>"XN*F,T@Q34,:%P/\94EVP&FPRSJ-8  ^5:*;VNVE2TL>G6T8V
MW+I*"]N'A V";CNVF9F >!PLY_5VZL4N\P[5_F]\%C!,2:7=:@(\Z9>0C@!6
M*^G.F ;#+ZO\T<V;3R+MBAY]^Y0X2#2=:(UENZPHYOL]$%O*"&&C;:<(0 ($
MC!%$#",TO>IUF:4*/?FG^NHP;JB\'7&QRQQP,;;*L_BVWD<@R"455$E:%/ T
MA))[:[QB^X&&\HQ L3XI^62_DN%E ]%Y%Z77)\/6CS@3V(ZU[1]F78A:N;@Q
M'H_=X*:NPD6 FQ-7=)?EI3]F#!KE\_Z<[3OBF\U<E!7)X9!#K,)3X =.$Z58
M@TV['6@A9E%'D^M2!N'<TSR.B*I%@CC*Q/2V]EKN[-(7=@S9QDW_(EW#<;+X
M(\S;0E:/OQMX<;VZ#&XIDNREF#Q[*#?CBPYBD"7ZWT<_[*SBATZ!27I2Q0QH
M\[HQBIDVMF:9B+KN^Q[SYNAWK.4U^'EV3_11@[":<\2V=%7RQG.62MQUZ-EQ
MS0=2\T:ZDE/XMPM*!WZA#/Y(K;A*_A\==[^K76C'@!>4YL7$-)0"D@LH> 4X
MC78[0Q 3H>!#ODM+Q$'-P<''/$,#RFEE_,X/7;OL(0BVS'$@+[(3CV_$Z")L
M"NFXB$X/ARH +[PC@_3>5V@^^;B2[_3QJ7N0>)4_[F&O-C)M?27'>@OFIQXD
M5;D!IQL;L%.'WTT_^"HBZ$V$EMV70JF@@#O;FIJ!2Q>RU"W>OI.7$PZ/*=&&
MWQZW&*G"7,MT0!B%C;G'5X]0\*WW\7A=!:3'\1/E:0MYO/4@EY?_N6&MZ1G:
MI69 FCJTJ(KG8U@+8\&9?PY'B3\.2SA6P_.P@C!X:VL/=(O'!!(^WYK^DEV=
M/AJ,F?O?&J3CDK9=(W(@A\ 2" @A2;'N5-0S+_,//V>"__ZCCF1.A["?F%G<
M>HSA0W7M25:<5 +BJHZ]$:]R2CCL(8'XK*\K&?"+J288#27]65PFJ''& T1*
M4"<.@I)"E/!2S^&*7_EE/1%]+>]95_9L*:TD(SU!_E/[5V7(468AVP% CJ"&
MX!S&%RC;MX"G0=4K*XA[3<?>YV?ZZF=@93?["BY=D4J6Y+9A=)Z9:5QYY/&]
M)T0PVU:F3RSERG"W8\Q"+)B]=#3W0.V&*M0+D^O,R =DM)0?ZMPVTOJ-9@%9
MSFG5)5FKZFZ6^9'7GN&WT^Z&.<Z:"(TMM5:\I4E(-#FF?\G+JW,*"Z-6G9J9
M*;4B7Y#ZGS_S!7&TO?M/XCN)TTYK[9 & SP\?8BL%KB!=*[HJ3R6UA#O-O66
MD+[D^D,?U<^6^#U0H['6AN4>B&MG%.VKE3DO"B2J)EVU^EB30IB\-8+ZZL$:
MCY7-/*U)63CN:<2GV+K*UN,[5TSD1>C>J %G6+UW>]R"B]TCB+#- RFMUAF]
MCY]N61P)F))^M+E6,OZ5-0KY:(0,I6AU/AYNN:$:#U5 P@ZU)I,/OM L&KX[
M*\UY0(=BT=N64_'H2!:J@BTN.F-H#VP&4;8.0)ZC-BX^J";&\L$;E]V$1QP&
M_IA4Y]UXS__NQ/,#O6^OT4#1%NSJ@:=@=A2M=1P9'<,RF+A+12?J1?Y]_Z*I
MOD&_UN5=4J_(Y^</DY4C.T._M7,)H]ZS7T)RA#U\V%F^O542 F;HTBUNFE)8
M9PI[)\C;%YS'3VZ<$1"[?[O!4:<T63(0Y%HF&V5KQ8Q%099Q-1E8BN8\ K=>
M[6)@4-CGOG$5'FCI\I)7VBE%X?"K,7[K;ZHK?FJ<9# 7BKW'ZPWB&'*>%-8D
M+7[D]!;/"J4Z[U4%HI3O@=6&6,#U)[A9PC/^\'PWT&TQ9WOZ*5;;!#O-_.K.
M/ R4G:=>:R(FZ,W)G?Z[,W"34V7FDJ#_=@NIH6'WQO7W[:Q&Z47,>[52<%R+
M+IV'<1?@)!<_ L= 9 *0*@MV@1OO?P[7%ZMHR0\4!#_;55<_U09B%%Q^T1CP
MJQJ L-O,?+HPM"%7B73.[9E$J8W!K0IG7'*O11<5VUXN>/;M/N2AR"O^$VR_
M8+I].!=^]__^#U[LL\\^^^RSSS[[[+///OOLL\\^^^RSSS[[[+///OOLL\\^
M^^RSSS[[[+///OOLL\\^^^RSSS[[[+///OOLL\\^^^SS_S\@>]/_#U!+ P04
M    "  Y@G=4/T@S*9$G 0"Y@@$ %0   &-N='@M,C R,3$R,S%?9S$P+FIP
M9^R]!5A<S=(N.C@D0/"@P5T'A^ R6'!W=P9W@@0+08)# B2$X.[NG@1W"Q#<
M P0+?@?R)?NSO??_GW_?\YQS+[68M5975]5;7=U=JWL]\PS7D]=? &C2("D0
M  H*&LH#R@, N-ZAX5.PL'.V<[*PLR=A8V(!<(M(R<+" B!$0]*$1DT>2!$W
M*"1T4X9N;<%^!P"6J3BTD   9(#H%G)[0  Y##DF3"P,I- "*,<TA@F B2F'
M@="-GHC"C1[4@SQOM)'DPW&$1=C$_#64E8";.M%W-W6H$ FHFQNTFQ.@&H$J
M84WL1%T"0?T&\D8=#H%+G)/J^+CE1@(V80VDIK:F-OC;_8T +&<WU4WYY$97
MG#/Q.41BF2H1=*/SRR9(G6(59UQ53#5(Z!?8#P4$B)PII[J$.NPQ518+A-T"
M!T @@=^#' ;0 #@6> 4$(00%A%L-0/8OZ9\^PU)U@U9_\ZB+6BVA&Y2P<B-D
M "DGWMR8L(_%E=Q&0[3D1HEL\/<MAJ+^1XO%3A! "<=K$!^@[&\L<R& 5G\V
M I:SBYKJ9P&.RHU]_%<-%]4RYS_$UL3^4>BBZOY'8=5-PNQ706V\XU=\('&4
M^&4:EHJSROFW0/R($AR%,\5-B>466 0:'G2B1@%_!?A)L&Y4BW_A4;7]58Z:
M2EQ<;4W,B(.J6P@ ^)ULEPC<W_#AJ#F[?\@C!'<@,/SB9YNI<8%.*$ /03@_
M1P4<O L"YV]]<'//\N,*RW(;!#7SOX.% YU _RTL)V?;#SX"%3M<U$\V%#P7
MU0F<:[#:RNUH2EAU_1FQU9L**C4N,:H3"=#Q>-?QJOUO.ET_:R N@'[''_^-
M+TZ5X/K\]Q55/RM )_ _V;<C1V#PU@< 1LMMMY#\=KV=FR(&M[I??K4 YOMO
M6D*W6@!(ZZ"6;LK"47\L"[+<EG^U$>U&:]CA1^'=;]T/^($B>#N38?V@C\T,
M &CP79#S#URT'YQ[>*_?_>3 D-R<X=Y!SC\Y"K>2@[\XF+<V_6YN(3/KP?7?
MT9[ 3?U_ONY';/Q^1/0VC@ *P(_/CSKA+S_C]%OYIB4 -H5?WM\2\1X X"KT
M,W2 O]+O>#=R-_+_5. G_2X5PJ^I=;5 KC?!-*,Z45N58/_CO*3B$D7[S<V;
MP0S_NX$$^Z<1!TO]:V3>N@%']6O@W3;!G+,K@5.=PZRC^\8^UA]PU&_J;K+T
MC2-N-P65N-_;=G6C.E&'_0/+[ 0RLA-^9L4.U5NE6]X72'G\H3KHT%5M59WJ
M(4CMUGN)1/B?23WC5E@5PKE-[0GCCH#_#>WG4J?J_,.CX2;X?^3 3G"Z_O'Q
M88;3+0["<?D#;Y43H@=2?RZ6R!XD-MKU,T$%_\86_X-P0O )=09.5X+KST@=
M_HC43_9-L%Q!:F8/U6XS5**9.K787\55?[+_)%Y%Y<QYW'5"^8_@0F']L$_Q
MJ^(VQJO'JS?71- )+.0QQ*G^^\!E00(I]A=NUVVJ&_T+O_HFH?U)_,<ZP.^V
MO@7R(;_^(?MC9OT(!!K:CY+0;>GF+'H[1V_D ?T&/P)V#W*!ACQ!'T&Z[^:^
M]QV4'X#X,O)J$-"! SJF4CUD'P0P7WT!+-^4%. E;Y2)+TL0A0 M?GY^47XM
M45&M:"7O2M$5]EI:]A6? 8&*0. SM)8;:OUQ^2>$-EA2,OAE"/!E 4KHRY<%
M8<@)<KY5:47_+Q@8N ! H?E!E]P#L&"0 $C1T(!HQ)>#D(867PAA0L8CF@+:
M+?T61A8 &HF0@H&]7]2[$K0_5T*R/\MOE:60DA :"XD0B8*]@9\"2SL+&L0X
MBP@Z.9H*-@XZ*S4N)HFA%#X!%AFKL"H##CF;! TC%HNC)J4@*C$.%YNB%3T-
MJXD4!TA,AXY+U-";4H]*GY[["3^7GB"[D8>TI+:4CJR<O+2VCJZ>OJJ9N86E
ME;4-V-;.V-G%U<W=P]/KJ;>/KP/$'1*(MT*W/MD;*"O<N,"*B4XBAHWS$(.4
M19D&#UT:X@$?-B,Q#"N(Z2$-+04'4(V+31Y#P1#B (NCL0XCA12'--!53%79
M'*3'_-,%RW_J@9'3+Q=\+]\!6FZ;#42#V7N@\*%V=**Q4F"IMG!*Q_8$;7;N
M1&VVX,VNS$.RA@(MQ[Q4N6/.<5LTUP:$:ONKX;X-7:V>?5G[[89I5]YC/[SM
MNAXX.U3?;.TJ9;W+YKU[0,UU_3UH8KGKMHKKM2J*K"9?J9[^VJYSBVHLHE&%
M,]VZZIW)&7[/;_3S7T^NN0X%A;>O7)2)U1Q]PG;>5017=E4MJ\AH$6ASGFG.
M=5^^"<_VW4-Q<):BR";(.GR;&6#)6(VE:AU0/*/:N?NL6H:YIWGDN-"ML;*B
M<9K=*4TPFFW;&O:;Z7L$@:4*AHN&,$= /E&_V>I4TV:[C3'_8WJS>7LG7:_+
M&?K#R]2,(_1PL%R2C&"AJ7Y8Z Q-8\TN)T?F;G<Y#9IH8]-+^LW2YCVH9F'5
MY@*!@FJU[;JD+KX^7[/&@<GN!\J'A3[=@G;57M:3P6\ZCXA$W&5A0"^[TPIG
M,^*?/MFV:3EXN;B@"34\P:7$Y1MHC1T8M69P%+J[\?W4 V;$1^;MIRF]M:].
M_.JB_,F-1\:-UQ*G2&^. C+'!\^W?1[K+'8EYY75,D)]G=E4F^]S[.\PM"46
MLWA:6VM'V<\BR;%Z++#&4%PP<S4@[.0XB2H;];FLVS< YE @N< M8_W8=T*Y
MM$-:A#I7<;)1G,@K?=GS[4MEX@VU+9L70Q%#NTL';O3<M36UX4[[!3B5+Z<7
MY_K]=II7:^V][[]-N\XZO][,UT48(YBO9\:';]&V</.P/_QP532M['15S.<0
MD<&L.[5OB+E29E;>"0WG$^'IN_O6/]^ZKM14#M6XQO[;D$A#@S4KN-/TV<0@
M/KC <7"?(76+Y#!R#XDW=<=WC,=D:<98H-9D? *MQ_I1NO,$V"7!-[GVPQ*A
M8O/F/HOH&,%5,>8@ 2X#-N:N/1/*-U@$XKU[8-6SYTJM&Q7(X5O)XDQ>U@^<
MN]8LNL[--^@:E4F6S VGB2K3W<O<)V7!/KN;U7-ES5U<%\\TB<IRR9=U5.Q3
ML;(?E9!OQ[DG]A C&S+%(ES9U.AE4J8.>F;OV$9'C-YWY5V--C8">!%N@J>^
M^JY?:LUO>#4G:R%M$5^BSJ0]']O"IS<NFY7C\7JTIL;/>A$\N@ZVRVL>ZUZ_
MY+V4\=V1SS8:6E<^?Y M+VB:?<U?JK3N_AJYU5:7I3=LLHLGD:4"7AT\,+L1
MD>"9H.YUE?A=7#_;VW0#]\T#[*Q][\GO*I-GEB?<?@0O5TM'-LXB:B.-<X_X
M56*@'D,_?1NA[*:88^8=Q_TPC$ [:;RVXZ':1?#N]&S\N>;I56=$ZAY<3/?H
M\3#*DY3-MYMIQSX%$YZN2XWS[XLF'L^7'IF0J\?&7;W[M&67_9*Y2&NM?M1)
M/\(E6$M0HGGTI'YV=P_5:2.S$VHB9$?Q,;7?5\G(UQ,]SU?E^*VWF'O@LWAJ
MNH>9D,N\U7WYH\6;DAMG7%7E]Y#5-R[U9=$[*]7&C8S/9C2=.0OC1ZD^G0#[
M9S>JNKV9TT\3?#G+["]=C>"KZH"S&PM@W.^!%3YO!Q0+CQA]5L%7=GNH2]>/
MS]2SR[9W2X&5=75$&Z9>5NU,9KL58QN-E4W'/,WILYOJS7NPXSZI>S"8ICR2
MZ$_)6YWEN)-/<XX.7T*6(:;G_0-:>-38S69%6_J;G-J1UK3.UA13#M:NOJ0J
M5>'9,UZM?2C@EPQ@#VRP:]&5#??7POKD0\:I\JNJ[*.D)7WYPFT?>M\G0SS.
MFO'Z#_;NL2_Q1(+KF]OHJI,B3I/A$0V<FD8VC;7TR7WFU>YKVZYZ)L_O/<A4
M1%!B/_?67V!($QK/]DW/'9YU<@CR0*[*QY??@PW#,_X@L#$ODS*_G-\3Y[:=
MMPZWLS&SX]3(/&8S ]M9_[QV7K;*M[4H%NDU<I<U*S_CSJ G(X/9T"%GZ5>?
M485O;X#!!9]QBTIT'();4&S,+TIFXU6FI\J'B_<0FE.JK]C&0%M$&!?U>>WM
M!L60R&@QUIU,3D3*E2R5'S:%53?;#NPA$N\AJCS%A].X?'3"9GIB8N/U%LFU
MJSQ'6\9[O_STY+S98=.;,HXM1XG>#).(Z^LYYLEQ]Y6G5K=G:O/> RT0*Y D
MHBU,/>M2;?/5<_HQ;]2C?9MNLPGN]K=:JXE?"YL&K&J'2AQYU;SR/TR?F+$=
M^KRF>""M<ZWL97TMLZT+G1XS\2C?_\NPUOA\;0LN!GU$)QM7D3'IZ;-PGY0G
MWUDE1=Q]18R4^+^G/>*^'K0.K_?DO.\SHW>,4%N9].35XT*S!?/LK],3I(^2
MD_5UR_,KU#8)/V!_);T6#K_L2_UR[:V]56/.G#4Y'MOT#FQ@,5M3643 >>5Z
M7*M+4O=^*(TQXFD;=V\ZF2#(C[BR$(;FD^(E/L!G@FSPJC8L(CD$AHYT;R;\
M\0;\OG[>_![ MR'WZ&OD:%VJ5'9ZZ1ARTEQ/4*13%?[68]+^R7-^.]^]>QR9
M1U;9RD,Y:?M-B=K:Z8JU"3/:5=?43FK/,K/VG[Y9"/)S]1=MWLV-:2-/4 Y>
M'MIIF^3Q%I@Z)7_*O]-^EA\YZJG'^ :3M4J@5X@I:]K-4Z[H1&M7:D*+H)[V
M-?:R9[+59*\74#'O;.2%F0RP:<"+T3LBYWEP1)'#U.X>"M7NWCUZ2T<B!;7Y
M0A>.=^S)#BE"SRB:/R^7?5($!(PG+(5$DQQ77U\2*S96UT:+=MK!XCFY^4,E
MEMMN7B5[-TL9+RP<\0)9]K?+2I4= IA<XKBF-JI*I@L%K=R&DP6>%^KOH89_
M5JGKOG@=?4FP?CT]OWX1N4'\07)89UXTA__5M:49]]$;8R;K_<UC BC4Z\KB
M/=3XTZO4:8;*R#V$'#9BGO$AKYRLAN>ZS![OWZV*ZD=&>*7SSW^Q.9PJ'_/-
MWO()6V=H%.B:O$[VE;V6]A9,.TUN?GSM$I]V33-Q37()[W!QO0>CXLMUC7#U
M_&K3.YYKY,N;I\H3 ?99>.+8XUOY>5VL61SO\_2V')@@39P>5[6NOL[TNI0?
M4]8<.4 !I3ZIX>P>[6)!6Q(?YSS_)G&JO*YI"D'*O*Z;2RU5; X5W(/B.L2[
M6#O2O.B^>'C&O(<H*&OEK7,5[W81??A@#_GUQ=J(X(!OZ_7ZLJ#ZI6Z#@,I9
M@Z[.?;84.S/C)^/?\V8+#;Q(K,;++A*]^>?EAZ[#U(:E^(UBI"CB5KXXU^=N
M3%8T7KWYOMH#L.%)WCXR'AUZ63YR=-U:EZI\]B*8R@>(9X?<4U;85@?,!\.U
M7L7KK>EZY5]BT@/NZ([NZ([NZ([NZ([NZ([NZ([NZ([NZ([NZ([NZ/\W=+T@
MO&GA[&S/R\QLZ\1D:&)G9,ID; =F=C>T9P8RL3 #^ 3=[0V-K4V=28Q,S2UM
M^<EVZYO)2"Q-^,G4.6199.U%32TL)3T=394]Y52,/:V->4S(! 7N\;GSNH/M
MP:;.AB3N8!M;)UYW?K);X[R0^QLV,QG)K8BS-3^9\$T%B8:L HFHG:,I"0<3
M&Z,Q"Q!(PLG)!&3GX.0$,I"PL@!9F5D@?YR,0'9>#DY>5BZ2WXA,X![DS.=H
M8L:K) ;Z#0Y2XB?[K5UN;FY,;FQ,=H[FS$ >'IX;,ZRLC! )1B</6V=#=T9;
M)_(?1G[:$3-U,G:TM'>VM+,EN2D;&MFY./.3D=TC^1W]UBZP_2^@OPW@+\LW
MQB'2O**.IH;.=HXJ=G8V NJ6MB9V;DXDM]_?)!$WL814D !9F%B8@"R0"# !
M.=FXV?F8_ZSV=Q9-Q2 ? 5865B C"P_D3P7(R<O"S<O"\SOU'S)_TI:U,[$T
M\_B#-I!%!<C&R\;)R\%#S\+!R\;RP\;O)/]L ]*C)H;.AO\E*[^7_1EUYC^%
M_7_0';*R_[I#P&#FO]-T<A9W=?[7FDXJ'O:FS$JF3G8NCL:FXJZFML[D?V]*
MR=3LOV,*(D[^YW$B*\LK9>OD;&AK;"HE)@!A,%E:FO "N<7%N,6 K"SB0%9Q
M42"01XR3DT>4&RC.RL$APBG.<1OB/ZK^Q:R8G;$+&.+[;V9-(&;9A5DX.5A%
MQ5A$_[79WZG^Q:R\HR4D/QC:_$Z&AU68FY6=0Y25C95+E%-$C 7(*<S. YG2
MK.(\0'$QSI]F_T;U+^8E+9T@P]]#X _QOAT>RJ8.?^3^K+"QO!TN]H:.3J8W
M\>8G^QEPLK\HW.C<#@%>0^/; >ADZ&IJPL?\!]X_5[+\:U>Q\_R[F/Y%]9_;
M=[,PM?V;B<7R<V+]3NJ?&W&R,W-V,W0T%3:'Q%C@1];]QS?'194Y26A^2TBT
M/RW^4>6?FS:V,+0U-S418/ZI^)/QEXYA_M$S_R_TF+&=K:NIH_-_H]<@.(:0
MAY&IHY. F:,=F,02;&ANRFQE;VI. DG'AO;V-I;&AC<VF%UM37Z;Q?8_ _83
MY7=&_C<VUL34T?*_,T!_Y^6O.)'\W];H__F<_+=Y[FY._I_58T"N?_? ^Y_W
M&,]=C_TGL^B_22$W6>9'SC&U=S+[_TH6_;^HT?_S.?EO%Z%W<_*/W#\N47\N
M>_^ZI/VY0O\Q+$$W ^N_UL]\MWN._]4$^B?5O[-L\K^R:?B+ZM]9MOM?V3?\
M4]6_1OEWP?R/;S=_S>^_W^W]JO[KFX!?5;PW^^ ?NW.3O]N^,['P0-K[]^)_
M:T_4SL;.$;)5-Q5@_[W>/]C_Z2"8&/]JO;V+H\WMBQ838V93&].;/G&"M!WX
MQ[:;&/.:V3F"#9T%?I\2_\']EP[^X"J)@03N07KXYUNFOYO _WFZ [D#N0.Y
M [D#N0.Y [D#N0.Y [D#N0.Y [D#N0.Y [D#N0.Y [D#N0.Y [D#N0.Y [D#
MN0.Y [D#N0.Y [D#N0.Y [D#N0.Y [D#N0.Y [D#N0.Y [D#N0.Y _D/@]S[
MQ^\VF-J:\).YD0D*7,\ 1 %0_T.Z,?(_M0%UW0) 1P1D0.O"0*$#H-&A8-"A
MKCL Q  H #0T- P4U*^?IT!$@D> NP<% PM]'R)@A : @H6&!MP4[R$BW$>!
M@H.&@86'0H#(H6-@8F&3X@ ?<O,(*SJXN9=659.Q<G 9NCZ+KMS#)6=C]TBK
M:+U'P>GD4K9/245-*Z&DIFYN,81'(RXII:%I9&P6G)BU ,$@ND%'^)T+  #4
M#0@"(AP2I-H2XB\4##0L-"PL.CP"$L0%2"T %AT. QZ3%(@@C$6F:(C-ZK"'
M2,[!R77S3PZ>1:>5EE=4MN*PL8L,+2 ]5#)R*MNGH!254%$S-G&DXA%35E4W
MC<NH:J/F%@<%! ;%QJ=GMG=T7D\#D&$@X4"'00<( G;W.VG_=-"QN3U!;:LX
M/*A4?2/Y<8I J7V"?Q136R*_W]DT_GQ!U\$X0-&L2>J%0JH?N'VW1:BVH#=D
M6W/*<'6Y),-P-/?@=#57>FB8_S1+.3UYBGX[U>0HZ.5.=5'BK,SX_>/#POH\
MRIBM,;)X463\3O?MBITP2HIC!0PN(S9)FQP7EN-R"M/[A?!^KYEDE<J^-FQ<
M7<#L4*OMU']YM%=B%=I4/12/VEV*:<%!PY]=3WZ(5.KD11S:\&1AY$RD@-.9
M4;,D'86.M=YR-A)V>F=82B*CKP)+J:FO47[W4KM*-^ES';DF>*1N )MHZ6&^
MBK5 FTF0-(+]JU&L#R-<'I^@D 99QN,G%SN()\[>-CA^ !40VW24Z&2IT.]S
MOCK'Y:"GRM9[JO?QY4173W>I:(2^+$L:F@E'4W$K?QH@U3'?67GQ6'1@U*K#
MNAS>Q;TQ:Y?1.:F_A&PSO_*<NK55SGY,)28^[5C"OD'FT!2':*2DZ\/&-!Y1
M9.&6%]V^6<[1^RS/6!]&G>W7UK8U6_ZV51HJ*)&9,9Z9$S4L=O5T3Y-'CK29
M6I)H/B\I)AX"I5=%;5-Q91*505_MB4UB9HB-RB=>C=)5ZJNMM^R+094>N@94
M,=6SQVE3U5>\2L3_.(UA7OET<+BKA5@7/";NZD)!H5X$11RV]O(:T!9?[MF7
M]W@<LR&*RW6R_)BVT:6*"W5$=RZN9HP6O]< UL58J&>,$0LUIQBW0+%M&RGY
M?0;>_C"!)U%6,<(BO:8V3UD5'-T5=^;_"8<J<4C7\%=^-U.7>:7#SQ&A'#-F
M6_W]FBG$>@_2S<L%^@H6-ZHL'GP.V:5DY=:K\]<Z%N:B&*%8W&="[E)!I:@V
M7$/.59C0=Y-I8CCAV02/)INY3'P'[7I3XF2L1\CHCB;6XY1L/;W_79<\GSD4
MZ;[)L]EQ77\M8-(+_GI+;*&2K1(W3HU$@5ZBZ'Y:M>*1IH\VC .%N?VNS%J@
MK?'3\I?UFF16,/#!9%U683(E<-!R9TR%L7 ,9/E+'Z;I6Z4RIF/I@+1+JXR,
MJ +H2EAYOL5NY!UZG3(HDR::#HI#C<^G!M<]S<2_-J:M" ? 6)Z@)CU4UG"Q
MV+21JL[UH^/G#RC?J:=IVG5BCN9'=,#_$ND@&JBAO'9P&GK&>PU8))ZR7LUH
MT/.2J-_2%:9_+*14+1<<:9!EC1"XS0]NY@16KWL9[ P/?77>#-\+T$#(L'99
MV@TM4NB9S/5ZZ/*D:: A(CM2J8Q(<'YVWI$K&VYW;E+9L]4^(/OLN=>+_(CU
MTBZ&-REN=N.))2=PP^T:%"WG;ZRUAC:'D)0BIX^R++%GE>V*=%QQ6I@Z67&G
M\_0%Y@4_2L_J:NS#S\P$&+@I=/6E3P9OD6C!/K"H:RS</2OH+Z)JU&"OFB]>
MPT#1:"L#?0V;K).KF#Q@>")!PYHE;RR=C:P2./[M8DS 5S"U1ZMQ'B]B0.N^
M0?D\1#U(W9_U7$ZRR(X>F,NR2EU\=K_\JQQK3))M([*W 7SA'%Z0,=<+6R;^
MI"+QXP6R^M07A@HG/A KIV<3?;;[B=5(DV[MPG N.WUT9/$E[ZT?#H =VR<J
MBCCT#GS]2WI>S;R:5LR[!@Q*':E#Z6 SYJ+GDU%JP5.U.CW7I[XWR*]8;,5G
M?.(RH*W^]?!1]=90[^<<CB[0A\=5#" DZ)F3_I1=GP'UYTP-!%I4E,%QL%5A
MM+(<_/DTL8$Q3TT^0),WXIB8YJI+C<^&2-BZG$B#,6$W5F6V470EJW'HB_NR
MNF7>/CGRA,+ H <-(3LBANI4S_6ZC<#3.82;-K"FD/>$JFTOQOW;([XSA9.L
M#*TSI@5$X\>Q;X*2S,@S6@JK\4SQT5O)\.Z)\P2CMN=$&ZQ$ZE^U33.+!1G,
M0]5>CO"7;JD;2>,AI7/9UD\'Y9?@TCA[TW4B?TX3S90\D3PPJ\265D:?B[TB
MK<9>">(Y3WGZ/5-2CU;N/W@H-E?7=T1J\TY4NX4\(T.-GU!UP<,EV4>"#AAX
M>XI(ME B\M1,5\?]:I^_,I^)!YX^5%HK28>!BY@9/JY I>6=GWE#:<5GA\"'
MB5%:%7X/(S3?:X:'1E!8;3]#C@Z>JR27O9A;B[?V< 1LU$Q/RSJBI1"E]0KC
MM=6*&[42^@7CJ#4H/@_=\JF8FWE8-!M<(UXYO/OPOL?7ZLT8+W6=X7=;6^"W
M)>"EXR=XH2T23CBE9"V'A/+\T%C4.B<$'(%>R 2D+NQ& E+*\4G]7>LFL9$R
MY?[K6=)II/A&H;TAO7F$[W&F:<@Q1M+=@E=7/Z>JCQ]Z+(< [WVC8<C!S7&=
MED* Q<;AR*HJ5/?<9-2OIZDE3U*;FQC=>:WX,<2=4)LCN>^I]ZM'4BTRP\J(
MP2#,B-UH3-(+B>@=_/9^PT>52KE;)OO2#I!C/RZ;IZT\W%2CRR'('/>@"WME
M+=Q\JXMM)9+/>.M;=^K82UK]5+,Y'P\PWD#QM,^^X I?0V/VV/DU@#FQ^&1.
MGUF0B59'^QVT@"O1FP4%HE)4#$G$ UN0I<D"'!N#RK?%Q2=*CH?NE%3^]VD"
MS1*"LP0HK&,P%M,D>JS4:;>3#S,?]3T*]/#$7)?/?*31#]R03XQY6IJR]$BC
M.X$MQ7BEDWZO9F@6I.T0K&/'>,Z0!B:UZ-&S'"C_I)*2S7B:R7/HX?ET..7T
M:6DG_:?TDFJ,S4E3V\S*LD2L::Q%+:>11'SI;RGY*+5QV?0@M@WU3($"\QY"
MI6:?/N+3D,NU\LNO@A[7@-='/@?7@)XC7VJLXK;TDHQ<.L-X2@TEE7C.\$PI
M)9;IF )3GB[[K/W@L?#3)9HN]-3/2SVAZH4*"\6XTHM=6DI!G'&YP?'AG)6D
MUB!@G#FN2,*,M9+#>3QM!3UWOU+*@O3Q0H+#RO*(^[>!MWS)<GSEX;3<_0+Z
M>AB9U -;WY1*C\P%K-039L 9I%E1P3-@;E%P55P:HHC#<EP:4A=&7#9N%TO<
M$FX7<"7<0?KRMTY;BVR/W%IFY4\OI!\@OV7]_>'MJX^5Q[RW^P$X^W6GAMM+
MY!K@QO0]3#?$KT=O<N*Q'I8$Y5<\HV73<(5SGKJ'Q=H8@VG1G2-/K'98C=F0
MM3-CC9Q! "67I+2UE0OO^:YBT= (3^]5 1,S*F)SUIAA8A4[JTAW&51&"]$I
M\[$=EN'QD1S1U_)I,F#+MO(X>ERE"MV "EVOO+GBNN'V:EH1._QR3>G/R0RP
M97WOQ1$TVW1,/E1]IEB@>Z87%+PJEC!J%)..'B/PQ-%AH8Y_5+HWLZJ3H1=7
M_'X[8:2_R$=[2A:)0=.WMD_>LPOU=@IU:0J_(F<#O3/-6G7L FG'EB=)Z#V#
M#=%( 1#PM'"/'5P(>WI2O6?=TW8.Q=:G-B@;=]J7'EMV& RR# A\79.WH/A:
MW6@&A*F(9%#\IF+2UA#@5^1? N T2"$%=4+64<:[H:P9?)_Z_;[0JM;BR&F^
MN/]HIHU10U(QJ!4-O8^43J^&L6*' #A4S1(#7RN*O^2<MC.TJHQF/T3^ 774
MB.JQ7-4!N*$GQ"5;(1'?I=(07#,]$D1JH>44EWM?SCXCEZ<?.WR)N]_AK;0P
M;#"<) 6+H3\B-TG 9,#@*!0R#"V<!C0B#RQZE/ !K M\LU[&%:&O'@]RI,5%
M);YG['>'2_<E\FE!1MK;4="-]VCHU+NQF9$V?$E0S2&U,\7<3WA;^!2%%C*-
M]#RZ^*Z*^4X]KIA \4NCJ1?+UP ]P>_[T3LG/GQ+Q(G9/=*&%NJC%6N[3^/#
M+_:_]0MHGD^=.D1Y$0XWZRBE*#482O5#YJ.Y8 !>EU,G_0!6-N0HQNL'1O*M
MX78O0.J^"\IC%>-JL:4RT/(,?&DK3;F\!C2N7;R^*MB/GN'WCBN>^$U'R>%H
M#??"HXL[T^-?/XO68_'9)W?%7K6SOO]HV44!BII^9'BL"])V27SM= \\GB(2
M]YQ 2R4HFT<:XACW,B(R2PN:5\ H<9Q'I,.&(FQ E"1Y*1'BA0O^XZ![N%?)
MKJ'(B*4+(F'CL\,=&@YXMGP:O1R%#"&6K_:GI/%-LX;"*5$J M-H;R?9LIR<
M%$7LY]C8&;R/F_(-HS6X7?#\;W6]QIOV>L]3&N]=]/..G1-F.RCF-O]EE_3'
M@WY\2U9@I$!@QH[EP-IR55=$QW(\14YAR9:SP?0^V$)-J8(>3SHV)5.CGRW%
MD21*&-8?D<1?&);0'W$3D01-G(['I3]:IB"B2:Y(A>YHHPCL74;ZT6]K4>R3
ML\).L$?:DFXT-(5;RC.XJF1;0HY"Q<6TK.%V"VG,<*\+40\W)TI_G=E9';(-
M3Y6\V,^R=$AZ;=#?X*(GD0AC=/=K7U"^H%@-I,LC#%)X$A/N!]427<+V;-#K
ML1>=Y %QWN$_[YBPV0F4.MW&MGOE[Z'IUB9XG!,B!)W$V%\DY-+ELFE;GF..
M.Y<'+=\7PG,?"7) ATYR=-4 J>19[K7E;4N?&-13^J]Q+G@B4TR)0#\N>;T#
M!>6%[ZS;;!W%NH!6M#-Z2"=DK+K9/F@9**;$[)4D'O$A!HRJE09\C9JJ5'0>
MJHHT0:M:)L UD1^+88)$1KJ/(H_F9BQL,);5AY#K8(A:IK(9Q;LJEDMDPIGI
M1O$ &U,W 9GU4>MSN\9*I=X$N#":3(WCHPW4TFW*"9,99I#-=N>TMU:5B]PG
M9()V \[0B+HQ_ FF0;Z ])5/9A/0.I+;J*[2IF&B#)6[HIF4CX*D*JODTJ:>
M'%BZ0;4>I25+)9Q9JX43%A\D]@[#JZ'T" FKV5MG[.!5T>5?K5H?!*1(UX6K
MV??'N+:@3^4H9;"L F>CZHUEL]M<$YW@K9<N@V91MV6V=WK'9Z?1@C8ES5QE
M'_L,5:J53[&[;7V?0%7)6\I2/'Q;@8/69\!RCJMIH$\1$S-+RU-M1A=1B<]B
M,$4G#S!7J5FSN@:@\D3'O< *6Q3Y-BM9234OB".>W9=H5'2$@AX031)*Z1Y4
M&=\7J!WZ[B$R27U*12*TA"6RNR$R4*1F/M1-S?.,*_O-FSF62ET]SL5B:UPG
M49LLW)B^FJ>;B]8M(G+AFKDTWK7&@4+/H?D"3[D3<$4<"]8&>)+4+;6D3!YG
M1+^5L&/]VCEYV,7:\?95ZS:<4BC["_(7\!@<DD..<NA89#D4IS0PC2[;4P2^
M8&!N]44"9T*7V1-B]"]?TB2M=LW ZX;8VK/6"NY%[[(>$FHEHI*-\F=2D27B
M\,:-J_1XR%MO>()BIK/\"C,W.O7;<\U<.-4ZM6Q]PF$+D#4L0<?0(EQGW<7*
M6G.KJRL&C?0.W/0=?)5DEE :QT]<8>I)!?N(>%'?P)DV)LYX:7@U47]_5EY%
MR*!>GUK<X=<A4Y@@V-+);[-M+8^,OOTB?2%]S@H6?O;Y_4F00XTB6E7<J^T%
MG :>C TY/C96RZ2GP3XHHZ8IC6_*7V=JRQ'24W2^I]*$BO[@1EFV.S%N+"NR
MNB*!ME/SQL/S35[WBPP"K,8INE=VJE**@P:>Z=G"FJA;T^=R5'Q*3@2FVXCS
M$E(N.QS7 $.GTO(]]OXI@_0^R4@S64'DCBJ<*HKSQ)+V[4+9QUMV='+@0UUJ
M&:<%GQW.UMK]K8O+<=>= =JLWH_]O>:O2TL^Z3N@C!*.GB1RW7./M#E U2Q9
MV4D07PF.A[%I1ZD/%@5_;XGR3"H51-%>66Q=U*T3>EL[@^(?-J)+HT6C=,P&
M&]A%RZQ]]%:L[ EJ,G =C!9WBK3[\56P,N5)]A.7"95:9EK/\PYK EP^[B%S
M_T_#2#/A'#E)%N"%4+4(%U0*U8@,,75@7H95CEP+NA",17=Y>@_]5F+(MP_K
M=2[I=.PO/^&V6\C 4?AUQ,:&I[QME)6Q(_ 23TH?E=Z7S@S9,4A.SDM#,;'N
M0H1+J7DY;ONU'MNQZT/X63KW$D/-$IV>MM:TI96<RC3;2[I]V\W5D:"%A.%%
M+TNY0JM@&8^,H$\$7FT*#3:%%?%*ZMR4$F5-@=Z ,Z:(8O>9W,FM)-#K@JEB
MP);;?<M\#:U-SAY>JVEHBAZX966QLCPILH)G,$%N"BU ^!PORG).H0,!JH_/
M2NS0E/6:+5P!9)05%R8!1J:-JYEEI Q1(J!*VF*J9:X'R)FK^X&/@Z@?Z8R?
M767F='.%^/.+'.%,'XCA+#!]Q1*BJ'>)$L$1(D?E9=&!)T*U+FV@^S*'5CMR
M%3A>LZ!'4 -6?LXGYJV8/7CX,5DI9D8L8F?NXJ-5U_[.\M&"]4MCL;D*4WFM
ME"NB:IGH 3391;39JEX3!H%2RV] 6&P^E9":#DHE9^MA\^YGK-I#>,FD4S&S
M/LI@RA.=>$IKR"+O<S'+%^N9C]]GM/RMZU^GR<+(. =KKL10N%8,R_!V]2L\
MQC$:B.C5?$%1.L#GC4GXN/W,;G!H83PSVT*+,S7GLWMY5T+Y_.2&*V=BK%9[
MT7?_J!D9)SM8)RD[#&WM#(7Z5TN2I"JJ&E&,EP?.ZOU6>\7Y@F&"Z:&J2BZK
MG8;)B\8S]I@/\!,032FTVT6DZ06$GGTMQC^@<T6<R&#"DF#;F3_01N8L.#?W
M\5UZN#GV6=#!_HI\7[=^@$T8.^G5@H>)153"2*-)Q*OWJ9HE*LBV!BQ(_8$+
M]V>FGMKOX_=K]^2"&0^3<:HK8Q;-JYZ%6BR_2G,#=G74)]"$RAU3O.GFK.U+
MU_Z: EFKO-M]P>/_A??QI#) &N.>'HJ"<DDHXAL:2UQ;NGD=2UOQ9)1QDVZM
M).V(7#!OD&EE(5Z_4J4QCR"\..%GQ70)=DL&.\?6I6C1KJ58VG9RZ )6J%:$
MG#Z3IQ0OJ-$M7Y#1IR7HI.>8<E>_"@^(LA<B)T_#RXO80#D[-&X@$D'5V@+3
M4*1*^R=2,$1$]0YU2.?E6[B(K8G$ B='$&G'9YS8*#B7PVNF'R;R2\HYE' G
M]0\+X"[R&%=6O=3XGF6Q%$WR@D*RX_@:(".ABIP[&N$7U$J.RY&RS]C8\%2P
ML,%U+[VH[@NO6&BKQQ[*NR!8 "L+*HN#;CQ/%KWB2*ARJ*JK'BJ!=8>=(L#B
MH]DSF=&,3&G$*=H<="HETFWD]Z)+2L>DO&=.1$&4$W@]KY09Z>\=@ 5TAHHW
M\0-]Q:X!L!NYWIY)SA?87NSC2"Z\4S*L[1V9IC&CDB0>4*%D1.F,KY9XCAX2
M,;ZSK'-.%7V(O^EH><R<*]Q5I=">PY]9/R]Z7[9=^'WH3CH7>H=8&?0+$N5>
MA_#'9AVGPT=][#<+AYQS*#H5(I1Z<^%8,L))SS"33\]9Z?LEXG%4/"VSTS]&
MD,:3CE.P;*)M,;-7U(R\D![,R.7NQRKR]R%^O.9!5.:.4F7GM./$.%OO.VVH
MSOEI6_L9K+9X>.5F<'!$>99F8HPGX#A3VA:+[%4B/KFCOBAC5>+GMKB#TXLS
MR//QK<LEQI_?"EHBUG]-9@;+#1> DNH'VVG\Q;1D!W62X9NI7H25] 6P-O0-
M]81KD>8R1J6'T).5C9XF*G2F4TA;#SD8NTC/7D#&6KJZ4]/(U9B/K7;U,=AT
M,;[P*9O &K-(,]O+2I]NVL]*6=> VV7O/SN*6#XB="*_$F'QE] /G<,9]#O%
MCW&*C\]\U$4E$XW!A7I*3W_P"D2N%TC_L;=X.$CE!8X4]B.-+VK<K)\H@.]:
M>1R0'3]&,BMQ\9!GL8HAM7R /0]F]:6%^9;449G5%E2^0<J<+JPA!%OZTL^$
M7,VL'2C@KA2PB$FHR0#/[A"RGRG^*CSS=8SQ@&G7VR>OGA@C*B=JQ8=9)L9.
M2?%A]H$IHOK!X9T8%AGNRV%L[3!L]-1=XA:3K#NN/- :GR5#O[ &0R6Z?HX2
M(CDK:''K0OI <GB\,5=LLV-7$KC]?93^B'6+!&=M>HJ]3ZD7O^U+"D[39%:8
M(A92,J/"H#3QA1E,Y +BJRZL91?N.'K:(_=$^5'GTXIVW^RY*<:NR,QO^%^G
MK1VXZ+I@$^-,51[T/&5XYJ@8@N(/LIB116[34RGM*;-4/76DW[8U=@9G[ @L
M!2B%O5K1N9D%?W^H,7IP@TJE:C1%PZ3:QC8K_;Z4Y$E59K2BDYD.!#)*%OA5
M3F'%8!A78M(6CQ5DC3UO"/1C$P1V2RGEJK=-CZF6'RM7<DJJU+IL,7VP7UDX
MQYR<JZ!B?+< )D#$43W&JSBLSL6W!8;N/P#KE\[#]<TD^VO2(,'X3.)0B-ND
M?WIZY>WC\ZE1@%;7O>(CMPHQ+MZ9SLKD6,(BX_"W]-;()PTP80R,Z9):MM$H
ME;#=UD6*/MV50AL(DHGE1"-YJ&X6'\]H47&5PEK'5?)/:J/*D?(TD)2A TNU
MWH6^ID%\3!DCRP<E\J0BLSM8;P2CT3H&&J:G.TL*9&WV.60^=_EE[,:Q1PR(
M)K-1!QF':09; ;TQ#$UHNI:<'PF7 CF:%="+E0!81LF'<%W]:O%Z# @)_:0
MT0%*.(*8EV.Z6]XP)2\V/C$LN6*W&W%S3%.-3JJ'XKZY7V0]TO-I6S9X1G-+
MF-Y^&OSV":'9N\?XC6L]XY+WJPH"-6(.4%Z_21"0X BG.P:=N;W6 EH35!"&
MK%"@E?6@M.FP-K5"([Q4HI(BEZ1C>QT/).]V3G"@L"DXP43GXN[*ANU&+N$C
M&'%/4,IB,8JAU1]9#)KN YF_;XQ.Z_:\9!VP&#&BC$AX*&-'[GFLQ.B0STFJ
M9+B3D]2'/[7P (4:^_/K:)/G]^@2<CJ^"7AAI$GD.V *,^SQEC6PRF#F PH*
M"5A93.'\#%3\83@?/'E[)(T$6]K.0E*0$P.=$=_NUPZ;AU'#C_L^AC<*J=.E
M;FJ^XQI@Y',-N&)CF?]X-.Z6/7<EO[GF:"G*6_P YAJ0;-EL,20@XGFE->ZF
M/[3;="KXG:J@NT)_I4'U&L!_Z7(V/Y6Z>W0-T)^K7$@-6W";4\L\)T9Y>KXT
MC<+QZ+/$B=+(I=>GCUR)"0Z+G>&7^IA;B:G7@&D2P0<]*]]]BS=7FI[/MZ4^
MU1'QO6*U6TK]J#RWQB>[-B%WL,TSY%M./*4FN^!]HLCU?%4V7=!,5WNU9I]Y
MV_R]EV""Y_SN(ZJKS>-#_?R)>2>;:X"RN3)FM_X.1^&5SD9JWD2__4"XKY:]
M]U3Y9=)Q4^0U(*!G>R?/YP''[CPAS_<F7TH507/?X OE:P"-KL^EH^_-V[Z%
M@1Z^<1WQBVO "U_;=;V!4^NGV3TSWY\G6G^7.GJ\+G ^M<]\@N5S</"-*.^I
MN\WE4,31:;YEY*@L4N^ GT_3T4#C#O4Q/UEM]7KF-6"U<B%[(>"EK^_W2-T0
MCP;K5;"[^EAJ9^I0)UTZ[\*)XOD+2"",0B_Q9P8N/X\1/CY^LKA;$7NXT;2P
MEFK7HW/2VFP>B7&UK'%5+'9Z49OOO#I1%'B35W/P%KV.@UU%3]]1'WVJ[,WW
M%Z@[U*]*/L)4DVF]!N@DZ9]I-IN]S6DO?$S(F;I#K<.9&4I+V^*R^]P3O$H:
M;$6_DHD*)UHSD-"R:O8I 'WJ)>NG$2(,*G%3.5-NA^.1E'P"&>WR6,5!EWI$
M/!SK?C;.H8J@0&N*";4/F9_R2Q0T;.G"A6#]K(VW.&/T-W@+XVQ>4$Y@,J!7
M! :J>84(F=,5M I_I(!VN%1>F;(K]NHJGD(1E)UE+^T65[/=?_$11Z#G$:RR
MPR#- @L&D.=9H'0K6.85G6CX@C\&1LZ6J8P2H=(,*&ZLHB>"0+%VQ%:/^NU8
MM(G[_0JQ!BF::5UR1^@/4)18:^2X>+R1*B-9PW9K(U\?<25]?N<:4AI^0"ZE
M;ND"^EX$]2F<,/3SQ4'^0#967N8V4:B+1!.VMD'78@.H>+QG-AB&36$I:BX)
MO[3B \A*VZ:>:*7387U==,/T6%=94X_ I=+\?C?Q]_C<@?>7:-,"Y5:E_/W1
M"_(85JX?6<O;#B8W= R=[O6&[->+#8N]%RHC9[6]]\F^O?B":X1DO.EYA#6H
MUL.X:JQ!96&6<U7R'L-0JU?N7E!#\7W)&))X)1"-'I=0BZT:'KSED;'-Y(E/
M=)Y-L@[+("I1M(&5C@+Z:B?.M#@Q!9V <9F(!X^4TE*[I9WIQY<+\K16( *0
MTK1;:L"%>9[#-0"P0:A<(&P,SM'OR95@YW5VZK1X/Z!06Q'>E?CPH9+_4%O!
M>9:!3DP:",LB%><[F]P75+YQ;G7IFL:ZTI'TD;=X1T@D,3M]JV^L/:B!.X4[
MAJ0F;\:@VS)(%#J3&4P$.<'65@[2(]YAY_I<U<MVYE<9*8OQ%_M/>017!"^(
MY1,A ^UJ^NF5[YENCF_ZU4!W)_V9_)]?S*;MN(@2&.PG?ZY>'Z5GH!FMUX%R
MZ@?JS,#EFC!+;O++ HL=;6L_['CK59*]+EFQO@:\QV U> 3B]=]/,YJV!4K>
M@]@77%!O[Z1OBXNCIE,JB<O&4XHK6*"5=@A?X^EW6@DWQNUR2EF#7'D&>J(H
M %+K"$K> 3/2$40?7;+/W*;-7SM4)SD5$12"ZX:'EVQ)M<8_9!3>!SG&4VKT
ML\93\W0YI)CC]?-@OFV:]ZV>5_C0Y30R3:_C;N;=KQ?D8TYD=?E2N29G=/Y?
MO<CKSBC)E.JEB/'+?:65W"O68\S:^!X8S_AH]SE_<2%METK&&;]&%UO*4@_>
MMU<9S]Q>+4_YN6V#7PD8EOJSC9!GR?>$F+A^&+ Q<3M6)_WXX,A'_XL5Q[W*
MRU;#NL*)3P9 !YO$V<BL#>S->#.MU):39%5"7M0IAOX.)5.AC+%WG\1F2'%&
M1\)4HN/W7S)U&L*AZFE[6U$M@GTV/?2FV^7'=IF8BJ)@R%+E$H=V"@,BRO1F
M)8,?NY>(!,4L*J[OR9-I@;Y7/<.R=0OF@.3R[0F&R>VPE-@1ZGO\9M"5@L\E
M))V+E0+ &$D+ 2.,.-I];Y.-2]XR+%?VHA<S9K<'A0&,)<T -5/])G+>-+9B
MW2:2A_S\J^1=X&;CCD?LXS5E8$8.G&>,X )P,;CP2PB)5"6!).6;C+A5*<DC
M1<\\."4QP]<O*H8KZF4YS#@_+61&%81_U8C&9,T!'"J.IK+%CJ;<*YNSKCO*
M;VMH*%];6UE)%60NCK+M7F8O*IA]%[#DWM3YM7.#THZY]%Z5::/6S!>G')3@
M,]QTUG+][T;4TD]&VUIV#;<Q:6FC@R]*OO+[/-WHQ[6#:XZM8VXG%\,O&0'[
MH!\&-K.=&;SP)I'J40J6,]OI],2</+>7%7;/'[&-R.:;P4N-#@!7QZ<4<7E.
M'MM21 )'X&?X&%]_%<5_M/GVJ]G&F\PW9::J ]G, 5'JZP\'-T$(YW5^W,M\
M0GW/<70J$IU>".SO\JCQ)VCUNTB\R Z8T2OGPV*X0OE.1BQY2,K;N3'WVJMW
MCAKJ]&WD>BT)>KDMJI,F:B 'T)*Z+;.O.T.@WYS>C=K$2V*X4<=V/OSH0J/0
MVW&R<3&\/@\FV[.<DR/T*"0\:%CK50WI!(U3U7U/UV>R5"+0'Z<.O3M4>,5F
M$TMZ4=T[K4SV"T'3+EPHVD%;1([9[Y?/6K%#-F&D/;R6;)YJ3+!B^ZI$82U7
M2Q]/NH SC#U@^FJ-7U=V*R!'A)PPX2*7M,"X6!?&J'?$IXSW!9> N3ZR[6LK
M"[=:-SY=1U>308&I=<G!:BLA4=6*-<H8^SCFN6/D/Y:D2#LO8PO\%,^^C?0E
M>'Q-*5D!,\%BL0<]H/'MZ =YA?Q*E-:=03^D;BU LRSCI!2)4,:1.&;()*')
M+E]A.U&(@1!\-0NM;E?L%*.X=DGLS#&C@]I,,OEVBL:82*QJ-E 506E2=0?'
M #LF!"/_</-17Y%\A.-G-$1V9SAUJ^Z"%D1B/9;/^-/+K912ZS ]-5[A;$$
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ML,IBAJH)U&@?Z=[!W[CZ^3IQRG[<0_A#U4:]/'G5X"S'XJTFB%9R%7OZ4)(
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M_;WCO:JS$GO<9N-RY)_L/S;IZ&L6P9@_($F;=(.H$>P<</6W*BB<S]0''BW
MYL2)%16<S@.-A6T>J;GA/,3ZR1:!=)JV@YM!$^JDU#D\IZN@$DY[V,16\H()
MODU'YCV'J73]UFF?/7</G]<1CG;L;%/\&U#:!-=;7A^(*$P89N-97$W \.LE
M1S&[,IZ)]UGY#S0_EOS8!;>V>;.OGU2THG"*N9]0:;_(+%6RSSLP2HM@=>YP
M#V-FO[0='#'5_6EWBW4OM&Z./7N3J6HTCQS1 R!PC1W-8&J#B/L8MR)>C&WM
MPG2C<EF6SK8CG3Y+ERXQD4?"2>%[?52G#$QD=5YJ!*GP2A:T%+4\;_Y<*:RV
M"-6K<;]FAN_CQEYI6D->*0H<9S3_T&LN-RT6AK5FY:Q",) ^4%G$!4I+&? 5
M+SRAOD9F4_IQKE7M4&TFM:2D@G!>S,)](!&,]/$/ FENO@9P#S?$@.+1/9O[
MEW,>XN8?SF]@SN B\+J^HBF=;+DUF*JVJU&]J;TU7MI!^8&M<'A-8<0F<WW<
M5F)>P$#[YOD?,;>X_]*I4NA7T[DA7*2MH%JU]@[073Z]2W2%SH43&\;/_5()
MGSRX@HE_SWVO0L$7VGS,=Y-<Q3WL[WG8Y=B_+NH*J\D)YC^M58AB4!E!H*5T
M8*TNF](B##Y ]HEWVNQP17+M*]4;0YJMK),JX.QT@*%GTL/ 0Y-4R%_:6B3(
M4[L@Q:SR#KLQZ%D.Q_7NX9MR,* >B+9@YZ(T_'S3*L*:(2]" ZV2.<WV>[)9
M,V[KI?/DE?,=()MA?T<@77F82,8JR8/E'M&1[\2WT,X3?*9JX'>>YU,Z7KNE
M.V9//TRE%@_089TL&$; 8XCF?5#54II> EY.T9C:*6<Q$(X[E+,X?O!@G:?T
MR\; DI;(UV9F)<\O]4NE=.'H0-L9M%661>7G@_II9([A:S;(9B35;_HS'KI[
M&#G;7\_R]XF&:3G%I,<3#_")U?GZ]D(WDZBT4CITE,086H3->'LEVQM="V-5
M"-K_'7 Y4.$<OBXBFO"HK.A,D[V+U1,&>O!8?^ FGJ;\SBH%TR:@->RB:&<*
M3S-!?&Q:X]"V=C'*+]E"&CR_IB=\EE)-5Q"\4OEP+._08^)I"T A:0Q"(OT=
MS&T*M8(B%?UG9JQ;D]74R%8IUV]LU2]:7+8-V*,64*GZW!NO">]$40#K 4N(
MTGT<)L&6$.>8MG^FTWRQ1MQR,D3+F=,G9<IR'F-;OX*CWD%L^TW2M(=^&Y=0
M4TD3:]5N*(9<KA/L0I;NO H\<J@'8U7*,+LVFGV8=CT^0TG(KOL#\#*%K[E;
M%E#'3(C->?:Y5E]WNQD?_FW:/1^]- '3! 3FU^9CYR2(U!%R:\1Y?\3"[N[4
MJOLAUW*%PSBHM0)K)D>FGD0K'4,\@)X6PD^F9=[VPY5+D9J$FF7=AP=:D 76
M"TV8Z&.IC\\S:H#_5OSA:O!I)>1_=EY>QZ;O!0MGN%G&.(/JY2GS[AVTEO$W
M59^@] DH^Q*9FHA:#)U;10O&$AN9Y^,8&<T9FYOV:<=3I',_%]K]94"/#B!-
MFR2LP)=<R&)FC<_)7.,'X="&KY+D-*8G=&:J]T1^:G&P,J5P_-2?0^U"IU>*
M^W-KENAG)0X62DS WQQL-XQWA6NO@(7C]UFX%H[ZBI4>S%/VM8,HGH%$BRI6
MBZS64M^>O-,KE2 *9SBE,F<PVG%-;39-XF&^6UU3K?&Y)::\DO5);N%1V$$C
M3FM^D5FE;V,Z#RKQ19$QLGE5'S9B[CJ1$A;<Q:7.DEE_%J':VB)M:, P>S=E
M97P:8/P19O1G^Y*RO<2=<C<%NX-E79]_$:XB"HS7-N4_C'/E,(C(P=<T[BD?
M4$D63E;OSA'VI9BVK[&=019 HQ@_TI(5FA9(:+7+FGM/&\^3(6>>XEXH31DK
M,H0A[8Q<[$B?%U'CS.<,UX=O,A@B:<PYLG\#G?CI.AX@R]>94<UMQ8N#UD>_
MG8*GGW]AIA'939<U("?[Q]#6>M*^RZ(C>DKOUJH)R>#XL;&'SFQF;E?,H2,Q
MG;G<Q:1](8S"!+<%F(:V2Z""E7U0_&,V [U/4V3\V!O;?-3(+P1-^)=SNU0Y
M.;.94V4UBBB]41A\'2QA\!KVXJ$EK:#QV^#;$=?U%>NGPYN1B>F&+KZ_*]<$
MZ'#_\*W;0R!5<$N!"!XT\,\-#W !.,(ON1)-,3-_R7/+[1UP0JVHR)@$%+A@
M6#(&4]&L>5:\7.W'7IS4".8*])2\IE\_O0,4'Z[W6Y!@6OIW!0\TB@7O!0A(
M>F]O.) E:Z[CB%Q_Z20\YIX:^?@L"W:92U@;T,>T0QBKI6/;6? _ 1N99$=7
M PV<4S%*C!7:P_#\]IOC5.;FF=J2=Y"KM)IG^D9"S:#=!P8I$Y9AML?"#8U
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MKEHBBFB<\[URNQ)7ISY_?JQ0F'L1Z$B*!+9662QX/O]]Q/GI<L_UDXJQ2K=
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MP'#&Q<6M\$QCSL.>^=HJ2Z49;!##O8:W8D-&Z^.P)(6!T6'='P<P47.1%NJ
M(VK9G G_TDEM32[^HE2?CXI"AJ)6F"_^2FQ,\I=78J]U6G;>^3B@K![XB_MB
MK@KAT8+P.&4_O;!E_UU\&\+5UA83]@U,3Z&&HU:^4.M<000K"4AVKH23$YJH
MU;N%0[ 75%YA82Z(GEU 1_(H#H$L8R%[I[KGF%:.P8A1Q6D^#I83#MSH)U3^
M,<.]_!:Q=I>XG_Q#1=ED/SE$7("3$B,VZ\0**WVQ2$XB=C+^U[\RE-X(HO^4
MX=F_^^D]3Z>(-^''+-0R6]@>B_#1@MH#(=]=J-A_.L%[F\EDG'_<6$\$V6M
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MZ<J960;L2.]Z"4F&Q%B4)7& YS34GS<"KM#W:%_O9TYC_#X'=3@!5F8?5K1
M?U>V$Q%8I]:685]+OB;**5=A \/(A</Z<_#B=8G_Q0.7P+B@!NOEJ[]H'W)'
M1CT[>?\$+T'_V2%\O8YD %;2:-Y^>2$CWI^_RLQ:XF 1^?,1T<V $VXS-1NN
M<1'48<8X<S)H2@MS=AQ ^2< 20RW_@P&]8D=\YH^^U!W5E'1!!C%%#^X,[@T
MY:.BNLJV.A+G5+M(&AE5H+Z(Q44')QT372\H$\]]R+$QM ;"",A2S7$4=.?#
M;"X)*PA7+[T#)_VL,#+Y!.SQ!L,;E3S[=)F@T&.7=E6H$9G]/BB(=:X_#2GN
MP/'A'@2&J8013BSJD#%7=PXQ93 HM:;*>C%I"HZ-!ZI\2W_S@+@J><.,*!KV
MFQV5_TQR U7*CJM4NO<[-5 S=V1XA!TK)MZ9CR:R_&ULD^DCC3!G22-TD-.T
M0^BP<5"HIPUF<%WU8$*4;VG$O>M6]]:UI67<YVMGD6R0(E]T4)2CA>"QE'27
MI45 \+@[$#V@]TJRB+>^JRP1K=_4D'?X,:R<SQ_'"A@84L "H^()"3 0!P"[
MEB0H1ALFQGJ(*PO'=AZ=8;OMNL5 O0)GK:(D,<BY&%4YM>5N;.;9#ND9PF*A
MX=-LP?!SNHH^?@1^6('C4AC-<H&QMS;.OK$7LC9G; TK7QB(5[_[GQ#U+YO$
MD 7H#_95F"8/#1C36K<E=)!C1VTH V;?+UCE; PT48W5'#K5?K+BX-6.L<",
MNCJO"L6AJZ+J$Y8N^.%Z%%WE[WD2]?NS<>NKM&/1^_ZII%&.TO&'I?KJQ(GM
MEQ6'=2Q%#&FZ8-5NC?]NG:!TF];CQK)JYR>@DO]!XP<;/UD.JD*9#*$#0OH!
M]1_#X9R89+$%917E,F%076\CV9383_9 FE-2-/('Z,O1*AA<C").7*A!^7J'
M$GD4%F8*1#)&96G4Z>!;MFF91F$\(Z#Q^5A3W[X>:="H]CHU,6^6-.)%6R51
M@"Z;<0^TJ27:3ZA+7*="2L?=X!8V"&NI[%J/_)CII(I$,C$U=@@BG?#VY@/2
MLJL47@2CE#_5G9I8&9ID1)BHQR%Z"&D9A:C"E)G",*^C(KB]H;Z:G=2UF.$7
MU;>N5 _6G$?AL2L!DR4::X'9-"^)=1>1P$_ ;(LHJ4)W@=W'"=89#7SI<:4^
M)'+)/63K#[D1+<HPMN^?E9EZ2"DI36V:FE7#0Z7S%H@081..)>7J)-MA\H&7
MC48FSD?[$?^54 _N)C;( -15>-6D(H^JRXWMB)Y ,=]($1UE&LHHL++NF_V,
M]"-QW2:*PP[U2M^C=BE?!B8FO']J@MV 1KZWED&MJF/'YA-@V_>=9>.5I_%6
M?J67,,\MK< D8TR_S^+7-</_7>C--RKL,P<60?.^VDZ-VW!8/N?V3BW]+5<0
M#,NS<"2G3QJP2I9"4>YL*A9!V%:*Q:CL'SDDB?AC.)DF:C*2U]^&T[)^*/7*
MH:PG5\! =WIQ4E92'0"EV=75A9$T@L4DQ]S(,89CNR [&2V;FJ&FP-Y/.C?I
M#-^=+ K=0?>EBJE!2+G@J0KXV/@)6-_R7QK&A%A6X@JYGB%*E&B?(BQU.7X"
M(K^[+C>R;_']EVYL'IMH1YJEE7P;IZF7A^G#OS:2-MD[?MVOD0A[N*:LW\N1
M+)UA9W5LP8VS5,CZ!(2Y5Y$!8W4P.X?LG!R\7%"PTE?VS[(W9Z8V'%#;TKS*
M-DPF'&@NH29E?=3 9@THKGQH&C965G&$B6 I:.M9P^:)*VZK-J:JK''JRF<]
M,0M;A:ZD87E\.-%6$F*#/'*_.'2?L&$'9TNVH3\KX<[E<QR+U4?(#HRC5$/8
ML]E*A<I-TTVM558H4TS5-=/M4HF$T'""(U9HG!$H XV(51>_I%LS"+42A_NK
MZ(%49*8AZ&WE-ZL]LA1#8Y'!**;MJJ.HP821B3+]L</TJH4RXOKF7+))OQ<Q
MB]@@ZAO,'! BF^8]U *&4?8YQ*TC+[",#W52QF&RC WI5A3S]:4")_N$%76R
M;TIF+0  "P"P 0  P1_0I<+R^<B@:!=1,H:;QW&\GII-.%ZKBD(]1I2+*B&A
M00U3/2M6^#YY8MV)<3<%.;+RIFGQD(6"HPY7O<2(WPE(@53+L)5GK2N9-)L2
M46.RSPF21DK-367BC5NE&:Q%I*O\ LN9:P;-"DSI YI\*+YC2B]DSSQ!R'-?
M;3>=:JSUIYRE9KO^.!8,$>4O4*T<+#GAS<FEJ+8MU@(/#<\8;"K<]N1,TCRK
MRZ>RK8RIME8M%*]Z *Q#^9[,%6JY%&YQ-UW5M1T>A[P\.Y*:!+\]@,F3%&/U
M573#.)Z&HTC'7*!@/V9D&III"T&%_=RJ 2]M;3Q?Z><6&IMOZG>DM-(=;=+6
M*TM<*YD9AS%A;5T45C%GK?.D.0JQ9:?^+SCN)H3/.G&/70D8[E,V7*%HJ>80
MSZ3*'9JP=0<![0"E'=6L""LL[E_XF3KD!LK95?] )_!Q9GY!6D5VF#:$\-72
MR#;#!\BN5X$_>=S]F2 ERM^1<I$^ 5CJ\[^:#Q2KNS6[([0BJ-D.?!ST?F0^
M!T\VR*[RSBQ#I'<]'ELW)#QC?='N?JS/'IQ,,I4ZES1A!HS@Z]B7Y?]N#_2K
M\D% $F\9;0D86AQ%TU.HR2Z1G2P*U>KYW4]&L>])^^K5P-,I]_L?)YXPE>R(
MC<.)J7F/6N)E*VEQ&"9[:6!8CTYTB7":*8.]P.4^92"U\!/BP&^7X>^=$ZNU
M]J61DP7X9S#( Z@-S$)X]+H,+7; B4FL:O&(S9FE/DGAL@<.$^?5B*@]QYAA
M?L=\9B!83FP9YQ- AU90-4*"1=M5;B(.?';AEAL<:?30P^ :W1PA\?V!>M +
MWL$X>SE^.OC2[(+X-+E.V )GNW_25D5!?8LQC@L$MK*RK3(.$>%(X2:D>[K+
M!&RV4"+59R@:#'9[?2=LUJE \87.2N784#!/064CC.MCE4PTKK"+UT]#H$.0
MHPGD]EU="$#V=?I]Y53A?/AWM9?1 )75FKFE2YBNHT'0?LJ\,[VK.7/IS]:P
M]HM<9RZOL4VSC54T%^6!%ZU"K>C\$G]EH28C^G0D$:LS3X5V/R\V+8.R!2LW
M(FCJ!W*4"LLJ4"Y1=5I0SNU;]UN99=<')T@&156R?C &1Y:MO B <IAG8^XZ
M$J^7#J9NH&U/45WZUJ(PX?1(W''CQ/K5?16?@ZNQ%X>Q5C>G@HBQ6*U<=S\.
MCW=934NZ\@(JF?KEOK)$J6*-:6YPU?VY(3P]13O0QI-R&88EA"H;"LC+URZI
MV=V&"@N*)0]K[4X,A>H37P469I\1Z3V=K8 ^ :#XQB!,5^]/0-S])T" -W3G
M$["09B1V#S_^\,%]=G&5/[_FY3W\N#R9.25 !51T]$CV[$W%4[AS@N,X'<54
M[=$OH[5G/M)-/DQW&?M&;](QEQ9;Q)2G_&%[<!U>\&JY+!'35VK][O<G#^GA
M*:@;'/#^[G)YZJPDF^N+&ZT3%J!W]P\T)2(R<'=P<C_#F/'WF[\?C3AD RG-
MH&B9+KC: "4,D\=(>I%5L1R#IGT8E)>*<>F]0&I@,PB^0.%:N,_CHN"=2^,U
MB>^-3,#Q=HMM3Q-;>$"E#!"06W&JMB_-DEZV AO8^610)LM9],;S$29^,<)4
M:TH%F'>%!@=&U"%[)X2VVQDO>V=IM2RU.)#-OCQ!6.RDP^D=09&"#<4:NA/,
MMK6RB%1=M6RZF=FDW%M9R'X7&BM;B22ZG!:UQ4RW%-%XLI(>L=%HW6(9:-(,
M/.YAG1V21ZUEO^_TU(G%L;;Q(G!J?_SA3/!.&Q;&7?+(I6]HJ>]K6:UU7S-O
M;NYHBKJBK%^L59? 75H<-YSRX$A#P_D)H&<</A4A?D8/[Q;:KT(E#GLDKI$?
M/!%O72II[^IJ[DER+.U=<LBE <\B4"(TZ(L/$"*'>YJ/Z(GWQ^Q$DJTOXY >
M$QT)IU(Y'L:OL)0USD,U@)?=I2%7/,U1)+#*4E8H58*D!NABFLAK)XEZ95:S
M:W\V>!7=L*$&DSH&8(:+F VJ(\HJ^="%_3NQPBDVZC*HZ)1_M">FQ'5 ^H[(
M+-4.VIP;"65A'M0.?95[7-8-1D>J;BCW/5 6M$G)C ,[:#11K+X/VV>%UYY]
M9S6MFM/#U@^FK"'@ZN2#K)]A%_:91IGE$&(439,,:9282_KU3_#UW[QKSCF^
M CDD10EI.5R6K "^KZX(!%/^U?U^C:I,_TQYX><(:'>NWN\U;)2D&IA?(%VU
M#FWGMXL\2"M[;92U7-PA7:I)P(BJ?)RZ)AM;Y:EUMW196UB/L5\2"'(Z)>A4
MILB9/HQA+E3EII/!X\A+$RWSGF4I?"BZIC\\OS(GL09HT5$Q5RKSLQYYL@Y1
M(?"89C]8B?IFQ@A(C'PUM4.JZ$*<T:G-E],]Q:N,;,R",_62@_+O PT>5W'%
MI0.M6K/>3EXVHM1,]T<PE]F]?6&M:4Z/^)+29 $N9+J.25B*M 0.[F$A%;S4
M[US_0,O47Z!QL6\C47!DYX]^P.""C(:_!*CCL(WZDNVFPM^P[^O41W6 T%6*
M+RCCI2E:*-M=F^K'B5/JJ"Z(@FRNW*I6Z6<7CM'"FF.C+M*+R$,4[:A,A]<N
M%1@ ^9G#B'YP #S4<&A,ZHZK+N^$I001PB+0<!$IU%<:R==@X0:")X#LYA9G
M^$?!5X(0?M/,_9GG],LUG1AR[^89Z[5W+Y^UEAA B9&KLERKU%*K"Y*]UV7+
MN#9YO_R0<AM5P!KW/Z6!=2UY0PU7U O @70(GT>.M!BSZ"0;:2O5_14&)X_<
M6M(,E8A$F&%.-:&FGSO,7LHX\->(ZRO/29& %%'!<U<Z5**8X%;H<)\U]!?C
MM:\J%^])V@#-%K6F9H>?4@,;,,E,[['U7]9PQ%-^O)/9:??!BXV!#1NH&M>C
MX-:,W35<I=76&-P33S"3DJ8]E8H!%A"H';I_]-)Z*JJ:9>8&]M*(*76R\R39
M&%_]&"\3"K;/#6P _J9#I(S#_'WM4S<]3-H0>*8A)K?XV9;!857/S)II1'J/
M*9?)WZ_D"JB,8XXU4_A6/VCYUFXC].*+E4'5$F$3'5"2-)+__!#@Y\@/7[O[
MY[JXZ?GFV@^.3M&/9]&[B1))-&W^IS<XUQ>YP;?.Z\K$;N!,B3-@98/8,+=U
MR2D%U5Y\Q1GYP>!G(HU@?*_ODC9<:9-1E ))H@40]J?A#)-1/\)TI 7WJ]8>
M\X?CKYJ I4$P02!]3AI,Y/ZNQC25-V$"@8ZELH'HM""GJ6I^JC]KB@FHCNJG
M/M6^I@:Q8/9VVWG+DKT7+>.0;#.W><P5M\3ZSLFAR_W?UP#^HRF'LA'FN$4;
M-=N'[NCUMDKE]FB6 %5V2L)8#^D,P5]VP%)4\M*/G%8'3;-Z1WMT[$:8\; R
MHTK$'.,1XPYKR2/I&@V?&_F/7%B^#I@?R&US%9L)2X<[#2YUYZUDY>'NS>M=
M5-: ,OU!N^AN/.<HZADR"4=S+&IZ=[FYYM(&N9TOBCCJT;4S5#A2L0WJ(_'?
MV9".U!"M&*M^=Z;PL^I!H4GTL4C:]4K[HU96)#HKT(.$*[_HGMC@JNH$X5X=
M&%V<DO;C%:P6.9<Y&#6SZVC9,[98.]3)V.98<9QQ N>;CS<W,_W,IQOQ!#4H
MQBZ6UT#ZN96H5N]_W$5;5^#&*^@6IDD&J$4A6X:&19*6N;3A'P*R&JF$WSJM
M+0VB*#7!!GI(>I-$>ZU+#6@V&1;6A\#VEA \G2_XG) IP8ST=_IJ=4FS>/7;
M,6=.05!RV.S8K>CEN>*#14/S"I>7.9UTTUEB"N'ZO(=YP7EI1O-@]5='_Z:?
MS*@X^ BN<N90GE91T_/4!XI?*<IR8LMT]+UCL96039LY)K Q!@;8NR@HTI#Z
M4\=- 53ET+R5;!W)!,6\M++S$X#@BW*+'PH8_ \PV2@HN8\>[)^ F;5/0(;=
M1Z&/?.5JU__50:M%L=A[';CPMFD66'M1=_;Q?%S8_,IVWN?W^Q-041;X;3^(
MQNNX[1/@M_%3!"G-I/NYL/8^R[,=[7^F-G6^_M6X.H0$Z4 LZGOK)G(.WDU"
M,XEC/GJX)58O]#\!?[7&? ^=L(4G7_[NUAF,?0**[80#Y])JW=:\%H5D7RW]
M!8*H_> ?_S:^W3Z;7(0.[71 $FY0?1ORT#ZZWXA>UU;>^A[*2-[N3YXOFKSX
MQ?S0$P.CKUY<N<IP*K%NT5^+A$3?DB_[\O:QZP--YC\^'!S17V;V53KQON;:
MR:]G,SS6U/C5%7P"WE([_=$_%M*"F/'[GI#&!'>P/SK1-U]5%KE]<BD"3$R:
M6?KTA SIN+=,E_['B>^?R8W;^]<R$O6JH*&QO^\9;UUY;U\_^O[^\_\$%,UE
M=SQP>MYJ_ DM#XQB^F\';N,$HG/=S'^=J]'#YX_O\,U6;RD=7R0*=>4TB6OC
MMNJ$L)^'$S=HK:UI=AY-9.X])5U">!"[,/;IL?2: _=@3,VBK%6NU9_8[_93
M&_^G+$[C;PQ/T9H?9=_R,Z3+$%);N_H*H'^/RP1:)HU$8"R1\)RYGF)B29N)
MB3?\9+7OYIG42E V'.,VB8)H/17AH]3FF+EX.K2';!\?S)OZ^+"5/Y:DF0[F
M3TRQ RPVF41VE:1G1Y7<M[>&'.;F2T/093/,L2;E-K#PR?&%%?)F4C1UNC\!
MTP(!'RG\?:]?;?B*N?.B1H)^^@7-#Q-^3$*(O +@;QB=%HM7#" J=]OT07Z?
M@!RKHH_MS4] PL4GH&TJ[4UI8WBN-P[_*<>XQEWQ9C>H/;.6_Z".=NCH9I$7
MNJ^)>V/#* A_2>78P>(5"YT_3^DEQ^PIM>X<JQEWYZ&KKI7VW4*+V%HH'>L3
ML-\7V"",H*B0PD-,FU\_N-+US10IPIA3=;Y@!M\84@1U-ML2VDX26ZX6 MUU
M@WIKB:R<P4N?X\\/%;D/.]E3Y?OW*H:45R3:,*!#V,-C8)!\OC+YHFY%\L#[
M33M\MA]/Z\6QO/%A#.0T$TN04B;#I]=X&C<O4;L.UQME<:?,@2,*20VT55=-
M9; =5,\&RJLW_2QA&!6\3P4)ZXZR)^2Z9?^S^&H"$[QY<%0B'7]4@^9^WX+&
MTUR#?!%^J8X79B:KKE5CWR&?7.U3QC#+&7O >S_JDB?H<Q"ZV$Z>P.SQE@H0
M(X3!\,-<^CJF?_#_,X(9D?X_/C#5Q.:7Y$2=-<('(-.+'U+?*<7D $Q'U4[Q
MH5@XC5@32N%$S!.*:%%XV)-)[$I^>*M@O<G&BRL*+S >Y[D.^_H& >SPB#9-
M[CXQ,%G&/8Y*)F->7QID5(YH_AV#K0Q+CG*X9(="6H["Z ^ .AE3]P?@)M;'
MB[(9O'D):XM7TJA<I35EG_4OFF$(IX8@2;IPA_5BVF8^3"9++UY8ZR>L_?"Q
M0?QC=?I:_KYDXF9:)%<:T62/PS>)CC3-MOCS?1:>0>)3LYY5E'JAL$A48L4)
MUSMJ[,TA8CP#W9P3D'H5(>-:B> &15*1!',AC_6NT11U+-1:3V/P!G+/#V@A
ME]\$(GNN/45=Y<E/=69<9TKFTEEVN71ZJY-#_()J7D*_6E+6IG!M/,4:M8,G
M:3B2F1].\ 1E(]T*M3.BZ./B_NG51<64G';^]-5!O\"T5=N&4'=FWW)A*6'E
M9-<(*MC"L.M/4BJLFR9@37%%_F4^(ZU7X90&GU_#93XM7^7RZ9G'M5V9+64X
MG[B83EMH4T';;(3H9FA .FG ZXV^S?7@,^Z5XZO%'^H;<#R\.\#O1.@!V<]Y
MA:D-#$EWU<,$?V[LP1@FB.#2/R9[T6!6J[Y%I^H:ED=>1P?'6F*U)@.6/T82
MCA1Q3M5.?\/ DX?-89?:0@-+,$GAF[%Y^I(@Z\G.VK&=</&-^#%%=X]/ )-(
M3(]I(*WG%E#F/(GV:;GQP@#/,6B>K8E^?Y PUWQ;.LU1MD%JT085-*W*N1'#
MMWY89,X')K7B(>:8:PG:9B>UBS';S;)<S0B90SDCRYZ#ZD LATGVT[&>+]*&
MF%(W,20 PL6)<3L%4?Z4Z=[&Q._N*=$I+C[J[C7RM[;!%91OVB2-%!B<$WGD
M%KDXN3BX.'$:Y?=%D8<9M;F1/K''8C:XDUG<L B)T>@T0K)^IT";F1:#Q_/_
M2^LH?RN46%XU'MGS(Y:8+I(CUL=M#\5&E=E)\Z(F,:'6]Z)5FWN4:5IC5%MI
M=V2ZC"W52D^/NQ,J<5.8%S8,PK4UL"9FTT_\QM!.@6W[,_AOZK=D-4.986%A
M8U]M\(WC_)H";M#_](R.'VDM8CU>H[551!9+/US<TN:97F]'.?FY@U_":NV%
M!VJ_>'+BG,*=B8-$EP:@$ZJDZ)%0QIU*-X14PR40EL+SS(:'-/U'0J8MZS#O
M5O3M4(\$,ZC;(O0,W+TMM!:+@BFUX\0;9R\;J&U%U3%"J+1@:!%4V[F/#2%V
MW[?)2)6/-S2[?9Y'[]7;E^C"KW=GD&TPI%@>5M69;N+*]*B2SS8K4HV(E/9^
M#':)K"NWGRDEK2)='VWY5NGKHMEGE(1%]FPQ+0]BA8C4/"E)%0F?&]M[$2(=
MU?8C=:_K(5J[QN'\%,%R8SG\/OD20]XQ_Y<-?H^.EQHM#\Y6HDXM=8+TCC,^
M8\1GDX[DIL@[;"(>- >_ 3#7,25Q&8-M(*OS7"-))6OM'R.6P&2L_FYKQ.N?
M[%D%=&WFP0$=3V6[K^VYI,>0EE&/)UXL6C;^;%YD:;];/3G\12/_TC"G71]K
M42J"Q_^A$J =).JO\!*VA5JWYDL6OD8]JT]A@-^P%R>DUK"T:EK08%1P,>;
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MXP^'K_GMNT7\MG?I=!?1?EQP$GW-GH#FN+''.\H>IR1","I<;;$?TMW= 97
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M[Q^]%F_?'H/^-PO7]Z%]] @2O:ZN]/FZS#+]'PP^_U\8C/G_87#=94[83,W
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MG3UG!IG:Q<6*FVZ,-&<UHE\Z]OVL7PT%6\8,[J]X/+/XF)2&)6[YEO)0BQZ
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M6;@T7P(197LY,'MRVFKK*WJQ9_D1M[#WEI2OZU]M-[K1JFND=8P"A[1)E'Q
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MQ'<41A0[7TS:4T8VK%SX;IR<+-0#1B0R E%BJKW\/BIA?YPF5TS-:HRDK/(
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MN541#R,B7)BE9&.Y.592.^F5^FCL8##4?5YA<D'4ZAVG)]T9N!>AA+P^&P,
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M\6$# O;Z(!Z>C>%"(S"2=_%$2&LKCX39T&<@PR@Q4]0U/H2^[1/D!'YCMQ;
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M'^&0)V\'>V^5M:_K8R/0^I=A]-I##)M8.+M:D37^H%%2U.9XM>!@U0D>\*L
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MU.'G[P+:5)M(<ZX]H>%B7%.92S$,;Y#]#MC:RR&2MEZ+:JS<5XWIZ89\FUK
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M/>(L1A72G8I*":[:L$JGK@T46YI6O\1RH@W'1F=Y5G=W/C39'!&,@H-UZJ5
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MURC(>?MU.#[A[/70YO2&=DFSMG:M*,GPGNNLP8O5T(WL*E@-B;7D&;_O(@:
MS.:"D+4?HMJ&96G3A1:>Y[6ED101/8N?>R_7ESN/R-X2>RY=<>'KO(TXN"7(
MH:MFXFDV-H802[<E1:^"*-#R0P0]3)+AHY%W2KC$5(42SJ$MP#FY+3U7Q0J#
M;!S)5W%OPE7.T 3-T]?QGF\F>.'MMGA2=*QLS>,>TT@+Y1_C4<IJ!QXS K,H
MN8L<B&;@CQ>O!NK&>UG9Z=0JF[E%P M4'((58 7EM3LMC9CER__!:?=_ RPO
MTY68,5+-8VG+\/COB_;P\0%Z/.T'/IAMYW&RUQUM;%2RKZF;K=_ZH7@M4U_Q
M$#GQAV+-?1%"FV6M0T*RM,E:O\NA6M:Q>_75.]O[(7E.;4DO:49+>(3E]9\I
M6K>>)KDIB'8AF](20<BZ9[<'3D/9/'1YXIVN*M/%_EB0W_\W4R]YUW+Y^UHW
M-^\@ /8+3.@A$E1?CJQY\K8X'.(NU_Q4CI*&YPIU!J."9ZW/.J.[6U=9/(8X
MF4)<H>.:(BR?QZ"5/YYQ]SME";1^6NDPO'7.\E[2O]8,EPO)'*R\MDB7WQ;=
MJ"TE>!Q$-:^=RUC-B!D4BX@>P]P31'=E \0&:B !G5=O'X=Y.IJN1B^.6*Q]
ML<>OK0?P6^I 0B8B0;LS?(M[B+C5N*Q$J<;OXN-L0%FRJJ#;2J9,+GJKRM::
MP/]\EO"/$=_&3P*&2V+&B@.6BV"]Z ]JMCW;ZE\N6@XCSB?C[B.W^0236(?F
MIS@#>FB[[#<?CT'XFA/S0KO,\38CIJV8J"N9@HE4[L?!/;Z]Z\K78']B=HW+
M5D+R/9]DI7K!7YX]J*^4)J.L&@P%21(0OKDDOX/!1RQ5Y<MLC-BE #@(HU=O
M_>5?L@5S/Z=,A#"?'(S5AE/@4YBZMXE+/6R1#<;TAEW.FPZ;V.]7DL<;WVN,
MR7S?D,Y^))K?56( G7DM3RI,Y&J#> W2Q"2TL,R3AT),?R\_/"$T9),H#<3Y
MLV)R&E=#]; .MIM?#DLTQ+^'[O4D3-BF.^.W96SZ933@BY/P8^Q[94"+RF9F
M=RI_*RGP51M6-_IO/ANX2FUSI;?O@YF4YM4.NTY"C0"G.W>@AS%C.!NCCJ]2
MT\.MH"C18!=J#TVC]>LHV,'':9)SU P$VL7\/P0Q_+]%7<3V[RBNS==.'UU(
M3:&_UAP#]&^:&SOAW\F& 5^%&Z^C46_R=9?)%QWD.:Y ?P8W\/,:RY8V(?]4
M D.X?*2&%V -I\F[7VLKN;-\CW0GT1%=JQW;DQ]&L?))9V,SQ..U;8>BT,Y!
M=/;3N&&:]7.!Q-YW0!5C8W@H.-Z6!T A4KEO*$X>=/_NH>1/:*UZ"J*TQ5NW
MG[MY=78C9ZS-#]E+_G0FWG;<I'IN.K-E"INS?$V=$W;(.'T%DO?<\U:-,>+6
MR%];?1TB\%SZK]$,>-IWE99_UO\74$L#!!0    ( #F"=U2<?(L2_SH" !"6
M @ 5    8VYT>"TR,#(Q,3(S,5]G,3$N:G!GM+S)LJQ(MC9VKX9WI*&&Q_*:
MR:2+,H&@"4A5Y6_T/4'?Q P""/H> G@U#?0:&DI/H$>X8N\X)_NJO^J7%'9V
MG+T#]^7+EZ_F^]P)_O/_^,__\U_^>YF7^'_YUW_][_YU_]?]7_[E/_^O[G_(
MY[G_$03;Z8<HZ>+TAT?7@%O4@_ /$/@O?_DO6Q\]JG3^$J?/HOWK=__W__:_
M?_>E2/[ZG8]ID-8S:5Z(QYC:A^X\CNI!)M_]EY_^[2_;CUO3-^D<?=F:NIU^
MW/[ZW:?P'\_?/SX&O_ORV62N_OH=]7'A2Z 97YAN3+]@/R#?/R 8_H+C/\ H
MAN/P__+E L$7$#K_X=_#Z(\8_N/E^N7KZ[N?_NU\_\N89#]:+/]UN/.OOW[W
M=5ZOU^N'%_)#-SY!F"3)#S&7R_=GB^^GO9VC[?MV^O>WD&]RV'1ZC$4_%UW[
MY>/O*.Z6^:_???=O7W[U>@^4/'X>IU_&^G.4Y &F==JD[3R=-H3!GX5_R$\>
M/V;=V$3S3U'?U\4C^A@%[+MI?H_Y%_"7%K_M-A=SG?[T&QT^M:7J^;>??KM0
M%Q]*_EA'[?.OWVW?)VD6+?7\W4_&6+3G..\FOQ,(_E'BIT:_'_Q#H>07,_V_
M4&M,^Z@8O_N)+^KTBQXUZ8^_ZP1=?XB*__'?-^I_=:=T;/_88APO)')%B<\V
M:O>(ZB].\?M6%_)[JA^_OT 7^ N,_(@A/U[(SPZ<[?Q)\]^TA] ?+S^WMS_G
M_,5+Q^F<^"^]+C_@G]>ENEZF>8SF;OQ-(QC_ ?H!^FPBC%&?%X\O\][_>EAJ
MG%_=6'TV^7S[C__X#R=/O_1CFM7%,Y^_//+T47TIIB]GB/9U.J<_?#'J-)K2
M+VD[+6?L-%&[G-/_;#=]B<Y/OK5,OO3I>(KJ'NDT_7!*_F68CS&RKJZ[5]$^
MS]].O_WL>HX[G4[\I6B_S&>3I'LL'T[]XV>G7ZM=1+7F_-FGW]-=G7R]]"=#
M/;JZ&_^IL>CZS$6_^XS10N67$;[___/U.<(_&3E_$B7OMNR?7/@GL\^90'].
M/W^:OO]&)T%JGG^_XQ,LFN=O,]?9[T?M3-U)-$=L-*<_?<3&]Q#Z_85TWA&%
M7  (^Q&!_@+^H>WOY71)D>W_D)1?6OY.!C.FYZ?_B(Q?M?PS&=WH=%W]T[L,
M_3I\&1O_\C_Y19MTK^E__I6HKQU^)\O)ER9NHZ*>_LEL^/%?'XU3ZISYX*_?
M6>G4+>,C_>X/';Z.]+%Z/[Z*9,Y_NF#XIUZ_^NCO=<K3CS3R$XRBO_3Z^MG?
MZ_:U',D&)_S2[P\UZH_]BB9ZIC^!9 FB%&7:U5VVGA1-/3G*IFB)HECP:E*3
M*^1K(I!')) OB=46C:)0LZIU"H"HSQ=-G>T_7ASU&8"4^='Y?)D4#0(HQ59\
M%5_DFA*<=X<,C"GIO/@T.9IR.?KI\O2S$F@SE)G74Z"?3Y6E.H5Y=>_$P=*4
MQE*OCQ^3I5"#HX@;2VL.3YL.M[UB89L>XD9D/_^\.)%^/726@L)SA%#(78NW
MNL]KGP)_T_B?_ &)<Z+FDZK.Z5(OSGI/F9(LRM2L<VH<%7W.7J0^9F=RU"\O
MDZ=>DG":162HZIS>>>TIL;]O]]6&%'/.]K3+0V+,3CTO,^< +/4TF?.STR*G
MH%8[%TNS3OOSDB5MIL<)W(4K'B'G:KV0TYN_F85!OVOS+.;:=B\(QMJ?*U>;
MA^54@[*'B,'HKME6^.W0\\2]BPX++9(D=YK,Y,][+I^F&VS(FW5/H<<=!0WN
M4R!\<Z![X/-UY,-;$M2D?[_D?=3,4^QC:XA8<-(F:!KTUTR$@0RY<7D8B874
M* 6ZZV4',!5F>W6?ALW]4^ 0M_(E;3&E[!6_Z?&B'X9E&B-\[:S3ON?T)98V
M3W<Q0XXY'2+^L%G.L33#V9K+\:ZEY]+SOCWOW/XIL(O%%Z^)%FKK#._)Q6/E
M#IFUV&<>V>[N%^%596C$L/54YIY;XE:OY^>4Y?+."T52);R+$,/M>.W/_E,@
M!!A'+MO5K#DN9EAU$OI>'P<\G :P5=^;I(O\?HP%>(DO_[7I?PH$V%KV_1HK
M[DV_/-H[GE7#K>JCJ!V49ACP?1X'8 6CT]'8#X_@/ER,):@6"C ;2"]E: >#
MN5NVH4V? HO@['U?AB=GL= !=]MHS^D%V&_#1B*7FX$^&ANX9Q+87CT44Q,R
M+NKYLO1Q064BC4?:L&U;"^%UOJ6? LW*(PPQ:L5FVY"Q.VK&PCM_ U7Q"/IF
M9<AICN]HE:<,8WN8<$^]91\.2QAJKM9YIXK8(H*#U((U^1TI74YME=C,<$90
MZAE+F@]450,Z0^8; SV5RK@*,HOS.L14ZEY7#WZ9*?8:O@YT@_"N+JMTM50#
M\%S@K:%\C8BY'R\W;D?B0$$81!L;4^4?A<:G3)TAU9 <IF=$>0M$6U$&#FD;
M;)5MUTL >*O:-L +!EUUQY;P4R :"UA5&+WM.,%U[YZ/+,J@S,[0G#!ID5-6
M$3WML6.2(%$8*+>"-JHB21-/L+%Z$DFT9;0NT(.\3(?]AKR&K/F^'N>U[*&
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M-FI\4X4<%QJEKWNQ93(WB1RGS]09CBQ#?5@%V91&#^=>@(EGVI&#$ 9 7E5
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M-,($L\)61K'"0BALFC,*?+2OT#*]#(_2,\*SCK3\":3$SZQ("3<81&NUX4?
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MYZB"RT"5:TU,0)AI^B('\4U\4+5$LA*3!X_83@O/O JBBF/%B@E>SZS73Q9
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M%C, (;/K@2#.03/M'ZXZU2\>)>4FI:S3/(,_!=_OO$,=IR]N%""BQS=X2W
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M(8UZ%P77!0_VKXCJ/:0J]?"F[;&B1JN;K&W,*YO6X3/KSC@MVX.29)4E;?#
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MK#BD)%.%+7& :+-S ' ;EPH!&7GI!H0"S/UT)A9)[!%UF"V'NM<]8Y2>C@8
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M2>)#F$@('2.W2F6?_")E0 C$EL0 PH&$Q2X,@FTZ25I&9[Q%R-89<J,S9VU
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M53QPQ"J)ZZRK>;@0OUC&RVV 02V@!TC?:"WP^&BD"NOQI&]_;LY"Z21\^8D
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M3&MUSBM$K$5!K(=""ZWG"ZQB9-6-0-TNJ5*%8QCXU'5$18QZBG)R&-G%G6S
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MW\S@C5:O$J?<+)RATH@3?NUZ=6GF_1SWEZ]</P@^J5YZC7J&T=HFB)*MX^^
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M=3JM)M03]LX$A]6+DL31S:^/&SH#N!5L=G15I5G(!T XA*U@0@ F1DSP#%[
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M_N*,ELN8Q(KG_F[Y\BOQ9X1*;&T7+5\"_NT<AW*PCHP*\ ,]ZY\DZ;<JGX5
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MHUNLF:+"OW=8K\%Y 6:XS,4LZX25SI+@:J"8X+U/,%? %5(FW@T+EEH5/SI
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M;XSB- '[_E[5AL"=AF48SF:E((4D#RSWMZ6^HWQ)@$ T$'0^*PRW0QS-"NY
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M&7'JVY/U=M052=""EVD8REZ6U<!L\%R'$^3*.R:%;KN/*[B*-#Y-H7?"]0M
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MY\NJ_-\NAP*HM]ZJSGE?05/56M_%5%OHNAF[,<:Q'I))8\1J^3FG(1$C ?.
M6K>2!I;=EGT\*T?IROUI'?D.RX%7P?=M133JQ9GC6\A.H"W;62<F1)L)9R;;
M)=]ZHR/\-N70N/03 K?FRGTPE8:ZA J=__0 TQ7$NB@K@V?7*G>H-)UAG%&A
MT-0RPO_7/]MI.P&Y=GW^\&NJ^RY5=7>X0O.I<C+?E%9]8>4-CUX/&^Y*B.TW
M,*0M+%*[_ N<=6U:3;W-),'AW$JS#F!$@4VN;N\G@'L_:?#AY/A8E*QL1Y,Z
M<BK!WP-F;I;[50TIZP'>-G?].V"WSFII;.EX1>.K+XR"\1ZU!3A6$S16R\NU
M7!L7UJ#W&:6MG9;^#"04EQ^JED**H!#+(&GU*9&!FN0'6:*:J9C_$CQ-XB)X
M?O[@O+[^0&OQ?W+QZ7\M'7*Q2 -ZOP8G^^OM5(=J7:>'F(M*.J5ISE V;L?4
M.B4S&]*!]Y2"KB*]9Z8#KZ38S]GJ%O(6E%2LBIH0R+R>A#-,'91QG!,FI?5H
M4YX)V-TQBTM_<-S#V=( :,:&44G; $NR6N'@YZ8@$#.L8-=-ASBFQ,T"9YPS
M=_(L6)VX>'VWPH==L^[>)=DF(A':Q*E%7!.)0'X+&CL)LU5"]U'MIJ:Q',F+
M9NDP9V>P/"AP!B@.*3EC:_6 TLT+4W=G.&_?">JZK>R)5']2L:R!ZX/5HE%<
M6D<CXCU;YE7E:_6-R&Y>IV^UW2UI5% 4)9*;KQ?/M))3BULE6(I3;SN9;2&?
MTLT^#-H,G'8OZH=;>,:YEI5PD%*_.=J.L^B?#( A3'RZ]K5LC0G9GP@DHFY,
MIIWD_.23PRME,VQ0+%!GU4[N7]\#O A(_AB]68:KZ_A5ES,M.Z(RD7H6(\T4
M&D"\H#DCG?DTQ8S=U%G]N37KT',%2L-DP'43JX\V7U3)V00UDI:81/0O=RC*
M9:Q>Q:<.<,##D,OK9T?8W@=YQR+U/_VI#!D#,^M %TKW-4-T>W&/@F5 KVU=
M. FR'52CQ2]I5X%S?1MS 3I&]50Y_ X$04/:W*VPDK4/<?34W-J92_6$AD"Y
M$['.&M3O"S6B@290]09Q!@6M8-6?#E-6I:;>I#)WNWQ'TRV7PK0DU3;.:&MU
MRX,5EUR[".S6K'Q;$1L9^BT82'IH-98B[D*<"05F\"=G%0(8/L?KSTUG*JK/
M\P;S @P9@SU3-GP!W*XJUBEAN8[\-5"*,MYU,A&+S(CQ*#[YW[3BBEEV8:QM
M8!HFXLY3::N/U ;D6CUN<\S\!9\Y;USK@JX:R_3KL"] 4'&9%#HACGHX-A[
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M1E8)L\[$YQ((@K@]7)><:W;EKD*_J*3R3NQ\GDMSZAFW')U()%%.X3(BB.H
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MZU)FGUXW^*0T]E.11 )X'*'3I]=#@I/M/" H3840C+JH!3G-B%!#].YB^8Z
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M]=ARY<^F,V>0L:F^J2F-73D)-(CF^ZU;4R=F")NYDT 'B)= >IY!,]:@Y$I
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MU! 0Z95A\1VXPQ\4;AEI&%'_NIF$G8N-F/Z;0->+M_L/WWIW3J>S_HD-,)'
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M;*;@-YGY2=LEF?FE5C>%:8?)PX"0\A W69$]O683;]S"F\ 5MT(*WPW#Q)_
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M2Y[-;B=\_M?#WS;XC71K0NVFJG;R;P $<\4GS:%JW(C0*<704UAC_XG(KN7
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MN-($DEOP<\/5#P@;L5>C-(1WU>IY@U'MQ#6Y]NF>[]J]F/E&#B[*S[C\"UV
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M?24GEH)FMY]B=3P_%:6_<0L43K154WU;[U@&?<%1G?@]6-J@2]7IK6N0WE_
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M,A9;ZV'1MFA .>U@SOR!XUUT2LQJHFVW5\-,R9;,2$<4Z%562SN>W,;]0J.
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M(4SAENYLU5RQIVV(.II"':V0HL&I4\1'>+*0\"-Z$RTMC2L3"<J!HY[) SD
M+(M27PE3 .=@ :N7O=U /F[S)OZ&N-G=94>EAE/N \4R=#N>HCVDBB!2P$@^
M/@* 2)8"R\$3H3AC?89_W5\\IY$G6 Z*3R"24" Y^*-_C5\OZ\5DB4\2)TP]
M&N>J#TWR;%_.I#W\I=H5AE]^UF@Z?*;PX*YX9T;*3YG6APY_ 3OU-/DC_S_9
MQRL/*3(OC[F+NQJ?>9R['C[[56?;T_13NNLOP._6-_:W)??W#@HJ^2B[W#ND
MZO"=\D B(/VP9O#K@PL>@26WG%],R-/U(&?W+@@=/$IKYQ7^W:AZQ.0BKJ<1
M-'2Z9?' HV"\0=![,K97Y6!S!%JL\GRH30LA<UU(UC%S4E&L3Q"C>C?%NX'8
M?F# PC+)!_L@K+S4K-K&NX#[E?88A2B[!C0U11NL$E^T%=G$RD7$V"2N2%35
M",'XM6![D[4T[O.#+F-TE;/]=3;W&3G:+ ]0'?:@EA3Y3U6$W)_]FEM?I9':
M1?Q7 U>WJCW9NYE>24M^8K3"M4D_![B"QFU4>-@IQ^8"!K5E<%F;48&NV4F]
MJ'V02-OZL+ )IV836UP6HV^1 HR<ZYUG.9T#3"Q!&K<,^&S[>9,I[!S>@>/W
MY.@C-XQY,N5J%(+2#DXBT/%%MK_&/L:L:;OE5<TGCCKH6RH"(\S,">#-8SN-
MLX:8@QH%1^&3((>CPA]J,F![\N:AS&6QK*Q]NZE1Q^DVE:*MTU313!=9U*B"
MMHH5KS"7B?N]5>9M!U2!'.2E&"NJP;3B4O,TXG7&ER3VY%[T"R':)N9=D*17
M54=G^NG=F+>CDV<?1MG<MX'#*EUF62+E2X\N3CL\$!\!\YX*%_%VQMQY@EWT
M_WZWX8=F4E#/=2MP79P\MU!EX)TF!-4^]&V4-ZZ.=A[;RR/%?S%U9VIB-1CG
M43KLN!_1D(&^\1<P&\0KF"ENF*<K^<OF<<E ,?ZBATI6DAI/\Y1!40FO70&+
M.Z2]4KU[ZIHLSUIVAXV7.[! ;D?IUBN78\=7_&U)^VM/]M$UR.IE3]PB0?CW
MBT5#-Z\-'^,K85N#:4WS#UX*I[8-'<CRT6IY)"]#@M(+OC:>RRZ*+_/^&S[&
MTYTJO<Q>3B0>O.8SC*7=P=G@@>89!W:50>;%<LAG$ *07;9"M="NW%I6ESU\
M(:WYDW?+>"^B +V;#^>KY-UM[ CS7WL_ES_J&\5;*2[\S)0\0U=.KKU9A?Q<
MH0%X4<^]S!=RF3QT>WR&=@'WY@X3(4</$+FZ%!OF'X]IB,B^.II^,\S2-GE(
MXI>*4FJ)&P,/&1$KQ+D8]GRRN*O3?212U3'P-@J%)I7",50(;X'UO6$[(H2Z
MTXW+JJ2;FLU$"8G4LFA^DVVN\XHD@H/DV)*M,\O\TY>?K%[5R5-7QU(XM3G*
M^;%\9-H42U]:08]O%;+3UM+HZ>M;/OUL(LX,"Z&43SMVSVTCTP:^<+Y:R16V
MJ(]$QQ[J-00TX\_]J"A$LF-V06U)>/+2P Y3:D'FV;%#M%E3?BH&49PNB'"V
MGJ8+LBK5D'3),Z[8HIYDS2 282:!H& I"FK$?YC%'/C65D$S?\+$>L_:G>P]
M'EY0IW+9VH4MN]A+^43N7A\G/Y#$4/I]XH:EO8['D)JB\OQX5MG)[JA/X(X$
M>7OGJIKTK90+*:%+GI!RPUR)/N^ON#9DBAB;J>S^I2H0T!L48UR.QQ-KQ'G@
M<#P"%PJ%X_7>V]R^-%9O@DBEP\4_+Y5-D)61@2'B_EVOI$ 23R4X_4G_.?8A
M?'ET=.5/PE^ ][/?9<\^_?JJ^]+[SR3UY5^ _2[D;<71M07CL>^+OZ;WO[_<
MK;(OL!E^6WTFO=BMX1S@>4.LT*2K087&\%HF*\1[(%N%.="=/B4B/5[4Q;XK
M33*8:W@DROH*Z*#Q^$6U<I#%B,\[E872 HYAC+F[SAR!H9@">?^1[Q&!U"VV
M@>-Y7'-19V&6RTE20T8DZ0I:D5$IDD#WH-7"RP\^R4O:\C.1&QD*"!=^FVUE
MLI3[X'5$BTM#CO,<394_NV7(<]_QNZ_;Q[IFVL6)#,M_!#_32S _#FF)$VOT
MMF&N?@>@$+U2*L=MWZI'/L'7X U\YL.=7AT.X4Z?20>&,SK6U5'D8LL7D<4*
M31OEI*T@@40[WB7QF9ZOTA8[IFT!2$F!#2VDP045*7FSGP$FEMX#[=S<>25H
M55/X.U 0,8^/9BWSS^'Q[//7G"QJ 8Z5S6JANZXO?7DE[Y67&P53576^G2'"
M7DIL(9A<U& 9/VX;?-9\,J#<\7CH0>9*_;C'VK'@$FH,NL)=8&(F;BF,G!&P
M">S;$8=MTT$W/[X! 96_K,NY@M?H1L:._5EM\ 4654+=Q9W8>MAM=$9WRVT9
M!=#O,;.LYPHUJ=:CJ9Q?!N;7JOV*5N2(U;V44DFKPGGQXV_QPWL5(Y>?H"ZU
MS66@D5_E2G45CX-Z:P93:@IQRR?BSZ(2@?LM28,:6CN>>478"-T\Q]2&Y2;/
M!.KL!U/OA%XFQZ6GKI\BE_-;NY=@EF:A#1_8P,%"-9!.N+"U*7XI=PXE+' @
M;YT2>XDY=8&][7 \5(Y[-@DLEX472#&NE"J[X3TUSPJFSTWE'"S63ST?;$(F
MBC0^\7A;NY0]GQ:[3ZY7F/"H%+1<3E74=VJP5\#2<<2NCZ5\Q.^INHV)%MNN
MUBF9F*)-4O&7/9K&BE".*5XN0IE?*DRB31VO)R26H#@5&/UGOK&RUA*1Z-?&
MF&&/42OVT>@MK0V#$_W6]I]6J^?<V!LO]#&5-MAMK;E1!%Q>T/76&7U+N3US
MWL&3SDE3[T&("BS/)X<S]BIR->!,9.Y](<W;Z$#L\;5Y0+H79=E)-6E*H72L
M]]<87D!CO>62P0>W(5_PV.5!626R*F@8\VTO%.'*WC;:EHKFV1;E+PN^1M1"
MW[W!T%1IF/2I%L+ 6*O,-V"_[+XM*5=HG1F:L8!\EJY&0J&B9<U'KAAKW.B[
ML1/">T_9TJT+L&W1Y%66G7AJP7_-9^:L=]#"B[-QT(/' )+7L#"<J7*/4LS#
M4_;@ -F>X&&4E=&FF>@I6JR57..8[1A+FTJX5G9[X(%UC"FN;<P@1ACE'Z1&
MJ27L1R<QHS2N-4^Y<N7.@YD-"4U+M'U1.5/5Q=2=TA7G&9N=2E&H/;"2.ZM8
M_?1"^(;7#V<*4D4W</:>")*;DOI/ X3O=^9[=L<[<\(SQT%M#>CGA6Z"7CIF
MWT09FBR9%"]EKXUT80/'&_2]3'P_2OY6*),WQ7B7S6L(Y6U\O"8=WG[4)93
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MRZX$.9_ 3\@R;K5;>'?,JGJM[J(UT$)6<X?4=B5J('E0Q=(^$9$+TEE"%,O
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M%0]65UBF3ZG+(S;DV[UMVGK+0?4)?F#/H<^]SO,>MCS)8K6L8"I(Z85_[UX
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M5XK91%G9@VV^30CO@;5Q JE@[$2V&4/'QGU>%0OV#%I-:79DUZ++M/2N$:]
M90G]JL98!KU9%)F .!69J*':%);X'V=LR,'&.#7&*K9MS+ ($UA-GGH'6@/M
M$T2O?C-6H>P3D<-,6&05K=VF3AB]K-A-BM0LN[24;DU7:O,4,8/?6G&&MM1
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M+]) [)"\>"+:E(6Z&RP:1HS6M\6;ZJSSNM\M>5OL!K2B$)(;0YF3MXKP&^;
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M3Q8LC/=6%CT=99L?=_U_LAI%_&$O\WE+ C/!1,A)M^YMA%T5!0^E@U/)T&B
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M+"2ER6 OC?LP[8PG'^OX)O9SA+=8P[. -KI8/BQGJ5NQ;"V[J'W52E6#=(\
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M&/E]XUU2/L^;TZX%!W?*@6<D#';^X1].TQ_=W'&7JYP7G@OHTGWTM5RK@/+
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MKP"/JOYB_<5J=L20$C^K>DN2<]D>%4 K-U;^W9AA7033X$P0R'F? .1X_XO
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MM]8K^X.:V"652;DQ<?,28JEH@RQ?:G%7*$.?CD&&43W^AL)3 *9THK9DZ^;
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M58QL,%U9Y\-0M&L8[B-16B-H?:L.9]>W7_:FW1H6Y<?8+%HR2K8UUCC%=1(
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MZ[2.'J=HW,T-/C)-[N67;MJP>-!>N0J$54^7V*RN EQ# 4JF]+8 @ N]!H'
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MLG8N^6>6HSWUJ7W["3:>4D6]>X'H2A;DC\7$PR%^B:__JJE;,Z- 1R>QB,.
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M<$[NO(]JV.0+#C&R-,^7LN#S!0URBE5!MN]HJUII"$RW ^<D;:YYAH3)8(9
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MQWLF'DFCN"N>BG0:??3%^;I!TO*$$?4EWK[RZ8R]"'D&PW(Z4>\0.H!(]96
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M?X7Z[4&U%2I[SI$1+\'87$U;2%*QA*B"#DNCL.*Y.3)[![+?]] ?RIYJBO,
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M]"<KO\>)ZO\VI__]-?D/R^?EFOP?-F-\_]MGC)OG<L;^DU7T'Y20\RKSM>:
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M]W%?QK[<B6%[2<$AO3@Q;=B#M0Z!XB,FG#\7,N#E503 C?_V*5Q'2 7QNL#
MY-[(\<&VI+]NA*/@E+G%](NGIX <PW54"E&)#WQ56Y+HDB-$W7(/U<2B#[F,
M&-UN^P!X(\@F2JJCL!$UT![M,(:X].[1N,$MWBPOPA8P/K1MA2E,3(\5#<M'
M.ER/V%GUYE5ELZ"^OH2[0@!QR\Z@5TMW@'$GYC,RA_7A%#MU>N],W+DI&$:F
M8ECBKAXXUZL/E#(<8E9YSVS"IB(G1-/"P\?&B:L@EI=,4RT= D'#!R,)D3VH
MIBYA5N\8(B_+[U06?YY32AW&B.Y^/<MD%"9_3]@A1/^S<;5-]-4=+;");'L.
M*SS[E*7T&^.EYDH]+@&0(E!9+U%#H>9^X9@EF_/,;%9:,?>[3,,B3@+.AN(G
MTF^A]]6:2!C>Q$1)=93'2 N&I=:X4(54JLG@8IWL^JJV:7F8JK9BCQD+%$7E
M3GNUMS27E<CV+X:%XD4^IM#(FZC2&PEZ(Y_;A;Q"PG.WN,+&'72KXF4XPCSO
M+-)^4M)1I R6:Z4INX$JIF]@$X6$WG8/^0I6.#^T%QI]WW)20:E6GL]8V'D_
M^'7(  ]6JJ#S'!6?==VGWE*#R>0D* $?^\33FRH2*:\JW;)9=(R9B=J9JGGA
M! PP$K@[&RF66HSF9F<)-VNR@+>L PJ1S54CMU6V@PMXU1\]#M$T[W'IACU<
MR5\GW-OW=9KR1L+WY$=/#GBIM.?PY1'8YKI0IQ$0"*(F2XNTG!FTB:'""\=>
MIC=+RAJ:?MI,S:\8;RM*<=2%G=X3!684?V$W[]7B2DL#- UP4OVX+Q2"J"/U
MFA&!Y8:X^W)2E]7KM2XB=E6&'9%^HNH(V5;!3=50Q 9G(&K$0TTDZ=#$6UB:
M4SB!IMH&SXXL FZ8ND_?R1$<SMD>N6VESC1LN,07$S*R,5G)4V)2%@L=_C*R
M]!FUW*&FF)DJ8!--(:^W;:*]L[#+8X9N 1M9-G@V92BT7&.$*)FMM_WPFCRL
MB63Z>=1#RQL!5;S/FY5>MS MA$T3@*@^K.#14BG32#<^#J)&'W_I52I![N)A
M6H 7-DU""S\7HL1\%;E=J7G?D"[D,-/\I?*NM!E/[@G/(!8)+04KH?X=A.LV
M^XGS*L^EK_-84Z@IOU-A&]DENS910+LVUU>'OD62(Z-MO)=LU\N1\]2X,,5,
MHMG6_2JQ^LP'V*#!/8]7T;4K,497T]]^O.,KR9 ]/I+4.9#&NCIC-4L-7$#@
MQP[*M.N]#@WNPHVS0RYS'FEJ;6MKU9VRH* >]6YCRNG>R+$:5\1S2DW">H37
M4/(X6DFS3)MQ%+D+UB3WMM(K/S*J/[)P.O\UQ&LS*!SK:CJ^POJ]3MWUOH7
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MQL$I"< 4@09C& &_3EMIOK#QB*?DWEDMW]JN,_>F#J)H&)T-(]==$N2^ JL
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M0.C]0$FDRH@UL$Z9>'A@':^!G/94]@,EY>*>A/^1D7N1I?LT6Q**OWFRZ"F
M4FMY_^!$LSEJ;-#C!./VD><FY8 Y0(<I!F/R@SCY\4G*B]3NO;K2,#E8*6S3
M7/!]N$/>JYMJBLN]ABE400 1/XR<'DN\HYD^GR/9P=Q;5Q72:1AFY=3\CJ9#
M!O;RYPN"0ZN+-LH_JTYRQ)M0(>K X0&V#NY$KFT=W?'?.I(>[(ZNB.-H2O[<
MKG>SZO#F&VA3NHD8H?YP?C9Z07!" !#'7W%J@48<H4?\U<*>7_0T9D,26W!>
M<#%&JZ>JI3,"OYZIBXMF"NL3Q$!*2O-DD2/Q<1_/K3TQZL6]UH_-4;N3L4>K
M<^[5&"&.9K@?\-1$MN"P&R0H WT>:8;DO-J7H%HH-S_<?"%8C:.W;@*4P,/C
M&<M_L;R'+,V+BNJ_"UV<W$!%]?01O8^0T[P.?4U#DY_M$!@2@7%B\#). VVN
MBW@<3S%(L\3\WOAD;VZ@^]X;E.=^3)Y0[&01%.5A.5C)@]WBXV,OUS&MZ:#Q
MQ;4EBI2U]<7#.ZE*V[E]JB8G-0Q$[5JNL+*&P>1XUZKR';$'/!''\1_(%7.:
MCF_?N;OE@\#,]@32,EI>G4/;AI &0'FU\3'[^=?TLFIHK=W.OIM9-^1KWA%K
MG-O=PR:_\:1=1<B-:HX1H_K&:Q[RQ'W&]T3R&5F!]_2#G^ [E^>LXRM]8J)4
MU7<B=9Y+EUYQN++KLLP[=PM+-S(X.B#&;I-%?DRL7K>>KE.!IQM_ W^%4D&Y
M1:G2>35Q("2M7)Y;M,FXK&86W#_DH1@5G_(H.%S]HR+Y44PB@UH[%:C^R=7D
MSMA>J>+FUCV  /<K2T,D+L;[Y%PXA1RX.$3PY5(L_NAFNE1>'R@"X%.U3J[B
M7%^@7T+HXY(SR=IUVQ4/ (B+',$C[#=F( TB-#5?*3%//O;97NZ3;2R16AY,
M<_^\0/F!A!#/Z993'624=6O\Y9UCMR\38EHB4-SEQ:T#WZ:TDXCWZ]/MX5Y?
MJL2TAW("LK>[=&]^2I6HOZ4NIG+[%/#J+.=2SY8SI49&;[%&A_'0:'[QMFD\
MYB LP!8TIFI]^\BU,<7;LAM \P2Z@/ !)1?%_+.BIN(T'LX;&I)X"I_WGH],
M7_-?H5,KBEOQSY2&@UMO?+!X@NN_Z[[8FY/1>X#P<:T=7#T:7NV\5*]K8CQ3
M#X_F#P7@?L9;HPQ];7E,^T#ULVE19[L,?=1HR:UH["<4YFP-(M"U \GYXT8!
MC28M0CP\3G=3P=JE@AEW]L%P(](]I.7!G%>]7W!,J^0'-<6BV^"84%%O(2SB
M2-V2'#Q F'Z=SDE^4K,<D(_?EA(T%U\S,]VY@)U&B8LCA=,5PN"ANK&U\]*D
M"<.R:/11,*.GY]Y$LFAK78[G+/;:23(WN,PDW?APUW>DLUWWQ9!E'68I!5.J
MYJ?/1R=)-&>- 34PJ)MGDT)DH-C;'X BU<'NXO;'%TH"Q]G#AADOVXV=]:\:
M%SF0/Z^-*S4$/FUJ4JA"($@1WHK>?FPWS"W<]E0M/PN!"8(K\J09#L&&LQ[:
M:=5-<!,&&V%>18@4=TV/OPK/Z",2\%2'7FWZ"$,,A%W.C$LKW_JPO)W&/#]?
MYBIF)C)3H/]51-DC5X!_D-]5P.X-TH^8 .K!WDCMG=GJ313_;"T '';:V6*Q
M")4:/P7$\'B8Q)8VK-8NY,Z:Y^8&ASQWFWC*L?5Z8@(Y[3H @",%>/2)(F.A
M<UC5>,QGQG<F91WQ >Z"^&TJ\=?4)X+=A[<D<4R3XXI7%YY;AD Z'V$^"F_T
M?8G[;.% 4M$\M3/6.,0Q:S78@HSCZH'#$I8/BD:R:.WV48-/1,[,GA^%*',3
MN]>G1NKBG,#'V92HLGMF(G O<'$"43[B+%_ST''O%J)9-SDJ"<ACBY>?2-S=
M>KX!6I[RW%[;BKB^1M$@@LV6< 34:4,'B,M.+Q[XG$CNBY8&!@4@7%\[!<0S
MJ0EO__9GNVD'*#DY:5LO65DP-->$PFV87UA"H>H,C63:8]N^W<_6^/:1R=R3
M*BL1!YZ7#HP*R#2*35IJB(30>,"J\!\]*"JSR]0E@ZEL;:JBU?"J55NEF*S6
ML4ZU-1&=4*[5S1UP9XIAOKN?Z/1B]V%GY>8G"^.%K&&>VI'/6G5\V?W4P8M)
MLYWM-A#]A"VW7$==WOQZ5A4M\E*]]A8FU %8O;,Y<Z<AM!%3-_)VS"&&E1,V
MYA*KQT"])CBDHR=1@<A\U9:7]KTA?H&3;Y$-^^RSC 1NH*TT(7X[(5*%W!4\
MS5P&<E>A[3V9-Z5:?_<;,/3WJ])#@7I;,?0V7(\CBKX0.S0'2# 8QSUH'GG,
M'\0CG.1GHN" KY_Y[O78,K=#2%"S,4N2]; >+39GQV2:HZ<D.2.ON&N6XI<D
MD\%E3:X0&UYFTSCU0C%5X\'0@,B:84W,^D*PJ.$\6Q'.C0'@?$^A,;. <4ME
M=$MP4@&A&ZPPJ&7?>7-"KF&U)2SO\-[#Q,%:HF=^]C:39 ^-%92]\Z]V.8P;
M>*=4*OEF#G95\3A3F:X8/3>"2+6*/N9Y6)#'<. .:1.]<0^ER)&[27S$Q&=M
MYGGK<3KIBQ*MF5846U)="]TUTLY8,>I!=W?SH7$UXWS^(+,&F?NI^?657)%Z
M)--M7!$R$C='0L1E+)ISG\5<#PY\(GCH-EUC$0?JO_';2Y'STZL6?OI%.PV.
MC%<4\AV7&_SITE(S](?#*5L'Z4<4.BN]CNN\GP]H.R][\/ J@Y8&9.3;B?!O
M,^#TV3S#NX*K;GGX97TR4D/MD,_["IF*MQJXJL"3LH()P^%39DQY9YOXC)X9
MMMS0KJY8,HU[L\XH>9Z]+8J=.?7VW3T=&P8.7/[]?1+";G6]'D<CK["#3P>,
M9C9X#UPJ>Z8'R*F!88\>$)H0WJ4C-.)C "NMC1((VZ96(2'5!5DK\('?O'^;
M&A.BJR.E2]"F[6_2R^ED/"8RI(_^CW\HB!7M-VQ\J&<P %LI2'8(,7%.MRO@
MMW]BC4&!42B!SMXVM=D6:<"*BDHW3BW2@8KC+PNE\/>!3;P?]'6NCZTP''<T
MJ!WI9!FJX/>V@:P$SR%XL?(;*03GLH_3B(LYVB(I0P Q:D_@@FE(!PI=ZA$^
M+!_E?SH% *I[3P$F@J_6/Q)&#GWZ?,=!<GNX_A20ZA3A;[3SMQ8C>>R$C&5.
MPY(U'I$7<A#'D_%LFQ3)*1L\56QOX:Y@VU+'PV!XDS@H:]C\ME:YP2QC:%2J
MA4M!O#<H(!BDS LK&5+S'!FI4FTY!60PN&)V^?DXYSD/R S2<+>-TE"2KMTU
M,1I2DYT ET6[0I20:H_2I2WB''8((TW-BC@>BM_3$4E\;*KKZLH@ &<@7M@X
MHAB1:N&,=PJ0[&>[X@.U".C^FX4(D+A[DJHX]Y*9,;J^;?A UF=\AJ2ASI#U
M8%XECY!#_]! 47LXGVCI5O*&(G=MPONB3';>]<>XD9T";B#CZ0%^;T0]E]4,
M+5N6>J^XQ>35Y>2]F3C1#S7!A2,"QLT>;R8[Q%)\T!E .*Q@MF1T'C!9@YII
M^94D8Z%U8IQK?1J6SB7WX^^[(+S&57?T,SLJE]A!EZJ:V%]YWZ< .SH%&->=
M EPB$*M,XTZ"4^E>EQD_X0]-=,&RSJ6VE9&0%HK[TLL>&:$"#HM%W<KJE7XI
MKOQ8?(-J+S?F6BP.R?2]%B_J@!COROV;(Q4% H,4,+HHLZ2H\EO!,-,E6'M@
M)\6\F)Y3,T<TL[?'6IL[(4V>@,]K9AMVS+Z0JQ;Y01I(:G(OD7)O=GQJP-*(
MIC 8%OH8N\ZHC^K:[8&V[3!CLBF0HL&#7%N8]%C-VS,>/FT,*2<:P9)J[SV)
MOPJ!OGP'LY!SOF-:.4B/,%)85UDW_#HW@;H,6B#D6CHR<P>-#L#?/Q ;P).'
M>^M*_E.4'/.'PBKB$A(!5.*BCQH!.>&6'O?<&(,B322M&C[JTG<J?& T5%1<
M44A*R&[I,$S/+L2#/6=VS28MWM3F>S\+,HK49RDL#VUS8\H/D+GZ$BV"HR:J
M-=2D,\Y7QL>LFOIY(EQK0BT7^^SRCM#J%[T11PWEXBG<J[%6U-1620H$H7VB
M)>Q&>E>XHS<HV'*XL.$$4"'71![/":&X!F$B RA#<E$_4K"P1-&O#^CQA0SF
MW'_6(;--*>6E@(N=L>&^["]KKOI%@#?,3>\YB ^%OMJV5J@URI(Y;=M[ATZ.
M,TJ8U=):;!O-!BG\L2G6S*@@-S9+-7/LNC] %G'2R<_B!3+:S"G  406&:?"
MQB\:DO3N7LED9FQX^# Q.U4F44T(\E(]>.YH]8GM6!8YQ?@,"F:<*U/>1Q$F
M.KJM0(P(5O?&K 8.HR4-$S8:75.:/'^10+H\ ER<4*F'9UL4SPA/+<">+*"_
MZ>$JGE9G5C=X'!\]1.A_4?:6075\;;IW8\'=W3T$=P@$=]\0W-W=);B[N[O#
MQIW@DN#N$-R"!GWSGWEF:IXYYWQX^]NN7=75M59?]_6[[K6ZVZ$"79P"MVM$
M&82D-D<&6SS, OA0!D@HB/]&F:NPE+/1\E>N&&.DS!ANB+7$EL^IK<! ,L:Q
M.P"5@5(Z95FC0$VF"5\:5BDJ<LK=Q7CAJ.2_ (SJ6:N'O75+4V4UUL19_)QW
MO7(R&N0M1$[9L7MS' 5Y:^3P1D'2\+"I6'CC*?,BP2ZN1DMN68ZD&.U)^I6&
MS!/ZGW%/0@Y=[O3%Q/4Y1 ZJ<-,]CSQP[76_B\I/#(_P>FH)!A*(OZ@E#8\Q
M[.*=CG2".I<^ZM"YA6FFET>%8&"C8=(8A<\17@_6MAF/;K;1_4^-D]E;B"7:
MN!2HBM@9)='59!9O,U]_WOI2@:P? Q:56C/$7&'!GN"]JPZI;5F4(>":H"?Z
M:I)3*T;*9[V7J-;@&M/%LXNDO#(JJSIFNV(DLV;6?N(Y=,HX2\.4ZJD;^2H=
MG]K)R+;*;C8!LAYN_BZAOE3RO5SJ<!$OU5FN)-GJE3.'[W=4XM>H/.W;%V^<
MI,#<L"\+5?&/:]6D;QGU"*-GS@^]KJ1/9YO^/UI&^CX^_S^- /+#?=08.>G(
ML,6H@,]7>M^"NH*S>.Q?*%N;%S\5]A?Y5_W:/OK:+;Z"5V6_4_T27*-S=(GZ
M@&$0'?TE[KSH"W,D+>&3]F^37$Q:4]EHOAI^0WUJNFR7,4*.U+J>:OF1/IPI
M#FR/3FBY&+/,LX^LKKU6Z0JC)'4(FIYFE]0J%O0"%*<(,MF0M=Z:_LUQI)][
MUBG?_"N_TKP#,",36]O--EBUGR7N$^8]NG K=%.&>S1)(NKVM4<F;)[>:L.3
M"P1AZS(E6'TQ&:R#S.WQ/L?[+&29QA!%3/Z%:RKA$[(/'C^[LIV[S:@IDO>6
M*.X@T7\>R9'SMELDN$I)!W[JL$B(%FW!T003C4)@P])\$4.GXZ)/AA'KWX;#
M2/J_ >5#0-@P5( :4KRCNY$3A;\VN=!D*R;\IN_0"GC.Z].6=57VJ!P-VVPE
M=1.-A2$Y5)UP9)N>88FWN<B<'A4#U;3@FKBRO"%;]WD[<^]S]Q\C[4&ST2:;
M((GOT%E@<9HC&D@*^,((A$PQ"):(8#B1Y'P:='3@$IWD!9NSJN*RCTS;WN?>
M^H12Z\V_1B_;6NL/K,:(E<G^K&!1U[HT?H38K&)BIT%$:790(XT(SA*92G(P
M0Y]*<CX 0R\,  !4&PLFU;JPZI0<G4NRBI:\.!IK=,3TZTQL1*P^\$MJ6$TN
M(UIQ.UV*C(;Y2DR,OQ[5O /^,O7@'>A1%+I;AG40,L.(K%F9&X!)53K]6(?K
M4AC)4#!9&$DTC_>%=9[WNYQQNE=$- 4%Y28%92#-6R]<[V=SA%Y3VR8W<>YF
M21WQ>2[DS2J".CRZ2^RX6JU#0[SR<]E?X]*2DN8$KTW.;<H<*G*G&:Q*!W+!
MK,&8=$ 9[ICN2*OY5R9L[N9[CN_&"7(ZDC(;U8U(N%@@BJ/(*>*QZ@UE:9<Y
M358^,PR&#"QFT>1"P!?R,F97);EDO5.MA%XXA-X-NQE!!0M 4 F0O84,   L
MJ/R_ ^$"]/%#O$:D#*PY[ZC_\7=H_EJCF.6$/:C^PR;)234VJ^4!54M-.W]7
M?JY$672XW!4&:U+%8Q!O5Q]N@ =V[?[KC2J+;MY3^SI5<S9_"2^NMK@DJWV.
M9*V+1(DM2[%K)D-BJ)R"2KH4#49$ &R9$D0?WX60BVW(S<7AJ=C66CVJK/?Y
M<2&5W>RQC=6&$.)0_NH02R#]HP1F5I\T;;!<+OIW!7OH@OD!&I)""AY81D4C
M1:MFA9LX3ZZL1D4Y+MG8.G7YKNKOP8%47S_=!4(62Z^%A(L#I:S"!W1X",8
MZA>2FC=_@D6F37V^1:(>;Q,<S5[30VY<N\KPCZGA8&+.!-XD$#ML$H#/"4?-
MBT3L':T,@1K@@%*TY8*YQ33Q#OCD^I_6HRK3F&$J@U13$N5!WTLU13Z[@'!8
M$;?C0;P@*#IJYBL96G2,M#8^6#<((?Z/AS1IYR0[&(QR,I6)V6GS%>69B2C3
MHO&+R]L81*%J0ZQR4#]E#-#02 *)65"VJO]-42)OCN>".65@,=,)C8TC,+[:
MI5JXN8WMTX6U:4]K2X-FD<$$J*IO4,>RE&I^(NRH2?SF#_1>1FEE5:<[288
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ME>GF]PE'\4W6!H"O2'M%C2W79#10T2.-5R]\+K0+-6$WWYSZ,?WU@WFRMXN
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MX:OV ^P)QZ*DZ6[N$28'>9U)V9^#PY%%4:T7WZW;<@O%L=L''PK>+T[_:N>
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M<".L,J3=X%%7UH""UWHKP8U702'8@S[>*K=XIR?%P!>.]:[BNGF*%J*6VK@
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MU0E)?#]3'F=O(6W_]P<8/%C3AP9=3:Q.1DH(\40Y?_?7-D&4 @3!_:J'6]8
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M_JJ*<CJ71AI7L@L>V\H#!E$ @H%0*QC0]BKZ>ZX_BSK&C\:7DDN-$LB>^O]
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M SVLU4F1R_>SDR;V#.'BN+E.U,B'MFW^$NL%3R/V_)%XRMA(Z:7D._56[]H
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MHRP_JI*YH=*ARA)2^[9%/(3&CC^^-V6Q3",%/V32?WR4J@LQH2;:E>R X%&
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M!;4KG0+$Q5ZPI;X9NVWG,W\I7RYK3@XL(7]16FB*]9%SL@5UIPO1=IVA-U%
M?DD=O._USNX$N(!S,_:XD@HD(K\=SR%C%^BG_T+GQ)<[=/U (T=P<;1)+XCQ
M4=1C!TC;+I!S>$L_/&FRJB"4%3FALB[R+?4'J!Z=M<OCE=Q]+A212KL3I.9
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M\ [#D T5/MO2_Y+>MQWQ"0-<H6)S<,9<94:-4]A'GX#,A)22>^:%-5!4U:7
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M U8 K8I('@&NT.?CNOP68^\FMK<(!55J\!OT#(J_W.8Y7':C/"%\PH987!H
MN"/K%'+YZ*X!%\_DA?EV)=PF3M$V+XO]_L(X76S8U+OLHN[^<4+;1[HO4<C,
ME^CL%5<> ELUR9GYU/.B)VT-;\I5F\)#HHQ%9B?,: (:W=*J6=7!4J86A'VA
MDWE"IJ4*,>IN57INF9'H=EY&&:RQ=JW4AT[-+DU2]II;I:;NN:&>.G-U")S#
M (8J1GFATJAC\Z2;-?Y8K'VD>Q$../L+RS?>A$JZT=:H6D\_<]:9$9UY3NF9
M#++A.NWT].<L%@"9]%H%&%.K1E791-M6V&<!?7MR'1@##+"]R%81<*;Y%*;*
M^.>)QX96;G?;B9]^4REV/?H"$S6&Z3^;2SC!"]OGD=- DF,FMFOE9,G3HISH
M@6])&'*7V2API(Z-S39H*KLW>*:3&F8<?"3F2LU"G:G:1+RM?B[I4U1,K,"F
ME//EE4%C%>9D[<MT@<TID_3=.X5HMEC"5=G0.9R[Y>N F*3^;NI[+_/X='!G
M6^RJ3IN>MI6%"/KML@@5;IG>@\+J"(WJ6YX9^&>N/1KIH134TJY:,B.&'\ZH
M3W@2']TT#-P\0K.9+7J F;N_+OAYKFIOM\,-J-JO?R/+AI_G.P#C^<&M1II7
M-"Q5>D5]S44K3$P'V#ML\(I*LKBF\LPAUK,S__5)MUNOW&\^,I?*H?0K!A[>
M[+29W?1JJ0;*!_8L&V,F$B0;N)*X!9EM---XZ,R@Q%5J*!XHOI]Z9:<F4T8"
M6^LN6U=[6&+Z<J4P'!A-(E15$NI!)B,Q*(+4$:+F=1(S,TZ>TE,E +K!]N:E
MC4CTZF,EG.7#>-2N;Z[5?)L/89X#O5H3G_3F<5NB<_:;?+#?;2.W=!HE=H:X
M/MD^-]W83,_Q*U=\U8'L131R<Q(KX^@-]J(J\H;,6]L(Q=R[M^(&AQ7<[T4Q
M*O6Q;9Y)<$8_Z&"_K\.]W]U=]70X;C!4X*MN9NUB82SFH.P=8"07?H)0_/.^
M>.,;J'WM1+M.F_1@\^+&FA"*O/ CDD)D3YJCEIQM7$VG'=5!^"V(LZ0L^(L.
M.C%,%-M9_DYP=)FX4XHJ:X=Y;J'+Z@IAS!,G[  5EH_N&^W"<QL,FZPEZVZZ
M%D^H#^8L*S,#;='K(S@,7>UIX@V_ V2?IRZ5OWI*L\SI[T=)_BJV=1,$#JRC
MBU$WX.5R7/KH,C2+E#M5^+R702.W)J'OJ#!MX)!,KQM[M[A$0PO86Y[RE$@@
M;P4<A%DB2II>1%O46%/OF+QI%&!X(K94>:"V0YI2/"HC"327<UIY_ E][D,>
M6NLM?M7L*8$X)NZX(H4V"]E]$[7N/ 1&@1RW3FX$Z.!(:XYUV4VD/ M.8HB,
MFTIOHN%,X?G#9/6P::RQ32C3P&?SQL*RI>0NJ\S:^24/J,CFH\#\H*K&-G7S
MO+<^%#Y$N;9DJ^>/.R6,G*-J-2D1/U$-"GHB&0,JLMK'R8V\YPF71J)O?1O>
MP>F+)(G5#R50;]W4-67HYW@L&_BX<&D^WY=16DVBW-IC8MY6_CA:/@V!8NW.
M^/F>&"@/B.@N"IX#?7CCR+'QG.@-9D+)"5-R(<60H$1RQ=Q\FS:FA*F/IYMA
MVK;#\1-3E9[CQ)Q]]D2_ZK)"83)L)8'5*K0/_=A1RJWW$OOB45*I$ER\?9RH
MRQ0-CY_.H;[0\SAF7GAG) XQJ*AKKFT--N$S?(&W.>@V?:]8\=8;SVU2[JG/
MY[:($-0I_/B!+!F2F6QIU/@(U9019\F$^KM.O4Q9ZAYO:,;JSU+?>S=/'[U?
M)1UIJ#T0-K52M0LZG-70-[,(B!\>;7/Q(561$=,4D#;_>KZR!G.;Z@7Y/W9J
M>YGE"9:YB^Z-J($AQ_E&=S+L4?43).G!Q)71S-W9HA+5D&;QIB /)B6^TG!]
M<:^6/!N!1\E\8XI\K'!J[#<J:/0LC?[Z"@XW!$:=\ 5I[7'MID]0$+B!U>#!
M@UK$'G"6+LOF\Q=C;XSQ^GS>6D*CVDW]G4?RGT$KV0,&PXVYN8&);Y0:>ZV[
M@G6:"%(BO>KL>?M8(_-XL8,KVUJ22Q;BA";B(]2K2*ON/FUQDM2H."U]R[\"
M$_1B2>%8/4%<H)S$IEH0+L:5/9>5'M.OI>?/Z!'!B*+1C'_1*:LA&+3 4[3E
M0E,9^:(XRW*578;<6YY1:=@-F8[L_V'=K6/JBIYVX=-2O+B[N[M#<:=%#GXH
M'-R+.RWN[NYZ<'>*._3@3G&'X@Z7-^^]WY?[Y4ON'_>7[&0EDS7/9,^:M6>>
M/6MM27N ^ 8=!B9=M^T=<Z:9=UJ>-&=FP+]WYL).)W3Y.Y:ODG#^+#;SE=<8
M_,)-7S$K[UXA<EG VVUPPFS='&B>&T?$O.R?0%3W88D>7^ZVRM?S1@R&_,,$
MJ0LOF8>>&U?(\IEHHIG+N 8IMRVMA<V9<R."0D-(PCJ.;Z=FD"104Y_:%,W*
MVC>-QT+4),TECD.61^.FE=$__[-P@ZFOYY/YMP0?":TG#9])23N,;*_GLK14
M^;5[UFD(=1NDPW>/8TFL\&R*RNTDH?TL2#'_FK_#S:7K> @JD"69$!(:8B^\
MRB'3^F+5MCB4XCO([8D944\(_NW?_EWQ*\;Z[+SA$;W2ESE[(ZYJS\ZY8X2X
M0[K544'18R_+M$4"OUTZS>_&>6A4<H-P==-PB>'$E&.L*JN&XN,=[IJ!NH%#
MW0]" :N3LII^2Y&-3AUG[ J^'B4#P; S&I(I=&CE.<<$SR-LBK4 PS9LK&'$
MI)B'D,1) JX2Z(Q.2Q>;>$.7-KR'M9C2\3QTF'9&$>.:?E90KO'[UJ,+F.:%
MRSI'Q&72(<LIRR'S.(=-V&-[:DQ49U+XXL9\3& H9R[SQ?M^SJ?<A]"W)72+
M*C2:DO\_,X0%*UNGWXZ QT$1,,%?@Z-]P\2WBVM_Q"<SRS</+C=33N3-LZTT
M^0;S;2!TB(L0TT3=#H9;1]7O4XE6ZGR.H<TB4.J=E\T:EX\?N_L59L+[!01I
M65O<L/=,!V41P@5(8%Y@7F(X]A1(&\P"96@T@%J^-Z"7_;^-YOID\;)F=-;W
MXF7.DM\EZ!A9L#_*R.//3-EVXA\.1>+2XGU7]+F]EFFSC1%IFDK)7KJ"ZU14
M_]8IB!ORU$F^AY3U<P""F6O^!ABDX=3Y8Z.GS,@+65*B\>-P><9UY15_ _Q;
M4P%!RI]\;M7=F85\[E**#,^[H+\R[!L>/C6($W2MF$8[-71BJRMC%[9.*M/&
M>](5K%H6MPR*6FM95:?]M)+>+;])6ZY;6UNWJF9[PG-SLWP#-+NYN8I>7!Z<
MNQU .IL7VJ_[.KL@C8*O.:YS0*VRIQ=(L\<\D9:FD0FGCH7G$1*M%I>LV14B
M^V*D3V2P9O"K03RFNK)LH=R1D(?QM%)!BJ[Y&*GG_ACQR,G\ )T0CP68Z[OW
M(5]#8L23F\)P!8Y/-SM&J]]4)OY@.":+6WTZ(Y*Q]7([^X%%S#+DKNIU[IE.
MBD3@V^"G&!C"\F/W?Q2<&F9@_X" P4]A!.RV^R>7M=NIR'83B4G=1<UE@DO8
MHS3[.>+S71[[3?:KV[3M=DTU,QX3D7^VN:9^.F/$+6':7P'7@MX M^-P^N48
ML'L2OW6.0C]J?F2Y>Q;'("PW[WQQT3"X.S\70BNWJLC&F$TR_QX[US'#*^DM
M&BQ+LHF,)63=95ZZZ5!NQ%#L.J-<SS #%<AJ7!#PV:_BBJ%J-G3[MU#H7?^<
MY]Y9L$'7_<)S*WB>L_X&@'L#H*V_YGC$3V2V>YC+N]I7&RB ;G^^ 3I!0TO=
M;P"GNS= YM;/K[-%5+E;GXZ.#B)5V*4Q+TK;[Y4L5UV%==J.V^R^X<O"8!-2
MAZ-F"3A&S*-DM,J[(5?FMY769=C&KC40#@5/?+F#K9Q$0<5M8"VOP!\5Y$+.
M(ZRE;&LCA%1;I3*WRAOFC_NKC4994U?-UT/:\P&UM9B0]C:*\K;V]O-SI^*]
MF"(#"QJ^)%C]0W9*$X"XQ5YW6'7N-[4)T"$#$AU0ZKQTDQ.$(#;_12 ;P\Q<
MJ^J&,B)30(_HL4K21X^UV09BC3V_9NFB1Q@!D21P_JF'!>8M8-UI)_S7=JH^
ML3WB*W*YU_W!$-Z9\5F\\^4;Z?9UA'#$+.&I[/IS^=/JS?>YI##)BS0=P3TX
M&54DVP)^F[AG"=%_S_+INJ?EML:TQ*C?0G%'CIN6#WZ5L&#.@)H&VXP)IG)^
M+55:.<)HQLKXUWF*G^((5Y^I@'!@D)ZTO#B8NK=%DFWVK"S-Y3EXEIAI6">
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M8<2DT07"L[D 0<%=D3-)9A#IF(!1GH24O-74<X[6^7I'K_N/0Q?LL5OKN3?
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M%9"LJ_=0\W[L4HQC2[W<:'JU*V^\FWUZ*,_+*X>NY41I\$@:E*08E5<W-PR
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M@!5<'_A3L'BBT!M=WE^H+00.WKDPO\3O,5%2(]K4="4@HP*8+KJR6GNLJI#
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M](;$Y2KQ^QY1^ 85RH%%?1J6*DH$POZ9"VS0Z+[/0F"3O=@'H<V#^,7)9_5
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M/#H^3:-5V+A :=<5VHW'?OE>1$F-F_Y\<?X(B5Z>3/F:>L=Z<ZHED50["F=
M884E(N?I+?<R4QVTEKJ>2/XL[^5L ]QJ>3IJTZ1*<_8_SQ)QGI[.96CJ8CWN
MB2SH?-XP<F%: @GN4IKC=W3;<IRX,JO5!A8/8MLPX4)[6&&[8X<52>4O+2J,
M'3#R1X;D[0,5^C<&)OGENENI;B(L,8]C S29%;B3<G"91/S3.TH)[!%I%T_=
M!;\PHA$Z.?F14*:5$UCB;\<M6019/]N)0$)"DS+Z"P;(RC!]@\88TP+? #RG
M;X E)#@6Y@#UZ@+U^G.\977.629>W?$>*>+>1GG)VH1QW79&$\'RW!&^:AU4
MZ#+#+MF^6'[V_Y;LLXGC&#![$&BPW2D" YP=_*K1T%R_*2![SEYU36ES4#*L
M!%X&X\XHJ_H&.^N9S*W,'Q8/,U7.KJA.VX)7JO.7J:TA;X K=)XX+?O12/ON
M?9J_S%3U HY6\Z^BT>=J-9T"383/]HT4YU-E3&)B1.UFKL H]#G@&OH1?-XW
M,6R$EWK[SI.3B?)_LJP\OSMIJW644E.XSB> WX)L1KG(23N^H6ZZN&>7=BEG
M?'HI!7L.)?Y8&M3SGBG@='D48/W6EJ!,RM0U4OG9P,^ZT^YVE3(X:D^Z9+3T
M\Q>K82;H)?+ID^(KE6? *Y: 2N2!\S/1WYR,,NQJUB_WD4_\;N !?9\@DZ,4
MQY;L*N/$ATMQK#K2X(V\FNJ$HD;1"FOGFS= G:/"&?0#;%7E+2B6G:L]JO(X
MBF"R@/*.Q46@U L)+CRX=Y1"9!0B[,*7I(IV3'_\XR_)M&UNB1X_"_9@:(G
MH_>SM$C$QZ"+CYGX]6VOPV&V5-6$LQ>QG:E"IAUASSH&&E15B%(RVF'T[@_$
MR4*NMH(9:DHECUN$LRR_;JMJAAG\+BSY->GSS=8:PMTR:M:\ VB3= >Q.*BP
M<DS&U3 $J*__>0B7E/)I2 VG%2C/AL-K<Q'E[KB;\,CM]*]_YM167?A*=<9S
M$X7!?*Y1"B&LMEXJ7[9K@YHY,F2X 7>2"Y6?=1ME\.T^,DMRS6G(@-@;(A:X
MXDR7DN==B>/\>T *VBAI\-9QER)+Q6'*.E"?.F/L/+]P9"O>)JK$[SH%<Z>A
MNNY_.SPK4J5.]'#> .9-#?J=J1T_# <"-+J"9?F8M34Z9_NC Z#RDP8!K@_Y
MU+N*OY]P"/,K,-#1;^?X'Y4=;CPB#;W'*PSLC:0ISYJ.3ZP;$U1U)\*7.!IN
M02*L, :S>A*G4V.I\LQY8#2P-G=%&&;AVEV,]^.NJHW=4G,%!U-2.8@8GM*:
M^,C)LJ^K!SEL[0@6(@T?-RC>A]+[^1BE<FH,%I%48LB#*IXR4[AE,:*52#N?
MIOF,6&:(AHZ)D4L&M!88S;;0\E?044!!249:97XM9%Z=>=V41UT-Z_$&H:/L
M^<<J()!S=&XF*S_*>BE5D[I@X/V9@%(P%G>W&S6A9W#*ZN@+ZN2RCO!DN!BP
MK-DA81A^0[$ 6W:%Y:$PL!)KJNTI\MY)_'B\685-6'1.JY?<X2)2$VLBIE1\
MF:PLUD2IF%<A36QCSB)U4;$E*T-8<*3.[6=J/^G/\D,H*RE9G\I-^Y4!GF%9
M/:77&7S C<"C-V=B*L9OE0HINC,/%>&@::@@6+$D8%Q'B!#IDT8J4.'#L%3P
M-V#7IB^_K/!<IL))>'J]@U!CRO-X(NZ$&YZ.G_]-W4[[!K.L\/<@_[O'KM$/
M3*R9(5@SQQ&;Y;K:W!@[O NPA11E@D@M,B.O.6O"8.!?(8F>#))!T(?(LOR>
M(48COH=/_UIR"P/R]?]/=_H07'F5K?H.'Z2"DS[3WT0.S'[_LAWU*5%NT#1@
MQ)"7TSSZHT2&6%+WHC-H).54_1-SWRE)DUT33*(TCPYSF-1Z]8K*A+^7AAX/
MKI$1Z#O(()6*P@S%O>W;HK*Y-9WGV(I<)EX*L3U%?*NYJE2>S5T%J0I5;V%3
M*"?1&+&A<P>);YBYS3+JXL3\&Z"&Q+.!O 9QMJTV0H.7W5JMGL^\MU UE3C=
MG,F/#'.0S008(JZX55BATV>*N_K 'D^^CP7^HJX%EDD4QZRLW-3!7L<R&G!N
MVO&4*[P1T24EL=P291%X1JMQ.84L">4V&RU6)43!,+]:BYP$)DG&:O;!?W#!
MTE7\1+Z3J*O]X(^03?05B==J?C\ML[/XC V#X[45IM#F_B&"E0X1XJMNQ$Z;
MZ-;%0.Z:H4V3/HQ23Y"R0KTRCN%XL=W.*$L&EC*6PN^0QU0\N0O^AWR)0QDJ
M>XI8J*5C:KW,+]ZL^:ENIHO[3XFI54QK@K\A9@/S-O* L8/^&Z#I0)S*;F!P
MW3IKJ<&&0AK'HXUZ3/ZZJ>58^EBXMNT2%^8;D'><7HB(-"I \^*^PW:N ,LG
M'R-"@?Y(J"8YS@V-DG54A@XCT;\=BQH4J"(S9FB6*H^73.E<?9;!VT6CQ1QV
M<N&^[)JC!W;6GEWZ)1?0$AF-8:IH<[\65%Z%F#\[:D,-'WC>8>0:.>V:"E37
M;L*BRM+-ESAV!I^KF+-V?=H MG2-Z%39HL\\D%XW^+WH+G<U,!ETS4,^!HHG
M-NN-2.>$%\TK]&I2/_M[49K);8<54)+/8+J#56>_&I3_V_OP+:-",V+R9ID'
MZ"JRMDV">LM1WJ\!4RU^?;"H;5Q/F#:#A$XL #>CA6FK;0V9G5[F*S5;W("]
MD2J^F9)](I&>LJCJ$I<6352M9>(KQHV*^4$<OF )SZL'Z;2'6"; 4>W/=O#5
M&-F:L)3)Y>X!BQ,SQ^,QU12Q)194D"R.$99I^^U\FS:HF<LZ*^?6>P8.6H'5
MV)5@3=$9*P\BOY B(*FH&@]S".>Z)8J4ZB7Y+IP1%YPL=VP$#^%O%S\P"0U&
M&$R_0KN6NYLK;7Y <C73Y-#<OW^X>""K<$PH^U%BPB0S<4?5HG:ORA)P-6V@
M'2/<+V$2JS9"SB=<77]<4J9PY;C.9A+!OO0&RB)R/MM*O ?[92%Q(K/H*U$!
MG@T'><2I<?&T(IH1*+9: M&-HHR%T6H O,4;D2R=03YJE^DK62\=-/HQSFX3
M$A>:-%WXKUVB+5]VFI9E(S2#+]:%.F&)"L'NKUP[SMQC>&.9)GCC>]@(_<#S
M1";L2'!_@W-3;0J=FZ1,4,V,Z5K^5Q*U(Y<$J<D(I0IK70SP9C>(GK5.,DW2
M*L6E+7)3Q)?+*AZ>(K'BS(M;JC]?+BD]WS0#SIHX*D)#4V28I(X-YZN&$B\+
M= P!VZSA^.FIF%FRE/LF";;6\.9*MR&"*>C/8_(0F<TL3V#YK.[@3[R?"+]4
M %))?1<\%I8:V5P8*,3<6LB"<42"88B0304P_TR9(U)*C;46;XDN8QJ.IYU*
M)HQ:K;6F3(B>O0)J;MV$E .384L9B'_K(94$J=UI\E:,C/R,T,'ECS4^ Z%4
MFJ$!_NRI,D,TD_8$:VJG6^5'RE_9?>HG\&!?BOB/53L7AT!J%1I3CN9%I?+9
M8UE/[>VFR)Z<B(CA %TUC"G89IN4<N>P8[&#AJ"!_HVZ*-8KEO/?F#T7+29!
MBS,T6Q)MB7/4_=A'AP>; E[QCM#+IHRV.NHF54M4,[;S/:C7!^79",E^K4RI
M?L'ZS0A]Y^<2[=V&[)L35B=M5; %ZA!)I,:FL>V3+#X6CE&!@,>\/V*S$W%]
MR!*%MA*A<I9H8BPYH+^+@G;VMM]XGPHA7GIS1H=ES=)&J?^LW?HK?FWIF*X4
M\AD[FV)M17P@._4].H9BC7 H9=069K[J9M1.#EY_,6>P0_S5O8VOA* 8"^DR
M?1C&;V$!FKQH:$@%40/VR()>B,M>%^22LMZ)>&GNZT))_'X?=]KN[,YKX,E2
M_GZ/F3S]YU3^=I(M%CQX)--6OK;BL%]+I&3U5D==_@H0KJD*RQMRAI">6OYG
M5J[\(1,]-S#:LA0UJJ02"SVV\V++$6 ]F@?#03@T*8X7"L4?'Q5CN!/4EAJC
M (FV5*GXKSK[_.D =]57'X_.M83QQG_Q'S8VTI5_HJ[L @CW-D<L7;)/+A'!
M<7O)?];P::=:@ZBSPG>GX=.N'0\AY(3F!$O^.3X"]F]E^?/K7OQ:124G<<O5
M**;?\_I]I >N'NTY]JEH]8^R(<AN\F<KX44JF5O\6RK,*?;O$1\ECT>5AK3U
MNG>Y&O=HE"]IX?O2%T]+;<OOTU^8%#S%M8Q&QN<##E].%-$+TS<:\6+)K$$E
MY)_H]3T:I(A,B]4^?M6-![&'(4@M;OR_K;G W36'PI)XJLLE%T_RU>BO9/.<
M^I"D4=I-\72[(1]-X^"I/U(<$SZS%,(*,+2BRH&2P?;G/[^16]FJ<BA[.LQ=
M0U4_6?)+.C<'L%<Y!(_CV=9AB-O+8AH&\!"U*LO0IL=]QGETG/>B8+G]XT=B
MXV3:%Z5:3F-\(1(V:+B.3Y(4(MGS.6H@__H8G>,OQ3+UL.&/;679= [2@3K!
MXWR4#+ZO4@TS^A[[^).NDRNV34M22SG_^UEH3'D*$FP$"8GO:EY1N-&0CM\_
MS I->&1-U649*4F%?^>Y>=(D_8!$-H"[B'BAYG8BZIK'%=FS-.GZ"%HE1\V=
M\!77^Z D8 K8-9B!PFVEYJ'&.Z(&S9$",K"& MKPG7MF/'L#-+IU'S\7,1VG
M>% MI(UH<\82H1+O&S.KS.FH-=<AT!A"+Y/<C '-FL[S]/7L'W;1A@@F->C;
M-:G2\B>TV'A6W/@E:XY((Z&]=%0+[3&+HF$%B1<[[G,I9!.[U2+/RA^."_Z<
M0,!>:E*+,_6Y:$:7 0GN1[11%0LN8,LS^/LEG9-*G.L72E/I4Y\*Z\&QYA2K
MH9)72E6D+1R:QA@-7*M&(M?F(YSQ:Z]AK,!*'5D#\EL?/]IH6)B&5B[5V6+5
M1\=!!]WA(MN@CR*A^X6VJ\;PE"VQ#FK>UZ:^5-R%KA_(:X8^Y"C*!D5K<N)"
M_U(L;ME86EZM2.I0 R,UTG@_?<O4^,#@)2%N+A7Z/UAYJZ XP*?=$PU.8' -
M,KB[)\C@%FQPAP$&"38X!(?!W0GN,,C@%MPAN$."!@\0G"3__7;K['=J3^VI
MO=F;M_KZK>JGNZN?_NWEIDS(:\,==YX?<./W@;^"?&R^GH]0DM6)R6[@UH=9
MEWZ;*^5N2V^.*6.F_^EHG%:JR-EU6PKQ3 R5#?M$3@F[;9G,,!#) 5+MH:,M
M<.44$:O8Y@^;$.VXA(B]=[9:-8@,YSP;K,)>%W@VR#=8:R_S50/+5\U5.NPU
MOR$7'UCRKP=YAU(JA]E#2 PN=-\__8O-Q4@?0>M =3/37R3&X:@Q5[*A(%Y
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M@]A1O"/.Y?5@XG73LS/"S-Y+46Q FPAB#_@]+)Q-+,"^]_-JFV :Y\0(.K\
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MS'3D#QBE917)'SHD@Z9Q\B#J,7'E]@23=JQYTN@'G)6UX1)SB91BGD?ZBQL
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M'M76"+'5>>_8Y[V>'Y6NRYGMB0@U+B5O!$L^OYC\FS;S,@7-:I 550ZA%3M
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M&QMOM<9@_ZRZ%);80P\1,5E6VZ)Q;$S(=7"?/=(AS)17SUHA8EPE*V<,+3U
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M:*_CN@3K8BFQ2!SN*I,<0(QQ_Y-,XN >"?[]'XT4NAF>K:0>GK;9Z-NN-*M
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M.:_*\F$=,:(CT%(SYN)DQR@YIEM?VME"88=(V9!PPJ:+E3#G@U$0=A\LL'\
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MA?34('=_<XR7&8O^E**4B4Q=%D@)*&W,3*4([C]?DZ)#)I1A&9<ATP@I#F,
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M5A^3H_=.$2.ES<$GW4')!^C@NSF%!LLCXC+_SX>-9G]&B!#R1,*I)>9-1GP
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MA[':?%SVVY/&8U1O]9@3)*X%9X4IK>T8E</"+IHM):W:5&H^SIX>XN2L2OY
M,*B,F_$<;H1?TBD/=<:MR=LF;6Q.!,$KMR4MTA[H*.!JU%QM7';84GT*V?%
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M"[DW= <CA8*#?QP]][6%)2@O3S3D=J1L$M=9_K*#6G!6^YY\CQ5!=217+&.
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ME-I<U!$R6EC'NQ:(^>J/^!/)OGYQ_)"&RW0'S)I!-3+!=S A=]<V"V7KFKC
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M=H_7:5(NFP6GU<NB5*J#,GX/KD"%[! 8TM/E*(_VXW]_Z%!81"YB-FN6O+:
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M,3NPO+:(HR$'AU)D-?:S@M.LP8W] E71S/DI.@F)OQ(J59(XZ'4Z-2KQ'Y$
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MXJQF(1W8ZO&YO=H\"S,B*]0AI] 1T]I7P E%-9U=UMWCPTDVPY; >2>"?T6
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M!;@ \8A?Y&NM\8LV^U@*@RF'KHB<RZ(#].CGQF:)R]1O#XC%F-]>YRI&6[*
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M@1OPS"1[9QNE;%4O)3^1'LXX(<SS>M5Y3(U8$A$Y]68O;L@J@?B=+-;=/9M
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MA-U6(O%1_3Z@:ABG[/^4&C^[IDM*92="R(L]E*U0RM'A<<I?"T3B$DV.KZ/
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MM+KE :5JAL22Q4I\E2OY2][!1T_$!,SN^_R[65?H-C14D89C<087;PN;HC1
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M2BO%,9!1#X&)HMXL*RQ<[S>O1<?+EC .U?QI0("6I;27 ,3K-57I+DF^NW5
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M=I-1M/P;:IL#.5^)?(GLSOH\@Z$;^C"]>9U[3+#$N<U]*I8O6L8N?,)>OYR
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M&P<\NZ)MQ%,$[+:QUB8[#20H9IL%LM$IF+J=['\0>RN91W<8.E([?OK2F2Q
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M3-+QRM+PHM+PZ*2"&Z@G'G&^TS3?:R C/%?7B&Z8<-4D+4Q ^#GS32H^\T8
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MV1+J\K,B90>2_%F!\?B':7$S6\OO1'QS$* F(RX!.\!?GIM34II#G$WO0J8
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MJ)R3K(:2XH\%"N6'^#=E5"N(HX<8R-KR!U-8WX*7_2&^8-<<:&'B?+E"H;H
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M:U*GJII9.,-QFBA9[:D%@-/B>1:IWCDDK6X:W7\08EJT7MFX&Z.=9KA]6RK
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MSK2P#WRN 4H-*U"7>U,];""J1EL(]D\,I\8G2*>,^(C>];C))B+H55Q0H+G
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MBYJZJFX_\*O]&OMQJ9\<A<O^ 4F35XFDZ!$^L7-@\E0VEH3H\;S#FJ]KZD[
M0[<'CUWO'1G'3L[U?WW5\]%Y9I*,\#2YT3735:<P,.V -/Z!WV&QP0^/BP0+
M)S:_3FPCQROO$O/;[ALQ@XT$&!^TPK3SUYO4H#:6IT>>%[K34^23B8)9WF,+
MJ368(<>%! =+#VZI3W0SUQ(;0>#/ ;5)K=H>I _NOD!>4U[^LG?@^05@/R-<
ME02SNI&G/YMRXBMSZ4#YT9.AELQB@L]AW;07-)P#C)W)EK@@$VZ%+1*':*[.
M09# R"DGV(YGB4S$_ \"[DX/G)&[G]0F\V3^(*Q\[8PJ<<*TEB$R_CU)V3D
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MY?:!Q4OTO/?#R0PRPYRYRZ'[;YK,5MG0<,P22)Y)Y**QNWY2Q9VF]+V6I4.
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M68#?3_<AY-BAJBB:VUL@.RNZLDHP?JH$_^M!H9]M/Z<?GMFU;7M8EG>X5_V
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M^L-WZT?H),L*]D,*< L*ETPZ4?O$I8$(=39RMLOX4%O93_$>BA#_T(0<2I(
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M*$X IY)6CU90)\#S > I[HK_8-"72H2_PHU*40[^$F,"YE?]G=\WM8"GH0,
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M#I2!@$'F>[,2_S,/4B!<*:;&G/@U_EX>%=ZP2@W=>6Q4TK]1 ^6,LLU@L>]
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M0Z;.#KG#6,7V1V^,O1^9L>QB<00]0\J393HQZ"1<$XY4%\2AJR"_8503@T'
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MG+9HYZ^%3DT4.'(ESKS0,P$92-661<2]RKSP88 /LI3$(N['I]&(M4[$D\R
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MS]0XT&=PPQK-EYFXW8V'?%OXR'DK@M^^06AX#$"H.NO/8!J&:*=,TBF69(C
M*_+*P,+4^2N(2WWJ7[KS6"+\WO/[D^DQPM8M[L3&RY8T(-&\B3#0@=NGY:&T
MRE/06F)V(%2=91YUY ]@N_T"\ -P!]^<=6/=+CS*$VT)0P9C;*(-V 0 M,QI
MARJ*IA\/B.0#IFZ[KT8!GY]'#!LBO7?;#JS!.+2NON7?-4M(37&G:)/2(',,
M ;LV.)CSX"N#'L?$ J0KQ^AV@GD.1T:3HGW3(+FK5)%5#ML9ER\2+A4;T8DV
M3/42Q"WZ]<0HAA7&E'I-RAL'!$@*S7R6Q<T9$)%M2-L? 'E[V^<&D4YW@RH=
M4A-OK*:FJJ<U%Z,OM VR+0;'SRJUHE47)" "JN -Z0,/D1BCG4P/.%T!\SXZ
MY^;P9&^R939W>38_"OY$",G7"<%8\Q(9+!T6-LHSA/BOP+WQN*[RXC3)H1LM
MIG1'F366I?G'4B_2XN*MDQ\%1=[(,%(@K0.\%?'(-+<YF%SIDE*30U&FV>@T
M4QFC3Z=1],D6.-H'6L56?"HYQ?M:W.5E84O'#5-[-]M*@2.S28P%Z^JQ*M;K
M0_K< E&NB WE=(B5]-4D/U@K@I@QXKJRW?)25!SQ3-<TDFHE0.Y8R=+&8I*]
M-IM5O;'RG63&4QM^3\T^8Q;@<?'E+YUK M:%8^D=66WBXY2>$M&O&MNOV5$3
M?J^HR*3O\J>1^SV/EU$3_IH.!MOVXE^Q'WO!ZCHO T'O=UY C]KNW\8-.\M$
MV(_9<Y^&?*\WL-/>ZW9[N[8C\ABN_58AK??A<&_'O\1O#+P?ALQZ(;PLUSR%
M-%&_=UH8F-Z,^OP]NS$$-+;?ZK7LSU&1?T_]'X7U_'=AN/__A!G\GX5I_)_O
M[#\35O\',,O+<N:7[&5W<J34Y4*:Z0$\(C3\P>,+^A;ORT9EY+; ,%6X;Z>&
M5TQIFDK/&#"=1_6!$ TSZP25Z'9DF-T.0$H?B)!#_3]"IWOKXBQQ^QKMOXN/
M =NCCY<X$^9N,XS7]0:);[43JX^D600#^HQ-$G/]WSL:L,-<$6JVJ?:ZK3X?
M.N2.5]N82K[>)=HYJ\?F_(I,@/M>2"/]HO&QMZE-NFX&B^^:U%EF[/ANPVO&
M$A_A4TUK6_CCS<G1SMS)?>)_?P & LSE#<5$WJ/E:4JWGY+4-6*5L59R,B2)
MNW(B!T]XF2_Q$-LT71:A,RH"6*/-XUE#,:05:/@B*CN NQX!:&@\>T^^6R)K
M+=M?7B,T,M\UWQ5S5R[%G)IR_(-NC55?(,,$@2W2$A5*I5\SK4Z6SYM,TKN7
MC -3/!*(8\2]!*>3@[A9Q&;H)90DY/SF^H8C+1^$@I>6]A=G\DH9119OUBNE
MOV*O_I3^O$24F)-W@F*L8+?4(N+\QC!\(\?>@V=I;@/T9?4.B$T"&<2F%EVO
M[L)728P"-C]>."_6UJJ,<QQ-7[8]"W'(Z1W_ <"\OOI>NC _=. V-L_OO-A^
M/1*(UKAJE?9=ZMV<]5.P3_-NAY\H^S=JJM.K]R]J[8%TH_S:YIO^H\S9DE#*
M;9EKA]C57__1'N'PI)P/_%6_*,6BCJ/3SCWYCG.HZ"$LCQ3LX?E+@.!4<]2H
M(=F!:6V)IY[,X&=B'>$SNS)GJ[0,8(G3=G*AKRK]_0NJ!4L/#O=&O5? 8<BF
MG]$6\R+QX>:.-57/<9YRZ_(8?0HG$08R&C:IGEZT_E[MR'#]";#J41([M%6A
M@!90& Z-&XZZ!P,_4,?H7^?0UE9I)/&5NI:8<27Q*ETWF3()_2* FX*,G?"%
M)%ICV5C3JKS&T>4MD8+9Q-20DYT=1@S0-OU(8;VNWQ3:\!_0#D;?)'^Q,_]Q
MIC^ TQP;BM!W+/\UF1](X[T/:*^VXP]'YZX?&^-X5%CV+N*CD_SF61_70X8,
M*4DY.1YL1=6^K6=J,(X62KIL(CF>*<(ASR?(*;%"A;CF.HO',O&%FTJTQ(ER
MOZ0Q<Y3O[S7QON9-]2B8D583LI<^:='8#,G3X<7."ILTVYPNG=9#5EM'\6:H
MF!)V(=QXHZ[DRGGAGD/T%TV6O&:4$+'P@F&]X&_61]T4<K.7YEKQ-I(U8JJ)
MQBPVN2I-J[%E(/I"!RC3D#9>C+0-7G3;3M=A'2DR/;6'O53SI;'&!T(_=F7U
M]^WBJ2&H*?4=]X$[^5T(9J,;*3+#RGG(]XC-C7%,2M'B\<;=?38VU$2!^0C:
MP%T19M,>UO/C642K+?#H1+KOM1G0'$"P>DAF.J_+XAUGK__:H#O//>,_<AC6
MM,RD:KE1XK=FEQA81H-B8X"A09MN?<2,U!=GPYBO1:RYF\7")A'9W9QLN$?-
M"(D[)N"I2J*7$8\\%:$ [YZN7P_!D#$U'!XMG"N>B0TU2\-<1U)H'H/M^.!U
M6E<OU;A!KJ.L:6&>><"#+XXY^EHL3FGWE#:-$0<56?</""3J:9624LUYRGVH
M7*N3,G%J,760=YG!X*?,YOPARNW^;$O%T*F$B18-\W-DE $&NU'G[>?M<;F"
M.M9XJ/:F'8$K.W?")"="EM3'L:B/$OV8-4LE+XOK!S9JF\4Q35T^_(IL="0*
M2IO!EI:\A8QG QZROWE0]H SE.^R>@O<'[I2$ISN^X>1"M WIZ;B[/B+0.]/
M']OYG53UC(F$QZ>Y<68HO*].6A/=\#)W-X\C+$;+OS<_L8GRULB:9;?C-@K.
M7ES\ 30 LU/Z8$?;@[,JLG-*SN4\#G6!EVH<V<@;=-45:)F3/TGZX)BK\&FN
MFU'KR8ZY K?K9OG%XI;U/?0 _3^OF'-3":YC7WT=O/-1PDJ; Q \8<%(E\N"
MYFG(FR0?8C>9J+D3F3QZ9M>'-FW274K8?H\?:.$VI/+0C_:SIDJN:+6(R8CR
M9%U]&!AIC^ E42>@&I%3;F:W?LJ# L$@;WZ7F*[@.P)?(!X*@NRZI<A#7_:J
M/?GT=KJ)-M.@5P['C'0MFL9><#8<_+;-G+Y$!PO8>Q2L72XD073(.'XV,7AI
MG+Y *"3ET1D0XS\8,Y13RWSZ[&8I6;O>F>"R-Z?!1+V@38[AG$-PG'M"YF96
MIZF3+MB.[.U2,*H_5RGML-1[@ R3-X_R.I#J\ZC2M&8[J%DUDRF]7YY&.R"A
M<<3H!C;\@JI:3H'O%=X&^T[3VYH6YZV="7)#HU"ROL<^T!9PB]GC.^?1RJ[(
M^L20<?RC557[$%.R.F*)!\9R[7RU:X@V J>-[Y%Z"A6@&R# $!,):V#WKL:+
M1#0?X'J/@)9&XM@]QY,B-?Y9::GOK$=8%UG_NQT(-^:N;6ERE;AELU<;I:@8
MF.AB,-NDZ47\!W Y_>^/"7_QW[6>F'M'P17K/7"*U>D+BDNL531/K=NQ=G:-
M=FY=>KYPCK\;%LD3F0PUMZ8ZYY'C?C=>RQ07-+Y4[G3D5SN/8DYFIPTLB<:J
MY(XZ,A$8\&P:!$_@"K0<=.K\3@UC@:\VB4\-:=P@4C+?T#QM:%11;TP[D\U7
MMFOJL,L?Y$[K$).67\]@"T]TJ"JKP>.E&G;;.KECK&THM\[!^202RF5%@R%_
MZ6:.3,>"8A[D%_R$(+VT'*;.O^$S>L>D7%D$NUT\EM1BTAIA KN,D@/6\6C@
MD+\KT^]QI61>/K6&XU_SJJ<O9,4:7SRJL555.5.7!7;C'6M+B"OOZZ<J-UG6
M%>?S%G[[7@P%1<(/C(8\!F-3Z5-."A)/1>Z#6;AE$%^:CR/-+*?3XXQ^.*N/
M)4V+38%BM8TB[>H4S]12.32N3E!/"=K4NR1;>$*4WZ*7&^0R1QLTX_"%K+?.
MI3[$8ZU8GP&9MXS14J**OZ$JW:;T%3(O_T>Q):!ED<>I$(\!_;MG3JG)^_76
MRGW\6:_@(I&0H\6R $(\FA I2Y&!_BG+E134>]#\9VZ%=H.U@5_Q#X^8^!L-
M;F@/X,GK5N:KW&BS?(IO2^V3^Z3;/%<&].OSO&9O)?UH;Z?^1\4/D*O 56/7
M[W:%]S.X!CFUAB_/1Z[_RM&)K+IYNGDJB1!/73,8=WIV#RVTLCE7K+ HJZ6E
MX0VKM+4<N+I4FTVF%#M+T8UKE+>86Y)9T8ZI1HU)C?'*G='69V-PS2OI5<',
M==,/G9E6?#_[054<YR[\*!$Q/]^DL"Q%$8[+I8M&R2X]76=EYP:;EL":$4<3
MI*2P>H/;O[9%T@F;TC!Y@-.8_3@9)KFA5:R]>]2PEG%T7G@KZ>IG[7$P]WZR
MF?_0RRYH_CM\#VTS-6=GK_)CAU __4#K.L.!E?_6W;ML7@<+I<7<5R+_%]^Q
M/P O0= _9[KF7U>B3<MLO&'?+/9>/?\!4&F18EP7)0N!#F67:89PB3S!H[@(
M:-HK#&=&R$ULAQIQT;Z<OP)I#(<=62^]\$9'ID-F3 DQA(65I<>9"V7H3"(M
MA[/W.)WV>4.XFGZEO&JEV:TO?*D8EA[-<"6O2=+0ER$0@"?4/_Z.64/GJ$=4
MG9FR6%.:9(7<3'&!KU5=.7^P)R,WC,Q5O-D&KION [L1P!-TK4X6%!KO:>&+
M:&H-2C7&6C(0 <ITVM> 0:(5XZ)0BYC.,7"TB!%879QC5&GN-\FRS\5DJ.Q2
MW==,A% LSG%:&P(UC7/#HUF$A/B$'/PQ)GBS\K7)!/!'&BNA2O_7/]#+8ZA0
M%>)-<<$[?<A5A5)FA -64AHJ!ABG>(YEE*+O.@,"XJ$.E@DJL&I#]Z6G<MCA
M5S9:@5V?N:6W-*+C.A\]L5OW;ZM_3_E7$?T!T&>U\Z::GR&D^ S4' G/];OS
MNO#&]13?>*J_'?<NU?@7+[2H;;/E(_RB,1H8O0Y1&3K2><SZ U!O?T]66-/P
M&/8A++^0%AI_^A*/VZRT]S1GUS,S\A?UBO#O6M+9LKK=0_=^0:\CLYGH\=9K
MKG>(\QMU;D/-3<R3(*CC!7+!RT?\,VK7\4@7IB)I7U!DH%,WW/+GY1D,!"2V
M4 8^%YF67/\#B/JPD3#I=.BNA4*$P\?[![ O5%2SF<896;:@/OZPVE^7S'"<
MLIY<DLJ9&3,XE2NK%;$9028^?L0#RX^,[UQYICHM5JB:)"?M3)>>U8J!1_RQ
M"TPD5D_PP!8$I$0#JX9>>\<'';?AA*WJXK0EV>% (WGA6C%3X)EN)4W2H+#X
M$TQ31'%A3\5"(NN;+Q-PVKJO$ONFF*"JR8?6.(:.#/ZE$+Y'(9=?YQ@;]#MX
M4SO=$XP/+I#GHH K]WZ!'=[[JZ^XJ89_ (&U]R;Y9[S>VWH@,[T#_)G=EX8Q
M%"*BN%O>]YZNJK\:M"/RCO4C?3:I/>.\3'6/L>A3& A/W$&L\=%7Z_6LO;?)
M_]_'>R=S(Q$H>C#^MFN_;?.F??(B_Z\F?]KEAJ/]S^-?P57NH]O>G#Z9KO<@
M5!(I'V!-^>E#/7C.<#1,OH'H/2:,;Y'5)8I8Y88_R"0[<MKH'&-O), 58#UW
M[1+OO&UW0IC<<+S\G#J@O<S)5?@=C*Q#5'2K]O[+Z#A9P?+:>)\=J4%]E"&8
MB,_..L9TB>"96-OOD?1XLBK*&K-Z>UJB6Y9=T2QO:J0CQJ^+TFMJ0Z%FH3]?
M2&&&[+.(/S#%U1K.@/ZRC&!Q\M*2E\<E1X]//_4;3Z4:=LV86A=1BTKI#\=[
M&5 S$F6=BL,<II(C!J;;#T7*V<10]3[ M[Z]K\H-ZJS#B1D=<*]B=)U4I9)V
M7K)S9BTZVZR>)@VK9K)KN,I)YA$Q(:%V#N9C(=[F#G7U;-5:;."DCQ'&Y84A
M!CG)$?7'VA&>:#Z0$07J'[T6D,)GET_7Q;IZ_>0>?+>#0ICXEO?;([S\U'I0
M, &!*,N4*!A&N#HR83Z>=#R>('(Z<'YL;K66;7F1C 4Y2+9^J=(57SOK9HI>
M^GL]&&)+W77VP6.TU/G2C)!Q[P,[EZX65I1&H^5:L"0$'YAM#LXNF"MRB8*3
M@9]*HJ<%9HJ55Q0G(HIB\0>4 &XMH^O_/R0X("PGF>-6+[WN1B-580;YI,+A
MPJ,(59L_H,YOS\^GX-Y&=X5F==X.H\//<"^O:'R78&^C'1V#TR6G.A6^_#/V
MO)1Q1/P!>.R\"U3Y$7?,M_TS_/"!K*^?K81$IRVQ.RWTWI#'GL3=]/ON[_I_
M5/Q+^EPZG3WEUIUOYGA]:N6S7Y&PB<%PO8N:,<UY(_OT9GM\@S8-&EERQHDE
M4!Q+X7NR4Z'ID##(#)7F.*<$]=LW73+ETQI")9'/A$J:SS:DJFO /-XL@B>K
M?13R24=*1]CM/X">WYN-"[^")<V&*PO+XZH3$'<Q<'IH/A_*4%PA>MOZ.G#[
M/3QJ_WS@]0R/1U,=YOS]H>G5Y-?KMIX=\?.IX'[5KU&_LEK:K8 KI'+_9<7\
MUTB!WGZ8X_6VOX#@#;;8S_VV0G@_0'>S.@]1M66-P-Y' _:\7>NWVW"+R.1S
M[E].GD?,XYX8#>;+/$)1SIO'KH4;P/K#F+N5U*>LYJ#/DN+)6+]1;#DW.CWN
MU4<SL4N3G!Q5PV" @0LL$T2%>,2T>Y^3I5GI-X&,U*69]T$H6B7EL9<6GY2P
MCB_ AEO]P#X+E((KGC'#%_+/^)$BNC]6R\! ><OUD?H1?1Y)QOU]=F8$0^ :
M>&9NN.T4A]CG7:V'NN3_-BS\[XU$Z<4JG>BD1?J*G/F7]_V4B23V58<%=#Z'
M-/R/VN.-@!:NJ(WNET#E>CZ(7 EP-8;1=L\4B-_06@W.:,U$/#G4FG3R[/ER
M=+QCFXO8P"F*=XG\UB<W$^^D%NT<?24X& LMVJO;FK>;!M*^QBOET _UMY9T
M0&_S@R&-QKI5-<;AK>P?-O,S<HSUYV$B6U9;.2*9>TG.=NRE_GUBLC#3;$L+
M$^!'^L9%-]N^2)KC-6=B&2S[---,7=4B&884JWBQAC'H68SN8\5 !M(;,!WI
MB6S1PFP!(G4 +"LCZ=4+Z:E[/Q:'P03/_6A04F2H"JEE2A$]=G3I"(QS7X\>
M:)X(%F!2WO)IM@\-;X@3TM5_DJ>Q_KGWT7!@I,5NM/9 ]R$L<@#9E8OH5E.A
MSA*6SS37!,=*M$:1D)BYJL5;=>HX-L$IQ,:JHV[81,ZEN@]W90.?6J<60:N)
M)&5KL_R@U1Z=_O%PL\F;H-D($J1@4H(-\A@)42K,U\X1HK'#'5!*LV$629M(
M]])GSLY6[O8-0LQJ[F6A8TDUTAPYU#R=@*A11\<2Z-&[\BRKQVQU!84'<1@!
MDSY^6K0EL>WT;7U>\+R])54+>G**98_6O@[+4Z_RM'VWKEYWY HGR:K0&F>_
M_\WD1\BV0K)9SOF%2^8@BYMK3 6C>I0[6V^YY1FN/O#PVR;==GH-R<!7?8/D
MVE2$J?2)EM=,^_9C'2?4[P</OWV)? 5 +A+3?^UW18CV*'02!8:8YA,H]9RC
MH;69D".K?[J"S3WL\H-NELA/3 OJ0R1ND 5BID%ITPVXVO8*,Y)A3?95 &M0
MQ_M(8J5ZUG9K!43H>E>AT=+.:=[R&%*2W<CIQ:Y9$_83@HH*I2[:;<UY8MGJ
MNF[/+.'VXT.2KD:G+@YVA*/RW&<C? UQK59QS7-*T_4>[L"4A(SL&NYLR5;+
M_-H5<\CLTHB;R=+>YD27%0FDLQCQ W42[-7)=PG"8;(RURY,,C%"<<4?R!X\
M$T2<@<85V#.(YS_QX>_84];LU"B)56^.:'#7=]BL]!O$6%M%IR9D3 \9$K]:
M'"3&.BWWW*XN=:YF6K:4 G,E&L5#-9GI*SL4?7>1Z:/=*<I0E:.N'62)%0WG
ML+=KV@D<>3G!6^ZR.?Q8RDHJ6$$2X5\[!*AE[[R5(&F 8%?V6R@$\M@&SQP"
MM6@<9>8$3B.K(MHD2@NR.='/:HEXC*ZH6PBRO"+],ACJ&IO4-+9"3%K:;J:-
MK XU8';;"?%1)+*8+[RBJ[K,,5%JSL."FHDT]$>&0P>9<!K[?=1E"719@=C$
MMG-[G.2%8*0UF@EL'G(:7((V$W">:YHWJO3!*'45UEFIWQ1G-/V@LM-]E5O-
MD 32E 6\]2DZL(IW\S.U%9=%+0N(6\8:[!-3$@H]VX!4WF2&A8A\1- K"RGV
MZ8@,3I'@GITN)N8_(6S',"A2R9)0X#YA[=-<H90WSH-/6_FZ)ER.=T(5N<47
MX[$4W,]KAPWEB".^)6 GOIPJ$X4J;0)9DTB0,/L$O&)HFQ2/_AUBG'QG^! 6
M/,(=TA^8B)I-J?FE,<C%/$Y&E<.J"%/^MZIT#N:\+'-4F-=F5+V$!5VB3])F
M'HE.'VI<'^]G8H@I Y'CE12-6Z5,LTTI0X^O=/<1ZF]@(<!S^B%A%""--4#D
M!&+#A6J7XZ?3P4'^>"(ES6[6$!^]&0<]J98N^3%@-ECY9/(F68]2W @9""?=
M_VMSF1*4E.A&:,> "4HHD_@FR&W1NKA>I2[]BR@LDA3C<&(4?O]F?$EU0_3#
M$<46F?$,$YY+(CDIH^HJ\]9\L>HO'L'0S:&O4T4F>9RV1I,V,B6Q<>S&UBWZ
M>A-A,8C!7'2'WD U72[=* :"K7UY6>7*BU/*2BD^;/F6O1N.=J\NS$^-4BGM
M4AQIM636)"(R-&"#RGN<R@ZO:LT88RS^Q*OOEZ6Z(QW"G\A7)(#,F^.)RNA;
M))\<X:C,),<,.07$8TR_/,(/KPERS?NSQ@3=G%$157,F*22KT;8.JRU(1C=;
MTE%+1;>"TH8THR#R@\9JU$:&'T"<["V(DFEXQ?"A"5%1-RR%RYG@CNM8-?B/
MN )>2)5NF*C:HV05(H67*AY./&S89-DE_5*U%59,2=]9(^4H .X4L4X>O!^D
M/JHER@!B""QE\3]QBJADWF@A8RW2\BB-Z1)SQDBH$P\:*^8HM'$T^CYJ=^&D
M;(0BD"/!(%K7UP0<FD)7L@TY[IY]O.XN<],2=B$^P1%A)R>A5 V^2D<L VQ/
MVS ^B79DN *B X;;!:91:,>2^7!I"3B;YI+E,3G]ED1[E#+QZ/\:#JXLKX1+
M,A#"TA8CN^VDT ;Y-6>VMY>K24F8%IJ0(D);JFADXM"A_&'I*]&EL3@>$48T
MCTVOEO_H+^T*(/0L8OFY739B:UA,'8-I'0Z]L:0RO:#3@6Y!X<3G,%DV*]@4
MXUS6ZW7J)&>,_>1T6T7KGVJ*,6D.;C7C@=AZT_N.%'Q53)Z#O^:H*AE-3<L2
MF)#)Z:/5':FD9U+ ;P25B;=ETKAR*O;H9W?ANN($E&T)N\KTUMD%_16LM6-Y
M(Y\_5J,6X_>7X^U0YTHQ S>;+7]%MU#Q3A=%95T3IG*9SIE')^6,MRB9*FN)
MCW:.7X'0"]^W\(I?5P4+"^ZG,EE'GM'/&B0_:^50-'(ZR7[+EL?GH[E4 CK8
MR-!V2(&&#]62D-ND\_F?:-I]N,O58-/PYY ;RB1;G_-,@Z*'/K 6?PB<)2B$
M055,D3Z%.@X2"(J F<_0S*@1C_R1/N SH9R'/GUG92Q<CQ8]F3Q4)L,<@@%*
MZ4&\*^4=:Y? N&:5=E9BRR<,AEUT$HT]*'A9[\*Z#5_=M]W8V=Q*@W/=') W
MDVF=J]&M2XC2,Q\O7"CBKY^?TI1IY(V4BD+#;]6%"<ADA8):6>E 8BKD17F<
M;?40ZI>Q#6?6?2VRU!62CKV95-C^ 7S6WHO!V1CG\<F6'.:#MG>-<<SGZ"[<
M?M[TH?!AG"NLP>N?UB3"=F^'AT0[P=HZ<6O+B^8J ,Q4S$V56"8@A:;/AO-M
MIKA]#D$(;Q;D-,GJ><("[\ZN.;,4[Y]J#B\86[P+A3)8M)AX/D62RJD9ZGR5
MSU/^,983ZP@SZX1)VVGY-C$<J^IV[U4)-IIV_TB,?BK/%^\0*"VA(4.9+OSC
M]:JC>H1^K-E&G&F^%]^RIEWOD+(?WIGD:!&<(Q:J1%])1JW.;9;CDRWF$DG$
MSQ.S44D&<"!+.&2+J$'!< "209,?SXE,ZMB9+.-F*FC)/]N=VVQDEB@Y4"M[
MRI9/&&40"L1H8R/I/N/F>]IU#'?X,%^X>K86L\<8FR2<8CI)'L*_WE)*8"N.
MN_FAN.A(L741U)1A%P455O(_BO;_B-Q+CL3Z*9,1.J#U[=K-U-:U-@$Y_TR?
M(VIOZ>>0!.@@=''*.XO"9*W&-+'7YZ$-0:M@?:6.^J%C,;X695SM,BCIB6/(
MP'O+1?^Q _=:ER1;[]>C_3-.[99"@G?%#C:\;F^?_5=]PI1R_ZN@I,?Z/(:#
M/X#.V=_?RKRWD';"5.(,.AGBTX8>;GDWTOJ^NO*+Y&\I"/33VK]M+YWO)'LS
M'LH=-$P2IC1TO;3X!-I&-+37*[ 0XF-6W:_J0>J9/EH^F;/55[_0'G^<>P6/
M0><7P:&JT#OG[ A8I<+A8!>OEL 3#0])P4Z!/Z*QFQK%B5G8\/K>Y7P-4;B<
M*#?$YL+.D*>25XFNI+29#)W\Z*;<78 3$R9/S*T2KST_^1\QI0H.#KG=K-2#
MJ^QO[$/"_+!]8G?3*AE=PG**@%V1?:!@%Y<Z'F6Y/RXZW'K)6@([SMWE9L4$
M ]"N<0PF ].G3_N=[3Q':.\MQW^[!,W_-W?-,+Z&T6[3T=/.-YT'%]*C_%<$
MOYG/AS>).G<]+QGY"U;KX[U#]OUO']9FG61^(GF,5C_O^,I]/6NZ-#/8;]WS
M"[E8Y:,\6_SLI_I?D-[_ '+J2?F$L-Y&E*BW*S#G.U(5\$@G-7$,U\1KIKB^
M#)5FMHO&5W>>9BUA2KEJLR.T#7*@.7Z 6'SRK*!*8VH :"7X[&<JV=5/9RN9
M,F6/:\4%*@K#UD3L8JD9.116T2:%8$%1SK.I8K//[]V?P!08[>O!V)Q/P,BP
M(V14P$SD9R-+HRS9.,/RYA:NOPFJH<^#987'ORD[Q' UM$\:ALYQEW8-4T -
MRSM\F9@(L((K,$>YM8^)VLE]7!Q\S];,6U9[9_##/=5ZGPY.^AK@V[DP+.$\
M_?N'\1^ ?)D-_1\ =B_R+QH+L3&:[Y\7_Z62'W\ 0Y%OW+F0JE?)5_+C\W1^
M-S#IM _,U,JH9\W_FY[U=\!/"#,M9P? UA/?>S:ATH7F5/^HG="73XT%[PY_
M +MT!\#V0]Q^H6<V_]+9O51#4KA_RWPW2"V&FE?;P:=<UXO"1.%7.'&<1_*E
MXPM_E5<IM',4EH.Z/<L.AR*AVOVL3]"0Q"/^*'ECP;D:F+?K*Z%;OR\9SF.T
MMK)A,@Z]Z$[[^Q#^_FNXX;G;@ANNBX8 [>H.[F%5S?JF9+>_8:2R!L7D'-Y0
MCY%- OA!'^Z _JC0^CNVFJ*R0L0+U8:$@<>;]Q^ 1J+WD0[U=TMD7=((PH^6
M8NZ?.8H*V. $2T2'HM3*%X<%RCI7Z'$_862DZ"0L9U7;?:>2 ]W 8?T!=. #
M)=*:).S7K%,[8\1SL LQ^9VHC>F5425R@DV7*2(R2V5'QNO/8*%,$WW&7'5X
M3['D3N3VB7;1H: 96<]M-%WOS#!\<2V]+N<.96AXK\EW<K1*]X_V@>>WKA43
M[&EB"A.+._W]8E*=D%Z_+OJC&,N+BV'AH)^#RMB<HXF(2:;T5J6BI5FFM%@A
MY  D4?02 )VL<@!6">#?98XIM15L4/V7INZ2&/Z+J?(B9/][_?/B=Z[V/U:J
MZ?2/N3J@<?]WV_V.T/0/M0WP#&X,[SY^_+LOJ7%2?V?FG^DO,*VB\+EV:^6Y
MRW[&BQ= -A$/]>LGZG3!+YO_)^QQ$1U^1OS;,_+63<$BP1'<X^T\4;B1-O%9
M2NQ>_@3]_>;;KRZ!*D^0S]9_!3XX_@"JB?\ F&AJBU(M.%&W&FLFGA*V>N/C
M?DN,2)YOE*T* >[@>SSTU/Y>"+J'I[<@/_DYN#L*T<XY!<9\0[U[:)8'P95@
M:UR[;GJ):+)M^]+NS*;6U(Q"FQ>?_DC9-DK@\499_(J+.''<%U?6!2GK+%>^
M"&I.'CA285;93S>9<C-IG+B52@20Q1O14;ME/U&:XC-@8*2FB-WC-;T,ZI"7
M,2#%VQ@TV+7A_?A=J >U#B3_D%U^=#[E9/"&O?B$.M[K/64!VK3J;1?Z RCZ
M>C]!NF47YW%S>O7" +K<22$U!56.T@RU\6^G=ES(OJ86W"C4VZXW)1H!=5FM
MWW9\((M/$7WL#&,-<M6!J^V:ZB? I%!Y$6I2_#E!FKD7);W(?L-2G]@(ON;8
MU&%1(N&EV*L6><>>R4:>,?V]IV.,R&FKTVW*=-6>8>A9 D:436'\3Q.]UOF7
M&SR6B>C66SBC-(.?)#ID"A,!_=2L&)SCRKB1,=0DE@@8&!CG&,OE)WR#[8/M
M(^PGF#(@9IG)0\"4A9CV+(PV ?QW ," PY =_[AG/93N/PF-_9.$;_KPWY+P
MV'\ J33E#/RWXO"#\2A%%.#&,<EH@1_87E-AXWL-<0DU?5\4:M8PR-6=4L2=
M;I$*$A=W,]4T(_ Y)PL" <=0K &.RQ[97-.O2DXLN8T/C"IVNH3Y(9>*,FO.
MAO!O&RUF9K&7GI&Y;HDBC:R02<V3ANCU0R[4=*)]OJ:4H: 1P,NB.BH5I2Y7
M>(P9FDYX7EYVBL<NICTN_),6.070G*WFM4-XN7X9MBN 0+HWU,;%]OA,/VO6
M-<O B*0Q9U>$"65L!<:RNU=!Q*3*[2A?D5X\O?, 8<D;)B;P4[SFR.06O1P=
ML[Y\?T^>T>>>KVY'S4[L/6YSM>0*Q57F3GT.5P3C; QMZ1%.[]EEB^;U42,&
MJKE&1H^#'AHM6M$&0AHMX@8.5(VV$!;\=IXZ'#),+QY/%D7F/7/3+PJ!U?LR
MS[KIUF%-:WK*)%KT-V R^E3\X_OTEC(-T4[_#U0PANG^>-J@"-,=_B:I'LX,
MCG@+8F:/9_:V5;:L&3)>%$/)\HV,MO9>[LLU1(P?6T/[*XMP*W:FX"7N=OR3
M*:/1#K [<W7!SY^\C[A:U?@?W%I.TL;E<H;<:G?1 I9+3ALO&=5QXTD&^+WV
M5]<NS"Q3CZBU9[B,KZQH;(T1I:QG2(@=AG';MB\H-%1A3!XF4%K;CNN(2HDQ
M#']NPZ!$D __9DGLWNKEJ*-#4\U5GM()S7>$X=%P9"):.L^Z3"QD+/M&Q"Q\
M%=%N?IDC8*T!7CXIJ(S9!ID>9*#B\SO-J6HH5\DPH;94.%"/ !%A-PQO5YU-
M*[H"'9.S7 ,IV SG[5/O1G7R1IQ^<##<M,M%%=MOSP6$P(] LR*(_B29?%12
MXP-0AF*6,@T!VS$L$=@+-VZ4G/M_W0A"2E$./&[4%/71\ ?#\*P@FL2[-NGG
M-M;'DM6W#8,#Q"J.XR-CA#JR%RRHZ&TM*;*FGU;P82:%51U]##!-,+>R7MUJ
M0R$UTU#'J#W;U5J,_<//SE0#1A?NEJ.-CNITPUP91R0A3 KPDD-&&2Y&IYG#
M?PN/4SG]Y=R\C,8U5)/X%V<&&O;WSW1%K1$>B:\ZQ.1PZT4F$M/JDW$**O/R
MESGU<=Y9W[6Y<C,=H?L?1G_9M='DKE5A^WX7+6I%)!Y*ZZ2%V&:3*EW-IF+2
M!QYO]X[&%@15J\B/BZN5CX_*:186C.\"M+$7XC*.&8PS]J"5RL>^./E5!\((
MV@:M(=\YE58<Z*'C,C'C$@H0;EX_OVB,,%^Q5T>P:+J3R*S8+CBOQ=W#2<>Y
MHL$_W5>N3L=4Z,AJ7GYI58"K7]0FWY<S5/8K"9,N9[[ILI1J<KJA.++Y:.O
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M/_<1I1 &JKEX)S;VSY17QF/"I4A?1BB3.2AZ)C,:Z[/T-V92Z/D/ ZXG&.Q
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ML-;>,UJ35*.^I;HM[W;2P0>-P>5[O$2&7>"JFA&&>%?^KU:^*B@.9MT6"81
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M3#,& <PJ>R2$3.#-Z,ASMS31K_HIF V48J+81>;KI;7_9B!)M@QBSR)L2:Y
M>'&+A[ C:VT*PA;HQ3J&Q4M[P2<9QUT-C;;P>D.FEV[R?B1]%9S,7X+R1KUT
M&JNL; %FU>-UH-X,]J8&)(5LP 0\W:8Q9RKX_IG]40Y= *.;W=O(VC>CYE]R
M #HM:&J*Z?3\0 %VIJW3B[(L/VQZ&\<=1Z<0/=/C."4!NOZ>PN1?7WD6?4.1
MH9,-3R=&HAUX?CQ"1\O\L_(Z:_3!_<&UMR%M81SN#_*?$[G49$+TBN!<?V%,
M\L@[*\WTE]O)JC1VZ(38<NM'UL>Z%=:8=]]S#,/_+'76'HAA;U@-B:[S#[^7
MN7JMKNK[O=BMQ!WKL_''T>P>9[AF[UF0QE,KN=\6VOT/>!D@:T#KB>AT/JP)
MTA'[[T>[_T)E(COI$<84\X7MC!HS0?+YQSNK!D@Z2*G;Z83M=KQ58_5@.<"]
M9?%,P',VI2>WB5%="X%CR[(+R,W<S"I0FB#-@5NKSSSX[Z31L(6XH6Y"UW3D
M5&FL]9$K*XZLTT8>[AGI!0T(ZYYE$OAJSA6F2SH_QVGC7?#'F2!1_!FE !W)
MVX??(/O"L'R!8FVW)WV\*_3<?4F]Z#EZJJ=D=H, 0;DLZ<'&/3A6EV,;]U2T
M49#]&5EM"TP728&A_4081(T0X^"E'$%2,ML4*(HL,MH$S'M>0UI&2V7D-C<-
M7O)N%XZ!EA.#V>2-:UJ^%PXCD)7"U= @(7GQ]W*H!!MBNY1,Y$2Q2+O&"L,B
MWYWXHYF(R5B6NW["*J6^JR&F=V9F>A2L@P&,(A7_%0<&@*WUX;R$*^R8%L[&
MJ X-(YE4_9._Z9.+$5U^I3E4L,,IL3EO)OKQ_J/:&GM]I#$>NBT.VC*J7K1@
M<IL_) :!)T.:'S8>B^43JLP*E+K20X/_PI#O[IL!N8&^Y3QG@8$0:A2]#(47
M_O@'JE?U@PSB]^NQF>6_4LP.[("]%PV01I7UQ?K"/FO/C!7@3;"J=%'C&%,S
M'3X?:D(Y_R\,&?77\SY*P/%KV&TW*QKI4E"7555@1< $&VI3_$P_6C2A5C72
M<Y=Z8"03'WPIX>"VJH$((+K58RG@71*$Q_)M#%?:]/3\"N)+0T^>O4TJTTE,
MC*X'GC%WO,T:RD/2] 2LX!+:[.ZL&7)[+$![F;7L'!RPV=KI7=X WF@GC?:@
M4]QV4U]X-,N*+"V*2$I13'9G0SXNUQ +4>;4KDS"P6I(L8R#D^;YJXD!FV0F
M@AM;O'EP8 I09*2*)QT:.T=V_/:*FH)[GQ:K?^NGTC>BIWC<2YZ@>19S)O/6
M*+8>OXAX#HZHDTS;]!E->;(#@3?)[?^EKSGB:1%T3XJ.^/>E>*S4&]*%3!RX
M84<M*'4>:K*BN JM2M6Q_H'.#'E"D:%J$QM<</UT&;1#.M7<45G7>9"8"DW:
MU/2^J1;=ZB;D?L^EV7C@,#(+T[WW)^%V/>T+$'9$DA]\6#-@J6=IA&K#QW_V
MK&^Z^H6%1E*23: =19^7R@\37]!V:I3)PAQDU<H5SS^Y-GO#\[K.#6FR1@S>
M0"_L* O:^S**L^5G#R\'#9EZPV0.1B&PN.[> ,^F<=MVGL:SCARNU;?9:;G:
MGQ7CWWUNO05>B=9%D+SFU!-H4]>_6J SIU;V';DY>PJO_L5[NGY&C4@-G#%^
MJMI1GWIWO%A#;_>,A](A/Z[HF4K\68L$WMG'KV(6<*8;R/^W)>-OA2NZ%:^4
MO?=&O@GF@0'?4Z-<N]H/G[NY9$R:K[;;*_*J#(SJ 0ZW/C75Z;X:0$"M.3=)
M;:H(;Z+6Y]?K+ZA$'Y#79VA+;PX">R?4U#)XO*UN\SA&$Y<;75\ E1*7JND,
M$E$8\9<JH$F^G[TL-/I&34#_ B/',1X*659N(']O(8%7QQ*[=8T$ ;Z+D+K>
M0E7M'GG543=Z7EDH@;ZMCU;Y\"IF8^,SM0J$?855Q+B7=L/.B_!W(MI]*!13
M(EG^.U&42OQT7I?S2(G2-[9O^0]^T^9YWGS.1,U(S:!*H>6<D(%&$WLW4O'L
M/FN4F&J^<+APZ1Z79FTKLWQ\B[J\+I.S!B<G%TN_)H7IDS;GE'&T>U"K XB+
M>'[538IWWS]+T)9^U.0<HE7O*_4$/C"C&E/I<,O? /7VNA5<LJ*Y(5=#%\M
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M/J@(#1F(!$0""@>J0H9%,]X6.2GA((!LM63+N^)@EFF]:K)E!*_SPPL A/N
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M[RJU:0B J1;):E:V*/:&-9M,13"E\6V@3KJE+(O)_+#1*0R2<41MP_$T1](
MZ"1\5?0K."[2+M-A&Z$@& :6\#K3(.4*/-^J,LDZXN-J",X$^VR)IGG <;G8
M&2195=6HG,H3%3B)CV4KURRCJ%T66#<2L;  >756:%-@.UD,U:G[*M %+&N%
MO)D&1%_ QY*O *WAC&>)*D,KT>?A2A9,=T4X,C-U/HEFM%[4,@N93#6F>=W(
MRW(UP $D!JQ,TXH&J#D:2!<$T/)$P/:U;IM!P83FM]FAZM!M3"YF-%5#71UM
M>J)9Y7%"\CA&5R2B"EG^>!*A.2H_RC*=U&2Z]"27U$.]BG0Z([!=C%U8J<*
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ME(J$<@Z+0'M,L:#= D>1:P6ARL@Y:]23$,R#)C*6C"<)&XU\4"'!B6A5$R/
M!S@&<%U72[*SG(FHXSUIRF#;0F'@:PD%5<1.P;;)4G<4U;B,RE-IA<()G&^S
M'[\S[#35-N:VZY..7R].W5<RWU '=C?'!4U<C>.\6\3%D* 429]AZ*V*"@4I
M%>I),56OJ#5%[E><9M]@:;E"5DI"=9*&B\P@;/1=+3OUV%A'ZCI&A0/B3*(#
M!T44,?VDV>K8<-YA2)GOHP)(0E(?9(S"&,TXV5&"LI.H@CL"$&!\*^EI5F["
MM_UV<KK=IZ345,"PHRQ2E>F<4G(\EZJ1V8'<'V-$VJ69RJB?+/0QOMAJ)"%@
MZ&>A038ULJK]26G2'Y:+M525+&689#H[=5]9ISVS"RY02<M*FA,Y3- 3NV^&
M$BOB!,P4<,7LL&*^T> BULDP5-9*.<F*$9%4RQE'.%AI3#*=L%) >RUF];8S
M,+(:=3_7)SI1$603+9KAO#1757(1D@T\)Q(C=EAS  %)I;")Q&$]6IETH%')
M;30J!;;%\J;>IX,:PT\9K)>B(UF+.;1;!B%;TPA!3\TDD_X,EPYT)P\+"%Q(
M^62OP56<X<!'"R@C-9&P89>20&H"1';L<:H@JF+3;#079Q]MV8"L;EM00V@$
MMQG.$.AQ3N:< @_J0YOD,\/"..$SG/:>1J0&@9B+D/61FXR9AVJ*ODU.Z1P)
ME64]*Y2SDT2W6(8H/4[ATM6&[D;">!0GF^DJ6A3S&E IV7F"#<'>Q%"!80#H
M.;G?RLBR)H$!$\:#R493PQYK_(0')\2H/0SH.%UIXC +B.,DY3M8TB@@H%:&
M +<^*:>T FOH:+'='G1D3P8K1E..J30>^444Z(X&36WJ;6HDP25 R(HS7#UI
M-+14<=P'%<-$<^U6L9/R(+!1F]DN:!*))%CR \!1F[3> D2_"0NBD*K5Q(DA
M)R&92T]CBD09&3L#4MEF@0H:G4]Z N,(:KO85@JC[,AUAXUFIN!42T*^GLM8
MB5&ZY4_95Z88Q@8E3.!<L]<I>0'J2%JME<V/6CD)TPJATN=)AVFB91XTTBG<
M4:@6SQ*F0R>+,9^PF4D. E X7<Z'H^DVBYR0(,#KD;Y>@LQLL]\6*(-P33\.
MTEE,M$54QTS&J21$M)OH$-ULE*C&N;J@C)LJ#YM%EQJF,UP53]?:Z)0YX)-Z
MJD4VL#@B,9W ,;4JXEM$>T)R$Q]M$OEQ)E_,]PJ9O-_.X:P+87++&12Z0L)/
M$'U<\$0I"4=E.T=V*'V:!?3'9I#4RLUTLS#HZ3,+$??@9)WFX1I AW;2HA"H
MG:EHXT8"@2P.%(16,C_63:&5TD9A"&04(TR&G,G;Z-2P\93;"1M)9F!A:HFC
M<'\8F.&H'",.@^;031FRZ75X55=[L=]!6[//3%D93#/H,,Z#8LH6  (U^_AS
MZK%C!@I(5;XN>*PJDGZ^RMO*$!U5XG055H'BV.^PO=YHH,3Y@%NL%"/0<<2$
M55-4"\Z._?H8+A<@"S'Z([73F[HO+C3JO8)0[;%CQ!BQ>L\JOJ=VG.T+L0W&
M&IO#BH $%5VBM2 .T!+GRHT"#3H$[A?R[:%D4MG>])%ZW!L.PX)!69L,X:A1
MKS3JR2 D&< HY@$KU[0&@*V-@*;<T)%BJ*B<@:BC1+OD]L@$E%!+MH+&/#O+
MV]Q@^@C)2UI "-6ER ]I; C',V"7,SG,$VW B(E<3=12I()7U:+JUCG%M?.:
M"<M JP /)M4 H_"16*EFL";I,O9T8]R(W136$ F@(B&H6Y?!8@,)M%);K;?K
MJ&F)6 V?Q./<M+%B["A(,F:XIA O/AD0E6*\[K%)NY$LFB*7XJ8K):][1#(S
M1F?X<M6L]&(!-N0Q\1.>@7H\QTQ<DJF@RJC9Q8.QVD:E81.:>AM4+=2HIC,N
ME56$1\(Q %$&*90!4ZO)DH2!E4(DX):E=]-5V*":>M6HI?R2UT[G6W6N628;
M7BZRFXXKM=O3$)#3RG)20S7!-]LB'>:R9<CR7;/)E6I>G.CVM3$;5O)&1^G:
M+2CI\KREQFS>+IA!+3$0^LJPTK4QO>[D&\24VP29>CY.<;MXILL7D=4/;26P
M2L6.FY9$&K<&G"\E\Z%A!*S#.'W&+98 "[:BT%#S';4%P)R=Y9V8/TZ[S*&X
M'V)M.N=65&&(B;6!0(!%<.+)9M[RQS&3DFJ<;%*,X[584]/5,@JU8N(Z2/9%
MCFYKO#SAM3(NFG$:-F4.$M:%I68D03%+9L@BYO3:DY"R<'\BRD J;=?[,*]Z
M@!!/&IF$N0:8!['8,ERMK+$@&[CJ8$R4X]P%!O75V6A0,YF$I& (R3-5O4=4
ML_E,%YZTNXX$T;)3B>,&*7;AP+:,B4"CDEYA6YE.PNRUR4H+@]-)$NK&+>60
M:0@ ;)G@W*R1D0H!-2+%@#&MR<BM1(0-VTJIE+*R2<.PZO0DW>:'K*CAM)=U
M@ZH&4HQD@Y-L XR-(.1U2)QZ&Q%H5#0\+&LU9-"1L+"-YJ66:E%CH-\8@W#5
M0R9C*$18Q<N":)3V4Q*!0RI?YJ$L!L/-2EKD!^52O@=J;&H6D,$ZG2$3>P73
MJO251!5H)1I "J2*$8_&R4@3;C1<"@A0GVN3(U=IZT*I&C@\IQ?, C&R>"XJ
MU(=>+Y\QP.E*8>H!8/,Q ^YW0) OEJH#O];-TDH6@EO(H&N0;C:F^;185RT_
MWX)(+H@]O&/@:UI!TX?^[X8T5E50NJKCHTFRX$BV@C&M!-ZO0C#1\K &54+Y
M5H7/]UL.6B3'9+(Y($5+DF(WYX^(8;S.<^34?8U'N._+$W9(3#K]B,TB/&2V
M61DN.CY' R;OT!YE]^PFV < PQAX#"-:!5;/T;%'\MQLD^NH="GAAQ&8G.8I
M=%[H :54VM>=GBP-T#3,47"OAQ,2461R>9J.<X:DQU!2,D,(;,AD0X+78:%M
M("TG=I_@I($;8TF1XD3$7?U5MU 5<-8P3=.7/:8$I?M\$J!HB]:<U*!C.HHR
M&3D3JR!1L1N1REV\Z?209+'NC)TL8U6S+LZW6*=H%2-S%M#VQYC8[Q-ZVY9M
M2!#YDLNV<SDJ=F.MOF'T@Y(QSCF3@JX/?-WD+#P!<$BE+3LJ;NJ^A?3:27B4
M:985#IONM+>2!*/S'(MT6T.! SI@"6]P;EGC'#S-VR;8:!;+9*=CMD-"<X94
M"F9DS=8=)619+BQ72!MP(I:C"D9?G *FHWAHAZ52(.7S+<<6(=HMIEU1,#&O
M%?"]>,WR18>FAC.>/6@G^M2 I/@!'Y1KPTB*"5E9Y42P3%!US)^2=JH-9$J*
MV]%$8X*87&Z,5YMEE.#CP .WG228CA.T---&=:<(9PNPX54L+@4%O.4W=<7M
M-;1.MS6V*_H GDS36Z33]&@\U/J%D:=VE#@=&8AM).=X58B!^:;C::X0CZ?H
MY**4)D5(6R*;L%4@[!8#=*0F:0YA%]1K2%PGG.[!XA[(]((RY@YCQT3Z#0AG
M#)7#BS'!P2="G@#M !:R@ EA',=*8J=8L08%5_/,1AVRX:AGF;6>*J T,YH^
M 9=U A^+,<F5([I<,"+.S2=KU=!L-RNU<IK"31>*W9? @6)% ^*,- W&WC7F
M1TDP'HHT0U1YA>CX( J.T]--7;!!BMIGJ/R1>FDI12B!4AK)(J?$7#S/3Q\'
M5QW(]UDB(P\@(1XGHL#I@>_7D3BK07!'L[HISBKB4<) JT(O TF3%FOT$XE0
M'."9+$CB@$]1ME$<,@-CNO0T 2>X H/9Y6RF:)M#0Q,$2^)JB!-%69VMEH*&
M78=0WM4=D0-X9A(3@!(XH=H%GG.B(NO6!XHEN;E^OCS-1GDQQ:1J<&Q>3591
MQ6!2E*1J AP$72-9E9.9FB403;]O: ,R;^<<H=^GP+PRKJ%#DG(,&NV -%MI
M!W6P6JA--X*0;*[K67T!DCQ,9PB? W-6Q#3QPK"8*([CH-^6L*1%$Z68^1<\
M$!H*!L)HNH@%8]2 .3:O:I6>:*0@UU^]]U50&32A\4G>G(ET>3D">I4RH1A-
M@TB41,K%S%P]PC$-I6L -1RI#3Q1KN@:9I/#?C7+L6XNSA?]ZF1(KMYS\($4
MG>&#!J*EJ"'&\PTY0D!+E^ 1HE5QTJKTRGJ_(8C5,5?W]+[,F18H4;Y@$8HC
MFSR=DQ*AKSD#>[J91@B(:F(TTR-J@Z+1&-NQ8QSJ)9W2*9*MDSQ/IM-T-YW1
M794*2@$-^7;&(8?^1!)(@ @[R7Y5@P$$&A7:4\-V+;#OHT,D/TI)?*(^1"M:
MD0UBWA!SK!RO\!">@&,NC*J0A/DIW8-\!QBJ8@/ #=V@.C7%*24D/V*C<GKU
MM_NPD6/RQ:1IH*H)U8H\ Y5M*5EP*Q++96R"U/M2 6.M0792D:@4G=5E:I32
M/+ ]=J4J9. 16%5018?RS=4[[;HT\W65G#OJ3?A\JL?TV%*-YUV<@IQDO46J
M70RU?<0W"P(L8:V9[Q2T35_*^G">2M5S-AS&X;;LT$Y_=6KF5 N&4#71H==1
M0MN<2%AO:#?I6E0S1EZS2)%9"&6<O$;"B1P_=@@):E=23;_LTW604Y(Y0M:Y
M%@MYB6%Q.LN:GTV2VFA,>?A8DE5W6+.KBC :I/UVQ%,)/\?1OL&EBZ10G]F;
M:!8U+%[@EH=J+A_*8!,-1*3.=4@+R$PW)(E:J\G0C.Z&>+W*LQ9E*ZYE:+:4
MZ'6!0(R3 (,A.ZK;B@"C!-JT" WH LH&D*(B(5_M\-QD4AQR\;@84WZHPH0J
M=8R1X7>$?#!LY$OCECU!?+Q"%(J=EF-5JRU=YZI5(4N1:%7RI*S):46R679K
M)F@W&DDO<)5)"T\84X\=LWA.-:I,0Q&1'D;7F1#Q$:>A.RE.J34:=,6G:YPD
M(=RDQV7:*1-L6AW6(7,<4^]8-#V)[=.15&N8R/M3;X-#7I:#,J:?)&KUCI#3
MLG .MNM @O*EA@UB-!0E/,:M$B@A& *#P4JDNDPY+";L-I7KARG+HD:PW.C#
ME>DW)%-!(SFP_/X(&?0DQ!\05#N-(/@P2:J5;)QM\NWAR,QQ/B-,R&0G.60'
M+9%$RQ@4HB,1,;$*3L&(B^1(7IT^_O SJD"'4D$2DF18P$4WD;)J[9IDJAW9
M2%4J@C.(4>N0S+'Q=)7EF$VY$$/'\4&.FA..*HL5P'+S:3SO3H-4O3BLH2%?
M\((RYW.4;K)Q,LL%$8&J#596$#Y()9N%?EZK2:!%J'6+HEL8[E1&8\%5R\F0
MI_^Q3S'-]6:H7%T4^Y.&:UM5W.4<R&U0?8\<5,FV;7325%M6$D//G>$YAN[D
M+; B1TDF6RH/2^U6/;#U<JH2>Z/5V6@9P1L29 ,I44X4XXQ^AN%7@GI3R-3)
M.#"7D)1B^7(FP9::U4XK1\MDT&,339G(QK;#>T54 N*F:EB8R4RC'MG)0";1
MKA0;O :7HEP!+ F^RN7Y)N'QC5H*X@3$$+((K&*4A]4<4J[S4KE7"@",)J X
MTO @[D"XWTV7I]^JZM?3K);D;1MO(V$O3K%LN<*G/<D-XYRU%B^<@22E$X-$
M4_%ES%7J@N]U!;I&VVRSJ9:[8!YQ1B,E-ZHX\)3.^:@BCA*] 3M$TZ2?X44R
M-RHQ:<2Q/O4+XA]YFWX3XWUE#IUL"V:R4'*M<KO/=S%G[+(]J*5FBJTX4,M-
M)BJ#E3@GJ*AH'^JSE4RA9/F(J,0$G"N-IV93X'HH/NR7D:J;-MP$2?):,V8*
M3E"I\H$F6CU)E VQ')5;8E!.3;!1VXP))=0U^I5T#C*!J):@G5 =QXG(=%<D
M5><FX-"M%P)[9LXL!&[VVFZM#+6H250=-_-&EQW5!13WJ*$*@V518.I2HZG4
MH%HJ0.)4.*7 (Z5M\,/V=*N**A?,MHTV(J6M#O*X$B_>H>,U\"%8I5,RG@KJ
M?KY'^V0G3JAC\Q-B'TS*T3 QJ)2B1F1 8TATJFE8ZPN=UM1C&W80F; J((!K
MVX)N#[TF[!&#7%G!/&+<[^29. !IC7:/+A9CEZ"6RC37X360Z._]CT-/TQ--
M'SG(!4Y/<GWHW!?XT8-?TU-D'STI-JW[OI-__[LG I7.>^?Z[)%KSIX[5#J@
M:JJ6.O ]$%X"?_!4G])Y]R279-NFWI%FM(#QZ/A3G<O ?]3XH)BO^Z;Z3QYU
MBQNYU)0&W;T7AHL559-&IK]P>2+QSPS@&C3/M*8S/6BXAO9PJO-Q[5GNNG 2
MPI.I3VK !^5G&_ A9?^VV;/?=W#T \<RXQOQU"4_.'5QX5+&'2JC.(RO/HW)
MY,@%IBZ[DALM@*$E$+P,_$"M?W>#8VNN5C_Y)*EEK?$4JN>SZL=T]EU);^8\
M)/CN<<BX^J(U ^4#_Y\!R@?Q2ECTX:.MU>K2W+ SFEDEI=SRN&")HBM+4TD$
MSF5P+(_ 4#X+PYDTEB,3&$;FT_EL+I^<7<\?%/T(;&G@^=*@HZZ&U?\)V/>)
M?@2VYNI=?2"9[U,]&L78&BQU%%B#%V.=!+884=#$8J*#RXN))*9*J"*C>$IY
M%W\-&!_1PZH#19^QA:PI>=YRVQT.M1E#?1?C0_<_.JJJJP>J0KI#ZS.>=%TV
M:QM+]7]T?K9CA$I & 0G%R=0&5Z,$!"R6$:3^.*D%&=H*06)F2NZ#/R([)J@
ME8_.=(+ $B2*I?/H=$H(',GF8^J6)S-8(IG(OHNLK&FH_H$\_)=FY6,QUJ3*
M_=B)6>/]#P6A#\[,1Z>MJ'NQAXO^.7_ZSQUEGEVY2Z7.K /RI+@I,TU_7]G'
M"^D?75.?90(_)/KQ^..>.OC 6?#$4AAYWUGP]]7Z>!!OJ/ECR573W7@2/_VX
M_)J$/AZ\TXO#J*HL!]\5?+?@LY&3_S/F[-/]X+\R9Q\ZO___^3E;,QU9XW+]
M=P;X!O,IOQ7A@W;W8V)\3K<^2VB.J\T<)QO._!;&&G'(P6<*\>1P)K)_S&]>
M?-H/7GR8$<3]7DHS,=_WEL.SP_R^@H_6+$H>KWNZ;*H-5QIX\8)2!YUH.2F9
MGOJ>],=4^B2T6J"ZMJO'=M5P1VM"^D>%C\)4I7"FO9P^43][[(TG8^EX.8Y
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M_/@MBO_=Z5K\WGV^DCSA\3/M_[IN[@T[_#_V6OM+K\]OOP0_=NT%YQ_%7?G
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M:)6#[K N2Y6739+1?$@GTM5X5ND8[%&&*TD".C#.S8A)A)O8C_=,#=+,(?N
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MM?P+T)])<'%;)9=D5["L(Q-]UI#F77@FE]VZKFN"K06\+':,-N'U9)Z$CT/
MF=2QK#0&:2N(BMFH1SBVDJO\6 G=6O"> T^1:*.UJ%./U55_J]-U%'BFD"4O
M].,@M)0VM>^2Z8WJ9%Q]W:FWZU*Z<SF+T_!:GF_?7MS,/[(]UBTZI$O+:<GH
M[M9],=X*@^\:;A\BMVU#TV8O4WW5Q8B(!&*(;'7-5VPTUE.JT1QHTYB6EL7"
M9$X2O?V=]M,9_ZS/^'3/>H]FK _[&+IDQY;,L_P"7/%ZGN\-#L'[RNUMX0U8
MK[AV,)JG"5''( C^DCB46*>0<^,VP$EQQ;>\H">D2WW1P?+LQJ/*754A<&N;
M\FS8[0G&0Z\K:A6!V&I^%C0=CK(5C6"$66ZL/,&J(VK&83: P#NW5/ A\Z)5
MFQ SYD:G556E[L]%="A>BS,5KP7R^BT%04R8<H<WBV583O>%8$]KD)(*2/]0
M9R&I4QI9+N?6+BU-'IBW[XQS]K/LX'V 6'RGS%-^<1[L2<6#^OA;ZQ_%91#?
M:?*"WV^_>>;^S'Q%NK&=R3#U(=3D#[UW,(WQJ>E ^A38^TGG$[)'.'*)ZW>E
MT],;YTEP^#[KYGX*7_&L0,C@T7+;'T#8B8%X8[+/B/4IX;#^Y+7Y"><]\L1Y
M&-70HVAKT.?Q'T<D)/88ON4-W>Y8NKHVV9)HZV'3RWD-LOY$'1[/I7^O_2MQ
M!1[TKOD".R28L,'QL=7B'T1PRS_Y CJ_6L#5N,X5T+VQ/P@#$_2@(]P='M%G
M?H_=:;E\Z'C'>DJXM)_$M/#[O=83?'-[%.5/QX7\UFOX!< 0$+Z)VW>'[W&O
MVOX[D26MVC4"Z:0ZE%;YQD*,C*&+!AI,"=4VF<-(@O[98HVL]+FG-)L(;)2Q
MX.U856VR+=?2,6,;REC'@\1Y9_LKZD?;.A)D<MT06%?EL0&VXT-+@YYEKX5,
MC]6<+(^X!I<09M&?DJF5-C60Z4(QQJ*%P5M0R=$K%EXE<LRG?$T9ZN"QN#M%
MW])+@-I79^08]&<DM5-&_4^3EEE__6H?+_M2T 7EY!A9 1DV58(>UTF1E-MX
MH5AT&3R>%_J3R9I]"N<7X&8<\Z7:'XVW:(@P[GIZKFHZW-^Q(VI0<)-/WPL2
MXA/I_Z#[#RK>_];\M^;_GQKD1IQ?3U$XB\G,FGRT!<,D.B$21#)ZF)"F@VMQ
MPZ]BOJ@1(S=HC>$F(AVV1T9]=#&)(GI,J:ZNW<[9-F]14<-3HG\5(':U$3,B
M>,Y84":Z'6<-V([3\M1BCT_KU.Z+U$DJRJ3S)O4YB+6N/89W@FEI\))I>? ;
M\.L=S@]_AI&-<!)O AO($X@X"+S(R,35&TDQ-<GU.1G>]>Q^N>L*)]O/HMG0
MG-B &[+H0$W:$]2J!1\YM+O&2K&'#AY"E(AB/)I$F7.TTMLH%=SNG-4'49B"
ME5HT"'AXH?]% /S%*5-IZPIXJCV[TTQA9$U?==8&\E;\7,VL=X*/MCY<$X2V
M=A/8Y?O]_+;$&TQ+RLY,%/6M2"(1&]L7C[ UU&\CK7^P-$57"17'1)?-JD0Z
MWP'ZXLI(2^([08:*-*OEL9:PQP:YE0LAA\?/#-$Q(H?GYYEXVG:42SP6K)@^
M:1PY?Z"\X;QEIWJ7RZM1,X<7242->.-4.\>IGM9"4_@3;I.-6$&-A.M]U OO
M*+]%Q7.E,K[ 1G^XIU0E6W"N1. <(#8_2-,4F=2E]UH[@\J.W:B>D1\.N.G$
M7W81H,0\K$TI/[@8XZP!)K*\F=)2Z!)?05:B1QE"KE"YTDDMZ0%A;&+:%$L@
MB((C;UK;=EZJCE,;2T[,T.NOQF4%GB>N3F7F4;HXV1()CM)V$F+=N<Y+ 719
MPPPSNSH%C=>"#9>NFNXBS)'K)4=*I0]K4/&WW=U19:OKT_)$NW!3KH8.D0U=
MF(QE)@&0_N+!!?M8'<H3(C$3_I N=I&UBCR_>+$:A':7:"*934XF70IR@I0B
MAQ)$K![LH[NII^;5$I.2D)P6"AQUBTM"F3E'D./.P^&S4V:R;Q07R^X'_R4O
M22!Y* "3F5;%7KT9L9;2I?>X7>N5% <1IR)[:(U+QH7K#"1:CG; /1234X"D
MM=CSQ&-&!^L#50P6),S_,:"Z'@5S3I@+H'"$6^+ZM,3R;%?C#\G4Z/SXA:'M
MB.V^7(;[72E]5#Q?]DI]C9SX5@9-%E0<$PF,^)9U+E0H[%L51LH6X Y4-/D>
MN^Q$ZIU;6S\DS,%"$5$SJ2HVT7F<7L1IZ*3@';/ZMUJ;$?^W_ @N9'T]A/0:
M)T0.71)7XJCNC0L9N)[TH(1V$D)S A?]\^" 1ZO<; @!X??$1(C[4D^^9&$2
M>NO2S/+&N=P]DI7-7YU;0M9'-[.6BW-E73R5[^NH?PMC.="DFGI_BL:4=$?;
MV(B^VQ+59IPWYE[*: Q#!/NI\RAKM"N5WD='&H7R^+X\%D_E<$<VQGX!SK,D
M%\5/D>7I7A9R"W_)F+UI!A1U'PN/F1D6QNH'4/51$D ,YH??U<(O)#8H6J(W
MNNG%3WR/,[OE-H:5KA&(]?/5<4^_'W:]&H*B$V)HEGJ2V0QBMOO&$:HE2H8\
M*]!CW@#D/HT5#H EY60GA(J4_I7PXP/M%U@=5HPV/UU: 72L]C>YL@:[;M.U
MQIIZQSF4O09+B&)3SUEEV>*E1B$6'DZYZGK PT,96X"$6898=T3#LE6P%QN#
M4G=_DJ1R5MJJ$C49IUO9*=&XS[<_Q'+BTLI8F!YP0@$M27)B!JGY5#ZV:\_6
M2T+4)@I+L05_-]K'2HT:G 83+7O-;MNYQ#AQJ5-4[GP^Q'1>M]<,'*/PM[M2
MPN+<2<.$Z'*'!OLDR,"A$)+G6,9X>N-'D[= IB3TR#B'3,LP'.;B.BS4B12@
M?H<))!3F902S'[M#Q:N8(*"8M@H>*K]-'OIBRX0;Q&-#TX!6),-R&<02;D-V
M,Q'[G>>"F[(8&]!C7] B:!@EHI*.LF8HCI;5.L!9/KW1$F\I%KX5CM4*]5?Q
MPGJ#7_;BK.P]#]P;_7K?O.@"H8AM.M5OXDG>10_T/\C[+7HH34M)+6"G2D@H
MFD)Z&+&]?X*_$<? 4%X((R@<J3 'S69WP5!@'4WKX3==*J?DGCPF69\O+/,S
MUFFA8DW3<(31X^3VI/0P[4O.R_UJ1AKCK+"@'V[=V!#-3BD+4=1-^A::#KEJ
M_#8 &<)<I)+74MM%Y#M>?\CZ1ZFJ#'TF=J*J34T#(Y$VHY21K9!EH%9\5(ED
M3@L.\BQ"XA3&S]44(PER<\!$RNKTL\3ZHC>P/$N3.DP_>HWM3'6V<27N7V%1
MP%\DD@AJ7O"=QY$#W2 )=2[MZC%F<--7'FGMQ?=2+6SOOR;)T6%T</F3X4AV
M062A<72CZT5I<FRJZSX[Y( QBLIQ*83!9:8ZI5L%FKMOJE9T'LDX?X!_5=,
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M8"HT"XVN;:0L!W?L>OO!UY S4&\4<K&\7MFF^^["!>N(B<47KP%J>@;CXN7
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MA"63ADB2^A'!W!'R(S$IP9<NO;@ZO;3\V[1]3@RZLLV4%K7+@*JJ8AU%6:6
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MQ]NCV2F\"7Q_1UM>PH^4(0F<X:H!1!2E'I0M1TI:OZB_[%Y<G27PDXW8P3(
M+4I0U^HW2J7Y-"*BZ. GC!;> "I?/Q@V>7'H R\!<?;6Z^\B;X^RNF?6J/8'
MET,49OU3CJ4FM*EYO?F<P8'\PP&&KY .$[[,ME040F>(L=P1M!S)"!SPHN-9
M:LB.A'8\$M/ QN69P1H-F1Y&\)53D2,+K OAH/U2"&2P1K3_A9T)OOH"LUES
M.1+FJ*&OH S5#H;NE>R&X P2<V?7"S."'1#Q$\;T7;1E)KA0648DQD;ON+45
MHNC28GZ0Q#=;A%"%"SG_E)DX4(\)P(4=^D,K$Y)4C6DBV2:JSD:S9ZV*LQ+B
M:;[8L:B>-F-P2UM_0VM/Q:M)Q\W>82:G+3$B++O3QHAI4AN]/E0RG92B(.Y=
MI:ETS%=-EF.<A]O60(L6WS?.]JE]ZP/,(!R(7K'CM0VQ^MP'YA$#_:F!Z)$%
M@?1^BC4> ZU<M#MA \WK &\H+!3ZX_>P_8?.FX\[$N)'4W8[+?!=1R;@GJ=W
MI+D+V*]N1I/&TPF2Z=*[MA27Y,J+/#4(AY2^2BI.4@6+A?#,ITYMAL]W=$*K
M*N)NOH.H-8?HBBVX2[9'*H=J%14&R;#>>8:IP45*6AC?#!DCO/0S2NB]S&I5
M^69_.P,/[AN*VA9<]"[NSO#/&XSE&>1ZL&43T(?!X$BP]DQ9.@X/%,AV6,UA
MRJ&O(P@'>T(22Q-4+AH28$#,?UC1P$9!I]!R/9TI9P&6DTISQEKH/1%Z-HRG
MC/\0E?5-A;29R>24ZBZVL+X6N[?Q--2.G=?G_(<^!069>J ?=<_[]2>X*PKR
M6W/>*]UW_P8/X+[+WSLLS$<;Y245,*UQ"M=?\$[ 3*L=A1B&?"8[*X07.-3S
M?I%OK>L6-%5\8%NO?DA?)TB7(&>=LF*FV"PK=%WE.JN[ 7Q,S%TMZM^VVT;D
MN<B1KS@2+^-K[#^_*1K,(Y8M*LI?W_<YOBUWM4C1PJ4JJ?;2^8TX0;SI)WJT
M/BX^[:FOJ3I]PX,3-FJ<K)_FC:H<5[1H_KQDW6BEP9/J**MP"SGBQNV'/',F
MK@8LMGHWVO'KN%$G%-%%:N]^GEL6%4'17Q9K$-Q<:KK!#BV?8KBPA ;7BHQ%
M,8>3\]UK_+6>SZHL767S(34*^4I7\ZK5XG#X2NF<M*0VJ^KC4.QTJH0L5K^+
M^ZW>@0(B&8BZG<==)E.+$=$H#=G4GDG;8ZLX]F4Z&?GBW,!#T1?Q/.Z5;(42
M<2/'Z,1,7\\/Z)Y%;?<-@IHMKS9?I?*(4/QP?]%?Y-S"%V$H>"AD719YI=[>
M&MSR^B)#(4RF$6KXF>>@:DC>"V?.D&<;9.9*=6)Z6Z^:D-#6&@QCCYB!S\ H
MG<'P!D#[W2RZ?LS:E:X,YEY(JCTI2Y%H*-JME+FJ2,G29$P,1ED"66'&$\?H
MPUD$8X!X4AJ9\=&LH\SOO/'/8QGB+1_BB1*E^;WAUXI42LM!@Z291+V374)2
M#5ULY_:DN&N>!:_GG]D%M<P47H<U4PC\?%J(-6243+ K4I>'K4Z&"O?1M#=:
M#;M4QBZXT50'?"BR;AI/'A>%QD>69[$(=-15L%A[@U:CI'=9!K\M0R\.FK6[
MD!8P4ZQW*I3T'<?]X7<SN3'NC21=05'#ZP''(PU61\EJ_71)W!J7!<YX;P J
MX6*?*AV1%U2;YT0+GU?>@PNWC(D#F==IYF?SYTFW7<%S"9>1CF.G]")]1I/>
MR:-75N:P_O+I^$> N2:K81L0H=?NFXKY\^G*!XE(8!_T1@G;'IH#:5WCKM\[
MO5HJ;DU497*:I\PDY=2]E6-<78R1],PWB-B5'\F8>\+&:R9_!VP&3AE"N-FE
M\FLAT9(@2 $0R- ZJK^=>*0Q;C-]*]#\*KWO?^C#S:I^>3E\R[C7=/"4K?.G
MX(*UN.AH79A?N,A[?HU,M=QOSA?N9JY39W"0=JXZ8Z7@R,7N*?9G5T9JN?O#
MSE/RM8ZSC]+?;/\'O%F56SLRXER5+BO;V#)H]Y$(S).E7N7VOS>XH:\H#^W(
M(=$[402OT+WS(NR(($'"YOH91#^K%:=Y#1.!38PK[."&0('^R[]JC->"TB1#
MCNZ2EHA/=KZ]<5H($V1HHJ8&P11?HNBN__ &"+!Y _1MQ)_$ZR\%O@%Z>-X
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M\\64TC S,4N^O[<@YKB](*[@_PJY6\K\,0*-!F&52:2@8%@6F(8H'AC.8Z^
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MUYTR':+9'3:,7F'J'Y;097F%R#"P9]"WNDMRJVFHS1E-MPVS[*ZW?VM#@&1
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M1T.7%G6X4GT-49>$R:Y9*FYWF+.&STQ/SY)"B^?+T&O G&K.8\[A%6>.HV%
M-)/;(E_?9-HGE<Z(0H6&5]XJPF(+CT&B=7@MZA#-*9ME4_X5$;2M\SL\@[X!
MQA7Z_F1"B7'LCOTL?/JU'XLM(CTEU4I,,\QIE ";']C@%ZEQ3,W? *]7//8/
M7\R'X5(H(D9:HP9R^41@[[!?X*.P%F$K,%F'-@^:K\<,=!;M=$+04Z(2%2I;
M6#X!G\ 5+\Y2^-H@0KW.R(\GQ$WX495)D(8:2L>G2YI?UGUU@S$S;&2J4T-3
MH;9329R6Z#590"QN]GN;JLHNXP+!@!OWTT :%5%7R5[-DV]VU$7:377DBHJ#
MIN^^-F).[VV%<7I%Y\#:NUH>LH5D8)K<NON5XN)J:F(9K<(+^F4+-2H58"IO
M=I%\,=Y32="WT:6[C2[Y%-?ZGCN"E,<,ZPF&G*5>-MX E^]%A\1$K5&"12OH
M!I^8;H #-V-0)TQ*_CUQF%'; MHP_?Z87)L8X@)/*G9=;VFEMQRUV:#R;QG#
MGCWV@"^J>CX&*%ER,?%(V#HJ$R8P2G14@M^H8,,$0@,IYH0KI9_=&.*0G0\7
M:M*]T?\+>:OE5'3\0?'R*%)::N0QRN]84D7Y[.)8B8$Q/UGF:-E#+7Y]@8O#
M^\R-R.2NM+]81]#U_+U':,Z=G@2;80C+KQXKL!I=KPF'4P/S1\6AN!DZ/AOY
M:"0JW!B)/"X#,O[W15X3%#?4:&9RFHMB%:4OBK,2.@97=H!2[J@,NEGWC>2J
M',O]\3Q!%Q:^I^H2"UQ'PCES^14+1+X"3_)Y:1IN"<(CNA\C*^88Q;]J2+@'
M;)Q89\+>QX>1LFS&2+>G?42Z*?="ZAX( &G(&>KR,&B .#5,!3%#YMP9^/Y;
MSP9%\RG#RBLI!/TPQBMS=DG?VOESM>&EKA5^=]&-J8'.QYG8>W#]2;]6^UC!
MFA2"E/T*VBM9K<\D:TJ77V.61Z<9W(8V1JL;>;9)]KIB<C?+<%21A^2(_E,J
MW=/LL9[<JQK_&;ID0O POV[!7K5C5/;B>:!C^L?;]MMJ4$.55;G"D57]SX):
M4KP[UK!H'[RC\U#=^ZJ4ZU*2XAW%?+\F5YPF+H-B^_OR+,)"%C'^ED$( 1FD
M0L4=TO+5]\APA&_%ASW&NO+12@\G$^?:-8N_%!$32>"CR:8H"!06!I6NQVYK
M "GR1Q$1"F5B^A)]*Z3X$E$1*1.3$8Z#@1%1)1\CQZQ2!B:8=-;=4!JZ0GR6
MUO +'==:M.V*/*.5-@67I6(5(XF$CU *)6:J,!>PC]/"K52]&])LQU-4J*KE
M6L7HD18T;[.H+E>P2II=^'SRP,EJ(962KD5P)UM+V4@Z.-(74^VJB$,<X\O<
MAT2#K[9;^3"#7OR):C5S3Z\&I+TW)HS$W;R::KZ*8P6"'.<A>C,]DVWJLS_T
M=6Y[\UH3.JT.AI!94<^?-[9[&2V2/F&GV9 +GQUA="T2QK;4U7_F(PI)G,Y)
M:O!:>M[-8/!<SE$XUE9?,'/R4"Q#%7I6!\;9#HN%QL><%"MQK*F-4 DP&[;W
MN#CH(@L*&(WYL0XM79*#ZTUS<>N!9$D!Z9\+J2#N2$]%I&E-:6;<&A<_+_C?
M ,-;"\]O )W?@==V0RVB]ZMD&E^X.R #SQ#6XOY5KQYZ)V=4,CV75NC]N^ H
M#.JC5Q:]PF@E*[<%=H0L\B^V238D<G(5<E]V%8,:[=F\FF.:33=Z3^U?U=Q4
M;>JK1XOC#[DYXHECP^*W*=?#74AOPG:<XLL"@1.0?!K+J2=86D[R=\ &H]Z0
M"LL'N?E5&T)(2R5F.)BKS.J%MH/$5WS&S\4MMYCX@M4C%WHD>I%SX?*()OL*
M7?=-LV?E?.J4$<9:1^TF/Q1I:Y^<187;\],H^]#KU;.P(T1[K^'Q9/BS8_+H
M]M.#LKO 2VCAGZ-S$04^O/17O4):!:2@P[D[>NR:3;!/OMY@$07<\#9U8]%F
M(#$?L21L;K1/N5EM2! !8YU.85-9BVA[(>^5L?.LJNXVS$&TFF2^<2VB<@_E
M?^9"^GM0"B-::6 B.&O["IO"\47-T))E#43A>A7ZB0'Y58QX 5;,:!N&\(KA
MUMZ,)HF?I@N2<I-,N'L1NO6EEF!B.Q\EJ03%D<#<'$;8)JU4(^?&XC<D+7LE
M7%$"?@6G49M-8YFR.'*?VRM!(PA9JJ(,].6OMW9Q^4<,,<S+G2V'EXJTEQPH
ME@.L"(ME03P_GQ^,39G#VO6U #\BT>GXUX&8RM#!JDF-<QR#PW:>T19IYQJ:
MR!"":QOV@HF5KY1#^+AGYK*TTU?:L5PYGW#%RF*L$NJ^RHUD"4A1%"AH*(R+
M%\'(:@NP-MHSA7$@#XUHMTA/[]!UBB0\3PT%5QS9$'CQD:^@ULEY#J6=Q(:D
MI$@VI#9PR#A6P>YF>6PB$WS)O&1)U77]:E90(I[%4& GLP2^6Y3$$V*;5]73
MO_%BRY"IM]&(E6#"E*<R/?C<0+\V_#V$ZM3#P?X4IL/W9A:A#9F,R<=!<=V<
MFD?ISN> ;<V.#;GS563ZKX459#B2?/S67"A3'<4%V+O<9+*&6WD+6@D&MVFH
M?9WFNBA(E:_8'7A8F-#J':DH=@4JW@V15/UO8Q(=]X-Q=M&^4"0*1<'Y,(QC
M^<G)EH KBBXK74Q*3&K 0F"&H#FH%CMQ24$(6;(]Y)D6$L80XJ**/^&=AB-7
M9 ^"0#:5/?,TLG31=>CKWUWGU-S521$$9@DN\SV5)1HQ@$U6N5Q_:WW6ZHC'
M?VFMY[76$30:^,K5AZN,"5TQ'?YK4#9N9%05'2KNIAO)6F9*//-+-%=T_E([
MQJLQ.^C"@,T:O&R'+'E<MRB=9<"EL)M< \B6$K:L;YR7;.RU%GM7MAV!B]=Y
M1G8L16\ I&<-0RG!3AP*US(8'Z73+IDR:BM.B4@^V!.G/<R>*T$C/08)]EF"
M0!>I9#2Z=B;5?!+.)9)0#*8>TQ9EC(.[ EB0T[1?WWA%<_: Y\9MN]290/A*
MYZNR;%5;ZSV>\>9UY8GG';_ZQ&J\3WAW9:(78U"_Q$>VAX J<*M+Z-Y%4RA2
M/,4.0UMJN8=WKPDWG)O1B(UFKKJ@M8 5QXQTWI7< A8F\YJ1#OVO&=&@D/BD
M-E(H;9VBO6R[^NFL*0E(YAFQ9M)V2 B" Y:'=EMD^N+0^9 *@NY8Q"_UX#3^
MYHLA)0G'DD">\<@?JF'*RSR;8X/ER*1CH#Z1<2\:_J"_>6>]16@%@Y9=_4.^
MC#\A1WJ5VYLJH=/;C?I&.R(X&R 75O4KMMG$?OA;9V8<T]O11MF3.T::"/EE
M.(C^_L>(^&3>^CO%"%[:?:N"3=@KJ$O<-:ZRY#P4!TL##)IC*,O3*%@O>M%S
M>L=I#-.0?-QMMR3WO;TOR0T'V$;<_Z<-#1J @&6YMM[.6H<_\.REB).9[=S?
M=]!^-;%I(B,%_NL5W@"A'M_>^R'#$R(1, @V1^:A?A3K)X84T3R#E"4]ISR5
MF<KPJZ.5OO' ?1B)Y62G9)I5*/DTIQUX2\R>^4(SA -R9G$!$WKO)#^HY?UE
MJ6DLMJ+UN_^-5H<WP]>GSZ[E)[JA6QU(57]S\OY'\#+J+IW-;.X9*Z<R>A..
M-8R&Y'K EZV;L"8N=?$# H/!/T]*KQM5O&^*54#SA44PSM/%+3<1E&W'QJ]J
MO!OE\2"ZL-8[FV4IOV70P7/.'ODL"9%K?=&:\7VK1LVS7;-=]>>9Y?'.!0OI
M;5V-UE_:BF>)YONMV?6,@_&IM1>NO+G/@XTB)P+K'R<+8UDJLF[6-1+> &*I
MHSMGCK$S[M;MOF\ _YS;!<N_C(WAJRKI/[/TK(F[9#,%A43W5V0%Y6#/T]\?
MN5EYM:JZ86*1\3KU+C&J*Z'/AYN5/L4T'RPBQAWF<V9,9QN'=G:$+E[0<=#&
MT/&JD+&2?9QGN\U+CI"Q@),%&N/7G'7-IR:9]10]9R[EK)Y4."/C<B8&18MA
M#4Y7,?EM29:J.#\7%IO\:'-#\5*6+@^&RA)3,V1JU:]Q&**DJ(&,&LSV$B"A
MZ>OO@N)#M*<D[CZ"9V2&;:\L=JLQ(2[EFMEL*OP-3DUK(>.\C/'6'1L](C;]
M@5MD5'<='DQ\MW#AGJ-^4K)X*#[P/F2%*_4;_84)*K-,6D12EB^N;2])3>#H
M0B[Y:E=@*K@X21<'MX31;NBJ+ QMUU'EWJ#<=ER!"J^]SW'=DA&LOBVW(/0U
MJ O7%Q>M]'>4X,S#]P=C[3_/.?@^%458]RFGMF9Z]T@3#4'&.DKS5S\EO6*+
M\_7&)TRO8U^D%_&]>85'W8[U[SSN&BL22<;? )F5YOQ$VDHBL\,[5Z5C)=.B
M3QKZ,4^OQ)]9IQWD\%UM,FI:_9Y=LO$83<=%GP@*PQ-'=)\TNV!T@Y;=[09.
M5=^#_#"61%[F.W"[7@5]4YSLUFZ><]9N/;V-M5:#GR>&;G8>S%HR/_3YZ8U]
M:>OEUAD"H)2M5ZK&Z6:$2M4:_]I+E^ ,>9;9_G"7),%Q)/!,T6E->0Y<60X$
M-WGM<5^_H@F#N9ZO55G;[O33HI[C,8^7/"E3CE= ;7?S,7*5.#@,/DC8 E^^
MKXSKQ.4U7:M?@Z6X6;GMR]63)8OI2HOI'J+1GY09[SA+CJK91W?N;GV-M[C$
M#S]7+T[D0CJ0<]:KQ[REPGQHDY\)9F\U_HOH$3:-5GC5;2S@"[GXF^7!?DE(
M?I.C<6*F#-6#5[;3V+.M2J^J!:I!Q\&!!'%&W2&#6WS\*:0CP]8PQ-_? .8F
MMJ3Q?<1M-Z2I4!^?_;SK3K(*QKW'1SR)? I+.0+.@/_P.,6_W:L^LM["VV8,
MBU#C\TVG3@+8JN#YN)T)JZ^VLQCNZ7)GTG#O*9>%@-(1B5A$B=!I(Z]68@6)
MM%ZD# ,]L=OR^;(:S'(PXD)'J[^S.CQ.CRQ+$W=N9Y:-.P8FCVT&](''W_(/
M#E]E?QL!D4J->HOM$M1+A!/5EWN.Y!AND0/)2^I0B8"5R9VBC=MK9,@W>3X.
M,F*FNQ!D IB.[\GJ"Q+@.'U?^@Y(Q##47+"3)*U>D(M_)[$UQEP?)(NI)?8S
M#8WXM;?:E4+M>P8$HD%L-9GIH,P]@Y^4G;6;E;+4@EID(G>?+-_,'.$<_Z%E
MKGR6X@N/\%GV\I<A$_KME QH_W*BE!6PD-BNTP1"6+4S1X&CR^/'TBEP'.ZP
M!&8KJ71*Y*R#4F=6"U'7$A 9!H=&VVY_ [OXCX94KE(041,V.\44S:,D 2GX
M? K<$K)XW0/.WU63(E5U_,ZY9:]=__Z+K"->-DT'MXJV3G,L7]CVB[3G:=JC
MROY1/?9!ZJQ]7-L9<?CF5(N_^M$@A?@J(,ID0XKV=ZR>V)?'NCQ0G^G3817C
M"C+B3G^FPUAZK%75,K<1M)UGV:;KR*; ==@\0. D/],Z/],R)V-;\+QIY33+
MS*9I8FG"_=/IO_=O-";JVG1MZ^<,THOLL*\G7-TU5&T2=)%[GDQ:'6@&(%$Y
MF1^WA2$"[3N:V*2;HZ[!NG0KJ F* V7E^Q:EV-TAP7BO.LUGY<MVTSF !W.@
M'[3=]ZBS^)5@ ^W_Q5O8FR0'QWF7XY$!U+9$F/?@>].OTIK/ C).G5@:SMAK
M]?/.5^.I"Y()0)([6? EI.PL9VG@R2;J'?#_:;7>F2M^EO!,U?EHZSJ8-6$U
M93M$15U6!GVW&.8>*JEA?;@%LX(5#Z+48I$TC2(3E(SX.[(^EO-W9-VRZS#8
MXB79)S15?P4/7R;2#O7<+-;S>:IZA57QR ;/Y:"3PL?JQC=QBK8[??\Q\S''
M+7'BFN?:N\O6._LW3#)6FXN:\H$6%&O@-LL/:5HC#HCC5V3Z!E@A3'Q-!Q1K
MN3= 64C#::91+)^;P:G./;/.+BOF[YBLJM1 S'\G<CA;(%@9S?ISXN$T/HF4
M!:TMH."'M&IY8P U;BJYLT@DY55P@'[21-*OF;&'>9/)N>*?X?\LI"4$"7Z#
M2N*C?'KD>CJS4KPW'1_-YOK- WRM+7ZFR'DZ;G*9X-S;YYM,_.L:GLRW9Q^7
MY1^!T#[+.T%H7VB.^6*P\ROF&C$T7K.=_9;YYM\  7SBBKX\^EKHP.X*=Y;[
MZ#K2+*\&'\%@E<I70H0G"9>;2/J=R;24'-?G1\Z]XUP:C_KF5>B9$'&DO*.H
M>D0:[<Q6<=>0Y!L@FTW__O-9[ NE=,Z>B1_M7],+DM]+-^_]TNM?F'CP9GBR
M%!VH/@F[TK%:_E9[Q5^H#CR'+O(<@DF32K3]B=XS8U"?6701T'AINK+%Q-K'
M5+&M:#ST/LA_-&0RUK6;#)_8%N17)DQ[ W#O0PTH*AH:L?[ LEXM2KP!'-=I
M]!?7?O_9NMZC/W18;IMUOV?>^O8:O?8&.&,5AANT/%;<7FT.3[WC=7L#M'3\
MDWGPKZ?^BZ[@";B8-'9&.TXLON^S8J_8YN'*EIAIO$T\I+\C[3->-&Q*2WD#
M;'6-CCQU]BEL_SD^M#^>>@-4'[H+$4:$2RZT+"K#A?['_W=4;M6;,KH4-^!G
MNIS#)XGF$<O#_>-L[YO[P?-I1>\NU\SM^^,F]BS?%WL4BR;VY1$;[0=G=XFM
M*2FS12]DW<?3N!DM03U>F; 3=_,DX(U[EL5\F-307D!<9BZJ^A=6PZM<!W?@
M4J?)<DSH)&P1>Q5A4R7>>MKU@<"[TTGT$)3M8Z6-&I,0//QA#]F#;")!'K%.
MAT8W\1%=IGD8X1,FSY]+T$##I=N0?-AN_!M!AEW9S!+8KYB&\5_ZI)NO%+/K
MOXYK^I*K+@"^\U5D0H?*K+]&R1#'^/O>OP$2Z\V\F\M#3;#J0 MJ6U9-K.^M
MZY@U6Z@)< 6VHC$7<#\9<#\85DOK2UD?0T,RZ\J:.T2IAD1E-$%@*P)%#\TD
MVKR@W@K%=1YD.:WY@\=-9%G9G<LL-C<$P\\GB-XCBZ%I_;N5C "[@JK?'Z#3
MLE\-&UWW%AY=-F1T&$27/DRCSH7'BO4&.*-6IVY7UX45IC^&1Z68;R$INO\Y
M@F'%(L9(QZ9*MX 0TF@]FP9Q27BV88N[(!R1U/;];G>FF.F_9(X8H3[/^*(E
M&^H9+*@O/9L#3W<G<-/OR_(:JUGO;\P(;Q?[4>6J[J?H!&\"R6^,M"(=RN\"
M? ,T]0D[O\(+G$]UN9GIIT%56:AC?JT^U6F3][$_\]#++F3&YE$))QQ(*LS.
M-,7TVAI(!BL9H/0_Z,=J+):X2-LEM<P]7'^^DRH41'5I3_J5[H$=H"@6+E>U
M#'0ZTG4V6UE0: 6OD6P*\I1)#4,."A"R_+^N:$Z,J*LK\(7-H(8@:/^,DEXK
MH<T*)IVOHB@+ZILH/C/^<D:<'[;\FB=UHIHT#!.=/ZW>G>-#<$.AGJ$VU'AF
MF]Y83<0F9BS\@3!&R8LS$@%35I([)(X(I8DJSE(8=\/X8:2._6P79_.'JUC(
M+V+#8W'#+]EGT\[[DPA5E"CZ\1&]RZ]O ,L>&%49+AQ<UE\#>'2%MNE9&(P(
M7[__J4Y/BI,3&-GBT?:L\/K-\AK=% TOZN\V:4GUL>%_L?>6P74LRYKHLF4Q
M,S,S,UF,2[)@B9F9&2R+F9EML9:8F9DM9F9FEJS9>Y\S$_?&S+MQ)^*]?Z^C
MHG]T=V555%5W?YF5^>4#>(49AP_'3>?YP=GY;'JY\J)R,RN]%TK;]>J(+_:
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M+^G/0Z\0,6L3AR//4:1(DL$OF-GC;RK*)"]%?+T43Z^^ 5*2Z5SBF4^SS@@
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M)+U$+/IG_@/@N?#7!_3?OOOD!K[PK^KOAQH?@/&F?WG\!T7[WS&?ZS]F&W\
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M&:AWPRV+OOQ6;136I!0A;3=/'6%S*8$F@SF@$U$J+C%59S?KQM;Z B'0AZ!
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MZ^8DC9GD8AO-ZZ>A6.7?OE=!>:MFWHVBD-<@4;4C5V(Y=C\>O-00Q(LO5FP
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MZ#_( ^G\I[>&H^3_6:*-<OCSVP>1K;.[D:W#GV24$-B!'<S;70.E;J2M];-
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M3U]A*;M>T7Q.!;$DB@W!+ U;Q3-X'-E&P4JLRY0D+S)[9'0+-%(@==WOQ B
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MYQ[<3R+?3V(0#. _V-CN%ORX<>4"XY"#F-YKA40%]J6HO-+@7$CD,@\=Z=O
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ML-)%OD"L7B\2*.2\.4K*65HM="^CD&4O1O?6FUAJ6@:?MW>8:9)]T)'B!ON
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M!CD?;X:)/@UPP@F.:X)\)S>H(SJR//<O%_P)E+FFQTI)TS_''?)S2-9.3_Z
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M^7X,N>_$M=\_@(,F&@_PH ]-R[8-60NL^^Z)7R6_BYQ] R^>[K3QYVKD339
M;"JT7_<Y/.[$OSN,7JRX)O"""8E>45DKP/9YDI^4 J-($(,>'_RY<6/W.\($
M\0*^PC[7L/N$@0[@,3@'E1<GL$/HVCX";-\%V_W'P]MQ=6D.',#LX#]I?4O9
M- 6)K7JFG.0 (G/V!9Y?O#[]A( H]X61Z="7JU"$7P%55?8T9\4N<P6L\G:W
M;ZYC7)O^*:B7_-XCY3N.>.,*$;LX?/7Z7CX)([R#_UU@M$<^X(9N0?=Q3];%
M4$I?+K^2FIW+US^ A][Z.40?[1+75'=$6*V1N!=RJ TZT,O7Z_KM<>_:FG5R
ME"#]DZ(!/$;,O_H'>'ES3]$KXQ<C-7T!EN 5?AVI_Q/PIGG][ 'E=+0*U>S7
MC@7M]6)W='J_D[BS3WC=\/"W#,(EV9_O]<2TUT2HI]IH%L 'O$>-?Q5N/EDD
M::6TO[:+&!Y-_ =0NB(3N&ZKH<P@Q("_XQWY!T )_.1?5F]PNUC_$.CT!5T>
MQ6XG^AS2O$8Z"ROOG+9[>YV93#D[HG"O%8!SKWNO[P-OT>>0?/_XY-TNFIXK
M;R;%WI:9!XHVIM(G\OR23%8X6F//_H68S:Y?)5<86B,W@*!49)9B?0H6"2 X
MJFXTNSV@9+*HRZ4HC4LO]3"FSY[Q8CYD')NJ$=K 8(\OI_NK!35VUH=6C@]8
M5BPN7K-VC.0BU*K[K:F-;:Z7ZC:&2EB)2@@8=HXE3,N283C$\\[[_G!8<R0Y
MIL<G:L,E&EJS4EE?;$PX3  R+),62*L2E:#&8];EB@E,2O1_8HM"?T+^Z7DD
M/@;9F0^$67U4(;I%/ \A7ISD&AB;)$^7F3=-6R^!Z<CGE. %PN@91=>EA+7@
MIF\XE8*9TI-^P#07M1@@:<XL_" HL8U6I74WUU1E'^6KDEV5V6)=+"XOLL%C
M)1!M:!YN"<[_D6:7!"N)'%N%64N.K34$#-U+RK%>T6N49DB!2+;=.LW)&OA&
MIZAZBU,/'+H[PV7G9#&+;*8[3"R6- , ^#YX/%]GM"BQH1%&X;[]Q:GD=']3
M*+%QPHNV967S#(VABVUN_AXK6TT;7JK<CAP;:'UI=]I;GM.I&7K9[D$ZDWYJ
M8^75&G-V3XTJ[& )X%*_4&5(C*KJKEH.8=;W/U14D^GO],&DOK8E[;$_P.*_
MJK2=RW2HH^"^R?DE[0BMS''_(K?D:2*VSY ;ELA8@50EJ1N//V\?.G"BT)IF
M;Z]ZMML):=:A%=:>%9VX>4PD?H%Z2LE4AX>9-S"P]OM*-5V DZ&FB#&MU]&!
M]PC4A44.IMLL,R:8X&-C#5JXQ$ W"4J1J&*.NHP7FJJDZ $A.R[_ V!LNE1Z
M,E$&7%2O0A]>Z #];5] S/G.2FNJVU3=0V'>*&P'@HPA-4.RE2Y5DR1,+4OF
MRC'MVG5>DD8M\LX,L2U!HB( U?E'YW+5X-(?3?6KF4FQ/A3P6(44;AE:[SZ6
M]JO<)XZG+@!\\U3T[Q>J6 A9\*)OF(J+-0_5O+:VQEIV>W@:A,ULGU94MI!W
MPC_=-_,Z 7"I7'8Z_P"ZO06J2U<D^V=[499V:6C^)2J20E/*(]SQG "ZG<<8
M3.JEL[JRU++4&OREH"9C-JS7V^]:L&O:UL9Y, *M!UO"[,'GAD1)KXER1LB.
MS\)GOC@.TR:3MD%EGV,8I-[/?EJG!B?7\S[/$;MX5Z(OQS\@.K@7?3+;OW\E
MZK[OA!Q@G9*R"5MF%QF\?%UM7T[ONPP7H&8,WW2KWWZP!#3NOPA\D7)OKEU'
MS^70:)[=S#TQ_8@9MT.,42RX? TF<:$<-'W]6$12M[B3T"F0:AU>*M%>Q-^R
MBT=-L.7TJ,NDLTQ,>U]B.F.MN54JX5HG;YJ33[+&O43M;*N&B6W4%IS2\>TM
M;LW>]_'((M@%]Q4=XP\T(G*N-(EKPFE4A;<O!=IH"8A1K/<L=(]C;E9HT\3S
MFJM3L#'U_OZU'OXWA1'.S0)[I>;WJ[A>C]E=:YP.E/?GL8H&!;)J0I2=F?EK
M:5ZVNO7U3F^/+']BA:*,E%'E._:V(']*9^YTFRC7@0MG6(-XOVGP9!@?L65/
MHF?Z/$R2Q2T!#>:IY+%Z%+F$=C+/TD'XME2N$I;L>?BO(W_GV9I[>FDLZ*1Q
M PF$@^0;*7S+'(%8U>62C'1:*>="XRS3BD;SF1YBJ:(!'H)N'7;)M(R)X[X=
MPG38(4QYAF>(0458O [5'\L:GR-K\]WZ02E.S:S:"5'52KR<#%[H)HLOPZ:#
M9/?C_IK25YPW%#R06K$.G)2JC'2-&EG,E[,"+.(FFLF>K^;/&E8)+M6[H2"D
M,L9ZT%ZHOUO<YQ(V+G2Q'#TB#;LRE5WH;62"@R-V,X_6$>LE!XR7]:WQT8J5
M[J\\%;J_]4WH^4WLH5ZD;H1#^\\1F,NP&C:<,\L$$UQ961$WUOR^I]C%OT^Y
MZ%Q?TC?7)@]<"JVTIJ<^1NAT1)Z^+G&[(J\(/%,>%O&3N1(9*G\FC\Q?Y97B
M,HZI1$J@!W9WW\%0&*+'=L_#YT5$D%(V(^7>E4U:UY7_S\:)/ZFUI&? L@4E
M#"DR9;0?-1LR54^#T'"4[LWT)6)T^S)1\29%VUH(AH2A\O3D%"1<W5:]MS&7
M:?T?5E<D.!DU0*[X<1OWT<SUPUT)UOOLM90G+?/?ZX[S=B0%!]>6$6KLY_Q8
MUAF[^*Q,ZJ%R%Y#R#7%I+ GWJPP@_).Q3'1AK*9C^I_,LJ9,2:+C];>M_P#$
M.#/>=F<8!#W.,7[:8VQ(Q9=H3<H<H3HT%C3&O)T?77"1O/9'L25$IB-7FA:6
M-?F7/I_,K7#-7<W=-KHQYJG]+EC*F\7@+8J:QCOIS?AX'#ZQX.^3A&9APU:"
M/%I?"G*70F_]K,SV_WFY*7#2_G9SO<.3B-]$RT)T8>COV,3\V$$Z'X1%OSM)
M9$:K<$-;[ADBA9R:,S,MBLH]$]80EZSJ>!JEX\%X!_SCT;6BEE\I[/["?C]=
M6I;LH:]W=*-KL=:PZ8SD%5IM1GAIN@S4&8\#S!".YG-CMW(WR,ILJJ^G'Y'*
MPI0R2MX:E9ZA$$EC2, BD<J.),6&>+ITI=BE;)(HXQMRR-DW A[J0B&BHDWQ
M<*STGT0GK--!N5OQ-[)+L?.)'.HKLCF=,_ID,>K6PTLP.NTQ"!LX4BN\;4^T
M&IYCRZPN&BW;U#^KUDZ2F$*)^8H<2^!0#&3'Q]9T?LTZ!#CY/W,H4-URDAOP
MFB*2QNU7)!4KKZ+B#7T?IX2-AT'?O5+0?_H#RM;/ST".U9S7G6#!7[&)XBN_
MP=CZ@#_VPEBA]Y*_UQWPY6/!+Z-"J^C"*+Z[ GZ+>T1#[B79^C((V3@UI@6\
MO9*VYR)W);"F*6>U7<"?-\R 3?%F9X6ZH@NU7RX_"ED+'68+RB'N#V:UTXF(
M/^+_ 8B\'\%U)^6R???HR8HB8(#'_6@^!^A@>VKO>8LXPOZ@/1+^0M@P,WZ[
M0-]2'1"+= %XB7__DA!/]^\!C>:##TT)4?-=GD?S! %0+J-37J0B.P7Z'\^;
M0M=V\M$8WG%O03MM0/3'%U^;LO;-H-7[9[?S^_&-(J4=#P#W /FH8#?H)-^W
M.^(O?W,X&6#6,.C\"%P^N5AGW;-3*:A4>?T.^P_0R[7])V&&]G04CT@J $N]
M7OA3CINTV4#A*91MQ/OO77O(Y\S.DRGHYFFU:7&Z3X#7)1>L=_T/L('K-F70
M3/0N5,(*LV,$FV8@=: 9@?Y)W"/.<UT/_Z[IS'NN3BS\H]STI!P,41!)_/[0
M/Q.@*!@A,7TQ*4J&E!-G])KR#\"X'2R\3"S0W'9HLVAIW!<4*-8&CB#MW05>
MG]1%$$4X_)X=/%@<>\1[@&R3GW/#$^Q"!Q\\O'@;C>D*H0'>MSZ>#^P^/C[>
MKXA[/)=>3J" AV\%2IF4@D\O=AI-(N5$?2DWE,2 T;T7C4O</B#LN\M10_A7
M[M/;!_?24BYZ&SADD6_V"JIQ!V1=[V,*]@/-<!./\7T\3NNE>-W>.HPZHG\*
MOJ"*(,MH]W@__O7O.CE-8 B?>QP;@>4A%@K(U9 6W(4:(B.\7//7O2('[[6?
MD^6B)I1)7=30[+3W@_V:[R_?S]=Q$>JJ?O$P5#,U115%TV--,#15X6$J<*8H
M#;EA\84BB&)!'W]/+8% !ZQR)HY-1/+E1:I+J,Y,*4Y45&A' 0&P,KSXM-AQ
M"[SSAVD'T;S+^3)4C 049$PS%T/0$H!T=W(LLT8 IFYUA+=J=CZ'+JP<8Z2T
M,9NF:),:/GXE1OS(AGP?M8"86O@V%8*P506D,Q'EE"K1NVFX8*Z^/MZUV\U*
M RPR23Y>3%:J0]26ED\39J :,@<=@SC5/3'NR)]5I@OQ3@>$%@]0YJ_#Y9M:
M<UL/M:N*OIAUM@6Q&.-&V%V,HOFE KE7*&R#G,>$>2Q.'_E9[>"$T$E/9FH9
M=/FS8CP1&D"<@0A"=JVQ\[!5M.FGHH.Y;?4\.[UF:>P5]<"OTB[FR]V6<*#/
M+]-@O%0J)_'HR$B.,&5 'S[?/P#=9W&RBX%39U?'G_;LJSLO^[IR%Z;%J4NJ
MIK&U22 ;U04 <%$%68=ETO8/4'95PI:A_M+)R&#RBBLKQ>M\A3.NDVV/#B+R
M<XYB0V^89W6$59'B>M?WF^_'O9T1EZUBX$HV:FX'71BTSZI\"1<PS.JH9O]'
MPXQWJQF_O:". WY_Z%%@.D(7;HZF!2NBZ$I)N39[DS:AROG"',<J+IH3(Y]O
MGC^)<<RS:&9-5.Y[8V9G7OD/*R=GBNZ<@<A1-KUIXH9D\ZC8[ZU+XU3<XU29
MJ)P58U6H9\GX)@;C3E@PE\6W5"<2PD9CJMQ&)!)1V@06$IN2Q')>ER'%K&]A
M9RNKQBU]!V_#7F:-L-*#<\^6<TLGJJJXW!W?X!'52T6,Y)P;>$<=?LVQ1_4=
M#@JY .DA:W+=DIKBC%7U)=X1K/BQT/JYIJ<ZEI@><4&H[!1@F5^+NJ-L*0,Q
MVSC[XACK81(RR_IP8/BBRGHW>BK/W2B9MO8V;=DR7_."9$W1,E'C&Q-'$!QU
M4A;\.U5C8=ATGI><(=LDZ"7)W?-U'Q</N!G,^V7QIPK&?1:JHUZ+4+FT)L5=
MLQDMH^,C*V[1>W_GB:-3'#OD^V_#[$ACK/Y9>M<O?%W=8061UCGNA8UB):R)
MM0P5#/%5V<31O9YD[6WV&,TT^VU!OCSBK/,+#_[F:0@;"W1TBBEQ20$S7>?V
MJ+S#8VT=3Z^8%PLLFR3\@=H E/O5(ZBPZO<-/&X$\[D54Y3(WM\&<?0PE$2V
M3-LFBG:YS'GW[TWWU-UFE,WUFL9&A\4CX;>GJ.PI/Z=:""R19%B$4[<%IFF_
MX^),$D4/JKI*9Q5" F!J,]EE[R#M@W<Q\07\KK4U'"Z4_P&,(3$1[^E)SO!W
M,$U4MSE'TW"^E]&<8:W,/=RGO$5T;-\1!W":>G:&$G%24RA6,NL'@UK#=40-
MJ*JUC7+7[7M-:BV2XU/8"Z/.-0R;\*4*E5II9+[_-=Y0L];TUN_&23Y]=G"\
M$YQ03)ZT7X @JB'/Z <IS=4DA6U8\:W=LQ>*X-<PG?2D6RV<H2)PHG,J5DR$
M-D&>SEQFX6OE)A%4Y34G \!;:LMQG*6<I5XLG<Q)VI-IR?9;G;(LG><5XDD_
ML"(9&)HF*J@IK&A$,\_H7+!"R<5'T #H"VFC8/VVTU<5YA2M<G1%194WB(HI
MWI"IUS_H$@>TWE59T9YT\B9(;"Q1"XZS&#S:U'AF1.G]RH))9EL:Y_N>_;ZW
M_P"S,S^N4,O^ 5+N75]>25F%#7H=[VN'>UWM8HX8T-(^3&&^Q>)6B+(%5;<&
MQBNDN3:B,\NN\).(LM4'_NG'4I7!.IPC+TD&W-99'I+Q\+CM^7/V[AWK>D$9
MG/JN<\>O^3B[L^L S6B&4KX-*<H(&T=YK^::7[PK[H?YM"-8O8VI37I79M9U
M2&H"_RZ%4"1#QH1]"ABA7E9 NTWY7&*<QI8A?W,.<\+9E2_OZ,2(3FJ*++,+
MFS(+$MO:+FY(5;J80B2CA=XL">XS&_3_]3:350?V6<ES3*&#&HX1:.Y3W+.,
M$)@'U2&PP25M(JUFM6ZA:NYU%5M5ZW0CN>PI!*\\(_"/0P]>2&>=!R-@8"_C
MA570]9(R1YRV^Y/VIF^G?P02F0;T!O0^11=9-9XN BUO@:3"AOE6\2_N7X:"
M[=]?O^HV;8D']8)))A<720)&S[6R[9JT(';\_^BZ72[Y+8M47X+ _GY2]I\?
M_P#%;RY,5+MY$7IN+ZB##0^76B1[DCZ! :B_*4%Z5\#L%EY_XD"/$Z--=Y1-
M7QYPPA))4W%(&>!TM0[L3KLZ.ULJEFSR>@=G>B\(Z]N@Z"[(<TWB1MX>B35
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M7Q?8J)*M:LV_B24*5)&J@; '':'B_JL(O:>R5O]#RU3?@%8F,[8P*BX/WJX
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M92@++HLT,QW3RDOHZC;@IZ[ZJ_ !1?+'(//U0RCP\;=OK"FI\-[="Z9AS1R
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M@3?79.H3%">#S+Z-+:IH\W@^$NYLF*P]%II6R^R-*RCRV$W=EB"W]=2T\]]
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MZV_,:==?(__KHMQ-;6"Z41.(Y:I>K^/4TGGD08IQZTL'UY-]RL\H [3JZ[[
MR]L04;7>)"JN\"?5?2H(YJ9Z^1T3RY4KVR,[>V^BJ*V'A!A.Y/_0@VF6+60
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M>>A\XE>RG<_?WQY")=5WELT(L _SHFW"!-B9MPNJ(\-^&X["EQ*X&YH;'%C
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MT+9>6#VX1*<;.#TKF6>[N47#99 '7![JS_I6S":O$^M20AS^VX;' &2M/Y4
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M  4+!0,-"PUW!QX!#@:%]8J)#@-+C,$,)Z2HCTEBX\D"CQ627"Q,2H:M],&
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MJW0H@:<2A^<7EX!'2<>=T-N2'6E!;Q,YVIXT^T$'.L+.+RD+O?2/]GZ%EJ7
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MW0Q.8EQD 60RTPU$*N3"%- >H;?P6CE7W!9SS3#/0Q(7<1#&%\DB,2T+EI/
M8!H:D6_C8\+=_IS/I*$MS;(?1&'1>0#A+^*('+6%*3!_"TA,D\CR9A'<=XA#
M(?"NA;-TIE5.4H[1R#,5 XH(_O?RBP8#.=8-5V<MTNF],&C!&XY[T[H]G^@4
MZKKKZ?LE3\7CGU> #'9=_*F['KRQ]\;+]TB?/>HE+WI2,=$[R2D@(!^A_#$4
ML5+-!A2@6>+9L"(] I>>DW* Z,FV?D:&C"///@C=*9OT*J:4MSKV;  +-DU2
MZE6(\0?.^V]P55[/@$RYQA)H>'I"W3X;A++%I7#,&ZY(($)(U"957 G=OA83
MSCALTTU:DU37J/?/QG/GUYB-BN%9GY;:\RL:Z!)G1>T@6="B[58U6]E8MO8>
M+$[[K1YSU&XM&S\ \;WG?U\G-YC1T,HS(CBL^4Y3WXK2 WD 1W>7!Y,Y=/$3
ME7B"*"1<5LK,65+?N(M"-6L_4/8!=(SVP#M2)029H+1D0ILO9)H(REB/4NMC
M^:3Q'$T[G5Z-!JG1*9",E(/[ICL[S, "<<_$2NE=BU+,^% H2+7ZHG2=#_=3
M?< =KP?S9.2MM(8-XV,"I-N=S?S&R^1S.;Q._(E4T[V(NKHLL-!J$458VD5^
M75$$F4.W*?;WB-7MALCYNQ@#'A1\07D:5@!7-:CB\(H<Y$-#P R+$(4G?@&I
M61DPDQ8'O<R/RYG&4R"0W_9B?[M+:64WI8TVH)'DS,C:-M!H\<$O!2G7M"BD
M=%*:0!;M?9KI0V+5M.G8@0/C4XL'\SLC:6=Z+*+XG62QDP; +Z+0&R-JP"+!
M !HR40M,8 FD5-!_RM<P==[HY;T!B$A^JJ2%EG3"(5A:ALY,:[::CBEA-4W3
M;K18HX3QW>+*!%XH?F+1 7T-+'SL^[LP*F2JR]^@U-U D36-0)$1S2"UL$^I
M\B)V,BRR&^VFI+4:Z#H1(0C3JM,A>@>DP-&&73P.B?_.WC&\>M]R!\<EKKB'
M6S33^^RTHP?8Y_UT<'G/S4I@VD)E?8,\!Y9J(-WIH7RY ./!NZ$%NAV8\4"&
M"J0>IV"8!.%/(8&AHH,7:7%?U;:P>)_4*UJ\< P9>YC;@6V3M7]_=3*(=('U
M\!) F*%/V\[1)+%]6C^ '[2@'A,L\RJ\7-U\R 5Y^-N\5S&";+PU.$5CU'O:
MH7"$:T@?.X<>-]$<X:5W</X.X.ORMN ,OZ[&!^QN9]3" .NC B_NY!<8!Z0Y
M90M0R (43Z5>A<N8<BW(5U]U29DT2:Q >/7P%>9TK66^7<84 X?VF>Q2EK&L
MQJMJL6^9O:B=S["ILCDHX^N_(05,J"UEO$DHH5L=.]Y/-(I1+DS1<+SW6<*&
M@2?0$&^0#N, VDI=)F]6W $Z!R4^PN?4,;JVEXO=0M%GQ&#^8@FX4N1I2CGT
M'J5L_54C26: #:;#7%,H.5&(+-^Q4NN*CF^H48>14!O?P<G^(EKT*0"-2K9&
M>+]2K>\E$P]6?GIDG'AH @FH9#B+.[-/:"Y?M&*F=1PZ&N*RA5"_"H)5+FY!
M6GV6K9NC(9K=[U!N)6UB/G-8,QV?1Z I-Q!*<2;N91"_L<'[244B(3,FFY.D
ML_V%;,6=JL"UG*ZZSMY&74'R] ;<G;>KEEKQ@,^%T(LO/WA5/KD$*'34P&RK
M<*B+J"K2+U"-+%!HFWH'WL?^C$]7_,Z?\]"-U.SQET@O,KQ[[ ^,QP9\E14-
M,$E(A+ &#JK.X3F^%9P\X7$&5$0;2U RF9I7]P[PQ_1@IT15QF^<LJ(93U E
M6'0FG"AJ1B2/[E]@)2JV6'1K='D:'T+*,%0V?54/9WI?3H>9S\9< O3=.8MX
MUVUW:Y?-5=5V[$0,^ VZFN?S[]R/&FCV%^S;!"',$\3X,@>K4U*<9[_N)X M
MCK>5JO>QD'37"C1K+@+//:O(Y7M<"S7 (\[LV)*)[S1_5BKN.>O9V:/-P5J5
M\N#%(#*?_7XBX>F##F)4W'QB(N/V3CIHJT']'5(1^P3(O9>MQ>+;W>%.J 2C
M_1E/@(P)G 8"1BL!V#$M2B/&28VSZ\Q5O\P6-AFK3M6/[^'HQ9.;O'D+&Q.C
MQ=SP*CYHO+%6:<NC1FVD.O ;;/+R#$M'83;BD4$TT;)]63QQH;4QWN+D>J*8
M*2:07,==]8HE%C9$RQ?_Q1JX5[S\A>ZLMX+%?>B:E(IEVRUGB.EA0^MCN[2P
M(#SPJ&-*K,I6 4/O/,L% 3SGXN&+;F$/A!@' C*4C(PY4N  LU"*)'J 8 ;G
M-A8/@AE:>BC!R% X;P#C1#VYC/PY7[ON8#W8X>FY?2..7$HFF?VRFJ?,)^_<
M#(\2SY=Z@Z)L;KP!1S3;[DG-+POY%H93J9FMZ+X:2/G5DB?DM=%Y%.1L@#Z=
M.>4T[L:\B"/]]-?T<;5.6+T$])X;=FWGK[MG?MN_V-JZF-UH77_4.'O:Q=:\
M8CUK_'J2+F5!\DGQ]F?F$F3Z/:95!C.>B3A]'RW]J(?/4Q_=%[??$"E,;HT1
M">;84_39]7PY=6Y%MM@=HS;*YY'!M?)BC-H 21EEXB!;9,ZGQ_^]M*ZLU>BN
M!D9X7D>FJ<NXC%:4E99HX3=9?4RM(NQT*S.7O"PZV#;7$$S!;O\4X<F30=%0
M/!2,QRGAQ)XU&=)8(3/2#ZQ&XN7W\]>ES98.QF&JOO6R["8]=R1]]]:97SK9
MXLDPMU%F\LIC[>#%1UXPF@&C23@5J&^5+*7RO7<+28LKPM<(2K2F*NA:LFVU
MV,S-8W$-GHFX)W7C]_C*85>A&D:VA[+]XJ'K9R:Z-9> PHW6,X$K5PF,7KGK
M1'3WMTW>\>I)UXZF.]%)X</%\EA>\#-5QP@=GE&%A>T&9CO".-.(1=4XNJ<V
M&*PZL5N+N&_5><KYVILFL'156[_Z5D*X<<@F(RW7UH&?@GWM==DZ54W.[#ZS
MEDGD+ Q05!7216:$2&2&]%*+JAJ9]HFK)V4]00Z)9@A0=R#^/.61&<%()69,
M+2Q<3V+G216E2-'U]]]28(Y;Y7?+2*85=<HD4SS6-^<;'^\XU<>9S[511FV$
M+HS>X9B9,!'!S'#H$)=NXN6K4TOZ])@W?])^<."+ 2WE>SS-QN1NE EJ?X$E
MZ![[2;;2"<%&[S*<&HU8-I)>,8ZMA$;"IP<969%;Q;NZ$7,M=8FQ@,(TBRG^
MKK5#Q4==*0*N1=[',T0YJ/#F33K 132-X5///NN0KG9)3#8F%H?*3X.7 +:G
MLH+/XOG\1V:LENU1I.28>/->0G/X<*BURW,/K.YB."10+SN4[3I5\X]$@72M
MZDN13'6?<J$G"3M_S4!&7JE.25\;0[B7XAI?V_(RI?_8KM21FL!QA8WX_L39
ME!^+>@!^!7L.F!T'!_L0"_:3<9LL"8UZ*^4G#F]2Z0,7AT+0003EL=2%M'U:
M[N"HEI([6>Z@6^Q,Y;E>X@&7SKWAT:3>M]ON61>T+=AN+W34@_C!W7KKQ]%R
MHQ67 '[>X:,SMZ2DUOF]W:5&;#<!]HO=U=ZJ/^/CA4\BBAT2A6"Q)QYAK"9<
MW=@&J;E:: +]J(K/X%>UO?#3B$+;RGR+4?=(>^[5'IQN-"5<=55+.RA]=<>Y
MG+8-\8*M<Y.)D=9'Q3(<"</3T._]"W)W'879'=UH=]V#6MQ*)_.+I#'RK>YR
MY!,W;^EU")<WBB6;S9[4G@VF$TOM[\V4UX.USW;7/XZQVV\R-YH%#/>C7KA^
M%'&//;>85M>;R<HY.ZK>/2:H.?-5#Z%I9%-=*L@#][XM;)G6T3N>UG$KYYL8
MS5Q,L@LB%'!O/)H]_)OUAZ]G"2K#4R$1H= 0HZ>#CX'#N7+D5A4R#*&,4V=P
M=.2Q-(]04R>QHDBG7"G>&>!\U-1QE]/6\^U8KE+,JD\B0#HO-Z#7Y-:C+*X(
M[?,TOR-&71D?HX#-%$EJ6\Q*4TX=AR7?PW\)>([J4MB=UR)[="&F[(8SQC-H
MI<H?94:1)]]1EB:A!T 8AE_/LCJFZO7BKE8S2?_@)ZR:[2@845S"U4MH6&MB
MZ$NS*@S;:533+\\E^/FMD&:]6!Q'D$>/Q_["48G:Q.K7;G_17)NEV2$EM4U\
MM!$+\4'GTC<<(W,<N3P@Q#.3<CVJX6C@X%;_/B.\Q#JCU>(=H_<CH7T>J1@@
M0>4''Y$,5@2GNH94N$N9MTIM[P+)?<5"X+/O-O6S,67CH99)@=_G$R'21,V&
M D.)I\VT_:R-&LK"5]^TCWU;F4WX,"W115R=MZSKU_-X.#&T/+^0WTD)O72!
M[RV\ 7-MLV3&-.\,"T6 ]*=]UO!)34)!W37U#HV)2T!T6V3Y!H%AR40K<^R^
M9] DSL3:$%7-1.K<_-QK2\F^,03CH;6!MI5!J[.@JLHD>RV%\_G>NOD@_K7S
M'M[=MT[#]"W9VM7=4?QL@2^RM3!P'&B?G$I,-5$P?<V]!"CC-W&P>R^,-9&R
MD-#6YKM,9Z>=HW*R99E&?RRAO8>DU=I]X5'^QNMC'0+@#=R3 %778Q+[/P."
M:82"O.-E&"%L9',T1 *=4"1'^MXXP=[!24UQEPB26GV;$"W"D'\YF3>L<=Q8
MS_LU1KOJ2>PN:U*G=ZVTFD=05A>)"G/NK4!=49UO_*%B<F4\+^>XGRO0'!@;
M+V*6((OO49E_;7=S%QB4E2O).4.G2?0R'2Y(C*-YMC[,1$<<196-BL\KTA8T
M9/DBO",S[0YU?DRU<'RP"Y@G1&[2,^W)Q;>THI#('8Q'4WGB%E7CSIH))7N3
MH]XO(XL7!NM.M)0^U\,5+^<W++W@H=OU*IU,D$Y'#_I(7U:@)W447S?DI[F&
MV7\ (27Y1NS;^,HFRXYVHC%"!8VC)CP76"5XH:1:'S=BA)'QRYU6.N[$'W'^
M^0&"T\R'.>V$N>F'GYSINH#[!1_F&>G- WISR+V)P23V#WO;&] YK#@J7M21
M;688L. WJ7B:2Z+V2$-+I:+L4%H<.6F7*[^0W 8E._N\*IC.:>"QH5G\U*BI
M8]\QA9UQ-U;-D.[>_B$-;)SR4S*CHG1OC)IJ[U$5&)BO6%'S#JPYHBM3/VX-
MI='\GMF[C%5IR14U$N8VP[G:$T\F7;V.*G$;%7K[$:0C&CO=(QOEEK4U$#7+
MHS;A/)DZ6V8]H$IIS]R#AV<O9O.'3M!)F3140XJ: 1:MH2PTR3F[)\>UVQ?N
M,;GC=\-J(J,=8.+,D;J?A#IP\<D@ZT(VZ3]\(E$4\_%5@C!X104>PKMYT2E4
M3>:\C-!*E-6M75L=7<-U9]#B05ZR/]+JI7%;JY8=_$J>77-A.5\^$M=9RWBA
M+67\[$4DL'=([!(0T>74(8&G]R+N3>7.J::(#)B4A^@MOB%F9/!.5XUC;Y"4
M=BBCYBF5!4@:O5X+V, QK NONFOT@$9LHL6<A'O,SW!+;!P8%S*@68@QQ9Q\
M!X?.?]!3K'![.1I=,32(@]KKS5[NXY2O7S9V=B :RY/EN+@AKUF9OB'LV)]
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M]]YSU_)$T")9Z<>XZ#P,'D4"6QQ79TS*W#8K/,RGQT1.]HA=JMRJRQ0++9;
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M80OUC?K*Z.B)[O;-?#EE#V;LXK(CF*SR6*;#Q/=_YW! 0;Y/2[V!)FLK+[T
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MO.TGM*O^M%4UT,H-C<6QRU1,:M JH.NI8S;<6HQQ'@N6144EX$;T^P0GW;X
M)GO@JCQ;L_2>7F)F+=5SAQC@$V'$L^?Z"T#[!?"D?_4D'M?;:U+G&E3Z FA]
M?@'T/K&)BZ]>/6^>O0!:BNN%.VL/#CMOR4[YT]G$A*;M4N,2N.Q7E&1&:)LE
M*5UD4W%U.?>>+DHP/#A1';55/H)"$!IPU\ /+X C4M!!T^S@/E+7LN?>\L*J
M\T0R-H3ULC!33W%R]D!GL+Y;>(6I>UP_9UC4X8YDCMWZ!8"X^Z<ZK8Z DY(I
MMN[I@8D^>VBULTITL7IKW=+Q!^=5JZ3S$'(@B8HB+#?F=@Y)Q'6N+K<*&#*\
MQ<<O^&W4EIDTR=X-"&O,]>DB9AFN;?-$BCTY+WJ%^:;G.L<3#P+ 8*/E_& &
M9C@RKB_FOW>?%="KAST_!_&7J#;W3;2VY,)F2BB;0&%^T&0F[E?+'!%,[M11
M:6&Q+CB*;J)&DU?L==<,E"7@;*!(@>Y"705)I4B*X/89A1_&THF07LG(_:=6
M;JE1,>W,S=EYE_4Z+YJTMH_^,+OX/;QO>P=W71;CF@5)%XZX[DQKZ%Y%Y*:?
M6MH4T\Z![S^=+QP98(6O[,-R@V01Y_>*U2;53^U/C-D8;]L[9)5G\PM;R,LO
M9U\1<GS-]9AVC_^CJ&.E60" (^)Q8/Y//8U,(X=J7O$Z=DOBV#U5!_C''W($
MXR+P8"7LLC]*UUF]UDD,SK_R')^I#9[.XJIPN+G$SQWMGW;H2"C&9C4K$3J0
M2!?35UQ-<]0WNJ@7?Y H1-K"!T6+]*,Z65(M/CT]?CH&NC<>/I((Z-TK<&V[
M*T#@!,T&2:RK.<1G#UUA2M:0A^RKL$)-J,.S.'NS./(+ -\WX%2M0DC0C^W7
MN(E)$5*/U1=+C:<.P\]25YSO,+F$\9_=].YTD6R?JO HFI_.+W&NYTB?F7L'
M%E\ S8_<]B;_1!=_^YQLI(I^H7,D-7GG>@QCX@1SN8U&H].,)[U+0@S.HV-5
M;&W0_*VN^M3,$7%F8RNK+FV!RB7Y@3=-A<">K/;09,OEG,:[_#4]&XICW$%7
M@9V%D.@+0.6<*PLWEOJO02<8IZDMKD_]!4 &;T/: .P8N'=?3__=OPV*GZ];
M+&^M5S44_*LQR/'WX0GL<0T2+5K.3H_^TY(FZ2XZU(ULK=BDH9@1M<.\"%.L
M%E0JQJO*U^#J/\Y-=3OGZA[IZ%\PP;1!T.IAJVDS$8SL8V(Q^LD32<;CYZ9
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MUM;VK:10N-\"V+M^6C>2^O_(@CZRDKB*P0+S.C>?@9MUO;TO /$)@<[+^Q=
M_:,_#+;X6"<>=/%$'V/"NI>$4B3_["<GI !2OZ!5KI3 !QI)MK0()%/$Z[UU
M15?43#V<=O-*.3-8N*I7]NR)0R0C D;N3:!URV>$VFU_[V*@%UBP:#&W"<>;
M2"T"RLZHNJK'N\?U"U&MHY@.)4(7=>_+[8^M:=)>0NCC2DR='-WP.:8&IJYJ
M4E+2ZL[.SJ[*V.2MM3C3QNGD/0\:U?>IA+.6FJ:&02XLZE(;H\:_KE@I7[D
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ME[\6+!X6O,FIMSLKN- *$<:5* XL7,Q[6OF&JL\71_G1!14YQ-WA6B*F&6L
MX%8\VYAW(&24=4BF7-<_?^%!UQNF&AH+?:,S::4&R.DU8053<#@%&T47+A7
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M1N*KUL3AN\I);\=:H)C$"P&YRBF9;= K[5R^\1:1W@I+N:\>D7M4LEBJ*3.
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M"F<&.@!UX2CE[*$S#TP88IBIM(WOO)A <M( @6.LD))/.Q$%77$F,4A]N[_
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M,1-7WE _8G[F;P  PM+:M3%LC)LBHIHO+(B6IP#JJ/4:FU";7#NX2_ Y;:%
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M+_D?Z;)AFU/ *XXVD*%IHP+(1BQT:)3PGLJ6/J5U4WGE3UT';A,AH^S",5B
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M&[4A+N9*M.KDS"K6 NI !^#K$9!1\H1'RIQ9+!;B5EO-0YH0[\0HDE-T3)P
M'#(]#Z'MI,\V6$:B<%^6$#?5E^(0K3!MDRFZ#:&N4((N50<5DA2M<C8ZP(8>
M%?A-(ASNHEX<(!-ZARBP(X\-]DIMGD4-Q1),,>2[74UG>RE7-#7!&Q;4AN"[
MO*8V8;,B]PS5%/*HTJ_TXAV7RX)",2+!981NQRP%B_5'<3D*(%V0%F4E&@Q1
M IKY#*C8* AU@N(8$5@H,EX5C_VCD.4)7NDE/!")R$'YRJ85G.V,%J5K1:U,
M,M](ESC(X;2V[I"HG@\FUZIZNC1(E.I(IJV:C7&+9BS<!^K1%&X+7,C$D$8:
MAH BU-:<.)'/F1. Z0 Z#VB6SI(A-",23-Y$-"OPTQTCY/2%=KV#NJ*<@6ID
M6N]05&H8!&^(=LQ"NI9P20EHA3PV-I1I,,^U)@!#R2X5J812.BQSO#4,X7VH
M,<S5>]E$UVR!3#A=C"6:8IN7=;JJ6IER67.[%J50.B1#?=02PFXX+V01KH]H
MC0G 5E-C@7JVT[6S()N/RXE>I!M05X=@7-4!ARU=@7G<"NAL>E@M&T,!+A8;
MQ42JU^=-2_*\'J2I19I7V5@QT9T '&C]P&KQ 2#I=CY4 WBEJO4CH1#9$H>$
MGX4<4>.=.E>$T_UZC5(<O^KZ@"^3),N%. ?L<&+3Y\L::N03^&B5,U'"3:):
M& <:=:U>0;L*;#<%@N%K+!+)]7)!7"DC@6M5\K!E$9%>HR6G(XY4@KE!"Y8C
MFE:$4SA38!K)_,A28)(DZVDC36@D*S2AP %T,AJ=&69,O8]W.R58LTM!?=@B
M!20*X8VF+C-@ N,EO\VTN7(/D=U*,\[J/#9B7]_1L9CE0O$:&(FZ93QF%-TR
M8#HY!ZP0;= -X2!6%8>@&?C)?]0"M*!XD)BH-0$X7C667WD',\-F,\I 3F+8
M;'6;'0?6N(A- +F(TV7,*)QNQTR\G:NPM6:S3?#!(#)#N*=T+,;.]:T)0*6:
MAW7<E1N1?!6-=.J]O$!89F'8XYI:#<F8^;1O#DF/5:U$B[,K9K3CL7F;!1$'
M$L%.00'-I%-@F;J;DYL3@-4*DLISPYP-%W2O #7Z4+4CD$VL9'F.9?K]7GF@
MU?DDD2;)&&J'>*;JQQ)4GT+)9$/1/("3!KK?=U2S*CDCLJ1[V7[4[[?R3KL?
MS_:;$HMZ.3FGY7G;$4+%G%$&F#(J#Q%"+Y.&Q$-A.@$9Y5*)U U?Z"DZ+WI!
M%->C%C !2+DH@]54IUBH$W0O22,VXL6"T60+@VJX(B2")#96CS4@E2P-D*KE
M(V@=;\N<94:<8BJ:AH2H:H?K8:_$5]L3@$(<5@.[+WJ]OEYT8_6DUY/"@%@/
MIZN H&A^/4/!R=Z@GD:2.:$)TH5.4B&M;#:4EXEDGY54:_S%Y*N!OH[TD J5
MP4)& @=),A08>D"K@DI>&<>54L=$RGIW:/020C;<+^8X+XPY2(Y." (=[J/E
M2JZ8R&)0M^3[!<D>C$* I/.VP(;S? TB*- .A!&PP4$"+_!@H5Y7HI3&Y?I5
M?"B(=8J/(#F9,>JHI>+M)(\7VKUZ&2F8=G;0!UD]/ &HI7JLQC**CM<9,0P4
M2[Q1Q+-HL8\S62_5RJ8I5&W;45TAFP6NK>B0KH4SJ #4RR8"&^FV2MBR6K?:
MS7!J),,84B\;.7< UTTQFF-*A,G:/%3V>0G#"!>/X:[$.2[?ZEN<$&W*@$[G
M"B&-H0-GT ^4%$HUPI4('+@A-S>BQ'4VSO,ZB#L=",I0BH_@@RK?;TBNS*D^
MA3!,%69)315DFL;:)BM""$"8:;<RSO>&?L G7#TYS*-MN#HD1C+$>+.H%P5>
M@^TH[:8U&]:UAB'94B.5<^%NF,25(-G$99YB,;X>@G6CU.'@CJ668#O;"V<[
M>BV&U^"$Y==&BFT*R:ROQ1V.J6F16.#B:+D3J$">3X*Q0CL%6EHYW4+::!^,
M^<JPBNMT.F+7?2I9S.0HI]*.FTJCH:<;5;\X\C;U&DJAS1;K5^,!1^*-M('8
MH((U!^TV2*7R)%'C:=UE.AJOY9LZ'2LE;(JI9<*N&F%(EL>"SB,#3\$]71_%
MY4%\7#/<F)NOB0$[[2,MFRK6!0FH%2B;#-OE5M^'=4PPXL4&%8IVTTTTP; R
M72SZ<9]K]LQH'Y;S0TQ2U)':0#)?A:$JYJ2Z;3>9@WK=0HO4J"S$]=@<$]>!
M/!A+R$[.J!N$CN(MN.3K.!2$0R2KN7Z>AOMAE6A38@D=A5%/KU%]KM$OMW*=
M)A]P.X(3PL2$1<EUH)X/R1@>1M(=GNW92$*AN9"J*1#,$C%=TH56CR<H1D1[
M158KC/@AVLYR11, (\%B$VJJ6" ]?="5 5<K:TT7JB9DL@W1)-QFG#"!.%B6
M'EIX!8 '&J^8I?+0[PY:4+,<+0*E45P&/!=O1!NM0)9Y&%.$) X-P+S"9G38
MX2"[5A5#<=MAM'+1(*)4.A:E+2F!Y#I\M%.G&WJ,3;L#/AVI#V*UU@KGX"C$
M$!6E(=0MXK@?\ U'9-OQ<IF0O42VA7$T5:BC]3"0)14H6&H[3684S](I'Q+*
M PS!,V2Z&VXF8\@HIL225BA51;@JG4[WL;[&1+T@$7.-J)W)LJKN6!Z#4F*#
M%]MIK%<%<]5HJ9#4=+\==;$FQU6)5INWR!!B!C1O1$50 H@2&&E&+1-NYIU0
MI]VM=G"Q3/BY1CB4ZQ/Y%JUT@[#<3C.2T4#273;"\QV["Z)TR0/19L0%M8A8
M2^=&EC*1)@U9-.I$2RUHB(?%(6VI$6( A=HFU.\YA)ER"%6!4!1-RQ25QU2<
MI1BV$C/J L.XDEUK![[3$(:ED1[Z@ES,!08A6S+0AUQ3A\-N.@MGLKFF6'-R
M,- E$JPZQ*-DJFXKXZE""W PN4\80J7HA657;'0%RF_'018=V3*1*)5 6=6Y
M^@KUFWBIY8%:T3(5C($P@!XJ3+%D#Q3&9N-UN5Z.T)!HYD1HR$B]0=?S=)Y(
M29D1@Y4TM*"TALUZ(S6$:V8_W.;2*8#KH(5AFNE;.DH49=IBR\U>CLFIO2&G
MLDPY"8K1MMU.1\HJV <0)6RTT'I_Q&T ?ABOT5Q)"YQ\4BQQ#HGD.WTJX^6&
M!1.VW"H*Q'R0#J.9?,I3:\T&V @#MC](IRO=0I5,#T*HRQ8P$BWFI G FMYQ
MC+"=MOE"0_<-S:U#Q;1J5X1BI1W)^]UPJ@ST!PA/,,-6J]5LM5LMJA:NZ0G*
M,P,.'IA@+X;%D@23M%;H8=E-$N PS?$@4R=4"T5P@S2+0T-N\8VAP,N54+=;
M*H7LJM>&C(RJVV&R9G5*Y:JE0G:R8:73H$1;).F3HYB"-7N^'BV$>W2$5:(1
M.PVB[0R(-2-M@O%6Y)(YNX[W!=)*9J.@J-)<$&IUMD,Y94YGLV:YVREWH4XY
M[TX 9D6'-VPIR- J);^BA'-X+P0$R9[?'/2RV6X;K?8#;R:P/))/.'Z[D,?;
MS7:A&1&35@2I*;YNUFL#RG7DKC08J4V7:X<47:'"G38$T(D\7$0SA5Z]8T#F
M,-4M6,ED4LT864!L"6W2+'A.35.:;;'-Y1,YHML.#$M/0XT<G>.D%8J=ZR$1
M#?)#G)Q->W$A*PCU8BJ5=(U<U['K71>5BFJGJ[I,@J;Y6+L%F)3G,G!52VN*
M,>C!N8Z!Q: >N6(SK5'LJ@"A6(U!#6=JR6PEF5&$H9=JNUC2#3G-5C3KB*&P
MDT>JD;A"ZS9*!T2+Z27M0DZ+#4P:*38'=44%XHE1OAS+1+(^7BK4(BD;;8 *
MD@)-(%S*FXU6E\I 441"FDK=Q:,0#"$^4N.8"%)HTSR,1>RLC<I$O:XE&2!1
M!'*C+""5J;,A'Y!K&NMGM' O4;;%TM!.U?-<HH10B$#!*L7$I2';R3()JR#Y
M#:.=2FJA>D$S.FBJ:[A(EE; &$F71C%EP@'A,;04"A'-3FE<38*L1<FG:UP&
M5?E0CPMU,"N([D%<$EI&4^^[)F\!EL1+>L%R RMC PT9=N@\/-HBZ"I=+Y\K
MMY,U(\AY*K%V)=&,Q8RJ 7F59E$)0D.X%G38*?1=H.?GO];.%2\].0(!L!-J
MRR-_.+Y[6! ]/W#TI4K -4-,!.7+:9)5JN&B4R[FB*:D9#,1.!]-AKH F.^"
M1LY1 +.3'-0 !>CH@*T#-1VA0&A%G@*3=;DDYF@!MT,-+J1KKEPL2WRRY6%D
MK=>O1SD[AO635:M?,,)53VX#&5>3HFX[8!B93#,JR3V139="8'D"T$!2N:Z.
MT);8)2T<3R0YJ<JDT6X,*-8J"L*Z/JBK7#,:,A&ET"DXV5AK@ X*=$56Y3JI
MZJ% ', *>CK*4Z(KF$@.< 14PN*HK,,9+@+(E%MJ5+M,..*G<<;S*V96)#LI
MVZS!'5H,]S0T+I3]2H'*J!;"<TJA,4HK.CSL"FU:!  ZS.BB.E0YKLBC\4J[
MJ[E)#RU2BF)1;#::Q6'!LAPC1#E@/HKV8#NN=$J([I9;0MTU)9\W5F3TEFFV
MVSB']:N53"UL#OE_[!@:54XR2@-!2)389B[FF/U*V4A3>H)$U5"CH?5PM6*
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M3B6$9KX2BT0IQO1)L*"@55)&"+5J1!#=2)-6)SW:MX&3?3/P\UR6*[HVR-6
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M^8)\#A7<$.8%J'M!1-,R0"V[3(4$G14R,,_YX[=\A1A]V"]'#8[T26M@ENH
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M:R?Z'=5JI5PL*QV^@BBY$O-]EUH!!*C)NE0OU,([W#>DZU>4>1!@[VMX-[A
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MHCNZ8_TJN0^#C5W'$>=>CK^5P&F!/<W:F7J9];(;;I@OZL???+/4XCJ:6M0
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M$\4C6D%2V:GPY21#? 6K^28*-'9'Y1X$C-W(14+FXN7C1>A^)?/XHCHO$QI
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M+%.,='F:\2J&\9#EZB4GW&"EH_Y#+O,N:P-)2HD?DAHS+>LOAQWKT7R3UTN
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MQSB#@6]M9$VG:GE=>F_*6$V(=] H!:G9-O>''\W-&^;OPC@C"8>ZH]QP'MO
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M,YH"@-+RJ=N[CK)ZG-?-EBJ_8_&CZ:N=:3AT_IDHZU:JGO J?[RB,NZ6B'%
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MVI4,5I$#6I\;9UCBI6F,"&_,*%V L]#LC_)#_I[SY -'I>]M@7!VR3"6B#J
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MQ^/]W]Q5V$8'FKX&K] %J<S#VK5^SN6WA,U:A4@HJ2U$%9B6OZR8]90F6_I
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MRD8V&V>^-4_Y/%X(A(-^(I1(ZL (:W!\[WA[])[?TM7 ^54.:X>[](XA=6*
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MN-&J_BCWTB,6UXN6$^<5W8@@.)Z9E!5'-M/<QII;+?M,RWK.W7C4W6#<E^@
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MXQ>+LR0$CMDH#?"0O8)JS1!I1PYYM3V4LL&D9(]FDG$"F!),2OVN5'66H^<
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MR)#DK@U%2$,A4$S,<[^^%C<QOS6F2*/LU8P=:PR8\^U(4NFK)_@9I6(!N2'
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M7\HL*V+4M]R::_55UZDLZ;N*B%H.1?$0"E;JB22YDDE/>IZ&ZJ<O8>T9N%9
M^K!",,78;F0%A #2*MS/+X (SJ'4H!9@H@;M-2CMDM>N4]+KYL8YDJ'YQ2"]
M@;-M)#A=Q$#\;./'K73RB WI!$%^1F EEO7 ^:,EBZKG+]4$20J%R(%M,Z?H
MF3@J!$/$.ST%K4@;LAR-KD&#4AS3CJ'J-5,[CUB3D^*4*,FBE!N;C ]-MWLN
M;O)=9WTA7[5Y<0'P^&0K<!R]$%'B8+I':+7 =;+Y=?#61=_NGC%.O%0-2#4M
M1C%20C>N5;<MJOZ([.[;!AU;\(N^WL"S9I?[W*EOWEGO_5%KQO%I)BY;@9"Y
M[FY2$36=\@20#/=G>B4IBGHSLKAU4W)'Y5R39&M*?:SMT4"((UJ%=EM;JV9+
MUFWKU;:'CIM%I$,LZGV7#M5X'E,MQMSI)?@=D.^,]C#X+8"IZI,\UH]V%(QF
MBI_%703:'  .B6)$4H<#IB:: >4XZ4QFM<_C. S4)P;3@ 0EJK'KC7S:K#-'
MP7B]UH?6\?,M9^G>TZQ'9_*R0,X*KX^+$_E]G$E9TZW"28_G>?<$5N<RGT@_
M:HQ'5K%<A<IAB<ELR6[$FMDB**"&TC5\XUJ+4TTR8@AD;>:%8)5M=+2L8+3_
MV?+42*IL8U/[P;!1>R&M7'V\D\;JL"H)*Q8H9JO=(H:YQZ2X[/WL8NG;-(]L
MLTG*J5&'0Q^*JC;$H4-CV8GV96$LUB5JLHN5_F!@5P_G@JC0]]._F&#^E^D&
M@]=FE4I0B<0!IV!3N+PN40%&?$XJL4!5B;EV041VS!K'MBJ"HJMO(4R(#)45
M*E\VX_3-F'*&%]9@U^N15?+LEU3UNM]?S9%_?@?HB65C$PJ@\#*VB+KZFYO!
M-AA\9JW#X#.N(R='I;AP<=6];CD!"6K280>,U$=Q<Q0]$I$@02]);J=0P3M<
M]FZ>$7R2'Z\FKQD:./K#?I8$'<I4);643)-"W'+M^F7)J36(:,V@0D>\P*!(
M?-N6N'@-A(.?)C0UC, 2&>AI)AY?(0:U=J[+Z<#@L<M]&MD:[YIT1FTD#D8N
M3EW^J9CENJW*M%?4H/4B@:7_J5 N+7)@0;XU#C%M9+VYQ5E,75Z@RI]J6[!)
M*@U[K4@#&\WF\9S7]N3>.4;S8GC-,B\XF%89A)+(64,'J^HKV(JZJS?<#W/J
MK%#IDOGB_M!!"J+[1FTH:V)ZPS(G*SM6AZW\D3TF)EI>KQ'N\#>[ OURTJL&
M"S.)OAL''"FC(IX/<A8.O9UX?OR'[JV/>'A2M,M\37@Z$9]5"\+7&!$V!.H/
MIC5I34:9D(2\MF4P4^## SXPD.##-KNY"=KO?/5.5T.BX_]=4_(<OC#Q>\YY
M@">UE2F$E37F[#&8E'G-RO,E C8500@?K;81__1C70S$D-U>Q!ASVN(Y#*=N
M^5-=EUP'$2%OJW,XE5]C8Q 8\4LVAATM*.A-E#KP U*J*GK<_EA8/JU4M.YO
MOSX748_9870:<3A8]L#!,3D9'(MN!_857K"P@0ZO^^5B>]C6]DO\- M*9%J$
M)-VP>Y9P:FH#-;8A- W]K3>9IGQK#I4:+8R2_X<6%\.^%3X,1@_\=#%GRDLK
M..JOL9RZ(P9_(P5"03\&2 /_Q1[I"%;#HAD:ENR-;<]VU-(1K%N>:(Y$R9'
M($8R&==*BS0Q=[/A"4?AP8C<K7_T4OA')),G<8E*DB5,WM7J>3\W]U6,TZBP
MM6%_[:<V:#"#P,^"TZ/3$'/SV.]),-@=!:@0E+M+ID.)0H=ECV[CK5"93*&*
M;4S$F9'/\-AQ4E(")'\,=&AO5ML?XJ;D[W&5,Z%BLGN/D4.G&CU+><XRHT#/
M<A89+8D\78@@'$:LV';I%@A2RL@W<B?B-?7]M<5N3DVHC'@69JAO<^YR]7SW
M!,WZ.0J24KLQ?#G]&7G";4G K"\PZW#&7Z*^*W[7N# EQ;T#P.B>X#Q_F$[5
MC5&N /L(,*DZ].09#10QU3&U&A2AI-4-#R[&!6JTTSTSVIY/F(D6?[WHD]?H
M,,+0[]4G:B]86?QBAN3PF!H%A+H36BP,^@E9NB"9#$/ZO-6@/D-(ZRV$F220
M.'?M;BGE["G+[% 2I-.>IOFVV1SN1/N<Y8;DC2JD%I6>')8'AT569(A)0M6_
MNR)MX#QPVH*DC#+PIZ=\$9#O:/%P%/D!*08U2:X\#=D_&/98FY!'@= #6Q?S
MZ,"Z%>/%;C(6)>W+&NEY_B@/*VCH33OB%)??.ZZ;E+*!2ZWUGEV&UA35?UU&
M2,.=859H[W.=FJ/L_U7967Y% 7#=GF[I[J%C:)#N3HFA>TCI!A&0SH&A!0&)
M 40Z%"F5GD%Z".D!9D"ZE%3T?>[[[:YUU[/6_1/.E[WW.ONLWT%W[#*_Q#2*
M\!>H%>488*JXOE)OOG(Z9],DHD%,X_ECY3"=\O 4?@@9KS; 8^@\FDQ5>,N1
MJ#-/0*_^P<E&:R)2C2',$C#_:7XEL34U*\_ [K,LR^*!2$7_^6OGR%=JO^>O
M.+Z_XZ_06C\7=[(;-B@*^2N4FWND9^/0I&\[2EV_18K4?OUDST /(4F78?=F
MMV+DG?'"VNQWC_SQ[8X[3$R,5]Y>7K9I9>Y=E>(SRJ3KT6)5.D].V )R1#C?
MEYL\MLX;/.WF?.S(RQAD]FL'D7XXZOAAKH\* ]+S 6 Z<?9D2#;H$="W9].W
M&,7KA+7&LZ;TX;UE\5X_$?E2)*<,+H\O!Q47#@; J\T>I%UPR/7DR2?&/65Z
MOT*R9 2DUCX5SGG"BVTY1(9'SNZ,2 G+D"L9-&4ZGO:H49]@*LB3=65BA-A9
MRS5MMT_0KU5MWZ?H3F>NDDIG>Y>\>CE7Z+'?&7&9?D]/'9OH7W3F[/_'[D_;
M+" 7'Z-3%$KCSU^"V\YI3TI').(E*8[-/[$(\4L(OV>DDG?K@+ZV/7A1T^VG
M71CNC<;9S[?<8:N+YRJ%3%I $^'H..NOX1 _*O:+(1[)U3"R19)O:=/)1H3:
MKG.)0RR*KU?>_K0>:N%J52=GO$:TL.M@3Y=]SB,S.OY#@GM1$(#BZJT8@6 7
M]=I7DCO&-9]$]+Q9F7W'. N3^X5F^N5U,*.L>C*CNEK^ZE,"[NQ_^_3U3'A
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MJD=]A@EO:DJTA!%S<^\XJ/_J0-7+B!L;<Y(*3 :O;[X^NW[B]OP\>TJ"1V9
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M?:<)Q*E>Z!/0$6 N[VAP\&G) :2YG"!L9C(?LMR=[]ZCB^P6Y2&?$%A,\$!
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MH&QYEFN:)D=O#+VK<C.?X,^*9J-&UF?3QX:B@QVU,K=F#8L+IG2<UHA9K>1
M\Y[JN\$7-+XJ(P22U"5(/;G4?CJA[CV*$NJ4-H:YZ&98"KXX!S^[CI8[=TK?
M8\0MV8.CXO%P(,<7<W+CX\1S["*I2U_R:<F$"=JP9M.Y]PG+*?7/[%@J#AXH
M:$=6=T!L4UD2Y/'Y/SA(;!=XAX('K#[0F9DQYR)<J-X!I@SP$PELT1-*??J5
M">,5K#%D K6\A)!N:!K[C5[PKL8@ET1B3H;H3L11T\GM'-]^W%?G#Q&B_U]W
M"<*YD3ER."%F5U)2NGM?*'@2"UUX!W1$!>P'YTBG-O\"046->O)&]^;4]UK)
MMA/L#YV@\G"U0R%% CBE0A#?/ZS YI:3WT8N'%%C;5M"7?Y S6QL3 %NB]W3
M3.V/3^?ZO4"JG_S*7PMX+'.A2(\'Z-)7OHF8&KU,Z^3W5>5$>0\>M(L5#03?
M5C9URZ^'L]H5G$4Z'B'LGOSR76&*E1"1?KSP?I@&BR@T??;9E>,B%Z$R7LYI
M$T,.A)0W] Q/+<:6$I1$3/]4,RIMI;:'W%,%H%\6Q^Y&<"-+%EX:M>0F3QSY
M8^CE2%GGC'02/?YA?=4\<2L^\<AETGV'Q[W6IE2(L"A3]EZUEHI2V7&%MD^J
MFV31$_6&7$[]P\I@4+O5Z\L):E_% VFC>',&6=?PSWJ:]0>L5'X"3M[CS\W\
M!AX9>'A8O)#*Z.Z0>:JA2K\J;@_QYXE>R8!])<YJP./H7T*A@X:,'D FT[[@
MU(Z FCW8TZ&2C>$(,CQV5;:)%P.B["3\%'P)=&_?1,A1ZDK(03Y)W#A-3!!+
MO^AF9]M2^-7\XH+HM)0^$CWY^OSPJ+L,>/G>#C$SS2%=83BB>R+-B)L_QOS
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M@?F.\0I:B\NDVAOL[Y@P<TDPS/)RHJ0HGAA,5@V%G($,>-E" MDS8/F8LU+
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M8B_.P3ZFJR\-I -1''91GIZF:P)"'YVORAUI&8\0YR9M"RO+.VK;S"P!1L=
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MRLA!G]C%RM+:GL>%G_3..,_-]2V;D93X3L3!@I]4^+:#6%U&GE@4;&=$S,[
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M@@+7<P!1 ,3_D&Z-_$]M0%RW ]#@ 060.E 0: !(- @H-(CK;@ 1  ( !0&
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M^XBU6:*/Q9*3.M-6P]6/\[W[FW@6B:\HOJ([\:&+?;\&\ 7#S,28YRX53<>
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M !C&7"H?L%X&]D=],PONQXPC4D>0)3"E<;+@CRR!:Z[J1=V$8@4;#SOT-D:
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M#HOO@ $;3D <:+^LC1E+;"0H5B5C&5+.ZY&D997DV-L4G8GJG+W*Y;UO*DM
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M)^_&_J^L@@XG3YMU7,1'!HMAN[M'5PQL]OSE\Z:"@Z]O*8J? ,?V3T"^W"?
MAEE@D]?/WTW_HY!GR:5E\2HHYX-2X<YGU3%+T%0\2USNBPW3156MP.8CO^0G
M(.$XYA^,P%[]+]ZN3%WXW]X.]F-C3)"1.,2[O[Q3LK\,8QM3\FG![1-@!R''
M]'JL\N'S+'IX^OC6$NW<L '#_[:"(O@X$?.JE+%G]RP!VGR1GGY)2VUX.%4_
MNIJ8<-C<J'P^Y/X$!,]TQ1PD]^\Y+5WZ+,G=<>7,)T68$C0*4A&</W_(OUOV
M8&T]LV-%H ?*:W80DVXL>S.J"AX]"/VW'[?^UV2;\D^RG4]\]?Z/5&OZKU3+
M]/,=S^3CKDZN?\WF9"7')N[_;8F-Z%HN1/+ ]VS.+.%E7C!8H=S'^;?IP,'"
M.2>34*.QH;#6+)$YDO]N?H4U3=W=32(HB<M*DS'"52MIN$ !ZZ[2=TG$K@=Y
M)H]FB&^YTC_2SVN7+W,T@_*4\6KI^<3YMD#7_2=-7W2X'2$E])44TJNA#(>P
MEI2+.@9#XE!OYP\8J\5X"*1ZE=2:V@%=3W-#'#EI0P%OM0&^VQCQ3\#H)Z#A
M]NF=N.9P_]K-/J#HW;3H YF?K.3N2;: "YD'HD_C!3DZ!C,H.F)O7UDQ4+W+
M[B;N&O,34,F8_PEXR_+_!)A>>X%_O]J]\GA*"-I,GC^ -6ZKO>*JK$YAL.6T
M+LN6JA>O)-UR#;\G%92[J:/'-1IF-E)_N*$G=.J-8Z&J1*V>$JO]7'EM.!FI
M:%TV;Y.(&B&V>2XVP@V [+$E( /TZ?57X[)@=V&%=TK^*3&V$J4^&*?PHB.$
M-P*Y<#ZDV-@X;X.1T 0-5@E&7W_]M8N4PNZSLZ"I'E-.E*]#]B(S3$:70MP;
MHC6G)2#?]%CM'(1HU5SQGY'U/!@>R=[GUI=O-<,3 5:2X6/]Q<HHNZOP=G0=
MIN#$BFY6SG?11?XV#W:>:)X7FK1K-:=JDZZZDM&%=L+TC,DD^&G3.O8+G)9X
MPXKS?E-0: =2X+Y !MD4^%BZ$"ZK068*#XUEH.?%AX#P!8-JLGL""$;K,6YY
M5+@O,9#[<%=KFKZW)+"^(!W"HN'!(4R;? )4++RZ_+>]/P%G%3&7GX#B<T_/
M+*+#33O.C'VMAI/FD1NO>=DW9]%K2[9WJY#*02>8(0IY5X7?G#A^]-$8T0K,
MXR$1Y-?.B(2\E,8E1OQ+QW4NLFC6_H&VV[H*P2<T>=Q2TL=95T5=_]6PVD;O
MZW>E*GA!62"R7<M>9E$#-RQG*^NM[HU'YU*)JO+O1#,-RI!'<!'9H#'DW-17
M14CZ$MD2#W<61$FBO!2#U 4&FH48I@::I<PT94;:F'NOSE2!2LK3VT_9))=&
MF.QSBJK6RLX4HH::]$JOL\$"M.H:B[54?B1ZKI:2MD-N3*0FB.__Y+O]I=+B
MBMQ\S)E>>45"QC?"."1NEF&&?";+0\,(K0?M/\GKZZ7[Z[[7\="D\@'P7[1#
MBE8.(EK3M#$*0*J:A[&+BB2Q^B(A0$L^OM%C?VEA[8)]:(G0@<T^H*>OOC59
MWHQ="_20IYN+)3<OASY&\P"NHN:2TPTGC_50[TE>W'AV:Q5*8=*X)3D(5!H?
M=U,M\3!,H"!BH0X%=I1YO=;.-/'LB.1%K J.G)OACI<;4^EY8.^7DU+_W:VE
M=LB#I03#%8S5<>;#>JR&]VB*-OZ4YQ.\YO8^>0V1[6+_;1'$U=1';[@W8'^R
M3-SJ=@6;Y(DO^U=<7$QS7#@_O^3XYA1<E7OSC#'Y"<!5[SI:R=TK6@WQ22*2
M[O6..I5M$6^._03(R-\5JC:SK6=6_I+RD* ="<1.UJE.GT/%0 ]$]AN*:A&(
MMR!84=87PD6*C1X+L']ROIM#A5L^H.CN#V^RO]0S8U-@/A<'3L;6$@EFE.:%
MF]N:'1D?'!1[*2(ZX61A8DR<F:CH7V2=A1?>B&.;S(0,+33,LA0D)7/Z).=.
MX';!CCH,D\OOQ)3'>--H(O1N]9Z<Y-GPO5@T]@V.0N*39T5P@XS[:UH6$$)_
MM?7O\")569;))Q4B_-1&1 4D2IF.CEL_LR=;GQO #(QTW*7E)!C5]NX_A5>
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MNG-?PW"3$7F#_-;]+H4^*W!T'@9\XC $DK\ ,,U 3F3 T5U0ZVL>-7(<[G4
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M5; 7P P!,/Z^%9?G7UN&\=VAV)R&43J)GIS_/T5S3[52H-@: G_)YK/7 <Q
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MI,."L"_W3B3_X?%35'8C%3?X,_6*7?&C1?L.>K:P=367\VPO4W%65I_;[Q>
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M#3UQ%=D\+)76^58K#&A1)(NCO&,C2?Q%'M\@\<*04T74H=(Y0NHKBXC+U.A
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M(DUIZ;;;> 5525/5Z%=+&MUEC82!G93,I]^  .\U\\"&=R7E@4 'IX+ZR1'
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MM!\Z[T5''D(O@"=_AR$#_28Q*:JG'NY+^(H(Z+42.E]_02$,9:&H,VE&C=5
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M!3,29)2[0(+>QTH3Z(,+_+#3T\0E#BT3'WS&!4CV\XY_"18H0*/L=OH)C@
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M*;C/9QS/;"G M+9'=<AC7MVD^P%4!](Q?.I"#:@IQH0WS!6MXZX/[M!0G^+
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M,H/"'UK<@VH3S/;G^ $DD/1U3'[?&-.#0(>3F3_AT,\9%XQ*,"#R!!T8#'[
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MBU6H0\1XOMB3U(GDHD"&N-T6W!_O,!SFPT$2Q4\!3W>^*^" 4R"SLI#/(TJ
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MVOR4T@UBZRJJ[G@GJ<LOA-^[?K<(?R?W3V;US<@_*UTL";3^=P7G.W>[.W=
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M#"^KUPIK2\,8[A9=H3$/*(@W-&DI!B[&UA9;FK1,)F/=+[6GK0FYZ&N6!((
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MX#W??OA6+'3JM-K\RU%KP%+H]8;8*G@G>U>N-GO>N_)(+V;8JO#+>77 <E,
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MZF0,P:,1]$+O;V!G%AURO:_L>\(V^LE2DI.()E83.#Z2D.'EFY5E["Q&INV
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M?E]AEEIK<J)-*=2L'2$",S=:<K9:3O-DUFJ[JVNKC8C/QQ7VKC(^05,)Q=\
MHSA)U%,,0"]ZP+IPZD8.J-*2R,K#%IC]#+Q]"R);4\I8*]N5EJR,A2$5)'UV
M*I8B%A_9:>;0@G7"FP206H2>N& JHSERUI"/6)0GL[-L$%.T^<AIJ\GH< @\
M(. %INTV) A5E_B(JJ@TA1:SRZ884="]1:N0I,$X&5(V5PD.7&*134T7B2Q_
MFBQ7@>^#6D2-6RO'_5"_D6I4+2"TB.*-1HU0LW-9V+KV;Y>RGKY:I]^7QX(]
MUROU ?$I(P?C:D/WW^=9W&[K%NPXKB^I?=IZ?6A?>%_0KNYWOJ!Z:_BE-M/E
M]GKWP3E2VY#*5YAUYKD)O@?-;7JD8H.S[?E OXV75SFG3^PK=P=0:\YGDM\[
MSLTL;?"?GSZB%3Q*K+I07R_7[M:G?NE$9VA_O"FL#:?<*5D0.2!?#144Y3IS
MU&@?W-"JLJHFX>G+5;"C'?D01M=+)NU%EP1NH7F5'_)N^>%^<ZMF S:BV8R0
M<V[+]4E:?%<\#=@MA-2M_E7OF0/?:ULF9GO/6.VHNB(;*#$!IH/IS+@;YL$5
M:WB;!^V'M(M7]48LXI2S&X%%@8L>1J+M!<,,]X+S3>J6\LM<3_<%1:/T&G&#
M*6C4AD)FZ;N4SNJUHHG[#\ZAI9W8(,%=]7R.(+[1-&JS,-Q.2HPGM;8N#"I,
ML&6OG,#R$R/\^V$KBXJSJC0*1L=^?%"ZAL2IYY)YR"U-<3YRLV'5'4-A\R*,
M]*PY&57US1@')(KS@J9P@=1F$VSY[S1$P:"%4D9W'A#_KHYE1='0)C\S[@R_
M2-_$T5L;H=I,_\R7O(='<4V\VYA&=3UH[#)-BP>/=SNQN8REMO3#2!06QHT4
M]'-78N/U%:=35R8?-G:O]7PR_@KCH86<XG'M5W_-N/"E <&]]TU6ARV0?1J+
MUZ"N1LEZ,J?-M$8DG<N@\KF=0F'&8X>9R4,5 ).D44;12\)DW%[3ROO2O!P^
M,;G-\3ZD<_U:JI@IK^HQS'ES8ED:B-C!WC[.G7/AJZUQ(6%]&I%"*$ ,8R;B
M8-XS:N$,([O/(/N>9V*O7S)&=]L2 ]GDF)?T3(Q)7HS/U.R/[Z;L&M@&,3)7
M4D\+=DKHBW:<P$;!>#.J;XZJ$J+9[$##/J0A-:>&:2&WE UE0Z^&Y%$=JW"6
M!>=SECTWGK0].8.<JPE*/F\9L08:*E8Y2=.4LL2S=L^DQ.W#/T&#?D9B[OE0
MQ_H(D7^[1Q4;-MH7.>:UC#'XPJ-R(;D;=2E!+S1-4@$I4)JYVF98OJJ;%)/[
M/0MF,ECS/H_A"LC9,(#?]FW54$4S>1T#FF8><FN*8,Y4:]#L4#VD&D+>=/ZA
MXWZJSKRK5S)SO3SI[()NN G2&1L1= J+-DW13'2HJ)H#YZ'%F!2EF0][A++S
M"Q">]H>3#YXNEZ<ZG6+55X%]9NA&.<OV0J)0]"">O-(YP)5.00NQ@!FD#WF@
ME1-K,)Z&$M?CT8*XA#81[6:S61 ]:6Q:-,?T&SNSZ\]MN46J3(P]_TQCXEYL
M7!#<)W>MTQC&==H<GN%A((Z]CJ06=@BK9M9.M50O'*_G_S3?9Y))'@QD?7V-
M6;<[OIB4);^V+9JCPJ2\_D_LTR^6EZ!""N7: WKKW"0&#CWYC%/&WMQ<\55Z
M#G<Q>M[B!7:!C<..A))J]'#B&K8,=+H_.E]TR5XYIN/J28&R\6_"T?_=L$1?
MLITI)K/@0P.=YCUP;J^]V(7EJX$$Y3+FZ4[KYOK$6L:[J3+FF[,$L)%?REI8
MN13;*6![QT^I4:]0'SBG(!$T*/>]"X*\)^+4+:LG]2]O=$?B/DD:LBDUPTT$
MY\?:I#9*Q+!I;]+P3#>W5C.>,6")M2"R'F2L/19V0IIXHRN/(&&TE.]]&K!O
MFTXR856-FJ$;K#0G0Q568=?I3(HHVV!RL+HYX\#'ZF77O-?*$G8YA:%89W^-
M"3[3ED:2ICTAA E2[FV<<:+UOO7<VM[8*27IVU^=FD6=:1XQ!E R=&B)3[Z-
M)W?UC4TGR?9M!^]JS->&3RI4M-N6F;K+1)YQYY ^85RPQ;]N/P\B2DGB\A5(
MV-DR)NFK34XPJ(:OYVQJ&.J3<<!94C5PI['G1 Z+?\JM&)EJ:E(FVA[L&*93
M*S>A8].H@3.V<1^ZL1]EE&R3\!A];GK,.KWQ5=97&(IW)AEV)B[%JS3VF:P2
M%0<.*?JIN=L@7A/-NQ7N)CHA9D)2@5X26YG^S/VI;LY9=TCE; K2&[A*F#KS
MI&W-3&]M7$(JJ^DQ,;RL]P'8(@:)62&:MJWEF:L7XXO)0QA*"A'25 VI/ O'
MJ4Z/E\\HG1H5:]6C;)+9FH2J/9I@5@>$UYS,L$JZHI-3"17HIP=Z1:Y%LAV,
MJMLRK@XI&NS5J^L!+?4=K[109TMQJRMHJ[!VE-C+L*6;RN+KKU328L5[2XG9
MG+@1Z?0697)7\)T^::2H0)(+?6\S7/JR145%7VBZ/2A8' S.OXR.Q#(?;?D*
M8X:L3_D.LR0M]G2XW6:Z?D3:YIGL$YVG<Q\&XP&M$=2&GF3%#@81!''/%BBN
MI9YK"4L<7B1\FBEWW,;*:Y&4_YCL%T3"_J;AL<P'UZLI+#:VA>!Y?0"#[Y'.
M>@%7+N\"<UY@YMG'D&P\0V=[K6JRE^@E6<;(V!O[YVFK:MLJVEF]>#56AZS-
M#Y^2SF!;QB+2#:+/!#:BL<[H*1."-8L_B:,"4MXG4LRPU7T(U(('T'KNK+Z(
M\1<@0!WEQX*'SVZL*3_Q'\5T(JG:T,2:72JA, UBUUBF\/)>WFDT45?3L5$1
M-GTN,U9:5T-@N2OBEO]BB4[C,8!_2LF([@T5\>?'QA5,[C&A ;'K=V8G&5#1
MF6,"Y#/EP=+=YV3&]U8A$64APF:\EZOAX.._R-'-THV'V+]EI;2LVT1;2#7,
MLSV+S$DA;.VL\)$I\OI*)$GL1..W[P'\:/J@BKJ6RN'WX%:X]_.PF_D0APDT
M!,[K*7=-1$X=@MIR>-M^;&-X%PR*>P%YG#(WK&^Z%B.XL%^P%KQ*N07=XBU'
M2U51O,D:O8KT\F-8TGRP$)]PY3%?>2(Q+_;*7U8M-,>'\<G:CNBB7RJC6)%?
M^%<8?/*@Z[XUAJYQD<2.D[-L!]'AQ.RIUST!X5AO;M=.$E:V*0;-/*_4&K*M
M%-5VWINW]R";?3GY-'!\A@WB$+YCH59+QW!V5/UH-:@JP//&\I,W<LUS"M&$
M@Z+?<.;R%8%?4,9^H' QM3^@<"NTK_<I9__!.S%B48HG^X7(,?G7MA>6^5\R
M+YAOU-VQCQY$9F.+7VC!]TWZU2NS3I>;NSV;4#'D6[ 9'PCCQ0D427J?0!QI
MADK4TXD/;+R@>6;G&5^UBDO.2M1UO"5KKNW6<"IO:/ =6OAUPL'+['^3+'77
M7)H!JM<$7QX*(5_&]/XOT.8<GN(LQF2#[&&9Y>L^3I6GATTI&G%5%7SV[]1/
MT-8O61R>5BT/IF6L^ZK: :RDPD2@N?V#T.0TZ/"*)O1I%O%:AI>G$S[Y:U.R
M,;.CLJ2MD>];#'#(,+"VMG'T(K4JV$!1'/==1:BV+JO>8[CGX;<RGQ&7"#NX
M<^5$-FDRV%RB&O;"$K*1=9.VNL0,.E0YLP0^H&YUYKA_]O1&7DMK%QT49#[3
MWKJ,J_T*D]'\7<$E10MR,O[A&5\^ @).4[YW%?R&K.F[-A@O-"8>Y1:)O8K*
MOMGXH6EC S^IO1VD13L_VL39YTFX+JQ#\Z3T2N"1!W0EL?0\H>5[2LXOE$&I
M&K0T1-X\R89^22]FQ\L ,=_'5M9$A]\2"-RN@[_";+%]5Z"B7Z*KWG;)V!&-
M]5<8 >AWXVCMY^6VRZ@&>)&*?1[Z;GC-;! YP163RW7_PE>84>/O)DF\?KA=
M.:&5_4YV[(OS#VL7Z7<K5*J74Y*#AS@"(5&K+ @N">BQ*12UZ':&!A4UW5/Q
M=''QO-6,$4\JA>C.!- GC-C*"^@,*/R!%VA//F5K\,89AZ=!%7^T/=1/:NWC
MR/KMOH#*CYJ?VUI0/YM?GX$#VM"FVUAOTFV_PI!=+H_8YNE='BGO^1%/13%]
M< :4P</@FQX\=TKL<^NM3<%N<5?IHIY!UK,V$I9\7T^]Y_G8B""@<A]5@TIO
M3$1WQ-E68C+/&C0Z>5^@T4')%2M7]'S+N/Y%/JU*1I)MLD.NX-;Y^+/9<Q6M
M@OX8*<794TG96Q1#'7T6%04DUH8^QX=:2YA4>-.KT^;=FHZCH^ST#W28_,W-
M"ZK"6!6H6/D-EAEMJ<LATQ[("HY&[?H0V&%5R?H :P].GX0EPD8AIQ35E]G^
MT[-,B"&*#(@SP\:\K^+@R\&PXV/X%(JUQZTH'PD?.IB:*X8=%9TMSTZ1W!+W
MQDI?$U0WY>)M-S0>!U*])4[N?^CLG:>J%&'6ZH%9CGU$;$BL$9Y?VGOB^P3J
M/WX-8>8XG)K]G#A9Q%[R4IG!0E!RZ=F#</64+O?5.L;R4,U&35HZ*38'HZ-\
MH[LM3;<T'=FJR/Y!"^[<8U1T"@LGZ1E(G[730AD'//U1/9/W(Y!B&1:9*?[:
M#&:J;4VC DIE+HGA+;56<3 Z68S-C*ZG8SL6:F,] 9Z)5#2O@TX'G@,PJ7G&
M3+ZY4^F0?S%V^CD+!TA0L&>46A.0Y..]472H26*G7,T[@!Z^&)LTHLP5)["E
M^5[_>3>JHBTCE D:YBA(T_@5!AM.0AB!H.&%CQ"OY?[>GHB8YF ;28X*Y,(J
M,O-8V81^4NTE0R1LMK3]CO)F9WQ 37-Q]4."%I;5F7E-NL@:/7M833M\]/IF
MPU%O[S5<"..SZ6ZB*"5 \MLD\C;Q(4=J@[>4+4\L]YB4)L(-_124(H6OTY/8
MWO,*FI*TU Y+<AE'5M0T=:[6R7FY6QO;:KSQDJB_86U23/-E=* MP:H;!$R&
MN:>\$DE>S.HE;M')N%>=/Z+>8ZHZOKL<CY. O\MGV[)3!9=A&X%BS9JX),A;
MA9G'DT>PI)/8Y8@M7V8*SM^ &TX'EZJ^;JI92>P:9<54=F;F6C<@6QY( ;[J
M@N8:NLK%]YFZPQFQRP'+V+UF#"1-%LICG":.,\6!F^-)%4+.9-$C,[!@N=8E
MVH8/6 V/@!,$S>'ZMEL9GYZ0 V=*VHK9]6KW/RWB/E'?XR%W?]=-(%-DGJ/:
M=3XJVF;75EHX\0P\V6H0-MN$K2\[URK(Y<N15.Y"0C6%W4H^6&ZZ89#$F'II
MNSL+.&OCDAYHDQEP;ADD!O2T4;!O<,7!MGHINX60>7?6E<QMEBC7<<_2ROHQ
M/FSHODE++ERK)6$WE';G0_>H+"C*]T5(4C+N3HDWD?)P9:$J+L%JCC4 723F
ME)+27AF\%%)8:M%Y0DD^J66YPS1"46U:XZ# (T2J,]KI]G&LWGZRS#6L40@^
M:5JSM)7W/):.:8::9CR.NCJ(\--YP[H.Y%RF\TWA!H?I)QW4EG8FJ?T.W 7V
MA2.<@R,D.GINH37&;4HJ5+.'#T,O-8:Z/1WFJ9:/H,N81&@Z;<7[=?M=Q.,S
MHXMGO1'5,U2=<WIV!DL&OH$9]:]\>3/H#FJOZ'6W&9@K'$-\C!3*IS*EW";T
M-,Q6%DZ-*"(L.8?F,2*KDQWRGB67(,WIYD70\0ZP!17H=:WB&V\8.IDD@"4=
M)29XV0>(_?I+W30N]SBGJS'*DP=L\I$:/V9(2DK59+G8ZIBUD3H7E>C6!.'7
MO>F2CPV9O-@16L\K>RI8139JS-(GF:AM!&RXD#'ZS2%GS.<K3+]>92Y$S,7[
M5=E7&&;#+W'!E\FENT&CB!7MQ:^K6\Y9Y\S!Y$I:\SI&2$,S\BB;/?D1S!0Z
M@3D19,8C:'D<1KK&,6'5U<%K76/;C [US!->LTLZ/A>MD?I.A[A4_5:87=Y4
MBM!ZNE2A8+!0BP&1;F>3NW68JCBM)K<H?I@FD)LQ!=2UG*HQ7E6D_RZJ\#*,
M3';\X]IC752X/)\M^W.K^D4/5B4'R!C,,FDEWC6'V9)YKGQ9FR019!#7YDD"
M*<.)0(HK4Z%E'L'[IX#459KFA[Z?5:7I*# 1=<W61/E/1O1/KL]GS^VN9L>I
M+-G(2RE>S::3:WO!DC/Z(8G9HN12H!IS<%5]/AXU"0I=X/EXD=9$L[D5C&1.
M$&=Z8I3%\VH&A4:D:0QG96G]X_0SK89E%W3*&RX?93+;I#S]RL30PY!WSW-+
MKAR.(L.?=119ZM,@7]7-?ZZ*@UG@K']EO]<9,T0:GGH3HP[GY7/]A>:5CC"[
MT]65[7Z/RAH-'3/(X%Q8%CU("$?KH-[>)IPEV]4-/CLJ-H1UEN3 N=HL]@8*
MD+J J3_ARL^B[.AA#-H=2W\_TUNLHWKB-CBEA>AN,L4;?I"(POS0^@#*P9&0
M,X+BNQZ_7CHL)MACA&Q _H"KW-U'/*?>;'PY7*,+$II$%A%NMAY]2/%EU#\\
MX8@\8I)D>B'\_-)RCNGIWHR7!_<GKK-G5;!S0%0ALSB.-QE]_<!X3M/2!3!+
M>+I(X,?2\S5KZ@Y/]9+)>2WBL]7RQ(O3\E1-_=&E\CJYY0)%3XR0"-DZR6ZN
M$KBF[I?Q2/66A(H2EZ&/R6B?%1>@4_ 9H;&1=;I[GVG:F64'!%RL#3:C'V0;
MDYSI?GE?W!.Y#>?.>R^%7EN"DS(8R[G3')8;U[R.125#G:0G<8+$0"'V\%ZP
M7O2]>-3B7.M6<N4'_O[1_MZ-]9?@$B,C()_"7,<8R1.2/HN7F56#2G#9&*JM
MABHAQCLZ"@(FB38HD],]XAE[EDPO'LYITG1$HCEHE./:H^%$>IZ4E:SF_OG3
MB9P]P)<B74 &J_ 'G^K2ISDS]A@Q>?5AB%*AF%!A]R9<K_AG7H5F-3LD$QG]
M)TKA,20D^:RB.@S$&4YCJTQ<(@:G>F&9J7O[C#.?V" FD*NR*;!%B%*0(X*X
M)FCZ\>J(N4V<IU8V$>F*!&'W@A(K&PENJE-Z9\W9?/FK-X>B,61^=?U'Y*\K
M_,-;D \=1 U]@9(-#0VTFC:YR,"H!UZEP]DLE"D,->K=-M!! :H3*1-"E>9U
M$@<H59.@-ZWPXHO^+C#%VG9)_]$EV5X$GK<MXW$(;E!3O>5$;S2?/I8D_9L2
MA:>&_6?ZW*F5F(D#;M7\:U7A&,_GGU<(B4#EW_AQ?IQNVH,&O?6CN.U-<IIU
M%VUKP>&ASO0M7$+7G1URIW(KY9?*AZF0JM$'(@'1,YGDZU_=,$;6I8Y4IY"'
MT=59, .G<SE\2N+>ZV7C%_VEE2K>NL.7VUQBAMJZ2Q&\Y+59KKL>7V.S+ S2
MZY-_J- _07KLK+0=1C##T\F]Y>:IB'>JR[^EJD,TW<I>=(!+CY%J;15L&6C%
M?W^75(AS6S=%?IC@D0 B_-,'"<1=+"KW[2H58VBYGQ*=L&)QE]H991V%O;E<
M%:'.N1>0C77D8 QQ+"?J?ZB;XB%:9%>CZ+LB508!&P;"JCUD ]#CDJ*T1)KY
MEJRME'!M29E+Q5/+:C[R:U@<O9^,#3W3GI%T7Y^F?EM3IV2W!QV=HI4(<X*X
MK5;C#.;7.%X7SS=(RS]<?-)/Q? E"YWVA&# \2O,0'0*V4T6AT\4E]#NHGV-
M(<Y \G.(PX$/\K9E2S<SPF1R5>Y3V3AGM A,(&=D7"J1 7XJ;H'"TP^?G=/=
ME <LT,]7^QT:OK&VA!YOZ4SZ="DA.J73NU]4XAY+WI-.M<G\4@+[!E%A/4TV
MDCY,)DT;#@'_WBB59%)(_F!_H">P4:13+__.B\(M/<(OVYK=$+PNJ-0.',!O
M%!]_EBD/,GTU2YJM3X!DQ$$?7]5E(-V/#D>V@[.B^%RA:6)MR._Y:%-HI@.:
MV>4#&56Y@';VQF#3-RK!-:@4WBW&!L>@W'H>C9S:57Q<1=+Y4VX6+R*V=BQ+
M/:W/*O*1IU$",6EZ&<Z,.J*_.H*KQ[WNV/M@A"XX<V:$0A(B64'=J4W.U0LI
M467WT+(M1FLT"(F)9<&?^N1/4SU!MY^+H0EO3>QDB:MNV9^9$'GY<6T88XM"
M6=O26XRD.0\B(L-[? (\4'%D4WF6_L3^9,V4&?NUZQ#GAR%/>?>TAXVH"7:,
M$O'&3U#9!Z6=.4RU]"'&;OS?=)&VFK6\Z%]O3./ 6<N(L[?Z-&<]%\, 4:VS
MM\V4 1QR1M2U/IBL,NF64Q"-_(PWS'D8DYQ+OX&NKBM<";GI.L/O%6,6\>F,
MD*GC@5@].@&\[.LYE73\-0-]J[ NFU<G1S 5!B3"M%J5.6%,N[V&G5]A]N+,
MRYRM1/<)7J=J+-M2HUQ>'O*,M;<G%Q-DC=BU,@,D[3/,2[1+DT2Q_+Y<$>HP
MF YP&C8HY]\G8=HR'[YG:<4)(A=V <NE)+U>%R"V1N^R6T,.I<EZ,]:>)"MQ
M<'E) #6ZALTO-L=,JW,0Y/B4M!O.7D!3:TXBW\DX!NB*8^&$0?>W[;1 6=76
M[1'E\7U%X&\LOU;-^%ECZ6Y9>ZV-28IO^MHUGK>5M'UXJE:.Z7$D*8/.K\LW
M93CW"@,%JGX/_PV2/\.N)+X)2";' )410H6(^_AYC$AJW/$:<M/TNL?IA@[)
M9M]<"O''8&W'Q"$-?G5*@C3!9ALD9U\)$)&Y>J?FB\A,)FE/! N%*&J$/B-I
MKTAYX/8A_U)YB4;0LN*K3_^%MY3KDDK/'$V'SL-?F#.*SX)L-JZFVB'7Z35/
M+PPTEO2TW=U+^6QIU'=C>9(;4([G0T#C@I[J5QG+KDXAG:0UT?-4J=;PYF)&
MBWB'<\E'-:G2 R-#=I]MPL#5C8CU2X>$C*B/(7S(^<_M74MRS@=Z^I5GXS#[
M5;@*7PL&?4)0\JMW3R8WMHF(;M49E+Y^N=$4%EM1]M(L&+-I5=%HP3 ]\&E-
M<323(EW3KC$I3+U3ZH7WN1] B85$=6$^97^JO+4B* VF5#63U'<!L1[2N7<+
MC##!?Q,*G)&=<=%>#H74KA%)?^;JM:O]N)9(1&'@7#>&5)_YJ:ISPVA%:H_S
MP 6AC^9M1BAJ\_$1+H:M0QT!E;-W3WEQ,6LB'9L:B*Z13,EAX-Q%>1&^@EYX
M0;.1W9CF^4@;(I=E!5FZ/=7VGE-!8GUSUGIP@8^,?,AJX/ABAA'A@=;"P=Q4
M+N]T2>M\&;Z!PNQD*]=^6BC!2+#P6\QJX=ZB''J"Q&[%+UT%2CFZ>P!FC5;>
MM*<+]F7FT0(HV!/-[D=>)(/'0PF:Z4IV;ZD^$KTU]C@>GSS8MEMA*4\>&M^@
MMSBJ)2\D3C8*+^S06CKK_6BMO&0LK5D:/O7:2+RM+:@YO@B/5RF4%+2%^[9X
M-WR*[=7::!^Z+\M^@R&[\<4CJ_9'I6>M!QG1YYS&'(0)*@T=183LNH)6.0>E
MXNJ-1,]F:PC$+9D:-/2$0!W)):7ZU/K;XZ\9]-.,M3PDG0T*Z3.CH)[>RK*D
M=777D,$$<F<C.RD5!9S#CP<53(*TPF$8 H3"EL:T7(5T[,"SAI7(>2[[Y0-F
ML)UP: H4FM1('AH_% 'JJ3)MZ,N8]U(&-)A(AV8; XR5JJ?J!C/D]#4PT%I%
MX':%-BIF<I9FG'JXJZ)V\Q>.0#MJ&2%RC]S3FDNV#$LJ4<6,RGM#:QC73UG0
M <GHF.2[(H(*D9BCBMBGNI73P*:85CLTIRZ[E:9G;W,&)P =YV]P-I")_<[9
M\!/!+18E]96PJ(Z.J^S[MJV,QB%Q3@OBB>L<^RE$[^B@CIA26L/X_%/B2D"0
M"G)\'4UX8EM,=)2N.XT1XHP0DXKRO6L;^>>5.I'M1FWIN?,.,X'($ET,_+"3
M:6>)'97*CV^"O8PR *464>2S%O-V,*@--ZI@=)8M"(=TJ![YC.,ZSX-GTPT6
M\E*J)2A>R9M4;$_+L&R,0[0E6 :\$)BJ]O*E)9,+295&BMR'@DNP9-TN$M<4
M#-.A4-W"P7@U.KH4<4K!+GL$;=*A>J.='B:/W;GSC+WLH_?J7V&*>0\-[_9'
M*M/784VW([M-"U]TZV]IT(]8]6:0,]!- C1N [3M20K>'=3LD7S)?C1O1$<5
M5\7V9J^S;Y'-ME)&^YYM37H$<0T2!Q-U+04A_>O+G+DDQN-.K17]\T[79]5F
M[5Q*XRN.ROP5PJOS4:]UIUI#$G-#&L,_#<[#,X2]M'K1;24=!NX%EFA>FBL_
MY7GZZLN.$.N1,0SCR--CU0E^,B;6A3;MZ6L7,_0%/GHP+HO$@.VDTP3"J%FD
M5IK\YHR ;B@7'E0G'DZIU-DDV!AAQ.MD]MXD9:<[-W%82E;>R[+LQKG(VR1X
MM NK\PZ\&%%,@(;FJ4+QM%ERM)A^NQ6N;$SE=LM@FT>P:W:YE0E%55_Q7LLZ
M7T=B5?PLUZ99JM[Y;G]2.MT,*L/[[NSNN0]'M8^4YL/?C>"U@ILM&W!HXX5H
M'Q]0>@U7<-Z& O%3[H,F-Y/=3;RM)AIKC:K>$H :GD0?RT16]:9KEP[?*_05
M<-[:.NBC>#>&UC1\+>8FD:<3^)'=R)YEJH%C),\$FZ< :P@%5"S:57!@PTV%
MVVP_1)>+GP1&T[8HB!:OZFDPL"#F-JB=CYQ61X&1X?+3/[4@NCQ\&2L:;A]>
M]MARE_2^\_2^...H_<.&EMOX4K3N-LUKV!?M%7[GVJ&&%*S]!':6LN5F:Z@+
MQV1%""Q<UPC71>A$V@'L.M[7S)-, 4"TA4.O)D,FOLFKWJ$*1%P"BI?/. RK
MM"%U9\,9!BTM[L)OG')-Y9-DZ-)O5'S/,YQ(7=,29N-P(J%:&3[7UPFFJYF8
M4\D:UR:MU1'E5STM[U_$S:>0AH[C@K#F>=T*V\%SR<BERN/ /9EVW135 DPS
MO#.^G1"X:1GQ6IU1*XVMR))L/K%'\&.\#^0OS,^OE!^KKA^^B2!I3<"3QL(?
M+4'%-S@]6TH2;N[ A=NMWF <5G+^"%E/XZ6,LM>1FD>#O!4-NA<9F$I=.'$C
MG-<ZC>POD#9X:Y2[N_BF*UA;>>;+ED5]2M/S>8_M>F(^AJ%T?%K:V5RE4AT[
M\Z#P3V;ZG,2X]_BW67E22)4$I%)5"8@OSZY55(3_SENEU?Z?9S[<CWI+X[TY
MP:,2:^*?8OS));$-:!]8K!TADCP)D!^X#%>)/3?.3W5//=E(?)F$*<12)3+[
MR,Z8Z".. *7%T/NEZ+45=7$&4=7#X<L8D@CB;1&Z\%<O:XW8S7G1)!TXB!U"
M=DYD,>$A,U;U5$XK]G&EK'JE!_UP$ FZ6W(2:G2K1= G&LHW?5V?A>0$.LXO
MS*+?8SMPKO6O.Y&_]1%R=MDM3;Z=7)29<;?<[ &&$W;3#?<7 &*K]F(,\W:D
MO/$5>N(#B4O5MSF+0S* Q^:8TB0K#_?C'9XR#DP4 6)"4]JC/3_??.&A?!#
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MQSOI8D2J;&,.L5?]U@/_J:S.X1<Z/9$R$'2MKHM# 2;2C,)@##BVUOL8RVN
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M:_"5YU:66E5WH7$,77*^G!<=5M6UC5N*NM>+WK=HDI,^FOFQ/J43*9G1NQ3
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M+H6^^FV;^A\_'4)_!=B/^B=0"/^^]97PH(D/\*#U/%-9Z1!<C(TL%\R9RZX
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M%L[9F:54N*Y^72?P*S<FG7CGJ+)LX5>!?-PT=H 5HEFG+:9/D5,#M&X("S.
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M&>(89JPAHBQ+\B$1A.!LT^&_>I=2%Z>:AF*]1LZJO#[-IZ'P[B9@=H="85;
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M^%W 7#4CM\ZS;0,J>:LB!*Y>@0P"K--48[KB2M#="HG$1&S'%8_^N)4%O6]
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MRA8R3%5)A;@-W71.TR0J@!C)O[."KW%1[N**29T-]=]>=29+6LTZ8\=2,KI
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M<?=1SZ"%!YIK4<<N/Z@$>!.!J2HTF62345HQ%<VXUO.R*<<M/(Y_:<BJP#W
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M_+T$E"MQM%J#Q.J]RK&LS4WM\^=Y4B87A48.C&;D"HDVX>SF(BSK62I!1GM
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M*>Q^!-Z0W70.=_HG7^GK/;D9O#Z93"4WD7+?!#MI11'A^]\O_@FFDW4KQ23
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M05NRT+;,>]HDP/HO1E[X=^+ H%ZU[6)<D9U:EMW*F]G!7SOCZ\=7&U\'F<^
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M9W>_[['!*HF%]>_)ECFZH]96)E4Q,'3<@N,F.V<<>6XNL)*5TV3Q,#[F#:7
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MW,_(_*'U6TSM7%4;_D#4W%:0WIF0I6A2N*XA:^L?K6!#6A/TMGOJ]^5,GW#
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MZYRR!4.2<JSF_1X3M'ISG$^JQ&=*3ZL#."0RSZZ-QK8_^RC\#O'@.MJPJC=
MFAT,--&DWQ?WM..D#1-1Q4S3=T@+[?H5LL]K.\A.OCUL<&)7UJKUI5)QH^41
M&DO1@+N[;&UMO:G"LPMY?I7(E!ZI5&HY?"3GW+)\6'M]W IJ#*[RJ."F6M(=
MZ[4NJ,LI[RNTYLI/Y8HQ=@[==\W5/,#R<NUZUS#D)[SY-BV3\:XMY_E?'#9V
M4[F/L_GK"99RQET^4XGJ#7LSD'X:$Z0I><JRDV2*?16#OKIGNQ?1V9(3N(L@
MI'"Q'_IK(/(3"K^5LR3]RYGX*W^)3SE/7!5Z]<+I >[/:Q*0L*@OESDQ#07D
MN61]\3Q$"V\6/3R3NY=OM\R<7](\>,?QM6X$=561FY>"!CM3?!*UVN/W)O9/
M6*&76%T=&,D.ZUDDYBJI-Q(9^LDK3P?F2:OEIKWJ?P29U** 4B7<L5"R<.*>
MF2P2^8]%RMLTJ=NSVM$ES'T:0-(\,8Z;?X73EB6QFCS)]F=Z2_3+^0BY_3?)
MF3>J%@(7=]:;#"':%MSZGZ)Q]1_[Q#HWK70N!SSQB$C;V3'9UT5M!"_:",L8
M06:"3W?JG$[%5?@-!7G<BQIP3_='L%LF:SU%$1PV#A:U(>[]Y#S.[(%R!YF-
MG[((M"*M5\,\U]ZK2Y):%;&OOV'_BV-ZI,@\2GJOGQ>,F-<_=Q(,\(JVB &T
M?GZF]UHT3/;2(9:2GJW@V#EZRAO%,N(8H59BE@1QGJ+6/ _-H WHOFB W*X8
M0%>0J;KBU %9YF6^5P<$]:_F<*($?:#D2[WRENE5^,DV9Q+OVM@.6JC_XD#*
M)IBCESQ]7D*BO>998VORN!]0(!YW!7WD/;T<S*NI,:LXD]R/;&%URDXW4W15
MW:-JHA0B;H_30VJ_TV>S^[/(LGC[JC;2M>C#DH;T#J'R^5HHZ?:A,["#_0>N
M[965A#IU;E\<N0I3[J>*A)R]?D=']M)QG6S\4'ZN$I4W_:4=%H]6KY98$WX0
M\IYTXN2?4<!ZJI),"&9.4!2:J*\'[S1[LB?>40[&87&H[Z6(]3W(R#2?]F5E
M/Y(42F:),995N%\/"73!FGK.G/A[03\M$0@QG%*Z>)RHIJ>[T)0E#[(FCZ4.
M6!"#=RF6K":K%RQRW]XQY,6\&[!#$:>?ACM7C%U64<H3B8:Q_79?F;&2FTY<
M;98B#>C)/J6@)UL45?7>8Q02YW=:N\6S#=IM8""Q8V]G\ZY^BW5O,T,-BW/,
M/H22I[<IRKNW5NGZ#N1]:IL_.3LT1PVI_E<'\?M]O6 -Q7QQE?12\R2^KO2S
M#*,1'D'R_]1#F**7)C;BB8-5'E6:7W6W+Y.;O&MZQMGN8UF6E9X*Y>+JRU9J
M-2QBF#GX.I/C81RK#72@%)TZT!F5EO( *&>462BC>(;75/: @-3LB"(E\/RY
M9S$EG=PO0RX3]RZKX<LPFG6MY+65Z#8FKEI#^)-""U\[SQK.>79Q2PY2H(6N
M%Q. @()Z^R/+5485O1CZU4_K=J&7),[I04NZIOEGA8EP+%@>#T:ZX=G)^8.S
M6;2^./$]YV#3(FQ.:0E%</Y-@)IXE?3S<;;%Z/*<]C[1,NE!SE+2'/5"#$IG
M1.O!TC@BNKW/?U#/:D6H+8]2@9$F^Q@6Q;#&.YY$1,^#UHRJF E8JC3W\=D4
MSKN@Z-<_5G:/2PP"%7ACYL?#A)!> C!_9DCPAR5JW:P?'A8&4KX6A#F^\W+M
MR(>O$EJ@?WIQ%P,2T]Q3AYV6TF]@ V% 09B7XQ2-E*B<T/'58-G+:*-PE@YC
MV(\"#DT7=VWP:B1/?'IZ.U#YD<L^>MX+R6%+3(TU3(A9FVMS;&EV0GD10.<;
M7C;374SHP4B@\HS1\9J&F ,SN.?3LI9A2V14/!DH/<;R+\Y^>DS<Y&_0T/I%
MPH;?U&4)Y+)#2K?E(X+IF]]RJN3U_6MS*Q>5SJ(DH,(2HZN4/I?@'9E- FH"
M/4;(SRM@&%]!Z?$VGL+/!ZZY?"]=;6O)W,NYDCBW5*[>+K6.<PEC8.+ E'-D
M+U3L]EIK<2RSP348MT3DE;EBG7K^^<(;-XW5M"(Y])3A8^YNGD0F9,E/*TTR
M40>1(.\2BO<"  H^ KYNS]Y6A> 2L/"<QW"-N+ DZ6+U;5'V<TZS4RHS927A
M\\#?EBXR"%?@ ;^;V:]I[\FC3VV(7WSYLFXDD#DZ!EHDM]"+YO<DN,H?7SH&
M,JT!>#0UV<M3230/TM4TGG.EU7YX)_ET)\MUJ[8<MI (LU6(0ZI\//EF9R_$
MP=U#C?*N:]=[^G3]42[DT6EB?@4O3]VAD,: ;/(MB]TRL[XO*[I670M:!ZTA
M</WHI_PP8-*^I'[1[WE*(%$@\N&4A2V9L]SR%^&75.[)OP-;Q#=IN$.;))H*
MGX*$+3/Z[HMU/QF_W+^^"7&WW#.:3S!N,"J;._(^3"XWJC7ZMJ_#T$P7;4HH
M2JYD\G#>BAMZ]FMG5]7=W.=R*]B.$TR[-]9L:3''!A]RLKR#C[":S-<+#=GR
MN0U5NZ]J]!MFT7JG]9%_IL2+#BTAAD)+2)1\=*E3T])]=''PN+_QY3W3L6+Y
M]:][4S$7DG:F"5GYN? &,X4J$L@WJ6]1^T%1UF1?'0%UM8S]UK"VA5W*P$#,
M=^H=WV@^QB&*N0VV+[!W'ME%56V/?>PT\(I/M 2<G/B:% 5X2 ^R<-2(Z7V;
M-Y K]===ZP10'?0ZQ[I]U:'+:XKK/2D&HJ< G:CV8I B6(,]S6QBGLS.7&XX
MO!+3A=CRHX@)J&O"U!V2I8M*)/,6.T6) *W5TAHJGIG1TB'MK55'4Q$W#,6V
M"@R6Y;*V(;J6607#28771849J98I]""&,0W-L9,O2L1N6>FOBLP]GM EK"E(
MK7%*UCB<G,J)578JM:DO9B\BZ-J$W<%>^H5@[^)6IAW+8"U;BD^6L-906P^1
MCA8!G7]EO494O3_?%_%9L6%B-#%G9'Y;;T[#0D5DS1/]H\\P6!@'!7*$BR2B
M;<6O0U*J8@>]J]T6RPN*&U@);UJ<19?SDCIT^/18;IX$" B&B]<;YD0AV7&T
MX/E I?)1   &!!'.UTM%N]P_.0+D[^QS"QN:A,D[.VQ3Z%3M?U9JP1J@D2B0
M <@J]U9_QVZ(C#3(#;*@/Z$G$W>JXS]3(/74\Z*/.C%\T[% JS$5C;S-KHWH
MKEZYZF1?W%]IVHR,I5O/:!](+WJ]9*G^?2\"/W'U:6]<:OR B8<TMOOD<(YN
MAET86PF1!;.;K_#HE.@00#L$G89$H.ANU,^]O?SE\MQZ"]WHH^\2G2&*J@;*
M0T"A34G'-P]8.K;VRCF6:;@< ;5!JVX4,0-346U,@H(]!Q,H69.IN0+S%7]Y
M>H8#GHQ%>=OX]U!%QRZ>W'U\6B>#RI=A*UYJZ3&.C:WH"_,PY#ZIB6AWX&&Q
M.%<3((=KS.V?6X2V3U23P0;W6+-*S$'I&HR@M_C>[!&J1JI9O'0Q2)6PE3ES
M T.1YF8LBK^\$M9:'LUA^S":.YK[FR8^GED$\VK+'&CWO,=RID]@BL/<6AU/
M'L[ ,>0R,"!,$FOO&MSXCHJ%B^8KXH\3C]F-+T67GU=I0[I%EE^3!,_!7QP7
M9^VC\^)S#!?(*>OM>L7HEU%4M,/QZ_(P:1)L6(&A1CSC.HQ ":/E]WJ6UQ%
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M=5'LIUMH.XL&ZX_:DAS[2>>G[1=B@%@+E2H?B*'7TUV]UIWUN"]<0*742\K
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M6'XO-:[>?A:C:]O"?#"NEGS*O/R-J="LA)B3&?L2+P,=H+3V8XNXE W@MAQ
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M +45%%GG>[/7Q@<7M<=Z:"C#_)K]%R&%1RF3WX,VAA[=U#0 0SV=?\\$J_U
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MA#05)&F+ Y7)#8!FVA)*V0RXU>);SA\N2,.9QNQQQ#0D)G09[+>\]2(;>6[
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MJ9GASPR2(I8Z]:^N@[HJ$P?35A%D,T8EAL?GYE7%(D87^"OADS7(E#'336U
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MZQ;):@<EG1XY+OZ;UNB+F%^9OVC8X;;.W@W2#&[E$B@ \U4_YFM-<'>U,"W
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MK;@MZ-I6[22W5#G4E<I+FBD <"(JW$WK3@NSHP5-+2U.PX2:8G.L!@D2[;;
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M@,6.W!3#%];D_N6.(UG:@%!B4NK ^[OSBZ)@4JKLDU_R(90!BTV^E07_V"Y
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M1+>%MG?J=@&Q&]@+6Z&@\]H%E)GP;.7+!F-6QHFCHQ0.8/P'B(*:=?>1&<0
M0K6.&UA[*#:(8+E)D?Y!CKEFS[\3O.E8B/O(&6$%E3J[W!NH20GE'H 1VXOA
M2]*'V\051NTQP+#"#F4RSSN"TR$.9[]= EP9FJQM#_GWI0[2B,PB7(QZ)Y">
M0967<1-UF@R522T4/Y'R5K@G#4ZV%N!>LC\B%;^:3B?,F8]BC(#@S$5:<)?-
M8\)OJJ$3"7#\4X>M7>.RI=?]=%$6C28,JLPOO(*3?GUK8.>>EOK!Z,;7]L5.
M9C5ZO<GF-*":2AP$MPNW+?GQ/D\>?<%(JJ_,"Q.+RWZVF:3B52R'%$5!?NSH
M]*P?*I'OS=^HDG\W+#/%N.F94E1!VP=^2F+S(+[2[_K,;ZRL53.X6M5*/Z3V
MJ,_'NG)GKLWR4J;YS$P,9L])=!YGM#S^R5>SB9,L&_!=R8UM2^..24VMXMLA
MU_E:_(58V%X,&Q>?J[YR-,GX<R@$T^D,<)0##(I5M\&Y+S-2!N[JQXI<19A^
M7Z@0D18VIQXPTZLHQ8=>)<E3!GQ(*Z 17>OR_"Q$:JQXN"C$#V*/8>-$-GE[
MHQBD/FU^.?>'E1/"U+_S>'XDRA [6E37:(-X\,TVZSH8U;LI<S]439VOS1AF
MY,TI?:848-=@CY)G;H._]M8!\F-G1M[_8P]5_\97^Q(D/@UL+;7O<7\AAFX;
M/JXI6_.Z#D,EOO */-""1_G=^V7GF+WYH;(78?8YB;3:\(>KIY4LGO>SOX5P
ML42<9\J4NI2/TG(U6WN__.D!_E[7=^B(PV7D_'V11K//<I8<J8Y/@7GQ].N-
M[V5N-22M7;%)/8P,4IBS>-I0?Y87L2!4OD%IX"N>!>)W$!,6'!-E&73%\O=0
M(3+3,/['L3VS'X(^,N#C;APYQV'XH!3%DHE9-C,S_8G%$0.3.?<@Y[75.]M(
M5T3KA76'L*)D4A%)-Q8K*_5YC@6U"'I-&2H@%8=LU)U38QUF,P11+SE[NDM0
M-"<?]??:%^)XF;S- 09Y6'IHF^ Y=EM?=>Z.*&6NO%)9+5OG>4=UW5'-^MF(
M 5:#ZV:^OR_DG;GJN+MB&>:CGJ"B@->U8-?QMKIJ*]4.+[ < \CNUFV&P"SX
MQRH'XFEA7#:)Z7RC!O2F*4VE*EPRRO\DJ\(+3;R%+=F'QTM(P3^\8\.3+C/A
M:C>-2ZA<YQ:I7##16DNS"]^>9M'@YU;F<*B5S*[2VU9TJ#!9'\8*"M1&6_43
M-E+6K[R&YRF=B@=/5["Z<L8)"[FJQ^GNRR&C$2%".E0&X DSJARI6U1:6Q22
M!A9]Q#WB7-=8]>F#]LB'^ME3!(Z)T/L^,TV$A396"O%&E7 '^:9[F6',($JQ
M@W) VWZVF/++"(IDNYY7;HN0-C0^ET?9LP2O?I=_ER!'<]E#:^4C(FXA+WW/
MKDPY%_I50G30GVB>E*NL7#R]3!J9I\^$GS/+;,QMG"?5/2V)J;7A?K*.!3IK
M"((#F4=-LT#J;EPKQ!P2R;IBWF3O )@**2DT.]+.79ESOA:N\[K@:%C_U_KQ
M$Q;[N O6,?8=G 9$: UI)T/.6TXQ")I[@&<=ML+LFG8-@ZN_9;">6Y>(<Q/C
M*NBTC5KEV[')VSJ/#B9"KO8O*S]M\+F>'&V?#)/E"W6633G$JL_BP1&/^MQ'
MW/7-[_MFNJC7[! KN$ICIQ^@$3-[!HADWACB8 $7G?>):8W+\F\X3I8L3(M?
M(DPS99PD@(L9>[YW?NK4=:FBIJ.(F8HF^TA MOP\%7=<'RLK7:ZFJQ.CC7HB
M0^4 IA)XL-ZX.XGKO-[XY?@?'?=DW7([#HTAGM'4&D1Q2TF@[M0<:'TU:(8F
M^RI4=SX'W#KLH3]>I09WF<BX1N^9="42K.8V2]SI<N(C^&F^]2,RCS:MJ\TU
M0&\CD^9]IA50>(^Q3)15Q0%5#2%QT@E7L!;_J^4QMBR^,.Y$:IA2]7)M8EES
MC_I281$[BJ5<[;WO)Q57W]I1FWY5ZGS82OWVC,->ME=_@$DG@()AY::X2;M5
M&<FCJ=BAT:J^)L6>.E_05Z*\B?>Z?>^:8\6:!*IV5Z6G Z7)G]F>H382[$Z?
M6^@P[V@.& #'HI=C!DA28/VC(XADC.&6AO(N[+K@J3*XRN//3"&)4I"?LX_@
M.F ?9-6C 97!TM?K^X<JR87)]PD]K",T+A DUI?Q@/IH0!BI:8FJ<A$3[V9S
MU/#/N-I!4(RQBP6M"-'KT8[E6$H0J*]9 ZG"Z^AY!MHP::W'48DM@"JG+8 F
M!H+>BIJY4'GC[+['M(A\IXX_V;YRPG>5?VU94%19M^C\#6NESXVSW583^DYD
M-;<N72/:QF(IAV+H-&K=\HS'2'Y5/T$%3EN(,3'SRJS1_,T:X_P-6,'B+.![
MJ^/W;U9,'K26!F1A-(& LJ?7HYB*YC""<W%U8KMBD$(PSF%.W&E>*7F%3E\(
M_U[_?$?07Y3]/"^3$#?EIHRWK7YM=#.9'BLO3?23DZ4S[Q:-++N+>ZTX7Y?<
MK. /*/<[=7"N9LI*?6:7JQ2A;^8552@W7^T,0S.##^A@6?@>/>>W0S/%-DL%
MA9>JU]Z&.\S_A?A: ]1M9M!)X,B<[3#!0"^=DKDWF_IZT&T-3U^!1H!O6/5B
M=%@TA:',#=OY-?4G[2Q:(#8X/TAA"N'D#G,4+ZC)6P9J#;4H@5 V$6M"I N&
M]5QM6E43^#EXPE,VZ+PY&)^/R$++WK*OL;JRME"+XG(QCM,!CY:RAAL$7@\K
M9:F@&"S+OX>/F(E9*X'WQRI>GO&DS*.\H.%<*V4/BAI>^;B6,]4M9+B:D344
M[%O#?7?4:]XO5K#8SOFR6#.93)B()/OP&C]$QF![OT;LO+959OJ0IL!4$H.K
M=K2OLY*Z K",WU]/8NBN/$VD+!\R-I:#J)_3@O C68N_;NIS1_3)]Q#L3O!H
M>=GW'*O.9#E(,)R* E+L1F)OK>ST5O4]8C?,S$RB* \I%BD,:GR2V.'E"M@>
M/@E9YJYSI/.?]IT7< X2HI&]&.@N;8II_"$.>&A=_%6VWU7#;;1X3T@U^+A9
MR2QYDYOP\&TPAWH@A+LZ3T: WP^2BAV*_]('96[2Q/U.>14R+LW)#S(Z[&%*
M@E]!^2W2MTW35YWKU&S0P/[$.<EDR]PS#R;>Z ]K%7LN?4AA]T?-C+WL.>$V
M&,/ZV<VL5/;D8'A6+T%.H",5;%_JC7KX=24"18CCT?8>%:!%Z7"S_[*@D9<V
MQ8+S0_4 DSW)$ZH2">1HJDWL9]QQ^MI,VRF-4TO"9G/A\#&;D_*UKA)=F-"3
M/7$[>^SIUL$X[(IQV7H8OI(7[.M'XVM>+[RCI>]9U2*8+F\#952,:1U]_R_$
M \F( IU^0('HN),VBMG2]]:B>[7$JGZB'Z$.BM3,G89 EK)*6>:DD1[\]BQ#
M*8 5D^2=#_92W$R>L+ XRELMK?;U.I(JJ 59NR_QI:86)EK=+.>#M%*('N67
M)7OD"ZYOW/+\TV$17Q9U:<3T]RB3G][#KG>S-"3 ':L K2$#,) R^Z3"5B$%
MO'SD62(^,Q1+]%U^S025P:\ARD!MS,X)U&Q#")$U)_U[AVN([U,L6[<'+D70
M@GM8TIPVR2?40=ZD@M5R0'=$7:L.PRJWVL?-5G40<LV)07]&C*^VWG#\-. \
M9Q;RV4+75(\S<E@8\MTRPF0)S5ZRTL.A6&$W$:X8JG1KD7%^.+Z_=J['_P=R
MJ3LM/RUE=!^02.)4,(=WN/1:+OW!43/-*<0_LH4LHYDFB[Q5>'1$+W]54IK-
M1!XQ6Z^M!9)PUUS 3VG3L$G@N*EO?^4=1J$#F&I!G]4VIY+U9]#;$6"=NXH>
M4J,\UIT3Z=*=.YO7J+BNKY5&.A8%PY5S/OK5&W<-6Y2]C70HBE2FB]$]?L-B
M:J+W9CRSXJ<,MV:0^V:\O'^+%/OB;';G.>) /9# J<N_< 4I=!#871GFXM"F
M>G1@WQKWN8*-/I+F8U5&ZPYCP9>9&8.M3!&P8<"A\,F?B44Z[>4"V['$5/C?
MV-8->RFL(!<42Q9W8RY"%#>3 F\(E%G/$-CS0$(P0\5PE @VMEA?-J BG<$;
M(3'=9*6(C$V>"@<)OT90O_I 9/X]6>N;#945*]*;V<LKXQ%'E8G6404A36+L
ML#58X:MVC5<(FLXKU>PB16FR+O<9GQ'+)F!J'/.7*NCM\V'+29G&\&UJJ@3A
M9\WT:E:-#+<XJ9P>:BJ 8"K-TB?^8S_\C?WU2\U _?H>G%]L>G(^JD-0(N3%
M+\VS]<Z,YK,GFN8S6&Z3QZU4CXA3=^G)$_()$F#,>+*0'U;CG\84H^K.L.;E
M[##ANHNDN/D_TSQ>FK\'Y M$)(+Y2R:\C>CH*,_$!?7KRYG=GCZ< 5K*'<;#
M;=0\J[_/30)+!X/X24KFHFPE?.*K"&=T<'#PA2_R5QS(7LU2FCKH[[FX_*Y[
M*U/[$UC/N(V^+;Q?RK2V.Q+?&JT2S$F<#1O34%5?84\-G1UC2%W-<OW1;KZY
M?R)*@SCF24#W3:LU\*/'4R:HB^07WZ6F$KO "3]X&#(J)(J!] D(9:VQ1<A1
M<%"+$?/I4Y7T GS\*#/7$0QK[ZSYQ\1  R(( O,LFOE.,WU>1JAN;Q9]E$Z+
MRJ@&H#SSH#1OUA5TNM(^D=0NPA&44J='CQ/^SA%/A+VOY8T^WJ#Z08IO;IFZ
MOA$8$%%,J!*LKRVYPHK"FI,0"@V_+@,GU)J8$A*L<_K40/OCTH@<%H08""/-
MAATYWSB*B)O[>VA@,T=8\:U>F35+ #AM! D#!(N$)VK"B-,6=2G:@I0.^.T&
MO9#<=<OR3*M%@!)@C/^<:(7M0,"Z#D1?2NMEB&_!+&G]6B6A:QK(%,EM-Q5,
M;+N+;5!>Z#AP>JVE!A_8$$//X!V-A^;,;%OXQ:QS+V2JF<O45914MF]KF8[B
MMPCY=!E*O'AG2,>&Z]_8J+1'(S\I>/#I'(N';T19=>J4 ^MF9BY&\T,011QA
M!M/;%OP4N,E5WSV7N3ZX8Z4E+P!B'YF=15CY6 /Z@4I)'MU!,C1Q\ZL+$,.0
M1!&A*RY,'H+E7=]<+9S<HEBG.E@B3Z>WVV$;I(>\3C)<,I]:^#RS=Z*_BY'.
MOK3MBPN(77'1$O9KX.+TBY9<R&@]%I,JR-P6JI_50T_T/WG;+@=;?*L 4KO:
M_>[1J7)B6$<^F<41;B"(E>W#/I(\JETLIF9AZ8-X(&Q3"YDA+9? -MH[&KL3
MH'J].:"/=9^0*N9016CJYQP?#K4F(-%T3CID<HKP.2AYY% C7.!*!?A)!(Z\
M<LG!;E/Z<J#6MGF79B\ PT1W RF^+V;LX/#I<+ND_%]_B*PTXGP?\/5N%U^&
M59*=]3ACSR)6,,=PIP[VG;\>*XLI)DI<G; LCU=:L$0;MC2MN_XQQ>6CLE(6
M7P3'Q,#^?$XC2?7>.5;SS[_"I6'KR0@2O-BC,/K.7F]:E]90#.7@[Y1,]M'?
M*%\/SRZ'O-'(B0%'SE7?!X4HH[4?.]9=-[DA*3PZC#5F>9F>/A]/63%/I8AY
M/=GZ[M,K!Y@Q-66TEA-&;-/B?,A1VQ7PK5#QH!H#<O+ 9>T&OHH/;WJ(B KZ
M+2?0PX5*]-*8[8BL'"5F42-;\,=Q0:3>=K26076I4K\T"T8I81079S*O86KC
MCA#_ZY"VI%^J!90&#N)SV?7*SVB%LV/L?>(+'Q$79344(QG6+6W7@;^W1URW
M^+QVP^>%1<\VB3_7AZ\+F\[]T5(2'3-WFNXPC=0BX*08H%','AW;VQ)(;X=J
MO5TYVC>FNEWF,B)FU9RIH.2?DWN?_"=>@@L@;\B'KI=EGITY5QQ'+?>:+\*)
M-^.-K?UFY\ _F :&=39KRSTU'R.4I)SZJ'#G%\VLOKB]_LK(O(JI0JP9X8SL
M(64MU6'RX:&8)ME$I(7L+X]4A;3<[3BIQ?>.&![CHXSH#_:L3=TN"[DWE15;
M<(<.N=,_45Y,ET<)CV74NX6LJ>6]7W47+SX>T.7!K:$8)*G<FU_2E%)K)*DQ
M]7"7:\1T#V;!M5<*+_U%#.!HPS4T,0N/R1\>17VH%T+'7RPV9_A40#D/S"/K
M/!$HV4BO^G%[N[L]4I4$\5%B%IN=$B9XI#_J,DOQ:P["IK#NFJPW$!9MQF 7
M5OAQ&/KV'0'M=X(7=GP5!&$TF8K]/]AC$[ UC#?T,;+R.I+ FJ7[_>POL435
M@<G1O0G23(F\3\;4<8!TE40DDYI+CNY">;Y\9E^F:1#4"= YZ\&BTE/2]A^4
M;=G>Z*ZBW,A(SN)XA:>VE.Y\R?A5(K&%QJAZ%<G'/NVUTUW&B])-(]KY >@^
M)MQAM7D_ZK,8P):EYCL\/=?E\))E9BR\+1#.L-!GR/Y>A)R;8*NTN#\Y?<AF
MRCP^HPK3!'Q%"JKJ]/6\"CST>/MA477!0GYK>=9OGQRL3Q31#A 1UC-3K*!T
M9^]73!]6%R!9IO:"]1GK%2S33EJIX^E-ZS'?!6KZ[GZ$.U2UO=+"SN?PX53V
MSF#QJN#M73J?D)%)ZQ6]WQ8;\"KT\ET!]RP_;*W2CX:QO(YHXA>8+E2EQ@1T
MAG,%<%YIK4%:UIE$A&>]PWRBC^3S,EX"B9;,5(;8P5'4<D//:&>303YN2!Q#
M+=(R\.>XTN(U63'C9ECVQQWKK^^<Y)EWT+G-3?&5U,H3(Y_1.N7,74Q&197I
M>M6]<*[#?%M7S%KYL*YYYQ>(ZFY?O\FU,HFL, O22#UVT[=N[U5?<4;L]Z-P
M4!P8 [L.\+6-%M76 8VL6C^2-9 ;C_2&82NCQ&]]>I8LH'H9'\O-K2=T(5AZ
MVA/$KJ=0+]PDI Z@]W]G9_AODD]NBNT3]6!.'QE-*WAS 94B'9YN?M&C;Y"N
MD$&#_/-Y2X^NA[('U_R,KV[VE*N[#'CFT1OL&S2K]K;CA38'XV@L2%NDC9^6
M7G"+J.O; GIX!98P4&.TI?Z1E=^\'97=JHP8Y9%.H\@KL2L)>/4>S+=VC!7[
MG2.HPF#]%U<5#)IA7+#\2'/\O2OY-%3^K'@3BP9M71F[9Q:-7MG-;DLU+.2.
M7%Y<MG&I2C,Y@IVY^"&!J*]3\L:\UJBTF^.4]J&J1L2D3MDF)S#Z'K<O.AH7
MO@TLZ#T@F,J>8+G)?]L"S[KM<%M&5JBXE)E 7=)7@&1B#6-IC&]-L\(8?6^Y
MO2U=+NE'$C=;1:O<ZR5.R1O<J]F=( EYPX4#H(BT,/J4\&Y:KF6J,Z-03#PU
MHFS*G4,<4FL317WT5Q:JT:_'WF6NS+O')%?96V8_IC)#6\H/"KPJYQFRF-5P
MXE<0X&I<E6F0;IBP6)(6<C :H+N9YTJ1PJH>8]A1P]7^L&8*#&$V-9ZN3]5P
MP1L(+]_K[/^#U3:1(W[/-337R 3T@.USW'('>.*KQ&$3<WB<+E+B#H B9U:4
M5$7VYD\3)NXQ/\;.$8$9=/M/=)G_<NAH-E9%4RG)S;I0[@RXDH:$]5>+BFK*
MN7\4W9VZ;!Z:$%;,O]US_%W9_J'=DM)6\DT18E Q<,?IH2]ZD8+?=([U?>O@
M_];+>7ZSP3C\VRXJ:F\J5JW80JU;K9+:(T90>R=&C9:ZV]+:,V:L6K%CB]TB
M8F]B:^T5XZ:H5GWOYWG_.\^+WSG/><[U/WS.Y\5U+HLJK&;*1%!<LG#QH(X!
MK<5T+^C7(]!JH[=&G!_V0?EX9R_;.6@T'.'F6,WD7BKTE,O4"(PR< [++Z]F
MPF5\AQUGJ"_[P!EWGD=S"07+0AE2QA";28]2J19Q2;&(W+3)C$KSY$W!WU?0
M9_-QGVXG$7_K<%'S0GA&^U>27 S=Q9@K(5-OUUOTEL+KQ3GAM0DL<:-M<=7I
M?FTO&-G=DPD@_T&BJ>/Q7*F><.:$:YC8(!/?&]Q0PP\5V9GY B3Q)I9IE^ X
ML:?;\YT?-7G\U"7R6.$,_2IUR6DJCR*K+Z/WXWPQQ\4*.2L^<3ERE'-QL9M'
M2Q*KH3\=RU,Q=T)J'R\^KW%2IT\6A-54J)8]U7W"]5C%\(%'4@;0*"6=3<YT
MX.W:XFHA+<64]Q453VI'CF^;45Q%04=OJ&K 7G^X1(I28-I5!5]@ECHO/@V7
M7$SQR#I<:1:!UH3QI;3I^UC;1H=_@54"]S&R)]HA&I13"HMV0?-L:IR2BD Z
MB'=C-:CKR'RR7LG7+U )N28BG&!W]GQ=KF7/LY_'*AJSC#P&X!1XRCD_/*03
MB5U'F*)VW.CLU!5<!,S'E1'?ADJ_Z'6/?FE3Q 7G5NNYQ>:Y:(G0]&O!S+='
MO)>1KB,/38/D)T!1,DI.PLK=D#D[A$,,'RI\=:1Y+8,2?)O^/8-Q/!R#IB*?
M\1B,C/]G3]?"V\)"< QA"IU+',2X6^]JS)R_EB\2F.Q2169Z"2<\_F)>-2A(
M*F_/-J*9X1/@N2C47RD:X'42[YQ7%W#Q'Z[4H,"LX;'\R;WZ-,4(:="5_9H4
M9Z"G8F^;W6,$3Y79/),@=M'Q_0YX8-!21([97\<-07587O;)]3S8JOBE,V..
M1PB(6A[3<.8?=CNU#K3?JW^[+W4^W-5Z?VA0L+VOW-V=84\4_X[V#J!\J <]
M7'W%<KF[4JY<S2+VNW]]4Q/Z9\$\9M?F@'2(BRT)^"@O1\#_:QF-Z%S!%6?!
MNALP<XV7H/)IN^VINH]$BWKE0GBKSOZL "RC*(;,]3U3IW''V2_E-"3F8U=V
MGV9/6ZE"&9 &L;BJ'1ZC4:/G/@65ON!7]$L-$#;/M*S8;)SG== 9-#6^\!,C
MB'GLHE8BB2KZ8@T;>R+PMT4 710+P(>NU$.&\W@?8K>K1<.[UOI38LZ=_&\K
MO*=CFHC]['GUR+P[]CZBZX>UVNYSZ]  59H+L798+&FED &CU8,Z>^B"COC)
M90EH)#'HT ,46!B2E04FQCM@BA*OF $FSMT/=1.3+"CW'3X'1^;.=%U*N0BC
M*P^4$UF"[>U\(OQ6+$@!$^[Q +14XU@ZW*9=:J*UKY%&"EX0VX*OZY?D<$>T
M4F@XS:.1GV$?%6SXRXK)XL"!04$7'#R!$^,9*B]^S(HML7PQ-2*P$Z/E70VR
M4VK5.^A&$OGHJ /#P.V/PQ^:[6@GX&16G5?D>#9PVM2!PP6P?KQH7A>L%9K;
MIM]N&$LZU>D3>OCG:7-]V(N/??='N;-G_F,Y&L$H]@=H67H)X94S YC1<V\L
MRYPYI:AJOB>16IYJKHZ3E=99=+^)SY3_@;G:E?ZT=J(S12T),K%^N6PP<GGB
M,UD)?LU33,MC!Z"X:]MF])^^^3J[BNO0PD@F+$\\O9.'J[Z%T63LDJN^C">P
MK;IU,L8F,Y,A[8RI0)$^?FX5?>/V';0!OW%]^N#UPET2N0#Y5,E/^#R^RTUG
M'5.OMNK@T+4IK&7>;^:4)5H4I#2TH?LZQ/-(I8!'F-PF6NSW?9!1? ?I1.F
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M7OGQ^6V,^5>>?O3I3XZPQ'YY?]HPGZ#YB?57ZO[>_B [F7<R_U].^-5^)P8
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M'6_N"4#2.I3VZ":TJD:-P@A)N9"D%T5G725(.SVB9:-##-"EER<:R4P<0N]
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ME/0])[9/<]W_\=0=R_2YSO,WRPMK-E6U;7'CW=3NQ39[/P/GC$2GVY?")TQ
M[?@=TA:+[O.S^Y=DK@;SCXRMBC,43^.[2I'>66E#F \=,LVV8SO.*SB/7+![
MHA__8;J)*B'+W%8D4JM^PD]U:'^/WN:&-4NC$$E3)*X $^^3C@#:"Y3LM'Q"
MEZ&N+153RT]]&]Z-2I7-8]HD[I.R#$^Q@DD% N6-7>Y$P6E-4YV4[XLUD(%6
MN);Y&O@I'=;#\_H:W@XD"7/GR-UO%M)J&AJJ\/ZZ$:,@+@%^*\C8[9)5'32<
ME*;-1595SEHN?A6D:T&MB#4$)$ZI&8LE-OE'$*^RAS[""^5+PI9LH5Q9K])9
MZSX'%=Q7BO1@)VO(N!\60CH_Y7*C[3P86B0[)_?D787V**/0%-VF6R9+0VJ;
M2RUFO1VL.CF07,(9]#GT=BA%E>-8Z)P#$/@ZK;/"A(I&VT]FZK.^<R[-85+@
M*K5UTDC(>P8]B[CNT(PTAM(AN6MC#X-CW+#KL$I+C6Z8WG>BGI'A\A8Q[N9I
M69+O;1#4[6@NJ[GP>?JY+1[U)SZZ_<<R[^#LQ7!>*H&ZK#!?-]$*#U7C]5M,
MY"^Q;(Y4):C8)2%D(<7U*4)"'7R;1Y2$;<D]!]&RRP]C'*.D=AD)'$O9 GH2
M55:K7%O@1UOCG5);;MZ'QTC'@I*" /W]-V^@]3P>JU4(S^7JZB.?<N7-996.
M"@1TW2*F)[SJR"='?G6<B5Q79JO]\"BI='"D(Q->@_3=#-(1-6]-S[DT+#D?
M;4"3:"[7GJ7&NZ:%GICM[=L:&E:_U2UO@;WON;F_$!'/<R13\#E=@'E[.E/*
M_'L[8FL=/5%J5C:1IA9\!.U.W9NO!9D?^7YERW'7IBF%^R'71,W]D,SH,Y!/
M/TQYOK3VH?E2-9+9S&,343V:$V\?_BH#L3)7)2"/ OBII&:]M[8L/"LSR"41
M1PB#?4^#20.CBARB>C9OQ&;F/;:9[OF^CDZ9G-0]%8NT:!2@D]2@#UE2T+V!
M[-UY>$PH=\X!!<PL+*:A $Y^OZ6L]1(4,%DPHU!A0,97UH+D8'R  BKJOA1\
MDT531?&0P'44L)-9S3/X.>FKT9;HTB+-_M*]N.G:@WNK!9"C[8HM1%));:D7
M-R(I$ 7,[LN'(.=I1I8V+OB+3*. CHU4%)"3IH,"/([]_ L=BS8CAN5&N9GO
MUL!7VUJRF!YU>IF[;SIVA;]=G>[(U"7W0?#X.8Y\J]Y6MD@QH$R<'MO:G24G
MET&?]F>;0T-K6=PV5@T.R"7W> YK"CQ"7[U=6ZE'KV;!T-LQ&;8W'HA$V;)>
M*KU:PNI^ \I.'^_=U4R_FBS.^<1Y90-MRN_307N>B')MK[VM]?FL!^3D79/D
M4O./L_V/97E<YV?>=OM'WQ\F88C';7XX1L.4.D92W2C*1( =]/TI!_$7#'[6
M>)D\:C/8\)-,=V7>>#PGC :18:>KQ7;%"1P:!&S,@V*FDB\(P^-B8V;#!+>4
MTPL(.'3,._*MU+G"NE<L?2&.SWR81+4<1YBCMT9[\WJ<A['NWB).D,M=GK7^
MZJ,JV[P[RWUK34)1@ET[Z!)_!]1SC=M*?W25>=U&B' ?8F+DD#2WN\RT(WQX
M9_ Z=@>%Z?E^:,.*TA"'ELO-IN]6C[G%&#/QWYDQ$--Q>)DS80MK,/+QA5\\
M5-_ MB>1$8TG?VX1!7\15UZB]F(__T)!A[5FHZT2MP,KWQVQY C'0*B>RGV"
MER6M T.&<V#$S<1'*64^"==WVW$T4NA,/'2%J!UCDN7Z00X>6\P(DFOLL;QW
M)^;8]',OXTC:3Z;U:^9W?G3Y:!TR(:D:RO%8M;#,XX@SKW$WTC>Z[&WQ<H>Q
MV>IT!!$!=T5YA:^]O>OC*Y^F!&0H:'MP[2LGFYY^G.4,^-8[_R$[,36)OWOQ
MTJ:0Z_(SX5=/:W>40-,WQ\P>Z,*&4Z^1RFO@<RJ2/+)U>E%T,8]!6BZ>G($^
MUS=OT(&U7HN?=IJMH2.4^%&1;Z'EB\1"RR!(N.30KJ"J$D=80W%%CW?=1U7-
M\ [V9_$WZNF9!S3DYN._<CWI?1O*:H+G,Z99KJ"7LJKR7JSR,HGVI8@II;HH
M)4]^GLL[KG2FKA=10$*1F1%5'$M8?]R*LW/_S)"'6$3GXQFG&/;V<7>/+R(6
M='B/]J]+D-M1-&I$/#HWT,'!94DY@N4J3/K%]%FT"?-"QS/BU.M*[-:?R$D_
M+:ZD15B!ZDKQ:)<GVZCOA:W"QG&Q5:?JV(=((OA)PIKS/L;26S%TUG5O6MF(
M<'2)$ >U+:6I7/(T$1LKO-DK&AH.$GW.[$"I<3.HB?QR+O0;I4;PI1[88W$Y
M>4-B+E)A]A B8IS]1V*6[PK?X\E2AXT.L3G%7QM(X1'_L.H<V]DJ3R!$>8W1
M)G&V.M/H0<9,\^0WYUC&'IZ.*ZSWH89O&<7KZS_#>#XU\!$8J]+A2Z9T7,##
MUOU([&^F.9/(BB\4@F\L:XX1'( Q8>/2Q,#06Q@ZA8/^N,;5/2C7@*:W=/"F
M7LE&S'BY7,CGYZ#^.K>YO.J3?M3[(*6;NV;@W;E;I 7$EI@CED^'/=]5%,JK
MFPTVSC=Q@#6,]],7OK59>T;%"WTR+(\7:YM2RZ$0\\E^LY5'+2]>WAG6M3SM
M6RY.ZH)=&)1*XJVP\&UBRX.AR(2?79!4"I_=2)1T7;3/MJ[Z%4E_DP!_&JR<
MDO]R_/$ I:DT@D]+L_2KCDAX:M^L?MK(F/4E?E<*NA5"O3GHG&\$>_J*VSE%
M=B?BL!Q,?JYW[QY+D^\7#<RNR5QUO6\#F15[<NNED=3Q:[@)XT3#!>GXBYB3
ME5<1:R_C'<4>0O,ZBZ_=E?&US;K<MN1:]5!O]NA> 6M)P;-J0Y'^#^"[@?P\
MAV(VZG%BS60BJ=V-LY0E14<<(C52,PV6D6.M*2+9N*JX-(^%BF)O,QAC^#"1
ME[3>MJE^\.R9*VVPL'KCYU*1P"*\]!@?X10">Y\KG _+BT/PBB\ZZDAER2SY
MR'>)C[-\'>B?&@H6NF8N8Z_ILE#$,RP %I+N>[/@'$'8PO'AR9-DR3QGG71&
MTC2R5\65Q?RK[64=$HWZ"F3!$UY\XEQP-ALXFXE5H^4D7%!Y5XU4-%#<RN3\
M?E)5,T"QV^UP(15#;42!*M-,Q&7%T3*JJ"44.OFP[N%&P-#7 6FUX+BM9XY:
M8'I]J^.!,2EAXV()L.U$6\I'BD&EQ[7"K5D)BI@?3):%S(^R2WI#)J&]JI8:
M1,E[[,_6RUO7$N!8.$,:9'6LKE(YODI$P5 ,#OQ9P1;*$$?R3[3"TC=&*Z*,
M(B8EXP_C34P@=.D(5^)( @)A6Y\98E!/;C==&(F#F.;SRH@R7NSZ2ME.?8=E
MG=)T3Q -.,#4T1OW\<!78S// $T9J0>$CI29@^>=LJ,NW&S=9S=T'B+&X! A
MP;UK0P<G"X8]B((VF"2HWD[EEFI:ILN@S#1E=7Q $MW8M?NA*V5WK[JK7.'2
M1SQ;?H\[B_3T _,7NDFP;7O>8I1*B O5$!%%*$W&M]=/;C#=L72IF>J,Y<QX
M.Z3\N4C35/2\8=:=N;*&&Y:IRI\/0G4S@OA"BXM"!7<I5!@:;0]I;Y&R$'X>
M0,1751:3E#QZIA5NPG73G'&O3(0O/^C]O(CZ%*VR>T;+]>[+#N3O1Z/OB,/S
M6S<YQ7TD+,:.LF]#%SL*31UQ)-^D\)I>/\@F=B6\OE.D7\ACD__8B(C3FJ*Z
MYU5H[$L9_"#G:'5K6V;A0=SJ!WF/;S)()3X)A\59F6TNC+AA?IX:?4[IHS9?
MR!ZY[&!9>M^LX5E@;KB# V8GB2\!8TK\C//[^,44G&G^%Q17[$I!U1'.-ICW
M6FYVG1^XS#["07HO1#I;UT*X[K)I EYA7;EES^2DH[("'IFU&=>R*0$;GU*T
MG>:8@Z-ZT^R7C"Z7ZQZ3,FIA1$'Y_,27!:!%) ^$,-5) ::FP"N!(/<8KLE>
M#!-[E;2GKYBL<G'KK;)([',Z.=/C@$L"AMA2SRDY(U)%716O/Z]JVI"WNS;-
M@(^IWG"Y<X6S4?##2LH>^\7J%^/<YX7PZ B64^(CZEZ^NLTI3,EM#\ B[[A
MDR_G<;-RUG=\!9ZH<RMB\+X0;+S2RO&8X*FE;FZ#!M]-H2#%88Z'MDQKRDZ]
MXO8O'UJPA-4425DC[TEDPZBG)GKF;5RL0QTC;FWVK-=/$"EUF W.5 V;,>D[
MXS^U37NQ%XI;4L%!GI\&R=YW[69ZE&"@HB,@$".'V,_Q?PVC'UYP2^L9?]);
MP%2E7_O<>(,YXU&69Y(<0GDU2]AUV]/B ^7#7BK?RCWS;]M[" '9S8AV%"#[
MZG5+2X7#VIK]ZV[9'()N]_T"@IE,S;7ITCJYMG%E;7(_]!4C_$C W>+MV-K*
M.OI:9I(FB[\U4Z,[5<!FUB@:>3O.:%<_K-XEBTPA)(OEUIN"90_ES5XJ<KT8
M) _Z8O:H@&BDNV/QY#G3-OF1MN=AH03W(9:Y?S2M1^VEPW?^PUX*6]<ECAG5
M:LLM/#<!(R9XUAZCSK&QQ,;WY9E:APHDR.+]R] J0>1%F>-Z]_'A8IS]@L/>
MQ&.-'3_>@G[DM/]N 27Z/&E5^WTBJ:=FP7].LA9QI'#,IU,PKNVXOC>L:]21
MY#$]MC$_4<6M0 :O?5G.HG[\=J/&N@=>DHWP2:^"KJX,RSX:[\Z2MY HMWJ3
M[CHVZKW1P@S?,4>::ZZNK6ZI]%+.FR_60UN85_6*/(XL#@YY>/)#(^;7M_9Y
M7,?DP;Z/@M8V5JL6PJNXF:H71^:U1[>Z">;G9ZJ\7;/Y+T9T)Q%&M'S*4LOJ
MJD%GW3XT_4C27-=H98]MHP4NM=:=5*EL9+^0_^)UZJJTC\8EU8R .'#[U+@)
M@8ZA%U["7,-R82P*,&$)H&D?9IJVFWHC1^6=\M2I@731&GQAP#08^G54L\7P
MRA275]Y51WSV&Q7X+_B$\4%"@:KF[=JM#$_ZN,P>-"XPI EYPHAZ73/C9VZM
MYQ&\+J;/;_HL7--\=W,*>Z]QC3B7N*6Q-\)7>[; B4)]KK(Q^JX4E2BE\B(+
M)8=-?//H9Q7*H*+F;T5-=-!IO#@?T]2HV_1=:K@?9O3,,!RC<&._O^$8>&Z4
MH_2:Z(/\Y4<D5N^WII-Z3-^+%=XJ7R(+;_JP$7%I34[1:X5[:(CX9LH%\X(O
MHNHSG)\YA*H7&61)0S\-9PN&8:N">S-B[BKA1WS@7_Z4L8M%Z^%171>-,<\S
M:"WHXA!L6/6A@!BFX[@IE>]C$==)VCI7V$6:^YRH6F7(IR")MUMV8T-_:V]W
M;4UY92M'>KG'7,EX4*HQ^#X]N'-)Q1@<_,WA20\'A4 L:X 30,+8**'7BJ<K
M_\3(FS>7'LM9GY(B;_85<:&N^A5S'\O=AS@O>>52FEF_KY!2<9K$4VD89.;I
M=CQ6[_K2K'6M9SXT\_-@F2@]U-H+9R/I1A=&]#:_J5!%;CA=H%/LI49C(%ZF
MT0EG;-G#Y#E#<<73SZ7T--!28B<W02;#3W#B$8[@J,3HJ(:*UXDWAM]1#^:2
M&3,R6%ZMUJR^V5Q8\-"WUF?? ]Z?3,P[X]F1.4(2XCQ-%.QLZ<CMF.)=:50F
M+,-1655!;"O YRKNG4KF75BX&C6!J6K7J.Z"4Y^LCO%E:B0[;WF4[^!\RP@U
M-+EQ5(,+?#&R;8T=+!C?M&1G*S,I1?%8RFI#A<W0A]<FIHDA[E8^N."C"T8!
M.T$(V\U-$)2-)-,PN/921F]<*&DRT*;9P6A%8CWV5.>AU;=;U_OB!\6BH-\T
M'-N\:&R'3=+'[/?6G(VN5?)W.*S>:5TJ2H\N9J4UQ+^\XSSVQ-,ZC)8O+]38
M68V+/9N:?FC8O&[J0MP[_%0V(=R[*OE9. W)&0R38>N,W3:VXC4277LA%6K-
MN_@S18L12O0<=.E.$9<[;%.BN\QV:<1RN_:H)7B=H^Q]6NU@Q)49]*+9_*;U
M]V)'+U<WK GQV3CI6T'ZN"Q-<A/X'LE%^M;G.12HF@4(3VJ*=YAMW7G+RTHX
MU4#O_N'3?EU"L7&2* I@B-ST#YXJ++3BL+2W?@*U$J:I[ZJ;<N(U(?<I4DL0
MN61GQQB%*77%1JA&QXE1DXZ8/T"F0\#)QTY"S2.7O);OQ8O\E_?');?IPW5%
MO3,M\6&)+J 44;'DMN^.48-*?@ZTM"MI+Q59K)79"=4O=<,6@B[<5Y7BE=A4
M>33 #8G?)Z50N\;TL.'3XM?)T%>"?7BJ>\$:S&PC[.DM[_":.?A+ 3KM)U7<
MY*&LHNV;"U-=G_*?ZO990SVPR=-TWQ7IB-DD;,T%705)EN/F[RSA;Y*+QF*_
MN#;<NJN>OJ?,&YI24P(+*SQH,XZ)HUJ(R!-AM^&WC)%Q:N,-F2ZBCJY7PT@L
M%JPQ; MQI6B>*\^W-L,W$7!E2ONFR>X%Q6IS3 >)UP](9^Z6,9#>@:I+V&3X
MO/7SW<PC]1NK[*R,5@=?C_\T2 =N"[L_/%W":;<SH)50%R)L'!4/BXV;O-!:
M5,<P+,,G*=1,AV5"9K=N_SKGW86<8FLE"%^A4)=<,IOJA\;9CNH59HLTF6)C
M"O7!)(**<[=T8/2.MY]P@!R*,/UZOKW>?1Q=5>:7,>IQ;LSDZ"4TIBRXO\O]
MV>6NG2652$-MZ$#32TT1$FCBM9VJRK3AAGAQ#]W0"S!P9(GL<M"'HAHI5=7R
M/)OK%+XOH^Q=Q<]53VY2V%"T#N*%B0BM.@86AXAMSP7,O:.8S/OV<5#]6;=4
M@&##-2%,"L$ 18WD!&+)++Y"3!Y-CE#!0@W1HG=>!K%"FQUL(BT<X2NJ7Z6L
M;;R?ORXD#?6XW[5Y"ZQJZPPB3Y*MO$ACH_LL<YX<0D;'#IA'K9"H/>XJ?Q5.
M'S@/T!A0)J[4;[6DYA"U0[O=5?01?9D+&8BCVS=N:=E%4I@8L3-871]F'NW"
MZ*WDO1]7RA19GGO?UNB;+N.++QJ.5G%=]J3$G)V.&O:?KI0"I--:!N141D':
MNGI!6^9CAQMSZ3D@?64=_\>OUISSGSCDOT0!%4[+HA6%T"]:YSY?X7S:2$%O
M=OEI(]88U_:PGRKC,P+&JWCIV6&)L807>S6D.,A%O@X]8:;]BK#-=& <F@X7
ME]J4:VT6,YO1 JTY.?G&7(@KS(=^6Z$?>&?K$R:M9_I:!GB%72:*.5]V?T"4
M1JZI413WG6FZ!BO0HU$ME4\:M?&F1-EX=%"JP+&7=DZ.YJ%U:@V-T*T\?4]9
M'AZ752GE_I* @?).!^^7<]!;!*])3$.=9Z/FPG#OR\@]_)3_:6X&;FO7)2P]
M'%]L2S4F[O"DUYN4^)/QTB$UW1URP>#P*S;1,S;3E-BQE%B)86PEZER.'&'M
M+6*M@X4T'V<\"</#7Y876,9+%*DWKT:MQ#T;J%\U*'CV2DVT*+!949WN]IA?
MQ@/+'#)CANBW>:LJ!OKFY-Z'<+C/UNJD3'9!YQNVZ-2(\U=[AF:T[I'6$+JO
MB[[)O)LNP%.-T#;06]2FC-:+"?$/X,_FYIU?W=)Q\SY$?EBM05)1?JM@\\Y)
MS1:HS5+P=#>7TI%OKT*XA*:R>?OT4R9.&F5Z35*V2<Y*32^C+X@,]$J;=.%9
M&3);+;6)>VP"7U24E]?D9?NEIJ?K]V;A++?0%QCWV&;I]W1B+M9*P!7L2ON[
M\3,J=6M?C^O>6/D.&:#9OKBMR";P[-E+L*X1(J%\'P7<+D4!)/YL?I_#F$U<
MPUE]GS.VS+USM_A?[+IE6QQ/U_8["1YT0G -3O! 8' (KA."NUO0 8*[.\$=
M$@B08(.[,S@$"^Z#$V!PE\U?GONYKOO-WA]@O^KCJ*ESK;-657?_:KI:/$@>
M 985!NF/@#_"GNK0[]":O\[*#1Y/@3\*/P+6)S_[NCP"[%/UKKW=K[Q%DAZ6
M5W.WE'%K[Q&=MS@X'+A%/V>\_CDJM__W4;G)UH?:\A;G)?>#1\#.A=H5="('
MX4:1F.V=</JFF*4M+@Z]S9N#TO=0Z%K99_&VOZ&88[YUW'V_Q<W-5VB<:#16
M>(4"J)D,=A,Z?>*DX]/CKC>,+R*.-GTVU _;SA%]J:GF:X/9S:Z7=P_GXP1$
MV\J[VWU37<5W7M?%'+[NZY*2;AE>S32N5]>NRH.Y.DXY>M=6D9#=<N&A7-^Z
M%+;,WC?5%).^=O+#N.0M1:@W*7UT[X$V2Y;JEG=E6:37'M4,SE-YS_"4*QAD
M5X$GW.N@M0X<[+C;W8A4#'\@"!S>/6@""\\:GY<AU'6.JO)'O]ZP9_9J<+ [
MNF-Q'*_SEBC #0)9V] )=_1M69/(D31W!'EF!]YC;I&P(^P<5%LIX%[)-9E3
MOR].]^DY5*ZEY9J"UC\8;QY:."?"-^;+D:HNKW?>*?URC$F*=##4Y>'2^06A
M%^8B_]S)X_CBSA"3"!LNA#\8+8/;MWI%A 5// )57!'!+7IDNM=BAFT@62KQ
M#1N9$>/<6/O]EW@W;I_;O\+I8&ONJ:AAP.!>TV,MU/6M#(L^?#*AZNCA.$Q3
MNOU.4BQ<AXR%WPZD]GPJC;Z=B.E>RXLIP:=G@\?HQUN)FFFU9L'<S;/?S9MU
M1%JQMQ+Q'P_L1D9<D9\OVTT?+*J !-^8'NOHVF397[@D5Q[C>5ZL7A$213K:
M,X>9W7&$=G: H,!8W]>AD=8-EL#NH6Z*L%0*?,;T$SY@D&WZT43E%JC RIU0
MRA%VS"J-%&Y4E+B6ENX>2X9%%N*U3KQ(F]?'A[?(Q6H4*UO)86R3GD3(U5,D
MAC&5\[W)2)1I-MW>$;NC^]M"6U9)?>P 5\:G(?Y/SL.7^,,7544_A3;TLAPV
MA6T>]OFX\;LO>K_W#V32+=RWX07(EGMV/ELQ7LWYP(?;LQ#6N\9EWP=Q#HXV
ML?S":\N 5@43#5Y;0K7M:4?M5@KO59]F>:50&F9^%4O;G<V'DV'+>F!/%!:Q
ML3^W' 6,=HG/TKO_^DJ6^RT3RN2Z/__7Y]Q2K21VTZ(-%!R(+R0D?%7J<^?&
M8[XD-M(HYS'F4K4,#IGVV$KSVC/!DL 4,^K:_>*G.VRG^"<ZPP?S4+GOOFT2
M@]YF#6 FD)B-:8+6E6@R?@3Y.*TN+QE2]PH)]:6"B(+&%XE?!FI$./B8AEWN
MF84>@&-*S#!S\O)!@\,%.QF7A!DG/G7/@ZE4J6S*0_T+N_!U8OWE(<R:Y00L
MP0(%[X';N,\)1*EVO_0MDU%=4H!F?]ZQ$8P5CL$80(X2?7CP%#I-]FH&FEB6
M/T /E4U"E"\F!;"UJ\3*95D3T#KG(^ YUA4O.PEU@XZ1C1GKOODHBT2LJZ5]
M3)6(RAU^L/RE%"9]5Q8555!(NC0MGUV8EV+C#5J3=/B\U;MRZ@;4,/;"U^-M
M@UOWLG:]%#DNVDT^(G8UZ7YJ6AX;\X<YRA6'=O83=KY**2;3/+7I\H5F[.(Z
M^K*\KMILW$OU,R)3Q(YA@GK'DS4/'X]M^=!@<,?E#VN@%%:)CDJE\-7UD=#4
M</@<5F5[!2J:\6P?94\5(3QO\(_ 6+>[#&XN%3G^49;R"WQ&@H@3;VKS[#0K
M\M6M/Q9.6]&'@-Z[#IFRA-VB H,XMP7KGY=U/BD-=@9[#K'B=6BK5RDROPF]
M?"IG4YB#33=J]O47_$(W)_0L/=CBZTBRS.UAM0U.07L[Q9ED-.Q:_,<K3"UY
M:WH*"'<XL2HO9K#Q<1\).Q52*+DA?A0,?.)\]_J -0IG--[4,<;EHI,V0T$A
M],KMQ1KHC@SRJVO0%QB;B36K6,T_RRH$E"$9G W5W':T#:NE8:'6C]2[8/E*
MD3AP0;B1-6-/5UG=SZO[4VERH15>/,3GOU@X[%->/?"LRW[X6VGWGSI#AS^R
M>KY<O[JJR6-OA6IRW)0X"9BYG[T\]F,%99'K!V''<ET(200=[=NCRCKJ1W\T
MK3@6)5Z>.@3=24YO-;$J0NH8N!7H\"XP_8WI.N4MN_E'??'#359A;ZV'1R.)
MTN!UG-XX-,NC&JV'[#AMQCIN:-_* JMV3?(Y%X;1%[EIOR[<1X[PX7,O80JO
M=E8W@9R]%.WSV0;>D]YDK)BXL1!49IR\A]S<B9P2U:.V\<;_*<4@=-PX"#YI
MCHQC,HLBB[K2 \..B8_2%)&UF%][57#V[Y!2 <EEL$$V,@YTQZ[V/M&_4!>&
M\#N.+$.J;(5H7G2O+K'3$C$P\%4H;J$U#KN#^+6V7Y+.;HRZ./VQQ#\+=O&8
M3.DZ2'$368:3B+Q.LDO9-]'"84[ZVKSF+-,,6BH ]NC.;E[CN 5-V%4TVD+]
M]3)"E<I;*WM'OJ>-:<')F0H(%OI'F4$KQ'!WUW6&2"M(&KD&NQ7Q(@M5"$PJ
M/$%(Z$-/&.0+#,"6?O5E3C)D9HEM9&B0';>;$Z0=2\JO38<O\0K<:&8[[$K)
M3,6RD;2)Z^MI8R*<'LY;U@G[9#]NATHN/7+ H#P2V+J'2[^LU+_H3?GP2:B(
ML2]BX0<7Y[':C^*O;R+=CP>CRWO)3JOFRMVP!%M\DKYA1:D0(^FFM1O#]31)
MJ CAQ*Z0:#XT!\P.QSLUMA1"V6&SAI]ZBZKT;^M;R4S-TJS2D3*.N<Q2R^*B
M.E=70>0\(QU@F&%D*A!I@3Q=FEBLM[5\2(=RJ#4M$.,5:HIEO*?\PJO9D>[(
M1P @KW"4\U>R=?V^S8U0E/M)U@1FU.OCJ+WJMPOG7W_N;NB9,A<UI7!R*3KI
MMJ04\W\UNPR>U] =H>H1'&3U:OA%5-F#P8E_/ =22[.4"HS#,0ZI;I"F]7JX
MX@.^*D68?&<+?4^NTS4<X-6'WAV-M78,% 2YI/W8>@G__B5P9T@RI SDQE6:
M$&Q7_QQ0M;H9OW'/=3:0BF@[MU7"03[X7C#WZT>=JBW:HBSW<.'>X3KVHE*W
M*,I@7W_>$&LI5^5FH*3_HD%74UW5IQK*U_9F;2ZP5 ZFEJ_K5_8$75<M#77'
M1,>4N# N-!0&@A@S?&/'7*Q(*RJ 3;;3"QC:2P-G/!ULRH2C7V2\W.%&^?YB
MG%D2&,C. N^WV_CI3.F\TV-:USFY=C!M:^90C&[-)P_G#F-EO&Q2SB;M*LZ;
M/:(0R;7VW) D^Z4"Y3]+!PU7#A7&%RZ.4?&'<T1:H&OL%'"#JY?K.$I3$2IG
M20DDP9BUWJWWN,4/MW,M/7@= N%;ET$^J%2*0F58+7JUZR6#I4V+04;/%7X4
MD[4= 4O'*7 *"S6&@"(D%X5GI8TI8NR)^2?,^J+IS05 BI?8AN%#VO,28H?)
MCH,7FH5VK0OWOY=I>!,481D^);.EA5"'Z+KE85RTGP.7+$ZGPX330Y2T['&D
MB[?>;T<IO_WL_T3;G@R+\89+$D[TQL2W+&O9L_4VQ'*@=9/!\H.5HN%< W$V
MG%JEBFGNCE?:2)1:D\BJ#6W2_5>QECQAS[+\N1GP0\7#8/"58)>R,&Q_2+<"
M PUO#UVU">EV7]JVQ[,81UQ^.2NT]QJY9YMQ!Y\.$"K-N8V";I1;<K5:.2MS
M\-G.=&FE*%6@=:J]$BJA[L%03UQY/;6X#;L\)V25QZW,/Z TT8L[(M*P'M("
M?D5\B!'6N6Z^MAX!9[RRH,4E=Y(U[7:\@--:O7PW3)&_T\[K_U*6(15V=%7Q
MJPN" <&RC>TR_N:B OHR/<K -NLS+Y%%*LNSY!1U*@X5Z]O=MJQ:O*7]V5_)
MHEC/V5J_VXW5<U@O,N/]JPN+BFEWP>YP"_;)#=^6B*&FN_IR?J'QS,)>@\\G
M\%E,C 8>$(M J<;N!G?EU^O0M2OOM+2*-)#CX@=X7D=W '$Z75RD"1P49EPT
MR 52";,Y[0ES3SYY4(B:!\_&X73!N5XN?E0(=W;W,[O>B+_RH,E\,9")[NWA
MA9G!ONL;4Y<HH1**8!A:,W>)J.4G6XWC7E8JV^W=JZ.HCAP[3@\]N-/7.,=6
M3W)0Y'6)#L3N225I\+'#WWU.)S#_P=9\&"I5762+A'FXUJ+Z<H49%,SFU]%@
MSQ?=M1;+1;4)JCOR)=^IZ,PTUN7FEM>3&;0F'M1A&8WN7&L[,T:G*'^#A97;
MG[$%?$5+)&(=';@B.+N64KII/?*#WOWHT,/-;#OIL,U7825$'3'G593J>U][
M$W3J&O<+W9W'/B2R9<XUWQ-8>08MPD[_2=@E:>GJ;V-H*3Z3X;8))!!J(W>[
M(5K;GB,*V6^Q>5/.,MK>!&W.&5KR@JP,^"Q>>Q.H\$BI;==3-)X>+'EL>C]0
MI(9<'8_V2:H=9E])KN<ZY7E<2EUR#(>W;5Q>?'QSNA"\*>AZ6+*P,B>DY]C^
M_NA'5F%XP^7!>1Z'V8W7[</48=NGEIVH!&C&\9)J^^>3]3CVI<E<OZE17_1V
M<2K8]B.@F<BIS2>L9?M\+<SF!-J,=O_7<8%WW9ZB^!&7%] 6C^=^N8:/@'ZX
MW-E%&N26Q;F^_B(=NB5U^]XJJAL7'M2^2*]_BK# /'KX;N['URC2+@(Z^*\_
MGV^CB=IR=6Z(EO#O!H@>C,,> 041-[ZCEFN(IJ).H,=U,I H=BDQ]L[CVN;&
M)OXL[@>T]SI._*:KJ!6_/</IYTINT3I"_9Z#G+'U,X'ZB9JR*-'*H,>U-_Z(
MR(NLB\/66Z!J7-RO\&60LM?QR@IB376YY?9,4IE $+)2C]G'/,K<YV+X#G%:
M)$3CU1^>J\/87>7A47S-82_\<+Y=%Y[UQN.D30&AIKQT?2)UD^S=<)T4L85P
M.NVC:%#F/QB\0&SDZ'FEYCK["%S-3 Y-#O#^V5N9@K=+Z#(:3OW"V#EM753<
M)EL4ALV3KQ2-],W[1.S>.AR]E.NP@7@Y*=</-"6N,!=_TLAKTO,9%5G'::N#
M:,<JL')IW<JJ[>MB^W+!5C8>6(9 %=XB[IQ"$K@]1Z!EVEXNT!Q5!"@<&<(7
MXEAEL-7$O%M&*XUUK=R3?X;%!'>\%F1@(< _!O$=W6D0873#0Y8RJ;VBH7"M
M^E#_166R5CI+35V)T "W4@>!J+X;C*4JSX"B6M(5ZT-/B27L-D&1(&#%[BEC
MQ_%=$EWGD7(F$8I1V@BEL:FB6/4A29)]/UU[4>QT'OQ-H%G6O=;:&G$<2P76
MZB4E53@NDZ-6PU&521AQH%NW5HLA,2BL0127;)WQ^9"5\>?H7Z\_>V=)9;TP
MA6F-AW<-=1_;>@_[K])'DH@3>^/36#DZITD45' 3-F3FE5I8Y/891@UD"PEB
M%XQ<RECPE5!V@2N9RE:6!-JR*_9G!)=:;X;VPF+)Z4JC]R]9AE*-+Q("F3_=
M1Z' +LD]RKZ'DEADBB+?=M,Z0MG@:<H4,$[W13-J+$I,1!T?=DC'T3[+,F:0
M+BH9]M&^BS_>ONK7ND3UH5HA]3*8M/1+;PTB8'# +[9<X!&Z12)11*X-^]M'
M 'TWC\ "TG?[%-G31*L;;1CU60@\F\Y!0]]@7Q+[*M7FE#4G*?V39#-E,:R2
M^F5+H-X$L^50Y"L!8O43YF14/?>/VN@$5:*(+-4XDX*G#=\F+QJ:^T"#5>_:
M:V>)6. (6QROV)YPEK)+>Q*F;MISIKBRU08#,L2='@L%4P+A.E6(=PRUZ[#5
M 45&!X#_/@T9#\ZMF0FMNEI1]K)NS!2?W!HX3 6[MKY9U9;YKNID)&@WTG]:
M'Y_2&>F"R )']5+$?E*9L\+(UEU_UY Y# @)7"R@:U')'S4C,[GK57X'XTP[
M9.MQ]R,0^6#*^2!KM$0INGK4F*9WM9/-_3V0]^)E]7-ZY^SL9#,2#/N20\>C
M.UY:W,!.$T>D,,D'T?!10/Q:.WT8#0VEG(?9MV_!"5()I!Q2Z*GC?(J$7NG!
M&83#9O$6+UV6?FL\/4S(\(:7L]L+EO00GQ#%-A?P$GS]&7==V,X))RLT-UXE
M@'-SGB"4.6VPX'/2("(U;M!7X!=9N#4<SY5]78@((/35V]VC:&W6ES8$IA#G
M\@A =NC0/G)[*S+DAFH298XR7L\1<8<;*A=A!.(?>K@\9HX%R/&X>TNF,:_9
MD\O0_3I8U%\82D/3F)-M!CH*HE2FA5),29\Y$$E^7^4E,ZRXYSZ49JZ8N9W,
MZ&>:R4QN,#>N)T(>,'3 \0D?W\#S#&I;K4X8'MS+?R']K4O"$NOH=I0(/IME
MF+@H&.:A<:?F+1$)T4.^L\0-C(&ZXC\+-;NR1-^,-MYP>9GZ3(3B6^RD#'^!
M!U50AP0N<2^\01%"S"G$K@5RF6R<H\O$G]-5("=G+ZW=:&XUVBP><8J-%OA(
M]#W V8C31E-GY2Q2Y!$0TC*[2#;B-*BT6EM%:;'J2C0IX!.+CUHD8,V)] /W
MC7XO]A^"\001:443;U^J00>F[$V,0#T;+R$^,B$1/1SF61 ).PZQET2L*:D(
M\;6%M<NZM/$BTGHTX%X8W]$>9YERSJ2+O-KQ$DZ;@08G-X4-GG0B=4(B2F/.
M,$29%NHIY$><5V0.>TP7F'VE52O13+7;INP99<_J0@]\99I=)[:3!.L3U#Y:
M)C^S1]UC9ZGCG]I=79"VJB-SB)M83TMN5*]5W4"1>2O_0 QF;6AIT2_KAK@7
M=D&P&)-B0\G-W&4K&I@Y\[0Y8RV(L'-L:?6()U!?;VEC#Y*2KFK*M>1V5*-Q
M%W2 3#B[@]Z=K!D*+G'!6GB])V05G2:5U!3MK+#'6\+HSES/>N(14"4Q!A+M
MVEO1#(?"#;O6(U1P6[-I(S\7\2&^9;J)EQ<DS('$K6V!R^)W5#1!$YEA&ECI
M"YE+)_.G(%XC0Z),W,TBLNZC6+[7/>2^HMC=G.YI$5%A\*/X'KKC3MXWY/:8
M+//&'&_[@GK?E1I9CZ0A^9B?N(6VDW4;XT7SHOJ^CH@9#X-S;I[(D'@KIF(R
MUZ.E;+[MND$9 2#EG8(G"*J\Y&J!MI^GEXU<%[03+%U(2J][T=[A(,9,*PL%
M$Z6TX\Q _62;R(*AW&S!7\;LI6ND,*8)V'B+XK&<LR]7:-W;\>$Q<"W?U[!\
M.-=J0;=<6-) D"M=!??F6N9JS!67C9Z(TGC"+K'XL'+)GS85HXH&T4"YL.Z!
M8*^,;3")*8R=]EC9IA)EDD)H5<Q9SY540\)TLI7DG;O!LE'VNX&,WV9>@I5S
M"YXIB2(#%5L$J8=R6O)F-O3G4^E>VI1\Z@D;TYD*E SL;^_2=#\5Z0I-X" ?
M;VY2D6<I1/2,]*Z$9HBP]52$!40+,B2G69FXN%NZ*MJX!S"B$'7E<J6MG2P@
MO^\D\\,QB@4YWHG6O'2<9;S=S61I]OANWI>6B!Z.=F&<XZR_0KJT/^\24#%M
ML2JI9T>@1$<@K#^^7RZC'\[W0]$SY1$ %,19U+41>'X2L_:F;H:I]6=5-\N$
MWBA>SS'I'#UGDI%SAU9^Q/GD)A]Q)'\VVLN7C0_*HS#.+0O';6(NMKY.9#1<
MPE=F(=>05[.5--;BQ>[4R2?Y049Z)F^-)(VS9'"QRF(2:^3(*UHL<K3+3H%T
MRAS)-6-LAZ^D;.J6#P@'['^A!#C0N_:K/_.[Q)SB6K/U94NT%S]KKDS:;R'[
M:$^):6B</+^-R_NBK*?_+7E.,V$+JG=H-8;C><74%[.)/]N5+>!HQWUICM#F
M* 6&5R8-!,="BB"C?2&MM6CB_"1.L>DZ*[)7X&0HME=WC/_\50-G&KDR(;F:
M.R^)B3V(&Y7<+ZD)@Y3:NMK3@MT1V6IY;YB3,H?WQQW?VR7RF:*&HY8!JJJ.
M&=L %43HEOK',4N"QI8ZLHA+JGH2L>;6F.X,[74"]88I7QMO]]^X%1X<UO&;
MH"C3$],&!-"VXFB8B"+!FYS8EW7KF$$IL+L9*$)J]8L*C?V-F*-6/A(]!T>@
MR-1!0P=*N?[1'0<&J].H"$J%/'U 65>#"7U_WQ<S/XLYY#8_CV^'K-,7U.%>
M/\OJ9K.3YQ<CL3AL#.W\DCXSMNLZR*5NN\T971LLPS/=8FS-[S\COWIUS72U
MECI%1+(L)6V>(HE=6OU"L+6"J=00CKD!(@*NZYF&U\ZVT;]2[#JRQX])Q Z.
MB0G#YV6>39$GW^86#+#E:F@23;2)RY;.78=KV>)@HNOC  ]3E!EA7VT3015=
M_=)4U6Q17'F+""OV:LE]Y>S#)(AP<1S5KMAM63WEI> R9<WW!1KN)\YEZ^@]
M/!I6(.8H^@,L[)X+-W_U/"2!V:-U,,Y33>H+DIGFB^BW7%@OKA4BX!R]'N+D
M6HVO.U:%,D -1S&1))RG8$%(?/,:>P8SM\2)$2%G30+V+ GV&N<:3(]#B#43
M/QH>$^FMFG.A@,75Q.\KV7LU1/]*PD"._(?.L.+NMNT)90YT?X>W$V41R#OD
M>DFZ\G819:GIA)TB]!#'H'RP[M*Y\M8[WWRT#-IG'=@;O9 -ZSTF+^^F"1TD
MW'#679B08TQ0YH\+BVY".R;K)#? 1!\FI)CE6_MFW;VF+>3>@KD61;S=_LI@
M"_[-J]ND",3+"&+O"S,V[^"Y T)AX<?$/R'XS:\FMF6$Y@P&O#2Y.N/[OML_
MSS*4ZNEZ6$Y@J^EDL7M[T+^PEIZEIVN?]GMA-!/(UL!X8*"V^#)X6-5>HI>&
M00#66^6I_:*!3+C:/'A.^(!MB5Z"J:]7UGSSA(,B.D&64RLUF@YXM'[9_*)K
M@"2ZJTJ;C)?YQ%^/(?+#&ITR=0]&S"]V7"M[[V]=:SI])M^P8<,6II"W/..1
M]@/IIC&9A.A!RG9#U2_L57UEC[(;'$8'BXL2H)0(#HZXYAS\&-](L8GR*/'?
M]C@P=Z":=%);Z:KX[T3//=ZC;=]<37IP9JQJCE<>9+,OU^QT4S5.9&E<_?,K
MM2NW3?YC9\1-H_KUW0/E^4'>&^CG&W71;,29\]E)NV6[I*0:F,= =0O,+KSL
MTW#8>G=MH,XCN1YR,YFDO),+%H*,"C%.1XRFA&<W@MU>M#;NE_RU,1@8%;KS
M_;P?K#?;TCQ4S[;F?B/HO) C>-LV\I]?I!C/Q(L9__HBI?GP0N\1$%-_\R!Q
M6\"3R]K0@_T]J&BK@N._SW$SJZ\1: X U=U/#U8,Y<\RR =FW9,O<J6+ONRU
M/V^5]^3UW!WV#%]1A)+LYCH=5.ZGNET2GD3^_K0FG--;.,-:Q]ZP(VP]WFK$
MJ@W/H7<F+8^5+BYRF3F?03_I'G!OX,.(51;L-DU.(^>FB[GZT;W.VBU#-G^Q
M59C5,2- ZB_%L;WO]FQ=N7>=_!=1K)<RC=@,'RXS[HC@=Y2:I1]3AV#Z%[XA
MJ=_)AJZFW&1"#/R^=7KX^1U%+>2(^-6O7%EOY-Y*=+5OP6\ULQQQ>%W7A,0>
M ;=R;3E;.;7@L:JS(+='P,>ZG8O]W,&Q1C4#[T? ^/W]XH7AW#:X&TSW")BG
M)'@$\!'-Y[J#YJHOB\*MVT_DVAN*<Z)$9?G:"^S&;TH"I1"C?A=^O]KYQA&^
MI!Z,#V-'T.N&MM^WG;V7MY,P%ILKNI5%R3-M3_'FXXGRG9/BJ.4&^DLH['!%
M/N]A8O<_'*HBT,B:GB0<19T,[8^ HK#6D+\M.B\4V$VL;Y=A""76?Q9<;'%%
MC))#!?XS%SE2+-4#/DQTDX&R3+L]T#<D]SM9^TURO4+[PPS*]LIR&"-SW[W.
M_W)W\91*P"\!?-]C^'>6E:?A7#>48U8YM39>;-S@MR><Y!R(8@LE/@*LW#7O
M%@T_^>(>CXX+23SMN>7X+@FF4\=S=ZE[RY!:^@3LEVU]#UM'W?E>V9GK?W52
MP H:/&9]5N-?F4U]JH"TA%6JV4T7+YC2V-^R>=+>OSMKDAGGZ-:[-SS'&&@A
M$'.9[U65.[>K8XE\$LAH&14*85HQ;1NFFPLX>IU#4SMCGJI]1K6KVRR2,[UM
MU9107]/WPN/J/"9'ZA/DMXPPC0R9HK8V\G<-PK-0.@_  -9>?&^LYQ5IQ+9E
MDH$8; X>%7'$(!5N9/&Z-!.#W/W+4J8(1>4%V,9O?/N @G+Z#_UGOQ<G.>_[
M1-%ZZ5GCJS!R<:@5TCR^U<R@AEJ+D7F<!MFGBC_$Y<KS-$8+1K#W(L[FCC:[
MC5%MI0*0-S_DL+Q\/1SYX/6334MVO#(^3E!!SMB4=#:KMQ;X[DII0[13.]"!
M>%5E;0ZK\D+1EZS*,>T2GH"G2Y8GH/M#H"<4<^P0?Y.ER()N]:JZ$M@ZR>MF
M;'X@6894.<;'+G:@QS?31)%W%;5S?)8;%*FS:FPK<A\1;)"+7;!,_2X SY2(
MT%& L=O86@)[R ;[+1&.8#Y=?$%R.24:[=T'6*GHH,-K,Q@W$2/A:EP/;$!K
M6+62R[6S2GCTJTRF1P2/U]<+N[I,;7*J07',HX,.B+0X2U L18-VM'90MKI)
M_Z".W'5W8>&<[L[L6=)DI!@!A8"#OJP4E?8G6?4JIM>)UG*LB:IS>)S38]WO
M0B0GP>^T$[A@SU@G9%GC^0^=SOR2<Z2&CUD7'8($-/I8;3U@72?3O\8&0@2@
M@@ [*R;6^L!KL0Y32URX"1]_56L[2JJVZ2ENQC/ 4C:%3L@<RWC?+K< IC'6
M[JWWX,N;M72"V>^)K.N+9L#2<O.#FK=+PBE$K!\9-+33$C*F<BQYS33;>[YM
M.L3;>9DY4*R6<4G,=NDR4(3R9GWMG9@)I&4S]<KKI(E2L*6@!&YB!@5G"4;T
M#Q3@#_:)AULER/?K*>BZDNJ)GT:0V#Z7;9MS(=G5:J@M;:F=>\C?/_QI@U[X
MHZ&RO99WHO#[MTV\XL'N@7YSIC?PD R5""QM$TIW^@024Q<')P[TNX(3'-0F
M$"@UL3163II&/!<'J9(D*)LE;;C4:U_+N?/W<]*I>L=1YIP+>4<]71XQKG).
M$XH4/)MJNYKGBXT9O+0*SLE0RC/W&_ Q7OD?+N&(E6&39CJBV;> RM/!0IPS
M#J3\"X5X&_O>P&$'3;K*FT1=(=D!RA5<'#>!W,$X&@B.3=&Z'N:K*W]B;V6Z
MM>SP<-TL">M5GC#A ].,HZW::71JE+0&F23'VN&X,(@BE+'YR%95"REGF[^#
MFPE"6_WJ;D3XX&=)N^H81\''T"Q%UT2+F\C"KU"F;O_\XN:J\B+T!6 A3D<\
M2W![.->VT'M9XKFU4/X7_A%KZ:-F">\F#)F]@S+<3 KA+:BV$M%@#J^C$:]H
ML7>5<H*W'AN1&1BNKK*R2&(H&HY^3' ;D[BP8XW>7@'>V&YB@&UPXP:,DIIG
M6R!#._G"6>5Y4ZBG\#U3'?$/K=<+9+\Q&J1LAQG:<=C')KB,&$WZMQ0)D&><
MU&)8"+4)$L3HG-Z9>>;'ZQTJG63V2X/9F5O  ?5 $0TE%HB6A=RLKL+:RRK"
MX:O=?%I#:NJ ]$. FA#M(#\-GFC8,9\D4_A2<,\ 1;W&P)R(\A!O>Q06EC'O
MDHLA"T+&[_OEFY+OWP=YJ?S>"GA_PC7O^X2PE:\O_TJBU=^:DX:)V0@K#3")
M!4USKH7DH+[+<M<)3Z%BO@L)E1G%)5AML%6,]?!E(->@JH\OZ*..'S%[#>/D
M(<+34UK(%DO*HAW43B-A1XML#/A*W(89SE7CC^;&[Q5DPWSW98$-@'WUT5.@
ME1$T9;?)RU_A=1PWN='M12FC+FM,H#X#9XQH&W)!)Y*(L1*HDM.JR 8"K\R\
M5++XA\J4-L%?KE*K%&4(5_&%8U'*LX^4M<$Q<^O#%RG"!R]YHEZ7.\;7':":
MK#Y\Z)IQ%>*+@%%DW(*XJ 4Y^V])>.K&)GU<"I83Q^]W%3."L33TD_=(%2U^
M2(B5]%$Y.HW-/#,G^U:)3%K0^@$9[\K,FR$:=-REI^SBW'M1DJBGOTGU)>0$
M?+D0( KD-GDK:]Y5)4%GX'#B/S-@RQ \YR7#@]J85^: D$D*R$[K@%AP<O8D
M240.S>&;-XU-GX_AZ.R5AGKR"M,3OES\Y:><.>TR!\1+_Z*H^SO=08'2#?^9
MYDL%VTOM1(RWLI*J:;L%D6Y-%OR4Q0>>?IC>D22DRUR=R) P7E[O-V]"8JUC
MI:5)2<<88H/]WWTE&YS_VIB#N0ETB7-%BR2A<_2.O>+IX^[T_:@G[AR7WMBV
MRS>\\FL'<R+7VDTN<6Y_5$5F(VT8"3MF)=/)(U4-*;1<Q:B@)N>Z3ZU+H'6Y
MD)HQH)(V>U5R<_'8(6E9@I?9Q(%P%2(3[NC*B#-088DK\E'!N=?8!L.=!V[*
M;FYADP77E'&$,F73,KCAP..\]=.[4R7"1S&0TS'-L>GP9-FLC7&K9L8([=PH
M8^/DVMXKS:6C=CJTKGFP?AN-3[57NS#;X-9L-7NNVQC3E*$K$WCNW.4Q@9<G
M[/WABF)[ O=-2T1 O P1^6I%'>"A7X:!F*M0C(S:3#N#9GBZ!NT=@HVF6WF(
M8XWRPY"%(AI!4@OJ(%5P1I26G,4'4ONH+.48@@)_]2P_:;[O>F*C (-T-V\C
M.U-*,LZ^0'2IJN"/M*Q6^VBQ/95$Q#T20(F*4-E^V9A$+C):G8T=!&M+/"1B
M>Q"'8-YX<?L)J$)@"I@9M)"9]+@F*]70T "61'=<*AN]Z:-R:JSOKD&KU9,9
M,^EDA>(N#\?#+'UB5<4Y_C[,9V\7P')52Q*32E\TL55\WBF-A-BF)HN'=R"7
MU;MKCHET )^;(A%+4(&.T'L[7]E&_("M/@*86X(S*XESV#HL\13F*XB,TR8N
M06URQ!UP3@3$.:!_NR;C2SUO4+,[.*G4.8HS2[OUJY$S*N%'$5E"&&M48=#8
MA[;WR1FXTHCO#>K ;I?3UB.!MJP] "'&1DC'V+S0->M/26\W;,=S7MR::H^I
MBBLDY@O4)G=*^+8VWY7FAA0_=)V<4$QO@)0B,AS(C5FE1-M;+=N;4AOKK)OT
M(@^ B;VZK,);$@;AC2?+<^XE-5G'SZ+<,F<K9B]YWDA:5?D(&*L^"_)J4E\B
M0(QZKK;</:&5X248^F?&X0DV^QX!&WIL&U$<ONRLEZ=2+]_&ZJRH]WN(]F$P
M(L!X=%841W*E03.-OYWHK*W:HCAD^<R5D^MEJDZ7:R@UX24/<:=7C Z92]U'
MDP.B%V$A?B,]%R6703$Q5V \RBRZ;H<K M'W0Q,O2D:/2^PC;YNG@VZ%*+,<
M<QZ\H*V@R?\0%2WC\!6=@O%F'#82G1=.^&_W2VX(?;^8;=_+-W\;O(;HX=HO
M.L\B;EKNFO\+7H_\8GTCX%0GB50_,][\!Y$;[EGI';6+UCMF>0LU0U-R0]OD
M'@$U0BP/]ARU(D>0RF]/2.[IF.@'P1\WWT55%OU=TL1\!*\1C6N_-LJM:C/P
MOLT-S?D_$M&_)".B&>ZAS7YTF;=1"9ZL]]0#"U=3]3)K]]AHBZW-MWZ4!HA(
M"$+_?Y/K$+15Z/TCX%JNK26IX>')'X7H1EF3R"/@S6KJ8ON5GVCUH-MZVW_D
M^MM>A\Q3*=H?-!P*,XO&6O//*%P<IM"4LU6VM5TO]LMMZK6FRD=UQP*<OR A
M4\<[\(*CB/#8$EY::HQ0=\5SDU[D\7_I_U%<IC:SM?*9@^F*"O_$E5P4!Y[&
M:ML=T7%*204DC\.R=:YII^8O7AS#MI<Z)%H4BEC34T#K-<\D"N@QSB>6RQ_E
MP375NVSC>P$A<35N=5!9-RQ1\A.%3JM*&LAZ6KEBNMW$[N)AM\T)48Z*#FLW
M7<6L[^P5EI.GJ,U,FT&(G3=K>( )3'1,%OS";J6:BC!3BI6X<=_-.\/0(S#3
M5L^QHIJ[$/>5/0.0YWNH*S3SQ59U$T8]JD -GX;\C5O*HB@)S%W2<?6;]TD]
M&7)(-$GV7!U_=[;^,V=Q$4&.@9D=J1MI=='%Y@R:T]$S0RRUFT= AD,^/.?>
M]_;*9\-'<^4.YSO%YD3 RL:=CPB%*/L=T?JEGQ>7CM:IP$Q<8-%?<C^$_HC@
M(^"@E[C%J06*<2D;L;)_4RN*VQ)W+QQX,71VE]MJ,%^TVDYU3Q1YKYS3?KP1
ML1-U%GW<==:<#G7@2.'\?05Y!&#X].<ZC*Z NQ&T>P^/ */6JGO][%MK492K
MZT? FCOT-[0T[X;FGI;E$4"_.+IEF'RT[+/T"%C@LW=_!$!'7.Y$3D3!V_N$
M;6]W=Z]Y[HC7'P%YQX8_[U3/:%II,38G#BW/%XU;H+FYIPIGKNM_GMXHE(8>
ME'Y7%Y@S\_<^N=47U@Z=L:(W' 0WN3V:9T^)1"_+MWP? 9<KV)+KL4N)#.M;
MEQ?K?]D[>_#MM'D$1!45;3R4@/]'I.(#](W/\7AXMS^9\PA M!'G\CEL);L?
M7'"(4JH\U=)O=Y]PWI=OUA<L<8;S\XKKZ7$A!6]7O2IFS&.9>!LUZ-*<7F3V
M"/ Y^O7PM*?O,EB\]_2E\J""GEY@@DD\7*Y%+:\85]LI%Q &+.<"-]/R*U*(
M @K_ E->JL_K9>*M,2QS&1^^RE(%37G1H*<'XHS[?"PU^$9[;DU:(D2)<O0G
M;*WHR^CG@9XK%0C_XB,@*%7V,D9JT 3'+KYDWM:CJU]?%*VEX%G9%0ZHMC"(
MJ3;=OI_5^G7''J9RDFRKW>?(,\T;Y;@?T+Y?NZ?.T7G%"=J?=N4'C_/>L-#E
M!N?([\U5S822)^1!:/M"^9[N/]>27R5"-2<D"0*07I I!#]"!"CD2+Q%4?;N
M(&8M92LE9I'4&>!"6MH\,,I,WBOM2'S2B];,LGQ-:GX7$/\;V<4J^P9)'DZ4
M3SN1KVTCX:5=V5RO[Q:EV:,>K1>0.8YB':LA!L]%\0&N;^Z_^<ID (%&BS'X
MNS9,$E3F);YM3UK6NL8(C[4J@.NQ,-"TO1R?CP_WU:A>>[GE[UT!E$B),"JR
MV0H:\Q#>I"7OD_'OE=S9@>D,]<_P7%3$'OT8BF"[*RO59W7/E9SYGM0M6\51
M&'U5\C(B:0*7EAI6R!-4E'SZRQA%+DG (S+#LLE:-D%&B?672YQGJ_K0KHC^
M-0GQ$!II1V5,)&@MHCP]OB^1&T M*9$^V\QLC-(8!17C2&Q)/PE ."]U<SE
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MHRX!1TD0G-D49@D>\7H)D^/.NY+-&0U19<%+NAZ[ZY$O(DI/L5RN;5Y''"2
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M]+9,:2B;#%[X72>EXS_08@)3G3AG?-)$UJ-C%R%ZO[TN$/<N:G>24<.DR1Y
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M.L?9PZIG8_%.A'(+;B@3O6@H@:V$5)0/P!19$RP3Z1G+2/WFX>X[XUQN<C5
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M?_WQ,%J_F04F_"V^PC RX"Q47(FE<,QC)ZO^WA$A<3GU=_Y+I7Y'GVMC5=!
M.6[8;[7"2O-/C1&]);^,I^A*N# VB!-TSLSPK]0^D3DT%>_QOZ$UZRKP$*=!
MM'1.- J?#2ZNCVO-71?-M?461-?6ZP/T4FE&F^OJB-9L2/YP*AH-?15(?TZW
M- H?1O:?8%4C.+.+*,-]-)#EY6&(U]-K4#?0C@@SBBF=5VO_KJ[<U*!PY;'N
M[:]4"M&*CX]:*Z$WBI=SI',?HJ-SB\IC1L]/#9>[RBDS9+B11MY8H?Q3/=6%
M63RAOSMGBK\ZOG5+OJ&GT^+7F/,GZ!\@(8WSTJSW];/R[Z#\/S63@AQQR?Y$
MF@H2RI(J1A2KCR_(JY8J7NC([&MNX6V!N/SNMH\I_G#:_&0)AF2*5<4^(@#*
M6@9 H#RDZ0%7UIHA"8$AV G1"PW2*-/_LQ#Y34!+9^C[4B6\D"IH[O.N43 "
M+$<_7^!-H_T]:/0PH]W7[#_KN'A[$Y37E=-@D'O%__]X#UV]?<+ 7^J^B\1)
MQ@;GRCNF=P-5/AKV$F24EG8]KAF"4X$&W U3HA8-J+_)I@,PE><(V'<>:V%4
MQ-0@$Z>XUUMT_;%$D-&Z@+YYB#SM%^JO.O\ ]YJ/^:]/Y^Q_D[K[&VNWOMW^
ME/O[$;?R'^"D^%+L\7K)X ^M-_#AH^)F].\@2HU_@%G9-9_+K;+&5YGS(+2S
M-ZV/B</5_P O5?YS?P*\TO\!E$RY!OY0.S+?_O+^^ \@\,[P>Z-+RK=SK/)?
MU*77SXTR_X>@LNH_W>D>]U?^ 7ZO2-@U_OV/FK]FQ3HJ/S^:KP:]T6U1I78G
M%%\L6[BI_1V[52U$K9ECF$915>0S\IX\ [K-?&<8:+B\WI&V<5=].>@>O2(2
M8;^:H9+>P=KB[9J#.'+$_G?9)G[YG^Q_XA0QJ_I+].35IV+B/$HJJ1[,7FGA
M]^;YZJ&OWN?F[&>>Y5?W'J*^]$%"WWR7/6S2%X^8.752DQ-.-A:AS_IK+Y*N
MB4L)C&H";M+ UGSR<H:8FMLBSRCY1%%;^RUS*?C#>66U)JZ!6*H4T\")/R&+
MV<%N? XYSC+RWV1[0*Y#4:U)3LN])P]V $=XK:,J[@5+S!!'AU-@2AK L).0
M=NN(.,1@85V=LNP>](:WF"H9S&F?FEI^)2A@Z_?S"7? =C@%-SP,# 9Y5H]&
MML7-RS3D$N@L1[AF6((UO^,0S,WE2%#S.E>P=@X_%,?O_-DP-='6U-S?6+6U
MO2\?/V^)R]@.N7/ZXJ$R'!5.$8#[K2F]]+NR*!Z]XQ^#*=XR=-_)-+&[NW4N
M,2T?LV\6[55S 721QCTK#D7'<]WFO-U"/1AGFW6S/+T?2BO(XF#_ "P#Y\^H
M-?TIMX<;A%HI:\=$H,Y@7?,;0H'\^O0CW_A>GD$3X!GYBJ%:"JTUG;LZ..SV
M/='E5R:A=>,2SHXS[WK[S> 4>FBZ\,SR6:WH2ZF+Q6?,C:]7=J6U/-MQ8"?Y
M<\F$FILG[.316?>L*);'<; ADV?L>W-3"N-H$</ 8]#UC;3XNU&:M@2R,3F'
M!O+53+RVEFWO>T,H_T).#=F&0/5Q-5UH TI(^'H@]VL^Q0?-[A5L681Z-4I!
M0UXGC1('#@Y'IBUL.4]6FVZ29T+E7D3$R3/*'$4;]+61%K+68T/8J2A97PB)
M;$/<R _9"MFIQ@*B_?PG6P=<<$@E(DXHO$!]#=?PP$>3@;BFO/*CK=2\A7ZF
MWQ%$JEX@4!OGW=&]@_.A'^>R/UOS%'M>2 \Z89/7KQMY_UOV,Q])]A+T,8Y6
M,F-_O?$K'-RG[@%R"C3.R)':FHM-HXP5X%J&E0R(JU#5(?DJ^FN?>%U(1Z6_
M7P [ 9!?9 1T[S4MA;RR(<8O.(L):$^@>&F?E>Q3JVYJB),@H[G!T5\A;B<'
M21[M:I*FKNSK6*\W'Z%JAW GIUGKU::^J207;!$TCR6_;HR%MUB"Q]"[:*>=
MYWW1>L="KQ$ $DOB#E-WG:::6XZ8PLO2_ ANSE?>Q0L?G!Z/.XTR,Q=>N9NV
M/0*&NY592A2V*1^WEAP.V-RF\.HC2B<:6RB"[YTZD$6;>'IN6895W>YPK%MZ
MZ&HS%OSA-+"<;WE<U_3#RHUW5=C7E&149Y'!>MN*6W;9IL@N7BDCZ"_$T !7
M*;$E+Q_8XZJM[\G**[\'DIM1QT./GJE-K@OEW []WH0.77$-;T$/4>%-Q(L9
M5Z<!R?48T'G7)]PRS'"A$ PTS%"8P@_'RYGV1FL"YYPT.6)K9$RNH'ZXZHYM
M&5/]"P:JHWE/%%QNH\,DZN@;P*=8A#M0J3V(XCT1P8:0?!]:?+>4LWL?$RHI
MT>K3Z=+1,LA0-&&#!7(!K$^SW)NUZ8\#E/8BHYD2:@JH-*081694 '&8'.F3
M_P%2D8RS\C'L?6PI1#/]=GM$-]_763WFG,6K*)%&B=HK:+/+0,9!WYV?J!<+
M.\E=W;O+O?;C#X7;S;148L8F.3GOWN[BIX#5Y[<*T_'7?W72=M9!UE"A1Z1U
M+2H" Y7KPVENK8''Y"+6>N:[1_*_FK/EO\B+FU865NW;OHJ$D]M^S1CK^A'4
M<^EXBCOZRH1>W]!.#7%W0&@7QD-*YKD^4=9R6G[G[1QB!62Q\4:H[20Q1IUT
MLL"GRG!*:4$U B[7DA=1X"!4<R">/1?2TUL0^WA(E*JQ7!:Q(>5RDQU#MJ]%
M>(64_CBV@2DN^@VZB+>'NFT?G.PVXJEP$A].]01F=P35_->G42&42GKP>W=9
M!<,?DJ;>/*B[FB?P,15S0U,+YZBV#L"\FP!D(I*57EI4#W6(AVPGZ9R4T)O_
M'-T-FN-4N@VRCS>E;QIWWMB<@"2M$6L1J(?>[<B9I?1'BFIM4H6^5F]?MVQL
MFM"[<7\NF?  *G(4=TTC=8W?##SY(;4V,/*B@+!(?W>SBK/OZYEI:>D1U#S-
MA>BMZ#9XU.9=Y!Q[YO5V314/U=34[N@9=#?V><E#_]L.0VZ1P+S'^%OXU1AG
MEZ2].X<L3F@F^;A#6,$IYVP+..<?(.56G(L<HP5T9$A9"C\BZF7)2Y8E)4*;
MH;2PS1%MN"S^!Z#6]N_[\[=1^[9P<4Q?LR#N)I0A\4<=U69Z],WR?=LF7@N=
M#R;YJ5VV5R=@:31BR$4-A7H*RVU:KU8QM,-IO&B""2K$4:(\-_O<YFIQAQN<
MS:>8A'A GA6W0B5K8H]OC6*BH&A3MU/*&2Q ^%&DV*5)-G"LZ[%IH9J+6:BJ
MLK6*EZ[Y^R"OSPI@YUN]:&SU)*=\0Q ]S .N04H.H8>A0I2BH.;7M\XCRIF2
MU\#BT4GO$LQH[TEKGSG:@37'][^Y4=?<*!2D !PSPT0Z6:$&]DBX]-_21N%6
M$('WA7M+&2D"*Q^6%EZ#+'!,S28-Y[NTO)[#/L^!7 ;+^8#3.IQBU'7?I>^?
M<;=U/F8222/NAO-!EWI^!&<!D?LGK2O<:HYHP4/YUG$7WBGD14,*_L766$2"
M1(K<G*,-.$4,LU559ZO)I $!BH+S>22N M?>DT;/[Y@NT /OB=KY/T^XT&O
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M1EXE>,S)(%UEA%?;Y_Y"C[[ALDBM\QJ+_%B*!7T$[.8N82\/!:!J $5>XZ'
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MJL0<6(Y#&V["?UX9>U%::J<A,QQX&ZCZMO3XJ;1BSJ;Y=)VI1/8CMP^O:,T
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MHCLZ]T3<SVG(5%YCK'T4O;]G26:>K'MC8AISLJR3-=01K:[\&L.\$=.[9PZ
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MB?GGB=TO+5M5"V L+?_7(M3F\DSZE[\OSJ&#-/S8<K/.P;FRKW02M+<$G'"
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M=&?5N46,ZA*(B)1R81;HV+0_M>LH(^IH[J',XP!T4J'NE:AB+V'2_U4844L
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M)6;\I+R,FB:]13.TA:;R;I#U4I5/@KOHRR*5]8YBUT0ZZ69V;\["WR(-U@)
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MQ\/80-FAM\VAPH-TU77U2?8X:":"0B]LGE:8X90VIW3UY!(_1F3>D$8![*%
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MQF[:&/0^J*"N9_X=BQ?XC4NBT[C_NC*Q++8YFXF#,QU)C:),6)"N0NQ(.DQ
M[FS('U"H1Q>DP4T[L&L[T%*/'T80 1DKZ+.R/MU)$,'SV#R&D7;E 9:F0-4
M!^6BVF7LVG.A=K4KP])&45-S+O-9@Y!6*!3JZVNHF30N)2B0HPXU3D0 I=>]
M=V_^_!19BFRFC2S\Z#/_AWMC=^J>F[S[8]SNA8W!"CD=:Q+RN-"VJY:\.HG"
M/2$#+A"E=R6HHS,K0EZEJZNG)5+,__/>/^BY;,!YWTY[YG#UM\0#[%>45[U*
MZM*K]Q_#$T>3<LR/N84@PI32>W;T(_F83F(\&)F":FQJ-J_1HI@>9O_\3:Q,
M/MO<<LE.K=E4QXV1DG(8R>XJ[3ES'JD9CN,3BHRG?0%E^TORA!8TJEDE0NUR
MJR/3.Y2X D,U4CA/T-&S[F@2/B^7!O\J/RFP 1B@D@&': 4'&!.):)@CNK'!
M$&8X7%EQX!(Y_QZ/9J4LNJ"B%:$<.ZH\H'NM"];Y>*(X\TH&&#B7\S]M;9,S
MR&Y396UE>IA29 ^S0DKF7$QE7:B052!_.@UQ<7@/7G2-0;QA@Z+L' M[I+(J
MLHUIFD'N_>< <X=;;LQW?Q9^0AA2?#)_HG(ZH0B^Y&Q1WQNLT9@DV\$Z._F9
MA""XG5^IC%<4#$\_3"RZ).E/"5P$+VH6H>.S^H=ES*2%Z<\LV\JT@_DY47M>
MI582M,:*Q>3AF7"*6/_5^Z)CXC?8K%4-VY@T_^945O!GZ6_8SH\5!<B/H4Q-
MX#OJ_S7:Y>*ZS+Z:.GQZNOQ&/L\>,2.#YG&6?\;H6]I=4>(<I9>?;&6IW1-,
M?)UF58+ +L#FP?=,3E(CE:Z3E1*LFU67BH?J()>D+Y2;]-BMRMBC&E*6&0$\
M.9P 35+[K[KSIS@TJ*(<>5?&B+8@*TL ACW\%)Y#^'@!!%*9Q5JVZMUIMD*2
M_0M8JAEX6RE&B8].B!_3QT!Q;>=*-?<=AK_VJZKK>-XG];FM*[/-=.N/1/2V
MU21I0&>DTV%DEJ_2BYFJ,F7Q%,!6;),>)I:M%D,[C^&4;@=-XP/6J\9(RVU$
MPD &*PC9+:!> (YZPX+4CVS]A8+7$>SY#R ]):C9L;.MQX=J4]W&RKNZI_QG
MG(*1XM/J:"5U%K>1629!S.(2RKN^L,JZ0O4QV8FF5L>&E92:N2M#;#D[/%SZ
M@VD7?G*7E#NW?I(CHZP/:.-%#@KMV^F!T%M8>C(--OJVP#S+JZ E:Z%H&P^O
M"Y BYXSCAA:J,Q_J:]R/1QOV$EI GJ^,C6TCW_ 79O,!W5@V^J(Q$C'OF 19
MZ:NJF.JFMN_JE.]OI-1I$FLU4TM%HG9CWHH!+@3AS#UH\IQF+JYYV^D\3^-,
MDP"\P*1A;.>T \CF02;K]=(W.28%= 4D0H[6#;F@!V&"(^K$S0TB18!EY?]*
M],]O\9U:'IOJV0_BR*I)\6P'_:*?3+]N';KBX(@6%LI%D)E(, B/]10PO_&-
M)(C[*'KHSR?(;76#^8_WW;G<>A<7WH%Z7M[_69KZWSI'#@NJJG-@_?S^M*UC
M>*I'&V6)C);&7@_IWK1FY')&]HJ/_ MEKZ7G%"[3K/K:ZKTXFV$HC$(HBHGV
MV^$ #_ZDAU<U[ >",:<ZR^7HE4-$=../I+F>>\3,[)_[Q93MN1Q?/1.:QKN[
MP<9+I1[!J$CQ"%WJ?NMWO0MX5H9_#C05A+'UC(R?)5]B/N/-<$.Q@4S^SVS>
MCFK,T1 Z962\P]XO'R9OK,7.T\Y2DR<US9._M<\J\_[!]=2\^ZNFWWCJ>ZZZ
MQGOY&YP<3R.;![Y?MZO3)M7&^'7E+GL<*XJ:H'!4LCRA7&E)N9)8['D4,CRV
M'Q"<M5@XS?YW%>$+2FS_&7M%1=_54$=N@%O.X\7HS0OUUQ-I\24SA]>?)ML_
M;!U3#WADERTV2;:-PA6?]=8_KZW)JM5BY( HM+K)/XW)R_Z4FT\$+#;52TF7
MRW1N!*(Q9.33)2U.05[/Z,,5WK-<7+,0IB#ZY<*'RG9KVW*N2'1Y7L^$UH4/
M!A[(H.RDZ0>X_7Y+%3T)[F^K0Z(5YQH(T4I9M@@(O1?.(+,,=H^F'>KN@'LU
M__:-9XKHMR5*D5#Y:8\N-S?%1LTL9@792X*OP&L("K.;X=;+Q023]H$=T5E+
MAO-Y-LMRP5:BN0,_$U\7:^\D,'60&:0DV?K$XQRJX+ -G[I7YI=/RU9E01^>
M!87ZPV*W*-\,,B'RET\]"5,ROMG<$[<K#RA3RYQH&2ZS(XH'1BBM9*!21,AW
M@LNM>Y:0['5Z0FBPXB@#KS#E$R6,[P+HZA?]A1/?S^WC!^6H3=)X*2F.UQ>/
MY=XW-[J[$P86)"AS,_D=;C+HFZG%Y]WZW34&)OGS%Z>F.)R6^3!,(*!6N"\A
M/1H<2O&82CWOF=16Z1H]"G?B[FC3(4W574S5_K3M2MK#E&Z^N !LS<IP*"04
M">+1SDJP"C,L&O_"MZ[>0DU@2R]&5/&!C,)P)-F\D SJG3:IF-.?_'.VFMGY
M[WYWIYCSFSF>CUWI^BN:!C'.M;!WZD8,S:T,COUQ*88<J6QR?\"'F=BY/_<2
M$%%_2'_^7.=&4C4:FI.BYPZ+1/RI2R0B0+[/6/V6MK<43QDV%@_AAK2-I>I%
M&#.PLF#W<O?'>.(#!K%ARL$QZO%B.V#FZ+@8L=4X&UA3)9AR7A%BB"P0J?HW
M*A4!_H>(S;R2_L^,T^+U?CRV7:8C%;Z@\A-KFD$A2[RHH.D3:T J-5*PK#I@
MO>Q?E:3JD.9839:T9M*$!#CGOWP.!:@!\%A#%#[6R(W?TBYEY!#.$,2XE#SI
MS.DOD<L^OJZV&D,=R(BGL/(1%[6PHG,>_-XAV-3B9^6^1"PR;#!K[@(09<XN
M_MU .P!:RY&G%<BO=H04)!..L???R.YL 19J$EHMTIU!_D>_&FR%55A4GW1B
MV/*<>E8L"5B?BFOX$'!>R7Z.$&&#CVM=7LU^A&3!!QG*W-I*[#H07XJW"6>.
M26;-W<91??'-2QY5)QG26Q6"#C+<< P/#Q\<KGO9?[7\KM" XA8 OZO'.GN6
M.")WQJJ(NK5U<59AUC0PEG H.IN:N$I]"47:M85*Q8R]74T>_/XZB<A&D6CL
M%ZY:+G>^M?RA$OI4$D>1:\3,\ *\&T.1#H?N;<)R+4&PZL_2+PMWOK^:T92*
M_D=6;!5^ KU'CB[?/SDRW^0Y6]YN5'JXL@+4=?WTO;63H$RR>@[$6!_0OMC"
M]Q<FMA=T=;V8576)014F3+J[;%&XR^.BBB'2AH$LAS$:<@%,_0/&2Q/LUNOG
M%,OIE$L2:M@MMI;BAGC9LG@C,KR)P^-BX.*!8;P,-*$O-B[7G6V]=4B"-\+K
M:W[XSDFX$2;=DCDIUE5-_0+,A\UM9$)7O7E]-P%<T4Q-B*2/PUIJ24/-\]=#
MG"0]SAD(37);$QN$"M]^6/_9'[.':J'53T+>89L>)F3.7BYH+FK41,P*;208
MTWM$I &F> *)4G!J,YYX!ZFQ^OHWP#J*-].IBP/^T%'WBET/F9*&)Q_38S8,
M6%43X,.Q:  Q,7"A;-?M3M3_]R$'Z[&=6/875FJYP4#+7O6/YEM% N?Q._%Q
M%&Y'D:B2]?= =L[,BD?U55O+0B^@*R]$:=P-^<X#AJ,EHXU=^D4ELG*5(4SY
M?N#&;'V*L*[5Q$@O?E8'AYBL2205139>%;VRAAC%VN!FUQ,<2Z8C:%XQME#U
MGN'S*ZF;&OR&"<G8PTS'[#-Z6\2U^&YA]HY:M4I:8]?,]E9$%51@$,_(%AXI
MJKQ(VN;@0/XY=2FS4R1JT_>AO/Q>\?R'T*?/%E)7].R__1:.< X-%'J]\O@:
MNX("IXIN3)OT_C_I8"B*[Q0D;*?!+WQH#GG#0J.5A1*88WQ1*S '^;4?"$--
M/][OZP1MK6F+JT.<WXDQ,'_Y<B/5:4QD]['9(&V=1H[U0B85EEMRCHZB&#JL
M&W",.QI(K,ALCL:;8Z)5^*^9DJR+X<,_0E+B$I]61KBG&AH)7CQB)4C/@='6
M'_7+/MFPS1AO#G(U;;(K*OJT()+1K',EL^Q4OR!:))Y0=!IQYY0;"2)L.>25
M'-2PM-M *.EH)3X=7_=I"H^Z1&Y/G-#62(CPOM,F"CY$5K"1K+Y(\ZU15(2J
MJC ;IAZQ!>93$ 1QZJ?KRG_1=+6/,=Y[T-\+?K )GF^67V?/4!;V3Y3#FE5E
MJ4D0[.XPSW9<(R; /39&.YE[K(H<BAH=WL2S:/>/\Z_H;;%L[MCCB1Q]4F,X
M+QA:5'4=I42*GWXH!?HRA;P'=W[@KW$-D?([".2^?SD[D8J!_(_\/#H&"6\3
MJ,,1M1SFIITZXEJ^?Z8V#L^TWH+5003^-587(^^#$GZ\K<DW+#%)7]CN6T)8
M)T_Q=K6"1$1ZF\5YG%UXS*N( 4QIABQ)]H+)J9+[F9SHV!_BV VWZ%5:9K[T
MJ\<$9%"!36A=TXQLV.H&:;C6KU%$;' )6)/0Y-C\KL32+^N^=-4$Y-XKT<*"
MCUD1>_L0A>P9&U0U/I2\5Z2R9:6LD^[A5ZE> =%0ES<2RWI+1H<1LW1))H:B
MHFHHC!@/\NS2IL-84;LJM+%XUS'PQ'?.ED"D[-1M2'_M! ,VWPX1^[BOGQDF
M+4!3MSC248W* S]Q_P)@)OM-. $XR+#WY$90Q0""YKH[F#OT#\!F.HMDM#TE
MCP3:VYI;>*G5QZBEES:V]8?[(:?7&L)\]7EI=EJL5^\3=$@-/L)!E,4 @_EE
MC'?+!TYBB"FF"%7%_H$K7A=3@5CTOL7@=9 F_'9Z"Z]4O(X0-NY!/P\ZWB"C
M^(+?GR7V13W63_0F*O5:( FC42%==B:O).J( *7!28V4@SVF'%AG%CNA?-E.
MV?^=4K-K*#0:_W5NT\UHAKL\Y<YW4GIP%GH#EXI$GSB&C)C-M;K43=>L)JA!
M]1>FFDU@ @A =_B5#@" U%8UFJ?77LK/T/YKG]3.E3&BR-ZJW!-CFN^LR?IJ
M4F=!VV9W7<%JK%]<1/\!("VJF%$I'F \RC4.R2PJ_G ^ L,3'$U/_C15;$8Y
M3)O$OM(1%IR$8"HE$&(^1XT.9_9OQ#J*]\%!?EZ]R,F= ]3]=C&0P^LLA]6[
M8W1UFKY')ZY/]&]!Y- 3T/V]==+RWOW*G*^4JSWF*TS*#R@DY"#7] QD.EW
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MXG!L7N1]9)B%9($0L:EK/0GVZO2A& @T]IIO4>7KW)X'2W1=GZDBE&-O^RQ
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MN")% _.(;*'LAQ^\#<8G,MK>)\E*EW>?H*"WH3?&NN1:4-TX9^38--HRY'@
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MK00MN4;9I%\SA1%;(W$5D81MPU5]9>P4ZP^ZQ@XJ<&+%M"F0I$W*>-"$O6;
ME6S14,.+;=; +D#X]."F?*SF^C*6K><B-_N$VGVO8@D_%E7$$4_S9QLM@TQ9
M=8/O7[[/?M\H5:+!EUQI<;4(/YLG9M=5PW4>U6C)O];)\M RZ3-"TC8YCJ9L
M/Y7B.P02U*3;<Q#AD!O9V,K4*$"/!A$B7(AL,KH\)Z.?BF,D0[:ER+,;DT2Z
MO;*YJ@D\5U6A9I^V0W'@4)S;1DOUTB)I<5/3L=RU/TZY"(;#3!;[QT_J*I>U
M^/AGS^20[_%-.@7R[2P%EH.".Y5-#FZ5S Q#W)1@?%X;">V97!O&J\OO#*,-
MV'ZF55"B86!JOT-7WB=ZSR/%Z3 ]L[GA^W"WYI8KNO8P=DZ?43VZ;-Y*MZMY
M1&\E%/8\8$6=EYIX<&5W8L!?"]@L80&3AAIZM=;:6N.Z1D_QDI.3K9J/E)+%
MQ1529G-/MN8MM#0;![[W=G<M%?CS?:,ZNMF]BJNW;U-WHR>?>MJ2SG_7GQ0U
MYW5Z),4G/,+*4\X!\WPLOB$!*H_S7HTB8HQ&DX6NJ8E+\PAJTWJ)^G6MA[O]
M.2!*_/C>\;*5;ICO=B/ E-,9DY-QI']ZB^R7E^:Y(@7,[^1;$O(73TZ!9;@)
M-P_(A1R(E>[]65I7MKXR,T,$,XI01ZZ-DPWN58=EM,LRV1I#[O4[BHRF%KPU
M*D5X84Q;R@L[Y%@13K>G#JPQ1!/5Y)%(.Y ATCQI,W+VNW$GS(#F\111OH:8
MV7O!, \)/8^X_7NCD) Z2E2#F,FT@\.EB&,\%6A1CPZC-U1K]\-:D>$U71^S
M2H1#:S(XX3*K(/=6H+Z&:]K6[.C>.<!I-\4R>:"-TFY_70JA>6(#Z)9WV2Z;
M2*.W,MI ]4?T+>1E,"'YBA^W[HJ_3E;6Q5_6V6L-%S]*=D^4+BA#UK1%5N]?
MI6LK94W%5-5UH%"]HXF"DN#SFC]ZKSZ/#V02@ZAWE=^7'U(=SSM/XTLX,]8P
M"D;'Q@J>8%G"E]:="7T/PN.3>OZW<NK^\^*_N]XYO1C VKNW-DZ?6_Y)HCYK
M\,O.$R,#765='4?:NTH-DYT_ZAFPT'D6+NOIA9Q7UVSY:'QJ!?W[)HFV(&3L
M+GFLZKA$''=:#Z0GI&N^-:]'*'Y:7?2;#U8QT@7:.#__VCM0@EHZ][MFFKPO
M33 E"D/ M>VD&XVF=Z6Y&7?(MMW73L_U:2EK:J.WJZ8UE;(KC<+!@V=CTC1,
M#*GUUD; D^@*E1_%!N6C4#P\YL/NPL]-N_KYP@XNY'-61KP2 2R)7[EF5,="
M*C+:*W$BW+\SH.6#X:3'[.">*FQ=PG2)[)>IYH[IJ?' R&:JMBG7M#?M9H(M
MM\%OCD9F>7C,B+6'!XQ*6BF-*)+7UZWV"GH*ULM<..7@6A!_,T^XMVWZ9H#0
M=X#-RO1<*L4[\Z5/@Z#5B^CDZARAU8:,"TAR'6K]78Z"?I_5,?\=OL,IB,W"
MU;,GR+,>Z?O4V1D*_)]=&?8+JT8>%,61F1_D)WW[T%BI<V.SZ(@VT(3K<*VF
M@/T0M9/IJ/B,Y<20+,)D%^=9\^F6M^.BN^W\T;>&/6,?;5%MH<5^J U9P=5*
MJ7%<=4_#?B5J0?5-;P_L!"9*^7%CV.E?CC E7JX!3^X:M%+N>3_I3<M=_"2>
MQO67_8A><+TSJ3VJ!0M5L/DA-TY(/*X5&GVB1^@C:RYD'MS[]NQU>YJ8RNY,
MY[VD ?P95]@[_A Z4IX(/UP8??Y1)##\@<"T58M/;L!X%D^Q:A9?RSA55P./
M?Y.E1#BHA!.U.JZ'$[7FFW7]L.]A8E$U8UQ554)"RC^9V\2_"L$_Z.J:3TX$
M];[0[2>2XY(LV^!6Q25I8&A5%8)QOPW2T3&AQL7%C[J)_\Y_Q7\*$0T*X C\
M]Y%EA@F:(>_.QAQ9>NY$JHX,PHA!OAPT;R(XT6\' DQ$"':X#Z@BN&0%9!*$
M0;I5PO=U0Y.12NXO(<Y);;P8;HF4TBO3G=O).]TCC_"S]!M3MNG7AC>*CJG#
MMQ?&,RE_'FI?$>'CFF([&5F$T8@/QS+9%*,Z""^SH)['_"6))1LVBDR\K60K
M43_DHY?#)'^'2[[?JY_O.=5"CBG3SR?;J>BNCR?/7/8QK$.:HI18Q$_/%=8^
M)($*;ZGRZ X)/W 9Q B7L0VL31":ZAT5J,K!X>HCMC&7DMAGGG^>,SJAF&'W
MQ<I?5Y>)KX9OHJ88,J;UQ8S8V?$+$\[N%"\ +I^=G%!?I:EGM?&Z7#8'U6*0
M-&W6>@:KB-(U?>@*A-,@&M-THTTW9-)2PU:RS+$.T2:%YU&HU<)9+=,-=E\I
M_"P4YK/X);;Z@=YEWOM[2.;66AO)&E/TFA_7FIRM-CY^PWFZU$'AD0)B!D3E
M6GJ\#'%UWR=N9>QJPH;05&QL_,&B.OZ['+Q',9-EO8$1J5H"1'ZX@\]PTR3.
M\7P?L!0=C'CEAD VTCC/YC(=PR,CA$?+QC.:&_<41P+> >(/L5+ 1MDT@CVL
M2_..Y.26__6&K?SNJ<(W6QQ?1-RJ1@]-QU0M1*I8N8TE/1N_M2Q:*=;BW@E(
MEU%>JH&,6X"!&:LV+4,CV(PT6OI.L3_"QKPZ?A>/5.DCSLAC*?CC8=B^!@WY
M"9X?W/?,Q4(6."  C;$*SG:-QJ L D4;E:RFW+=7#ZI!5S'3MX L7!N\/)+D
MJAIT8%MG<TAF9 @3>4\/KC.@ZQ*$G"; ^'6#RF(=C?=A"%^Q/0H6L&<H!I9
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M=.WXL%I(G@69:-=/D::N&?)I1UPNV"[&E"[F%,\+&(P0B%[.3NCHW2A2@MD
M:)LZXKD,P?XT&19"=E;/#7[)7EUD5.5N[=O%:!,?JQ%R886.XA*0;T$ZW#;N
M(R2\+]E;8L.1F^%& BRAK.D86EZBCNIZ5-LZEU_$=&!Q:4I6HI$QA 'C3C[O
M;8<O]0I;;ET,=R\.J26DCX6442G"/.L^DB4LB$@>QQS:VX_MJCA?AK4.9><I
M-C&;@99>HHJ4[D)# X]+H@/CWA=?S.R2O V>P%DNJ1>NN8O0.ICK NT2JL_3
M^K/P%<6@?PQ2<9H$/BKJA!@K'MZ[C],0X4G"R^.'($2_U"PAUWBE/.;G=_UF
M-3.4>TGI2R/*M28NM<754B76R<\&DW"H+S+P]:@PXG5=\#2[]23A;*-6*!E.
MW&5SUL#57X^,+.Q@WI822-K?]\4LDDW-+T_B=\.Z"Z$F^$JEFVD]XH/W.%"_
M8J'>@:D @)V+!7G<$:,I:QQ3[@0L_9T!.8%!!;B!34Y.3OV-!;03K?MX\[WI
M^R&L,&8=]55@[K= R*4;: 4<\*OW&U?^0"#?ELQACK#@S"!>)!Y+HB?CB$NE
M2#9]50,F+Z0@(HD.QMS4T :$*#"2*R41"4FG\0RG>-_ ?4.#NVP_L[1#9H(S
M-OI%7OR1@#E-?3)O,WIZCC]2D$ZV*</&+=&U2%=I34V<<]KXXA,'67L@>WMA
MY"'_XKB5!SL8_\"U=;BJ'J%4^]*,UE9Q5YWB1NNF-(HF%X[&<I9D;VUY,#*H
MU3+-9PE/<:.XF-W25<3[SOOL5\G:;RL"RB47-;.B20IDG72K*/GU>-*T??HQ
M>UFFB)O6$#7+QD(S8=ZB'H/B@_0HO(5"1&XUMJ3HIX#:RM!7-=_2]N*+$+$'
MW5#]=4B_!9VQ8\+*[PMV(+29Y.)654GZ',/K#<6=2(@T4WK_N:#C]^3^I@LK
M\]G%[(3W!O](%8=+V#,S:%T6UPS@CQ7MOLMHG.T+OXUM,2Z^("F8%<*,(4*4
M?T7QS3Y%M0TC^;'^CH[:+JO'J;?;3>F>O4]I]G?OVY]>.SV]&XM/T]=+HF2;
M%XFS(6LL(]D@T-?X+?8-9%$5"O?CKKST^LTDY8@N\>Y)W7-!0KW/*^K]'#:C
MM0UU=N'."34T1/EP\'B:1$GV\$Q<8; 8L5S%^>\3GMX.JWD7!^E8BG\!S&*+
MK$E)GI[LC3R42DQ8"5%.-O)J?$*%\7_4!0'?;BMB-+!ITU+4]X]>TV0#M,$,
M64X:=BIN.I1M_"EF\:KS=88+7S"DF\FF;WA_HY%FR:&STL;YQ!?:(N*[3=YD
MD#5Z1[*.65TGE]?2K,W;XCBFWGO!^Y3( (":"!9EB9N9D+SCEA+QVQQ<OXFW
M#5&Q]*(./&:,1E&<]$$V<+$,6._]@:Y$_439'0_T@X497I))A4V"DA7VH.,!
M:E)WVK'IG,A&LF#.9A[RXPO?K-!'F9YWXC]6?5^$&\0%FGEJ,UB&Y"._3<],
ME8Y])"<S/G6'O*5Y':64W1RQ4K$,FIS"X>7-80327@#[**#B/,9HR E!TI(D
MH25Q\0/A*VL4E+^)I:]@H&-CA7B WNKDI'>/OH&#%1:3)D*I")5UN%C,2?I]
M;F_>DOI8LOH.]OHQ$@#7P& N<:KN?MJ33/4+%_I)R".KZXU-4^+ZNB1<-E=N
M<JL=\G:0*.3\JLG)66T4 "A-$2"-)(*_O(D&BT>O7N-PTA8[S3TF<ZVR,ZJ$
M6MD2">'80+9*))NDSP' /(A;334_KH=4E<@GX]HMPM80-FK*HMDE2NQC"_=#
MH(F%",4.([SR1HUAKAV?ZF<($'Q&SJ3XNX<_@1;)DQ%S=XA"+CKO3NDDH-,5
M2_QW(=^\)U)7F'S4V>+0\EVA_K +AC+9CC"*.Z49J4"NGICML:&_JR"6";#[
M(>*7'(64T8U>N58U*70<QP]U'-T!HO&A#MW>OY#*;%)S1V)\%8X@JN.)=U;4
M<;DB#2L-M<U1S6*"9\/^;6_K_B6K\>*/(N^-6V>M_;'[MOT-PT@Y22)+]]?K
M'U7)&\'[(R3L=(T] ?1/U>BU'>TI,ZWE6$%RYB%A$,( ,Q&?[%XNN/!.NR_\
MX*U:/E(CTSA@9[''1JKR(1P[_$";8^!F\V-##DW<KR\.$]G%3H<%;_SAB\4F
M<C<6G)R?LF&WSEK3G^8;S$IN0+Z/,AX),[R.SEW9FZHTU4DU0-6B1AQ0AK,S
M0YV8J[)6C<UK99A5361S?6.[C70XJ0THU9"GQ5X';*4$,H;%V%?8P:=8HB'/
MFLE?^A7DFTX0=?XD59]>=7]GO'"'U.V(_<#NT:[!G39=4YY6, F<)0+=H%F/
M>4/L\(X-R0/]K^-YF7)R[:(^:#9B&Z?+8,97J>(%B4&X"VT%]JR*C^QBYJ@<
M5V+"[J^7?E1':DTNM^4Y7=R[5FR!]%R8=*/*2++(T=U35%HSUMPIV0VS##L0
M5\G]E#(?4=>M#2GVTX1PH>/UBDSKI)@6#-P.MI>ZT<^B+68NIUUU'V+Y*])X
M#5'4@ZL2Q9Y!QIW-1H)56Y>=99#S#Z FGMJ+K%U3:MK!2_B:<9:=MC4&10BQ
M=YLM!I:0??,1RT$F--PKQ AS]N$@L::9O)&/H6.  U\G)<IBP+GE _=>:0[G
MT4?D.G _#BR8@F^.;OW1OM3TPG ACGR-=?$2I,4G-[PST^#^Z?+VI><OP$/S
M(@2).*WM:6M"=V5W([Q)].Y"T;3O!R,T?B,#Q>JG2I4;''^NV.?/11TL\V28
MH>/"P&%P&D/!L00*OR5J)%LSMIG5_')J'A^![Y)O":>)N("ZO?+-7D$>EH 2
MT8&-6E<$/T1&YI/9=_CT2-!90^2J><W Z^?6N(1\4>WX9Y'#QTE?7=6LEG!]
M&?6<.\E!ZLU-S[:><*:NS_ (Y<6-39QF T Q>_NR;7>;&O?9TD+").@1I,K-
MD!*[+7!GJ1<$[@/J/^X9WQT1!J@;?UL+F;PR_S%[\3S]TB.X^A++HI/S8:_C
M59S2(&78FE%/W9R.J/_GP#+M*"A5QVB[;]!8F(%:A(QE[DQIM#$;5W/!R>V=
M6&(^34EQ!8[24&G*@M(ET:S61A =MFEOREW0E.UG1;IOQ>E[QKV0$5>QZ.49
MSZ#X4/L9V]G/>8Z7C;< 7ZJ@?4?D<1N9 N:%N]3*^#J'M0MAF&%O&Z7EF!MM
M5LKMM9OAJOM%2<+86*]DWR3#H9K;!KR4O*66H3R;S0 %6WQ^R$?O?'CFF"YP
MED +WY<)D"3<C$@VO%JA!E$+7V=)#;<7O>L-'-O7[D<3UNV1>Q>IXXHZ*Z>
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MA8(Y)@ !Z<8-  +R[=LHJ'=O8P&0;R BW41  =S"NHV-<^\^+@'PL:*:>M0
M'CXAD;[-FYA!2HT7X=%]&W>H:+A%'-\7E]7U#E&S<?&HVCM%YG=/<7""))1\
M2DHW:>D>L(LJ/U4Q !L:FT!?I\(NT$@OXD! 0D3XPZ]EW$1 0D:Y@7CK]D4S
M&.NB%>$BW#LW;V/<1KIS&?9%-,@WL;#OH^  [^'A/U94U7_3NX%+J6+S(IR
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M,O[F:*<W7,-Y9=XP7U?C]MR,QU@G3=-^]YXQ&?G)_7W?ALU5L\'0^3VRC7/
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MYF_@VP=YHZ,FNK7.'+)Y+VK-21;$Y<=R*\Z<3:WL_I-BH8M[UJ^7P'/&8O7
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MSEV[@HVUT_T,D -G UQPEQA1MM+#=>U0/!)Q0]II'!F .VI9==9RAVS+8ZG
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MU%\+E?LU?)3X=-J4T(AD7#H79QG6G[IF9L#H%DF&)2D<,YBQ!U;<KE6GN4'
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MV:PO8-A@K,WYO5>V'(6I;$J)CO^V$#L\6)ME)JZVD\7N3"">HXK$GX^TG20
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M@$>U7N[QT\'(^^$%X/\]IFT"-G_J\_\6K9C$<AL(8+,N F)LUZFND3I",LN
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M0DQW,_*;)U;.Y/QG#P_7Q2(4%"&_ AP>?$24+#PDC&\E].$ZSYMSSP_"+B\
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M/Q>5!3J-,VP97/J66HD'93,4(M'^#//L&$IM70PCK#T2=<.V\@2 1XY4"VC
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MM3%L T4Y.EW@VA0#?L]H=T$NS#NJ=@9L%/BMM;YV$&E:W0X$^HD=.EAMB!Y
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M8YI]?H=1TEK3^J9K+SA8,:.VAY/[Y!2CVR::L]2PQ=:+A=3L:6'6RUY'6D3
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M(AWM[*A6245<;=RT0NFX/I"-D5R59\JDYSQ;Y\:@]+@<#,"K9WQM<-2]X=W
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MHC]J@+ZO#>3(K'RX,.:Y4->,JDG!Y:3Y>X$1$'W9*WM&N#&;'+CE?K\41?7
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M3N6[/6=(ST10/=L:.4\%K+<5YLW'4 Q[V#12H(Z4GQFW>X^O,3C6.=9[<:.
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MF_#R:>?H[?1GRK=NZ&  WLY4UQNF6^$16<6]4MTYN^B;:/W;_?P?&#FAFZ?
MN\",]>=G%20]Y)DI]EW0C>/!C>MS2C^^_&_3LP2-C1O'W^4I!5/Y;Z(-?O<+
M8G)"UWYB;P5[^P-:P;=-R$_Z?O[Y[$3EP6PI;X-+ORM;]L__P'"/=/O^?!F\
M797]17%U&Z ]H!Q\6X?ZI!_(51=,EBH\N$Q6V?(K]%]*ZB4_9^2^^QW9\4@%
M7H3!.Z)*1-WN%>EJ"(H^:TA^%_)]^NDO*&__""4?T>?++;*&3]GJ _9.Q IY
M?J?8*4)@SO4N_2?OU? WUN]9PAAW_X25_CMVC9B(6^ "VA\8OOT!Y9#_(8@7
MY:GDE(CJ68[QFDH N4Z S\D?F!+2WXZCH7D(QT;$/UM_6ZC &](_1U0)/ 0,
M;1S?^DD][KG_2WD#_E%>S9^2"Q&9>L7+@-[O[7]@R"7^)7)AFA-VP9\[86VW
M]/\^\(#_!?#!?P6\^Y^ =WZYN$+_&_GL[Z+_<9WGP*N0[PB3?V!<KW>9_R;@
M)C"MK6U\[:_!*K?H_Q%+ZO^OBH_W_\"HBCSEF3Y#BW\G>CY_)\-R(\_S<AR
M/*?Y_3.7_])NWG82_C:8;KY=T-OXCYB2/S <][)5H$!3D2=_L]'!SE/RO]F<
M\%*8DVW2,@W\"Y\&*:9;?N#=/XJ$GQ! _\^D3SS]&SI]_I'.Z[K_Z8IMO=V
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M%L$C4;3CCC*O..]D4%ZT)-8M<\J 0+$^@J>W9TI=6K91*Z'#K8&+^#/"OCO
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MVV+DZ\X(NU-M4AJ>UDW$4RI$H 9I,_KDK3 ,<8$P8*'430KA&#49(Z_.#P-
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M._H%Z>'4]KTBP%ZGJ$>,Z85.TPD$RG@O.8E+O^"U!]]B2JM<?RK1I*MZM:A
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MCWQ)@65#57R_*LD])Q=R5T)+%Z!#FC_**1^::IKV)%$88'4J[MR_YEG_;,0
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M%O%$#B&S<LPLTN@.[O]6[7BL/4$R,??O[/9=1NY[:[3(ELI!EZ:HS@&O,PY
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M/L[JK*'954,#>HN2NZ[R3!9AW$ )HADEF+Z9S."G) " $SS'_S]02P,$%
M  @ .8)W5 A(4/_^9P  S\$  !0   !C;G1X+3(P,C$Q,C,Q7V<U+FIP9^R\
M!5B47;<W/G1+B'1W,T.#= R-=(/4T-U(JG0.':*T2#<*"-(ETEW2H @"$HH"
MWX"/OOH\SWO.>]YSSG?]O__%<F;N>Z^]UOKMO?;:Z]YKF,N+Z8LE (X"6!X,
M@(.#A_.!\P$ +G:8C56MG=R=W*R=G*FX.8   4EY941$ (R8)5MPM&F#Z9*&
MQ<4OVX#]UEO9 %"UIDLK%0  >R%<]DFJ7G;!8<Y?%,Y&^RY!=5!LW^\9\JQ>
M]DEE7_;=@$G 7=[@7%EYCL*0LBE]HB.+HG-I]E(="85?AH_A^+CU4@(Q91.L
MK;VI/?S'_:4 (E\/PV7[Y%)7AB\U#":QQI *OM3Y:1.L0[=!,*DEK14B_A/L
MNP(*3 ["IR.K@WC,\!0(8[<B 5"HD/=@_TS@ 4A 9%44<115E"L-0.%/Z1]C
M1F3H 6_\,:)N1NV4'G#*^J60":R=>GECP3.15'GE#:G*2R6:X5]G#,?XCQE+
MGZ" 4XXW86. <[ZTS(\"WO@Q"42^;D:&'PTD!B^>R9\]_ QK?/\0VY3^1Z.;
MH><?C0TO6<N?#>W)SI_^@?E1]J=I1 :^>O<_'/'=2TAT[G27+> 5L"0\,OA$
MFP[Y'/"#$+T85O["8VC_JQPC@XR,]J:T&2]#CS@ \(MLMR32W_"1&/EZOLNC
MA':BL/WD%UIJ\X-/Z,"$8((?48&$[('"]\<:7-X#OU\1@5=.T+;Z.U@D\ G\
MW\+R\;5_YZ,P\"!!?[#AD/D93I \0[77KZ(I9</SA\<V+CL8M/FE&4YDP<>3
MW<<;SG_H=/_H@0T!_ M_\@^^#$.*9]BO'?4_.L GR#_85Y$C.GPU!@!>Z]6R
MX/QQO7FUQTRN=)=^S@#A\Q]:XE=: -CLX*YVG 3T][88\*K]<XXXEUJC+M\;
MV7\L/^ [BMB5C^"H$"YW' [\I6637WJOA@K7"L"^^#O:$PWZ8T1!W^=Q-7H
M'>#[^WN?Q-*/T?W1SKYL<JO^1+HB5M@>$@WZ,6# 7^D7WJ4<:^5_(/"#?DE
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MS7BMZAT)W2O]-&]<A]O'\:;,9JL7\9;-UMJW:+9==U<.)(]RO^!]<[U81=!
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M<_9PM;\J:BW,.2'VD,OAN,%*/1#G;X6=A;F0I9.K@ZF[Z*_9X!_<_^D!_DQ
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MF28V\"DV"T:-1ZP!:7;&@-#GM%S2"!\PZQ7KO>]<]!.D@M[!=KB+JQ9?TAA
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M<:+X8$%R<S.+[;M2'1XK9U?NB- IH<C.K>&N9LJ^+I51(*\\Q[:6\Z;A:?P
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MSA=M@98RH" 48*.^Y&:]K 7(XI5__-[-**+^]=L/3T-T@WZD4&]LHJ)5TSI
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M1K#>-#"YATMY;6XE"Z-&OVH[.#5B6S(*9B$Z,Y5O\T1^=73QK^;=79)J[37
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M# QL?$)<7'Q<7$(<C$OZ[>.?"0$3'1T3"_,F%M9-/"PL++R+$Q;>#Q6<?\?
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M:M-IF'^4I!J^F2/W-QK4"P?0:'G>]\&=R+QM+J7!ZP2:^>7"O_: [G<7SL<
M#*1+3!Q #-CU!'?P-G3U[#8_H6QX)G0O EHKM3??B>)]#Y'*WI&)$X$X.8M-
M:*5I%HDQO'2 H\GLJVZ75^@R9 BIX2PT5=L[@=RQBD+EC-V14_==Q.<CQS5!
M@=*;R_;C&U8GK7EAJ]7?^W3H(_,_0XNRRY?IB-G]Q<#W>S L'<9W&J/B"]EK
M%_?]S!X\-=-MO4DL.M1Y^FF?C>\<2&G0O:,TN)&,A1R0"US1%5W1%5W1%5W1
M%5W1%5W1?T3GT^(/K9R<[ 79V.P<64TNMG:L9E (FYN)/1L'*SL;("SF9F]B
M9@-RHC %68+M1"@WZYLH*<#F(I1:/(KLBO:2("NPK <,I.;Q4-W,P\9,P)Q2
M3/2&L)N@&\0> G(RH7"#V-HY"KJ)4%X:%X1?7[#9*"DN19QL1"@O-Y04VHK*
M%))0&(B"AY6+Q8R=@X."EY>5@YN'EY>#F8*3G8.3C1W^S\O"P2W(PRO(R4?Q
M&U&*WH"?A6'F%H*J]Z5_@X.W1"A_B\O5U975E8L5"K-DXQ 0$+@PP\G) I=@
M<72W<S)Q8[%SI/IAY*>=^R!',QCX\FDQQ47;Q!3J["1"27F#X@_T6UP0>T7%
M7U#_F$((A.V?-!V=I%R<_F--QXMG"&RJ($>H,\P,).4"LG.B^F=3JB"+_XHI
MN/CO(5]$?1F&X'VHF3,$#B)W7Q3.8#4'FPMRB4OSLTMP<W-)BPM(27!P\+-S
M\TI)"T@)\ OPL7/>9Q=F^YOJW\S*V3DZF=A=/->Z- N^,"OY[YG]@^K?S/YX
MXF5B^P?H^^P"[!S\XO?YI'FX.#BE>*6X)?FY[_/S\=P7YY*6X.']:?8?5/]F
M7A;LZ 2%N8O^*=^7TT,-Y/!G[L\.6_#E=+$W@3E>/F(3H?R9<,J_*5SH7$X!
M01.SBXDFZFCB C(79OL3[U\K@?\AIP+_64[_IOJO[;M:@>Q$.=DY.5C8N5FX
MV-79N06YN00Y!9C8>02Y?IFZE/K71ARA%DZN)C"0N"4\QZ(_EOGO/WA)JO%2
MT&N![<RAKHX,/RW^6>5?FS:S,K&S!)F+LOU4_,GXV\"P_1B9_P,C9@:UNWAF
M^%\8-3B.";SZ@6".HA8P*(0"##&Q!+%9VX,L*9R@%";V]K9@,Y,+&VPN=N:_
MK6+[GPG[B?('(_\7@S4'P<#_E0GZ!R]_Y8GB_VM!_\_7Y']:/J_6Y/_+1DSB
M__B(<7%>C=C_9A7]3TK(197Y47- ]HX6_W^IHO\?"OI_OB;_T[O%JS7Y9^Z?
M;U%_WO;^_9;VYXW_CVDI?3&Q_KUQ%K[<<_QW"^A?5/_)LOE_9R_R-]5_L@S]
M[^P;_J7JW[/\AV3^VE6R_65;^=_=;IJ;_=KFV3O#;"\WM>9F;"!;T(4[CO"M
M'@?;GS9VYF:"%E 8Q,1)](_5X'?N_[:#OPK0/V]'?W5?;DK_Y.FO+L'+G\\5
MH>8@46YAMG]B_V\[#1^W_WCW_->]LJ D#&3B!+H//_Y22KC8!3EY?I:2OTC^
MQ08\%+"%^S_8^%,Y^HOD7VV G$S,39Q,_BTK?Y3]#U/X@ZMZ7UKT!ESUYY.<
M?ZI9__MT!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%
M<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R
M!7(%<@5R!?*_#'+C]W<C@.S,12A=*<5$S\<!20#A?T@71OZG-A!^O!2O#M$
M"0'GYTOQ/@#D (" C(B$\,>W9Z*B7;O@7;^!#A> W 00D)"0$)&0D:^A7L?
MO(:.</E&/!P [>ZU6[@<XM?Q*%5NX)LX$-PFY-1Z%)E.1$4=6[I%0TLG$?>N
M=V"(BYN'ET]&54U]</K;?2EI#4U3D(6+:U!PJZ3VX\"HF.P*>EESF'/ RXRL
MRBHX'"G<$\0_^X.,@H2*@(AV[3J\VQ[N.@+B;Z^_PT!'OW[]PAL< .76750.
M<5Q*%1,T/(='D?A4G.FE6P2WJ;DDWO5>H^'6')C^1L@C"?="PQ06'1-+RWM?
MRMS)_W%4V9RTEF/@BXR*]Q_Z!_G,0,X!Y<U]LW3T_#(6+EG9E7]^W=WQCM?C
MBDI</X!ZD33MIGQYP#,LKP81X;UF;]Q:@[#VD4>0=A',6O)JS+JQ+U[!J?4I
ME/4VKNM,B?9\2';+&QT\!K598QHAZU(#+7A:IH8<!:K+*?,B^0_CXH@*U"/Y
MW_1C<E;2L-0<?$LAA8B"%57T#"02/D3C]'4R5=935EJM^?,B^ZM+2XY#9$Q=
M*T58726U$BQT%!06<AEST_(+HPL\2B,X=(-RU^:U( H9"88#G'EJ68BN%=&#
MF@E;5N6B5/F^+<SYN>,.;*@<LP31,3>_VE!]H&=<.SN^DU+6>@Y(WX=FL181
M&LAA(,!Q_ DQWQ$_"C5>NG<W.@@EVI^Y(Z>K UJ#9BK]=J]5M"K')=WG'+A)
M\\'M%8-2U?-5[X\R3Z9@P4_"]]))ES:4//J>'= C<K8"%I'XLC7,[\1O(\[,
MZ>N'DDG/3+3RWY*6>+XD20\J1W)FQN/]L)X7V,3T7#!TOU04+SJF-:KK,8TU
MY(&)R5SPK8P87O4I>RR:>_[^GD%8T@C#=WNK-361C52?:[;!O:VNG?<\-'MM
MW*SZO+.F;H,UYX.^&VE$RLBJAFI"U)+Z=S S34LC1M C$"9SU<H7%'<P2TW4
M>(B1E:1?^GVF,)ZT)G?;Z\A?IF5K!"-H2I&)Q[UKU\,;LEQ-QF@&;DWN;03R
MFHX?2"2_3 3<QTDMRN4PJN]J$%J%'T#]C^9X@\@VD+.XMP=B)QF!Y\2J3X$D
MLX>]*$^-$6XC3R *L[HT&? -0M;#A:PD"O=+K7S3)C/ -E^&^$H;GKY>;F*&
M'0V]K-+<9KPYT*<ZJI8?U9<HZX6-(*]M9"W9\+9*#L']N]PP:9'Y+5)"H+H<
M$;4,43_@-4PZRL5F0M\LI4_(FC7!-E<S/:>+-8NOMQSS72U:]K<[ZPM;NGI/
M0D>/=+/57KX^()@?O_$F9.0I2BT?35$>.(\U*:O32]9O.FFX3G@EX?D2.E/X
MR/5N9RSH T.F.[3TT3P[\WUONIZ\$D;DM8AX(\FT'X*W)D?0'U)4(I3>'<=N
M[>ITR,=;]+' TUF[4N/S$JZ+ELOP[4_%P34L34[:SP2I[$A?L&[GKZ_9A"?M
M+<ID]!<SQC0&UFZ6TE=:+K3E?M)A"<*;B /O(.I!YM\\YIJIZ[NC9Z,?TT7_
MI4RAP1JG\&X@([6?]<#K=EF9AHKGLA.H-.(H?AA9'0H=_@KO]?,9IVU;;[A9
MSV=B[WQ44NXKXHPY&Y(.NE=%?7"= O&Z?4:IG+XK#6TV<JO5\[4(#\MW5OX(
M6#6:-T>1_23:*9YCT^D<6_E9<%)H'"ETX;&^W9 #O&D:#O61:C\T]HF0YCEQ
MZ =0@.BO+: '9.$,X#IL?G"N]'P%L>MFG2L:OYZ7@U_B8S"$O#>@;>*_9]J9
M7QRI'HG!0:EJD"MR%V5$*29]>%Q9[5G9FS3Q3D=&KSZ!^=QU1-6A@<_U'*IE
M'Q6S=7ICX@WI,$J($5G%I&RE&;>]%B*$@HHS0BMQ>A<T#O4GW]@0\0@X/U#[
MU(MB@8G$61HB"9&WDWAA0EFMDU4_Z^9,S^KY6C?+10XD];BJ>!AO"9VF(MWH
M1G01 +O>+IA"\Z20/?+&JSW>]"R]>-K]UW-*%"ZTQZ9=#W"8"61'TNH#G4W3
MG&UP34HG=DJWWA9TTV!0JA8HOR#Z4%,U%\_B6?>Y5UY?E7QC*SJV(XI HOVA
M^][G!SC*[Z7HAQ'>H6"&17BYN@@Y+EQ;P$PN$L=(SO) C&5[Y12HBD!3 GEZ
M>RKO6QN?=<60R%1K,GXFBY4=O<,<]4>'M^A6QK?0.[0ILGCQ9"G"K[5WWPJD
ME4)HUZ .W[D%('W8P R^6SONY<(:FJN6-G1/K^[@Z6T$UXG(CHDC(Y+QO+<>
M\M.5G%Q1X_<<VO/=426(J8&9D8UOM_QE$4!WJ;>N"]R9DPT,03,P@\7=*8*:
MY<:KF5D@MK9^&,<$%[7E>TH!9?HV@)\XD_>]F^(3SLVW':NA=BYVXSYK$X5E
M+ZQ5$F@P:I6]XIV)^#N,^QB*:,;"#-,6SP$ZU$0"]1B,/)Z1&'K7-ELAEKH3
M](*I#/V*BH=VB4;9]XK>VN4JQ<OG99#*,ZE1T3ISIG6Y?Z9!-;SG0UUU)Y+T
MTT(RA$D.(8B@HAGUI7$_QAV3  5V<! F^[L<0NY_DW5SO;XI4</1CJ:GXG-Q
MWM;!G?Y8,W4(XP0X^D[%T FR+#ZQ=TC]S9:V!VH/-O%O4.;*7)-SL'E@#;$Q
M>?HD"=%'?SF(6[0B9QKY88AD1#&7FW?Y%,WKC#DGOPSU8Q-T5D[.69,;3++7
M^9>H)6Q)KP_UCBLW6:65TXGE -0E'&95;:3'#!"?3Q+<S''7YESL;$OL,7OK
MV#=2C,>)3/,5HU?B0P6I@Y^/*['DD$,6;W4V,]=E\6;3<R_-5U];LX?%D,)(
M[QP98/I1HZK>$WYZNP8MG7)D/B,&3ZB%,O-6P3IQ(#-F2! %@[%X#>I,ZZPM
MR)G14XF/:+14[_EF\#3[;'?ZHK#QLM7=;'H6J;?-\P!U#*H!U=W*6?\E0@80
MQKV[<K?Y!FVP+(YTAYIZ10F_2C'=C31[WIH50"%-?V.D<@*3<BSV>/Q-(^6I
M;)&JOL7]H!5E?5/*H8'<7H88+J+6('T[R7P=229;6 5_5CY2#,#ST0DH!=W
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MD*% <\,@W'5,YT"R$M&W$F61_(OJUK?+N.Y%XY>"O^_LMUCGX_54]_Y)_L]
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MQYU0S\'2F$UB@93-/<R^LS?N($Q/)O\/$,3DV9Z44I/8G!H&N<O@YA)\ZNM
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MTDWX_7VVGV+"F-0DLC4K^B*A+T>NF^WF"WQK>:YER*(9<\^8J/M)%/D? !]
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MON;6V\#AH17V3%J;:7VN]^H-.-H2XGN>;\5LJ4A.<K1@8)3E.!SY'/9@;WV
MZ6Y=3ML.H^-L;!40R">A8QOICHYE=V0E8Y.SD50S6LK$D6OO?$XW"XEWJ;LR
M0E86PNYK8[74J"VE!-)B)6$K![%]JDD* /PJ&#R #4A=.2S@@J1!4;6L?I.=
MQS YGEO[[XTW+ 5]&F<H1:5<OS(E=@XO5N5N/I"X((-MQOB.KW['MT;P#)2\
M4W/<60UA> *O+[LA&2 D9)SP #GC4VC%J*F&^\$(Z[VB7;Q._P!>-@R<]GPI
MEADM&&R[+[&2R WHX@NG58'4;!;7N3MOB-H,:0Q7MTY;L=YJ,_'MGP)#C2VV
M'@S >0ZIIY20VX&EJ2APH4?#5VI402!JRE9?5J0!E)42W4$74M(I (%R+Z2>
M5S?EUQ;2R(]/PA$KJTBS9GK16#.NN12 R@ZEU $@,!J%R-M\,ZKP9C];8<:A
MRG4?5394IN.ZXE*0\I1)4E)& #GG P<C@YUT! 0BXN6.VP.]M[? >/*^^V-H
MI)X8Z5]<T27J74:I8UNVW=%R+MMRY['J#B<++JM,BS[6:>J,".ZU&G!;3LN.
MTXVHQ7^%(4XE2%8(P" >1CSYBS*Q1K G<#D3^F+>P>'+]9\^SVCJY(\[=:2H
M=9):8JRPNRNHDCN58*P=18WL>F]C?$8R5-LVC<C;I0TM]FX VA:DH4ZIQM_L
M2A*L%PN9'8$@E8/ ]-2DWGB/35'OS [PW)Z6Y^[;;?&V:7;-,N*HS",Y<SLJ
MDZ-+QZBQ'T0H!+$VTVWMBJ^[RTII>WR"H!3=I14N)) 4A7<D%*TGE)'800<'
MC'D-;-E0O-7D;AIS8C<'=N1&WG[-SOCWST6&T/%9(L&SF(ACL&'9S&X)V(WY
MW]F*\U%UH-L NM@A2L@K3P2!Z?,^OGGC[M;% K7-U:UAT/CTQOV9RH4A D0_
M.&X#*; @#??D?@<(L1QL1Y)*T@&42"I0 (*1\0R1P3GD#&I; F12 ; <[&W,
M8J(F44\PU"YG!47 )VN2.6UP3<;>=\=U$4)-P4IN,H2%F1(PA@^*LDA1&$M]
MQ)(Y&!Y<CC6.K98Z2:20A%6,$LQTJ!J6Y+-:P]O2]\.'XI*GB:GCIHWGDEF
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M<6J>>:.&)2Z60&21E0%RP"W:[&U@2<0'.*5&G $**)65 $$H!"L*4.< YX)
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MM4D$I4""E6,'S!UZ#DKH:52'6P!!L1M8V(Y^[V;\L>SY$5>DE*%7"T\URA#
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MOSMS=SZ_2*Q?U<Z9*#MS=%QR;>F6^*M795<WDA56[6KA-[T)<*CU&9(J5M7
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MC[>8 \]@+\MQ?;K:TGL88U#+W\V"_P#*9F OM;Q&_A\8L;!_"ZG8]%R02#@
MB(?/GYXX.1K.+=F]^9 ]^XY?6.E[V\;;9,?WKFOU4$;;_G1?;X^/.U\*MSE0
MHB^#GND$#CU:<\N?SL_/UQSKK&/G$/($CVWN+>(L+=.0O;&#+P/77Y?FUOSY
MW&_+P]_EBKN\^ S:23P4VXUGY?ZNYCGR_P I^>MGR3<U7AVVWP:_GX8]L]&M
MO4N)#R!S.,@G86[*0=0#S(VM]F*T589\,#_ACG[TXY],<_UXUMD0[N_@!YW
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M//S'&/M].<$2".M[[W%]]KB_,6V'3]8@U9_>*B/45-4=NFHO:_Z]K7WQ0:G
M_A#N_C](]TD'_P"F2N><<\$X\O+!.MDKMER?< >H4VWL(W\+<_U],>_-_6OA
M6XW.0Y:>?+YE/CSZ?JQ&EH_[.2/3*V$Y(XRI+R<^7D2K&=7.8_P53Y,=O :;
M^_;X6Q<UQ_)D-K_28V']KH-NF_4>?7&Y:)0+<N,$X)N*XL@\?GA&"?LR//YY
M^S6&M_AM*>GJM+O;^U9K\_#PZXPUP/K=&/"FI.7C=K>^_+PWZX_1!Z,ZCN'3
M_H]>PS6U.VNZ.Z^X54VQ;H]J6GL_<]SV;>2*K4-YJRVQ< N.R+QL"\8=O6R
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M.>)5. ]-F"/NK4H#=+@NAZ6WW^H>>-=R:U1PCGT$@U1OE58&%[:@9Y 1=;$
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M22.XOY//!\P,<G[?EJ+K)IG)M<J+[<QIW\ASVMB(CM)+FM,WYFF@S..%.JI
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M7!.FU[.[6V\_KPJ6]<E7JM7JB9KZ%B)!@O1^UAEOL<44I4HA"!WY&,!8(&.
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MP5$,[C6G:&KS'UAI!I1.]%2:8H[(FI]R.;%$W,]F_O=?=<ZDY3$;8UZB;O\
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M]?8B4MW6A#!3;40#JZ#F+#ROC2H]C(P3]9.93'=3Q&&,! 4#D/(.,$<D?9Y
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MZVMSQ6U+ 1/#OKDTD;;64DFY\?V<^>.R4ZF-N!M=)=R&6;QBO+4 3\ 4QG
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MB)\0X2*7'/#(A]%$+OID9D#JGR#)Q#^DL0+4<V)/-8'G&LL=>TJSRR>*QQ-
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MN3LFOT,.1?^J9X4^FWL[V]C[#!?X+H(JP;)\X40 XEL^YY3"?GB_$?]LR&K
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M[A3^N4BBR'?>6#A4<X3@I'+4M$.Q1UW _":J/JNR%=Q1^.V$=!P,Z! &JA+
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M11K.JPO.8E 7$"3XIXX5N7DO19X+>Q,?=]\?H6U^OA#]VG;Q2X,C_/C YZ7
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MDHS!.%,$>!B4Z]NJ9;P^X,YGW!"\:/\R=!:)5(/IIR2%X'MB^FAZ"^QV*&1
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M1ZPT9=!)SU,QE<>CX"UW7JA[SKG2*7?@BABOX*,0D<D=,# 7^"U]G)^VM2'
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M[3+S/[ZL+" T+#-JS,N;IHXDK)(0.V4S]5^$N#58<?-X[.44.!?(4>0>JVW
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M1\.VQ'--6VG)M)082&9RQ$_3U9<4ASH^6)%-.6(R(11;F$RZCJI5\6LQ47?
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MRD1+PPMC.%:I7I'0AQITV&>>'2CX_B.$]4X2/LLN;!+[5!410S/T/Q%9]R1
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MA5()!11C8E&)WZ%$G%88]J5M".6.VZ,6/LP8<_I /EGRV 41QJO46(($+M*
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M11[V*2#$ EG\.3^>U/K"478HEJ@YGV-[ A&3R%SIKWDNF29F :4VP"3@\0%
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M)"S&*,G64E(N0!N=-DC!-]!9T?TZA40E@$RO2$?,-K&2#TI E4#!>'1@+J2
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MD<**=P\S5_;\.7,J_^BWE6&Q["^]_R!X(50,<<(/I/R>Y,]%53S ':5)!G^
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M71/.6;M\5*.M7[6YW?HP>?XGS=5 N9-J]7KZ^M,GZJ3?:W$L-6O;F:/0OO3
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MOW79FX5-/WC_IZV=]O7?NH$<W&;T=[W7=1R]=D!*$CC_#:ENW$9=.]'RQK'
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M08Z??3VB60?>J,H=C\ZN:(YL;53)[*Q&AJB[UR36#Z\M72F;;-4IB KND '
MV?-X^7L"4[A8DJN+=<W P>)_9&;_.?HGDMC;Z!WM>'KQ6G)%D0'13<%O!GOJ
MEQI\@_?^B/)@EMC#I_(@9Y8W$SQ]T=.J)-_Q0GVWB1A3?;<V&FCQ1G#1UF$<
MHLH)]8U'#55F4 _ECQ80J)-ZO-.T4CW"!5IBD1&QT1E4>ZBR!B%R]!],!_=*
MO!VYT/T"8HZ2#Z].I]ZV,7B'!?(BJ+X(7AU2^_E.=#]_<AW;25PL\<F?VXJ\
M@?VMJC3I1C*0_G4A;"1*9M@KTKP'/Y/?[M,S1JPM%UDY1367Q.[/>)'AYY&/
MB?0<>.&9VYQ)Z=P)]8F9K'1)0QE>Q!E;TMB,L0F]1*J^&P$;+O+PX"N:"QNC
M"Y&>Y/F)? R8.KFNL6$ZZS]&=0%J+Q[M<6&Z>FJZ]RVO_'"\L[ETQ$\_$%87
MO:VKUK'7JGV\&KC0%!J$;0/^.XS^=Z=.#LQ=R0P:G/.%S:Q2-RYZR'XCO"M+
M.V+(6*@V9"HTGD<_]#!6#G$-R!^W-F?R *Y.K*_YD2S 6]9IEMJ;0ZD[YA<=
MA5DUA[[8Z817=A$4Q*2[XJ[=D[ZR<_V =A9N56A?'-SG>9ND[,ZTIU8&J^]L
MMGP \&TU=$B\!X,D/>A_$E6$4(<AOK7H32#H9):53P6M76<8F&-'1RV4_,=B
MZ>0-9^&7DWAF[?R31G9W^_IBR2NMK)G3Z<>O4Q2(Z ]Q<:<4,!@C<['?3<38
M;%9G)FE_Q@S"^HQ$21E4U^=9\>6=!F2><.G0?CA5R#.'M&=+$%;3=O.*WD9J
M;]D![3UF!?#(=F9\J-'^KC=F/PC"GOB6V<?\Q+GQ,7W>"22@$1!;AV454WUO
M9?>L>G&R /]IM C4YZF[(<ZSYF+BMZWS^:(?.ZE(G]VAH2J\\*3:'8SAN;.&
M*S#1IWI@8./F;+NEP#6Z['=#[#\FGE#JU@JU_2ECL-Z3VZ>6J-%"8-X.5KLJ
M(V_#W*86(QZ.AR34O9\'@R2>*-0AC,"?T9E#;/H#B00T>35Q!WC3+W+L;.U)
MWZ[W9L;PG6<&9$ZEH<5':9]\$=:KQ-Z\5Y6(PZN*ZWNAVQB=\&<]'ZNO0"+<
M;<=MNX9Q&;.]2 -<&RA0GL:ARX!H3C?@,^O +YD32=7A=W*AZE0L/'O1I]:L
M[9QZ]=[G_9O+A/?L1F%(N=4+D+O89]1Z.,T'V,N<$'Z1W"L/S44J3_5 2B+^
M%2><T'#1T\("U]0H8@>M',BXWV^5@1-W1OQRXLRQY=3CT9T_J:AU/VI^^^;=
M,LC6,Q>L.4]^]$X@0T4S+*UMNY*V(KX<L[E5M]TRXE-UHBB -66!,W'9@K;F
M4"NX;YH0QKH%'!]29$4&NY/1U;]IMW@UES. 9\4_)H#*:H\+&TZSK.#0FD;O
M0$Y%IUYBGZP_3<\%5.S$]B^0$<SY+=1WT4<HT(.D5WML\,(3Q!L0JFXH1/V)
M[0]ZRU=]TS;_@K(HFN4?#P!K9_=[6H'['R+7N7?8-YD.B-[T&U_6#G>W_8/*
M1E,:TKO6"#T -&KJ[X4J,#=TI>XV]R8O]EZKG+5U)P5-27X"#=_[Q>:XHX_V
M!9UXV.^/E6.RUI7\_J>@\_]%J$:S5XYIPUM31N[T-Y%:IV(JKEO=C8:I(M?Q
M@8N,[10EQ/6/GKT/&?I=*5#X#@=&Z_IUX&OP:75"R.JC4U?15@4)$.FK'$.>
MG\,?H]A4PWB@7WY93=2M$TVT;X(AYB*%7 1#5&, GM5XRZ??\G@%EA'UD/M^
MCP U$YXKW;7.M:T&=B)V?,D=K/?\3Y9*KMV_!+4L'C5^V#9!I>1V+P?+^WYI
M)>) [<Y7'06QI&:<#5H0GC80LN@VAO*^\,\7HO,CM>UFRZ18FT(F>0Q9^5F]
M7N;&Y0LG4GA9RL&K_YU0EE.2A-Q _I1F<7SO^8;:M[0@D:[1V[:S<4^,_$\_
MN5]\FT:7OZH^MY]=D.(CD"L[:2599^,S*@$MNVOM-?CTRKHDV1OB0_RT09"%
MS%R';K573/*X*C%5ATTLF2P[678EM9P*DJ+%J2>O#!L3OT4Z%D[OS[C,( U>
M";HP48Q%5^D3O5>@I+6,'5?!<1SAG^@AR,=*IQ,8]Z#V)AR^P%C;_G3R " H
M%T]8$IGOS9S99,EIZ_(1DF2NU7\<-'^V^=BK=4;ENXTRR2N\=GD:656%8?JV
MUR/S*&;/"93%DS"LL81Y0V]6,#;Q/K;GMR*8!P^[12:D?R#UY9>8,,Q'CDAQ
M>3B-.=A$0OI5Q^?/3IF$^4@:3K<E1-O)M9*D0!HVE7;AOX3 ?PX:]]^4*)R.
MVER-C][;/\82W=8?.=8-8(%2S%6^)G2W/AU+/[JW4:V)</W8[XPZTLN<B?.S
M\+B+V]L2N/0!&J,S[UXY,E-0TR#OE JAN_3DQML*5,SA@4))"4[I:GVT3_]0
M&XCLEQ9]#VKG_^-DO,MG6]7+;-7'UGT02<OJM?C3?%TT[!?Z%/2<0OADTAB?
M'HP_43[<X;3\ ,!"W"=QQN]U4AZ2=MAU+NN S[D3+O8"1:26)L_L0-Q9L,ZN
M\P= <>3?GM":ZI!=*;_=> !XJO_KE[!4W#JWF5Q5/ "\U36O\ /*3I/OEJ3D
MRWBO6GUO:4VO%7,KCSN.?;<J[S8EE#<DKO-&U2_<[BBRA[90AT?^@;L,/C7P
MF][#S)J+E'_J%I2<3T7OZB"SKZ\\P5]<=LAKY%8I52X679!FB\2>M:OQR7XA
MW_%#<R06+_K\G'MN:<,0/R_'G!X CT5\Z$#$=55SDM4#<S\]0($QLPLU1.9"
MGI[,R<;"3LL(3U7YS-/?FCX4+AX\-0N28JN!Y*T2K;] 2V4X6Q<PV'J\JM<W
M50&DZ.Z0OA#K8HG,/RT)_CNY:O<Y#=C'2EV!'W,C-_L_%>[LSSO1WLFB# ?)
MW<"H&ZGC=4EX'Z<,QYQ]S]_.O+C5ATL"9KT1%[2QINF'RA_.NI&"OIN6 56N
M"4N/?24JKH35:SA*R1JB$O_C !&]=;X_<E-%HQM(V=-9GTZO&5U48]L4>([?
MZ,QJ^1L&0SX ^F)N**D:G]5;UOR-8A.U2_&FWIAMFRX&" 28MG.R3^+7SAVF
MIEY#!F7=GB/1E1NKDFUU&>:_W\C]Q_F<.PM1(W10ZVU\Z_SJ?M0H] -77'OI
MZ@-@2G*ZK2#]P_)*_0. A@_IX#K%,)+6]K=V1//L=E 7%9X3Z'(Y?15PUE"C
M(MEMW:&CN]?'ACO.4C]?DQQR?3)H%JU83O0/OH)HC6++Q:6OQ=LU3*D1@_4Q
MM-<'7KDQ[6)\B$V$3' XW+)-&-F]MW8=JF[,F0<9=V!D[:/0CMGLU:]8MP9_
M1UGQZJVPX<>B\(!AZZ-QME,$/[#R8C@=)S'E[QF+C,$#Y@?Z?2OE<7$?$&]4
M+CD0"8L5ORY+8QJ/FR"CMIQT!TUQOPIAUSQ^X = C[7UK;F!U)ZRS;5ZU'UU
MV<;Q_=Y5YW[E;].[J\; &E[:T[*=WA/87]4B)^\XTN8!4,Y2?%FSMQ>@3GM0
M5EVC%'BQ-7W?UA\X6D-HW#I(-EWMZR2VI2M-]NHOG)+H'%T33TVUC$Z])8[&
M_A;!A^>4N*G/0> H:Q[^G,:D2H&>"T>V]YOP*K>;5RR'?EH/SVH^Z ]Q_W(-
MX9,V;^9X_^*&1"(K%M)^Z>F"WEB/V.7!+"@U0U]\UR:7&S@+K,4CZ,2&H]_6
MV,RSC:U [3^N-FN)DW2W<Z*]5JDI(LN8JV?>:E64 ZQ OVJY2/WFI%/+W-:
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M5R3'3.1"TFPPBPT>,@G>9^.+MY^-%RY;,*FF''\N@W%Q)+4J;+I2[>7JN_
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M8 ;[-\J&D^FKF;-J-R6$SA1HI8 JSC0]60/[2&N!S7EJ_B<[8NX(-['6^H;
MM X)3"\."8__@\P&-J6,9#_!NHN/O&/"A-*^O]_)XKSK4)]%@JTG:9O3$ \
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MQ' 58CT;=I'S )@O,=4[,HTX6EG2.YRCUYZ'LE?\P_@BZK!J;.X+XQ5EZ0-
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M=ZG'SWS2 /,1!&PE;0=A%FD-<T$\N4+>&Z:>?;AA\G$^H=.]]I;Y>#-!BE+
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MMSW_28'MOU?[_[R#P:#O,NEQ2..-?X*-]*1R]2" ?-&1Y%ZKPSK5G)8%IK#
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M>!T;'?<!,#PV7+ SG.@S]-YF?(GUX9COX"8SM;3O?U\(R=D("R$EKY2WD&
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MI;&.I7R#M GGW=M((7N#K6\(IPZ(TU-F@8@@*B*/R9:0S-'OF 4"P2'<4-Z
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MOV>I;"L?6!N*/]6XY3ZVQ4,2K+A[6^'-EMUFK>8NITO,Q=7E#/DG]=I"H_O
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M_[FQCDJV5='%F)L7NP:/29OB%W%\'9:'SW_@U2^0=N:@:A)]WSEX=< D1G1
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M[2_F&LY;IZ*OU'HFYL;#7;R<S]!+0O_5JH]:XL=46L$;EH(B3IP5]8B7"N:
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M["M=29O7G?T72L$P1-<-:=0^65#*/H L8>=H$_H0#+8^QNB9MF'Q&BX LA>
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M,$0=%);)@;4NN0"X98$4=*0<76.6%YY< +*K=]:#Q:2^L:YVLY%? %:';"\
MHM7(Q<75Y3W;N!-*+)<2^L (<X51:F'K'596 =V5!.JV,IXS,FKXRA34YTV8
M+1?Y>&015L[$T!CM;X]I%EH$2VU[[IT)P .0T._[>WMX3.,.#S?'P7!'CN.]
MX^E%5_CZGK?W_FK80J&:@?_#U3[/<S28U,!N?W;;O]E;NIZZ4CQ&SA'F*'&T
MG&9S)VR@A$M2^8,G3UA*?T;ZVR"7E$"".V%//+="R5X[K6DP/.9IX-DH+TRK
M)"[H9NB@%I-E%9B6Y]'A<2#"GRG3?KMWPQ$.@D%(T,>D02.+JU"GU4HDYFN
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MN<9^N9F_SR_E\IR^@G+$,JH[R/'V.<@Q"9!I_OOXKZ%#_ZZ-4+(S(=FT+<G
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MTN\3B,X#T,._W>'I3[JY_X='S/Y4^&#?]_NYT.H)UNB_> 1U\L=R_A+OU;.
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M1S\%/7:SFSH(_RLGUVJXO6')#$M7VZPPIJ:[3.?]ZL/@$VCS>"^?>;A6D-_
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M]3\O"-8VJ:*1Y#L=UY:&W"KJF*HI>69R1Y2E+&.+:P3WLZZRK]YCY)K;ID+
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M7'B%P@NQFT4\YETYJ[>#IG"@&A+//"ONQZ<$&"X+6"836FB0;_.]W7B/<U!
M,@F7E20MKUGLDLB:/.U-CRI\Q_I9G05]I%YZX.L:H=$0R^546E,WA2E2!:M+
M!5Z[I@Q)EK$FO>)P9)3!0VN^]NZQJ6^S6O_8>.OPI>T?P,-&]OY+[<;$;#^=
MVS_ 3%O_!V6!J1_30?\ #+ZBV_;O&F29UALW=RFG8F(^BX?_[FG\!Y!]L[>2
M5;([TOWL6]8_P/"2L^."T1@T1N?EIX]C6;_. LN5-^V/=E^6+RSB/_F.D-VL
M;3ECKX<OC\J1,\$".;R^AN86-.#<0K-9>SL+!)S)+L**Z9/71CXM6[.N[5%&
MCQ/P_5*!;[5BY]J>=]:DR;77Z*08V[^IG3YSK,_/S^/,<Z!/\-3D=3: ;!-/
M*S8+6I$YE$@76WY[U?.J:LC="&S JQ0T>\.%/B4P&(NE%279^ !F1IG+$KQ_
MD88/QO_<9OUQ-F2>H4?SW8LN[[!D67\V1F+E9:8G; +4;;\)HRWL+@2- X/%
M+_>/+/1Y3Q^"(&3/TB/R3>*V8'(Q!4^3P2#Z>>)B08JH P]6_F3%]R0Z?&[P
M@V)JM9G*Y #-RW$DHP6/T(PP&AY'5\FK9?%"Q/^=%IZM!-O)LR2<RA?_S)X,
M,I'@'_(>7J!A3[;1H7K@ZC9@LQ*3*_]9@OUY$-G$<F#W]].L)*SQL@JY;Q8\
MF51V)CJ-/)XIJI!;&3':Q#/#$HI2RYC_4OZATI.T64\N$GQ9<$NF6]8D!"(P
M"<)1],IM$9,P>ZVL*M3@O<M>*+\B4@'Y3;<OD2YJM'W!W%4 G2<IJ_A^<M[%
MA[PVGV$L\K@?[NE].?3]G19QEQVJ:J13*EW ;4@/^WUK?G/<K'2W\1B""LB@
MS<U_?G,CL33H8#P31.'/;N7U58 ' UZI2Z E(S;:4:7M)&M',.1)C'[")*KR
M1# R^AI%"'SVV,\$\Y9?EAA!C/V];3;7'\3;I&4$_L'H9!54Z[[79K?)_I"V
MO@*L#+4NZ :%5M&Z:=6SF>=FYN1YI8V*G=>1;:81<(^&'OK6!0*AF>-5<X)>
MM8Q(YSQ7A(<YHL0,[<3PA +Y0*)<JP+_O)<QFQFY_HK2RZ8]HC0RKUR@VS)A
MZ3D!5ZH\S3G-:S%"HJ5?H!$5Q9#=^>OO5&3-$V=U555F[4[9038&J,)[ZC8=
M^Q :$XEY:%);UG"U"]JMS[-KOL.&U;9TOJ&>AQM28]C4V$V*Q-9A,6[D*JW4
M*VWL;^=PKL$49;)83Y9U1LNM'!V7ZA!$P+H+Q53E8!S03 2R+:'"9Y$<0=X@
ML276KH#>)S!]T+T]FOG@>8+\P)%%'=2&,9AGF>L8IVWIYS>/$K5)2S89,RT>
M;95\ZV^!')UQ=04%/6QA$%7N=W($G';_D('\*G7S&WQZC!K\W!HTA1-P\XJ/
M<"0B(NBJQ@CE3>413F-Y4C-**S)3<# 5,Z?W3I^F^.%*0LDKM,V*7@Q"91[I
M G2JZ8R@[V(URHAX27%7P#Z=>P-KXQ^E>NJ=\TO*A85FC X1,OFG2MP\ABQV
MG_09\R&Y2%1[RX^9.;'I.M!;0;TE=RJ+RO@W,1$_*]4E16=P+88\IG5II2::
M$JU ,$65(9WP\'DJS-EI?G)":,O+F&0DOX8%JTNJ2SL]&9)$@=(LMUSD3A*J
M7'H %0A?V&3W'MU[JFW]].=NXXM?=_9C[:OGHP+LR6\W6^:6]S_WKR:64]9/
M^4W9+U_XQ.3VEX[^G0_T/4T8W+W_870;>KAS\K+OX!_@\^K+'G#&;FGO64?_
ME^A?_')_];PGQ;<=JYC_Y/X#:$!^_PBX^F.^_@^PT7S_IFKC^S] L/U'^>K/
M 2_5;K_.YKTD+S^*^?+[Y1[_W-1\YFQ#'S\[O*]W94C_P9NYHZ?V+;F'B;GV
M$Q>K,0W:;^Q6A_2?9FS]ZNM:<ZS"O_<WZBAHWTJ8TE=Z/;+>D;8YGX)'O;NZ
MBGCX:6FW%ON5D?C>>H_L]=S)^?5C>T28DS1ST>_H:)FV<YFM7R_8T_2?N9?=
M;LTY]]\&?:F>\S\[R53JGR0N[+H7C?I_&&O>;CXY_;O(Y'ZGV=&1V8&YC7[V
M;"B._#:A]&7KW0.;_^S9O7[1_PQ[GUK 9HB)D7V<-_07V#DORG1-+#3^UES[
MCL^0"_FTES?T@=#6OL/A67)GW52_IR/(K.[0[JF,'[]I&MQ7ZNZPB_\A22N!
MEW#'U<9X>>_,6:UG=9R0*N?R8YK611:,Z:BF8#UC& AY%LRLZT_H+8DHX;"E
M?"J%XS&C?^OTVF9+HAV>*U,$N>4=;.@S\0O)9DU+.U2R'FIM["!1D<JP&C,G
M.4*GGIV7:3 ?XKILH!Q>MMFMM3GS$VH\+*Z@:Q@A13SS!-\RG-VNUO/Y"O2Y
MN&U!24J5N^7GWP<WVIJXFP/=H[CQ6+9TEVJA<Q>8;KG4(-]\>L;AU%KWV)![
MFJY&/:34*\UTA$MTACO>+'N<24^+%,(2"C(4_=W'0]/7;%T+>?L-EI(@O(_$
MF>6>)UEDOFX&CV3PC-8)&CWY@!('%17WL18']M;ML-J1SE3NDZQ+86QK42V(
M#@-I+W4]80,HV>NM4(8G8"!* R7MZSPKF/S"QG3G-."R_GTO B=45]6U7^%>
M!'7PE )]&6T9I3G )PND>>-0)2;DJHA#JLDSNO);=R)PCD(\J>B7-" ]3F6V
MPKJ^\9_T=:DL).?U*"%J8\"..!_"LP)MUV.;S1*R4549*^O[F1E99U8F6-LV
MR3]=$W^SDI2@ME!A]N<1]1X8; 1<%$8 .:<7L&J?7__>E.F<8F<?55 (9H7(
MTA=+3HCVN1 5F^F,_\'S6&:# "9:,O%>L=6BW\7*AWU&"**[6,O.R^3*0F;N
M?!XVO2!6[L]DKGRIQAG(BRF"Z)K'Y 5F2;)^>QV>I1MO795-^TMPSEFDNZVL
MDB7#E@)*.R(7/JG'E0Z%MGXW"9>E%5KSXN.6=S!9:$!@IUTX']&D^E:JFT G
M@(&]&F0?V9(_+"9_4E5.$3Q,?48E3V*L3NS+]:3:KJW#\<ON0[2WMWPGT,N<
M1Y#LT_<&Q@F44--U9]^#")3FY,/],EM;$4'+(IT#LX.2.<+[J1!$K)U(T8N7
M&LUKG =6*\OKA=?,5=(T5**Y=@J"Y"M6?19ZS9JD";19&F4:.H0EXZ-G+,2[
MP<9#G!'I)H]8)&J-6.OEO0)VB'',.E9A(1_LU/)-1B_2(GU4A[Z,;=<WWT C
M8QT^;0VS#=HYCD,+H=E5]9>Z)KR%WSV;!=>X$X>;FQ"A!>E;%5X)>9[2,*!W
M*]S$C:6JQA)_CB5:74RJV=;<\C0I)#&BAB5?-H-!ZS^%< MLP5<=C,/B%:LY
MAII+C)J[,,V#.#4K754]"<:M)L^A?O4<>?DM'L.6W$%'^79P/3-*5Y*[R6E#
MTQHHI_B]5,$>00JQN?4Y/0[8DQ(.94VGDHHD&_GZFTX+@JFZW%&=5E>,]V42
MAQY1+\*L0OH4IC-%[4745Z#J.:YIE" L[74*;U11$*!N04.;@:R]YA&9(!_3
M1^2(Q[JF";<ZP0KT#,T&H9700-#;F@ RF#5^9<.-)D-MI)E40RHY*]A$GO]1
MNJ^'MR[XB4P<;,DZ=1Q(,[XRUHWW% H7B, .?X!K2G_,04?2.<#VT?ND')UE
M.>*H"FFP'^%4+@V=2NW6WQDKQ$*L&)G-'$$K?+@+P1FAHC+&'"J^4.'>=3X-
M!_\<X'(6R$<7EV0[?_QRI%*#CS/0! (W-B'_IW7J0_N]V[$AB\4W>S/AOZR>
MW&*;"N8;Q\R*\OFO_P$BLQI?%N\4>E\U,_R1NVUX>!]]8/\C8??@OR:J(W]*
M_@&V//\::W[??R#YQSTW)ASR5RIW$>[7]'KUXO>+KO\ZB&QNSAT.Z2OM@*2&
M-C=/;GS$%FGV?_UQ/OG\>4C_8?G4?PV4#5D=+R;7/)/_.GN'^J[[8R^F_H<D
MXMGS>\'^%,N7CUYV\[_A'R:X.9M],=\?=_BXN*VWF^WXG<)E\I6,\UWS8Z9/
MP>?7&_>V&<^4A5^ZFOZ5_ ?8E[5?K-KX!OE?W?:"VZZ[[M^DIQ=,8U.F*3\N
M#M_M_"?9/#GZV]LC>[/;0BFNO+.C_]\;?H_HG1%G>_ZG-\9P,]3_N=30V<77
MJ#F+Q<3<0JD13FOGH\T<\;EAHHYO5XFY;YY8S&S.M=JP_^?@ZM'6;WL?J:&)
MPXW-W8U_ "-SH$+2((?"'RLGRKIH'_\F N2W#+?-'U__-R&Y_VXN\63\V7?]
MD\.IO5OU.3M?U#_ X^"KF>J+?P!A]<V+]79%BO^VDOX!*I/^;C1LWR,S 6=A
MGAOQ0]Y$?IJ6N,1DG0Z?._K-NC*=*:W>)*0^74CJ,8D"/.:B='B">83[2,))
MDTP]9]XM52&YF 6A9%32S+9VC.2UT^ HEE;DN'!NXF%'*0Z?7C=9V)K[N4W7
MI<OVBQW8U_Q<VV0*?2#FHN^4]DV0[D2]FOM>&>9W3]PA4Q[IT8YJ.N?=,W^K
MH5M/ -I1"'.3X^5<RD"8*QN<$6T)S0PFPU-KR'1'S7')72JG9!,@"QB9)$]R
M$4%IQ'Y0 [.7I@PA01K2; X?G:A6\M;I_R+MK:/B6K;MX<8)[N[N[N[NT$!C
MP=U=@SLT[I#@[@Y)<)<DN$-PA^ 2Y,LY]YY[S]7W>]_KOVIT]:Y:M>9<<\V]
M>XQNA.H@C@BU,6)]1="2O"'-P.J*?<";;(YL99)Z)^]<ZVF)=_$VGBG8,R8K
M]=MR3?WJ%C/JV7(,2Z>>? /2V34J";Y5EJHD4!G5^/Q.<"R%U+HS,@K#FO"S
MB"C8^ED,F'TTQY0--$]U)A8KF&O</!;;[;-3_)#CFV*0??W*4738]N*KE2FN
ML"Q8?/'CIU2Q3&.#2+W+$KV64@G#]WLB C0R+#)ZI@+O(/'SY.%M3VOBJJ\G
M0O7#,.&/-5B*UYER>Y4Z;JQWN6#X+''H/:FXI27M=.2*K(N9Z3DD1I$4C%VG
MT&+=5[!CQM(<%,DTF!W8!SKEK(R/2V S8):_Y/-U$(#GRXK>7_;!51.E%Z)V
MP,K&A\GKW0 MO_?J23+9[A;W _-G[:RD]T3!)LKO%"4XR5XZI^"'/_\T'Q-+
M2?N&+I#M8AOJ(_) Q[O-+?TM&B+J8JD4EAE:;G VQ(5X24O)7*D_/ !.8<-[
MGA4>&Z(W7H(M0"P?P1.'J*3IQ3#'#>M(8MU%X\T;V/H*CM ::<YH&WHE*_ Z
M)S@A.L*TMXB\6+:^NL4RU)0[(=9R"6]'#Q_Z"PC?$!X#!;:6)852*/EC@Q[X
M&/KC1WXS];MYT^6L:";ER:'&DAA>O)#@D$,M(,06&EJ!%H!/C(Q8#%$W2#K6
MI!-4PX.QO+>+M#6D(9VQ$A&/-R#,D5B]S [V+DP\U85LC"8;;9C/4"M+\S^)
M2'QW,QM2V:G)0$<10XE QHZ3U.[D@W/)R8GX"^D^,M;OE>%JD.60XY_ O4O1
MB= 0Z6/^ ,BV$+AP8T2>$^51ZFC:[WT+)G'QS5+LJ8;P/XMDE!SH@M75Y5O5
MKYBJF?6$W"L5!'%V<N/!:>I8&?*\K+J<AE,ZG%J"3>*(GSBX;(UR1[ZQM:,W
M-S1K8*M_QYAJHCE2B!!P</.5%(C&$K3)A$G%0$4'M@3)K_=&U%3+XQ[!X1>V
M#=QJ!H5D!KG1$IL97T;H80GJ4WO6")+"$(&0I$R<O2NBWN"M(+S?=VYA*$WQ
M([3!TAL<Y@:UN1\F,Z @+0D3?26*J7L#^EEH1)1"GK30.8(P<F3&S&/"53RD
ME6QT!X5/GZE5^$DZ+&8J:B&J\AC/<7^5,:2F5(!OFR 8LB?H#6\A9M33+##J
MY"Z#Q0*C'CF+?O];2P6A@$9$)VU2JC*CYKT.CU2!=E>AHE],GVM)=4<]O@\O
M.D*'Z_>CV245HYZ"4G5"R5YKX*ZN@A=_R:R)#CJ^-/OWZ)@L=QB"5C@(?1WG
M(4\FTBB2,0->?%LF*H:WLGCX7+9ORC_ N8%#E:[2\660%/W4Q2M,OX79=K8\
M-F59MZ?:.E]+ZXI_[0S3\^Q:5\AY&UG])1E%070-2Q K2Q4I648+J_TA@'"$
MVMJ?G#R[3UZ"*T(V4W"(-.(D>90J*4.;_6.Z,JV_!L,1@(%JL=QP6EA<R08=
MXOI(;6H@:JP8#LBP +V=5B5B4=6,F#WW?IG#Q4E<:P.UF3N"HQ$IO7G4"!F=
MW"0^S,(X$* ?]RF\@.%X5#I?+<\@V5JF^+0)J!;E.D;@HZUK#'_H0&D0%R,M
MH'$DEQ5GO9=-M\G!$,E>KC%/A=4"Y&2)MF"!;_BAKAMT2H?T'=9DT-*Y.&U^
ML"9@\*;W[8_>3;N7;^U.SYLZ+4X"3\HY@3SSKP"QEXTJ7([S(2YB[9K2ML.,
MC(2#52)'UJ:WS_6K;2^UIN<)C^LZ#S?WW2J^?_U98=6]YQGU-M:R&ZOKE(NY
MM\FD]][")(%S";0W\]N*IX?/WC91#T$G#Y_2=QTGM-=U]XK)31CK2,L_4;N
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M02="ZDLINO78$H@5H\]>"WE"+BG%52&(W5%P;&%A=GX6URW,!60]"I^*ID$
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MM%$8<JHB/2()XS)*9:]'3\)#=S#$PZ @D.9!Y522FMB?I"'>3HO56 7 @X2
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M9@:II:62^J'1/\TH,E:[2&,I&,E3)XU(Q:,KRIU(5(8,!*&PK[G>Q->QZM@
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M?K1U_H^J2:S#,K):=$.C]0I8+54I%)$P>4Q^,NM6#O)"UO>!], 1%D,)\']
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M6V8W+2"XD]16P39WF7$V\5D3C12UK7@@*->.OQHT4IC+9EU2H 9H&V&^9P_
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MA.L<2'B.3-T,]J(&T36HQ?B0O39 ;-E-[<@%Z4GR(%H,SE:!IM=BC3>D,N:
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MP'%&,>\4E2:[J>-&'O-C>BN??=-^$CSPE*G+J"C!F+ZW'/S4$'+ESOI*=5-
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MKHJX9N(N2=IIVI-3:;4-XX>LA]]Z6#PM_/TY:'1DD<AH#DR;'K@IF1%.2%C
M;H3%LYAAS$:,VW3TQ)A_+/'./,=Q#!F,+EI%1T:)H=*UY'VS7I-]Z!$JT,J!
M>Y,\CQM> A U"+BRS\BA:)$V[G9?(,;99X/;9VR+F^.-P\N;WY_=FU</*4U8
MO5?.5^E*Z!RJJZ!-F67J&EVB@S9$9H1G:A+4>X>?2C/LOO9FJ<(H;W4(GQ";
MXN7._ $#OI*[)L:.= Z$IU<:UZ!@KNI96+4B_;3^BEBZEMJ*X<C(+*/?-7II
MD)4-OT"-!TU5G3M=&_*V&*:U^,0M_F"PM'S4NF)(!Z57K6BHC>UR*BT&6Q>
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M6<-$CL-V8UIOO.&/]D["*)V>?2%]6\Z$%V50A9#RC%UT\I0Q//XPQVN^05M
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M='KH ]A@$**\-I!  ]$GV^HN#CTS?GT<-F-J@/V4-T2:PQ]@ ]LQA]\NF[F
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MJ@7.K*@7A->E$G(V_KGP4\@B9PG*L:.^B#KGHB^G-5.%?5!(>PC[6$MK@Q)
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M\^;L&R_AENEL5_8+Y93>>D7C [18*FUE/!8]'>WQ5J([;DK;7\K_!AD2?GV
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M.78%L:?Y7Y3L3KX5BEW4K6(E=GR>3O0Q2(67OV#R=S@O)',7\7U3^SFGV[R
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M'UJO_/<6@R]"WKO3GC5[2OTH3>+RXI9L7:I95O&<+"!52D.<MYE@68):G;9
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M/E\JX<CI190.S1YTU]EP$Q97)ZWQ*_KL!MY'YKED]%*Q$3N[A'03NSA%='1
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MFW1N2<'%CS$:CYZ'W^^?11=-/?MV#"Y&#'U0Q[\^:#R;!?A'5YP<1W.\OUO
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MLDJKXCE5XN(F87Q&O4HQ7JD%HXU6-"?1$AK:W=(J1T&._1E7>4:!GZ&4KBQ
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MC[YZYIMH\4TU8L/+OD0V1[:=(!N[8#J)Q1M-H:O40RE.!2GZ3"%R+947S3?
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M,C,Q7V<Y+FIP9^R\!UA37;<N&GI'.@HJO1-Z;T( A=!#DZ8?)6 @!4CH*JB
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M:QSEVC(]GO[Q=]/E5!CD;R:F8DUO;]S@:<@X!;U3?NEC_MOWL_E7WU@KXQ2
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M2"K'1Y9V,)FULF_$9RZP[NJ^0.>&*V6;G6K->S[Y<3_?NX&-7]UDP^GEK2/
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MO2]>95<&S,4JZ#-<YRDE,G/.23+CR0XKFTQ6%U%H[JX0Z[H/<[9M?8KOH6E
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MFYR(=.+F[.\+[7?WTK3C.9U4ZA7F)1CH2(-QQH8_]+W)?EU#77QLBIZP:+V
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MG;01C(U]*U)0-DYPY-ZPUAACIK/\V\$X652S4K2<HF^RN?0L0T[K,J;.9ZO
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M^=$G<[^#+K)8,2%W]EK\%58%/C&B3&SJ 0RZ#!(40_S79D4_I%$H1.,)&@%
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M%!5)-;9IE<VT8HD:-X6%.\SX9 B4FF@O8US&)<2__SX<R?F(%)\)ZM6GFVC
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M>*IO<%[H%9 A]-QV.#[VU3-"@E8E1S*+;(9DXJ34GRY@B6OXS%N@K0P9KP'
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M1(_71"E782BRY&P<5F,."AY@W^EZ:>O1 @.:$:>>_#/_8O%?,;%+_Z00NKY
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MDXJ0_'#8_056:-2DW/.*4;2N0MI)=O<7'T'Z3 HC7[?+2GMP600D1:HO2_U
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MD@'#",9A/[=H:[DE^_Y0/I04[?E@@',_VHH/*)KO);05 L_&DQKOQ*6]G[7
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M)Z4U_FKCN)FE,O9)8I$QLD11S;>3YS"P%A5AD6V4O^2)A*RBEX^'-$\EU6J
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MU)5./5]DMYN9-(\5<>3=]RP4,-+O;<Q9M 1=UZSZJL>$*IAA_H<V;BEFE^1
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M7PR%$MA>99(2XTZH[]:;)IW0MTC#_Q E_+_?P;Q,CQ"%W>&[ :K8E+ >W)O
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MU+1\04V)YL(ZP@'7K#I7$2D\ER(R 4-WT0>X<LK&P5L(HG'_G%=;HI.((YM
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MW\HZ76.^_N '-YS,;Z7TWI[2%/UL'!OQTU?^<DMSAQ2A7_O3'J@^]^:E%1B
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MB_?AK>6X8*E,3BT&*^"75L$7]Y,9$3F16LI4#D4."&1?1*&9 J&U\_"O3[?
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MRTRY 9V>0>- H-GHQ\=/1-P>^2L=R9T="<6H&TFA8EE:DX+E_?L.CHA8WXX
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MV&NWN>E?#:;E^?1HF>/5I4T-V\QUO3^)FV/N7/[Z[)=+/K;M_F)Z#H?4[H
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M08[HVKZY!'X/JA)O!%) V-+(SE<?OP"3Y^C8^C=H,UYKP/H69H4*OK HL89
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M7^2(J()0%L;*DNV[3_@Y&*#/2HQ?NMX_'@LP^Q@EF40J*/2A/. ("+P2X7O
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M"KH],%=R\7DP-T#5?(A[M Y%"0#6EX1C6T!KGR+JH [:'?F]6TT6T,@9)X2
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MN&&7]N76ZA;^PP]-\@@+XU'+"8OAO+Z7G0F=B:@8"7CA?-I[89E^@@=3.)>
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M)<(-8AVE-W' $K1<Y=\EQ*IF'+J)*-\)T%X"T S)=U)6@Y;BPQ;JZ(Z7Z__
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M5# 2\JY]QI2C87]V4=MN#'-F6T6K4,!;WY)[FZBVAUF:"9R0-#R#4S<-CD,
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MBB>U+HQ!KUDTIIS&&,,$ZUE'SS\4$A9',,G"@&F[.0LP=6%1A[;GR+'KC;3
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MSMN,2:'(1$8R"1,5F7SA*858VZ.0I9@C%$8RC9CU,=4  >9&\[4*8*L#:)4
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M1G&//JVSWY0=^TU,FWOCI'I'231.7S4T&\;2U%1X3XOJZ5-!5R6MJ]/N7L8
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MH >7J52VE%4=1_[0Z* G;P=6\]>C%K/)L_33R-/-GD[=)<P-:-2J%R<=Q6[
MKE=KW3:+&_U+J]ZS])_#M/4L_3C1O#9I?[I-?]YA[YT?_;4VW03J':&]&=;_
MT^>='F_!8T5BXUV;TIA#1-(,TEA$4 FL5V51%L1NWK53"3ZW:;R;W&[:8SC7
M'A]Y*W/$?IS_IN7 ?'0SV)D<V&WSV(-T%?ZWL=LXL$N>*PG<E3->;\7#ID"K
M7OC><BU48?(LO2_67.I5\+JL%D'*1%TM54D3%L\C"O47'&8BB4BL_Y<%3H7)
MKI!E;O/27OU/L5/&8_74"YUC-]],!/G(4\C%:JL_;%4!&UWJ::#1!AAUSML-
M?BNQVH$Z7876"_+,IW*K'7!.%5TM'SDTU;Y4LM /K9/Y-UF+XXBG*)8"IIB'
M$"4A@C13&10<A20)&$TSI]HA)]J8&Q-N102ED;'-*?3?@C\&00@>: &^&:G_
M#,+@)@CJ_UI#'M#'ZNNZR/]3BC^#U7KS;9M0<UV ]>Z(S35Q_W'/V-'EE7B/
M3(,[J&OQ;IILRC?>,UWVH. Y9_]Q.Q,G[#^KZ'&V_O.7/H\75^<$NG40#0,F
M(Y%PF!*--TI1!DG$$20\BE&(0TFD7#0.1!\K6E0C;SV<D]-E1!U*.^*IW$Y,
MXV?%Y)=\50?)K=7&Z>H'\%S.P,=]K13+:!P*R#G&>J9) T@ER2#/HH3$/$8H
M2-J^?KT2OYF>WL@Z63_/P=7[N'='WDSRT5_SWS7:[@OM>;/-S=7[;"?,8P_H
MK)2_C<V>2R#[]A8[W]#0[9N*YBLI7M/"3$9EF^B-Q6'&5"2AP,Q4-Q4$LC3B
MD(M$I2DG:18ZK3-.-S.WI<8MYX_WCTW&B5=2Y3QWWF\YB:;M5LJU&(V^2]((
M"#82CE#1JQ\$S[L:)YN:>,.B3]WCO8C>JX<QP-OW=^UK:L9\%DD*L1[U$'&I
M33Z<1I!J-HAXR%44.Z4KWCYY;N-<"^8VKG<8V0WE09J//'JU3".,UR--O0[1
MW=,G'95'2AT.Q.,+!GCLO2AR\:7.;_E_'NDR5[D4;_(577$]M#=E-0,2)CSC
M,$,JT0MND4&&!8=)DJ8DJYWQ[/,&7VYO;N.TD;C.OPJV,H.MT Z^6!98]X_L
M$1 <>;Q? &](DF +%!U<U?RB.9$/VM!7TLV=S!Z:7C\QB\=,YP!FK].>9Y?#
M;<.+E.T.RV^_Y^4B1&D09E$,DUA&$+$P@(QR_0F'"8FXJ;3C9 @=-S$WIJTK
M7^U$!)^-D(YY5TX :6<M70?/R#3JB,R@JE^GE?=>V>N@F<FK=YU6\U2%KC-7
M#ES@K'@A:2E?R>9O<T8K'V@N7K4G+NUAKO$2-9XR39K41898DA 2PJS.<2(T
MK(S%@5X7)4% 4JH0(8N5_&)V"SXY+(H&26,U($@S((YD&O7 T(A>!Y)KF1L'
M['7M.=<6- %T0%KC@3UFN38;KP,F6LBU"H ?-BK\H?%%:?IBX[)2^\+777$A
ML[3[FN\J!/TN$(>),NUJ\BJXCI:>USUMP#IUGY!/E$Q\7^3:''N@R]O[]>.J
M6I!$IC@,D,EJIU>M01Q"RJ(,8AG+@(@H%=3*K6]0ZW.SK'8E1!\V@CJLN)RQ
MMUC%CHGHM,;8N0*M6P5 H\&8@#LL>,<$?J+EK^\.<%L6#P6P=Y'L_-#IELQ#
M]=U;0 ]^R%"OQ3674I1OM"K=G.!&C$5,!"-AEL*4(3TS9"2!C$<1E!G#L8@2
M4PK-S7WQ?&-SFP@VL@+3R4!/S;4G(M5O0:>@=UUOBC5[3"M3^<C5,;$'?#OS
MV!>D(\\$^VCNEPDPHOIT5KP,B&>OQ9X&)W9?O*SZL1^CQ3T#TRH;>_9=3EF^
MS*M<EKO$S8[)W"\_:$9O>K.&ZTC;2:8^2BYU>W3\YO2]W.RT*7VM83C*Z&M_
MY["!\%.^6A=UC)>>N$RNJ%]7>@+[FC^\W^:9>/&D1YW)'9"A(.6"2!@QCB$B
MC$.<*@R31/$L(U' B%,R18>VYS8#;T7MY.,P+GX/U+TVL4L7V)'22,".S$ZF
M=+$I\K%>+LVAXD;X&[ #^_T>V._[P79FJP&P>:4ME_8GY:\!P!P2V9!'#&.T
ME^O[^[RJHU5O5\*4C=%OD]3+DBY[?I+?JQ=:Q;\O9( #%.G.(($4>AV!,<1$
M!#!.,R55AO020[J0FEOS<^.UCO3UKN^>_&ZTYM@/=LPV'KHCDULOL'MFF)$>
MU.)[-,2&X>:5W1Q%F)3@AL%SR'$#GS(P),O$=C71=*\>"]U0$X)?1WLU.S-E
MOE[=J4[]XX^2ZRN-&;G C-*$10$D&%&($DHARS)N2B\PI#0A(N16I>P::>9'
M@AN!#[=3RJW,CE$W5W66'35.U@4C,V6M1QLG"AI-VAPIVR#2_0[JUE?_>+F#
MW*-F? #K-T+F*HFFC8;Q =Y1Y(N7AP[D7?Y5BL>EO%.WFM]%OGPT><)VCV_B
M^*4PFU8F+N>Q.4>Y4QM/>RUK'9;SR=186,0TP#&.$524AA"%20A9B @,N;9'
MLP3C('6*CO$KWMR8>:.=&?9=_3KC'FPT;+9S.SJ:F[;A)EK-)AY/&UQ&4T<'
M-<]O@27#/UO?CDWYS]"M[M/ *.C[G1?\BCCM1#$*O$<SQSBM##[?_ _)J];=
MG9)8$"6D*1><012)!!*D/XDL0V'(%>6A4P:KO:?/C<A;X<#G5VM3X->1??>!
MLSZ,' ;'^*>/=D@,.6T\UMCW\6*GA:G/$X^5.W& >.*BH='-IXN2OWCJ_E*[
MJD<IRF024XACGIB2AC'$D4HU@(2%62AIA)Q*&MHW/;=AOG^8/B02P %V.QX8
M!\R12<()QP&!TJZ0> Z>MFY^XH!J5UB.@ZR=GS"H7,-VE;N+<-IF7R J20E+
M(",A-6>V#!**]7(SBQ,J0I8B:;6^O-C2W*BGNRO4B;2SW+B[#&P_VWB%:_2C
MB=-(#0GK[(7,J?: '^@F*R?@^+*YE@2XC,:%+/\]#Y@R<?]E/0YR\5O<,"@.
MH0EPN%/Z;[VL,RDVWZ[J."/QXK'2K?R[K-[37"Q4Q%.&]:2%91! ) (%*:(Q
MS&+%PC3.4LRL?%[<FIT;F?ZRJN.!UJW<@&O!Z^3EE'/CZ%O7K#$K8B?W>-L^
ML*#:49 =F7<W,H.-T'7N7[ 1&[#'RK (>)(5,**/@JU3S,$(&$\6;. ):]<H
M T?(+H07V#YMRK@"1PT/ @I<[[[VT&;3XB?ZO0EGNUV)CG]EO:VW<TH)0DPB
M'&=0:"L:HHC'D*6<PCB+HY00KEB<##N=<9)C;M-!=[^^HM^!U-W']21@_BGO
M']8%+9Z R$VG2OT*E:;V106^F!W]PM3BK=9UT(+8#$KSC":XM_:-6>YP&'HJ
MX];-KL<OHW7>A.<L6T;42K1AO37X7>_PY@P%C.*1="6:(YV;N,GR3 <D@P [
M?Q(R['%N1"QDOGB]JO+JZ6]RN?S?J_6OJX^2ENN5%/4Y?K'@ :5!%B,8X<A4
MH<(,DCA-($YC%1 5T3"S\DBZV-+<R+01%AAIX=^-N& C;^,$<S[_JR/"_2SG
M%;>1>6PX9-8T90W'"2(J)?_CE_6W'_4S:@[Z!S(?8?.Q)I[+3Y^$6JR5W)"'
M_0TC^FYO([1H%(@D9A@B1 E$-$TARYB"G 2<\I3R6#@5KG-J?6XT8N]@?#G.
MRT/?V)E4HR$^^I:I/[#'\>4>-;[.38+Y>7)?BKH;]I"A*:6:@)@VUTKW8&@1
M2B3",$4P#I1)'D<R2"0C9B$:$APG%,5.!-?3UMSH;"/J)A_49H/1K!V+]C3T
MP0CNF@[J/-IVE.4)PY$):@M?*^;-?ER[SP1.%^'PG*7I?'L3IV*ZJ/AQOJ7+
MMPPCD29__YVZ>Y"F;O'JRT?YI::O!<GB,(IC 0E'<6,H44%B&"9!B,-$FU#$
MB4+.MC0W FD$-3L=ZXVHH&QE=>.,\^#:,887R$;FBQU:6RG!QTMH.9/%122\
M4L7YUB8EBHM*']+$Y1N&D<2A"^L+6N9\D8:*D)1'D*>1<583,209DE E*HE(
M1B/FYJQVLI79D8.L0+[BZWL)?M#67/D'$\;?%%0"$# C<EUB29A:\$6Y^]6Q
MVM)IR.UHXVH@Q]Z$.?*YOP&UC/[XHA<"KUQQNJ5)>:)7V4..Z+]X8/;J8V_X
M^ESG;E4__;#).C7)(HTS$M%4:;X@#*)$44BI"&" J<JHD(I$PBF_]0 AYL8N
M[V19_@GPKZ8.DW&24#1O2XL>QI,^Z+<@+\MU\=2DZ*HW$_*#I8]CZNPAO6C'
M2&/WS<B$]>HXJN@&-!J ]:KAKA.11#=@>^/8D:;7 .PWQ?<00:9- GX%5$=I
MPJ]YUC"N_67U6#[2Y8>\_/M=\8O6N##EF*JG)APP3$(:1C* *$OUHDV%"M(H
MRF""&5-9EK PL*K58M7:W-BS%188:4UIY8Z\PV(U^[&VHSYO"([,<=> YTQ7
M5J!XY:7^%B<E("OE#YG&[J:):S2__L=CG9AID\2UK GNDS9?VD*1/YMIKZRD
M:"N^(E,:GFAF2IB);PK3"+(P26 <"8)E'$4B2B>LW>PJO\MPG5=-Y\F+_CJ_
M&BQBD50)AU&L)$0Q$9 FF3 %O@GF(@QE%$Q6ZGG\%V/R$M"F]O-OZH6PFUYG
MV<4C3]4>JD8WVG?2I9=MF8Y* ["K*;W%8$85I8=VW#PJ33M+_]NH0#VT4[Q5
MIAXLP#"3Z0W-BSIIT$^2FB-]T^3?\NKK+ZLU*V7QS5AE;U</FH(_2(-]OLQK
M3<P_'POCL&X6B.7&6?*I?M:"*QPH$420!XI!)% *:2 QY&D:QG'$N&+8W3P:
M1=9YFD)OMOME-QT[B-&ER7#O-M&-T\,*I0I3GD*>R3HL $,<B@ *A2,N6))%
M:>QJY<RD?\>W:+J]*QO#9D9=:V>O/'MGC6R;U'W4)MOKJ A^U3J"KI*@T1+L
MJVF\35H]ZVU5;8-L56T>Z\\"&;4KO%H;XT@ZJ64Q*MB'5L2XC0VM\-K$2IA
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M<"V><P*1+G)VAM5P/$;FP0X4+_N@&)+IXX3&OI-Z=)N8.G_'"?5.I.HX==7
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M\3B*,JS7J0F'*(T%Q)$@$!.1J#"EF-@50+U2CKE- _MIGC>J@%H7\&D-&FV
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MO]EQUD2],3*G=;6H,]]N]+CIUCS=ZE([TFVTV9S,^>,\#YAZY<1KY)F4,ST
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M0IB&*$P$4C(DJ.V-URLQF[[8R#)>3[RN7=6FZ@:[J7M48$>>RH\3Q!YL^]Z
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MY9S$Q$59"GLTNNM'D["O]D^M?%-K#B; ,6@U$-;8$:<.V04,%9UQ-FR<ISO
MN$&:,ZZ=1%C.?69H)EW=0::J/JE*6;WUQZ5\;1775\]UK'ZUF(N?,\(%9XRE
M@*44 2R4 !QI#B1"2A29*A!#?JET#J-.C1P>A2'F=7WD!%KSDZW]]7/?\:!N
M5>>=3^<R%6YL$!S@R#3Q;IE<@_0A::Q._FC_&R4([05<X#P[EY%'3K3S .,T
MT\[G8C_VJM:;V3_8C_G3RU.;C%4P*O.:D@B69I4"4T PM)T<$"H*#A$43G('
M)W>>&@NUQKE1RRE._?1QD_>1*:*U*V#QX45O^YYK<U'GF38_'3_/IW<=Y9F]
MZ,SVN;S\@6C!N_K\I]H+HD&&2H@)!E0P#7!!,>#2_I&9GZ5(2TF='M+A)DSM
M:;ZN0NA_<G+#! 6+P-T ^Z1";8T?3H)UH>8@>.CLAKF89(S,8TYBA,(NP!D@
MYG5\YZD%MRYX/B"*=>E.P_:PK^>56*RJE[6RX;!NHL&";6SN0=7V=JX37]J\
ME^J15YLU$YL9A@2:U6$&2BW-6XDP"1C6!<AA5I@W%F4(>JGHW&;.U-Y05U*&
MDC^VAGM66]PX:6[;X/&F(G88[?99\-X*AP$OZ![Y1I/&[7D?!+Z3[O9A[AJR
MC_TG)95ZLCE;G;.(C]NX>/T&F"&4$DTY LH*$6)-%6"9HD"F9H.>LQ(+[95%
M-=B2J='KY6[W1R<+(=K:N\R4&[&.@G]D3CV$OGOTL_?CX.QUYTFS/ W'M#>C
M&91DAULS*K_>#-HQM=Y^PX':)IUR>4Z1QA024"!& 980 _,UQK8@.,4%S00K
M4Y^V+4.E"49HU_+%CC%<?<!?9&":6@)1Q )B:P+<K?3?H<+_]D+^>B/[>6/6
M4_^/V;-6<EX?_+<!])P56.'<[!$5M^6GJ004ER50A,&RR N40_=,PPN#3&V1
M\MN']XGH-K3\UW\A"*)_K\WW"(A=PM0A[!@ J=A;-&MATC7Q^E&%.T0>4<$
M4(T4]SN%+% D[PH$O;&Z2]>.%XV[8OU!O.W:9P=&U-KES1?VX[&JU*;Z36UV
MH1?",YZG- 4ED3;7FN6 %EJ"E"%*8<HH\U.2[1ML:DRXM379L!\)JZW]-\^X
M5Q^TCE&M0(!%)L0=5L;.I#'4!NTC!:L<, D;BNH;<-Q DX/K)V$DEVL&K)H.
MY%\Z <JF7.1Q*3_PQ?QKTYOQ,UNHZA]S\\=FM53;4%5[1#V3*DLSI 5@*>(
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M+>Y]Q;%N"/S:1X=*)?/-/MS:]HBP]9359EV_,AZ?5B_+#9QEFNM2RPP@)2'
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M-EY^C:M!(^N]M\/_O8ERMOJZ_U3VW-J8^EVMV5=5__*UX?I=R?ZLQ#F!N""
M<*H QED*..$20(2*G)10YB6Z77TOFOU3>[]N#4Y88W&B#V2LOC:!>OE2E[,\
M-PV:0D1!Q_[:.!Z!3_?+,.(;=Z!,_$X(_N^[8\,&AX=D]RUKH6@^DE@PDKWJ
MRP34XF^;QVDHQ@_T80)BB=$G*)AR_(UF#-S>UGE>UM+5TAC2=A$298IU*5-
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M>W;$^[2U[7/^8JO:WHN&T<BC$*L7\W!\9#_K#N4O9K>WW,Q@RF&A,@U$I@J
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M-C&C&*$[<W\KMHUX^^;7#N5OLYWPV?UUF+TW OZ(1=T6> P_ZB;!'Y;76X:
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M?'FX<4L%7U7[I&3P]6^$D<:!J?+U:<V6#6O/^YIW\T8L5C;$YZ#SG")Y3;$
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M#L97[]^C2V&R:8W6U3"=A)>LB,/5]J/YZ:]_V7YB_K+R_?4O_P]02P,$%
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MP/BV)_)_>PIU^UJ36VM\#'&&DYR)(UL2%)D4*#*,$*/G$(+RB@54,3WTO'@
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M!>ZNQ;&!-J-0)H ,2-R:*, Q%B#FS) 9"@Q#F_?D1ZB"/F(5Z4@&>%C]CEK
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MS.;U$AU;,?N .ECFPTYG_[U+'.2WW/K4CR2.7V;U)6"1G$FL%5I(H9VR*.G
M+35S7[S&HD2ZF2W=E?++-<:Q!P-J[)K[,I LG^/&_ZV6PJRG7_& I-[C']K<
M,#S,1EM#P:-QDM,)FTH*H+*@J$E; 9PKMWFB$&P:QU!<G'2_S\]69V%6/__M
M\O=YPB4):4XPWSALSJAH/#<0I)<$;!<@\N# F)*TS+2-?!NW]D&RNK0P3U'U
M37=C."5TX-]^.(LK$DU8?O\09GAQJUMS"(5CB-)FL 8IAM2R7GMHLIK!>;39
M,=$HCWTO2>/ZK@.J_59M]1 ZZ %,/\BOHY??EH_+,%_1?B,5;3,3R!RK,W6
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M_+)8WN\OFCKH@TPFI$);@V+Q^EB ,4 AK'!2ZJ+:M G:B;QQ:T<:86QXQ72
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M X[#F>@D,C\4?X]DBHZFY@X\@"NWM!?'V?<7L[ Z+Z#B4B=AT !:C?7A1X2
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M*'R0J<T5UY<HZS ?-P[$1A5)!Q![DE4__8G+-%OAVGVX>_.NSS(_+RXGS"Y
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M =K'>B(%$3QC"9RQ6I?@/?(V\S%&6\*THWY[4(*C Z$##3B[6/\.YJ<%L#E
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M[R+I#M"^_1XL\S&4@ ),U+20;"0X5<@>$*$R99F9+?^^PGQ,M R^PKR+Z#K
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MG_ZL7<7Q/'"-Y*@7*&Q]YLX%<,(2O] XI0R]A\>LHFW(&E9T8*\6?^/);.K
M:I<2RLWKQ,H/N/Q"EK_Z*TF+9#-86]=7D$.HH^M8<$*C=NR[T[ CE+Z^(V,8
M&O]= SM0@*<!U?5HA.\7FCA#AL$#&EE[F&E)GK724'@) I/2H>@1D?HT%<.
M^DJ+84<3W]0XW273\5 .Y,O@I^N+^M%?'U<#5YMSM.>,126]JK=V? +EE0-G
MR;EQF7M!?K95/@_"<4LJA^'\W[6QMN(_)3U89_RVKEHB-Z3\#+P1 I2*]1!3
MT9"PY!1+"(D-:XHV&DG#$/[O"MJ(@CTE.'^<(5'W?O$U7%Q]O:VW\!R#SDR!
M"C4L\*@A>&G !IN9YI89.?YQG*<H&0;>?]?/#A=C!^F%7['V0JN;"\GXXC9$
M):8%I9"8)FNB6<@$WMH")J I]2)6?(S%D=(*3Y(S#)"OKS VGHPZ -K;SUB5
M:OYIO9K5S]=UBN7F]M^MW?_Q&L\IHI2V#FVBCR#]D9I!8$F"1B$\"I65%$V@
M-Y# 86!\O36L%G(\@0E<O\SI6_P8_MQOU.##/Q][JM96TD::GW7W^4],(XI<
M.^U5 9Y2K,ET!5Z&BB1I$W>!2=&F-]0S1!UJJ9[XZ/O!<BJ+A%HH$%%AO3 A
MP7-O0)0<&./!\-"FZ^!S5$U[R'\L?#RV-*/)X;3,R_IBSJ%&9O,A#4W-4V0>
MP>#HE)-W L$Q+VM&FMSK5.<\*EFXB(5%U6;H5D.#<W^?Z\<-.NDQ9ZL5K@..
M7V<ASB[6!T/6/'\PY)+ GIV1P*++]29KJ0=#+-@H NVOIK#2Z,;O?@3W:Z9V
M0=7VH7KMI->!_WZ_S)]*P53#XSN.O@]79/;(<B1:ZEJ@C]9:LO!)2@\^E%1/
M1O-Z,H]BE:2T-UYDQEACI.Y.];17D]K#M;$<>\#L]>5E6'Y]6^Z#EL5J]28L
MEU_+S93WU?W:M,C!Q>J@.$9K<Y9!3)S<"L/19QV-8JX-1G>@<MI;1<TPV4I.
MI^7YG>4\JY\<+GZ9U\A]_9@#!CP/_>B&7N+P)1W!=Y1U0$<B=)K"8TW-"@A!
MU"9%KF0OO!'J:+';6+[C,QJSON"/FEM%YAFXJT.""ZW9655[Q99"WD<,4K?9
M>5\@K%]?<!>4;$^.'2Z-#O;/.S:=75_]L5C.KKZN.^B$*)2N"Y"RI@^C6M^0
MSY"9LUQK\EUEFS8Q3],S+91&%?FV#,C^_.\219M&.L5*CLF;VNRF'@-7$:*A
M[[3)S/"4#&_4;F@;19T8I0.D_2* ]F#]U)7U7^GMB_]SO9RM\FP]@^%VFA(R
M(52-G8,CQ@1-FA65 %%BDHZLN'3#!E5M>4!O:-A'=(N1^=B!.=EN<!\4N)@O
M/CM/T6FMQ)LZ:$N0]D3NN62YZ,):%Q&W$C=M6J'E=C6V9#H VYT6;JKN/^ <
MR^SJW'@74'D&J2#IC @1@A<61)9HBHQ%/6[2,/;6]2U!O?I >PI^VS9V@!0Z
M %,]O'PCDXN+Q;_"/.'CC/&;.E@2?YF?7=8&*.?)29.U%%!RKC.VN0%O4P0>
MA$O<T](;C3C;E=)>;=HX\&LJMZF]J^W,(V6;+6^RP+B\/"\L.)Z9!EZXN9DJ
M3_Z" ^:8,I8SG@>>3QSZQ&ESG:U U8[I'5@XTH>;+DX/U[11"JNM%*QPR*4$
M4$ZI>C R@Q"A<%8BZ4N;:N4S1$W;Z*BUW1I+&AT Z_?Y$M/BTWSV/VNCNW$
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M@:%KTYEW*TF]]JX\W,D=1PH=."E/+N2W<(D;A?-9,1MC@"1](%O)(BU'(LA
M[!,V,LQMT@\O$#:MXS*2^(> :D]9= "MVWKIG0<6@S:F0 I"@W*T]08=/!A2
M027JV1319B3!MW1T")Q]1;P8C=\=H&5(?SFE+6;F.0B)EKB32<U21N!)D')%
M(Z0]=E[PUYUZST_04O?PO6YLR70-MO,L#'$*-3!9[W$[26KC6 &777$Y,:UC
MF_B\U^Y.HXM_,+QVDD4'J'K:*[AI"BQ8\9DE!F@,Q1F)%_!.1(ICDB^&9PRV
M3</19XCJU3T?!U=C2>,$&H:^QXMZ5NQ=6%Y]_;@,\U5(-P7Z/6JS6S]K[/+K
M,*)'JK!N>]A= <UHK8-$!MQ[ \IH#UXFO;Y2BL;6V5!MNOR]1-GA7OC3G__4
MY'>1HPK(.<20ZFD:B^ Q*6#>::6%DB*TN86R Y'3;H:CXNA[![Z-J$[ @GVX
MCBO\YS5]ZD]?UN<Y][!<WWW&V!;K>2)'LE2/'W*'+"&*,")KT+I>+3(R0:@]
MJI*P+*9LA9&MAB@_3='A(Z2__=Q[<$O/C';2D*/'*%IACK;]2EOB:!1JYTJC
MI--6DJ:U.J-@XOO)T&.P_P1MRV_D#X9ZP.^ $VPO?F9KV_/\(EK;HLRML"&0
M(^X*(<0[ Y[Y0#_FH&5RRF*;4L.1;-%-TL2SI+D4'EBQM>%1O9/$O*A-):3*
M'KUO-"3B*6HZM4"[(.$%"[0[TSN(^=]<A-7J;?E'5<?YU=OE^]FG/Z[6E0"7
M2F:</#1I$@>%21)G4B*9)^5*\#FE-NC92E)7$-I#VHL6K.\50YN"@%;")1-=
M/3E5]V(M(,08B4'%L.2$4K%-ROL9HJ;%T4AB'P*F/60P]7F17U:K:\P_+Y;O
MEHN"JQ4))5R\H2#R^J+FVC[@\LLLX6I3(]+9\1"D@T1F&E0)&;RJ#-1&2R\\
MLX_GA6PY1;+38SO$SSZ27AR%[1W8I\>6F_YLK6^9(:JL$R1G>&T-27N_4@JL
M2%8EF[SC1XE(;PF:-I\]^OXV!MO[1,_MN'6I1/'*@5&BCNSPI&@9+?B Z&(J
M$56;G.M6DOKRD/82^,L@VH/[_<%H8TD#9QSM>M:F#J""H2T_BP*1U[OY!0T:
M=@P(];"QC23JYP&T!]_[ \]]@=$Y4;1 )*9P"[2],XA)&4C1YXRN:.?;-#G?
M1M&TQTA:[V'[,;X# #WI-+Z]OEI=A7DF!^^\DFT*11Q*\EB[ULC:^1\A^I*1
M_$@TKDWI["7*NK))>\I_2*RVKS!Z!==/?^(RS5;X;DF!P]V;J\V[*W[.=0B,
MW *RXDG45G-D?1U*D$K)K'W$5LU ]R*W*]^\(0Q'%5L'V+Q=P-D\WZS@@9Y]
MQ.4EA<RT&6A2KAR<J)V7,S@6$4QRF%/Q&FT;#^PERKK:2<=!W*C"Z !</X?9
MLC9UP?O^1?<J<Z[KH("0$CA+!ER5S"%0! 3%%Y%T3EKF-@W0GR5KVFY]36 U
MGAC:5X,W;]0O,:SP?_^O_P]02P,$%     @ .8)W5!M6SEL !P  +R   !X
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M&< ,.%^ 5'*6X4H))#OF(6XI)C.4+B-]W$9 3B%IS=7"AF3\EC#N6I\:]R*
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MZS973?A$R[0PFTT>>7E=?OI7Z>ZE_ME?4$L#!!0    ( #F"=U3CE%+1" <
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M[MX+KP-FM/4A>N47*6M5T6NN77AD5%[:;9=O?+M>_H8OZ?Z;_MD?4$L#!!0
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MI=P>\I&K_N5G];.#_@'DY!]02P,$%     @ .8)W5/O>YT#G @  5@@  !X
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M]PGO(#>EQDOV>8>R$\]NS4Y\.2^PGRZLS[\T<L(PC2%S.X',_%>P8-_Q/KW
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M/LPR.AKK5B>6)K<"JO.9XB0BDUBZ=%@T4R#C3489WY7A$D'?U81:]^H4^W>
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M>C(?\C1&HDZZR.HQ[)@O:*Z\?[&_OU7L7X9L&'C(O!#"C#V+_0??5W@G@F*
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M]0*TE8L\$)#CN5 GF#+(H[+I1HEM^"-12Y40(8,#VW">J3\,^T1I=1#.-C%
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M&GE"I0SLMW 8A#\N:1UYW4"_@M!7=9L H #K$8:1Z'ZI=('' /ATF$7&WZS
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M9[<ZL;DG)>Y8+U2Z,A6S4J!%A88XAZ+$&L7#2I7.AMU*'=8V=;US/J[-<J=
MQC$G3OP*BE*FF$!$B:FC^V=1"AO0RJ/I,\V!4)U3D&2BR5DLK RS%V6;$">%
M+I/ #/MD\I #]KN=^BE,([+RH5#"_.$_.<&<-6"X4?MG8I6NF%1Z>_#INYW!
MNPW=?S@&(L$K+#[U#&7<CUCDCFXV;VT.<=[-&2I!+$'N]U?E<L"M?5*%0ZGU
MDS *1YAUSUB+;@='L<D)A6UNLKOUN,YZA"CU=E]97^<)/[;A/)>C((:[2A-
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M?V]9G(?7S^+\B"  ^)]YO<C^]O\ 4$L! A0#%     @ .8)W5#SVOF=4"0
M+DL  !X              ( !     &%M96YD;65N=#%T;W-A:&UO=60M;VYC
M;W-T+FAT;5!+ 0(4 Q0    ( #F"=U04#.^2KRD# *G2&@ 1
M  "  9 )  !C;G1X+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( #F"=U1T=YIB
MK1   /FR   1              "  6XS P!C;G1X+3(P,C$Q,C,Q+GAS9%!+
M 0(4 Q0    ( #F"=U1%TA7.M14  .3+   5              "  4I$ P!C
M;G1X+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  Y@G=4G]E6$1IB  !#
M:@0 %0              @ $R6@, 8VYT>"TR,#(Q,3(S,5]D968N>&UL4$L!
M A0#%     @ .8)W5(F\T@R^QP, U@ ' !0              ( !?[P# &-N
M='@M,C R,3$R,S%?9S$N:G!G4$L! A0#%     @ .8)W5#](,RF1)P$ N8(!
M !4              ( !;X0' &-N='@M,C R,3$R,S%?9S$P+FIP9U!+ 0(4
M Q0    ( #F"=U2<?(L2_SH" !"6 @ 5              "  3.L" !C;G1X
M+3(P,C$Q,C,Q7V<Q,2YJ<&=02P$"% ,4    "  Y@G=4OO]FZ:Z=   &]
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M,#(Q,3(S,5]G,34N:G!G4$L! A0#%     @ .8)W5$(K8OPXF   ?.L  !4
M             ( !864/ &-N='@M,C R,3$R,S%?9S$V+FIP9U!+ 0(4 Q0
M   ( #F"=U3Y+I"G]+4   T+ 0 5              "  <S]#P!C;G1X+3(P
M,C$Q,C,Q7V<Q-RYJ<&=02P$"% ,4    "  Y@G=4;3B5/M0> 0 M40$ %0
M            @ 'SLQ  8VYT>"TR,#(Q,3(S,5]G,3@N:G!G4$L! A0#%
M  @ .8)W5/G[S8?<UP  'C0! !4              ( !^M(1 &-N='@M,C R
M,3$R,S%?9S$Y+FIP9U!+ 0(4 Q0    ( #F"=U0;@(&]=]8! +X: @ 4
M          "  0FK$@!C;G1X+3(P,C$Q,C,Q7V<R+FIP9U!+ 0(4 Q0    (
M #F"=U2TW-N*<8H! %3E 0 4              "  ;*!% !C;G1X+3(P,C$Q
M,C,Q7V<S+FIP9U!+ 0(4 Q0    ( #F"=U31D8OPH.H  "M. 0 4
M      "  54,%@!C;G1X+3(P,C$Q,C,Q7V<T+FIP9U!+ 0(4 Q0    ( #F"
M=U0(2%#__F<  ,_!   4              "  2?W%@!C;G1X+3(P,C$Q,C,Q
M7V<U+FIP9U!+ 0(4 Q0    ( #F"=U0/M=J(E9D! -WK 0 4
M  "  5=?%P!C;G1X+3(P,C$Q,C,Q7V<V+FIP9U!+ 0(4 Q0    ( #F"=U00
MTPCZ][@  $7Y   4              "  1[Y& !C;G1X+3(P,C$Q,C,Q7V<W
M+FIP9U!+ 0(4 Q0    ( #F"=U1DO,M<C(P! ';R 0 4              "
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M975T:6-S97@S,3)C92YH=&U02P$"% ,4    "  Y@G=4Y;&2#]4%  !;&0
M'@              @ $>&!X 8V]N=&5X='1H97)A<&5U=&EC<V5X,S(Q8V4N
M:'1M4$L! A0#%     @ .8)W5/O>YT#G @  5@@  !X              ( !
M+QX> &5X:&EB:70R,S%C;VAN<F5Z;FEC:V-O;G-E+FAT;5!+ 0(4 Q0    (
M #F"=U3M2IK'O6L  !(6 P >              "  5(A'@!L979I=&5M<&QO
J>6UE;G1A9W)E96UE;G0Q,"YH=&U02P4&     !\ 'P!""   2XT>

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
